PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mathews, PM; Guerra, CB; Jiang, Y; Grbovic, OM; Kao, BH; Schmidt, SD; Dinakar, R; Mercken, M; Hille-Rehfeld, A; Rohrer, J; Mehta, P; Cataldo, AM; Nixon, RA				Mathews, PM; Guerra, CB; Jiang, Y; Grbovic, OM; Kao, BH; Schmidt, SD; Dinakar, R; Mercken, M; Hille-Rehfeld, A; Rohrer, J; Mehta, P; Cataldo, AM; Nixon, RA			Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases A beta secretion - Role for altered lysosomal hydrolase distribution in beta-amyloidogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CATHEPSIN-D; ENDOCYTIC PATHWAY; DEFICIENT FIBROBLASTS; CEREBROSPINAL-FLUID; MEMBRANE-PROTEIN; CYTOPLASMIC TAIL; GOLGI-APPARATUS; EXPRESSION; TRANSMEMBRANE	Prominent endosomal and lysosomal changes are an invariant feature of neurons in sporadic Alzheimer's disease (AD). These changes include increased levels of lysosomal hydrolases in early endosomes and increased expression of the cation-dependent mannose 6-phosphate receptor (CD-MPR), which is partially localized to early endosomes. To determine whether AD-associated redistribution of lysosomal hydrolases resulting from changes in CD-MPR expression affects amyloid precursor protein (APP) processing, we stably transfected APP-overexpressing murine L cells with human CD-MPR. As controls for these cells, we also expressed CD-MPR trafficking mutants that either localize to the plasma membrane (CD-MPRpm) or to early endosomes (CD-MPRendo). Expression of CD-MPR resulted in a partial redistribution of a representative lysosomal hydrolase, cathepsin D, to early endosomal compartments. Turnover of APP and secretion of sAPPalpha and sAPPbeta were not altered by overexpression of any of the CD-MPR constructs. However, secretion of both human Abeta40 and Abeta42 into the growth media nearly tripled in CD-MPR- and CD-MPRendo-expressing cells when compared with parental or CD-MPRpm-expressing cells. Comparable increases were confirmed for endogenous mouse Abeta40 in L cells expressing these CD-MPR constructs but not overexpressing human APP. These data suggest that redistribution of lysosomal hydrolases to early endocytic compartments mediated by increased expression of the CD-MPR may represent a potentially pathogenic mechanism for accelerating Abeta generation in sporadic AD, where the mechanism of amyloidogenesis is unknown.	Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA; NYU, Sch Med, Orangeburg, NY 10962 USA; Harvard Univ, McLean Hosp, Sch Med, Belmont, MA 02478 USA; Janssen Res Fdn, B-2340 Beerse, Belgium; Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37073 Gottingen, Germany; Friedrich Miescher Inst, CH-4058 Basel, Switzerland; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA	Nathan Kline Institute for Psychiatric Research; New York University; Harvard University; McLean Hospital; Johnson & Johnson; University of Gottingen; Friedrich Miescher Institute for Biomedical Research; Institute for Basic Research in Developmental Disabilities	Mathews, PM (corresponding author), Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA.	mathews@nki.rfmh.org	Schmidt, Stephen/AAC-6967-2019; Schmidt, Stephen/B-5398-2012	Rohrer, Jack/0000-0002-2058-490X	NATIONAL INSTITUTE ON AGING [P01AG017617] Funding Source: NIH RePORTER; NIA NIH HHS [AG14762, AG17617] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Bertram L, 2001, ANN NEUROL, V49, P114, DOI 10.1002/1531-8249(200101)49:1<114::AID-ANA18>3.0.CO;2-M; Bertram L, 2000, EXP GERONTOL, V35, P1353, DOI 10.1016/S0531-5565(00)00193-5; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Cataldo AM, 1996, J NEUROSCI, V16, P186; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; Chen CS, 2000, J BIOCHEM BIOPH METH, V42, P137, DOI 10.1016/S0165-022X(00)00048-8; Chevallier N, 1997, BRAIN RES, V750, P11, DOI 10.1016/S0006-8993(96)01330-3; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Gruninger-Leitch F, 2000, NAT BIOTECHNOL, V18, P66, DOI 10.1038/71944; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; KIT SAUL, 1967, J VIROL, V1, P238; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KOO EH, 1994, J BIOL CHEM, V269, P17386; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Mackay EA, 1997, EUR J BIOCHEM, V244, P414, DOI 10.1111/j.1432-1033.1997.00414.x; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; Matsui T, 2001, ANN NEUROL, V49, P544, DOI 10.1002/ana.110; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; Menzer G, 2001, AM J MED GENET, V105, P179, DOI 10.1002/ajmg.1204; MESSNER DJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P391, DOI 10.1006/abbi.1993.1528; MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; Papassotiropoulos A, 2000, ANN NEUROL, V47, P399, DOI 10.1002/1531-8249(200003)47:3<399::AID-ANA22>3.3.CO;2-X; Papassotiropoulos A, 1999, NEUROSCI LETT, V262, P171, DOI 10.1016/S0304-3940(99)00071-3; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Petanceska SS, 2000, J NEUROCHEM, V74, P1878, DOI 10.1046/j.1471-4159.2000.0741878.x; Petanceska SS, 1999, J NEUROCHEM, V73, P2316, DOI 10.1046/j.1471-4159.1999.0732316.x; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Ponnambalam S, 1996, J CELL SCI, V109, P675; Potempska A, 1999, AMYLOID, V6, P14, DOI 10.3109/13506129908993283; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; SCHWAGERL AL, 1995, J NEUROCHEM, V64, P443; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2000, JAMA-J AM MED ASSOC, V283, P1615, DOI 10.1001/jama.283.12.1615; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VANNOSTRAND WE, 1989, NATURE, V341, P546; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200	64	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5299	5307		10.1074/jbc.M108161200	http://dx.doi.org/10.1074/jbc.M108161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11551970	hybrid			2022-12-25	WOS:000173962900096
J	Al-Zoubi, AM; Efimova, EV; Kaithamana, S; Martinez, O; El-Idrissi, MEA; Dogan, RE; Prabhakar, BS				Al-Zoubi, AM; Efimova, EV; Kaithamana, S; Martinez, O; El-Idrissi, MEA; Dogan, RE; Prabhakar, BS			Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN PROTEIN; GENE-EXPRESSION; FACTOR RECEPTOR; FAMILY MEMBERS; SERPIN CRMA; CELL-DEATH; PATHWAYS; INHIBITION; ENCODES; VIRUSES	We identified a novel cDNA (IG20) that is homologous to cDNAs encoding a protein differentially expressed in normal and neoplastic cells (DENN-SV) and human MADD (MAPK-activating death domain-containing protein). Furthermore, we show that the above variants most likely result from alternative splicing of a single gene. Functional analyses of these variants in permanently transfected HeLa cells revealed that IG20 and DENN-SV render them more susceptible or resistant to tumor necrosis factor alpha (TNF-alpha)-induced apoptosis, respectively. All variants tested could interact with TNF receptor 1 and activate ERK and nuclear factor KB. However, relative to control cells, only cells expressing IG20 showed enhanced TNF-alpha -induced activation of caspase-8 and -3, whereas cells expressing DENN-SV showed either reduced or no caspase activation. Transfection of these cells with a cDNA encoding CrmA maximally inhibited apoptosis in HeLa-IG20 cells. Our results show that IG20 can promote TNF-alpha -induced apoptosis and activation of caspase-8 and -3 and suggest that it may play a novel role in the regulation of the pleiotropic effects of TNF-alpha through alternative splicing.	Univ Illinois, Dept Microbiol & Immunol MC 790, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol MC 790, Rm E-709,Bldg 935, Chicago, IL 60612 USA.			Martinez, Osvaldo/0000-0001-7335-4342				Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cunningham SJ, 1996, THESIS U TEXAS MED B; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Krajcsi P, 1998, SEMIN CELL DEV BIOL, V9, P351, DOI 10.1006/scdb.1998.0244; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; OBrien DP, 1997, MOL CELL BIOL, V17, P3477, DOI 10.1128/MCB.17.7.3477; Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898-6568(98)00018-7; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; VAN AD, 1996, SCIENCE, V274, P787; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Walter U, 2000, EUR J IMMUNOL, V30, P1224, DOI 10.1002/1521-4141(200004)30:4<1224::AID-IMMU1224>3.0.CO;2-B; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	27	51	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47202	47211		10.1074/jbc.M104835200	http://dx.doi.org/10.1074/jbc.M104835200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577081	hybrid			2022-12-25	WOS:000172768500072
J	Gori, F; Divieti, P; Demay, MB				Gori, F; Divieti, P; Demay, MB			Cloning and characterization of a novel WD-40 repeat protein that dramatically accelerates osteoblastic differentiation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARROW STROMAL CELLS; WD-REPEAT; FAMILY-MEMBERS; BETA-SUBUNITS; BONE; GENE; EXPRESSION; RECEPTOR; IDENTIFICATION; OSF2/CBFA1	The bone morphogenetic proteins (BMPs) play a pivotal role in endochondral bone formation. Using differential display polymerase chain reaction, we have identified a novel gene, named BIG-3 (BMP-2-induced gene 3 kb), that is induced as a murine prechondroblastic cell line, MLB13MYC clone 17, acquires osteoblastic features in response to BMP-2 treatment. The 3-kilobase mRNA encodes a 34-kDa protein containing seven WD-40 repeats. Northern and Western analyses demonstrated that BIG-3 mRNA and protein were induced after 24 h of BMP-2 treatment. BIG-3 mRNA was expressed in conditionally immortalized murine bone marrow stromal cells, osteoblasts, osteocytes, and growth plate chondrocytes, as well as in primary calvarial osteoblasts. Immunohistochemistry demonstrated that BIG-3 was expressed in the osteoblasts of calvariae isolated from mouse embryos. To identify a role for BIG-3 in osteoblast differentiation, MC3T3-E1 cells were stably transfected with the full-length coding region of BIG-3 (MC3T3E1-BIG-3) cloned downstream of a cytomegalovirus promoter in pcDNA3.1. Pooled MC3T3E1-BlG-3 clones expressed alkaline phosphatase activity earlier and achieved a peak level of activity 10-fold higher than cells transfected with the empty vector (MC3T3E1-EV) at 14 days. Cyclic AMP production in response to parathyroid hormone was increased 10- and 14-fold at 7 and 14 days, respectively, in MC3T3E1-BlG-3 clones, relative to MC3T3E1-EV clones. This increase in cAMP production was associated with an increase in PTH binding. Expression of BIG-3 increased mRNA levels encoding Cbfa1, type I collagen, and osteocalcin and accelerated formation of mineralized nodules. In conclusion, we have identified a novel WD-40 protein, induced by BMP-2 treatment, that dramatically accelerates the program of osteoblastic differentiation in stably transfected MC3T3E1 cells.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Demay, MB (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA.	demay@helix.mgh.harvard.edu	Gori, Francesca/S-9422-2019	Divieti Pajevic, Paola/0000-0001-9853-9837	NIDCR NIH HHS [1 F32 DE-05754] Funding Source: Medline; NIDDK NIH HHS [DK36597, 1 KO8 DK02889] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036597, K08DK002889] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; Bos MP, 1996, CALCIFIED TISSUE INT, V58, P95, DOI 10.1007/s002239900017; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; Divieti P, 1998, J BONE MINER RES, V13, P1835, DOI 10.1359/jbmr.1998.13.12.1835; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DUCY P, 1996, PRINCIPLES BONE BIOL; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; HANEVOLD CD, 1993, J BONE MINER RES, V8, P1191; Harris Stephen E., 1995, Molecular and Cellular Differentiation, V3, P137; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; LEE K, 1993, BONE, V14, P341, DOI 10.1016/8756-3282(93)90162-4; Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952; MacLean HE, 1999, J BONE MINER RES, V14, pS219; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; QUARLES LD, 1991, ENDOCRINOLOGY, V128, P3144, DOI 10.1210/endo-128-6-3144; ROSEN V, 1994, J BONE MINER RES, V9, P1759; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SASANO Y, 1993, ANAT REC, V236, P373, DOI 10.1002/ar.1092360211; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STEIN GS, 1996, PRINCIPLES BONE BIOL; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHANG M, 1991, GENE, V97, P153, DOI 10.1016/0378-1119(91)90047-F	47	74	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46515	46522		10.1074/jbc.M105757200	http://dx.doi.org/10.1074/jbc.M105757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11551928	hybrid			2022-12-25	WOS:000172573100137
J	Weixel, KM; Bradbury, NA				Weixel, KM; Bradbury, NA			mu 2 binding directs the cystic fibrosis transmembrane conductance regulator to the clathrin-mediated endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; GROWTH-FACTOR RECEPTORS; EPITOPE-TAGGED CFTR; SORTING SIGNALS; COATED VESICLES; INTERNALIZATION MOTIF; TRANSFERRIN RECEPTOR; CHLORIDE CHANNELS; CARBOXYL-TERMINUS; AP-2 COMPLEXES	The cystic fibrosis transmembrane conductance regulator (CFTR) contains a conserved tyrosine-based internalization motif, (DSI)-D-1424y, which interacts with the endocytic clathrin adaptor complex, AP-2, and is required for its efficient endocytosis. Although direct interactions between several endocytic sequences and the medium chain and endocytic clathrin adaptor complexes have been shown by protein-protein interaction assays, whether all these interactions occur in vivo or are physiologically important has not always been addressed. Here we show, using both in vitro and in vivo assays, a physiologically relevant interaction between CFTR and the tt subunit of AP-2. Cross-linking experiments were performed using photoreactive peptides containing the YDSI motif and purified adaptor complexes. CFTR peptides cross-linked a 50-kDa subunit of purified AP-2 complexes, the apparent molecular mass of mu2. Furthermore, isolated mu2 bound to the sorting motif, YDSI, both in cross-linking experiments and glutathione S-transferase pull-down experiments, confirming that mu2 mediates the interaction between CFTR and A-P-2 complexes. Inducible overexpression of dominant-negative mu2 in HeLa cells results in AP-2 complexes that fail to interact with CFTR. Moreover, internalization of CFTR in mutant cells is greatly reduced compared with wild type HeLa cells. These results indicate that the AP-2 endocytic complex selectively interacts with the conserved tyrosine-based internalization signal in the carboxyl terminus of CFTR, YDSI. Furthermore, this interaction is mediated by the mu2 subunit of AP-2 and mutations in mu2 that block its interaction with YDSI inhibit the incorporation of CFTR into the clathrin-mediated endocytic pathway.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bradbury, NA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, 3500 Terrace St, Pittsburgh, PA 15261 USA.				NIDDK NIH HHS [1P50DK56490] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COHN JA, 1994, CYSTIC FIBROSIS CURR, V2; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Tousson A, 1996, J CELL SCI, V109, P1325; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WEBSTER P, 1994, AM J PHYSIOL, V267, P340; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; WEIXEL KM, 2001, IN PRESS METHODS MOL	53	39	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46251	46259		10.1074/jbc.M104545200	http://dx.doi.org/10.1074/jbc.M104545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11560923	hybrid			2022-12-25	WOS:000172573100104
J	Chen, CP; Hsu, CH; Su, NY; Lin, YC; Chiou, SH; Wu, SH				Chen, CP; Hsu, CH; Su, NY; Lin, YC; Chiou, SH; Wu, SH			Solution structure of a Kunitz-type chymotrypsin inhibitor isolated from the elapid snake Bungarus fasciatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; TICK ANTICOAGULANT PEPTIDE; BETA-PROTEIN PRECURSOR; NMR SOLUTION STRUCTURE; FACTOR-XA INHIBITOR; CRYSTAL-STRUCTURE; DENDROTOXIN-K; DOMAIN; VENOM	Bungarus fasciatus fraction IX (BF9), a chymotrypsin inhibitor, consists of 65 amino acid residues with three disulfide bridges. It was isolated from the snake venom of B. fasciatus by ion-exchange chromatography and belongs to the bovine pancreatic trypsin inhibitor (BPTI)-like superfamily. It showed a dissociation constant of 5.8 x 10(-8) mr with a-chymotrypsin as measured by a BIAcore binding assay system. The isothermal titration calorimetry revealed a 1:1 binding stoichiometry between this inhibitor and chymotrypsin and apparently no binding with trypsin. We further used CD and NMR to determine the solution structure of this venom-derived chymotrypsin inhibitor. The three-dimensional NMR solution structures of BF9 were determined on the basis of 582 restraints by simulated annealing and energy minimization calculations. The final set of 10 NMR structures was well defined, with average root mean square deviations of 0.47 Angstrom for the backbone atoms in the secondary structure regions and 0.86 Angstrom for residues The side chains of Phe(23), Tyr(24), Tyr(25), Phe(35), and Phe(47) exhibited many long-range nuclear Overhauser effects and were the principal components of the hydrophobic core in BF9. To gain insight into the structure-function relationships among proteins in the BPTI-like superfamily, we compared the three-dimensional structure of BF9 with three BPTI-like proteins that possess distinct biological functions. These proteins possessed similar secondary structure elements, but the loop regions and beta -turn were different from one another. Based on residues at the functional site of each protein, we suggest that the flexibility, rigidity, and variations of the amino acid residues in both the loop and beta -turn regions are related to their biological functions.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, CP (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.		HSU, CHUN-HUA/W-4554-2019; Chen, Chinpan/O-4202-2018	HSU, CHUN-HUA/0000-0002-0008-7383; 				ANTUCH W, 1994, FEBS LETT, V352, P251, DOI 10.1016/0014-5793(94)00941-4; ANTUCH W, 1993, EUR J BIOCHEM, V212, P675, DOI 10.1111/j.1432-1033.1993.tb17705.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; BERNDT KD, 1993, J MOL BIOL, V234, P735, DOI 10.1006/jmbi.1993.1623; BRUNGER AT, 1998, XPLOR VERSION 98; DUFTON MJ, 1985, EUR J BIOCHEM, V153, P647, DOI 10.1111/j.1432-1033.1985.tb09349.x; DUNWIDDIE CT, 1992, BIOCHEMISTRY-US, V31, P12126, DOI 10.1021/bi00163a022; FORAY MF, 1993, EUR J BIOCHEM, V211, P813, DOI 10.1111/j.1432-1033.1993.tb17613.x; Gilquin B, 1999, PROTEINS, V34, P520, DOI 10.1002/(SICI)1097-0134(19990301)34:4<520::AID-PROT11>3.0.CO;2-N; HARVEY AL, 1991, DENDROTOXINS SNAKE T, P131; HEALD SL, 1991, BIOCHEMISTRY-US, V30, P10467, DOI 10.1021/bi00107a015; HYBERTS SG, 1987, EUR J BIOCHEM, V164, P625, DOI 10.1111/j.1432-1033.1987.tb11173.x; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIMWILBY MSL, 1995, PROTEIN SCI, V4, P178; LIU CS, 1983, INT J PEPT PROT RES, V21, P209; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RITONJA A, 1983, BIOCHIM BIOPHYS ACTA, V746, P138, DOI 10.1016/0167-4838(83)90067-5; SASAKI T, 1984, J BIOCHEM-TOKYO, V95, P1009, DOI 10.1093/oxfordjournals.jbchem.a134688; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; Sorensen MD, 1997, BIOCHEMISTRY-US, V36, P10439, DOI 10.1021/bi9705570; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; vandeLocht A, 1996, EMBO J, V15, P6011, DOI 10.1002/j.1460-2075.1996.tb00989.x; WAGNER G, 1982, J MOL BIOL, V160, P343, DOI 10.1016/0022-2836(82)90180-2; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Zweckstetter M, 1996, STRUCTURE, V4, P195, DOI 10.1016/S0969-2126(96)00022-6	38	55	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45079	45087		10.1074/jbc.M106182200	http://dx.doi.org/10.1074/jbc.M106182200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11562364	Green Published, hybrid			2022-12-25	WOS:000172406700098
J	Fukushima, T; Takata, M; Morrison, C; Araki, R; Fujimori, A; Abe, M; Tatsumi, K; Jasin, M; Dhar, PK; Sonoda, E; Chiba, T; Takeda, S				Fukushima, T; Takata, M; Morrison, C; Araki, R; Fujimori, A; Abe, M; Tatsumi, K; Jasin, M; Dhar, PK; Sonoda, E; Chiba, T; Takeda, S			Genetic analysis of the DNA-dependent protein kinase reveals an inhibitory role of Ku in late S-G(2) phase DNA double-strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CELL ANTIGEN RECEPTOR; V(D)J RECOMBINATION; LIGASE-IV; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; CATALYTIC SUBUNIT; VERTEBRATE CELLS; MAMMALIAN-CELLS; IN-VIVO	Two major complementary double-strand break (DSB) repair pathways exist in vertebrates, homologous recombination (HR), which involves Rad54, and non-homologous end joining, which requires the DNA-dependent protein kinase (DNA-PK). DNA-PK comprises a catalytic subunit (DNA-PKcs) and a DNA-binding Ku70 and Ku80 heterodimer. To define the activities of individual DNA-PK components in DSB repair, we targeted the DNA-PKcs gene in chicken DT40 cells. DNA-PKcs deficiency caused a DSB repair defect that was, unexpectedly, suppressed by KU70 disruption. We have shown previously that genetic ablation of Ku70 confers RAD54-dependent radioresistance on S-G(2) phase cells, when sister chromatids are available for HR repair. To test whether direct interference by Ku70 with HR might explain the Ku70(-/-)/DNA-PKcs(-/-/-) radioresistance, we monitored HR activities directly in Ku- and DNA-PKcs-deficient cells. The frequency of intrachromosomal HR induced by the I-SceI restriction enzyme was increased in the absence of Ku but not of DNA-PKcs. Significantly, abrogation of HR activity by targeting RAD54 in Ku 70(-/-) or DNA-PKcs(-/-/-) cells caused extreme radiosensitivity, suggesting that the relative radioresistance seen with loss of Ku70 was because of HR-dependent repair pathways. Our findings suggest that Ku can interfere with HR-mediated DSB repair, perhaps competing with HR for DSB recognition.	Kyoto Univ, Fac Med, CREST Res Project, Sakyo Ku, Kyoto 6068501, Japan; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Natl Inst Radiol Sci, Inage Ku, Chiba 2638555, Japan; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Kyoto Univ, Grad Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Sakyo Ku, Kyoto 6068507, Japan	Japan Science & Technology Agency (JST); Kyoto University; University of Edinburgh; National Institutes for Quantum Science & Technology; Memorial Sloan Kettering Cancer Center; Cornell University; Kyoto University	Takeda, S (corresponding author), Kyoto Univ, Fac Med, CREST Res Project, Sakyo Ku, Konoe Yoshida, Kyoto 6068501, Japan.		Morrison, Ciaran/B-6568-2008; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Abe, Masumi/0000-0003-1550-2006; Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991				Adachi N, 2001, P NATL ACAD SCI USA, V98, P12109, DOI 10.1073/pnas.201271098; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fujimori A, 2000, IMMUNOGENETICS, V51, P965, DOI 10.1007/s002510000227; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	37	134	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44413	44418		10.1074/jbc.M106295200	http://dx.doi.org/10.1074/jbc.M106295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577093	Green Submitted, hybrid			2022-12-25	WOS:000172406700010
J	Yamasaki, S; Nishida, K; Hibi, M; Sakuma, M; Shiina, R; Takeuchi, A; Ohnishi, H; Hirano, T; Saito, T				Yamasaki, S; Nishida, K; Hibi, M; Sakuma, M; Shiina, R; Takeuchi, A; Ohnishi, H; Hirano, T; Saito, T			Docking protein Gab2 is phosphorylated by ZAP-70 and negatively regulates T cell receptor signaling by recruitment of inhibitory molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEINS; ACTIVATION; CYTOKINE; KINASE; SHP-2; TRANSDUCTION	To maintain various T cell responses and immune equilibrium, activation signals triggered by T cell antigen receptor (TCR) must be regulated by inhibitory signals. Gab2, an adaptor protein of the insulin receptor substrate-1 family, has been shown to be involved in the downstream signaling from cytokine receptors. We investigated the functional role of Gab2 in TCR-mediated signal transduction. Gab2 was phosphorylated by ZAP-70 and co-precipitated with phosphoproteins, such as ZAP-70, LAT, and CD3 zeta, upon TCR stimulation. Overexpression of Gab2 in Jurkat cells or antigen-specific T cell hybridomas resulted in the inhibition of NF-AT activation, interleukin-2 production, and tyrosine phosphorylation. The structure-function relationship of Gab2 was analyzed by mutants of Gab2. The Gab2 mutants lacking SHP-2-binding sites mostly abrogated the inhibitory activity of Gab2, but its inhibitory function was restored by fusing to active SHP-2 as a chimeric protein. A mutant with defective phosphatidylinositol 3-kinase binding capacity also impaired the inhibitory activity, and the pleckstrin homology domain-deletion mutant revealed a crucial function of the pleckstrin homology domain for localization to the plasma membrane. These results suggest that Gab2 is a substrate of ZAP-70 and functions as a switch molecule toward inhibition of TCR signal transduction by mediating the recruitment of inhibitory molecules to the TCR signaling complex.	Chiba Univ, Grad Sch Med, Chiba 2608670, Japan; Osaka Univ, Grad Sch Med, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan	Chiba University; Osaka University	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Chiba 2608670, Japan.		Hibi, Masahiko/I-6215-2014; Hirano, Toshio/C-8194-2009	Hibi, Masahiko/0000-0002-9142-4444; Takeuchi, Arata/0000-0003-0412-533X				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; CANTRELL D, 1994, CURR OPIN IMMUNOL, V6, P380, DOI 10.1016/0952-7915(94)90116-3; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HANSBURG D, 1983, J IMMUNOL, V131, P319; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 2001, J BIOL CHEM, V276, P12257, DOI 10.1074/jbc.M010590200; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kitamura T, 1998, INT J HEMATOL, V67, P351; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NAKAMURA K, 1994, BBA-MOL CELL RES, V1224, P495, DOI 10.1016/0167-4889(94)90287-9; Nakaseko C, 1999, J EXP MED, V190, P765, DOI 10.1084/jem.190.6.765; NAKAYAMA T, 1988, EUR J IMMUNOL, V18, P761, DOI 10.1002/eji.1830180516; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Newman DK, 2001, BLOOD, V97, P2351, DOI 10.1182/blood.V97.8.2351; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Olcese L, 1996, J IMMUNOL, V156, P4531; Pratt JC, 2000, J IMMUNOL, V165, P4158, DOI 10.4049/jimmunol.165.8.4158; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Saito T, 1998, CURR OPIN IMMUNOL, V10, P313, DOI 10.1016/S0952-7915(98)80170-2; Samelson LE, 1995, ANN NY ACAD SCI, V766, P157, DOI 10.1111/j.1749-6632.1995.tb26659.x; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	55	70	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45175	45183		10.1074/jbc.M105384200	http://dx.doi.org/10.1074/jbc.M105384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572860	hybrid			2022-12-25	WOS:000172406700110
J	Zhou, MS; Nekhai, S; Bharucha, DC; Kumar, A; Ge, H; Price, DH; Egly, JM; Brady, JN				Zhou, MS; Nekhai, S; Bharucha, DC; Kumar, A; Ge, H; Price, DH; Egly, JM; Brady, JN			TFIIH inhibits CDK9 phosphorylation during human immunodeficiency virus type 1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; TAT-ASSOCIATED KINASE; HUMAN CYCLIN T1; PROTEINS SPECIFICALLY ASSOCIATE; ELONGATION-FACTOR-B; FACTOR P-TEFB; HIV-1 TAT; ACTIVATING KINASE; SACCHAROMYCES-CEREVISIAE	Tat stimulates human immunodeficiency virus, type 1 (HIV-1), transcription elongation by recruitment of the human transcription elongation factor P-TEFb, consisting of CDK9 and cyclin T1, to the TAR RNA structure. It has been demonstrated further that CDK9 phosphorylation is required for high affinity binding of Tat/P-TEFb to the TAR RNA structure and that the state of P-TEFb phosphorylation may regulate Tat transactivation. We now demonstrate that CDK9 phosphorylation is uniquely regulated in the HIV-1 preinitiation and elongation complexes. The presence of TFIIH in the HIV-1 preinitiation complex inhibits CDK9 phosphorylation. As TFIIH is released from the elongation complex between +14 and +36, CDK9 phosphorylation is observed. In contrast to the activity in the "soluble" complex, phosphorylation of CDK9 is increased by the presence of Tat in the transcription complexes. Consistent with these observations, we have demonstrated that purified TFIIH directly inhibits CDK9 autophosphorylation. By using recombinant TFIIH subcomplexes, our results suggest that the XPB subunit of TFIIH is responsible for this inhibition of CDK9 phosphorylation. Interestingly, our results further suggest that the phosphorylated form of CDK9 is the active kinase for RNA polymerase II carboxyl-terminal domain phosphorylation.	NCI, Virus Tumor Biol Sect, Basic Res Lab, Div Basic Sci,NIH, Bethesda, MD 20892 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; NICHHD, Mol Embryol Lab, Bethesda, MD 20892 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU De Strasbour, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Iowa; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Basic Res Lab, Div Basic Sci,NIH, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov	, nekhai/AAW-3105-2021; Price, David H/F-6173-2010; , nekhai/AFO-2652-2022	Price, David/0000-0002-5597-385X				Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Bieniasz PD, 1999, J VIROL, V73, P5777, DOI 10.1128/JVI.73.7.5777-5786.1999; Bieniasz PD, 1999, MOL CELL BIOL, V19, P4592, DOI 10.1128/mcb.19.7.4592; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Boris-Lawrie Kathleen A., 1992, Gene Expression, V2, P215; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Chen D, 1999, MOL CELL BIOL, V19, P2863; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; GARRIGA J, 1996, BIOCHEM J, V320, P4; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGAN DO, 1998, CANC J SCI AM S1, V4, P77; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Parada CA, 1999, EMBO J, V18, P3688, DOI 10.1093/emboj/18.13.3688; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; POON RYC, 1994, J CELL SCI, V107, P2789; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Taube R, 2000, J VIROL, V74, P892, DOI 10.1128/JVI.74.2.892-898.2000; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Yankulov K, 1998, CURR BIOL, V8, pR447, DOI 10.1016/S0960-9822(98)70289-1; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zhau MS, 2000, VIROLOGY, V268, P452, DOI 10.1006/viro.1999.0177; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	105	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44633	44640		10.1074/jbc.M107466200	http://dx.doi.org/10.1074/jbc.M107466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572868	hybrid			2022-12-25	WOS:000172406700041
J	Lelievre, V; Pineau, N; Hu, ZT; Ioffe, Y; Byun, JY; Muller, JM; Waschek, JA				Lelievre, V; Pineau, N; Hu, ZT; Ioffe, Y; Byun, JY; Muller, JM; Waschek, JA			Proliferative actions of natriuretic peptides on neuroblastoma cells - Involvement of guanylyl cyclase and non-guanylyl cyclase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; CLEARANCE RECEPTOR; SELECTIVE INHIBITOR; MESANGIAL CELLS; POTENTIAL ROLE; GROWTH-FACTOR; RAT-BRAIN; IN-VITRO	To identify neural tumor cell lines that could be used as models to study growth-related natriuretic peptide actions, we determined the effects of these peptides on the proliferation of human and rodent neuroblastoma cell lines. Subnanomolar concentrations of atrial natriuretic peptide (ANP) and type C natriuretic peptide (CNP) stimulated proliferation in all four cell lines. These actions were associated with cGMP elevation and were blocked by a protein kinase G inhibitor. These data imply the involvement of guanylyl cyclase (GC)-coupled natriuretic receptors. However, higher concentrations of ANP and CNP, and low concentrations of des-[Gln(18), Ser(19), Gly(20), Leu(21) , Gly(22)]-ANP(4-23)-NH2 (desANP(4-23)) (analog for NPR-C receptor) exerted antiproliferative actions in three of the cell lines. These effects were insensitive to a protein kinase G inhibitor and to HS-142-1, suggesting that growth-inhibitory actions involved a non-GC receptor. They did not appear to involve cAMP, protein kinase X protein kinase C, or calcium mobilization but were abolished when constitutive mitogen-activated protein kinase activity was inhibited. Radioligand binding experiments revealed the presence of a uniform class of binding sites in NG108 cells and multiple binding sites in Neuro2a cells. Northern and reverse transcriptase-polymerase chain reaction analyses revealed differential gene expression for NPRA/B/C in NG108 and Neuro2a cells. The results indicate that natriuretic peptides stimulate neuroblastoma cell proliferation through type NPRA/B (GC) receptors. Higher concentrations of ANP and CNP exerted a mitogen-activated protein kinase-dependent antiproliferative action mediated by a non-GC receptor that interacts with desANP(4-23) with relatively high affinity.	Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Mental Retardat Res Ctr, Los Angeles, CA 90024 USA; Univ Poitiers, UFR Sci, Lab Biol Interact Cellulaires, CNRS,UMR 6558, F-86022 Poitiers, France	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Waschek, JA (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat, 68-225 NPI,760 Westwood Plaza, Los Angeles, CA 90024 USA.			Lelievre, Vincent/0000-0003-4150-8233; Muller, Jean-Marc/0000-0001-6009-7471	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD004612] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034475] Funding Source: NIH RePORTER; NICHD NIH HHS [HD04612, HD34475, HD06576] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIHO H, 1995, GASTROENTEROLOGY, V109, P1105, DOI 10.1016/0016-5085(95)90568-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; APPEL RG, 1990, AM J PHYSIOL, V259, pE312, DOI 10.1152/ajpendo.1990.259.3.E312; Awazu M, 1997, KIDNEY INT, V52, P356, DOI 10.1038/ki.1997.341; BROWN J, 1995, AM J PHYSIOL-REG I, V269, pR261, DOI 10.1152/ajpregu.1995.269.2.R261; BROWN J, 1994, AM J PHYSIOL, V266, pR1383, DOI 10.1152/ajpregu.1994.266.4.R1383; CAHILL PA, 1991, BIOCHEM BIOPH RES CO, V179, P1606, DOI 10.1016/0006-291X(91)91758-5; Cameron VA, 1996, ENDOCRINOLOGY, V137, P817, DOI 10.1210/en.137.3.817; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELPORTE C, 1991, EUR J PHARM-MOLEC PH, V207, P81, DOI 10.1016/S0922-4106(05)80041-0; DELPORTE C, 1992, EUR J PHARM-MOLEC PH, V227, P247, DOI 10.1016/0922-4106(92)90002-D; ESPINER EA, 1995, ENDOCRIN METAB CLIN, V24, P481, DOI 10.1016/S0889-8529(18)30028-8; FULLER F, 1988, J BIOL CHEM, V263, P9395; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; HANEDA M, 1993, BIOCHEM BIOPH RES CO, V192, P642, DOI 10.1006/bbrc.1993.1463; Henning RJ, 2001, CARDIOVASC RES, V49, P27, DOI 10.1016/S0008-6363(00)00229-7; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; KASHIWAGI M, 1995, EUR J BIOCHEM, V233, P102, DOI 10.1111/j.1432-1033.1995.102_1.x; Koide M, 1996, DIFFERENTIATION, V61, P1, DOI 10.1046/j.1432-0436.1996.6110001.x; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; Lelievre V, 1998, J BIOL CHEM, V273, P19685, DOI 10.1074/jbc.273.31.19685; Lelievre V, 1998, EUR J PHARMACOL, V341, P299, DOI 10.1016/S0014-2999(97)01463-5; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Matsuda Yuzuru, 1997, P289; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; Murthy KS, 1998, AM J PHYSIOL-CELL PH, V275, pC1409, DOI 10.1152/ajpcell.1998.275.6.C1409; NAKAO K, 1992, J HYPERTENS, V10, P1111, DOI 10.1097/00004872-199210000-00002; NEEDLEMAN P, 1989, ANNU REV PHARMACOL, V29, P23, DOI 10.1146/annurev.pa.29.040189.000323; NIIMURA S, 1989, RES COMMUN CHEM PATH, V63, P189; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; ODORISIO MS, 1992, REGUL PEPTIDES, V37, P213; PANDEY KN, 1990, J BIOL CHEM, V265, P12342; PINCUS DW, 1990, BRAIN RES, V514, P355, DOI 10.1016/0006-8993(90)91433-H; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; RASHED HM, 1993, HEPATOLOGY, V17, P677, DOI 10.1002/hep.1840170423; Rozen S, 2000, Methods Mol Biol, V132, P365; Segawa K, 1998, N-S ARCH PHARMACOL, V357, P70; Sellitti DF, 2001, REGUL PEPTIDES, V97, P103, DOI 10.1016/S0167-0115(00)00184-1; Suda M, 1998, P NATL ACAD SCI USA, V95, P2337, DOI 10.1073/pnas.95.5.2337; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; TONG Y, 1990, NEUROPEPTIDES, V16, P63, DOI 10.1016/0143-4179(90)90113-D; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0; ZORAD S, 1993, EUR J PHARMACOL, V241, P195, DOI 10.1016/0014-2999(93)90203-T	49	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43668	43676		10.1074/jbc.M107341200	http://dx.doi.org/10.1074/jbc.M107341200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11553633	hybrid			2022-12-25	WOS:000172297700026
J	Willment, JA; Gordon, S; Brown, GD				Willment, JA; Gordon, S; Brown, GD			Characterization of the human beta-glucan receptor and its alternatively spliced isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR; LECTIN SITE; COMPLEMENT; BINDING; ACTIVATION; CLONING; CELLS; GENE; PHAGOCYTOSIS; LEUKOCYTES	beta -1,3-D-Glucans are biological response modifiers with potent effects on the immune system. A number of receptors are thought to play a role in mediating these responses, including murine Dectin-1, which we recently identified as a beta -glucan receptor. In this study we describe the characterization of the human homologue of this receptor and show that it is structurally and functionally similar to the mouse receptor. The human beta -glucan receptor is a type II transmembrane receptor with a single extracellular carbohydrate recognition domain and an immunoreceptor tyrosine activation motif in its cytoplasmic tail. The human beta -glucan receptor is widely expressed and functions as a pattern recognition receptor, recognizing a variety of beta -1,3- and/or beta -1,6-linked glucans as well as intact yeast. In contrast to the murine receptor, the human receptor mRNA is alternatively spliced, resulting in two major (A and B) and six minor isoforms. The two major isoforms differ by the presence of a stalk region separating the carbohydrate recognition domain from the transmembrane region and are the only isoforms that are functional for beta -glucan binding. The human receptor also binds T-lymphocytes at. a site distinct from the beta -glucan binding site, indicating that this receptor can recognize both endogenous and exogenous ligands.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Brown, GD (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	gbrown@molbiol.ox.ac.uk	brown, gordon/B-4249-2012	brown, gordon/0000-0002-0287-5383; Willment, Janet/0000-0002-7040-0857				Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; Battle J, 1998, BIOCHEM BIOPH RES CO, V249, P499, DOI 10.1006/bbrc.1998.9175; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; COOK JA, 1982, INFECT IMMUN, V37, P1261, DOI 10.1128/IAI.37.3.1261-1269.1982; CZOP JK, 1986, PATHOL IMMUNOPATH R, V5, P286, DOI 10.1159/000157022; CZOP JK, 1978, J IMMUNOL, V120, P1132; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; Furukawa H, 1998, IMMUNOGENETICS, V48, P87, DOI 10.1007/s002510050407; Gough PJ, 1998, J LIPID RES, V39, P531; Hernanz-Falcon P, 2001, IMMUNOGENETICS, V53, P288, DOI 10.1007/s002510100326; Itoh W, 1997, MEDIAT INFLAMM, V6, P267, DOI 10.1080/09629359791596; KOKOSHIS PL, 1978, SCIENCE, V199, P1340, DOI 10.1126/science.628841; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lian RH, 1998, J IMMUNOL, V161, P2301; Llera AS, 2001, J BIOL CHEM, V276, P7312, DOI 10.1074/jbc.M008573200; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Muller A, 1996, J IMMUNOL, V156, P3418; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2; ROSS GD, 1985, J IMMUNOL, V134, P3307; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Thornton BP, 1996, J IMMUNOL, V156, P1235; Tone M, 2001, P NATL ACAD SCI USA, V98, P1751, DOI 10.1073/pnas.98.4.1751; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WILLIAMS DL, 1978, J RETICULOENDOTH SOC, V23, P479; WILLIAMS DL, 1991, CARBOHYD RES, V219, P203, DOI 10.1016/0008-6215(91)89052-H; Williams DL, 1996, CLIN IMMUNOTHER, V5, P392, DOI 10.1007/BF03259335; Yokota K, 2001, GENE, V272, P51, DOI 10.1016/S0378-1119(01)00528-5; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	36	241	258	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43818	43823		10.1074/jbc.M107715200	http://dx.doi.org/10.1074/jbc.M107715200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11567029	hybrid			2022-12-25	WOS:000172297700045
J	Yoon, KS; Bobst, C; Hemann, CF; Hille, R; Tabita, FR				Yoon, KS; Bobst, C; Hemann, CF; Hille, R; Tabita, FR			Spectroscopic and functional properties of novel 2[4Fe-4S] cluster-containing ferredoxins from the green sulfur bacterium Chlorobium tepidum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGENOBACTER-THERMOPHILUS TK-6; PYROCOCCUS-FURIOSUS FERREDOXIN; 2 4FE-4S CLUSTERS; HYPERTHERMOPHILIC ARCHAEON; METHANOBACTERIUM-THERMOAUTOTROPHICUM; AZOTOBACTER-VINELANDII; RHODOBACTER-CAPSULATUS; REDUCTION POTENTIALS; THERMOTOGA-MARITIMA; CHROMATIUM-VINOSUM	Two distinct ferredoxins, Fd I and Fd II, were isolated and purified to homogeneity from photoautotrophically grown Chlorobium tepidum, a moderately thermophilic green sulfur bacterium that assimilates carbon dioxide by the reductive tricarboxylic acid cycle. Both ferredoxins serve a crucial role as electron donors for reductive carboxylation, catalyzed by a key enzyme of this pathway, pyruvate synthase/pyruvate ferredoxin oxidoreductase. The reduction potentials of Fd I and Fd II were determined by cyclic voltammetry to be -514 and -584 mV, respectively, which are more electronegative than any previously studied Fds in which two [4Fe-4S] clusters display a single transition. Further spectroscopic studies indicated that the CD spectrum of oxidized Fd I closely resembled that of Fd Il; however, both spectra appeared to be unique relative to ferredoxins studied previously. Double integration of the EPR signal of the two Fds yielded approximately similar to2.0 spins per molecule, compatible with the idea that C. tepidum Fd I and Fd II accept 2 electrons upon reduction. These results suggest that the C. tepidum Fd I and Fd Il polypeptides each contain two bound [4Fe-4S] clusters. C. tepidum Fd I and Fd II are novel 2[4Fe-4S] Fds, which were shown previously to function as biological electron donors or acceptors for C. tepidum pyruvate synthase/pyruvate ferredoxin oxidoreductase (Yoon, K.-S., Hille, R., Hemann, C. F., and Tabita, F. R. (1999) J. Biol. Chem. 274, 29772-29778). Kinetic measurements indicated that Fd I had similar to2.3-fold higher affinity than Fd IL The results of amino acid sequence alignments, molecular modeling, oxidation-reduction potentials, and spectral properties strongly indicate that the C. tepidum Fds are chimeras of both clostridial-type and chromatium-type Fds, suggesting that the two Fds are likely intermediates in the evolutional development of 2[4Fe-4S] clusters compared with the well described clostridial and chromatium types.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Plant Mol Biol Biotechnol Program, Columbus, OH 43210 USA; Ohio State Univ, Prot Res Grp, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.			Hemann, Craig/0000-0002-7380-4072	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058481] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58481] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; Boll M, 2000, BIOCHEMISTRY-US, V39, P4929, DOI 10.1021/bi9927890; Brereton PS, 1998, BIOCHEMISTRY-US, V37, P7351, DOI 10.1021/bi972864b; Brereton PS, 1999, BIOCHEMISTRY-US, V38, P10594, DOI 10.1021/bi990671d; BUCHANAN BB, 1969, BIOCHIM BIOPHYS ACTA, V189, P46, DOI 10.1016/0005-2728(69)90223-0; Camba R, 2000, BIOCHEMISTRY-US, V39, P10587, DOI 10.1021/bi000832+; CARTER KR, 1980, J BIOL CHEM, V255, P4213; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; CHEN JS, 1979, ANAL BIOCHEM, V93, P216, DOI 10.1016/S0003-2697(79)80140-2; CHEN JS, 1977, ANAL BIOCHEM, V79, P157, DOI 10.1016/0003-2697(77)90390-6; CHEN K, 1997, J BIOL CHEM, V274, P36479; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DARIMONT B, 1994, EMBO J, V13, P1772, DOI 10.1002/j.1460-2075.1994.tb06445.x; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; EVANS MCW, 1966, P NATL ACAD SCI USA, V55, P928, DOI 10.1073/pnas.55.4.928; EVANS MCW, 1965, P NATL ACAD SCI USA, V53, P1420, DOI 10.1073/pnas.53.6.1420; Florin L, 2001, J BIOL CHEM, V276, P6125, DOI 10.1074/jbc.M008470200; Furdui C, 2000, J BIOL CHEM, V275, P28494, DOI 10.1074/jbc.M003291200; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HUGHES NJ, 1995, J BACTERIOL, V177, P3953, DOI 10.1128/jb.177.14.3953-3959.1995; Ishii M, 1996, BIOSCI BIOTECH BIOCH, V60, P1513, DOI 10.1271/bbb.60.1513; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; JOUANNEAU Y, 1993, J BIOL CHEM, V268, P10636; Jung YS, 1999, J BIOL CHEM, V274, P2978, DOI 10.1074/jbc.274.5.2978; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Menon AL, 1998, BIOCHEMISTRY-US, V37, P12838, DOI 10.1021/bi980979p; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; Morelli X, 2000, BIOCHEMISTRY-US, V39, P2530, DOI 10.1021/bi992306s; MORENO SNJ, 1984, J BIOL CHEM, V259, P8252; MOULIS JM, 1984, BIOCHEMISTRY-US, V23, P6605, DOI 10.1021/bi00321a050; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; Moulis JM, 1996, FEBS LETT, V380, P287, DOI 10.1016/0014-5793(96)00062-2; Nakajima Y, 1998, J BIOCHEM-TOKYO, V123, P521; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PIEULLE L, 1995, BBA-PROTEIN STRUCT M, V1250, P49, DOI 10.1016/0167-4838(95)00029-T; Saeki K, 1996, J BIOL CHEM, V271, P31399, DOI 10.1074/jbc.271.49.31399; Schut GJ, 2001, METHOD ENZYMOL, V331, P144; Seo D, 2001, BBA-BIOENERGETICS, V1503, P377, DOI 10.1016/S0005-2728(00)00245-0; SIREVAG R, 1977, ARCH MICROBIOL, V112, P35, DOI 10.1007/BF00446651; SMITH ET, 1990, J BIOL CHEM, V265, P14371; Smith ET, 2001, J BIOL INORG CHEM, V6, P227, DOI 10.1007/s007750000179; SMITH ET, 1994, BIOCHEMISTRY-US, V33, P1008, DOI 10.1021/bi00170a020; STEIGERWALD VJ, 1992, P NATL ACAD SCI USA, V89, P6929, DOI 10.1073/pnas.89.15.6929; Sticht H, 1998, PROG BIOPHYS MOL BIO, V70, P95, DOI 10.1016/S0079-6107(98)00027-3; TANAKA M, 1974, BIOCHEMISTRY-US, V13, P2953, DOI 10.1021/bi00711a026; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAHL RC, 1987, J BIOL CHEM, V262, P10489; Wahlund TM, 1997, J BACTERIOL, V179, P4859, DOI 10.1128/jb.179.15.4859-4867.1997; WAHLUND TM, 1991, ARCH MICROBIOL, V156, P81, DOI 10.1007/BF00290978; Yoon KS, 1999, J BIOL CHEM, V274, P29772, DOI 10.1074/jbc.274.42.29772; Yoon KS, 1997, BIOSCI BIOTECH BIOCH, V61, P510, DOI 10.1271/bbb.61.510; Yoon KS, 1997, ARCH MICROBIOL, V167, P275, DOI 10.1007/s002030050443; Yoon KS, 1996, J BACTERIOL, V178, P3365, DOI 10.1128/jb.178.11.3365-3368.1996; Yoon KS, 1996, FEMS MICROBIOL LETT, V139, P139, DOI 10.1111/j.1574-6968.1996.tb08193.x; ZEIKUS JG, 1977, J BACTERIOL, V132, P604, DOI 10.1128/JB.132.2.604-613.1977; Zhou ZH, 1997, BIOCHEMISTRY-US, V36, P10892, DOI 10.1021/bi9708141	63	29	30	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44027	44036		10.1074/jbc.M107852200	http://dx.doi.org/10.1074/jbc.M107852200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11568186	hybrid			2022-12-25	WOS:000172297700071
J	Zhang, M; Chen, WG; Smith, SM; Napoli, JL				Zhang, M; Chen, WG; Smith, SM; Napoli, JL			Molecular characterization of a mouse short chain dehydrogenase/reductase active with all-trans-retinol in intact cells, mRDH1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; GENE-EXPRESSION; BINDING-PROTEIN; ACID RECEPTORS; ALDEHYDE DEHYDROGENASE; CDNA CLONING; SUBSTRATE; IDENTIFICATION; RAT; RECOGNITION	Metabolic activation of retinol (vitamin A) via sequential actions of retinol and retinal dehydrogenases pro. duces the active metabolite all-trans-retinoic acid. This work reports cDNA cloning, enzymatic characterization, function in a reconstituted path of all-trans-retinoic acid biosynthesis in cell culture, and mRNA expression patterns in adult tissues and embryos of a mouse retinol dehydrogenase, RDH1. RDH1 represents a new member of the short chain dehydrogenase/reductase superfamily that differs from other mouse RDH in relative activity with all-trans and cis-retinols. RDH1 has a multifunctional catalytic nature, as do other short chain dehydrogenase/reductases. In addition to retinol dehydrogenase activity, RDH1 has strong 3 alpha -hydroxy and weak 17 beta -hydroxy steroid dehydrogenase activities. RDH1 has widespread and intense mRNA expression in tissues of embryonic and adult mice. The mouse embryo expresses RDH1 as early as 7.0 days post-coitus, and expression is especially intense within the neural tube, gut, and neural crest at embryo day 10.5. Cells cotransfected with RDH1 and any one of three retinal dehydrogenase isozymes synthesize all-trans-retinoic acid from retinol, demonstrating that RDH1 contributes to a path of all-trans-retinoic acid biosynthesis in intact cells. These characteristics are consistent with RDH1 functioning in a path of all-trans-retinoic acid biosynthesis starting early during embryogenesis.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of California System; University of California Berkeley; University of Wisconsin System; University of Wisconsin Madison	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009090] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47839] Funding Source: Medline; NIEHS NIH HHS [ES09090] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Bailey TL, 1997, J STEROID BIOCHEM, V62, P29, DOI 10.1016/S0960-0760(97)00013-7; BAKER ME, 1994, STEROIDS, V59, P248, DOI 10.1016/0039-128X(94)90109-0; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Bok D, 1999, NEURON, V23, P412, DOI 10.1016/S0896-6273(00)80791-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HSU LC, 1994, GENOMICS, V24, P333, DOI 10.1006/geno.1994.1624; Huang XF, 2000, J BIOL CHEM, V275, P29452, DOI 10.1074/jbc.M000562200; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; Maden M, 2000, P NUTR SOC, V59, P65, DOI 10.1017/S0029665100000082; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Napoli JL, 2001, MOL CELL ENDOCRINOL, V171, P103, DOI 10.1016/S0303-7207(00)00392-0; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Schoonjans K, 1996, J LIPID RES, V37, P907; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; VONESCH JL, 1994, DEV DYNAM, V199, P199, DOI 10.1002/aja.1001990305; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; WILKINSON DG, 1998, IN SITU HYBRIDIZATIO; Zhai Y, 1997, J CELL PHYSIOL, V173, P36, DOI 10.1002/(SICI)1097-4652(199710)173:1<36::AID-JCP5>3.0.CO;2-K; ZHAO D, 1996, EUR J BIOCHEM, V240, P5	40	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44083	44090		10.1074/jbc.M105748200	http://dx.doi.org/10.1074/jbc.M105748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562362	hybrid			2022-12-25	WOS:000172297700078
J	Abadjieva, A; Pauwels, K; Hilven, P; Crabeel, M				Abadjieva, A; Pauwels, K; Hilven, P; Crabeel, M			A new yeast metabolon involving at least the two first enzymes of arginine biosynthesis - Acetylglutamate synthase activity requires complex formation with acetylglutamate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; GENE; CLONING; LOCALIZATION; DISRUPTION; EXPRESSION; SEQUENCES; PRECURSOR; PRODUCTS	Open reading frame YJL071W of Saccharomyces cer. evisiae was shown to be ARG2 and identified as the structural gene for acetylglutamate synthase, first step in arginine biosynthesis. The three Ascomycete acetylglutamate synthases characterized to date appear homologous, but unlike the other enzymes of the yeast arginine biosynthesis pathway, they showed no significant similarity to their prokaryotic equivalents. The measured synthase activity did not increase with the number of ARG2 gene copies unless the number of ARG5,6 gene copies was increased similarly. ARG5,6 encodes a precursor that is maturated in the mitochondria into acetylglutamate kinase and acetylglutamyl-phosphate reductase, catalyzing the second and third steps in the pathway. The results imply that the synthase must interact stoichiometrically in vivo with the kinase, the reductase, or both to be active. Results obtained with synthetic ARG5 and ARG6 genes suggested that both the kinase and the reductase could be needed. This situation, which has completely escaped notice in yeast until now, is reminiscent of the observation in Neurospora crassa that nonsense arg-6 kinase/reductase mutants lack synthase activity (Hinde, R. W., Jacobson, J. A., Weiss, R. L., and Davis, R. H. (1986) J. Biol. Chem. 261, 5848-5852). In immunoprecipitation experiments, hemagglutinin-tagged synthase coprecipitated with a protein proven by microsequencing to be the kinase. Western blot analyses showed that the synthase has reduced stability in the absence of the kinase/reductase. Our data demonstrate the existence of a new yeast arginine metabolon involving at least the first two, and possibly the first three, enzymes of the pathway. Hypotheses regarding the biological significance of this interaction are discussed.	Free Univ Brussels VIB, Dept Microbiol, COOVI, CERIA, B-1070 Brussels, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Crabeel, M (corresponding author), Free Univ Brussels VIB, Dept Microbiol, COOVI, CERIA, E Grysonlaan 1, B-1070 Brussels, Belgium.	merabeel@vub.ac.be						BOONCHIRD C, 1991, EUR J BIOCHEM, V199, P325, DOI 10.1111/j.1432-1033.1991.tb16128.x; Crabeel M, 1997, EUR J BIOCHEM, V250, P232, DOI 10.1111/j.1432-1033.1997.0232a.x; Crabeel M, 1996, J BIOL CHEM, V271, P25011, DOI 10.1074/jbc.271.40.25011; CUNIN R, 1986, MICROBIOL REV, V50, P193; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DEDEKEN RH, 1962, BIOCHEM BIOPH RES CO, V8, P462, DOI 10.1016/0006-291X(62)90297-8; DUBOIS E, 1991, MOL CELL BIOL, V11, P2162, DOI 10.1128/MCB.11.4.2162; GESSERT SF, 1994, J BIOL CHEM, V269, P8189; GRISOLIA S, 1953, J BIOL CHEM, V204, P753; HILGER F, 1973, J GEN MICROBIOL, V75, P33, DOI 10.1099/00221287-75-1-33; HINDE RW, 1986, J BIOL CHEM, V261, P5848; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; JAUNIAUX JC, 1987, THESIS U LIBRE BRUXE; KIM JH, 1995, MOL CELLS, V5, P461; MESSENGUY F, 1976, J BACTERIOL, V22, P277; MINET M, 1971, THESIS U LIBRE BRUXE; MOUNTAIN A, 1986, J BACTERIOL, V165, P1026, DOI 10.1128/jb.165.3.1026-1028.1986; Negredo A, 1997, MICROBIOL-UK, V143, P297, DOI 10.1099/00221287-143-2-297; SHIGESADA K, 1978, EUR J BIOCHEM, V84, P285, DOI 10.1111/j.1432-1033.1978.tb12167.x; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; Vandenbol M, 1999, YEAST, V15, P1411, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1411::AID-YEA463>3.0.CO;2-M; VANHUFFEL C, 1992, EUR J BIOCHEM, V205, P33; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wattiez R, 2000, ELECTROPHORESIS, V21, P2703, DOI 10.1002/1522-2683(20000701)21:13<2703::AID-ELPS2703>3.3.CO;2-N; WIPF B, 1979, J BACTERIOL, V140, P874, DOI 10.1128/JB.140.3.874-880.1979; WOLF EC, 1980, J BIOL CHEM, V255, P9189; Yu YG, 1996, MOL MICROBIOL, V22, P545, DOI 10.1046/j.1365-2958.1996.1321494.x	28	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42869	42880		10.1074/jbc.M103732200	http://dx.doi.org/10.1074/jbc.M103732200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553611	hybrid			2022-12-25	WOS:000172169300033
J	Kampfer, S; Windegger, M; Hochholdinger, F; Schwaiger, W; Pestell, RG; Baier, G; Grunicke, HH; Uberall, F				Kampfer, S; Windegger, M; Hochholdinger, F; Schwaiger, W; Pestell, RG; Baier, G; Grunicke, HH; Uberall, F			Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; SMOOTH-MUSCLE-CELLS; RHO FAMILY PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; INDEPENDENT ACTIVATION; BINDING PROTEIN; T-LYMPHOCYTES; PKC-EPSILON; MAP KINASE; GROWTH	Transcriptional activation of the cyclin D1 by oncogenic Ras appears to be mediated by several pathways leading to the activation of multiple transcription factors which interact with distinct elements of the cyclin D1 promoter. The present investigations revealed that cyclin D1 induction by transforming Ha-Ras is MEK and Rac-dependent and requires the PKC isotypes epsilon, lambda, and zeta, but not cPKC-alpha. This conclusion is based on observations indicating that cyclin D1 induction by transforming Ha-Ras was depressed in a dose-dependent manner by PD98059, a selective inhibitor of the mitogen-activated kinase kinase MEK-1, demonstrating that Ha-Ras employs extracellular signal-regulated kinases (ERKs) for signal transmission to the cyclin D1 promoter. Evidence is presented that PKC isotypes epsilon and zeta, but not lambda are required for the Ras-mediated activation of ERKs. Expression of kinase-defective, dominant negative (DN) mutants of nPKC-epsilon or aPKC-zeta inhibit ERK activation by constitutively active Raf-1. Phosphorylation within the TEY motif and subsequent activation of ERKs by constitutively active MEK-1 was significantly inhibited by DN aPKC-zeta, indicating that aPKC-zeta functions downstream of MEK-1 in the pathway leading to cyclin D1 induction. In contrast, TEY phosphorylation induced by constitutively active MEK-1 was not effected by nPKC-epsilon, suggesting another position for this kinase within the cascade investigated. Transformation by oncogenic Ras requires activation of several Ras effector pathways which may be PKC-dependent and converge on the cyclin D1 promoter. Therefore, we investigated a role for PKC isotypes in the Ras-Rac-mediated transcriptional regulation of cyclin D1. We have been able to reveal that cyclin D1 induction by oncogenic Ha-Ras is Rac-dependent and requires the PKC isotypes epsilon, lambda, and zeta, but not cPKC-alpha. Evidence is presented that aPKC-lambda acts upstream of Rac, between Ras and Rac, whereas the PKC isotypes epsilon and zeta act downstream of Rac and are required for the activation of ERKs.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Albert Einstein Coll Med, Bronx, NY 10461 USA; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria	University of Innsbruck; Yeshiva University; Albert Einstein College of Medicine; University of Innsbruck	Uberall, F (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Florian.Ueberall@uibk.ac.at	Baier, Gottfried/E-8755-2012	Baier, Gottfried/0000-0002-2085-8325				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HERBER B, 1994, ONCOGENE, V9, P1295; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MITEV V, 1995, BIOCHEM BIOPH RES CO, V208, P245, DOI 10.1006/bbrc.1995.1330; Ping PP, 1999, AM J PHYSIOL-HEART C, V276, pH1468, DOI 10.1152/ajpheart.1999.276.5.H1468; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Skaletz-Rorowski A, 1999, ARTERIOSCL THROM VAS, V19, P1608, DOI 10.1161/01.ATV.19.7.1608; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	52	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42834	42842		10.1074/jbc.M102047200	http://dx.doi.org/10.1074/jbc.M102047200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551901	hybrid			2022-12-25	WOS:000172169300028
J	Madril, AC; Johnson, RE; Washington, MT; Prakash, L; Prakash, S				Madril, AC; Johnson, RE; Washington, MT; Prakash, L; Prakash, S			Fidelity and damage bypass ability of Schizosaccharomyces pombe Eso1 protein, comprised of DNA polymerase eta and sister chromatid cohesion protein Ctf7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; THYMINE-THYMINE DIMER; XERODERMA-PIGMENTOSUM; POSTREPLICATION REPAIR; REPLICATION; YEAST; HYPERMUTABILITY; PHOTOPRODUCTS; PROCESSIVITY; REQUIREMENT	DNA polymerase eta (Pol eta) functions in error-free bypass of ultraviolet light-induced DNA lesions, and mutational inactivation of Pol eta in humans causes the cancer prone syndrome, the variant form of xeroderma pigmentosum (XPV). Both Saccharomyces cerevisiae and human Pol eta efficiently insert two adenines opposite the two thymines of a cyclobutane pyrimidine dimer. Interestingly, in the fission yeast Schizosaccharomyces pombe, the eso1(+) encoded protein is comprised of two domains, wherein the NH2 terminus is highly homologous to Pol eta, and the COOH terminus is highly homologous to the S. cerevisiae Ctf`7 protein which is essential for the establishment of sister chromatid cohesion during S phase. Here we characterize the DNA polymerase activity of S. pombe GST-Eso1 fusion protein and a truncated version containing only the Pol eta domain. Both proteins exhibit a similar DNA polymerase activity with a low processivity, and steady-state kinetic analyses show that on undamaged DNA, both proteins misincorporate nucleotides with frequencies of similar to 10(-2) to 10(-3). We also examine the two proteins for their ability to replicate a cyclobutane pyrimidine dimer-containing DNA template and find that both proteins replicate through the lesion equally well. Thus, fusion with Ctf`7 has no significant effect on the DNA replication or damage bypass properties of Pol eta. The possible role of Ctf`7 fusion with Pol eta in the replication of Cohesin-bound DNA sequences is discussed.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Blocker Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261; Washington, Todd/0000-0001-8680-2992				BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BOYER JC, 1990, CANCER RES, V50, P2593; CLEAVER JE, 1981, CYTOGENET CELL GENET, V31, P188, DOI 10.1159/000131646; Creighton S, 1995, METHOD ENZYMOL, V262, P232; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1997, GENETICS, V147, P1557; MODRICH P, 1975, J BIOL CHEM, V250, P5508; Pavlov YI, 2001, MUTAT RES-FUND MOL M, V478, P129, DOI 10.1016/S0027-5107(01)00131-2; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; VONHIPPEL PH, 1994, ANN NY ACAD SCI, V726, P118; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001	31	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42857	42862		10.1074/jbc.M106917200	http://dx.doi.org/10.1074/jbc.M106917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551952	hybrid			2022-12-25	WOS:000172169300031
J	English, WR; Holtz, B; Vogt, G; Knauper, V; Murphy, G				English, WR; Holtz, B; Vogt, G; Knauper, V; Murphy, G			Characterization of the role of the "MT-loop" - An eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT LINEAR PLOT; GELATINASE-A; TISSUE INHIBITORS; DOMAIN; IDENTIFICATION; STROMELYSIN-3; PROTEOLYSIS; EXPRESSION; SUBSTRATE; COMPLEX	Progelatinase A (proGLA) activation is thought to be initiated almost exclusively by the type I transmembrane members of the membrane type matrix metalloproteinase family (MT-MMP): MT1, -2, -3, and -5-MMP (MMP14, -15, -16, and -24). One difference between these enzymes and the other MMP family members is the insertion of eight amino acids between strands beta II and III in the catalytic domain. In MT1-MMP, the best characterized of these enzymes to date, these residues consist of (163)PYAYIREG(170). To investigate the role of this region of MT1-MMP on its catalytic activities, we have made a variety of mutations and deletions in both soluble and membrane-bound forms of the enzyme. Characterization of the activity of the soluble forms toward peptides and fibrinogen revealed that neither mutation nor deletion of residues 163-170 significantly impaired catalytic function, suggesting these residues have little influence on conformation of the active site cleft. Equally none of the mutants showed significant differences in K-l(app) for the N-terminal inhibitory domain of TIMP2, again indicating that mutation or deletion of resides 163-170 has no major effect on the overall topology of the active site of MT1-MMP. However, characterization of the kinetics of activation of proGLA with and without its gelatin binding region by the mutants generated have shown that efficient activation of proGLA is, at least in part, through an interaction with residues 163-170 of MT1-MMP. The expression, localization, and processing from the 63- to the 60/45-kDa forms of wild-type and key mutant forms of MT1-MMP were also examined by transient transfection in Chinese hamster ovary cells, but no differences were observed. Processing and activation of proGLA was also examined in transiently transfected cells. All the mutants examined were able process proGLA but, as found with the soluble forms, were kinetically impaired when compared with wild-type MT1-MMP.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Univ York, Dept Bion Bone & Joint Res, York YO10 5YW, N Yorkshire, England	University of East Anglia; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of York - UK	English, WR (corresponding author), Univ E Anglia, Sch Biol Sci, Univ Plain, Norwich NR4 7TJ, Norfolk, England.	w.english@uea.ac.uk		Knauper, Vera/0000-0002-3965-9924; English, William/0000-0003-3024-2441				Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; CORNISHB.A, 1974, BIOCHEM J, V139, P721, DOI 10.1042/bj1390721; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Ha HY, 2001, CANCER RES, V61, P984; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Holtz B, 1999, BIOCHEMISTRY-US, V38, P12174, DOI 10.1021/bi990876m; Imper V, 1998, BIOL EXTRAC, P219; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Llano E, 1999, CANCER RES, V59, P2570; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; Murphy G, 2000, FIBRINOLYSIS PROTEOL, V14, P165, DOI 10.1054/fipr.2000.0068; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nagase H, 1998, Cell Res, V8, P179; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Sang Q X, 1998, Cell Res, V8, P171; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Stanton H, 1998, J CELL SCI, V111, P2789; Terp GE, 2000, J BIOMOL STRUCT DYN, V17, P933, DOI 10.1080/07391102.2000.10506582; Velasco G, 2000, CANCER RES, V60, P877; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; Woessner J.F., 2000, PROTEIN PROFILE SER; Zhang YN, 1996, J BIOL CHEM, V271, P8015, DOI 10.1074/jbc.271.14.8015; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	44	60	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42018	42026		10.1074/jbc.M107783200	http://dx.doi.org/10.1074/jbc.M107783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11555661	hybrid			2022-12-25	WOS:000172450400065
J	Kishore, R; McMullen, MR; Nagy, LE				Kishore, R; McMullen, MR; Nagy, LE			Stabilization of tumor necrosis factor alpha mRNA by chronic ethanol - Role of A + U-rich elements and p38 mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ALCOHOLIC LIVER-INJURY; AU-RICH ELEMENTS; SIGNAL-TRANSDUCTION; POSTTRANSCRIPTIONAL STABILIZATION; UNTRANSLATED REGION; SMOOTH-MUSCLE; P38; STABILITY; TRANSCRIPTION	Increased expression of tumor necrosis factor a (TNF alpha) in response to chronic ethanol has been implicated in the pathogenesis of alcoholic liver disease. However, the molecular mechanisms by which ethanol increases the levels of TNF alpha are not well characterized. Utilizing Kupffer cells isolated from rats fed an ethanol containing diet and a murine macrophage cell line, RAW264.7, exposed to ethanol in culture, we have demonstrated that exposure to chronic ethanol results in an enhanced expression of lipopolysaccharide (LPS)-induced TNFa. While chronic ethanol had no effect on the rate of LPS-induced TNF alpha transcription as measured by nuclear run-on experiments, TNF alpha mRNA half-life was increased by chronic ethanol. Chronic ethanol also potentiated the activation of LPS-induced p38 mitogen-activated protein (MAP) kinase in Kupffer cells, as well as in RAW264.7 cells. Specific inhibition of p38 MAP kinase activation by SB203580 in Kupffer cells or by overexpression of dominant negative p38 MAP kinase in RAW264.7 cells blocked ethanol-mediated TNF alpha mRNA stabilization. Furthermore, using chimeric reporter constructs, we have shown that A + U-rich elements in the W-untranslated region of TNFa mRNA are not sufficient to impart ethanol-mediated stabilization on TNF alpha mRNA.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University	Nagy, LE (corresponding author), Case Western Reserve Univ, Dept Nutr, 2123 Abington Rd,Rm201, Cleveland, OH 44106 USA.	len2@po.cwru.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA011975, R01AA011975] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 11975] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADACHI Y, 1995, GASTROENTEROLOGY, V108, P218, DOI 10.1016/0016-5085(95)90027-6; AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Aldred A, 1999, AM J PHYSIOL-GASTR L, V276, pG98, DOI 10.1152/ajpgi.1999.276.1.G98; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEUTLER B, 1995, J INVEST MED, V43, P227; BICKEL M, 1990, J IMMUNOL, V145, P840; BJARNASON I, 1984, LANCET, V1, P179; BODE C, 1987, J HEPATOL, V4, P8, DOI 10.1016/S0168-8278(87)80003-X; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FUKUI H, 1991, J HEPATOL, V12, P162, DOI 10.1016/0168-8278(91)90933-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hanford DS, 1996, MOL ENDOCRINOL, V10, P1719, DOI 10.1210/me.10.12.1719; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; HONCHEL R, 1990, PROG LEUC B, V10, P171; Huang JS, 1999, ARCH BIOCHEM BIOPHYS, V366, P131, DOI 10.1006/abbi.1999.1203; Jacob CO, 1996, J IMMUNOL, V156, P3043; JACOB CO, 1992, IMMUNOL TODAY, V13, P122, DOI 10.1016/0167-5699(92)90107-I; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LIEBER CS, 1982, ALCOHOL CLIN EXP RES, V6, P523, DOI 10.1111/j.1530-0277.1982.tb05017.x; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Mathurin P, 2000, HEPATOLOGY, V32, P1008, DOI 10.1053/jhep.2000.19621; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Nanbu R, 1997, EUR J BIOCHEM, V247, P169, DOI 10.1111/j.1432-1033.1997.00169.x; Pauli Urs, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P323; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rovin BH, 1999, CYTOKINE, V11, P118, DOI 10.1006/cyto.1998.0409; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; SHALABY MR, 1989, TRANSPLANTATION, V47, P1057, DOI 10.1097/00007890-198906000-00028; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Short S, 2000, J BIOL CHEM, V275, P12963, DOI 10.1074/jbc.275.17.12963; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tebo JM, 2000, J BIOL CHEM, V275, P12987, DOI 10.1074/jbc.275.17.12987; Thurman RG, 1998, AM J PHYSIOL-GASTR L, V275, pG605, DOI 10.1152/ajpgi.1998.275.4.G605; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Wang YZ, 2000, J BIOL CHEM, V275, P22550, DOI 10.1074/jbc.M909785199; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Xu KM, 2000, J BIOL CHEM, V275, P7604, DOI 10.1074/jbc.275.11.7604; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200; Zeldin G, 1996, ALCOHOL CLIN EXP RES, V20, P1639, DOI 10.1111/j.1530-0277.1996.tb01710.x	62	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41930	41937		10.1074/jbc.M107181200	http://dx.doi.org/10.1074/jbc.M107181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551956	hybrid			2022-12-25	WOS:000172450400052
J	Wang, JF; Zhang, XF; Groopman, JE				Wang, JF; Zhang, XF; Groopman, JE			Stimulation of beta(1) integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; ALPHA(V)BETA(3) INTEGRIN; HEREDITARY LYMPHEDEMA; LYMPHATIC ENDOTHELIUM; FOCAL ADHESIONS; VEGF RECEPTOR-3; KINASE; ANGIOGENESIS; ACTIVATION; LIGAND	Interactions between integrins and tyrosine kinase receptors can modulate a variety of cell functions. We observed a cooperative interaction between the beta(1) integrin and vascular endothelial growth factor receptor-3 (VEGFR-3 or Flt4) that appeared to be required for cell migration. By using VEGFR-3-transfected 293 cells (293/VEGFR-3) or primary dermal microvascular endothelial cells (DMEC), we found that stimulation with either soluble or immobilized extracellular matrix (ECM) proteins, collagen or fibronectin (FN), resulted in the increased tyrosine phosphorylation of VEGFR-3 in the absence of a cognate ligand. This increased tyrosine phosphorylation of VEGFR-3 was diminished by pretreatment with a blocking antibody against the beta(1) integrin. Cross-linking with anti-beta(1) integrin antibody induced a similar degree of tyrosine phosphorylation of VEGFR-3. Stimulation with collagen or FN induced an association between beta(1) integrin and VEGFR-3 in both 293/VEGFR-3 and primary DMEC cells. Collagen or FN-induced tyrosine phosphorylation of VEGFR-3 was inhibited by treatment with cytochalasin D, an inhibitor of actin polymerization. Collagen or FN was able to induce the migration of 293/VEGFR-3 or DMEC cells to a limited extent. However, migration was dramatically enhanced when a gradient of the cognate ligand, VEGF-D, was added. VEGF-D failed to induce cell migration in the absence of ECM proteins. Introducing a mutation at the kinase domain of VEGFR-3 or treatment with blocking antibody against either VEGFR-3 or beta(1) integrin inhibited cell migration induced by ECM and VEGF-D, indicating that signals from both beta(1) integrin and VEGFR-3 are required for this cell function.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@caregroup.harvard.edu			NHLBI NIH HHS [HL 61940, HL 53745] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053745, R01HL061940] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Aplin AE, 1999, J CELL SCI, V112, P695; APRELIKOVA O, 1992, CANCER RES, V52, P746; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Ferrell RE, 1998, HUM MOL GENET, V7, P2073, DOI 10.1093/hmg/7.13.2073; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GALLAND F, 1993, ONCOGENE, V8, P1233; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karpanen T, 2001, CANCER RES, V61, P1786; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; POLVERINI PJ, 1995, CRIT REV ORAL BIOL M, V6, P230, DOI 10.1177/10454411950060030501; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Varner J A, 1997, EXS, V79, P361; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Woodard AS, 1998, J CELL SCI, V111, P469; Yu X, 2000, J CELL SCI, V113, P2139	58	97	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41950	41957		10.1074/jbc.M101370200	http://dx.doi.org/10.1074/jbc.M101370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553610	hybrid			2022-12-25	WOS:000172450400055
J	Zhang, YG; Liu, GM; Dong, ZG				Zhang, YG; Liu, GM; Dong, ZG			MSK1 and JNKs mediate phosphorylation of STAT3 in UVA-irradiated mouse epidermal JB6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; SERINE PHOSPHORYLATION; MAP KINASE; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; IFN-GAMMA; DEPENDENT ACTIVATION; AP-1 TRANSACTIVATION	Phosphorylation of Tyr(705) and Ser(727) of signal transducer and activator of transcription 3 (STAT3) are known to be required for maximal activation by diverse stimuli. Tyr(705) phosphorylation is generally accepted to be mediated by the Janus kinase family. But the mechanism for STAT3 (Ser(727)) phosphorylation is not well understood. Here, we provide evidence that LTVA-induced phosphorylation of STAT3 at Ser(727) is inhibited by pretreatment of JB6 cells with PD98059 or SB202190. Phosphorylation of STAT3 (Ser(727)) is also markedly prevented by a dominant negative mutant of ERK2, c-Jun N-terminal kinase 1 (JNK1), or p38 kinase and in knockout Jnk1(-/-) or Jnk2(-/-) cells. Furthermore, STAT3 (Ser(727)) phosphorylation is suppressed by C- or N-terminal "kinase-dead" mutants of mitogen- and stress-activated protein kinase 1 (MSK1), a downstream kinase of ERKs and p38 kinase, and H89, a potential MSK1 inhibitor. In vitro experiments showed that active MSK1 and JNKs, but not ERKs or p38 kinase, phosphorylate STAT3 (Ser(727)). Additionally, the role of MAPKs in mediating UVA-stimulated DNA binding activity of STAT3 was investigated. Overall, these results suggest that UVA-induced Ser(727) phosphorylation of STAT3 may occur through MSK1 and JNKs.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Zhang, Yiguo/0000-0003-3910-2779	NCI NIH HHS [CA77646, CA74916, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074916, R01CA081064, R01CA077646, R37CA081064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Bos M, 1997, CLIN CANCER RES, V3, P2099; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Chen NY, 2001, CANCER RES, V61, P3908; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; Frank DA, 1999, MOL MED, V5, P432; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Griffiths HR, 1998, CRIT REV CL LAB SCI, V35, P189, DOI 10.1080/10408369891234192; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Janknecht R, 1999, SCIENCE, V284, P443, DOI 10.1126/science.284.5413.443; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maziere C, 2000, FREE RADICAL BIO MED, V28, P1430, DOI 10.1016/S0891-5849(00)00264-1; Moan J, 1999, PHOTOCHEM PHOTOBIOL, V70, P243, DOI 10.1111/j.1751-1097.1999.tb07995.x; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sartor CI, 1997, CANCER RES, V57, P978; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schindler C, 2000, ADV PHARMACOL, V47, P113; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 2000, J BIOL CHEM, V275, P27634; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; Woodhead A D, 1999, J Epidemiol, V9, pS102; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	79	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42534	42542		10.1074/jbc.M106044200	http://dx.doi.org/10.1074/jbc.M106044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553624	hybrid			2022-12-25	WOS:000172450400128
J	Glassford, J; Holman, M; Banerji, L; Clayton, E; Klaus, GGB; Turner, M; Lam, EWF				Glassford, J; Holman, M; Banerji, L; Clayton, E; Klaus, GGB; Turner, M; Lam, EWF			Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR VAV; T-CELL RECEPTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; DEFICIENT MICE; GUANOSINE TRIPHOSPHATASES; RETINOBLASTOMA PROTEIN; MEDIATED PROLIFERATION; D1 EXPRESSION	B lymphocytes from mice null for the Rho-family guanine-nucleotide exchange factor, Vav, are defective in their ability to proliferate in response to BCR crosslinking, but are able to proliferate normally in response to LPS. In addition, they have a depletion of CD5(+) (B1) lymphocytes and defective IgG class switching. This phenotype is reminiscent of that observed in mice null for the cell cycle regulatory protein, cyclin D2. We demonstrate here that the inability of vav(-/-) B cells to proliferate in response to BCR ligation is due to an inability to induce cyclin D2. In addition, we show that the proliferative defect of these cells occurs after the cells have entered early Gl phase. Analyses of potential downstream signaling intermediates revealed differential activation of the stress-activated MAP kinases in the absence of Vav, normal activation of the ERK, MAPK, and phosphatidylinositol 3-kinase pathways, and defective intracellular calcium mobilization. We further demonstrate that intracellular calcium homeostasis is required for cyclin D2 induction, implicating a possible link with the defective calcium response of vav(-/-) B cells and their inability to induce cyclin D2.	Hammersmith Hosp, Imperial Coll, Sch Med, CRC Labs, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, Sect Canc Cell Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Sect Virol & Cell Biol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Ludwig Inst Canc Res, London W2 1PG, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Babraham Inst, Lab Lymphocyte Signalling & Dev, Mol Immunol Programme, Cambridge CB2 4AT, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; MRC National Institute for Medical Research; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Lam, EWF (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, CRC Labs, Du Cane Rd, London W12 0NN, England.		Lam, Eric W-F/AAW-8566-2020; Turner, Martin/N-9976-2014	Lam, Eric W-F/0000-0003-1274-3576; Turner, Martin/0000-0002-3801-9896				Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Bachmann MF, 1999, J IMMUNOL, V163, P137; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Gulbranson-Judge A, 1999, EUR J IMMUNOL, V29, P477, DOI 10.1002/(SICI)1521-4141(199902)29:02&lt;477::AID-IMMU477&gt;3.0.CO;2-V; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Johnson-Leger C, 1998, J IMMUNOL, V161, P4618; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee CH, 1999, IUBMB LIFE, V48, P585, DOI 10.1080/152165499306450; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Page K, 2001, AM J PHYSIOL-LUNG C, V280, pL955, DOI 10.1152/ajplung.2001.280.5.L955; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Ramakrishnan M, 1998, AM J RESP CELL MOL, V18, P736, DOI 10.1165/ajrcmb.18.6.3152; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Sakata N, 2000, CELL IMMUNOL, V201, P109, DOI 10.1006/cimm.2000.1645; Salmon RA, 1997, J IMMUNOL, V159, P5309; Salojin KV, 1999, J IMMUNOL, V163, P844; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Simon VR, 2001, CELL PROLIFERAT, V34, P15, DOI 10.1046/j.1365-2184.2001.00192.x; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Solvason N, 1996, J EXP MED, V184, P407, DOI 10.1084/jem.184.2.407; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Swart JM, 2000, BIOCHEM BIOPH RES CO, V276, P417, DOI 10.1006/bbrc.2000.3489; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Terada Y, 1999, KIDNEY INT, V56, P1258, DOI 10.1046/j.1523-1755.1999.00704.x; TOODY GM, 2001, NAT IMMUNOL, V2, P542; Turchi L, 2000, EXP CELL RES, V261, P220, DOI 10.1006/excr.2000.5060; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Williams CD, 1997, BLOOD, V90, P194; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	61	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41040	41048		10.1074/jbc.M105305200	http://dx.doi.org/10.1074/jbc.M105305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546804	hybrid			2022-12-25	WOS:000171925600090
J	Rizos, H; Puig, S; Badenas, C; Malvehy, J; Darmanian, AP; Jimenez, L; Mila, M; Kefford, RF				Rizos, H; Puig, S; Badenas, C; Malvehy, J; Darmanian, AP; Jimenez, L; Mila, M; Kefford, RF			A melanoma-associated germline mutation in exon 1 beta inactivates p14ARF	ONCOGENE			English	Article						p14ARF; p16(INK4a); melanoma; germline mutation	CUTANEOUS MALIGNANT-MELANOMA; NUCLEOLAR LOCALIZATION; TUMOR SUPPRESSION; CDKN2A MUTATIONS; P53; MDM2; P19(ARF); GENE; LOCUS; P14(ARF)	The INK4a/ARF locus encodes the cyclin dependent kinase inhibitor, p16(INK4a) and the p53 activator, p14ARF. These two proteins have an independent first exon (exon 1 alpha and exon 1 beta, respectively) but share exons 2 and 3 and are translated in different reading frames. Germline mutations in this locus are associated with melanoma susceptibility in 20-40% of multiple case melanoma families. Although most of these mutations specifically inactivate p16(INK4a), more than 40% of the INK4a/ARF alterations located in exon 2, affect both p16(INK4a) and p14ARF. We now report a 16 base pair exon 1 beta germline insertion specifically altering p14ARF, but not p16(INK4a), in an individual with multiple primary melanomas. This mutant p14ARF, 60ins16, was restricted to the cytoplasm, did not stabilize p53 and was unable to arrest the growth of a p53 expressing melanoma cell line. This is the first example of an exon 1 beta mutation that inactivates p14ARF, and thus implicates a role for this tumour suppressor in melanoma predisposition.	Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; Univ Barcelona, IDIBAPS, Hosp Clin, E-08036 Barcelona, Spain	University of Sydney; Westmead Institute for Medical Research; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Rizos, H (corresponding author), Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.		Rizos, Helen/AAE-5010-2020; Puig, Susana/AAB-2091-2020; Badenas, Celia/ABH-5480-2020	Rizos, Helen/0000-0002-2094-9198; Puig, Susana/0000-0003-1337-9745; Badenas, Celia/0000-0002-0621-0477; Mila, Montserrat/0000-0002-7906-0916; malvehy, josep/0000-0002-6998-914X; Kefford, Richard/0000-0001-9251-9229				Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Dracopoli NC, 1996, CANCER SURV, V26, P115; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Newcomb EW, 2000, HUM PATHOL, V31, P115, DOI 10.1016/S0046-8177(00)80207-5; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Puig S, 2000, MELANOMA RES, V10, P231, DOI 10.1097/00008390-200010030-00004; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruiz A, 1998, INT J CANCER, V76, P312, DOI 10.1002/(SICI)1097-0215(19980504)76:3<312::AID-IJC4>3.3.CO;2-B; Ruiz A, 1999, J MED GENET, V36, P490; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	37	142	146	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5543	5547		10.1038/sj.onc.1204728	http://dx.doi.org/10.1038/sj.onc.1204728			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571653				2022-12-25	WOS:000170781100016
J	Gratacap, MP; Payrastre, B; Nieswandt, B; Offermanns, S				Gratacap, MP; Payrastre, B; Nieswandt, B; Offermanns, S			Differential regulation of Rho and Rac through heterotrimeric G-proteins and cyclic nucleotides.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; STRESS FIBER FORMATION; PLATELET SHAPE CHANGE; BETA-GAMMA-SUBUNITS; SMALL GTPASE RHO; THROMBOXANE A(2); MYOSIN PHOSPHORYLATION; RECEPTOR LIGATION; G(12) FAMILY; ACTIVATION	Platelets were used to study the activation of Rho and Rac through G-protein-coupled receptors and its regulation by cyclic nucleotides. The thromboxane A(2) (TXA(2)) mimetic U46619 rapidly activated both small GTPases independently of integrin alpha (IIb)beta (3) activation. U46619, which leads to the activation of G(12)/G(13) and G(q) did not induce Rac activation in G alpha (q)-deficient platelets but was able to activate Rho, to stimulate actin polymerization and phosphatidylinositol 4,5-bisphosphate formation, and to induce shape change. Rac activation by U46619 in wild-type platelets could be blocked by chelation of intracellular Ca2+ and was partially sensitive to apyrase and AR-C69931MX an antagonist of the Gi-coupled ADP receptor. Cyclic AMP, which completely blocks platelet function, inhibited the U46619-induced activation of Gq and G(12)/G(13) as well as of Rac and Rho. In contrast, cGMP, which has no effect on platelet shape change blocked only activation of G(q) and Rac. These data demonstrate that Rho and Rac are differentially regulated through heterotrimeric G-proteins. The G(12)/G(13)-mediated Rho activation is involved in the shape change response, whereas Rac is activated through Gq and is not required for shape change. Cyclic AMP and cGMP differentially interfere with U46619-induced Rho and Rac activation at least in part by selective effects on the regulation of individual G-proteins through the TXA2 receptor.	Heidelberg Univ, Inst Pharmakol, D-69120 Heidelberg, Germany; Hop Purpan, INSERM Unite 326, F-31059 Toulouse, France; Univ Witten Herdecke, Dept Mol Oncol, D-42117 Wuppertal, Germany	Ruprecht Karls University Heidelberg; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Witten Herdecke University	Offermanns, S (corresponding author), Heidelberg Univ, Inst Pharmakol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	stefan.offermanns@urz.uni-heidelberg.de	; Offermanns, Stefan/L-3313-2017	, Bernard/0000-0002-8693-0190; Gratacap, Marie-Pierre/0000-0003-4362-6401; Offermanns, Stefan/0000-0001-8676-6805				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Azim AC, 2000, BLOOD, V95, P959, DOI 10.1182/blood.V95.3.959.003k22_959_964; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Belisle B, 2000, J BIOL CHEM, V275, P26225, DOI 10.1074/jbc.M002743200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GEIGER J, 1994, AM J PHYSIOL, V267, pC236, DOI 10.1152/ajpcell.1994.267.1.C236; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Haslam RJ, 1999, THROMB HAEMOSTASIS, V82, P412; Herault JP, 1998, THROMB HAEMOSTASIS, V79, P383, DOI 10.1055/s-0037-1614996; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Hofmann F, 2000, J CELL SCI, V113, P1671; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; MALMSTEN C, 1975, P NATL ACAD SCI USA, V72, P1446, DOI 10.1073/pnas.72.4.1446; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; MATSUOKA I, 1989, Japanese Journal of Pharmacology, V49, p142P; MENSHIKOV MY, 1993, EUR J PHARM-MOLEC PH, V245, P281, DOI 10.1016/0922-4106(93)90108-L; MORII N, 1992, J BIOL CHEM, V267, P20921; MORINELLI TA, 1983, BLOOD, V61, P41; Nieswandt B, 2000, BLOOD, V96, P2520; Nishioka H, 2001, BIOCHEM BIOPH RES CO, V280, P970, DOI 10.1006/bbrc.2001.4237; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Pulcinelli FM, 1998, FEBS LETT, V435, P115, DOI 10.1016/S0014-5793(98)01049-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Ueda H, 2000, J BIOL CHEM, V275, P2098, DOI 10.1074/jbc.275.3.2098; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; WURZINGER LJ, 1990, ADV ANAT EMBRYOL CEL, V120, P1	70	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47906	47913		10.1074/jbc.M104442200	http://dx.doi.org/10.1074/jbc.M104442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11560922	hybrid			2022-12-25	WOS:000172927000026
J	Chellaiah, MA; Biswas, RS; Yuen, D; Alvarez, UM; Hruska, KA				Chellaiah, MA; Biswas, RS; Yuen, D; Alvarez, UM; Hruska, KA			Phosphatidylinositol 3,4,5-trisphosphate directs association of Src homology 2-containing signaling proteins with gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FOCAL ADHESION KINASE; PHOSPHATASE PTP-PEST; BONE-RESORPTION; SH3 DOMAINS; CELL-MIGRATION; C-SRC; OSTEOCLAST CYTOSKELETON; CYTOPLASMIC DOMAIN; INTEGRIN FUNCTIONS; ACTIN-FILAMENTS	Podosomes are adhesion structures in osteoclasts and are structurally related to focal adhesions mediating cell motility during bone resorption. Here we show that gelsolin coprecipitates some of the focal adhesion-associated proteins such as c-Src, phosphoinositide 3-kinase (PI3K), p130(Cas), focal adhesion kinase, integrin alpha (v)beta (3), vinculin, talin, and paxillin. These proteins were inducibly tyrosine-phosphorylated in response to integrin activation by osteopontin. Previous studies have defined unique biochemical properties of gelsolin related to phosphatidylinositol 3,4,5-trisphosphate in osteoclast podosomes, and here we demonstrate phosphatidylinositol 3,4,5-trisphosphate/gelsolin function in mediating organization of the podosome signaling complex. Overlay and GST pull-down assays demonstrated strong phosphatidylinositol 3,4,5-trisphosphate-PI3K interactions based on the Src homology 2 domains of PI3K. Furthermore, lipid extraction of lysates from activated osteoclasts eliminated interaction between gelsolin, c-Src, PI3K, and focal adhesion kinase despite equal amounts of gelsolin in both the lipid-extracted and unextracted experiment. The cytoplasmic protein tyrosine phosphatase (PTP)-proline-glutamic acid-serine-threonine amino acid sequences (PEST) was also found to be associated with gelsolin in osteoclast podosomes and with stimulation of alpha (v)beta (3)-regulated phosphorylation of PTP-PEST. We conclude that gelsolin plays a key role in recruitment of signaling proteins to the plasma membrane through phospholipid-protein interactions and by regulation of their phosphorylation status through its association with PTP-PEST. Because both gelsolin deficiency and PI3K inhibition impair bone resorption, we conclude that phosphatidylinositol 3,4,5-trisphosphate-based protein interactions are critical for osteoclast function.	Univ Maryland, Dept Oral & Craniofacial Biol Sci, Baltimore, MD 21201 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	University System of Maryland; University of Maryland Baltimore; Washington University (WUSTL)	Chellaiah, MA (corresponding author), Univ Maryland, Dept Oral & Craniofacial Biol Sci, 666 W Baltimore St, Baltimore, MD 21201 USA.	mac001@dental.umaryland.edu			NIAMS NIH HHS [AR 46292, AR 41677] Funding Source: Medline; NIDDK NIH HHS [DK 09976] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR046292, R01AR041677, R01AR046292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Baron Roland, 1993, P445; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; De Deyne PG, 1998, J CELL SCI, V111, P2729; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gopalakrishna P, 2000, J CELL BIOCHEM, V77, P517, DOI 10.1002/(SICI)1097-4644(20000615)77:4<517::AID-JCB1>3.3.CO;2-Y; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Gupta A, 1999, J BONE MINER RES, V14, pS182; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hawiger J, 1997, CURR OPIN IMMUNOL, V9, P189, DOI 10.1016/S0952-7915(97)80134-3; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Isenberg G, 1998, INT REV CYTOL, V178, P73; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756-3282(90)90082-A; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Levy JB, 1997, J BONE MINER RES, V12, P28; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Lu PJ, 1997, J BIOL CHEM, V272, P466; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MEENAKSHI T, 1993, J CELL BIOCHEM, V53, P145, DOI 10.1002/jcb.240530207; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Pande G, 2000, CURR OPIN CELL BIOL, V12, P569, DOI 10.1016/S0955-0674(00)00133-2; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schneider GB, 1998, CELL ADHES COMMUN, V5, P207, DOI 10.3109/15419069809040292; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; TURKSEN K, 1988, J BONE MINER RES, V3, P389; Turner CE, 2000, J CELL SCI, V113, P4139; TURNER CE, 1994, J CELL SCI, V107, P1583; Ueda H, 2000, J CELL BIOL, V149, P423, DOI 10.1083/jcb.149.2.423; WARSHAFSKY B, 1985, BONE, V6, P179, DOI 10.1016/8756-3282(85)90051-1; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xiong WC, 1998, J CELL SCI, V111, P1981; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YU FX, 1992, J BIOL CHEM, V267, P14616; ZALLONE AZ, 1983, J ANAT, V137, P57; ZAMBONINZALLONE A, 1988, J BONE MINER RES, V3, P517; ZHANG D, 1995, J CELL SCI, V108, P2285; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	116	88	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47434	47444		10.1074/jbc.M107494200	http://dx.doi.org/10.1074/jbc.M107494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577104	hybrid			2022-12-25	WOS:000172768500099
J	Simberg, D; Danino, D; Talmon, Y; Minsky, A; Ferrari, ME; Wheeler, CJ; Barenholz, Y				Simberg, D; Danino, D; Talmon, Y; Minsky, A; Ferrari, ME; Wheeler, CJ; Barenholz, Y			Phase behavior, DNA ordering, and size instability of cationic lipoplexes - Relevance to optimal transfection activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERTED HEXAGONAL PHASE; CIRCULAR-DICHROISM; GENE-TRANSFER; STRUCTURAL-PROPERTIES; LIPOSOME COMPLEXES; PLASMID DNA; IN-VITRO; CHOLESTEROL; TRANSITIONS; DELIVERY	Mechanisms of cationic lipid-based nucleic acid delivery are receiving increasing attention, but despite this the factors that determine high or low activity of lipoplexes are poorly understood. This study is focused on the fine structure of cationic lipid-DNA complexes (lipoplexes) and its relevance to transfection efficiency. Monocationic (N-(1-(2,3-dioleoyloxy)propyl),N,N,N-trimethylammonium chloride, N-(1-(2,3-dimyristyloxypropyl)-N,N-dimethyl-(2-hydroxyethyl)ammonium bromide) and polycationic (2,3-dioleyloxy-N-[2(sperminecarboxamido) ethyl]-N,N-dimethyl-1-propanammonium trifluoroacetate) lipid-based assemblies, with or without neutral lipid (1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, cholesterol) were used to prepare lipoplexes of different L+/DNA(-) charge ratios. Circular dichroism, cryogenic-transmission electron microscopy, and static light scattering were used for lipoplex characterization, whereas expression of human growth hormone or green fluorescent protein was used to quantify transfection efficiency. All monocationic lipids in the presence of inverted hexagonal phase-promoting helper lipids (1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine, cholesterol) induced appearance of Psi (-) DNA, a chiral tertiary DNA structure. The formation of Psi (-) DNA was also dependent on cationic lipid-DNA charge ratio. On the other hand, monocationic lipids either alone or with 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine as helper lipid, or polycationic 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]N,N-dimethyl-1-propanammonium trifluoroacetate-based assemblies, neither of which promotes a lipid-DNA hexagonal phase, did not induce the formation of Psi (-) DNA. Parallel transfection studies reveal that the size and phase instability of the lipoplexes, and not the formation of Psi (-) DNA structure, correlate with optimal transfection.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Liposome Res, IL-91120 Jerusalem, Israel; Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel; Weizmann Inst Sci, Dept Organ Chem & Struct Biol, IL-76100 Rehovot, Israel; Vical Inc, San Diego, CA 92121 USA	Hebrew University of Jerusalem; Technion Israel Institute of Technology; Weizmann Institute of Science	Barenholz, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Liposome Res, POB 12272, IL-91120 Jerusalem, Israel.	yb@cc.huji.ac.il	Talmon, Yeshayahu/N-1076-2019; Danino, Dganit/D-6832-2016	Talmon, Yeshayahu/0000-0002-9854-3972; Danino, Dganit/0000-0002-9782-4940				Birchall JC, 1999, INT J PHARM, V183, P195, DOI 10.1016/S0378-5173(99)00117-9; COORSSEN JR, 1990, BIOCHEM CELL BIOL, V68, P65, DOI 10.1139/o90-008; Daniels GA, 2001, CURR OPIN MOL THER, V3, P70; Dunlap DD, 1997, NUCLEIC ACIDS RES, V25, P3095, DOI 10.1093/nar/25.15.3095; Even-Chen S, 2000, BBA-BIOMEMBRANES, V1509, P176, DOI 10.1016/S0005-2736(00)00292-3; FELGNER PL, 1996, HDB NONMEDICAL APPL, V4, P43; Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GOSULE LC, 1976, NATURE, V259, P333, DOI 10.1038/259333a0; HAYNES M, 1970, BIOCHEMISTRY-US, V9, P4410, DOI 10.1021/bi00824a600; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Hofland HEJ, 1997, PHARMACEUT RES, V14, P742, DOI 10.1023/A:1012146305040; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683; Lin AJ, 2000, J DRUG TARGET, V8, P13, DOI 10.3109/10611860009009206; LIVOLANT F, 1988, BIOCHEMISTRY-US, V27, P3056, DOI 10.1021/bi00408a058; Madry H, 2001, J MOL MED-JMM, V79, P184, DOI 10.1007/s001090000186; MAESTRE MF, 1980, BIOCHEMISTRY-US, V19, P5214, DOI 10.1021/bi00564a010; May S, 2000, BIOPHYS J, V78, P1681, DOI 10.1016/S0006-3495(00)76720-8; Meidan VM, 2000, BBA-BIOMEMBRANES, V1464, P251, DOI 10.1016/S0005-2736(00)00151-6; Monk KWC, 1997, BIOPHYS J, V73, P2534, DOI 10.1016/S0006-3495(97)78282-1; Pector V, 2000, J BIOL CHEM, V275, P29533, DOI 10.1074/jbc.M909996199; Pitard B, 1997, P NATL ACAD SCI USA, V94, P14412, DOI 10.1073/pnas.94.26.14412; Sakurai F, 2001, GENE THER, V8, P677, DOI 10.1038/sj.gt.3301460; SIEGEL DP, 1994, BIOPHYS J, V66, P402, DOI 10.1016/S0006-3495(94)80790-8; Simberg D, 2000, J LIPOSOME RES, V10, P1, DOI 10.3109/08982100009031091; Strekas TC, 1999, ARCH BIOCHEM BIOPHYS, V364, P129, DOI 10.1006/abbi.1999.1108; Talmon Y, 1999, SURF SCI SERIES, V83, P147; TILCOCK CPS, 1982, BIOCHEMISTRY-US, V21, P4596, DOI 10.1021/bi00262a013; TINOCO I, 1980, ANNU REV BIOPHYS BIO, V9, P107, DOI 10.1146/annurev.bb.09.060180.000543; Wagner K, 2000, LANGMUIR, V16, P303, DOI 10.1021/la991268a; Zuidam NJ, 1999, FEBS LETT, V457, P419, DOI 10.1016/S0014-5793(99)01053-4; Zuidam NJ, 1999, BBA-BIOMEMBRANES, V1419, P207, DOI 10.1016/S0005-2736(99)00069-3; Zuidam NJ, 1998, BBA-BIOMEMBRANES, V1368, P115, DOI 10.1016/S0005-2736(97)00187-9; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	37	167	168	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47453	47459		10.1074/jbc.M105588200	http://dx.doi.org/10.1074/jbc.M105588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11564736	hybrid			2022-12-25	WOS:000172768500101
J	Tanoue, S; Nishioka, T				Tanoue, S; Nishioka, T			A receptor-type guanylyl cyclase expression is regulated under circadian clock in peripheral tissues of the silk moth - Light-induced shifting of the expression rhythm and correlation with eclosion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC PEPTIDE RECEPTOR; DROSOPHILA-MELANOGASTER; NITRIC-OXIDE; CYCLIC-GMP; MALPIGHIAN TUBULES; BEHAVIORAL RHYTHMS; SKELETAL-MUSCLE; TIMELESS; TRANSCRIPTION; PERIOD	The mechanisms by which the circadian clock controls behavior through regulating gene expression in peripheral tissues are largely unknown. Here we demonstrate that the expression of a receptor-type guanylyl cyclase (BmGC-I) from the silk moth Bombyx mori is regulated in the flight muscles in a circadian fashion. BmGC-I mRNA was expressed from the end of the light period through the middle of the dark period. BmGC-I protein expression and cGMP levels were high around the initiation of eclosion events at the beginning of the photoperiod. The rhythm of the BmGC-I and cGMP levels free-ran in constant light and synchronized to the environmental photoperiodic cycle. The circadian regulation of BmGC-I expression was also observed in the legs but not in other tissues examined. BmGC-I therefore represents a circadian output gene that regulates eclosion behavior.	Kyoto Univ, Lab Insect Physiol, Grad Sch Agr Sci, Kyoto 6068502, Japan	Kyoto University	Nishioka, T (corresponding author), Kyoto Univ, Lab Insect Physiol, Grad Sch Agr Sci, Kyoto 6068502, Japan.							Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Ball EE, 1998, J COMP NEUROL, V394, P1, DOI 10.1002/(SICI)1096-9861(19980427)394:1<1::AID-CNE1>3.0.CO;2-4; Benavides A, 1998, AM J PHYSIOL-REG I, V275, pR811, DOI 10.1152/ajpregu.1998.275.3.R811; BOEKHOFF I, 1993, INSECT BIOCHEM MOLEC, V23, P757, DOI 10.1016/0965-1748(93)90063-X; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Emery P, 2000, NEURON, V26, P493, DOI 10.1016/S0896-6273(00)81181-2; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; GIGLIOTTI S, 1993, DEV BIOL, V159, P450, DOI 10.1006/dbio.1993.1255; Helfrich-Forster C, 2000, J NEUROSCI, V20, P3339, DOI 10.1523/JNEUROSCI.20-09-03339.2000; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee C, 1999, MOL CELL BIOL, V19, P5316; LIU WC, 1995, J BIOL CHEM, V270, P12418, DOI 10.1074/jbc.270.21.12418; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; MCNEIL L, 1995, J BIOL CHEM, V270, P7189, DOI 10.1074/jbc.270.13.7189; NICOLE M, 1987, NUCLEIC ACIDS RES, V15, P2781; ODonnell MJ, 1996, J EXP BIOL, V199, P1163; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; PIECE J, 1977, ANAL BIOCHEM, V81, P478; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; QUILAN MC, 1997, J EXP BIOL, V200, P2363; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SAEZ L, 1996, NEURON, V17, P979; SAMBROOK J, 1989, MOL CLONING, V1, P7; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SHIBANAKA Y, 1991, BIOCHEM BIOPH RES CO, V180, P881, DOI 10.1016/S0006-291X(05)81147-7; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Tanoue S, 2001, INSECT BIOCHEM MOLEC, V31, P971, DOI 10.1016/S0965-1748(01)00045-5; TRUMAN JW, 1971, P NATL ACAD SCI USA, V68, P595, DOI 10.1073/pnas.68.3.595; Young ME, 1998, FEBS LETT, V424, P79, DOI 10.1016/S0014-5793(98)00143-4; Young ME, 1997, BIOCHEM J, V322, P223, DOI 10.1042/bj3220223; ZIEGELBERGER G, 1990, J NEUROSCI, V10, P1217	41	9	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46765	46769		10.1074/jbc.M106980200	http://dx.doi.org/10.1074/jbc.M106980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11557767	hybrid			2022-12-25	WOS:000172768500014
J	Woldman, I; Varinou, L; Ramsauer, K; Rapp, B; Decker, T				Woldman, I; Varinou, L; Ramsauer, K; Rapp, B; Decker, T			The Stat1 binding motif of the interferon-gamma receptor is sufficient to mediate Stat5 activation and its repression by SOCS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; PHASE RESPONSE FACTOR/STAT3; JANUS TYROSINE KINASE; IFN-GAMMA; DIFFERENTIAL ACTIVATION; ANTIAPOPTOTIC ACTIVITY; TARGETED DISRUPTION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTORS; IMMUNE INTERFERON	Signal transduction via the interferon-gamma (IFN-gamma) receptor requires the tyrosine phosphorylation of signal transducers and activators of transcription (Stats). Whereas tyrosine phosphorylation of Stat1 occurs in all cells, activation of Stat5 by IFN-gamma is cell type-restricted. Here we investigated the mechanism of Stat5 activation by the IFN-gamma receptor. In transfection assays both Stat5 isoforms, Stat5a and Stat5b, were phosphorylated on tyrosine in response to IFN-gamma. Stat5 activation required the presence of tyrosine 420 (Tyr-420) in the murine IFNGR1 receptor chain, which also serves as the Stat1 binding site. Moreover, a peptide including Tyr-440, the Stat1 binding site of the human IFNGR1 chain, conferred the ability upon a synthetic receptor to activate Stat5. Suppressor of cytokine signaling 3 (SOCS3) inhibited the activation of Stat5 by the IFN-gamma receptor, and the Tyr-440-containing peptide stretch was sufficient for repression. SOCS3 expression had little effect on the activity of Jak kinases not associated with cytokine receptors. In IFN-gamma -treated, Stat1-deficient fibroblasts Stat5 was inefficient in inducing transcription of a Stat-dependent reporter gene, suggesting it does not per se make a major contribution to the expression of IFN-gamma -responsive genes.	Inst Microbiol & Genet, Vienna Bioctr, A-1030 Vienna, Austria	Vienna Biocenter (VBC)	Decker, T (corresponding author), Inst Microbiol & Genet, Vienna Bioctr, Dr Bohr Gasse 9, A-1030 Vienna, Austria.							Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Barahmand-Pour F, 1998, J BIOL CHEM, V273, P12567, DOI 10.1074/jbc.273.20.12567; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Kieslinger M, 2000, GENE DEV, V14, P232; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; NACY CA, 1991, CURR OPIN IMMUNOL, V3, P330, DOI 10.1016/0952-7915(91)90033-W; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stoiber D, 1999, J IMMUNOL, V163, P2640; Stoiber D, 2001, J IMMUNOL, V166, P466, DOI 10.4049/jimmunol.166.1.466; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Woldman I, 1997, J IMMUNOL, V159, P877; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	57	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45722	45728		10.1074/jbc.M105320200	http://dx.doi.org/10.1074/jbc.M105320200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577084	hybrid			2022-12-25	WOS:000172573100031
J	Arakaki, AK; Orellano, EG; Calcaterra, NB; Ottado, J; Ceccarelli, EA				Arakaki, AK; Orellano, EG; Calcaterra, NB; Ottado, J; Ceccarelli, EA			Involvement of the flavin si-face function of ferredoxin-NADP(+) reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANABAENA PCC 7119; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; OXIDIZED FLAVODOXIN; ELECTRON-TRANSFER; 3-DIMENSIONAL STRUCTURE; WILD-TYPE; ANGSTROM RESOLUTION; REFINED STRUCTURES	In ferredoxin-NADP(+) reductase (FNR), FAD is bound outside of an anti-parallel beta -barrel with the Isoalloxazine lying in a two-tyrosine pocket. To elucidate the function of the flavin si-face tyrosine (Tyr-89 in pea FNR) on the enzyme structure and catalysis, we performed ab initio molecular orbital calculations and site-directed mutagenesis. Our results indicate that the position of Tyr-89 in pea FNR is mainly governed by the energetic minimum of the pairwise interaction between the phenol ring and the flavin. Moreover, most of FNR-like proteins displayed geometries for the si-face tyrosine phenol and the flavin, which correspond to the more negative free energy theoretical value. FNR mutants were obtained replacing Tyr-89 by Phe, Trp, Ser, or Gly. Structural and functional features of purified FNR mutants indicate that aromaticity on residue 89 is essential for FAD binding and proper folding of the protein. Moreover, hydrogen bonding through the Tyr-89 hydroxyl group may be responsible of the correct positioning of FAD and the substrate NADP(+).	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn,Div Mol Biol, Rosario, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario	Ceccarelli, EA (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn,Div Mol Biol, Suipacha 531,S2002LRK, Rosario, Argentina.	cecca@arnet.com.ar	Arakaki, Adrian K/C-6564-2008; Ceccarelli, Eduardo A./V-2600-2019; Ceccarelli, Eduardo A./M-8699-2014; Calcaterra, Nora/AAP-7469-2021	Ceccarelli, Eduardo A./0000-0001-5776-3306; Ceccarelli, Eduardo A./0000-0001-5776-3306; 				Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; ALIVERTI A, 1991, EUR J BIOCHEM, V198, P21, DOI 10.1111/j.1432-1033.1991.tb15981.x; ALIVERTI A, 1991, J BIOL CHEM, V266, P17760; Aliverti A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P653; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; BURKHART BM, 1995, ACTA CRYSTALLOGR D, V51, P318, DOI 10.1107/S0907444994011716; CARRILLO N, 1987, LIGHT REACTIONS, P527; CECCARELLI EA, 1991, J BIOL CHEM, V266, P14283; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Cunane LM, 2000, J MOL BIOL, V295, P357, DOI 10.1006/jmbi.1999.3290; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Dorowski A, 2001, J BIOL CHEM, V276, P9253, DOI 10.1074/jbc.M004576200; Drennan CL, 1999, J MOL BIOL, V294, P711, DOI 10.1006/jmbi.1999.3151; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Feller D., 1990, REV COMPUTATIONAL CH, V1, P1; FUKUYAMA K, 1992, J MOL BIOL, V225, P775, DOI 10.1016/0022-2836(92)90400-E; GADDA G, 1990, J BIOL CHEM, V265, P11955; HANUKOGLU I, 1987, EUR J BIOCHEM, V169, P449, DOI 10.1111/j.1432-1033.1987.tb13632.x; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Hoover DM, 1999, J MOL BIOL, V294, P725, DOI 10.1006/jmbi.1999.3152; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; Itoh T, 2000, BIOCONJUGATE CHEM, V11, P8, DOI 10.1021/bc990045t; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; JUNGERMA.K, 1974, FEBS LETT, V43, P203, DOI 10.1016/0014-5793(74)81000-8; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Krapp AR, 1997, EUR J BIOCHEM, V249, P556, DOI 10.1111/j.1432-1033.1997.00556.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; Martinez-Julvez M, 1999, J BIOL INORG CHEM, V4, P568, DOI 10.1007/s007750050379; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P17680, DOI 10.1021/bi981718i; Mattevi A, 1997, PROTEINS, V27, P601, DOI 10.1002/(SICI)1097-0134(199704)27:4<601::AID-PROT12>3.0.CO;2-O; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; MOORE SA, 1992, J MOL BIOL, V224, P523, DOI 10.1016/0022-2836(92)91015-H; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; Piubelli L, 2000, J BIOL CHEM, V275, P10472, DOI 10.1074/jbc.275.14.10472; SANCHO J, 1988, ARCH BIOCHEM BIOPHYS, V260, P200, DOI 10.1016/0003-9861(88)90441-9; SERRA EC, 1993, PROTEIN EXPRES PURIF, V4, P539, DOI 10.1006/prep.1993.1071; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRIDHAR P, 1998, PROTEIN SCI, V0007; STOCKMAN BJ, 1994, BIOCHEMISTRY-US, V33, P15298, DOI 10.1021/bi00255a011; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; ZANETTI G, 1976, BIOCHIM BIOPHYS ACTA, V445, P14, DOI 10.1016/0005-2744(76)90157-1; Zhao Q, 1999, PROTEIN SCI, V8, P298; Zheng YJ, 1996, J AM CHEM SOC, V118, P9402, DOI 10.1021/ja9608151; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029	72	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44419	44426		10.1074/jbc.M107568200	http://dx.doi.org/10.1074/jbc.M107568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577105	hybrid			2022-12-25	WOS:000172406700011
J	Korn, T; Kuhlkamp, T; Track, C; Schatz, I; Baumgarten, K; Gorboulev, V; Koepsell, H				Korn, T; Kuhlkamp, T; Track, C; Schatz, I; Baumgarten, K; Gorboulev, V; Koepsell, H			The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/GLUCOSE COTRANSPORTER SGLT1; D-GLUCOSE COTRANSPORTER; DEPENDENT HEXOSE-TRANSPORT; CYCLIC-AMP ELEVATION; GENE-EXPRESSION; MESSENGER-RNA; 3'-UNTRANSLATED REGION; MODIFIER RS1; KINASE-C; CLONING	Previously we cloned RS1, a 67-kDa polypeptide that is associated with the intracellular side of the plasma membrane. Upon co-expression in Xenopus laevis oocytes, human RS1 decreased the concentration of the Na+-D-glucose co-transporter hSGLT1 in the plasma membrane (Valentin, M., Kuhlkamp, T., Wagner, K., Krohne, G., Arndt, P., Baumgarten, K., Weber, W.-M., Segal, A., Veyhl, M., and Koepsell, H. (2000) Biochim. Biophys. Acta 1468, 367-380). Here, the porcine renal epithelial cell line LLC-PK1 was used to investigate whether porcine RS1 (pRS1) plays a role in transcriptional up-regulation of SGLT1 after confluence and in down-regulation of SGLT1 by high extracellular D-glucose concentrations. Western blots indicated a dramatic decrease of endogenous pRS1 protein at the plasma membrane after confluence but no significant effect of D-glucose. In confluent LLC-PK1 cells overexpressing pRS1, SGLT1 mRNA, protein, and methyl-alpha -D-glucopyranoside uptakes were drastically decreased; however, the reduction of methyl-alpha -D-glucopyranoside uptake after cultivation with 25 mM D-glucose remained. In confluent pRS1 antisense cells, the expression of SGLT1 mRNA and protein was strongly increased, whereas the reduction of SGLT1 expression during cultivation with high D-glucose was not influenced. Nuclear run-on assays showed that the transcription of SGLT1 was 10-fold increased in the pRS1 antisense cells. The data suggest that RSI participates in transcriptional up-regulation of SGLT1 after confluence but not in down-regulation by D-glucose.	Univ Wurzburg, Inst Anat, D-97070 Wurzburg, Germany	University of Wurzburg	Koepsell, H (corresponding author), Univ Wurzburg, Inst Anat, Koellikerstr 6, D-97070 Wurzburg, Germany.		Korn, Thomas/AAE-6960-2019	Korn, Thomas/0000-0002-3633-0955				AMSLER K, 1991, AM J PHYSIOL, V260, pC1290, DOI 10.1152/ajpcell.1991.260.6.C1290; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; AYO SH, 1991, AM J PHYSIOL, V261, pF571, DOI 10.1152/ajprenal.1991.261.4.F571; BELL GI, 1993, J BIOL CHEM, V268, P19161; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; FARRELL CR, 1992, MOL BRAIN RES, V15, P221, DOI 10.1016/0169-328X(92)90112-O; FERRARIS RP, 1992, AM J PHYSIOL, V262, pG1069, DOI 10.1152/ajpgi.1992.262.6.G1069; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; HAASE W, 1990, EUR J CELL BIOL, V52, P297; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HEILIG CW, 1995, J CLIN INVEST, V96, P1802, DOI 10.1172/JCI118226; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; Ishikawa Y, 1997, BBA-MOL CELL RES, V1357, P306, DOI 10.1016/S0167-4889(97)00043-8; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KIMMICH GA, 1994, AM J PHYSIOL-CELL PH, V267, pC1119; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambotte S, 1996, DNA CELL BIOL, V15, P769, DOI 10.1089/dna.1996.15.769; LASHERAS C, 1988, AM J PHYSIOL, V255, pC745, DOI 10.1152/ajpcell.1988.255.6.C745; Lee WY, 2000, J BIOL CHEM, V275, P33998, DOI 10.1074/jbc.M005040200; MORAN A, 1983, J BIOL CHEM, V258, P5087; MORAN A, 1982, AM J PHYSIOL, V243, pC293, DOI 10.1152/ajpcell.1982.243.5.C293; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; Oku A, 1999, DIABETES, V48, P1794, DOI 10.2337/diabetes.48.9.1794; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; Reinhardt J, 1999, BBA-BIOMEMBRANES, V1417, P131, DOI 10.1016/S0005-2736(98)00250-8; Rhoads DB, 1998, J BIOL CHEM, V273, P9510, DOI 10.1074/jbc.273.16.9510; Sambrook J., 2002, MOL CLONING LAB MANU; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIODA T, 1994, P NATL ACAD SCI USA, V91, P11919, DOI 10.1073/pnas.91.25.11919; SHIRAZIBEECHEY SP, 1991, J PHYSIOL-LONDON, V437, P699, DOI 10.1113/jphysiol.1991.sp018620; Tanaka T, 1998, BIOCHEM J, V331, P225, DOI 10.1042/bj3310225; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valentin M, 2000, BBA-BIOMEMBRANES, V1468, P367, DOI 10.1016/S0005-2736(00)00277-7; VEYHL M, 1993, J BIOL CHEM, V268, P25041; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315	50	26	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45330	45340		10.1074/jbc.M105975200	http://dx.doi.org/10.1074/jbc.M105975200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11562363	hybrid			2022-12-25	WOS:000172406700128
J	Folcher, M; Gaillard, H; Nguyen, LT; Nguyen, KT; Lacroix, P; Bamas-Jacques, N; Rinkel, M; Thompson, CJ				Folcher, M; Gaillard, H; Nguyen, LT; Nguyen, KT; Lacroix, P; Bamas-Jacques, N; Rinkel, M; Thompson, CJ			Pleiotropic functions of a Streptomyces pristinaespiralis autoregulator receptor in development, antibiotic biosynthesis, and expression of a superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-FACTOR RECEPTOR; COELICOLOR A3(2); TRANSCRIPTIONAL REGULATOR; ESCHERICHIA-COLI; GRISEUS; BUTYROLACTONE; GENE; PROTEIN; DNA; DIFFERENTIATION	In Streptomyces, a family of related butyrolactones and their corresponding receptor proteins serve as quorum-sensing systems that can activate morphological development and antibiotic biosynthesis. Streptomyces pristinaespiralis contains a gene cluster encoding enzymes and regulatory proteins for the biosynthesis of pristinamycin, a clinically important streptogramin antibiotic complex. One of these proteins, PapR1, belongs to a well known family of Streptomyces antibiotic regulatory proteins. Gel shift assays using crude cytoplasmic extracts detected SpbR, a developmentally regulated protein that bound to the papR1 promoter. SpbR was purified, and its gene was cloned using reverse genetics. spbR encoded a 25-kDa protein similar to Streptomyces autoregulatory proteins of the butyrolactone receptor family, including scbR from Streptomyces coelicolor. In Escherichia coli, purified SpbR and ScbR produced bound sequences immediately upstream of papR1, spbR, and scbR. SpbR DNA-binding activity was inhibited by an extracellular metabolite with chromatographic properties similar to those of the well known gamma -butyrolactone signaling compounds. DNase I protection assays mapped the SpbR-binding site in the papR1 promoter to a sequence homologous to other known butyrolactone autoregulatory elements. A nucleotide data base search showed that these binding motifs were primarily located upstream of genes encoding Streptomyces antibiotic regulatory proteins and butyrolactone receptors in various Streptomyces species. Disruption of the spbR gene in S. pristinaespiralis resulted in severe defects in growth, morphological differentiation, pristinamycin biosynthesis, and expression of a secreted superoxide dismutase.	Univ Basel, Bioctr, Dept Mol Microbiol, CH-4056 Basel, Switzerland	University of Basel	Thompson, CJ (corresponding author), Univ Basel, Bioctr, Dept Mol Microbiol, 70 Klingelbergstr, CH-4056 Basel, Switzerland.		Gaillard, Helene/M-2914-2014; Nguyen, Kien/F-9234-2019	Gaillard, Helene/0000-0002-5740-0641; Nguyen, Kien/0000-0003-2685-3928				Bate N, 1999, CHEM BIOL, V6, P617, DOI 10.1016/S1074-5521(99)80113-6; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bibb M, 1996, MICROBIOL-SGM, V142, P1335, DOI 10.1099/13500872-142-6-1335; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; BlondeletRouault MH, 1997, GENE, V190, P315, DOI 10.1016/S0378-1119(97)00014-0; BRAUN D, 1995, FEMS MICROBIOL LETT, V126, P37, DOI 10.1111/j.1574-6968.1995.tb07387.x; Cho YH, 2000, MOL MICROBIOL, V35, P150, DOI 10.1046/j.1365-2958.2000.01685.x; Folcher M, 2001, J BIOL CHEM, V276, P1479, DOI 10.1074/jbc.M007690200; Fuqua C, 1998, CURR OPIN MICROBIOL, V1, P183, DOI 10.1016/S1369-5274(98)80009-X; GRANOZZI C, 1990, J GEN MICROBIOL, V136, P713, DOI 10.1099/00221287-136-4-713; Harth G, 1999, J BIOL CHEM, V274, P4281, DOI 10.1074/jbc.274.7.4281; Hassett DJ, 1999, MOL MICROBIOL, V34, P1082, DOI 10.1046/j.1365-2958.1999.01672.x; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; Hopwood D. A., 1985, GENETIC MANIPULATION; HORINOUCHI S, 1994, MOL MICROBIOL, V12, P859, DOI 10.1111/j.1365-2958.1994.tb01073.x; KHOKHLOV AS, 1973, Z ALLG MIKROBIOL, V13, P647, DOI 10.1002/jobm.3630130803; KHOKHLOV AS, 1967, DOKL AKAD NAUK SSSR+, V177, P232; Kim EJ, 1996, EUR J BIOCHEM, V241, P178, DOI 10.1111/j.1432-1033.1996.0178t.x; Kinoshita H, 1997, J BACTERIOL, V179, P6986, DOI 10.1128/jb.179.22.6986-6993.1997; Kinoshita H, 1999, J BACTERIOL, V181, P5075, DOI 10.1128/JB.181.16.5075-5080.1999; Kitani S, 1999, J BACTERIOL, V181, P5081, DOI 10.1128/JB.181.16.5081-5084.1999; MANIATIS T, 1989, MOL CLONING LAB MANU, P74; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Nakano H, 1998, J BACTERIOL, V180, P3317, DOI 10.1128/JB.180.13.3317-3322.1998; Neumann T, 1996, MICROBIOL-UK, V142, P1953, DOI 10.1099/13500872-142-8-1953; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; Ohnishi Y, 1999, MOL MICROBIOL, V34, P102, DOI 10.1046/j.1365-2958.1999.01579.x; Onaka H, 1997, J BACTERIOL, V179, P2748, DOI 10.1128/jb.179.8.2748-2752.1997; ONAKA H, 1995, J BACTERIOL, V177, P6083, DOI 10.1128/jb.177.21.6083-6092.1995; Parsek MR, 2000, P NATL ACAD SCI USA, V97, P8789, DOI 10.1073/pnas.97.16.8789; PREUDHOM.J, 1968, B SOC CHIM FR, P585; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SCHNELL S, 1995, J BACTERIOL, V177, P5924, DOI 10.1128/jb.177.20.5924-5929.1995; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Susstrunk U, 1998, MOL MICROBIOL, V30, P33, DOI 10.1046/j.1365-2958.1998.01033.x; Takano E, 2000, J BIOL CHEM, V275, P11010, DOI 10.1074/jbc.275.15.11010; Viollier PH, 2001, J BACTERIOL, V183, P3184, DOI 10.1128/JB.183.10.3184-3192.2001; Waki M, 1997, J BACTERIOL, V179, P5131, DOI 10.1128/jb.179.16.5131-5137.1997; YAMADA Y, 1987, J ANTIBIOT, V40, P496, DOI 10.7164/antibiotics.40.496	39	107	114	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44297	44306		10.1074/jbc.M101109200	http://dx.doi.org/10.1074/jbc.M101109200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557748	hybrid			2022-12-25	WOS:000172297700102
J	Foster, LJ; Li, DL; Randhawa, VK; Klip, A				Foster, LJ; Li, DL; Randhawa, VK; Klip, A			Insulin accelerates inter-endosomal GLUT4 traffic via phosphatidylinositol 3-kinase and protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; GLUCOSE-TRANSPORTER TRANSLOCATION; AMINO-ACID-TRANSPORT; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; BREFELDIN-A; SUBCELLULAR TRAFFICKING; SENSITIVE TRAFFICKING; COMPARTMENT-ABLATION; PLASMA-MEMBRANE	Insulin enhances plasmalemmal-directed traffic of glucose transporter-4 (GLUT4), but it is unknown whether insulin regulates GLUT4 traffic through endosomal compartments. In L6 myoblasts expressing Myc-tagged GLUT4, insulin markedly stimulated the rate of GLUT4myc recycling. In myoblasts stimulated with insulin to maximize surface GLUT4myc levels, we followed the rates of surface-labeled GLUT4myc endocytosis and chased its intracellular distribution in space and time using confocal immunofluorescence microscopy. Surface-labeled GLUT4myc internalized rapidly (t(1/2) 3 min), reaching the early endosome by 2 min and the transferrin receptor-rich, perinuclear recycling endosome by 20 min. Upon re-addition of insulin, the t(1/2) of GLUT4 disappearance from the plasma membrane was unchanged (3 min), but strikingly, GLUT4myc reached the recycling endosome by 10 and left by 20 min. This effect of insulin was blocked by the phosphatidylinositol 3-kinase inhibitor LY294002 or by transiently transfected dominant-negative phosphatidylinositol 3-kinase and protein kinase B mutants. In contrast, insulin did not alter the rate of arrival of rhodamine-labeled transferrin at the recycling endosome. These results reveal a heretofore unknown effect of insulin to accelerate interendosomal travel rates of GLUT4 and identify the recycling endosome as an obligatory stage in insulin-dependent GLUT4 recycling.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BAO SC, 1995, J BIOL CHEM, V270, P30199; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CZECH MP, 1993, J BIOL CHEM, V268, P9187; FOSTER LJ, 1999, DIABET ANN, V12, P111; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Gillingham AK, 1999, J CELL SCI, V112, P4793; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; HUNDAL HS, 1994, BIOCHEM J, V297, P289, DOI 10.1042/bj2970289; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kawanaka K, 2001, J BIOL CHEM, V276, P20101, DOI 10.1074/jbc.M010599200; Khayat ZA, 1998, AM J PHYSIOL-CELL PH, V275, pC1487, DOI 10.1152/ajpcell.1998.275.6.C1487; Khayat ZA, 2000, J CELL SCI, V113, P279; KING PA, 1992, J CLIN INVEST, V90, P1568, DOI 10.1172/JCI116025; KonoSugita E, 1996, EUR J BIOCHEM, V236, P1033, DOI 10.1111/j.1432-1033.1996.01033.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; LACHAAL M, 1994, J BIOL CHEM, V269, P23689; Lee W, 2000, BIOCHEMISTRY-US, V39, P9358, DOI 10.1021/bi0007021; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Martin S, 2000, TRAFFIC, V1, P652, DOI 10.1034/j.1600-0854.2000.010809.x; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Millar CA, 1997, BIOCHEM SOC T, V25, P974, DOI 10.1042/bst0250974; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; OKADA T, 1994, J BIOL CHEM, V269, P3568; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SATOH S, 1993, J BIOL CHEM, V268, P17820; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WITT DP, 1978, BIOCHEMISTRY-US, V17, P3913, DOI 10.1021/bi00612a004; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	53	86	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44212	44221		10.1074/jbc.M102964200	http://dx.doi.org/10.1074/jbc.M102964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11560920	hybrid			2022-12-25	WOS:000172297700093
J	Ge, YB; Matherly, LH; Taub, JW				Ge, YB; Matherly, LH; Taub, JW			Transcriptional regulation of cell-specific expression of the human cystathionine beta-synthase gene by differential binding of Sp1/Sp3 to the-1b promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; DEPENDENT PROTEIN-KINASE; DOWN-SYNDROME CHILDREN; IN-VITRO SENSITIVITY; ZINC-FINGER GENE; FACTORS NF-Y; CYTOSINE-ARABINOSIDE; MESSENGER-RNA; SP FAMILY; PHOSPHORYLATION	Cystathionine beta -synthase (CBS) catalyzes the condensation of serine and homocysteine to form cystathionine, an intermediate step in the synthesis of cysteine. We previously characterized the CBS -1b minimal promoter (-3792 to -3667) and found that Sp1/Sp3, nuclear factor Y, and USF-1 were involved in the regulation of basal promoter activity (Ge, Y., Konrad, M. A., Matherly, L. H., Taub, J. W. (2001) Biochem. J. 357, 97-105). In this study, the critical cis-elements and transcription factors in the CBS -1b upstream region (-4046 to -3792) were examined in HT1080 and HepG2 cells, which differ 10-fold in levels of CBS transcripts transcribed from the CBS -1b promoter. In DNase I footprint and gel shift analyses and transient transfections of mutant CBS -1b promoter constructs into HT1080 and HepG2 cells, transcriptionally important roles for Sp1/Sp3 binding to three GC boxes and one GT box and for binding of myeloid zinc finger 1-like proteins to two myeloid zinc finger I elements were indicated. In gel shift assays, very low levels of Sp1/Sp3 DNA-protein complexes were detected in HT1080 cells compared with HepG2 cells despite comparable levels of nuclear factor Y and USF-1 binding and similar levels of Spl and Sp3 proteins on Western blots. Mixing of HT1080 and HepG2 nuclear extracts resulted in no difference in total Sp factor binding in gel shift assays, thus excluding a role for an unknown activator or inhibitor in the disparate Sp1/Sp3 binding between the lines. Increased Sp1/Sp3 binding in gel shift assays was observed upon treatment of HT1080 nuclear extracts with protein kinase A, and decreased Sp1/Sp3 binding resulted from treatment of HepG2 nuclear extracts with calf alkaline phosphatase, suggesting a role for changes in Sp1/Sp3 phosphorylation in transcription factor binding and transactivation of the CBS -1b promoter. Characterization of CBS promoter structure and function should clarify the molecular bases for variations in CBS gene expression in genetic diseases and the relationship between CBS and Down syndrome.	Childrens Hosp Michigan, Div Pediat Hematol Oncol, Detroit, MI 48201 USA; Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA	Children's Hospital of Michigan; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Taub, JW (corresponding author), Childrens Hosp Michigan, Div Pediat Hematol Oncol, 3901 Beaubien Blvd, Detroit, MI 48201 USA.			Ge, Yubin/0000-0002-8748-716X	NATIONAL CANCER INSTITUTE [R01CA092308] Funding Source: NIH RePORTER; NCI NIH HHS [CA92308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1999, MOL CELL BIOL, V19, P1961; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bao LM, 1998, ARCH BIOCHEM BIOPHYS, V350, P95, DOI 10.1006/abbi.1997.0486; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BUKOVSKA G, 1994, PROTEIN EXPRES PURIF, V5, P442, DOI 10.1006/prep.1994.1063; CHADEFAUX B, 1988, LANCET, V2, P741; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Fodinger M, 1999, MINER ELECTROL METAB, V25, P269, DOI 10.1159/000057459; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kraus JP, 1998, GENOMICS, V52, P312, DOI 10.1006/geno.1998.5437; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Murakami Y, 1997, BBA-GENE STRUCT EXPR, V1352, P311, DOI 10.1016/S0167-4781(97)00032-8; PAN JL, 1993, J BIOL CHEM, V268, P22600; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SKOVBY F, 1984, AM J HUM GENET, V36, P452; Sugiura N, 2000, BIOCHEM J, V347, P155, DOI 10.1042/0264-6021:3470155; Taub JW, 1997, LEUKEMIA, V11, P1594, DOI 10.1038/sj.leu.2400747; Taub JW, 2000, CANCER RES, V60, P6421; Taub JW, 1999, BLOOD, V94, P1393; Taub JW, 1996, BLOOD, V87, P3395, DOI 10.1182/blood.V87.8.3395.bloodjournal8783395; Taub JW, 1999, BLOOD, V94, p382A; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; ZHAO ZD, 2000, J BIOL CHEM, V275, P18602	43	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43570	43579		10.1074/jbc.M104930200	http://dx.doi.org/10.1074/jbc.M104930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562358	hybrid			2022-12-25	WOS:000172297700014
J	Ghiso, JA; Holton, J; Miravalle, L; Calero, M; Lashley, T; Vidal, R; Houlden, H; Wood, N; Neubert, TA; Rostagno, A; Plant, G; Revesz, T; Frangione, B				Ghiso, JA; Holton, J; Miravalle, L; Calero, M; Lashley, T; Vidal, R; Houlden, H; Wood, N; Neubert, TA; Rostagno, A; Plant, G; Revesz, T; Frangione, B			Systemic amyloid deposits in familial British dementia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; BETA-PROTEIN; CYTOSKELETAL PATHOLOGY; PYROGLUTAMYL-PEPTIDES; PLAQUE-FORMATION; BLOOD-BRAIN; CYSTATIN-C; ANGIOPATHY; CLEARANCE	Familial British dementia (FBD) is an early onset inherited disorder that, like familial Alzheimer's disease (FAD), is characterized by progressive dementia, amyloid deposition in the brain, and neurofibrillary degeneration of limbic neurons. The primary structure of the amyloid subunit (ABri) extracted from FBD brain tissues (Vidal, R., Frangione, B., Rostagno, A., Mead, S., Revesz, T., Plant, G., and Ghiso, J. (1999) Nature 399, 776-781) is entirely different and unrelated to any previously known amyloid protein. Patients with FBD have a single nucleotide substitution at codon 267 in the BRI2 gene, resulting in an arginine replacing the stop codon and a longer open reading frame of 277 amino acids instead of 266. The ABri peptide comprises the 34 C-terminal residues of the mutated precursor ABriPP-277 and is generated via furin-like proteolytic processing. Here we report that carriers of the Stop-to-Arg mutation have a soluble form of the amyloid peptide (sABri) in the circulation with an estimated concentration in the range of 20 ng/ml, several fold higher than that of soluble A beta. In addition, ABri species identical to those identified in the brain were also found as fibrillar components of amyloid deposits predominantly in the blood vessels of several peripheral tissues, including pancreas and myocardium. We hypothesize that the high concentration of the soluble de novo created amyloidogenic peptide and/or the insufficient tissue clearance are the main causative factors for the formation of amyloid deposits outside the brain. Thus, FBD constitutes the first documented cerebral amyloidosis associated with neurodegeneration and dementia in which the amyloid deposition is also systemic.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; Inst Neurol, Div Neuropathol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Dept Mol Pathogenesis, London WC1N 3BG, England	New York University; New York University; New York University; New York University; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Ghiso, JA (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave,TH-432, New York, NY 10016 USA.	ghisoj01@popmail.med.nyu.edu	Wood, Nicholas W/C-2505-2009; Houlden, Henry J/C-1532-2008; Calero, Miguel/H-5691-2015; Rostagno, Agueda/A-5801-2008; Lashley, Tammaryn/D-2583-2009; Revesz, Tamas/A-8732-2010; Holton, Janice L/F-6831-2011	Wood, Nicholas W/0000-0002-9500-3348; Houlden, Henry J/0000-0002-2866-7777; Calero, Miguel/0000-0001-5366-3324; Revesz, Tamas/0000-0003-2501-0259; Holton, Janice L/0000-0002-3882-5249; Lashley, Tammaryn/0000-0001-7389-0348; Rostagno, Agueda/0000-0002-6817-2074	NCRR NIH HHS [RR14662, RR13077] Funding Source: Medline; NIA NIH HHS [AG08721, AG05891] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014662, S10RR013077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, R37AG005891, R01AG008721] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIKAWA H, 1985, ANN NEUROL, V17, P297, DOI 10.1002/ana.410170313; BARAISTER M, 1990, GENETICS NEUROLOGICA, P93; BATEMAN A, 1990, J BIOL CHEM, V265, P22130; BENEDIKZ E, 1990, VIRCHOWS ARCH A, V417, P325, DOI 10.1007/BF01605784; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; CASTANO EM, 1995, CURR OPIN NEUROL, V8, P279, DOI 10.1097/00019052-199508000-00006; COURTENMYERS G, 1987, NEUROLOGY, V37, P269; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; Garden RW, 1999, J NEUROCHEM, V72, P676, DOI 10.1046/j.1471-4159.1999.0720676.x; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; Ghiso J, 2000, ANN NY ACAD SCI, V920, P84; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GOLOLOBOV MY, 1994, ARCH BIOCHEM BIOPHYS, V309, P300, DOI 10.1006/abbi.1994.1117; GRIFFITHS RA, 1982, J NEUROL NEUROSUR PS, V45, P396, DOI 10.1136/jnnp.45.5.396; GUDMUNDSSON G, 1972, BRAIN, V95, P387, DOI 10.1093/brain/95.2.387; Holton JL, 2001, AM J PATHOL, V158, P515, DOI 10.1016/S0002-9440(10)63993-4; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; LOVE S, 1982, J NEUROL NEUROSUR PS, V45, P271, DOI 10.1136/jnnp.45.3.271; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MCDONALD JK, 1998, HDB PROTEOLYTIC ENZY, P408; Mead S, 2000, BRAIN, V123, P975, DOI 10.1093/brain/123.5.975; Messer M, 1965, C R Trav Lab Carlsberg, V35, P1; MISUMI Y, 1998, HDB PROTEOLYTIC ENZY, P378; MORI H, 1992, J BIOL CHEM, V267, P17082; Pittois K, 1998, GENE, V217, P141, DOI 10.1016/S0378-1119(98)00354-0; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; Revesz T, 1999, ACTA NEUROPATHOL, V97, P170, DOI 10.1007/s004010050970; SAIDO T, 1996, NEUROSCI LETT, V13, P173; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SKODRAS G, 1993, ANN CLIN LAB SCI, V23, P275; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Tekirian TL, 1998, J NEUROPATH EXP NEUR, V57, P76, DOI 10.1097/00005072-199801000-00009; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WEN GY, 1994, ACTA NEUROPATHOL, V88, P201; Worster-Drought C, 1933, J NEUROL PSYCHOPATHO, V14, P27; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	40	61	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43909	43914		10.1074/jbc.M105956200	http://dx.doi.org/10.1074/jbc.M105956200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557758	hybrid			2022-12-25	WOS:000172297700057
J	Khadilkar, A; Iannuzzi, P; Orlowski, J				Khadilkar, A; Iannuzzi, P; Orlowski, J			Identification of sites in the second exomembrane loop and ninth transmembrane helix of the mammalian Na+/H+ exchanger important for drug recognition and cation translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; H+ EXCHANGE; FUNCTIONAL-PROPERTIES; AMILORIDE; INHIBITOR; ISOFORM; ANTIPORT; NHE-1; TRANSFORMATION; MUTAGENESIS	Mammalian Na+/H+ exchanger (NHE) isoforms are differentially sensitive to inhibition by several distinct classes of pharmacological agents, including amiloride- and benzoyl guanidinium-based derivatives. The determinants of drug sensitivity, however, are only partially understood. Earlier studies of the drug-sensitive NHE1 isoform have shown that residues within the fourth membrane-spanning helix (M4) (Phe(165), Phe(166), Leu(167), and Gly(178)) and a 66-amino acid segment encompassing M9 contribute significantly to drug recognition. In this report, we have identified two residues within M9, one highly conserved (Glu(350)) and the other non-conserved (Gly(356)), that are major determinants of drug sensitivity. In addition, residues in the second exomembrane loop between M3 and M4 (Gly(152), Phe(157), and Pro(158)) were also found to modestly influence drug sensitivity. A double substitution of crucial sites within M4 and M9 of NHE1 with the corresponding residues present in the drug-resistant NHE3 isoform (i.e. L167F/G356A) greatly reduced drug sensitivity in a cooperative manner to levels nearing that of wild type NHE3. The above mutations did not appreciably affect Na-o(+) affinity but did markedly decrease the catalytic turnover of the transporter. These data suggest that specific sites encompassing M4 and M9 are critical determinants of both drug recognition and cation translocation.	McGill Univ, Dept Physiol, Montreal, PQ H3Q 1Y6, Canada	McGill University	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3Q 1Y6, Canada.	orlowski@med.mcgill.ca		Orlowski, John/0000-0001-7371-175X				Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V272, pC90, DOI 10.1152/ajpcell.1997.272.1.C90; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; FRELIN C, 1986, EUR J BIOCHEM, V154, P241, DOI 10.1111/j.1432-1033.1986.tb09388.x; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; Gumina RJ, 1998, J PHARMACOL EXP THER, V286, P175; HARPER IS, 1993, BASIC RES CARDIOL, V88, P430, DOI 10.1007/BF00795410; Humphreys RA, 1999, AM J PHYSIOL-HEART C, V276, pH749, DOI 10.1152/ajpheart.1999.276.2.H749; IVES HE, 1983, J BIOL CHEM, V258, P9710; Jandeleit-Dahm K, 2000, CIRC RES, V87, P1133, DOI 10.1161/01.RES.87.12.1133; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PARIS S, 1983, J BIOL CHEM, V258, P3503; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Rupprecht HJ, 2000, CIRCULATION, V101, P2902, DOI 10.1161/01.CIR.101.25.2902; SCHOLZ W, 1995, CARDIOVASC RES, V29, P260, DOI 10.1016/S0008-6363(96)88579-8; SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x; Schwark JR, 1998, PFLUG ARCH EUR J PHY, V436, P797, DOI 10.1007/s004240050704; Shrode LD, 1998, AM J PHYSIOL-CELL PH, V275, pC431, DOI 10.1152/ajpcell.1998.275.2.C431; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; Szabo EZ, 2000, J BIOL CHEM, V275, P6302, DOI 10.1074/jbc.275.9.6302; Touret N, 2001, BIOCHEMISTRY-US, V40, P5095, DOI 10.1021/bi0025464; Vallon V, 2000, AM J PHYSIOL-RENAL, V278, pF375, DOI 10.1152/ajprenal.2000.278.3.F375; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; WARNOCK DG, 1988, J BIOL CHEM, V263, P7216; YU FH, 1993, J BIOL CHEM, V268, P25536; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHU WH, 1995, BBA-MOL CELL RES, V1269, P122, DOI 10.1016/0167-4889(95)00102-X	47	45	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43792	43800		10.1074/jbc.M106659200	http://dx.doi.org/10.1074/jbc.M106659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564737	hybrid			2022-12-25	WOS:000172297700042
J	Otipoby, KL; Draves, KE; Clark, EA				Otipoby, KL; Draves, KE; Clark, EA			CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYN-DEFICIENT MICE; ACTIVATED PROTEIN-KINASE; TYROSINE-PHOSPHATASE SHP-1; ANTIGEN RECEPTOR; NEGATIVE REGULATOR; PHOSPHOLIPASE C-GAMMA-1; CD22-DEFICIENT MICE; AUTOIMMUNE-DISEASE; ADHESION MOLECULE; PATHWAYS	Recognition of antigen by the B cell antigen receptor (BCR) determines the subsequent fate of a B cell and is regulated in part by the involvement of other surface molecules, termed coreceptors. CD22 is a B cell-restricted coreceptor that gets rapidly tyrosyl-phosphorylated and recruits various signaling molecules to the membrane following BCR ligation. Although CD22 contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs), only the two carboxyl-terminal ITIM tyrosines are required for efficient recruitment of the SHP-1 phosphatase after BCR ligation. Furthermore, Grb2 is inducibly recruited to CD22 in human and mu- rine B cells. Unlike SHP-1, Grb2 recruitment to CD22 is not inhibited by specific doses of the Src family kinase-specific inhibitor PP1. The tyrosine residue in CD22 required for Grb2 recruitment (Tyr-828) is distinct and independent from the two ITIM tyrosines required for efficient SHP-1 recruitment (Tyr-843 and Tyr-863). Individually both Lyn and Syk are required for maximal phosphorylation of CD22 following ligation of the BCR, and together Lyn and Syk are required for all of the constitutive and induced tyrosine phosphorylation of CD22. We propose that the cytoplasmic tail of CD22 contains two domains that regulate signal transduction pathways initiated by the BCR and B cell fate.	Univ Washington, Reg Primate Res Ctr, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Otipoby, KL (corresponding author), Univ Washington, Reg Primate Res Ctr, Dept Immunol, Box 357330, Seattle, WA 98195 USA.		Clark, Edward/K-3462-2012	Clark, Edward A/0000-0001-8061-5475	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044250] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI44250] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; Carroll M C, 2000, Adv Immunol, V74, P61; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARDY RR, 1986, HDB EXPT IMMUNOLOGY, V1, P1; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; LAW CL, 1993, J IMMUNOL, V151, P175; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Pan C, 1999, IMMUNITY, V11, P495, DOI 10.1016/S1074-7613(00)80124-7; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, J IMMUNOL, V138, P98; Poe JC, 2000, J BIOL CHEM, V275, P17420, DOI 10.1074/jbc.M001892200; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; TORRES RM, 1992, J IMMUNOL, V149, P2641; Tuscano J, 1996, BLOOD, V87, P4723, DOI 10.1182/blood.V87.11.4723.bloodjournal87114723; Tuscano JM, 1999, BLOOD, V94, P1382, DOI 10.1182/blood.V94.4.1382.416k14_1382_1392; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Yohannan J, 1999, J BIOL CHEM, V274, P18769, DOI 10.1074/jbc.274.26.18769; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	56	89	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44315	44322		10.1074/jbc.M105446200	http://dx.doi.org/10.1074/jbc.M105446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551923	hybrid			2022-12-25	WOS:000172297700104
J	Schramek, N; Bracher, A; Bacher, A				Schramek, N; Bracher, A; Bacher, A			Biosynthesis of riboflavin - Single turnover kinetic analysis of GTP cyclohydrolase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN; TRIPHOSPHATE; COFACTOR	GTP cyclohydrolase II catalyzes the conversion of GTP into a mixture of 2,5-diamino-6-ribosylamino-4(3H)- Pyrimidinone 5'-phosphate (Compound 2), formate, and pyrophosphate. Moreover, GMP was recently shown to be formed as a minor product. The major product (Compound 2) serves as the first committed intermediate in the biosynthesis of the vitamin, riboflavin. Numerous pathogenic microorganisms are absolutely dependent on endogenous synthesis of riboflavin. The enzymes of this pathway are therefore potential drug targets, and mechanistic studies appear relevant for development of bactericidal inhibitors. Pre-steady state quenched flow analysis of GTP cyclohydrolase II shows the rate-determining step to be located at the beginning of the reaction sequence catalyzed by the enzyme. Thus, GTP is consumed at a rate constant of 0.064 s(-1), and the reaction product, Compound 2, is formed at an apparent rate constant of 0.062 s(-1). Stopped flow experiments monitored by multiwavelength photometry are well in line with these data. 2-Amino-5-formylamino-6-ribosylamino-4(3H)-pyrimidinone triphosphate can serve as substrate for GTP cyclohydrolase II but does not fulfill the criteria for a kinetically competent intermediate. A hypothetical reaction mechanism involves the slow formation of a phosphoguanosyl derivative of the enzyme under release of pyrophosphate. The covalently bound phosphoguanosyl moiety is proposed to undergo rapid hydrolytic release of formate from the imidazole ring and/or hydrolytic cleavage of the phosphodiester bond.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Bacher, A (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.							Bacher A, 1997, METHOD ENZYMOL, V280, P382; BLAU N, 1982, BIOCH CLIN ASPECTS P, V1, P103; Bracher A, 2001, BIOCHEMISTRY-US, V40, P7896, DOI 10.1021/bi010322v; Bracher A, 1999, J BIOL CHEM, V274, P16727, DOI 10.1074/jbc.274.24.16727; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; DAWSON RCM, 1986, DATA BIOCH RES, P109; DIETRICH R, 1979, J AM CHEM SOC, V101, P6144, DOI 10.1021/ja00514a059; FOOR F, 1975, J BIOL CHEM, V250, P3545; KWON NS, 1989, J BIOL CHEM, V264, P20496; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Ritz H, 2001, J BIOL CHEM, V276, P22273, DOI 10.1074/jbc.M100752200; Schramek N, 2001, J BIOL CHEM, V276, P2622, DOI 10.1074/jbc.M004912200; TAYEH MA, 1989, J BIOL CHEM, V264, P19654	13	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44157	44162		10.1074/jbc.M107306200	http://dx.doi.org/10.1074/jbc.M107306200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11553632	hybrid			2022-12-25	WOS:000172297700086
J	Treins, C; Giorgetti-Peraldi, S; Murdaca, J; Van Obberghen, E				Treins, C; Giorgetti-Peraldi, S; Murdaca, J; Van Obberghen, E			Regulation of vascular endothelial growth factor expression by advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; HYPOXIA-INDUCIBLE FACTOR-1; DIABETIC-RETINOPATHY; GLIOMA-CELLS; FACTOR GENE; TRANSCRIPTIONAL ACTIVATION; OXIDANT STRESS; FACTOR-I; PROTEIN; RECEPTOR	Advanced glycation end products (AGEs) are generated during long term diabetes and are correlated with the development of diabetic complications, such as retinopathy. Diabetic retinopathy is characterized by an increased retinal neovascularization due to the action of the angiogenic factor, vascular endothelial growth factor (VEGF). In this report, we show that injection of insulin and glycated albumin (Alb-AGE) to mice increases VEGF mRNA expression in eyes. Insulin and Alb-AGE stimulate VEGF mRNA and protein expression in retinal epithelial cells (ARPE-19). Alb-AGE-induced VEGF expression is not modulated by the use of antioxidants, N-acetyl-L-cysteine or pyrrolidinedithiocarbamate, or by an inhibitor of phosphatidylinositol 3-kinase (PI3K), wortmannin. However, using an inhibitor of ERK activation, U0126, we show that Alb-AGE stimulates VEGF expression through an ERK-dependent pathway. Accordingly, we found that Alb-AGE activated mitogen-activate protein kinase, ERK1/2, JNK1/2, but not p38, and that Alb-AGE did not activate PI3K and PKB. Moreover, Alb-AGE activated the transcription factor, hypoxia inducible factor-1 (HIF-1) DNA binding activity. This activation is mediated by an increase in accumulation of the HIF-1 alpha protein through an ERK-dependent pathway. Thus, stimulation of VEGF expression by Alb-AGE, through the activation of HIF-1, could play an important role in the development of diabetic retinopathy.	Fac Med, INSERM, U145, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Giorgetti-Peraldi, S (corresponding author), Fac Med, INSERM, U145, Ave Valombrose,IFR 50, F-06107 Nice 2, France.			Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Fonseca V, 1996, SOUTH MED J, V89, P839, DOI 10.1097/00007611-199609000-00001; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; McKinlay J, 2000, LANCET, V356, P757, DOI 10.1016/S0140-6736(00)02641-6; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	45	169	188	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43836	43841		10.1074/jbc.M106534200	http://dx.doi.org/10.1074/jbc.M106534200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571295	hybrid			2022-12-25	WOS:000172297700048
J	Lopez-Corcuera, B; Nunez, E; Martinez-Maza, R; Geerlings, A; Aragon, C				Lopez-Corcuera, B; Nunez, E; Martinez-Maza, R; Geerlings, A; Aragon, C			Substrate-induced conformational changes of extracellular loop 1 in the glycine transporter GLYT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN TRANSPORTER; TRANSMEMBRANE DOMAIN; GABA TRANSPORTER; ION-BINDING; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; ACID TRANSPORTERS; RECOMBINANT GLYT1; COCAINE BINDING	The neurotransmitter glycine is removed from the synaptic cleft by two Na+-and Cl--dependent transporters, the glial (GLYT1) and neuronal (GLYT2) glycine transporters. GLYT2 lacks a conserved cysteine in the first hydrophilic loop (EL1) that is reactive to [2-(trimethylammonium)ethyl] methanethiosulfonate (MTSET) in related transporters. A chimeric GLYT2 (GLYT2a-EL1) that contains GLYT1 sequences in this region, including the relevant cysteine, was sensitive to the reagent, and its sensitivity was decreased by co-substrates. We combined cysteine-specific biotinylation to detect transporter-reagent interactions with MTSET inactivation assays and temperature dependence analysis to study the mechanism by which Cl-, Na+, and glycine reduce methanethiosulfonate reagent inhibition. We demonstrate a Na+ protective effect rather than an increased susceptibility to the reagent exerted by Li+, as reported for the serotonin transporter. The different inhibition, protection, and reactivation properties between GLYT2a-EL1 and serotonin transporter suggest that EL1 is a source of structural heterogeneity involved in the specific effect of lithium on serotonin transport. The protection by Na+ or Cl- on GLYT2a-EL1 was clearly dependent on temperature, suggesting that EL1 is not involved in ion binding but is subjected to ion-induced conformational changes. Na+ and Cl- were required for glycine protection, indicating the necessity of prior ion interaction with the transporter for the binding of glycine. We conclude that EL1 acts as a fluctuating hinge undergoing sequential conformational changes during the transport cycle.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Aragon, C (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Maza, Rodrigo Martínez/ABH-3989-2020; Corcuera, Beatriz López/D-5188-2009; Aragon, Carmen/K-9783-2014	Maza, Rodrigo Martínez/0000-0002-7249-9205; Corcuera, Beatriz López/0000-0002-0383-4241; Aragon, Carmen/0000-0001-8287-9386				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Barker EL, 1999, J NEUROSCI, V19, P4705; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Borowsky B, 1998, J BIOL CHEM, V273, P29077, DOI 10.1074/jbc.273.44.29077; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Hanley JG, 2000, J BIOL CHEM, V275, P840, DOI 10.1074/jbc.275.2.840; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; Li M, 2000, J GEN PHYSIOL, V115, P491, DOI 10.1085/jgp.115.4.491; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Lopez-Corcuera B, 2001, MOL MEMBR BIOL, V18, P13, DOI 10.1080/09687680120521; Lopez-Corcuera B, 1998, J NEUROCHEM, V71, P2211; Mager S, 1996, J NEUROSCI, V16, P5405; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; Nelson N, 1998, J NEUROCHEM, V71, P1785; Ni YG, 2001, J BIOL CHEM, V276, P30942, DOI 10.1074/jbc.M104653200; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; Nunez E, 2000, BRIT J PHARMACOL, V129, P200, DOI 10.1038/sj.bjp.0703049; Nunez E, 2000, BRIT J PHARMACOL, V129, P802, DOI 10.1038/sj.bjp.0703100; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; Ponce J, 2000, J BIOL CHEM, V275, P13856, DOI 10.1074/jbc.275.18.13856; Ponce J, 1998, NEUROSCI LETT, V242, P25, DOI 10.1016/S0304-3940(98)00037-8; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Roux MJ, 2001, J BIOL CHEM, V276, P17699, DOI 10.1074/jbc.M009196200; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Simpson RK, 1995, NEUROCHEM RES, V20, P1203, DOI 10.1007/BF00995384; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; Tsai GC, 1998, BIOL PSYCHIAT, V44, P1081, DOI 10.1016/S0006-3223(98)00279-0; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WERMAN R, 1967, NATURE, V214, P681, DOI 10.1038/214681a0; Yu N, 1998, FEBS LETT, V426, P174, DOI 10.1016/S0014-5793(98)00333-0; ZAFRA F, 1995, J NEUROSCI, V15, P3952	55	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43463	43470		10.1074/jbc.M107438200	http://dx.doi.org/10.1074/jbc.M107438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551961	hybrid			2022-12-25	WOS:000172169300107
J	Maurice, D; Pierreux, CE; Howell, M; Wilentz, RE; Owen, MJ; Hill, CS				Maurice, D; Pierreux, CE; Howell, M; Wilentz, RE; Owen, MJ; Hill, CS			Loss of Smad4 function in pancreatic tumors - C-terminal truncation leads to decreased stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; MUTATIONAL INACTIVATION; SUPPRESSORS SMAD2; CRYSTAL-STRUCTURE; MAD PROTEINS; DPC4; GENE; DOMAIN	At early stages of tumorigenesis, the transforming growth factor-beta (TGF-beta) signaling pathway is thought to have tumor suppressor activity as a result of its ability to arrest the growth of epithelial cells. Smad4 plays a pivotal role in the TGF-beta signaling pathway and has been identified as a tumor suppressor, being mutated or deleted in similar to 50% of pancreatic carcinomas and 15% of colorectal cancers. A nonsense mutation generating a C-terminal truncation of 38 amino acids in the Smad4 protein has been identified in a pancreatic adenocarcinoma (Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. (1996) Science 271, 350-353), and here we investigate the functional consequences of this mutation. We demonstrate that the C-terminal truncation prevents Smad4 homomeric complex formation and heteromeric complex formation with activated Smad2. Furthermore, the mutant protein is unable to be recruited to DNA by transcription factors and hence cannot form transcriptionally active DNA-binding complexes. These observations are supported by molecular modeling, which indicates that the truncation removes residues critical for homomeric and heteromeric Smad complex formation. We go on to show that the mutant Smad4 is highly unstable compared with wild type Smad4 and is rapidly degraded through the ubiquitin-proteasome pathway. Consistent with this, we demonstrate that the pancreatic adenocarcinoma harboring this mutated allele, in conjunction with loss of the other allele, expresses no Smad4 protein. Thus we conclude that these tumors completely lack Smad4 activity.	Imperial Canc Res Fund, Lab Lymphocyte Mol Biol, London WC2A 3PX, England; Imperial Canc Res Fund, Lab Dev Signalling, London WC2A 3PX, England; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA	Cancer Research UK; Cancer Research UK; Johns Hopkins University; Johns Hopkins Medicine	Hill, CS (corresponding author), Imperial Canc Res Fund, Lab Lymphocyte Mol Biol, 44 Lincolns Inn Fields, London WC2A 3PX, England.	c.hill@icrf.icnet.uk	Maurice, Donald/AAE-9332-2019; Wilentz, Robb/AAJ-3857-2020	Howell, Michael/0000-0003-0912-0079; Hill, Caroline/0000-0002-8632-0480				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Duff EK, 1998, BRIT J CANCER, V78, P1615, DOI 10.1038/bjc.1998.731; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Germain S, 2000, GENE DEV, V14, P435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grady WM, 1999, CANCER RES, V59, P320; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Houlston R, 1998, HUM MOL GENET, V7, P1907, DOI 10.1093/hmg/7.12.1907; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; Reiss M, 1997, ONCOL RES, V9, P447; Riggins GJ, 1997, CANCER RES, V57, P2578; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wong C, 1999, MOL CELL BIOL, V19, P1821; Woodford-Richens K, 2000, CANCER RES, V60, P2477; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	51	71	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43175	43181		10.1074/jbc.M105895200	http://dx.doi.org/10.1074/jbc.M105895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553622	hybrid			2022-12-25	WOS:000172169300071
J	Schaefer, LK; Wang, SG; Schaefer, TS				Schaefer, LK; Wang, SG; Schaefer, TS			Functional interaction of Jun and homeodomain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; C-JUN; LEUCINE-ZIPPER; TRANSCRIPTION FACTORS; FOS JUN; NEGATIVE REGULATOR; CRYSTAL-STRUCTURE; RESPONSIVE GENES; NUCLEAR FACTOR; GROWTH-FACTORS	We have used the yeast two-hybrid system to identify proteins that interact with the N-terminal region of c-Jun, which is known to be involved in regulatory interactions. One of the proteins identified is the homeodomain-containing protein Hex. The Hex homeodomain is sufficient for interaction; moreover, the homeodomains of several other transcription factors also interact. Mutations within helix III of the Hex homeodomain greatly reduce the interaction. In vitro, c-Jun/c-Fos, JunB/c-Fos, and JunD/c-Fos all interact with the Hex homeodomain more strongly than the respective Jun proteins (or c-Fos) alone, suggesting that heterodimerization exposes reactive regions in the N termini of the Jun proteins. In transfected cells, Hex expression inhibits Jun- or Jun/cFos-dependent transcription of a reporter gene; the presence of Hex-binding sites in the promoter enhances the inhibitory effect. Jun-dependent activation of transcription from the basic fibroblast growth factor gene, previously shown to be regulated by both Jun and homeodomain proteins, was also dramatically reduced by Hex expression. Furthermore, in contrast to the reduction of Jun-mediated transcription by Hex, we found that expression of the Drosophila ultrabithorax gene enhanced c-Jun-dependent transcription. We conclude that the functional interaction between members of the Jun and homeodomain families of transcription factors could play a critical role in regulating developmental and differentiation programs.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Schaefer, TS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Box 064, Houston, TX 77030 USA.							AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BREIER G, 1988, EMBO J, V7, P1329, DOI 10.1002/j.1460-2075.1988.tb02948.x; Care A, 1996, MOL CELL BIOL, V16, P4842; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; CURRAN T, 1992, TRANSCRIPTIONAL REGU, P797; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES DH, 1992, BIOTECHNIQUES, V12, P528; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Miller H., 1972, EXPT MOL GENETICS; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; MOFFETT J, 1996, P NATL ACAD SCI USA, V93, P2770; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RASONE L, 1993, GENE EXPRESSION, V3, P37; RUBIN MR, 1987, MOL CELL BIOL, V7, P3836, DOI 10.1128/MCB.7.10.3836; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P24; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; van der Eb A J, 1980, Methods Enzymol, V65, P826; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	66	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43074	43082		10.1074/jbc.M102552200	http://dx.doi.org/10.1074/jbc.M102552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551904	hybrid			2022-12-25	WOS:000172169300059
J	Engers, R; Springer, E; Michiels, F; Collard, JG; Gabbert, HE				Engers, R; Springer, E; Michiels, F; Collard, JG; Gabbert, HE			Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MATRIX-METALLOPROTEINASE; EPITHELIAL-CELLS; I COLLAGEN; RHO; ADHESION; KINASE; GENE; INVASIVENESS; METASTASIS	Rho-like GTPases, including Cdc42, Rac1, and RhoA, regulate distinct actin cytoskeleton changes required for adhesion, migration, and invasion of cells. Tiam1 specifically activates Rac, and earlier studies have demonstrated that Tiam1-Rac signaling affects migration and invasion in a cell type- and cell substrate-specific manner. In the present study, we examined the role of Tiam1-Rac signaling in migration and invasion of human renal cell carcinomas. Stable overexpression of Tiam1 or constitutively active V12-Rac1 in a human renal cell carcinoma cell line (clearCa-28) strongly inhibited cell migration by promoting E-cadherin-mediated cell-cell adhesion. Blocking E-cadherin-mediated adhesion by E-cadherin-specific HAV peptides allowed cells to migrate, but was not sufficient to antagonize Tiam1- and V12-Rac1-induced inhibition of Matrigel invasion, suggesting that Rac may influence invasion also through other mechanisms. Indeed, Tiam1-mediated Rac activation induced transcriptional up-regulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) and post-transcriptional up-regulation of TIMP-2, whereas secretion and activity levels of their counterparts, matrix metalloproteinase-9 and matrix metalloproteinase-2, respectively, were not affected. Application of recombinant TIMP-1 and TIMP-2 proteins significantly inhibited invasion of mock-transfected clearCa-28 cells, supporting a role of TIMPs in Rac-mediated inhibition of invasion. To our knowledge, this is the first evidence that increased Rac signaling may inhibit invasion of epithelial tumor cells by up-regulation of TIMP-1 and TIMP-2.	Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Heinrich Heine University Dusseldorf; Netherlands Cancer Institute	Engers, R (corresponding author), Univ Dusseldorf, Inst Pathol, Moorenstr 5, D-40225 Dusseldorf, Germany.	engers@med.uni-duesseldorf.de						Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Cockett MI, 1998, BIOCHEM SOC SYMP, P295; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Engers R, 2000, J CANCER RES CLIN, V126, P682, DOI 10.1007/s004320000148; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Engers R, 1999, INT J CANCER, V80, P406, DOI 10.1002/(SICI)1097-0215(19990129)80:3<406::AID-IJC12>3.0.CO;2-L; Engers R, 1996, BRIT J CANCER, V73, P491, DOI 10.1038/bjc.1996.86; Evers EE, 2000, METHOD ENZYMOL, V325, P403; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Li YY, 1999, CARDIOVASC RES, V42, P162, DOI 10.1016/S0008-6363(98)00297-1; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Quirin N, 1999, J CELL PHYSIOL, V180, P372, DOI 10.1002/(SICI)1097-4652(199909)180:3<372::AID-JCP8>3.0.CO;2-G; RAY JM, 1994, EUR RESPIR J, V7, P2062; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	51	88	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41889	41897		10.1074/jbc.M105049200	http://dx.doi.org/10.1074/jbc.M105049200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551917	hybrid			2022-12-25	WOS:000172450400047
J	Kanzaki, M; Pessin, JE				Kanzaki, M; Pessin, JE			Insulin-stimulated GLUT4 translocation in adipocytes is dependent upon cortical actin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER; SUBCELLULAR TRAFFICKING; 3T3-L1 ADIPOCYTES; RHO-PROTEINS; KINASE; FILAMENTS; MEMBRANE; RAC	Rhodamine-labeled phalloidin staining of morphologically differentiated 3T3L1 adipocytes demonstrated that F-actin predominantly exists juxtaposed to and lining the inner face of the plasma membrane (cortical actin) with a smaller amount of stress fiber and/or ruffling actin confined to the cell bottom in contact with the substratum. The extent of cortical actin disruption with various doses of either latrunculin B or Clostridium difficile toxin B (a Rho family small GTP-binding protein toxin) directly correlated with the inhibition of insulin-stimulated glucose uptake and GLUT4 translocation. The dissolution of the cortical actin network had no significant effect on proximal insulin receptor signaling events including insulin receptor autophosphorylation, tyrosine phosphorylation of insulin receptor substrate and Cb1, or serine/threonine phosphorylation of Akt. Surprisingly, however, stabilization of F-actin with jasplakinolide also resulted in a dose-dependent inhibition of insulin-stimulated glucose uptake and GLUT4 translocation. In vivo time-lapse confocal fluorescent microscopy of actin-yellow fluorescent protein demonstrated that insulin stimulation initially results in cortical actin remodeling followed by an increase in polymerized actin in the peri-nuclear region. Importantly, the insulin stimulation of cortical actin rearrangements was completely blocked by treatment of the cells with latrunculin B, C. difficile toxin B, and jasplakinolide. Furthermore, expression of the dominant-interfering TC10/T31N mutant completely disrupted cortical actin and prevents any insulin-stimulated actin remodeling. Together, these data demonstrate that cortical actin, but not stress fibers, lamellipodia, or filopodia, plays an important regulatory role in insulin-stimulated GLUT4 translocation. In addition, cortical F-actin does not function in a static manner (e.g. barrier or scaffold), but insulin-stimulated dynamic cortical actin remodeling is necessary for the GLUT4 translocation process.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	Jeffrey-Pessin@uiowa.edu	Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955	NIDDK NIH HHS [DK33823, DK25295, DK59291] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, P30DK025295, R01DK033823, R01DK059291] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG Q, 1999, MOL CELL BIOL, V19, P4008; Ballestrem C, 1998, J CELL SCI, V111, P1649; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; Carbajal ME, 1997, ENDOCRINOLOGY, V138, P5374, DOI 10.1210/en.138.12.5374; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dorrestijn J, 1996, DIABETOLOGIA, V39, P558, DOI 10.1007/s001250050478; Dorrestijn J, 1997, EXP CLIN ENDOCR DIAB, V105, P254, DOI 10.1055/s-0029-1211762; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Khayat ZA, 2000, J CELL SCI, V113, P279; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; LI GD, 1994, MOL BIOL CELL, V5, P1199, DOI 10.1091/mbc.5.11.1199; Machesky LM, 1999, NAT CELL BIOL, V1, pE29, DOI 10.1038/10020; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; Martin MAE, 1999, CELL MOL LIFE SCI, V56, P200, DOI 10.1007/s000180050422; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; MORITA K, 1988, BIOCHEM PHARMACOL, V37, P3357; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OKONSKI MS, 1990, J CLIN INVEST, V86, P1649, DOI 10.1172/JCI114887; OKONSKI MS, 1993, PANCREAS, V8, P638, DOI 10.1097/00006676-199309000-00018; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SATOH S, 1993, J BIOL CHEM, V268, P17820; Schroer T A, 1992, Curr Opin Neurobiol, V2, P618, DOI 10.1016/0959-4388(92)90028-J; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Terada S, 2000, CURR OPIN NEUROBIOL, V10, P566, DOI 10.1016/S0959-4388(00)00129-X; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; YANG J, 1993, J BIOL CHEM, V268, P4600	82	232	242	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42436	42444		10.1074/jbc.M108297200	http://dx.doi.org/10.1074/jbc.M108297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546823	hybrid			2022-12-25	WOS:000172450400115
J	Takeda, M; Dohmae, N; Takio, K; Arai, K; Watanabe, S				Takeda, M; Dohmae, N; Takio, K; Arai, K; Watanabe, S			Cell cycle-dependent interaction of Mad2 with conserved box1/2 region of human granulocyte-macrophage colony-stimulating factor receptor common beta c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT PROTEIN MAD2; CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; GROWTH SIGNAL-TRANSDUCTION; SPINDLE CHECKPOINT; BUDDING YEAST; TYROSINE PHOSPHORYLATION; INSULIN-RECEPTOR; MITOTIC ARREST; GM-CSF; ACTIVATION	Box1 and 2 (box1/2) are conserved cytoplasmic motifs located in the membrane proximal region of cytokine receptors, including the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor common betac. Deletion of box1/2 abrogated all the examined activities of GM-CSF, and this phenomenon is explained by the loss of binding by Jak2. To test if a molecule other than Jak2 interacting with the box1/2 region plays a role in GM-CSF receptor signal transduction, we screened for molecules interacting with the box1/2 region by a pull-down assay using recombinant purified protein of GST fused with the betac box1/2 region and a Ba/F3 cell lysate. The mouse homologue of Mad2 protein, which plays an important role in the M phase of the cell cycle, was revealed to associate with the box1/2 region specifically. Peptides corresponding to the box1 sequence also bound to Mad2, and mutation of the box1 decreased the Mad2 interaction. Deletion analysis indicated that interaction with box1/2 occurred through the C-terminal portion of Mad2. Mad2 is known to change affinity for binding partners cell cycle dependently. Binding affinity of Mad2 to box1/2 increased in the late M phase, suggesting the possibility that GM-CSF participates in regulation of the M phase check point through interaction with Mad2.	Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Japan Sci & Technol Corp, Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Biomol Characterizat Div, Wako, Saitama 3510198, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; RIKEN	Watanabe, S (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P284, DOI 10.1016/S0968-0004(98)01257-2; AVALOS BR, 1995, BLOOD, V85, P3117, DOI 10.1182/blood.V85.11.3117.bloodjournal85113117; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; DINERSTEIN H, 1995, MOL ENDOCRINOL, V9, P1701, DOI 10.1210/me.9.12.1701; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nelson KK, 1999, BIOCHEM J, V343, P673, DOI 10.1042/0264-6021:3430673; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; ONEAL KD, 1995, MOL CELL BIOL, V15, P4657; ONeal KD, 1995, ANN NY ACAD SCI, V766, P282, DOI 10.1111/j.1749-6632.1995.tb26677.x; ONeill TJ, 1997, J BIOL CHEM, V272, P10035; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pennisi E, 1998, SCIENCE, V279, P477, DOI 10.1126/science.279.5350.477; Poelzl G, 2000, P NATL ACAD SCI USA, V97, P2836, DOI 10.1073/pnas.050580997; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681	42	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41803	41809		10.1074/jbc.M101488200	http://dx.doi.org/10.1074/jbc.M101488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551900	hybrid			2022-12-25	WOS:000172450400036
J	Loven, MA; Likhite, VS; Choi, I; Nardulli, AM				Loven, MA; Likhite, VS; Choi, I; Nardulli, AM			Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; TRANSCRIPTIONAL COACTIVATOR; HORMONE RECEPTORS; BINDING DOMAINS; ER-BETA; DNA; ACTIVATION; SEQUENCE; REGION; MCF-7	Estrogen receptor beta (ER beta) activates transcription by binding to estrogen response elements (EREs) and coactivator proteins that act as bridging proteins between the receptor and the basal transcription machinery. Although the imperfect vitellogenin B1, pS2, and oxytocin (OT) EREs each differ from the consensus vitellogenin A2 ERE sequence by a single base pair, ER beta activates transcription of reporter plasmids containing A2, pS2, Bl, and OT EREs to different extents. To explain how these differences in transactivation might occur, we have examined the interaction of ER beta with these EREs and monitored recruitment of the coactivators amplified in breast cancer (AIB1) and transcription intermediary factor 2 (TIF2). Protease sensitivity, antibody interaction, and DNA pull-down assays demonstrated that ER beta undergoes ERE-dependent changes in conformation resulting in differential recruitment of AI beta1 and TIF2 to the DNA-bound receptor. Overexpression of TIF2 or AIB1 in transient transfection assays differentially enhanced ER beta -mediated transcription of reporter plasmids containing the A2, pS2, B1, and OT EREs. Our studies demonstrate that individual ERE sequences induce changes in conformation of the DNA-bound receptor and influence coactivator recruitment. DNA-induced modulation of receptor conformation may contribute to the ability of ER beta to differentially activate transcription of genes containing divergent ERE sequences.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Nardulli, AM (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NCI NIH HHS [CA18119] Funding Source: Medline; NICHD NIH HHS [5T32 HD07028] Funding Source: Medline; NIDDK NIH HHS [DK53884] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007028] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053884, R01DK053884] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Choi I, 2001, MOL CELL ENDOCRINOL, V181, P139, DOI 10.1016/S0303-7207(01)00492-0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; ECKERT RL, 1982, CANCER RES, V42, P139; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hanstein B, 1999, MOL ENDOCRINOL, V13, P129, DOI 10.1210/me.13.1.129; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; NUNEZ AM, 1987, ENDOCRINOLOGY, V121, P1759, DOI 10.1210/endo-121-5-1759; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; ONATE SA, 1995, SCIENCE, V270, P1354; Peters GA, 1999, MOL ENDOCRINOL, V13, P286, DOI 10.1210/me.13.2.286; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VOEGEL JJ, 1996, EMBO J, V15, P101; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114	45	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45282	45288		10.1074/jbc.M106211200	http://dx.doi.org/10.1074/jbc.M106211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574541	hybrid			2022-12-25	WOS:000172406700123
J	Masters, SC; Fu, H				Masters, SC; Fu, H			14-3-3 proteins mediate an essential anti-apoptotic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOENZYME-S; PHOSPHOINOSITIDE 3-KINASE; SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS-AERUGINOSA; AMPHIPATHIC GROOVE; 14-3-3-PROTEINS; PHOSPHORYLATION; SURVIVAL; KINASE; DEATH	The 14-3-3 proteins are a family of highly conserved eukaryotic regulatory molecules that play important roles in many biological processes including cell cycle control and regulation of cell death. They are able to carry out these effects through binding and modulating the activity of a host of signaling proteins. The ability of 14-3-3 to inhibit Bad and other proapoptotic proteins argues that 14-3-3 can support cell survival. To examine this issue in a global sense, a specific inhibitor of 14-3-3/ligand interactions, difopein, was used. Difopein expression led to induction of apoptosis. Studies using various components of survival and death signaling pathways were consistent with a vital role for 14-3-3/ligand interactions in signal transduction from upstream pro-survival kinases to the core apoptotic machinery. Because these kinases often become activated during oncogenesis, the effect of difopein on cell death induced by antineoplastic drugs was examined. It was found that difopein enhances the ability of cisplatin to kill cells. These data support the model that 14-3-3, through binding to Bad and other ligands, is critical for cell survival signaling. Inhibition of 14-3-3 may represent a useful therapeutic target for treatment of cancer and other diseases involving inappropriate cell survival.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA	Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.				NIGMS NIH HHS [GM60033, GM53165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060033, R01GM053165, R29GM053165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARANTEMENDES GP, 1998, CELLS LAB MANUAL, V1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Henriksson ML, 2000, BIOCHEM J, V349, P697, DOI 10.1042/bj3490697; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MASTERS SC, 2001, IN PRESS MOL PHARM; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; YAFFE MB, 1997, CELL, V91, P9619; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	32	241	258	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45193	45200		10.1074/jbc.M105971200	http://dx.doi.org/10.1074/jbc.M105971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577088	hybrid			2022-12-25	WOS:000172406700112
J	Sarin, J; Aggarwal, S; Chaba, R; Varshney, GC; Chakraborti, PK				Sarin, J; Aggarwal, S; Chaba, R; Varshney, GC; Chakraborti, PK			B-subunit of phosphate-specific transporter from Mycobacterium tuberculosis is a thermostable ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-BINDING; MALTOSE TRANSPORT; ABC TRANSPORTER; MULTIDRUG-RESISTANCE; ENCODING PROTEINS; BACILLUS-SUBTILIS; TRAFFIC ATPASE	The B-subunit of phosphate-specific transporter (PstB) is an ABC protein. pstB was polymerase chain reaction-amplified from Mycobacterium tuberculosis and overexpressed in Escherichia coli. The overexpressed protein was found to be in inclusion bodies. The protein was solubilized using 1.5% N-lauroylsarcosine and was purified by gel permeation chromatography. The molecular mass of the protein was similar to 31 kDa. The eluted protein showed ATP-binding ability and exhibited ATPase activity. Among different nucleotide triphosphates, ATP was found to be the preferred substrate for M. tuberculosis PstB-ATPase. The study of the kinetics of ATP hydrolysis yielded K-m of similar to 72 muM and V-max of similar to0.12 mu mol/min/mg of protein. Divalent cation like manganese was inhibitory to the ATPase activity. Magnesium or calcium, on the other hand, had no influence on the functionality of the enzyme. The classical ATPase inhibitors like sodium azide, sodium vanadate, and N-ethylmaleimide were without any effect but an ATP analogue, 5'-p-fluorosulfonylbenzoyl adenosine, inhibited the ATPase function of the recombinant protein with a K-i of similar to0.40 mM. Furthermore, there was hardly any ATP hydrolyzing ability of the PstB as a result of mutation of the conserved aspartic acid residue to lysine in the Walker motif B, confirming the recombinant protein is an ATPase. Interestingly, analysis of the recombinant PstB revealed that it is a thermostable ATPase; thus, our results highlight for the first time the presence of such an enzyme in any mesophilic bacteria.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Chakraborti, PK (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.							ANOSTARIO M, 1990, ANAL BIOCHEM, V190, P60, DOI 10.1016/0003-2697(90)90133-T; Banerjee SK, 1998, FEBS LETT, V425, P151, DOI 10.1016/S0014-5793(98)00214-2; Banerjee SK, 2000, MOL GEN GENET, V262, P949, DOI 10.1007/PL00008663; Bhatt K, 2000, EUR J BIOCHEM, V267, P4028, DOI 10.1046/j.1432-1327.2000.01437.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braibant M, 1996, FEBS LETT, V394, P206, DOI 10.1016/0014-5793(96)00953-2; Braibant M, 2000, FEMS MICROBIOL REV, V24, P449, DOI 10.1111/j.1574-6976.2000.tb00550.x; Chakravarty S, 2000, FEBS LETT, V470, P65, DOI 10.1016/S0014-5793(00)01267-9; Chan FY, 1996, J BACTERIOL, V178, P3974, DOI 10.1128/jb.178.13.3974-3977.1996; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coligan JE, 1995, CURRENT PROTOCOLS PR; Cross SJ, 1996, BIOCHEM J, V316, P615, DOI 10.1042/bj3160615; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HANLEY P, 1999, P NATL ACAD SCI USA, V96, P3578; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 1999, FEBS LETT, V448, P131, DOI 10.1016/S0014-5793(99)00356-7; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Lefevre P, 1997, J BACTERIOL, V179, P2900, DOI 10.1128/jb.179.9.2900-2906.1997; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Morlang S, 1999, J MOL BIOL, V294, P795, DOI 10.1006/jmbi.1999.3282; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Novak R, 1999, J BACTERIOL, V181, P1126, DOI 10.1128/JB.181.4.1126-1133.1999; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Qi Y, 1997, J BACTERIOL, V179, P2534, DOI 10.1128/jb.179.8.2534-2539.1997; Quentin Y, 1999, J MOL BIOL, V287, P467, DOI 10.1006/jmbi.1999.2624; Rana S, 1999, J MOL BIOL, V286, P669, DOI 10.1006/jmbi.1998.2505; Sambrook J., 2002, MOL CLONING LAB MANU; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; STUDIER OFW, 1990, METHOD ENZYMOL, V185, P60; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WAKAGI T, 1985, BIOCHIM BIOPHYS ACTA, V817, P33, DOI 10.1016/0005-2736(85)90065-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; WANNER BL, 1996, E COLI SALMONELLA CE, V1, P1356; WEBB DC, 1992, J BIOL CHEM, V267, P24661; Welsh MJ, 1998, NATURE, V396, P623, DOI 10.1038/25234	50	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44590	44597		10.1074/jbc.M105401200	http://dx.doi.org/10.1074/jbc.M105401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567022	hybrid			2022-12-25	WOS:000172406700035
J	Yin, L; Laevsky, G; Giardina, C				Yin, L; Laevsky, G; Giardina, C			Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; QUIESCENT ULCERATIVE-COLITIS; COLONIC EPITHELIAL-CELLS; SODIUM-BUTYRATE; DIETARY FIBER; CANCER CELLS; WHEAT BRAN; PROTEOLYTIC PATHWAY; GENE-EXPRESSION; BETA-CATENIN	Butyrate is derived from the microbial metabolism of dietary fiber in the colon where it plays an important role in linking colonocyte turnover and differentiation to luminal content. In addition, butyrate appears to have both anti-inflammatory and cancer chemopreventive activities. Using confocal microscopy and cell fractionation studies, butyrate pretreatment of a human colon cell line (HT-29 cells) inhibited the tumor necrosis factor-alpha (TNF-alpha)-induced nuclear translocation of the proinflammatory transcription factor NF-kappaB. Butyrate inhibited NF-kappaB DNA binding within 30 min of TNF-alpha stimulation, consistent with an inhibition of nuclear translocation. I kappaB.NF-kappaB complexes extracted from butyrate-treated cells were relatively resistant to in vitro dissociation by deoxycholate, suggesting a change in cellular I kappaB composition. Butyrate treatment increased p100 expression, an I kappaB that was not degraded upon TNF-alpha treatment. Butyrate also reduced the extent of TNF-alpha -induced I kappaB-alpha degradation and enhanced the presence of ubiquitin-conjugated I kappaB-alpha. The suppression of I kappaB-alpha degradation corresponded with a reduction in cellular proteasome activity as determined by in vitro proteasome assays and the increased presence of ubiquitin-conjugated proteins. The butyrate suppression of I kappaB-alpha degradation and proteasome activity may derive from its ability to inhibit histone deacetylases since the specific deacetylase inhibitor trichostatin A had similar effects. These results suggest a potential mechanism for the anti-inflammatory activity of butyrate and demonstrate the interplay between short chain fatty acids and cellular proteasome activity.	Univ Connecticut, Dept Mol & Cellular Biol, Storrs, CT 06269 USA	University of Connecticut	Giardina, C (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 75 N Eagleville Rd,U-125, Storrs, CT 06269 USA.	Giardina@uconnvm.uconn.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; ANTALIS TM, 1995, INT J CANCER, V62, P619, DOI 10.1002/ijc.2910620521; Avivi-Green C, 2000, ONCOL RES, V12, P83, DOI 10.3727/096504001108747558; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Barshishat M, 2000, BRIT J CANCER, V82, P195; Benard O, 1997, MOL CELL BIOCHEM, V170, P109, DOI 10.1023/A:1006892929652; BINDER HJ, 1989, GASTROENTEROLOGY, V96, P989, DOI 10.1016/0016-5085(89)91614-4; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BOFFA LC, 1992, CANCER RES, V52, P5906; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakravortty D, 2000, J ENDOTOXIN RES, V6, P243, DOI 10.1179/096805100101532108; CHAPMAN MAS, 1995, BRIT J SURG, V82, P36, DOI 10.1002/bjs.1800820115; CHAPMAN MAS, 1994, GUT, V35, P1152, DOI 10.1136/gut.35.8.1152-a; CHAPMAN MAS, 1994, GUT, V35, P73, DOI 10.1136/gut.35.1.73; Ciechanover A, 2000, J CELL BIOCHEM, P40; Compher CW, 1999, JPEN-PARENTER ENTER, V23, P269, DOI 10.1177/0148607199023005269; Crinelli R, 1999, EUR J BIOCHEM, V263, P202, DOI 10.1046/j.1432-1327.1999.00485.x; Csordas A, 1996, EUR J CANCER PREV, V5, P221, DOI 10.1097/00008469-199608000-00002; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; EDMONDS CJ, 1982, PHILOS T ROY SOC B, V299, P575, DOI 10.1098/rstb.1982.0153; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Giardina C, 1998, BBA-MOL CELL RES, V1401, P277, DOI 10.1016/S0167-4889(97)00140-7; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOPE R, 1993, CELL MOL BIOL, V39, P589; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1996, P NUTR SOC, V55, P937, DOI 10.1079/PNS19960090; Hallahan DE, 2000, INT J RADIAT ONCOL, V47, P859, DOI 10.1016/S0360-3016(00)00517-4; Hassig CA, 1997, CHEM BIOL, V4, P783, DOI 10.1016/S1074-5521(97)90111-3; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hodin R, 2000, GASTROENTEROLOGY, V118, P798, DOI 10.1016/S0016-5085(00)70150-8; HOWARD MD, 1995, J NUTR, V125, P2604; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; JACOBS LR, 1987, PREV MED, V16, P566, DOI 10.1016/0091-7435(87)90073-9; JACOBS LR, 1986, CANCER RES, V46, P1727; JACOBS LR, 1983, AM J CLIN NUTR, V37, P945, DOI 10.1093/ajcn/37.6.945; JACOBS LR, 1984, AM J PHYSIOL, V246, pG378, DOI 10.1152/ajpgi.1984.246.4.G378; Jobin C, 1997, J IMMUNOL, V158, P226; Kanauchi O, 1999, J GASTROEN HEPATOL, V14, P880, DOI 10.1046/j.1440-1746.1999.01971.x; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Luciano L, 1996, CELL TISSUE RES, V286, P81, DOI 10.1007/s004410050677; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Maki CG, 1996, CANCER RES, V56, P2649; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PETIT JM, 1993, ANTICANCER RES, V13, P487; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; SCHEPPACH W, 1995, EUR J CANCER, V31A, P1077, DOI 10.1016/0959-8049(95)00165-F; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; SOULEIMANI A, 1993, BIOCHEM BIOPH RES CO, V193, P330, DOI 10.1006/bbrc.1993.1628; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Takahashi T, 1999, CANCER LETT, V141, P139, DOI 10.1016/S0304-3835(99)00096-8; Thomas GL, 1996, IN VITRO CELL DEV-AN, V32, P505; Tomoda H, 2000, YAKUGAKU ZASSHI, V120, P935, DOI 10.1248/yakushi1947.120.10_935; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; UMESAKI Y, 1979, PFLUG ARCH EUR J PHY, V379, P43, DOI 10.1007/BF00622903; Velazquez OC, 1996, DIGEST DIS SCI, V41, P727, DOI 10.1007/BF02213129; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P169; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wachtershauser A, 2000, EUR J NUTR, V39, P164, DOI 10.1007/s003940070020; Whiteley LO, 2000, NUTR CANCER, V36, P131, DOI 10.1207/S15327914NC3602_1; Williams A, 1999, SURGERY, V126, P744, DOI 10.1067/msy.2099.99888; Wilson L, 1999, GASTROENTEROLOGY, V117, P106, DOI 10.1016/S0016-5085(99)70556-1; Wu GD, 1999, J LEUKOCYTE BIOL, V66, P1049, DOI 10.1002/jlb.66.6.1049	85	211	222	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44641	44646		10.1074/jbc.M105170200	http://dx.doi.org/10.1074/jbc.M105170200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572859	hybrid			2022-12-25	WOS:000172406700042
J	Koc, EC; Burkhart, W; Blackburn, K; Moyer, MB; Schlatzer, DM; Moseley, A; Spremulli, LL				Koc, EC; Burkhart, W; Blackburn, K; Moyer, MB; Schlatzer, DM; Moseley, A; Spremulli, LL			The large subunit of the mammalian mitochondrial ribosome - Analysis of the complement of ribosomal proteins present	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRESPONDING GENE-SEQUENCES; ANGSTROM RESOLUTION; MASS-SPECTROMETRY; IDENTIFICATION; RNA; TRANSCRIPTION; YEAST; CELLS; MRPS	Identification of all the protein components of the large subunit (39 S) of the mammalian mitochondrial ribosome has been achieved by carrying out proteolytic digestions of whole 39 S subunits followed by analysis of the resultant peptides by liquid chromatography and mass spectrometry. Peptide sequence information was used to search the human EST data bases and complete coding sequences were assembled. The human mitochondrial 39 S subunit has 48 distinct proteins. Twenty eight of these are homologs of the Escherichia coli 50 S ribosomal proteins L1, L2, L3, L4, L7/L12, L9, L10, L11, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L27, L28, L30, L32, L33, L34, L35, and L36. Almost all of these proteins have homologs in Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae mitochondrial ribosomes. No mitochondrial homologs to prokaryotic ribosomal proteins L5, L6, L25, L29, and L31 could be found either in the peptides obtained or by analysis of the available data bases. The remaining 20 proteins present in the 39 S subunits are specific to mitochondrial ribosomes. Proteins in this group have no apparent homologs in bacterial, chloroplast, archaebacterial, or cytosolic ribosomes. All but two of the proteins has a clear homolog in D. melanogaster while all can be found in the genome of C. elegans. Ten of the 20 mitochondrial specific 39 S proteins have homologs in S. cerevisiae. Homologs of 2 of these new classes of ribosomal proteins could be identified in the Arabidopsis thaliana genome.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; GlaxoSmithKline Res & Dev, Dept Pathway Genom, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BEHAL RH, 1994, J BIOL CHEM, V269, P31372; Bogdanov AA, 1995, BIOCHEM CELL BIOL, V73, P869, DOI 10.1139/o95-094; BURKHART W, 1992, TECHNIQUES PROTEIN C, V4, P399; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; CLAROS MG, 1996, EUR J BIOCHEM, V241, P770, DOI DOI 10.1111/J.1432-1033.1996.00779.X; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; Furumoto H, 2000, FEBS LETT, V486, P195, DOI 10.1016/S0014-5793(00)02293-6; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HEROLD M, 1987, J BIOL CHEM, V262, P8826; Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463; JOSEFSSON LG, 1981, CELL, V25, P151, DOI 10.1016/0092-8674(81)90239-7; Khaitovich P, 1999, P NATL ACAD SCI USA, V96, P85, DOI 10.1073/pnas.96.1.85; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200; Koc EC, 2001, PROTEIN SCI, V10, P471, DOI 10.1110/ps.35301; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; Magalhaes PJ, 1998, MOL BIOL CELL, V9, P2375, DOI 10.1091/mbc.9.9.2375; Mariottini P, 1999, J BIOL CHEM, V274, P31853, DOI 10.1074/jbc.274.45.31853; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; Mueller F, 2000, J MOL BIOL, V298, P35, DOI 10.1006/jmbi.2000.3635; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; Patel VB, 2001, J BIOL CHEM, V276, P6739, DOI 10.1074/jbc.M005781200; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PIETROMONACO SF, 1991, BIOCHIMIE, V73, P827, DOI 10.1016/0300-9084(91)90062-6; Rodeheffer MS, 2001, J BIOL CHEM, V276, P8616, DOI 10.1074/jbc.M009901200; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spahr CS, 2000, ELECTROPHORESIS, V21, P1635, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1635::AID-ELPS1635>3.0.CO;2-1; Spirina O, 2000, GENE, V261, P229, DOI 10.1016/S0378-1119(00)00504-7; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Wang YH, 1999, P NATL ACAD SCI USA, V96, P8046, DOI 10.1073/pnas.96.14.8046; WITTMANNLIEBOLD B, 1985, RIBOSOMAL PROTEINS S; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	47	188	228	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43958	43969		10.1074/jbc.M106510200	http://dx.doi.org/10.1074/jbc.M106510200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551941	hybrid			2022-12-25	WOS:000172297700063
J	Shin, DM; Luo, X; Wilkie, TM; Miller, LJ; Peck, AB; Humphreys-Beher, MG; Muallem, S				Shin, DM; Luo, X; Wilkie, TM; Miller, LJ; Peck, AB; Humphreys-Beher, MG; Muallem, S			Polarized expression of G protein-coupled receptors and an all-or-none discharge of Ca2+ pools at initiation sites of [Ca2+]i waves in polarized exocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SALIVARY-GLAND CELLS; CALCIUM-RELEASE; INTRACELLULAR STORES; SIGNALING COMPLEXES; OSCILLATIONS; TRISPHOSPHATE; ACETYLCHOLINE; PROPAGATION	In the present work we examined localization and behavior of G protein-coupled receptors (GPCR) in polarized exocrine cells to address the questions of how luminal to basal Ca2+ waves can be generated in a receptor-specific manner and whether quantal Ca2+ release reflects partial release from a continuous pool or an all-or-none release from a compartmentalized pool. Immunolocalization revealed that expression of GPCRs in polarized cells is not uniform, with high levels of GPCR expression at or near the tight junctions. Measurement of phospholipase C beta activity and receptor-dependent recruitment and trapping of the box domain of RGS4 in GPCRs complexes indicated autonomous functioning of G(q)-coupled receptors in acinar cells. These findings explain the generation of receptor-specific Ca2+ waves and why the waves are always initiated at the apical pole. The initiation site of Ca2+ wave at the apical pole and the pattern of wave propagation were independent of inositol 1,4,5-trisphosphate concentration. Furthermore, a second Ca2+ wave with the same initiation site and pattern was launched by inhibition of sarco/endoplasmic reticulum Ca2+-ATPase pumps of cells continuously stimulated with sub-maximal agonist concentration. By contrast, rapid sequential application of sub-maximal and maximal agonist concentrations to the same cell triggered C2+ waves with different initiation sites. These findings indicate that signaling specificity in pancreatic acinar cells is aided by polarized expression and autonomous functioning of GPCRs and that quantal C2+ release is not due to a partial Ca2+ release from a continuous pool, but rather, it is due to an all-or-none Ca2+ release from a compartmentalized Ca2+ pool.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Univ Florida, Dept Pathol & Lab Med, Gainesville, FL 32610 USA; Univ Florida, Dept Oral Biol, Gainesville, FL 32610 USA; Univ Florida, Dept Therapeut & Pharmacol, Gainesville, FL 32610 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Mayo Clinic; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Shin, Dong Min/0000-0001-6042-0435				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; Callamaras N, 2000, EMBO J, V19, P3608, DOI 10.1093/emboj/19.14.3608; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; DeToledo CF, 1997, AM J PHYSIOL-GASTR L, V272, pG488, DOI 10.1152/ajpgi.1997.272.3.G488; Fogarty KE, 2000, J PHYSIOL-LONDON, V526, P515, DOI 10.1111/j.1469-7793.2000.t01-1-00515.x; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ito K, 1999, J CELL BIOL, V146, P405, DOI 10.1083/jcb.146.2.405; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; LeBeau AP, 1999, J GEN PHYSIOL, V113, P851, DOI 10.1085/jgp.113.6.851; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1994, MOL CELL ENDOCRINOL, V98, P147, DOI 10.1016/0303-7207(94)90133-3; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1987, BIOCHEM BIOPH RES CO, V149, P213, DOI 10.1016/0006-291X(87)91626-3; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Nguyen KHT, 2000, ARTHRITIS RHEUM-US, V43, P2297, DOI 10.1002/1529-0131(200010)43:10<2297::AID-ANR18>3.0.CO;2-X; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rios JD, 1999, INVEST OPHTH VIS SCI, V40, P1102; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Takemura H, 1999, BIOCHEM BIOPH RES CO, V259, P656, DOI 10.1006/bbrc.1999.0818; Taylor Colin W., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P109; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOTORICI G, 1994, J BIOL CHEM, V269, P29621; Williams JA, 1997, DIGESTION, V58, P42, DOI 10.1159/000201524; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Xu X, 1997, CELL CALCIUM, V22, P217, DOI 10.1016/S0143-4160(97)90015-4; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yule DI, 1997, J BIOL CHEM, V272, P9093; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520; ZHANG BX, 1994, J BIOL CHEM, V269, P17132; Zhao XS, 2001, EMBO J, V20, P2680, DOI 10.1093/emboj/20.11.2680	42	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44146	44156		10.1074/jbc.M105203200	http://dx.doi.org/10.1074/jbc.M105203200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11553617	hybrid			2022-12-25	WOS:000172297700085
J	Zhang, LH; Youn, HD; Liu, JO				Zhang, LH; Youn, HD; Liu, JO			Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NF kappa B-dependent activation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SP A92-308110; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORINE-A; GENE-EXPRESSION; IMMUNOSUPPRESSANT FK506; SIGNAL TRANSMISSION; MAMMALIAN PROTEIN; MACROLIDES FK-506; NUCLEAR-FACTOR	Sanglifehrin A belongs to a novel family of immunophilin-binding ligands. Sanglifehrin A is similar to cyclosporin A in that it binds to cyclophilins. Unlike cyclosporin A, however, the cyclophilin-sanglifehrin A complex has no effect on the calcium-dependent protein phosphatase calcineurin. It has been previously shown that sanglifehrin A specifically blocks T cell proliferation in response to interleukin 2 by inhibiting the appearance of cell cycle kinase activity cyclinE-Cdk2. How sanglifehrin A treatment leads to the cell cycle blockade has remained unknown. We report that sanglifehrin A is capable of activating the tumor suppressor gene p53 at the transcription level, leading to up-regulation of p21 that then binds and inhibits the cylcinE-Cdk2 complex. Further analysis of different elements in the p53 promoter showed that sanglifehrin A activates p53 transcription primarily through the activation of the transcription factor NF kappaB by activating I kappaB kinase in a manner that is similar to several genotoxic agents. Unlike other genotoxic drugs, sanglifehrin A does not cause DNA damage, making it a unique natural product that is capable of activating the NF kappaB signaling pathway without affecting DNA.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; MIT, Canc Res Ctr, Dept Chem, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Dept Biol, Cambridge, MA 02139 USA	Johns Hopkins University; Johns Hopkins University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Liu, JO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.		Youn, Hong-Duk/J-2774-2012					Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Cardenas ME, 1999, CLIN MICROBIOL REV, V12, P583, DOI 10.1128/CMR.12.4.583; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; Fehr T, 1999, J ANTIBIOT, V52, P474, DOI 10.7164/antibiotics.52.474; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sanglier JJ, 1999, J ANTIBIOT, V52, P466, DOI 10.7164/antibiotics.52.466; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WIEDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9, DOI 10.1111/j.1749-6632.1993.tb17137.x; WU HY, 1994, J BIOL CHEM, V269, P20067; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang LH, 2001, J IMMUNOL, V166, P5611, DOI 10.4049/jimmunol.166.9.5611; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	39	44	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43534	43540		10.1074/jbc.M104257200	http://dx.doi.org/10.1074/jbc.M104257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557753	hybrid			2022-12-25	WOS:000172297700009
J	Ardon, O; Bussey, H; Philpott, C; Ward, DM; Davis-Kaplan, S; Verroneau, S; Jiang, B; Kaplan, J				Ardon, O; Bussey, H; Philpott, C; Ward, DM; Davis-Kaplan, S; Verroneau, S; Jiang, B; Kaplan, J			Identification of a Candida albicans ferrichrome transporter and its characterization by expression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBIAL IRON TRANSPORT; USTILAGO-MAYDIS; GENE; PERMEASE; ENCODES; YEAST; SIDEROPHORES	Saccharomyces cerevisiae can accumulate iron through the uptake of siderophore-iron. Siderophore-iron uptake can occur through the reduction of the complex and the subsequent uptake of iron by the high affinity iron transporter Fet3p/Ftr1p. Alternatively, specific siderophore transporters can take up the siderophore-iron complex. The pathogenic fungus Candida albicans can also take up siderophore-iron. Here we identify a C. albicans siderophore transporter, CaArn1p, and characterize its activity. CaARN1 is transcriptionally regulated in response to iron. Through expression studies in S. cerevisiae strains lacking endogenous siderophore transporters, we demonstrate that CaArn1p specifically mediates the uptake of ferrichrome-iron. Iron-ferrichrome and gallium-ferrichrome, but not desferri-ferrichrome, could competitively inhibit the uptake of iron from ferrichrome. Uptake of siderophore-iron resulting from expression of CaARN1 under the control of the MET25-promoter in S. cerevisiae was independent of the iron status of the cells and of Aft1p, the iron-sensing transcription factor. These studies demonstrate that the expression of CaArn1p is both necessary and sufficient for the non-reductive uptake of ferrichrome-iron and suggests that the transporter may be the only required component of the siderophore uptake system that is regulated by iron and Aft1p.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; McGill Univ, Dept Biol, Montreal, PQ M3A 25T, Canada; NIDDK, Liver Dis Sect, NIH, Bethesda, MD USA; Elitra, Montreal, PQ H2X 248, Canada	Utah System of Higher Education; University of Utah; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu		Ardon, Orly/0000-0001-8147-933X	NCI NIH HHS [5 P30 CA 42014] Funding Source: Medline; NIDDK NIH HHS [DK 30534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, Z01DK054507, R01DK030534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ardon O, 1998, J BACTERIOL, V180, P2021, DOI 10.1128/JB.180.8.2021-2026.1998; Ardon O, 1997, MICROBIOL-UK, V143, P3625, DOI 10.1099/00221287-143-11-3625; Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; De Luca NG, 2000, ADV MICROB PHYSIOL, V43, P39, DOI 10.1016/S0065-2911(00)43002-X; Diarra MS, 1996, ANTIMICROB AGENTS CH, V40, P2610, DOI 10.1128/AAC.40.11.2610; Eck R, 1999, MICROBIOL-UK, V145, P2415, DOI 10.1099/00221287-145-9-2415; EMERY T, 1971, BIOCHEMISTRY-US, V10, P1483, DOI 10.1021/bi00784a033; FONZI WA, 1993, GENETICS, V134, P717; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Howard DH, 1999, CLIN MICROBIOL REV, V12, P394, DOI 10.1128/CMR.12.3.394; ISMAIL A, 1986, MYCOPATHOLOGIA, V96, P109, DOI 10.1007/BF00436669; ISMAIL A, 1985, BIOCHEM BIOPH RES CO, V130, P885, DOI 10.1016/0006-291X(85)90499-1; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; MINNICK AA, 1991, ANAL BIOCHEM, V194, P223, DOI 10.1016/0003-2697(91)90171-O; Moore DD, 1995, GLOB MOB SURV; Morrissey JA, 1996, MICROBIOL-UK, V142, P485, DOI 10.1099/13500872-142-3-485; Neilands J.B., 1987, IRON TRANSPORT MICRO, P3; NEILANDS JB, 1981, ANNU REV BIOCHEM, V50, P715, DOI 10.1146/annurev.bi.50.070181.003435; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Nudelman R, 1998, J MED CHEM, V41, P1671, DOI 10.1021/jm970581b; Ramanan N, 2000, SCIENCE, V288, P1062, DOI 10.1126/science.288.5468.1062; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10691, DOI 10.1073/pnas.200318797; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	34	47	49	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43049	43055		10.1074/jbc.M108701200	http://dx.doi.org/10.1074/jbc.M108701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562378	hybrid			2022-12-25	WOS:000172169300056
J	Gonzalez-Baro, MR; Granger, DA; Coleman, RA				Gonzalez-Baro, MR; Granger, DA; Coleman, RA			Mitochondrial glycerol phosphate acyltransferase contains two transmembrane domains with the active site in the N-terminal domain facing the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; ACYL-COA; DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE; GLYCEROPHOSPHATE ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; TRANSVERSE-PLANE; TOPOGRAPHY	The topography of mitochondrial glycerol-3-phosphate acyltransferase (GPAT) was determined using rat liver mitochondria and mutagenized recombinant rat GPAT (828 aa (amino acids)) expressed in CHO cells. Hydrophobicity analysis of GPAT predicts two transmembrane domains (TMDs), residues 472-493 and 576-592. Residues 224-323 correspond to the active site of the enzyme, which is believed to lie on the cytosolic face of the outer mitochondrial membrane. Protease treatment of rat liver mitochondria revealed that GPAT has a membrane-protected segment of 14 kDa that could correspond to the mass of the two predicted TMDs plus a loop between aa 494 and 575. Recombinant GPAT constructs containing tagged epitopes were transiently expressed in Chinese hamster ovary cells and immunolocalized. Both the C and N termini epitope tags could be detected after selective permeabilization of only the plasma membrane, indicating that both termini face the cytosol. A 6-8-fold increase in GPAT-specific activity in the transfected cells confirmed correct protein folding and orientation. When the C terminus and loop-tagged GPAT construct was immunoassayed, the epitope at the C terminus could be detected when the plasma membrane was permeabilized, but loop-epitope accessibility required disruption of the outer mitochondrial membrane. Similar results were observed when GPAT was truncated before the second TMD, again consistent with an orientation in which the loop faces the mitochondrial intermembrane space. Although protease digestion of the HA-tagged loop resulted in preservation of a 14-kDa fragment, consistent with a membrane protected loop domain, neither the truncated nor loop-tagged enzymes conferred GPAT activity when overexpressed, suggesting that the loop plays a critical structural or regulatory role for GPAT function. Based on these data, we propose a GPAT topography model with two transmembrane domains in which both the N (aa 1-471) and C (aa 593-end) termini face the cytosol and a single loop (aa 494-575) faces the intermembrane space.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Coleman, RA (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NIDDK NIH HHS [DK56598] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056598] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balija VS, 2000, J BIOL CHEM, V275, P31668, DOI 10.1074/jbc.M002963200; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; Chakraborty TR, 1999, J BIOL CHEM, V274, P29786, DOI 10.1074/jbc.274.42.29786; CHANG YY, 1967, J LIPID RES, V8, P447; COLEMAN RA, 1980, BIOCHIM BIOPHYS ACTA, V595, P184, DOI 10.1016/0005-2736(80)90082-6; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; COLEMAN RA, 1983, ENZYMES, V16, P605; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dircks LK, 1999, J BIOL CHEM, V274, P34728, DOI 10.1074/jbc.274.49.34728; Dircks LK, 1997, BBA-LIPID LIPID MET, V1348, P17, DOI 10.1016/S0005-2760(97)00106-9; Fleischer S, 1979, Methods Enzymol, V55, P32; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Heath RJ, 1999, J BACTERIOL, V181, P1944, DOI 10.1128/JB.181.6.1944-1946.1999; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HESLER CB, 1990, J BIOL CHEM, V265, P6600; HUBBARD SJ, 2001, PROTEOLYTIC ENZYMES, P233; IGAL RA, 2001, J BIOL CHEM     0823; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P8829, DOI 10.1021/bi00152a020; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; NIKONOV AV, 1998, RRD LIP RES 2, V2, P207; Ofman R, 1998, HUM MOL GENET, V7, P847, DOI 10.1093/hmg/7.5.847; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Sun J, 1997, J BIOL CHEM, V272, P21793, DOI 10.1074/jbc.272.35.21793; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029; [No title captured]	42	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43182	43188		10.1074/jbc.M107885200	http://dx.doi.org/10.1074/jbc.M107885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11557771	hybrid			2022-12-25	WOS:000172169300072
J	Kumar, MB; Ramadoss, P; Reen, RK; Perdew, GH				Kumar, MB; Ramadoss, P; Reen, RK; Perdew, GH			The Q-rich subdomain of the human Ah receptor transactivation domain is required for dioxin-mediated transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; DNA-BINDING FORM; NUCLEAR TRANSLOCATOR; ACTIVATION DOMAINS; MICE LACKING; CORE COMPLEX; GAGA FACTOR; IN-VIVO; PROTEIN; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN	The aryl hydrocarbon receptor (AhR), a basic helix-loop-helix/Per-Arnt-Sim transcription factor, mediates many of the toxic and biological effects of the environmental contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin, which include the transcriptional activation of dioxin-responsive genes such as CYP1A1. Many aspects of this process are known; however, the mechanism of transcriptional activation and the proteins that are key to this process remain to be determined. The hAhR has a complex transactivation domain, composed of three potentially distinct subdomains. Deletional analysis of the hAhR transactivation domain indicates that removal of the P/S/T-rich subdomain enhances transcriptional activity, whereas the Q-rich subdomain is critical for hAhR transactivation potential, and the acidic subdomain by itself fails to activate a dioxin response element-driven reporter gene. Deletional analysis of the Q-rich subdomain identified a critical stretch of 23 amino acids between residues 666 and 688 of the hAhR, which are required for transactivation potential. Alanine scanning mutagenesis of this region identified a leucine residue (Leu-678), which is required for hAhR activity. Functional analysis of this point mutant revealed that it is capable of binding ligand, heterodimerization, and subsequent binding to dioxin response elements. Further, when bAhR/L678A and hAhR containing only the acidic subdomain were overexpressed they acted as dominant negative receptors and repressed wild-type hAhR activity. In addition, the hAhR/L678A failed to activate CYP1A1 gene transcription in transfected BP-8 cells and exhibited reduced binding to RIP140 in vitro. Thus, Leu-678 appears to be critical for efficient transactivation activity of the hAhR and appears to disrupt recruitment of co-regulators.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Perdew, GH (corresponding author), Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04869] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1999, TOXICOL APPL PHARM, V155, P62, DOI 10.1006/taap.1998.8601; Agianian B, 1999, J MOL BIOL, V285, P527, DOI 10.1006/jmbi.1998.2355; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dong LQ, 1997, J BIOL CHEM, V272, P29614, DOI 10.1074/jbc.272.47.29614; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; HENRY EC, 1993, BIOCHEM J, V294, P95, DOI 10.1042/bj2940095; HORD NG, 1994, MOL PHARMACOL, V46, P618; JAIN S, 1994, J BIOL CHEM, V269, P31518; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Korkalainen M, 2000, BIOCHEM BIOPH RES CO, V273, P272, DOI 10.1006/bbrc.2000.2931; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rojo-Niersbach E, 1999, J BIOL CHEM, V274, P33778, DOI 10.1074/jbc.274.47.33778; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Serra E, 1998, NUCLEIC ACIDS RES, V26, P3800, DOI 10.1093/nar/26.16.3800; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; Swanson HI, 1998, MOL PHARMACOL, V54, P671; TUKEY RH, 1984, BIOCHEMISTRY-US, V23, P6003, DOI 10.1021/bi00320a016; VANDENHEUVEL JP, 1998, PCR PROTOCOLS MOL TO, P41; Vaquero A, 2000, J BIOL CHEM, V275, P19461, DOI 10.1074/jbc.M000967200; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wilkins RC, 1999, J MOL BIOL, V285, P515, DOI 10.1006/jmbi.1998.2356; Zhou H, 1997, J IMMUNOL, V158, P4741	47	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42302	42310		10.1074/jbc.M104798200	http://dx.doi.org/10.1074/jbc.M104798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551916	hybrid			2022-12-25	WOS:000172450400101
J	McGuire, J; Okamoto, K; Whitelaw, ML; Tanaka, H; Poellinger, L				McGuire, J; Okamoto, K; Whitelaw, ML; Tanaka, H; Poellinger, L			Definition of a dioxin receptor mutant that is a constitutive activator of transcription - Delineation of overlapping repression and ligand binding functions within the PAS domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; HEAT-SHOCK PROTEIN; HELIX-LOOP-HELIX; AH-RECEPTOR; SIGNAL-TRANSDUCTION; MICE LACKING; IN-VIVO; HSP90; SPECIFICITY; COMPLEX	The intracellular dioxin (aryl hydrocarbon) receptor is a ligand-activated transcription factor that mediates the adaptive and toxic responses to environmental pollutants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and structurally related congeners. Whereas the ligand-free receptor is characterized by its association with the molecular chaperone hsp90, exposure to ligand initiates a multistep activation process involving nuclear translocation, dissociation from the hsp90 complex, an dimerization with its partner protein Arnt. In this study, we have characterized a dioxin receptor deletion mutant lacking the minimal ligand-binding domain of the receptor. This mutant did not bind ligand and localized constitutively to the nucleus. However, this protein was functionally inert since it failed to dimerize with Arnt and to bind DNA. In contrast, a dioxin receptor deletion mutant lacking the minimal PAS B motif but maintaining the N-terminal half of the ligand-binding domain showed constitutive dimerization with Arnt, bound DNA, and activated transcription in a ligand-independent manner. Interestingly, this mutant showed a more potent functional activity than the dioxin-activated wild-type receptor in several different cell lines. In conclusion, the constitutively active dioxin receptor may provide an important mechanistic tool to investigate receptor-mediated regulatory pathways in closer detail.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan	Karolinska Institutet; University of Adelaide; University of Tokyo	Poellinger, L (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.							ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; CHEN HS, 1994, J BIOL CHEM, V269, P27554; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRADIN K, 1994, J BIOL CHEM, V269, P23800; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JAIN S, 1994, J BIOL CHEM, V269, P31518; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Ma Q, 1997, J BIOL CHEM, V272, P8878; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; YAMAMOTO KR, 1988, COLD SPRING HARB SYM, V53, P803, DOI 10.1101/SQB.1988.053.01.091; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	39	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41841	41849		10.1074/jbc.M105607200	http://dx.doi.org/10.1074/jbc.M105607200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551926	hybrid			2022-12-25	WOS:000172450400041
J	Jiang, M; Axe, T; Holgate, R; Rubbi, CP; Okorokov, AL; Mee, T; Milner, J				Jiang, M; Axe, T; Holgate, R; Rubbi, CP; Okorokov, AL; Mee, T; Milner, J			p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress	ONCOGENE			English	Article						p53; nuclear matrix; proline-rich domain; DNA damage; SV40 large T	LARGE T-ANTIGEN; HYDROPHOBIC AMINO-ACIDS; A MOUSE CELLS; TERMINAL DOMAIN; DNA-BINDING; TRANSCRIPTIONAL COACTIVATOR; CELLULAR PROTEIN-P53; PROTEOLYTIC CLEAVAGE; FUNCTIONAL DOMAIN; GROWTH ARREST	The tumour suppressor p53 is a multifunctional protein important for the maintenance of genomic integrity. It is able to form molecular complexes with different DNA targets and also with cellular proteins involved in DNA transcription and DNA repair. In mammalian cells the biochemical processing of DNA occurs on a nuclear substructure termed the nuclear matrix. Previously Deppert and co-workers have identified p53 in association with the nuclear matrix in viral- and non-viral transformed cell lines. In the present study we demonstrate, for the first time, that p53 is bound to the nuclear matrix in primary cultures of normal mammalian cells and that this binding increases following DNA damage. Analysis of cell lines expressing structural mutants of p53 revealed that association with the nuclear matrix is independent of the tertiary and quaternary structure of p53. However, the proline-rich domain towards the N-terminus of p53 (residues 67 to 98) appeared important for binding to the nuclear matrix. This was demonstrated by TET-ON regulated expression of p53-derived constructs in p53(-/-) murine embryonic fibroblasts (MEF p53(-/-)). The proline-rich domain of p53 has potential for SH3 protein-protein interaction, and has a role in p53-mediated apoptosis and possibly base excision repair of DNA damage. We discuss our observations in relation to the ability of p53 to facilitate DNA repair and also review evidence indicating that matrix-bound p53 in SV40-transformed cells may facilitate the transforming potential of SV40 large T antigen.	Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England.			Okorokov, Andrei/0000-0003-2477-3254; Jiang, Ming/0000-0003-3361-9881				Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; Berezney R, 1995, INT REV CYTOL, V162A, P1; Boulikas T, 1995, INT REV CYTOL, V162A, P279; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cook Peter R., 2001, EMBO Reports, V2, P14, DOI 10.1093/embo-reports/kve011; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; Deppert W, 2000, CRIT REV EUKAR GENE, V10, P45; Deppert W, 1995, INT REV CYTOL, V162A, P485; DEPPERT W, 1990, ONCOGENE, V5, P1701; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jackson DA, 1995, INT REV CYTOL, V162A, P125; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN JY, 1995, ONCOGENE, V10, P2387; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mee T, 1999, BRIT J CANCER, V81, P212, DOI 10.1038/sj.bjc.6690679; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1993, ONCOGENE, V8, P2001; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Molinari M, 1996, ONCOGENE, V13, P2077; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; Offer H, 2001, CANCER RES, V61, P88; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; PARDOLL DM, 1980, EXP CELL RES, V128, P466, DOI 10.1016/0014-4827(80)90083-X; Peden KWC, 1998, VIRUS GENES, V16, P153, DOI 10.1023/A:1007941622680; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Spector D. L., 1998, CELLS LAB MANUAL; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1990, ONCOGENE, V5, P1691; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; Stratling WH, 1999, CRIT REV EUKAR GENE, V9, P311, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.150; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Will K, 1998, J CELL BIOCHEM, V69, P260, DOI 10.1002/(SICI)1097-4644(19980601)69:3<260::AID-JCB4>3.0.CO;2-P; ZERRAHN J, 1992, ONCOGENE, V7, P1371; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	58	31	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5449	5458		10.1038/sj.onc.1204705	http://dx.doi.org/10.1038/sj.onc.1204705			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571642				2022-12-25	WOS:000170781100005
J	Mason, JM; Xu, HP; Rao, SK; Leask, A; Barcia, M; Shan, JD; Stephenson, R; Tabibzadeh, S				Mason, JM; Xu, HP; Rao, SK; Leask, A; Barcia, M; Shan, JD; Stephenson, R; Tabibzadeh, S			Lefty contributes to the remodeling of extracellular matrix by inhibition of connective tissue growth factor and collagen mRNA expression and increased proteolytic activity in a fibrosarcoma model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; BETA TGF-BETA; HUMAN-FIBROBLASTS; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION; STROMAL FIBROBLASTS; MOLECULAR-CLONING; PROGELATINASE-A; LUNG FIBROSIS; MESSENGER-RNA	Homeostasis of the extracellular matrix (ECM) of tissues is regulated by controlling deposition and degradation of ECM proteins. The breakdown of ECM is essential in blastocyst implantation and embryonic development, tissue morphogenesis, menstrual shedding, bone formation, tissue resorption after delivery, and tumor growth and invasion. TGF-beta family members are one of the classes of proteins that actively participate in the homeostasis of ECM. Here, we report on the effect of lefty, a novel member of the TGF-beta family, on the homeostasis of extracellular matrix in a fibrosarcoma model. Fibroblastic cells forced to express lefty by retroviral transduction lost their ability to deposit collagen in vivo. This event was associated with down-regulation of the steady-state level of connective tissue growth factor that induces collagen type I mRNA. In addition, lefty transduction significantly decreased collagen type I mRNA expression and simultaneously increased collagenolytic, gelatinolytic, elastolytic, and caseinolytic activities in vivo by the transduced fibroblasts. These findings provide a new insight on the actions of lefty and suggest that this cytokine plays an active role in remodeling of the extracellular matrix in vivo.	N Shore Long Isl Jewish Res Inst, Dept Pathol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Res Inst, Gene Therapy Vector Lab, Res Dept, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Res Inst, Dept Mol Oncol, Manhasset, NY 11030 USA; NYU, Sch Med, Manhasset, NY 11030 USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA; FibroGen Inc, San Francisco, CA 94080 USA	Northwell Health; Northwell Health; Northwell Health; New York University; Northwell Health; Yeshiva University; FibroGen	Tabibzadeh, S (corresponding author), Frontiers Biosci, POB 160, Searingtown, NY 11507 USA.	tabibzadeh@bioscience.org	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015					Akagi Y, 1996, KIDNEY INT, V50, P148, DOI 10.1038/ki.1996.297; Asakura S, 1999, HUM PATHOL, V30, P195, DOI 10.1016/S0046-8177(99)90275-7; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Berndt A, 1995, HISTOCHEM J, V27, P1014; Bettinger DA, 1996, PLAST RECONSTR SURG, V98, P827, DOI 10.1097/00006534-199610000-00012; Bieth JG, 1986, REGULATION MATRIX AC, P217; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Cadene M, 1997, J BIOL CHEM, V272, P9950, DOI 10.1074/jbc.272.15.9950; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Clark RAF, 1997, J CELL PHYSIOL, V170, P69; Coker RK, 1997, AM J PATHOL, V150, P981; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Edwards DR, 1996, EXP GERONTOL, V31, P207, DOI 10.1016/0531-5565(95)02010-1; El-Gamel A, 1998, EUR J CARDIO-THORAC, V13, P424, DOI 10.1016/S1010-7940(98)00048-7; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; FRANZEN L, 1994, IN VITRO CELL DEV-AN, V30A, P460; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; GILFILLAN RF, 1968, CANCER RES, V28, P137; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hao JM, 1999, J MOL CELL CARDIOL, V31, P667, DOI 10.1006/jmcc.1998.0902; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Islam M, 2001, KIDNEY INT, V59, P498, DOI 10.1046/j.1523-1755.2001.059002498.x; KAHARI VM, 1991, LAB INVEST, V64, P807; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Khanna AK, 1999, TRANSPLANTATION, V67, P882, DOI 10.1097/00007890-199903270-00016; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kothapalli R, 1997, J CLIN INVEST, V99, P2342, DOI 10.1172/JCI119415; Kubo M, 1998, BRIT J DERMATOL, V139, P192; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Lohr M, 2001, CANCER RES, V61, P550; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; Martinet Y, 1996, ARCH TOX S, V18, P127; Mason JM, 1998, GENE THER, V5, P1098, DOI 10.1038/sj.gt.3300703; MASON JM, 2001, CLIN ORTHOPAEDICS, V379, pS171; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mathrubutham M, 2001, FRONT BIOSCI-LANDMRK, V6, pA13, DOI 10.2741/Mathrub; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEUMANN U, 1994, J BIOL CHEM, V269, P21561; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; OVERALL CM, 1989, CONNECT TISSUE RES, V20, P289, DOI 10.3109/03008208909023899; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Polo M., 1997, Journal of Burn Care and Rehabilitation, V18, P477, DOI 10.1097/00004630-199711000-00002; Querfeld C, 2000, BRIT J DERMATOL, V142, P1228, DOI 10.1046/j.1365-2133.2000.03579.x; Randall K, 1996, INT J RADIAT BIOL, V70, P351, DOI 10.1080/095530096145085; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SLAVIN J, 1994, GROWTH FACTORS, V11, P205, DOI 10.3109/08977199409046918; TABIBZADEH S, 1995, HUM REPROD, V10, P1579, DOI 10.1093/HUMREP/10.6.1579; TABIBZADEH S, 1997, FRONT BIOSCI, V2, P18; TABIBZADEH SS, 1985, J HISTOCHEM CYTOCHEM, V33, P884, DOI 10.1177/33.9.2410482; THOMPSON RW, 1995, J CLIN INVEST, V96, P318, DOI 10.1172/JCI118037; Ulloa L, 2001, J BIOL CHEM, V276, P21397, DOI 10.1074/jbc.M010783200; Ulloa L, 2001, J BIOL CHEM, V276, P21387, DOI 10.1074/jbc.M006933200; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Velasco G, 2000, CANCER RES, V60, P877; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	86	29	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					407	415		10.1074/jbc.M108103200	http://dx.doi.org/10.1074/jbc.M108103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11572876	hybrid			2022-12-25	WOS:000173087900055
J	Chang, WJ; Alvarez-Gonzalez, R				Chang, WJ; Alvarez-Gonzalez, R			The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTION FACTOR; DEPENDENT TRANSCRIPTION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; LIFE-SPAN; IN-VITRO; ACTIVATION; PROTEIN; CELLS	Recent studies suggest that the synthesis of protein-bound ADP-ribose polymers catalyzed by poly(ADP-ribose) polymerase-1 (PARP-1) regulates eucaryotic gene expression, including the NF-kappaB-dependent pathway. Here, we report the molecular mechanism by which PARP-1 activates the sequence-specific binding of NF-kappaB to its oligodeoxynucleotide. We co-incubated pure recombinant human PARP-1 and the p50 subunit of NF-kappaB (NF-kappaB-p50) in the presence or absence of beta NAD(+) in vitro. Electrophoretic mobility shift assays showed that, when PARP-1 was present, NF-kappaB-p50 DNA binding was dependent on the presence of beta NAD(+). DNA binding by NF-kappaB-p50 was not efficient in the absence of beta NAD(+). In fact, the binding was not efficient in the presence of 3-aminobenzamide (3-AB) either. Thus, we conclude that NF-kappaB-p50 DNA binding is protein-poly(ADP-ribosylation dependent. Co-immunoprecipitation and immunoblot analysis revealed that PARP-1 physically interacts with NF-kappaB-p50 with high specificity in the absence of beta NAD(+). Because NF-kappaB-p50 was not an efficient covalent target for poly(ADP-ribosylation, our results are consistent with the conclusion that the auto-poly(ADP-ribosyl)ation reaction catalyzed by PARP-1 facilitates the binding of NF-kappaB-p50 to its DNA by inhibiting the specific protein-protein interactions between NF-kappaB-p50 and PARP-1. We also report the activation of NF-kappaB(-)DNA binding by the automodification reaction of PARP-1 in cultured HeLa cells following exposure to H2O2. In these experiments, preincubation of HeLa cells with 3-AB, prior to oxidative damage, strongly inhibited NF-kappaB activation in vivo as well.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Alvarez-Gonzalez, R (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.		Gonzalez, Rafael Alvarez/I-4560-2019	Alvarez-Gonzalez, Rafael/0000-0003-1038-7512	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Beneke S, 2000, EXP GERONTOL, V35, P989, DOI 10.1016/S0531-5565(00)00134-0; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kumari SR, 1998, CANCER RES, V58, P5075; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P3481, DOI 10.1073/pnas.90.8.3481; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WesierskaGadek J, 1996, J CELL BIOCHEM, V62, P90, DOI 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879	48	120	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47664	47670		10.1074/jbc.M104666200	http://dx.doi.org/10.1074/jbc.M104666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577079	hybrid			2022-12-25	WOS:000172768500128
J	Chen, C; Wang, Q; Fang, XD; Xu, Q; Chi, CW; Gu, JX				Chen, C; Wang, Q; Fang, XD; Xu, Q; Chi, CW; Gu, JX			Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-VIII; HAMSTER OVARY CELLS; RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; GLUCOSE-REGULATED PROTEINS; VON-WILLEBRAND-FACTOR; PORCINE FACTOR-VIII; FACTOR-V; MAMMALIAN-CELLS; REFSUM-DISEASE; LIVER-TRANSPLANTATION	The coagulation factor VIII (FVIII) is the coagulation factor deficient in the X-chromosome-linked bleeding disorder hemophilia A. Previous transfection studies demonstrated that factor VIII was 10-100-fold less efficiently expressed than the homologous coagulation factor, factor V. To investigate the regulatory mechanisms of FVIII synthesis and secretion, we used the yeast two-hybrid system as an approach to search for proteins that associated with FVIII. The A2 domain (337-740 amino acids) of factor VIII (FVIII-A2) was used as a bait and phytanoyl-CoA alpha -hydroxylase (PAHX) was identified as a binding protein of FVIII-A2. PAHX had potential to interact with the residues 373-508 within the A2 domain, but not with A1 and A3 (the homologous domains of A2). The interaction between the A2 domain and PAHX was independent of the type 2 peroxisomal targeting signal (PTS2) of PAHX. Overexpression of PABX in FVIII-produced cells decreased the expression of FVIII by about 70%. The elevated expression of von Willebrand factor had no effect on the suppression of FVIII secretion by PAHX. Expression of the green fluorescent PAHX fusion protein in SMMC-7721 cells affected the intracellular trafficking of FVIII-A2. These results suggested that the interaction between PABX and FVIII-A2 was in part responsible for the low-level expression of factor VIII.	Fudan Univ, Ctr Gene Res, Med Ctr, Shanghai 200032, Peoples R China; Acad Sinica, Shanghai Inst Biochem, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Gu, JX (corresponding author), Fudan Univ, Ctr Gene Res, Med Ctr, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn						BONTEMPO FA, 1987, BLOOD, V69, P1721; Chambraud B, 1999, P NATL ACAD SCI USA, V96, P2104, DOI 10.1073/pnas.96.5.2104; Chen C, 1999, THROMB RES, V95, P105, DOI 10.1016/S0049-3848(99)00031-6; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; Fallaux FJ, 1996, MOL CELL BIOL, V16, P4264; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GROTH CG, 1974, SURGERY, V75, P725; HOEFLER G, 1988, J PEDIATR-US, V112, P726, DOI 10.1016/S0022-3476(88)80689-9; Iwano M, 1996, BIOCHEM BIOPH RES CO, V229, P355, DOI 10.1006/bbrc.1996.1805; Jansen GA, 1997, J INHERIT METAB DIS, V20, P444, DOI 10.1023/A:1005379406639; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Jansen GA, 1997, NEW ENGL J MED, V337, P133, DOI 10.1056/NEJM199707103370215; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Kaufman RJ, 1997, BLOOD COAGUL FIBRIN, V8, pS3; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KELLY DA, 1984, BRIT J HAEMATOL, V56, P535, DOI 10.1111/j.1365-2141.1984.tb02178.x; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; LAROCCA D, 1990, CANCER RES, V50, P5925; LEWIS JH, 1985, NEW ENGL J MED, V312, P1189; LIU LX, 1994, TRANSPLANT INT, V7, P201, DOI 10.1111/j.1432-2277.1994.tb01291.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MANN KG, 1993, METHOD ENZYMOL, V222, P1; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Saenko EL, 1999, J BIOL CHEM, V274, P37685, DOI 10.1074/jbc.274.53.37685; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Swaroop M, 1997, J BIOL CHEM, V272, P24121, DOI 10.1074/jbc.272.39.24121; Takayama M, 1999, EXP NEPHROL, V7, P295; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VELTKAMP JJ, 1968, THROMB DIATH HAEMOST, V19, P279, DOI 10.1055/s-0038-1651206; Waterham HR, 1997, BIOESSAYS, V19, P57, DOI 10.1002/bies.950190110; WEBSTER WP, 1971, AM J PHYSIOL, V220, P1147, DOI 10.1152/ajplegacy.1971.220.5.1147; WILSON DB, 1984, J CLIN INVEST, V73, P654, DOI 10.1172/JCI111256; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; ZELECHOWSKA MG, 1985, NATURE, V317, P729, DOI 10.1038/317729a0	50	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46340	46346		10.1074/jbc.M106124200	http://dx.doi.org/10.1074/jbc.M106124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574539	hybrid			2022-12-25	WOS:000172573100116
J	Ashton, AC; Volynski, KE; Lelianova, VG; Orlova, EV; Van Renterghem, C; Canepari, M; Seagar, M; Ushkaryov, YA				Ashton, AC; Volynski, KE; Lelianova, VG; Orlova, EV; Van Renterghem, C; Canepari, M; Seagar, M; Ushkaryov, YA			alpha-latrotoxin, acting via two Ca2+-dependent pathways, triggers exocytosis of two pools of synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; RAT HIPPOCAMPAL-NEURONS; WIDOW SPIDER VENOM; CEREBRAL CORTICAL SYNAPTOSOMES; FROG NEUROMUSCULAR-JUNCTION; GAMMA-AMINOBUTYRIC-ACID; READILY RELEASABLE POOL; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; DIVALENT-CATIONS	alpha -Latrotoxin stimulates three types of [H-3]gamma -aminobutyric acid and [C-14]glutamate release from synaptosomes. The Ca2+-independent component (i) is insensitive to SNAP-25 cleavage or depletion of vesicle contents by bafilomycin A1 and represents transmitter efflux mediated by alpha -latrotoxin pores. Two other components of release are Ca2+-dependent and vesicular but rely on distinct mechanisms. The fast receptor-mediated pathway (ii) involves intracellular Ca2+ stores and acts upon sucrose-sensitive readily releasable vesicles; this mechanism is insensitive to inhibition of phosphatidylinositol 4-kinase (PI 4-kinase). The delayed pore-dependent exocytotic component (iii) is stimulated by Ca2+ entering through alpha -latrotoxin pores; it requires PI 4-kinase and occurs mainly from depot vesicles. Lanthanum perturbs alpha -latrotoxin pores and blocks the two pore-mediated components (i, iii) but not the receptor-mediated release (ii). alpha -Latrotoxin mutant (LTXN4C) cannot form pores and stimulates only the Ca2+-dependent receptor-mediated amino acid exocytosis (ii) (detectable biochemically and electrophysiologically). These findings explain experimental data obtained by different laboratories and implicate the toxin receptors in the regulation of the readily releasable pool of synaptic vesicles. Our results also suggest that, similar to noradrenergic vesicles, amino acid-containing vesicles at some point in their cycle require PI 4-kinase.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Fac Med Secteur Nord Marseille, INSERM, U464, Lab Neurobiol Canaux Ion, F-13916 Marseille 20, France; Natl Inst Med Res, Div Neurophysiol, London NW7 1AA, England	Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; MRC National Institute for Medical Research	Ushkaryov, YA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Exhibit Rd, London SW7 2AY, England.		Canepari, Marco/H-6772-2012; Canepari, Marco/AAJ-6709-2021; Orlova, Elena/CAF-8290-2022; Ushkaryov, Yuri/AAQ-2985-2020	Canepari, Marco/0000-0001-9759-2388; Canepari, Marco/0000-0001-9759-2388; Ushkaryov, Yuri/0000-0002-5712-8297; Orlova, Elena/0000-0003-3371-415X; Volynski, Kirill/0000-0001-8208-1905				Ashton AC, 2000, J NEUROCHEM, V74, P1979, DOI 10.1046/j.1471-4159.2000.0741979.x; Ashton AC, 2000, BIOCHIMIE, V82, P453, DOI 10.1016/S0300-9084(00)00199-1; Ashton AC, 1997, J NEUROCHEM, V68, P649; Auger C, 1997, NEURON, V19, P139, DOI 10.1016/S0896-6273(00)80354-2; Bittner MA, 2000, J BIOL CHEM, V275, P25351, DOI 10.1074/jbc.M004884200; Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DERI Z, 1993, J NEUROCHEM, V60, P1065, DOI 10.1111/j.1471-4159.1993.tb03255.x; FESCE R, 1986, J GEN PHYSIOL, V88, P59, DOI 10.1085/jgp.88.1.59; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Irving AJ, 1998, J PHYSIOL-LONDON, V511, P747, DOI 10.1111/j.1469-7793.1998.747bg.x; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; Khvotchev M, 2000, EMBO J, V19, P3250, DOI 10.1093/emboj/19.13.3250; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Liu J, 1998, J NEUROSCI, V18, P6113; Lonart G, 2000, J BIOL CHEM, V275, P27703; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MISLER S, 1987, AM J PHYSIOL, V253, pC469, DOI 10.1152/ajpcell.1987.253.3.C469; NICHOLLS DG, 1989, J NEUROCHEM, V52, P331, DOI 10.1111/j.1471-4159.1989.tb09126.x; OKAMOTO M, 1971, SCIENCE, V172, P733, DOI 10.1126/science.172.3984.733; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Rahman MA, 1999, PHILOS T ROY SOC B, V354, P379, DOI 10.1098/rstb.1999.0390; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; Savic N, 1998, EUR J NEUROSCI, V10, P3379, DOI 10.1046/j.1460-9568.1998.00342.x; SCHEER HW, 1989, J NEUROCHEM, V52, P1590, DOI 10.1111/j.1471-4159.1989.tb09213.x; SIHRA TS, 1987, J NEUROCHEM, V49, P261, DOI 10.1111/j.1471-4159.1987.tb03424.x; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; Stevens CF, 1999, NEURON, V24, P1017, DOI 10.1016/S0896-6273(00)81047-8; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; VERHAGE M, 1992, J NEUROCHEM, V58, P1313, DOI 10.1111/j.1471-4159.1992.tb11344.x; VERHAGE M, 1991, NEUROSCIENCE, V43, P59, DOI 10.1016/0306-4522(91)90417-M; Volynski KE, 1999, FEBS LETT, V442, P25, DOI 10.1016/S0014-5793(98)01624-X; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; WATANABE O, 1983, NEUROSCIENCE, V10, P1011, DOI 10.1016/0306-4522(83)90239-7; Wiedemann C, 1998, J NEUROSCI, V18, P5594; WILKINSON RJ, 1989, NEUROCHEM INT, V15, P191, DOI 10.1016/0197-0186(89)90100-9; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	47	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44695	44703		10.1074/jbc.M108088200	http://dx.doi.org/10.1074/jbc.M108088200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572875	hybrid			2022-12-25	WOS:000172406700049
J	Ronald, KM; Mirshahi, T; Woodward, JJ				Ronald, KM; Mirshahi, T; Woodward, JJ			Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTORS; HIPPOCAMPAL-NEURONS; SUBSTITUTED CYSTEINES; WITHDRAWAL SEIZURES; TYROSINE KINASE; HEK-293 CELLS; CALCIUM FLUX; C0 DOMAIN; SENSITIVITY; CHANNEL	N-Methyl-D-aspartate (NMDA) receptors (NRs) are ionotropic receptors activated by glutamate and the coagonist glycine. Ethanol inhibits NMDA receptor function, although its site of action is undefined. We hypothesized that ethanol acts at specific amino acids contained within the transmembrane (TM) domains of the receptor. In this study, NR1 and NR2A subunits were altered by mutagenesis and tested for sensitivity to ethanol. Three NR1 mutants (W636A, F817A, and L819A) and one NR2A mutant (F637A) failed to generate functional receptors. Pre-TM1 (1546A, L551A, F554A, and F558A), TM1 (W563A), and TM2 (W611A) NR1 mutations did not affect ethanol sensitivity of heteromeric receptors. In contrast, altering a TM3 phenylalanine to alanine (F639A) reduced the ethanol inhibition of NMDA receptors expressed in oocytes and human embryonic kidney 293 cells. Mutation of the nearby methionine (M641) to alanine did not affect ethanol sensitivity, whereas changing Phe(639) to tryptophan slightly enhanced ethanol inhibition. NR1(F639A) did not alter the agonist potency of glutamate but did produce a leftward shift in the glycine concentration response for receptors containing NR2A and NR2B subunits. NR1(F639A) also reduced the potency of the competitive glycine antagonist 5,7-dichlorokynurenic acid and increased the efficacy of the glycine partial agonist 3-amino-1-hydroxy-2-pyrrolidinone ((+)-HA-966). These results suggest that ethanol may interact with amino acids contained in the TM3 domain of NMDA subunits that are involved in transducing agonist binding to channel opening.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Mt Sinai Sch Med, Dept Mol Biophys, New York, NY 10029 USA	Virginia Commonwealth University; Icahn School of Medicine at Mount Sinai	Woodward, JJ (corresponding author), Med Univ S Carolina, Dept Physiol & Neurosci, MUSC IOP 4N,POB 250861, Charleston, SC 29425 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000238, R37AA009986, R01AA009986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007027] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01-AA009986, R01 AA009986, K02-AA00238, R37 AA009986] Funding Source: Medline; NIDA NIH HHS [T32-DA07027] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Anders DL, 1999, J NEUROCHEM, V72, P1389, DOI 10.1046/j.1471-4159.1999.721389.x; Anders DL, 1999, ALCOHOL CLIN EXP RES, V23, P357, DOI 10.1111/j.1530-0277.1999.tb04122.x; Anders DL, 2000, J BIOL CHEM, V275, P15019, DOI 10.1074/jbc.275.20.15019; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; Blevins T, 1995, NEUROSCI LETT, V200, P214, DOI 10.1016/0304-3940(95)12086-J; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; CHU B, 1995, J NEUROCHEM, V65, P140; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DILDY JE, 1989, BRAIN RES, V499, P383, DOI 10.1016/0006-8993(89)90789-0; Feldmeyer D, 1996, J NEUROCYTOL, V25, P857, DOI 10.1007/BF02284847; GONZALES RA, 1990, J PHARMACOL EXP THER, V253, P1138; GOTHERT M, 1989, N-S ARCH PHARMACOL, V340, P516; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; IORIO KR, 1993, EUR J PHARM-ENVIRON, V248, P209, DOI 10.1016/0926-6917(93)90045-R; Kohda K, 2000, NAT NEUROSCI, V3, P315, DOI 10.1038/73877; Koltchine VV, 1999, MOL PHARMACOL, V56, P1087, DOI 10.1124/mol.56.5.1087; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; Krystal JH, 1998, ARCH GEN PSYCHIAT, V55, P354, DOI 10.1001/archpsyc.55.4.354; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MASOOD K, 1994, MOL PHARMACOL, V45, P324; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Mirshahi T, 1998, J NEUROCHEM, V71, P1095; MORRISETT RA, 1990, EUR J PHARMACOL, V176, P103, DOI 10.1016/0014-2999(90)90138-V; Peoples RW, 2000, NEUROPHARMACOLOGY, V39, P1681, DOI 10.1016/S0028-3908(00)00067-8; Peoples RW, 1997, BRIT J PHARMACOL, V122, P1035, DOI 10.1038/sj.bjp.0701483; RONALD KM, 2000, ALCOHOL CLIN EXP RES, V24, P9; SIMSON PE, 1991, J PHARMACOL EXP THER, V257, P225; WOODWARD JJ, 1994, J NEUROCHEM, V62, P987; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	35	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44729	44735		10.1074/jbc.M102800200	http://dx.doi.org/10.1074/jbc.M102800200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572853	hybrid			2022-12-25	WOS:000172406700053
J	Ho, YY; Deckelbaum, RJ; Chen, YH; Vogel, T; Talmage, DA				Ho, YY; Deckelbaum, RJ; Chen, YH; Vogel, T; Talmage, DA			Apolipoprotein E inhibits serum-stimulated cell proliferation and enhances serum-independent cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; APOPROTEIN-E; SIGNAL-TRANSDUCTION; EXPRESSION; MACROPHAGES; BINDING; GROWTH; RAT; ACTIVATION	Independently of its role in lipid homeostasis, apolipoprotein E (apoE) inhibits cell proliferation. We compared the effects of apoE added to media (exogenous apoE) with the effects of stably expressed apoE (endogenous apoE) on cell proliferation. Exogenous and endogenous apoE increased population doubling times by 30-50% over a period of 14 days by prolonging the G(1) phase of the cell cycle. Exogenous and endogenous apoE also decreased serum-stimulated DNA synthesis by 30-50%. However, apoE did not cause cell cycle arrest; both apoE-treated and control cells achieved equivalent saturation densities at 14 days. Further analyses demonstrated that exogenous and endogenous apoE prevented activation of MAPK but not induction of c-fos expression in response to serum growth factors. Endogenous (but not exogenous) apoE altered serum concentration-dependent effects on proliferation. Whereas control (non-apoE-expressing) cell numbers increased with increasing serum concentrations (1.6-fold for every 2-fold increase in serum), apoE-expressing cell numbers did not differ as serum levels were raised from 2.5 to 10%. In addition, in low serum (0.1%), apoE-expressing cells had elevated DNA synthesis levels compared with control cells. We conclude that apoE does not simply inhibit cell proliferation; rather, the presence of apoE alters the response to and requirement for serum mitogens.	Columbia Univ, Inst Human Nutr, HHSC 5 503, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA; Biotechnol Gen Ltd, IL-76326 Rehovot, Israel	Columbia University; Columbia University	Talmage, DA (corresponding author), Columbia Univ, Inst Human Nutr, HHSC 5 503, 701 W 168th St, New York, NY 10032 USA.	dat1@columbia.edu		Talmage, David/0000-0003-4627-3007	NATIONAL CANCER INSTITUTE [R01CA079737] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040404] Funding Source: NIH RePORTER; NCI NIH HHS [CA79737] Funding Source: Medline; NHLBI NIH HHS [HL40404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BROWNING PJ, 1994, J EXP MED, V180, P1949, DOI 10.1084/jem.180.5.1949; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chen SC, 1998, J CLIN INVEST, V102, P653, DOI 10.1172/JCI3483; Chen YC, 1999, ONCOGENE, V18, P139, DOI 10.1038/sj.onc.1202272; CRESPO P, 1993, LEUKEMIA RES, V17, P771, DOI 10.1016/0145-2126(93)90111-W; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; DORY L, 1991, J LIPID RES, V32, P783; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Garcia JH, 1996, NEUROIMAG CLIN N AM, V6, P801; GRANOT E, 1995, ATHEROSCLEROSIS, V114, P115, DOI 10.1016/0021-9150(94)05475-X; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Ho YY, 2000, BIOCHEMISTRY-US, V39, P4746, DOI 10.1021/bi992294a; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Khuri FR, 1996, CELL GROWTH DIFFER, V7, P595; Lin CY, 1998, J LIPID RES, V39, P293; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAJACK RA, 1988, J CELL BIOL, V107, P1207, DOI 10.1083/jcb.107.3.1207; Mamdouh Z, 2000, CIRCULATION, V102, P87; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MAZZONE T, 1994, J LIPID RES, V35, P1345; OSEIFRIMPONG J, 1994, MOL CARCINOGEN, V10, P72, DOI 10.1002/mc.2940100204; Paka L, 1999, J BIOL CHEM, V274, P36403, DOI 10.1074/jbc.274.51.36403; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; REYLAND ME, 1992, J BIOL CHEM, V267, P17933; RIFAI N, 1987, CLIN CHIM ACTA, V163, P207, DOI 10.1016/0009-8981(87)90024-6; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; ROSES AD, 1995, ARZNEIMITTEL-FORSCH, V45-1, P413; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; SEITZ WR, 1984, CLIN BIOCHEM, V17, P120; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; TALMAGE DA, 1992, ONCOGENE, V7, P1837; Thommes KB, 1996, EXP CELL RES, V226, P59, DOI 10.1006/excr.1996.0202; VOGEL T, 1994, J CELL BIOCHEM, V54, P299, DOI 10.1002/jcb.240540306; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068	41	22	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43455	43462		10.1074/jbc.M105325200	http://dx.doi.org/10.1074/jbc.M105325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551921	hybrid			2022-12-25	WOS:000172169300106
J	Nakajima, H; Kiyokawa, N; Katagiri, YU; Taguchi, T; Suzuki, T; Sekino, T; Mimori, K; Ebata, T; Saito, M; Nakao, H; Takeda, T; Fujimoto, J				Nakajima, H; Kiyokawa, N; Katagiri, YU; Taguchi, T; Suzuki, T; Sekino, T; Mimori, K; Ebata, T; Saito, M; Nakao, H; Takeda, T; Fujimoto, J			Kinetic analysis of binding between shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI O157-H7; HEMOLYTIC UREMIC SYNDROMES; N-GLYCOSIDASE ACTIVITY; MELANOMA B16 CELLS; GLOBOTRIAOSYL CERAMIDE; CHOLERA-TOXIN; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; SHIGELLA-DYSENTERIAE; CRYSTAL-STRUCTURE	Shiga toxin (Stx) binds to the receptor glycolipid Gb3Cer on the cell surface and is responsible for hemolytic uremic syndrome. Stx has two isoforms, Stx1 and Stx2, and in clinical settings Stx2 is known to cause more severe symptoms, although the differences between the mechanisms of action of Stx1 and Stx2 are as yet unknown. In this study, the binding modes of these two isoforms to the receptor were investigated with a surface plasmon resonance analyzer to compare differences by real time receptor binding analysis. A sensor chip having a lipophilically modified dextran matrix or quasicrystalline hydrophobic layer was used to immobilize an amphipathic lipid layer that mimics the plasma membrane surface. Dose responsiveness was observed with both isoforms when either the toxin concentration or the Gb3Cer concentration was increased. In addition, this assay was shown to be specific, because neither Stx1 nor Stx2 bound to GM3, but both bound weakly to Gb4Cer. It was also shown that a number of fitting models can be used to analyze the sensorgrams obtained with different concentrations of the toxins, and the "bivalent analyte" model was found to best fit the interaction between Stxs and Gb3Cer. This shows that,the interaction between Stxs and Gb3Cer in the lipid bilayer has a multivalent effect. The presence of cholesterol in the lipid bilayer significantly enhanced the binding of Stxs to Gb3Cer, although kinetics were unaffected. The association and dissociation rate constants of Stx1 were larger than those of Stx2: Stx2 binds to the receptor more slowly than Stx1 but, once bound, is difficult to dissociate. The data described herein clearly demonstrate differences between the binding properties of Stx1 and Stx2 and may facilitate understanding of the differences in clinical manifestations caused by these toxins.	Natl Childrens Med Res Ctr, Dept Pathol, Setagaya Ku, Tokyo 1548509, Japan; Natl Childrens Med Res Ctr, Dept Infect Dis, Setagaya Ku, Tokyo 1548509, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan	National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; Japan Science & Technology Agency (JST)	Fujimoto, J (corresponding author), Natl Childrens Med Res Ctr, Dept Pathol, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548509, Japan.							Arab S, 1996, GLYCOCONJUGATE J, V13, P159, DOI 10.1007/BF00731490; Boerlin P, 1999, J CLIN MICROBIOL, V37, P497, DOI 10.1128/JCM.37.3.497-503.1999; Brigotti M, 1997, TOXICON, V35, P1431, DOI 10.1016/S0041-0101(96)00225-5; BRULET P, 1977, BIOCHEMISTRY-US, V16, P1209, DOI 10.1021/bi00625a028; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; Erb EM, 2000, ANAL BIOCHEM, V280, P29, DOI 10.1006/abio.1999.4469; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAMALAINEN M, 1998, BIA J, V5, P12; HEAD SC, 1991, J BIOL CHEM, V266, P3617; IUPAC-IUB Commission on Biochemical Nomenclature, 1977, LIPIDS, V12, P455; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Iwabuchi K, 2000, J BIOL CHEM, V275, P15174, DOI 10.1074/jbc.275.20.15174; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; JACKSON MP, 1987, MICROB PATHOGENESIS, V2, P147, DOI 10.1016/0882-4010(87)90106-9; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; KAYE SA, 1993, INFECT IMMUN, V61, P3886, DOI 10.1128/IAI.61.9.3886-3891.1993; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KHINE AA, 1994, J CELL PHYSIOL, V161, P319, DOI 10.1002/jcp.1041610217; KLEANTHOUS H, 1990, ARCH DIS CHILD, V65, P722, DOI 10.1136/adc.65.7.722; Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i; Lange S, 1997, J BIOL CHEM, V272, P20884, DOI 10.1074/jbc.272.33.20884; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Lingwood CA, 2000, METHOD ENZYMOL, V312, P459; LOUISE CB, 1995, INFECT IMMUN, V63, P2766, DOI 10.1128/IAI.63.7.2766-2769.1995; LOUISE CB, 1995, J INFECT DIS, V172, P1397, DOI 10.1093/infdis/172.5.1397; MacKenzie CR, 2000, METHOD ENZYMOL, V312, P205; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; MASSERINI M, 1992, BIOCHEMISTRY-US, V31, P2422, DOI 10.1021/bi00123a030; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; Mori T, 2000, EXP HEMATOL, V28, P1260, DOI 10.1016/S0301-472X(00)00538-5; Mylvaganam M, 2000, METHOD ENZYMOL, V312, P473; Nakajima H, 2001, PROTEIN EXPRES PURIF, V22, P267, DOI 10.1006/prep.2001.1449; NYHOLM PG, 1995, INT J BIOL MACROMOL, V17, P199, DOI 10.1016/0141-8130(95)92686-K; Nyholm PG, 1996, CHEM BIOL, V3, P263, DOI 10.1016/S1074-5521(96)90106-4; OGASAWARA T, 1988, MICROB PATHOGENESIS, V4, P127, DOI 10.1016/0882-4010(88)90054-X; OSTROFF SM, 1989, J INFECT DIS, V160, P994, DOI 10.1093/infdis/160.6.994; Peter MG, 2000, BBA-MOL BASIS DIS, V1501, P116, DOI 10.1016/S0925-4439(00)00011-9; Picking WD, 1999, BIOCHEMISTRY-US, V38, P7177, DOI 10.1021/bi982335n; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SAXENA SK, 1989, J BIOL CHEM, V264, P596; SCOTLAND SM, 1987, EPIDEMIOL INFECT, V99, P613, DOI 10.1017/S0950268800066462; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STEFFNER P, 1997, BIA J, V4, P10; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TESH VL, 1993, INFECT IMMUN, V61, P3392, DOI 10.1128/IAI.61.8.3392-3402.1993; Yuan CB, 2000, BIOPHYS J, V79, P2768, DOI 10.1016/S0006-3495(00)76516-7	53	106	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42915	42922		10.1074/jbc.M106015200	http://dx.doi.org/10.1074/jbc.M106015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11557760	hybrid			2022-12-25	WOS:000172169300039
J	Heeren, J; Grewal, T; Jackle, S; Beisiegel, U				Heeren, J; Grewal, T; Jackle, S; Beisiegel, U			Recycling of apolipoprotein E and lipoprotein lipase through endosomal compartments in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; LDL-RECEPTOR; RAT-LIVER; BETA-VLDL; DEGRADATION; FRACTIONS	We have recently described a novel recycling pathway of triglyceride-rich lipoprotein (TRL)-associated apolipoprotein (apo) E in human hepatoma cells. We now demonstrate that not only TRL-derived apoE but also lipoprotein lipase (LPL) is efficiently recycled in vitro and in vivo. Similar recycling kinetics of apoE and LPL in normal and low density lipoprotein receptor-negative human fibroblasts also indicate that the low density lipoprotein receptor-related protein seems to be involved. Intracellular sorting mechanisms are responsible for reduced lysosomal degradation of both ligands after receptor-mediated internalization. Immediately after internalization in rat liver, TRLs are disintegrated, and apoE and LPL are found in endosomal compartments, whereas TRL-derived phospholipids accumulate in the perinuclear region of hepatocytes. Subsequently, substantial amounts of both proteins can be found in purified recycling endosomes, indicating a potential resecretion of these TRL components. Pulse-chase experiments of perfused rat livers with radiolabeled TRLs demonstrated a serum-induced release of internalized apoE and LPL into the perfusate. Analysis of the secreted proteins identified similar to 80% of the recycled TRL-derived proteins in the high density lipoprotein fractions. These results provide the first evidence that recycling of TRL-derived apoE and LPL could play an important role in the modulation of lipoproteins in vivo.	Univ Hamburg, Hosp Eppendorf, Dept Med Biochem & Mol Biol, D-20246 Hamburg, Germany	University of Hamburg	Heeren, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Internal Med, Martinistr 52, D-20249 Hamburg, Germany.		Eckhardt, Erik/G-1567-2010	Grewal, Thomas/0000-0002-7937-8887				BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Beisiegel U, 1997, P NUTR SOC, V56, P731, DOI 10.1079/PNS19970073; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BRADLEY WA, 1986, J LIPID RES, V27, P40; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Enrich C, 1999, HEPATOLOGY, V30, P1115, DOI 10.1002/hep.510300505; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Havel R J, 1986, Methods Enzymol, V129, P591; Heeren J, 1999, J CELL SCI, V112, P349; Heeren J, 2001, CURR OPIN LIPIDOL, V12, P255, DOI 10.1097/00041433-200106000-00003; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; JACKLE S, 1991, J LIPID RES, V32, P485; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; JONES AL, 1984, J LIPID RES, V25, P1151; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LOMBARDI P, 1993, J BIOL CHEM, V268, P26113; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; Mahley RW, 1999, J LIPID RES, V40, P1; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Pol A, 1997, BIOCHEM J, V323, P435, DOI 10.1042/bj3230435; Pol A, 1997, ELECTROPHORESIS, V18, P2548, DOI 10.1002/elps.1150181410; Rensen PCN, 2000, J BIOL CHEM, V275, P8564, DOI 10.1074/jbc.275.12.8564; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Zambon A, 1996, J LIPID RES, V37, P2394	33	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42333	42338		10.1074/jbc.M107461200	http://dx.doi.org/10.1074/jbc.M107461200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546820	hybrid			2022-12-25	WOS:000172450400104
J	Hong, ERL; Shinohara, A; Bishop, DK				Hong, ERL; Shinohara, A; Bishop, DK			Saccharomyces cerevisiae Dmc1 protein promotes renaturation of single-strand DNA (ssDNA) and assimilation of ssDNA into homologous super-coiled duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; HUMAN RAD51 PROTEIN; FORMS RING STRUCTURES; MEIOTIC RECOMBINATION; NUCLEOPROTEIN FILAMENT; ATP HYDROLYSIS; BREAK REPAIR; EXCHANGE; COMPLEXES; SYNAPSIS	Dmc1 and Rad51 are eukaryotic RecA homologues that are involved in meiotic recombination. The expression of Dmc1 is limited to meiosis, whereas Rad51 is expressed in mitosis and meiosis. Dmc1 and Ptad51 have unique and overlapping functions during meiotic recombination. Here we report the purification of the Dmc1 protein from the budding yeast Saccharomyces cerevisiae and present basic characterization of its biochemical activity. The protein has a weak DNA-dependent ATPase activity and binds both single-strand DNA (ssDNA) and double-strand DNA. Electrophoretic mobility shift assays suggest that DNA binding by Dmc1 is cooperative. Dmc1 renatures linearized plasmid DNA with first order reaction kinetics and without requiring added nucleotide cofactor. In addition, Dmc1 catalyzes strand assimilation of ssDNA oligonucleotides into homologous supercoiled duplex DNA in a reaction promoted by ATP or the non-hydrolyzable ATP analogue AMP-PNP.	Univ Chicago, Cummings Life Sci Ctr, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	University of Chicago; University of Chicago; Osaka University	Bishop, DK (corresponding author), Univ Chicago, Cummings Life Sci Ctr, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.				NIGMS NIH HHS [GM50936] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRYANT FR, 1989, BIOCHEMISTRY-US, V28, P1062, DOI 10.1021/bi00429a021; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; De Zutter SK, 1999, J MOL BIOL, V293, P769, DOI 10.1006/jmbi.1999.3200; Dresser ME, 1997, GENETICS, V147, P533; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 2001, P NATL ACAD SCI USA, V98, P8433, DOI 10.1073/pnas.121005298; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; Huang H V, 1988, Biotechnology, V10, P269; Ivanov EL, 1996, GENETICS, V142, P693; KOLODNER R, 1980, P NATL ACAD SCI-BIOL, V77, P4847, DOI 10.1073/pnas.77.8.4847; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MCENTEE K, 1985, BIOCHEMISTRY-US, V24, P4345, DOI 10.1021/bi00337a014; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Passy SI, 1999, P NATL ACAD SCI USA, V96, P10684, DOI 10.1073/pnas.96.19.10684; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RATTRAY AJ, 1994, GENETICS, V138, P587; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1981, J BIOL CHEM, V256, P7565; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; Shinohara A, 1997, GENES CELLS, V2, P615, DOI 10.1046/j.1365-2443.1997.1480347.x; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Shinohara M, 1997, GENETICS, V147, P1545; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	65	108	109	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41906	41912		10.1074/jbc.M105563200	http://dx.doi.org/10.1074/jbc.M105563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551925	hybrid			2022-12-25	WOS:000172450400049
J	Saelens, X; Kalai, M; Vandenabeele, P				Saelens, X; Kalai, M; Vandenabeele, P			Translation inhibition in apoptosis - Caspase-dependent PKR activation and eIF2-alpha phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PROTEIN-KINASE PKR; TUMOR-NECROSIS-FACTOR; INITIATION-FACTOR 4G; INTERFERON-GAMMA; BINDING DOMAINS; TNF-ALPHA; CLEAVAGE; DIMERIZATION; CELLS	The protein kinase PKR is a major player in the cellular antiviral response, acting mainly by phosphorylation of the alpha -subunit of the eukaryotic translation initiation factor 2 (eIF2-alpha) to block de novo protein synthesis. PKR activation requires binding of double-stranded RNA or PACT/RAX proteins to its regulatory domain. Since several reports have demonstrated that translation is inhibited in apoptosis, we investigated whether PKR and eIF2-alpha phosphorylation contribute to this process. We show that PKR is proteolysed and that eIF2-alpha is phosphorylated at the early stages of apoptosis induced by various stimuli. Both events coincide with the onset of caspase activity and are prevented by caspase inhibitors. Using site-directed mutagenesis we show that PKR is specifically proteolysed at Asp(251) during cellular apoptosis. This site is cleaved in vitro by recombinant caspase-3, caspase-7, and caspase-8 and not by the proinflammatory caspase-1 and caspase-11. The released kinase domain efficiently phosphorylates eIF2-alpha at the cognate Ser(51) residue, and its overexpression in mammalian cells impairs the translation of its own mRNA and of reporter mRNAs. Our results demonstrate a new and caspase-dependent activation mode for PKR, leading to eIF2-alpha phosphorylation and translation inhibition in apoptosis.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signaling & Cell Death, B-9000 Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Vandenabeele, P (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signaling & Cell Death, KL Ledaganckstr 35, B-9000 Ghent, Belgium.	peter.vandenabeele@dmb.rug.ac.be	Vandenabeele, Peter/AAD-5793-2022; Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; , Xavier/0000-0002-3861-6965				Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; de la Vega CM, 1999, CELL SIGNAL, V11, P399, DOI 10.1016/S0898-6568(99)00009-1; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; Fulda S, 2000, CANCER RES, V60, P3947; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Marissen WE, 2000, J BIOL CHEM, V275, P9314, DOI 10.1074/jbc.275.13.9314; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; McCarthy JEG, 2000, CURR BIOL, V10, pR715, DOI 10.1016/S0960-9822(00)00706-5; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIN JW, 1980, CELL, V19, P683; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tang NM, 1999, MOL CELL BIOL, V19, P4757; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	54	150	155	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41620	41628		10.1074/jbc.M103674200	http://dx.doi.org/10.1074/jbc.M103674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11555640	hybrid			2022-12-25	WOS:000172450400013
J	Okamura, Y; Takeyama, H; Matsunaga, T				Okamura, Y; Takeyama, H; Matsunaga, T			A magnetosome-specific GTPase from the magnetic bacterium Magnetospirillum magneticum AMB-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SP STRAIN AMB-1; SIGNAL RECOGNITION PARTICLE; BINDING PROTEIN OBG; ESCHERICHIA-COLI; SUCCESSIVE COMPARTMENTS; NUCLEOTIDE BINDING; BACILLUS-SUBTILIS; GOLGI MEMBRANES; COATED VESICLES	Magnetic bacteria produce intracellular vesicles that envelope single domain magnetite crystals. Although many proteins are present in this intracellular vesicle membrane, five are specific to this membrane. A 16-kDa protein, designated Mms16, is the most abundant of the magnetosome-specific proteins, and to establish its function we cloned and sequenced its gene from Magnetospirillum magneticum AMB-1. This was achieved by determination of the N-terminal amino acid sequence of the protein following two dimensional polyacrylamide gel electrophoresis, and sequencing of the gene was performed by gene walking using anchored polymerase chain reaction. Mms16 contains a putative ATP/GTP binding motif (P-loop). Recombinant Mms16 with a hemagglutinin tag, was expressed in Escherichia coli and purified. Recombinant Mms16 protein could bind GTP and showed GTPase activity. GTP was the preferred substrate for Mms16-catalyzed nucleotide triphosphate hydrolysis. These results suggest that a novel protein specifically localized on the magnetic particle membrane, Mms16, is a GTPase. Mms16 protein showed similar characteristics to small GTPases involved in the formation of intracellular vesicles. Furthermore, addition of the GTPase inhibitor AlF4- also inhibited magnetic particle synthesis, suggesting that GTPase is required for magnetic particles synthesis.	Tokyo Univ Agr & Technol, Dept Biotechnol, Tokyo 1848588, Japan	Tokyo University of Agriculture & Technology	Matsunaga, T (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	tmatsuna@cc.tuat.ac.jp	Matsunaga, Tadashi/A-6293-2015; Okamura, Yoshiko/M-4019-2019; Okamura, Yoshiko/W-2677-2017	Matsunaga, Tadashi/0000-0002-6216-3687; Okamura, Yoshiko/0000-0001-8333-7722; Okamura, Yoshiko/0000-0001-8333-7722				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Anthony C., 1982, BIOCH METHYLOTROPHS; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BAZYLINSKI DA, 1995, APPL ENVIRON MICROB, V61, P3232, DOI 10.1128/AEM.61.9.3232-3239.1995; BLAKEMORE RP, 1979, J BACTERIOL, V140, P720, DOI 10.1128/JB.140.2.720-729.1979; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Britton RA, 1998, MOL MICROBIOL, V27, P739, DOI 10.1046/j.1365-2958.1998.00719.x; Britton RA, 1997, J BACTERIOL, V179, P4575, DOI 10.1128/jb.179.14.4575-4582.1997; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; FRANKEL RB, 1983, BIOCHIM BIOPHYS ACTA, V763, P147, DOI 10.1016/0167-4889(83)90038-1; GORBY YA, 1988, J BACTERIOL, V170, P834, DOI 10.1128/jb.170.2.834-841.1988; HELMS JB, 1993, J CELL BIOL, V119, P139; HOOPER AB, 1984, EUR J BIOCHEM, V141, P565, DOI 10.1111/j.1432-1033.1984.tb08230.x; HUREK T, 1995, MOL MICROBIOL, V18, P225, DOI 10.1111/j.1365-2958.1995.mmi_18020225.x; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; ISEGAWA Y, 1992, MOL CELL PROBE, V6, P467, DOI 10.1016/0890-8508(92)90043-W; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KOK J, 1994, J BACTERIOL, V176, P7155, DOI 10.1128/JB.176.23.7155-7160.1994; Kondratieva E.N., 1992, PROKARYOTES, VVolume 1, P312; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; MARCH PE, 1988, ONCOGENE, V2, P539; MATSUNAGA T, 1991, APPL MICROBIOL BIOT, V35, P651; Matsunaga T, 2000, BIOCHEM BIOPH RES CO, V268, P932, DOI 10.1006/bbrc.2000.2236; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; NAKAMURA C, 1995, J BIOCHEM-TOKYO, V118, P23, DOI 10.1093/oxfordjournals.jbchem.a124884; NAKAMURA C, 1995, J BIOL CHEM, V270, P28392; NOKIHARA K, 1992, ELECTROPHORESIS, V13, P701, DOI 10.1002/elps.11501301149; Okamura Y, 2000, APPL BIOCHEM BIOTECH, V84-6, P441, DOI 10.1385/ABAB:84-86:1-9:441; Okuda Y, 1996, GENE, V171, P99, DOI 10.1016/0378-1119(95)00008-9; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Rothman JE, 1996, PROTEIN SCI, V5, P185; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J, 2001, MOL CLONING LAB MANU; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; Schuler D, 1999, APPL MICROBIOL BIOT, V52, P464, DOI 10.1007/s002530051547; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIDWANS SJ, 1995, J BACTERIOL, V177, P3308, DOI 10.1128/jb.177.11.3308-3311.1995; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATSON WS, 1989, BERGEYS MANUAL SYSTE, V3, P1808; WEISS O, 1989, J BIOL CHEM, V264, P21066; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	58	65	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48183	48188		10.1074/jbc.M106408200	http://dx.doi.org/10.1074/jbc.M106408200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11557762	hybrid			2022-12-25	WOS:000172927000060
J	Pal, GP; Elce, JS; Jia, ZC				Pal, GP; Elce, JS; Jia, ZC			Dissociation and aggregation of calpain in the presence of calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SUBUNITS; HETERODIMER; PROTEASE; REVEALS	Calpain is a heterodimeric Ca2+-dependent cysteine protease consisting of a large (80 kDa) catalytic subunit and a small (28 kDa) regulatory subunit. The effects of Ca2+ on the enzyme include activation, aggregation, and autolysis. They may also include subunit dissociation, which has been the subject of some debate. Using the inactive C105S-80k/21k form of calpain to eliminate autolysis, we have studied its disassociation and aggregation in the presence of Ca2+ and the inhibition of its aggregation by means of crystallization, light scattering, and sedimentation. Aggregation, as assessed by light scattering, depended on the ionic strength and pH of the buffer, on the Ca2+ concentration, and on the presence or absence of calpastatin. At low ionic strength, calpain aggregated rapidly in the presence of Ca2+, but this was fully reversible by EDTA. With Ca2+ in 0.2 M NaCl, no aggregation was visible but ultracentrifugation showed that a mixture of soluble high molecular weight complexes was present. Calpastatin prevented aggregation, leading instead to the formation of a calpastatin-calpain complex. Crystallization in the presence of Ca2+ gave rise to crystals mixed with an amorphous precipitate. The crystals contained only the small subunit, thereby demonstrating subunit dissociation, and the precipitate was highly enriched in the large subunit. Reversible dissociation in the presence of Ca2+ was also unequivocally demonstrated by the exchange of slightly different small subunits between mu -calpain and m-calpain. We conclude that subunit dissociation is a dynamic process and is not complete in most buffer conditions unless driven by factors such as crystal formation or autolysis of active enzymes. Exposure of the hydrophobic dimerization surface following subunit dissociation may be the main factor responsible for Ca2+-induced aggregation of calpain. It is likely that dissociation serves as an early step in calpain activation by releasing the constraints upon protease domain I.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Stuart St, Kingston, ON K7L 3N6, Canada.	jia@post.queensu.ca						Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Dourdin N, 1999, EXP CELL RES, V246, P433, DOI 10.1006/excr.1998.4325; Dutt P, 1998, FEBS LETT, V436, P367, DOI 10.1016/S0014-5793(98)01167-3; Elce JS, 1997, BIOCHEM J, V326, P31, DOI 10.1042/bj3260031; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; GOLL DE, 1990, INTRACELLULAR CALCIU, P103; Harada K, 1999, J NEUROCHEM, V72, P2556, DOI 10.1046/j.1471-4159.1999.0722556.x; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; KAPPRELL HP, 1989, J BIOL CHEM, V264, P17888; Kitagaki H, 2000, BIOSCI BIOTECH BIOCH, V64, P689, DOI 10.1271/bbb.64.689; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Maki M, 2000, METH MOL B, V144, P85; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; Zhang WL, 1996, BIOCHEM BIOPH RES CO, V227, P890, DOI 10.1006/bbrc.1996.1601	28	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47233	47238		10.1074/jbc.M105149200	http://dx.doi.org/10.1074/jbc.M105149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11551918	hybrid			2022-12-25	WOS:000172768500076
J	Ahuja, A; Purcarea, C; Guy, HI; Evans, DR				Ahuja, A; Purcarea, C; Guy, HI; Evans, DR			A novel carbamoyl-phosphate synthetase from Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; SITE-DIRECTED MUTAGENESIS; ARCHAEON PYROCOCCUS-FURIOSUS; COOH-TERMINAL DOMAIN; ATP-BINDING-SITES; ESCHERICHIA-COLI; AMIDOTRANSFERASE DOMAIN; LARGE SUBUNIT; ASPARTATE TRANSCARBAMOYLASE; REVERSIBLE DISSOCIATION	Aquifex aeolicus, an extreme hyperthermophile, has neither a full-length carbamoyl-phosphate synthetase (CPSase) resembling the enzyme found in all mesophilic organisms nor a carbamate kinase-like CPSase such as those present in several hyperthermophilic archaea. However, the genome has open reading frames encoding putative proteins that are homologous to the major CPSase domains. The glutaminase, CPS.A and CPS.B homologs from A. aeolicus were cloned, overexpressed in Escherichia coli, and purified to homogeneity. The isolated proteins could catalyze several partial reactions but not the overall synthesis of carbamoyl phosphate. However, a stable 124-kDa complex could be reconstituted from stoichiometric amounts of CPS.A and CPS.B proteins that synthesized carbamoyl phosphate from ATP, bicarbonate, and ammonia. The inclusion of the glutaminase subunit resulted in the formation of a 171-kDa complex that could utilize glutamine as the nitrogen-donating substrate, although the catalytic efficiency was significantly compromised. Molecular modeling, using E. coli CPSase as a template, showed that the enzyme has a similar structural organization and interdomain interfaces and that. all of the residues known to be essential for function are conserved and properly positioned. A steady state kinetic study at 78 degreesC indicated that although the substrate affinity was similar for bicarbonate, ammonia, and glutamine, the K-m for ATP was appreciably higher than that of any known CPSase. The A. aeolicus complex, with a split gene encoding the major synthetase domains and relatively inefficient coupling of amidotransferase and synthetase functions, may be more closely related to the ancestral precursor of contemporary mesophilic CPSases.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu		Purcarea, Cristina/0000-0001-5784-8545	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM/CA60371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; Bueso J, 1999, BIOCHEMISTRY-US, V38, P3910, DOI 10.1021/bi982871f; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cervera J, 1996, BIOCHEMISTRY-US, V35, P7247, DOI 10.1021/bi952549u; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Durbecq V, 1997, P NATL ACAD SCI USA, V94, P12803, DOI 10.1073/pnas.94.24.12803; GUY HI, 1995, J BIOL CHEM, V270, P2190, DOI 10.1074/jbc.270.5.2190; Guy HI, 1998, J BIOL CHEM, V273, P14172, DOI 10.1074/jbc.273.23.14172; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hewagama A, 1998, BBA-PROTEIN STRUCT M, V1388, P489, DOI 10.1016/S0167-4838(98)00212-X; HOOGENRAAD NJ, 1971, BIOCHEM BIOPH RES CO, V44, P981, DOI 10.1016/0006-291X(71)90808-4; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; Marina A, 1999, PROTEIN SCI, V8, P934; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; Mora P, 1999, FEBS LETT, V446, P133, DOI 10.1016/S0014-5793(99)00197-0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; Purcarea C, 1999, J BIOL CHEM, V274, P6122, DOI 10.1074/jbc.274.10.6122; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; Serre V, 1999, J BIOL CHEM, V274, P23794, DOI 10.1074/jbc.274.34.23794; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; Thoden JB, 1999, J BIOL CHEM, V274, P22502, DOI 10.1074/jbc.274.32.22502; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; ZALKIN H, 1985, METHOD ENZYMOL, V113, P263	52	14	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45694	45703		10.1074/jbc.M106382200	http://dx.doi.org/10.1074/jbc.M106382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574542	hybrid			2022-12-25	WOS:000172573100028
J	Hatae, T; Wada, M; Yokoyama, C; Shimonishi, M; Tanabe, T				Hatae, T; Wada, M; Yokoyama, C; Shimonishi, M; Tanabe, T			Prostacyclin-dependent apoptosis mediated by PPAR delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; PEROXISOME PROLIFERATOR; PROSTANOID RECEPTORS; PROTEIN-KINASE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); DIFFERENTIAL EXPRESSION; ENDOTHELIAL-CELLS; MOLECULAR-BIOLOGY; INDUCE APOPTOSIS; RETINOIC ACID	Prostacyclin (PGI(2)) plays important roles in hemostasis both as a vasodilator and an endogenous inhibitor of platelet aggregation. PGI(2) functions in these roles through a specific IP receptor, a G protein-coupled receptor linked to G. and increases in cAMP. Here, we report that intracellular prostacyclin formed by expressing prostacyclin synthase in human embryonic kidney 293 cells promotes apoptosis by activating endogenous peroxisome proliferator-activated receptor delta (PPAR delta). In contrast, treatment of cells with extracellular prostacyclin or dibutyryl cAMP actually reduced apoptosis. On the contrary, treatment of the cells with RpcAMP (adenosine 3',5'-cyclic monophosphothioate, Rp-isomer), an antagonist of cAMP, enhanced prostacyclin-mediated apoptosis. The expression of an L431A/G434A mutant of PPAR delta completely blocked prostacyclin-mediated PPAR delta activation and apoptosis. These observations indicate that prostacyclin can act through endogenous PPAR delta as a second signaling pathway that controls cell fate.	Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Tanabe, T (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Suita, Osaka 5658565, Japan.							Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Beauchamp MH, 2001, J APPL PHYSIOL, V90, P2279, DOI 10.1152/jappl.2001.90.6.2279; Bellosillo B, 1998, BLOOD, V92, P1406, DOI 10.1182/blood.V92.4.1406.416k17_1406_1414; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Diep QN, 2000, HYPERTENSION, V36, P851, DOI 10.1161/01.HYP.36.5.851; DOHLMAN HG, 1993, NATURE, V366, P307, DOI 10.1038/366307b0; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; HARA S, 1994, J BIOL CHEM, V269, P19897; HATAE T, 1996, FEBS LETT, V289, P268; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kedzie KM, 1998, MOL PHARMACOL, V54, P584, DOI 10.1124/mol.54.3.584; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Lazar MA, 2001, NAT MED, V7, P23, DOI 10.1038/83301; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Ono-Saito N, 1999, PHARMACOL THERAPEUT, V82, P123, DOI 10.1016/S0163-7258(98)00070-9; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Roberts RA, 1998, CARCINOGENESIS, V19, P43, DOI 10.1093/carcin/19.1.43; Robinson SW, 1996, J NEUROCHEM, V67, P212; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SMITH EM, 1996, J BIOL CHEM, V271, P33698; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; TANABE T, 1995, J LIPID MEDIAT CELL, V12, P243, DOI 10.1016/0929-7855(95)00031-K; Todaka T, 1999, STROKE, V30, P419, DOI 10.1161/01.STR.30.2.419; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; Valmaseda A, 1999, MOL CELL ENDOCRINOL, V154, P101, DOI 10.1016/S0303-7207(99)00081-7; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; WATABE A, 1993, J BIOL CHEM, V268, P20175; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	53	112	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46260	46267		10.1074/jbc.M107180200	http://dx.doi.org/10.1074/jbc.M107180200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11551955	hybrid			2022-12-25	WOS:000172573100105
J	Martelli, MP; Boomer, J; Bu, M; Bierer, BE				Martelli, MP; Boomer, J; Bu, M; Bierer, BE			T cell regulation of p62(dok) (Dok1) association with Crk-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; ZETA-CHAIN; BCR-ABL; DOCKING PROTEIN; FAMILY KINASES; LIGAND AVIDITY; CD2 ANTIGEN	In addition to engagement of the T cell receptor-CD3 complex, T lymphocytes can be activated by a variety of cell surface molecules including the similar to 50-kDa surface receptor CD2. While the majority of biochemical signaling elements are triggered by either CD2 or TcR-CD3 receptors, a small number of proteins are engaged by only one receptor. Recently, p62(dok) (Dok1), a member of the Dok family of adapter molecules, has been reported to be activated by CD2 and not by C133 engagement. Here we have examined the role of p62(dok) in CD2-dependent signaling in Jurkat T cells. As previously reported, we find that ligation of the CD2 molecule by mitogenic pairs of anti-CD2 mAbs led to phosphorylation of p62(dok). While CD2-induced p62(dok) tyrosine phosphorylation was independent of both the p36/38 membrane adapter protein linker of activated T cells (LAT) and the ZAP70/Syk family of kinases, it was dependent upon the Src family of kinases including Lck and Fyn. We find further that CD2 engagement induced the association of tyrosine-phosphorylated p62(dok) to Crk-L. The CD2-dependent association of p62(dok) to Crk-L was independent of expression of the ZAP70/Syk family of kinases. Of note, while T cell receptor-CD3 engagement did not induce either p62(dok) phosphorylation or Crk-L association in Jurkat T cells, it did inhibit CD2-dependent p62 (dok)-Crk-L complexes; this TcR-CD3-mediated regulation was dependent upon ZAP70 kinase activity. Our data suggest that phosphorylation of p62(dok) and its interaction with other signaling proteins may depend upon integrated signals emanating from the CD2 receptor, utilizing a ZAP70/LAT-independent pathway, and the TcR-CD3 receptor, which is ZAP70/Syk-dependent.	NHLBI, Lab Lymphocyte Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bierer, BE (corresponding author), NHLBI, Lab Lymphocyte Biol, NIH, Bldg 10,Rm 6C208,10 Ctr Dr, Bethesda, MD 20892 USA.	biererb@nih.gov	Martelli, Maria Paola/ABH-3300-2021; Martelli, Maria Paola/I-5618-2012	Martelli, Maria Paola/0000-0001-9139-1729; Bierer, Barbara/0000-0001-6448-8170				ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; Berg KL, 1999, J BIOL CHEM, V274, P35855, DOI 10.1074/jbc.274.50.35855; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Bierer B E, 1993, Semin Immunol, V5, P249, DOI 10.1006/smim.1993.1029; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fukai I, 2000, EUR J IMMUNOL, V30, P3507, DOI 10.1002/1521-4141(2000012)30:12<3507::AID-IMMU3507>3.0.CO;2-O; GASSMANN M, 1994, EUR J IMMUNOL, V24, P139, DOI 10.1002/eji.1830240121; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Green JM, 2000, J IMMUNOL, V164, P3591, DOI 10.4049/jimmunol.164.7.3591; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAHN WC, 1993, J EXP MED, V178, P1831, DOI 10.1084/jem.178.5.1831; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HAHN WC, 1993, J IMMUNOL, V150, P2607; Harriague J, 2000, EUR J IMMUNOL, V30, P3319, DOI 10.1002/1521-4141(200011)30:11<3319::AID-IMMU3319>3.0.CO;2-1; HUBERT P, 1993, J EXP MED, V178, P1587, DOI 10.1084/jem.178.5.1587; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; King PD, 1996, INT IMMUNOL, V8, P1707, DOI 10.1093/intimm/8.11.1707; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; KIYOKAWA E, 1997, CRIT REV ONCOL, P329; Lee SJ, 2000, BRIT J HAEMATOL, V111, P993, DOI 10.1046/j.1365-2141.2000.02216.x; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; Lin HM, 1998, J BIOL CHEM, V273, P19914, DOI 10.1074/jbc.273.31.19914; Lin HM, 2001, INT IMMUNOL, V13, P13, DOI 10.1093/intimm/13.1.13; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MarieCardine A, 1996, J BIOL CHEM, V271, P20734, DOI 10.1074/jbc.271.34.20734; Martelli MP, 2000, BLOOD, V96, P2181; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Meinl E, 2000, J IMMUNOL, V165, P3578, DOI 10.4049/jimmunol.165.7.3578; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; MONOSTORI E, 1990, J IMMUNOL, V144, P1010; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORLEY P, 2001, ADV IMMUNOL, V77, P1; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; ODA T, 1995, LEUKEMIA, V9, P295; OHNO H, 1991, J IMMUNOL, V146, P3742; PANTALEO G, 1987, EUR J IMMUNOL, V17, P55, DOI 10.1002/eji.1830170110; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Sattler M, 2001, INT J HEMATOL, V73, P278, DOI 10.1007/BF02981952; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; SPRUYT LL, 1991, J EXP MED, V174, P1407, DOI 10.1084/jem.174.6.1407; Steeg C, 1997, EUR J IMMUNOL, V27, P2233, DOI 10.1002/eji.1830270917; Sunder-Plassmann R, 1998, J BIOL CHEM, V273, P24249, DOI 10.1074/jbc.273.37.24249; Suzu S, 2000, EMBO J, V19, P5114, DOI 10.1093/emboj/19.19.5114; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Ueno H, 2000, EUR J IMMUNOL, V30, P78; van Dijk TB, 2000, BLOOD, V96, P3406; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Verhagen AM, 1996, EUR J IMMUNOL, V26, P2841, DOI 10.1002/eji.1830261207; Von Bonin A, 1998, IMMUNOLOGY, V93, P376; Vuica M, 1997, J EXP MED, V186, P259, DOI 10.1084/jem.186.2.259; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943	85	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45654	45661		10.1074/jbc.M105777200	http://dx.doi.org/10.1074/jbc.M105777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11553620	hybrid			2022-12-25	WOS:000172573100023
J	Mikita, T; Porter, G; Lawn, RM; Shiffman, D				Mikita, T; Porter, G; Lawn, RM; Shiffman, D			Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED RECEPTOR-GAMMA; RETINOID-X-RECEPTOR; GENE-EXPRESSION; PPAR-GAMMA; INTERLEUKIN-12 PRODUCTION; CHOLESTEROL EFFLUX; LIVER DEGENERATION; NUCLEAR RECEPTOR; MESSENGER-RNA	av6Macrophage-derived foam cells in atherosclerotic lesions are generally thought to play a major role in the pathology of the disease. Because macrophages play a central role in the inflammatory response, and the atherosclerotic lesion has features associated with chronic inflammatory settings, we investigated foam cell inflammatory potential. THP-IL-derived macrophages were treated with oxidized low density lipoprotein (OxLDL) for 3 days to lipid load the macrophages and establish a foam cell-like phenotype. The cells were then activated by treatment with lipopolysaccharide (LPS), and RNA was harvested at 0, 1, and 6 h after LPS addition. RNA from treated and control cells was hybridized to microarrays containing similar to 16,000 human cDNAs. Genes that exhibited a 4-fold or greater increase or decrease at either 1 or 6 h after LPS treatment were counted as LPS-responsive genes. Employing these criteria, 127 LPS-responsive genes were identified. Prior treatment of THP-1 macrophages with OxLDL affected the expression of 57 of these 127 genes. Among these 57 genes was a group of chemokine, cytokine, and signal transduction genes with pronounced expression changes. OxLDL pretreatment resulted in a significant perturbation of LPS-induced NF kappaB activation. Furthermore, some of the OxLDL effects appear to be mediated by the nuclear receptors retinoid X receptor and peroxisomal proliferator-activated receptor gamma because pretreatment of THP-1 macrophages with ligands for these receptors, followed by LPS treatment, recapitulates the OxLDL plus LPS results for several of the most significantly modulated genes.	CV Therapeut, Palo Alto, CA 94304 USA; Incyte Genom, Palo Alto, CA 94304 USA	Incyte	Mikita, T (corresponding author), CV Therapeut, 3172 Porter Dr, Palo Alto, CA 94304 USA.	tomm@cvt.com						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; Costet P, 2000, J BIOL CHEM, V275, P28240; de Boer OJ, 2000, J PATHOL, V190, P237, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;237::AID-PATH541&gt;3.0.CO;2-N; Denecke B, 1999, J BIOL CHEM, V274, P26860, DOI 10.1074/jbc.274.38.26860; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Eligini S, 1999, ARTERIOSCL THROM VAS, V19, P1719, DOI 10.1161/01.ATV.19.7.1719; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Gimbrone MA, 1999, AM J PATHOL, V155, P1, DOI 10.1016/S0002-9440(10)65090-0; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; Hansson GK, 1997, CURR OPIN LIPIDOL, V8, P301, DOI 10.1097/00041433-199710000-00009; Heermeier K, 2001, J AM SOC NEPHROL, V12, P456, DOI 10.1681/ASN.V123456; Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kim CH, 1998, J IMMUNOL, V161, P2580; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee H, 2000, CIRC RES, V87, P516; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIBBY P, 2000, AM J CARDIOL S, V86, P3, DOI DOI 10.1016/S0002-9149(00)01339-4; Liu Y, 1997, ARTERIOSCL THROM VAS, V17, P317, DOI 10.1161/01.ATV.17.2.317; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rudolph D, 2000, GENE DEV, V14, P854; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shanley TP, 2000, CYTOKINE, V12, P1054, DOI 10.1006/cyto.1999.0655; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; Simpson AECM, 1997, INFLAMM RES, V46, P65, DOI 10.1007/s000110050078; Stenvinkel P, 2001, BLOOD PURIFICAT, V19, P53, DOI 10.1159/000014479; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sullivan GW, 2000, J LEUKOCYTE BIOL, V67, P591, DOI 10.1002/jlb.67.5.591; Suzuki T, 2000, BLOOD, V96, P2584; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TEMESGEN Z, 2001, EXPERT OPIN PHARMACO, V2, P765; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YUE H, 2001, NUCLEIC ACIDS RES, V15, P29	65	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45729	45739		10.1074/jbc.M106114200	http://dx.doi.org/10.1074/jbc.M106114200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577090	hybrid			2022-12-25	WOS:000172573100032
J	Spodsberg, N; Alfalah, M; Naim, HY				Spodsberg, N; Alfalah, M; Naim, HY			Characteristics and structural requirements of apical sorting of the rat growth hormone through the O-glycosylated stalk region of intestinal sucrase-isomaltase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS NEURAMINIDASE; CANINE KIDNEY-CELLS; POLARIZED EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE DOMAIN; MDCK CELLS; MEMBRANE GLYCOPROTEIN; SECRETORY PATHWAY; SURFACE TRANSPORT; GLYCANS MEDIATE	The apical sorting of the small intestinal membrane glycoprotein sucrase-isomaltase (SI) depends on the presence of O-linked glycans and the transmembrane domain. Here, we investigate the role of O-glycans carried by the Ser/Thr-rich stalk region of SI as an apical sorting signal and evaluate the spatial requirements for an efficient recognition of this signal. Several hybrid proteins are generated comprising the unsorted and unglycosylated protein, the rat growth hormone (rGH), fused to either the transmembrane domain of SI (GHSI(TM)), or the transmembrane and the stalk domains (GH-SISR/TM). Both constructs are randomly distributed over the apical and basolateral membranes of MDCK cells indicating that neither the transmembrane domain nor the O-glycans are sufficient per se for an apical delivery. Only when a polyglycine spacer is inserted between the stalk region of Sl and the luminal part of rGH in the GH-SIGly/SR/TM fusion protein does efficient apical sorting of an O-glycosylated protein as well as a time-dependent association with detergent-insoluble lipid microdomains occur. Obviously, the polyglycine spacer facilitates the accessibility of the O-glycans in GH-SIGly/SR/TM to a putative sorting receptor, whereas these glycans are inadequately recognized in GH-SISR/TM. We conclude that the O-glycans in the stalk region of SI act as an apical sorting signal within a sorting machinery that comprises at least a carbohydrate-binding protein and fulfills specific spatial requirements provided, for example by a polyglycine spacer in the context of rGH or the P-domain within the Sl enzyme complex.	Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Hannover Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Al Falah, Dr. Marwan/C-6281-2011					Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Barman S, 2000, J VIROL, V74, P6538, DOI 10.1128/JVI.74.14.6538-6545.2000; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Fiedler K, 1996, J CELL SCI, V109, P271; Fullekrug J, 1999, J CELL SCI, V112, P2813; GARCIA M, 1993, J CELL SCI, V104, P1281; GORMAN CM, 1984, PHILOS T ROY SOC B, V307, P343, DOI 10.1098/rstb.1984.0137; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Huang XF, 1997, J BIOL CHEM, V272, P27598, DOI 10.1074/jbc.272.44.27598; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JACOB R, 1994, J BIOL CHEM, V269, P2712; JONES LV, 1985, MOL CELL BIOL, V5, P2181, DOI 10.1128/MCB.5.9.2181; Keller P, 1997, J CELL SCI, V110, P3001; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J BIOL CHEM, V263, P7242; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAIM HY, 1991, J BIOL CHEM, V266, P12313; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SINHA YN, 1972, ENDOCRINOLOGY, V91, P784, DOI 10.1210/endo-91-3-784; THIBAULT V, 1993, ENDOCRINOLOGY, V132, P468, DOI 10.1210/en.132.1.468; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	44	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46597	46604		10.1074/jbc.M108187200	http://dx.doi.org/10.1074/jbc.M108187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577111	hybrid			2022-12-25	WOS:000172573100146
J	Chakraborty, S; Senyuk, V; Sitailo, S; Chi, YQ; Nucifora, G				Chakraborty, S; Senyuk, V; Sitailo, S; Chi, YQ; Nucifora, G			Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASES; TRANSCRIPTIONAL CONTROL; CO-REPRESSOR; EV11 GENE; EXPRESSION; ENCODES; RAR; DNA	EVIL is a very complex protein with two domains of zinc fingers and is inappropriately expressed in many types of human myeloid leukemias. Using reporter gene assays, several investigators showed that EVI1 is a transcription repressor, and recently it was shown that EVI1 interacts with the co-repressor carboxyl-terminal binding protein 1 (CtBP1). Earlier, we showed that the inappropriate expression of EVI1 in murine hematopoietic precursor cells leads to their abnormal differentiation and to increased proliferation. Using biochemical assays, we have identified two groups of transcription co-regulators that associate with EVIL presumably to regulate gene expression. One group of co-regulators includes the CtBP1 and histone deacetylase. The second group includes the two co-activators cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF), both of which have histone acetyltransferase (HAT) activity. All of these proteins require separate regions of EVI1 for efficient interaction, and they divergently affect the ability of EVI1 to regulate gene transcription in reporter gene assays. Confocal microscopy analysis shows that in the majority of the cells, EVI1 is nuclear and diffused, whereas in about 10%, of the cells EVI1 localizes in nuclear speckles. However, in the presence of the added exogenous co-repressors histone deacetylase or CtBP1, all of the nuclei have a diffuse EVI1 staining, and the proteins do not appear to reside together in obvious nuclear structures. In contrast, when CBP or P/CAF are added, defined speckled bodies appear in the nucleus. Analysis of the staining pattern indicates that EVI1 and CBP or EVIL and P/CAF are contained within these structures. These nuclear structures are not observed when CBP is substituted with a point mutant HAT-inactive CBP with which EVI1 also physically interacts. Finally, we show that the interaction of EVI1 with either CBP or P/CAF leads to acetylation of EVI1. These results suggest that the assembly of EVIL in nuclear speckles requires the intact HAT activity of the co-activators.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,M-C 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu			NCI NIH HHS [CA72675, CA67189] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072675, R29CA067189, R01CA067189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; FICHELSON S, 1992, LEUKEMIA, V6, P93; FontenayRoupie M, 1997, HEMATOL CELL THER, V39, P5, DOI 10.1007/s00282-997-0005-8; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P167, DOI 10.1016/0165-4608(89)90182-9; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; RUSSELL M, 1993, LEUKEMIA, V7, P1654; Sitailo S, 1999, LEUKEMIA, V13, P1639, DOI 10.1038/sj.leu.2401585; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; SUZUKAWA K, 1994, BLOOD, V84, P2681; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang JX, 1999, CANCER RES, V59, P2766; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535	39	75	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44936	44943		10.1074/jbc.M106733200	http://dx.doi.org/10.1074/jbc.M106733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11568182	hybrid			2022-12-25	WOS:000172406700081
J	Hawkins, SM; Kohwi-Shigematsu, T; Skalnik, DG				Hawkins, SM; Kohwi-Shigematsu, T; Skalnik, DG			The matrix attachment region-binding protein SATB1 interacts with multiple elements within the gp91(phox) promoter and is down-regulated during myeloid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; CHROMOSOMAL LOOP ANCHORAGE; CUT HOMEODOMAIN PROTEINS; LEUKEMIA CELL-LINE; NUCLEAR-MATRIX; DNA-BINDING; GP91-PHOX PROMOTER; GENE-EXPRESSION; T-CELLS	The gp91(phox) gene encodes a component of the respiratory burst NADPH oxidase complex and is highly expressed in mature myeloid cells. The transcriptional repressor CCAAT displacement protein binds to at least five sites within the proximal gp91(phox) promoter and represses expression prior to terminal phagocyte differentiation. The DNA binding activity of CCAAT displacement protein decreases during terminal phagocyte differentiation, thus permitting the binding of transcriptional activators and induction of gp91(phox) expression. We report here that the matrix attachment region-binding protein SATB1 interacts with at least seven sites within the -1542 to +12-base pair gp91(phox) promoter. Four additional binding sites for CCAAT displacement protein were also identified. Furthermore, the most proximal SATB1-binding site within the gp91(phox) promoter binds specifically to the nuclear matrix fraction in vitro. SATB1 expression is downregulated during terminal myeloid cell differentiation, coincident with induction of gp91(phox) expression. Transient transfection assays demonstrate that a SATB1-binding site derived from the gp91(phox) promoter represses promoter activity in cells expressing SATB1. These findings underscore the importance of transcriptional repression in the regulation of gp91(phox) expression and reveal a candidate myeloid cell target gene for SATB1, a factor previously found to be essential for T cell development.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Canc Res Bldg,1044 W Walnut St,Rm 472, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu	Hawkins, Shannon/AAX-5216-2020; Hawkins, Shannon M/B-7095-2015	Hawkins, Shannon/0000-0002-0727-3971; Hawkins, Shannon M/0000-0002-0727-3971	NCI NIH HHS [R01 CA39681, R01 CA58947] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058947, R01CA039681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; Alvarez JD, 2000, GENE DEV, V14, P521; AMREIN PC, 1980, BLOOD, V56, P442; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BIDWELL JP, 1994, CANCER RES, V54, P28; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Case SS, 1999, DNA CELL BIOL, V18, P805, DOI 10.1089/104454999314809; Catt D, 1999, BLOOD, V94, P3151, DOI 10.1182/blood.V94.9.3151.421k38_3151_3160; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chen HY, 1996, BIOCHEM J, V320, P257, DOI 10.1042/bj3200257; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COCKERILL PN, 1986, FEBS LETT, V204, P5, DOI 10.1016/0014-5793(86)81377-1; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DWORETZKY SI, 1990, P NATL ACAD SCI USA, V87, P4605, DOI 10.1073/pnas.87.12.4605; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Getzenberg RH, 1996, CANCER RES, V56, P1690; GEY GO, 1952, CANCER RES, V12, P264; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gotzmann J, 2000, CELL DEATH DIFFER, V7, P425, DOI 10.1038/sj.cdd.4400668; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Lien LL, 1997, MOL CELL BIOL, V17, P2279, DOI 10.1128/MCB.17.4.2279; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1999, MOL CELL BIOL, V19, P4918; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Martelli AM, 1997, HISTOCHEM CELL BIOL, V108, P1, DOI 10.1007/s004180050140; Martelli AM, 1999, J CELL BIOCHEM, V72, P35, DOI 10.1002/(SICI)1097-4644(19990101)72:1<35::AID-JCB5>3.0.CO;2-S; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; NEWBURGER PE, 1984, J BIOL CHEM, V259, P3771; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 1989, MOL CLONING, P1666; Samuel SK, 1997, CANCER RES, V57, P147; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; STUURMAN N, 1989, EXP CELL RES, V180, P460, DOI 10.1016/0014-4827(89)90072-4; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; TUCKER KA, 1987, BLOOD, V70, P372; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; WEISS A, 1984, J IMMUNOL, V133, P123; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; Yang D, 2000, J BIOL CHEM, V275, P9425, DOI 10.1074/jbc.275.13.9425	70	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44472	44480		10.1074/jbc.M104193200	http://dx.doi.org/10.1074/jbc.M104193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577075	hybrid			2022-12-25	WOS:000172406700018
J	Hirono, M; Sugiyama, T; Kishimoto, Y; Sakai, I; Miyazawa, T; Kishio, M; Inoue, H; Nakao, K; Ikeda, M; Kawahara, S; Kirino, Y; Katsuki, M; Horie, H; Ishikawa, Y; Yoshioka, T				Hirono, M; Sugiyama, T; Kishimoto, Y; Sakai, I; Miyazawa, T; Kishio, M; Inoue, H; Nakao, K; Ikeda, M; Kawahara, S; Kirino, Y; Katsuki, M; Horie, H; Ishikawa, Y; Yoshioka, T			Phospholipase C beta 4 and protein kinase C alpha and/or protein kinase C beta I are involved in the induction of long term depression in cerebellar Purkinje cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLIMBING FIBER INNERVATION; MICE LACKING MGLUR1; GAMMA MUTANT MICE; MOTOR COORDINATION; DIFFERENTIAL REGULATION; GLUTAMATE SENSITIVITY; SYNAPTIC DEPRESSION; RAT-BRAIN; TRANSLOCATION; POTENTIATION	Activation of the type-1 metabotropic glutamate receptor (mG1uR1) signaling pathway in the cerebellum involves activation of phospholipase C (PLC) and protein kinase C (PKC) for the induction of cerebellar long term depression (LTD). The PLC and PKC isoforms that are involved in LTD remain unclear, however. One previous study found no change in LTD in PKC gamma -deficient mice, thus, in the present study, we examined cerebellar LTD in PLC beta4-deficient mice. Immunohistochemical and Western blot analyses of cerebellum from wild-type mice revealed that PLC beta1 was expressed weakly and uniformly, PLC beta2 was not detected, PLC beta3 was expressed predominantly in caudal cerebellum (lobes 7-10), and PLC beta4 was expressed uniformly throughout. In PLC beta4-deficient mice, expression of total PLC beta, the mGluR1-mediated Ca2+ response, and LTD induction were greatly reduced in rostral cerebellum (lobes 1-6). Furthermore, we used immunohistochemistry to localize PKC alpha, -betaI, -beta II, and -gamma in mouse cerebellar Purkinje cells during LTD induction. Both PKC alpha and PKC betaI were found to be translocated to the plasmamembrane under these conditions. Taken together, these results suggest that mG1uR1-mediated activation of PLC beta4 in rostral cerebellar Purkinje cells induced LTD via PKC alpha and/or PKC betaI.	Waseda Univ, Adv Res Inst Sci & Engn, Dept Mol Neurobiol, Shinjuku Ku, Tokyo 1698555, Japan; Waseda Univ, Sch Human Sci, Dept Mol Neurobiol, Tokorozawa, Saitama 3591192, Japan; Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan; Yokohama City Univ, Sch Med, Dept Physiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan; Univ Tokyo, Inst Med Sci, Res Ctr Anim Models Human Dis, Dept DNA Biol & Embryo Engn,Minato Ku, Tokyo 1088639, Japan	Waseda University; Waseda University; University of Tokyo; Yokohama City University; National Defense Medical College - Japan; University of Tokyo	Yoshioka, T (corresponding author), Waseda Univ, Adv Res Inst Sci & Engn, Dept Mol Neurobiol, Shinjuku Ku, 3-4-1 Okubo, Tokyo 1698555, Japan.			Sugiyama, Takashi/0000-0002-7872-1540; Kishimoto, Yasushi/0000-0002-4828-1249; Hirono, Moritoshi/0000-0001-6068-1045				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Angenstein F, 1999, NEUROSCIENCE, V93, P1289, DOI 10.1016/S0306-4522(99)00315-2; Buchner K, 1999, MOL BRAIN RES, V64, P222, DOI 10.1016/S0169-328X(98)00324-6; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CHEN S, 1993, NEUROSCIENCE, V56, P177, DOI 10.1016/0306-4522(93)90572-W; COCKCROFT S, 1992, BIOCHEM J, V288, P1; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; De Zeeuw CI, 1998, NEURON, V20, P495, DOI 10.1016/S0896-6273(00)80990-3; EKEROT CF, 1985, BRAIN RES, V342, P357, DOI 10.1016/0006-8993(85)91136-9; Garcia MM, 1997, J COMP NEUROL, V385, P26; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; Kano M, 1998, P NATL ACAD SCI USA, V95, P15724, DOI 10.1073/pnas.95.26.15724; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Kim D, 1997, NATURE, V389, P290, DOI 10.1038/38508; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KISHIMOTO Y, 2001, IN PRESS NEUROREPORT; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MIN DS, 1993, J BIOL CHEM, V268, P12207; Murashima M, 1999, J NEUROSCI, V19, P7326, DOI 10.1523/JNEUROSCI.19-17-07326.1999; Nakao K, 1998, EXP ANIM TOKYO, V47, P167, DOI 10.1538/expanim.47.167; NAKAZAWA K, 1995, NEURON, V15, P697, DOI 10.1016/0896-6273(95)90157-4; Netzeband JG, 1997, J NEUROPHYSIOL, V78, P63, DOI 10.1152/jn.1997.78.1.63; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROUSTAN P, 1995, NEUROREPORT, V6, P1837, DOI 10.1097/00001756-199510020-00004; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; Sena CM, 1996, J NEUROCHEM, V66, P1086; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; Son H, 1996, BRAIN RES, V739, P282, DOI 10.1016/S0006-8993(96)00836-0; STAAK S, 1995, BRAIN RES, V682, P55, DOI 10.1016/0006-8993(95)00319-L; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; VanderZee EA, 1997, PROG NEURO-PSYCHOPH, V21, P531, DOI 10.1016/S0278-5846(97)00017-1; WARNKE R, 1980, J HISTOCHEM CYTOCHEM, V28, P771, DOI 10.1177/28.8.7003003; Watanabe M, 1998, EUR J NEUROSCI, V10, P2016, DOI 10.1046/j.1460-9568.1998.00213.x; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V98, P657, DOI 10.1093/oxfordjournals.jbchem.a135322	47	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45236	45242		10.1074/jbc.M105413200	http://dx.doi.org/10.1074/jbc.M105413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11551922	hybrid, Green Published			2022-12-25	WOS:000172406700117
J	Martin, MC; Dransfield, I; Haslett, C; Rossi, AG				Martin, MC; Dransfield, I; Haslett, C; Rossi, AG			Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GRANULOCYTE APOPTOSIS; AGING NEUTROPHILS; BINDING PROTEINS; ACTIVATION; INHIBITOR; PHAGOCYTOSIS; MITOCHONDRIA; 3-KINASE; RELEASE	The second messenger molecule cyclic AMP dramatically modulates the apoptotic program in a wide variety of cells, accelerating apoptosis in some and delaying the rate of apoptosis in others. Human neutrophil apoptosis, a process that regulates the fate and numbers of these potentially histotoxic cells in inflammatory sites, is profoundly delayed by the cell-permeable analog of cyclic AMP, dibutyryl-cAMP. We have investigated the mechanisms underlying cyclic AMP-mediated delay of neutrophil apoptosis, and we show that cyclic AMP inhibits loss of mitochondrial potential occurring during constitutive neutrophil apoptosis. Furthermore, we demonstrate that cyclic AMP also suppresses caspase activation in these inflammatory cells. Despite increasing protein kinase A activity, this kinase is unlikely to mediate the effect of cyclic AMP on apoptosis because blockade of protein kinase A activation did not influence the survival effects of cyclic AMP. Further investigation of the signaling mechanism demonstrated that the delay of apoptosis is independent of phosphoinositide 3-kinase and MAPK activation. Our results suggest cyclic AMP delays neutrophil apoptosis via a novel, reversible, and transcriptionally independent mechanism. We show that proteasome activity in the neutrophil is vitally involved in this process, and we suggest that a balance of pro-apoptotic and anti-apoptotic proteins plays a key role in the powerful ability of cyclic AMP to delay neutrophil death.	Univ Edinburgh, Sch Med, Resp Med Unit, MRC,Ctr Inflammat Res, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Martin, MC (corresponding author), Univ Edinburgh, Sch Med, Resp Med Unit, MRC,Ctr Inflammat Res, Edinburgh EH8 9AG, Midlothian, Scotland.	moragmartin@hotmail.com		Martin, Morag/0000-0002-8667-6057; Dransfield, Ian/0000-0001-5848-7059				AHMED MU, 1996, BIOCHEM J, V318, P965; Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANNAH S, 1995, FEBS LETT, V372, P233, DOI 10.1016/0014-5793(95)00986-J; Haslett C, 1999, AM J RESP CRIT CARE, V160, pS5, DOI 10.1164/ajrccm.160.supplement_1.4; HASLETT C, 1985, AM J PATHOL, V119, P101; HASLETT C, 1989, CURR OPIN IMMUNOL, V2, P10, DOI 10.1016/0952-7915(89)90091-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KIEFER J, 1995, J IMMUNOL, V155, P4525; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Liu YQ, 1999, J IMMUNOL, V162, P3639; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MEAGHER LC, 1992, J LEUKOCYTE BIOL, V52, P269, DOI 10.1002/jlb.52.3.269; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nedachi T, 2000, ENDOCRINOLOGY, V141, P2429, DOI 10.1210/en.141.7.2429; Ottonello L, 1998, EXP HEMATOL, V26, P895; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Plevin R, 1997, CELL SIGNAL, V9, P323, DOI 10.1016/S0898-6568(96)00193-3; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Pryde JG, 2000, J BIOL CHEM, V275, P33574, DOI 10.1074/jbc.M001008200; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; ROSSI AG, 1998, LUNG BIOL HEALTH DIS, V112, P9; ROSSI AG, 1994, IMMUNOPHARMACOLOGY N, P223; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Simon HU, 2001, IMMUNOL REV, V179, P156, DOI 10.1034/j.1600-065X.2001.790115.x; Staples KJ, 2001, J IMMUNOL, V167, P2074, DOI 10.4049/jimmunol.167.4.2074; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VANHOOIJDONK CAEM, 1994, CYTOMETRY, V17, P185, DOI 10.1002/cyto.990170212; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Whyte MKB, 1997, J LEUKOCYTE BIOL, V62, P195, DOI 10.1002/jlb.62.2.195; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	90	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45041	45050		10.1074/jbc.M105197200	http://dx.doi.org/10.1074/jbc.M105197200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11560927	hybrid			2022-12-25	WOS:000172406700094
J	Nomizu, M; Pietrzynski, G; Kato, T; Lachance, P; Menard, R; Ziomek, E				Nomizu, M; Pietrzynski, G; Kato, T; Lachance, P; Menard, R; Ziomek, E			Substrate specificity of the streptococcal cysteine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC INACTIVATION; PROTEINASE PRECURSOR; CATHEPSIN-B; PYOGENES; MECHANISM; CLEAVAGE; TOXIN; INFECTIONS; RESISTANCE; SURFACE	The streptococcal pyrogenic exotoxin B (SpeB) is an important factor in mediating Streptococcus pyogenes infections. SpeB is the zymogen of the streptococcal cysteine protease (SCP), of which relatively little is known regarding substrate specificity. To investigate this aspect of SCP function, a series of internally quenched fluorescent substrates was designed based on the cleavage sites identified in the autocatalytic processing of Spell to mature SCP. The best substrates for SCP contain three amino acids in the nonprimed position (i.e. AIK in P-3-P-2-P-1). Varying the length of the substrate on the primed side of the scissile bond has a relatively lower effect on activity. The highest activity (k(cat)/K-M = 2.8 +/- 0.6 (10(5) x M-1 s(-1)) is observed for the pentamer 3-aminobenzoic acid-AIKAG-3-nitrotyrosine, which spans subsites S-3 to S-2' on the enzyme. High pressure liquid chromatography and mass spectrometry analyses show that the substrates are cleaved at the site predicted from the autoprocessing experiments. These results show that SCP can display an important level of endopeptidase activity. Substitutions at position P-2 of the substrate clearly indicate that the S-2 subsite of SCP can readily accommodate substrates containing a hydrophobic residue at that position and that some topological preference exists for that subsite. Substitutions in positions P-3, P-1, and P-1' had little or no effect on SCP activity. The substrate specificity outlined in this work further supports the similarity between SCP and the cysteine proteases of the papain family. From the data regarding the identified or proposed natural substrates for SCP, it appears that this substrate specificity profile may also apply to the processing of mammalian and streptococcal protein targets by SCP.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	National Research Council Canada	Ziomek, E (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Burns EH, 1998, MICROB PATHOGENESIS, V24, P333, DOI 10.1006/mpat.1998.0204; BUSTIN M, 1970, J BIOL CHEM, V245, P846; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Doran JD, 1999, EUR J BIOCHEM, V263, P145, DOI 10.1046/j.1432-1327.1999.00473.x; GERLACH D, 1983, ZBL BAKT-INT J MED M, V255, P221, DOI 10.1016/S0174-3031(83)80161-9; GERWIN BI, 1966, J BIOL CHEM, V241, P3331; HAUSER AR, 1990, J BACTERIOL, V172, P4536, DOI 10.1128/jb.172.8.4536-4542.1990; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; Kagawa TF, 2000, P NATL ACAD SCI USA, V97, P2235, DOI 10.1073/pnas.040549997; KAPUR V, 1993, P NATL ACAD SCI USA, V90, P7676, DOI 10.1073/pnas.90.16.7676; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; KORTT AA, 1973, BIOCHEMISTRY-US, V12, P338, DOI 10.1021/bi00726a025; LIU TY, 1971, ENZYMES, V8, P609; Lukomski S, 1998, INFECT IMMUN, V66, P771, DOI 10.1128/IAI.66.2.771-776.1998; Lukomski S, 1997, J CLIN INVEST, V99, P2574, DOI 10.1172/JCI119445; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; MENARD R, 1993, FEBS LETT, V328, P107, DOI 10.1016/0014-5793(93)80975-Z; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; NOMIZU M, 1993, INT J PEPT PROT RES, V42, P216; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PINKNEY M, 1995, INFECT IMMUN, V63, P2776, DOI 10.1128/IAI.63.7.2776-2779.1995; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Storer AC, 1996, PERSPECT DRUG DISCOV, V6, P33, DOI 10.1007/BF02174044; Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P1817, DOI 10.1128/AAC.40.8.1817; WOLF BB, 1994, J BIOL CHEM, V269, P30682	30	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44551	44556		10.1074/jbc.M106306200	http://dx.doi.org/10.1074/jbc.M106306200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11553627	hybrid			2022-12-25	WOS:000172406700029
J	Saha, S; Nicholson, A; Kapler, GM				Saha, S; Nicholson, A; Kapler, GM			Cloning and biochemical analysis of the Tetrahymena origin binding protein TIF1 - Competitive DNA binding in vitro and in vivo to critical rDNA replication determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; RIBOSOMAL-RNA GENE; BETA-GLOBIN LOCUS; IN-VIVO; SACCHAROMYCES-CEREVISIAE; SPECIFICALLY RECOGNIZES; PROMOTER REGION; FISSION YEAST; ARS ELEMENTS; THERMOPHILA	Cis-acting type I elements regulate the initiation of DNA replication, replication fork movement, and transcription of the Tetrahymena thermophila rDNA minichromosome and are required for cell cycle-controlled replication and developmentally programmed gene amplification. Previous studies identified three in vitro single-stranded type I element binding activities that were proposed to play distinct roles in replication control. Here we describe the cloning of one of these genes, TIF1, and we provide evidence for its association with type I elements in vivo. Furthermore, we show that TIF1 interacts (in vitro and an vivo) with pause site elements (PSE), which co-localize with replication initiation and fork arrest sites, and are shown to be essential. The in vivo accessibility of PSE and type I elements to potassium permanganate suggests that origin regions are frequently unwound in native chromatin. TIF1 contains sequence similarity to the Solanum tuberosum single strand-specific transcription factor, p24, and a related Arabidopsis protein. Antisense inhibition studies suggest that TIF1 competes with other proteins for PSE and type I element binding. TIF1 displays a marked strand bias in vivo, discriminating between origin- and promoter-proximal type I elements. We propose that this bias selectively modulates the binding of a different subset of proteins to the respective regulatory elements.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Kapler, GM (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053572, R29GM053572] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53572] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; Baber JL, 1999, J MOL BIOL, V289, P949, DOI 10.1006/jmbi.1999.2818; Bayarsaihan D, 1996, BIOCHEM J, V314, P293, DOI 10.1042/bj3140293; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; Desveaux D, 2000, PLANT CELL, V12, P1477, DOI 10.1105/tpc.12.8.1477; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DU CY, 1995, NUCLEIC ACIDS RES, V23, P1766, DOI 10.1093/nar/23.10.1766; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; ENGBERG J, 1990, NUCLEIC ACIDS RES, V18, P6915, DOI 10.1093/nar/18.23.6915; GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196; Gallagher RC, 1998, MOL CELL BIOL, V18, P3021, DOI 10.1128/MCB.18.5.3021; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; HOU Z, 1995, BIOCHEMISTRY-US, V34, P4583, DOI 10.1021/bi00014a011; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KAPLER GM, 1994, GENE DEV, V8, P84, DOI 10.1101/gad.8.1.84; KAPLER GM, 1994, GENETICS, V137, P455; KAPLER GM, 1996, DNA REPLICATION EUKA, P915; Kim Soo-Mi, 2001, BMC Molecular Biology, V2, P1, DOI 10.1186/1471-2199-2-1; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LARSON DD, 1986, CELL, V47, P229, DOI 10.1016/0092-8674(86)90445-9; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Lu L, 2001, GENE DEV, V15, P134, DOI 10.1101/gad.822101; MacAlpine DM, 1997, MOL CELL BIOL, V17, P4517, DOI 10.1128/MCB.17.8.4517; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Menon RK, 1997, MOL ENDOCRINOL, V11, P1291, DOI 10.1210/me.11.9.1291; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIYAHARA K, 1993, GENE, V127, P209; Mohammad M, 2000, NUCLEIC ACIDS RES, V28, P843, DOI 10.1093/nar/28.3.843; Muralidharan V, 1997, J CELL BIOCHEM, V66, P524, DOI 10.1002/(SICI)1097-4644(19970915)66:4<524::AID-JCB11>3.0.CO;2-B; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; ORIAS E, 1992, DEV GENET, V13, P87, DOI 10.1002/dvg.1020130114; ORIAS E, 1975, METHOD CELL BIOL, V13, P247; PALEN TE, 1984, CELL, V36, P933, DOI 10.1016/0092-8674(84)90043-6; PAN WJ, 1995, MOL CELL BIOL, V15, P3372; Reischmann KP, 1999, NUCLEIC ACIDS RES, V27, P3079, DOI 10.1093/nar/27.15.3079; Saha S, 2000, J MOL BIOL, V295, P423, DOI 10.1006/jmbi.1999.3365; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; Sweeney R, 1996, P NATL ACAD SCI USA, V93, P8518, DOI 10.1073/pnas.93.16.8518; Tomonaga T, 1998, MOL CELL, V1, P759, DOI 10.1016/S1097-2765(00)80075-1; UMTHUN AR, 1994, NUCLEIC ACIDS RES, V22, P4432, DOI 10.1093/nar/22.21.4432; YAEGER PC, 1989, MOL CELL BIOL, V9, P452, DOI 10.1128/MCB.9.2.452; YAO MC, 1989, MOL CELL BIOL, V9, P1092, DOI 10.1128/MCB.9.3.1092; YU GL, 1989, P NATL ACAD SCI USA, V86, P8487, DOI 10.1073/pnas.86.21.8487; Yue M, 1998, NUCLEIC ACIDS RES, V26, P4635, DOI 10.1093/nar/26.20.4635; Zhang Z, 1997, MOL CELL BIOL, V17, P6147, DOI 10.1128/MCB.17.10.6147; ZHU JG, 1994, CHROMOSOMA, V103, P414, DOI 10.1007/s004120050050	58	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45417	45426		10.1074/jbc.M106162200	http://dx.doi.org/10.1074/jbc.M106162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577092	hybrid			2022-12-25	WOS:000172406700139
J	Siman, R; Flood, DG; Thinakaran, G; Neumar, RW				Siman, R; Flood, DG; Thinakaran, G; Neumar, RW			Endoplasmic reticulum stress-induced cysteine protease activation in cortical neurons - Effect of an Alzheimer's disease-linked presenilin-1 knock-in mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CELL-DEATH; HIPPOCAMPAL-NEURONS; TRANSLATIONAL CONTROL; AMYLOID-BETA; CALPAIN-I; LAMIN-A; APOPTOSIS; EXPRESSION; BRAIN	Endoplasmic reticulum (ER) stress elicits protective responses of chaperone induction and translational suppression and, when unimpeded, leads to caspase-mediated apoptosis. Alzheimer's disease-linked mutations in presenilin-1 (PS-1) reportedly impair ER stress-mediated protective responses and enhance vulnerability to degeneration. We used cleavage site-specific antibodies to characterize the cysteine protease activation responses of primary mouse cortical neurons to ER stress and evaluate the influence of a PS-1 knock-in mutation on these and other stress responses. Two different ER stressors lead to processing of the ER-resident protease procaspase-12, activation of calpain, caspase-3, and caspase-6, and degradation of ER and non-ER protein substrates. Immunocytochemical localization of activated caspase-3 and a cleaved substrate of caspase-6 confirms that caspase activation extends into the cytosol and nucleus. ER stress-induced proteolysis is unchanged in cortical neurons derived from the PS-1 P264L knock-in mouse. Furthermore, the PS-1 genotype does not influence stress-induced increases in chaperones Grp78/BiP and Grp94 or apoptotic neurodegeneration. A similar lack of effect of the PS-1 P264L mutation on the activation of caspases and induction of chaperones is observed in fibroblasts. Finally, the PS-1 knock-in mutation does not alter activation of the protein kinase PKR-like ER kinase (PERK), a trigger for stress-induced translational suppression. These data demonstrate that ER stress in cortical neurons leads to activation of several cysteine proteases within diverse neuronal compartments and indicate that Alzheimer's disease-linked PS-1 mutations do not invariably alter the proteolytic, chaperone induction, translational suppression, and apoptotic responses to ER stress.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Cephalon Inc, W Chester, PA 19380 USA; Univ Chicago, Sch Med, Chicago, IL 60637 USA	University of Pennsylvania; Teva Pharmaceutical Industries; Cephalon Inc.; University of Chicago	Siman, R (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	siman@pharm.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017138] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG17138] Funding Source: Medline; NINDS NIH HHS [R01-NS29481] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chang JY, 1996, EXP NEUROL, V137, P201, DOI 10.1006/exnr.1996.0019; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Fraser PE, 2000, BBA-MOL BASIS DIS, V1502, P1, DOI 10.1016/S0925-4439(00)00028-4; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Lord JM, 2000, SEMIN CELL DEV BIOL, V11, P159; Masters CL, 1998, BRIT MED J, V316, P446, DOI 10.1136/bmj.316.7129.446; Mattson MP, 1998, J NEUROCHEM, V70, P1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Siman R, 1999, NEUROSCIENCE, V92, P1425, DOI 10.1016/S0306-4522(99)00034-2; SIMAN R, 1983, J NEUROCHEM, V41, P950, DOI 10.1111/j.1471-4159.1983.tb09039.x; Siman R, 2000, J NEUROSCI, V20, P8717; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	60	85	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44736	44743		10.1074/jbc.M104092200	http://dx.doi.org/10.1074/jbc.M104092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574534	hybrid			2022-12-25	WOS:000172406700054
J	Szczesna-Skorupa, E; Kemper, B				Szczesna-Skorupa, E; Kemper, B			The juxtamembrane sequence of cytochrome P-4502C1 contains an endoplasmic reticulum retention signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAINS; TRANSPORT VESICLES; VIRUS GLYCOPROTEIN; PLASMA-MEMBRANE; PROTEIN; GOLGI; YEAST; ER; DETERMINANTS; LOCALIZATION	The N-terminal signal anchor of cytochrome P-450 2C1 mediates retention in the endoplasmic reticulum (ER) membrane of several reporter proteins. The same sequence fused to the C terminus of the extracellular domain of the epidermal growth factor receptor permits transport of the chimeric protein to the plasma membrane. In the N-terminal position, the ER retention function of this signal depends on the polarity of the hydrophobic domain and the sequence KQS in the short hydrophilic linker immediately following the transmembrane domain. To determine what properties are required for the ER retention function of the signal anchor in a position other than the N terminus, the effect of mutations in the linker and hydrophobic domains on subcellular localization in COST cells of chimeric proteins with the P-450 signal anchor in an internal or C-terminal position was analyzed. For the C-terminal position, the signal anchor was fused to the end of the luminal domain of epidermal growth factor receptor, and green fluorescent protein was additionally fused at the C terminus of the signal anchor for the internal position. In these chimeras, the ER retention function of the signal anchor was rescued by deletion of three leucines at the C-terminal side of its hydrophobic domain; however, deletion of three valines from the N-terminal side did not affect transport to the cell surface. ER retention of the C-terminal deletion mutants was eliminated by substitution of alanines for glutamine and serine in the linker sequence. These data are consistent with a model in which the position of the linker sequence at the membrane surface, which is critical for ER retention, is dependent on the transmembrane domain.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hoppe HC, 2000, CELL MICROBIOL, V2, P569, DOI 10.1046/j.1462-5822.2000.00081.x; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Milland J, 2001, J BIOL CHEM, V276, P12012, DOI 10.1074/jbc.M010018200; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Puertollano R, 1998, J BIOL CHEM, V273, P12740, DOI 10.1074/jbc.273.21.12740; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; Satoh J, 1996, Mult Scler, V1, P279; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; Shenkman M, 1997, P NATL ACAD SCI USA, V94, P11363, DOI 10.1073/pnas.94.21.11363; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZEZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; Tolchinsky S, 1996, J BIOL CHEM, V271, P14496, DOI 10.1074/jbc.271.24.14496; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970	40	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45009	45014		10.1074/jbc.M104676200	http://dx.doi.org/10.1074/jbc.M104676200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11557755	hybrid			2022-12-25	WOS:000172406700090
J	Empadinhas, N; Marugg, JD; Borges, N; Santos, H; da Costa, MS				Empadinhas, N; Marugg, JD; Borges, N; Santos, H; da Costa, MS			Pathway for the synthesis of mannosylglycerate in the hyperthermophilic archaeon Pyrococcus horikoshii - Biochemical and genetic characterization of key enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL-PHOSPHATE; COMPATIBLE SOLUTES; RHODOTHERMUS-MARINUS; ACCUMULATION; SALINITY; ACID; GLYCOSYLTRANSFERASES; CLASSIFICATION; BIOSYNTHESIS; TEMPERATURE	The biosynthetic pathway for the synthesis of the compatible solute alpha -mannosylglycerate in the hyperthermophilic archaeon Pyrococcus horikoshii is proposed based on the activities of purified recombinant mannosyl-3-phosphoglycerate (MPG) synthase and mannosyl-3-phosphoglycerate phosphatase. The former activity was purified from cell extracts, and the N-terminal sequence was used to identify the encoding gene in the completely sequenced P. horikoshii genome. This gene, designated PH0927, and a gene immediately downstream (PH0926) were cloned and overexpressed in Escherichia coli. The recombinant product of gene PH0927 catalyzed the synthesis of alpha -mannosyl-beta -phosphoglycerate (MPG) from GDP-mannose and D-3-phosphoglycerate retaining the configuration about the anomeric carbon, whereas the recombinant gene product of PH0926 catalyzed the dephosphorylation of mannosyl-3-phosphoglycerate to yield the compatible solute a-mannosylglycerate. The MPG synthase and the MPG phosphatase were specific for these substrates. Two genes immediately downstream from mpgs and mpgp were identified as a putative bifunctional phosphomannose isomeraselmannose-1-phosphateguanylyltransferase (PH0925) and as a putative phosphomannose mutase (PH0923). Genes PH0927, PH0926, PH0925, and PH0923 were contained in an operon-like structure, leading to the hypothesis that these genes were under the control of an unknown osmosensing mechanism that would lead to a-mannosylglycerate synthesis. Recombinant MPG synthase had a molecular mass of 45,208 Da, a temperature for optimal activity between 90 and 100 degreesC, and a pH optimum between 6.4 and 7.4; the recombinant MPG phosphatase had a molecular mass of 27,958 Da and optimum activity between 95 and 100 degreesC and between pH 5.2 and 6.4. This is the first report of the characterization of MPG synthase and MPG phosphatase and the elucidation of a pathway for the synthesis of mannosylglycerate in an archaeon.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland; Univ Coimbra, Dept Bioquim, P-3000 Coimbra, Portugal	Universidade Nova de Lisboa; Nestle SA; Universidade de Coimbra	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apartado 127, P-2780156 Oeiras, Portugal.	santos@itqb.unl.pt	Santos, Helena/B-9141-2011; Borges, Nuno/Q-3515-2019; Empadinhas, Nuno/G-3118-2011; Borges, Nuno/A-1427-2011	Santos, Helena/0000-0002-8050-9485; Borges, Nuno/0000-0002-3277-8517; Empadinhas, Nuno/0000-0001-8938-7560; Borges, Nuno/0000-0002-3277-8517; da Costa, Milton/0000-0003-4027-4412; Marugg, John/0000-0003-2657-6692				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Bauer MW, 1998, CURR OPIN BIOTECH, V9, P141, DOI 10.1016/S0958-1669(98)80106-7; BORGES N, 2001, IN PRESS EXTREMOPHIL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; da Costa M. S., 1998, V61, P117; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Galinski E A, 1995, Adv Microb Physiol, V37, P272, DOI 10.1016/S0065-2911(08)60148-4; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; Gonzalez JM, 1998, EXTREMOPHILES, V2, P123, DOI 10.1007/s007920050051; Hagemann M, 1997, J BACTERIOL, V179, P1727, DOI 10.1128/jb.179.5.1727-1733.1997; HAGEMANN M, 1994, MICROBIOL-SGM, V140, P1427, DOI 10.1099/00221287-140-6-1427; Hansen T, 2001, J BACTERIOL, V183, P3428, DOI 10.1128/JB.183.11.3428-3435.2001; Henrissat B, 2001, METHOD ENZYMOL, V330, P183; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; JACIN H, 1965, J CHROMATOGR, V18, P170, DOI 10.1016/S0021-9673(01)80341-1; Jensen SO, 1998, BBA-PROTEIN STRUCT M, V1382, P5, DOI 10.1016/S0167-4838(97)00122-2; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; KOPLIN R, 1992, J BACTERIOL, V174, P191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamosa P, 1998, APPL ENVIRON MICROB, V64, P3591; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Martin D D, 2001, Biochim Biophys Acta, V1524, P1; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; Martins LO, 1996, J BACTERIOL, V178, P5644, DOI 10.1128/jb.178.19.5644-5651.1996; Martins LO, 1997, APPL ENVIRON MICROB, V63, P896, DOI 10.1128/AEM.63.3.896-902.1997; Martins LO, 1999, J BIOL CHEM, V274, P35407, DOI 10.1074/jbc.274.50.35407; NUNES OC, 1995, APPL ENVIRON MICROB, V61, P2351, DOI 10.1128/AEM.61.6.2351-2357.1995; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Ramos A, 1997, APPL ENVIRON MICROB, V63, P4020, DOI 10.1128/AEM.63.10.4020-4025.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santos H, 2001, METHOD ENZYMOL, V334, P302; Scandurra R, 1998, BIOCHIMIE, V80, P933, DOI 10.1016/S0300-9084(00)88890-2; Silva Z, 1999, EXTREMOPHILES, V3, P163, DOI 10.1007/s007920050112; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YOKOYAMA K, 1987, EUR J BIOCHEM, V165, P47, DOI 10.1111/j.1432-1033.1987.tb11192.x	45	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43580	43588		10.1074/jbc.M108054200	http://dx.doi.org/10.1074/jbc.M108054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562374	hybrid			2022-12-25	WOS:000172297700015
J	Imamura, T; Huang, J; Dalle, S; Ugi, S; Usui, I; Luttrell, LM; Miller, WE; Lefkowitz, RJ; Olefsky, JM				Imamura, T; Huang, J; Dalle, S; Ugi, S; Usui, I; Luttrell, LM; Miller, WE; Lefkowitz, RJ; Olefsky, JM			beta-arrestin-mediated recruitment of the Src family kinase yes mediates endothelin-1-stimulated glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; STIMULATED GLUT4 TRANSLOCATION; INSULIN-RECEPTOR; 3T3-L1 ADIPOCYTES; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; ALPHA-SUBUNIT; C-SRC; ACTIVATION; CELLS	The insulin and the endothelin type A (ETA) receptor both can couple into the heterotrimeric G protein alpha (q/11) (G alpha (q/11)), leading to G alpha (q/11) tyrosine phosphorylation, phosphatidylinositol 3-kinase activation, and subsequent stimulation of glucose transport. In this study, we assessed the potential role of Src kinase in ET-1 signaling to glucose transport in 3T3-L1 adipocytes. Src kinase inhibitor PP2 blocked ET-1-induced Src kinase activity, G alpha (q/11) tyrosine phosphorylation, and glucose transport stimulation. To determine which Src family kinase member was involved, we microinjected anti-c-Src, -c-Fyn, or -c-Yes antibody into these cells and found that only anti-e-Yes antibody blocked GLUT4 translocation (70% decreased). Overexpression or microinjection of a dominant negative mutant (K298M) of Src kinase also inhibited ET-1-induced Ga,,,, tyrosine phosphorylation and GLUT4 translocation. In co-immunoprecipitation experiments, we found that beta -arrestin 1 associated with the ETA receptor in an agonist-dependent manner and that beta -arrestin 1 recruited Src kinase to a molecular complex that included the ETA receptor. Microinjection of beta -arrestin 1 antibody inhibited ET-1- but not insulin-stimulated GLUT4 translocation. In conclusion, 1) the Src kinase Yes can induce tyrosine phosphorylation of G alpha (q/11) in response to ET-1 stimulation, and 2) beta -arrestin I and Src kinase form a molecular complex with the ETA receptor to mediate ET-1 signaling to G alpha (q/11) with subsequent glucose transport stimulation.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949; Miller, William/0000-0001-6900-4884	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Ishibashi K, 2001, J CLIN INVEST, V107, P1193, DOI 10.1172/JCI11753; Ishibashi KI, 2000, ENDOCRINOLOGY, V141, P4623, DOI 10.1210/en.141.12.4623; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MEYERSON G, 1993, FEBS LETT, V332, P27, DOI 10.1016/0014-5793(93)80475-A; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; SHIA MA, 1983, J BIOL CHEM, V258, P4450; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANOBBERGHEN E, 1983, P NATL ACAD SCI-BIOL, V80, P945; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103	32	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43663	43667		10.1074/jbc.M105364200	http://dx.doi.org/10.1074/jbc.M105364200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546805	hybrid			2022-12-25	WOS:000172297700025
J	Kaplan, DD; Meigs, TE; Casey, PJ				Kaplan, DD; Meigs, TE; Casey, PJ			Distinct regions of the cadherin cytoplasmic domain are essential for functional interaction with G alpha(12) and beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; CELL-ADHESION; COMPLEX-FORMATION; ACTIVATION; RHO; INHIBITION; EXCHANGE; BINDING; KINASE; PHOSPHORYLATION	Heterotrimeric G proteins of the G(12) subfamily mediate cellular signals leading to events such as cytoskeletal rearrangements, cell proliferation, and oncogenic transformation. Several recent studies have revealed direct effector proteins through which G(12) subfamily members may transmit signals leading to various cellular responses. Our laboratory recently demonstrated that G alpha (12) and G alpha (13) specifically interact with the cytoplasmic domains of several members of the cadherin family of cell adhesion molecules (Meigs, T. E., Fields, T. A., McKee, D. D., and Casey, P. J. (2001) Proc. Natl. Acad. Sei. U. S. A. 98, 519-524). This interaction causes beta -catenin to release from cadherin and relocalize to the cytoplasm and nucleus, where it participates in transcriptional activation. Here we report that two distinct regions of the epithelial cadherin (E-cadherin) tail are required for interaction with beta -catenin and G alpha (12), respectively. Deletion of an acidic, 19-amino acid region of E-cadherin abolishes its ability to bind beta -catenin in vitro, to inhibit beta -catenin-mediated transactivation, or to stabilize beta -catenin; causes subcellular mislocalization of beta -catenin; and disrupts cadherin-mediated cell adhesion. On the other hand, deletion of a distinct 11-amino acid region of E-cadherin dramatically attenuates interaction with G alpha (12); furthermore, G alpha (12) is ineffective in stimulating beta -catenin release from an E-cadherin cytoplasmic domain lacking this putative G alpha (12)-binding region. These findings indicate that G alpha (12) and beta -catenin do not compete for the same binding site on cadherin and provide molecular targets for selectively disrupting the interaction of these proteins with cadherin.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu		Kaplan, Daniel/0000-0001-8297-560X; Casey, Patrick/0000-0002-7366-9309	NATIONAL CANCER INSTITUTE [R21CA091159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055717, R55GM055717] Funding Source: NIH RePORTER; NCI NIH HHS [CA91159] Funding Source: Medline; NIGMS NIH HHS [GM55717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Postma FR, 2001, CURR BIOL, V11, P121, DOI 10.1016/S0960-9822(01)00030-6; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Serres M, 2000, EXP CELL RES, V257, P255, DOI 10.1006/excr.2000.4895; SIMEHA I, 2001, MOL BIOL CELL, V12, P1177; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200	47	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44037	44043		10.1074/jbc.M106121200	http://dx.doi.org/10.1074/jbc.M106121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546809	hybrid			2022-12-25	WOS:000172297700072
J	Mansell, A; Khelef, N; Cossart, P; O'Neill, LAJ				Mansell, A; Khelef, N; Cossart, P; O'Neill, LAJ			Internalin B activates nuclear factor-kappa B via Ras, phosphoinositide 3-kinase, and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOVEMENT; LISTERIA-MONOCYTOGENES; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN-CELLS; GROWTH-FACTOR; TYROSINE KINASE; INVASION PROTEIN; T-LYMPHOCYTES; INIB PROTEIN; RECEPTOR	Internalin B (InIB), a 630-amino acid protein loosely attached to the surface of Listeria monocytogenes, participates in the entry of the bacterium into mammalian cells. This process requires the activation of phosphoinositide (Pl) 3-kinase by InIB. Previously, we demonstrated that InIB activates the transcription factor Nuclear Factor-kappaB in murine J774 macrophage-like cells, an event that also requires PI 3-kinase. Here we have further investigated this phenomenon. InIB activated the small G-protein Ras in J774 cells. Inhibition of Ras with the farnesyltransferase inhibitor manumycin A inhibited NF-kappaB activation and the recruitment of the p85 subunit of PI 3-kinase, implying that Ras is required for PI 3-kinase activation. InIB also activated the PI 3-kinase downstream effector, Akt, as assessed by increased phosphorylation of Akt on serine 473. Transfection of Hep2 cells with dominant negative Ras N17 or dominant negative Akt inhibited the induction of a reporter gene linked to the interleukin-8 promoter by InIB. Furthermore, the Ras inhibitor manumycin A, the PI 3-kinase inhibitor LY294002, and an Akt inhibitor all blocked the induction of interleukin-8 by InIB. Our study is the first report of a bacterial product activating a pathway involving Ras, PI 3-kinase, and Akt, which leads to NF-kappaB activation. This process could be involved in host defense or the inhibition of apoptosis during infection.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Biotechnol, Dublin 2, Ireland; Inst Pasteur, Unite Interact Bacteries Cellules, Paris 15, France	Trinity College Dublin; Trinity College Dublin; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.		Mansell, Ashley/B-9553-2008	Mansell, Ashley/0000-0002-6540-1281; KHELEF, Nadia/0000-0003-0391-2403; O'Neill, Luke/0000-0002-4333-2748				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Braun L, 1999, MOL MICROBIOL, V34, P10, DOI 10.1046/j.1365-2958.1999.01560.x; Braun L, 1998, MOL MICROBIOL, V27, P1077, DOI 10.1046/j.1365-2958.1998.00750.x; Braun L, 1997, MOL MICROBIOL, V25, P285, DOI 10.1046/j.1365-2958.1997.4621825.x; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chakraborty T, 1999, IMMUNOBIOLOGY, V201, P155, DOI 10.1016/S0171-2985(99)80055-2; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Cossart P, 2001, TRENDS MICROBIOL, V9, P105, DOI 10.1016/S0966-842X(00)01943-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Dramsi S, 1996, CURR TOP MICROBIOL, V209, P61; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Hu YH, 2001, BIOORG MED CHEM LETT, V11, P173, DOI 10.1016/S0960-894X(00)00640-5; Ireton K, 1997, ANNU REV GENET, V31, P113, DOI 10.1146/annurev.genet.31.1.113; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; LACASSE EC, 1998, MOL CELL BIOL, V19, P3247; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mansell A, 2000, CELL MICROBIOL, V2, P127, DOI 10.1046/j.1462-5822.2000.00038.x; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125	44	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43597	43603		10.1074/jbc.M105202200	http://dx.doi.org/10.1074/jbc.M105202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571285	hybrid, Green Published			2022-12-25	WOS:000172297700017
J	Molero, JC; Whitehead, JP; Meerloo, T; James, DE				Molero, JC; Whitehead, JP; Meerloo, T; James, DE			Nocodazole inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes via a microtubule-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; GLUT4; LOCALIZATION; TRANSLOCATION; TRAFFICKING; BIOGENESIS; MEMBRANE; VESICLES; TERMINUS	Insulin stimulates glucose transport in adipocytes and muscle cells by triggering redistribution of the GLUT4 glucose transporter from an intracellular perinuclear location to the cell surface. Recent reports have shown that the microtubule-depolymerizing agent nocodazole inhibits insulin-stimulated glucose transport, implicating an important role for microtubules in this process. In the present study we show that 2 mum nocodazole completely depolymerized microtubules in 3T3-L1 adipocytes, as determined morphologically and biochemically, resulting in dispersal of the perinuclear GLUT4 compartment and the Golgi apparatus. However, 2 mum nocodazole did not significantly effect either the kinetics or magnitude of insulin-stimulated glucose transport. Consistent with previous studies, higher concentrations of nocodazole (10-33 mum) significantly inhibited basal and insulin-stimulated glucose uptake in adi. pocytes. This effect was not likely the result of microtubule depolymerization because in the presence of taxol, which blocked nocodazole-induced depolymerization of microtubules as well as the dispersal of the perinuclear GLUT4 compartment, the inhibitory effect of 10-33 muM nocodazole on insulin-stimulated glucose uptake prevailed. Despite the decrease in insulin-stimulated glucose transport with 33 muM nocodazole we did not observe inhibition of insulin-stimulated GLUT4 translocation to the cell surface under these conditions. Consistent with a direct effect of nocodazole on glucose transporter function we observed a rapid inhibitory effect of nocodazole on glucose transport activity when added to either 3T3-L1 adipocytes or to Chinese hamster ovary cells at 4 degreesC. These studies reveal a new and unexpected effect of nocodazole in mammalian cells which appears to occur independently of its microtubule-depolymerizing effects.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland	Molero, JC (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.		Whitehead, Jonathan/F-5022-2014	James, David/0000-0001-5946-5257; Whitehead, Jonathan/0000-0003-3978-3148				Arcangeletti C, 1997, J STRUCT BIOL, V119, P35, DOI 10.1006/jsbi.1997.3871; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; JIN MJ, 1993, J BIOL CHEM, V268, P18390; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Martin S, 2000, J CELL SCI, V113, P3427; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1991, AM J PHYSIOL, V260, P570; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162	28	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43829	43835		10.1074/jbc.M105452200	http://dx.doi.org/10.1074/jbc.M105452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571289	Green Submitted, hybrid			2022-12-25	WOS:000172297700047
J	Yu, JW; Lemmon, MA				Yu, JW; Lemmon, MA			All phox homology (PX) domains from Saccharomyces cerevisiae specifically recognize phosphatidylinositol 3-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INHERITANCE; MEMBRANE-PROTEINS; LATE-GOLGI; BINDING; YEAST; NUCLEAR; COMPLEX	Phox homology (PX) domains are named for a 130-amino acid region of homology shared with part of two components of the phagocyte NADPH oxidase (phox) complex. They are found in proteins involved in vesicular trafficking, protein sorting, and lipid modification. It was recently reported that certain PX domains specifically recognize phosphatidylinositol 3-phosphate (PtdIns-3-P) and drive recruitment of their host proteins to the cytoplasmic leaflet of endosomal and/or vacuolar membranes where this phosphoinositide is enriched. We have analyzed phosphoinositide binding by all 15 PX domains encoded by the Saccharomyces cerevisiae genome. All yeast PX domains specifically recognize PtdIns-3-P in protein-lipid overlay experiments, with just one exception (a significant sequence outlier). In surface plasmon resonance studies, four of the yeast PX domains bind PtdIns-3-P with high (micromolar range) affinity. Although the remaining PX domains specifically recognize PtdIns-3-P, they bind this lipid with only low affinity. Interestingly, many proteins with "low affinity" PX domains are known to form large multimeric complexes, which may increase the overall avidity for membranes. Our results establish that PtdIns-3-P, and not other phosphoinositides, is the target of all PX domains in S. cerevisiae and suggest a role for PX domains in assembly of multiprotein complexes at specific membrane surfaces.	Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 809, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Grad Grp Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 809, 422 Curie Blvd, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu		Lemmon, Mark/0000-0002-3379-5319	NIGMS NIH HHS [R01-GM56846, R01 GM056846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Fisk HA, 1997, J CELL BIOL, V138, P485, DOI 10.1083/jcb.138.3.485; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kurten RC, 2001, J CELL SCI, V114, P1743; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; MCCONNELL SJ, 1992, J CELL BIOL, V118, P385, DOI 10.1083/jcb.118.2.385; Nothwehr SF, 1997, J CELL SCI, V110, P1063; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Prehoda KE, 2001, NAT STRUCT BIOL, V8, P570, DOI 10.1038/89586; RON D, 1992, BIOTECHNIQUES, V13, P866; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051	35	162	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44179	44184		10.1074/jbc.M108811200	http://dx.doi.org/10.1074/jbc.M108811200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557775	hybrid			2022-12-25	WOS:000172297700089
J	Dunphy, JT; Greentree, WK; Linder, ME				Dunphy, JT; Greentree, WK; Linder, ME			Enrichment of G-protein palmitoyltransferase activity in low density membranes - In vitro reconstitution of G(alpha i) to these domains requires palmitoyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; G-BETA-GAMMA; PLASMA-MEMBRANE; CAVEOLAE MEMBRANE; ALPHA-SUBUNITS; EPITHELIAL-CELLS; LIPID RAFTS; PALMITOYLATION; LOCALIZATION; ACTIVATION	Many signaling proteins are targeted to low density, sphingomyelin- and cholesterol-enriched membranes, also called lipid rafts. These domains organize receptor-mediated signaling events at the plasma membrane. Fatty acylation is one mechanism for targeting proteins to rafts. It was therefore of interest to determine if protein palmitoyltransferase activity is also present in these domains. In this study, protein palmitoyltransferase activity, assayed using G-protein alpha subunits as a substrate, was found to be highly enriched in low density membranes derived from cells that express caveolin as well as those that do not. Depletion of cellular cholesterol with the drug methyl-beta -cyclodextrin resulted in inhibition of palmitoyltransferase activity and a redistribution of the remaining activity to membranes of higher density. This effect was reversed by adding cholesterol to cyclodextrin-treated cells. When reconstituted into cell membranes, the population of purified recombinant G(alphai) that was palmitoylated was highly enriched in the low density membrane fractions, whereas the bulk unmodified G(alphai)-protein was largely excluded. This effect required palmitoyltransferase activity and was abolished if the palmitoylated cysteine was mutated. Thus, palmitoyltransferase facilitates the enrichment of fatty acylated signaling molecules in plasma membrane subdomains.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Linder, ME (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 So Euclid Ave, St Louis, MO 63110 USA.	mlinder@cellbio.wustl.edu	Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NIGMS NIH HHS [GM51466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Dunphy JT, 2000, BBA-MOL CELL BIOL L, V1485, P185, DOI 10.1016/S1388-1981(00)00060-3; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	48	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43300	43304		10.1074/jbc.M104275200	http://dx.doi.org/10.1074/jbc.M104275200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11557754	hybrid			2022-12-25	WOS:000172169300087
J	Martinelli, R; Sabroe, I; LaRosa, G; Williams, TJ; Pease, JE				Martinelli, R; Sabroe, I; LaRosa, G; Williams, TJ; Pease, JE			The CC chemokine eotaxin (CCL11) is a partial agonist of CC chemokine receptor 2b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-3; TERNARY COMPLEX MODEL; GUINEA-PIG MODEL; MCP-1 RECEPTOR; CHEMOTACTIC PROTEIN-1; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; IN-VIVO; EXPRESSION; CELLS	Despite sharing considerable homology with the members of the monocyte chemoattractant protein (MCP) family, the CC chemokine eotaxin (CCL11) has previously been reported to signal exclusively via the receptor CC chemokine receptor 3 (CCR3) Using the monocyte cell line THP-1, we investigated the relative abilities of eotaxin and MCPs 1-4 to induce CCR2 signaling, employing assays of directed cell migration and intracellular calcium flux. Surprisingly, 1 muM concentrations of eotaxin were able to recruit THP-1 cells in chemotaxis assays, and this migration was sensitive to antagonism of CCR2 but not CCR3. Radiolabeled eotaxin binding assays performed on transfectants bearing CCR2b or CCR3 confirmed eotaxin binding to CCR2 with a K-d of 7.50 +/- 3.30 nm, compared with a K-d of 1.68 +/- 0.91 nM at CCR3. In addition, whereas 1 muM concentrations of eotaxin were able to recruit CCR2b transfectants, substimulatory concentrations of eotaxin inhibited MCP-1-induced chemotaxis of CCR2b transfectants and also inhibited MCP-1-induced intracellular calcium flux of THP-1 cells. Collectively, these findings suggest that eotaxin is a partial agonist of the CCR2b receptor. A greater understanding of the interaction of CCR2 with all of its ligands, both full and partial agonists, may aid the rational design of specific antagonists that hold great promise as future therapeutic treatments for a variety of inflammatory disorders.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Imperial College London; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Pease, JE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, Sir Alexander Fleming Bldg, London SW7 2AZ, England.		Sabroe, Ian/AAE-5858-2019; Pease, James/X-4521-2018; Sabroe, Ian/I-5981-2013	Pease, James/0000-0003-3749-0341; Sabroe, Ian/0000-0001-9750-8975; Martinelli, Roberta/0000-0003-0784-5973				Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DELEAN A, 1980, J BIOL CHEM, V255, P7108; FRANCI C, 1995, J IMMUNOL, V154, P6511; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Han KH, 1999, J BIOL CHEM, V274, P32055, DOI 10.1074/jbc.274.45.32055; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Heinemann A, 2000, J IMMUNOL, V165, P7224, DOI 10.4049/jimmunol.165.12.7224; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kim Y, 2001, J IMMUNOL, V166, P5183, DOI 10.4049/jimmunol.166.8.5183; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy PM, 2000, PHARMACOL REV, V52, P145; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Nakamura H, 1999, AM J RESP CRIT CARE, V160, P1952, DOI 10.1164/ajrccm.160.6.9811089; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Ogilvie P, 2001, BLOOD, V97, P1920, DOI 10.1182/blood.V97.7.1920; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Polentarutti N, 1997, J IMMUNOL, V158, P2689; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Ruffing N, 1998, CELL IMMUNOL, V189, P160, DOI 10.1006/cimm.1998.1379; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 1998, J IMMUNOL, V161, P6139; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sato N, 2000, J EXP MED, V192, P205, DOI 10.1084/jem.192.2.205; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; Struyf S, 1999, J IMMUNOL, V162, P4903; Traynor TR, 2000, J IMMUNOL, V164, P2021, DOI 10.4049/jimmunol.164.4.2021; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Weng YM, 1998, J BIOL CHEM, V273, P18288, DOI 10.1074/jbc.273.29.18288; Yamagami S, 1997, FEBS LETT, V400, P329, DOI 10.1016/S0014-5793(96)01411-1; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	49	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42957	42964		10.1074/jbc.M103933200	http://dx.doi.org/10.1074/jbc.M103933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11559700	hybrid			2022-12-25	WOS:000172169300044
J	Park, SH; Waxman, DJ				Park, SH; Waxman, DJ			Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3 beta - Impact on the regulation of growth hormone pulse-stimulated, male-specific liver cytochrome P-450 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SIGNAL TRANSDUCER; SEXUAL DIMORPHISM; TYROSINE PHOSPHORYLATION; ACID 6-BETA-HYDROXYLASE; GENDER DIFFERENCES; BINDING-PROTEIN; TRANSCRIPTION; ACTIVATION; RECEPTOR	STAT5b is repeatedly activated in rodent liver by the male pattern of intermittent plasma growth hormone (GH) stimulation and is required to maintain the GH pulse-regulated, male-specific pattern of liver gene expression. We presently investigate the interactions between STAT5b and hepatocyte-enriched nuclear factors (HNFs) that contribute to regulation of GH pulse-inducible, male-specific liver cytochrome P-450 (CYP) genes. STAT5 binding sites were identified in the 5'-flank of the adult male-expressed genes CYP2A2 (nucleotides -2255 to -2247), CYP4A2 (nucleotides -1872 to -1864), and CYP2C11 (nucleotides -1150 to -1142). STAT5-DNA complexes were formed by each CYP sequence with nuclear extract from GH pulse-activated male, but not female, rat liver. The CYP2C11 STAT5 site, which is flanked by HNF3 consensus sequences, conferred STAT5b-inducible reporter gene activity in GH-treated HepG2 cells. trans-Activation of the intact CYP2C11 promoter (1.8-kilobase 5'-flank) was strongly induced by the liver nuclear factors HNF1 alpha and HNF3 beta but, unexpectedly, was inhibited by GH-activated STAT5b. This STAT5b inhibitory effect could be reversed by HNF1 alpha and reflects a functional antagonism between STAT5b and HNF3 beta, as evidenced by the inhibition of HNF3 beta DNA binding and transcriptional activity by STAT5b. HNF3 beta, in turn, inhibited STAT5b by a novel mechanism that leads to suppression of GH-inducible STAT5b tyrosine phosphorylation, DNA binding activity, and transcriptional activity. The potential for GH-activated STAT5b to stimulate male-specific liver CYP expression can thus be modulated by HNF3 beta, highlighting the complex interrelationship between STAT5b and liver transcription factors controlling expression of GH-regulated CYP genes.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bu.edu		Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765, DK33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Buggs C, 1998, MOL ENDOCRINOL, V12, P1294, DOI 10.1210/me.12.9.1294; Choi HK, 1999, ENDOCRINOLOGY, V140, P5126, DOI 10.1210/en.140.11.5126; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Delesque-Touchard N, 2000, J BIOL CHEM, V275, P34173, DOI 10.1074/jbc.M004027200; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Gonzalez FJ, 1996, FASEB J, V10, P1112, DOI 10.1096/fasebj.10.10.8751713; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Iber H, 2000, ARCH BIOCHEM BIOPHYS, V377, P187, DOI 10.1006/abbi.2000.1772; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; John S, 1999, MOL CELL BIOL, V19, P1910; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; MODE A, 1993, J REPROD FERTIL, P77; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Rastegar M, 2000, MOL CELL ENDOCRINOL, V164, P1, DOI 10.1016/S0303-7207(00)00263-X; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sasaki Y, 1999, J BIOL CHEM, V274, P37117, DOI 10.1074/jbc.274.52.37117; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; Sueyoshi T, 1999, MOL PHARMACOL, V56, P473, DOI 10.1124/mol.56.3.473; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Tannenbaum GS, 2001, ENDOCRINOLOGY, V142, P4599, DOI 10.1210/en.142.11.4599; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Veldhuis JD, 1996, EUR J ENDOCRINOL, V134, P287, DOI 10.1530/eje.0.1340287; Waxman David J., 1995, P391; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Waxman DJ, 2000, PRINCIPLES OF MOLECULAR REGULATION, P55; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zaphiropoulos P G, 1988, Acta Med Scand Suppl, V723, P161; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672	49	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43031	43039		10.1074/jbc.M107597200	http://dx.doi.org/10.1074/jbc.M107597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562369	hybrid			2022-12-25	WOS:000172169300054
J	Shigaki, T; Cheng, NH; Pittman, JK; Hirschi, K				Shigaki, T; Cheng, NH; Pittman, JK; Hirschi, K			Structural determinants of Ca2+ transport in the Arabidopsis H+/Ca2+ antiporter CAX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; NA+/H+ ANTIPORTER; NHAA; YEAST; SENSITIVITY; SELECTIVITY; EXPRESSION; MANGANESE; RETICULUM	Ca2+ levels in plants, fungi, and bacteria are controlled in part by H+/Ca2+ exchangers; however, the relationship between primary sequence and biological activity of these transporters has not been reported. The Arabidopsis H+/cation exchangers, CAX1 and CAX2, were identified by their ability to suppress yeast mutants defective in vacuolar Ca2+ transport. CAX1 has a much higher capacity for Ca2+ transport than CAX2. An Arabidopsis thaliana homolog of CAX1, CAX3, is 77% identical (93% similar) and, when expressed in yeast, localized to the vacuole but did not suppress yeast mutants defective in vacuolar Ca2+ transport. Chimeric constructs and site-directed mutagenesis showed that CAX3 could suppress yeast vacuolar Ca2+ transport mutants if a nine-amino acid region of CAX1 was inserted into CAX3 (CAX3-9). Biochemical analysis in yeast showed CAX3-9 had 36% of the H+/Ca2+ exchange activity as compared with CAX1; however, CAX3-9 and CAX1 appear to differ in their transport of other ions. Exchanging the nine-amino acid region of CAX1 into CAX2 doubled yeast vacuolar Ca2+ transport but did not appear to alter the transport of other ions. This nine-amino acid region is highly variable among the plant CAX-like transporters. These findings suggest that this region is involved in CAX-mediated Ca2+ specificity.	Baylor Coll Med, Plant Physiol Grp, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Texas A&M University System; Texas A&M University College Station	Hirschi, K (corresponding author), Baylor Coll Med, Plant Physiol Grp, USDA ARS, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.		hirschi, kendal/GNP-0351-2022	Pittman, Jon/0000-0001-7197-1494	NIGMS NIH HHS [1R01 GM57427] Funding Source: Medline; PHS HHS [5 P30] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057427] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE S, 1986, Memoirs of the College of Agriculture Ehime University, V31, P187; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Del Pozo L, 1999, YEAST, V15, P371, DOI 10.1002/(SICI)1097-0061(19990330)15:5<371::AID-YEA380>3.3.CO;2-G; DIBROV PA, 1993, FEBS LETT, V336, P530, DOI 10.1016/0014-5793(93)80870-Z; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hirschi K, 2001, TRENDS PLANT SCI, V6, P100, DOI 10.1016/S1360-1385(00)01863-X; Hirschi KD, 2000, PLANT PHYSIOL, V124, P125, DOI 10.1104/pp.124.1.125; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; IVEY DM, 1993, J BIOL CHEM, V268, P11296; Liang F, 1998, PLANT PHYSIOL, V118, P817, DOI 10.1104/pp.118.3.817; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; PITTMAN JK, 2001, IN PRESS PLANT PHYSL; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Shigaki T, 2000, GENE, V257, P291, DOI 10.1016/S0378-1119(00)00390-5; SHIGAKI T, 2001, ANAL BIOCH; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueoka-Nakanishi H, 1999, EUR J BIOCHEM, V262, P417, DOI 10.1046/j.1432-1327.1999.00377.x; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; Wiebe CA, 2001, BIOCHEM J, V357, P1, DOI 10.1042/0264-6021:3570001; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534	30	58	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43152	43159		10.1074/jbc.M106637200	http://dx.doi.org/10.1074/jbc.M106637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562366	hybrid			2022-12-25	WOS:000172169300068
J	Perrin, RJ; Woods, WS; Clayton, DF; George, JM				Perrin, RJ; Woods, WS; Clayton, DF; George, JM			Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; FAMILIAL PARKINSONS-DISEASE; HUMAN ALPHA-SYNUCLEIN; GLIAL CYTOPLASMIC INCLUSIONS; BRAIN IRON ACCUMULATION; ALZHEIMERS-DISEASE; IN-VITRO; NACP/ALPHA-SYNUCLEIN; SPORADIC PARKINSONS	Detergent-stable multimers of alpha -synuclein have been found specifically in the brains of patients with Parkinson's disease and other neurodegenerative diseases. Here we show that recombinant alpha -synuclein forms multimers in vitro upon exposure to vesicles containing certain Polyunsaturated fatty acid (PUFA) acyl groups, including arachidonoyl and docosahexaenoyl. This process occurs at physiological concentrations and much faster than in aqueous solution. PUFA-induced aggregation involves physical association with the vesicle surface via the large apolipoprotein-like lipid-binding domain that constitutes the majority of the protein. beta- and gamma -synucleins, as well as the Parkinson's disease-associated alpha -synuclein variants A30P and A53T, show similar tendencies to multimerize in the presence of PUFAs. Multimerization does not require the presence of any tyrosine residues in the sequence. The membrane-based interaction of the synucleins with specific long chain polyunsaturated phospholipids may be relevant to the protein family's physiological functions and may also contribute to the aggregation of alpha -synuclein observed in neurodegenerative disease.	Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	George, JM (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, 601 S Goodwin, Urbana, IL 61801 USA.		George, Julia M/B-2169-2008; Woods, Wendy/B-6602-2008; Clayton, David/B-2190-2008	George, Julia M/0000-0001-6194-6914; Clayton, David/0000-0002-6395-3488	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013762] Funding Source: NIH RePORTER; NIA NIH HHS [1R01 AG13762] Funding Source: Medline; NIGMS NIH HHS [5T32GM07143-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Baba M, 1998, AM J PATHOL, V152, P879; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Celis A, 1999, ELECTROPHORESIS, V20, P355, DOI 10.1002/(SICI)1522-2683(19990201)20:2<355::AID-ELPS355>3.0.CO;2-N; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; El-Agnaf OMA, 1998, NEUROREPORT, V9, P3925, DOI 10.1097/00001756-199812010-00029; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Farrer M, 1998, ANN NEUROL, V43, P394, DOI 10.1002/ana.410430320; FOLCH J, 1957, J BIOL CHEM, V226, P497; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Galvin JE, 2000, AM J PATHOL, V157, P361, DOI 10.1016/S0002-9440(10)64548-8; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Hartman VN, 2001, NEUROREPORT, V12, P943, DOI 10.1097/00001756-200104170-00016; Harvey S, 2001, PHYSIOL GENOMICS, V5, P129, DOI 10.1152/physiolgenomics.2001.5.3.129; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Jin H, 1997, NEUROBIOL LEARN MEM, V68, P271, DOI 10.1006/nlme.1997.3795; KIKUGAWA K, 1991, MEMBRANE LIPID OXIDA, V2, P171; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kruger R, 2000, J NEURAL TRANSM, V107, P31, DOI 10.1007/s007020050002; Langston JW, 1998, EXP NEUROL, V154, P684, DOI 10.1006/exnr.1998.6975; Leaf A, 1999, J MEMBRANE BIOL, V172, P1, DOI 10.1007/s002329900578; Lin JJ, 1999, EUR NEUROL, V42, P217, DOI 10.1159/000008110; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; McKeith IG, 2000, ANN NY ACAD SCI, V920, P1; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nagar S, 2001, ACTA NEUROL SCAND, V103, P120, DOI 10.1034/j.1600-0404.2001.103002120.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Neumann M, 2000, ACTA NEUROPATHOL, V100, P568, DOI 10.1007/s004010000224; Parsian A, 1998, NEUROLOGY, V51, P1757, DOI 10.1212/WNL.51.6.1757; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shoji M, 2000, J NEUROL NEUROSUR PS, V68, P605, DOI 10.1136/jnnp.68.5.605; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Vaughan J, 1998, ANN NEUROL, V44, P270, DOI 10.1002/ana.410440221; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Warner TT, 1998, J NEUROL NEUROSUR PS, V65, P378, DOI 10.1136/jnnp.65.3.378; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	71	223	226	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41958	41962		10.1074/jbc.M105022200	http://dx.doi.org/10.1074/jbc.M105022200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553616	hybrid			2022-12-25	WOS:000172450400056
J	Sargent, TG; Lloyd, JA				Sargent, TG; Lloyd, JA			The human gamma-globin TATA and CACCC elements have key, distinct roles in suppressing beta-globin gene expression in embryonic/fetal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; LOCUS-CONTROL REGION; KRUPPEL-LIKE FACTOR; TRANSGENIC MICE; CHROMATIN STRUCTURE; HEREDITARY PERSISTENCE; FETAL HEMOGLOBIN; TRANSCRIPTION; ACTIVATION; PROMOTER	The competition model of globin gene regulation states that the gamma -globin gene precludes expression of the beta -globin gene in early development by competing for the enhancing activity of the locus control region. The gamma -globin gene with a - 161 promoter is sufficient for suppressing beta -globin gene expression, and the gamma -globin TATA and CACCC elements are necessary for this effect. In this work, stable transfection and transgenic mouse assays have been performed with constructs containing HS3 and HS2 from the locus control region, the gamma -globin gene with promoter mutation(s), and the beta -globin gene. The data indicate that the gamma -globin TATA and CACCC elements together have at least an additive effect on the beta/gamma -globin mRNA ratio in early erythroid cells, suggesting that the elements work coordinately to suppress beta -globin gene expression. The TATA and CACCC are the major gamma -globin promoter elements responsible for this effect. Transgenic mouse experiments indicate that the gamma -globin TATA element plays a role in gamma -globin expression and beta -globin suppression in the embryo and fetus; in contrast, the CACCC element has a stage-specific effect in the fetus. The results suggest that, as is true for the erythroid Kruppel-like factor (EKLF) and the beta -globin promoter CACCC, a protein(s) binds to the gamma -globin CACCC element to coordinate stage-specific gene expression.	Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA 23298 USA	Virginia Commonwealth University	Lloyd, JA (corresponding author), Virginia Commonwealth Univ, Dept Human Genet, Med Coll Virginia Campus,POB 980033, Richmond, VA 23298 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062154] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60080, R01 HL060080] Funding Source: Medline; NIDDK NIH HHS [R21 DK062154] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1993, MOL BIOL CELL, V4, P1077, DOI 10.1091/mbc.4.10.1077; Asano H, 1999, MOL CELL BIOL, V19, P3571; Asano H, 2000, BLOOD, V95, P3578, DOI 10.1182/blood.V95.11.3578.011k48_3578_3584; Bagga R, 2000, NUCLEIC ACIDS RES, V28, P2541, DOI 10.1093/nar/28.13.2541; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; Elnitski L, 2001, J BIOL CHEM, V276, P6289, DOI 10.1074/jbc.M009624200; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; Ryan TM, 2000, NUCLEIC ACIDS RES, V28, P2736, DOI 10.1093/nar/28.14.2736; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; Sargent TG, 1999, J BIOL CHEM, V274, P11229, DOI 10.1074/jbc.274.16.11229; Sargent TG, 1999, DNA CELL BIOL, V18, P293, DOI 10.1089/104454999315358; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41817	41824		10.1074/jbc.M103073200	http://dx.doi.org/10.1074/jbc.M103073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551906	hybrid			2022-12-25	WOS:000172450400038
J	Seifert, R; Wenzel-Seifert, K				Seifert, R; Wenzel-Seifert, K			Defective G(i) protein coupling in two formyl peptide receptor mutants associated with localized juvenile periodontitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-FORMYLPEPTIDE RECEPTOR; NEUTROPHIL FUNCTION; LIGAND-BINDING; CELLS; GLYCOSYLATION; ACTIVATION; RECONSTITUTION; EXPRESSION; LEUKOCYTES; MEMBRANES	The formyl peptide receptor (FPR) is a prototypical chemoattractant receptor expressed in neutrophils. It is well known that the FPR couples to G(i) proteins to activate phospholipase C, chemotaxis, and cytotoxic cell functions, but the in vivo role of the FPR in man has remained elusive. Recently, F110S and C126W mutations of the FPR have been associated with localized juvenile periodontitis. We studied FPR-F110S and FPR-C126W in comparison with wild-type FPR (FPR-WT) by coexpressing epitope-tagged versions of these receptors with the G protein G alpha (i2)beta (1)gamma (2) in Sf9 insect cells. FPRs were efficiently expressed in Sf9 membranes as assessed by immunoblotting using the beta (2)-adrenoreceptor as a standard. FPR-C126W differed from FPR-WT and FPR-F110S in migration on SDS-polyacrylamide gels and tunicamycin-sensitive glycosylation. FPR-WT efficiently reconstituted high-affinity agonist binding and agonist- and inverse agonist-regulated guanosine 5'-O-(3-thiotriphosphate) (GTP gammaS) binding to G alpha (i2)beta (1)gamma (2). In contrast, FPR-F110S only weakly reconstituted agonist-stimulated GTP gammaS binding, and FPR-C126W was completely inefficient. Collectively, our data show almost complete and complete loss of G(i) protein coupling in FPR-F110S and FPR-C126W, respectively. The severe functional defects in FPR-F110S and FPR-C126W contrast with the discrete clinical symptoms associated with these mutations, indicating that loss of FPR function in host defense is, for the most part, readily compensated.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	University of Kansas	Wenzel-Seifert, K (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 5003 Malott Hall, Lawrence, KS 66045 USA.		Seifert, Roland/G-3189-2013					Benya RV, 2000, MOL PHARMACOL, V58, P1490, DOI 10.1124/mol.58.6.1490; Boer U, 2000, BIOCHEM J, V350, P839, DOI 10.1042/0264-6021:3500839; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; COWEN DS, 1990, J BIOL CHEM, V265, P16181; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; DANIEL MA, 1993, J PERIODONTOL, V64, P617, DOI 10.1902/jop.1993.64.7.617; Dennison DK, 1997, PERIODONTOL 2000, V14, P54, DOI 10.1111/j.1600-0757.1997.tb00192.x; DILLON SB, 1988, VIRCHOWS ARCH B, V55, P65; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15149, DOI 10.1021/bi9607564; Gwinn MR, 1999, J PERIODONTOL, V70, P1194, DOI 10.1902/jop.1999.70.10.1194; JACOBS AA, 1995, J LEUKOCYTE BIOL, V57, P679, DOI 10.1002/jlb.57.4.679; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; Le YY, 2000, IMMUNOL REV, V177, P185, DOI 10.1034/j.1600-065X.2000.17704.x; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; Miettinen HM, 1999, J BIOL CHEM, V274, P27934, DOI 10.1074/jbc.274.39.27934; Miettinen HM, 1997, J IMMUNOL, V159, P4045; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PEREZ HD, 1991, J CLIN INVEST, V87, P971, DOI 10.1172/JCI115105; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 2001, RECEPTOR CHANNEL, V7, P357; SEIFERT R, 1991, REV PHYSIOL BIOCH P, V117, P1; VANDYKE TE, 1986, J PERIODONTOL, V57, P703, DOI 10.1902/jop.1986.57.11.703; VANDYKE TE, 1981, BIOCHEM BIOPH RES CO, V100, P1278, DOI 10.1016/0006-291X(81)91962-8; Wara-aswapati N, 1999, J DENT CHILD, V66, P167; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954, DOI 10.1124/mol.58.5.954; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; Wenzel-Seifert K., 2001, PHYSL INFLAMMATION, P146; WENZELSEIFERT K, 1993, J IMMUNOL, V150, P4591; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f	41	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42043	42049		10.1074/jbc.M106621200	http://dx.doi.org/10.1074/jbc.M106621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11559706	hybrid			2022-12-25	WOS:000172450400068
J	Falck, J; Lukas, C; Protopopova, M; Lukas, J; Selivanova, G; Bartek, J				Falck, J; Lukas, C; Protopopova, M; Lukas, J; Selivanova, G; Bartek, J			Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway	ONCOGENE			English	Article						DNA damage; cell cycle checkpoints; Chk2; p53; tumour suppressor	DNA-DAMAGE; S-PHASE; PRB/E2F PATHWAY; CELL-LINES; P53; CHECKPOINT; ATM; ACTIVATION; CANCER; PHOSPHORYLATION	Recent evidence identified a genetic and functional link between Chk2 kinase and p53 as a candidate genome integrity checkpoint and a tumour suppressor pathway. Here we report that in human cells, Chk2 and p53 form protein-protein complexes whose abundance increased upon DNA damage, and whose formation was abrogated through cancer associated mutations in the FHA domain of Chk2, or mutations in the tetramerization domain of p53. Whereas among Li-Fraumeni syndrome families mutations of Chk2 or p53 occur in a mutually exclusive manner, we document that the colon cancer cell line HCT-15 concomitantly lacks functions of both Chk2 and p53, the latter demonstrated by a non-invasive reporter assay monitoring p53-dependent transactivation in live cells. Despite the preserved ability of common cancer-derived mutant p53 proteins to bind and potentially 'titrate' activated Chk2, the integrity of the S phase checkpoint response to ionizing radiation remained largely intact and dependent on Chk2 in cells with wild-type, mutant, or no p53. These results provide new mechanistic insights into the Chk2-p53 interplay, suggest how mutations in Chk2 may abrogate its tumour suppressor function, and indicate that compared with individual defects in either Chk2 or p53, concomitant mutations in both of these cell cycle checkpoint regulators may provide some additional selective advantage to tumour cells.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Karolinska Inst, Canc Ctr Karolinska R8 04, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Danish Cancer Society; Karolinska Institutet	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Selivanova, Galina/0000-0002-8698-4332; Lukas, Claudia/0000-0001-7169-6883; Lukas, Jiri/0000-0001-9087-506X				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BARTEK J, 1990, ONCOGENE, V5, P893; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Haruki N, 2000, CANCER RES, V60, P4689; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meek DW, 2000, PATHOL BIOL, V48, P246; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; OConnor PM, 1997, CANCER RES, V57, P4285; Petrini JHJ, 2000, NAT GENET, V26, P257, DOI 10.1038/81529; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	31	96	97	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5503	5510		10.1038/sj.onc.1204811	http://dx.doi.org/10.1038/sj.onc.1204811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571648				2022-12-25	WOS:000170781100011
J	Marquez, DC; Pietras, RJ				Marquez, DC; Pietras, RJ			Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast cancer; plasma membrane; MAP kinase; Akt kinase	ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; RECEPTOR-ALPHA; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; MCF-7 CELLS; FACTOR-I; ESTRADIOL; IDENTIFICATION	Membrane-associated binding sites for estrogen may mediate rapid effects of estradiol-17 beta that contribute to proliferation of human breast cancers. After controlled homogenization and fractionation of MCF-7 breast cancer cells, the bulk of specific estradiol binding is found in nuclear fractions. However, a significant portion of specific, high-affinity estradiol-17 beta binding-sites are also enriched in plasma membranes. These estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and are free from major contamination by cytosol or nuclei. Electrophoresis of membrane fractions allowed detection of a primary 67-kDa protein and a secondary 46-kDa protein recognized by estradiol-17 beta and by a monoclonal antibody directed to the ligand-binding domain of the nuclear form of estrogen receptor. Estrogen-induced growth of MCF-7 breast cancer cells in vitro was blocked by treatment with the antibody to estrogen receptor and correlated closely with acute hormonal activation of mitogen-activated protein kinase and Akt kinase signaling. Estrogen-promoted growth of human breast cancer xenografts in nude mice was also significantly reduced by treatment in vivo with the estrogen receptor antibody. Thus, membrane-associated forms of estrogen receptor may play a role in promoting intracellular signaling for hormone-mediated proliferation and survival of breast cancers and offer a new target for antitumor therapy.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pietras, RJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, 10833 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.		Marquez-Garban, Diana/M-4660-2014	Marquez-Garban, Diana/0000-0002-7866-5323; Pietras, Richard/0000-0002-2846-3192				Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen FH, 1999, J CELL BIOCHEM, V74, P430, DOI 10.1002/(SICI)1097-4644(19990901)74:3<430::AID-JCB11>3.0.CO;2-5; Chun TY, 1998, P NATL ACAD SCI USA, V95, P2325, DOI 10.1073/pnas.95.5.2325; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fuqua SAW, 1999, CANCER RES, V59, P5425; GERMAIN PS, 1993, ANTICANCER RES, V13, P2347; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; Hawkins MB, 2000, P NATL ACAD SCI USA, V97, P10751, DOI 10.1073/pnas.97.20.10751; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; HENDERSON BE, 1988, CANCER RES, V48, P246; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Levin ER, 1999, TRENDS ENDOCRIN MET, V10, P374, DOI 10.1016/S1043-2760(99)00192-7; Luconi M, 1999, J CLIN ENDOCR METAB, V84, P1670, DOI 10.1210/jc.84.5.1670; McKenna N, 2000, NAT MED, V6, P960, DOI 10.1038/79637; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Monje P, 1999, MOL CELL ENDOCRINOL, V147, P75, DOI 10.1016/S0303-7207(98)00212-3; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NENCI I, 1981, J STEROID BIOCHEM, V14, P1139, DOI 10.1016/0022-4731(81)90043-1; Norfleet AM, 2000, FASEB J, V14, P157, DOI 10.1096/fasebj.14.1.157; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1984, BIOCHEM BIOPH RES CO, V123, P84, DOI 10.1016/0006-291X(84)90383-8; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PIETRAS RJ, 1975, NATURE, V253, P357, DOI 10.1038/253357a0; PIETRAS RJ, 1980, BIOCHEM J, V191, P743, DOI 10.1042/bj1910743; Ramirez VD, 1996, FRONT NEUROENDOCRIN, V17, P402, DOI 10.1006/frne.1996.0011; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Register TC, 1998, J STEROID BIOCHEM, V64, P187, DOI 10.1016/S0960-0760(97)00155-6; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SICA V, 1973, NATURE-NEW BIOL, V244, P36, DOI 10.1038/newbio244036a0; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; SZEGO CM, 1984, INT REV CYTOL, V88, P1, DOI 10.1016/S0074-7696(08)62759-X; SZEGO CM, 1967, P NATL ACAD SCI USA, V58, P1711, DOI 10.1073/pnas.58.4.1711; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Weiler PJ, 2000, BIOCHEM BIOPH RES CO, V272, P731, DOI 10.1006/bbrc.2000.2847; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WELSHONS WV, 1993, MOL CELL ENDOCRINOL, V94, P183, DOI 10.1016/0303-7207(93)90167-I; ZYZEK E, 1981, BIOCHEM BIOPH RES CO, V102, P1151, DOI 10.1016/S0006-291X(81)80132-5	57	138	144	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5420	5430		10.1038/sj.onc.1204729	http://dx.doi.org/10.1038/sj.onc.1204729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571639				2022-12-25	WOS:000170781100002
J	Miralem, T; Steinberg, R; Price, D; Avraham, H				Miralem, T; Steinberg, R; Price, D; Avraham, H			VEGF(165) requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells	ONCOGENE			English	Article						VEGF; breast cancer; cell signaling; mitogenic response; cell migration	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; PHOSPHATIDYLINOSITOL 3-KINASE; FIBROBLAST-GROWTH; TYROSINE KINASE; VEGF RECEPTORS; IV COLLAGEN; INHIBITING FACTORS; BINDING DOMAIN; HEPARIN	The expression of VEGF and the relapse-free survival rate of breast cancer patients are inversely related. While VEGF induces the proliferation and migration of vascular endothelial cells, its function in breast cancer cells is not well studied. We reported previously that fibronectin increased VEGF-dependent migration in breast cancer cells. Since VEGF has an extracellular matrix (ECTM)-binding domain and possesses binding affinity for heparin, we sought to determine the effects of VEGF in breast cancer cells and the role of heparin and/ or fibronectin in VEGF-induced signaling. Cells grown on plastic were compared to those grown on fibronectin or to those grown on plastic in the presence of heparin, and analysed for intracellular signaling, proliferation and migration in response to VEGF(165). Both heparin and fibronectin enhanced the binding of VEGF to T47D cells. After treatment with VEGF, [H-3]thymidine incorporation, c-fos induction, and the number of migrating cells were significantly higher (similar to twofold) in cells grown on fibronectin or in cells grown on plastic in the presence of heparin when compared to those grown on plastic only. Likewise, tyrosine phosphorylation of VEGF receptors, MAPK activity and PI3-kinase activity were all severalfold higher in cells seeded on fibronectin or in the presence of heparin as compared to cells exposed to VEGF alone. VEGF-dependent c-fos induction was found to be regulated through a MAPK-dependent, but PI3-kinase-independent pathway. In contrast, the migration of T47D cells in response to VEGF, in the presence of ECM, was regulated through PI3-kinase. Therefore, VEGF requires ECM components to induce a mitogenic response and cell migration in T47D breast cancer cells.	Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, H (corresponding author), Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu	Mordwinkin, Nicholas M/A-4347-2010; Miralem, Tihomir/F-7576-2013	Avraham, Hava/0000-0002-7545-3640; Miralem, Tihomir/0000-0001-7705-0442	NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NIAMS NIH HHS [AR21 CA 87290-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHN NG, 1990, J BIOL CHEM, V265, P11487; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; BACIC M, 1995, GROWTH FACTORS, V12, P11, DOI 10.3109/08977199509003209; Blancher C, 2000, CANCER RES, V60, P7106; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; CHRISTIANSEN NO, 1992, ACTA BIOCHIM BIOPHYS, V26, P1; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; De Jong JS, 1998, J PATHOL, V184, P44; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Derman MP, 1996, J BIOL CHEM, V271, P4251; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GRINNELL F, 1979, CELL, V17, P117, DOI 10.1016/0092-8674(79)90300-3; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HALPER J, 1990, EXP CELL RES, V187, P324, DOI 10.1016/0014-4827(90)90099-V; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; HICKS K, 1989, BIOCHEM BIOPH RES CO, V164, P1323, DOI 10.1016/0006-291X(89)91814-7; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JEANNY JC, 1987, EXP CELL RES, V171, P63, DOI 10.1016/0014-4827(87)90251-5; Joukov V, 1996, EMBO J, V15, P290; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livant DL, 2000, J CLIN INVEST, V105, P1537, DOI 10.1172/JCI8527; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Miralem T, 1996, J BIOL CHEM, V271, P17100, DOI 10.1074/jbc.271.29.17100; Miralem T, 1996, AM J PHYSIOL-RENAL, V270, pF960, DOI 10.1152/ajprenal.1996.270.6.F960; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; ORMEROD EJ, 1985, HISTOCHEM J, V17, P1155, DOI 10.1007/BF01002540; PAOLELLA G, 1988, NUCLEIC ACIDS RES, V16, P3545, DOI 10.1093/nar/16.8.3545; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285; Shahan TA, 1999, CANCER RES, V59, P4584; SHIBUYA M, 1999, CURR TOP MICROBIOL, P237; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Speirs V, 1999, BRIT J CANCER, V80, P898, DOI 10.1038/sj.bjc.6690438; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TEMPLETON DM, 1992, CRIT REV CL LAB SCI, V29, P141, DOI 10.3109/10408369209114599; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshiji H, 1996, CANCER RES, V56, P2013; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	80	51	54	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5511	5524		10.1038/sj.onc.1204753	http://dx.doi.org/10.1038/sj.onc.1204753			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571649	Bronze			2022-12-25	WOS:000170781100012
J	Leu, FP; O'Donnell, M				Leu, FP; O'Donnell, M			Interplay of clamp loader subunits in opening the beta sliding clamp of Escherichia coli DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; ACCESSORY PROTEINS; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; LAGGING-STRAND; GAMMA-SUBUNIT; COMPLEX; BINDING; MACHINE; PCNA	The Escherichia coli beta dimer is a ring-shaped protein that encircles DNA and acts as a sliding clamp to tether the replicase, DNA polymerase III holoenzyme, to DNA. The gamma complex (gamma delta delta'chi psi) clamp loader couples ATP to the opening and closing of beta in assembly of the ring onto DNA. These proteins are functionally and structurally conserved in all cells. The eukaryotic equivalents are the replication factor C (RFQ clamp loader and the proliferating cell nuclear antigen (PCNA) clamp. The delta subunit of the E. coli gamma complex clamp loader is known to bind beta and open it by parting one of the dimer interfaces. This study demonstrates that other subunits of gamma complex also bind beta, although weaker than delta. The gamma subunit like delta, affects the opening of beta, but with a lower efficiency than delta. The delta' subunit regulates both gamma and ring opening activities in a fashion that is modulated by ATP interaction with gamma. The implications of these actions for the workings of the E. coli clamp loading machinery and for eukaryotic RFC and PCNA are discussed.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Dept Pharmacol, Ithaca, NY 14853 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BONNER CA, 1992, J BIOL CHEM, V267, P11431; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; MAKI S, 1988, J BIOL CHEM, V263, P6555; McAlear MA, 1996, GENETICS, V142, P65; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; ROWEN L, 1978, J BIOL CHEM, V253, P758; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	56	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47185	47194		10.1074/jbc.M106780200	http://dx.doi.org/10.1074/jbc.M106780200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11572866	hybrid			2022-12-25	WOS:000172768500070
J	Kim, RH; Flanders, KC; Reffey, SB; Anderson, LA; Duckett, CS; Perkins, ND; Roberts, AB				Kim, RH; Flanders, KC; Reffey, SB; Anderson, LA; Duckett, CS; Perkins, ND; Roberts, AB			SNIP1 inhibits NF-kappa B signaling by competing for its binding to the C/H1 domain of CBP/p300 transcriptional Co-activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MOLECULAR-CLONING; COACTIVATOR P300; GENE-EXPRESSION; MICE LACKING; GROWTH; PROTEIN; CBP; AP-1; TRANSACTIVATION	SNIP1 is a 396-amino acid nuclear protein shown to be an inhibitor of the TGF-beta signal transduction. pathway and to be important in suppressing transcriptional activation dependent on the co-activators CBP and p300. In this report we show that SNIP1 potently inhibits the activity of NF-kappaB, which binds the C/H1 domain of CBP/p300, but does not interfere with the activity of transcription factors such as p53, which bind to other domains of p300, or factors such as VP16, which are independent of these co-activators. Inhibition of NF-kappaB activity is a function of the N-terminal domain of SNIP1 and involves competition of SNIP1 and the NF-kappaB subunit, RelA/p65, for binding to p300, similar to the mechanism of inhibition of Smad signaling by SNIP1. Immunohistochemical staining shows that expression of SNIP1 is strictly regulated in development and that it colocalizes, in certain tissues, with nuclear staining for RelA/p65 and for p300, suggesting that they may regulate NF-kappaB activity in vivo in a spatially and temporally controlled manner. These data led us to suggest that SNIP1 may be an inhibitor of multiple transcriptional pathways that require the C/H1 domain of CBP/p300.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NCI, Metab Branch, Bethesda, MD 20892 USA; Univ Dundee, Dept Biochem, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Dundee	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bldg 41,Rm C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.			Duckett, Colin/0000-0001-9413-2263				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goodman RH, 2000, GENE DEV, V14, P1553; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kim RH, 2000, GENE DEV, V14, P1605; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, P418; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	54	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46297	46304		10.1074/jbc.M103819200	http://dx.doi.org/10.1074/jbc.M103819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567019	hybrid			2022-12-25	WOS:000172573100110
J	Miyao, T; Barnett, JD; Woychik, NA				Miyao, T; Barnett, JD; Woychik, NA			Deletion of the RNA polymerase subunit RPB4 acts as a global, not stress-specific, shut-off switch for RNA polymerase II transcription at high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PROTEIN; MEDIATOR; GROWTH; MUTANT	We used whole genome expression analysis to investigate the changes in the mRNA profile in cells lacking the Saccharomyces cerevisiae RNA polymerase II subunit RPB4 (Delta RPB4). Our results indicated that an essentially complete shutdown of transcription occurs upon temperature shift of this conditionally lethal mutant; 98% of mRNA transcript levels decrease at least 2-fold, 96% at least 4-fold. This data was supported by in vivo experiments that revealed a rapid and greater than 5-fold decline in steady state poly(A) RNA levels after the temperature shift. Expression of several individual genes, measured by Northern analysis, was also consistent with the whole genome expression profile. Finally we demonstrated that the loss of RNA polymerase II activity causes secondary effects on RNA polymerase I, but not RNA polymerase III, transcription. The transcription phenotype of the Delta RPB4 mutant closely mirrors that of the temperature-sensitive rpb1-1 mutant frequently implemented as a tool to inactivate the RNA polymerase II in vivo. Therefore, the Delta RPB4 mutant can be used to easily design strains that enable the study of distinct post-transcriptional cellular processes in the absence of RNA polymerase II transcription.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Massachusetts Institute of Technology (MIT); Whitehead Institute	Woychik, NA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	nancy.woychik@umdnj.edu			NIGMS NIH HHS [GM 55736] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Bourbonnais Y, 2001, MOL GEN GENET, V264, P763, DOI 10.1007/s004380000365; BURKE D, 2000, METHODS YEAST GENETI, P117; CHODER M, 1993, J BACTERIOL, V175, P6358, DOI 10.1128/JB.175.19.6358-6363.1993; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Li BJ, 1999, MOL CELL BIOL, V19, P5393; Maillet I, 1999, J BIOL CHEM, V274, P22586, DOI 10.1074/jbc.274.32.22586; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; Pillai B, 2001, J BIOL CHEM, V276, P30641, DOI 10.1074/jbc.M010952200; Rosenheck S, 1998, J BACTERIOL, V180, P6187; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; Tan Q, 2000, MOL CELL BIOL, V20, P8124, DOI 10.1128/MCB.20.21.8124-8133.2000; Tan Q, 2000, GENE DEV, V14, P339; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; WARNER JR, 1978, NATURE, V275, P338, DOI 10.1038/275338a0; Woychik NA, 1998, COLD SPRING HARB SYM, V63, P311, DOI 10.1101/sqb.1998.63.311; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	29	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46408	46413		10.1074/jbc.M107012200	http://dx.doi.org/10.1074/jbc.M107012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577101	hybrid			2022-12-25	WOS:000172573100124
J	Chai, YH; Wu, LZ; Griffin, JD; Paulson, HL				Chai, YH; Wu, LZ; Griffin, JD; Paulson, HL			The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACHADO-JOSEPH-DISEASE; CREB-BINDING-PROTEIN; SCA1 TRANSGENIC MICE; HUNTINGTONS-DISEASE; EXPANDED POLYGLUTAMINE; MOUSE MODEL; GENE-PRODUCT; IN-VITRO; NEURODEGENERATIVE DISEASES; INTRANUCLEAR INCLUSIONS	Intracellular inclusions are a unifying feature of polyglutamine (polyQ) neurodegenerative diseases, yet each polyQ disease displays a unique pattern of neuronal degeneration. This implies that the protein context of expanded polyQ plays an important role in establishing selective neurotoxicity. Here, in studies of the spinocerebellar ataxia type 3 disease protein ataxia-3, we demonstrate that the protein sequence surrounding polyQ specifies the constituents of nuclear inclusions (NI) formed by the disease protein. The nuclear proteins cAMP response element-binding protein-binding protein (CBP) and Mastermind-like-1 strongly colocalize only to NI formed by full-length ataxia-3, whereas the splicing factor SC35 colocalizes only to NI formed by a polyQ-containing, carboxyl-terminal fragment of ataxia-3. These differences in NI formation reflect specific protein interactions normally undertaken by ataxia-3, as both normal and mutant full-length ataxia-3 co-immunoprecipitate with CBP and sediment on density gradients as macromolecular complexes. Moreover, normal ataxia-3 represses cAMP response element-binding protein-mediated transcription, indicating a functional consequence of ataxia-3 interactions with CBP. Finally, we show that mutant ataxia-3 forms insoluble intranuclear complexes, or MIL croaggregates, before NI can be detected, implying a precursor-product relationship. These results suggest that protein context-dependent recruitment of nuclear proteins to intranuclear microaggregates, and subsequently to NI, may contribute to selective neurotoxicity in polyQ diseases.	Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Iowa; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Paulson, HL (corresponding author), Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu			NINDS NIH HHS [NS38712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038712] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 1999, J NEUROSCI, V19, P10338; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Goodman RH, 2000, GENE DEV, V14, P1553; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Holbert S, 2001, P NATL ACAD SCI USA, V98, P1811, DOI 10.1073/pnas.041566798; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nayler O, 2000, J CELL BIOL, V150, P949, DOI 10.1083/jcb.150.5.949; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perez MK, 1999, HUM MOL GENET, V8, P2377, DOI 10.1093/hmg/8.13.2377; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SANDOU F, 1998, CELL, V95, P55; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tait D, 1998, HUM MOL GENET, V7, P991, DOI 10.1093/hmg/7.6.991; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yasuda S, 1999, GENES CELLS, V4, P743, DOI 10.1046/j.1365-2443.1999.00294.x; Zhu QZ, 2001, CANCER RES, V61, P64; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	55	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44889	44897		10.1074/jbc.M106575200	http://dx.doi.org/10.1074/jbc.M106575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572863	hybrid			2022-12-25	WOS:000172406700075
J	Spielhaupter, C; Schatzl, HM				Spielhaupter, C; Schatzl, HM			PrPC directly interacts with proteins involved in signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PRION PROTEIN; GROWTH-FACTOR RECEPTORS; SYNAPSIN-I; SCRAPIE ISOFORM; SYNTHETIC PEPTIDES; SYNAPTIC FUNCTION; SH3 DOMAIN; BINDING; MICE; CELLS	The cellular prion protein (PrPc) is a conserved glycoprotein predominantly expressed in neuronal cells. Its purpose in living cells is still enigmatic. To elucidate on its cellular function, we performed a yeast two-hybrid screen for interactors. We used murine PrPc (amino acids 23-231) as bait to search a mouse brain cDNA expression library. Several interaction partners were identified. Three of them with a high homology to known sequences were further characterized. These candidates were the neuronal phosphoprotein synapsin Ib, the adaptor protein Grb2, and the still uncharacterized prion interactor Pint1. The in vivo interaction of the three proteins with PrPc was confirmed by co-immunoprecipitation assays with recombinant and authentic proteins in mammalian cells. The binding regions were mapped using truncated PrP constructs. As both synapsin Ib and Grb2 are implicated in neuronal signaling processes, our findings further strengthen the putative role of the prion protein in signal transduction.	Univ Munich, Gene Ctr Munich, Dept Virol, Max von Pettenkofer Inst, D-81377 Munich, Germany	University of Munich	Schatzl, HM (corresponding author), Univ Munich, Gene Ctr Munich, Dept Virol, Max von Pettenkofer Inst, Feodor Lynen Str 25, D-81377 Munich, Germany.	schaetzl@lmb.uni-muenchen.de	Schatzl, Hermann/G-4958-2011	Schatzl, Hermann/0000-0003-4972-8740				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CLINTON J, 1993, NEUROREPORT, V4, P65, DOI 10.1097/00001756-199301000-00017; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; Gohel C, 1999, J NEUROSCI RES, V55, P261, DOI 10.1002/(SICI)1097-4547(19990115)55:2<261::AID-JNR14>3.0.CO;2-I; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HARPER JW, 1993, CELL, V75, P805; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Matsumoto K, 1999, J BIOL CHEM, V274, P2053, DOI 10.1074/jbc.274.4.2053; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Meyer RK, 2000, J BIOL CHEM, V275, P38081, DOI 10.1074/jbc.M007114200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; Negro A, 2000, BIOCHEM BIOPH RES CO, V271, P337, DOI 10.1006/bbrc.2000.2628; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130	57	180	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44604	44612		10.1074/jbc.M103289200	http://dx.doi.org/10.1074/jbc.M103289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571277	hybrid			2022-12-25	WOS:000172406700037
J	van der Vliet, HN; Sammels, MG; Leegwater, ACJ; Levels, JHM; Reitsma, PH; Boers, W; Chamuleau, RAFM				van der Vliet, HN; Sammels, MG; Leegwater, ACJ; Levels, JHM; Reitsma, PH; Boers, W; Chamuleau, RAFM			Apolipoprotein A-V - A novel apolipoprotein associated with an early phase of liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED H-35 CELLS; FACTOR-KAPPA-B; MESSENGER-RNA; PROTEIN SECRETION; GENE-EXPRESSION; DEFICIENT MICE; 3T3 CELLS; IV GENE; C-III; RAT	Liver regeneration in response to various forms of liver injury is a complex process, which ultimately results in restoration of the original liver mass and function. Because the underlying mechanisms that initiate this response are still incompletely defined, this study was aimed to identify novel factors. Liver genes that were up-regulated 6 h after 70% hepatectomy (PHx) in the rat were selected by cDNA subtractive hybridization. Besides known genes associated with cell proliferation, several novel genes were isolated. The novel gene that was most up-regulated was further studied. Its mRNA showed a liver-specific expression and encoded a protein comprising 367 amino acids. The mouse and human cDNA analogues were also isolated and appeared to be highly homologous. The human gene analogue was located at an apolipoprotein gene cluster on chromosome 11q23. The protein encoded by this gene had appreciable homology with apolipoproteins A-I and A-IV. Maximal expression of the gene in the rat liver and its gene product in rat plasma was observed 6 h after PHx. The protein was present in plasma fractions containing high density lipoprotein particles. Therefore, we have identified a novel apolipoprotein, designated apolipoprotein A-V, that is associated with an early phase of liver regeneration.	Univ Amsterdam, Acad Med Ctr, Dept Expt Hepatol, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Chamuleau, RAFM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Room C2-331,POB 22660, NL-1100 DD Amsterdam, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BOGUSKI MS, 1984, P NATL ACAD SCI-BIOL, V81, P5021, DOI 10.1073/pnas.81.16.5021; CAPUTI M, 1995, NUCLEIC ACIDS RES, V23, P238, DOI 10.1093/nar/23.2.238; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DALLINGATHIE GM, 1985, J LIPID RES, V26, P970; Davies C, 1998, J MOL BIOL, V279, P873, DOI 10.1006/jmbi.1998.1780; DRAGANI TA, 1987, CANCER RES, V47, P795; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto Nelson, 1994, P1059; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; GOYETTE M, 1983, SCIENCE, V219, P510, DOI 10.1126/science.6297003; GROEN AK, 1995, GASTROENTEROLOGY, V109, P1997, DOI 10.1016/0016-5085(95)90768-8; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HELPS NR, 1995, GENE, V162, P245, DOI 10.1016/0378-1119(95)00356-B; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Jensen LE, 1998, BIOCHEM J, V334, P489, DOI 10.1042/bj3340489; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Kurumiya Y, 2000, J HEPATOL, V32, P636, DOI 10.1016/S0168-8278(00)80226-3; Lambotte L, 1997, AM J PHYSIOL-GASTR L, V273, pG905, DOI 10.1152/ajpgi.1997.273.4.G905; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Levels JHM, 2001, INFECT IMMUN, V69, P2821, DOI 10.1128/IAI.69.5.2821-2828.2001; LU XP, 1992, J BIOL CHEM, V267, P2841; Metzger S, 1996, EUR J CLIN INVEST, V26, P71, DOI 10.1046/j.1365-2362.1996.00100.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; RABES H, 1970, VIRCHOWS ARCH B, V6, P302; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Sakaguchi M, 1997, CURR OPIN BIOTECH, V8, P595, DOI 10.1016/S0958-1669(97)80035-3; Sambrook J., 2002, MOL CLONING LAB MANU; Scriver C. R., 2000, METABOLIC MOL BASES; Starkel P, 1999, HEPATOLOGY, V29, P1463, DOI 10.1002/hep.510290503; TANAHASHI T, 1995, J BIOCHEM-TOKYO, V118, P355, DOI 10.1093/oxfordjournals.jbchem.a124914; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON NL, 1986, CANCER RES, V46, P3111; VanKempen MJA, 1996, CARDIOVASC RES, V32, P886; Voshol PJ, 1998, GASTROENTEROLOGY, V114, P1024, DOI 10.1016/S0016-5085(98)70323-3; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679; WOLLENBERG GK, 1991, INT J CANCER, V47, P311, DOI 10.1002/ijc.2910470223; Wu CG, 1997, CARCINOGENESIS, V18, P47, DOI 10.1093/carcin/18.1.47; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	49	237	251	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44512	44520		10.1074/jbc.M106888200	http://dx.doi.org/10.1074/jbc.M106888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577099	hybrid			2022-12-25	WOS:000172406700024
J	Chellappa, R; Kandasamy, P; Oh, CS; Jiang, Y; Vemula, M; Martin, CE				Chellappa, R; Kandasamy, P; Oh, CS; Jiang, Y; Vemula, M; Martin, CE			The membrane proteins, Spt23p and Mga2p, play distinct roles in the activation of Saccharomyces cerevisiae OLE1 gene expression - Fatty acid-mediated regulation of Mga2p activity is independent of its proteolytic processing into a soluble transcription activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESATURASE GENE; ENCODES; YEAST; CHAIN; ATF6	The Saccharomyces OLE1 gene encodes the Delta -9 fatty acid desaturase, an enzyme that converts saturated fatty acyl-CoAs into cis-Delta -9 unsaturated fatty acids. OLE1 gene expression is regulated by unsaturated fatty acids, which repress transcription and destabilize the OLE1 mRNA. Expression of OLE1 is activated by N-terminal proteolytic fragments of two homologous endoplasmic reticulum membrane proteins, Spt23p and Mga2p. Disruption of either gene does not significantly affect cell growth or fatty acid metabolism; cells that contain null alleles of both genes, however, are unsaturated fatty acid auxotrophs. An analysis of spt23 Delta and mga2 Delta strains shows that Spt23p and Mga2p differentially activate and regulate OLE1 transcription. In glucose-grown cells, both genes activate transcription to similar levels of activity. Expressed alone, Mga2p induces high levels of OLE1 transcription in cells exposed to cobalt or grown in glycerol-containing medium. Spt23p expressed alone activates OLE1 transcription to levels similar to those in wild type cells. OLE1 expression is strongly repressed by unsaturated fatty acids in spt23 Delta or mga2 Delta cells, under all growth conditions. To test if OLE1 expression is controlled by fatty acids at the level of membrane proteolysis, soluble N-terminal fragments of Spt23p and Mga2p that lack their membrane-spanning regions (Atm) were expressed under the control of their native promoters in spt23 Delta ;mga2 Delta cells. Under those conditions, Mga2p Delta tm acts as a powerful transcription activator that is strongly repressed by unsaturated fatty acids. By comparison, the Spt23p Delta tm polypeptide weakly activates transcription and shows little regulation by unsaturated fatty acids. Co-expression of the two soluble fragments results in activation to levels observed with the Mga2p Delta tm protein alone. The fatty acid repression of transcription under those conditions is attenuated by Spt23 Delta tm, however, suggesting that the two proteins may interact to modulate OLE1 gene expression.	Rutgers State Univ, Nelson Labs, Div Life Sci, Piscataway, NJ 08854 USA; Rutgers State Univ, Bur Biol Res, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Genzyme Corp, Boston, MA 01701 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Sanofi-Aventis; Genzyme Corporation	Martin, CE (corresponding author), Rutgers State Univ, Nelson Labs, Div Life Sci, 604 Allison Rd, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Choi JY, 1996, J BIOL CHEM, V271, P3581; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Nakagawa Y, 2001, J BACTERIOL, V183, P745, DOI 10.1128/JB.183.2.745-751.2001; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zhang SR, 1999, GENETICS, V151, P473; Zhang SR, 1997, MOL CELL BIOL, V17, P4718, DOI 10.1128/MCB.17.8.4718	20	80	83	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43548	43556		10.1074/jbc.M107845200	http://dx.doi.org/10.1074/jbc.M107845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557770	hybrid			2022-12-25	WOS:000172297700011
J	Koh, SD; Monaghan, K; Sergeant, GP; Ro, S; Walker, RL; Sanders, KM; Horowitz, B				Koh, SD; Monaghan, K; Sergeant, GP; Ro, S; Walker, RL; Sanders, KM; Horowitz, B			TREK-1 regulation by nitric oxide and cGMP-dependent protein kinase - An essential role in smooth muscle inhibitory neurotransmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE PROXIMAL COLON; RECTIFIER K+ CHANNEL; POTASSIUM CHANNELS; GUANYLATE-CYCLASE; MEMBRANE STRETCH; FATTY-ACIDS; CELLS; ACTIVATION; ARTERY; EXPRESSION	Potassium channels activated by membrane stretch may contribute to maintenance of relaxation of smooth muscle cells in visceral hollow organs. Previous work has identified K+ channels in murine colon that are activated by stretch and further regulated by NO-dependent mechanisms. We have screened murine gastrointestinal, vascular, bladder, and uterine smooth muscles for the expression of TREK and TRAAK mRNA. Although TREK-1 was expressed in many of these smooth muscles, TREK-2 was expressed only in murine antrum and pulmonary artery. TRAAK was not expressed in any smooth muscle cells tested. Whole cell currents from TREK-1 expressed in mammalian COS cells were activated by stretch, and single channel re cordings showed that the stretch-dependent conductance was due to 90 pS channels. Sodium nitroprusside (10(-6) or 10(-5) M) and 8-Br-cGMP (10(-4) or 10(-3) M) increased TREK-1 currents in perforated whole cell and single channel recordings. Mutation of the PKG consensus sequence at serine 351 blocked the stimulatory effects of sodium nitroprusside and 8-Br-cGMP on open probability without affecting the inhibitory effects of 8-Br-cAMP. TREK-1 encodes a component of the stretch-activated K+ conductance in smooth muscles and may contribute to nitrergic inhibition of gastrointestinal muscles.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Horowitz, B (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA.			Ro, Seungil/0000-0003-0861-8334; Sergeant, Gerard/0000-0001-9443-5491	NHLBI NIH HHS [HL 49254] Funding Source: Medline; NIDDK NIH HHS [DK 41315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049254, R01HL049254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; DALZIEL HH, 1991, AM J PHYSIOL, V260, pG789, DOI 10.1152/ajpgi.1991.260.5.G789; DOPICO AM, 1994, AM J HYPERTENS, V7, P82, DOI 10.1093/ajh/7.1.82; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Edwards G, 1996, BRIT J PHARMACOL, V119, P691, DOI 10.1111/j.1476-5381.1996.tb15728.x; Epperson A, 1999, AM J PHYSIOL-GASTR L, V277, pG127, DOI 10.1152/ajpgi.1999.277.1.G127; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Franck H, 1997, BRIT J PHARMACOL, V122, P1223, DOI 10.1038/sj.bjp.0701487; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; HART PJ, 1993, P NATL ACAD SCI USA, V90, P9659, DOI 10.1073/pnas.90.20.9659; Horowitz B, 1999, ANNU REV PHYSIOL, V61, P19, DOI 10.1146/annurev.physiol.61.1.19; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; Koh SD, 1996, PFLUG ARCH EUR J PHY, V432, P401, DOI 10.1007/s004240050151; Koh SD, 2001, J PHYSIOL-LONDON, V533, P155, DOI 10.1111/j.1469-7793.2001.0155b.x; Koh SD, 1995, J PHYSIOL-LONDON, V489, P735, DOI 10.1113/jphysiol.1995.sp021087; KRISHNAN BR, 1991, NUCLEIC ACIDS RES, V19, P1153, DOI 10.1093/nar/19.5.1153; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; ORDWAY RW, 1995, J PHYSIOL-LONDON, V484, P331, DOI 10.1113/jphysiol.1995.sp020668; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Rajan S, 2001, J BIOL CHEM, V276, P7302, DOI 10.1074/jbc.M008985200; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Shuttleworth CWR, 1999, BRIT J PHARMACOL, V127, P1495, DOI 10.1038/sj.bjp.0702674; Vogalis F, 1997, J PHYSIOL-LONDON, V502, P497, DOI 10.1111/j.1469-7793.1997.497bj.x; Zygmunt PM, 1997, BRIT J PHARMACOL, V121, P141, DOI 10.1038/sj.bjp.0701108	34	115	120	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44338	44346		10.1074/jbc.M108125200	http://dx.doi.org/10.1074/jbc.M108125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11560940	hybrid			2022-12-25	WOS:000172297700107
J	Singer, E; Landgraf, R; Horan, T; Slamon, D; Eisenberg, D				Singer, E; Landgraf, R; Horan, T; Slamon, D; Eisenberg, D			Identification of a heregulin binding site in HER3 extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR EGF RECEPTOR; INSULIN-RECEPTOR; HUMAN-BREAST; DIFFERENTIATION FACTOR; ERBB3; AFFINITY; ACTIVATION; GENE; SUBSTITUTION	HER3 (also known as c-Erb-b3) is a type I receptor tyrosine kinase similar in sequence to the epidermal growth factor (EGF) receptor. The extracellular segment of this transmembrane receptor contains four domains. Domains I and II are similar in sequence to domains III and IV, respectively, and domains II and IV are cysteine-rich. We show that the EGF-like domain of heregulin (hrg) binds to domains I and II of HER3, in contrast to the EGF receptor, for which prior studies have shown that a construct consisting of domains III and portions of domain IV binds EGF. Next, we identified a putative hrg binding site by limited proteolysis of the recombinant extracellular domains of HER3 (HER3-ECDI-IV) in both the presence and absence of hrg. In the absence of hrg, HER3-ECDI-IV is cleaved after position Tyr(50), near the beginning of domain I. Binding of hrg to HER3-ECDI-IV fully protects position Tyr(50) from proteolysis. To confirm that domain I contains a hrg binding site, we expressed domains I and II (HERS-ECDI-II) and find that it binds hrg with 68 nm affinity. These data suggest that domains I and II of HER3-ECDI-IV act as a functional unit in folding and binding of hrg. Thus, our biochemical findings reinforce the structural hypothesis of others that HER3-ECDI-IV is similar to the insulinlike growth factor-1 receptor (IGF-IR), as follows: 1) The protected cleavage site in HER3-ECDI-IV corresponds to a binding footprint in domain I of IGF-1R; 2) HER3-ECDI-II binds hrg with a 68 nm dissociation constant, supporting the hypothesis that domain I is involved in ligand binding;, and 3) the large accessible surface area (1749 Angstrom) of domain L1 of IGF-1R that is buried by domain S1, as well as the presence of conserved contacts in this interface of type 1 RTKs, suggests that domains L1 and S1 of IGF-1R function as a unit as observed for HER3-ECDI-II. Our results are consistent with the propos that HER3 has a structure similar to IGF-1R and binds ligand at a site in corresponding domains.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Amgen Inc, Amgen Ctr, Thousand Oaks, CA 91320 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Amgen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Inst Mol Biol, Box 951750, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu			NCI NIH HHS [CA 16042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dougall WC, 1996, DNA CELL BIOL, V15, P31, DOI 10.1089/dna.1996.15.31; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Jorissen RN, 2000, PROTEIN SCI, V9, P310; Kita Y, 1996, BIOCHEM BIOPH RES CO, V226, P59, DOI 10.1006/bbrc.1996.1311; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Landgraf R, 1998, BIOCHEMISTRY-US, V37, P3220, DOI 10.1021/bi972326z; Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; NAKAE J, 1995, J BIOL CHEM, V270, P22017, DOI 10.1074/jbc.270.37.22017; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WU DG, 1989, J BIOL CHEM, V264, P17469; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	46	33	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44266	44274		10.1074/jbc.M105428200	http://dx.doi.org/10.1074/jbc.M105428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11555649	hybrid			2022-12-25	WOS:000172297700099
J	Mao, YW; Xiang, H; Wang, J; Korsmeyer, S; Reddan, J; Li, DWC				Mao, YW; Xiang, H; Wang, J; Korsmeyer, S; Reddan, J; Li, DWC			Human bcl-2 gene attenuates the ability of rabbit lens epithelial cells against H2O2-induced apoptosis through down-regulation of the alpha B-crystallin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CAMPTOTHECIN-INDUCED APOPTOSIS; A-CRYSTALLIN; FIBER DIFFERENTIATION; NUCLEOTIDE-SEQUENCE; OXIDATIVE DAMAGE; DEATH; EXPRESSION; PROTEIN; INHIBITION	It is well established that the proto-oncogene, bcl-2, can prevent apoptosis induced by a variety of factors. Regarding the mechanism by which BCL-2 prevents cell death, one theory suggests that it acts by protecting cells from oxidative stress. In the lens system, oxidative stress-induced apoptosis is implicated in cataractogenesis. To explore the possibility of anti-apoptotic gene therapy development for cataract prevention and also to further test the anti-oxidative stress theory of BCL-2 action, we have introduced the human bcl-2 gene into an immortalized rabbit lens epithelial cell line, N/N1003A. The stable expression clones of both vector- and bcl-2-transfected cells have been established. Treatment of the two cell lines With H2O2 revealed that bcl-2-transfected cells were less capable of detoxifying H2O2 than the control cells. Moreover, bcl-2-transfected cells are more susceptible to H2O2-induced apoptosis. To explore why bcl-2-transfected cells have reduced resistance to H2O2-induced apoptosis, we examined the expression patterns of several relevant genes and found that expression of the alphaB-crystallin gene was distinctly downregulated in bcl-2-transfected cells compared with that in vector-transfected cells. This down-regulation was specific because a substantial inhibition of BCL-2 expression through antisense bcl-2 RNA significantly restored the level of alphaB-crystallin and, moreover, enhanced the ability of the bcl-2-transfected cells against H2O2-induced apoptosis. Introduction of a mouse alphaB-crystallin gene into bcl-2-transfected cells also counteracted the BCL-2 effects. Down-regulation of alphaB-crystallin gene was largely derived from changed lens epithelial cell-derived growth factor activity. Besides, alphaB-crystallin prevents apoptosis through interaction with procaspase-3 and partially processed procaspase-3 to prevent caspase-3 activation. Together, our results reveal that BCL-2 can regulate gene expression in rabbit lens epithelial cells. Through down-regulation of the alphaB-crystallin gene, BCL-2 attenuates the ability of rabbit lens epithelial cells against H2O2-induced apoptosis.	Univ Med & Dent New Jersey, Sch Osteopath Med, Ctr Sci, Dept Mol Biol, Stratford, NJ 08084 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oakland University	Li, DWC (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Ctr Sci, Dept Mol Biol, Rm 347,2 Med Ctr Dr, Stratford, NJ 08084 USA.			Mao, Yingwei/0000-0001-7339-1565; xiang, hua/0000-0003-0369-1225	NATIONAL EYE INSTITUTE [R29EY011372] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; Andersson M, 2000, INVEST OPHTH VIS SCI, V41, P2623; Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; DUBIN RA, 1991, MOL CELL BIOL, V9, P4340; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Feng LX, 1999, J CELL BIOCHEM, V74, P576, DOI 10.1002/(SICI)1097-4644(19990915)74:4<576::AID-JCB7>3.0.CO;2-N; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Furuya Y, 1996, CLIN CANCER RES, V2, P389; GIBLIN FJ, 1987, EXP EYE RES, V45, P77, DOI 10.1016/S0014-4835(87)80080-5; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; Hochman A, 2000, CELL MOL BIOL, V46, P41; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KORSMEYER SJ, 1992, BLOOD, V80, P879; Krausz E, 1996, INVEST OPHTH VIS SCI, V37, P2120; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; LI DWC, 1995, J CELL BIOL, V130, P169; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li WC, 1996, FREE RADICAL BIO MED, V20, P301, DOI 10.1016/0891-5849(96)02050-3; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1992, CANCER RES, V52, P5407; NIESON DA, 1983, P NATL ACAD SCI USA, V80, P5198; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; REED JC, 1992, LAB INVEST, V67, P443; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740; SARAFIAN TA, 1994, TOXICOL LETT, V74, P149, DOI 10.1016/0378-4274(94)90093-0; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; Smith J.A., 2000, CURRENT PROTOCOLS MO; Spector A, 1996, EXP EYE RES, V62, P521, DOI 10.1006/exer.1996.0063; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; WALTON MI, 1993, CANCER RES, V53, P1853; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; ZIGLER JS, 1989, FREE RADICAL BIO MED, V7, P499	72	95	99	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43435	43445		10.1074/jbc.M102195200	http://dx.doi.org/10.1074/jbc.M102195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11546795	hybrid			2022-12-25	WOS:000172169300104
J	Abbott, DW; Ivanova, VS; Wang, XY; Bonner, WM; Ausio, J				Abbott, DW; Ivanova, VS; Wang, XY; Bonner, WM; Ausio, J			Characterization of the stability and folding of H2A.Z chromatin particles - Implications for transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; TETRAHYMENA-THERMOPHILA; HISTONE H2A.Z; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; IONIC STRENGTHS; VARIANT; DNA	H2A.Z and H2A.1 nucleosome core particles and oligonucleosome arrays were obtained using recombinant versions of these histones and a native histone H2B/H3/H4 complement reconstituted onto appropriate DNA templates. Analysis of the reconstituted nucleosome core particles using native polyacrylamide gel electrophoresis and DNase I footprinting showed that H2A.Z nucleosome core particles were almost structurally indistinguishable from its H2A.1 or native chicken erythrocyte counterparts. While this result is in good agreement with the recently published crystallographic structure of the H2A.Z nucleosome core particle (Suto, R. K., Clarkson, M J., Tremethick, D. J., and Luger, YL (2000) Nat. Struct. Biol. 7,1121-1124), the ionic strength dependence of the sedimentation coefficient of these particles exhibits a substantial destabilization, which is most likely the result of the histone H2A.Z-H213 dimer binding less tightly to the nucleosome. Analytical ultracentrifuge analysis of the H2A.Z 208-12, a DNA template consisting of 12 tandem repeats of a 208-base pair sequence derived from the sea urchin Lytechinus variegatus 5 S rRNA gene, reconstituted oligonucleosome complexes in the absence of histone HI shows that their NaCl-dependent folding ability is significantly reduced. These results support the notion that the histone H2A.Z variant may play a chromatin-destabilizing role, which may be important for transcriptional activation.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	University of Victoria; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055,Petch Bldg,220, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca						Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; ALLIS CD, 1982, CELL, V31, P131, DOI 10.1016/0092-8674(82)90412-3; ALLIS CD, 1980, CELL, V20, P609, DOI 10.1016/0092-8674(80)90307-4; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Ausio J, 1998, METHODS, V15, P333, DOI 10.1006/meth.1998.0637; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; COTTON RW, 1981, NUCLEIC ACIDS RES, V9, P445, DOI 10.1093/nar/9.2.445; Dhillon N, 2000, MOL CELL, V6, P769, DOI 10.1016/S1097-2765(00)00076-9; DONG F, 1990, BIOCHEMISTRY-US, V29, P10710, DOI 10.1021/bi00499a020; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; EICKBUSH TH, 1976, CELL, V9, P785, DOI 10.1016/0092-8674(76)90141-0; EICKBUSH TH, 1988, J BIOL CHEM, V263, P18972; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GREULICH KO, 1985, J MOL BIOL, V186, P167, DOI 10.1016/0022-2836(85)90266-9; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HATCH CL, 1988, NUCLEIC ACIDS RES, V16, P1113, DOI 10.1093/nar/16.3.1113; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; HURLEY CK, 1977, ANAL BIOCHEM, V80, P624, DOI 10.1016/0003-2697(77)90687-X; Jackson JD, 1996, TRENDS BIOCHEM SCI, V21, P466, DOI 10.1016/S0968-0004(96)20028-3; Jackson JD, 2000, NUCLEIC ACIDS RES, V28, P3811, DOI 10.1093/nar/28.19.3811; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leach TJ, 2000, J BIOL CHEM, V275, P23267, DOI 10.1074/jbc.M910206199; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; PEHRSON JR, 1992, SCIENCE, V257, P1398; READ CM, 1985, BIOCHEMISTRY-US, V24, P4435, DOI 10.1021/bi00337a027; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; STARGELL LA, 1993, GENE DEV, V7, P2641, DOI 10.1101/gad.7.12b.2641; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; VANDAAL A, 1988, NUCLEIC ACIDS RES, V16, P7487, DOI 10.1093/nar/16.15.7487; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; WENKERT D, 1984, J CELL BIOL, V98, P2107, DOI 10.1083/jcb.98.6.2107; Widom J, 1999, METH MOL B, V119, P61; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; YAGER TD, 1984, J BIOL CHEM, V259, P4212	57	119	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41945	41949		10.1074/jbc.M108217200	http://dx.doi.org/10.1074/jbc.M108217200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551971	hybrid			2022-12-25	WOS:000172450400054
J	Casula, S; Shmukler, BE; Wilhelm, S; Stuart-Tilley, AK; Su, WF; Chernova, MN; Brugnara, C; Alper, SL				Casula, S; Shmukler, BE; Wilhelm, S; Stuart-Tilley, AK; Su, WF; Chernova, MN; Brugnara, C; Alper, SL			A dominant negative mutant of the KCC1K-Cl cotransporter - Both N- and C-terminal cytoplasmic domains are required for K-Cl cotransport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL DISEASE; FUNCTIONAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; ERYTHROCYTE DEHYDRATION; NA-K-2CL COTRANSPORTER; CARBOXY-TERMINUS; XENOPUS OOCYTES; CLONING; EXPRESSION; ISOFORMS	K-Cl cotransport regulates cell volume and chloride equilibrium potential. Inhibition of erythroid K-Cl cotransport has emerged as an important adjunct strategy for the treatment of sickle cell anemia. However, structure-function relationships among the polypeptide products of the four K-Cl cotransporter (KCC) genes are little understood. We have investigated the importance of the N- and C-terminal cytoplasmic domains of mouse KCC1 to its K-Cl cotransport function expressed in Xenopus oocytes. Truncation of as few as eight C-terminal amino acids (aa) abolished function despite continued polypeptide accumulation and surface expression. These C-terminal loss-of-function mutants lacked a dominant negative phenotype. Truncation of the N-terminal 46 aa diminished function. Removal of 89 or 117 aa (Delta (N)117) abolished function despite continued polypeptide accumulation and surface expression and exhibited dominant negative phenotypes that required the presence of the C-terminal cytoplasmic domain. The dominant negative loss-of-function mutant Delta (N)117 was co-immunoprecipitated with wild type KCC1 polypeptide, and its co-expression did not reduce wild type KCC1 at the oocyte surface. Delta (N)117 also exhibited dominant negative inhibition of human KCC1 and KCC3 and, with lower potency, mouse KCC4 and rat KCC2.	Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Alper, SL (corresponding author), Beth Israel Deaconess Med Ctr, Mol Med Unit, RW763 East Campus,330 Brookline Ave, Boston, MA 02215 USA.	salper@caregroup.harvard.edu	Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Casula, Sabina/0000-0003-2817-9295	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009853, P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050422] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL15157, F32-HL09853] Funding Source: Medline; NIDDK NIH HHS [R01-DK50422, DK35854] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bianchi L, 2000, AM J PHYSIOL-HEART C, V279, pH3003, DOI 10.1152/ajpheart.2000.279.6.H3003; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; Brugnara C, 1995, Ann N Y Acad Sci, V763, P262, DOI 10.1111/j.1749-6632.1995.tb32411.x; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; DeFranceschi L, 1997, J CLIN INVEST, V100, P1847, DOI 10.1172/JCI119713; Gard DL, 1999, MICROSC RES TECHNIQ, V44, P388; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Holtzman EJ, 1998, AM J PHYSIOL-RENAL, V275, pF550, DOI 10.1152/ajprenal.1998.275.4.F550; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Lauf PK, 2001, CELL PHYSIOL BIOCHEM, V11, P143, DOI 10.1159/000047802; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Mercado A, 2001, AM J PHYSIOL-CELL PH, V281, pC670, DOI 10.1152/ajpcell.2001.281.2.C670; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Monroy A, 2000, AM J PHYSIOL-RENAL, V279, pF161, DOI 10.1152/ajprenal.2000.279.1.F161; Moore-Hoon ML, 2000, BIOCHEMISTRY-US, V39, P3718, DOI 10.1021/bi992301v; Mount DB, 1999, AM J PHYSIOL-RENAL, V276, pF347, DOI 10.1152/ajprenal.1999.276.3.F347; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Pellegrino CM, 1998, BLOOD CELL MOL DIS, V24, P31, DOI 10.1006/bcmd.1998.0168; Plata C, 1999, AM J PHYSIOL-RENAL, V276, pF359, DOI 10.1152/ajprenal.1999.276.3.F359; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Sangan P, 2000, J BIOL CHEM, V275, P30813, DOI 10.1074/jbc.M003931200; Sanguinetti MC, 1999, ANN NY ACAD SCI, V868, P406, DOI 10.1111/j.1749-6632.1999.tb11302.x; Shmukler BE, 2000, BBA-GENE STRUCT EXPR, V1492, P353, DOI 10.1016/S0167-4781(00)00118-4; Strange K, 2000, AM J PHYSIOL-CELL PH, V279, pC860, DOI 10.1152/ajpcell.2000.279.3.C860; Su WF, 1999, AM J PHYSIOL-CELL PH, V277, pC899, DOI 10.1152/ajpcell.1999.277.5.C899	36	89	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41870	41878		10.1074/jbc.M107155200	http://dx.doi.org/10.1074/jbc.M107155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551954	hybrid, Green Published			2022-12-25	WOS:000172450400045
J	Iancu, CV; Borza, T; Choe, JY; Fromm, HJ; Honzatko, RB				Iancu, CV; Borza, T; Choe, JY; Fromm, HJ; Honzatko, RB			Recombinant mouse muscle adenylosuccinate synthetase - Overexpression, kinetics, and crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; BINDING; PURIFICATION; HYDANTOCIDIN; RESIDUES; TARGET; GDP	Vertebrates possess two isozymes of adenylosuccinate synthetase. The acidic isozyme is similar to the synthetase from bacteria and plants, being involved in the de novo biosynthesis of AMP, whereas the basic isozyme participates in the purine nucleotide cycle. Reported here is the first instance of overexpression and crystal structure determination of a basic isozyme of adenylosuccinate synthetase. The recombinant mouse muscle enzyme purified to homogeneity in milligram quantities exhibits a specific activity comparable with that of the rat muscle enzyme isolated from tissue and K-m parameters for GTP, IMP, and L-aspartate (12, 45, and 140 mum, respectively) similar to those of the enzyme from Escherichia coli. The mouse muscle and E. coli enzymes have similar polypeptide folds, differing primarily in the conformation of loops, involved in substrate recognition and stabilization of the transition state. Residues 65-68 of the muscle isozyme adopt a conformation not observed in any previous synthetase structure. In its new conformation, segment 65-68 forms intramolecular hydrogen bonds with residues essential for the recognition of IMP and, in fact, sterically excludes IMP from the active site. Observed differences in ligand recognition among adenylosuccinate synthetases may be due in part to conformational variations in the IMP pocket of the ligand-free enzymes.	Iowa State Univ, DEpt Biochem Biophys & Molec Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, DEpt Biochem Biophys & Molec Biol, Molec Biol Bldg, Ames, IA 50011 USA.	honzatko@iastate.edu	Borza, Tudor/A-8510-2012; Borza, Tudor/M-4937-2019	Borza, Tudor/0000-0002-2527-6551; Borza, Tudor/0000-0002-2527-6551	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASS MB, 1984, J BIOL CHEM, V259, P2330; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe JY, 1999, BIOCHEMISTRY-US, V38, P6953, DOI 10.1021/bi990159s; CLARK SW, 1977, COMP BIOCHEM PHYS B, V58, P63, DOI 10.1016/0305-0491(77)90128-6; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; DONG Q, 1990, J BIOL CHEM, V265, P6235; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fischer H E, 1978, Methods Enzymol, V51, P207; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; GOODMAN MN, 1977, J BIOL CHEM, V252, P5054; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HARADA S, 1979, J MOL BIOL, V132, P729, DOI 10.1016/0022-2836(79)90385-1; Honzatko RB, 1999, ADV ENZYMOL RAMB, V73, P57, DOI 10.1002/9780470123195.ch3; Honzatko RB, 1999, ARCH BIOCHEM BIOPHYS, V370, P1, DOI 10.1006/abbi.1999.1383; Hou ZL, 1999, J BIOL CHEM, V274, P17505, DOI 10.1074/jbc.274.25.17505; KANG C, 1997, BIOL CHEM, V272, P11881; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 1977, ENZFITTER; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOWENSTEIN JM, 1972, PHYSIOL REV, V52, P382, DOI 10.1152/physrev.1972.52.2.382; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MANFREDI JP, 1989, AM J PHYSIOL, V257, pC29, DOI 10.1152/ajpcell.1989.257.1.C29; MATSUDA Y, 1977, BIOCHEM BIOPH RES CO, V78, P766, DOI 10.1016/0006-291X(77)90245-5; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MUIRHEAD KM, 1974, J BIOL CHEM, V249, P459; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OGAWA H, 1977, J BIOCHEM, V81, P859, DOI 10.1093/oxfordjournals.jbchem.a131550; OGAWA H, 1978, EUR J BIOCHEM, V85, P331, DOI 10.1111/j.1432-1033.1978.tb12243.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; Prade L, 2000, J MOL BIOL, V296, P569, DOI 10.1006/jmbi.1999.3473; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; SPECTOR T, 1984, BIOCHEM PHARMACOL, V33, P1611, DOI 10.1016/0006-2952(84)90282-X; SPECTOR T, 1976, BIOCHIM BIOPHYS ACTA, V445, P509, DOI 10.1016/0005-2744(76)90104-2; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Wang WY, 1997, J BIOL CHEM, V272, P7078, DOI 10.1074/jbc.272.11.7078; Wang WY, 1997, J BIOL CHEM, V272, P16911, DOI 10.1074/jbc.272.27.16911; Wang WY, 1998, J BIOL CHEM, V273, P16000, DOI 10.1074/jbc.273.26.16000; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	47	15	17	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42146	42152		10.1074/jbc.M106294200	http://dx.doi.org/10.1074/jbc.M106294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11560929	hybrid			2022-12-25	WOS:000172450400082
J	Yu, ST; Cao, WQ; Kashireddy, P; Meyer, K; Jia, YZ; Hughes, DE; Tan, YJ; Feng, JC; Yeldandi, AV; Rao, MS; Costa, RH; Gonzalez, FJ; Reddy, JK				Yu, ST; Cao, WQ; Kashireddy, P; Meyer, K; Jia, YZ; Hughes, DE; Tan, YJ; Feng, JC; Yeldandi, AV; Rao, MS; Costa, RH; Gonzalez, FJ; Reddy, JK			Human peroxisome proliferator-activated receptor alpha (PPAR alpha) supports the induction of peroxisome proliferation in PPAR alpha-deficient mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; ACID BETA-OXIDATION; FUNCTIONAL-CHARACTERIZATION; TISSUE DISTRIBUTION; MICE LACKING; CDNA CLONING; GENE; EXPRESSION; RAT; IDENTIFICATION	Peroxisome proliferators, which function as peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, induce peroxisomal, microsomal, and mitochondrial fatty acid oxidation enzymes, in conjunction with peroxisome proliferation, in liver cells. Sustained activation of PPAR alpha leads to the development of liver tumors in rats and mice. The assertion that synthetic PPAR alpha ligands pose negligible carcinogenic risk to humans is attributable, in part, to the failure to observe peroxisome proliferation in human hepatocytes. To explore the mechanism(s) of species-specific differences in response to PPAR alpha ligands, we determined the functional competency of human PPAR alpha in vivo and compared its potency with that of mouse PPAR alpha. Recombinant adenovirus that expresses human or mouse PPAR alpha was produced and administered intravenously to PPAR alpha -deficient mice. Human as well as mouse PPAR alpha fully restored the development of peroxisome proliferator-induced immediate pleiotropic responses, including peroxisome proliferation and enhanced expression of genes involved in lipid metabolism as well as nonperoxisomal genes, such as CD36, Ly-6D, Rbp7, monoglyceride lipase, pyruvate dehydrogenase kinase-4, and CV, that have been identified recently to be up-regulated in livers with peroxisome proliferation. These studies establish that human PPAR alpha is functionally competent and is equally as dose-sensitive as mouse PPAR alpha in inducing peroxisome proliferation within the context of mouse liver environment and that it can heterodimerize with mouse retinoid X receptor, and this human PPAR alpha -mouse retinoid X receptor chimeric heterodimer transcriptionally activates mouse PPAR alpha target genes in a manner qualitatively similar to that of mouse PPAR alpha.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER; NCI NIH HHS [CA84472] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansari-Lari MA, 1998, GENOME RES, V8, P29; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; ASHBY J, 1994, HUM EXP TOXICOL, V13, pS1, DOI 10.1177/096032719401300201; Cherkaoui-Malki M, 2001, GENE EXPRESSION, V9, P291, DOI 10.3727/000000001783992533; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; Cook WS, 2000, BIOCHEM BIOPH RES CO, V278, P250, DOI 10.1006/bbrc.2000.3739; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Dandri M, 2001, HEPATOLOGY, V33, P981, DOI 10.1053/jhep.2001.23314; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Elcombe CR, 1996, ANN NY ACAD SCI, V804, P628, DOI 10.1111/j.1749-6632.1996.tb18649.x; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; Karlsson M, 1997, J BIOL CHEM, V272, P27218, DOI 10.1074/jbc.272.43.27218; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; LEE SST, 1995, MOL CELL BIOL, V15, P3012; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MOODY DE, 1985, TOXICOL APPL PHARM, V78, P351, DOI 10.1016/0041-008X(85)90240-6; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NEMALI MR, 1988, CANCER RES, V48, P5316; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; QI C, 1999, CELL BIOCH BIOPHYS, V31, P1; RAO MS, 1987, CARCINOGENESIS, V8, P631; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1979, CANCER RES, V39, P152; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Sapone A, 2000, PHARMACOGENETICS, V10, P321, DOI 10.1097/00008571-200006000-00006; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Witz IP, 2000, J CELL BIOCHEM, P61; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1	49	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42485	42491		10.1074/jbc.M106480200	http://dx.doi.org/10.1074/jbc.M106480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551940	hybrid			2022-12-25	WOS:000172450400121
J	Bittner, F; Oreb, M; Mendel, RR				Bittner, F; Oreb, M; Mendel, RR			ABA3 is a molybdenum cofactor sulfurase required for activation of aldehyde oxidase and xanthine dehydrogenase in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; MUTANTS; GENES; MUTATION; NIFS	The xanthine oxidase class of molybdenum enyzmes requires a terminal sulfur ligand at the active site. It has been proposed that a special sulfurase catalyzes the insertion of this ligand thereby activating the enzymes. Previous analyses of mutants in plants indicated that the genetic locus aba3 is involved in this step leading to activation of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase. Here we report the cloning of the aba3 gene from Arabidopsis thaliana and the biochemical characterization of the purified protein. ABA3 is a two-domain protein with a N-terminal NifS-like sulfurase domain and a C-terminal domain that might be involved in recognizing the target enzymes. Molecular analysis of three aba3 mutants identified mutations in both domains. ABA3 contains highly conserved binding motifs for pyridoxal phosphate and for a persulfide. The purified recombinant protein possesses a cysteine desulfurase activity, is yellow in color, and shows a NifS-like change in absorbance in the presence of L-cysteine. Pretreatment of ABA3 with a thiol-specific alkylating reagent inhibited its desulfurase activity. These data indicate a transsulfuration reaction similar to bacterial NifS. In a fully defined in vitro system, the purified protein was able to activate aldehyde oxidase by using L-cysteine as sulfur donor. Finally, we show that the expression of the aba3 gene is inducible by drought-stress.	Tech Univ Braunschweig, Bot Inst, D-38023 Braunschweig, Germany	Braunschweig University of Technology	Mendel, RR (corresponding author), Tech Univ Braunschweig, Bot Inst, D-38023 Braunschweig, Germany.	R.Mendel@tu-bs.de		Oreb, Mislav/0000-0002-6118-1517				Akaba S, 1999, J BIOCHEM-TOKYO, V126, P395, DOI 10.1093/oxfordjournals.jbchem.a022463; Amrani L, 2000, MOL MICROBIOL, V38, P114, DOI 10.1046/j.1365-2958.2000.02119.x; FINNERTY V, 1976, GENET BIOL DROSOPHIL, P721; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Ichida K, 2001, BIOCHEM BIOPH RES CO, V282, P1194, DOI 10.1006/bbrc.2001.4719; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Koiwai H, 2000, J BIOCHEM-TOKYO, V127, P659, DOI 10.1093/oxfordjournals.jbchem.a022654; Koshiba T, 1996, PLANT PHYSIOL, V110, P781, DOI 10.1104/pp.110.3.781; LEYDECKER MT, 1995, PLANT PHYSIOL, V107, P1427, DOI 10.1104/pp.107.4.1427; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Marin E, 1997, PLANT PHYSIOL BIOCH, V35, P369; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheible WR, 1997, PLANTA, V203, P304, DOI 10.1007/s004250050196; Schwartz SH, 1997, PLANT PHYSIOL, V114, P161, DOI 10.1104/pp.114.1.161; Sekimoto H, 1998, PLANT CELL PHYSIOL, V39, P433, DOI 10.1093/oxfordjournals.pcp.a029387; Seo M, 2000, P NATL ACAD SCI USA, V97, P12908, DOI 10.1073/pnas.220426197; Seo M, 2000, PLANT J, V23, P481, DOI 10.1046/j.1365-313x.2000.00812.x; WAHL RC, 1982, J BIOL CHEM, V257, P3958; Watanabe T, 2000, J BIOL CHEM, V275, P21789, DOI 10.1074/jbc.C000230200; Zeevaart JAD, 1999, N COMP BIOC, V33, P189; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	22	228	244	3	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40381	40384		10.1074/jbc.C100472200	http://dx.doi.org/10.1074/jbc.C100472200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11553608	hybrid			2022-12-25	WOS:000171925600004
J	Kurihara, N; Menaa, C; Maeda, H; Haile, DJ; Reddy, SV				Kurihara, N; Menaa, C; Maeda, H; Haile, DJ; Reddy, SV			Osteoclast-stimulating factor interacts with the spinal muscular atrophy gene product to stimulate osteoclast formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL MOTOR-NEURON; BONE; PROTEIN; SMN; IDENTIFICATION; DIFFERENTIATION; MOUSE; OSTEOPETROSIS; EXPRESSION; HOMOLOGY	We have recently identified and cloned an intracellular peptide termed osteoclast-stimulating factor (OSF) that increases osteoclast (OCL) formation and bone resorption through a cellular signal transduction cascade, possibly through its interaction with c-Src or related family members. To further identify participants in the OSF signaling cascade, we used yeast two-hybrid screening with Saccharomyces cerevisiae, and we found that the 40-kDa spinal muscular atrophy disease-determining gene product, survival motor neuron (SMN), interacts with the OSF-Src homology 3 domain. Reverse transcription-polymerase chain reaction analysis of SMN mRNA expression in cells of the OCL lineage demonstrates that expression of the exon 7 splice variant of SMN is restricted to mature OCLs, whereas the unspliced transcript was expressed in OCL precursors as well as mature OCLs. Treatment of murine bone marrow cultures with conditioned media (5% (v/v)) from 293 cells transiently expressing the SMN cDNA significantly increased OCL formation, compared with treatment with conditioned media from mock-transfected cells. Furthermore, OCL-stimulatory activity by OSF or SMN was abolished by antisense constructs to SMN or OSF, respectively. These data confirm the participation of SMN in the OSF-enhanced expression of an OCL stimulator. OSF-SMN interaction may provide more insights into novel cellular signaling mechanisms that may play an important role in congenital bone fractures associated with type I spinal muscular atrophy disease.	Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Reddy, SV (corresponding author), Univ Pittsburgh, Div Hematol Oncol, 3500 5th Ave,Suite 206, Pittsburgh, PA 15213 USA.	reddysv@msx.upmc.edu			NIDCR NIH HHS [DE 12603] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012603] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bergin A, 1997, GENE, V204, P47, DOI 10.1016/S0378-1119(97)00510-6; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Choi SJ, 1998, J CLIN INVEST, V102, P1360, DOI 10.1172/JCI2667; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HORTON MA, 1985, CANCER RES, V45, P5663; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Kelly TE, 1999, AM J MED GENET, V87, P65, DOI 10.1002/(SICI)1096-8628(19991105)87:1<65::AID-AJMG13>3.0.CO;2-5; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; KURIHARA N, 1990, ENDOCRINOLOGY, V127, P3215, DOI 10.1210/endo-127-6-3215; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097-4652(199812)177:4<636::AID-JCP14>3.3.CO;2-8; Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Schaub R, 2000, CYTOGENET CELL GENET, V88, P87, DOI 10.1159/000015492; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X	33	37	41	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41035	41039		10.1074/jbc.M100233200	http://dx.doi.org/10.1074/jbc.M100233200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11551898	hybrid			2022-12-25	WOS:000171925600089
J	Zhang, WH; Srihari, R; Day, RN; Schaufele, F				Zhang, WH; Srihari, R; Day, RN; Schaufele, F			CCAAT/enhancer-binding protein alpha alters histone H3 acetylation at large subnuclear domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; CENTROMERIC HETEROCHROMATIN; CHROMATIN STRUCTURE; MAMMALIAN-CELLS; TRANSCRIPTION; ORGANIZATION; LOCALIZATION; ACTIVATION; GENES; SUFFICIENT	Transcriptional regulation is commonly associated with local levels of histone acetylation, which controls chromatin structure at specific genes or within contiguous chromosomal domains. Less well understood are the higher order determinants of histone acetylation. The transcription factor, CCAAT/enhancer-binding protein alpha (C/EBP alpha), concentrates at one higher order structure, the peri-centromeric chromatin, and regulates differentiation in many cell types, including pituitary cells. We used quantitative fluorescence microscopy to show that immunostained acetylated histone H3 is relatively absent from peri-centromeric domains visible as large structures in mouse pituitary progenitor GHFT1-5 cells. GHFT1-5 cells do not contain C/EBP alpha. We observed that expression of C/EBP alpha in GHFT1-5 cells leads to an increased level of acetylated historic H3, but not acetylated historic H4, at the peri-centromeric domains. Only transcriptionally active forms of C/EBP alpha altered histone acetylation at the peri-centromeric domain. The altered state of histone acetylation at large intranuclear domains may complement, counteract, or supercede the more gene-local activities of other transcription factors to coordinate C/EBP alpha -induced cellular differentiation.	Univ Calif San Francisco, Diabet Ctr, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Natl Sci Fdn Ctr Biol Timing, Charlottesville, VA 22908 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia	Schaufele, F (corresponding author), Univ Calif San Francisco, Diabet Ctr, Metab Res Unit, San Francisco, CA 94143 USA.				NIDDK NIH HHS [R01 DK054345-02, DK54345] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; EARNSHAW WC, 1991, COLD SH Q B, V56, P675; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; He D, 1996, J CELL SCI, V109, P2693; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hendzel MJ, 2001, J STEROID BIOCHEM, V76, P9, DOI 10.1016/S0960-0760(00)00153-9; Jacob KK, 1999, ENDOCRINOLOGY, V140, P4542, DOI 10.1210/en.140.10.4542; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schubeler D, 2000, GENE DEV, V14, P940; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	32	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40373	40376		10.1074/jbc.C100505200	http://dx.doi.org/10.1074/jbc.C100505200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11568179	hybrid			2022-12-25	WOS:000171925600002
J	Hodge, DR; Xiao, WH; Clausen, PA; Heidecker, G; Szyf, M; Farrar, WL				Hodge, DR; Xiao, WH; Clausen, PA; Heidecker, G; Szyf, M; Farrar, WL			Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; BINDING PROTEIN; METHYLATED DNA; EXPRESSION; PROMOTER; IL-6; 5-METHYLCYTOSINE; DIFFERENTIATION; INDUCTION; TISSUES	Methylation of mammalian DNA by the DNA methyltransferase enzyme (dnmt-1) at CpG dinucleotide sequences has been recognized as an important epigenetic control mechanism in regulating the expression of cellular genes (Yen, R. W., Vertino, P. M., Nelkin, B. D., Yu, J. J., el-Deiry, W., Cumaraswamy, A., Lennon, G. G., Trask, B. J., Celano, P., and Baylin, S. B. (1992) Nucleic Acids Res. 20, 2287-2291; Ramehandani, S., Bigey, P., and Szyf, M. (1998) Biol. Chem. 379, 535-5401). Here we show that interleukin (IL)-6 regulates the methyltransferase promoter and resulting enzyme activity, which requires transcriptional activation by the Fli-1 transcription factor (Spyropoulos, D. D., Pharr, P. N., Lavenburg, K. R., Jackers, P., Papas, T. S., Ogawa, M., and Watson, D. K. (1998) Mol. Cell. Biol. 15, 5643-5652). The data suggest that inflammatory cytokines such as IL-6 may exert many epigenetic changes in cells via the regulation of the methyltransferase gene. Furthermore, IL-6 regulation of transcription factors like Fli-1, which can help to direct cells along opposing differentiation pathways, may in fact be reflected in part by their ability to regulate the methylation of cellular genes.	NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick,NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Cytokine Mol Mechanisms Sect, NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, NIH, Frederick, MD 21702 USA; Invitrogen Corp, Gaithersburg, MD 20852 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Leukocyte Biol, NIH, Frederick, MD 21702 USA; McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Thermo Fisher Scientific; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; McGill University	Hodge, DR (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick,NIH, Frederick, MD 21702 USA.		Xiao, Weihua/N-2775-2013	Xiao, Weihua/0000-0001-9102-6326	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; Belinsky SA, 1995, TOXICOL LETT, V82-3, P335, DOI 10.1016/0378-4274(95)03486-2; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Chung TDK, 1999, PROSTATE, V38, P199; De Marzo AM, 1999, CANCER RES, V59, P3855; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; Ferry AE, 1997, J BIOL CHEM, V272, P20030, DOI 10.1074/jbc.272.32.20030; GOLDBERG DM, 1993, CLIN CHEM, V39, P2360; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Malik K, 2000, BRIT J CANCER, V83, P1583, DOI 10.1054/bjoc.2000.1549; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NAVARRO S, 1991, EXP HEMATOL, V19, P11; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; PETRANGELI E, 1995, BRIT J CANCER, V72, P973, DOI 10.1038/bjc.1995.444; Ramchandani S, 1998, BIOL CHEM, V379, P535; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; SPYROPOULOS DD, 1998, MOL CELL BIOL, V15, P5643; Stirzaker C, 1997, CANCER RES, V57, P2229; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TILG H, 1994, BLOOD, V83, P113; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; VOGEL MC, 1988, FEBS LETT, V236, P9, DOI 10.1016/0014-5793(88)80275-8; Wierzbowska A, 1999, BRIT J HAEMATOL, V105, P412, DOI 10.1046/j.1365-2141.1999.01350.x; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	33	132	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39508	39511		10.1074/jbc.C100343200	http://dx.doi.org/10.1074/jbc.C100343200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11551897	hybrid			2022-12-25	WOS:000171789200003
J	Tian, XJ; Feig, LA				Tian, XJ; Feig, LA			Basis for signaling specificity difference between Sos and Ras-GRF guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-RAS; INTEGRIN ACTIVATION; CATALYTIC DOMAIN; PROTEIN; IDENTIFICATION; RESIDUES; RAS-GRF1/CDC25(MM); PHOSPHORYLATION; P21RAS; M-RAS/R-RAS3	Sos and Ras-GRF are two families of guanine nucleotide exchange factors that activate Ras proteins in cells. Sos proteins are ubiquitously expressed and are activated in response to cell-surface tyrosine kinase stimulation. In contrast, Ras-GRF proteins are expressed primarily in central nervous system neurons and are activated by calcium/calmodulin binding and by phosphorylation. Although both Sos1 and Ras-GRF1 activate the Ras proteins Ha-Ras, N-Ras, and Ki-Ras, only Ras-GRF1 also activates the functionally distinct R-Ras GTPase. In this study, we determined which amino acid sequences in these exchange factors and their target GTPases are responsible for this signaling specificity difference. Analysis of chimeras and individual amino acid exchanges between Sos1 and Ras-GRF1 revealed that the critical amino acids reside within an 11-amino acid segment of their catalytic domains between the second and third structurally conserved regions (amino acids (aa) 828-838 in Sos1 and 1057-1067 in Ras-GRF1) of Ras guanine nucleotide exchange factors. In Sos1, this segment is in helix B, which is known to interact with the switch 2 region of Ha-Ras. Interestingly, a similar analysis of Ha-Ras and R-Ras chimeras did not identify the switch 2 region of Ha-Ras as encoding specificity. Instead, we found a more distal protein segment, helix 3 (aa 91-103 in Ha-Ras and 117-129 in R-Ras), which interacts instead primarily with helix K (aa 1002-1016) of Sos1. These findings suggest that specificity derives from the fact that R-Ras-specific amino acids in the region analogous to Ha-Ras helix 3 prevent a functional interaction with Sos1 indirectly, possibly by preventing an appropriate association of its switch 2 region with helix B of Sos1. Although previous studies have shown that helix B of Sos1 and helix 3 of Ha-Ras are involved in promoting nucleotide exchange on Ras proteins, this study highlights the importance of these regions in establishing signaling specificity.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.							BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; COX AD, 1994, ONCOGENE, V9, P3281; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Gotoh T, 2001, J BIOL CHEM, V276, P38029; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOWE LR, 1993, ONCOGENE, V8, P2583; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MITSOU MY, 1992, EMBO J, V11, P2391; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Nielsen KH, 2001, ONCOGENE, V20, P2091, DOI 10.1038/sj.onc.1204306; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; Self AJ, 2001, J CELL SCI, V114, P1357; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wang BC, 2000, J BIOL CHEM, V275, P5222, DOI 10.1074/jbc.275.7.5222; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	45	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47248	47256		10.1074/jbc.M107407200	http://dx.doi.org/10.1074/jbc.M107407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11560935	hybrid			2022-12-25	WOS:000172768500078
J	Grosshans, H; Lecointe, F; Grosjean, H; Hurt, E; Simos, G				Grosshans, H; Lecointe, F; Grosjean, H; Hurt, E; Simos, G			Pus1p-dependent tRNA pseudouridinylation becomes essential when tRNA biogenesis is compromised in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEAR EXPORT; SYNTHASE PUS1P; SUBSTRATE-SPECIFICITY; NUCLEOPORIN MUTANTS; RIBOSOMAL-RNA; AMINOACYLATION; CLONING; GENES	Yeast Pus1p catalyzes the formation of pseudouridine (psi) at specific sites of several tRNAs, but its function is not essential for cell viability. We show here that Pus1p becomes essential when another tRNA: pseudouridine synthase, Pus4p, or the essential minor tRNA for glutamine are mutated. Strikingly, this mutant tRNA, which carries a mismatch in the T psiC arm, displays a nuclear export defect. Furthermore, nuclear export of at least one wild-type tRNA species becomes defective in the absence of Pus1p. Our data, thus, show that the modifications formed by Pus1p are essential when other aspects of tRNA biogenesis or function are compromised and suggest that impairment of nuclear tRNA export in the absence of Pus1p might contribute to this phenotype.	Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; CNRS, Lab Enzymol & Biochim Struct, UPR, F-91198 Gif Sur Yvette, France	Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Simos, G (corresponding author), Univ Thessaly, Biochem Lab, Sch Med, 22 Papakiriazi Str, Larisa 41222, Greece.		Ed Hurt, Dr./AAE-8874-2019; Grosshans, Helge/W-8931-2019; Simos, George/AAH-2596-2021	Ed Hurt, Dr./0000-0002-4535-8255; Grosshans, Helge/0000-0002-8169-6905; Simos, George/0000-0001-5453-3185; Lecointe, Francois/0000-0002-9596-2514				Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Arluison V, 1999, J MOL BIOL, V289, P491, DOI 10.1006/jmbi.1999.2789; Azad AK, 2001, MOL BIOL CELL, V12, P1381, DOI 10.1091/mbc.12.5.1381; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; BERGES T, 1994, EMBO J, V13, P3136, DOI 10.1002/j.1460-2075.1994.tb06612.x; Bjork Glenn R., 1995, P165; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; Charette M, 2000, IUBMB LIFE, V49, P341; Chen JG, 1999, RNA, V5, P409, DOI 10.1017/S1355838299981591; Chen JG, 2000, BIOCHEM J, V352, P465, DOI 10.1042/0264-6021:3520465; Davis DR., 1998, MODIFICATION EDITING, P85; EDELMAN I, 1991, EMBO J, V10, P1481, DOI 10.1002/j.1460-2075.1991.tb07668.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; Grosjean H, 1997, BIOCHIMIE, V79, P293, DOI 10.1016/S0300-9084(97)83517-1; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; Grosshans H, 2000, GENE DEV, V14, P830; Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hellmuth K, 2000, NUCLEIC ACIDS RES, V28, P4604, DOI 10.1093/nar/28.23.4604; HURT DJ, 1987, MOL CELL BIOL, V7, P1208, DOI 10.1128/MCB.7.3.1208; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; Jiang HQ, 1997, NUCLEIC ACIDS RES, V25, P2694, DOI 10.1093/nar/25.14.2694; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; LIN JP, 1986, GENE, V49, P383, DOI 10.1016/0378-1119(86)90375-6; Lipowsky G, 1999, RNA, V5, P539, DOI 10.1017/S1355838299982134; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Meroueh M, 2000, NUCLEIC ACIDS RES, V28, P2075, DOI 10.1093/nar/28.10.2075; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Murray LE, 1998, P NATL ACAD SCI USA, V95, P8619, DOI 10.1073/pnas.95.15.8619; Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Sambrook J., 2002, MOL CLONING LAB MANU; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Sharma K, 1996, MOL CELL BIOL, V16, P294; SIKORSKI RS, 1989, GENETICS, V122, P19; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WEISS WA, 1987, P NATL ACAD SCI USA, V84, P8031, DOI 10.1073/pnas.84.22.8031; Winkler ME, 1998, MODIFICATION EDITING, P441; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	50	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46333	46339		10.1074/jbc.M107141200	http://dx.doi.org/10.1074/jbc.M107141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571299	hybrid, Green Published			2022-12-25	WOS:000172573100115
J	Litterst, CM; Pfitzner, E				Litterst, CM; Pfitzner, E			Transcriptional activation by STAT6 requires the direct interaction with NCoA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; GERMLINE EPSILON-PROMOTER; CREB-BINDING PROTEIN; NF-KAPPA-B; DNA-BINDING; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; TYROSINE PHOSPHORYLATION; SYNERGISTIC ACTIVATION; INTERFERON ACTIVATION	Signal transducer and activator of transcription 6 (STAT6) is a transcription factor that is activated by interleukin-4 (IL-4)-induced tyrosine phosphorylation and mediates most of the IL-4-induced gene expression. Transcriptional activation by STAT6 requires the interaction with coactivators like p300 and the CREB-binding protein (CBP). In this study we have investigated the function of the CBP-associated members of the p160/ steroid receptor coactivator family in the transcriptional activation by STAT6. We found that only one of them, NCoA-1, acts as a coactivator for STAT6 and interacts directly with the transactivation domain of STAT6. The N-terminal part of NCoA-1 interacts with the far C-terminal part of the STAT6 transactivation domain but does not interact with the other members of the STAT family. This domain of NCoA-1 has a strong inhibitory effect on STAT6-mediated transactivation when overexpressed in cells, illustrating the importance of NCoA-1 for STAT6-mediated transactivation. In addition, we showed that both coactivators CBP and NCoA-1 bind independently to specific regions within the STAT6 transactivation domain. Our results suggest that multiple contacts between NCoA-1, CBP, and STAT6 are required for transcriptional activation. These findings provide new mechanistic insights into how STAT6 can recruit coactivators required for IL-4-dependent transactivation.	Inst Biomed Res, D-60596 Frankfurt, Germany		Pfitzner, E (corresponding author), Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Pfitzner, Edith/AAU-7927-2021	Pfitzner, Edith/0000-0002-3484-9649				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Goenka S, 1999, J IMMUNOL, V163, P4663; Goodman RH, 2000, GENE DEV, V14, P1553; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; LISCHKE A, 1995, EUR J BIOCHEM, V234, P100, DOI 10.1111/j.1432-1033.1995.100_c.x; Lu BF, 1997, J IMMUNOL, V159, P1255; LUNDGREN M, 1994, J IMMUNOL, V153, P2983; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Richards ML, 1997, J IMMUNOL, V158, P263; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Stutz AM, 1999, J IMMUNOL, V163, P4383; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WARREN WD, 1995, J IMMUNOL, V155, P5637; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	64	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45713	45721		10.1074/jbc.M108132200	http://dx.doi.org/10.1074/jbc.M108132200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574547	hybrid			2022-12-25	WOS:000172573100030
J	Bijnens, AP; Gils, A; Stassen, JM; Komissarov, AA; Knockaert, I; Brouwers, E; Shore, JD; Declerck, PJ				Bijnens, AP; Gils, A; Stassen, JM; Komissarov, AA; Knockaert, I; Brouwers, E; Shore, JD; Declerck, PJ			The distal hinge of the reactive site loop and its proximity - A target to modulate plasminogen activator inhibitor-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ACTING INHIBITOR; TISSUE-TYPE; MONOCLONAL-ANTIBODIES; ANTITHROMBIN-III; SERPIN; IDENTIFICATION; TYPE-1; EPITOPE; SUBSTRATE; MECHANISM	The serpin plasminogen activator inhibitor type 1 (PAI-1) plays a regulatory role in various physiological processes (e.g. fibrinolysis and pericellular proteolysis) and forms a potential target for therapeutic interventions. In this study we identified the epitopes of three PAI-1 inhibitory monoclonal antibodies (MA-44E4, MA-42A2F6, and MA-56A7C10). Differential cross-reactivities of these monoclonals with PAI-1 from different species and sequence alignments between these PAI-1s, combined with the three-dimensional structure, revealed several charged residues as possible candidates to contribute to the respective epitopes. The production, characterization, and subsequent evaluation of a variety of alanine mutants using surface plasmon resonance revealed that the residues His(185), Arg(186), and Arg(187) formed the major sites of interaction for MA-44E4. In contrast, the epitopes of MA-42A2F6 and MA-56A7C10 were found to be conformational. The epitope of MA-42A2F6 comprises residues Lys(243) and Glu(350), whereas the epitope of MA-56A7C10 comprises residues Glu(242), Lys(243), Glu(244), Glu(350) Asp(355) and Arg(356). The participation of Glu(350), Asp(355), and Arg(356) provides a molecular explanation for the differential exposure of this epitope in the different conformations of PAI-1 and for the effect of these antibodies on the kinetics of the formation of the initial PAI-1-proteinase complexes. The localization of the epitopes of MA-44E4, MA42A2F6, and MA-56A7C10 elucidates two previously unidentified molecular mechanisms to modulate PAI-1 activity and opens new perspectives for the rational development of PAI-1 neutralizing compounds.	Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Boehringer Ingelheim Pharma KG, Cardiovasc Pharmacol, D-88397 Biberach, Germany; Henry Ford Hlth Ctr, Div Biochem Res, Detroit, MI 48202 USA	KU Leuven; Boehringer Ingelheim; Henry Ford Health System	Declerck, PJ (corresponding author), Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, Van Evenstr 4, B-3000 Louvain, Belgium.	Paul.declerek@farm.kuleuven.ac.be	Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105	NHLBI NIH HHS [HL 54930] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; ASAKURA S, 1990, J BIOL CHEM, V265, P5135; ASAKURA S, 1989, J BIOL CHEM, V264, P13736; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350; Bijnens AP, 2001, THROMB HAEMOSTASIS, V85, P866; Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; Gils A, 1998, THROMB HAEMOSTASIS, V80, P531; Gils A, 1997, FEBS LETT, V415, P192, DOI 10.1016/S0014-5793(97)01122-8; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOESS RH, 1994, J IMMUNOL, V153, P724; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jonsson U., 1992, ADV BIOSENSOR, P291; JUHANVAGUE I, 1995, BAILLIERE CLIN HAEM, V8, P329, DOI 10.1016/S0950-3536(05)80271-9; KEIJER J, 1991, BLOOD, V78, P401; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lijnen HR, 1999, THROMB HAEMOSTASIS, V82, P837; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Muehlenweg B, 2000, THROMB RES, V98, P73, DOI 10.1016/S0049-3848(99)00238-8; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 1997, FIBRINOLYSIS PROTEOL, V11, P37, DOI 10.1016/S0268-9499(97)80007-0; Ngo TH, 2001, J BIOL CHEM, V276, P26243, DOI 10.1074/jbc.M008241200; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; OLSON ST, 1982, J BIOL CHEM, V257, P4891; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PERRIE AM, 1993, FIBRINOLYSIS, V7, P257, DOI 10.1016/0268-9499(93)90134-H; PRINS MH, 1991, ARCH INTERN MED, V151, P1721, DOI 10.1001/archinte.151.9.1721; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Stoop AA, 2000, J MOL BIOL, V301, P1135, DOI 10.1006/jmbi.2000.4035; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; VAGUE IJ, 1987, THROMB HAEMOSTASIS, V58, P1096; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; Vleugels N, 2000, THROMB HAEMOSTASIS, V84, P871, DOI 10.1055/s-0037-1614130; Vleugels N, 1998, FIBRINOLYSIS PROTEOL, V12, P277, DOI 10.1016/S0268-9499(98)80020-9; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wiman B, 1999, SCAND J CLIN LAB INV, V59, P23; Wind T, 2001, EUR J BIOCHEM, V268, P1095, DOI 10.1046/j.1432-1327.2001.2680041095.x	57	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44912	44918		10.1074/jbc.M103077200	http://dx.doi.org/10.1074/jbc.M103077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11559698	hybrid			2022-12-25	WOS:000172406700078
J	Di Fulvio, M; Lauf, PK; Adragna, NC				Di Fulvio, M; Lauf, PK; Adragna, NC			Nitric oxide signaling pathway regulates potassium chloride cotransporter-1 mRNA expression in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SOLUBLE GUANYLATE-CYCLASE; K-CL COTRANSPORTER; MESSENGER-RNA; CYCLIC-GMP; GENE-TRANSCRIPTION; MOLECULAR-CLONING; I-ALPHA; ACTIVATION; TRANSLATION	Rat vascular smooth muscle cells (VSMCs) express at least two mRNAs for K-Cl cotransporters (KCC): KCC1 and KCC3. cGMP-dependent protein kinase I regulates KCC3 mRNA expression in these cells. Here, we show evidence implicating the nitric oxide (NO)/cGMP signaling pathway in the expression of KCC1 mRNA, considered to be the major cell volume regulator. VSMCs, expressing soluble guanylyl cyclase (sGC) and PKG-I isoforms showed a time- and concentration-dependent increase in KCC1 mRNA levels after treatment with sodium nitroprusside as demonstrated by semiquantitative RT-PCR. sGC-dependent regulation of KCC1 mRNA expression was confirmed using YC-1, a NO-independent sGC stimulator. The sGC inhibitor LY83583 blocked the effects of sodium nitroprusside and YC-1. Moreover, 8-Br-cGMP increased KCC1 mRNA expression in a concentration- and time-dependent fashion. The 8-Br-cGMP effect was partially blocked by KT5823 but not by actinomycin D. However, actinomycin D and cycloheximide increased basal KCC1 mRNA in an additive manner, suggesting different mechanisms of action for both drugs. These findings suggest that in VSMCs, the NO/cGMP-signaling pathway participates in KCC1 mRNA regulation at the post-transcriptional level.	Wright State Univ, Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA; Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton	Adragna, NC (corresponding author), Wright State Univ, Sch Med, Dept Pharmacol & Toxicol, Biol Sci Bldg,Rm 152-6,3640 Colonel Glenn Hwy, Dayton, OH 45435 USA.							Adragna NC, 1998, J MEMBRANE BIOL, V166, P157, DOI 10.1007/s002329900457; Adragna NC, 2000, AM J PHYSIOL-CELL PH, V278, pC381, DOI 10.1152/ajpcell.2000.278.2.C381; Adragna NC, 2001, FASEB J, V15, pA114; Andreopoulos S, 2000, GEN PHARMACOL-VASC S, V34, P147, DOI 10.1016/S0306-3623(00)00062-8; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; Budworth J, 1999, BIOCHEM BIOPH RES CO, V263, P696, DOI 10.1006/bbrc.1999.1444; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; Di Fulvio M, 2001, J BIOL CHEM, V276, P21046, DOI 10.1074/jbc.M100901200; Di Fulvio M, 2001, FASEB J, V15, pA114; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Gudi T, 1996, J BIOL CHEM, V271, P4597; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Hofmann F, 2000, J CELL SCI, V113, P1671; Holtzman EJ, 1998, AM J PHYSIOL-RENAL, V275, pF550, DOI 10.1152/ajprenal.1998.275.4.F550; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; JENNINGS ML, 1990, J GEN PHYSIOL, V95, P1021, DOI 10.1085/jgp.95.6.1021; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; Kim SO, 2000, BBA-MOL CELL RES, V1496, P277, DOI 10.1016/S0167-4889(00)00026-4; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Lincoln TM, 1998, ACTA PHYSIOL SCAND, V164, P507, DOI 10.1111/j.1365-201X.1998.tb10700.x; Lincoln TM, 1996, METHOD ENZYMOL, V269, P149; Lucas KA, 2000, PHARMACOL REV, V52, P375; Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PAPAPETROPOULOS A, 1995, HYPERTENSION, V26, P696, DOI 10.1161/01.HYP.26.4.696; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Ruetten H, 1999, CIRC RES, V85, P534, DOI 10.1161/01.RES.85.6.534; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Schwartz DC, 1999, MOL CELL BIOL, V19, P5247; Scott WS, 1998, J SURG RES, V79, P66, DOI 10.1006/jsre.1998.5382; Shen MR, 2000, PFLUG ARCH EUR J PHY, V440, P751, DOI 10.1007/s004240000338; Soff GA, 1997, J CLIN INVEST, V100, P2580, DOI 10.1172/JCI119801; Su WF, 1999, AM J PHYSIOL-CELL PH, V277, pC899, DOI 10.1152/ajpcell.1999.277.5.C899; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	49	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44534	44540		10.1074/jbc.M104899200	http://dx.doi.org/10.1074/jbc.M104899200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11553613	hybrid			2022-12-25	WOS:000172406700027
J	Samejima, K; Tone, S; Earnshaw, WC				Samejima, K; Tone, S; Earnshaw, WC			CAD/DFF40 nuclease is dispensable for high molecular weight DNA cleavage and stage I chromatin condensation in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENTATION FACTOR; TOPOISOMERASE-II; ENDONUCLEASE-G; ACTIVATION; INHIBITOR; CELLS; CAD; DEGRADATION; EXTRACTS; EXCISION	DNA degradation during apoptotic execution generally occurs at two levels: early as high molecular weight (HMW) fragments and later on as oligonucleosomal fragments. Two nucleases, CAD/CPAN/DFF40 and endonuclease G, can digest nuclear chromatin to produce the oligonucleosomal fragments, and it has been suggested that CAD might be responsible for HMW DNA cleavage. To more clearly define the role of CAD in nuclear disassembly, we have generated CAD(-/-) sublines of chicken DT40 cells in which the entire CAD open reading frame has been deleted. These cells grow normally and undergo apoptosis with kinetics essentially identical to wild type cells. However, they fail to undergo detectable oligonucleosomal fragmentation, proving that CAD is essential for this stage of DNA cleavage, at least in DT40 cells. Other aspects of nuclear disassembly, including HMW DNA cleavage and early stage apoptotic chromatin condensation against the nuclear periphery proceed normally in the absence of CAD. However, the final stages of chromatin condensation and nuclear fragmentation do not occur. Our results demonstrate that CAD is required for complete disassembly of the nucleus during apoptosis and reveal the existence of one or more as yet unidentified second factors responsible for HMW DNA cleavage and the early stages of apoptotic chromatin condensation.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Inst Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Kawasaki Med Sch, Dept Biochem, Okayama 7010192, Japan	University of Edinburgh; Kawasaki Medical School	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Inst Cell Biol, Swann Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	bill.earnshaw@ed.ac.uk	Earnshaw, William/AAY-7438-2020; Tone, Shigenobu/L-2694-2019	Earnshaw, William/0000-0002-7191-0621	Wellcome Trust [073915] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEERE HM, 1995, MOL PHARMACOL, V47, P986; Boulares AH, 2001, J BIOL CHEM, V276, P38185; COHEN JJ, 1984, J IMMUNOL, V132, P38; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kawane K, 1999, CELL DEATH DIFFER, V6, P745, DOI 10.1038/sj.cdd.4400547; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; TANABE K, 1991, CANCER RES, V51, P4903; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122	37	88	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45427	45432		10.1074/jbc.M108844200	http://dx.doi.org/10.1074/jbc.M108844200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577114	hybrid			2022-12-25	WOS:000172406700140
J	Gagliardi, D; Perrin, R; Marechal-Drouard, L; Grienenberger, JM; Leaver, CJ				Gagliardi, D; Perrin, R; Marechal-Drouard, L; Grienenberger, JM; Leaver, CJ			Plant mitochondrial polyadenylated mRNAs are degraded by a 3 '- to 5 '-exoribonuclease activity, which proceeds unimpeded by stable secondary structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MESSENGER-RNA; CYTOPLASMIC MALE-STERILITY; PROTEIN COMPLEX; DEGRADATION; SITES; ENDONUCLEASE; SUBUNIT-9; SEQUENCE; PATHWAYS	Recently, we and others have reported that mRNAs may be polyadenylated in plant mitochondria, and that polyadenylation accelerates the degradation rate of mRNAs. To further characterize the molecular mechanisms involved in plant mitochondrial mRNA degradation, we have analyzed the polyadenylation and degradation processes of potato atp9 mRNAs. The overall majority of polyadenylation sites of potato atp9 mRNAs is located at or in the vicinity of their mature 3'-extremities. We show that a 3'- to 5'-exoribonuclease activity is responsible for the preferential degradation of polyadenylated mRNAs as compared with non-polyadenylated mRNAs, and that 20-30 adenosine residues constitute the optimal poly(A) tail size for inducing degradation of RNA substrates in vitro. The addition of as few as seven non-adenosine nucleotides 3' to the poly(A) tail is sufficient to aim st completely inhibit the in vitro degradation of the RNA substrate. Interestingly, the exoribonuclease activity proceeds unimpeded by stable secondary structures present in RNA substrates. From these results, we propose that in plant mitochondria, poly(A) tails added at the 3' ends of mRNAs promote an efficient 3'- to 5'-degradation process.	CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France; Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Oxford	Gagliardi, D (corresponding author), CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.		Gagliardi, Dominique/P-2834-2016; Gagliardi, Dominique/AAS-1783-2021; Drouard, Laurence/D-2385-2010	Gagliardi, Dominique/0000-0002-5871-7544; Gagliardi, Dominique/0000-0002-5871-7544; Drouard, Laurence/0000-0001-6537-524X				Bellaoui M, 1997, EMBO J, V16, P5057, DOI 10.1093/emboj/16.16.5057; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; DELLORTO P, 1993, PLANT SCI, V88, P45, DOI 10.1016/0168-9452(93)90108-C; Dombrowski S, 1997, EMBO J, V16, P5069, DOI 10.1093/emboj/16.16.5069; Drager RG, 1999, PLANT J, V19, P521, DOI 10.1046/j.1365-313X.1999.00546.x; Fey J, 1999, FEBS LETT, V458, P124, DOI 10.1016/S0014-5793(99)01140-0; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; Giege P, 2001, CR ACAD SCI III-VIE, V324, P209, DOI 10.1016/S0764-4469(00)01293-2; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; KALEIKAU EK, 1992, CURR GENET, V22, P463, DOI 10.1007/BF00326411; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; KUNH J, 2001, MOL CELL BIOL, V21, P731; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; LIZAMA L, 1994, FEBS LETT, V349, P243, DOI 10.1016/0014-5793(94)00677-6; Lupold DS, 1999, PLANT CELL, V11, P1565, DOI 10.1105/tpc.11.8.1565; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; Militello KT, 2000, MOL CELL BIOL, V20, P2308, DOI 10.1128/MCB.20.7.2308-2316.2000; MIN JJ, 1993, MOL CELL BIOL, V13, P4167, DOI 10.1128/MCB.13.7.4167; Regnier P, 2000, BIOESSAYS, V22, P235; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; SCHUSTER W, 1986, NUCLEIC ACIDS RES, V14, P5943, DOI 10.1093/nar/14.15.5943; Williams MA, 2000, NUCLEIC ACIDS RES, V28, P4444, DOI 10.1093/nar/28.22.4444	24	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43541	43547		10.1074/jbc.M106601200	http://dx.doi.org/10.1074/jbc.M106601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557765	hybrid			2022-12-25	WOS:000172297700010
J	Louro, RO; Bento, I; Matias, PM; Catarino, T; Baptista, AM; Soares, CM; Carrondo, MA; Turner, DL; Xavier, AV				Louro, RO; Bento, I; Matias, PM; Catarino, T; Baptista, AM; Soares, CM; Carrondo, MA; Turner, DL; Xavier, AV			Conformational component in the coupled transfer of multiple electrons and protons in a monomeric tetraheme cytochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; X-RAY-DIFFRACTION; DESULFURICANS ATCC-27774; ENERGY TRANSDUCTION; ANGSTROM RESOLUTION; STRUCTURAL BASIS; C-OXIDASE; C(3); REDOX; TRANSLOCATION	Cell metabolism relies on energy transduction usually performed by complex membrane-spanning proteins that couple different chemical processes, e.g. electron and proton transfer in proton-pumps. There is great interest in determining at the molecular level the structural details that control these energy transduction events, particularly those involving multiple electrons and protons, because tight control is required to avoid the production of dangerous reactive intermediates. Tetraheme cytochrome c(3) is a small soluble and monomeric protein that performs a central step in the bioenergetic, metabolism of sulfate reducing bacteria, termed "proton-thrusting," linking the oxidation of molecular hydrogen with the reduction of sulfate. The mechanochemical coupling involved in the transfer of multiple electrons and protons in cytochrome c. from Desulfovibrio desulfuricans ATCC 27774 is described using results derived from the microscopic thermodynamic characterization of the redox and acid-base centers involved, crystallographic studies in the oxidized and reduced states of the cytochrome, and theoretical studies of the redox and acid-base transitions. This proton-assisted two-electron step involves very small, localized structural changes that are sufficient to generate the complex network of functional cooperativities leading to energy transduction, while using molecular mechanisms distinct from those established for other Desulfovibrio sp. cytochromes from the same structural family.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, P-2825114 Monte De Caparica, Portugal; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	Universidade Nova de Lisboa; Universidade Nova de Lisboa; University of Southampton	Xavier, AV (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande,6,Apt 127, P-2780156 Oeiras, Portugal.		Soares, Claudio M/E-2675-2012; Baptista, Antonio M./C-7246-2012; Turner, David/B-8267-2009; Bento, Isabel/A-5436-2011; Turner, David L/B-9061-2011; Louro, Ricardo O./AAB-4601-2020; Matias, Pedro M/B-7180-2008; Catarino, Teresa/A-9267-2012	Soares, Claudio M/0000-0003-1154-556X; Baptista, Antonio M./0000-0002-7044-1210; Turner, David L/0000-0002-3754-6459; Louro, Ricardo O./0000-0002-2392-6450; Matias, Pedro M/0000-0001-6170-451X; Catarino, Teresa/0000-0003-3782-4014; Carrondo, Maria Armenia/0000-0002-1261-1162; Bento, Isabel/0000-0003-3801-4929				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baptista AM, 1999, BIOPHYS J, V76, P2978, DOI 10.1016/S0006-3495(99)77452-7; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; Behr J, 1998, BIOCHEMISTRY-US, V37, P7400, DOI 10.1021/bi9731697; BLAIR DF, 1986, BIOPHYS J, V50, P713, DOI 10.1016/S0006-3495(86)83511-1; Brennan L, 2000, J MOL BIOL, V298, P61, DOI 10.1006/jmbi.2000.3652; BRUNGER AT, 1992, XPLORA SYSTEM CRYSTA; Chen KS, 2000, NATURE, V405, P814, DOI 10.1038/35015610; GILSON MK, 1987, J COMPUT CHEM, V9, P327; HIGUCHI Y, 1984, J MOL BIOL, V172, P109, DOI 10.1016/0022-2836(84)90417-0; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Iverson TM, 2001, J BIOL INORG CHEM, V6, P390, DOI 10.1007/s007750100213; KRAB K, 1987, BIOCHIM BIOPHYS ACTA, V895, P25, DOI 10.1016/S0304-4173(87)80015-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Louro RO, 1998, BIOCHEMISTRY-US, V37, P15808, DOI 10.1021/bi981505t; Louro RO, 1997, J BIOL INORG CHEM, V2, P488, DOI 10.1007/s007750050160; Louro RO, 1996, J BIOL INORG CHEM, V1, P34, DOI 10.1007/s007750050020; LOURO RO, 2001, IN PRESS CHEMBIOCHEM; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Martel PJ, 1999, J BIOL INORG CHEM, V4, P73, DOI 10.1007/s007750050291; Matias PM, 1996, PROTEIN SCI, V5, P1342, DOI 10.1002/pro.5560050713; MATIAS PM, 1993, J MOL BIOL, V234, P680, DOI 10.1006/jmbi.1993.1620; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Messias AC, 1998, J MOL BIOL, V281, P719, DOI 10.1006/jmbi.1998.1974; MOORE GR, 1980, BIOCHIM BIOPHYS ACTA, V590, P261, DOI 10.1016/0005-2728(80)90030-4; MORAIS J, 1995, BIOCHEMISTRY-US, V34, P12830, DOI 10.1021/bi00039a044; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAPA S, 1976, BIOCHIM BIOPHYS ACTA, V456, P39, DOI 10.1016/0304-4173(76)90008-2; Pereira MM, 1999, BBA-BIOENERGETICS, V1413, P1, DOI 10.1016/S0005-2728(99)00073-0; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, TURBO FRODO SILICON, P77; Salgueiro CA, 2001, BIOCHEMISTRY-US, V40, P9709, DOI 10.1021/bi010330b; Salgueiro CA, 1997, J BIOL INORG CHEM, V2, P343, DOI 10.1007/s007750050141; Santana M, 2001, J BACTERIOL, V183, P687, DOI 10.1128/JB.183.2.687-699.2001; Simoes P, 1998, INORG CHIM ACTA, V273, P213, DOI 10.1016/S0020-1693(97)06018-0; Soares CM, 1997, J BIOL INORG CHEM, V2, P714, DOI 10.1007/s007750050188; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Turner DL, 1996, EUR J BIOCHEM, V241, P723, DOI 10.1111/j.1432-1033.1996.00723.x; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; Williams RJP, 1999, J SOLID STATE CHEM, V145, P488, DOI 10.1006/jssc.1999.8192; Wyman J, 1968, Q Rev Biophys, V1, P35; XAVIER AV, 2001, EUR J BIOCH S1, V268, pR2	46	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44044	44051		10.1074/jbc.M107136200	http://dx.doi.org/10.1074/jbc.M107136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551953	hybrid			2022-12-25	WOS:000172297700073
J	Reese, J; Das, SK; Paria, BC; Lim, H; Song, H; Matsumoto, H; Knudtson, KL; DuBois, RN; Dey, SK				Reese, J; Das, SK; Paria, BC; Lim, H; Song, H; Matsumoto, H; Knudtson, KL; DuBois, RN; Dey, SK			Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIIMPLANTATION MOUSE UTERUS; BLASTOCYST IMPLANTATION; LUMINAL EPITHELIUM; OVARIAN-STEROIDS; MESSENGER-RNA; CELLS; MICE; RECEPTOR; DIFFERENTIATION; PROGESTERONE	Infertility and spontaneous pregnancy losses are an enduring problem to women's health. The establishment of pregnancy depends on successful implantation, where a complex series of interactions occurs between the heterogeneous cell types of the uterus and blastocyst. Although a number of genes are implicated in embryo-uterine interactions during implantation, genetic evidence suggests that only a small number of them are critical to this process. To obtain a global view and identify novel pathways of implantation, we used a dual screening strategy to analyze the expression of nearly 10,000 mouse genes by microarray analysis. Comparison of implantation and interimplantation sites by a conservative statistical approach revealed 36 up-regulated genes and 27 down-regulated genes at the implantation site. We also compared the uterine gene expression profile of progesterone-treated, delayed implanting mice to that of mice in which delayed implantation was terminated by estrogen. The results show up-regulation of 128 genes and down-regulation of 101 genes after termination of the delayed implantation. A combined analysis of these experiments showed specific up-regulation of 27 genes both at the implantation site and during uterine activation, representing a broad diversity of molecular functions. In contrast, the majority of genes that were decreased in the combined analysis were related to host immunity or the immune response, suggesting the importance of these genes in regulating the uterine environment for the implanting blastocyst. Collectively, we identified genes with recognized roles in implantation, genes with potential roles in this process, and genes whose functions have yet to be defined in this event. The identification of unique genetic markers for the onset of implantation signifies that genome-wide analysis coupled with functional assays is a promising approach to resolve the molecular pathways required for successful implantation.	Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pediat, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Obstet & Gynecol, Kansas City, KS 66160 USA; Univ Iowa, Dept Internal Med, Diabet & Endocrinol Res Ctr, Iowa City, IA 52242 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Gastroenterol, Nashville, TN 37232 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Iowa; Vanderbilt University; Vanderbilt University	Dey, SK (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, MRRC 3017,3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Lim, Hyunjung J/D-5343-2011; DuBois, Raymond N./AAX-8869-2020	Lim, Hyunjung J/0000-0003-2191-666X; Reese, Jeff/0000-0001-8751-6146; Song, Haengseok/0000-0002-5027-7310	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002528] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037394, R01HD012304, U01HD029968, R37HD012304, R03HD037677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK047297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007814] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29968, HD33994, HD37677, HD37394, HD02528, HD12304] Funding Source: Medline; NIDDK NIH HHS [DK47297] Funding Source: Medline; NIEHS NIH HHS [ES07814] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Benson GV, 1996, DEVELOPMENT, V122, P2687; BILLINGTON WD, 1992, BAILLIERE CLIN OB GY, V6, P417, DOI 10.1016/S0950-3552(05)80004-5; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; Choe YS, 1997, MOL REPROD DEV, V48, P261, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;261::AID-MRD14&gt;3.0.CO;2-0; Das SK, 2000, J BIOL CHEM, V275, P28834, DOI 10.1074/jbc.M003827200; Das SK, 1997, DEV BIOL, V190, P178, DOI 10.1006/dbio.1997.8694; Das SK, 1999, J MOL ENDOCRINOL, V22, P91, DOI 10.1677/jme.0.0220091; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; DAS SK, 1994, DEVELOPMENT, V120, P1071; DAYA S, 1986, NEW ENGL J MED, V315, P1551; DEY SK, 1981, J REPROD IMMUNOL, V3, P141, DOI 10.1016/0165-0378(81)90055-3; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; GRUMMER R, 1994, BIOL REPROD, V51, P1109, DOI 10.1095/biolreprod51.6.1109; Head JR, 1996, NAT IMMUN, V15, P7; Jin H, 2001, CIRCULATION, V103, P736; Kim NK, 2001, THROMB RES, V103, P135, DOI 10.1016/S0049-3848(01)00288-2; Kimber SJ, 2000, SEMIN CELL DEV BIOL, V11, P61, DOI 10.1006/scdb.2000.0152; Kumar S, 1998, J CLIN ENDOCR METAB, V83, P4443, DOI 10.1210/jc.83.12.4443; Lim H, 1997, ENDOCRINOLOGY, V138, P4599, DOI 10.1210/en.138.11.4599; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; LIM H, 2001, IN PRESS VITAM HORM; MCMASTER MT, 1992, J IMMUNOL, V148, P1699; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Paria BC, 1999, DEV BIOL, V208, P488, DOI 10.1006/dbio.1999.9206; Paria BC, 2000, SEMIN CELL DEV BIOL, V11, P67, DOI 10.1006/scdb.2000.0153; Paria BC, 1998, ENDOCRINOLOGY, V139, P5235, DOI 10.1210/en.139.12.5235; Paria BC, 1998, ENDOCRINOLOGY, V139, P3958, DOI 10.1210/en.139.9.3958; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Popovici RM, 2000, ENDOCRINOLOGY, V141, P3510, DOI 10.1210/en.141.9.3510; PSYCHOYOS A, 1973, HDB PHYSL, P187; Reese J, 1998, BIOL REPROD, V58, P719, DOI 10.1095/biolreprod58.3.719; SAKOFF JA, 1994, J REPROD FERTIL, V101, P97; Salamonsen LA, 1996, REPROD FERT DEVELOP, V8, P1157, DOI 10.1071/RD9961157; Salamonsen LA, 1999, REV REPROD, V4, P11; Shim C, 1997, MOL REPROD DEV, V48, P176, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;176::AID-MRD5&gt;3.0.CO;2-P; Smith SE, 1997, DEV BIOL, V184, P38, DOI 10.1006/dbio.1997.8521; Song HS, 2000, MOL ENDOCRINOL, V14, P1147, DOI 10.1210/me.14.8.1147; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Suzuki N, 2000, ENDOCRINOLOGY, V141, P4247, DOI 10.1210/en.141.11.4247; Tatsumi K, 1999, MOL HUM REPROD, V5, P153, DOI 10.1093/molehr/5.2.153; Tinel H, 2000, MOL HUM REPROD, V6, P1119, DOI 10.1093/molehr/6.12.1119; WEITLAUF HM, 1994, BIOL IMPLANTATION, P391; Yang ZM, 1997, BIOL REPROD, V56, P368, DOI 10.1095/biolreprod56.2.368; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593; Yoshioka K, 2000, BIOCHEM BIOPH RES CO, V272, P531, DOI 10.1006/bbrc.2000.2818	48	173	189	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44137	44145		10.1074/jbc.M107563200	http://dx.doi.org/10.1074/jbc.M107563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551965	hybrid			2022-12-25	WOS:000172297700084
J	Rose, SD; Swift, GH; Peyton, MJ; Hammer, RE; MacDonald, RJ				Rose, SD; Swift, GH; Peyton, MJ; Hammer, RE; MacDonald, RJ			The role of PTF1-P48 in pancreatic acinar gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PTF1; CELL-SPECIFIC TRANSCRIPTION; DNA-BINDING SUBUNIT; ELASTASE-I GENE; HOMEODOMAIN PROTEIN; EXOCRINE; INSULIN; BETA; ENHANCER; ELEMENT	The 100-base pair ELA1 transcriptional enhancer drives high level transcription to pancreatic acinar cells of transgenic mice and in transfected pancreatic acinar cells in culture. The A element within the enhancer is the sole positively acting element for acinar specificity. We show that the acinar cell-specific bHLH protein PTF1-P48 and the common bHLH cofactor HEB are part of the PTF1 complex that binds the A element and mediates its activity. Acinar-like activity of the enhancer can be reconstituted in HeLa cells by the introduction of P48, HEB, and the PDX1-containing trimeric homeodomain complex that binds the second pancreatic element of the enhancer. The 5' region of the mouse Ptf1-p48 gene from -12.5 to +0.2 kilobase pairs contains the regulatory information to direct expression in transgenic mice to the pancreas and other organs of the gat that express the endogenous Ptf1-p48 gene. The 5'-flanking sequence contains two activating regions, one of which is specific for acinar cells, and a repressing domain active in non-pancreatic cells. Comparison of the 5'-gene flanking regions of the mouse, rat, and human genes identified conserved sequence blocks containing binding sites for known gut transcription factors within the acinar cell-specific control region.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MacDonald, RJ (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	raymond.macdonald@utsouthwestern.edu	MacDonald, Ray/AAA-1290-2022; Peyton, Michael/A-8728-2008	Hammer, Robert E./0000-0001-5487-7551	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061220, R01DK055266] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61220, DK055266] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; CECI JD, 1991, ONCOGENE, V6, P323; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DAVIS BP, 1992, J BIOL CHEM, V267, P26070; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GOLDSTEIN S, 1989, NUCLEIC ACIDS RES, V17, P3959, DOI 10.1093/nar/17.10.3959; GUZ Y, 1995, DEVELOPMENT, V121, P11; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jonsson J, 1995, INT J DEV BIOL, V39, P789; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Knofler M, 1996, J BIOL CHEM, V271, P21993; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LIN HH, 1993, J BIOL CHEM, V268, P10214; Liu Y, 2001, J BIOL CHEM, V276, P17985, DOI 10.1074/jbc.M100678200; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; Rose SD, 1997, HUM MOL GENET, V6, P897, DOI 10.1093/hmg/6.6.897; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; SOUTHARDSMITH M, 1994, GENOMICS, V22, P404, DOI 10.1006/geno.1994.1402; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; SWIFT GH, 1984, CELL, V38, P639, DOI 10.1016/0092-8674(84)90258-7; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Viswanath RL, 2000, J BIOL CHEM, V275, P40273, DOI 10.1074/jbc.M007021200; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	53	86	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44018	44026		10.1074/jbc.M106264200	http://dx.doi.org/10.1074/jbc.M106264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562365	hybrid			2022-12-25	WOS:000172297700070
J	Yasuda, S; Kitagawa, H; Ueno, M; Ishitani, H; Fukasawa, M; Nishijima, M; Kobayashi, S; Hanada, K				Yasuda, S; Kitagawa, H; Ueno, M; Ishitani, H; Fukasawa, M; Nishijima, M; Kobayashi, S; Hanada, K			A novel inhibitor of ceramide trafficking from the endoplasmic reticulum to the site of sphingomyelin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SERINE PALMITOYLTRANSFERASE; GOLGI-APPARATUS; SPHINGOID BASE; RAT-LIVER; CYTOSOLIC SURFACE; GLUCOSYLCERAMIDE; SPHINGOLIPIDS; BIOSYNTHESIS; MEMBRANES	Ceramide produced at the endoplasmic reticulum. (ER) is transported to the lumen of the Golgi apparatus for conversion to sphingomyelin (SM). N-(3-Hydroxy-1-hydroxymethyl-3-phenylpropyl)dodecanamide (HPA-12) is a novel analog of ceramide. Metabolic labeling experiments showed that HPA-12 inhibits conversion of ceramide to SM, but not to glucosylceramide, in Chinese hamster ovary cells. Cultivation of cells with HPA-12 significantly reduced the content of SM. HPA-12 did not inhibit the activity of SM synthase. The inhibition of SM formation by HPA-12 was abrogated when the Golgi apparatus was made to merge with the ER by brefeldin A. Moreover, HPA-12 inhibited redistribution of a fluorescent analog of ceramide, N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)-D-erythro-sphin-gosine (C-5-DWE-Cer), from intracellular membranes to the Golgi region. Among four stereoisomers of the drug, (1R,3R)-HPA-12, which resembles natural ceramide stereochemically, was found to be the most active, although (1R,3R)-HPA-12 did not affect ER-to-Golgi trafficking of protein. Interestingly, (1R,3R)-HPA-12 inhibited conversion of ceramide to SM little in mutant cells defective in an ATP- and cytosol-dependent pathway of ceramide transport. These results indicated that (1R,3R)-HPA-12 inhibits ceramide trafficking from the ER to the site of SM synthesis, possibly due to an antagonistic interaction with a ceramide-recognizing factor(s) involved in the ATP- and cytosol-dependent pathway.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST); University of Tokyo	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1,Toyama, Tokyo 1628640, Japan.		Kobayashi, Shu/E-9214-2012; UENO, Masaharu/M-1609-2013	UENO, Masaharu/0000-0001-5253-0968; YASUDA, Satoshi/0000-0002-1011-0815; Hanada, Kentaro/0000-0003-1383-2781				Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Funakoshi T, 2000, J BIOL CHEM, V275, P29938, DOI 10.1074/jbc.M004470200; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hanada K, 2000, BIOCHEM J, V346, P671, DOI 10.1042/0264-6021:3460671; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; INOKUCHI JI, 1987, J LIPID RES, V28, P565; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Michel C, 1997, FEBS LETT, V416, P153, DOI 10.1016/S0014-5793(97)01187-3; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Wang E, 2000, METHOD ENZYMOL, V311, P15; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	34	115	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43994	44002		10.1074/jbc.M104884200	http://dx.doi.org/10.1074/jbc.M104884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546801	hybrid, Green Published			2022-12-25	WOS:000172297700067
J	Castro, DS; Hermanson, E; Joseph, B; Wallen, A; Aarnisalo, P; Heller, A; Perlmann, T				Castro, DS; Hermanson, E; Joseph, B; Wallen, A; Aarnisalo, P; Heller, A; Perlmann, T			Induction of cell cycle arrest and morphological differentiation by Nurr1 and retinoids in dopamine MN9D cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; NGFI-B; X-RECEPTOR; FUNCTIONAL DOMAINS; HORMONE RECEPTORS; RESPONSE PATHWAYS; PROGENITOR CELLS; ACID RESPONSE; GENE; EXPRESSION	Dopamine cells are generated in the ventral midbrain during embryonic development. The progressive degeneration of these cells in patients with Parkinson's disease, and the potential therapeutic benefit by transplantation of in vitro generated dopamine cells, has triggered intense interest in understanding the process whereby these cells develop. Nurr1 is an orphan nuclear receptor essential for the development of midbrain dopaminergic neurons. However, the mechanism by which Nurr1 promotes dopamine cell differentiation has remained unknown. In this study we have used a dopamine-synthesizing cell line (MN9D) with immature characteristics to analyze the function of Nurr1 in dopamine cell development. The results demonstrate that Nurr1 can induce cell cycle arrest and a highly differentiated cell morphology in these cells. These two functions were both mediated through a DNA binding-dependent mechanism that did not require Nurr1 interaction with the heterodimerization partner retinoid X receptor. However, retinoids can promote the differentiation of MN9D cells independently of Nurr1. Importantly, the closely related orphan receptors NGFI-B and Nor1 were also able to induce cell cycle arrest and differentiation. Thus, the growth inhibitory activities of the NGFI-B/Nurr1/ Nor1 orphan receptors, along with their widespread expression patterns both during development and in the adult, suggest a more general role in control of cell proliferation in the developing embryo and in adult tissues.	Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	Ludwig Institute for Cancer Research; Karolinska Institutet; University of Chicago	Perlmann, T (corresponding author), Ludwig Inst Canc Res, Box 240, S-17177 Stockholm, Sweden.	Thomas.Perlmann@licr.ki.se	Castro, Diogo S/I-6217-2016; Wallén-Mackenzie, Åsa/B-9105-2017	Castro, Diogo S/0000-0001-8178-9565; Wallén-Mackenzie, Åsa/0000-0002-8713-070X; Joseph, Bertrand/0000-0001-5655-9979				BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Botling J, 1997, J BIOL CHEM, V272, P9443; CASTELLANO F, 1994, INT J DEV NEUROSCI, V12, P77, DOI 10.1016/0736-5748(94)90098-1; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Crispino M, 1998, MOL BRAIN RES, V59, P178, DOI 10.1016/S0169-328X(98)00143-0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Heller A, 1996, BRAIN RES, V725, P132, DOI 10.1016/S0006-8993(96)00345-9; Honkaniemi J, 1999, EUR J NEUROSCI, V11, P10, DOI 10.1046/j.1460-9568.1999.00401.x; Honkaniemi J, 2000, BRAIN RES, V877, P203, DOI 10.1016/S0006-8993(00)02673-1; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; Iwawaki T, 2000, BIOCHEM BIOPH RES CO, V274, P590, DOI 10.1006/bbrc.2000.3204; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; JOHN A, 1995, DEVELOPMENT, V121, P1801; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Maira M, 1999, MOL CELL BIOL, V19, P7549; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maruyama K, 1998, INT J ONCOL, V12, P1237; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; Ogura T, 1996, DEVELOPMENT, V122, P537; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Smidt MP, 2000, NAT NEUROSCI, V3, P337, DOI 10.1038/73902; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; SPORN MB, 1994, RETINOIDS, P319; Tetradis S, 2001, BIOCHEM BIOPH RES CO, V281, P913, DOI 10.1006/bbrc.2001.4459; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; Wallen A, 1999, EXP CELL RES, V253, P737, DOI 10.1006/excr.1999.4691; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Xing GQ, 1997, MOL BRAIN RES, V47, P251, DOI 10.1016/S0169-328X(97)00056-9; Yoshikawa K, 2000, NEUROSCI RES, V37, P1, DOI 10.1016/S0168-0102(00)00101-2; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462	60	111	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43277	43284		10.1074/jbc.M107013200	http://dx.doi.org/10.1074/jbc.M107013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553630	hybrid			2022-12-25	WOS:000172169300084
J	Chandel, NS; Schumacker, PT; Arch, RH				Chandel, NS; Schumacker, PT; Arch, RH			Reactive oxygen species are downstream products of TRAF-mediated signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-RECEPTOR; ACTIVATED PROTEIN-KINASE; CELL-DEATH; TRANSCRIPTION FACTOR; INTERACTING PROTEIN; NEGATIVE SELECTION; GENE-TRANSCRIPTION; CONTAINS 2; T-CELLS	Members of the TNFR (tumor necrosis factor receptor) superfamily are involved in regulating activation and differentiation of cells as well as cell survival and programmed cell death/apoptosis. Multimerization of TNFRs can lead to recruitment of TRAFs (TNFR-associated factors) by the receptors resulting in activation of kinases and transcription factors, such as c-Jun N-terminal kinase and nuclear factor kappaB (NF-kappaB). Signal transduction triggered by TNF-alpha also induces an increase in intracellular reactive oxygen species (ROS). ROS have been suggested to play a role in NF-kappaB activation, which is thought to promote cell survival. However, oxidation of proteins and lipids by ROS can also result in apoptosis. The processes generating intracellular ROS and the mechanism(s) regulating the cellular redox status have not been fully elucidated. We investigated whether TRAFs play a role in controlling intracellular ROS levels. Our results indicate that recruitment of TRAFs to the plasma membrane of human embryonic kidney (HEK) 293 cells is crucial for activation of signaling pathways, which regulate ROS production in mitochondria. TRAF-mediated changes in ROS levels enhanced NF-kappaB activation but were not dependent on NF-kappaB-inducing kinase. Consistent with its anti-apoptotic function, Bcl-x(L) interfered with TRAF-mediated ROS generation but not NF-kappaB activation. Taken together, our results suggest a novel role of TRAFs in signal transduction pathways triggered by TNFR-related proteins, which balance cell survival and apoptosis by regulating the electron transport in mitochondria.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Washington University (WUSTL); Washington University (WUSTL); University of Chicago	Arch, RH (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA.			Schumacker, Paul T/0000-0001-9591-2034				Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Arch RH, 2000, BIOCHEM BIOPH RES CO, V272, P936, DOI 10.1006/bbrc.2000.2873; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Baichwal V. R., 1997, CURR BIOL, V7, P94; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Brodersen J, 1999, EUR J BIOCHEM, V259, P218, DOI 10.1046/j.1432-1327.1999.00017.x; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 2000, J IMMUNOL, V165, P1013, DOI 10.4049/jimmunol.165.2.1013; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chiarle R, 1999, J IMMUNOL, V163, P194; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Fagarasan S, 2000, J EXP MED, V191, P1477, DOI 10.1084/jem.191.9.1477; FUKAMI JI, 1967, SCIENCE, V155, P713, DOI 10.1126/science.155.3763.713; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Jang IK, 1998, BIOCHEM BIOPH RES CO, V242, P613, DOI 10.1006/bbrc.1997.8016; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, CANCER J SCI AM, V4, pS92; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; PENNICA D, 1992, J BIOL CHEM, V267, P21172; Piette J, 1997, BIOL CHEM, V378, P1237; RAO KMK, 1992, J LEUKOCYTE BIOL, V51, P496; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; van der Eb A J, 1980, Methods Enzymol, V65, P826; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	54	155	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42728	42736		10.1074/jbc.M103074200	http://dx.doi.org/10.1074/jbc.M103074200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11559697	hybrid			2022-12-25	WOS:000172169300014
J	Mottley, C; Mason, RP				Mottley, C; Mason, RP			Sulfur-centered radical formation from the antioxidant dihydrolipoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LIPOIC ACID; MICROSOMAL LIPID-PEROXIDATION; ELECTRON-SPIN-RESONANCE; PULSE-RADIOLYSIS; DEPENDENT GENERATION; PHENOXYL RADICALS; HYPOCHLOROUS ACID; AQUEOUS-SOLUTIONS; INDUCED OXIDATION; HL-60 CELLS	Lipoic acid and its reduced form, dihydrolipoic acid, are thought to be strong antioxidants. There are also reports of dihydrolipoic acid acting as a pro-oxidant under certain circumstances. This article reports the direct observation by ESR spectrometry of the disulfide radical anion and the spin trapping of the primary thiyl radical formed from the oxidation of dihydrolipoic acid through thiol pumping with phenol and horseradish peroxidase. The disulfide radical anion reacts rapidly with oxygen to form the reactive radical superoxide, which is also trapped. The radical species formed show a potential for pro-oxidant activity of this compound. Although antioxidants, in general, have been shown to have pro-oxidant potential, the pro-oxidant chemistry of dihydrolipoic acid has not been well characterized.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Luther Coll, Dept Chem, Decorah, IA 52101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Mason, RP (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050139, ZIAES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKHLAQ MS, 1987, Z NATURFORSCH C, V42, P134; ALTENKIRCH H, 1990, NEUROTOXICOL TERATOL, V12, P619, DOI 10.1016/0892-0362(90)90073-L; BAST A, 1988, BIOCHIM BIOPHYS ACTA, V963, P558, DOI 10.1016/0005-2760(88)90326-8; BONOMI F, 1989, BIOCHIM BIOPHYS ACTA, V994, P180, DOI 10.1016/0167-4838(89)90158-1; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CHAN PC, 1973, J AM CHEM SOC, V95, P5504, DOI 10.1021/ja00798a012; Coombes JS, 2000, AM J PHYSIOL-REG I, V279, pR2149, DOI 10.1152/ajpregu.2000.279.6.R2149; CREMONINI MA, 1993, J ORG CHEM, V58, P3805, DOI 10.1021/jo00067a011; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; ELLIOT AJ, 1982, RADIAT PHYS CHEM, V19, P417; Galati G, 1999, CHEM RES TOXICOL, V12, P521, DOI 10.1021/tx980271b; GILBERT BC, 1975, J CHEM SOC PERK T 2, P892, DOI 10.1039/p29750000892; Goldman R, 1999, FREE RADICAL BIO MED, V27, P1050, DOI 10.1016/S0891-5849(99)00140-9; GOLDMAN R, 1995, BIOCHEMISTRY-US, V34, P4765, DOI 10.1021/bi00014a034; GRIERSON L, 1992, INT J RADIAT BIOL, V62, P265, DOI 10.1080/09553009214552111; HAENEN GRMM, 1991, BIOCHEM PHARMACOL, V42, P2244, DOI 10.1016/0006-2952(91)90363-A; HOFFMAN MZ, 1972, J AM CHEM SOC, V94, P7950, DOI 10.1021/ja00778a002; KAGAN VE, 1992, J LIPID RES, V33, P385; LAL M, 1994, RADIAT PHYS CHEM, V43, P595, DOI 10.1016/0969-806X(94)90174-0; Lal M, 1997, J AM CHEM SOC, V119, P5735, DOI 10.1021/ja970744l; MATSUGO S, 1995, BIOCHEM BIOPH RES CO, V208, P161, DOI 10.1006/bbrc.1995.1318; MOTTLEY C, 1986, BIOCHEM BIOPH RES CO, V141, P622, DOI 10.1016/S0006-291X(86)80218-2; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; MURPHY ME, 1992, EUR J BIOCHEM, V210, P139, DOI 10.1111/j.1432-1033.1992.tb17401.x; NETA P, 1974, J PHYS CHEM-US, V78, P523, DOI 10.1021/j100598a013; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Packer L, 1998, DRUG METAB REV, V30, P245, DOI 10.3109/03602539808996311; PICHORNER H, 1995, ARCH BIOCHEM BIOPHYS, V323, P429, DOI 10.1006/abbi.1995.0064; PIERING WF, 1990, CLIN CHEM, V36, P571; PREHN JHM, 1992, J CEREBR BLOOD F MET, V12, P78, DOI 10.1038/jcbfm.1992.10; RAO DNR, 1990, J BIOL CHEM, V265, P844; REDPATH JL, 1973, RADIAT RES, V54, P364, DOI 10.2307/3573731; ROMERO FJ, 1992, J BIOL CHEM, V267, P1680; SCHEER B, 1993, ARCH BIOCHEM BIOPHYS, V302, P385, DOI 10.1006/abbi.1993.1228; SCHOLICH H, 1989, BIOCHIM BIOPHYS ACTA, V1001, P256, DOI 10.1016/0005-2760(89)90108-2; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; SCOTT BC, 1994, FREE RADICAL RES, V20, P119, DOI 10.3109/10715769409147509; STARY FE, 1975, J ORG CHEM, V40, P58, DOI 10.1021/jo00889a013; STEVENS B, 1974, PHOTOCHEM PHOTOBIOL, V19, P315, DOI 10.1111/j.1751-1097.1974.tb06517.x; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V317, P315, DOI 10.1006/abbi.1995.1169; SUZUKI YJ, 1991, FREE RADICAL RES COM, V15, P255, DOI 10.3109/10715769109105221; WEINER SA, 1972, J AM CHEM SOC, V94, P581, DOI 10.1021/ja00757a043; WERTZ JE, 1972, ELECT SPIN RESONANCE, P464; Yan LJ, 1996, ARCH BIOCHEM BIOPHYS, V327, P330, DOI 10.1006/abbi.1996.0130	45	35	35	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42677	42683		10.1074/jbc.M104889200	http://dx.doi.org/10.1074/jbc.M104889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11546802	hybrid			2022-12-25	WOS:000172169300007
J	Rimoldi, D; Muehlethaler, K; Salvi, S; Valmori, D; Romero, P; Cerottini, JC; Levy, F				Rimoldi, D; Muehlethaler, K; Salvi, S; Valmori, D; Romero, P; Cerottini, JC; Levy, F			Subcellular localization of the melanoma-associated protein Melan-A(MART-1) influences the processing of its HLA-A2-restricted epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELAN-A/MART-1 ANTIGENIC PEPTIDE; NEWLY SYNTHESIZED PROTEINS; TUMOR-ASSOCIATED ANTIGEN; ENDOPLASMIC-RETICULUM; IN-VIVO; MONOCLONAL-ANTIBODIES; CTL RESPONSES; DEGRADATION; MEMBRANE; CELLS	The peptide derived from the melanoma-associated protein Melan-A (Melan-A(26-35)/HLA-A2) is an attractive candidate for tumor immunotherapy but little is known about the intracellular processing of this antigen. Here we show that Melan-A is a single-pass membrane protein with an NH2 terminus exposed to the lumen of the exocytic compartment. In transfected melanoma cells, Melan-A accumulates in the Golgi region. Inversion of the membrane topology leads to the retention of Melan-A in the endoplasmic reticulum. Most strikingly, melanoma cells expressing this form of Melan-A are more effectively recognized by specific CTL than those expressing either Melan-A in its native membrane orientation or Melan-A artificially localized in the cytosol. Our data are compatible with the notion that proteins retained in the endoplasmic reticulum are more efficiently degraded and produce more antigenic peptides.	Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; Univ Hosp, Ludwig Inst Canc Res, Div Clin Oncoimmunol, CH-1011 Lausanne, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Rimoldi, D (corresponding author), Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.		Romero, Pedro/S-6015-2017; Valmori, Danila/K-2439-2015; Valmori, Danila/AAL-9766-2021	Romero, Pedro/0000-0002-9688-2882; 				AMARCOSTESEC A, 1994, BIOCHEM BIOPH RES CO, V204, P710, DOI 10.1006/bbrc.1994.2517; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Chen YT, 1996, P NATL ACAD SCI USA, V93, P5915, DOI 10.1073/pnas.93.12.5915; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; Eusebio A, 1998, EXP CELL RES, V241, P181, DOI 10.1006/excr.1998.4042; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hauri HP, 2000, J CELL SCI, V113, P587; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kawakami Y, 1997, J IMMUNOL METHODS, V202, P13, DOI 10.1016/S0022-1759(96)00211-6; KOCHER T, 1995, CANCER RES, V55, P2236; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Noppen C, 2000, INT J CANCER, V87, P241, DOI 10.1002/1097-0215(20000715)87:2<241::AID-IJC15>3.0.CO;2-L; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rimoldi D, 1999, INT J CANCER, V82, P901, DOI 10.1002/(SICI)1097-0215(19990909)82:6<901::AID-IJC21>3.0.CO;2-X; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Romero P, 1997, J IMMUNOL, V159, P2366; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schultz-Thater E, 2000, BRIT J CANCER, V83, P204; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Valmori D, 1999, J EXP MED, V189, P895, DOI 10.1084/jem.189.6.895; Valmori D, 2000, J IMMUNOL, V164, P1125, DOI 10.4049/jimmunol.164.2.1125; Valmori D, 1998, J IMMUNOL, V161, P6956; Valmori D, 1998, J IMMUNOL, V160, P1750; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; Wang Y, 1999, IMMUNOL REV, V172, P67, DOI 10.1111/j.1600-065X.1999.tb01356.x; Yewdell JW, 1996, J IMMUNOL, V157, P1823	37	24	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43189	43196		10.1074/jbc.M103221200	http://dx.doi.org/10.1074/jbc.M103221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551907	hybrid			2022-12-25	WOS:000172169300073
J	Wallace, AD; Cidlowski, JA				Wallace, AD; Cidlowski, JA			Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; DOWN-REGULATION; ESTROGEN-RECEPTOR; GENE-EXPRESSION; 26S PROTEASOME; PHOSPHORYLATED SITES; MULTIPLE MECHANISMS; HORMONE RECEPTORS; PROTEIN STABILITY; UBIQUITIN SYSTEM	Ligand-dependent down-regulation of the glucocorticoid receptor (GR) has been shown to limit hormone responsiveness, but the mechanisms involved in this process are poorly understood. The glucocorticoid receptor is a phosphoprotein that upon ligand binding becomes hyperphosphorylated, and recent evidence indicates that phosphorylation status of the glucocorticoid receptor plays a prominent role in receptor protein turnover. Because phosphorylation is a key signal for ubiquitination and proteasomal catabolism of many proteins, we evaluated whether the ubiquitin-proteasomal pathway had a role in glucocorticoid receptor down-regulation and the subsequent transcriptional response to glucocorticoids. Pretreatment of COS-1 cells expressing mouse glucocorticoid receptor with the proteasome inhibitor MG-132 effectively blocks glucocorticoid receptor protein down-regulation by the glucocorticoid dexamethasone. Interestingly, both MG-132 and a second proteasome inhibitor beta -lactone significantly enhanced hormone response of transfected mouse glucocorticoid receptor toward transcriptional activation of glucocorticoid receptor-mediated reporter gene expression. The transcriptional activity of the endogenous human glucocorticoid receptor in HeLa cells was also enhanced by MG-132. Direct evidence for ubiquitination of the glucocorticoid receptor was obtained by immunoprecipitation of cellular extracts from proteasome-impaired cells. Examination of the primary sequence of mouse, hu man, and rat glucocorticoid receptor has identified a candidate PEST degradation motif. Mutation of Lys-426 within this PEST element both abrogated ligand-dependent down-regulation of glucocorticoid receptor protein and simultaneously enhanced glucocorticoid receptor-induced transcriptional activation of gene expression. Unlike wild type GR, proteasomal inhibition failed to enhance significantly transcriptional activity of K426A mutant GR. Together these findings suggest a major role of the ubiquitin-proteasome pathway in regulating glucocorticoid receptor protein turnover, thereby providing a mechanism to terminate glucocorticoid responses.	NIEHS, Mol Endocrinol Grp, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Mol Endocrinol Grp, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	cidlowski@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ALLGOOD VE, 1990, J BIOL CHEM, V265, P12424; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; BELLINGHAM DL, 1992, MOL ENDOCRINOL, V6, P2090, DOI 10.1210/me.6.12.2090; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BODWELL JE, 1995, J STEROID BIOCHEM, V52, P135, DOI 10.1016/0960-0760(94)00157-H; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; BURNSTEIN KL, 1991, STEROIDS, V56, P52, DOI 10.1016/0039-128X(91)90124-E; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; CIDLOWSKI JA, 1981, ENDOCRINOLOGY, V109, P1975; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; DANIELSEN M, 1989, CANCER RES, V49, pS2286; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOECK W, 1989, J BIOL CHEM, V264, P14396; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCINTYRE WR, 1985, J BIOL CHEM, V260, P418; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, CANCER RES, V59, P372; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; Oakley Robert H., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P63; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; SCHEIBLE PP, 1987, J STEROID BIOCHEM, V26, P181, DOI 10.1016/0022-4731(87)90069-0; SCHMIDT TJ, 1994, RECEPTOR, V4, P229; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; SILVA CM, 1994, STEROIDS, V59, P436, DOI 10.1016/0039-128X(94)90013-2; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SVEC F, 1981, J BIOL CHEM, V256, P5984; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VEDECKIS WV, 1989, CANCER RES, V49, pS2295; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Webster JC, 1997, J BIOL CHEM, V272, P9287; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	68	297	313	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42714	42721		10.1074/jbc.M106033200	http://dx.doi.org/10.1074/jbc.M106033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555652	hybrid			2022-12-25	WOS:000172169300012
J	Janknecht, R				Janknecht, R			Cell type-specific inhibition of the ETS transcription factor ER81 by mitogen-activated protein kinase-activated protein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HEAT-SHOCK PROTEINS; MAPKAP KINASE-2; NUCLEAR EXPORT; TNF-ALPHA; IN-VIVO; PHOSPHORYLATION; STRESS; EXPRESSION; SUBSTRATE	Mitogen-activated protein kinase-activated protein kinase 2 (MK2) is an important intracellular mediator of stress signals. In this report, a novel target of MK2 has been identified, the ETS transcription factor family member ER81, whose dysregulation contributes to tumorigenesis and whose normal function is required during development. MK2 phosphorylates ER81 in vitro within its central inhibitory domain, and overexpression of MK2 leads to increased in vivo phosphorylation of ER81. Two serine residues, ER81 amino acids 191 and 216, were identified as MK2 phosphorylation sites. MK2 suppresses basal ER81-dependent transcription, and this suppressive effect is alleviated upon mutation of the NM phosphorylation sites in a cell type-specific manner. However, NM can also interfere with ER81-mediated transcription independently of serine 191 and serine 216 phosphorylation. Furthermore, MM overexpression counteracts the stimulation of ER81 activity by p38 mitogen-activated protein kinase. Altogether, AM may regulate ER81 transcriptional activity in a cell type-specific manner and thereby modulate various physiological processes beyond stress responses.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562	NCI NIH HHS [CA85257, R01 CA085257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fluck M, 2000, BIOCHEM BIOPH RES CO, V270, P488, DOI 10.1006/bbrc.2000.2457; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JEON IS, 1995, ONCOGENE, V10, P1229; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTE D, 1995, ONCOGENE, V11, P771; Neufeld B, 2000, J BIOL CHEM, V275, P20239, DOI 10.1074/jbc.C901040199; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946	37	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41856	41861		10.1074/jbc.M106630200	http://dx.doi.org/10.1074/jbc.M106630200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551945	hybrid			2022-12-25	WOS:000172450400043
J	Renner, DB; Yamaguchi, Y; Wada, T; Handa, H; Price, DH				Renner, DB; Yamaguchi, Y; Wada, T; Handa, H; Price, DH			A highly purified RNA polymerase II elongation control system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT RELEASE FACTOR; COLI NUSG PROTEIN; P-TEFB KINASE; IN-VITRO; MESSENGER-RNA; HIV-1 TAT; TERMINAL DOMAIN; DROSOPHILA; SPT5; COMPLEX	Studying the sensitivity of transcription to the nucleotide analog 5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole has led to the discovery of a number of proteins involved in the regulation of transcription elongation by RNA polymerase II. We have developed a highly purified elongation control system composed of three purified proteins added back to isolated RNA polymerase II elongation complexes. Two of the proteins, 5,6-dichloro-1-13D-ribofuranosylbenzimidazole sensitivity-inducing factor (DSIF) and negative elongation factor (NELF), act as negative transcription elongation factors by increasing the time the polymerase spent at pause sites. reverses the negative effect of DSIF and NELF through a mechanism dependent on its kinase activity. TFIIF is a general initiation factor that positively affects elongation by decreasing pausing. We show that TFIIF functionally competes with DSIF and NELF, and this competition is dependent on the relative concentrations of TFIIF and NELF.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Yokohama, Kanagawa 2268501, Japan	University of Iowa; Tokyo Institute of Technology; Tokyo Institute of Technology	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Yamaguchi, Yuki/B-9390-2015; Price, David H/F-6173-2010	Yamaguchi, Yuki/0000-0002-0197-614X; Price, David/0000-0002-5597-385X	NIGMS NIH HHS [GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BUROVA E, 1995, J BACTERIOL, V177, P1388, DOI 10.1128/jb.177.5.1388-1392.1995; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; Clement JQ, 2000, J MOL BIOL, V299, P1179, DOI 10.1006/jmbi.2000.3745; Conaway JW, 1999, ANNU REV BIOCHEM, V68, P301, DOI 10.1146/annurev.biochem.68.1.301; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hirose Y, 2000, GENE DEV, V14, P1415; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kyrpides NC, 1996, TRENDS BIOCHEM SCI, V21, P425, DOI 10.1016/S0968-0004(96)30036-4; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; LI J, 1992, J BIOL CHEM, V267, P6012; Lis JT, 2000, GENE DEV, V14, P792; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Xie Z, 1998, J BIOL CHEM, V273, P3771, DOI 10.1074/jbc.273.6.3771; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yamaguchi Y, 2001, J BIOCHEM, V129, P185, DOI 10.1093/oxfordjournals.jbchem.a002842; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zorio DAR, 2001, CURR BIOL, V11, pR144, DOI 10.1016/S0960-9822(01)00063-X	55	142	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42601	42609		10.1074/jbc.M104967200	http://dx.doi.org/10.1074/jbc.M104967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553615	hybrid			2022-12-25	WOS:000172450400136
J	Welford, SM; Hebert, SP; Deneen, B; Arvand, A; Denny, CT				Welford, SM; Hebert, SP; Deneen, B; Arvand, A; Denny, CT			DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION PROTEIN; INTERACTS; EWS/FLI; FLI-1; EWS; GENES	Specific chromosomal translocations involving the ews gene and one of five members of the ets family of transcription factors create ews/ets fusion genes that are found in similar to 85% of Ewing's family of tumors. ews/ets fusion genes consistently maintain an intact and functional ets DNA binding domain (DBD) in all of these cases. We demonstrate here, however, that EWS/FLI1, the most prevalent EWS/ETS fusion, activates oncogenic pathways independent of its DBD. In in vivo tumor assays, EWS/FLI1 molecules with either point mutations or a large deletion in the ets DBD retain the ability to accelerate tumors in NIH 3T3 cells, whereas they lose the ability to bind DNA in vitro. Additionally, whereas inhibition of DBD functions of EWS/FLI1 with a dominant negative form of FLI1 is sufficient to inhibit anchorage-independent growth in NIH 3T3 cells, it is ineffective in inhibiting tumor growth in SCID mice. Usage of this dominant negative construct in a Ewing's tumor cell line, however, does reduce the rate of tumor formation, supporting the need for a functional DBD in this context. Together, these results suggest that EWS/FLI1 induces both DBD-dependent and DBD-independent oncogenic pathways.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pediat, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Expt Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Denny, CT (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.	cdenny@ucla.edu		Deneen, Benjmain/0000-0002-6335-1081	NCI NIH HHS [CA32737, CA87771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087771, P01CA032737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvand A, 2001, CANCER RES, V61, P5311; ARVAND A, 2001, IN PRESS ONCOGENE; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Chansky HA, 2001, CANCER RES, V61, P3586; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	25	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41977	41984		10.1074/jbc.M106757200	http://dx.doi.org/10.1074/jbc.M106757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553628	hybrid			2022-12-25	WOS:000172450400059
J	Liang, CP; Tall, AR				Liang, CP; Tall, AR			Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETICALLY-OBESE MICE; GENE-EXPRESSION; HEPATIC EXPRESSION; DIABETES-MELLITUS; MESSENGER-RNA; BODY-WEIGHT; CHOLESTEROL; ALPHA; PATTERNS; HEPATOCYTES	Leptin, a hormone secreted by adipose tissue, has been shown to have a major influence on hepatic lipid and lipoprotein metabolism. To characterize changes in lipid and lipoprotein gene expression in mouse liver, suppression subtractive hybridization and cDNA microarray analysis were used to identify mRNAs differentially expressed after leptin treatment of ob/ob mice. Ob/ob mice showed a profound decrease in mRNAs encoding genes controlling bile acid synthesis and transport as well as a variety of apolipoprotein genes and hepatic lipase with reversal upon leptin administration, suggesting that leptin coordinately regulates high density lipoprotein and bile salt metabolism. Leptin administration also resulted in decreased expression of genes involved in fatty acid and cholesterol synthesis, glycolysis, gluconeogenesis, and urea synthesis, and increased expression of genes mediating fatty acid oxidation, ATP synthesis, and oxidant defenses. The changes in mRNA expression are consistent with a switch in energy metabolism from glucose utilization and fatty acid synthesis to fatty acid oxidation and increased respiration. The latter changes may produce oxidant stress, explaining the unexpected finding that leptin induces a battery of genes involved in antioxidant defenses. Expression cluster analysis revealed responses of several sets of genes that were kinetically linked. Thus, the mRNA levels of genes involved in fatty acid and cholesterol synthesis are rapidly (<1 h) repressed by leptin administration, in association with an acute decrease in plasma insulin levels and decreased sterol regulator element-binding protein-1 expression. In contrast, genes participating in fatty acid oxidation and ketogenesis were induced more slowly (24 h), following an increase in expression of their common regulatory factor, peroxisome proliferator-activated receptor a. However, the regulation of genes involved in high density lipoprotein and bile salt metabolism shows complex kinetics and is likely to be mediated by novel transcription factors.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Liang, CP (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th St, New York, NY 10032 USA.	CL534@columbia.edu	Tall, Alan/AAT-8528-2021					Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Crosson SM, 1997, DIABETOLOGIA, V40, P1117, DOI 10.1007/s001250050796; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Enriquez A, 1999, BIOCHEM BIOPH RES CO, V255, P300, DOI 10.1006/bbrc.1999.0202; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruhbeck G, 2000, DIABETOLOGIA, V43, P3, DOI 10.1007/s001250050002; GE RW, 1994, J BIOL CHEM, V269, P13185; Green RM, 2000, GENE, V241, P117, DOI 10.1016/S0378-1119(99)00460-6; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pessayre D, 1999, CELL BIOL TOXICOL, V15, P367, DOI 10.1023/A:1007649815992; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Reidy SP, 2000, COMP BIOCHEM PHYS A, V125, P285, DOI 10.1016/S1095-6433(00)00159-8; Renz M, 2000, J BIOL CHEM, V275, P10429, DOI 10.1074/jbc.275.14.10429; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; Soukas A, 2000, GENE DEV, V14, P963; Stroup D, 2000, J LIPID RES, V41, P1; Tall AR, 2000, NAT MED, V6, P1104, DOI 10.1038/80433; TALL AR, 2001, METABOLIC MOL BASES, P2915; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Vicent D, 1998, DIABETES, V47, P1451, DOI 10.2337/diabetes.47.9.1451; Watson AM, 1999, DRUG METAB DISPOS, V27, P695; White DW, 2000, DIABETES, V49, P1443, DOI 10.2337/diabetes.49.9.1443; Wiesenthal SR, 1999, DIABETES, V48, P766, DOI 10.2337/diabetes.48.4.766; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zaiou M, 1998, J CLIN INVEST, V101, P1699, DOI 10.1172/JCI2166; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898	56	116	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49066	49076		10.1074/jbc.M107250200	http://dx.doi.org/10.1074/jbc.M107250200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11551957	hybrid			2022-12-25	WOS:000173922100060
J	Anant, S; Henderson, JO; Mukhopadhyay, D; Navaratnam, N; Kennedy, S; Min, J; Davidson, NO				Anant, S; Henderson, JO; Mukhopadhyay, D; Navaratnam, N; Kennedy, S; Min, J; Davidson, NO			Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing - CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSKAR MESSENGER-RNA; TRANSLATIONAL REPRESSOR BRUNO; MOLECULAR-CLONING; CYTIDINE DEAMINASE; CATALYTIC SUBUNIT; EVOLUTIONARY ORIGINS; MYOTONIC-DYSTROPHY; GENE-EXPRESSION; ENZYME-COMPLEX; SITE	Mammalian apolipoprotein B (apoB) mRNA editing is mediated by a multicomponent holoenzyme containing apobec-1 and ACF. We have now identified CUGBP2, a 54-kDa RNA-binding protein, as a component of this holoenzyme. CUGBP2 and ACF co-fractionate in bovine liver S-100 extracts, and addition of recombinant apobec-1 leads to assembly of a holoenzyme. Immunodepletion of CUGBP2 co-precipitates ACF, and these proteins co-localize the nucleus of transfected cells, suggesting that CUGBP2 and ACF are bound in vivo. CUGBP2 binds apoB RNA, specifically an AU-rich sequence located immediately upstream of the edited cytidine. ApoB RNA from McA cells, bound to CUGBP2, was more extensively edited than the unbound fraction. However, addition of recombinant CUGBP2 to a reconstituted system demonstrated a dose-dependent inhibition of C to U RNA editing, which was rescued with either apobec-1 or ACF. Antisense CUGBP2 knockout increased endogenous apoB RNA editing, whereas antisense knockout of either apobec-1 or ACF expression eliminated apoB RNA editing, establishing the absolute requirement of these components of the core enzyme. These data suggest that CUGBP2 plays a role in apoB mRNA editing by forming a regulatory complex with the three components of the minimal editing enzyme, apobec-1, ACF, and apoB RNA.	Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol & Mol Biol, St Louis, MO 63110 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, Med Res Council Mol Med Grp, London W12 0NN, England	Washington University (WUSTL); Washington University (WUSTL); Imperial College London	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Campus Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.		Anant, Shrikant/AAF-8020-2020		NHLBI NIH HHS [HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 52574, DK 56260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056260, P30DK052574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Anant S, 1998, BIOL CHEM, V379, P1075, DOI 10.1515/bchm.1998.379.8-9.1075; ANANT S, 1997, NUCL ACIDS S SER, V36, P115; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Chen L, 1996, J THEOR BIOL, V183, P391, DOI 10.1006/jtbi.1996.0230; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Choi DK, 1999, GENE, V237, P135, DOI 10.1016/S0378-1119(99)00312-1; Choi DK, 1998, GENE, V223, P21, DOI 10.1016/S0378-1119(98)00364-3; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; FUNAHASHI T, 1995, J LIPID RES, V36, P414; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Lie YS, 1999, DEVELOPMENT, V126, P4989; Lie YS, 1999, DEVELOPMENT, V126, P1129; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; Morrison JR, 1996, P NATL ACAD SCI USA, V93, P7154, DOI 10.1073/pnas.93.14.7154; Nakamuta M, 1996, J BIOL CHEM, V271, P25981, DOI 10.1074/jbc.271.42.25981; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	57	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47338	47351		10.1074/jbc.M104911200	http://dx.doi.org/10.1074/jbc.M104911200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577082	hybrid			2022-12-25	WOS:000172768500089
J	Bauer, Z; Gomez-Gomez, L; Boller, T; Felix, G				Bauer, Z; Gomez-Gomez, L; Boller, T; Felix, G			Sensitivity of different ecotypes and mutants of Arabidopsis thaliana toward the bacterial elicitor flagellin correlates with the presence of receptor-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PLANT-DISEASE RESISTANCE; PLASMA-MEMBRANES; SYRINGOLIDE ELICITORS; CLADOSPORIUM-FULVUM; TOBACCO CELLS; TOMATO CELLS; PROTEIN; KINASE; GENE	Flagellin, the main building block of the bacterial flagellum, acts as potent elicitor of defense responses in different plant species. Genetic analysis in Arabidopsis thaliana identified two distinct loci, termed FLS1 and FLS2, that are essential for perception of flagellin-derived elicitors. FLS2 was found to encode a leucine-rich repeat transmembrane receptor-like kinase with similarities to Toll-like receptors involved in the innate immune system of mammals and insects. Here we used a radiolabeled derivative of flg22, a synthetic peptide representing the elicitor-active domain of flagellin, to probe the interaction of flagellin with its receptor in A. thaliana The high affinity binding site detected in in- tact cells and membrane preparations exhibited specificity for flagellin-derived peptides with biological activity as agonists or antagonists of the elicitor responses. Specific binding activity was measurable in all ecotypes of A. thaliana that show sensitivity to flagellin but was barely detectable in the flagellin-insensitive ecotype Ws-O affected in FLS1. A strongly impaired binding of flagellin was observed also in several independent flagellin-insensitive mutants isolated from the flagellin-sensitive ecotype La-er. In particular, no binding was found in plants carrying a mutation in the LRR domain of FLS2. These data indicate that the formation of functional receptor-binding sites depends on genes encoded by both loci, FLS1 and FLS2. The tight correlation between the presence of the binding site and elicitor response provides strong evidence that this binding site acts as the physiological receptor of flagellin.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Felix, G (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	Felix@fmi.ch	Gomez-Gomez, Lourdes/AAF-2371-2020; Bruening, Stefan/B-8505-2011; Boller, Thomas/G-3500-2012	Gomez-Gomez, Lourdes/0000-0003-2586-4457; Boller, Thomas/0000-0001-6768-7503				Alfano JR, 1996, PLANT CELL, V8, P1683, DOI 10.1105/tpc.8.10.1683; Atkinson MM, 1996, PLANT PHYSIOL, V112, P297, DOI 10.1104/pp.112.1.297; BAUREITHEL K, 1994, J BIOL CHEM, V269, P17931; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Bonas U, 1997, PLANT J, V12, P1, DOI 10.1046/j.1365-313X.1997.12010001.x; Bourque S, 1999, J BIOL CHEM, V274, P34699, DOI 10.1074/jbc.274.49.34699; CHEONG JJ, 1993, PLANT PHYSIOL, V103, P1173, DOI 10.1104/pp.103.4.1173; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gomez-Gomez L, 2001, PLANT CELL, V13, P1155, DOI 10.1105/tpc.13.5.1155; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; He ZH, 2000, SCIENCE, V288, P2360, DOI 10.1126/science.288.5475.2360; Heath MC, 2000, CURR OPIN PLANT BIOL, V3, P315, DOI 10.1016/S1369-5266(00)00087-X; Ji C, 1998, P NATL ACAD SCI USA, V95, P3306, DOI 10.1073/pnas.95.6.3306; Ji C, 1997, PLANT CELL, V9, P1425, DOI 10.1105/tpc.9.8.1425; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KEEN NT, 1992, PLANT MOL BIOL, V19, P109, DOI 10.1007/BF00015609; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KoomanGersmann M, 1996, PLANT CELL, V8, P929, DOI 10.1105/tpc.8.5.929; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Meindl T, 2000, PLANT CELL, V12, P1783, DOI 10.1105/tpc.12.9.1783; Mithofer A, 2000, BIOL CHEM, V381, P705, DOI 10.1515/BC.2000.091; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Shibuya N, 1996, PLANT CELL PHYSIOL, V37, P894, DOI 10.1093/oxfordjournals.pcp.a029030; Song WY, 1997, PLANT CELL, V9, P1279, DOI 10.1105/tpc.9.8.1279; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; Umemoto N, 1997, P NATL ACAD SCI USA, V94, P1029, DOI 10.1073/pnas.94.3.1029	35	140	147	4	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45669	45676		10.1074/jbc.M102390200	http://dx.doi.org/10.1074/jbc.M102390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11564731	hybrid			2022-12-25	WOS:000172573100025
J	Pan, L; Black, TA; Shi, Q; Jones, CA; Petrovic, N; Loudon, J; Kane, C; Sigmund, CD; Gross, KW				Pan, L; Black, TA; Shi, Q; Jones, CA; Petrovic, N; Loudon, J; Kane, C; Sigmund, CD; Gross, KW			Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM STIMULATORY FACTOR-1; CELL SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR USF; G(S) PROTEIN MUTATIONS; MOLECULAR-BIOLOGY; PROXIMAL PROMOTER; PITUITARY-TUMORS; TRANSGENIC MICE; MURINE REN-1; MUSCLE CELLS	Mouse As4.1 cells, obtained after transgene-targeted oncogenesis to induce neoplasia in renal renin expressing cells, express high levels of renin mRNA from their endogenous Ren-1(c) gene. We have previously identified a 242-base pair enhancer (coordinates -2866 to -2625 relative to the CAP site) upstream of the mouse Ren-1(c) gene. This enhancer, in combination with the proximal promoter (-117 to +6), activates transcription nearly 2 orders of magnitude in an orientation independent fashion. To further delimit sequences necessary for transcriptional activation, renin promoter-luciferase reporter gene constructs containing selected regions of the Ren-1(c) enhancer were analyzed after transfection into As4.1 cells. These results demonstrate that several regions are required for full enhancer activity. Sequences from -2699 to -2672, which are critical for the enhancer activity, contain a cyclic AMP responsive element (CRE) and an E-box. Electrophoretic mobility shift assays demonstrated that transcription factors CREB/CREM and USF1/USF2 in As4.1 cell nuclear extracts bind to oligonucleotides containing the Ren-1(c) CRE and E-box, respectively. These two elements are capable of synergistically activating transcription from the Ren-1(c) promoter. Moreover, mutation of either the CRE or E-box results in almost complete loss of enhancer activity, suggesting the critical roles these two elements play in regulating mouse Ren-1(c) gene expression. Although the Ren-1(c) gene contains a CRE, its expression is not induced by cAMP in As4.1 cells. This appears to reflect constitutive activation of protein kinase A in As4.1 cells since treatment with the protein kinase A inhibitor, H-89, caused a significant reduction in Ren-1(c) gene expression and this reduction is mediated through the CRE at -2699 to -2688.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Roswell Park Cancer Institute; University of Iowa; University of Iowa	Gross, KW (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Sts, Buffalo, NY 14263 USA.	gross@acsu.buffalo.edu	Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006, R01HL048058, R01HL061446, R01HL048459, R37HL048058] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056] Funding Source: Medline; NHLBI NIH HHS [HL61446, HL48459, HL55006, HL48058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL KJ, 1990, GENETICS, V124, P937; ABEL KJ, 1988, NUCLEIC ACIDS RES, V16, P2111, DOI 10.1093/nar/16.5.2111; Affolter M, 2001, SCIENCE, V292, P1080, DOI 10.1126/science.1060856; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Breen GAM, 2000, BBA-GENE STRUCT EXPR, V1517, P119, DOI 10.1016/S0167-4781(00)00269-4; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; Faglia G, 1996, METABOLISM, V45, P117, DOI 10.1016/S0026-0495(96)90103-1; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; Guss KA, 2001, SCIENCE, V292, P1164, DOI 10.1126/science.1058312; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Harris PE, 1996, METABOLISM, V45, P120, DOI 10.1016/S0026-0495(96)90104-3; HARTROFT PM, 1963, CIRC RES, V12, P525, DOI 10.1161/01.RES.12.5.525; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; Jensen BL, 1998, PFLUG ARCH EUR J PHY, V436, P673, DOI 10.1007/s004240050688; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Kim JC, 1998, J BIOL CHEM, V273, P26130, DOI 10.1074/jbc.273.40.26130; KINGSLEYKALLESE.M, 1996, J BIOL CHEM, V274, P34020; KURTZ A, 1989, REV PHYSIOL BIOCH P, V113, P1; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Malyankar UM, 1999, EXP CELL RES, V250, P535, DOI 10.1006/excr.1999.4537; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Marty T, 2001, DEVELOPMENT, V128, P2833; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Petrovic N, 1997, HYPERTENSION, V30, P230, DOI 10.1161/01.HYP.30.2.230; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; Shi Q, 2001, J BIOL CHEM, V276, P3597, DOI 10.1074/jbc.M008361200; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; Takahashi Y, 1997, J BIOL CHEM, V272, P30025, DOI 10.1074/jbc.272.48.30025; TAMURA K, 1994, J CLIN INVEST, V94, P1959, DOI 10.1172/JCI117547; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558; Ying LH, 1997, J BIOL CHEM, V272, P2412	55	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45530	45538		10.1074/jbc.M103010200	http://dx.doi.org/10.1074/jbc.M103010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11564732	hybrid			2022-12-25	WOS:000172573100008
J	Todisco, A; Pausawasdi, N; Ramamoorthy, S; Del Valle, J; Van Dyke, RW; Askari, FK				Todisco, A; Pausawasdi, N; Ramamoorthy, S; Del Valle, J; Van Dyke, RW; Askari, FK			Functional role of protein kinase B/Akt in gastric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FORKHEAD TRANSCRIPTION FACTOR; SUBUNIT GENE-EXPRESSION; PARIETAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; ACTIVATION; AKT; ALPHA; PHOSPHORYLATION	Epidermal growth factor (EGF) stimulates gastric acid secretion and H+/K+-ATPase a-subunit gene expression. Because EGF activates the serine-threonine protein kinase Akt, we explored the role of Akt in gastric acid secretion. Akt phosphorylation and activation were measured by kinase assays and by Western blots with an anti-phospho-Akt antibody, using lysates of purified (> 95%) canine gastric parietal cells in primary culture. EGF induced Akt phosphorylation and activation, whereas carbachol had no effect. LY294002, an inhibitor of phosphoinositide 3-kinase, completely blocked EGF induction of Akt phosphorylation, whereas the MEK1 inhibitor PD98059 and the protein kinase C inhibitor GF109203X had no effect. We examined the role of Akt in H+/K+-ATPase gene expression by Northern blotting using a canine H+/K+-ATPase a-subunit cDNA probe. The parietal cells were transduced with a multiplicity of infection of 100 of the adenoviral vector Ad.Myr-Akt, which overexpresses a constitutively active Akt gene, or with the control vector Ad.CMV-beta -gal, which expresses beta -galactosidase. Ad.Myr-Akt induced H+/K+-ATPase alpha -subunit gene expression 3-fold, whereas it failed to stimulate the gene cyclooxygenase-2, which was potently induced by carbachol in the same parietal cells. Ad.Myr-Akt induced aminopyrine uptake 4-fold, and it potentiated the stimulatory action of carbachol 3-fold. In contrast, Ad.Myr-Akt failed to induce changes in either parietal cell actin content, measured by Western blots with an anti-actin antibody or in the organization of the actin cellular cytoskeleton, visualized by fluorescein phalloidin staining and confocal microscopy. Transduction of the parietal cells with a multiplicity of infection of 100 of the adenoviral vector Ad.dom. neg.Akt, which overexpresses an inhibitor of Akt, blocked the stimulatory effect of EGF on both aminopyrine uptake and H+/K+-ATPase production, measured by Western blots with an anti-H+/K+-ATPase alpha -subunit antibody. Thus, EGF induces a cascade of events in the parietal cells that results in the activation of Akt. The functional role of AAt appears to be stimulation of gastric acid secretion through induction of H+/K+-ATPase expression.	Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Todisco, A (corresponding author), 6520 MSRB 1, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, K08DK002336] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-05813, K08DK02336, P30DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agnew BJ, 1999, J CELL SCI, V112, P2639; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Askari FK, 1996, GENE THER, V3, P381; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAMPBELL VW, 1989, J BIOL CHEM, V264, P11381; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEW CS, 1994, AM J PHYSIOL-GASTR L, V267, pG818, DOI 10.1152/ajpgi.1994.267.5.G818; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DELVALLE J, 1992, AM J PHYSIOL, V262, pG420, DOI 10.1152/ajpgi.1992.262.3.G420; DELVALLE J, 1994, TXB GASTROENTEROLOGY, P278; DEMBINSKI AB, 1985, ENDOCRINOLOGY, V116, P90, DOI 10.1210/endo-116-1-90; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Dufner A, 1999, MOL CELL BIOL, V19, P4525; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gooz M, 2000, AM J PHYSIOL-GASTR L, V278, pG981, DOI 10.1152/ajpgi.2000.278.6.G981; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; KAISE M, 1995, J BIOL CHEM, V270, P18637, DOI 10.1074/jbc.270.31.18637; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LJUNGSTROM M, 1991, AM J PHYSIOL, V260, pC67, DOI 10.1152/ajpcell.1991.260.1.C67; Muraoka A, 1996, AM J PHYSIOL-GASTR L, V271, pG1104, DOI 10.1152/ajpgi.1996.271.6.G1104; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nagahara A, 1998, AM J PHYSIOL-GASTR L, V275, pG740, DOI 10.1152/ajpgi.1998.275.4.G740; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Podolsky Daniel K., 1994, P129; Smolka AJ, 1999, BIOCHEM J, V340, P601, DOI 10.1042/0264-6021:3400601; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SOROKA CJ, 1993, EUR J CELL BIOL, V60, P76; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Takeuchi Y, 1999, AM J PHYSIOL-GASTR L, V276, pG1484, DOI 10.1152/ajpgi.1999.276.6.G1484; Takeuchi Y, 1997, AM J PHYSIOL-GASTR L, V273, pG1263, DOI 10.1152/ajpgi.1997.273.6.G1263; Van Dyke RW, 2000, HEPATOLOGY, V32, P1357, DOI 10.1053/jhep.2000.19790; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Wang LD, 1996, GASTROENTEROLOGY, V110, P469, DOI 10.1053/gast.1996.v110.pm8566594; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46436	46444		10.1074/jbc.M009645200	http://dx.doi.org/10.1074/jbc.M009645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11564730	hybrid			2022-12-25	WOS:000172573100128
J	Watson, PA; Nesterova, A; Burant, CF; Klemm, DJ; Reusch, JEB				Watson, PA; Nesterova, A; Burant, CF; Klemm, DJ; Reusch, JEB			Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH GLUCOSE; CARDIOVASCULAR-DISEASE; KINASE PATHWAY; CYCLIC-AMP; VITAMIN-E; TRANSCRIPTION; ACTIVATION; GROWTH; CREB; CBP	We hypothesized that diabetes and glucose-induced reactive oxygen species lead to depletion of cAMP response element-binding protein (CREB) content in the vasculature. In primary cultures of smooth muscle cells (SMC) high medium glucose decreased CREB function but increased SMC chemokinesis and entry into the cell cycle. These effects were blocked by pretreatment with the antioxidants. High glucose increased intracellular reactive oxygen species detected by CM-H(2)DCFA. SMC exposed to oxidative stress (H2O2) demonstrated a 3.5-fold increase in chemokinesis (p < 0.05) and accelerated entry into cell cycle, accompanied by a significant decrease in CREB content. Chronic oxidative challenge similar to the microenvironment in diabetes (glucose oxidase treatment) decreases CREB content (40-50%). Adenoviral-mediated expression of constitutively active CREB abolished the increase in chemokinesis and cell cycle progression induced by either high glucose or oxidative stress. Analysis of vessels from insulin resistant or diabetic animals indicates that CREB content is decreased in the vascular stroma. Treatment of insulin-resistant animals with the insulin sensitizer rosiglitazone restores vessel wall CREB content toward that observed in normal animals. In summary, high glucose and oxidative stress decrease SMC CREB content increase chemokinesis and entry into the cell cycle, which is blocked by antioxidants or restoration of CREB content. Thus, decreased vascular CREB content could be one of the molecular mechanisms leading to increased atherosclerosis in diabetes.	Denver Vet Affairs Med Ctr, Denver Res Inst, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Sect, Denver, CO 80220 USA; Pfizer Inc, Ann Arbor, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pfizer	Reusch, JEB (corresponding author), Denver Vet Affairs Med Ctr, Denver Res Inst, Rm 9C-120,1055 Clermont St, Denver, CO 80220 USA.		Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003; Reusch, Jane/0000-0001-8620-1003	NIDDK NIH HHS [R01 DK53969, K08 DK02351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002351, R01DK053969] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham E, 2000, CRIT CARE MED, V28, pN100, DOI 10.1097/00003246-200004001-00012; Absher PM, 1999, ATHEROSCLEROSIS, V143, P245, DOI 10.1016/S0021-9150(98)00295-0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Bornfeldt KE, 1996, TRENDS CARDIOVAS MED, V6, P143, DOI 10.1016/1050-1738(96)00038-2; Carter AM, 1997, DIABETIC MED, V14, P423, DOI 10.1002/(SICI)1096-9136(199706)14:6<423::AID-DIA421>3.3.CO;2-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Costa M, 1996, EUR J BIOCHEM, V237, P532, DOI 10.1111/j.1432-1033.1996.00532.x; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Etienne P, 1998, DIFFERENTIATION, V63, P225, DOI 10.1111/j.1432-0436.1998.00225.x; Gerstein HC, 1996, DIABETES CARE, V19, P1225, DOI 10.2337/diacare.19.11.1225; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Goalstone ML, 1999, DIABETOLOGIA, V42, P310, DOI 10.1007/s001250051156; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GROUP ND, 1995, NIH PUBLICATION; Haffner SM, 1998, ENDOCR REV, V19, P583, DOI 10.1210/er.19.5.583; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; INOGUCHI T, 1994, AM J PHYSIOL, V267, pE369, DOI 10.1152/ajpendo.1994.267.3.E369; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Karasu C, 1997, METABOLISM, V46, P872, DOI 10.1016/S0026-0495(97)90072-X; Karasu C, 2000, EUR J PHARMACOL, V392, P163, DOI 10.1016/S0014-2999(00)00140-0; Kimura I, 1998, IMMUNOPHARMACOLOGY, V40, P105, DOI 10.1016/S0162-3109(98)00024-1; Klemm DJ, 2001, J BIOL CHEM, V276, P46132, DOI 10.1074/jbc.M104769200; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; Kreisberg JI, 1996, KIDNEY INT, V50, P805, DOI 10.1038/ki.1996.379; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LopesVirella MF, 1996, DIABETES, V45, pS40, DOI 10.2337/diab.45.3.S40; Mompeo B, 1999, ANN VASC SURG, V13, P294, DOI 10.1007/s100169900260; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Osanai H, 1998, AM J CARDIOL, V81, P698, DOI 10.1016/S0002-9149(97)01021-7; Owens GK, 1996, J HYPERTENS, V14, pS55; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rybalkin SD, 1997, J CLIN INVEST, V100, P2611, DOI 10.1172/JCI119805; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; Shimomura A, 1998, J NEUROCHEM, V70, P1029; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; Suzuki LA, 2001, DIABETES, V50, P851, DOI 10.2337/diabetes.50.4.851; Wang R, 1998, Nihon Ika Daigaku Zasshi, V65, P284; Yasunari K, 1997, CIRC RES, V81, P953; Yasunari K, 1999, CIRCULATION, V99, P1370, DOI 10.1161/01.CIR.99.10.1370; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855; YOUNG JK, 1994, NEUROSCI LETT, V165, P13, DOI 10.1016/0304-3940(94)90698-X	55	67	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46142	46150		10.1074/jbc.M104770200	http://dx.doi.org/10.1074/jbc.M104770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11560925	hybrid			2022-12-25	WOS:000172573100089
J	Jana, M; Liu, XJ; Koka, S; Ghosh, S; Petro, TM; Pahan, K				Jana, M; Liu, XJ; Koka, S; Ghosh, S; Petro, TM; Pahan, K			Ligation of CD40 stimulates the induction of nitric-oxide synthase in microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RAT PRIMARY ASTROCYTES; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; C-6 GLIAL-CELLS; MULTIPLE-SCLEROSIS; C/EBP-BETA; AUTOIMMUNE ENCEPHALOMYELITIS; INHIBITS INDUCTION; GENE-EXPRESSION; MESSENGER-RNA	The present study was undertaken to investigate the role of CD40 ligation in the expression of inducible nitric-oxide synthase (iNOS) in mouse BV-2 microglial cells and primary microglia. Ligation of CD40 alone by either cross-linking antibodies against CD40 or a recombinant CD40 ligand (CD154) was unable to induce the production of NO in BV-2 microglial cells. The absence of induction of NO production by CD40 ligation alone even in CD40-overexpressed BV-2 microglial cells suggests that a signal transduced by the ligation of CD40 alone is not sufficient to induce NO production. However, CD40 ligation markedly stimulated interferon-gamma (IFN-gamma)-mediated NO production. Ligation of CD40 in CD40-overexpressed cells further stimulated IFN-gamma -induced production of NO. This stimulation of NO production was accompanied by stimulation of the iNOS protein and mRNA In addition to BV-2 glial cells, CD40 ligation also stimulated IFN-gamma -mediated NO production in mouse primary microglia and peritoneal macrophages. To understand the mechanism of induction/stimulation of iNOS, we investigated the roles of nuclear factor kappaB (NF-kappaB) and CCAAT/enhancer-binding protein beta (C/EBP beta), transcription factors responsible for the induction of iNOS. IFN-gamma alone was able to induce the activation of NF-kappaB as well as C/EBP beta. However, CD40 ligation alone induced the activation of only NF-kappaB but not of C/EBP beta, suggesting that the activation of NF-kappaB alone by CD40 ligation is not sufficient to induce the expression of iNOS and that the activation of C/EBP beta is also necessary for the expression of iNOS. Consistently, dominant-negative mutants of p65 (Delta p65) and C/EBP beta (DeltaC/EBP beta) inhibited the expression of iNOS in BV-2 microglial cells that were stimulated with the combination of IFN-gamma and CD40 ligand. Stimulation of IFN-gamma -mediated activation of NF-kappaB but not of C/EBP beta by CD40 ligation suggests that CD40 ligation stimulates the expression of iNOS in IFN-gamma -treated BV-2 microglial cells through the stimulation of NF-kappaB activation. This study illustrates a novel role for CD40 ligation in stimulating the expression of iNOS in microglial cells, which may participate in the pathogenesis of neuroinflammatory diseases.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; Yale University	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.				NINDS NIH HHS [R01 NS039940-02, R01 NS039940-01A1, R01 NS039940, NS39940] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 1997, J IMMUNOL, V158, P2940; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eberhardt W, 1998, J IMMUNOL, V160, P4961; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; Hecker M, 1997, BRIT J PHARMACOL, V120, P1067, DOI 10.1038/sj.bjp.0701026; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hu SX, 1995, GLIA, V15, P491, DOI 10.1002/glia.440150412; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JOHNSON AW, 1995, J NEUROL NEUROSUR PS, V58, P107, DOI 10.1136/jnnp.58.1.107; KOLB H, 1992, IMMUNOL TODAY, V13, P157, DOI 10.1016/0167-5699(92)90118-Q; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nguyen VT, 1998, EUR J IMMUNOL, V28, P2537, DOI 10.1002/(SICI)1521-4141(199808)28:08<2537::AID-IMMU2537>3.0.CO;2-1; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Salkowski CA, 1997, J IMMUNOL, V158, P905; Samoilova EB, 1997, J MOL MED, V75, P603, DOI 10.1007/s001090050145; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	52	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44527	44533		10.1074/jbc.M106771200	http://dx.doi.org/10.1074/jbc.M106771200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11551948	hybrid, Green Accepted			2022-12-25	WOS:000172406700026
J	Morillas, M; Gomez-Puertas, P; Roca, R; Serra, D; Asins, G; Valencia, A; Hegardt, FG				Morillas, M; Gomez-Puertas, P; Roca, R; Serra, D; Asins, G; Valencia, A; Hegardt, FG			Structural model of the catalytic core of carnitine palmitoyltransferase I and carnitine octanoyltransferase (COT) - Mutation of CPT I histidine 473 and alanine 381 and COT alanine 238 impairs the catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-LIVER; SEQUENCE ALIGNMENT; PROTEIN STRUCTURES; MALONYL-COA; SWISS-MODEL; RESIDUES; CDNA; CLASSIFICATION; INHIBITION	Carnitine palmitoyltransferase I (CPT I) and carnitine octanoyltransferase (COT) catalyze the conversion of long- and medium-chain acyl-CoA to acylcarnitines in the presence of carnitine. We propose a common three-dimensional structural model for the catalytic domain of both, based on fold identification for 200 amino acids surrounding the active site through a threading approach. The model is based on the three-dimensional structure of the rat enoyl-CoA hydratase, established by x-ray diffraction analysis. The study shows that the structural model of 200 amino acids of the catalytic site is practically identical in CPT I and COT with identical distribution of 4 beta -sheets and 6 alpha -helices. Functional analysis of the model was done by site-directed mutagenesis. When the critical histidine residue 473 in CPT I (327 in COT), localized in the acyl-CoA pocket in the model, was mutated to alanine, the catalytic activity was abolished. Mutation of the conserved alanine residue to aspartic acid, A381D (in CPT I) and A238D (in COT), which are 92/89 amino acids far from the catalytic histidine, respectively (but very close to the acyl-CoA pocket in the structural model), decreased the activity by 86 and 80%, respectively. The K-m for acyl-CoA increased 6-8-fold, whereas the K-m for carnitine hardly changed. The inhibition of the mutant CPT I by malonyl-CoA was not altered. The structural model explains the loss of activity reported for the CPT I mutations R451A, W452A, D454G, W391A, del 8395, P479L, and L484P, all of which occur in or near the modeled catalytic domain.	Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; CSIC, Natl Biotechnol Ctr, Prot Design Grp, E-28049 Madrid, Spain	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC)	Hegardt, FG (corresponding author), Sch Pharm, Dept Biochem, Avda Diagonal 643, E-08028 Barcelona, Spain.	hegardt@farmacia.far.ub.es	Valencia, Alfonso/I-3127-2015; Serra, Dolors/L-3657-2014; Gomez-Puertas, Paulino/G-8821-2014	Valencia, Alfonso/0000-0002-8937-6789; Serra, Dolors/0000-0002-4936-4206; Gomez-Puertas, Paulino/0000-0003-3131-729X; Morillas, Montserrat/0000-0001-7068-3167				a'Bhaird NN, 1998, BIOCHEM J, V330, P1029, DOI 10.1042/bj3301029; ABHAIRD NN, 1992, BIOCHEM J, V286, P637, DOI 10.1042/bj2860637; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Brown NF, 2001, J LIPID RES, V42, P1134; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; Cronin CN, 1998, J BIOL CHEM, V273, P24465, DOI 10.1074/jbc.273.38.24465; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V238, P784, DOI 10.1006/bbrc.1997.7390; Cronin CN, 1997, EUR J BIOCHEM, V247, P1029, DOI 10.1111/j.1432-1033.1997.01029.x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Engel CK, 1998, J MOL BIOL, V275, P847, DOI 10.1006/jmbi.1997.1491; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Ijlst L, 1998, J CLIN INVEST, V102, P527, DOI 10.1172/JCI2927; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; JONES DT, 1995, PROTEINS, V23, P387, DOI 10.1002/prot.340230312; Jones DT, 1999, PROTEINS, P104; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Morillas M, 2000, BIOCHEM J, V351, P495, DOI 10.1042/0264-6021:3510495; Morillas M, 2000, FEBS LETT, V466, P183, DOI 10.1016/S0014-5793(99)01788-3; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Pazos F., 1997, BIOCOMPUTING EMERGEN, P132; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMALIX W, 1993, J BIOL CHEM, V268, P27428; Sherman F, 1986, LAB COURSE MANUAL ME; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Leij FR, 2000, MOL GENET METAB, V71, P139, DOI 10.1006/mgme.2000.3055; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3	47	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45001	45008		10.1074/jbc.M106920200	http://dx.doi.org/10.1074/jbc.M106920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11553629	hybrid			2022-12-25	WOS:000172406700089
J	Abe, Y; Matsumoto, S; Wei, SM; Nezu, K; Miyoshi, A; Kito, K; Ueda, N; Shigemoto, K; Hitsumoto, Y; Nikawa, J				Abe, Y; Matsumoto, S; Wei, SM; Nezu, K; Miyoshi, A; Kito, K; Ueda, N; Shigemoto, K; Hitsumoto, Y; Nikawa, J			Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED KILLER-CELLS; SACCHAROMYCES-CEREVISIAE; KILLING ACTIVITY; TYROSINE KINASE; NUCLEAR IMPORT; DNA-DAMAGE; LAK CELLS; LYMPHOTOXIN; GENE; P53	A human protein kinase, p53-related protein kinase (PRPK), was cloned from an interleukin-2-activated cytotoxic T-cell subtraction library. PRPK appears to be a homologue of a growth-related yeast serine/threonine protein kinase, YGR262c. However, a complementation assay using YGR262c-disrupted yeast indicated that PRPK is not functionally identical to the yeast enzyme. PRPK expression was observed in interleukin-2-activated cytotoxic T-cells, some human epithelial tumor cell lines, and the testes. The intrinsic transcriptional activity of p53 was up-regulated by a transient transfection of PRPK to COS-7 cells. PRPK was shown to bind to p53 and to phosphorylate p53 at Ser-15. These results indicate that PRPK may play an important role in the cell cycle and cell apoptosis through phosphorylation of p53.	Ehime Univ, Sch Med, Dept Pathol & Hyg 1, Shigenobu, Ehime 7910295, Japan; Okayama Univ, Fac Sci, Dept Biol Chem, Div Clin Immunol, Okayama 7000005, Japan; Kyushu Inst Technol, Fac Comp Sci & Syst Engn, Dept Biochem Engn & Sci, Kawazu, Fukuoka 8208502, Japan	Ehime University; Okayama University; Kyushu Institute of Technology	Abe, Y (corresponding author), Ehime Univ, Sch Med, Dept Pathol & Hyg 1, Shigenobu, Ehime 7910295, Japan.							ABE Y, 1993, LYMPHOKINE CYTOK RES, V12, P279; ABE Y, 1991, JPN J CANCER RES, V82, P23, DOI 10.1111/j.1349-7006.1991.tb01740.x; ABE Y, 1992, LYMPHOKINE CYTOK RES, V11, P115; Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; AIELLO L, 1979, VIROLOGY, V94, P460, DOI 10.1016/0042-6822(79)90476-8; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Becker W, 1996, BBA-MOL CELL RES, V1312, P63, DOI 10.1016/0167-4889(96)00036-5; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Clemente ML, 1997, YEAST, V13, P287, DOI 10.1002/(SICI)1097-0061(19970315)13:3<287::AID-YEA75>3.0.CO;2-5; HOLLINGS PE, 1997, HUM GENET, V93, P609; HORIUCHI A, 1994, CLIN EXP IMMUNOL, V96, P152; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kueng P, 1997, J CELL BIOL, V139, P1851, DOI 10.1083/jcb.139.7.1851; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MIYAKE M, 1992, EUR J IMMUNOL, V22, P2147, DOI 10.1002/eji.1830220828; Nikawa J, 1998, NUCLEIC ACIDS RES, V26, P860, DOI 10.1093/nar/26.3.860; Park SH, 1997, CYTOGENET CELL GENET, V77, P271, DOI 10.1159/000134595; QINGBAI S, 2000, J BIOL CHEM, V275, P20444; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Stocchetto S, 1997, FEBS LETT, V414, P171, DOI 10.1016/S0014-5793(97)00980-0; TANGUAY DA, 1994, MOL IMMUNOL, V31, P643, DOI 10.1016/0161-5890(94)90173-2; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Toshima J, 1998, BIOCHEM BIOPH RES CO, V249, P107, DOI 10.1006/bbrc.1998.9099; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331	27	57	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44003	44011		10.1074/jbc.M105669200	http://dx.doi.org/10.1074/jbc.M105669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546806	hybrid			2022-12-25	WOS:000172297700068
J	Diviani, D; Soderling, J; Scott, JD				Diviani, D; Soderling, J; Scott, JD			AKAP-Lbc anchors protein kinase A and nucleates G alpha(12)-selective Rho-mediated stress fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SIGNALING ENZYMES; SCAFFOLD PROTEIN; FAMILY GTPASES; CELL-POLARITY; P115 RHOGEF; DBL FAMILY; CG-NAP; G-ALPHA(13); ONCOGENE	Guanine nucleotide exchange factors of the Dbl family relay signals from membrane receptors to Rho family GTPases. We now demonstrate that a longer transcript of the Lbc gene encodes a chimeric molecule, which we have called AKAP-Lbc, that functions as an A-kinase-anchoring protein (AKAP) and a Rho-selective guanine nucleotide exchange factor. Expression of AKAP-Lbc in fibroblasts favors the formation of stress fibers in a Rho-dependent manner. Application of lysophosphatidic acid or selective expression of G alpha (12) enhances cellular AKAP-Lbc activation. Furthermore, biochemical studies indicate that AKAP-Lbc functions as an adaptor protein to selectively couple G alpha (12) to Rho. Thus, AKAP-Lbc anchors PKA and nucleates the assembly of a Rho-mediated signaling pathway.	Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA	Howard Hughes Medical Institute; Oregon Health & Science University	Scott, JD (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Diviani, Dario/0000-0003-4375-3718	NIDDK NIH HHS [DK44239] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Corbin J D, 1974, Methods Enzymol, V38, P287; Diviani D, 2001, J CELL SCI, V114, P1431; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Scott JN, 2000, SCI AM, V282, P72, DOI 10.1038/scientificamerican0600-72; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Takahashi M, 2000, J BIOL CHEM, V275, P34592, DOI 10.1074/jbc.M005285200; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Takenawa T, 2001, J CELL SCI, V114, P1801; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; TOKSOZ D, 1994, ONCOGENE, V9, P621; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	48	189	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44247	44257		10.1074/jbc.M106629200	http://dx.doi.org/10.1074/jbc.M106629200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546812	hybrid			2022-12-25	WOS:000172297700097
J	Dong, K; Xu, J; Vanoye, CG; Welch, R; MacGregor, GG; Giebisch, G; Hebert, SC				Dong, K; Xu, J; Vanoye, CG; Welch, R; MacGregor, GG; Giebisch, G; Hebert, SC			An amino acid triplet in the NH2 terminus of rat ROMK1 determines interaction with SUR2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; SULFONYLUREA RECEPTOR; REGULATOR; STOICHIOMETRY; GLIBENCLAMIDE; SENSITIVITY; EXPRESSION; CLONING; PROTEIN; KIR6.2	ATP-regulated (K-ATP) channels are formed by an inward rectifier pore-forming subunit (Kir) and a sulfonylurea (glibenclamide)-binding protein, a member of the ATP binding cassette family (sulfonylurea receptor (SUR) or cystic fibrosis transmembrane conductance regulator). The latter is required to confer glibenclamide sensitivity to KATP channels. In the mammalian kidney ROMK1-3 are components of K-ATP channels that mediate K+ secretion into urine. ROMK1 and ROMK3 splice variants share the core polypeptide of ROMK2 but also have distinct NH2-terminal extensions of 19 and 26 amino acids, respectively. The SUR2B is also expressed in rat kidney tubules and may combine with Kir.1 to form renal K-ATP channels. Our previous studies showed that co-expression of ROMK2, but not ROMK1 or ROMK3, with rat SUR2B in oocytes generated glibenclamide-sensitive K+ currents. These data suggest that the NH2-terminal extensions in both ROMK1 and ROMK3 block ROMK-SUR2B interaction. Seven amino acids in the NH2-terminal extensions of ROMK1 and ROMK3 are identical (amino acids 13-19 in ROMK1 and 20-26 in ROMK3) and may determine ROMK-SUR2B interaction. We constructed a series of hemagglutinin-tagged ROM]KI NH2-terminal deletion and substitution mutants and examined glibenclamide-sensitive K+ currents in oocytes when co-expressed with SUR2B. These studies identified an amino acid triplet "IRA" within the conserved segment in the NH2 terminus of ROMK1 and ROMK3 that blocks the ability of SUR2B to confer glibenclamide sensitivity to the expressed K+ currents. The position of this triplet in the ROMK1 NH2-terminal extension is also important for the ROMK-SUR2B interactions. In vitro co-translation and immunoprecipitation studies with hemagglutinin-tagged ROMK mutants and SUR2B indicted that direct interaction between these two proteins is required for glibenclamide sensitivity of induced K+ currents in oocytes. These results suggest that the IRA triplet in the NH2-terminal extensions of both ROMK1 and ROMK3 plays a key role in subunit assembly of the renal secretary K-ATP channel.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Vanderbilt Univ, Med Ctr, Div Med Genet, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Nephrol, Nashville, TN 37232 USA	Yale University; Vanderbilt University; Vanderbilt University	Hebert, SC (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	steven.hebert@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054998, R01DK037605, R01DK054999] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54999, DK54998, DK37605] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Beesley AH, 1999, PFLUG ARCH EUR J PHY, V438, P1, DOI 10.1007/s004240050872; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Bryan J, 1999, BBA-BIOMEMBRANES, V1461, P285, DOI 10.1016/S0005-2736(99)00164-9; Cahill P, 2000, J BIOL CHEM, V275, P16697, DOI 10.1074/jbc.M910205199; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KOZAK M, 1991, J BIOL CHEM, V266, P19867; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Misler S, 1992, Curr Opin Nephrol Hypertens, V1, P21, DOI 10.1097/00041552-199210000-00005; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Reimann F, 1999, J PHYSIOL-LONDON, V518, P325, DOI 10.1111/j.1469-7793.1999.0325p.x; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Tanemoto M, 2000, AM J PHYSIOL-RENAL, V278, pF659, DOI 10.1152/ajprenal.2000.278.4.F659; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44347	44353		10.1074/jbc.M108072200	http://dx.doi.org/10.1074/jbc.M108072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11567030	hybrid			2022-12-25	WOS:000172297700108
J	Wang, NS; Unkila, MT; Reineks, EZ; Distelhorst, CW				Wang, NS; Unkila, MT; Reineks, EZ; Distelhorst, CW			Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CHROMOSOMAL BREAKPOINT; SUBCELLULAR LOCATION; OUTER-MEMBRANE; BCL-X(L); PROTEIN; FAMILY; LOCALIZATION; DIMERIZATION; ACTIVATION	Bcl-2 protein family members function either to promote or inhibit programmed cell death. Bcl-2, typically an inhibitor of apoptosis, has also been demonstrated to have pro-apoptotic activity (Cheng, E. H., Kirsch, D. G., Clem, R. J., et al. (1997) Science 278, 1966-1968). The pro-apoptotic activity has been attributed to the cleavage of Bcl-2 by caspase-3, which converts Bcl-2 to a proapoptotic molecule. Bcl-2 is a membrane protein that is localized in the endoplasmic reticulum (ER) membrane, the outer mitochondrial membrane, and the nuclear envelope. Here, we demonstrate that transient expression of Bcl-2 at levels comparable to those found in stably transfected cells induces apoptosis in human embryonic kidney 293 cells and in the human breast cell line MDA-MB-468 cells. Furthermore, we have targeted Bcl-2 specifically to either the ER or the outer mitochondrial membrane to test whether induction of apoptosis by Bcl-2 is dependent upon its localization within either of these membranes. Our findings indicate that Bcl-2 specifically targeted to the mitochondria induces cell death, whereas Bcl-2 that is targeted to the ER does not. The expression of Bcl-2 does result in its cleavage to a 20-kDa protein; however, mutation of the caspase-3 cleavage site (D34A) does not inhibit its ability to induce cell death. Additionally, we find that transiently expressed ER-targeted Bcl-2 inhibits cell death induced by Bax overexpression. In conclusion, the ability of Bcl-2 to promote apoptosis is associated with its localization at the mitochondria. Furthermore, the ability of ER-targeted Bcl-2 to protect against Bax-induced apoptosis suggests that the ER localization of Bcl-2 may play an important role in its protective function.	Case Western Reserve Univ, Dept Med, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Dept Med, Ctr Comprehens Canc, 329 Biomed Res Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.				NCI NIH HHS [R01 CA85804, T32 CA59366] Funding Source: Medline; NIGMS NIH HHS [T32GM07250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085804, T32CA059366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAO Y, 1994, CANCER RES, V54, P2468; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dragowska WH, 2000, CYTOMETRY, V40, P346, DOI 10.1002/1097-0320(20000801)40:4<346::AID-CYTO10>3.0.CO;2-W; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; JANIAK F, 1994, J BIOL CHEM, V269, P9842; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; SHERWOOD SW, 1995, METHOD CELL BIOL, V46, P77; Shinoura N, 1999, CANCER RES, V59, P4119; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wei MC, 2000, GENE DEV, V14, P2060; Wolf CM, 1999, BIOCHEM BIOPH RES CO, V254, P821, DOI 10.1006/bbrc.1998.0132; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	46	148	154	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44117	44128		10.1074/jbc.M101958200	http://dx.doi.org/10.1074/jbc.M101958200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546793	hybrid			2022-12-25	WOS:000172297700082
J	Beck, CG; Studer, C; Zuber, JF; Demange, BJ; Manning, U; Urfer, R				Beck, CG; Studer, C; Zuber, JF; Demange, BJ; Manning, U; Urfer, R			The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; T1/35KDA FAMILY; VACCINIA VIRUS; MCP-1 RECEPTOR; GROWTH-FACTOR; COWPOX VIRUS; RESIDUES; COMPLEX; DOMAIN	Monocyte chemoattractant protein-1 (MCP-1) is a chemotactic cytokine mainly acting on monocytes and T cells that elicits its biological effects by interacting with the seven-transmembrane helix receptor CCR2B. The vaccinia virus strain Lister and many other poxviruses express soluble proteins (vCCI) that bind MCP-1 and other CC chemokines and inhibit their function. In order to define the interaction site of MCP-1 with vCCI from vaccinia, surface exposed residues of MCP-1 were identified and mutated to alanine. The MCP-1 variants were expressed, purified, and their interaction with vCCI was characterized. The site on MCP-1 for vCCI binding is dominated by arginine 18 with important additional contributions from tyrosine 13 and arginine 24. These residues define a binding site that largely overlaps with the CCR2B receptor interaction site. The viral chemokine-binding protein vCCI thus inhibits the biological function of MCP-1 by directly masking its CCR2B receptor-binding site.	Novartis Pharma AG, Dept Arthrit Biol, CH-4002 Basel, Switzerland	Novartis	Urfer, R (corresponding author), AGY Therapeut, 290 Utah Ave, San Francisco, CA 94080 USA.	roman@agyinc.com						Alcami A, 1998, J IMMUNOL, V160, P624; Beall CJ, 1996, BIOCHEM J, V313, P633, DOI 10.1042/bj3130633; Carfi A, 1999, P NATL ACAD SCI USA, V96, P12379, DOI 10.1073/pnas.96.22.12379; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Dabbagh K, 2000, J IMMUNOL, V165, P3418, DOI 10.4049/jimmunol.165.6.3418; Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; Lalani AS, 2000, IMMUNOL TODAY, V21, P100, DOI 10.1016/S0167-5699(99)01556-X; Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Lalani AS, 1997, J LEUKOCYTE BIOL, V62, P570, DOI 10.1002/jlb.62.5.570; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; MARTINEZPOMARES L, 1995, VIROLOGY, V206, P591, DOI 10.1016/S0042-6822(95)80076-X; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; NOVAK EJ, 1994, CYTOMETRY, V17, P135, DOI 10.1002/cyto.990170205; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; PATEL AH, 1990, J GEN VIROL, V71, P2013, DOI 10.1099/0022-1317-71-9-2013; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Steitz SA, 1998, FEBS LETT, V430, P158, DOI 10.1016/S0014-5793(98)00637-1; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	39	44	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43270	43276		10.1074/jbc.M106305200	http://dx.doi.org/10.1074/jbc.M106305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551937	hybrid			2022-12-25	WOS:000172169300083
J	Belden, WJ; Barlowe, C				Belden, WJ; Barlowe, C			Distinct roles for the cytoplasmic tail sequences of Emp24p and Erv25p in transport between the endoplasmic reticulum and Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPII-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; FAMILY MEMBERS; YEAST; MEMBRANE; COATOMER; LOCALIZATION; COMPONENT	Heteromeric complexes of p24 proteins cycle between early compartments of the secretory pathway and are required for efficient protein sorting. Here we investigated the role of cytoplasmically exposed tail sequences on two p24 proteins, Emp24p and Erv25p, in directing their movement and subcellular location in yeast. Studies on a series of deletion and chimeric Emp24p-Erv25p proteins indicated that the tail sequences impart distinct functional properties that were partially redundant but not entirely interchangeable. Export of an Emp24p-Erv25p complex from the endoplasmic reticulum (ER) did not depend on two other associated p24 proteins, Erp1 and Erp2p. To examine interactions between the Emp24p and Erv25p tail sequences with the COPI and COPII coat proteins, binding experiments with immobilized tail peptides and coat proteins were performed. The Emp24p and Erv25p tail sequences bound the Sec13p/Sec31p subunit of the COPII coat (K-d similar to 100 mum), and binding depended on a pair of aromatic residues found in both tail sequences. COPI subunits also bound to these Emp24p and Erv25p peptides; however, the Erv25p tail sequence, which contains a dilysine motif, bound COPI more efficiently. These results suggest that both the Emp24p and Erv25p cytoplasmic sequences contain a di-aromatic motif that binds subunits of the COPII coat and promotes export from the ER. The Erv25p tail sequence binds COPI and is responsible for returning this complex to the ER.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	Barlowe@Dartmouth.edu						ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Belden WJ, 2001, MOL BIOL CELL, V12, P957, DOI 10.1091/mbc.12.4.957; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Ciufo LF, 2000, J BIOL CHEM, V275, P8382, DOI 10.1074/jbc.275.12.8382; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DUDEN R, 1994, J BIOL CHEM, V269, P24486; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Rojo M, 2000, J CELL SCI, V113, P1043; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WADA I, 1991, J BIOL CHEM, V266, P19599; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	37	60	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43040	43048		10.1074/jbc.M108113200	http://dx.doi.org/10.1074/jbc.M108113200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560939	hybrid			2022-12-25	WOS:000172169300055
J	Murphy, OJ; Yi, XH; Weis, RM; Thompson, LK				Murphy, OJ; Yi, XH; Weis, RM; Thompson, LK			Hydrogen exchange reveals a stable and expandable core within the aspartate receptor cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; DISULFIDE CROSS-LINKING; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; CONFORMATIONAL-CHANGES; COVALENT MODIFICATION; SERINE CHEMORECEPTOR; F-19 NMR	Intensive study of bacterial chemoreceptors has not yet revealed how receptor methylation and ligand binding alter the interactions between the receptor cytoplasmic domain and the CheA kinase to control kinase activity. Both monomeric and dimeric forms of an Asp receptor cytoplasmic fragment have been shown to be highly dynamic, with a small core of slowly exchanging amide hydrogens (Seeley, S. K., Weis, R. M., and Thompson, L. K. (1996) Biochemistry 35, 5199-5206). Hydrogen exchange studies of the wildtype cytoplasmic fragment and an S461L mutant thought to mimic the kinase-inactivating state are used to investigate the relationship between the stable core and dimer dissociation. Our results establish that (i) decreasing pH stabilizes the dimeric state, (ii) the stable core is present also in the transition state for dissociation, and (iii) this core is expanded significantly by small changes in electrostatic and hydrophobic interactions. These kinase-inactivating changes stabilize both the monomeric and the dimeric states of the protein, which has interesting implications for the mechanism of kinase activation. We conclude that the cytoplasmic domain is a flexible region poised for stabilization by small changes in electrostatic and hydrophobic interactions such as those caused by methylation of glutamate residues and by ligand-induced conformational changes during signaling.	Univ Massachusetts, Grad Program Mol & Cellular Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Weis, RM (corresponding author), Univ Massachusetts, Grad Program Mol & Cellular Biol, Amherst, MA 01003 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047601, R01GM053210, R29GM047601] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047601, GM47601, GM53210] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; Amsler CD., 1995, 2 COMPONENT SIGNAL T, P89; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAI YW, 1994, PROTEINS, V20, P4, DOI 10.1002/prot.340200103; Bass RB, 1999, BIOCHEMISTRY-US, V38, P9317, DOI 10.1021/bi9908179; Bass RB, 1999, STRUCT FOLD DES, V7, P829, DOI 10.1016/S0969-2126(99)80106-3; Biemann HP, 1996, J BIOL CHEM, V271, P27927, DOI 10.1074/jbc.271.44.27927; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; Bornhorst JA, 2000, BIOCHEMISTRY-US, V39, P9486, DOI 10.1021/bi0002737; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Clarke J, 1998, CURR OPIN STRUC BIOL, V8, P112, DOI 10.1016/S0959-440X(98)80018-3; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Danielson MA, 1996, ANNU REV BIOPH BIOM, V25, P163, DOI 10.1146/annurev.bb.25.060196.001115; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; Englander S W, 1978, Methods Enzymol, V49, P24; Englander S W, 1972, Methods Enzymol, V26, P406; ENGLANDER SW, 1963, BIOCHEMISTRY-US, V2, P798, DOI 10.1021/bi00904a030; ENGLANDER SW, 1969, BIOPOLYMERS, V7, P379, DOI 10.1002/bip.1969.360070309; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; Jurica MS, 1998, STRUCT FOLD DES, V6, P809, DOI 10.1016/S0969-2126(98)00082-3; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUWAJIMA K, 1976, J MOL BIOL, V106, P359, DOI 10.1016/0022-2836(76)90091-7; LeMoual H, 1997, BIOCHEMISTRY-US, V36, P13441, DOI 10.1021/bi9713207; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; Manson MD, 1998, J BACTERIOL, V180, P1009, DOI 10.1128/JB.180.5.1009-1022.1998; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MAYO SL, 1993, SCIENCE, V262, P873, DOI 10.1126/science.8235609; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; Murphy OJ, 2001, BIOCHEMISTRY-US, V40, P1358, DOI 10.1021/bi0015109; MUSKAVITCH MA, 1978, SCIENCE, V201, P63, DOI 10.1126/science.351803; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Seeley SK, 1996, BIOCHEMISTRY-US, V35, P5199, DOI 10.1021/bi9524979; Seeley SK, 1996, BIOCHEMISTRY-US, V35, P16336, DOI 10.1021/bi961749i; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Stock J, 2000, CURR BIOL, V10, pR11, DOI 10.1016/S0960-9822(99)00248-1; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; SwintKruse L, 1996, BIOCHEMISTRY-US, V35, P171, DOI 10.1021/bi9517603; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; Trammell MA, 1999, BIOCHEMISTRY-US, V38, P329, DOI 10.1021/bi981964u; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225; WOODWARD CK, 1980, BIOPHYS J, V32, P561, DOI 10.1016/S0006-3495(80)84990-3; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; WU JR, 1995, BIOCHEMISTRY-US, V34, P3056, DOI 10.1021/bi00009a037; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	66	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43262	43269		10.1074/jbc.M105585200	http://dx.doi.org/10.1074/jbc.M105585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553619	hybrid			2022-12-25	WOS:000172169300082
J	Cai, YF; Singh, BB; Aslanukov, A; Zhao, HY; Ferreira, PA				Cai, YF; Singh, BB; Aslanukov, A; Zhao, HY; Ferreira, PA			The docking of kinesins, KIF5B and KIF5C, to Ran-binding protein 2 (RanBP2) is mediated via a novel RanBP2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BOVINE BRAIN KINESIN; NUCLEAR-PORE COMPLEX; AXONAL-TRANSPORT; GTP HYDROLYSIS; EXPORT; IMPORT; MOTOR; EXPRESSION; REGULATOR	The Ran-binding protein 2 (RanBP2) is a vertebrate mosaic protein composed of four interspersed RanGTPase binding domains (RBDs), a variable and species-specific zinc finger cluster domain, leucine-rich, cyclophilin, and cyclophilin-like (CLD) domains. Functional mapping of RanBP2 showed that the domains, zinc finger and CLD, between RBD1 and RBD2, and RBD3 and RBD4, respectively, associate specifically with the nuclear export receptor, CRM1/exportin-1, and components of the 19 S regulatory particle of the 26 S proteasome. Now, we report the mapping of a novel RanBP2 domain located between RBD2 and RBD3, which is also conserved in the partially duplicated isoform RanBP2L1. Yet, this domain leads to the neuronal association of only RanBP2 with two kinesin microtubule-based motor proteins, KIF5B and KIF5C. These kinesins associate directly in vitro and in vivo with RanBP2. Moreover, the kinesin light chain and RanGTPase are part of this RanBP2 macroassembly complex. These data provide evidence of a specific docking site in RanBP2 for KIF5B and KIF5C. A model emerges whereby RanBP2 acts as a selective signal integrator of nuclear and cytoplasmic trafficking pathways in neurons.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Ferreira, PA (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ferreira@mcw.edu	Ferreira, Paulo/A-3893-2008; Ferreira, Paulo A/S-4209-2016	Ferreira, Paulo A/0000-0003-4585-1717; Singh, Brij/0000-0003-0535-5997	NATIONAL EYE INSTITUTE [R01EY011993, R01EY012665] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011993, EY11993, EY012665] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Adler R., 1986, RETINA MODEL CELL BI, P297; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BostUsinger L, 1997, EXP EYE RES, V64, P781, DOI 10.1006/exer.1996.0271; Braslavsky CIV, 2000, BIOCHEMISTRY-US, V39, P11629, DOI 10.1021/bi001010f; BUTLER G, 1994, BBA-GENE STRUCT EXPR, V1219, P711, DOI 10.1016/0167-4781(94)90233-X; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fauser S, 2001, MAMM GENOME, V12, P406, DOI 10.1007/s003350010291; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Ferreira PA, 1998, J BIOL CHEM, V273, P24676, DOI 10.1074/jbc.273.38.24676; Ferreira PA, 1997, P NATL ACAD SCI USA, V94, P1556, DOI 10.1073/pnas.94.4.1556; Ferreira PA, 2000, METHOD ENZYMOL, V315, P455; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; Nothwang HG, 1998, GENOMICS, V47, P383, DOI 10.1006/geno.1997.5119; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; REN MD, 1995, MOL CELL BIOL, V15, P2117; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Roepman R, 2000, HUM MOL GENET, V9, P2095, DOI 10.1093/hmg/9.14.2095; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	77	76	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41594	41602		10.1074/jbc.M104514200	http://dx.doi.org/10.1074/jbc.M104514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553612	hybrid			2022-12-25	WOS:000172450400010
J	Sweet, DH; Miller, DS; Pritchard, JB				Sweet, DH; Miller, DS; Pritchard, JB			Ventricular choline transport - A role for organic cation transporter 2 expressed in choroid plexus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; TISSUE DISTRIBUTION PATTERN; FUNCTIONAL-CHARACTERISTICS; RAT-KIDNEY; ANION TRANSPORTER; PROXIMAL TUBULES; APICAL MEMBRANE; BRAIN; CLONING; LOCALIZATION	To determine whether organic cation transporter (OCT) family members might mediate choline transport in choroid plexus (CP), the handling of choline by cloned transporters and by intact CP isolated from the adult rat was investigated. Expression of OCT1 and OCT2 in Xenopus oocytes increased hemicholinium-3-sensitive choline uptake. In contrast, OCT3 did not mediate choline transport. Estimated K-m values for choline in rOCT1-, rOCT2-, and hOCT2-expressing oocytes were 346 +/- 50, 441 +/- 67, and 102 +/- 80 mum, respectively. Membrane potential was the major driving force for choline uptake in rat and human OCT2-expressing oocytes and in intact CP in vitro. Lowering of medium pH (6 versus 7.4) was equally effective at inhibiting choline uptake in CP, suggesting that there might be a non-OCT component of choline uptake that is responsive to an H+ gradient. However, choline efflux from CP was not stimulated by a trans-applied H+ gradient. Choline uptake by CP was Na+-independent with an estimated K-m of 183 mum. Reverse transcriptase-polymerase chain reaction detected OCT2 and OCT3, but not OCT1, mRNA expression in CP. Transfection of intact CP with a rOCT2/green fluorescent protein fusion construct resulted in strong apical membrane fluorescence with no detectable signal in the basal and lateral plasma membranes. These data indicate that OCT2 mediates choline transport across the ventricular membrane of CP.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Sweet, DH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Sweet, Douglas H/H-7914-2013	Sweet, Douglas H/0000-0002-8911-9184	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080048, ZIAES080048, Z01ES048014, Z01ES080054] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AQUILONIUS SM, 1972, ACTA PHYSIOL SCAND, V85, P78, DOI 10.1111/j.1748-1716.1972.tb05237.x; Arndt P, 2001, AM J PHYSIOL-RENAL, V281, pF454, DOI 10.1152/ajprenal.2001.281.3.F454; BRODIE BB, 1960, J PHARMACOL EXP THER, V130, P20; Budiman T, 2000, J BIOL CHEM, V275, P29413, DOI 10.1074/jbc.M004645200; Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; CORNFORD EM, 1978, J NEUROCHEM, V30, P299, DOI 10.1111/j.1471-4159.1978.tb06530.x; CREWS FT, 1980, J NEUROCHEM, V34, P1491, DOI 10.1111/j.1471-4159.1980.tb11229.x; Dudley AJ, 2000, BRIT J PHARMACOL, V131, P71, DOI 10.1038/sj.bjp.0703518; EHRLICH BE, 1982, BRAIN RES, V250, P245, DOI 10.1016/0006-8993(82)90418-8; Erb C, 1999, BIOCHEM PHARMACOL, V57, P681, DOI 10.1016/S0006-2952(98)00338-4; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Grundemann D, 1997, J BIOL CHEM, V272, P10408; Grundemann D, 1999, MOL PHARMACOL, V56, P1, DOI 10.1124/mol.56.1.1; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HAMEL E, 1990, BRAIN RES, V516, P301, DOI 10.1016/0006-8993(90)90931-Z; HAPPE HK, 1993, J NEUROCHEM, V60, P1191, DOI 10.1111/j.1471-4159.1993.tb03277.x; HEDIGER MA, 1995, J PHYSL, V482, P7; Jenden D J, 1990, Adv Neurol, V51, P131; JOPE RS, 1979, BRAIN RES REV, V1, P313, DOI 10.1016/0165-0173(79)90009-2; Karbach U, 2000, AM J PHYSIOL-RENAL, V279, pF679, DOI 10.1152/ajprenal.2000.279.4.F679; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; KLEIN J, 1993, NEUROCHEM INT, V22, P293, DOI 10.1016/0197-0186(93)90058-D; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; KOPPEN A, 1993, J PHARMACOL EXP THER, V266, P720; KUHAR MJ, 1978, J NEUROCHEM, V30, P15, DOI 10.1111/j.1471-4159.1978.tb07029.x; LANMAN RC, 1980, J PHARMACOL EXP THER, V215, P563; LINDVALLAXELSSON M, 1989, EXP BRAIN RES, V77, P605; MALSTROM K, 1987, BIOCHIM BIOPHYS ACTA, V902, P269, DOI 10.1016/0005-2736(87)90305-1; Murakami H, 2000, PHARMACEUT RES, V17, P1526, DOI 10.1023/A:1007613326759; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Pritchard JB, 1999, J BIOL CHEM, V274, P33382, DOI 10.1074/jbc.274.47.33382; PRITCHARD JB, 1988, AM J PHYSIOL, V255, pF597, DOI 10.1152/ajprenal.1988.255.4.F597; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Rapoport SI, 1976, BLOOD BRAIN BARRIER; Ribeiro CMP, 2000, CELL CALCIUM, V27, P175, DOI 10.1054/ceca.2000.0108; Sawada N, 1999, J PHARM PHARMACOL, V51, P847, DOI 10.1211/0022357991773050; Schweifer N, 1996, MAMM GENOME, V7, P735, DOI 10.1007/s003359900223; Segal M., 1998, INTRO BLOOD BRAIN BA, P251; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SPECTOR R, 1979, J NEUROCHEM, V33, P291, DOI 10.1111/j.1471-4159.1979.tb11731.x; SPECTOR R, 1979, J NEUROCHEM, V33, P895, DOI 10.1111/j.1471-4159.1979.tb09919.x; Sweet D. H., 1997, FASEB Journal, V11, pA278; Sweet DH, 1999, AM J PHYSIOL-RENAL, V277, pF890, DOI 10.1152/ajprenal.1999.277.6.F890; Sweet DH, 2000, AM J PHYSIOL-RENAL, V279, pF826, DOI 10.1152/ajprenal.2000.279.5.F826; Sweet DH, 1999, AM J PHYSIOL-RENAL, V276, pF864, DOI 10.1152/ajprenal.1999.276.6.F864; Sweet DH, 1999, CELL BIOCHEM BIOPHYS, V31, P89, DOI 10.1007/BF02738157; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Terashita S, 1998, BBA-BIOMEMBRANES, V1369, P1, DOI 10.1016/S0005-2736(97)00207-1; Urakami Y, 1998, J PHARMACOL EXP THER, V287, P800; Uwai Y, 2000, EUR J PHARMACOL, V409, P31, DOI 10.1016/S0014-2999(00)00837-2; Vargas HM, 1996, LIFE SCI, V58, P1995, DOI 10.1016/0024-3205(96)00190-7; Villalobos AR, 1999, AM J PHYSIOL-CELL PH, V276, pC1288, DOI 10.1152/ajpcell.1999.276.6.C1288; Walsh R. C., 1996, FASEB Journal, V10, pA127; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1998, FASEB J, V12, pA1042; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482; Wu XA, 2000, AM J PHYSIOL-RENAL, V279, pF449, DOI 10.1152/ajprenal.2000.279.3.F449; Yabuuchi H, 1999, J PHARMACOL EXP THER, V289, P768; YAMAMURA HI, 1973, J NEUROCHEM, V21, P1355, DOI 10.1111/j.1471-4159.1973.tb06022.x; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913; Zhang L, 1998, ANNU REV PHARMACOL, V38, P431, DOI 10.1146/annurev.pharmtox.38.1.431	67	118	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41611	41619		10.1074/jbc.M108472200	http://dx.doi.org/10.1074/jbc.M108472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553644	hybrid			2022-12-25	WOS:000172450400012
J	Youn, H; Kerby, RL; Thorsteinsson, MV; Conrad, M; Staples, CR; Serate, J; Beack, J; Roberts, GP				Youn, H; Kerby, RL; Thorsteinsson, MV; Conrad, M; Staples, CR; Serate, J; Beack, J; Roberts, GP			The heme pocket afforded by Gly(117) is crucial for proper heme ligation and activity of CooA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING TRANSCRIPTIONAL ACTIVATOR; ELECTRON-PARAMAGNETIC-RESONANCE; CAMP RECEPTOR PROTEIN; NITRIC-OXIDE SYNTHASE; RHODOSPIRILLUM-RUBRUM; BINDING; LIGAND; DNA; SPECTROSCOPY; HEMOPROTEIN	CooA, a CO-sensing homodimeric transcription activator from Rhodospirillum rubrum, undergoes a conformational change in response to CO binding to its heme prosthetic group that allows it to bind specific DNA sequences. In a recent structural study (Lanzilotta, W. N., Schuller, D. J., Thorsteinsson, M. V., Kerby, R. L., Roberts, G. P., and Poulos, T. L. (2000) Nat. Struct. Biol. 7, 876-880), it was suggested that CO binding to CooA results in a modest repositioning of the C-helices that serve as the dimer interface. Gly(117) is one of the residues on the C-helix within 7 Angstrom of the heme iron on the Pro(2) side of the heme in CooA. Analysis of a series of Gly(117) variants revealed altered CO-sensing function and heme ligation states dependent on the size of the substituted amino acid at this position; bulky substitutions perturbed CooA both spectrally and functionally. A combination of spectroscopic and mutagenic studies showed that a representative Gly(117) variant, G117I CooA, was specifically perturbed in its Pro(2) ligation in both Fe(III) and Fe(II) forms, but comparison with other CooA variants indicated that perturbation of Pro(2) ligation is not the basis for the lack of CO response in G117I CooA. These results have led to the hypothesis that (i) the heme and the C-helix region move toward each other following CO binding and the interaction of the heme with the C-helix is crucial for CooA activation, and (ii) this event occurs only when a properly sized heme pocket is afforded.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.				NIGMS NIH HHS [GM53228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; He YP, 1999, J BIOL CHEM, V274, P10840, DOI 10.1074/jbc.274.16.10840; HOLLENBERG PF, 1980, J BIOL CHEM, V255, P4801; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; Kumazaki S, 2000, J BIOL CHEM, V275, P38378, DOI 10.1074/jbc.M005533200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; Lukat-Rodgers GS, 1998, BIOCHEMISTRY-US, V37, P13543, DOI 10.1021/bi981439v; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Reynolds MF, 1998, J AM CHEM SOC, V120, P9080, DOI 10.1021/ja981146p; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; TANG SC, 1976, J AM CHEM SOC, V98, P2414, DOI 10.1021/ja00425a008; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; Thorsteinsson MV, 2001, J BIOL CHEM, V276, P26807, DOI 10.1074/jbc.M102758200; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	35	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41603	41610		10.1074/jbc.M106165200	http://dx.doi.org/10.1074/jbc.M106165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551932	hybrid			2022-12-25	WOS:000172450400011
J	Zhong, XT; Malhotra, R; Woodruff, R; Guidotti, G				Zhong, XT; Malhotra, R; Woodruff, R; Guidotti, G			Mammalian plasma membrane ecto-nucleoside triphosphate diphosphohydrolase 1, CD39, is not active intracellularly - The N-glycosylation state of CD39 correlates with surface activity and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ATP-DIPHOSPHOHYDROLASE; YEAST ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; PROTEIN TRANSLOCATION; QUATERNARY STRUCTURE; PLATELET-FUNCTION; GOLGI; APYRASE; GENE	CD39 is a member of the membrane-bound ecto-nucleoside triphosphate diphosphohydrolase family. The active site for native CD39 is located on the outer surface of the cellular plasma membrane; however, it is not yet known at what stage this enzyme becomes active along the secretory pathway to the plasma membrane. In this study, sucrose density fractionations performed on CD39-transfected COS-7 cell membranes suggest that CD39 activity resides primarily in the plasma membrane. Furthermore, we have created recombinant, soluble versions of CD39, one that is secreted and others that are retained in the endoplasmic reticulum, to demonstrate that CD39 is not active until it reaches the plasma membrane both in yeast and COS-7 cells. Moreover, the secreted active soluble CD39 in COS-7 cells is found to receive a higher degree of N-glycan addition than the inactive form retained intracellularly. When COS-7 cells were treated with tunicamycin to prevent N-glycosylation, soluble CD39 was not detected in the extracellular medium and remained inactive intracellularly. Surface biotinylation analysis also revealed that surface-expressed wild type CD39 receives a higher degree of N-glycosylation than intracellular forms and that inhibition of N-glycosylation prevents its plasma membrane localization. In addition, both intact and digitonin-permeablized COS-7 cells transfected with CD39 possess similar ecto-ATPase activities, further supporting the conclusion that only surface-expressed CD39 is enzymatically active. All of these data suggest that intracellular CD39 is inactive and that only a fully glycosylated CD39 has apyrase activity and is localized at the cell surface.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.			Malhotra, Rajeev/0000-0003-0120-4630	NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Ballensiefen W, 1997, EUR J BIOCHEM, V247, P142, DOI 10.1111/j.1432-1033.1997.00142.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; Coppi MV, 1997, ARCH BIOCHEM BIOPHYS, V346, P312, DOI 10.1006/abbi.1997.0332; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Esch JSA, 1999, BIOCHEMISTRY-US, V38, P2248, DOI 10.1021/bi982426k; Feraille E, 2000, MOL BIOL CELL, V11, P39, DOI 10.1091/mbc.11.1.39; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Grinthal A, 2000, BIOCHEMISTRY-US, V39, P9, DOI 10.1021/bi991751k; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hicks-Berger CA, 2000, J BIOL CHEM, V275, P34041, DOI 10.1074/jbc.M004723200; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Koziak K, 2000, J BIOL CHEM, V275, P2057, DOI 10.1074/jbc.275.3.2057; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Mateo J, 1999, BRIT J PHARMACOL, V128, P396, DOI 10.1038/sj.bjp.0702805; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MILLER JH, 1992, SHORT COURSE BACTERI, P439; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PLESNER L, 1995, INT REV CYTOL, V158, P141; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; Robson SC, 1997, BLOOD COAGUL FIBRIN, V8, P21, DOI 10.1097/00001721-199701000-00005; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sambrook J., 2002, MOL CLONING LAB MANU; SAROKIN L, 1984, MOL CELL BIOL, V4, P2750, DOI 10.1128/MCB.4.12.2750; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SHERMAN F, 1986, METHODS YEAST GENETI, P160; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Smith TM, 1999, BIOCHEMISTRY-US, V38, P1509, DOI 10.1021/bi9821768; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Wang TF, 1997, MOL BRAIN RES, V47, P295, DOI 10.1016/S0169-328X(97)00066-1; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Yeung G, 2000, BIOCHEMISTRY-US, V39, P12916, DOI 10.1021/bi000959z; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 2000, J BIOL CHEM, V275, P35592, DOI 10.1074/jbc.M006932200; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7; [No title captured]	58	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41518	41525		10.1074/jbc.M104415200	http://dx.doi.org/10.1074/jbc.M104415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546800	hybrid, Green Published			2022-12-25	WOS:000171925600150
J	Bartholin, L; Maguer-Satta, W; Hayette, S; Martel, S; Gadoux, M; Bertrand, S; Corbo, L; Lamadon, C; Morera, AM; Magaud, JP; Rimokh, R				Bartholin, L; Maguer-Satta, W; Hayette, S; Martel, S; Gadoux, M; Bertrand, S; Corbo, L; Lamadon, C; Morera, AM; Magaud, JP; Rimokh, R			FLRG, an activin-binding protein, is a new target of TGF beta transcription activation through Smad proteins	ONCOGENE			English	Article						FLRG; TGF beta; Smad; activin; follistatin	GROWTH-FACTOR-BETA; ERYTHROID-DIFFERENTIATION FACTOR; MAD PROTEINS; PROMOTER; GENE; SP1; FOLLISTATIN; EXPRESSION; RECEPTORS; FAMILY	The FLRG gene encodes a secreted glycoprotein that binds to activin and is highly homologous to follistatin, an activin ligand. We cloned the promoter region of the human FLRG gene, and defined the minimal region necessary for transcription activation in a reporter-system assay. We showed that the fragment between positions -130 and +6, which consists of multiple consensus Sp1-binding sites, is required for the constitutive expression of the FLRG gene. We demonstrate here that FLRG mRNA expression is rapidly induced by TGF beta or by transfection with Smad protein expression vectors in human HepG2 cells. We investigated the transcription-regulation mechanism of FLRG expression in HepG2 cells following treatment with TGF beta. By deletion and point-mutation analysis of the FLRG promoter, we identified a Smad-binding element involved in the TGF beta -inducible expression of the FLRG gene. Moreover, transactivation of the FLRG promoter by TGF beta was compromised by dominant-negative mutants of Smad3 and Smad4 proteins. In addition, get electrophoresis mobility-shift assays demonstrated the specific interaction of Smad3 and Smad4 proteins with the Smad-binding element consensus motif found in the FLRG promoter. Taken together, our data imply that Smad proteins participate in the regulation of expression of FLRG, a new target of TGF beta transcription activation.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France; Hop Debrousse, INSERM, U329, F-69322 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France.	rimokh@lyon.fnclcc.fr	Bartholin, Laurent/Q-6655-2017; Maguer-Satta, Veronique/U-8857-2019; Rimokh, Ruth/G-7506-2014; HAYETTE, sandrine/Z-2283-2019	Bartholin, Laurent/0000-0002-5637-3223; Maguer-Satta, Veronique/0000-0002-1556-068X; 				Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DYBEDAL I, 1995, BLOOD, V86, P949; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kitamura K, 2000, BLOOD, V95, P3371, DOI 10.1182/blood.V95.11.3371.011k37_3371_3379; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Maguer-Satta V, 2001, EXP HEMATOL, V29, P301, DOI 10.1016/S0301-472X(00)00675-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Pierelli L, 2000, BLOOD, V95, P3001; SHAO LE, 1992, BLOOD, V79, P773; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMASHITA T, 1992, BLOOD, V79, P304; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu J, 1997, CYTOKINES CELL MOL T, V3, P169; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YQ, 1997, BBA-GENE STRUCT EXPR, V1354, P204, DOI 10.1016/S0167-4781(97)00085-7	44	34	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5409	5419		10.1038/sj.onc.1204720	http://dx.doi.org/10.1038/sj.onc.1204720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571638				2022-12-25	WOS:000170781100001
J	Aman, MJ; Tosello-Trampont, AC; Ravichandran, K				Aman, MJ; Tosello-Trampont, AC; Ravichandran, K			Fc gamma RIIB1/SHIP-mediated inhibitory signaling in B cells involves lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATASE SHIP; FC-GAMMA-RIIB; ANTIGEN RECEPTOR; 5'-PHOSPHATASE SHIP; 5-PHOSPHATASE SHIP; DEFICIENT MICE; MEMBRANE RAFTS; LINKER PROTEIN; ACTIVATION; TRANSDUCTION	One type of membrane microdomain, enriched in glycosphingolipids and cholesterol and referred to as lipid rafts, has been implicated in the generation of activating signals triggered by a variety of stimuli. Several laboratories, including ours, have recently demonstrated that the B cell receptor (BCR) inducibly localizes to the rafts upon activation and that functional lipid rafts are important for BCR-mediated "positive" signaling. In the later phases of the immune response, coligation of the BCR and the inhibitory receptor Fc gamma RIIB1 leads to potent inhibition of BCR-induced positive signaling through the recruitment of the inositol phosphatase SHIP to Fc gamma RIIB1. One potential model is that the Fc gamma RIIB1 itself might be excluded from the rafts basally and that destabilization of raft-dependent BCR signaling might be part of the mechanism for the Fc gamma RIIB1-mediated negative regulation. We tested this hypothesis and observed that preventing BCR raft localization is not the mechanism for this inhibition. Surprisingly, a fraction of Fc gamma RIIB1 is constitutively localized in the rafts and increases further after BCR + Felt coligation. SHIP is actively recruited to lipid rafts under negative stimulation conditions, and the majority of Fc gamma RIIB1-SHIP complexes localize to lipid rafts compared with non-raft regions of the plasma membrane. This suggested that this negative feedback loop is also initiated in the lipid rafts. Despite its basal localization to the rafts, Fc gamma RIIB1 did not become phosphorylated after BCR alone cross-linking and did not colocalize with the BCR that moves to rafts upon BCR engagement alone (positive signaling conditions), perhaps suggesting the existence of different subsets of rafts. Taken together, these data suggest that lipid rafts play a role in both the positive signaling via the BCR as well as the inhibitory signaling through Fc gamma RIIB1/SHIP.	Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Ravichandran, K (corresponding author), Univ Virginia, Carter Immunol Ctr, HSC, Bldg MR4,Rm 4012F, Charlottesville, VA 22908 USA.				NIAID NIH HHS [R01 AI43425] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brauweiler A, 2000, J EXP MED, V191, P1545, DOI 10.1084/jem.191.9.1545; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cherukuri A, 2001, IMMUNITY, V14, P169; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gold MR, 1999, J IMMUNOL, V163, P1894; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Hashimoto A, 1999, J BIOL CHEM, V274, P11203, DOI 10.1074/jbc.274.16.11203; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; LEVIS GM, 1976, BIOCHEM J, V156, P103, DOI 10.1042/bj1560103; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Lou ZK, 2000, J EXP MED, V191, P347, DOI 10.1084/jem.191.2.347; March ME, 2000, J BIOL CHEM, V275, P29960, DOI 10.1074/jbc.M003714200; Okada H, 1998, J IMMUNOL, V161, P5129; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tridandapani S, 1997, J IMMUNOL, V158, P1125; Vely F, 1997, J IMMUNOL, V159, P2075; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Weintraub BC, 1998, CURR BIOL, V8, pR575, DOI 10.1016/S0960-9822(07)00365-X; Wollscheid B, 1999, CURR TOP MICROBIOL, V246, P283; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	59	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46371	46378		10.1074/jbc.M104069200	http://dx.doi.org/10.1074/jbc.M104069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571279	hybrid			2022-12-25	WOS:000172573100119
J	Levine, A; Belenghi, B; Damari-Weisler, H; Granot, D				Levine, A; Belenghi, B; Damari-Weisler, H; Granot, D			Vesicle-associated membrane protein of Arabidopsis suppresses Bax-induced apoptosis in yeast downstream of oxidative burst	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DISEASE RESISTANCE RESPONSE; VESICULAR TRANSPORT; SUSPENSION-CULTURES; MEDIATED APOPTOSIS; THALIANA CDNAS; PLANTS; FUSION; TRANSCRIPTION; INVOLVEMENT	Programmed cell death (PCD) in many systems is controlled by relative amounts of the apoptosis-regulating proteins Bax and Bcl-2 through homo- or heterodimerization. Here we show that Bax-induced PCD of yeast was suppressed by transformation with a vesicle-associated membrane protein from Arabidopsis (AtVAMP), which was isolated by screening a cDNA expression library against sugar-induced cell death in yeast. AtVAMP expression blocked Bax-induced PCD downstream of oxidative burst. AtVAMP also prevented H2O2-induced apoptosis in yeast and in Arabidopsis cells. Reduced oxidation of lipids and plasma membrane proteins was detected in the AtVAMP-transformed yeast, suggesting improved membrane repair. Inhibition of intracellular vesicle trafficking by brefeldin A induced apoptosis from a sublethal concentration of H2O2. No protection occurred by overexpression of the yeast homolog SCN2. However, efficient suppression of yeast PCD occurred by expression of a chimeric gene, composed of the conserved domains from yeast, fused to the variable N-terminal domain from Arabidopsis, resulting in exchange of the proline-rich N-terminal domain of SCN2 with a proline-poor Arabidopsis sequence. Our results suggest that intracellular vesicle traffic can regulate execution of apoptosis by affecting the rate of membrane recycling and that the proline-rich N-terminal domain of VAMP inhibited this process.	Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel; Agr Res Org, Volcani Ctr, Inst Field & Garden Crops, IL-50250 Bet Dagan, Israel	Hebrew University of Jerusalem; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Levine, A (corresponding author), Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel.							Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; Amor Y, 1998, FEBS LETT, V440, P1, DOI 10.1016/S0014-5793(98)01408-2; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; Coco S, 1999, J NEUROSCI, V19, P9803; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; Cosulich SC, 1997, EMBO J, V16, P6182, DOI 10.1093/emboj/16.20.6182; Desikan R, 1998, BIOCHEM J, V330, P115, DOI 10.1042/bj3300115; Frohlich KU, 2000, FEBS LETT, V473, P6, DOI 10.1016/S0014-5793(00)01474-5; Gerst JE, 1997, J BIOL CHEM, V272, P16591, DOI 10.1074/jbc.272.26.16591; Granot D, 1997, CELL DEATH DIFFER, V4, P555, DOI 10.1038/sj.cdd.4400280; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hazzard J, 1999, J BIOMOL NMR, V14, P203, DOI 10.1023/A:1008382027065; Hibi T, 2000, BIOCHEM BIOPH RES CO, V271, P36, DOI 10.1006/bbrc.2000.2591; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Jayadev S, 1999, J BIOL CHEM, V274, P8261, DOI 10.1074/jbc.274.12.8261; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Krausgrill S, 1998, PLANT J, V13, P275, DOI 10.1046/j.1365-313X.1998.00026.x; KUSHNIR S, 1995, P NATL ACAD SCI USA, V92, P10580, DOI 10.1073/pnas.92.23.10580; Lacomme C, 1999, P NATL ACAD SCI USA, V96, P7956, DOI 10.1073/pnas.96.14.7956; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Long AR, 1998, MECH DEVELOP, V76, P33, DOI 10.1016/S0925-4773(98)00110-5; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; Matsuyama S, 1999, CURR OPIN MICROBIOL, V2, P618, DOI 10.1016/S1369-5274(99)00031-4; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; MINET M, 1992, PLANT J, V2, P417; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Ryerson DE, 1996, TRENDS PLANT SCI, V1, P212; Sanderfoot AA, 2000, PLANT PHYSIOL, V124, P1558, DOI 10.1104/pp.124.4.1558; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Solomon M, 1999, PLANT CELL, V11, P431, DOI 10.1105/tpc.11.3.431; Swanton E, 1999, J BIOL CHEM, V274, P37583, DOI 10.1074/jbc.274.53.37583; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vardi A, 1999, CURR BIOL, V9, P1061, DOI 10.1016/S0960-9822(99)80459-X; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	49	66	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46284	46289		10.1074/jbc.M107375200	http://dx.doi.org/10.1074/jbc.M107375200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11551960	hybrid			2022-12-25	WOS:000172573100108
J	Chaya, D; Hayamizu, T; Bustin, M; Zaret, KS				Chaya, D; Hayamizu, T; Bustin, M; Zaret, KS			Transcription factor FoxA (HNF3) on a nucleosome at an enhancer complex in liver chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MMTV PROMOTER; GENE-EXPRESSION; CORE PARTICLE; DNASE-I; BINDING; SITE; DIFFERENTIATION; RESOLUTION; INVITRO; VIVO	Nucleosome-like particles and acetylated histones occur near active promoters and enhancers, and certain transcription factors can recognize their target sites on the surface of a nucleosome in vitro; yet it has been unclear whether transcription factors can occupy target sites on nucleosomes in native chromatin. We developed a method for sequential chromatin immunoprecipitation of distinct nuclear proteins that are simultaneously cross-linked to nucleosome-sized genomic DNA segments. We find that core histone H2A co-occupies, along with the FoxA (hepatocyte nuclear factor-3) transcription factor, DNA for the albumin transcriptional enhancer in native liver chromatin, where the enhancer is active. Because histone H2A on nuclear DNA is only known to exist in nucleosomes, we conclude that transcription factors can form a stable complex on nucleosomes at an active enhancer element in. vivo.	Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA; Ctr Canc Res, Lab Metab, Prot Sect, Bethesda, MD 20892 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zaret, KS (corresponding author), Fox Chase Canc Ctr, Program Cell & Dev Biol, 7701 Burholme Ave,Rm W410, Philadelphia, PA 19111 USA.	zaret@fccc.edu	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047903] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [R01 GM47903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; AUSUBEL FM, 1999, CURRENT PROTOCOLS MO, V1; Bossard P, 1998, DEVELOPMENT, V125, P4909; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLDBLATT D, 1975, BIOCHEMISTRY-US, V14, P1689, DOI 10.1021/bi00679a022; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Harlow E., 1988, ANTIBODIES LAB MANUA; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; Kruger G, 1999, GENE, V236, P63, DOI 10.1016/S0378-1119(99)00271-1; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Stevens K, 2000, J BIOL CHEM, V275, P30471, DOI 10.1074/jbc.M004891200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VANHOLDE KE, 1989, CHROMATIN, V1; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	36	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44385	44389		10.1074/jbc.M108214200	http://dx.doi.org/10.1074/jbc.M108214200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571307	hybrid			2022-12-25	WOS:000172406700006
J	Lowry, WE; Huang, JY; Lei, M; Rawlings, D; Huang, XY				Lowry, WE; Huang, JY; Lei, M; Rawlings, D; Huang, XY			Role of the PHTH module in protein substrate recognition by Bruton's agammaglobulinemia tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SRC-FAMILY; CRYSTAL-STRUCTURE; HOMOLOGY DOMAIN; SH3 DOMAIN; BTK; PHOSPHORYLATION; ACTIVATION; HCK; ASSOCIATION	Defects in Bruton's tyrosine kinase (Btk) are responsible for X chromosome-linked agammaglobulinemia in patients. Mutations in each of the structural domains of Btk have been detected in patients, yet a mechanistic explanation for most of these mutant phenotypes is lacking. To understand the possible role of the unique pleckstrin homology and Tee homology (PHTH) module of Btk, we have compared the enzymatic properties of full-length Btk and a Btk mutant lacking the PHTH module (Btk Delta PHTH). Here we show that Btk and Btk Delta PHTH have similar basal catalytic activity but very different abilities to recognize protein substrates. Furthermore, the catalytic domain of Btk is inactive, in contrast to the catalytic domain of the prototypical Src tyrosine kinase that retains full catalytic ability. These data suggest that the PHTH module plays an important role in protein substrate recognition, that. Btk and Src likely have different interdomain organizations and regulations, and that alterations in substrate recognition might play a role in X chromosome-linked agammaglobulinemia.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA	Cornell University; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, 1300 York Ave,Rm C512, New York, NY 10021 USA.							Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Baba K, 1999, MOL CELL BIOL, V19, P4405; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACHIDE M, 1995, ONCOGENE, V11, P619; Mao C, 2001, J BIOL CHEM, V276, P41435, DOI 10.1074/jbc.M104828200; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2	32	12	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45276	45281		10.1074/jbc.M104449200	http://dx.doi.org/10.1074/jbc.M104449200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577078	hybrid			2022-12-25	WOS:000172406700122
J	Matsuura, T; Sakai, H; Unno, M; Ida, K; Sato, M; Sakiyama, F; Norioka, S				Matsuura, T; Sakai, H; Unno, M; Ida, K; Sato, M; Sakiyama, F; Norioka, S			Crystal structure at 1.5-angstrom resolution of Pyrus pyrifolia pistil ribonuclease responsible for gametophytic self-incompatibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-RNASE; POSITIVE SELECTION; RHIZOPUS-NIVEUS; JAPANESE PEAR; NUCLEOTIDE SUBSTITUTION; HISTIDINE-RESIDUES; ENZYMATIC-ACTIVITY; POLLEN; PROTEIN; RH	The crystal structure of the Pyrus pyrifolia pistil ribonuclease (S-3-RNase) responsible for gametophytic self-incompatibility was determined at 1.5-Angstrom resolution. It consists of eight helices and seven beta -strands, and its folding topology is typical of RNase T-2 family enzymes. Based on a structural comparison of S-3-RNase with RNase Rh, a fungal RNase T-2 family enzyme, the active site residues of S-3-RNase assigned were His(33) and His(88) as catalysts and Glu(84) and Lys(87) as stabilizers of an intermediate in the transition state. Moreover, amino acid residues that constitute substrate binding sites of the two RNases could be superimposed geometrically. A hypervariable (HV) region that has an S-allele-specific sequence comprises a long loop and short alpha -helix. This region is far from the active site cleft, exposed on the molecule's surface, and positively charged. Four positively selected (PS) regions, in which the number of nonsynonymous substitutions exceeds that of synonymous ones, are located on either side of the active site cleft, and accessible to solvent. These structural features suggest that the HV or PS regions may interact with a pollen S-gene product(s) to recognize self and non-self pollen.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Int Buddhist Univ, Osaka 5388501, Japan	Osaka University; Yokohama City University	Norioka, S (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Osaka 5650871, Japan.	norioka@protein.osaka-u.ac.jp	Matsuura, Takanori/J-1413-2012	Matsuura, Takanori/0000-0003-2001-9537				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRANDEN C, 1999, INTRO PROTEIN STRUCT, P16; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dodds PN, 1996, CELL, V85, P141, DOI 10.1016/S0092-8674(00)81090-9; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; HUANG S, 1994, PLANT CELL, V6, P1021, DOI 10.1105/tpc.6.7.1021; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; Ishimizu T, 1996, J BIOCHEM-TOKYO, V120, P326, DOI 10.1093/oxfordjournals.jbchem.a021417; Ishimizu T, 1998, FEBS LETT, V440, P337, DOI 10.1016/S0014-5793(98)01470-7; Ishimizu T, 1998, PLANT MOL BIOL, V37, P931, DOI 10.1023/A:1006078500664; Ishimizu T, 1999, EUR J BIOCHEM, V263, P624, DOI 10.1046/j.1432-1327.1999.00499.x; Ishimizu T, 1996, EUR J BIOCHEM, V242, P627, DOI 10.1111/j.1432-1033.1996.0627r.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kao TH, 1996, P NATL ACAD SCI USA, V93, P12059, DOI 10.1073/pnas.93.22.12059; KARUNANANDAA B, 1994, PLANT CELL, V6, P1933, DOI 10.1105/tpc.6.12.1933; KAWATA Y, 1990, EUR J BIOCHEM, V187, P255, DOI 10.1111/j.1432-1033.1990.tb15303.x; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIHARA H, 1992, FEBS LETT, V306, P189, DOI 10.1016/0014-5793(92)80997-U; Kurihara H, 1996, J MOL BIOL, V255, P310, DOI 10.1006/jmbi.1996.0025; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE HS, 1994, NATURE, V367, P560, DOI 10.1038/367560a0; LEE YH, 1995, MOL BIOL EVOL, V12, P231; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; Luu DT, 2000, NATURE, V407, P649, DOI 10.1038/35036623; Matsuura T, 2001, ACTA CRYSTALLOGR D, V57, P172, DOI 10.1107/S090744490001756X; Matton DP, 1997, PLANT CELL, V9, P1757, DOI 10.1105/tpc.9.10.1757; Matton DP, 1999, PLANT CELL, V11, P2087, DOI 10.1105/tpc.11.11.2087; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; McCubbin AG, 1997, PLANT CELL, V9, P85, DOI 10.2307/3870373; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURFETT J, 1994, NATURE, V367, P563, DOI 10.1038/367563a0; Nakagawa A, 1999, BBA-PROTEIN STRUCT M, V1433, P253, DOI 10.1016/S0167-4838(99)00126-0; Nettancourt, 2001, INCOMPATIBILITY INCO; NEWBIGIN E, 1993, PLANT CELL, V5, P1315, DOI 10.1105/tpc.5.10.1315; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norioka N, 1996, J BIOCHEM-TOKYO, V120, P335, DOI 10.1093/oxfordjournals.jbchem.a021418; OHGI K, 1991, J BIOCHEM-TOKYO, V109, P776, DOI 10.1093/oxfordjournals.jbchem.a123456; Ohgi K, 1996, BIOL PHARM BULL, V19, P1080; OHGI K, 1992, J BIOCHEM-TOKYO, V112, P132, DOI 10.1093/oxfordjournals.jbchem.a123852; OHGI K, 1993, J BIOCHEM-TOKYO, V113, P219, DOI 10.1093/oxfordjournals.jbchem.a124029; OHGI K, 1995, J BIOCHEM-TOKYO, V117, P27, DOI 10.1093/oxfordjournals.jbchem.a124716; Ohgi K, 1997, BIOSCI BIOTECH BIOCH, V61, P432, DOI 10.1271/bbb.61.432; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oxley D, 1996, EUR J BIOCHEM, V242, P75, DOI 10.1111/j.1432-1033.1996.0075r.x; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; RICHARDS FM, 1971, ENZYMES, V4, P647; Richman AD, 1997, AM J BOT, V84, P912, DOI 10.2307/2446281; SANDA A, 1980, J BIOCHEM-TOKYO, V87, P1079; SANDA A, 1985, J BIOCHEM, V98, P125, DOI 10.1093/oxfordjournals.jbchem.a135250; SANDA A, 1985, CHEM PHARM BULL, V33, P4515; SWANSON WJ, 1995, P NATL ACAD SCI USA, V92, P4957, DOI 10.1073/pnas.92.11.4957; Tanaka N, 2000, J MOL BIOL, V298, P859, DOI 10.1006/jmbi.2000.3707; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	57	50	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45261	45269		10.1074/jbc.M107617200	http://dx.doi.org/10.1074/jbc.M107617200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577107	hybrid			2022-12-25	WOS:000172406700120
J	Samuel, T; Weber, HO; Rauch, P; Verdoodt, B; Eppel, JT; McShea, A; Hermeking, H; Funk, JO				Samuel, T; Weber, HO; Rauch, P; Verdoodt, B; Eppel, JT; McShea, A; Hermeking, H; Funk, JO			The G(2)/M regulator 14-3-3 sigma prevents apoptosis through sequestration of Bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; PROTEIN FAMILY; CELL-CYCLE; IN-VIVO; P53; CHECKPOINT; INHIBITORS; EXPRESSION; CASPASES; KINASES	In response to DNA damage and genotoxic stress, the p53 tumor suppressor triggers either cell cycle arrest or apoptosis. The G(2) arrest after damage is, in part, mediated by the p53 target, 14-3-3 sigma (sigma). Colorectal tumor cells lacking a are exquisitely sensitive to DNA damage. Here we analyzed the mechanism of this sensitivity in sigma (-/-) as compared with sigma (+/+) human colorectal tumor cells. Exposure to adriamycin resulted in rapid apoptosis only in sigma (-/-) cells. This was further characterized by caspase-3 activation, p21(CIP1) cleavage, and CDK2 activation. Moreover, Bax was rapidly translocated out of the cytoplasm, and cytochrome c was released in sigma (-/-) cells. Transient adenovirus-mediated reconstitution of or in the sigma (-/-) cells led to effective rescue of this phenotype and protected cells against apoptosis. The association of sigma, Bax, and CDK1 in protein complexes may be the basis for this antiapoptotic mechanism. In conclusion, a not only enforces the p53-dependent G(2) arrest but also delays the apoptotic signal transduction.	Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, D-91052 Erlangen, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Erlangen Nuremberg; Fred Hutchinson Cancer Center; Max Planck Society	Funk, JO (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, Hartmannstr 14, D-91052 Erlangen, Germany.							Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Herzinger T, 1995, ONCOGENE, V11, P2051; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krajewski S, 1996, CANCER RES, V56, P2849; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	39	139	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45201	45206		10.1074/jbc.M106427200	http://dx.doi.org/10.1074/jbc.M106427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574543	hybrid			2022-12-25	WOS:000172406700113
J	Young, ME; Laws, FA; Goodwin, GW; Taegtmeyer, H				Young, ME; Laws, FA; Goodwin, GW; Taegtmeyer, H			Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; HYPOLIPIDEMIC DRUGS; PRESSURE-OVERLOAD; MECHANICAL-STRESS; FATTY-ACIDS; MYOCYTES; METABOLISM; INCREASE	In pressure overload-induced hypertrophy, the heart increases its reliance on glucose as a fuel while decreasing fatty acid oxidation. A key regulator of this substrate switching in the hypertrophied heart is peroxisome proliferator-activated receptor alpha (PPAR alpha). We tested the hypothesis that down-regulation of PPAR alpha is an essential component of cardiac hypertrophy at the levels of increased mass, gene expression, and metabolism by pharmacologically reactivating PPA alpha. Pressure overload (induced by constriction of the ascending aorta for 7 days in rats) resulted in cardiac hypertrophy, increased expression of fetal genes (atrial natriuretic factor and skeletal alpha -actin), decreased expression of PPAR alpha and PPAR alpha -regulated genes (medium chain acyl-CoA dehydrogenase and pyruvate dehydrogenase kinase 4), and caused substrate switching (measured ex vivo in the isolated working heart preparation). Treatment of rats with the specific PPAR alpha agonist WY-14,643 (8 days) did not affect the trophic response or atrial natriuretic factor induction to pressure overload. However, PPAR alpha activation blocked skeletal alpha -actin induction, reversed the down-regulation of measured PPAR alpha -regulated genes in the hypertrophied heart, and prevented substrate switching. This PPAR alpha reactivation concomitantly resulted in severe depression of cardiac power and efficiency in the hypertrophied heart (measured ex vivo). Thus, PPAR alpha down-regulation is essential for the maintenance of contractile function of the hypertrophied heart.	Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA	University of Texas System	Taegtmeyer, H (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, 6431 Fannin,MSB 1-246, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061483, R01HL043133, F32HL067609] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43133, F32HL-67609, HL-61483] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLARD MF, 1994, AM J PHYSIOL, V267, pH742, DOI 10.1152/ajpheart.1994.267.2.H742; ANDERSON PG, 1990, CIRC RES, V67, P948, DOI 10.1161/01.RES.67.4.948; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Barger PM, 2000, TRENDS CARDIOVAS MED, V10, P238, DOI 10.1016/S1050-1738(00)00077-3; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Doenst T, 2001, METABOLISM, V50, P1083, DOI 10.1053/meta.2001.25605; FACTOR SM, 1981, AM J PATHOL, V102, P219; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goodwin GW, 1998, J BIOL CHEM, V273, P29530, DOI 10.1074/jbc.273.45.29530; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; KAGAYA Y, 1990, CIRCULATION, V81, P1353, DOI 10.1161/01.CIR.81.4.1353; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Katz Arnold M., 1998, Cardiology Clinics, V16, P633, DOI 10.1016/S0733-8651(05)70040-0; KLEINMAN LH, 1978, AM J PHYSIOL, V234, pH515, DOI 10.1152/ajpheart.1978.234.5.H515; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LAZAROW PB, 1977, SCIENCE, V197, P580, DOI 10.1126/science.195342; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Meguro T, 1999, CIRC RES, V84, P735, DOI 10.1161/01.RES.84.6.735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; PAULSON DJ, 1992, LIFE SCI, V51, P1557, DOI 10.1016/0024-3205(92)90618-Y; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Takeishi Y, 2000, CIRC RES, V86, P1218, DOI 10.1161/01.RES.86.12.1218; van der Lee KAJM, 2000, J LIPID RES, V41, P41; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Young ME, 2001, AM J PHYSIOL-ENDOC M, V280, pE471, DOI 10.1152/ajpendo.2001.280.3.E471; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	35	195	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44390	44395		10.1074/jbc.M103826200	http://dx.doi.org/10.1074/jbc.M103826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574533	hybrid			2022-12-25	WOS:000172406700007
J	Kamata, T; Tieu, KK; Irie, A; Springer, TA; Takada, Y				Kamata, T; Tieu, KK; Irie, A; Springer, TA; Takada, Y			Amino acid residues in the alpha(IIb) subunit that are critical for ligand binding to integrin alpha(IIb)beta(3) are clustered in the beta-propeller model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; GPIIB-IIIA; MONOCLONAL-ANTIBODY; GLANZMANN THROMBASTHENIA; FIBRINOGEN BINDING; IIB/IIIA COMPLEX; DOMAIN; SITE; SEQUENCE; RECEPTOR	Several distinct regions of the integrin am, subunit have been implicated in ligand binding. To localize the ligand binding sites in alpha (IIb), we swapped all 27 predicted loops with the corresponding sequences of alpha (4) or alpha (5). 19 of the 27 swapping mutations had no effect on binding to both fibrinogen and ligand-mimetic antibodies (e.g. LJ-CP3), suggesting that these regions do not contain major ligand binding sites. In contrast, swapping the remaining 8 predicted loops completely blocked ligand binding. Ala scanning mutagenesis of these critical predicted loops identified more than 30 discontinuous residues in repeats 2-4 and at the boundary between repeats 4 and 5 as critical for ligand binding. Interestingly, these residues are clustered in the predicted beta -propeller model consistent with this model. Most of the critical residues are located at the edge of the upper face of the propeller, and several critical residues are located on the side of the propeller domain. None of the predicted loops in repeats 1, 6, and 7, and none of the four putative Ca2+ binding predicted loops on the lower surface of the beta -propeller were important for ligand binding. The results map an important ligand binding interface at the edge of the top and on the side of the beta -propeller toroid, centering on repeat 3.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Ctr Blood Res, Dept Pathol, Boston, MA 02115 USA	Scripps Research Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Kamata, T (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kamata@sc.itc.keio.ac.jp; takada@scripps.edu		takada, yoshikazu/0000-0001-5481-9589	NHLBI NIH HHS [HL48675] Funding Source: Medline; NIGMS NIH HHS [GM49899] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baneres JL, 1998, J BIOL CHEM, V273, P24744, DOI 10.1074/jbc.273.38.24744; Baneres JL, 2000, J BIOL CHEM, V275, P5888, DOI 10.1074/jbc.275.8.5888; Basani RB, 2000, BLOOD, V95, P180, DOI 10.1182/blood.V95.1.180.001k16_180_188; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BRANDON C, 1991, INTRO PROTEIN STRUCT; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; Gidwitz S, 2000, J BIOL CHEM, V275, P6680, DOI 10.1074/jbc.275.9.6680; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Grimaldi CM, 1998, BLOOD, V91, P1562, DOI 10.1182/blood.V91.5.1562.1562_1562_1571; GULINO D, 1992, J BIOL CHEM, V267, P1001; Honda S, 1998, J CLIN INVEST, V102, P1183, DOI 10.1172/JCI3206; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Niewiarowska J, 1997, THROMB HAEMOSTASIS, V78, P1510; NIIYA K, 1987, BLOOD, V70, P475; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PONCZ M, 1990, BLOOD, V75, P1282; PRAMMER KV, 1994, RECEPTOR, V4, P93; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Russell RB, 1998, J MOL BIOL, V282, P903, DOI 10.1006/jmbi.1998.2043; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Springer TA, 2000, CELL, V102, P275, DOI 10.1016/S0092-8674(00)00033-7; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; TAUB R, 1989, J BIOL CHEM, V264, P259; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Thornton MA, 1999, BLOOD, V94, P3947, DOI 10.1182/blood.V94.11.3947.423k41_3947_3950; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; Tozer EC, 1999, BLOOD, V93, P918, DOI 10.1182/blood.V93.3.918.403k26_918_924; WOODS VL, 1984, BLOOD, V63, P368; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x; YLANNE J, 1988, BLOOD, V72, P1478; Zhang XP, 1999, BIOCHEMISTRY-US, V38, P14424, DOI 10.1021/bi990323b	58	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44275	44283		10.1074/jbc.M107021200	http://dx.doi.org/10.1074/jbc.M107021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557768	hybrid			2022-12-25	WOS:000172297700100
J	Vosper, H; Patel, L; Graham, TL; Khoudoli, GA; Hill, A; Macphee, CH; Pinto, I; Smith, SA; Suckling, KE; Wolf, CR; Palmer, CNA				Vosper, H; Patel, L; Graham, TL; Khoudoli, GA; Hill, A; Macphee, CH; Pinto, I; Smith, SA; Suckling, KE; Wolf, CR; Palmer, CNA			The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; INSULIN ACTION ENHANCER; PPAR-GAMMA; STEROL 27-HYDROXYLASE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GENE-EXPRESSION; CHOLESTEROL; TROGLITAZONE; ATHEROSCLEROSIS; EFFLUX	The peroxisome Proliferator-activated receptors (PPARs) are a family of fatty acid-activated transcription factors which control lipid homeostasis and cellular differentiation. PPAR alpha (NR1C1) controls lipid oxidation and clearance in hepatocytes and PPAR gamma (NR1C3) promotes preadipocyte differentiation and lipogenesis. Drugs that activate PPAR alpha are effective in lowering plasma levels of lipids and have been used in the management of hyperlipidemia. PPAR gamma agonists increase insulin sensitivity and are used in the management of type 2 diabetes. In contrast, there are no marketed drugs that selectively target PPAR delta (NR1C2) and the physiological roles of PPAR delta are unclear. In this report we demonstrate that the expression of PPAR5 is increased during the differentiation of human macrophages in vitro. In addition, a highly selective agonist of PPAR delta (compound F) promotes lipid accumulation in primary human macrophages and in macrophages derived from the human monocytic cell line, THP-1. Compound F increases the expression of genes involved in lipid uptake and storage such as the class A and B scavenger receptors (SRA, CD36) and adipophilin. PPAR delta activation also represses key genes involved in lipid metabolism and efflux, ie. cholesterol 27-hydroxylase and apolipoprotein E. We have generated THP-1 sublines that overexpress PPAR delta and have confirmed that PPAR delta is a powerful promoter of macrophage lipid accumulation. These data suggest that PPAR5 may play a role in the pathology of diseases associated with lipid-filled macrophages, such as atherosclerosis, arthritis, and neurodegeneration.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland; GlaxoSmithKline, Harlow CM19 5AW, Essex, England	University of Dundee; University of Dundee; University of Dundee; GlaxoSmithKline	Palmer, CNA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	palmerc@icrf.icnet.uk	Eckhardt, Erik/G-1567-2010; Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560; Vosper, Helen/0000-0001-7796-5183; Wolf, Charles Roland/0000-0002-6969-0113				Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4; CALI JJ, 1991, J BIOL CHEM, V266, P7779; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Collins AR, 2001, ARTERIOSCL THROM VAS, V21, P365, DOI 10.1161/01.ATV.21.3.365; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kang AK, 1997, MUTAT RES-GENOMICS, V382, P57, DOI 10.1016/S1383-5726(97)00009-5; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Koshiyama H, 2001, J CLIN ENDOCR METAB, V86, P3452, DOI 10.1210/jc.86.7.3452; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Kumar S, 1996, DIABETOLOGIA, V39, P701; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Lim H, 2000, TRENDS ENDOCRIN MET, V11, P137, DOI 10.1016/S1043-2760(00)00243-5; Mano H, 2000, J BIOL CHEM, V275, P8126, DOI 10.1074/jbc.275.11.8126; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Seed B, 1998, NAT MED, V4, P1004, DOI 10.1038/1990; Shanahan CM, 2001, ATHEROSCLEROSIS, V154, P269, DOI 10.1016/S0021-9150(00)00473-1; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Shinohara E, 1998, ATHEROSCLEROSIS, V136, P275, DOI 10.1016/S0021-9150(97)00220-7; Shiomi M, 1999, ATHEROSCLEROSIS, V142, P345, DOI 10.1016/S0021-9150(98)00259-7; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Westman J, 1998, ARTERIOSCL THROM VAS, V18, P554, DOI 10.1161/01.ATV.18.4.554; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585; 1997, Patent No. 9728149	52	219	237	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44258	44265		10.1074/jbc.M108482200	http://dx.doi.org/10.1074/jbc.M108482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557774	hybrid			2022-12-25	WOS:000172297700098
J	Blaine, SA; Wick, M; Dessev, C; Nemenoff, RA				Blaine, SA; Wick, M; Dessev, C; Nemenoff, RA			Induction of cPLA(2) in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; CYTOSOLIC PHOSPHOLIPASE A(2); INDUCED GENE-EXPRESSION; TRANSCRIPTION FACTORS; HUMAN 12-LIPOXYGENASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; A431 CELLS; SP-FAMILY; PROMOTER	Activating mutations in ras genes are frequently associated with non-small cell lung cancer cells (NSCLC) and contribute to transformed growth in these cells. Expression of oncogenic forms of Ras in these cells is associated with increased expression and activity of cytosolic phospholipase A(2) (cPLA(2)) and cyclooxygenase-2 (COX-2), leading to constitutively elevated levels of prostaglandin production. Expression of oncogenic Ras is sufficient to induce these enzymes in normal lung epithelial cells. We have previously reported that the JNK and ERK pathways are necessary for induction of cPLA(2) and have defined a minimal region of the cPLA(2) promoter from -58 to -12 that is required for Ha-Ras-mediated induction. To further characterize the cis-regulatory elements within this region involved in this response, site-directed mutagenesis was used to make mutations at various sites. Three cis-regulatory elements were identified: regions -21/-18, -37/-30, and -55/-53. Mutations in any of these elements decreased basal and Ha-Ras-induced cPLA(2) promoter activity in both normal lung epithelial cells, as well as steady state promoter activity in A549 cells, with a mutation in element -21/-18 completely eliminating all promoter activity. Overexpression studies and gel shift assays indicated that Spl may serve as a transcription factor functionally regulating promoter activity by directly interacting with two of the cis-regulatory elements, -21/-18 and -37/-30. Expression of Ha-Ras led to induction of e-Jun protein, which showed functional cooperation with Sp1 in driving promoter activity. Additional unidentified transcription factors bound to the regions from -55/-53 and -37/-34.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Pharmacol, Box C-281,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039902, P01DK019928] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58187] Funding Source: Medline; NIDDK NIH HHS [DK 39902, DK 19928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen BK, 1997, BBA-LIPID LIPID MET, V1344, P270, DOI 10.1016/S0005-2760(96)00151-8; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen BK, 2000, MOL PHARMACOL, V57, P153; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; DEBRAVO MG, 1991, LIPIDS, V26, P866, DOI 10.1007/BF02535969; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DeWitt D L, 1993, Am J Med, V95, p40S, DOI 10.1016/0002-9343(93)90396-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hida T, 1998, ANTICANCER RES, V18, P775; HUBBARD WC, 1989, CANCER RES, V49, P826; HUBBARD WC, 1988, CANCER RES, V48, P4770; Huber R, 1998, GENE, V214, P35, DOI 10.1016/S0378-1119(98)00233-9; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; ROBERTS PE, 1990, AM J PHYSIOL, V259, pL415, DOI 10.1152/ajplung.1990.259.6.L415; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TAY A, 1994, BBA-GENE STRUCT EXPR, V1217, P345, DOI 10.1016/0167-4781(94)90299-2; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Van Putten V, 2001, J BIOL CHEM, V276, P1226, DOI 10.1074/jbc.M003581200; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	41	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42737	42743		10.1074/jbc.M107773200	http://dx.doi.org/10.1074/jbc.M107773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11559711	hybrid			2022-12-25	WOS:000172169300015
J	Fu, YX; Sies, H; Lei, XG				Fu, YX; Sies, H; Lei, XG			Opposite roles of selenium-dependent glutathione peroxidase-1 in superoxide generator diquat- and peroxynitrite-induced apoptosis and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MICE; ACTIVATION; PARAQUAT; CYTOTOXICITY; OXIDATION; KNOCKOUT; OXYGEN; CELLS; P21(WAF1/CIP1)	Oxidative injuries including apoptosis can be induced by reactive oxygen species (ROS) and reactive nitrogen species (RNS) in aerobic metabolism. We determined impacts of a selenium-dependent glutathione peroxidase-1 (GPX1) on apoptosis induced by diquat (DQ), a ROS (superoxide) generator, and peroxynitrite (PN), a potent RNS. Hepatocytes were isolated from GPX1 knockout (GPX1-/-) or wild-type (WT) mice, and treated with 0.5 mm DQ or 0.1-0.8 mm PN for up to 12 h. Loss of cell viability, high levels of apoptotic cells, and severe DNA fragmentation were produced by DQ in only GPX1-/- cells and by PN in only WT cells. These two groups of cells shared similar cytochrome c release, caspase-3 activation, and p21(WAF1/CIP1) cleavage. Higher levels of protein nitration were induced by PN in WT than GPX1-/- cells. Much less and/or slower cellular GSH depletion was caused by DQ or PN in GPX1-/- than in WT cells, and corresponding GSSG accumulation occurred only in the latter. In conclusion, it is most striking that, although GPX1 protects against apoptosis induced by superoxide-generator DQ, the enzyme actually promotes apoptosis induced by PN in murine hepatocytes. Indeed, GSH is a physiological substrate for GPX1 in coping with ROS in these cells.	Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA; Univ Dusseldorf, Inst Physiol Chem 1, D-40001 Dusseldorf, Germany	Cornell University; Heinrich Heine University Dusseldorf	Lei, XG (corresponding author), Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA.	xl20@cornell.edu	Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Sies, Helmut/0000-0002-1000-3198; fu, yang-xin/0000-0001-8441-6617	NIDDK NIH HHS [R01 DK053018, DK53018] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON AE, 1985, CRC HDB METHOD OXYGE, P317; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brito C, 1999, J IMMUNOL, V162, P3356; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070; Cheng WH, 1999, FASEB J, V13, P1467, DOI 10.1096/fasebj.13.11.1467; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; EVANS MD, 1997, ADV MOL CEL, V20, P25; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; Flohe L, 2000, IUBMB LIFE, V49, P411; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Fu YX, 1999, FREE RADICAL BIO MED, V27, P605, DOI 10.1016/S0891-5849(99)00104-5; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; HOEKSTRA WG, 1975, FED PROC, V34, P2083; Jiang D, 2000, EXP NEUROL, V164, P257, DOI 10.1006/exnr.2000.7431; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LIU RH, 1992, CANCER RES, V52, P4139; Lu YP, 1997, CANCER RES, V57, P1468; MAIORINO M, 1993, FEBS LETT, V330, P174, DOI 10.1016/0014-5793(93)80267-X; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Midorikawa K, 2001, FEBS LETT, V495, P187, DOI 10.1016/S0014-5793(01)02383-3; Mirochnitchenko O, 1999, J BIOL CHEM, V274, P10349, DOI 10.1074/jbc.274.15.10349; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; SIES H, 1972, FEBS LETT, V27, P171, DOI 10.1016/0014-5793(72)80434-4; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369	59	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43004	43009		10.1074/jbc.M106946200	http://dx.doi.org/10.1074/jbc.M106946200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562367	hybrid			2022-12-25	WOS:000172169300050
J	Jordan, BWM; Dinev, D; LeMellay, V; Troppmair, J; Gotz, R; Wixler, L; Sendtner, M; Ludwig, S; Rapp, UR				Jordan, BWM; Dinev, D; LeMellay, V; Troppmair, J; Gotz, R; Wixler, L; Sendtner, M; Ludwig, S; Rapp, UR			Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY PROTEINS; IAP; GROWTH; GENE; ACTIVATION; HILP; RAF; ITA	The inhibitor of apoptosis proteins (IAPs) have been shown to interact with a growing number of intracellular proteins and pathways to fulfil their anti-apoptotic role. In the search for novel IAP-interacting proteins we identified the neurotrophin receptor-interacting MAGE homologue (NRAGE) as being able to bind to the avian LAP homologue ITA. This interaction requires the RING domain of ITA. NRAGE additionally coimmunoprecipitates with XLAP. When overexpressed in 32D cells NRAGE augments interleukin-3 withdrawal induced apoptosis, possibly through binding endogenous XIAP. Moreover, NRAGE is able to overcome the anti-apoptotic effect of Bcl-2.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Neurobiol, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.		Sendtner, Michael/J-1542-2012; Sendtner, Michael/M-8137-2014	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Ludwig, Stephan/0000-0003-4490-3052; Troppmair, Jakob/0000-0002-0611-3837				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Digby MR, 1996, DNA CELL BIOL, V15, P981, DOI 10.1089/dna.1996.15.981; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Gotz R, 2000, HUM MOL GENET, V9, P2479, DOI 10.1093/hmg/9.17.2479; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Johnson DE, 2000, CANCER RES, V60, P1818; Kalmes A, 1998, CANCER RES, V58, P2986; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	32	73	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39985	39989		10.1074/jbc.C100171200	http://dx.doi.org/10.1074/jbc.C100171200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546791	hybrid			2022-12-25	WOS:000171789200066
J	Tanaka, S; Sugimachi, K; Saeki, H; Kinoshita, J; Ohga, T; Shimada, M; Maehara, Y; Sugimachi, K				Tanaka, S; Sugimachi, K; Saeki, H; Kinoshita, J; Ohga, T; Shimada, M; Maehara, Y; Sugimachi, K			A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma	ONCOGENE			English	Article						gastric carcinoma; scirrhous; stroma; WISP1; CCN	TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TUMOR-GROWTH; IN-VIVO; FAMILY; CYR61; ANGIOGENESIS; ADHESION; CELLS; IDENTIFICATION	Scirrhous carcinoma of the stomach is characterized by rapid growth with a vast fibrous stroma, high invasiveness, and substantially a poor prognosis. Little is known of the molecular pathogenesis of this disease. Members of the emerging family of the CCN gene (for connective tissue growth factor, cysteine-rich 61, nephroblastoma overexpressed) encode cysteine-rich secreted proteins with roles in human fibrotic disorders and cancer progression. Using targeted differential displays, we identified a novel variant of the CCN family member WISP1 (Wnt-induced secreted protein 1), named WISP1v, as overexpressed in scirrhous. gastric carcinomas. Predicted protein of the WISP1v completely lacks a module of Von Willebrand type C that is thought to participate in protein complex formation. Ectopic expression revealed WISP1v to be a secreted oncoprotein inducing a striking cellular transformation and rapid piling-up growth. It is noteworthy that WISP1v transfectants enhanced the invasive phenotype of cocultured gastric carcinoma cells, while wild-type WISP1 had no such potential. These findings suggest that CCN protein WISP1v is involved in the aggressive progression of scirrhous gastric carcinoma.	Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Fukuoka, Japan	Kyushu University; Kyushu University	Tanaka, S (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Maehara, Yoshihiko/A-4867-2010					Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHUNG LWK, 1995, CANCER SURV, V23, P33; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; KITAMURA K, 1995, J SURG ONCOL, V58, P112, DOI 10.1002/jso.2930580208; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Scholz G, 1996, MOL CELL BIOL, V16, P481; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; SUGIMACHI K, 1993, CURR OPIN GEN SURG, V1, P216; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Tanaka S, 1998, P NATL ACAD SCI USA, V95, P10164, DOI 10.1073/pnas.95.17.10164; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Xu LF, 2000, GENE DEV, V14, P585; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	25	73	76	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5525	5532		10.1038/sj.onc.1204723	http://dx.doi.org/10.1038/sj.onc.1204723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571650				2022-12-25	WOS:000170781100013
J	Homma, KJ; Tanaka, Y; Matsushita, T; Yokoyama, K; Matsui, H; Natori, S				Homma, KJ; Tanaka, Y; Matsushita, T; Yokoyama, K; Matsui, H; Natori, S			Adenosine deaminase activity of insect-derived growth factor is essential for its growth factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAT EYE SYNDROME; EMBRYONIC-CELL LINE; PEREGRINA FLESH FLY; SARCOPHAGA-PEREGRINA; CRITICAL REGION; CULTURE-MEDIUM; CDNA CLONING; PURIFICATION; NIH-SAPE-4; RECEPTORS	Insect-derived growth factor (IDGF) was originally isolated from conditioned medium of NIH-Sape-4 cells derived from flesh fly embryos. Here we demonstrated that IDGF has adenosine deaminase activity. The substrate specificity of IDGF was similar to that of the mammalian cytoplasmic adenosine deaminase. The adenosine deaminase activity of IDGF was shown to be indispensable for its growth factor activity toward NIH-Sape-4 cells. We found that there are specific binding sites for IDGF on the surface of NIH-Sape-4 cells and that it binds to these sites with a K-d, value of 2.4 X 10(-10) m. We propose that the cell surface binding sites for IDGF are specific receptors modified with an adenosine moiety. When IDGF binds to these receptors, it may deaminate the adenosine moiety, and this process may be prerequisite for the signal transduction via this receptor.	RIKEN, Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Natori, S (corresponding author), RIKEN, Inst Phys & Chem Res, Natori Special Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Dong RP, 1997, J IMMUNOL, V159, P6070; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hershfield M., 1995, METABOLIC MOL BASIS; HOMMA K, 1994, J BIOL CHEM, V269, P15258; Homma K, 1996, J BIOL CHEM, V271, P13770, DOI 10.1074/jbc.271.23.13770; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KODAMA K, 1979, AGR BIOL CHEM TOKYO, V43, P2375, DOI 10.1080/00021369.1979.10863817; KOMANO H, 1987, BIOCHEM J, V248, P217, DOI 10.1042/bj2480217; KRAUT EH, 1986, BLOOD, V68, P1119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li S, 2000, GENE, V252, P83, DOI 10.1016/S0378-1119(00)00226-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsushita T, 2000, J BIOL CHEM, V275, P36934, DOI 10.1074/jbc.M003455200; MCDERMID HE, 1986, SCIENCE, V232, P646, DOI 10.1126/science.3961499; McDermid HE, 1996, GENOME RES, V6, P1149, DOI 10.1101/gr.6.12.1149; MEARS AJ, 1995, AM J HUM GENET, V57, P667; MITSUHAS.J, 1964, CONTRIB BOYCE THOMPS, V22, P435; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; OHTAKI T, 1966, JPN J MED SCI BIOL, V19, P97, DOI 10.7883/yoken1952.19.97; PAGE B, 1993, INT J ONCOL, V3, P473; Raffery L.A., 1999, DEV BIOL, V210, P251; Riazi MA, 2000, GENOMICS, V64, P277, DOI 10.1006/geno.1999.6099; RUETER SM, 1998, MODIFICATION EDITING, V1, P1725; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINZEL A, 1981, HUM GENET, V57, P148; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Sideraki V, 1996, BIOCHEMISTRY-US, V35, P15019, DOI 10.1021/bi961427e; Sideraki V, 1996, BIOCHEMISTRY-US, V35, P7862, DOI 10.1021/bi952920d; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; VALLEJO AN, 1994, PCR METH APPL, V4, P123; Westermark B, 1989, CURR OPIN CELL BIOL, V1, P279, DOI 10.1016/0955-0674(89)90101-4; WIGINTON DA, 1981, BIOCHEM J, V195, P389, DOI 10.1042/bj1950389; YAMAGUCHI K, 1986, LEUKEMIA RES, V10, P989, DOI 10.1016/0145-2126(86)90251-1	45	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43761	43766		10.1074/jbc.M105088200	http://dx.doi.org/10.1074/jbc.M105088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562360				2022-12-25	WOS:000172297700038
J	Ibrahim, HR; Thomas, U; Pellegrini, A				Ibrahim, HR; Thomas, U; Pellegrini, A			A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIALLY UNFOLDED LYSOZYME; EGG-WHITE LYSOZYME; SOLID-STATE NMR; ESCHERICHIA-COLI; BACTERICIDAL ACTIVITY; DAMAGE MECHANISM; MODEL SYSTEM; BILAYERS; CHANNEL; PROTEINS	Recently, we have found that partially unfolded lysozyme exerts broad spectrum antimicrobial action in vitro against Gram-negative and Gram-positive bacteria independent of its catalytic activity. In parallel, an internal peptide (residues 98-112) of hen egg white lysozyme, obtained after digestion with clostripain, possessed broad spectrum antimicrobial action in vitro. This internal peptide is part of a helix-loop-helix domain (87-114 sequence of hen lysozyme) located at the upper lip of the active site cleft of lysozyme. The helix-loop-helix (HLH) structures are known motifs commonly found in membrane-active and DNA-binding proteins. To evaluate the contribution of the HLH peptide to the antimicrobial properties of lysozyme, the HLH sequence and its secondary structure derivatives of chicken and human lysozyme were synthesized and tested for antimicrobial activity against several bacterial strains. We found that the full HLH peptide of both chicken and human lysozymes was potently microbicidal against both Gram-positive and Gram-negative bacteria and the fungus Candida albicans. The N-terminal helix of HLH was specifically bactericidal to Gram-positive bacteria, whereas the C-terminal helix was bactericidal to all tested strains. Outer and inner membrane permeabilization studies, as well as measurements of transmembrane electrochemical potentials, provided evidence that HLH peptide and its C-terminal helix domain kill Gram-negative bacteria by crossing the outer membrane via self-promoted uptake and causing damage to the inner membrane through channel formation. The results are discussed in terms of proposed mechanisms for the catalytically independent antimicrobial activity of lysozyme that offer a new strategy for the design of potential antimicrobial drugs in the treatment of infectious diseases.	Kagoshima Univ, Fac Agr, Dept Biochem & Biotechnol, Kagoshima 8900065, Japan; Univ Zurich, Inst Vet Physiol, Dept Appl Vet Physiol, CH-8057 Zurich, Switzerland	Kagoshima University; University of Zurich	Ibrahim, HR (corresponding author), Kagoshima Univ, Fac Agr, Dept Biochem & Biotechnol, 1-21-24 Korimoto, Kagoshima 8900065, Japan.		Ibrahim, Hisham/AAB-3945-2021	Ibrahim, Hisham/0000-0002-7809-900X				ANDREU D, 1985, BIOCHEMISTRY-US, V24, P1683, DOI 10.1021/bi00328a017; BANKS J G, 1986, Biotechnology and Applied Biochemistry, V8, P103; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BUKHARIN OV, 1976, ANTIBIOT MED BIOTEK, V21, P805; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; Coonrod J D, 1986, Semin Respir Infect, V1, P118; Cross TA, 1999, NAT STRUCT BIOL, V6, P610, DOI 10.1038/10650; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; HASSELBERGER FX, 1978, USES ENZYMES IMMOBIL, P128; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; HUGHEY VL, 1987, APPL ENVIRON MICROB, V53, P2165, DOI 10.1128/AEM.53.9.2165-2170.1987; HULTMARK D, 1980, EUR J BIOCHEM, V106, P7, DOI 10.1111/j.1432-1033.1980.tb05991.x; Hung SC, 1999, BIOPHYS J, V77, P3120, DOI 10.1016/S0006-3495(99)77142-0; Ibrahim HR, 2000, BBA-GEN SUBJECTS, V1523, P196, DOI 10.1016/S0304-4165(00)00122-7; Ibrahim HR, 1996, J AGR FOOD CHEM, V44, P3799, DOI 10.1021/jf960133x; Ibrahim HR, 1998, NAHRUNG, V42, P187, DOI 10.1002/(SICI)1521-3803(199808)42:03/04<187::AID-FOOD187>3.3.CO;2-6; Ibrahim HR, 1996, J AGR FOOD CHEM, V44, P1416, DOI 10.1021/jf9507147; IBRAHIM HR, 1994, J BIOL CHEM, V269, P5059; Ibrahim HR, 1997, J AGR FOOD CHEM, V45, P89, DOI 10.1021/jf9604899; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; Kim Y, 1998, PROTEIN SCI, V7, P342; KOKOSHIS PL, 1978, SCIENCE, V199, P1340, DOI 10.1126/science.628841; Kovacs F, 1999, P NATL ACAD SCI USA, V96, P7910, DOI 10.1073/pnas.96.14.7910; KUDINOVA TI, 1976, ANTIBIOT MED BIOTEK, V21, P441; LAIBLE NJ, 1985, INFECT IMMUN, V48, P720, DOI 10.1128/IAI.48.3.720-728.1985; Lee-Huang S, 1999, P NATL ACAD SCI USA, V96, P2678, DOI 10.1073/pnas.96.6.2678; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEIVE L, 1974, ANN NY ACAD SCI, V235, P109, DOI 10.1111/j.1749-6632.1974.tb43261.x; LEMARBRE P, 1981, BLOOD, V58, P994, DOI 10.1182/blood.V58.5.994.994; Lindeberg M, 2000, J MOL BIOL, V295, P679, DOI 10.1006/jmbi.1999.3396; OHNO N, 1989, J BIOL CHEM, V264, P4434; Osserman E.F., 1974, LYSOZYME; Pellegrini A, 1997, J APPL MICROBIOL, V82, P372, DOI 10.1046/j.1365-2672.1997.00372.x; POSSE E, 1994, BBA-BIOMEMBRANES, V1193, P101, DOI 10.1016/0005-2736(94)90338-7; POST CB, 1986, J MOL BIOL, V190, P455, DOI 10.1016/0022-2836(86)90015-X; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; SAVA G, 1988, EUR J CANCER CLIN ON, V24, P1737, DOI 10.1016/0277-5379(88)90075-2; SCHINDLER M, 1977, BIOCHEMISTRY-US, V16, P423, DOI 10.1021/bi00622a013; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SONG HW, 1994, J MOL BIOL, V244, P522, DOI 10.1006/jmbi.1994.1750; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; SRISAILAM S, 2000, BIOCHIM BIOPHYS ACTA, V15, P1; THACORE H, 1966, AM REV RESPIR DIS, V93, P786; TOMIZAWA H, 1994, BIOCHEMISTRY-US, V33, P8770, DOI 10.1021/bi00195a019; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Wang W, 1999, BBA-GEN SUBJECTS, V1473, P418, DOI 10.1016/S0304-4165(99)00200-7; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902	51	231	250	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43767	43774		10.1074/jbc.M106317200	http://dx.doi.org/10.1074/jbc.M106317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11560930	hybrid			2022-12-25	WOS:000172297700039
J	McQuibban, GA; Butler, GS; Gong, JH; Bendall, L; Power, C; Clark-Lewis, I; Overall, CM				McQuibban, GA; Butler, GS; Gong, JH; Bendall, L; Power, C; Clark-Lewis, I; Overall, CM			Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A; CD34(+) CELLS; GROWTH-FACTOR; LYMPHOCYTE CHEMOATTRACTANT; EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; HEPARIN-BINDING; LEUKEMIA CELLS; ACTIVATION; MARROW	Chemokines provide directional cues for leukocyte migration and activation that are essential for normal leukocytic trafficking and for host responses during processes such as inflammation, infection, and cancer. Recently we reported that matrix metalloproteinases (MMPs) modulate the activity of the CC chemokine monocyte chemoattractant protein-3 by selective proteolysis to release the N-terminal tetrapeptide. Here we report the N-terminal processing, also at position 4-5, of the CXC chemokines stromal cell-derived factor (SDF)-1 alpha and beta by MMP-2 (gelatinase A). Robustness of the MMP family for chemokine cleavage was revealed from identical cleavage site specificity of MMPs 1, 3, 9, 13, and 14 (MT1-MMP) toward SDF-1; selectivity was indicated by absence of cleavage by AMP's 7 and 8. Efficient cleavage of SDF-1 alpha by MMP-2 is the result of a strong interaction with the NMP hemopexin C domain at an exosite that overlaps the monocyte chemoattractant protein-3 binding site. The association of SDF-1 alpha with different glycosaminoglycans did not inhibit cleavage. MMP cleavage of SDF-1 alpha resulted in loss of binding to its cognate receptor CXCR-4. This was reflected in a loss of chemoattractant activity for CD34(+) hematopoietic progenitor stem cells and pre-B cells, and unlike full-length SDF-1 alpha, the MMP-cleaved chemokine was unable to block CXCR-4-dependent human immunodeficiency virus-1 infection of CD4(+) cells. These data suggest that MMPs may be important regulatory proteases in attenuating SDF-1 function and point to a deep convergence of two important networks, chemokines and MMPs, to regulate leukocytic activity in vivo.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ Sydney, Westmead Inst Canc Res, Sydney, NSW 2145, Australia; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of Sydney; University of Calgary	Overall, CM (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca	Power, Christopher/C-7181-2013; Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578; Power, Christopher/0000-0002-5131-9711				Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bendall LJ, 1997, BRIT J HAEMATOL, V98, P828, DOI 10.1046/j.1365-2141.1997.2993116.x; BENDALL LJ, 1993, BLOOD, V82, P3125; Bigg HF, 2001, CANCER RES, V61, P3610; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Deryugina EI, 1997, J CELL SCI, V110, P2473; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Janowska-Wieczorek A, 1999, BLOOD, V93, P3379, DOI 10.1182/blood.V93.10.3379.410k09_3379_3390; Johnston JB, 2000, J VIROL, V74, P7211, DOI 10.1128/JVI.74.16.7211-7220.2000; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Overall CM, 2000, METH MOL B, V151, P79, DOI 10.1385/1-59259-046-2:079; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Power C, 1998, J VIROL, V72, P9045, DOI 10.1128/JVI.72.11.9045-9053.1998; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Shen HM, 2001, J IMMUNOL, V166, P5027, DOI 10.4049/jimmunol.166.8.5027; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; SODEK J, 1988, BIOL MECHANISMS TOOT, P303; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; Vecchi A, 1999, J LEUKOCYTE BIOL, V66, P489, DOI 10.1002/jlb.66.3.489; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WILLEMS J, 1989, IMMUNOLOGY, V67, P540; Xia MH, 1996, J IMMUNOL, V156, P160	52	507	532	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43503	43508		10.1074/jbc.M107736200	http://dx.doi.org/10.1074/jbc.M107736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571304	hybrid			2022-12-25	WOS:000172297700005
J	Fukunaga, K; Ishii, S; Asano, K; Yokomizo, T; Shiomi, T; Shimizu, T; Yamaguchi, K				Fukunaga, K; Ishii, S; Asano, K; Yokomizo, T; Shiomi, T; Shimizu, T; Yamaguchi, K			Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR ACETYLHYDROLASE DEFICIENCY; MISSENSE MUTATION; RISK FACTOR; CELLS; MICE; HYPERREACTIVITY; PHOSPHOLIPASE; EXPRESSION; CHEMOTAXIS; ENDOTOXIN	Various proinflammatory and vasoactive actions of platelet-activating factor (PAF) are mediated through a specific G-protein-coupled PAF receptor (PAFR). We identified a novel DNA variant in the human PAFR gene, which substitutes an aspartic acid for an alanine residue at position 224 (A224D) in the putative third cytoplasmic loop. This mutation was observed in a Japanese population at an allele frequency of 7.8%. To delineate the functional consequences of this structural alteration, Chinese hamster ovary cells were stably transfected with constructs encoding either wild-type or A224D mutated PAFR. No significant difference was observed in the expression level of the receptor or the affinity to PAF or to an antagonist, WEB2086, between the cells transfected with wild-type and mutant PAFR. Chinese hamster ovary cells expressing A224D mutant PAFR displayed partial but significant reduction of PAF-induced intracellular signals such as calcium mobilization, inositol phosphate production, inhibition of adenylyl cyclase, and chemotaxis. These findings suggest that this variant receptor produced by a naturally occurring mutation exhibits impaired coupling to G-proteins and may be a basis for interindividual variation in PAF-related physiological responses, disease predisposition or phenotypes, and drug responsiveness.	Keio Univ, Sch Med, Dept Med, Cardiopulm Div,Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1608582, Japan	Keio University; University of Tokyo; Japan Science & Technology Agency (JST)	Asano, K (corresponding author), Keio Univ, Sch Med, Dept Med, Cardiopulm Div,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Yokomizo, Takehiko/P-5673-2016; Fukunaga, Koichi/R-5338-2019	Yokomizo, Takehiko/0000-0002-5219-1553; 				ALI H, 1994, J BIOL CHEM, V269, P24557; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Brzustowicz LM, 1997, HYPERTENSION, V29, P158, DOI 10.1161/01.HYP.29.1.158; Carlson SA, 1998, MOL PHARMACOL, V53, P451, DOI 10.1124/mol.53.3.451; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; Hiramoto M, 1997, STROKE, V28, P2417, DOI 10.1161/01.STR.28.12.2417; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Longphre M, 1996, AM J RESP CELL MOL, V14, P461, DOI 10.1165/ajrcmb.14.5.8624251; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; RODRIGUEZROISIN R, 1994, J CLIN INVEST, V93, P188, DOI 10.1172/JCI116944; Satoh N, 1999, AM J RESP CRIT CARE, V159, P974, DOI 10.1164/ajrccm.159.3.9807093; Shi LC, 1996, J NEUROCHEM, V67, P1478; Small KM, 2000, J BIOL CHEM, V275, P23059, DOI 10.1074/jbc.M000796200; Small KM, 2001, J BIOL CHEM, V276, P4917, DOI 10.1074/jbc.M008118200; Small KM, 2000, J BIOL CHEM, V275, P38518, DOI 10.1074/jbc.M004550200; Stafforini DM, 1999, J CLIN INVEST, V103, P989, DOI 10.1172/JCI5574; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STRADER CD, 1987, J BIOL CHEM, V262, P16439; Tanaka R, 1999, AM J KIDNEY DIS, V34, P289, DOI 10.1016/S0272-6386(99)70357-4; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Yamada Y, 1998, METABOLISM, V47, P177, DOI 10.1016/S0026-0495(98)90216-5; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	34	38	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43025	43030		10.1074/jbc.M108288200	http://dx.doi.org/10.1074/jbc.M108288200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560941	hybrid			2022-12-25	WOS:000172169300053
J	Kalbfuss, B; Mabon, SA; Misteli, T				Kalbfuss, B; Mabon, SA; Misteli, T			Correction of alternative splicing of tau in frontotemporal dementia and Parkinsonism linked to chromosome 17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE SUPRANUCLEAR PALSY; ANTISENSE OLIGONUCLEOTIDES; MESSENGER-RNA; NEURODEGENERATIVE DISORDERS; MICROTUBULE-BINDING; ALZHEIMERS-DISEASE; NEURONAL CELLS; SR PROTEINS; MUTATIONS; GENE	Mutations in the human tau gene cause frontotemporal dementia and Parkinsonism associated with chromosome 17 (FTDP-17). One of the major disease mechanisms in FTDP-17 is the increased inclusion of tau exon 10 during pre-mRNA splicing. Here we show that modified oligonucleotides directed against the tau exon 10 splice junctions suppress inclusion of tau exon 10. The effect is mediated by the formation of a stable pre-mRNA-oligonucleotide hybrid, which blocks access of the splicing machinery to the pre-mRNA. Correction of tau splicing occurs in a tau minigene system and in endogenous tau RNA in neuronal pheochromocytoma cells and is specific to exon 10 of the tau gene. Antisense oligonucleotide-mediated exclusion of exon 10 has a physiological effect by increasing the ratio of protein lacking the microtubule-binding domain encoded by exon 10. As a consequence, the microtubule cytoskeleton becomes destabilized and cell morphology is altered. Our results demonstrate that alternative splicing defects of tau as found in FTDP-17 patients can be corrected by application of antisense oligonucleotides. These findings provide a tool to study specific tau isoforms in vivo and might lead to a novel therapeutic strategy for FTDP-17.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Misteli, T (corresponding author), NCI, NIH, 41 Lib Dr,Bldg 41, Bethesda, MD 20892 USA.							Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Conrad C, 1997, ANN NEUROL, V41, P277, DOI 10.1002/ana.410410222; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; FLAMENT S, 1991, ACTA NEUROPATHOL, V81, P591, DOI 10.1007/BF00296367; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; Friedhoff P, 2000, BBA-MOL BASIS DIS, V1502, P122, DOI 10.1016/S0925-4439(00)00038-7; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Higgins JJ, 1998, NEUROLOGY, V50, P270, DOI 10.1212/WNL.50.1.270; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ishizawa K, 2000, ACTA NEUROPATHOL, V100, P235, DOI 10.1007/s004019900177; Janke C, 2000, BRAIN RES PROTOC, V5, P231, DOI 10.1016/S1385-299X(00)00018-0; Jay P, 2000, EUR J BIOCHEM, V267, P2921, DOI 10.1046/j.1432-1327.2000.01306.x; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496; Lacerra G, 2000, P NATL ACAD SCI USA, V97, P9591, DOI 10.1073/pnas.97.17.9591; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lu M, 2001, MOL BIOL CELL, V12, P171, DOI 10.1091/mbc.12.1.171; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Vanier MT, 1998, J CELL SCI, V111, P1419; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Wilhelmsen KC, 1999, P NATL ACAD SCI USA, V96, P7120, DOI 10.1073/pnas.96.13.7120; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3	49	86	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42986	42993		10.1074/jbc.M105113200	http://dx.doi.org/10.1074/jbc.M105113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560926	hybrid			2022-12-25	WOS:000172169300048
J	Mathupala, SP; Rempel, A; Pedersen, PL				Mathupala, SP; Rempel, A; Pedersen, PL			Glucose catabolism in cancer cells - Identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-1; EXPRESSION; TUMOR; TRANSCRIPTION; ELEMENTS; LINE; MITOCHONDRIA; PURIFICATION; METABOLISM; ENHANCER	One of the most common signatures of highly malignant tumors is their capacity to metabolize more glucose to lactic acid than their tissues of origin. Hepatomas exhibiting this phenotype are dependent on the high expression of type Il hexokinase, which supplies such tumors with abundant amounts of glucose 6-phosphate, a significant carbon and energy source especially under hypoxic conditions. Here we report that the distal region of the hepatoma. type Il hexokinase promoter displays consensus motifs for hypoxia-inducible factor (HIF-1) that overlap E-box sequences known to be related in other gene promoters to glucose response. Moreover, we show that subjecting transfected hepatoma cells to hypoxic conditions activates the type II hexokinase promoter almost 3-fold, a value that approaches 7-fold in the presence of glucose. Consistent with these findings is the induction under hypoxic conditions of the HIF-1 protein. Reporter gene analyses with a series of nested deletion mutants of the hepatoma type II hexokinase promoter show that a significant fraction of the total activation observed under hypoxic conditions localizes to the distal region where the overlapping HIF-1/E-box sequences are located. Finally, DNase I footprint analysis with a segment of the promoter containing these elements reveals the binding of several nuclear proteins. In summary, these novel studies identify and characterize a marked glucose-modulated activation response of the type II hexokinase gene to hypoxic conditions within highly glycolytic hepatoma cells, a property that may help assure that such cells exhibit a growth and survival advantage over their parental cells of origin.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NCI NIH HHS [T32 CA 67751, CA 80118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080118, T32CA067751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Aisenberg AC, 1961, GLYCOLYSIS RESP TUMO; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BURK D, 1967, JNCI-J NATL CANCER I, V38, P839; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Mathupala S. P., 1996, FASEB Journal, V10, pA1514; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; NAKASHIMA RA, 1988, CANCER RES, V48, P913; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Rempel A, 1996, CANCER RES, V56, P2468; REMPEL A, 1996, FEBS LETT, V385, P223; Riddle SR, 2000, AM J PHYSIOL-LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza G L, 2000, Respir Res, V1, P159, DOI 10.1186/rr27; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; SHOWE MK, 1992, NUCLEIC ACIDS RES, V20, P3153, DOI 10.1093/nar/20.12.3153; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WEINHOUSE S, 1972, CANCER RES, V23, P987	32	280	304	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43407	43412		10.1074/jbc.M108181200	http://dx.doi.org/10.1074/jbc.M108181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11557773	hybrid			2022-12-25	WOS:000172169300100
J	Pombo, I; Martin-Verdeaux, S; Iannascoli, B; Le Mao, J; Deriano, L; Rivera, J; Blank, U				Pombo, I; Martin-Verdeaux, S; Iannascoli, B; Le Mao, J; Deriano, L; Rivera, J; Blank, U			IgE receptor type 1-dependent regulation of a Rab3D-associated kinase - A possible link in the calcium-dependent assembly of snare complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-VESICLE FUSION; MAST-CELL SECRETION; SMALL G-PROTEINS; FC-EPSILON-RI; MEMBRANE-PROTEIN; TARGET MEMBRANE; RAB3 SUBFAMILY; EXOCYTOSIS; PHOSPHORYLATION; SYNTAXIN-4	Following activation through high affinity IgE receptors (Fc epsilon RI), mast cells release, within a few minutes, their granule content of inflammatory and allergic mediators. Fc epsilon RI-induced degranulation is a SNARE (soluble N-ethylmaleimide attachment protein receptors)-dependent fusion process. It is regulated by Rab3D, a subfamily member of Rab GTPases. Evidence exists showing that Rab3 action is calcium-regulated although the molecular mechanisms remain unclear. To obtain an understanding of Rab3D function we have searched for Rab3D-associated effectors that respond to allergic triggering through Fc epsilon RI. Using the RBL-2H3 mast cell line we detected a Ser/Thr kinase activity, termed here Rak3D (from Rab3D-associated kinase), because it was specifically co-immunoprecipitated with anti-Rab3D antibody. Rak3D activity, as measured by its auto- or transphosphorylation, was maximal in resting cells and decreased upon stimulation. The down-regulation of the observed activity was blocked with EGTA, but not with other degranulation inhibitors, suggesting that its activity functions downstream of calcium influx. We found that Rak3D phosphorylates the NH2-terminal regulatory domain of the t-SNARE syntaxin 4, but not syntaxin 2 or 3. The phosphorylation of syntaxin 4 decreased its binding to its partner SNAP23. Thus, we propose a novel phosphorylation-dependent mechanism by which Rab3D controls SNARE assembly in a calcium-dependent manner.	Inst Pasteur, Unite Immunoallergie, F-75724 Paris 15, France; NIAMS, Mol Inflammat Sect, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Blank, U (corresponding author), Inst Pasteur, Unite Immunoallergie, 25-28 Rue Dr Roux, F-75724 Paris 15, France.		Deriano, Ludovic/D-2048-2019	Deriano, Ludovic/0000-0002-9673-9525; Blank, Ulrich/0000-0002-2661-2983	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041101, Z01AR041101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; Baram D, 1999, J EXP MED, V189, P1649, DOI 10.1084/jem.189.10.1649; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Doussau F, 1998, J NEUROSCI, V18, P3147; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Duprez V, 1998, J BIOL CHEM, V273, P33985, DOI 10.1074/jbc.273.51.33985; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Galli S., 1998, FUNDAMENTAL IMMUNOLO, P1127; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hackam DJ, 1996, J IMMUNOL, V156, P4377; Haynes LP, 2001, J BIOL CHEM, V276, P9726, DOI 10.1074/jbc.M006959200; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Johannes L, 1998, J NEUROCHEM, V71, P1127; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kim TD, 1997, J BIOL CHEM, V272, P31225, DOI 10.1074/jbc.272.50.31225; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nechushtan H, 2000, BLOOD, V95, P1752, DOI 10.1182/blood.V95.5.1752.005k18_1752_1757; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; OBERHAUSER AF, 1994, FEBS LETT, V339, P171, DOI 10.1016/0014-5793(94)80409-5; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Roa M, 1997, J IMMUNOL, V159, P2815; ROHLICH P, 1971, J CELL BIOL, V51, P465, DOI 10.1083/jcb.51.2.465; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Tuvim MJ, 1999, AM J RESP CELL MOL, V20, P79, DOI 10.1165/ajrcmb.20.1.3279; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Williams RM, 2000, J CELL SCI, V113, P3839; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YANO H, 1993, J BIOL CHEM, V268, P25846; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	62	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42893	42900		10.1074/jbc.M103527200	http://dx.doi.org/10.1074/jbc.M103527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555639	hybrid			2022-12-25	WOS:000172169300036
J	Zhang, Q; Fan, JS; Zhang, MJ				Zhang, Q; Fan, JS; Zhang, MJ			Interdomain chaperoning between PSD-95, Dlg, and Zo-1 (PDZ) domains of glutamate receptor-interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; AMPA RECEPTORS; POSTSYNAPTIC DENSITY; CRYSTAL-STRUCTURE; C-TERMINUS; BINDING; GLUR2; REQUIRES; COMPLEX; PHOSPHORYLATION	The multiple PSD-95, Dlg, and Zo-1 (PDZ) domain protein, glutamate receptor-interacting protein (GRIP), is involved in the clustering and trafficking of the alpha -amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor by directly binding to the cytoplasmic tail of the receptor's GluR2 subunit. Both the forth and fifth PDZ domains (PDZ4 and PDZ5) of GRIP are required for effective binding to the receptor. Using NAM and circular dichroism spectroscopic techniques, we show that PDZ5 is completely unstructured in solution. Freshly prepared PDZ4 is largely folded, but the domain can spontaneously unfold. Neither PDZ4 nor PDZ5 binds to GluR2 in solution. Unexpectedly, when PDZ4 and PDZ5 are covalently connected (i.e. PDZ45), both PDZ domains become well folded and stable in solution. The covalent linkage of the two PDZ domains is essential for proper folding of the tandem PDZ domains and its effective binding to GluR2. The interdomain chaperoning effect observed in the PDZ domains of GRIP represents a previously uncharacterized function of PDZ domains.	Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	mzhang@ust.hk		Zhang, Mingjie/0000-0001-9404-0190				Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Chung HJ, 2000, J NEUROSCI, V20, P7258; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li P, 1999, NAT NEUROSCI, V2, P972, DOI 10.1038/14771; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Tochio H, 2000, J MOL BIOL, V303, P359, DOI 10.1006/jmbi.2000.4148; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	34	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43216	43220		10.1074/jbc.M105996200	http://dx.doi.org/10.1074/jbc.M105996200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553623	hybrid			2022-12-25	WOS:000172169300076
J	Ahuja, D; Karow, DS; Kilpatrick, JE; Imperiale, MJ				Ahuja, D; Karow, DS; Kilpatrick, JE; Imperiale, MJ			RNA polymerase II-dependent positional effects on mRNA 3 ' end processing in the adenovirus major late transcription unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLY(A) SITE SELECTION; POLYADENYLATION SPECIFICITY FACTOR; GENE-EXPRESSION; SPLICE SITE; CLEAVAGE; SEQUENCES; PROTEIN; 3'-END; RECOGNITION	During the early phase of adenovirus infection, the promoter-proximal L1 poly(A) site in the major late transcription unit is used preferentially despite the fact that the distal L3 poly(A) site is stronger (i.e. it competes better for processing factors and is cleaved at a faster rate, in vitro). Previous work had established that this was due at least in part to the stable binding of the processing factor, cleavage and polyadenylation specificity factor, to the L1 poly(A) site as mediated by specific regulatory sequences. It is now demonstrated that in addition, the L1 poly(A) site has a positional advantage because of its 5' location in the transcription unit. We also show that preferential processing of a particular poly(A) site in a complex transcription unit is dependent on RNA polymerase II. Our results are consistent with recent reports demonstrating that the processing factors cleavage and polyadenylation specificity factor and cleavage stimulatory factor are associated with the RNA polymerase II holoenzyme; thus, processing at a weak poly(A) site like L1 can be enhanced by virtue of its being the first site to be transcribed.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Imperiale, MJ (corresponding author), 6310 Canc Ctr, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.							AKUSJARVI G, 1981, NATURE, V292, P420, DOI 10.1038/292420a0; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BAHRING S, 1994, BIOTECHNIQUES, V16, P807; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Cooke C, 1996, MOL CELL BIOL, V16, P2579; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; DENOME RM, 1988, MOL CELL BIOL, V8, P4829, DOI 10.1128/MCB.8.11.4829; DEZAZZO JD, 1989, MOL CELL BIOL, V9, P4951, DOI 10.1128/MCB.9.11.4951; DEZAZZO JD, 1991, MOL CELL BIOL, V11, P5977, DOI 10.1128/MCB.11.12.5977; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FALCKPEDERSEN E, 1989, J VIROL, V63, P532, DOI 10.1128/JVI.63.2.532-541.1989; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; Gilmartin GM, 1996, J VIROL, V70, P1775, DOI 10.1128/JVI.70.3.1775-1783.1996; Graveley BR, 1996, MOL CELL BIOL, V16, P4942; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Imperiale M J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P139; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KOBRIN BJ, 1986, MOL CELL BIOL, V6, P1687, DOI 10.1128/MCB.6.5.1687; LASSMAN CR, 1992, J IMMUNOL, V148, P2578; LASSMAN CR, 1992, J IMMUNOL, V148, P1251; MANLEY JL, 1982, J MOL BIOL, V159, P581, DOI 10.1016/0022-2836(82)90102-4; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; Nevins J R, 1981, Adv Virus Res, V26, P1, DOI 10.1016/S0065-3527(08)60419-4; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; NEVINS JR, 1981, NATURE, V290, P113, DOI 10.1038/290113a0; PRESCOTT JC, 1992, J BIOL CHEM, V267, P8175; Prescott JC, 1997, MOL CELL BIOL, V17, P2207, DOI 10.1128/MCB.17.4.2207; SANDIG V, 1993, GENE, V131, P255, DOI 10.1016/0378-1119(93)90302-J; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; SHAW AR, 1980, CELL, V22, P905, DOI 10.1016/0092-8674(80)90568-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Veraldi KL, 2001, MOL CELL BIOL, V21, P1228, DOI 10.1128/MCB.21.4.1228-1238.2001; Wahle E, 1997, PROG NUCLEIC ACID RE, V57, P41, DOI 10.1016/S0079-6603(08)60277-9; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILSONGUNN SI, 1992, J VIROL, V66, P5418, DOI 10.1128/JVI.66.9.5418-5424.1992; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397	59	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41825	41831		10.1074/jbc.M104709200	http://dx.doi.org/10.1074/jbc.M104709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551915	hybrid			2022-12-25	WOS:000172450400039
J	Azpiazu, I; Gautam, N				Azpiazu, I; Gautam, N			G protein gamma subunit interaction with a receptor regulates receptor-stimulated nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GTP-BINDING; RHODOPSIN; PURIFICATION; COMPLEX; SWITCH; G(Q)	The surfaces of heterotrimeric G proteins (alpha beta gamma) in contact with receptors and the molecular events at these sites, which lead to G protein activation, are largely unknown. We show here that a peptide from the C terminus of a G protein gamma subunit blocks muscarinic receptor-stimulated G protein activation in a sequence-dependent fashion. A G protein mutated at the same site on the gamma subunit shows enhanced receptor stimulated nucleotide exchange without affecting G protein hetero-trimerization. Ineffective contact between the gamma subunit and receptor increases the rate of receptor-stimulated nucleotide exchange. Specific interaction of the G protein gamma subunit with the receptor thus helps the beta gamma complex to act at a distance and control guanine nucleotide exchange in the a subunit.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.				NIGMS NIH HHS [GM46963, R01 GM046963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; AZPIAZU L, 2001, IN PRESS METHODS ENZ; BENNETT N, 1985, J BIOL CHEM, V260, P4156; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hayashi MK, 1996, J BIOCHEM, V120, P1232; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	20	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41742	41747		10.1074/jbc.M104034200	http://dx.doi.org/10.1074/jbc.M104034200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546799	hybrid			2022-12-25	WOS:000172450400028
J	Niccolai, N; Ciutti, A; Spiga, O; Scarselli, M; Bernini, A; Bracci, L; Di Maro, D; Dalvit, C; Molinari, H; Esposito, G; Temussi, PA				Niccolai, N; Ciutti, A; Spiga, O; Scarselli, M; Bernini, A; Bracci, L; Di Maro, D; Dalvit, C; Molinari, H; Esposito, G; Temussi, PA			NMR studies of protein surface accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; WATER-MOLECULES; ORGANIC-SOLVENTS; AQUEOUS-SOLUTION; BINDING-SITES; HYDRATION; SPECTROSCOPY; SUPPRESSION; REFINEMENT	Characterization of protein surface accessibility represents a new frontier of structural biology. A surface accessibility investigation for two structurally well-defined proteins, tendamistat and bovine pancreatic trypsin inhibitor, is performed here by a combined analysis of water-protein Overhauser effects and paramagnetic perturbation profiles induced by the soluble spin-label 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyI on NMR spectra. This approach seems to be reliable not only for distinguishing between buried and exposed residues but also for finding molecular locations where a network of more ordered waters covers the protein surface. From the presented set of data, an overall picture of the surface accessibility of the two proteins can be inferred. Detailed knowledge of protein accessibility can form the basis for successful design of mutants with increased activity and/or greater specificity.	Univ Siena, Biomol Struct Res Ctr, I-53100 Siena, Italy; Univ Siena, Dept Mol Biol, I-53100 Siena, Italy; BIOMODEN perl, I-53100 Siena, Italy; Pharmacia Dept Chem, I-20014 Nerviano, Milan, Italy; Univ Verona, Ist Policattedra, I-37100 Verona, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Naples, Dept Chem, I-80100 Naples, Italy	University of Siena; University of Siena; Pfizer; University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Naples Federico II	Niccolai, N (corresponding author), Univ Siena, Biomol Struct Res Ctr, Via Fiorentina 1, I-53100 Siena, Italy.		molinari, henriette/ABE-9775-2021; Molinari, Henriette/A-1695-2008; Bracci, Luisa/V-9913-2018; Temussi, Piero A/N-5830-2017; Bernini, Andrea/H-9412-2012	Molinari, Henriette/0000-0002-3678-130X; Bracci, Luisa/0000-0002-0738-5746; Temussi, Piero A/0000-0001-6032-4291; Bernini, Andrea/0000-0002-7528-2749				AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; BILLETER M, 1990, BIOPOLYMERS, V29, P695, DOI 10.1002/bip.360290404; BRUNNE RM, 1993, J MOL BIOL, V231, P1040, DOI 10.1006/jmbi.1993.1350; Dalvit C, 1996, J MAGN RESON SER B, V112, P282, DOI 10.1006/jmrb.1996.0143; Dalvit C, 1999, J BIOMOL NMR, V14, P23, DOI 10.1023/A:1008378929578; Dalvit C, 1998, J BIOMOL NMR, V11, P437, DOI 10.1023/A:1008272928075; DENISOV VP, 1995, J MOL BIOL, V245, P682, DOI 10.1006/jmbi.1994.0055; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Krantz A, 1998, TRENDS BIOTECHNOL, V16, P198, DOI 10.1016/S0167-7799(98)01177-9; Liepinsh E, 1997, NAT BIOTECHNOL, V15, P264, DOI 10.1038/nbt0397-264; Mattos C, 1996, NAT BIOTECHNOL, V14, P595, DOI 10.1038/nbt0596-595; Melacini G, 1999, J MAGN RESON, V136, P214, DOI 10.1006/jmre.1998.1646; Melacini G, 1999, J BIOMOL NMR, V15, P189, DOI 10.1023/A:1008316612907; Molinari H, 1997, BIOPHYS J, V73, P382, DOI 10.1016/S0006-3495(97)78078-0; Nakasako M, 1999, J MOL BIOL, V289, P547, DOI 10.1006/jmbi.1999.2795; Niccolai N, 2001, PROTEIN SCI, V10, P1498, DOI 10.1110/ps.30101; OTTING G, 1991, J AM CHEM SOC, V113, P4363, DOI 10.1021/ja00011a068; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; Otting G, 1997, PROG NUCL MAG RES SP, V31, P259, DOI 10.1016/S0079-6565(97)00012-5; PFLUGRATH JW, 1986, J MOL BIOL, V189, P383, DOI 10.1016/0022-2836(86)90520-6; Ringe D, 1995, CURR OPIN STRUC BIOL, V5, P825, DOI 10.1016/0959-440X(95)80017-4; Savvides SN, 1996, J BIOL CHEM, V271, P8101, DOI 10.1074/jbc.271.14.8101; Scarselli M, 1999, J BIOMOL NMR, V15, P125, DOI 10.1023/A:1008319507565; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	30	44	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42455	42461		10.1074/jbc.M107387200	http://dx.doi.org/10.1074/jbc.M107387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546818	Green Published, hybrid			2022-12-25	WOS:000172450400117
J	Thomas, M; Glaunsinger, B; Pim, D; Javier, R; Banks, L				Thomas, M; Glaunsinger, B; Pim, D; Javier, R; Banks, L			HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation	ONCOGENE			English	Article						HPV; E6; DIg; MAGI-1; transformation	HUMAN PAPILLOMAVIRUS TYPE-16; LARGE TUMOR-SUPPRESSOR; CARCINOMA CELL-LINES; GUANYLATE-KINASE; PDZ DOMAINS; PHOSPHOINOSITIDE 3-KINASE; ADENOVIRUS E4-ORF1; EPITHELIAL-CELLS; PLASMA-MEMBRANE; TIGHT JUNCTIONS	It has recently been shown that the high-risk human papillomavirus (HPV) E6 proteins can target the PDZ-domain containing proteins, Dlg, MUPP-1, MAGI-1 and hScrib for proteasome-mediated degradation. However, the E6 proteins from HPV-16 and HPV-18 (the two most common high-risk virus types) differ in their ability to target these proteins in a manner that correlates with their malignant potential. To investigate the underlying mechanisms for this, we have mutated HPV-16 and HPV-18 E6s to give each protein the other's PDZ-binding motif. Analysis of these mutants shows that the greater ability of HPV-18 E6 to bind to these proteins and to target them for degradation is indeed due to a single amino acid difference. Using a number of assays, we show that the E6 proteins interact specifically with only one of the five PDZ domains of MAGI-1, and this is the first interaction described for this particular PDZ domain. We also show that the guanylate kinase homology domain and the regions of MAGI-1 down stream of amino acid 733 are pot required for the degradation of MAGI-I. Finally, in a series of comparative analyses, we show that the degradation of MAGI-1 occurs through a different mechanism from that used by the E6 protein to induce the degradation of DIg and p53.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Thomas, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NCI NIH HHS [R01 CA58541, R01 CA058541-06, R01 CA058541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li J, 1998, CANCER RES, V58, P5667; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tashiro H, 1997, CANCER RES, V57, P3935; Thomas M, 1999, J GEN VIROL, V80, P1513, DOI 10.1099/0022-1317-80-6-1513; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	48	93	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5431	5439		10.1038/sj.onc.1204719	http://dx.doi.org/10.1038/sj.onc.1204719			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571640	Green Accepted			2022-12-25	WOS:000170781100003
J	Shimada, N; Suzuki, T; Watanabe, K				Shimada, N; Suzuki, T; Watanabe, K			Dual mode recognition of two isoacceptor tRNAs by mammalian mitochondrial seryl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; HIGHER-ORDER STRUCTURE; ESCHERICHIA-COLI; TRANSFER RNA(SER); AMINOACYLATION SPECIFICITY; TERTIARY STRUCTURE; CRYSTAL-STRUCTURE; CODON CUG; IN-VITRO; IDENTITY	Animal mitochondrial translation systems contain two serine tRNAs, corresponding to the codons AGY (Y = U and C) and UCN (N = U, C, A, and G), each possessing an unusual secondary structure; tRNA(GCU)(Ser) (for AGY) lacks the entire D arm, whereas tRNA(UGA)(Ser) (for UCN) has an unusual cloverleaf configuration. We previously demonstrated that a single bovine mitochondrial seryl-tRNA synthetase (mt SerRS) recognizes these topologically distinct isoacceptors having no common sequence or structure. Recombinant mt SerRS clearly footprinted at the T PsiC loop of each isoacceptor, and kinetic studies revealed that mt SerRS specifically recognized the T PsiC loop sequence in each isoacceptor. However, in the case of tRNA(UGA)(Ser), T PsiC loop-D loop interaction was further required for recognition, suggesting that mt SerRS recognizes the two substrates by distinct mechanisms. mt SerRS could slightly but significantly misacylate mitochondrial tRNA(Gln), which has the same T PsiC loop sequence as tRNA(UGA)(Ser), implying that the fidelity of mitochondrial translation is maintained by kinetic discrimination of tRNAs in the network of aminoacyl-tRNA synthetases.	Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778583, Japan	University of Tokyo; University of Tokyo	Watanabe, K (corresponding author), Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	kw@kwl.t.u-tokyo.ac.jp	Suzuki, Tsutomu/J-1776-2015	Suzuki, Tsutomu/0000-0002-9731-1731				ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; ASAHARA H, 1994, J MOL BIOL, V236, P738, DOI 10.1006/jmbi.1994.1186; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Chang KY, 1999, P NATL ACAD SCI USA, V96, P11764, DOI 10.1073/pnas.96.21.11764; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEBRUIJN MHL, 1983, EMBO J, V2, P1309, DOI 10.1002/j.1460-2075.1983.tb01586.x; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; Hayashi I, 1997, NUCLEIC ACIDS RES, V25, P3503, DOI 10.1093/nar/25.17.3503; Hayashi I, 1998, J MOL BIOL, V284, P57, DOI 10.1006/jmbi.1998.2151; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; Himeno H, 1997, J MOL BIOL, V268, P704, DOI 10.1006/jmbi.1997.0991; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; KAWAGUCHI Y, 1989, NATURE, V341, P164, DOI 10.1038/341164a0; KUMAZAWA Y, 1991, J BIOCHEM, V109, P421, DOI 10.1093/oxfordjournals.jbchem.a123397; Lenhard B, 1999, NUCLEIC ACIDS RES, V27, P721, DOI 10.1093/nar/27.3.721; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NISHIOKA N, 1994, NUCL ACIDS S SER, V31, P187; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; Oakley MG, 1997, BIOCHEMISTRY-US, V36, P2544, DOI 10.1021/bi962391t; OHAMA T, 1993, NUCLEIC ACIDS RES, V21, P4039, DOI 10.1093/nar/21.17.4039; PAPE LK, 1985, J BIOL CHEM, V260, P5362; PARKER J, 1989, MICROBIOL REV, V53, P273, DOI 10.1128/MMBR.53.3.273-298.1989; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; Ramos A, 1997, NUCLEIC ACIDS RES, V25, P2083, DOI 10.1093/nar/25.11.2083; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SHIMIZU M, 1992, J MOL EVOL, V35, P436; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STEINBERG S, 1994, J MOL BIOL, V236, P982, DOI 10.1016/0022-2836(94)90004-3; Suzuki T, 1997, EMBO J, V16, P1122, DOI 10.1093/emboj/16.5.1122; TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421; UEDA T, 1992, NUCLEIC ACIDS RES, V20, P2217, DOI 10.1093/nar/20.9.2217; VLASSOV VV, 1981, FEBS LETT, V123, P277, DOI 10.1016/0014-5793(81)80307-9; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WATANABE Y, 1994, NUCLEIC ACIDS RES, V22, P5378, DOI 10.1093/nar/22.24.5378; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; YOKOGAWA T, 1991, NUCLEIC ACIDS RES, V19, P6101, DOI 10.1093/nar/19.22.6101; Yokogawa T, 2000, J BIOL CHEM, V275, P19913, DOI 10.1074/jbc.M908473199	48	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46770	46778		10.1074/jbc.M105150200	http://dx.doi.org/10.1074/jbc.M105150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577083	hybrid			2022-12-25	WOS:000172768500015
J	Blanc, V; Henderson, JO; Kennedy, S; Davidson, NO				Blanc, V; Henderson, JO; Kennedy, S; Davidson, NO			Mutagenesis of apobec-1 complementation factor reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1, and complementation of C to U RNA-editing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; APOLIPOPROTEIN-B; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SECONDARY STRUCTURE; CYTIDINE DEAMINASE; SEQUENCE; SITE; ENZYME; DETERMINANTS	C to U editing of apolipoprotein B (apoB) RNA requires a multicomponent holoenzyme complex in which minimal constituents include apobec-1 and apobec-1 complementation factor (ACF). We have examined the predicted functional domains in ACF in binding apoB RNA, interaction with apobec-1, and complementation of RNA editing. We demonstrate that apoB RNA binding and apobec-1-interacting domains are defined by two partially overlapping regions containing the NH2-terminal RNA recognition motifs of ACF. Both apoB RNA binding and apobec-1 interaction are required for editing complementation activity. ACF is a nuclear protein that upon cotransfection with apobec-1 results in nuclear colocalization and redistribution of apobec-1 from the cytoplasm. ACF constructs with deletions or mutations in the putative nuclear localization signal (NLS) still localize in the nucleus of transfected cells but do not colocalize with apobec-1, the latter remaining predominantly cytoplasmic. These observations suggest that the putative NLS motif in ACF is not responsible for its nucleo-cytoplasmic trafficking. By contrast, protein-protein interaction is important for the nuclear import of apobec-1. Taken together, these data suggest that functional complementation of C to U RNA editing by apobec-1 involves the NH2-terminal 380 residues of ACF.	Washington Univ, Sch Med, Div Gastroenterol, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Davidson, NO (corresponding author), Washington Univ, Sch Med, Div Gastroenterol, Dept Internal Med, Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, R01DK056260] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-56260, DK52574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; HENDERSON JO, 2001, IN PRESS BIOCH BIOPH; Hersberger M, 1999, J BIOL CHEM, V274, P34590, DOI 10.1074/jbc.274.49.34590; Hersberger M, 1998, J BIOL CHEM, V273, P9435, DOI 10.1074/jbc.273.16.9435; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Maas S, 2000, BIOESSAYS, V22, P790, DOI 10.1002/1521-1878(200009)22:9<790::AID-BIES4>3.0.CO;2-0; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, RNA, V2, P274; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Wan LL, 2001, J BIOL CHEM, V276, P7681, DOI 10.1074/jbc.M010207200; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199	44	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46386	46393		10.1074/jbc.M107654200	http://dx.doi.org/10.1074/jbc.M107654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571303	hybrid			2022-12-25	WOS:000172573100121
J	Grisendi, S; Chambraud, B; Gout, I; Comoglio, PM; Crepaldi, T				Grisendi, S; Chambraud, B; Gout, I; Comoglio, PM; Crepaldi, T			Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR-RECEPTOR; MET RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL CONTROL; BIOLOGICAL RESPONSES; C-MET; PROTEIN; HGF; PHOSPHORYLATION	We have used the yeast two-hybrid system to identify proteins that interact with the intracellular portion of the hepatocyte growth factor (HGF) receptor (Met). We isolated a human cDNA encoding a novel protein of 68 kDa, which we termed FAP68. This protein is homologous to a previously described FK506-binding protein-associated protein, FAP48, which derives from an alternative spliced form of the same cDNA, lacking an 85-nucleotide exon and leading to an early stop codon. Here we show that epithelial cells, in which the HGF receptor is naturally expressed, contain FAP68 and not FAP48 proteins. FAP68 binding to Met requires the last 30 amino acids of the C-terminal tail, which are unique to the HGF receptor. Indeed, FAP68 does not interact with related tyrosine kinases of the Met and insulin receptor families. FAP68 interacts specifically with the inactive form of HGF receptor, such as a kinase-defective receptor or a dephosphorylated wild type receptor. In vivo, endogenous FAP68 can be coimmunoprecipitated with the HGF receptor in the absence of stimuli and not upon HGF stimulation. Thus, FAP68 represents a novel type of effector that interacts with the inactive HGF receptor and is released upon receptor phosphorylation. Free FAP68 exerts a specific stimulatory activity toward the downstream target p70 S6 protein kinase (p70S6K). Significantly, nonphosphorylated HGF receptor prevents FAP68 from stimulating p70S6K. These data suggest a role for FAP68 in coupling HGF receptor signaling to the p70S6K pathway.	Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; INSERM, U488, F-94276 Le Kremlin Bicetre, Paris, France; Ludwig Inst Canc Res, London W1P 8BY, England	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Institut National de la Sante et de la Recherche Medicale (Inserm); Ludwig Institute for Cancer Research	Crepaldi, T (corresponding author), Univ Turin, Dept Anat Pharmacol & Forens Med, Corso M DAzeglio 52, I-10126 Turin, Italy.		Comoglio, Paolo/G-6323-2011; crepaldi, tiziana/AAY-7207-2020	crepaldi, tiziana/0000-0003-3410-947X; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Chambraud B, 1996, J BIOL CHEM, V271, P32923, DOI 10.1074/jbc.271.51.32923; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOLEMIS EA, 1995, CURRENT PROTOCOLS MO; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kimura M, 1997, J PHARMACOL EXP THER, V282, P1146; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; ONeill TJ, 1997, J BIOL CHEM, V272, P10035; PELICCI G, 1995, ONCOGENE, V10, P1631; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621	39	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46632	46638		10.1074/jbc.M104323200	http://dx.doi.org/10.1074/jbc.M104323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571281	hybrid			2022-12-25	WOS:000172573100150
J	Miura, K; Miyazawa, S; Furuta, S; Mitsushita, J; Kamijo, K; Ishida, H; Miki, T; Suzukawa, K; Resau, J; Copeland, TD; Kamata, T				Miura, K; Miyazawa, S; Furuta, S; Mitsushita, J; Kamijo, K; Ishida, H; Miki, T; Suzukawa, K; Resau, J; Copeland, TD; Kamata, T			The Sos1-Rac1 signaling - Possible involvement of a vacuolar H+ -ATPase E subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTON ATPASE; RECEPTOR; GENE; DBL; DOMAIN; CDC42; MSOS1; RAC1; GRB2	We have purified and identified a 32-kDa protein interacting with the Dbl oncogene homology domain of mSos1(Sos-DH) from rat brains by glutathione S-transferase-Sos-DH affinity chromatography. Peptide sequencing revealed that the protein is identical to a positive regulatory E subunit (V-ATPase E) of a vacuolar H+-ATPase, which is responsible for acidification of endosome and alkalinization of intracellular pH. The interaction between V-ATPase E and Sos-DH was confirmed by yeast two-hybrid assay. A coimmunoprecipitation assay demonstrated that a V-ATPase E protein physiologically bound to mSos1, and the protein was colocalized with mSos1 in the cytoplasm, as determined by immunohistochemistry. mSos1 was found in the early endosome fraction together with V-ATPase E and Rac1, suggesting the functional involvement of mSos1/V-ATPase E complexes in the Rac1 activity at endosomes. Overexpression of V-ATPase E in COS cells enhanced the ability of mSos1 to promote the guanine nucleotide exchange activity for Rac1 and stimulated the kinase activity of Jun kinase, a downstream target of Rac1. Thus, the data indicate that V-ATPase E may participate in the regulation of the mSos1-dependent Rac1 signaling pathway involved in growth factor receptor-mediated cell growth control.	Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Matsumoto, Nagano 3908621, Japan; Sci Applicat Int Corp, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Adv BioSci Labs, NIH, Frederick, MD 21702 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	Shinshu University; Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318; Suzukawa, Kazumi/0000-0001-9904-3905				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Downward J, 1996, CANCER SURV, V27, P87; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HART MJ, 1994, J BIOL CHEM, V269, P62; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIGUCHI R, 1990, PCR TECHNOLOGY; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LaitalaLeinonen T, 1996, MOL BIOL CELL, V7, P129, DOI 10.1091/mbc.7.1.129; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Niessen H, 1997, BLOOD, V90, P4598; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; XIE XS, 1988, J BIOL CHEM, V263, P9859; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	35	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46276	46283		10.1074/jbc.M102387200	http://dx.doi.org/10.1074/jbc.M102387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11560919	hybrid			2022-12-25	WOS:000172573100107
J	Reddy, MS; Guhan, N; Muniyappa, K				Reddy, MS; Guhan, N; Muniyappa, K			Characterization of single-stranded DNA-binding proteins from mycobacteria - The carboxyl-terminal domain of SSB is essential for stable association with its cognate RecA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; TUBERCULOSIS-RECA; SSDNA COMPLEXES; ATPASE ACTIVITY; REPLICATION; MULTIPLE; RECOMBINATION; PURIFICATION; SEQUENCE	Single-stranded DNA-binding proteins (SSB) play an important role in most aspects of DNA metabolism including DNA replication, repair, and recombination. We report here the identification and characterization of SSB proteins of Mycobacterium smegmatis and Mycobacterium tuberculosis. Sequence comparison of M. smegmatis SSB revealed that it is homologous to M. tuberculosis SSB, except for a small spacer connecting the larger amino-terminal domain with the extreme carboxyl-terminal tail. The purified SSB proteins of mycobacteria bound single-stranded DNA with high affinity, and the association and dissociation constants were similar to that of the prototype SSB. The proteolytic signatures of free and bound forms of SSB proteins disclosed that DNA binding was associated with structural changes at the carboxyl-terminal domain. Significantly, SSB proteins from mycobacteria displayed high affinity for cognate RecA, whereas Escherichia coli SSB did not under comparable experimental conditions. Accordingly, SSB and RecA were coimmunoprecipitated from cell lysates, further supporting an interaction between these proteins in vivo. The carboxyl-terminal domain of M. smegmatis SSB, which is not essential for interaction with ssDNA, is the site of binding of its cognate RecA. These studies provide the first evidence for stable association of eubacterial SSB proteins with their cognate RecA, suggesting that these two proteins might function together during DNA repair and/or recombination.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Muniyappa, K (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	kmbc@biochem.iisc.ernet.in						ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALMA NCM, 1983, J MOL BIOL, V163, P47, DOI 10.1016/0022-2836(83)90029-3; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; BUJALOWSKI W, 1989, J MOL BIOL, V207, P269, DOI 10.1016/0022-2836(89)90455-5; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1991, J MOL BIOL, V217, P63, DOI 10.1016/0022-2836(91)90611-9; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COX MM, 1981, J BIOL CHEM, V256, P4676; Datta S, 2000, NUCLEIC ACIDS RES, V28, P4964, DOI 10.1093/nar/28.24.4964; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Gascon I, 2000, J MOL BIOL, V296, P989, DOI 10.1006/jmbi.2000.3521; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; Kumar RA, 1996, BIOCHEMISTRY-US, V35, P1793, DOI 10.1021/bi9517751; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LI L, 1995, MOL CELL BIOL, V15, P5396; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Mazin AV, 1998, EMBO J, V17, P1161, DOI 10.1093/emboj/17.4.1161; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; Muniyappa K, 2000, MICROBIOL-UK, V146, P2093, DOI 10.1099/00221287-146-9-2093; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Papavinasasundaram KG, 1998, MOL MICROBIOL, V30, P525, DOI 10.1046/j.1365-2958.1998.01083.x; Purnapatre K, 1999, EUR J BIOCHEM, V264, P591, DOI 10.1046/j.1432-1327.1999.00684.x; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Reddy MS, 2000, BIOCHEMISTRY-US, V39, P14250, DOI 10.1021/bi001187+; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sandigursky M, 1996, RADIAT RES, V145, P619, DOI 10.2307/3579281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEPPENHEIM R, 1987, EUR J CLIN MICROBIOL, V6, P49, DOI 10.1007/BF02097190; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; Vaze MB, 1999, BIOCHEMISTRY-US, V38, P3175, DOI 10.1021/bi9819125; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	59	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45959	45968		10.1074/jbc.M103523200	http://dx.doi.org/10.1074/jbc.M103523200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577073	hybrid			2022-12-25	WOS:000172573100065
J	Terao, M; Kurosaki, M; Marini, M; Vanoni, MA; Saltini, G; Bonetto, V; Bastone, A; Federico, C; Saccone, S; Fanelli, R; Salmona, M; Garattini, E				Terao, M; Kurosaki, M; Marini, M; Vanoni, MA; Saltini, G; Bonetto, V; Bastone, A; Federico, C; Saccone, S; Fanelli, R; Salmona, M; Garattini, E			Purification of the aldehyde oxidase homolog 1 (AOH1) protein and cloning of the AOH1 and aldehyde oxidase homolog 2 (AOH2) genes - Identification of a novel molybdo-flavoprotein gene cluster on mouse chromosome 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER XANTHINE DEHYDROGENASE; MOLECULAR-CLONING; CDNA CLONING; BINDING SITE; OXIDOREDUCTASE; SEQUENCE; EXPRESSION; HYDROXYLASES; CANDIDATE; MUTANTS	We report the cloning of the AOH1 and AOH2 genes, which encode two novel mammalian molybdo-flavoproteins. We have purified the AOH1 protein to homogeneity in its catalytically active form from mouse liver. Twenty tryptic peptides, identified or directly sequenced by mass spectrometry, confirm the primary structure of the polypeptide deduced from the AOH1 gene. The enzyme contains one molecule of FAD, one atom of molybdenum, and four atoms of iron per subunit and shows spectroscopic features similar to those of the prototypic molybdo-flavoprotein xanthine oxidoreductase. The AOH1 and AOH2 genes are 98 and 60 kilobases long, respectively, and consist of 35 coding exons. The AOH1 gene has the potential to transcribe an extra leader non-coding exon, which is located downstream of exon 26, and is transcribed in the opposite orientation relative to all the other exons. AOH1 and AOH2 map to chromosome I in close proximity to each other and to the aldehyde oxidase gene, forming a molybdo-flavoenzyme gene cluster. Conservation in the position of exon/intron junctions among the mouse AOH1, AOH2, aldehyde oxidase, and xanthine oxidoreductase loci indicates that these genes are derived from the duplication of an ancestral precursor.	Mario Negri Inst Pharmacol Res, Mol Biol Lab, Ctr Catullo & Daniela Borgomainerio, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Environm Toxicol, I-20157 Milan, Italy; Univ Insubria, Dipartimento Sci Chim Fis & Matemat, I-22100 Como, Italy; Univ Catania, Dipartimento Biol Anim, I-95124 Catania, Italy; Univ Bologna, Dipartimento Protez Valorizzaz Agroalimentare, I-42100 Reggio Emilia, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Insubria; University of Catania; University of Bologna	Garattini, E (corresponding author), Mario Negri Inst Pharmacol Res, Mol Biol Lab, Ctr Catullo & Daniela Borgomainerio, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@marionegri.it	Bonetto, Valentina/I-4694-2018; salmona, mario/AAA-7116-2020; Vanoni, Maria/AAP-2089-2021; Garattini, Enrico/AAI-1998-2019; salmona, mario/ABI-4066-2020; KUROSAKI, Mami/ABG-2224-2020; Bonetto, Valentina/ABB-6383-2020; Terao, Mineko/AAA-6415-2020; Saccone, Salvatore/H-1548-2012; terao, mineko/AAU-8089-2020; Federico, Concetta/M-5553-2015	Bonetto, Valentina/0000-0003-0456-2054; salmona, mario/0000-0002-9098-9873; Vanoni, Maria/0000-0001-7213-732X; KUROSAKI, Mami/0000-0001-8231-713X; Bonetto, Valentina/0000-0003-0456-2054; Terao, Mineko/0000-0002-9976-9869; Saccone, Salvatore/0000-0001-7568-5823; Federico, Concetta/0000-0002-0160-9040; Garattini, Enrico/0000-0001-8983-886X	Telethon [D.088] Funding Source: Medline	Telethon(Fondazione Telethon)		Aliverti A, 1999, METH MOL B, V131, P9; BEEDHAM C, 1990, BIOCHEM PHARMACOL, V39, P1213, DOI 10.1016/0006-2952(90)90265-M; BERGER R, 1995, SOMAT CELL MOLEC GEN, V21, P121, DOI 10.1007/BF02255787; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CATES LA, 1980, J MED CHEM, V23, P300, DOI 10.1021/jm00177a018; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Demontis S, 1999, BBA-GENE STRUCT EXPR, V1489, P207, DOI 10.1016/S0167-4781(99)00174-8; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; FABRE G, 1986, BIOCHEM PHARMACOL, V35, P1325, DOI 10.1016/0006-2952(86)90277-7; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HILLE R, 1992, CHEM BIOCH FLAVOENZY, V3, P21; HILLIKER AJ, 1992, P NATL ACAD SCI USA, V89, P4343, DOI 10.1073/pnas.89.10.4343; HOLMES RS, 1978, COMP BIOCHEM PHYS B, V61, P339, DOI 10.1016/0305-0491(78)90134-7; Huang DY, 1999, ARCH BIOCHEM BIOPHYS, V364, P264, DOI 10.1006/abbi.1999.1129; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; KUROSAKI M, 1995, BIOCHEM J, V306, P225, DOI 10.1042/bj3060225; Labrador M, 2001, NATURE, V409, P1000, DOI 10.1038/35059000; LI CZ, 1995, J BIOL CHEM, V270, P31037; NISHINO T, 1989, J BIOL CHEM, V264, P5468; Ori N, 1997, J BIOL CHEM, V272, P1019, DOI 10.1074/jbc.272.2.1019; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rebelo J, 2000, J MOL BIOL, V297, P135, DOI 10.1006/jmbi.2000.3552; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Saccone S, 1997, CHROMOSOME RES, V5, P293, DOI 10.1023/B:CHRO.0000038759.09018.a7; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Segel I.H., 1975, ENZYME KINETICS; Sekimoto H, 1997, J BIOL CHEM, V272, P15280, DOI 10.1074/jbc.272.24.15280; Shambrook J, 1989, MOL CLONING LAB MANU; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stover NA, 2001, P NATL ACAD SCI USA, V98, P5693, DOI 10.1073/pnas.101049998; Terao M, 1997, BIOCHEM SOC T, V25, P791, DOI 10.1042/bst0250791; Terao M, 2000, J BIOL CHEM, V275, P30690, DOI 10.1074/jbc.M005355200; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TRIPLETT EW, 1982, ARCH BIOCHEM BIOPHYS, V219, P39, DOI 10.1016/0003-9861(82)90131-X; Vandenberghe AE, 2001, GENE DEV, V15, P294, DOI 10.1101/gad.865401; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Wright RM, 1999, J BIOL CHEM, V274, P3878, DOI 10.1074/jbc.274.6.3878; Wright RM, 1997, REDOX REP, V3, P135, DOI 10.1080/13510002.1997.11747101; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; Yasukochi Y, 1998, GENET RES, V71, P11, DOI 10.1017/S0016672397003078; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	48	41	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46347	46363		10.1074/jbc.M105744200	http://dx.doi.org/10.1074/jbc.M105744200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11562361	hybrid			2022-12-25	WOS:000172573100117
J	Chen, HP; Wu, SH; Lin, YL; Chen, CM; Tsay, SS				Chen, HP; Wu, SH; Lin, YL; Chen, CM; Tsay, SS			Cloning, sequencing, heterologous expression, purification, and characterization of adenosylcobalamin-dependent D-ornithine aminomutase from Clostridium sticklandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; X-RAY STRUCTURE; GLUTAMATE MUTASE; RECOMBINANT ENZYME; ESCHERICHIA-COLI; B-12; COCHLEARIUM; BINDING	D-Ornithine aminomutase from Clostridium sticklandii catalyzes the reversible rearrangement of D-ornithine to (2R,4S)-2,4-diaminopentanoic acid. The two genes encoding D-ornithine aminomutase have been cloned, sequenced, and expressed in Escherichia coli. The oraS gene, which encodes a protein of 121 amino acid residues with M-r 12,800, is situated upstream of the oraE gene, which encodes a protein of 753 amino acid residues with M-r 82,900. The holoenzyme appears to comprise a alpha (2)beta (2)-heterotetramer. OraS shows no significant homology to other proteins in the Swiss-Prot data base. The deduced amino acid sequence of OraE includes a conserved base-off/histidine-on cobalamin-binding motif, DXHXXG. OraE was expressed in E. coli as inclusion bodies. Refolding experiments on OraE indicate that the interactions between OraS and OraE and the binding of either pyridoxal phosphate or adenosylcobalamin play important roles in refolding process. The K-m values for D-ornithine, 5'-deoxyadenosylcobalamin (AdoCbl), and pyridoxal 5'-phosphate (PLP) are 44.5 +/- 2.8, 0.43 +/- 0.04, and 1.5 +/- 0.1 muM, respectively; the k(cat) is 6.3 +/- 0.1 s(-1). The reaction was absolutely dependent upon OraE, OraS, AdoCbl, PLP, and D-ornithine being present in the assay; no other cofactors were required. A red-shift in UV-visible absorption spectrum is observed when free adenosylcobinamide is bound by recombinant D-ornithine aminomutase and no significant change in spectrum when free adenosylcobinamide is bound by mutant OraE-H618G, demonstrating that the enzyme binds adenosylcobalamin in base-off/histidine-on mode.	China Med Coll, Dept Biochem, Taichung 404, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Dept Bot, Taipei 106, Taiwan	China Medical University Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, HP (corresponding author), China Med Coll, Dept Biochem, 91 Hseuh Shih Rd, Taichung 404, Taiwan.		Chen, Hao-Ping/Q-3283-2019	Chen, Hao-Ping/0000-0002-6491-2178				ANDREESEN JR, 1989, CLOSTRIDIA, pCH2; BAKER JJ, 1984, B12, V2, P203; BARKER HA, 1981, ANNU REV BIOCHEM, V50, P23, DOI 10.1146/annurev.bi.50.070181.000323; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang CH, 2000, J BIOL CHEM, V275, P106, DOI 10.1074/jbc.275.1.106; Chen HP, 2000, J BACTERIOL, V182, P2052, DOI 10.1128/JB.182.7.2052-2054.2000; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Frey P A, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P1; HAN O, 1990, J AM CHEM SOC, V112, P8982, DOI 10.1021/ja00180a054; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLOWAY DE, 1994, J BIOL CHEM, V269, P20425; LEUTBECHER U, 1992, EUR J BIOCHEM, V205, P759, DOI 10.1111/j.1432-1033.1992.tb16840.x; LJUNGDAHL LG, 1989, CLOSTRIDIA, pCH5; Ludwig M. L., 1999, Chemistry and biochemistry of B12., P595; MANICA F, 1996, STRUCTURE, V4, P339; MARSH EN, 1993, BIOCHEM J, V290, P551, DOI 10.1042/bj2900551; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; Marston F. A. O., 1987, DNA CLONING, P59; MORLEY C G D, 1972, Biochemistry, V11, P600, DOI 10.1021/bi00754a019; PADMAKUMAR R, 1995, J AM CHEM SOC, V117, P7033, DOI 10.1021/ja00131a039; Ratnatilleke A, 1999, J BIOL CHEM, V274, P31679, DOI 10.1074/jbc.274.44.31679; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; Smith DM, 1999, J AM CHEM SOC, V121, P9388, DOI 10.1021/ja991649a; SOMACK R, 1973, BIOCHEMISTRY-US, V12, P2597, DOI 10.1021/bi00738a008; TAOKA S, 1994, J BIOL CHEM, V269, P31630; TSUDA Y, 1970, J BIOL CHEM, V245, P5914; Wetmore SD, 2000, J AM CHEM SOC, V122, P10208, DOI 10.1021/ja001651y	29	46	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44744	44750		10.1074/jbc.M108365200	http://dx.doi.org/10.1074/jbc.M108365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577113	Green Published, hybrid			2022-12-25	WOS:000172406700055
J	Cong, M; Perry, SJ; Hu, LYA; Hanson, PI; Claing, A; Lefkowitz, RJ				Cong, M; Perry, SJ; Hu, LYA; Hanson, PI; Claing, A; Lefkowitz, RJ			Binding of the beta 2 adrenergic receptor to N-ethylmaleimide-sensitive factor regulates receptor recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA(1)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; SYNAPTIC TRANSMISSION; MEDIATED ENDOCYTOSIS; CLATHRIN ADAPTER; SILENT SYNAPSES; AMPA RECEPTORS	Following agonist stimulation, most G protein-coupled receptors become desensitized and are internalized, either to be degraded or recycled back to the cell surface. What determines the fate of a specific receptor type after it is internalized is poorly understood. Here we show that the rapidly recycling beta2 adrenergic receptor (beta 2AR) binds via a determinant including the last three amino acids in its carboxyl-terminal tail to the membrane fusion regulatory protein, N-ethylmaleimide-sensitive factor (NSF). This is documented by in vitro overlay assays and by cellular coimmunoprecipitations. Receptors bearing mutations in any of the last three residues fail to interact with NSF. After stimulation with the agonist isoproterenol, a green fluorescent protein fusion of NSF colocalizes with the wild type beta 2AR but not with a tail-mutated beta 2AR. The beta 2AR-NSF interaction is required for efficient internalization of the receptors and for their recycling to the cell surface. Mutations in the beta 2AR tail that ablate NSF binding reduce the efficiency of receptor internalization upon agonist stimulation. Upon subsequent treatment of cells with the antagonist propranolol, wild type receptors return to the cell surface, while tail-mutated receptors remain sequestered. Thus, the direct binding of the beta 2AR to NSF demonstrates how, after internalization, the fate of a receptor is reliant on a specific interaction with a component of the cellular membrane-trafficking machinery.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Washington University (WUSTL)	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Hanson, Phyllis/E-9420-2012; Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1983, J CELL BIOL, V97, P1538, DOI 10.1083/jcb.97.5.1538; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Moore RH, 1999, J CELL SCI, V112, P329; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Neuwald AF, 1999, STRUCTURE, V7, pR19, DOI 10.1016/S0969-2126(99)80015-X; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	52	115	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45145	45152		10.1074/jbc.M106087200	http://dx.doi.org/10.1074/jbc.M106087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577089	hybrid			2022-12-25	WOS:000172406700106
J	Huang, KC; Gao, HL; Yamasaki, EF; Grabowski, DR; Liu, SJ; Shen, LL; Chan, KK; Ganapathi, R; Snapka, RM				Huang, KC; Gao, HL; Yamasaki, EF; Grabowski, DR; Liu, SJ; Shen, LL; Chan, KK; Ganapathi, R; Snapka, RM			Topoisomerase II poisoning by ICRF-193	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; SUMO-1 CONJUGATION; CELL-CYCLE; INHIBITION; BISDIOXOPIPERAZINES; PROTEIN; YEAST; LINE; DEXRAZOXANE; DERIVATIVES	Antineoplastic bis(dioxopiperazine)s, such as meso-2,3-bis(2,6-dioxopiperazin-4-yl)butane (ICRF-193), are widely believed to be only catalytic inhibitors of topoisomerase II. However, topoisomerase inhibitors have little or no antineoplastic activity unless they are topoisomerase poisons, a special subclass of topoisomerase-targeting drugs that stabilize topoisomerase-DNA strand passing intermediates and thus cause the topoisomerase to become a cytotoxic DNA-damaging agent. Here we report that ICRF-193 is a very significant topoisomerase II poison. Detection of topoisomerase II Poisoning by ICRF-193 required the use of a chaotropic protein denaturant in the topoisomerase poisoning assays. ICRF-193 caused dose-dependent cross-linking of human topoisomerase II beta to DNA and stimulated topoisomerase II beta -mediated DNA cleavage at specific sites on P-32-end-labeled DNA. Human topoisomerase Ha-mediated DNA cleavage was stimulated to a lesser extent by ICRF-193. In vivo experiments with MCF-7 cells also showed the requirement of a chaotropic protein denaturant in the assays and selectivity for the beta -isozyme of human topoisomerase II. Studies with two topoisomerase II beta -negative cell model systems confirmed significant topoisomerase II poisoning by ICRF-193 in the wild type cells and were consistent with beta -isozyme selectivity. Common use of only the detergent, SDS, in assays may have led to failure to detect topoisomerase II poisoning by ICRF-193 in earlier studies.	Ohio State Univ, Coll Med, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA; Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; Abbott Labs, Abbott Pk, IL 60064 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; University System of Ohio; Ohio State University; Abbott Laboratories	Snapka, RM (corresponding author), Ohio State Univ, Coll Med, Dept Radiol, 103 Wiseman Hall,400 W 12th Ave, Columbus, OH 43210 USA.				NCI NIH HHS [R01 CA80961, CA16058, CA74939, N01-CM-57201, U01CA63185] Funding Source: Medline; NIDDK NIH HHS [DK56917] Funding Source: Medline; DIVISION OF CANCER TREATMENT [N01CM057201] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA080961, R01CA074939, P30CA016058, U01CA063185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF CANCER TREATMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CREIGHTON AM, 1970, INT J CANCER, V5, P47, DOI 10.1002/ijc.2910050107; CREIGHTON AM, 1969, NATURE, V222, P384, DOI 10.1038/222384a0; CREIGHTON AM, 1970, PROGR ANTIMICROB ANT, V1, P167; FELIX CA, 1995, CANCER RES, V55, P4287; Gao HL, 1999, P NATL ACAD SCI USA, V96, P12168, DOI 10.1073/pnas.96.21.12168; Gao HL, 2000, CANCER RES, V60, P5937; HASINOFF BB, 1995, BIOCHEM PHARMACOL, V50, P953, DOI 10.1016/0006-2952(95)00218-O; Hasinoff BB, 1997, BIOCHEM PHARMACOL, V53, P1843, DOI 10.1016/S0006-2952(97)00013-0; HEMPEL A, 1982, J AM CHEM SOC, V104, P3453, DOI 10.1021/ja00376a034; HERMAN EH, 1982, ADV PHARMACOL CHEMOT, V19, P249, DOI 10.1016/S1054-3589(08)60025-3; Herzog CE, 1998, CANCER RES, V58, P5298; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; PERMANA PA, 1994, BIOCHEM BIOPH RES CO, V201, P1510, DOI 10.1006/bbrc.1994.1875; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sambrook J., 2002, MOL CLONING LAB MANU; Sehested M, 1996, BIOCHEM PHARMACOL, V51, P879, DOI 10.1016/0006-2952(95)02241-4; SHIN CG, 1990, TERATOGEN CARCIN MUT, V10, P41, DOI 10.1002/tcm.1770100106; Snapka RM, 2001, BIOCHEM BIOPH RES CO, V280, P1155, DOI 10.1006/bbrc.2001.4249; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; Snapka RM, 1996, BIOCHEM PHARMACOL, V52, P543, DOI 10.1016/0006-2952(96)00305-X; SNAPKA RM, 1996, SV40 REPLICON MODEL, P65; Strumberg D, 1999, J BIOL CHEM, V274, P28246, DOI 10.1074/jbc.274.40.28246; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; Tabata M, 2001, J BIOL CHEM, V276, P8029, DOI 10.1074/jbc.M009831200; TANABE K, 1991, CANCER RES, V51, P4903; van Hille B, 1999, BRIT J CANCER, V81, P800, DOI 10.1038/sj.bjc.6690767; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; Witiak D T, 1990, Prog Drug Res, V35, P249; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	37	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44488	44494		10.1074/jbc.M104383200	http://dx.doi.org/10.1074/jbc.M104383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577077	hybrid			2022-12-25	WOS:000172406700020
J	Tsou, CL; Haskell, CA; Charo, IF				Tsou, CL; Haskell, CA; Charo, IF			Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CX(3)CR1; TNF RECEPTOR; CHEMOKINE; METALLOPROTEINASE; IDENTIFICATION; LYMPHOCYTES; INHIBITOR; ADHESION; CELLS	Fractalkine (FK, CX3CL1) is a novel multidomain protein expressed on the surface of endothelial cells. As a full-length transmembrane protein, FK binds cells expressing CX3CR1, its cognate receptor, with high affinity. Proteolytic cleavage of FK releases a soluble form that is a potent chemoattractant for monocytes, T cells, and natural killer cells. Activation of protein kinase C dramatically increases the rate of this cleavage. Regulation of FK cleavage is critical for maintaining the balance between the immobilized and soluble forms, but the protease responsible has not been identified. Here we report that tumor necrosis factor-alpha -converting enzyme (TACE) is primarily responsible for the inducible cleavage of FK. After transfection into host cells, the proteolytic cleavage of FK was blocked by TACE-specific inhibitors and was not detected in cells genetically altered to remove TALE activity. In contrast, the constitutive cleavage of FK was not mediated by TALE and proceeded normally in TALE-null fibroblasts. We conclude that TALE is primarily responsible for the inducible cleavage of FK. These studies identify a potentially important link between local generation of potent cytokines and control of the balance between the cell adhesion and chemotactic properties of FK.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Charo, IF (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773, R01HL063894] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63894, HL 52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Lucas AD, 2001, AM J PATHOL, V158, P855, DOI 10.1016/S0002-9440(10)64034-5; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Robinson LA, 2000, J IMMUNOL, V165, P6067, DOI 10.4049/jimmunol.165.11.6067; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511	26	183	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44622	44626		10.1074/jbc.M107327200	http://dx.doi.org/10.1074/jbc.M107327200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571300	hybrid			2022-12-25	WOS:000172406700039
J	Vaux, EC; Wood, SM; Cockman, ME; Nicholls, LG; Yeates, KM; Pugh, CW; Maxwell, PH; Ratcliffe, PJ				Vaux, EC; Wood, SM; Cockman, ME; Nicholls, LG; Yeates, KM; Pugh, CW; Maxwell, PH; Ratcliffe, PJ			Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; ALPHA-SUBUNIT; RENAL-CARCINOMA; GENE-EXPRESSION; FACTOR-I; HYPOXIA; PROTEIN; FACTOR-1-ALPHA; HIF-1-ALPHA; BINDING	Hypoxia-inducible factor (HIF) mediates a widespread transcriptional response to hypoxia through binding to cis-acting DNA sequences termed hypoxia response elements (HREs). Activity of the transcriptional complex is suppressed in the presence of oxygen by processes that include the targeting of HIF-alpha subunits for ubiquitin-mediated proteolysis. To provide further insights into these processes we constructed Chinese hamster ovary (CHO) cells bearing stably integrated plasmids that expressed HRE-linked surface antigens and used these cells in genetic screens for mutants that demonstrated constitutive up-regulation of HRE activity. From mutagenized cultures, clones were isolated that demonstrated up-regulation of HRE activity and increased HIF-1 alpha protein levels in normoxic culture. Transfection and cell fusion studies suggested that these cells possess recessive defects that affect one or more pathways involved in HIF-alpha proteolysis. Two lines were demonstrated to harbor truncating mutations in the von Hippel-Lindau VHL) tumor suppressor gene. In these cells, defects in ubiquitylation of exogenous human HIF-1 alpha in vitro could be complemented by wild type pVHL, and re-expression of a wild type VHL gene restored a normal pattern of HIF/ HRE activity, demonstrating the critical dependence of HIF regulation on pVHL in CHO cells. In contrast, other mutant cells had no demonstrable mutation in the VHL gene, and ubiquitylated exogenous HIEF-1 alpha normally, suggesting that they contain defects at other points in the oxygen-regulated processing of HIF-alpha subunits.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	University of Oxford; Wellcome Centre for Human Genetics	Ratcliffe, PJ (corresponding author), Wellcome Trust Ctr Human Genet, Henry Wellcome Bldg Genomic Med,Roosevelt Dr, Oxford OX3 7BN, England.	peter.ratcliffe@imm.ox.ac.uk	Maxwell, Patrick H/C-5557-2008; Cockman, Matthew/V-9619-2019	Maxwell, Patrick H/0000-0002-0338-2679; Cockman, Matthew/0000-0002-3310-4821; Pugh, Chris/0000-0002-5170-1662; Ratcliffe, Peter/0000-0002-2853-806X				Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Ebert BL, 1999, BLOOD, V94, P1864; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; HASEGAWA K, 1990, BIOCHIM BIOPHYS ACTA, V1051, P221, DOI 10.1016/0167-4889(90)90126-X; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; ONEILL JP, 1978, CANCER RES, V38, P506; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Semenza GL, 2000, GENE DEV, V14, P1983; TAFT SA, 1994, ENVIRON MOL MUTAGEN, V23, P96, DOI 10.1002/em.2850230204; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Woodward ER, 2000, GENOMICS, V65, P253, DOI 10.1006/geno.2000.6144; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	44	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44323	44330		10.1074/jbc.M104678200	http://dx.doi.org/10.1074/jbc.M104678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11555645	hybrid			2022-12-25	WOS:000172297700105
J	Saunders, DN; Jankova, L; Harrop, SJ; Curmi, PMG; Gould, AR; Ranson, M; Baker, MS				Saunders, DN; Jankova, L; Harrop, SJ; Curmi, PMG; Gould, AR; Ranson, M; Baker, MS			Interaction between the P14 residue and strand 2 of beta-sheet B is critical for reactive center loop insertion in plasminogen activator inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; HINGE REGION; DATA-BANK; SERPIN; SUBSTRATE; OVALBUMIN; ANTITHROMBIN; RESOLUTION; TRANSITION	The molecular interactions driving reactive center loop (RCL) insertion are of considerable interest in gaining a better understanding of the serpin inhibitory mechanism. Previous studies have suggested that interactions in the proximal hinge/breach region may be critical determinants of RCL insertion in serpins. In this study, conformational and functional changes in plasminogen activator inhibitor-2 (PAI-2) following incubation with a panel of synthetic RCL peptides indicated that the P14 residue is critical for RCL insertion, and hence inhibitory activity, in PAI-2. Only RCL peptides with a P14 threonine were able to induce the stressed to relaxed transition and abolish inhibitory activity in PAI-2, indicating that RCL insertion into beta -sheet A of PAI-2 is dependent upon this residue. The recently solved crystal structure of relaxed PAI-2 (PAI-2-RCL peptide complex) allowed detailed analysis of molecular interactions involving P14 related to RCL insertion. Of most interest is the rearrangement of hydrogen bonding around the breach region that accompanies the stressed to relaxed transition, in particular the formation of a side chain hydrogen bond between the threonine at P14 and an adjacent tyrosine on strand 2 of beta -sheet B in relaxed PAI-2. Structural alignment of known serpin sequences showed that this pairing (or the equivalent serine/threonine pairing) is highly conserved (similar to 87%) in inhibitory serpins and may represent a general structural basis for serpin inhibitory activity.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Univ Wollongong, Dept Biol Sci, Wollongong, NSW 2522, Australia; Univ New S Wales, Sch Phys, Initiat Biomol Struct, Kensington, NSW 2052, Australia; Biotech Australia Pty Ltd, Roseville, NSW 2069, Australia; Royal Womens Hosp, Gynaecol Canc Res Ctr, Carlton, Vic 3053, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Wollongong; University of New South Wales Sydney	Saunders, DN (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		Ranson, Marie/A-6324-2008; Saunders, Darren/B-7677-2008; Ranson, Marie/AAC-4468-2019; Ranson, Marie/GRO-5792-2022; Curmi, Paul/G-7185-2011	Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Curmi, Paul/0000-0001-5762-7638; Saunders, Darren/0000-0003-0924-0513; Baker, Mark/0000-0001-5858-4035				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BJORK I, 1992, J BIOL CHEM, V267, P1976; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jankova L, 2001, J BIOL CHEM, V276, P43374, DOI 10.1074/jbc.M103021200; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Saunders DN, 1998, J BIOL CHEM, V273, P10965, DOI 10.1074/jbc.273.18.10965; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WRIGHT HT, 1990, J MOL BIOL, V213, P513; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1	27	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43383	43389		10.1074/jbc.M103123200	http://dx.doi.org/10.1074/jbc.M103123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555638	hybrid			2022-12-25	WOS:000172169300097
J	Xie, SQ; Wu, HY; Wang, Q; Cogswell, JP; Husain, I; Conn, C; Stambrook, P; Jhanwar-Uniyal, M; Dai, W				Xie, SQ; Wu, HY; Wang, Q; Cogswell, JP; Husain, I; Conn, C; Stambrook, P; Jhanwar-Uniyal, M; Dai, W			Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT; KINASE; ATM; PHOSPHORYLATION; PROTEIN; CHK2; EXPRESSION; CARCINOMAS; CANCER; SITES	Polo-like kinase 3 (Plk3, previously termed Prk) contributes to regulation of M phase of the cell cycle (Ouyang, B., Pan, H., Lu, L., Li, J., Stambrook, P., Li, B., and Dai, W. (1997) J. Biol. Chem. 272, 28646-28651). Plk3 physically interacts with Cdc25C and phosphorylates this protein phosphatase predominantly on serine 216 (Ouyang, B., Li, W., Pan, H., Meadows, J., Hoffmann, L, and Dai, W. (1999) Oncogene 18, 6029-6036), suggesting that the role of Plk3 in mitosis is mediated, at least in part, through direct regulation of Cdc25C. Here we show that ectopic expression of a kinase-active Plk3 (Plk3-A) induced apoptosis. In response to DNA damage, the kinase activity of Plk3 was rapidly increased in an ATM-dependent manner, whereas that of Plk1 was markedly inhibited. Recombinant Plk3 phosphorylated in vitro a glutathione S-transferase fusion protein containing p53, but not glutathione S-transferase alone. Recombinant Plk1 also phosphorylated p53 but on residues that differed from those targeted by Plk3. Co-immunoprecipitation and pull-down assays demonstrated that Plk3 physically interacted with p53 and that this interaction was enhanced upon DNA damage. An vitro kinase assays followed by immunoblotting showed that serine 20 of p53 was a target of Plk3. Furthermore, expression of a kinase-defective Plk3 mutant (Plk3(K52R)) resulted in significant reduction of p53 phosphorylation on serine 20, which was correlated with a decrease in the expression of p21 and with a concomitant increase in cell proliferation. These results strongly suggest that PIk3 functionally links DNA damage to cell cycle arrest and apoptosis via the p53 pathway.	Amer Hlth Fdn, Valhalla, NY 10595 USA; GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA; Univ Cincinnati, Dept Cell Biol, Cincinnati, OH 45267 USA	American Health Foundation; GlaxoSmithKline; University System of Ohio; University of Cincinnati	Dai, W (corresponding author), Amer Hlth Fdn, 1 Dana Rd, Valhalla, NY 10595 USA.	wei-dai_nyu@yahoo.com			PHS HHS [R01-74229] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 2000, GENE DEV, V14, P278; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Haggman MJ, 1997, UROLOGY, V50, P643, DOI 10.1016/S0090-4295(97)00304-X; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HUSSAIN RF, 1993, J IMMUNOL METHODS, V160, P89, DOI 10.1016/0022-1759(93)90012-V; KAGAN J, 1995, ONCOGENE, V11, P2121; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knecht R, 1999, CANCER RES, V59, P2794; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nakamura Y, 1998, NAT MED, V4, P1231, DOI 10.1038/3207; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shieh SY, 2000, GENE DEV, V14, P289; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Westphal CH, 1997, CURR BIOL, V7, pR789, DOI 10.1016/S0960-9822(06)00406-4; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	33	172	184	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43305	43312		10.1074/jbc.M106050200	http://dx.doi.org/10.1074/jbc.M106050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551930	hybrid			2022-12-25	WOS:000172169300088
J	Carr, A; Sledjeski, DD; Podbielski, A; Boyle, MDP; Kreikemeyer, B				Carr, A; Sledjeski, DD; Podbielski, A; Boyle, MDP; Kreikemeyer, B			Similarities between complement-mediated and streptolysin S-mediated hemolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE HEMOLYSIS; TERMINAL STAGES; IDENTIFICATION; STREPTOCOCCUS; CHANNEL; VIRULENCE; PROTEINS; TOXIN; LOCUS; C9	The oxygen-stable hemolysin streptolysin S (SLS) of Streptococcus pyogenes is encoded in part by the pel/sagA gene product. Antibodies to a synthetic peptide from the C terminus of the Pel/SagA open reading frame inhibited hemolysis mediated by both culture supernatants from multiple M serotypes of S. pyogenes isolates or a commercially available SLS preparation. Analysis of the SLS-mediated hemolytic reaction demonstrated that it was temperature- and concentration-dependent. Like complement-mediated hemolysis it conforms to the prediction of a one-hit mechanism of hemolysis. A number of intermediates in the SLS-mediated hemolysis of sheep erythrocytes could be distinguished. SLS could bind to erythrocytes below 17 degreesC; however, lysis could only occur at temperatures > 23 degreesC. Following binding of SLS and washing, a papain-sensitive intermediate could be distinguished prior to insertion of the SLS complex into the erythrocyte membrane, which resulted in formation of a transmembrane pore and led to irreversible osmotic lysis of the cell. These intermediates were similar to those described previously during complement-mediated hemolysis.	Med Coll Ohio, Dept Microbiol & Immunol, Toledo, OH 43614 USA; Univ Hosp Rostock, Dept Med Microbiol & Hyg, D-18055 Rostock, Germany	University of Rostock	Boyle, MDP (corresponding author), Med Coll Ohio, Dept Microbiol & Immunol, 3055 Arlington Ave, Toledo, OH 43614 USA.	mboyle@mco.edu		Kreikemeyer, Bernd/0000-0001-9527-5098; Sledjeski, Darren/0000-0001-9882-6625	NIAID NIH HHS [AI43474] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Betschel SD, 1998, INFECT IMMUN, V66, P1671, DOI 10.1128/IAI.66.4.1671-1679.1998; BHAKDI S, 1985, BIOCHEM SOC SYMP, P221; BHAKDI S, 1984, PHILOS T R SOC B, V306, P311, DOI 10.1098/rstb.1984.0092; BHAKDI S, 1982, MOL IMMUNOL, V19, P1167, DOI 10.1016/0161-5890(82)90327-3; BHAKDI S, 1978, J IMMUNOL, V121, P2526; BOYLE MDP, 1979, J IMMUNOL, V123, P71; BOYLE MDP, 1978, J IMMUNOL, V120, P1721; BOYLE MDP, 1979, J IMMUNOL, V123, P77; Boyle MDP, 2001, J MICROBIOL METH, V46, P87, DOI 10.1016/S0167-7012(01)00279-2; BOYLE MDP, 1980, MOL IMMUNOL, V17, P425, DOI 10.1016/0161-5890(80)90064-4; BOYLE MDP, 1981, IMMUNOL IMMUNOPATHOL, V20, P287; DELISI C, 1980, J IMMUNOL, V125, P2055; DELISI C, 1980, J IMMUNOL, V125, P2334; DISCIPIO RG, 1991, J IMMUNOL, V147, P4239; DOURMASHKIN RR, 1966, AM J MED, V41, P699, DOI 10.1016/0002-9343(66)90031-3; DROBNIEWSKI FA, 1989, J BACTERIOL, V171, P3060, DOI 10.1128/jb.171.6.3060-3067.1989; DUNCAN JL, 1976, INFECT IMMUN, V14, P77, DOI 10.1128/IAI.14.1.77-82.1976; EBERHARD TH, 2000, 100 GEN M AM SOC MIC; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; Ginsburg I, 1999, APMIS, V107, P1051, DOI 10.1111/j.1699-0463.1999.tb01509.x; GINSBURG I, 1963, J EXP MED, V118, P919, DOI 10.1084/jem.118.6.919; GINSBURG I, 1965, J EXP MED, V121, P633, DOI 10.1084/jem.121.4.633; GINSBURG I, 1972, MICROBIAL TOXINS BAC, V3, P100; HONDA T, 1992, CAN J MICROBIOL, V38, P1175, DOI 10.1139/m92-192; KOYAMA J, 1963, J BIOCHEM-TOKYO, V53, P147, DOI 10.1093/oxfordjournals.jbchem.a127670; KOYAMA J, 1963, J BIOCHEM-TOKYO, V54, P146; LAI CY, 1978, ARCH BIOCHEM BIOPHYS, V191, P804, DOI 10.1016/0003-9861(78)90423-X; LEE PK, 1991, J INFECT DIS, V164, P711, DOI 10.1093/infdis/164.4.711; Li ZQ, 1999, J BACTERIOL, V181, P6019, DOI 10.1128/JB.181.19.6019-6027.1999; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; MULLEREBERHARD HJ, 1985, J INVEST DERMATOL, V85, pS47; Nizet V, 2000, INFECT IMMUN, V68, P4245, DOI 10.1128/IAI.68.7.4245-4254.2000; OKADA M, 1980, BIOCHEM BIOPH RES CO, V94, P406, DOI 10.1016/S0006-291X(80)80235-X; PODLACK ER, 1984, MOL IMMUNOL, V21, P589; Pritzlaff CA, 2001, MOL MICROBIOL, V39, P236, DOI 10.1046/j.1365-2958.2001.02211.x; RAPP HJ, 1970, MOL BASIS COMPLEMENT; Spellerberg B, 1999, J BACTERIOL, V181, P3212, DOI 10.1128/JB.181.10.3212-3219.1999	37	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41790	41796		10.1074/jbc.M107401200	http://dx.doi.org/10.1074/jbc.M107401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546819	hybrid			2022-12-25	WOS:000172450400034
J	Choi, IR; Ostrovsky, M; Zhang, GC; White, KA				Choi, IR; Ostrovsky, M; Zhang, GC; White, KA			Regulatory activity of distal and core RNA elements in tombusvirus subgenomic mRNA2 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUSHY-STUNT VIRUS; CUCUMBER-NECROSIS VIRUS; FLOCK HOUSE VIRUS; COAT PROTEIN GENE; MESSENGER-RNA; VIRAL-RNA; POSITIVE-STRAND; EXPRESSION; SEQUENCE; ACCUMULATION	Positive-strand RNA viruses that encode multiple cistrons often mediate expression of T-encoded open reading frames via RNA-templated transcription of subgenomic (sg) mRNAs. Tomato bushy stunt virus (TBSV) is a positive-strand RNA virus that transcribes two such sg mRNAs during infections. We have previously identified a distal element (DE), located similar to 1100 nucleotides upstream from the initiation site of sg mRNA2 transcription, part of which must base pair with a portion of a core element (CE), located just 5' to the initiation site, for efficient transcription to occur (Zhang, G., Slowinski, V., and White, K. A (1999) RNA 5, 550-561). Here we have analyzed further this long distance RNA-RNA interaction and have investigated the regulatory roles of other subelements within the DE and CE. Our results indicate that M the functional base-pairing interaction between these elements occurs in the positive strand and that the interaction likely acts to properly position other subelements, (ii) two previously undefined subelements within the DE and CE are important and essential, respectively, for efficient sg mRNA2 accumulation, and (iii) the production of (-)-strand sg mRNA2 can be uncoupled from the synthesis of its (+)-strand complement. These data provide important insight into the mechanism of sg mRNA2 transcription.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada	York University - Canada	White, KA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.	kawhite@yorku.ca						CHAPMAN S, 1992, VIROLOGY, V191, P223, DOI 10.1016/0042-6822(92)90183-P; HEARNE PQ, 1990, VIROLOGY, V177, P141, DOI 10.1016/0042-6822(90)90468-7; HILLMAN BI, 1989, VIROLOGY, V169, P42, DOI 10.1016/0042-6822(89)90039-1; JOHNSTON JC, 1995, VIROLOGY, V214, P100, DOI 10.1006/viro.1995.9950; Kim KH, 1997, VIROLOGY, V232, P187, DOI 10.1006/viro.1997.8565; Kim KH, 1999, RNA, V5, P636, DOI 10.1017/S1355838299982006; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; Limmer S, 1997, PROG NUCLEIC ACID RE, V57, P1, DOI 10.1016/S0079-6603(08)60276-7; Maia IG, 1996, PLANT MOL BIOL, V32, P367, DOI 10.1007/BF00039391; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Miller WA, 2000, VIROLOGY, V273, P1, DOI 10.1006/viro.2000.0421; Miller WA, 1997, SEMIN VIROL, V8, P3, DOI 10.1006/smvy.1997.0101; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; Nagy PD, 2000, VIROLOGY, V276, P279, DOI 10.1006/viro.2000.0577; Oster SK, 1998, J VIROL, V72, P5845, DOI 10.1128/JVI.72.7.5845-5851.1998; Pasternak AO, 2000, J VIROL, V74, P11642, DOI 10.1128/JVI.74.24.11642-11653.2000; Price BD, 2000, J VIROL, V74, P11724, DOI 10.1128/JVI.74.24.11724-11733.2000; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOLTHOF HB, 1995, VIROLOGY, V213, P425, DOI 10.1006/viro.1995.0015; Siegel RW, 1997, P NATL ACAD SCI USA, V94, P11238, DOI 10.1073/pnas.94.21.11238; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; TAVAZZA M, 1994, J GEN VIROL, V75, P1515, DOI 10.1099/0022-1317-75-7-1515; van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; WHITE KA, 1994, J VIROL, V68, P14, DOI 10.1128/JVI.68.1.14-24.1994; Zhang GC, 1999, RNA, V5, P550, DOI 10.1017/S1355838299982080; ZHONG WD, 1993, J VIROL, V67, P2716, DOI 10.1128/JVI.67.5.2716-2722.1993; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	28	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41761	41768		10.1074/jbc.M106727200	http://dx.doi.org/10.1074/jbc.M106727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546813	hybrid			2022-12-25	WOS:000172450400031
J	Lukong, KE; Seyrantepe, V; Landry, K; Trudel, S; Ahmad, A; Gahl, WA; Lefrancois, S; Morales, CR; Pshezhetsky, AV				Lukong, KE; Seyrantepe, V; Landry, K; Trudel, S; Ahmad, A; Gahl, WA; Lefrancois, S; Morales, CR; Pshezhetsky, AV			Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-ASSOCIATED MOLECULE-4; FACTOR-II RECEPTOR; BETA-GALACTOSIDASE; RAPID INTERNALIZATION; CATHEPSIN-A; T-CELLS; TRANSFERRIN RECEPTOR; ACID-PHOSPHATASE; NEURAMINIDASE; MEMBRANE	Sialidase (neuraminidase), encoded by the neu-1 gene in the major histocompatibility complex locus catalyzes the intralysosomal degradation of sialylated glycoconjugates. Inherited deficiency of sialidase results in sialidosis or galactosialidosis, both severe metabolic disorders associated with lysosomal storage of oligosaccharides and glycopeptides. Sialidase also plays an important role in cellular signaling and is specifically required for the production of cytokine interleukin-4 by activated T lymphocytes. In these cells, neu-1-encoded sialidase activity is increased on the cell surface, suggesting that a specific mechanism regulates sorting of this enzyme to the plasma membrane. We investigated that mechanism by first showing that sialidase contains the internalization signal found in lysosomal membrane proteins targeted to endosomes via clathrin-coated pits. The signal consists of a C-terminal tetrapeptide (412)YGTL(415), with Tyr(412) and Leu(415) essential for endocytosis of the enzyme. We further demonstrated that redistribution of sialidase from lysosomes to the cell surface of activated lymphocytes is accompanied by increased reactivity of the enzyme with anti-phosphotyrosine antibodies. We speculate that phosphorylation of Tyr(412) results in inhibition of sialidase internalization in activated lymphocytes.	Hop St Justine, Serv Genet Med, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3T 1C5, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; NICHHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	Universite de Montreal; Universite de Montreal; McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Pshezhetsky, AV (corresponding author), Hop St Justine, Serv Genet Med, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	alex@justine.umontreal.ca	Morales, Carlos R./H-1055-2011	A, Pshezhetsky/0000-0002-6612-1062				Ahmad A, 2000, J VIROL, V74, P7196, DOI 10.1128/JVI.74.16.7196-7203.2000; AKASAKI K, 1994, J BIOCHEM, V116, P670; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Carrillo MB, 1997, GLYCOBIOLOGY, V7, P975; Chen XP, 1997, J IMMUNOL, V158, P3070; Chen XP, 2000, CYTOKINE, V12, P972, DOI 10.1006/cyto.1999.0596; Chikuma S, 2000, J CELL BIOCHEM, V78, P241, DOI 10.1002/(SICI)1097-4644(20000801)78:2<241::AID-JCB7>3.3.CO;2-B; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Gingras R, 1999, J BIOL CHEM, V274, P11742, DOI 10.1074/jbc.274.17.11742; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; Hinek A, 1996, BIOL CHEM, V377, P471; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Iida T, 2000, J IMMUNOL, V165, P5062, DOI 10.4049/jimmunol.165.9.5062; JADOT M, 1992, J BIOL CHEM, V267, P11069; Jarousse N, 2000, TRAFFIC, V1, P378, DOI 10.1034/j.1600-0854.2000.010502.x; KALISH DI, 1978, BIOCHIM BIOPHYS ACTA, V506, P97, DOI 10.1016/0005-2736(78)90437-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LANDOLFI NF, 1985, IMMUNOGENETICS, V22, P159, DOI 10.1007/BF00563513; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LEUNG HT, 1995, J BIOL CHEM, V270, P25107, DOI 10.1074/jbc.270.42.25107; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Lukong KE, 2000, HUM MOL GENET, V9, P1075, DOI 10.1093/hmg/9.7.1075; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Miyatake S, 1998, BIOCHEM BIOPH RES CO, V249, P444, DOI 10.1006/bbrc.1998.9191; NARAPARAJU VR, 1994, IMMUNOL LETT, V43, P143, DOI 10.1016/0165-2478(94)90214-3; OKADA S, 1968, SCIENCE, V160, P1002, DOI 10.1126/science.160.3831.1002; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; Ostrov DA, 2000, SCIENCE, V290, P816, DOI 10.1126/science.290.5492.816; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; PETERS C, 1994, FEBS LETT, V346, P108, DOI 10.1016/0014-5793(94)00499-4; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SEYMOUR CA, 1977, CLIN SCI MOL MED, V52, P229, DOI 10.1042/cs0520229; Thomas G., 2001, DISORDERS GLYCOPROTE, P3507; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VERHEIJEN FW, 1983, BIOCHEM BIOPH RES CO, V117, P470, DOI 10.1016/0006-291X(83)91224-X; Vinogradova MV, 1998, BIOCHEM J, V330, P641; WATTIAUX R, 1983, IODINATED DENSITY GR; YAMAMOTO N, 1993, J IMMUNOL, V151, P2794; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	84	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46172	46181		10.1074/jbc.M104547200	http://dx.doi.org/10.1074/jbc.M104547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571282	hybrid			2022-12-25	WOS:000172573100093
J	Mimura, Y; Sondermann, P; Ghirlando, R; Lund, J; Young, SP; Goodall, M; Jefferis, R				Mimura, Y; Sondermann, P; Ghirlando, R; Lund, J; Young, SP; Goodall, M; Jefferis, R			Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IGG-FC; CRYSTAL-STRUCTURE; CARBOHYDRATE STRUCTURE; PROTEIN INTERACTIONS; EFFECTOR FUNCTIONS; INTERACTION SITES; RECEPTOR IIB; ANTIBODY; GLYCOSYLATION; CELLS	Engagement of Fc gamma receptors (Fc gamma Rs) with the Fe region of IgG elicits immune responses by leukocytes. The recent crystal structure of Fc gamma RIII in complex with IgG-Fc has provided details of molecular interactions between these components (Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) Nature 406, 267-273). One of the most intriguing issues is that glycosylation of IgG-Fc is essential for the recognition by Fc gamma Rs although the carbohydrate moieties are on the periphery of the Fc gamma RIII-Fc interface. To better understand the role of Fe glycosylation in Fc gammaR binding we prepared homogeneous glycoforms of IgG-Fc (Cri) and investigated the interactions with a soluble form of Fc gamma RIIb (sFc gamma RIIb). A 1:1 complex stoichiometry was observed in solution at 30 degreesC (K-d, 0.94 muM; DeltaG, - 8.4 kcal mol(-1); DeltaH, -6.5 kcal mol(-1); T DeltaS, 1.9 kcal mol(-1); DeltaC(p), -160 cal mol(-1) K-1). Removal of terminal galactose residues did not alter the thermodynamic parameters significantly. Outer-arm GlcNAc residues contributed significantly to thermal stability of the C(H)2 domains but only slightly to sFc gamma RIIb binding. Truncation of 1,3- and 1,6-arm mannose residues generates a linear trisaccharide core structure and resulted in a significantly decreased affinity, a less exothermic DeltaH, and a more negative DeltaC(p) for sFc gamma RIIb binding, which may result from a conformational change coupled to complex formation. Deglycosylation of the C(H)2 domains abrogated sFc gamma RIIb binding and resulted in the lowest thermal stability accompanied with noncooperative unfolding. These results suggest that truncation of the oligosaccharides of IgG-Fc causes disorder and a closed disposition of the two C(H)2 domains, impairing sFc gamma RIIb binding.	Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Birmingham; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mimura, Y (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	mimuray@bioch.ox.ac.uk	Ghirlando, Rodolfo/A-8880-2009; Young, Stephen P/A-7380-2008	Young, Stephen P/0000-0002-6355-3361				ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; BOLT S, 1993, EUR J IMMUNOL, V23, P403, DOI 10.1002/eji.1830230216; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Davies J, 2001, BIOTECHNOL BIOENG, V74, P288, DOI 10.1002/bit.1119.abs; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dong X, 1999, J IMMUNOL, V163, P5427; ENGELHARDT W, 1990, EUR J IMMUNOL, V20, P1367, DOI 10.1002/eji.1830200624; FANGER MW, 1989, CHEM IMMUNOL, V47, P214; FLEISCHMAN JB, 1963, BIOCHEM J, V88, P220, DOI 10.1042/bj0880220; Ghirlando R, 1999, IMMUNOL LETT, V68, P47, DOI 10.1016/S0165-2478(99)00029-2; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; JEFFERIS R, 1990, BIOCHEM J, V268, P529, DOI 10.1042/bj2680529; Kato K, 2000, J MOL BIOL, V295, P213, DOI 10.1006/jmbi.1999.3351; LUND J, 1995, FASEB J, V9, P115, DOI 10.1096/fasebj.9.1.7821750; Lund J, 2000, EUR J BIOCHEM, V267, P7246, DOI 10.1046/j.1432-1327.2000.01839.x; LUND J, 1991, J IMMUNOL, V147, P2657; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; MAENAKA K, 2001, J BIOL CHEM     0905; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; Marino M, 2000, NAT BIOTECHNOL, V18, P735, DOI 10.1038/77296; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Metzger, 1990, FC RECEPTORS ACTION, P12; Mimura Y, 2000, MOL IMMUNOL, V37, P697, DOI 10.1016/S0161-5890(00)00105-X; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sondermann P, 1999, BIOL CHEM, V380, P717, DOI 10.1515/BC.1999.090; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TAO MH, 1989, J IMMUNOL, V143, P2595; Tishchenko VM, 1998, BIOCALORIMETRY, P267; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Wright A, 1998, J IMMUNOL, V160, P3393; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	50	196	320	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45539	45547		10.1074/jbc.M107478200	http://dx.doi.org/10.1074/jbc.M107478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567028	hybrid			2022-12-25	WOS:000172573100009
J	Barger, PM; Browning, AC; Garner, AN; Kelly, DP				Barger, PM; Browning, AC; Garner, AN; Kelly, DP			p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha - A potential role in the cardiac metabolic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ENZYME GENE-EXPRESSION; ACID OXIDATION ENZYME; RETINOID-X RECEPTOR; TRANSCRIPTIONAL ACTIVITY; LIPID-METABOLISM; PPAR-ALPHA; VENTRICULAR MYOCYTES; HYPERTROPHIC GROWTH; HORMONE-RECEPTOR	The expression of enzymes involved in fatty acid beta -oxidation (FAO), the principal source of energy production in the adult mammalian heart, is controlled at the transcriptional level via the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR alpha). Evidence has emerged that PPAR alpha activity is activated as a component of an energy metabolic stress response. The p38 mitogen-activated protein kinase (MAPK) pathway is activated by cellular stressors in the heart, including ischemia, hypoxia, and hypertrophic growth stimuli. We show here that PPAR alpha is phosphorylated in response to stress stimuli in rat neonatal cardiac myocytes; in vitro kinase assays demonstrated that p38 MAPK phosphorylates serine residues located within the NH2-terminal A/B domain of the protein. Transient transfection studies in cardiac myocytes and in CV-1 cells utilizing homologous and heterologous PPAR alpha target element reporters and mammalian one-hybrid transcription assays revealed that p38 MAPK phosphorylation of PPAR alpha significantly enhanced ligand-dependent transactivation. Cotransfection studies performed with several known coactivators of PPAR alpha demonstrated that p38 MAPK markedly increased coactivation specifically by PGC-1, a transcriptional coactivator implicated in myocyte energy metabolic gene regulation and mitochondrial biogenesis. These results identify PPAR alpha as a downstream effector of p38 kinase-dependent stress-activated signaling in the heart, linking extracellular stressors to alterations in energy metabolic gene expression.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.		Kelly, Daniel/ABG-2056-2021		NHLBI NIH HHS [R01 HL58493, K08 HL03808, P50 HL61006] Funding Source: Medline; NIDDK NIH HHS [P30 DK56341, P01 DK52574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058493, K08HL003808, P50HL061006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P30DK052574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Auricchio F, 1996, ANN NY ACAD SCI, V784, P149, DOI 10.1111/j.1749-6632.1996.tb16234.x; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Barger PM, 1997, J BIOL CHEM, V272, P2722, DOI 10.1074/jbc.272.5.2722; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Barger PM, 2000, TRENDS CARDIOVAS MED, V10, P238, DOI 10.1016/S1050-1738(00)00077-3; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Cresci S, 1996, AM J PHYSIOL-CELL PH, V270, pC1413, DOI 10.1152/ajpcell.1996.270.5.C1413; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Djouadi F, 1999, PROSTAG LEUKOTR ESS, V60, P339, DOI 10.1016/S0952-3278(99)80009-X; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Horowitz JF, 2000, AM J PHYSIOL-ENDOC M, V279, pE348, DOI 10.1152/ajpendo.2000.279.2.E348; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; KELLY DP, 1989, J BIOL CHEM, V264, P18921; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; NAGAO M, 1993, J BIOL CHEM, V268, P24114; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	47	207	233	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44495	44501		10.1074/jbc.M105945200	http://dx.doi.org/10.1074/jbc.M105945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577087	hybrid			2022-12-25	WOS:000172406700021
J	Feng, ZP; Arnot, MI; Doering, CJ; Zamponi, GW				Feng, ZP; Arnot, MI; Doering, CJ; Zamponi, GW			Calcium channel beta subunits differentially regulate the inhibition of N-type channels by individual G beta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN INHIBITION; VOLTAGE-DEPENDENT MODULATION; KINASE-C; CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; SYMPATHETIC NEURONS; CROSS-TALK; DETERMINANTS; GAMMA; INACTIVATION	The direct inhibition of N- and P/Q-type calcium channels by G protein beta gamma subunits is considered a key mechanism for regulating presynaptic calcium levels. We have recently reported that a number of features associated with this G protein inhibition are dependent on the G protein beta subunit isoform (Arnot, M. I., Stotz, S. C., Jarvis, S. E., Zamponi, G. W. (2000) J. Physiol. (Loud.) 527, 203-212; Cooper, C. B., Arnot, M. I., Feng, Z.-P., Jarvis, S. E., Hamid, J., Zamponi, G. W. (2000) J. Biol. Chem. 275, 40777-40781). Here, we have examined the abilities of different types of ancillary calcium channel beta subunits to modulate the inhibition of alpha (1B) N-type calcium channels by the five known different G beta subunit subtypes. Our data reveal that the degree of inhibition by a particular G beta subunit is strongly dependent on the specific calcium channel beta subunit, with N-type channels containing the beta (4) subunit being less susceptible to G beta gamma -induced inhibition. The calcium channel beta (2a) subunit uniquely slows the kinetics of recovery from G protein inhibition, in addition to mediating a dramatic enhancement of the G protein-induced kinetic slowing. For G beta (3)-mediated inhibition, the latter effect is reduced following site-directed mutagenesis of two palmitoylation sites in the beta (2a) N-terminal region, suggesting that the unique membrane tethering of this subunit serves to modulate G protein inhibition of N-type calcium channels. Taken together, our data suggest that the nature of the calcium channel beta subunit present is an important determinant of G protein inhibition of N-type channels, thereby providing a possible mechanism by which the cellular/subcellular expression pattern of the four calcium channel beta subunits may regulate the G protein sensitivity of N-type channels expressed at different loci throughout the brain and possibly within a neuron.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada	University of Calgary; University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca		Zamponi, Gerald W./0000-0002-0644-9066				Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bertram R, 1999, J COMPUT NEUROSCI, V7, P197, DOI 10.1023/A:1008976129832; BOLAND LM, 1993, J NEUROSCI, V13, P516; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; Canti C, 2000, J PHYSIOL-LONDON, V527, P419, DOI 10.1111/j.1469-7793.2000.t01-1-00419.x; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Cooper CB, 2000, J BIOL CHEM, V275, P40777, DOI 10.1074/jbc.C000673200; Currie KPM, 1997, J NEUROSCI, V17, P4570; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Garcia DE, 1998, J NEUROSCI, V18, P9163; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; Lu Q, 2001, J NEUROSCI, V21, P2949, DOI 10.1523/JNEUROSCI.21-09-02949.2001; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; Mirotznik RR, 2000, J NEUROSCI, V20, P7614; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Restituito S, 2000, J NEUROSCI, V20, P9046; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Stotz SC, 2001, J BIOL CHEM, V276, P33001, DOI 10.1074/jbc.M104387200; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V413, P319, DOI 10.1007/BF00583548; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; Wittemann S, 2000, J BIOL CHEM, V275, P37807, DOI 10.1074/jbc.M004653200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zamponi GW, 2001, CELL BIOCHEM BIOPHYS, V34, P79, DOI 10.1385/CBB:34:1:79; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; Zhou JY, 2000, J NEUROSCI, V20, P7143	45	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45051	45058		10.1074/jbc.M107784200	http://dx.doi.org/10.1074/jbc.M107784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11560937	hybrid			2022-12-25	WOS:000172406700095
J	Mollard, C; Moali, C; Papamicael, C; Damblon, C; Vessilier, S; Amicosante, G; Schofield, CJ; Galleni, M; Frere, JM; Roberts, GCK				Mollard, C; Moali, C; Papamicael, C; Damblon, C; Vessilier, S; Amicosante, G; Schofield, CJ; Galleni, M; Frere, JM; Roberts, GCK			Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases - Kinetic and spectroscopic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITOR; THIOL ESTER DERIVATIVES; N-TERMINAL DOMAIN; BACTEROIDES-FRAGILIS; BACILLUS-CEREUS; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; BIOCHEMICAL-CHARACTERIZATION; RESOLUTION STRUCTURE; ANGSTROM RESOLUTION	Resistance to beta -lactam antibiotics mediated by metallo-beta -lactamases is an increasingly worrying clinical problem. Candidate inhibitors include mercaptocarboxylic acids, and we report studies of a simple such compound, thiomandelic acid. A series of 35 analogues were synthesized and examined as metallo-beta -lactamase inhibitors. The K-i values (Bacillus cereus enzyme) are 0.09 muM for R-thiomandelic acid and 1.28 muM for the S-isomer. Structure-activity relationships show that the thiol is essential for activity and the carboxylate increases potency; the affinity is greatest when these groups are close together. Thioesters of thiomandelic acid are substrates for the enzyme, liberating thiomandelic acid, suggesting a starting point for the design of "pro-drugs." Importantly, thiomandelic acid is a broad spectrum inhibitor of metallo-beta -lactamases, with a submicromolar K-i value for all nine enzymes tested, except the Aeromonas hydrophila enzyme; such a wide spectrum of activity is unprecedented. The binding of thiomandelic acid to the B. cereus enzyme was studied by NMR; the results are consistent with the idea that the inhibitor thiol binds to both zinc ions, while its carboxylate binds to Arg(91). Amide chemical shift perturbations for residues 30-40 (the beta (3)-beta (4) loop) suggest that this small inhibitor induces a movement of this loop of the kind seen for other larger inhibitors.	Univ Leicester, Dept Biochem, Biol NMR Ctr, Leicester LE1 9HN, Leics, England; Univ Liege, Inst Chim B6, Ctr Ingn Prot, B-4000 Liege, Belgium; Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy	University of Leicester; University of Liege; University of Oxford; University of Oxford; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila	Roberts, GCK (corresponding author), Univ Leicester, Dept Biochem, Biol NMR Ctr, POB 138,Univ Rd, Leicester LE1 9HN, Leics, England.	gcr@le.ac.uk	Vessillier, Sandrine/E-2502-2013	Vessillier, Sandrine/0000-0002-9697-1834; papamicael, cyril/0000-0001-6884-6844; Schofield, Christopher/0000-0002-0290-6565; Roberts, Gordon/0000-0001-6200-1373; amicosante, gianfranco/0000-0002-6813-2101; MOALI, Catherine/0000-0003-2479-4290				BALDWIN GS, 1980, J INORG BIOCHEM, V13, P189, DOI 10.1016/S0162-0134(00)80068-9; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P1878, DOI 10.1128/AAC.44.7.1878-1886.2000; BONNER WA, 1968, J ORG CHEM, V33, P1831, DOI 10.1021/jo01269a027; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; Chu YW, 2001, ANTIMICROB AGENTS CH, V45, P710, DOI 10.1128/AAC.45.3.710-714.2001; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; Damblon C, 1999, J AM CHEM SOC, V121, P11575, DOI 10.1021/ja992896h; ELOY F, 1962, CHEM REV, V62, P155, DOI 10.1021/cr60216a003; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; Franceschini N, 2000, ANTIMICROB AGENTS CH, V44, P3003, DOI 10.1128/AAC.44.11.3003-3007.2000; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Goto M, 1997, BIOL PHARM BULL, V20, P1136, DOI 10.1248/bpb.20.1136; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Greenlee ML, 1999, BIOORG MED CHEM LETT, V9, P2549, DOI 10.1016/S0960-894X(99)00425-4; Hammond GG, 1999, FEMS MICROBIOL LETT, V179, P289, DOI 10.1111/j.1574-6968.1999.tb08740.x; Huntley JJA, 2000, BIOCHEMISTRY-US, V39, P13356, DOI 10.1021/bi001210r; Iranpoor N, 1999, SYNTHESIS-STUTTGART, P49; Iyobe S, 2000, ANTIMICROB AGENTS CH, V44, P2023, DOI 10.1128/AAC.44.8.2023-2027.2000; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUWABARA S, 1967, BIOCHEM J, V103, pC27, DOI 10.1042/bj1030027C; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P902, DOI 10.1128/AAC.43.4.902; Lian LY, 2000, STRUCT FOLD DES, V8, P47, DOI 10.1016/S0969-2126(00)00080-0; Matagne A, 1999, NAT PROD REP, V16, P1, DOI 10.1039/a705983c; Mercuri PS, 2001, ANTIMICROB AGENTS CH, V45, P1254, DOI 10.1128/AAC.45.4.1254-1262.2001; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Page MI, 1998, CHEM COMMUN, P1609, DOI 10.1039/a803578d; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; PAYNE DJ, 1993, J MED MICROBIOL, V39, P93, DOI 10.1099/00222615-39-2-93; Payne DJ, 1997, FEMS MICROBIOL LETT, V157, P171, DOI 10.1016/S0378-1097(97)00472-2; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Riccio ML, 2000, ANTIMICROB AGENTS CH, V44, P1229, DOI 10.1128/AAC.44.5.1229-1235.2000; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; STRIJTVEEN B, 1986, J ORG CHEM, V51, P3664, DOI 10.1021/jo00369a020; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; WALSH TR, 1994, BBA-GENE STRUCT EXPR, V1218, P199, DOI 10.1016/0167-4781(94)90011-6; Walter MW, 1999, BIOORG CHEM, V27, P35, DOI 10.1006/bioo.1998.1111; Walter MW, 1996, BIOORG MED CHEM LETT, V6, P2455, DOI 10.1016/0960-894X(96)00453-2; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Yano H, 2001, ANTIMICROB AGENTS CH, V45, P1343, DOI 10.1128/AAC.45.5.1343-1348.2001	57	97	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45015	45023		10.1074/jbc.M107054200	http://dx.doi.org/10.1074/jbc.M107054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564740	hybrid, Green Published			2022-12-25	WOS:000172406700091
J	Moon, YA; Shah, NA; Mohapatra, S; Warrington, JA; Horton, JD				Moon, YA; Shah, NA; Mohapatra, S; Warrington, JA; Horton, JD			Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID ELONGATION; SACCHAROMYCES-CEREVISIAE; SYNTHASE PROMOTER; TRANSGENIC MICE; ADIPOSE-TISSUE; CULTURED-CELLS; GENE FAMILY; FAE1 GENE; BIOSYNTHESIS; CHOLESTEROL	Fatty acids are synthesized de novo from acetyl-CoA and malonyl-CoA through a series of reactions mediated by acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). In rodents, the principal fatty acid produced by FAS is palmitic acid (16:0). Sterol regulatory element-binding proteins (SREBPs) enhance the transcription of many genes responsible for fatty acid synthesis. In transgenic mice that overexpress SREBPs in liver, the rate of fatty acid synthesis is markedly increased, owing to the activation of these biosynthetic genes, which include ATP citrate lyase, ACC, FAS, and stearoyl-CoA desaturase. The fatty acids that accumulate in livers of SREBP transgenic mice are 18 carbons rather than 16 carbons in length, suggesting that the enzymes required for the elongation of palmitic to stearic acid may be induced. Here, we report the cDNA cloning of a murine long chain fatty acyl elongase (LCE) that was identified initially by oligonucleotide array analysis of mRNA from SREBP transgenic mouse livers. LCE mRNA is highly expressed in liver and adipose tissue. The cDNA encodes a protein of 267 amino acids that shares sequence identity with previously identified very long chain fatty acid elongases. Cells that overexpress LCE show enhanced addition of 2-carbon units to C12-C16 fatty acids. We provide evidence that LCE catalyzes the rate-limiting condensing step in this reaction. The current studies suggest that mouse LCE expression is increased by SREBPs and that the enzyme is a component of the elusive mammalian elongation system that converts palmitic to stearic acid.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Affymetrix Inc, Santa Clara, CA 95051 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Affymetrix	Horton, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; APRAHAMIAN SA, 1982, COMP BIOCH PHYSL B, V71, P557; Barret P, 1998, THEOR APPL GENET, V96, P177, DOI 10.1007/s001220050725; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lassner MW, 1996, PLANT CELL, V8, P281, DOI 10.1105/tpc.8.2.281; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; NAGI MN, 1989, BIOCHEM BIOPH RES CO, V165, P1428, DOI 10.1016/0006-291X(89)92763-0; NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Todd J, 1999, PLANT J, V17, P119, DOI 10.1046/j.1365-313X.1999.00352.x; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817	34	263	297	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45358	45366		10.1074/jbc.M108413200	http://dx.doi.org/10.1074/jbc.M108413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567032	hybrid			2022-12-25	WOS:000172406700131
J	Murray, D; McLaughlin, S; Honig, B				Murray, D; McLaughlin, S; Honig, B			The role of electrostatic interactions in the regulation of the membrane association of G protein beta gamma heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSDUCIN-LIKE PROTEIN; SMALL BASIC PEPTIDES; CRYSTAL-STRUCTURE; LIPID MODIFICATIONS; ACIDIC LIPIDS; BINDING; SUBUNITS; RESIDUES; INSIGHTS; SRC	In this paper we report calculations of electrostatic interactions between the transducin (G(t)) beta gamma heterodimer (G(t)beta gamma) and phospholipid membranes. Although membrane association of G(t)beta gamma is due primarily to the hydrophobic penetration into the membrane interior of a farnesyl chain attached to the gamma subunit, structural studies have revealed that there is a prominent patch of basic residues on the surface of the beta subunit surrounding the site of farnesylation that is exposed upon dissociation from the G(t)alpha subunit. Moreover, phosducin, which produces dissociation of G(t)beta gamma from membranes, interacts directly with G(t)beta gamma and introduces a cluster of acidic residues into this region. The calculations, which are based on the finite difference Poisson-Boltzmann method, account for a number of experimental observations and suggest that charged residues play a role in mediating protein-membrane interactions. Specifically, the calculations predict the following. 1) Favorable electrostatic interactions enhance the membrane partitioning due to the farnesyl group by an order of magnitude although G(t)beta gamma has a large net negative charge (-12). 2) This electrostatic attraction positions G(t)beta gamma so that residues implicated in mediating the interaction of G(t)beta gamma with its membrane-bound effectors are close to the membrane surface. 3) The binding of phosducin to G(t)beta gamma diminishes the membrane partitioning of G(t)beta gamma by an order of magnitude. 4) Lowering the ionic strength of the solution converts the electrostatic attraction into a repulsion. Sequence analysis and homology model building suggest that our conclusions may be generalized to other G beta gamma and phosducin isoforms as well.	Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Columbia University; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Honig, B (corresponding author), Weill Cornell Med Sch, Dept Microbiol & Immunol, 1300 York Ave,Box 62, New York, NY 10021 USA.	bh6@columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024971, R37GM024971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24971] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Balcueva EA, 2000, EXP CELL RES, V257, P310, DOI 10.1006/excr.2000.4893; BenTal N, 1997, BIOPHYS J, V73, P1717, DOI 10.1016/S0006-3495(97)78203-1; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BIGAY J, 1994, METHOD ENZYMOL, V237, P449; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Burden LM, 1999, BIOCHEMISTRY-US, V38, P15141, DOI 10.1021/bi991571a; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hessel E, 2001, J BIOL CHEM, V276, P2538, DOI 10.1074/jbc.M009061200; HOLST M, 1993, J COMPUT CHEM, V14, P105, DOI 10.1002/jcc.540140114; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Kleinschmidt JH, 1997, BIOPHYS J, V73, P2546, DOI 10.1016/S0006-3495(97)78283-3; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; MONTICH G, 1993, BIOCHIM BIOPHYS ACTA, V1146, P17, DOI 10.1016/0005-2736(93)90333-U; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PEITZSCH RM, 1995, BIOPHYS J, V68, P729, DOI 10.1016/S0006-3495(95)80253-5; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; SHARP KA, 1990, J PHYS CHEM-US, V94, P7684, DOI 10.1021/j100382a068; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tanaka H, 1996, BIOCHEM BIOPH RES CO, V223, P587, DOI 10.1006/bbrc.1996.0939; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; WU G, 1993, BIOCHEMISTRY-US, V32, P879, DOI 10.1021/bi00054a020; Yang AS, 2000, J MOL BIOL, V301, P665, DOI 10.1006/jmbi.2000.3973; Yang AS, 1999, PROTEINS, P66	59	53	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45153	45159		10.1074/jbc.M101784200	http://dx.doi.org/10.1074/jbc.M101784200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11557749	hybrid			2022-12-25	WOS:000172406700107
J	Jacobs, RL; Stead, LM; Brosnan, ME; Brosnan, JT				Jacobs, RL; Stead, LM; Brosnan, ME; Brosnan, JT			Hyperglucagonemia in rats results in decreased plasma homocysteine and increased flux through the transsulfuration pathway in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE BETA-SYNTHASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; TYPE-1 DIABETES-MELLITUS; AMINO-ACID-TRANSPORT; HIGH-PROTEIN-DIET; METABOLISM; GLUCAGON; HYPERHOMOCYSTEINEMIA; CELLS; METHYLTRANSFERASE	An elevated plasma level of homocysteine is a risk factor for the development of cardiovascular disease. The purpose of this study was to investigate the effect of glucagon on homocysteine metabolism in the rat. Male Sprague-Dawley rats were treated with 4 mg/kg/day (3 injections per day) glucagon for 2 days while control rats received vehicle injections. Glucagon treatment resulted in a 30% decrease in total plasma homocysteine and increased hepatic activities of glycine N-methyltransferase, cystathionine beta -synthase, and cystathionine gamma -lyase. Enzyme activities of the remethylation pathway were unaffected. The 90% elevation in activity of cystathionine beta -synthase was accompanied by a 2-fold increase in its mRNA level. Hepatocytes prepared from glucagon-injected rats exported less homocysteine, when incubated with methionine, than did hepatocytes of saline-treated rats. Flux through cystathionine beta -synthase was increased 5-fold in hepatocytes isolated from glucagon-treated rats as determined by production of (CO2)-C-14 and alpha-[1-C-14]ketobutyrate from L-[1-C-14]methionine. Methionine transport was elevated 2-fold in hepatocytes isolated from glueagon-treated rats resulting in increased hepatic methionine levels. Hepatic concentrations of S-adenosylmethionine and S-adenosylhomocysteine, allosteric activators of cystathionine beta -synthase, were also increased following glucagon treatment. These results indicate that glucagon can regulate plasma homocysteine through its effects on the hepatic transsulfuration pathway.	Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada	Memorial University Newfoundland	Brosnan, JT (corresponding author), Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada.	jbrosnan@mun.ca		Jacobs, Rene/0000-0002-5525-1355				Barazzoni R, 1999, DIABETOLOGIA, V42, P326, DOI 10.1007/s001250051158; BERGMEYER HU, 1981, METHODS ENZYMATIC AN, V3; Berry MN, 1991, LAB TECHNIQUES BIOCH, V21, P44; BRATTSTROM L, 1989, J INHERIT METAB DIS, V12, P475, DOI 10.1007/BF01802045; CARR FPA, 1981, BIOCHEM J, V198, P655, DOI 10.1042/bj1980655; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELAHABA G, 1959, J BIOL CHEM, V234, P603; EASSERMAN DH, 1989, AM J PHYSIOL, V257, pE108; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; FOREMAN JW, 1982, METABOLISM, V31, P613, DOI 10.1016/0026-0495(82)90101-9; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOSS SJ, 1986, J CELL SCI, V82, P309; HANDLOGTEN ME, 1984, J BIOL CHEM, V259, P3519; HULTBERG B, 1991, SCAND J CLIN LAB INV, V51, P277, DOI 10.3109/00365519109091615; Hussein WI, 1999, ANN INTERN MED, V131, P348, DOI 10.7326/0003-4819-131-5-199909070-00005; JACOBS EE, 1956, J BIOL CHEM, V223, P147; Jacobs RL, 1998, DIABETES, V47, P1967, DOI 10.2337/diabetes.47.12.1967; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; Kluijtmans LAJ, 1999, AM J HUM GENET, V65, P59, DOI 10.1086/302439; KOLBIN DD, 1981, ANESTHESIOLOGY, V54, P318; Lakritz J, 1997, ANAL BIOCHEM, V247, P63, DOI 10.1006/abio.1997.2032; Mabrouk GM, 1998, BIOCHEM J, V330, P759; Martinov MV, 2000, J THEOR BIOL, V204, P521, DOI 10.1006/jtbi.2000.2035; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; MUDD SH, 1965, J BIOL CHEM, V240, P4382; Nedrebo BG, 1998, METABOLISM, V47, P89, DOI 10.1016/S0026-0495(98)90198-6; OSULLIVAN D, 2000, AM J PHYSIOL, V278, pE576; PERET J, 1981, J NUTR, V111, P1173, DOI 10.1093/jn/111.7.1173; QIAN D, 1998, BIOCHEM J, V313, P479; ROBILLON JF, 1994, DIABETES METAB, V20, P494; SALTER M, 1986, BIOCHEM J, V233, P499, DOI 10.1042/bj2330499; SNODGRASS PJ, 1978, J BIOL CHEM, V253, P2748; Squires SA, 1997, DIABETES, V46, P1945, DOI 10.2337/diabetes.46.12.1945; Stead LM, 2000, BIOCHEM J, V350, P685, DOI 10.1042/0264-6021:3500685; STIPANUK MH, 1979, J NUTR, V109, P2126, DOI 10.1093/jn/109.12.2126; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UNGER RH, 1976, DIABETES, V25, P136, DOI 10.2337/diab.25.2.136; Van Baal WM, 1999, OBSTET GYNECOL, V94, P485, DOI 10.1016/S0029-7844(99)00412-3; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; WAGNER C, 1989, J BIOL CHEM, V264, P9638; WANG J, 1991, CLIN CHIM ACTA, V204, P239, DOI 10.1016/0009-8981(91)90235-5; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WYSS M, 1994, MOL CELL BIOCHEM, V133, P51, DOI 10.1007/BF01267947; Yamamoto N, 1996, J NUTR SCI VITAMINOL, V42, P589, DOI 10.3177/jnsv.42.589	51	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43740	43747		10.1074/jbc.M107553200	http://dx.doi.org/10.1074/jbc.M107553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559709				2022-12-25	WOS:000172297700035
J	Thuahnai, ST; Lund-Katz, S; Williams, DL; Phillips, MC				Thuahnai, ST; Lund-Katz, S; Williams, DL; Phillips, MC			Scavenger receptor class B, type I-mediated uptake of various lipids into cells - Influence of the nature of the donor particle interaction with the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTERYL ESTER UPTAKE; APOLIPOPROTEIN-A-I; SR-BI; SELECTIVE UPTAKE; UNILAMELLAR VESICLES; BINDING; HDL; ATHEROSCLEROSIS; METABOLISM	Scavenger receptor (SR)-BI is the first molecularly defined receptor for high density lipoprotein (HDL) and it can mediate the selective uptake of cholesteryl ester into cells. To elucidate the molecular mechanisms by which SR-BI facilitates lipid uptake, we examined the connection between lipid donor particle binding and lipid uptake using kidney COS-7 cells transiently transfected with SR-BI. We systematically compared the uptake of [H-3]cholesteryl oleoyl ether (CE) and [C-14]sphingomyelin (SM) from apolipoprotein (apo) A-I-containing reconstituted HDL (rHDL) particles and apo-free lipid donor particles. Although both types of lipid donor could bind to SR-BI, only apo-containing lipid donors exhibited preferential delivery of CE over SM (i.e. nonstoichiometric lipid uptake). In contrast, apo-free lipid donor particles (phospholipid unilamellar vesicles, lipid emulsion particles) gave rise to stoichiometric lipid uptake due to interaction with SR-BI. This apparent whole particle uptake was not due to endocytosis, but rather fusion of the lipid components of the lipid donor with the cell plasma membrane; this process is perhaps mediated by a fusogenic motif in the extracellular domain of SR-BI. The interaction of apoA-I with SR-BI not only prevents fusion of the lipid donor with the plasma membrane but also allows the optimal selective lipid uptake. A comparison of rHDL particles containing apoA-I and apoE-3 showed that while both particles bound equally well to SR-BI, the apoA-I particle gave similar to2-fold greater CE selective uptake. Catabolism of all major HDL lipids can occur via SR-BI with the relative selective uptake rate constants for CE, free cholesterol, triglycerides (triolein), and phosphatidylcholine being 1, 1.6, 0.7, and 0.2, respectively. It follows that a putative nonpolar channel created by SR-BI between the bound HDL particle and the cell plasma membrane is better able to accommodate the uptake of neutral lipids (e.g. cholesterol) relative to polar phospholipids.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,GI Nutr Div, Philadelphia, PA 19104 USA; SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,GI Nutr Div, Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083, P01HL022633, T32HL007443, R01HL058012] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443, HL56083, HL22633, HL58012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; DIJKSTRA J, 1984, EXP CELL RES, V150, P161, DOI 10.1016/0014-4827(84)90711-0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAUSER H, 1973, J BIOL CHEM, V248, P8585; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, CURR OPIN LIPIDOL, V10, P491, DOI 10.1097/00041433-199912000-00003; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Reaven E, 1996, J BIOL CHEM, V271, P16208, DOI 10.1074/jbc.271.27.16208; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1987, J LIPID RES, V28, P1313; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P2132, DOI 10.1161/01.ATV.17.10.2132; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Saito H, 1996, J BIOL CHEM, V271, P15515, DOI 10.1074/jbc.271.26.15515; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200	44	102	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43801	43808		10.1074/jbc.M106695200	http://dx.doi.org/10.1074/jbc.M106695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564739	hybrid			2022-12-25	WOS:000172297700043
J	Andersson, U; Levander, F; Radstrom, P				Andersson, U; Levander, F; Radstrom, P			Trehalose-6-phosphate phosphorylase is part of a novel metabolic pathway for trehalose utilization in Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; SUBSP LACTIS; TREA GENE; PURIFICATION; PHOSPHOGLUCOMUTASE; EXPRESSION; CLEAVAGE; PROTEINS; CLONING	Lactococcus lactis splits phosphorylated trehalose by the action of inorganic phosphate-dependent trehalose-6-phosphate phosphorylase (TrePP) in a novel catabolic pathway. TrePP was found to catalyze the reversible conversion of trehalose 6-phosphate into beta -glucose 1-phosphate and glucose 6-phosphate by measuring intermediate sugar phosphates in cell extracts from trehalose-cultivated lactococci. According to native PAGE and SDS-PAGE, TrePP was shown to be a monomeric enzyme with a molecular mass of 94 kDa. Reaction kinetics suggested that the enzyme follows a ternary complex mechanism with optimal phosphorolysis at 35 degreesC and pH 6.3. The equilibrium constants were found to be 0.026 and 0.032 at pH 6.3 and 7.0, respectively, favoring the formation of trehalose 6-phosphate. The Michaelis-Menten constants of TrePP for trehalose 6-phosphate, inorganic phosphate, beta -glucose 1-phosphate, and glucose 6-phosphate were determined to be 6, 32, 0.9, and 4 mm, respectively. The TrePP-encoding gene, designated trePP, was localized in a putative trehalose operon of L. lactis. This operon includes the gene encoding beta -phosphoglucomutase in addition to three open reading frames believed to encode a transcriptional regulator and two trehalose-specific phosphotransferase system components. The identity of trePP was confirmed by determining the N-terminal amino acid sequence of TrePP and by its overexpression in Escherichia coli and L. lactis, as well as the construction of a lactococcal trePP knockout mutant. Furthermore, both TrePP and P-phosphoglucomutase activity were detected in Enterococcus faecalis cell extract, indicating that this bacterium exhibits the same trehalose assimilation route as L. lactis.	Lund Inst Technol, Ctr Chem & Chem Engn, SE-22100 Lund, Sweden	Lund University	Radstrom, P (corresponding author), Lund Inst Technol, Ctr Chem & Chem Engn, POB 124, SE-22100 Lund, Sweden.			Levander, Fredrik/0000-0002-0710-9792				Aisaka K, 1998, BIOSCI BIOTECH BIOCH, V62, P782, DOI 10.1271/bbb.62.782; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BHUMIRATANA A, 1974, J BACTERIOL, V119, P484, DOI 10.1128/JB.119.2.484-493.1974; BOLOTIN A, 1999, 6 S LACT AC BACT GEN, P27; BOOS W, 1990, J BACTERIOL, V172, P3450, DOI 10.1128/jb.172.6.3450-3461.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Dahl MK, 1997, FEMS MICROBIOL LETT, V148, P233, DOI 10.1016/S0378-1097(97)00039-6; Ehrmann MA, 1998, FEMS MICROBIOL LETT, V169, P81, DOI 10.1016/S0378-1097(98)00467-4; Eis C, 2001, BIOCHEM J, V356, P757, DOI 10.1042/0264-6021:3560757; Eis C, 1999, BIOCHEM J, V341, P385, DOI 10.1042/0264-6021:3410385; GOTSCHE S, 1995, J BACTERIOL, V177, P2721, DOI 10.1128/jb.177.10.2721-2726.1995; HELFERT C, 1995, MOL MICROBIOL, V16, P111, DOI 10.1111/j.1365-2958.1995.tb02396.x; KAASEN I, 1994, GENE, V145, P9, DOI 10.1016/0378-1119(94)90316-6; KLEIN W, 1995, J BACTERIOL, V177, P4043, DOI 10.1128/jb.177.14.4043-4052.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levander F, 2001, APPL ENVIRON MICROB, V67, P4546, DOI 10.1128/AEM.67.10.4546-4553.2001; MARECHAL LR, 1972, J BIOL CHEM, V247, P3223; Nilsson U, 2001, MICROBIOL-SGM, V147, P1565, DOI 10.1099/00221287-147-6-1565; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; POY F, 1990, INFECT IMMUN, V58, P1479, DOI 10.1128/IAI.58.5.1479-1480.1990; Qian N, 1997, MICROBIOL-SGM, V143, P855, DOI 10.1099/00221287-143-3-855; QIAN N, 1994, J BACTERIOL, V176, P5304, DOI 10.1128/JB.176.17.5304-5311.1994; RIMMELE M, 1994, J BACTERIOL, V176, P5654, DOI 10.1128/JB.176.18.5654-5664.1994; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; Schlosser A, 2000, FEMS MICROBIOL LETT, V184, P187, DOI 10.1016/S0378-1097(00)00045-8; Schock F, 1996, GENE, V175, P59, DOI 10.1016/0378-1119(96)00120-5; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Uhland K, 2000, J BIOL CHEM, V275, P23439, DOI 10.1074/jbc.M002793200; VANDEGUCHTE M, 1989, APPL ENVIRON MICROB, V55, P224, DOI 10.1128/AEM.55.1.224-228.1989; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WHITE JW, 1961, ANAL BIOCHEM, V2, P380, DOI 10.1016/0003-2697(61)90011-2; [No title captured]	35	56	66	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42707	42713		10.1074/jbc.M108279200	http://dx.doi.org/10.1074/jbc.M108279200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553642	hybrid			2022-12-25	WOS:000172169300011
J	Ando, T; Kawabe, T; Ohara, H; Ducommun, B; Itoh, M; Okamoto, T				Ando, T; Kawabe, T; Ohara, H; Ducommun, B; Itoh, M; Okamoto, T			Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G(2)/M arrest after DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CDC25 MITOTIC INDUCER; FISSION YEAST; POLYMERASE-DELTA; PROTEIN-KINASE; CHECKPOINT PATHWAY; AUXILIARY PROTEIN; 14-3-3 BINDING; MULTIPLE ROLES; INHIBITOR P21	Although a major effect of p21, a cyclin-dependent kinase inhibitor, is considered to be exerted during G(1) phase of the cell cycle, p21 gene knock-out studies suggested its involvement in G(2)/M checkpoint as well. Here we demonstrate evidence that p21 is required for the cell cycle arrest at G(2) upon DNA damage. We found that expression of wild-type p21 (p21(WT)), not mutant p21 (p21(PCNA-)) lacking the interaction with proliferating cell nuclear antigen (PCNA), caused G2 cell cycle arrest in p53-deficient DLD1 colon cancer cell line after the DNA damage by treatment with cis-diamminedichloroplatinum (II). We also found that p21(WT) was associated with Cdc2/cyclin B1 together with PCNA. Furthermore, coimmunoprecipitation experiments revealed that PCNA interacted with Cdc25C at the G(2)/M transition, and this interaction was abolished when p21(WT) was expressed presumably due to the competition between p21(WT) and Cdc25C in the binding to PCNA. These findings suggest that p21 plays a regulatory role in the maintenance of cell cycle arrest at G(2) by blocking the interaction of Cdc25C with PCNA.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Mizuho Ku, Aichi 4678601, Japan; Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat Cel, CNRS, UMR 5088, F-31062 Toulouse, France	Nagoya City University; Nagoya City University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp	DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Barboule N, 1999, FEBS LETT, V444, P32, DOI 10.1016/S0014-5793(99)00022-8; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chan TA, 2000, GENE DEV, V14, P1584; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GOUBIN F, 1995, ONCOGENE, V10, P2281; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hindges R, 1997, BIOL CHEM, V378, P345; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kobayashi K, 2000, CANCER RES, V60, P3978; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, ONCOGENE, V9, P2261; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; NAGATA A, 1991, NEW BIOL, V3, P959; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Suganuma M, 1999, CANCER RES, V59, P5887; SZEPESI A, 1994, BLOOD, V84, P3413; TAN CK, 1986, J BIOL CHEM, V261, P2310; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	76	147	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42971	42977		10.1074/jbc.M106460200	http://dx.doi.org/10.1074/jbc.M106460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11559705	hybrid			2022-12-25	WOS:000172169300046
J	Ishii, T; Satoh, E; Nishimura, M				Ishii, T; Satoh, E; Nishimura, M			Integrin-linked kinase controls neurite outgrowth in N1E-115 neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; RHO-FAMILY GTPASES; MAP KINASE; PC12 CELLS; FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; DEPENDENT GROWTH; ADAPTER PROTEIN	Mouse N1E-115 cells grown on a laminin matrix exhibit neurite outgrowth in response to serum deprivation. Treatment of cells with an antibody against beta (1) integrin inhibits neurite outgrowth. Thus, beta (1) integrin is involved in the neuritogenesis of N1E-115 cells on a laminin matrix. Integrin-linked kinase (ILK), a recently identified cytoplasmic serine/threonine protein kinase that binds to the cytoplasmic domain of beta (1) integrin, has an important role in transmembrane signal transduction via integrins. We report that ILK is expressed in N1E-115 cells, the expression levels of which are constant under both normal and differentiating conditions. A stable transfection of a kinase-deficient mutant of ILK (DN-ILK) results in inhibition of neurite outgrowth in serum-starved N1E-115 cells grown on laminin. On the other hand, a transient expression of wild type ILK stimulated neurite outgrowth. The ILK activity in the parental cells was transiently activated after seeding on the laminin matrix, whereas that in the DN-ILK-transfected cells was not. These results suggest that transient activation of ILK is required for neurite outgrowth in serum-starved N1E-115 cells on laminin. Under the same conditions, p38 mitogen-activated protein (MAP) kinase, but neither MAP kinase/extracellular signal-regulated kinase kinase (MEK) nor extracellular signal-regulated kinases (ERK), was transiently activated after N1E-115 cell attachment to laminin, but not in the DN-ILK-expressed cells. The time course of p38 MAP kinase activation was very similar to that of ILK activation. Furthermore, a p38 MAP kinase inhibitor, SB203580, significantly blocked neurite outgrowth. Thus' activation of p38 MAP kinase is involved in ILK-mediated signal transduction leading to integrin-dependent neurite outgrowth in N1E-115 cells.	Univ Obihiro, Sch Vet Med, Dept Pharmacol, Obihiro, Hokkaido 0808555, Japan	Obihiro University of Agriculture & Veterinary Medicine	Nishimura, M (corresponding author), Univ Obihiro, Sch Vet Med, Dept Pharmacol, Obihiro, Hokkaido 0808555, Japan.							CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Huang Y, 1999, INT J MOL MED, V3, P563; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Li FG, 1999, J CELL SCI, V112, P4589; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P6463; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; TURNER DC, 1989, J NEUROSCI, V9, P3287; TURNER DC, 1989, DEV NEUROSCI-BASEL, V11, P300, DOI 10.1159/000111908; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHANG ZY, 1993, J BIOL CHEM, V268, P5557; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	43	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42994	43003		10.1074/jbc.M105198200	http://dx.doi.org/10.1074/jbc.M105198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560928	hybrid			2022-12-25	WOS:000172169300049
J	Shen, W; Scearce, LM; Brestelli, JE; Sund, NJ; Kaestner, KH				Shen, W; Scearce, LM; Brestelli, JE; Sund, NJ; Kaestner, KH			Foxa3 (hepatocyte nuclear factor 3 gamma) is required for the regulation of hepatic GLUT2 expression and the maintenance of glucose homeostasis during a prolonged fast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; ENRICHED TRANSCRIPTION FACTORS; GLUCOCORTICOID RESPONSE UNIT; PHOSPHOENOLPYRUVATE CARBOXYKINASE; DEFINITIVE ENDODERM; FACTOR-BINDING; MOUSE EMBRYO; IN-VIVO; LIVER; DIFFERENTIATION	The winged helix transcription factors, hepatocyte nuclear factors 3 alpha, -beta, and -gamma (HN-F-3, encoded by the Foxa1, -a2, and -a3 genes, respectively), are expressed early in embryonic endoderm and play important roles in the regulation of gene expression in liver and pancreas. Foxa1 has been shown to be required for glucagon secretion in the pancreas, whereas Foxa2 is critical for the regulation of insulin secretion in pancreatic beta -cells. Here we address the role of Foxa3 in the maintenance of glucose homeostasis. Mice homozygous for a null mutation in Foxa3 appear normal under fed conditions. However, when fasted, Foxa3(-/-) mice have a significantly lower blood glucose compared with control mice. The fasting hypoglycemia in Foxa3(-/-) mice could not be attributed to defects in pancreatic hormone secretion, ketone production, or hepatic glycogen breakdown. Surprisingly, mRNA levels for several gluconeogenic enzymes were up-regulated appropriately in fasted Foxa3(-/-) mice, despite the fact that the corresponding genes had been shown to be activated by FOXA proteins in vitro. However, the mRNA for the plasma membrane glucose transporter GLUT2 was decreased by 64% in the fasted and 93% in the fed state, suggesting that efflux of newly synthesized glucose is limiting in Foxa3(-/-) hepatocytes. Thus, Foxa3 is the dominating transcriptional regulator of GLUT2 expression in hepatocytes in vivo. In addition, we investigated the hepatic transcription factor network in Foxa3(-/-) mice and found that the normal activation of HNF-4 alpha, HNF-1 alpha, and PGC-1 induced by fasting is attenuated in mice lacking Foxa3.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Kaestner, KH (corresponding author), Univ Penn, Sch Med, Dept Genet, 560 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [P30-DK50306, P30-DK19525, R01 DK55342, P01 DK49210] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK055342, P01DK049210, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Denson LA, 2000, GENE, V246, P311, DOI 10.1016/S0378-1119(00)00082-2; Duncan SA, 1997, DEVELOPMENT, V124, P279; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 2000, GENE DEV, V14, P142; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; THORENS B, 1990, AM J PHYSIOL, V259, P279; Wang GF, 1996, MICROW OPT TECHN LET, V11, P10, DOI 10.1002/(SICI)1098-2760(199601)11:1<10::AID-MOP3>3.0.CO;2-S; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; Zimmermann PL, 1997, DNA CELL BIOL, V16, P713, DOI 10.1089/dna.1997.16.713	31	86	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42812	42817		10.1074/jbc.M106344200	http://dx.doi.org/10.1074/jbc.M106344200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11546810	hybrid			2022-12-25	WOS:000172169300025
J	Xu, XH; Hamhouyia, F; Thomas, SD; Burke, TJ; Girvan, AC; McGregor, WG; Trent, JO; Miller, DM; Bates, PJ				Xu, XH; Hamhouyia, F; Thomas, SD; Burke, TJ; Girvan, AC; McGregor, WG; Trent, JO; Miller, DM; Bates, PJ			Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-ANTIGEN HELICASE; LARGE-TUMOR-ANTIGEN; ATPASE ACTIVITIES; ANTIPROLIFERATIVE ACTIVITY; INTERACTING LIGANDS; BINDING PROTEIN; NUCLEOLIN; COMPLEX; AGENTS; SITE	The discovery of G-rich oligonucleotides (GROs) that have non-antisense antiproliferative activity against a number of cancer cell lines has been recently described. This biological activity of GROs was found to be associated with their ability to form stable G-quartet-containing structures and their binding to a specific cellular protein, most likely nucleolin (Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., and Miller, D. M. (1999) J. Biol Chem. 274, 26369-26377). In this report, we further investigate the novel mechanism of GRO activity by examining their effects on cell cycle progression and on nucleic, acid and protein biosynthesis. Cell cycle analysis of several tumor cell lines showed that cells accumulate in S phase in response to treatment with an active GRO. Analysis of 5-bromodeoxyuridine incorporation by these cells indicated the absence of de novo DNA synthesis, suggesting an arrest of the cell cycle predominantly in S phase. At the same time point, RNA and protein synthesis were found to be ongoing, indicating that arrest of DNA replication is a primary event in GRO-mediated inhibition of proliferation. This specific blockade of DNA replication eventually resulted in altered cell morphology and induction of apoptosis. To characterize further GRO-mediated inhibition of DNA replication, we used an in vitro assay based on replication of SV40 DNA. GROs were found to be capable of inhibiting DNA replication in the in vitro assay, and this activity was correlated to their antiproliferative effects. Furthermore, the effect of GROs on DNA replication in this assay was related to their inhibition of SV40 large T antigen helicase activity. The data presented suggest that the antiproliferative activity of GROs is a direct result of their inhibition of DNA replication, which may result from modulation of a replicative helicase activity.	Univ Louisville, James Graham Brown Canc Ctr, Human Mol Biol Grp, Dept Med, Louisville, KY 40202 USA; Univ Louisville, James Graham Brown Canc Ctr, Human Mol Biol Grp, Dept Pharmacol Toxicol, Louisville, KY 40202 USA; Univ Louisville, James Graham Brown Canc Ctr, Human Mol Biol Grp, Dept Biochem Mol Biol, Louisville, KY 40202 USA; Univ Louisville, James Graham Brown Canc Ctr, Human Mol Biol Grp, Dept Chem, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville	Bates, PJ (corresponding author), 204B Baxter Bldg,570 S Preston St, Louisville, KY 40202 USA.	paula.bates@louisville.edu		Bates, Paula/0000-0002-4622-4152; trent, John/0000-0002-7346-4231				Bachur NR, 1998, BIOCHEM PHARMACOL, V55, P1025, DOI 10.1016/S0006-2952(97)00617-5; BACHUR NR, 1992, MOL PHARMACOL, V41, P993; Baran N, 1997, NUCLEIC ACIDS RES, V25, P297, DOI 10.1093/nar/25.2.297; Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369; Benimetskaya L, 1997, NUCLEIC ACIDS RES, V25, P2648, DOI 10.1093/nar/25.13.2648; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; Chino M, 1998, J ANTIBIOT, V51, P480, DOI 10.7164/antibiotics.51.480; Crooke ST, 2000, METHOD ENZYMOL, V313, P3; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DERENZINI M, 1995, LAB INVEST, V73, P497; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; GEORGE JW, 1992, J BIOL CHEM, V267, P10683; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; Gotzmann J, 1997, ELECTROPHORESIS, V18, P2645, DOI 10.1002/elps.1150181421; Haider SR, 1997, EXP CELL RES, V234, P498, DOI 10.1006/excr.1997.3644; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JENSEN PO, 1993, CYTOMETRY, V14, P455; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Larrucea S, 1998, J BIOL CHEM, V273, P31718, DOI 10.1074/jbc.273.48.31718; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; LegerSilvestre I, 1997, CHROMOSOMA, V105, P542, DOI 10.1007/BF02510491; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI USA, V81, P4249; MAINE IP, 1992, BIOCHEMISTRY-US, V31, P3968, DOI 10.1021/bi00131a012; Malkas LH, 1998, J CELL BIOCHEM, P18; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Morgan D M, 1998, Methods Mol Biol, V79, P179; Praseuth D, 1999, BBA-GENE STRUCT EXPR, V1489, P181, DOI 10.1016/S0167-4781(99)00149-9; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Sirri V, 2000, MICRON, V31, P121, DOI 10.1016/S0968-4328(99)00068-2; Sorokina EA, 1999, J BIOL CHEM, V274, P27491, DOI 10.1074/jbc.274.39.27491; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1985, J VIROL, V54, P473, DOI 10.1128/JVI.54.2.473-482.1985; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; THOMAS DC, 1993, P NATL ACAD SCI USA, V90, P7744, DOI 10.1073/pnas.90.16.7744; Tuteja N, 1998, BIOCHEM BIOPH RES CO, V244, P861, DOI 10.1006/bbrc.1998.8363; Tuteja N, 1997, BIOCHEM BIOPH RES CO, V236, P636, DOI 10.1006/bbrc.1997.7021; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Veaute X, 2000, MUTAT RES-DNA REPAIR, V459, P19, DOI 10.1016/S0921-8777(99)00052-X; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998; Zhu KC, 1999, BIOCHEM BIOPH RES CO, V266, P361, DOI 10.1006/bbrc.1999.1815	63	137	156	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43221	43230		10.1074/jbc.M104446200	http://dx.doi.org/10.1074/jbc.M104446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555643	hybrid			2022-12-25	WOS:000172169300077
J	Lin, Y; Rajala, MW; Berger, JP; Moller, DE; Barzilai, N; Scherer, PE				Lin, Y; Rajala, MW; Berger, JP; Moller, DE; Barzilai, N; Scherer, PE			Hyperglycemia-induced production of acute phase reactants in adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UTERINE LUMINAL FLUID; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; HEART-DISEASE; 24P3 GENE; EXPRESSION; PROTEIN; ASSOCIATION; ADIPOCYTES; COMPLEMENT	Chronic elevation of systemic levels of acute phase reactants and inflammatory cytokines found in patients with diabetes and the often-associated metabolic syndrome X (hypertriglyceridemia, low serum high density lipoprotein cholesterol, hypertension, and accelerated atherosclerosis) may be responsible for the increased incidence of cardiovascular problems in this population. Here we examine the contribution of adipose tissue to the systemic elevation of acute phase reactants associated with chronic hyperglycemia. We demonstrate that adipose tissue expresses a number of acute phase reactants at high levels, including serum amyloid A3 (SAA3), alpha1-acid glycoprotein, the lipocalin 24p3 as well as plasminogen activator inhibitor-1 (PAI-1). Additionally, we show SAA3 is expressed at low levels under normal conditions but in the diabetic state is dramatically up-regulated in adipose tissue while down-regulated in liver. Furthermore, pro-inflammatory stimuli and high glucose can lead to the induction of SAA3 in adipose tissue in vivo as well as in the 3T3-L1 adipocyte cell line. Adipose tissue may therefore play a major role in the pathogenic sequelae of Type II diabetes, in particular the cardiovascular problems associated with prolonged hyperglycemia.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Merck & Company	Scherer, PE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NIA NIH HHS [R01 AG18381] Funding Source: Medline; NIDDK NIH HHS [1R01-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018381] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Berger J, 2001, J BIOL CHEM, V276, P12629, DOI 10.1074/jbc.M003592200; Boncela J, 2001, J BIOL CHEM, V276, P35305, DOI 10.1074/jbc.M104028200; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; CABANA VG, 1989, J LIPID RES, V30, P39; CHOY LN, 1992, J BIOL CHEM, V267, P12736; Chu ST, 1996, BIOCHEM J, V316, P545, DOI 10.1042/bj3160545; Chu ST, 1998, J PEPT RES, V52, P390; Chu ST, 2000, MOL REPROD DEV, V57, P26, DOI 10.1002/1098-2795(200009)57:1&lt;26::AID-MRD5&gt;3.0.CO;2-4; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FIGUEREDO A, 1993, DIABETES CARE, V16, P445, DOI 10.2337/diacare.16.2.445; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; GANDA OP, 1992, DIABETES CARE, V15, P1245, DOI 10.2337/diacare.15.10.1245; GarayRojas E, 1996, GENE, V170, P173, DOI 10.1016/0378-1119(95)00896-9; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KANNEL WB, 1990, AM HEART J, V120, P672, DOI 10.1016/0002-8703(90)90026-T; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Mattacks CA, 1999, CYTOKINE, V11, P334, DOI 10.1006/cyto.1998.0442; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Orabona C, 2001, EUR CYTOKINE NETW, V12, P154; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pickup JC, 2000, CLIN ENDOCRINOL, V52, P107, DOI 10.1046/j.1365-2265.2000.00921.x; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; RIDKER PM, 1999, BLOOD COAGUL FIBRIN, V10, P9; RODBELL M, 1964, J BIOL CHEM, V239, P375; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Soukas A, 2000, GENE DEV, V14, P963; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; WHITE RT, 1992, J BIOL CHEM, V267, P9210; YOKOYAMA H, 1995, J INTERN MED, V237, P519, DOI 10.1111/j.1365-2796.1995.tb00878.x; YUDKIN JS, 1995, J INTERN MED, V238, P21, DOI 10.1111/j.1365-2796.1995.tb00895.x; Zerega B, 2000, EUR J CELL BIOL, V79, P165, DOI 10.1078/S0171-9335(04)70019-9	39	201	214	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42077	42083		10.1074/jbc.M107101200	http://dx.doi.org/10.1074/jbc.M107101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546817	hybrid			2022-12-25	WOS:000172450400073
J	Reeves, DC; Goren, EN; Akabas, MH; Lummis, SCR				Reeves, DC; Goren, EN; Akabas, MH; Lummis, SCR			Structural and electrostatic properties of the 5-HT3 receptor pore revealed by substituted cysteine accessibility mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; MEMBRANE-SPANNING SEGMENT; CHANNEL-LINING RESIDUES; ALPHA-SUBUNIT; M2 SEGMENT; XENOPUS-OOCYTES; DOMAIN; MUTATIONS; PERMEABILITY; BINDING	5-HT3 receptors are members of the Cys loop family of ligand-gated ion channels. We used the substituted cysteine accessibility method to identify amino acid residues in the channel forming domain, M2 that face the water-accessible surface and to locate their position in the ion conduction pathway. Cysteine was substituted for each residue, one at a time, in the M2 segment (Asp(274)-Asp(298)). 5-Hydroxytryptamine EC50 values for functional mutants did not vary from wild type (1.4 +/- 0.2 mum) by more than 10-fold, and five mutants were nonfunctional. Covalent modification of the mutant receptors with sulfydryl reagents revealed 11 residues to be water-accessible, with a pattern consistent with an a-helix except at Leu(285) and Leu(293). The data suggest that charge selectivity begins at a more cytoplasmic level than Val(291). Modification at some positions (Val(291) Leu(293), Ile(294), Leu(287), and Ser(280)) resulted in channels that were locked open. Reaction rates with accessible cysteines were voltage-dependent at some residues, suggesting that access occurs via the ion channel. Overall the data observed are similar but not identical to that reported for other members of the family and confirms the high degree of structural and functional homology between receptors in the Cys loop receptor family.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	University of Cambridge; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine		s.lummis@mole.bio.cam.ac.uk		Akabas, Myles/0000-0001-8781-7846				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Cruz H, 2001, BIOPHYS J, V80, p336A; Dalziel JE, 2000, MOL PHARMACOL, V57, P875; Dang H, 2000, MOL PHARMACOL, V57, P1114; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Gunthorpe MJ, 1999, J PHYSIOL-LONDON, V519, P713, DOI 10.1111/j.1469-7793.1999.0713n.x; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Pashkov VS, 1999, FEBS LETT, V457, P117, DOI 10.1016/S0014-5793(99)01023-6; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Spier AD, 1999, MOL BRAIN RES, V67, P221; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934	46	70	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42035	42042		10.1074/jbc.M106066200	http://dx.doi.org/10.1074/jbc.M106066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11557761	hybrid			2022-12-25	WOS:000172450400067
J	Seet, LF; Hong, WJ				Seet, LF; Hong, WJ			Endofin, an endosomal FYVE domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; RAB5 EFFECTOR EEA1; ZINC-FINGER DOMAIN; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; MEMBRANE TRAFFICKING; AUTOANTIGEN EEA1; LOCALIZATION; FUSION; HRS; BINDING	KIAA0305 is an uncharacterized member of the FYVE domain protein family. It is closely related to SARA, with about 50% identity in the carboxyl-terminal 800-amino acid region. Indirect immunofluorescence microscopy using polyclonal antibodies raised against KLAA0305 revealed that it is enriched in early endosomes. The Myc-tagged version is also faithfully targeted to the early endosome. We have tentatively called KLAA0305 endofin (for endosome-associated FYVE-domain protein). The association of endofin with endosomes is mediated by its FYVE domain because deletion mutants lacking the central FYVE finger motif are distributed in the cytoplasm. In addition, a single point mutation in the FYVW finger motif at cysteine, residue 753 (C753S) is sufficient to abolish its endosomal association. Its endosomal localization is also sensitive to the phosphatidylinositol 3-kinase inhibitor, wortmannin. Using in vitro liposome binding assays, we demonstrate that Myc-tagged endofin associates preferentially with phosphatidylinositol 3-phosphate, whereas the C753S point mutant was unable to do so. We also show that endofin co-localizes with SARA but that they are not associated in a common complex because they failed to co-immunoprecipitate in co-expressing cells. Endofin also does not associate with Smad2 nor behave like SARA in affecting transforming growth factor-beta signaling. At high levels of expression, both endofin and SARA can cause an endosome aggregation/fusion effect. In COS7 cells, which can support high levels of exogenous protein expression, both proteins can also cause other structural anomalies in the endocytic pathway, as represented by enlarged vesicular structures. These endosomal aggregates/fusions accumulated endocytosed epidermal growth factor. Taken together, this report provides evidence to suggest that endofin and the highly related SARA are endosomal proteins with potential roles in regulating membrane traffic.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Derubeis AR, 2000, GENE, V255, P195, DOI 10.1016/S0378-1119(00)00303-6; Estrada L, 2001, HUM MOL GENET, V10, P485, DOI 10.1093/hmg/10.5.485; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Herrgard S, 2000, FEBS LETT, V486, P107, DOI 10.1016/S0014-5793(00)02201-8; Ito K, 1999, BIOCHEM BIOPH RES CO, V257, P206, DOI 10.1006/bbrc.1999.0430; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; OKADA T, 1994, J BIOL CHEM, V269, P3563; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	39	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42445	42454		10.1074/jbc.M105917200	http://dx.doi.org/10.1074/jbc.M105917200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546807	hybrid			2022-12-25	WOS:000172450400116
J	Ueda, H; Morishita, R; Itoh, H; Narumiya, S; Mikoshiba, K; Kato, K; Asano, T				Ueda, H; Morishita, R; Itoh, H; Narumiya, S; Mikoshiba, K; Kato, K; Asano, T			G alpha(11) induces caspase-mediated proteolytic activation of Rho-associated kinase, ROCK-I, in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; STRESS FIBER FORMATION; BETA-GAMMA-SUBUNITS; G-ALPHA-Q; SERINE/THREONINE KINASE; SIGNALING PATHWAYS; FOCAL ADHESIONS; PHOSPHORYLATION; APOPTOSIS; MYOSIN	Expression of the constitutively active mutant of G(alpha 11) (G alpha (11)QL) induces the formation of vinculin-containing focal adhesion-like structures in HeLa cells. This was found to be inhibited by Y-27632, a specific inhibitor of Rho-associated kinases (ROCK), but not by co-expression with a dominant negative mutant of RhoA, suggesting Rho-independent activation of ROCK by G alpha (11)QL. Investigation of trypan blue exclusion and immunocytochemistry with an antibody against cleaved caspase revealed the cellular phenotype of G alpha (11)QL-expressing cells to be identical to that displayed by cells undergoing apoptosis, and the caspase inhibitor zVAD-fmk blocked all morphological changes induced by G alpha (11)QL. Transfection of G alpha (11)QL induced cleavage of ROCK-I, and this proteolysis was also prevented by zVAD-fmk. ROCK-I C-terminally truncated at its authentic caspase sites also induced the formation of vinculin-containing focal adhesion-like structures. In addition, cleavage of ROCK-I was observed when cells overexpressing ml muscarinic acetylcholine receptors were stimulated with carbachol. These results suggest that Gall induces proteolytic activation of ROCK-I by caspase and thereby regulates the actin cytoskeleton during apoptosis.	Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan	University of Tokyo; Kyoto University; University of Tokyo	Asano, T (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kamiyacho, Kasugai, Aichi 4800392, Japan.		Mikoshiba, Katsuhiko/N-7943-2015					Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Luthin GR, 1997, LIFE SCI, V60, P963, DOI 10.1016/S0024-3205(97)00035-0; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Ueda H, 1999, J BIOL CHEM, V274, P12124, DOI 10.1074/jbc.274.17.12124; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Ueda H, 2000, J BIOL CHEM, V275, P2098, DOI 10.1074/jbc.275.3.2098; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99	37	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42527	42533		10.1074/jbc.M102529200	http://dx.doi.org/10.1074/jbc.M102529200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546796	hybrid			2022-12-25	WOS:000172450400127
J	Le Scolan, E; Wendling, F; Barnache, S; Denis, N; Tulliez, M; Vainchenker, W; Moreau-Gachelin, F				Le Scolan, E; Wendling, F; Barnache, S; Denis, N; Tulliez, M; Vainchenker, W; Moreau-Gachelin, F			Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts	ONCOGENE			English	Article						erythroleukemia; Spi-1/PU.1; p53; p2l(Cip1/Waf1); transgenic mice	WILD-TYPE P53; VIRUS-INDUCED ERYTHROLEUKEMIA; TRANSCRIPTION FACTOR PU.1; LONG TERMINAL REPEAT; DNA-BINDING PROTEIN; FRIEND-VIRUS; ERYTHROPOIETIN RECEPTOR; CELL-DIFFERENTIATION; HEMATOPOIETIC-CELLS; MICE DEFICIENT	Activation of the spi-1/PU.1 proto-oneogene and loss of p53 function are genetic alterations associated with the emergence of Friend malignant erythroleukemic cells. To address the role of p53 during erythroleukemogenesis, spi-1 transgenic mice (spi-1-Tg) which develop erythroleukemia were bred with p53-deficient mice. Three classes of spi-1 transgenic mice differing in their p53 functional status (p53(+/+), p53(+/-) and p53(-/-)) were generated. These mice developed a unique pattern of erythroleukemia. In wild-type p53 spi-1-Tg mice, none of the primary erythroleukemic spleen cells displayed autonomous growth in vitro and in vivo. In contrast, in p53(+/-) spi-1-Tg mice, erythroleukemic cells gave rise to growth factor-independent cell lines and generated tumors in vivo. Malignancy was associated with loss of the wild-type p53 allele. The p53(-/-) spi-1-Tg mice developed erythroleukemia with a total incidence and a reduced latency compared to the two other genotypes. Unexpectedly, 50% of p53(-/-) spi-1-Tg erythroleukemic spleens generated cell lines that were strictly dependent upon erythropoietin (Epo) for proliferation, whereas the remainder proliferated independently of cytokines. Moreover, only 70% of these spleen cells were tumorigenic. These findings indicate that p53 germ-line deletion did not confer malignancy to spi-1-transgenic proerythroblasts. Moreover Epo independence and tumorigenicity appear as separable phenotypic characteristics revealing that the spi-1-Tg proerythroblasts progress towards malignancy through multiple oncogenic events.	Inst Curie, INSERM, U528, F-75005 Paris, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Cochin, Lab Anat, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75005 Paris, France.	framoreau@curie.fr		Vainchenker, William/0000-0003-4705-202X				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLYTH K, 1995, ONCOGENE, V10, P1717; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; DAVID YB, 1988, ONCOGENE, V3, P179; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELSON A, 1995, ONCOGENE, V11, P181; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MIYASHITA T, 1995, CELL, V80, P293; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1983, BIOCHIMIE, V65, P259, DOI 10.1016/S0300-9084(83)80277-6; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PURDIE CA, 1994, ONCOGENE, V9, P603; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Tang PP, 2000, LEUKEMIA, V14, P1292, DOI 10.1038/sj.leu.2401823; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	57	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5484	5492		10.1038/sj.onc.1204708	http://dx.doi.org/10.1038/sj.onc.1204708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571646				2022-12-25	WOS:000170781100009
J	Sokolova, A; Malfois, M; Caldentey, J; Svergun, DI; Koch, MHJ; Bamford, DH; Tuma, R				Sokolova, A; Malfois, M; Caldentey, J; Svergun, DI; Koch, MHJ; Bamford, DH; Tuma, R			Solution structure of bacteriophage PRD1 vertex complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING PROTEIN; ADENOVIRUS FIBER; BIOLOGICAL MACROMOLECULES; SOLUTION SCATTERING; HYDRODYNAMIC PROPERTIES; COAT PROTEIN; LINEAR DNA; RAY; MEMBRANE; PROGRAM	Bacteriophage PRD1 is a prototype of viruses with an internal membrane. The icosahedral capsid and major coat protein share structural similarity with the corresponding structures of adenovirus. The present study further explores similarities between these viruses, considering the 5-fold vertex assemblies. The vertex structure of bacteriophage PRD1 consists of proteins P2, P5, and P31. The vertex complex mediates host cell binding and controls double-stranded DNA delivery. Quaternary structures and interactions of purified spike proteins were studied by synchrotron radiation x-ray solution scattering. Low resolution models of the vertex proteins P5, P2, and P31 were reconstructed ab initio from the scattering data. Protein P5 is a long trimer that resembles the adenovirus spike protein pIV. The receptor-binding protein P2 is a 15.5-nm long, thin monomer and does not have an adenovirus counterpart. P31 forms a pentameric base with a maximum diameter of 8.5 nm, which is thinner than the adenovirus penton pIII P5 further polymerize into a nonameric form ((p5(3))(3)). In the presence of P31, P5 associates into a P5(6):P31 complex. The constructed models of these assemblies provided support for a model of vertex assembly onto the virion. Although similar in overall architecture, clear differences between PRD1 and adenovirus spike assemblies have been revealed.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, Viikki Bioctr, FIN-00014 Helsinki, Finland; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany	University of Helsinki; University of Helsinki; Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Tuma, R (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56 Viikinkaari 5, FIN-00014 Helsinki, Finland.	roman.tuma@helsinki.fi	Tuma, Roman/AAL-4436-2020; Malfois, Marc/L-2974-2014	Tuma, Roman/0000-0003-0047-0013; Malfois, Marc/0000-0001-5231-1896; Svergun, Dmitri/0000-0003-0830-5696; Sokolova, Anna/0000-0002-2772-7395				BAMFORD D, 1983, J VIROL, V47, P311, DOI 10.1128/JVI.47.2.311-316.1983; BAMFORD DH, 1990, NATURE, V344, P497, DOI 10.1038/344497b0; BAMFORD DH, 1995, ADV VIRUS RES, V45, P281, DOI 10.1016/S0065-3527(08)60064-0; BAMFORD DH, 1984, J VIROL, V50, P309, DOI 10.1128/JVI.50.2.309-315.1984; Bamford JKH, 2000, J VIROL, V74, P7781, DOI 10.1128/JVI.74.17.7781-7786.2000; BAMFORD JKH, 1991, VIROLOGY, V183, P658, DOI 10.1016/0042-6822(91)90995-N; BAMFORD JKH, 1990, VIROLOGY, V177, P445, DOI 10.1016/0042-6822(90)90508-O; Belnap DM, 2000, TRENDS MICROBIOL, V8, P91, DOI 10.1016/S0966-842X(00)01704-2; Benson SD, 1999, CELL, V98, P825, DOI 10.1016/S0092-8674(00)81516-0; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Butcher SJ, 1995, EMBO J, V14, P6078, DOI 10.1002/j.1460-2075.1995.tb00298.x; Caldentey J, 2000, BIOCHEMISTRY-US, V39, P10566, DOI 10.1021/bi000711+; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P68; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Grahn AM, 1999, J BACTERIOL, V181, P6689, DOI 10.1128/JB.181.21.6689-6696.1999; Hendrix RW, 1999, CURR BIOL, V9, pR914, DOI 10.1016/S0960-9822(00)80103-7; HONG JS, 1991, VIROLOGY, V185, P758; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LYRA C, 1991, MOL GEN GENET, V228, P65, DOI 10.1007/BF00282449; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; OLSEN RH, 1974, J VIROL, V14, P689, DOI 10.1128/JVI.14.3.689-699.1974; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; Rydman PS, 1999, J MOL BIOL, V291, P575, DOI 10.1006/jmbi.1999.2978; San Martin C, 2001, STRUCTURE, V9, P917, DOI 10.1016/S0969-2126(01)00642-6; SAVILAHTI H, 1986, GENE, V49, P199, DOI 10.1016/0378-1119(86)90280-5; Schoehn G, 1996, EMBO J, V15, P6841, DOI 10.1002/j.1460-2075.1996.tb01075.x; Smith MCM, 1998, SCIENCE, V279, P1834; STEWART PL, 1993, J MOL BIOL, V230, P349, DOI 10.1006/jmbi.1993.1148; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; Xu L, 2000, J STRUCT BIOL, V131, P159, DOI 10.1006/jsbi.2000.4275	46	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46187	46195		10.1074/jbc.M106848200	http://dx.doi.org/10.1074/jbc.M106848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577098	hybrid			2022-12-25	WOS:000172573100095
J	Inoue, T; Geyer, RK; Howard, D; Yu, ZK; Maki, CG				Inoue, T; Geyer, RK; Howard, D; Yu, ZK; Maki, CG			MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; RING-FINGER DOMAIN; DNA-DAMAGE; PROTEIN; PHOSPHORYLATION; PATHWAY; ASSOCIATION; INHIBITION; TERMINUS	MDM2 can bind the N terminus of p53 and promote its ubiquitination and export from the nucleus to the cytoplasm, where p53 can then be degraded by cytoplasmic proteasomes. Several studies have reported that an intact MDM2 binding domain is necessary for p53 to be targeted for ubiquitination, nuclear export, and degradation by MDM2. In the current study, we examined whether the MDM2 binding domain of p53 could be provided in trans through oligomerization between two p53 molecules. p53 proteins mutated in their MDM2 binding domains were unable to bind MDM2 directly and were resistant to MDM2-mediated ubiquitination, nuclear export, and degradation when expressed with MDM2 alone. However, these same p53 mutants formed a complex with MDM2 and were efficiently ubiquitinated, exported from the nucleus, and degraded when co-expressed with MDM2 and wild-type p53. Moreover, this effect required MDM2 binding by wild-type p53 as well as oligomerization between wild-type p53 and the MDM2 binding-deficient p53 mutants. Taken together, these results support a model whereby MDM2 binding-deficient forms of p53 can bind MDM2 indirectly through oligomerization with wild-type p53 and are subsequently targeted for ubiquitination, nuclear export, and degradation. These findings may have important implications regarding the DNA damage response of p53.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,4th Floor, Boston, MA 02115 USA.				NCI NIH HHS [1R01 CA80918-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Prives C, 1999, J PATHOL, V187, P112; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	28	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45255	45260		10.1074/jbc.M107477200	http://dx.doi.org/10.1074/jbc.M107477200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572869	hybrid			2022-12-25	WOS:000172406700119
J	Rashevsky-Finkel, A; Silkov, A; Dikstein, R				Rashevsky-Finkel, A; Silkov, A; Dikstein, R			A composite nuclear export signal in the TBP-associated factor TAF(II)105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION IN-VIVO; NF-KAPPA-B; CELL-CYCLE PROGRESSION; HISTONE-LIKE TAFS; ACTIVATION; COMPLEX; YEAST; PROMOTER; BINDING; SAGA	TAF(II)105 is a sub-stoichiometric subunit of TFIID important for activation of anti-apoptotic genes and B cell specific genes by the transcription factors NF-kappaB and OCA-B. This subunit is highly enriched in B and T lymphocytes, and its expression is regulated at a posttranscriptional level. In the present study we investigated the subcellular localization of TAF(II)105. In normal B cells, a significant portion of native TAF(II)105 protein is found in the cytoplasm. Treatment of these cells with B cell-specific stimuli decreased the level of cytoplasmic TAF(II)105. In adherent cultured cells, TAFII105 is predominantly nuclear; however, a small fraction of the cells showed either cytoplasmic or homogenous distribution of TAF(II)105. Analysis of different TAF(II)105 mutants and green fluorescence protein fusion proteins identified a region composed of two adjacent sequences displaying nuclear export activity, suggesting that nuclear export of TAF(II)105 is mediated by a composite nuclear export signal. TAF(II)105 nuclear export signal is leptomycin B-resistant indicating that it belongs to a CRM1-independent nuclear export pathway. These results reveal a novel mode of regulation of a specialized component of the general transcription apparatus that may affect the transcription of its target genes.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Allen TD, 2000, J CELL SCI, V113, P1651; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; FUKUDA M, 1997, NATURE, V390, P303; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193; Hay RT, 1999, PHILOS T R SOC B, V354, P1601, DOI 10.1098/rstb.1999.0504; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; Matza D, 2001, J BIOL CHEM, V276, P27203, DOI 10.1074/jbc.M104684200; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wolstein O, 2000, J BIOL CHEM, V275, P16459, DOI 10.1074/jbc.275.22.16459; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180	39	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44963	44969		10.1074/jbc.M106112200	http://dx.doi.org/10.1074/jbc.M106112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567023	hybrid			2022-12-25	WOS:000172406700084
J	Teckman, JH; Burrows, J; Hidvegi, T; Schmidt, B; Hale, PD; Perlmutter, DH				Teckman, JH; Burrows, J; Hidvegi, T; Schmidt, B; Hale, PD; Perlmutter, DH			The proteasome participates in degradation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; INTRACELLULAR DEGRADATION; MEMBRANE-PROTEIN; LIVER-DISEASE; DEFICIENCY; ER; SECRETION; DISTINCT; REQUIRES; PATHWAY	Because retention of mutant alpha (1)-antitrypsin (alpha (1)-AT) Z in the endoplasmic reticulum (ER) is associated with liver disease in alpha (1)-AT-deficient individuals, the mechanism by which this aggregated glycoprotein is degraded has received considerable attention. In previous studies using stable transfected human fibroblast cell lines and a cell-free microsomal translocation system, we found evidence for involvement of the proteasome in degradation of alpha (1)-ATZ (Qu, D., Teckman, J. H., Omura, S., and Perlmutter, D. H. (1996) J. Biol. Chem. 271,22791-22795). In more recent studies, Cabral et al. (Cabral, C. M., Choudhury, P., Liu, Y., and Sifers, R. N. (2000) J. Biol. Chem. 275, 25015-25022) found that degradation of alpha (1)-ATZ in a stable transfected marine hepatoma cell line was inhibited by tyrosine phosphatase inhibitors, but not by the proteasomal inhibitor lactacystin and concluded that the proteasome was only involved in ER degradation of alpha (1)-ATZ in nonhepatocytic cell types or in cell types with levels of alpha (1)-AT expression that are substantial lower than that which occurs in hepatocytes. To examine this important issue in further detail, in this study we established rat and murine hepatoma cell lines with constitutive and inducible expression of alpha (1)-ATZ. In each of these cell lines degradation of alpha (1)-ATZ was inhibited by lactacystin, MG132, epoxomicin, and clasto-lactacystin beta -lactone. Using the inducible expression system to regulate the relative level of alpha (1)-ATZ expression, we found that lactacystin had a similar inhibitory effect on degradation of alpha (1)-ATZ at high and low levels of al-AT expression. Although there is substantial evidence that other mechanisms contribute to ER degradation of alpha (1)-ATZ, the data reported here indicate that the proteasome plays an important role in many cell types including hepatocytes.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Physiol, Pittsburgh, PA 15213 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL)	Perlmutter, DH (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Hidvegi, Tunda/A-8041-2008	Schmidt, Bela Z/0000-0003-1085-9372; Teckman, Jeffrey/0000-0002-4870-2621				Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; COX DW, 1995, METABOLIC MOL BASES, P4125; Dul JL, 2001, J CELL BIOL, V152, P705, DOI 10.1083/jcb.152.4.705; DYCAICO JM, 1988, SCIENCE, V242, P1404; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; GELLER SA, 1994, HEPATOLOGY, V19, P389; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Novoradovskaya N, 1998, J CLIN INVEST, V101, P2693, DOI 10.1172/JCI549; PERLMUTTER DH, 1999, SCHIFFS DIS LIVER, P1131; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rollini P, 1999, P NATL ACAD SCI USA, V96, P10308, DOI 10.1073/pnas.96.18.10308; SVEGER T, 1995, HEPATOLOGY, V22, P514, DOI 10.1002/hep.1840220221; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V278, pG39, DOI 10.1152/ajpgi.2000.278.1.G39; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014	23	104	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44865	44872		10.1074/jbc.M103703200	http://dx.doi.org/10.1074/jbc.M103703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577074	hybrid			2022-12-25	WOS:000172406700072
J	Arocas, V; Bock, SC; Raja, S; Olson, ST; Bjork, I				Arocas, V; Bock, SC; Raja, S; Olson, ST; Bjork, I			Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; BETA-SHEET-A; CONFORMATIONAL CHANGE; RECOMBINANT ANTITHROMBIN; PROTEINASE REACTIONS; FACTOR-XA; ACTIVATION; SITE; GLYCOSYLATION; CARBOHYDRATE	Lys(114) of the plasma coagulation proteinase inhibitor, antithrombin, has been implicated in binding of the glycosaminoglycan activator, heparin, by previous mutagenesis studies and by the crystal structure of antithrombin in complex with the active pentasaccharide unit of heparin. In the present work, substitution of Lys(114) by Ala or Met was shown to decrease the affinity of antithrombin for heparin and the pentasaccharide by similar to 10(5)-fold at I 0.15, corresponding to a reduction in binding energy of similar to 50%,. The decrease in affinity was due to the loss of two to three ionic interactions, consistent with Lys(114) and at least one other basic residue of the inhibitor binding cooperatively to heparin, as well as to substantial nonionic interactions. The mutation minimally affected the initial, weak binding of the two-step mechanism of pentasaccharide binding to antithrombin but appreciably (> 40-fold) decreased the forward rate constant of the conformational change in the second step and greatly (> 1000-fold) increased the reverse rate constant of this step. Lys(114) is thus of greater importance for the affinity of heparin binding than any of the other antithrombin residues investigated so far, viz. Arg(47), Lys(125), and Arg(129). It contributes more than Arg(47) and Arg(129) to increasing the rate of induction of the activating conformational change, a role presumably exerted by interactions with the nonreducing end trisaccharide unit of the heparin pentasaccharide. However, its major effect, also larger than that of these two residues, is in maintaining antithrombin in the activated state by interactions that most likely involve the reducing end disaccharide unit.	Swedish Univ Agr Sci, Dept Vet Med Chem, Uppsala Biomed Ctr, SE-75123 Uppsala, Sweden; Univ Utah, Hlth Sci Ctr, Pulm Div, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Pulm Div, Dept Bioengn, Salt Lake City, UT 84132 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	Swedish University of Agricultural Sciences; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bjork, I (corresponding author), Swedish Univ Agr Sci, Dept Vet Med Chem, Uppsala Biomed Ctr, Box 575, SE-75123 Uppsala, Sweden.	Ingemar.Bjork@vmk.slu.se	Arocas, Veronique/M-7075-2017	Arocas, Veronique/0000-0002-2872-8058	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039888, R37HL039888, R01HL039888, R01HL030712] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39888, HL30712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; BJORK I, 1992, BIOCHEM J, V286, P793; BJROK I, 1997, CHEM BIOL SERPINS, P17; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P15; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; Kridel SJ, 1997, J BIOL CHEM, V272, P7656, DOI 10.1074/jbc.272.12.7656; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LIU CS, 1987, J BIOL CHEM, V262, P17356; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson ST, 1997, ARCH BIOCHEM BIOPHYS, V341, P212, DOI 10.1006/abbi.1997.9973; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188	40	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43809	43817		10.1074/jbc.M105294200	http://dx.doi.org/10.1074/jbc.M105294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11567021	hybrid			2022-12-25	WOS:000172297700044
J	Bouchier-Hayes, L; Conroy, H; Egan, H; Adrain, C; Creagh, EM; MacFarlane, M; Martin, SJ				Bouchier-Hayes, L; Conroy, H; Egan, H; Adrain, C; Creagh, EM; MacFarlane, M; Martin, SJ			CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NF-kappa B activation pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED-PROXIMITY MODEL; KINASE COMPLEX; CELL-DEATH; IKK-GAMMA; APOPTOSIS; OLIGOMERIZATION; RIP; RECEPTOR; NEMO	Proteins possessing the caspase recruitment domain (CARD) motif have been implicated in pathways leading to activation of caspases or NF-kappaB in the context of apoptosis or inflammation, respectively. Here we report the identification of a novel protein, CARDINAL, that contains a CARD motif and also exhibits a high degree of homology to the C terminus of DEFCAP/NAC, a recently described member of the Apaf-1/Nod-1 family. In contrast with the majority of CARD proteins described to date, CARDINAL failed to promote apoptosis or NF-kappaB activation. Rather, CARDINAL potently suppressed NF-kappaB activation associated with overexpression of TRAIL-R1, TRAIL-R2, RIP, RICK, Bcl10, and TRADD, or through ligand-induced stimulation of the interleukin-1 or tumor necrosis factor receptors. Co-immunoprecipitation experiments revealed that CARDINAL interacts with the regulatory subunit of the I kappaB kinase (IKK) complex, IKK gamma (NEMO), providing a molecular basis for CARDINAL function. Thus, CARDINAL is a novel regulator of NF-kappaB activation in the context of pro-inflammatory signals.	Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	Trinity College Dublin; University of Leicester	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland.		Creagh, Emma/AAX-1064-2021; Bouchier-Hayes, Lisa/T-9491-2019; Adrain, Colin/I-6259-2013	Creagh, Emma/0000-0001-7631-4370; Bouchier-Hayes, Lisa/0000-0003-3886-5977; Adrain, Colin/0000-0001-7597-4393; Conroy, Helen/0000-0002-5857-2760; Martin, Seamus/0000-0002-8539-3143				Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Martin Seamus J., 2001, Trends in Cell Biology, V11, P188, DOI 10.1016/S0962-8924(01)01971-7; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pathan N, 2001, J BIOL CHEM, V276, P32220, DOI 10.1074/jbc.M100433200; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	34	90	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44069	44077		10.1074/jbc.M107373200	http://dx.doi.org/10.1074/jbc.M107373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551959	hybrid			2022-12-25	WOS:000172297700076
J	Le Guiner, C; Plet, A; Galiana, D; Gesnel, MC; Del Gatto-Konczak, F; Breathnach, R				Le Guiner, C; Plet, A; Galiana, D; Gesnel, MC; Del Gatto-Konczak, F; Breathnach, R			Polypyrimidine tract-binding protein represses splicing of a fibroblast growth factor receptor-2 gene alternative exon through exon sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; 3'-SPLICE-SITE SELECTION; INTRON SEQUENCES; IN-VIVO; ENHANCER; COMPLEX; SITES; FGFR2; 5'-SPLICE-SITE; DETERMINANTS	The fibroblast growth factor receptor (FGFR)-2 gene contains two mutually exclusive exons, K-SAM and BEK. We made a cell line designed to become drug-resistant on repression of BEK exon splicing. One drug-resistant derivative of this line carried an insertion within the BEK exon of a sequence containing at least two independent splicing silencers. One silencer was a pyrimidine-rich sequence, which markedly increased binding of polypyrimidine tract-binding protein to the BEK exon. The BEK exon binds to polypyrimidine tract-binding protein even in the silencer's absence. Several exonic pyrimidine runs are required for this binding, and they are also required for overexpression of polypyrimidine tract-binding protein to repress BEK exon splicing. These results show that binding of polypyrimidine tract-binding protein to exon sequences can repress splicing. In epithelial cells, the K-SAM exon is spliced in preference to the BEK exon, whose splicing is repressed. Mutation of the BEK exon pyrimidine runs decreases this repression. If this mutation is combined with the deletion of a sequence in the intron upstream from the BEK exon, a complete switch from K-SAM to BEK exon splicing ensues. Binding of polypyrimidine tract binding protein to the BEK exon thus participates in the K-SAM/BEK alternative splicing choice.	CHR, Inst Biol, INSERM, CHR, F-44093 Nantes 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	Breathnach, R (corresponding author), CHR, Inst Biol, INSERM, CHR, 9 Quai Moncousu, F-44093 Nantes 1, France.		Breathnach, Richard/K-7599-2015; Del Gatto-Konczak, Fabienne/L-1506-2015					Ashiya M, 1997, RNA, V3, P996; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DELGATTO F, 1995, GENOMICS, V27, P558, DOI 10.1006/geno.1995.1095; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Jones RB, 2001, J BIOL CHEM, V276, P4158, DOI 10.1074/jbc.M006151200; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; LIN CH, 1995, RNA, V1, P234; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Oldridge M, 1999, AM J HUM GENET, V64, P446, DOI 10.1086/302245; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Perez I, 1997, RNA, V3, P764; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Southby J, 1999, MOL CELL BIOL, V19, P2699; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; VALCARCEL J, 1997, CURR BIOL, V7, P705; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Zheng ZM, 1998, P NATL ACAD SCI USA, V95, P14088, DOI 10.1073/pnas.95.24.14088	47	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43677	43687		10.1074/jbc.M107381200	http://dx.doi.org/10.1074/jbc.M107381200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557769	hybrid			2022-12-25	WOS:000172297700027
J	Beresford, PJ; Zhang, D; Oh, DY; Fan, ZS; Greer, EL; Russo, ML; Jaju, M; Lieberman, J				Beresford, PJ; Zhang, D; Oh, DY; Fan, ZS; Greer, EL; Russo, ML; Jaju, M; Lieberman, J			Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; CHROMATIN-LIKE STRUCTURE; FACTOR-I; CELL-DEATH; GRANULE-EXOCYTOSIS; MEDIATED APOPTOSIS; ADENOVIRUS GENOME; INHIBITOR; LEUKEMIA; TEMPLATE	The cytotoxic T lymphocyte protease granzyme A (GzmA) initiates a novel caspase-independent cell death pathway characterized by single-stranded DNA nicking. The previously identified GzmA substrate SET is in a multimeric 270-420-kDa endoplasmic reticulum-associated complex that also contains the tumor suppressor protein pp32. GzmA cleaved the nucleosome assembly protein SET after Lys(176) and disrupted its nucleosome assembly activity. The purified SET complex required only GzmA to reconstitute single-stranded DNA nicking in isolated nuclei. DNA nicking occurred independently of caspase activation. The SET complex contains a 25-kDa Mg2+-dependent nuclease that degrades calf thymus DNA and plasmid DNA. Thus, GzmA activates a DNase (GzmA-activated DNase) within the SET complex to produce a novel form of DNA damage during cytotoxic T lymphocyte-mediated death.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Lieberman, J (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 800 Huntington Ave, Boston, MA 02115 USA.	lieberman@cbr.med.harvard.edu	Lieberman, Judy/A-2717-2015	Greer, Eric/0000-0002-7501-7371; ZHANG, DONG/0000-0002-1068-8334	NIAID NIH HHS [AI45587] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI045587, R01AI045587] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; Beresford PJ, 1998, J IMMUNOL, V161, P161; Blink EJ, 1999, IMMUNOL CELL BIOL, V77, P206, DOI 10.1046/j.1440-1711.1999.00817.x; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; MATSUMOTO K, 1995, J BIOL CHEM, V270, P9645, DOI 10.1074/jbc.270.16.9645; Matsumoto K, 1999, FEBS LETT, V463, P285, DOI 10.1016/S0014-5793(99)01632-4; Mills JC, 1998, J CELL SCI, V111, P625; Nagata K, 1998, EXP CELL RES, V240, P274, DOI 10.1006/excr.1997.3930; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; Saito S, 1999, BIOCHEM BIOPH RES CO, V259, P471, DOI 10.1006/bbrc.1999.0790; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SELLINS KS, 1991, J IMMUNOL, V147, P795; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Sun J, 2001, J BIOL CHEM, V276, P15177, DOI 10.1074/jbc.M006645200; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Xia ZN, 1998, BIOCHEM BIOPH RES CO, V243, P384, DOI 10.1006/bbrc.1998.8102; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598; Zhang D, 2001, J BIOL CHEM, V276, P3683, DOI 10.1074/jbc.M005390200	47	132	140	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43285	43293		10.1074/jbc.M108137200	http://dx.doi.org/10.1074/jbc.M108137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555662	hybrid, Green Published			2022-12-25	WOS:000172169300085
J	Sekimata, M; Takahashi, A; Murakami-Sekimata, A; Homma, Y				Sekimata, M; Takahashi, A; Murakami-Sekimata, A; Homma, Y			Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methyl-CpG-binding protein, MBD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; GENE; METHYLTRANSFERASE; INHIBITION; CHROMATIN; FAMILY; YEAST; MECP2; IDENTIFICATION	MBD2, a methyl-CpG-binding protein, is a component of the MeCP1 histone deacetylase (HDAC) complex and plays a critical role in DNA methylation-mediated transcriptional repression. To understand the molecular basis of the methylation-associated repression, we attempted to identify MBD2-interacting proteins by a yeast two-hybrid system. Using MBD2 as bait, we isolated a novel zinc finger protein, referred to as MIZF. A direct interaction between MBD2 and MIZF was confirmed by in vitro binding assays and immunoprecipitation experiments. Four of seven zinc fingers present in the C-terminal region of MIZF are required for binding with MBD2. The MIZF mRNA is expressed in all human tissues and cell lines examined. The subcellular localization of MIZF is distinct from that of MBD2, although both proteins co-localize in some areas of the nuclei; MIZF localizes diffusely in the nucleoplasmic region, whereas MBD2 preferentially localizes in major satellites. A reporter assay demonstrated that MIZF significantly abrogates transcriptional activities. This repression is attenuated by an HDAC inhibitor, trichostatin A, and is completely dependent on the interaction with MBD2. These results suggest that MIZF is abundantly present in cells and functions as a negative regulator of transcription by binding to MBD2 and recruiting HDAC-containing complexes.	Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Biomol Sci, Fukushima 9601295, Japan; Miyagi Univ, Sch Nursing, Taiwa, Miyagi 9813298, Japan	Fukushima Medical University; Miyagi University	Homma, Y (corresponding author), Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Biomol Sci, Fukushima 9601295, Japan.			Murakami-Sekimata, Akiko/0000-0002-9417-2377				Ballabio A, 1992, CURR OPIN GENET DEV, V2, P439, DOI 10.1016/S0959-437X(05)80155-8; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Bender CM, 1998, CANCER RES, V58, P95; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; James P, 1996, GENETICS, V144, P1425; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; NG HH, CELL BIOL, V20, P1394; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	36	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42632	42638		10.1074/jbc.M107048200	http://dx.doi.org/10.1074/jbc.M107048200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553631	hybrid			2022-12-25	WOS:000172169300002
J	Ono, Y; De-Meyts, ER; Guellaen, G; Bulle, F				Ono, Y; De-Meyts, ER; Guellaen, G; Bulle, F			Sporadic testicular germ cell cancers do not exhibit specific alteration in CAG/CTG repeats containing genes expressed in human testis	ONCOGENE			English	Article						human testicular germ cell tumours; CAG/CTG repeat expansion; genetic anticipation	ANDROGEN RECEPTOR GENE; TRINUCLEOTIDE REPEAT; TRIPLET REPEAT; HUNTINGTON-DISEASE; PROSTATE-CANCER; HUMAN BRAIN; CAG REPEAT; EXPANSION; CARCINOMA; TUMORS	CAG/CTG repeat expansions in genomic DNA of testicular tumour cell lines, and germline DNA from members of families predisposed to this malignancy, have been previously described. In order to identify genes possibly concerned by this alteration, we attempted to clone all possible human testis cDNA containing at least five CAG/CTG repeats. Thirty-four different transcripts were identified. By using PCR and non denaturing gel electrophoresis, we determined the size of their repeats, as well as their polymorphisms in a collection of human testicular germ cell tumours and the normal surrounding tissues. For all tested genes, we detected the presence of several species of the same mRNA for each person. Nine genes exhibited specific patterns of expression among different groups of individuals, indicative of polymorphism. None of these polymorphisms was related to human testicular tumours.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Rigshospitalet; University of Copenhagen	Bulle, F (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Bulle-Thomas, Frederique/L-2528-2017					BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Bulle F, 1997, GENOME RES, V7, P705, DOI 10.1101/gr.7.7.705; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Debrauwere H, 1997, BIOCHIMIE, V79, P577, DOI 10.1016/S0300-9084(97)82006-8; Dieckmann KP, 1999, INT J CANCER, V83, P815, DOI 10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.3.CO;2-Q; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Han S, 2000, CANCER, V88, P2319, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2319::AID-CNCR16>3.0.CO;2-O; Holmes SE, 1999, NAT GENET, V23, P391, DOI 10.1038/70493; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; King BL, 1997, CANCER RES, V57, P209; Kinoshita M, 1997, MUSCLE NERVE, V20, P622, DOI 10.1002/(SICI)1097-4598(199705)20:5<622::AID-MUS16>3.0.CO;2-Y; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; Nataraj AJ, 1999, ELECTROPHORESIS, V20, P1177, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1177::AID-ELPS1177>3.0.CO;2-2; Panagopoulos I, 1999, HUM MUTAT, V13, P232, DOI 10.1002/(SICI)1098-1004(1999)13:3<232::AID-HUMU7>3.0.CO;2-N; Pawlak A, 1998, MAMM GENOME, V9, P745, DOI 10.1007/s003359900856; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Rajpert-De Meyts E, 1998, APMIS, V106, P198; Sasaki M, 2000, MOL CARCINOGEN, V27, P237, DOI 10.1002/(SICI)1098-2744(200003)27:3<237::AID-MC11>3.3.CO;2-S; Schmutte C, 1999, ANTICANCER RES, V19, P4665; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Stanford JL, 1997, CANCER RES, V57, P1194; Teh BT, 1999, J MED GENET, V36, P348; TELENIUS H, 1995, HUM MOL GENET, V4, P189, DOI 10.1093/hmg/4.2.189; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	30	3	3	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5548	5553		10.1038/sj.onc.1204714	http://dx.doi.org/10.1038/sj.onc.1204714			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571654	Bronze			2022-12-25	WOS:000170781100017
J	Santiago, J; Guzman, GR; Rojas, LV; Marti, R; Asmar-Rovira, GA; Santana, LF; McNamee, M; Lasalde-Dominicci, JA				Santiago, J; Guzman, GR; Rojas, LV; Marti, R; Asmar-Rovira, GA; Santana, LF; McNamee, M; Lasalde-Dominicci, JA			Probing the effects of membrane cholesterol in the Torpedo californica acetylcholine receptor and the novel lipid-exposed mutation alpha C418W in Xenopus oocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M4 TRANSMEMBRANE DOMAIN; ION-CHANNEL FUNCTION; SECONDARY STRUCTURE; TRYPTOPHAN SUBSTITUTIONS; BINDING-SITES; CYCLODEXTRINS; SPECTROSCOPY; INTERFACE; SUBUNIT; OXIDASE	The effects of cholesterol on the ion-channel function of the Torpedo acetylcholine receptor (nAChR) and the novel lipid-exposed gain in function alpha C418W mutation have been investigated in Xenopus laevis oocytes. We found conditions to increase the cholesterol/phospholipid (C/P) molar ratio on the plasma membrane of Xenopus oocytes from 0.5 to 0.87, without significant physical damage or change in morphology to the oocytes. In addition, we developed conditions to deplete endogenous cholesterol from oocytes using a methyl-beta -cyclodextrin incubation procedure without causing membrane instability of the cells. Methyl-beta -cyclodextrin was also used to examine the reversibility of the inhibitory effect of cholesterol on AChR function. Depletion of 43% of endogenous cholesterol from oocytes (C/P = 0.3) did not show any significant change in macroscopic response of the wild type, whereas in the alpha C418W mutant the same cholesterol depletion caused a dramatic gain-in-function response of this lipid-exposed mutation in addition to the increased response caused by the mutation itself. Increasing the C/P ratio to 0.87 caused an inhibition of the macroscopic response of the Torpedo wild type of about 52%, whereas the alpha C418W mutation showed an 81% inhibition compared with the responses of control oocytes. The wild type receptor did not recover from this inhibition when the excess cholesterol was depleted to near normal C/P ratios; however, the alpha C418W mutant displayed 63% of the original current, which indicates that the inhibition of this lipid-exposed mutant was significantly reversed. The ability of the alpha C418W mutation to recover from the inhibition caused by cholesterol enrichment suggests that the interaction of cholesterol with this lipid-exposed mutation is significantly different from that of the wild type. The present data demonstrate that a single lipid-exposed position in the AChR could alter the modulatory effect of cholesterol on AChR function.	Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA; Univ Puerto Rico, Inst Neurobiol, San Juan, PR 00901 USA; Univ Cent Caribe, Dept Physiol, Sch Med, Bayamon, PR 00960 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of California System; University of California Davis	Lasalde-Dominicci, JA (corresponding author), Univ Puerto Rico, Dept Biol, POB 23360, San Juan, PR 00931 USA.	joseal@coqui.net	Santana, Luis/AAF-9298-2019	Santana, Luis/0000-0002-4297-8029	NCRR NIH HHS [G12RR03035, RR 13705-01] Funding Source: Medline; NIGMS NIH HHS [GM56371-04, GM08102-27] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003035, S10RR013705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056371] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antollini SS, 1998, BIOCHEMISTRY-US, V37, P16653, DOI 10.1021/bi9808215; Arias HR, 1998, BBA-REV BIOMEMBRANES, V1376, P173, DOI 10.1016/S0304-4157(98)00004-5; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Barrantes FJ, 1997, SER CENT ES, P199; BARRY MA, 1993, MICROSC RES TECHNIQ, V26, P231, DOI 10.1002/jemt.1070260306; BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Christian AE, 1997, J LIPID RES, V38, P2264; Corbin J, 1998, BBA-BIOMEMBRANES, V1414, P65, DOI 10.1016/S0005-2736(98)00153-9; DIPAOLA M, 1989, J BIOL CHEM, V264, P15457; FERNANDEZBALLESTER G, 1994, BIOCHEM SOC T, V22, P776, DOI 10.1042/bst0220776; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; JOHNSON SM, 1979, ANAL BIOCHEM, V95, P344, DOI 10.1016/0003-2697(79)90737-1; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Lasalde JA, 1996, BIOCHEMISTRY-US, V35, P14139, DOI 10.1021/bi961583l; LASALDE JA, 1992, JERUS SYM Q, V25, P199; LASALDE JA, 1995, BIOCHIM BIOPHYS ACTA, V1235, P427; LECHLEITER J, 1986, BIOCHIM BIOPHYS ACTA, V856, P640, DOI 10.1016/0005-2736(86)90159-8; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NARAYANASWAMI V, 1993, BIOCHEMISTRY-US, V32, P12420, DOI 10.1021/bi00097a021; OCHOA ELM, 1983, BIOCHIM BIOPHYS ACTA, V727, P151, DOI 10.1016/0005-2736(83)90379-6; OHLSSON RI, 1981, EUR J BIOCHEM, V115, P367, DOI 10.1111/j.1432-1033.1981.tb05247.x; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; OrtizMiranda SI, 1997, J MEMBRANE BIOL, V158, P17, DOI 10.1007/s002329900240; PRADIER L, 1992, STRUCTURE BIOL MEMBR, P1047; Raines DE, 1998, BIOCHEMISTRY-US, V37, P956, DOI 10.1021/bi971689w; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; RICHMOND W, 1973, CLIN CHEM, V19, P1350; SUNSHINE C, 1994, BIOCHIM BIOPHYS ACTA, V1108, P240; Tamamizu S, 2000, BIOCHEMISTRY-US, V39, P4666, DOI 10.1021/bi992835w; Tamamizu S, 1999, J MEMBRANE BIOL, V170, P157, DOI 10.1007/s002329900545; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Zanello LP, 1996, BIOPHYS J, V70, P2155, DOI 10.1016/S0006-3495(96)79781-3	41	61	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46523	46532		10.1074/jbc.M104563200	http://dx.doi.org/10.1074/jbc.M104563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567020	hybrid			2022-12-25	WOS:000172573100138
J	Dessen, A; Mouz, N; Gordon, E; Hopkins, J; Dideberg, O				Dessen, A; Mouz, N; Gordon, E; Hopkins, J; Dideberg, O			Crystal structure of PBP2x from a highly penicillin-resistant Streptococcus pneumoniae clinical isolate - A mosaic framework containing 83 mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN 2X; BETA-LACTAMASES; BACTERIAL-RESISTANCE; IDENTIFICATION; TRANSPEPTIDASE; ANTIBIOTICS; VARIANTS	Penicillin-binding proteins (PBPs) are the main targets for beta -lactam antibiotics, such as penicillins and cephalosporins, in a wide range of bacterial species. In some Gram-positive strains, the surge of resistance to treatment with beta -lactams is primarily the result of the proliferation of mosaic PBP-encoding genes, which encode novel proteins by recombination. PBP2x is a primary resistance determinant in Streptococcus pneumoniae, and its modification is an essential step in the development of high level beta -lactam resistance. To understand such a resistance mechanism at an atomic level, we have solved the x-ray crystal structure of PBP2x from a highly penicillin-resistant clinical isolate of S. pneumoniae, Sp328, which harbors 83 mutations in the soluble region. In the proximity of the Sp328 PBP2x* active site, the Thr(338)--> Ala mutation weakens the local hydrogen bonding network, thus abrogating the stabilization of a crucial buried water molecule. In addition, the Ser(389)--> Leu and Asn(514)--> His mutations produce a destabilizing effect that generates an "open" active site. It has been suggested that peptidoglycan substrates for beta -lactam-resistant PBPs contain a large amount of abnormal, branched peptides, whereas sensitive strains tend to catalyze cross-linking of linear forms. Thus, in vivo, an "open" active site could facilitate the recognition of distinct, branched physiological substrates.	Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, CNRS, CEA, F-38027 Grenoble, France; Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, CNRS, CEA, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Dessen, A (corresponding author), Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, CNRS, CEA, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	dessen@ibs.fr		Dessen, Andrea/0000-0001-6487-4020; Gordon, Elspeth Jane/0000-0002-9876-8020				Asahi Y, 1999, ANTIMICROB AGENTS CH, V43, P1252, DOI 10.1128/AAC.43.5.1252; Bramhill D, 1997, ANNU REV CELL DEV BI, V13, P395, DOI 10.1146/annurev.cellbio.13.1.395; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dessen A., 2001, Current Drug Targets - Infectious Disorders, V1, P63, DOI 10.2174/1568005013343272; Di Guilmi AM, 1998, J BACTERIOL, V180, P5652, DOI 10.1128/JB.180.21.5652-5659.1998; Di Guilmi AM, 1999, J BACTERIOL, V181, P2773, DOI 10.1128/JB.181.9.2773-2781.1999; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gordon E, 2000, J MOL BIOL, V299, P477, DOI 10.1006/jmbi.2000.3740; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hakenbeck R, 1998, J BACTERIOL, V180, P1831, DOI 10.1128/JB.180.7.1831-1840.1998; Hakenbeck R, 1999, MICROB DRUG RESIST, V5, P91, DOI 10.1089/mdr.1999.5.91; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kernodle DS, 2000, GRAM-POSITIVE PATHOGENS, P609; LAIBLE G, 1987, MOL MICROBIOL, V1, P355; LAIBLE G, 1991, J BACTERIOL, V173, P6986, DOI 10.1128/jb.173.21.6986-6990.1991; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; Maveyraud L, 2000, STRUCTURE, V8, P1289, DOI 10.1016/S0969-2126(00)00534-7; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Reichmann P, 1996, MICROB DRUG RESIST, V2, P177, DOI 10.1089/mdr.1996.2.177; Reichmann P, 1997, J INFECT DIS, V176, P1001, DOI 10.1086/516532; Severin A, 1996, J BACTERIOL, V178, P1788, DOI 10.1128/jb.178.7.1788-1792.1996; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	33	99	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45106	45112		10.1074/jbc.M107608200	http://dx.doi.org/10.1074/jbc.M107608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11553637	hybrid			2022-12-25	WOS:000172406700101
J	Kurland, JF; Kodym, R; Story, MD; Spurgers, KB; McDonnell, TJ; Meyn, RE				Kurland, JF; Kodym, R; Story, MD; Spurgers, KB; McDonnell, TJ; Meyn, RE			NF-kappa B1 (p50) homodimers contribute to transcription of the bcl-2 oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CANDIDATE ONCOPROTEIN BCL-3; RADIATION-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CONSTITUTIVE ACTIVATION; PERSISTENT ACTIVATION; EXPRESSION; CELLS; INDUCTION; B/REL	The bcl-2 proto-oncogene is frequently expressed in human cancer. Although bcl-2 was first cloned as the t(14;18) translocation breakpoint from human follicular B-cell lymphoma, it has become apparent that many cell types express bcl-2 because of transcriptional regulation. As such, several transcription factors have been demonstrated to activate expression of bcl-2, including NF-kappaB. We investigated the role of NF-K beta1 (p50) homodimers in the expression of Bcl-2 in two murine B-cell lymphoma cell lines: LY-as, an apoptosis-proficient line with low Bcl-2 protein expression and no nuclear NF-kappaB activity, and LY-ar, a nonapoptotic line with constitutive p50 homodimer activity and 30 times more Bcl-2 protein expression than LY-as. We found that nuclear p50 homodimer activity correlated with Bcl-2 expression in these cell types and identified several sites within the bcl-2 5'-flanking region that p50 was capable of binding. In vitro transcription revealed that recombinant p50 enhanced the production of run-off transcripts from the bcl-2 P1 promoter. Additional in vitro transcription experiments suggested the sites by which p50 afforded this effect. We conclude that the p50 homodimer is capable of transcriptional activation of the bcl-2 gene and suggest that its nuclear activity contributes to the expression of bcl-2 in LY-ar cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	rmeyn@mdanderson.org	Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NATIONAL CANCER INSTITUTE [R01CA069003] Funding Source: NIH RePORTER; NCI NIH HHS [CA69003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Claudio E, 1996, EXP CELL RES, V224, P63, DOI 10.1006/excr.1996.0111; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYER RB, 1995, BIOTECHNIQUES, V19, P192; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; Kistler B, 1998, J IMMUNOL, V160, P2308; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mori N, 1999, BLOOD, V93, P2360; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Papakonstantinou G, 2001, BRIT J HAEMATOL, V113, P383, DOI 10.1046/j.1365-2141.2001.02727.x; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; Strasser A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	57	106	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45380	45386		10.1074/jbc.M108294200	http://dx.doi.org/10.1074/jbc.M108294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567031	hybrid			2022-12-25	WOS:000172406700134
J	Russwurm, M; Wittau, N; Koesling, D				Russwurm, M; Wittau, N; Koesling, D			Guanylyl cyclase/PSD-95 interaction - Targeting of the nitric oxide-sensitive alpha(2)beta(1) guanylyl cyclase to synaptic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; ACTIVITY REQUIRES; ENZYME SUBUNITS; PSD-95 FAMILY; PDZ DOMAINS; SYNTHASE; EXPRESSION; ACTIVATION; CLONING	The signaling molecule nitric oxide (NO) exerts most of its effects by the stimulation of the NO-sensitive guanylyl cyclase. Two isoforms of the NO receptor molecule exist: the ubiquitously occurring alpha (1)beta (1) and the alpha (2)beta (1) with a more limited distribution. As the isoforms are functionally indistinguishable, the physiological relevance of these isoforms remained unclear. The neuronal NO synthase has been reported to be associated with PSD-95. Here, we demonstrate the interaction of the so far unnoticed alpha (2)beta (1) isoform with PSD-95 in rat brain as shown by coprecipitation. The interaction is mediated by the alpha (2) C-terminal peptide and the third PDZ domain of PSD-95. As a consequence of the PSD-95 interaction, the so far considered "soluble" alpha (2)beta (1) isoform is recruited to the membrane fraction of synaptosomes, whereas the alpha (1)beta (1) isoform is found in the cytosol. Our results establish the alpha (1)beta (1) as the cytosolic and the alpha (2)beta (1) as the membrane-associated NO-sensitive guanylyl cyclase and suggest the alpha (2)beta (1) isoform as the sensor for the NO formed by the PSD-95-associated neuronal NO synthase.	Ruhr Univ Bochum, Med Fak MA N1, D-44780 Bochum, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Ruhr University Bochum; Free University of Berlin	Koesling, D (corresponding author), Ruhr Univ Bochum, Med Fak MA N1, D-44780 Bochum, Germany.							Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Budworth J, 1999, BIOCHEM BIOPH RES CO, V263, P696, DOI 10.1006/bbrc.1999.1444; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gibb BJ, 2001, EUR J NEUROSCI, V13, P539, DOI 10.1046/j.1460-9568.2001.01421.x; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Hoffmuller U, 1999, ANGEW CHEM INT EDIT, V38, P2000, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<2000::AID-ANIE2000>3.0.CO;2-V; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; KIEDROWSKI L, 1992, J NEUROCHEM, V58, P335, DOI 10.1111/j.1471-4159.1992.tb09315.x; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MAYER B, 1992, J NEUROCHEM, V59, P2024; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m	37	164	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44647	44652		10.1074/jbc.M105587200	http://dx.doi.org/10.1074/jbc.M105587200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572861	hybrid			2022-12-25	WOS:000172406700043
J	Toonkool, P; Jensen, SA; Maxwell, AL; Weiss, AS				Toonkool, P; Jensen, SA; Maxwell, AL; Weiss, AS			Hydrophobic domains of human tropoelastin interact in a context-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; CIRCULAR-DICHROISM; FIBER FORMATION; ELASTIN; COACERVATION; SEQUENCE; CHAINS	Tropoelastin is the soluble precursor of elastin, the major component of the extracellular elastic fiber. Tropoelastin undergoes self-association via an inverse temperature transition termed coacervation, which is a crucial step in elastogenesis. Coacervation of tropoelastin takes place through multiple intermolecular interactions of its hydrophobic domains. Previous work has implicated those hydrophobic domains located near the center of the polypeptide as playing a dominant role in coacervation. Short constructs of domains 18, 20, 24, and a mutated form of domain 26 were largely disordered at 20 degreesC but displayed increased order on heating that was consistent with the formation of beta -structures. However, their conformational transitions were not sensitive to physiological temperature in contrast to the observed behavior of the native domain 26. A polypeptide consisting of domains 17-27 of tropoelastin coacervated at temperatures above 60 degreesC, whereas individually expressed hydrophobic regions were not capable of coacervation. We conclude that coacervation depends on the hydrophobicity of the molecule and, by inference, the number of hydrophobic domains. Tropoelastin mutants were constructed to contain a Pro --> Ala mutation in domain 26, separate deletions of domains 18 and 26, and a displacement of domain 26. These constructs displayed unequal capacities for coacervation, even when they contained the same number of hydrophobic regions and comparable levels of secondary structure. Thus, the capability for coacervation is determined by contributions from individual hydrophobic domains for which function should be considered in the context of their positions in the intact tropoelastin molecule.	Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia	University of Sydney	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia.		Weiss, Anthony S/F-8103-2010; Weiss, Anthony S/GYV-0157-2022; Jensen, Sacha A./AAB-4034-2019	Weiss, Anthony S/0000-0002-8106-4836; Jensen, Sacha A./0000-0002-0560-9531; Kongsaeree, Prachumporn/0000-0003-0273-2638				BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BRESSAN GM, 1983, J ULTRA MOL STRUCT R, V82, P335, DOI 10.1016/S0022-5320(83)80021-5; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; COX BA, 1974, J BIOL CHEM, V249, P997; COX BA, 1973, BIOCHIM BIOPHYS ACTA, V317, P209, DOI 10.1016/0005-2795(73)90215-8; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; DEBELLE L, 1995, J MOL STRUCT, V348, P321, DOI 10.1016/0022-2860(95)08653-D; GOWDA DC, 1995, INT J PEPT PROT RES, V46, P453; Jensen SA, 2000, J BIOL CHEM, V275, P28449, DOI 10.1074/jbc.M004265200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; RAPAKA RS, 1978, INT J PEPT PROT RES, V11, P109; RAPAKA RS, 1978, INT J PEPT PROT RES, V11, P97; STARCHER BC, 1973, BIOCHIM BIOPHYS ACTA, V310, P481, DOI 10.1016/0005-2795(73)90132-3; TAMBURRO AM, 1992, J BIOMOL STRUCT DYN, V10, P441, DOI 10.1080/07391102.1992.10508661; TAMBURRO AM, 1977, BIOCHIM BIOPHYS ACTA, V492, P370, DOI 10.1016/0005-2795(77)90088-5; Toonkool P, 2001, J BIOL CHEM, V276, P28042, DOI 10.1074/jbc.M103391200; Urry D W, 1977, Adv Exp Med Biol, V79, P685; URRY D W, 1976, Critical Reviews in Biochemistry, V4, P1, DOI 10.3109/10409237609102557; Urry D W, 1974, Adv Exp Med Biol, V43, P211; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; URRY DW, 1982, METHOD ENZYMOL, V82, P673; Urry DW, 1995, CIBA F SYMP, V192, P4; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; WU J, 1992, ANAL BIOCHEM, V200, P359, DOI 10.1016/0003-2697(92)90479-Q; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719; Wu WJ, 1999, EUR J BIOCHEM, V266, P308, DOI 10.1046/j.1432-1327.1999.00891.x	29	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44575	44580		10.1074/jbc.M107920200	http://dx.doi.org/10.1074/jbc.M107920200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564742	hybrid			2022-12-25	WOS:000172406700033
J	Urbina, HD; Silberg, JJ; Hoff, KG; Vickery, LE				Urbina, HD; Silberg, JJ; Hoff, KG; Vickery, LE			Transfer of sulfur from IscS to IscU during Fe/S cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE SYSTEM; IN-VITRO BIOSYNTHESIS; NIFS-LIKE PROTEIN; COLI TRANSFER-RNA; ESCHERICHIA-COLI; EXTINCTION COEFFICIENTS; AZOTOBACTER-VINELANDII; CYSTEINE DESULFURASE; 2FE-2S CLUSTERS; S CLUSTER	The cysteine desulfurase enzymes NifS and IscS provide sulfur for the biosynthesis of Fe/S proteins. NifU and IscU have been proposed to serve as template or scaffold proteins in the initial Fe/S cluster assembly events, but the mechanism of sulfur transfer from NifS or IscS to NifU or IscU has not been elucidated. We have employed [S-35]cysteine radiotracer studies to monitor sulfur transfer between IscS and IscU from Escherichia coli and have used direct binding measurements to investigate interactions between the proteins. IscS catalyzed transfer of S-35 from [S-35]cysteine to IscU in the absence of additional thiol reagents, suggesting that transfer can occur directly and without involvement of an intermediate carrier. Surface plasmon resonance studies and isothermal titration calorimetry measurements further revealed that IscU binds to Ises with high affinity (K-d similar to2 muM) in support of a direct transfer mechanism. Transfer was inhibited by treatment of IscU with iodoacetamide, and 35S was released by reducing reagents, suggesting that transfer of persulfide sulfur occurs to cysteinyl groups of IscU. A deletion mutant of IscS lacking C-terminal residues 376-413 (IscS Delta 376-413) displayed cysteine desulfurase activity similar to the full-length protein but exhibited lower binding affinity for IscU, decreased ability to transfer S-35 to IscU, and reduced activity in assays of Fe/S cluster assembly on IscU. The findings with IscS Delta 376-413 provide additional support for a mechanism of sulfur transfer involving a direct interaction between IscS and IscU and suggest that the C-terminal region of IscS may be important for binding IscU.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Silberg, Jonathan J/A-3817-2010		NIGMS NIH HHS [GM07311, GM54264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Bui BTS, 2000, EUR J BIOCHEM, V267, P2688; Flint DH, 1996, J BIOL CHEM, V271, P16068; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; RIORDAN JF, 1967, METHOD ENZYMOL, V11, P545; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; STONE KL, 1989, TECHNIQUES PROTEIN C, P379; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	31	224	229	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44521	44526		10.1074/jbc.M106907200	http://dx.doi.org/10.1074/jbc.M106907200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577100	hybrid, Green Accepted			2022-12-25	WOS:000172406700025
J	Yamamoto, N; Yamamoto, S; Inagaki, F; Kawaichi, M; Fukamizu, A; Kishi, N; Matsuno, K; Nakamura, K; Weinmaster, G; Okano, H; Nakafuku, M				Yamamoto, N; Yamamoto, S; Inagaki, F; Kawaichi, M; Fukamizu, A; Kishi, N; Matsuno, K; Nakamura, K; Weinmaster, G; Okano, H; Nakafuku, M			Role of Deltex-1 as a transcriptional regulator downstream of the notch receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLIT COMPLEX GENES; LOOP-HELIX FACTORS; SIGNALING PATHWAY; CELL DIFFERENTIATION; ANKYRIN REPEATS; NERVOUS-SYSTEM; MADS-BOX; RBP-J; P300; PROTEIN	Intercellular signaling through the cell-surface receptor Notch plays important roles in a variety of developmental processes as well as in pathogenesis of some human cancers and genetic disorders. However, the mechanisms by which Notch signals are transduced into cells still remain elusive. Here we investigated the signaling mechanisms for Notch in the cell fate control of neural progenitor cells. We show that Deltex-1 (DTX1), a mammalian homolog of Drosophila Deltex, mediates a Notch signal to block differentiation of neural progenitor cells. We found that a significant fraction of DTX1 proteins were localized in the nucleus and physically interacted with the transcriptional coactivator p300. Through its binding to p300, DTX1 inhibited transcriptional activation by the neural-specific helix-loop-helix-type transcription factor MASH1, and this mechanism is likely responsible for the differentiation inhibition of neural progenitor cells. Our results further suggest that DTX1 regulates transcription independently of the previously characterized Notch signaling pathway involving RBP-J and HES1/HES5. Thus, DTX1 serves as an important signaling component downstream of Notch that regulates transcription in the nucleus.	Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1130033, Japan; Nara Adv Inst Sci & Technol, Div Anim Gene Funct, Nara 6300101, Japan; Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Keio Univ, Sch Med, Dept Physiol, Tokyo 1608582, Japan; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1050011, Japan; Tokyo Univ Sci, Dept Biol Sci & Technol, Chiba 2788510, Japan	University of Tokyo; University of Tokyo; Nara Institute of Science & Technology; University of Tsukuba; Keio University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Japan Science & Technology Agency (JST); Tokyo University of Science	Nakafuku, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	nakafuku@m.u-tokyo.ac.jp	fukamizu, akiyoshi/J-5350-2012; Nakafuku, Masato/J-3068-2013; Okano, Hideyuki/I-7584-2019; Kishi, Noriyuki/L-1379-2013	fukamizu, akiyoshi/0000-0002-8786-6020; Nakafuku, Masato/0000-0001-7783-9005				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gho M, 1996, DEVELOPMENT, V122, P1673; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; James P, 1996, GENETICS, V144, P1425; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kato H, 1997, DEVELOPMENT, V124, P4133; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Ligoxygakis P, 1998, DEVELOPMENT, V125, P2893; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Torii MA, 1999, DEVELOPMENT, V126, P443; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Wang SW, 1997, DEVELOPMENT, V124, P4435; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	56	152	163	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45031	45040		10.1074/jbc.M105245200	http://dx.doi.org/10.1074/jbc.M105245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564735	hybrid			2022-12-25	WOS:000172406700093
J	Funderburgh, JL; Funderburgh, ML; Mann, MM; Corpuz, L; Roth, MR				Funderburgh, JL; Funderburgh, ML; Mann, MM; Corpuz, L; Roth, MR			Proteoglycan expression during transforming growth factor beta-induced keratocyte-myofibroblast transdifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; PATHOLOGICAL HUMAN CORNEAS; COLLAGEN TYPE-I; EXTRACELLULAR-MATRIX; BOVINE KERATOCYTES; RADIAL KERATOTOMY; BIGLYCAN; LUMICAN; DECORIN; TISSUE	Keratocytes of the corneal stroma secrete a unique population of proteoglycan molecules considered essential for corneal transparency. In healing corneal wounds, keratocytes exhibit a myofibroblastic phenotype in response to transforming growth factor beta (TGF-beta), characterized by expression of a-smooth muscle actin. This study examined proteoglycan and collagen expression by keratocytes in vitro during the TGF-beta induced keratocyte-myofibroblast transition. TGF-beta treated primary bovine keratocytes developed myofibroblastic features, including actin stress fibers anchored to paxillin-containing focal adhesions, cell-associated fibronectin, a, integrin, and a-smooth muscle actin. Collagen I and III protein and mRNA increased in response to TGF-beta. Secretion of [S-35]sulfate-labeled keratan sulfate proteoglycans decreased markedly in response to TGF-beta. Dermatan sulfate proteoglycans, however, increased in size and abundance. Protein and mRNA transcripts for normal stromal proteoglycans (lumican, keratocan, mimecan, and decorin) all decreased in response to TGF-beta, but protein expression and mRNA for biglycan, a proteoglycan present in fibrotic tissue, was markedly up-regulated. These results show that TGF-beta in vitro induces a proteoglycan expression pattern similar to that of corneal scars in vivo. This altered proteoglycan expression occurred coordinately with transdifferentiation. of keratocytes to the myofibroblastic phenotype, implicating these cells as the source of fibrotic tissue in nontransparent corneal scars.	Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst 1011, Pittsburgh, PA 15213 USA; Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kansas State University	Funderburgh, JL (corresponding author), Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst 1011, 203 Lothrop St, Pittsburgh, PA 15213 USA.	jlfunder@pitt.edu			NEI NIH HHS [R01 EY009368, R01 EY000952, EY09368, R01 EY009368-09, P30 EY008098, P30-EY08098, EY00952] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009368, P30EY008098, R01EY000952] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANSETH A, 1969, EXP EYE RES, V8, P302, DOI 10.1016/S0014-4835(69)80043-6; Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CINTRON C, 1977, DEV BIOL, V61, P346, DOI 10.1016/0012-1606(77)90304-9; CINTRON C, 1990, INVEST OPHTH VIS SCI, V31, P1975; CIONNI RJ, 1986, CURR EYE RES, V5, P549, DOI 10.3109/02713688609015118; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DELAIGUE O, 1995, GRAEF ARCH CLIN EXP, V233, P331, DOI 10.1007/BF00200481; Dutt JE, 1996, CORNEA, V15, P606; Fini ME, 1999, PROG RETIN EYE RES, V18, P529, DOI 10.1016/S1350-9462(98)00033-0; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P435; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; Funderburgh JL, 1998, INVEST OPHTH VIS SCI, V39, P1957; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hogemann B, 1997, PATHOL RES PRACT, V193, P747; ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P3320; Jester JV, 1996, CORNEA, V15, P505; JESTER JV, 1994, INVEST OPHTH VIS SCI, V35, P730; Jester JV, 1999, INVEST OPHTH VIS SCI, V40, P1959; JESTER JV, 1995, INVEST OPHTH VIS SCI, V36, P809; JOST CJ, 1991, J BIOL CHEM, V266, P13336; Kato T, 2000, JPN J OPHTHALMOL, V44, P334, DOI 10.1016/S0021-5155(00)00168-4; Ljubimov AV, 1996, INVEST OPHTH VIS SCI, V37, P997; Ljubimov AV, 1998, EXP EYE RES, V67, P265, DOI 10.1006/exer.1998.0511; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Maguen E, 1997, CORNEA, V16, P675; Masur SK, 1996, P NATL ACAD SCI USA, V93, P4219, DOI 10.1073/pnas.93.9.4219; MATSUDA H, 1973, EXP EYE RES, V16, P427, DOI 10.1016/0014-4835(73)90100-0; Moller-Pedersen T, 1998, CURR EYE RES, V17, P736, DOI 10.1076/ceyr.17.7.736.5163; Nakazawa K, 1998, ARCH BIOCHEM BIOPHYS, V359, P269, DOI 10.1006/abbi.1998.0897; POWER WJ, 1995, CURR EYE RES, V14, P879, DOI 10.3109/02713689508995127; SAWAGUCHI S, 1991, INVEST OPHTH VIS SCI, V32, P1846; Song QH, 2000, J CELL BIOCHEM, V77, P186, DOI 10.1002/(SICI)1097-4644(20000501)77:2<186::AID-JCB3>3.0.CO;2-M; Stokes MB, 2000, KIDNEY INT, V57, P487, DOI 10.1046/j.1523-1755.2000.00868.x; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Venkatesan N, 2000, AM J RESP CRIT CARE, V161, P2066, DOI 10.1164/ajrccm.161.6.9909098; Vesaluoma MH, 1998, J REFRACT SURG, V14, P447; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	47	140	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44173	44178		10.1074/jbc.M107596200	http://dx.doi.org/10.1074/jbc.M107596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11555658	Green Accepted, hybrid			2022-12-25	WOS:000172297700088
J	Keates, AC; Keates, S; Kwon, JH; Arseneau, KO; Law, DJ; Bai, LC; Merchant, JL; Wang, TC; Kelly, CP				Keates, AC; Keates, S; Kwon, JH; Arseneau, KO; Law, DJ; Bai, LC; Merchant, JL; Wang, TC; Kelly, CP			ZBP-89, Sp1, and nuclear factor-kappa B regulate epithelial neutrophil-activating peptide-78 gene expression in Caco-2 human colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ZBP-89; BINDING PROTEIN; DNA-BINDING; ALPHA-GENE; INTERLEUKIN-8 GENE; CHEMOKINE; PROMOTER; ENA-78; CYTOKINE; CLONING	We reported previously that human colonic epithelial cells produce the C-X-C chemokine epithelial neutrophil-activating peptide-78 (ENA-78) and that its expression is up-regulated in ulcerative colitis. The aim of this study was to investigate the transcriptional regulation of ENA-78 gene expression in Caco-2 intestinal epithelial cells. Reporter gene transfection and electrophoretic mobility shift assay studies demonstrated that cooperation between two regions of the ENA-78 promoter were required for maximal gene expression in interleukin-1 beta -stimulated Caco-2 cells. Binding of activated p50/p65 nuclear factor-kappaB to nucleotides -82 to -91 was essential for interleukin-1 beta -dependent gene transcription, whereas binding of constitutively expressed zinc-requiring nuclear factors to nucleotides -125 to -134 (site A) was required for basal gene expression. Scanning mutagenesis of site A demonstrated overlapping binding elements at this locus. One site (CTCCCCC) bound Sp1 and Sp3, and overexpression of Sp1 (but not Sp3) up-regulated basal ENA-78 transcription. Another site (CCCCTCCCCC) was found to bind the zinc finger nuclear factor ZBP-89, and overexpression of this protein significantly repressed ENA-78 reporter gene activity. This study demonstrates that ENA-78 gene expression in Caco-2 intestinal epithelial cells is subject to complex regulation involving the coordinate binding of ZBP-89, Spl, and nuclear factor-kappaB to the ENA-78 promoter.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Massachusetts, Med Ctr, Dept Med, Worcester, MA 01655 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Keates, AC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	akeates@caregroup.harvard.edu	Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NIDDK NIH HHS [DK54920, DK55732, DK58858, DK43551] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054920, R01DK058858, R01DK055732, R56DK055732] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; CHANG MS, 1994, J BIOL CHEM, V269, P25277; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CORBETT MS, 1994, BIOCHEM BIOPH RES CO, V205, P612, DOI 10.1006/bbrc.1994.2709; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Jobin C, 1997, J IMMUNOL, V158, P226; Keates S, 1997, AM J PHYSIOL-GASTR L, V273, pG75, DOI 10.1152/ajpgi.1997.273.1.G75; KELLY CP, 1994, AM J PHYSIOL-GASTR L, V267, pG991, DOI 10.1152/ajpgi.1994.267.6.G991; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Miyamoto NG, 2000, J NEUROIMMUNOL, V105, P78, DOI 10.1016/S0165-5728(00)00195-8; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SchnyderCandrian S, 1997, J IMMUNOL, V158, P3888; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Taniuchi T, 1997, BIOCHEM BIOPH RES CO, V233, P154, DOI 10.1006/bbrc.1997.6310; UEDA A, 1994, J IMMUNOL, V153, P2052; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WALZ A, 1993, ADV EXP MED BIOL, V351, P129; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Wu GD, 1997, J BIOL CHEM, V272, P2396; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634; ZGraggen K, 1997, GASTROENTEROLOGY, V113, P808, DOI 10.1016/S0016-5085(97)70175-6	53	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43713	43722		10.1074/jbc.M107838200	http://dx.doi.org/10.1074/jbc.M107838200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559712	hybrid			2022-12-25	WOS:000172297700032
J	Kinkl, N; Sahel, J; Hicks, D				Kinkl, N; Sahel, J; Hicks, D			Alternate FGF2-ERK1/2 signaling pathways in retinal photoreceptor and glial cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; BASIC FIBROBLAST; FACTOR RECEPTORS; GANGLIOSIDE COMPOSITION; MAP KINASES; TGF-BETA; ERK; EXPRESSION; NEURONS	Basic fibroblast growth factor (FGF2) stimulates photoreceptor survival in vivo and in vitro, but the molecular signaling mechanism(s) involved are unknown. Immunohistochemical and immunoblotting analyses of pure photoreceptors, inner retinal neurons, and Muller glial cells (MGC) in vitro revealed differential expression of the high affinity FGF receptors (FGFR1-4), as well as many cytoplasmic signaling intermediates known to mediate the extracellular signal-regulated kinase (ERK1/2) pathway. FGF2-induced tyrosine phosphorylation in vitro exhibited distinct profiles for each culture type, and FGF2-induced ERK1/2 activation was observed for all three preparations. Whereas U0126, a specific inhibitor of ERK kinase (MEK), completely abolished FGF2-induced ERK1/2 tyrosine phosphorylation and survival in cultured photoreceptors, persistent ERK1/2 phosphorylation was observed in cultured inner retinal cells and MGC. Furthermore U0126 treatment entirely blocked nerve growth factor-induced ERK1/2 activation in MGC, as well as FGF2-induced ERK1/2 activation in cerebral glial cells. Taken together, these data indicate that FGF2-induced ERK1/2 activation is entirely mediated by MEK within photoreceptors, which is responsible for FGF2-stimulated photoreceptor survival. In contrast, inner retina/glia possess alternative, cell type, and growth factor-specific MEK-independent ERK1/2 activation pathways. Hence signaling and biological effects elicited by FGF2 within retina are mediated by cell type-specific pathways.	Univ Strasbourg, Ctr Hosp Reg, INSERM,Clin Med A, Lab Physiopathol Cellulaire & Mol Retine,EMI 9918, F-67091 Strasbourg, France	Centre Hospitalier Annecy Genevois; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hicks, D (corresponding author), Univ Strasbourg, Ctr Hosp Reg, INSERM,Clin Med A, Lab Physiopathol Cellulaire & Mol Retine,EMI 9918, BP 426,1 Pl Hop, F-67091 Strasbourg, France.	hicks@neurochem.u-strasbg.fr	Sahel, Jose-Alain/F-3172-2017	Sahel, Jose-Alain/0000-0002-4831-1153				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; Baron W, 2000, MOL CELL NEUROSCI, V15, P314, DOI 10.1006/mcne.1999.0827; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bhat NR, 1996, J NEUROCHEM, V66, P1986; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Campochiaro PA, 1996, J NEUROSCI, V16, P1679; Cha YK, 2000, J NEUROCHEM, V75, P298, DOI 10.1046/j.1471-4159.2000.0750298.x; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Delehedde M, 2000, J BIOL CHEM, V275, P33905, DOI 10.1074/jbc.M005949200; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Desire L, 2000, J NEUROCHEM, V75, P151, DOI 10.1046/j.1471-4159.2000.0750151.x; Dimitropoulou A, 2000, BRAIN RES, V858, P205, DOI 10.1016/S0006-8993(00)01946-6; Dreyfus H, 1996, INVEST OPHTH VIS SCI, V37, P574; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ECKENSTEIN FP, 1994, PROG BRAIN RES, V103, P55; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; Fontaine V, 1998, J NEUROSCI, V18, P9662; Fontaine V, 1998, GLYCOBIOLOGY, V8, P183, DOI 10.1093/glycob/8.2.183; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Gu X, 1996, INVEST OPHTH VIS SCI, V37, P2326; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1; HICKS D, 1990, EXP EYE RES, V51, P119, DOI 10.1016/0014-4835(90)90063-Z; HICKS D, 1992, J NEUROSCI, V12, P2022; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLINT P, 1999, FRONT BIOSCI, V4, P165; Lau D, 2000, INVEST OPHTH VIS SCI, V41, P3622; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Learish RD, 2000, DEV BRAIN RES, V122, P97; Lesort M, 1997, MOL BRAIN RES, V45, P127, DOI 10.1016/S0169-328X(96)00284-7; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Meuillet E, 1996, GLIA, V17, P206, DOI 10.1002/(SICI)1098-1136(199607)17:3<206::AID-GLIA3>3.0.CO;2-Z; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; Pizon V, 2000, ONCOGENE, V19, P6074, DOI 10.1038/sj.onc.1203984; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; Saeki Y, 2000, INT J MOL MED, V6, P155; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; Saneto RP., 1987, NEUROCHEMISTRY PRACT, P27; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SHAOUL E, 1995, ONCOGENE, V10, P1553; SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; TOURNIER C, 1994, GLIA, V10, P81, DOI 10.1002/glia.440100202; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEISE B, 1993, J NEUROSCI RES, V34, P442, DOI 10.1002/jnr.490340409; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yardin C, 1998, NEUROREPORT, V9, P2077, DOI 10.1097/00001756-199806220-00030; Yue JB, 1999, J CELL PHYSIOL, V178, P387	67	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43871	43878		10.1074/jbc.M105256200	http://dx.doi.org/10.1074/jbc.M105256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571286	hybrid			2022-12-25	WOS:000172297700052
J	Kraus, J; Borner, C; Giannini, E; Hickfang, K; Braun, H; Mayer, P; Hoehe, MR; Ambrosch, A; Konig, W; Holt, V				Kraus, J; Borner, C; Giannini, E; Hickfang, K; Braun, H; Mayer, P; Hoehe, MR; Ambrosch, A; Konig, W; Holt, V			Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTE-ENRICHED CULTURES; BETA-ENDORPHIN; DENDRITIC CELLS; T-CELLS; KAPPA-B; INTERLEUKIN-1-BETA-MEDIATED REGULATION; DIFFERENTIAL EXPRESSION; FUNCTIONAL-ANALYSIS; RESPONSE ELEMENT; NERVOUS-SYSTEM	Morphine and the endogenous opioid peptide P-endorphin exert neuromodulatory as well as immunomodulatory effects, which are transduced by mu -opioid receptors. In this report we show that stimulation with interleukin-4 induces Ik-opioid receptor transcripts in human primary blood cells (T cells and polymorphonuclear leukocytes), immune cell lines (Raji, U-937, and HMEC-1), and dendritic cells. In nonstimulated immune cells this gene is silent. In addition, mu receptor transcription is up-regulated by interleukin-4 in cultures of primary rat neurons. Transient transfection experiments in Raji and SH SY5Y neuronal cells with human and rat reporter gene constructs linked the interleukin-4 effect directly to cis-active mu receptor promoter elements located at nucleotide -997 on the human gene and nucleotide -727 on the rat gene. The interleukin-4 response elements function orientation independently. They bind STAT6 transcription factors as shown by electrophoretic mobility shift assays. In the human gene, a single nucleotide polymorphism within the interleukin-4 response element reduces the trans-activating potential of this element by 50%, which may affect the phenotype of persons carrying this variation. These findings provide a molecular basis for understanding bidirectional interactions between the opioid system and the immune system.	Univ Magdeburg, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Med Microbiol, D-39120 Magdeburg, Germany; Univ Rome, Dept Med Pharmacol, I-00185 Rome, Italy; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Otto von Guericke University; Otto von Guericke University; Sapienza University Rome; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kraus, J (corresponding author), Univ Magdeburg, Dept Pharmacol & Toxicol, 44 Leipziger Str, D-39120 Magdeburg, Germany.	juergen.kraus@medizin.uni-magdeburg.de	Ambrosch, Andreas/GRO-1438-2022					Aharoni R, 2000, P NATL ACAD SCI USA, V97, P11472, DOI 10.1073/pnas.97.21.11472; Bank U, 1999, J INTERF CYTOK RES, V19, P1277, DOI 10.1089/107999099312957; Bencsics A, 1997, J NEUROIMMUNOL, V73, P1, DOI 10.1016/S0165-5728(96)00163-4; Bianchi M, 1999, EUR J NEUROSCI, V11, P1501, DOI 10.1046/j.1460-9568.1999.00563.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De-Fraja C, 1998, J NEUROSCI RES, V54, P320, DOI 10.1002/(SICI)1097-4547(19981101)54:3<320::AID-JNR3>3.0.CO;2-R; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; GAVERIAUX C, 1995, FEBS LETT, V369, P272, DOI 10.1016/0014-5793(95)00766-3; Gaveriaux-Ruff C, 1998, P NATL ACAD SCI USA, V95, P6326, DOI 10.1073/pnas.95.11.6326; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; HEIJNEN CJ, 1991, IMMUNOL REV, V119, P41, DOI 10.1111/j.1600-065X.1991.tb00577.x; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Im HJ, 1999, BRAIN RES, V829, P174, DOI 10.1016/S0006-8993(99)01364-5; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KRAUS J, 1995, BIOCHEM BIOPH RES CO, V215, P591, DOI 10.1006/bbrc.1995.2505; LEFKOWITZ SS, 1975, LIFE SCI, V17, P1763, DOI 10.1016/0024-3205(75)90458-0; Li HL, 2001, J NEUROIMMUNOL, V116, P5, DOI 10.1016/S0165-5728(01)00264-8; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; Liu HY, 2000, CYTOKINE, V12, P1656, DOI 10.1006/cyto.2000.0773; Lovett-Racke AE, 2000, BRAIN RES, V870, P27, DOI 10.1016/S0006-8993(00)02398-2; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; McCarthy L, 2001, J NEUROIMMUNOL, V114, P173, DOI 10.1016/S0165-5728(01)00248-X; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Neumann M, 2000, BLOOD, V95, P277; Ohmori Y, 2000, J BIOL CHEM, V275, P38095, DOI 10.1074/jbc.M006227200; Peterson PK, 1998, J NEUROIMMUNOL, V83, P63, DOI 10.1016/S0165-5728(97)00222-1; Reisine Terry, 1994, Current Opinion in Neurobiology, V4, P406, DOI 10.1016/0959-4388(94)90103-1; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; ROUVEIX B, 1992, THERAPIE, V47, P503; Roy S, 1999, J NEUROIMMUNOL, V95, P107, DOI 10.1016/S0165-5728(98)00265-3; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; Ruzicka BB, 1996, J NEUROCHEM, V66, P425; Ruzicka BB, 1997, NEUROSCIENCE, V79, P517, DOI 10.1016/S0306-4522(96)00669-0; Sacerdote P, 1998, CLIN EXP IMMUNOL, V113, P465; Sacerdote P, 2000, BLOOD, V95, P2031, DOI 10.1182/blood.V95.6.2031; Sacerdote P, 1996, REGUL PEPTIDES, V63, P79; Sambrook J, 2001, MOL CLONING LAB MANU; SCHOUSBOE A, 1985, DEV NEUROSCI-BASEL, V7, P252, DOI 10.1159/000112294; SEDQI M, 1995, BIOCHEM BIOPH RES CO, V209, P563, DOI 10.1006/bbrc.1995.1538; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; Takeda K, 1997, J MOL MED-JMM, V75, P317, DOI 10.1007/s001090050117; VANDENBERGH P, 1993, CELL IMMUNOL, V149, P180, DOI 10.1006/cimm.1993.1146; VANDENBERGH P, 1994, LYMPHOKINE CYTOK RES, V13, P63; Vidal EL, 1998, IMMUNOPHARMACOLOGY, V38, P261, DOI 10.1016/S0162-3109(97)00085-4; WEBER RJ, 1989, SCIENCE, V245, P188, DOI 10.1126/science.2749256; Wendel B, 1998, J MOL MED-JMM, V76, P525, DOI 10.1007/s001090050246; Wick MJ, 1996, J NEUROIMMUNOL, V64, P29, DOI 10.1016/0165-5728(95)00144-1; Woltje M, 1998, FEBS LETT, V440, P107, DOI 10.1016/S0014-5793(98)01441-0; Woltje M, 2000, J NEUROCHEM, V74, P1355, DOI 10.1046/j.1471-4159.2000.0741355.x; ZADINA JE, 1993, J PHARMACOL EXP THER, V265, P254; Zimprich A, 2000, J NEUROCHEM, V74, P472, DOI 10.1046/j.1471-4159.2000.740472.x	60	138	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43901	43908		10.1074/jbc.M107543200	http://dx.doi.org/10.1074/jbc.M107543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11572871	hybrid			2022-12-25	WOS:000172297700056
J	Salmon, D; Montero-Lomeli, M; Goldenberg, S				Salmon, D; Montero-Lomeli, M; Goldenberg, S			A DnaJ-Iike protein homologous to the yeast co-chaperone Sis1 (TcJ6p) is involved in initiation of translation in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; FINGER-LIKE DOMAIN; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; TRANSFERRIN-RECEPTOR; MOLECULAR CHAPERONES; RICH REGION; GENE; EXPRESSION; HSP70	In eukaryotes, proteins homologous to the bacterial DnaJ protein are involved in regulation of the Hsp70 molecular chaperones, which are implicated in a variety of protein biogenesis pathways. We report herewith the molecular characterization of a T. cruzi DnaJ gene, termed TcJ6, encoding a protein that displays high sequence homology with the Saccharomyces cerevisiae Sis1 co-chaperone required for the initiation of translation. TcJ6 protein was expressed as a polypeptide of 36.5 kDa at a constant level during parasite differentiation and was associated to the cytoplasmic fraction. We showed that overexpression of TcJ6 complemented a temperature-sensitive yeast sis1 mutant. In addition, sucrose gradient sedimentation analysis of polysomes from T. cruzi and a yeast mutant overexpressing TcJ6p showed that the trypanosomal co-chaperone was closely associated with ribosomal subunits, 80 S monosomes and the smaller polysomes, as observed for Sis1p. Furthermore, in T. cruzi TcJ6p was also found to be preferentially concentrated around the nucleus, giving a speckled staining pattern. This suggests that TcJ6p is associated with the endoplasmic reticulum. Taken together, these data suggest that the trypanosomal DnaJ is involved in initiation of translation.	Inst Oswaldo Cruz, Dept Bioquim & Biol Mol, BR-21045900 Rio De Janeiro, Brazil; IBMP, BR-8135010 Curitiba, Parana, Brazil; Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941 Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro	Goldenberg, S (corresponding author), Inst Oswaldo Cruz, Dept Bioquim & Biol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.	sgoldenb@ioc.fiocruz.br	Salmon, Didier/M-5670-2013; GOLDENBERG, SAMUEL/B-4116-2009; Goldenberg, Samuel/ABD-8908-2022; Montero-Lomeli, Monica/D-9885-2013; P, CM/B-1358-2013	GOLDENBERG, SAMUEL/0000-0002-4892-163X; 				ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; Brecht M, 1998, MOL BIOCHEM PARASIT, V97, P189, DOI 10.1016/S0166-6851(98)00151-0; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; BUKAU B, 1992, TRENDS BIOCHEM SCI, V17, P129; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Carreira MAC, 1998, FEMS MICROBIOL LETT, V166, P141, DOI 10.1111/j.1574-6968.1998.tb13195.x; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CONTRERAS V T, 1988, Memorias do Instituto Oswaldo Cruz, V83, P123, DOI 10.1590/S0074-02761988000100016; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; CRAIG E, 1999, MOL CHAPERONES FOLDI, P139; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; FRAGOSO SP, 1992, MOL BIOCHEM PARASIT, V55, P127, DOI 10.1016/0166-6851(92)90133-5; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GOLDENBERG S, 1985, FEBS LETT, V180, P265, DOI 10.1016/0014-5793(85)81083-8; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Henriksson J, 1996, PARASITOL TODAY, V12, P108, DOI 10.1016/0169-4758(96)80670-3; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; KAISER C, 1994, METHODS YEAST GENETI, P149; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Krumlauf Robb, 1994, Molecular Biotechnology, V2, P227, DOI 10.1007/BF02745879; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; Ohba M, 1997, FEBS LETT, V409, P307, DOI 10.1016/S0014-5793(97)00535-8; OLSON CL, 1994, J BIOL CHEM, V269, P3868; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1980, NUCLEIC ACIDS RES, V8, P5965, DOI 10.1093/nar/8.24.5965; PAYS E, 1989, EUKARYOTIC GENOME OR, P127; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; STANSFIELD I, 1992, MOL MICROBIOL, V6, P3469, DOI 10.1111/j.1365-2958.1992.tb01782.x; SULLIVAN MA, 1994, MOL BIOCHEM PARASIT, V68, P197, DOI 10.1016/0166-6851(94)90165-1; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; TAKLE GB, 1992, MOL BIOCHEM PARASIT, V56, P117, DOI 10.1016/0166-6851(92)90159-H; TETAUD E, 1994, P NATL ACAD SCI USA, V91, P8278, DOI 10.1073/pnas.91.17.8278; Tibbetts RS, 1998, MOL BIOCHEM PARASIT, V91, P319, DOI 10.1016/S0166-6851(97)00214-4; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; Yan W, 1999, MOL CELL BIOL, V19, P7751; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; Zhong T, 1996, J BIOL CHEM, V271, P1349, DOI 10.1074/jbc.271.3.1349	54	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43970	43979		10.1074/jbc.M102427200	http://dx.doi.org/10.1074/jbc.M102427200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551903	hybrid			2022-12-25	WOS:000172297700064
J	Sirim, P; Zeitlmann, L; Kellersch, B; Falk, CS; Schendel, DJ; Kolanus, W				Sirim, P; Zeitlmann, L; Kellersch, B; Falk, CS; Schendel, DJ; Kolanus, W			Calcium signaling through the beta(2)-cytoplasmic domain of LFA-1 requires intracellular elements of the T cell receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN CYTOPLASMIC DOMAIN; ZAP-70 TYROSINE KINASE; ANTIGEN-RECEPTOR; IMMUNOLOGICAL SYNAPSE; ADHESION MOLECULE-1; ZETA-CHAIN; ACTIVATION; TRANSDUCTION; PHOSPHORYLATION; COSTIMULATION	The beta (2) integrin LFA-1 is an important cell-cell adhesion receptor of the immune system. Evidence suggests that the molecule also participates in signaling and costimulatory function. We show here that clustering of the intracellular domain of the beta (2) chain but not of the alpha (L)- or beta (1)-cytoplasmic domains, respectively, triggers intracellular Ca2+ mobilization in Jurkat cells. A beta (2)-specific NPXF motif, located in the C-terminal portion of the beta (2) tail, is required for Ca2+ signaling, and we show that this motif is important for the induction of allospecific target cell lysis by cytotoxic T cells in vitro. Significantly, the Ca2+-signaling capacity of the beta (2) integrin is abrogated in T cells that do not express the T cell receptor but may be reconstituted by co-expression of the T cell receptor-zeta chain. Our data suggest a specific function of the cytoplasmic domain of the beta (2) integrin chain in T cell signaling.	Univ Munich, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kolanus, W (corresponding author), Univ Munich, Genzentrum, Mol Biol Lab, Feodor Lynen Str 25, D-81377 Munich, Germany.		Zeitlmann, Lutz/AAF-3586-2019; Falk, Christine/Q-4143-2016	Falk, Christine/0000-0003-1376-7318				Abraham C, 1999, J IMMUNOL, V162, P4399; ALCOVER A, 1988, EMBO J, V7, P2077; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; Besser M, 1999, J IMMUNOL, V162, P6303; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; Fabbri M, 1999, EMBO J, V18, P4915, DOI 10.1093/emboj/18.18.4915; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; ROMEO C, 1992, COLD SPRING HARB SYM, V57, P117, DOI 10.1101/SQB.1992.057.01.015; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SCHENDEL DJ, 1979, TISSUE ANTIGENS, V13, P112; Sedwick CE, 1999, J IMMUNOL, V162, P1367; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Soede RDM, 1999, J IMMUNOL, V163, P4253; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SPRINGER TA, 1985, ADV EXP MED BIOL, V184, P311; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Ulivieri C, 1999, EUR J IMMUNOL, V29, P2625; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zuckerman LA, 1998, J IMMUNOL, V160, P3259	66	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42945	42956		10.1074/jbc.M103224200	http://dx.doi.org/10.1074/jbc.M103224200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11559699	hybrid			2022-12-25	WOS:000172169300043
J	Carballo, E; Cao, HP; Lai, WS; Kennington, EA; Campbell, D; Blackshear, PJ				Carballo, E; Cao, HP; Lai, WS; Kennington, EA; Campbell, D; Blackshear, PJ			Decreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENTS; FINGER TRANSCRIPTION FACTOR; MESSENGER-RNA DEGRADATION; FACTOR-ALPHA; MAP KINASE; TNF-ALPHA; INFLAMMATORY DISEASE; PYRIDINYL IMIDAZOLES	Treatment of macrophages with pyridinyl imidazole inhibitors of p38 protein kinases can inhibit lipopolysaccharide-stimulated tumor necrosis factor a secretion. However, bone marrow-derived macrophages from tristetraprolin (TTP)-deficient mice were less sensitive than normal macrophages to this effect of p38 inhibitors, despite evidence for normal p38 activation in response to lipopolysaccharide. TTP is known to cause decreased stability of tumor necrosis factor a and granulocyte-macrophage colony-stimulating factor mRNAs after binding to an AU-rich element in their 3'-untranslated regions. A recombinant TTP fusion protein could be phosphorylated by a recombinant p38 kinase in cell-free assays and was phosphorylated to the same extent by immunoprecipitated p38 derived from normal and TTP-deficient cells stimulated with lipopolysaccharide; in both cases, the enzyme activity was inhibited by the p38 inhibitors. TTP phosphorylation also was increased in intact macrophages after lipopolysaccharide stimulation, an effect that was blocked by the p38 inhibitors. Finally, TTP in mammalian cell extracts bound less well to an AU-rich element RNA probe than did the same amount of TTP following dephosphorylation. These results suggest that TTP may be a component of the signaling cascade, initiated by inflammatory stimuli and mediated in part by activation of p38, that ultimately leads to enhanced secretion of tumor necrosis factor a.	NIEHS, Off Clin Res, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; AstraZeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University; AstraZeneca	Blackshear, PJ (corresponding author), NIEHS, Off Clin Res, POB 12233, Res Triangle Pk, NC 27709 USA.		Blackshear, Perry J./C-6206-2019; Cao, Heping/AAC-1666-2021	Blackshear, Perry J./0000-0002-9561-8529; Cao, Heping/0000-0002-0958-1468	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090080] Funding Source: NIH RePORTER; NIEHS NIH HHS [Z01 ES090080-08] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Barlaam B, 1999, J MED CHEM, V42, P4890, DOI 10.1021/jm990377j; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHIN J, 1993, J IMMUNOL, V151, P5574; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Glaser KB, 1999, BIOCHEM PHARMACOL, V57, P291, DOI 10.1016/S0006-2952(98)00300-1; Hale KK, 1999, J IMMUNOL, V162, P4246; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; PRICHETT W, 1995, J INFLAMM, V45, P97; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582; Wadsworth SA, 1999, J PHARMACOL EXP THER, V291, P680; Wang SW, 1999, INFLAMM RES, V48, P533, DOI 10.1007/s000110050499; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	43	163	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42580	42587		10.1074/jbc.M104953200	http://dx.doi.org/10.1074/jbc.M104953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546803	Green Accepted, hybrid			2022-12-25	WOS:000172450400134
J	Gilmore, ES; Stutts, MJ; Milgram, SL				Gilmore, ES; Stutts, MJ; Milgram, SL			Src family kinases mediate epithelial Na+ channel inhibition by endothelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; SODIUM-CHANNEL; TYROSINE KINASE; LIDDLE SYNDROME; GROWTH-FACTOR; ENAC CHANNEL; COAT COLOR; ACTIVATION; PHOSPHORYLATION	The epithelial Na+ channel (ENaC) is implicated in the pathogenesis of salt-sensitive hypertension. Recent evidence from animal models suggests that the vasoactive peptide, endothelin (ET-1), may be an important negative regulator of ENaC in vivo. We investigated the signaling pathway involved in endothelin-mediated ENaC inhibition. Experiments were performed in NIH 3T3 cells stably expressing genes for the three (alpha, beta, and gamma) ENaC subunits. In whole cell patch clamp experiments, we found that ET-1 treatment induced a dose-dependent decrease in amiloride-sensitive currents. Using receptor-specific antagonists, we determined that the effects of ET-1 were attributed to activation of the ETB receptor. Moreover, the inhibitory effect of ET-1 on ENaC could be completely blocked when cells were pretreated with the selective Src family kinase inhibitor, PP2. Further studies revealed that basal Src family kinase activity strongly regulates ENaC whole cell currents and single channel gating. These results suggest that Src family kinases lie in a signaling pathway activated by ET-1 and are components of a novel negative regulatory cascade resulting in ENaC inhibition.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res & Tratment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, CB 7545, Chapel Hill, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABRY P, 1997, AM J PHYSIOL, V273, pG571; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1992, AM J PHYSIOL, V262, pF454, DOI 10.1152/ajprenal.1992.262.3.F454; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Chu TS, 1996, J CLIN INVEST, V97, P1454, DOI 10.1172/JCI118567; Chu TS, 1996, AM J PHYSIOL-CELL PH, V271, pC763, DOI 10.1152/ajpcell.1996.271.3.C763; Ciampolillo F, 1996, AM J PHYSIOL-CELL PH, V271, pC1303, DOI 10.1152/ajpcell.1996.271.4.C1303; DAVENPORT AP, 1989, J CARDIOVASC PHAR S5, V13, P166; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DETEJADA IS, 1992, J UROLOGY, V148, P1290, DOI 10.1016/S0022-5347(17)36895-7; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Donowitz M, 2000, ANN NY ACAD SCI, V915, P30; Emala CW, 1999, AM J PHYSIOL-LUNG C, V276, pL564, DOI 10.1152/ajplung.1999.276.4.L564; Gallego MS, 1996, AM J PHYSIOL-RENAL, V271, pF451, DOI 10.1152/ajprenal.1996.271.2.F451; Gariepy CE, 2000, J CLIN INVEST, V105, P925, DOI 10.1172/JCI8609; Gariepy CE, 1996, P NATL ACAD SCI USA, V93, P867, DOI 10.1073/pnas.93.2.867; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Garty H, 2000, KIDNEY INT, V57, P1270, DOI 10.1046/j.1523-1755.2000.00961.x; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HANEDA M, 1995, J AM SOC NEPHROL, V6, P1504; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Karet FE, 1996, CLIN SCI, V91, P267, DOI 10.1042/cs0910267; KIMURA S, 1989, J CARDIOVASC PHAR S5, V13, P5; Kleyman TR, 1999, SEMIN NEPHROL, V19, P524; Kovacic B, 1998, J BIOL CHEM, V273, P35185; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MacFarlane SN, 2000, J NEUROSCI, V20, P5245, DOI 10.1523/JNEUROSCI.20-14-05245.2000; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MARUNAKA Y, 1992, AM J PHYSIOL, V263, pF392, DOI 10.1152/ajprenal.1992.263.3.F392; MASAKI T, 1990, JPN CIRC J, V54, P1221, DOI 10.1253/jcj.54.1221; MASUDA Y, 1989, FEBS LETT, V257, P208, DOI 10.1016/0014-5793(89)81535-2; May A, 1997, J AM SOC NEPHROL, V8, P1813; Mizuguchi T, 1997, BRIT J PHARMACOL, V120, P1427, DOI 10.1038/sj.bjp.0701054; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Robey RB, 2001, AM J PHYSIOL-RENAL, V280, pF844, DOI 10.1152/ajprenal.2001.280.5.F844; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Schieffer B, 1997, AM J PHYSIOL-CELL PH, V272, pC2019, DOI 10.1152/ajpcell.1997.272.6.C2019; Schild L, 1996, NEPHROLOGIE, V17, P395; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Shraga-Levine Z, 2000, CELL MOL NEUROBIOL, V20, P305, DOI 10.1023/A:1007010125316; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; TAKAYANAGI R, 1996, J CARDIOVASC PHARM, V17, pS127; TAKEMOTO F, 1993, AM J PHYSIOL, V264, pF827, DOI 10.1152/ajprenal.1993.264.5.F827; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yue G, 2000, AM J PHYSIOL-CELL PH, V279, pC81, DOI 10.1152/ajpcell.2000.279.1.C81	56	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42610	42617		10.1074/jbc.M106919200	http://dx.doi.org/10.1074/jbc.M106919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11560932	hybrid, Green Published			2022-12-25	WOS:000172450400137
J	LaRochelle, O; Gagne, V; Charron, J; Soh, JW; Seguin, C				LaRochelle, O; Gagne, V; Charron, J; Soh, JW; Seguin, C			Phosphorylation is involved in the activation of metal-regulatory transcription factor 1 in response to metal ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; METALLOTHIONEIN GENE-EXPRESSION; FACTOR MTF-1; IN-VIVO; MEDIATED ACTIVATION; POTENT INHIBITORS; OXIDATIVE STRESS; BINDING-PROTEINS; HEME OXYGENASE-1; ZINC FINGERS	We have studied the role of phosphorylation in the activation of metal-regulatory transcription factor-1 (MTF-1) and metallothionein (MT) gene expression. We showed that MTF-1 is phosphorylated in vivo and that zinc stimulates MTF-1 phosphorylation 2-4-fold. Several kinase inhibitors were used to examine the possible involvement of kinase cascades in the activation of MTF-1. Metal-induced MT gene expression was abrogated by protein kinase C (PKC), c-Jun N-terminal kinase (JN-K), phosphoinositide 3-kinase, and tyrosine-specific protein kinases inhibitors, as assayed by Northern analysis and by cotransfection experiments using a metal regulatory element-luciferase reporter plasmid. The extracellular signal-activated protein kinase and the p38 kinase cascades did not appear to be essential for the activation Aff gene transcription by metals. By using dominant-negative mutants of PKC, JNK., mitogen-activated kinase kinase 4 (MKK4), and MKK7, we provide further evidence supporting a role for PKC and JNK in the activation of MTF-1 in response to metals. Notably, increased MTF-1 DNA binding in response to zinc and MTF-1 nuclear localization was not inhibited in cells preincubated with the different kinase inhibitors despite strong inhibition of MTF-1-mediated gene expression. This suggests that phosphorylation is essential for MTF-1 transactivation function. We hypothesize that metal-induced phosphorylation of MTF-1 is one of the primary events leading to increased MTF-1 activity. Thus, metal ions such as cadmium could activate MTF-1 and induce MT gene expression by stimulating one or several kinases in the MTF-1 signal transduction pathway.	Univ Laval, CHUQ, Hotel Dieu, Ctr Rech Canc, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Dept Anat & Physiol, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1K 7P4, Canada; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Laval University; Laval University; Laval University; Columbia University	Seguin, C (corresponding author), Univ Laval, CHUQ, Hotel Dieu, Ctr Rech Canc, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.	Carl.Seguin@crhdq.ulaval.ca	Charron, Jean/A-9792-2013	Charron, Jean/0000-0002-5133-0056				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Alam J, 2000, J BIOL CHEM, V275, P27694; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; ARIZONO K, 1993, LIFE SCI, V53, P1031, DOI 10.1016/0024-3205(93)90126-N; Bagchi D, 1997, TOXICOL LETT, V91, P31, DOI 10.1016/S0378-4274(97)03868-X; Bellmann K, 2000, J BIOL CHEM, V275, P18172, DOI 10.1074/jbc.M000340200; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Bittel DC, 2000, J BIOL CHEM, V275, P37194, DOI 10.1074/jbc.M003863200; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chu WA, 1999, J BIOL CHEM, V274, P5279, DOI 10.1074/jbc.274.9.5279; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; DAFFADA AAI, 1994, BBA-MOL CELL RES, V1222, P234, DOI 10.1016/0167-4889(94)90174-0; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran N, 1998, ONCOGENE, V17, P1329, DOI 10.1038/sj.onc.1202170; Faraonio R, 2000, EUR J BIOCHEM, V267, P1743, DOI 10.1046/j.1432-1327.2000.01167.x; Giedroc DP, 2001, ANTIOXID REDOX SIGN, V3, P577, DOI 10.1089/15230860152542943; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Koizumi S, 2000, J CELL PHYSIOL, V185, P464, DOI 10.1002/1097-4652(200012)185:3<464::AID-JCP18>3.0.CO;2-4; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; KOIZUMI S, 1992, EUR J BIOCHEM, V210, P555, DOI 10.1111/j.1432-1033.1992.tb17454.x; Kumahara E, 1999, J BIOL CHEM, V274, P10430, DOI 10.1074/jbc.274.15.10430; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; LaRochelle O, 2001, BIOCHEM J, V353, P591, DOI 10.1042/0264-6021:3530591; Maeshima H, 1996, NUCLEIC ACIDS RES, V24, P2959, DOI 10.1093/nar/24.15.2959; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moffatt P, 1998, DNA CELL BIOL, V17, P501, DOI 10.1089/dna.1998.17.501; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Murphy BJ, 1999, CANCER RES, V59, P1315; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Otsuka F, 2000, BBA-GENE STRUCT EXPR, V1492, P330, DOI 10.1016/S0167-4781(00)00110-X; Ozes ON, 1999, NATURE, V401, P82; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; Pouyssegur J, 2000, SCIENCE, V290, P1515, DOI 10.1126/science.290.5496.1515; PRASAD AS, 1995, NUTRITION, V11, P93; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Rajanna B, 1995, TOXICOL LETT, V81, P197, DOI 10.1016/0378-4274(95)03433-1; Ray A, 2000, J BIOL CHEM, V275, P39727, DOI 10.1074/jbc.M007907200; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEFTON BM, 1996, CURRENT PROTOCOLS MO; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Wang Z, 1998, J BIOL CHEM, V273, P73, DOI 10.1074/jbc.273.1.73; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; WHITE C, 1995, DIS EPID MED, V2, P9; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yoo HY, 1999, MOL GEN GENET, V262, P310, DOI 10.1007/s004380051088; Yu CW, 1997, FEBS LETT, V420, P69, DOI 10.1016/S0014-5793(97)01489-0; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200	68	97	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41879	41888		10.1074/jbc.M108313200	http://dx.doi.org/10.1074/jbc.M108313200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551972	hybrid			2022-12-25	WOS:000172450400046
J	Shichiri, M; Hoshikawa, C; Nakamori, S; Takagi, H				Shichiri, M; Hoshikawa, C; Nakamori, S; Takagi, H			A novel acetyltransferase found in Saccharomyces cerevisiae Sigma 1278b that detoxifies a proline analogue, azetidine-2-carboxylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; SERRATIA-MARCESCENS; HEAT-SHOCK; ESCHERICHIA-COLI; PROBA OPERON; GENE; YEAST; BIOSYNTHESIS; SUPERFAMILY	L-Azetidine-2-carboxylic acid (AZC), a toxic four-membered ring analogue Of L-proline, is transported into the cells via proline transporters. It causes misfolding of the proteins into which it is incorporated competitively with L-proline and thereby inhibits the growth of the cells. We recently have discovered, on the chromosome of Saccharomyces cerevisiae Sigma 1278b, a novel gene MPR1 required for the resistance of Sigma 1278 background strains to toxic AZC. This gene was missing in the particular yeast strain used for the genomic sequence determination. Although the protein sequence was homologous to that of the S. cerevisiae transcriptional regulator, Mpr1p did not affect the expression of genes involved in proline uptake. However, gene expression in Escherichia coli and enzymatic analysis showed that the MPR1 gene encodes a novel AZC acetyltransferase, by which L-proline itself and other L-proline analogues are not acetylated. Mpr1p was considered to be a member of the N-acetyl-transferase superfamily based on the results of an Ala-scan mutagenesis through the highly conserved region involved in binding acetyl-CoA in members of the superfamily. Our findings suggest that Mpr1p detoxifies AZC by acetylating it in the cytoplasm. This enzyme might be utilized as a selective marker in a wide variety of organisms, because the cells expressing the MPR1 gene acquire the AZC-resistant phenotype.	Fukui Prefectural Unit, Dept Biosci, Fukui 9101195, Japan		Takagi, H (corresponding author), Fukui Prefectural Unit, Dept Biosci, 4-1-1 Kenjojima,Matsuokacho, Fukui 9101195, Japan.	hiro@fpu.ac.jp		Takagi, Hiroshi/0000-0002-1786-3174				ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Bonhivers M, 1998, J BIOL CHEM, V273, P27565, DOI 10.1074/jbc.273.42.27565; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; FOWDEN L, 1963, BIOCHIM BIOPHYS ACTA, V71, P459, DOI 10.1016/0006-3002(63)91104-1; GRENSON M, 1972, BIOCHEM BIOPH RES CO, V48, P749, DOI 10.1016/0006-291X(72)90670-5; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; Inouye S, 1997, GENE, V189, P159, DOI 10.1016/S0378-1119(96)00753-6; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KLOHS WD, 1985, J NATL CANCER I, V75, P353; Kobayashi O, 1996, MOL GEN GENET, V251, P707, DOI 10.1007/s004380050220; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LEETE E, 1964, J AM CHEM SOC, V86, P3162, DOI 10.1021/ja01069a045; LEETE E, 1986, PHYTOCHEMISTRY, V25, P2753, DOI 10.1016/S0031-9422(00)83735-8; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Liu HP, 1996, GENETICS, V144, P967; MINAKATA H, 1985, EXPERIENTIA, V41, P1622, DOI 10.1007/BF01964840; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; NATSOULIS G, 1994, GENETICS, V136, P93; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; OMORI K, 1991, J GEN MICROBIOL, V137, P509, DOI 10.1099/00221287-137-3-509; OMORI K, 1992, J GEN MICROBIOL, V138, P693, DOI 10.1099/00221287-138-4-693; PETERSON PJ, 1963, NATURE, V200, P148, DOI 10.1038/200148a0; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Reese LM, 1996, LETT APPL MICROBIOL, V22, P202, DOI 10.1111/j.1472-765X.1996.tb01143.x; Sambrook J, 2001, MOL CLONING LAB MANU; SMITH CJ, 1984, J BACTERIOL, V157, P545, DOI 10.1128/JB.157.2.545-551.1984; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; SUGIURA M, 1985, APPL MICROBIOL BIOT, V21, P213, DOI 10.1007/BF00295125; Takagi H, 2000, J BACTERIOL, V182, P4249, DOI 10.1128/JB.182.15.4249-4256.2000; Takagi H, 1997, APPL MICROBIOL BIOT, V47, P405, DOI 10.1007/s002530050948; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; YAMASHITA I, 1993, MOL GEN GENET, V241, P616, DOI 10.1007/BF00279904; Yokota S, 2000, EUR J BIOCHEM, V267, P1658, DOI 10.1046/j.1432-1327.2000.01157.x	40	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41998	42002		10.1074/jbc.C100487200	http://dx.doi.org/10.1074/jbc.C100487200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11555637	hybrid			2022-12-25	WOS:000172450400062
J	Liu, XH; Collier, RJ; Youle, RJ				Liu, XH; Collier, RJ; Youle, RJ			Inhibition of axotomy-induced neuronal apoptosis by extracellular delivery of a Bcl-XL fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL GANGLION-CELLS; NERVE GROWTH-FACTOR; TOXIN-MEDIATED DELIVERY; TRANSGENIC MICE; ANTHRAX TOXIN; LETHAL FACTOR; PROTECTIVE ANTIGEN; IN-VITRO; DEATH; EXPRESSION	Bcl-2 and Bcl-XL prevent neuronal apoptosis during development, neurodegenerative disease, and trauma. To test a new anti-apoptosis strategy for neuroprotection, we engineered nontoxic components of anthrax toxin into a Bcl-XL delivery system. Delivery of Bcl-XL by this system prevented apoptosis of cultured rat cerebellar granule cells and macrophages, and the prevention depended on both the Bcl-XL and the anthrax toxin receptor binding/translocation moieties. Furthermore, neuronal death in vivo in a retinal ganglion cell model of axotomy-induced apoptosis was inhibited by administration of this fusion protein. Thus, Bcl-XL protein can he delivered into cells from the medium or interstitial space, offering a new way to block apoptosis upstream of many caspases and the mitochondria dysfunction phase of apoptosis.	NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Harvard University; Harvard Medical School	Youle, RJ (corresponding author), NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bldg 10,Rm 5D-37,MSC 1414,10 Ctr Dr, Bethesda, MD 20892 USA.	youle@helix.nih.gov		Collier, R John/0000-0002-2427-4239	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002674, ZIANS002859, ZIANS002674, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; ARORA N, 1994, J BIOL CHEM, V269, P26165; Ballard JD, 1998, INFECT IMMUN, V66, P615, DOI 10.1128/IAI.66.2.615-619.1998; Ballard JD, 1996, P NATL ACAD SCI USA, V93, P12531, DOI 10.1073/pnas.93.22.12531; Ballard JD, 1998, INFECT IMMUN, V66, P4696, DOI 10.1128/IAI.66.10.4696-4699.1998; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonfanti L, 1996, J NEUROSCI, V16, P4186; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BRAGG TS, 1989, GENE, V81, P45, DOI 10.1016/0378-1119(89)90335-1; Cenni MC, 1996, EUR J NEUROSCI, V8, P1735, DOI 10.1111/j.1460-9568.1996.tb01317.x; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doling AM, 1999, INFECT IMMUN, V67, P3290, DOI 10.1128/IAI.67.7.3290-3296.1999; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FANG W, 1994, J IMMUNOL, V153, P4388; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goletz TJ, 1997, P NATL ACAD SCI USA, V94, P12059, DOI 10.1073/pnas.94.22.12059; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HARVEY AR, 1994, EUR J NEUROSCI, V6, P550, DOI 10.1111/j.1460-9568.1994.tb00299.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Kasarskis EJ, 1999, NEUROLOGY, V52, P1427; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Lawrence MS, 1996, J NEUROSCI, V16, P486; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu XH, 1999, P NATL ACAD SCI USA, V96, P9563, DOI 10.1073/pnas.96.17.9563; Lonser RR, 1998, J NEUROSURG, V89, P616, DOI 10.3171/jns.1998.89.4.0616; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McArthur, 2000, NEUROLOGY, V55, P162; McArthur JC, 2000, NEUROLOGY, V54, P1080, DOI 10.1212/WNL.54.5.1080; MERRY DE, 1994, DEVELOPMENT, V120, P301; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Mufson EJ, 1999, PROG NEUROBIOL, V57, P451, DOI 10.1016/S0301-0082(98)00059-8; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nir I, 2000, J NEUROSCI, V20, P2150; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Porciatti V, 1996, P NATL ACAD SCI USA, V93, P14955, DOI 10.1073/pnas.93.25.14955; RABACCHI SA, 1994, J NEUROSCI, V14, P5292; Rosenblum WI, 1999, STROKE, V30, P1154, DOI 10.1161/01.STR.30.5.1154; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SMALE G, 1995, EXP NEUROL, V55, P481; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	72	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46326	46332		10.1074/jbc.M108930200	http://dx.doi.org/10.1074/jbc.M108930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574549	hybrid			2022-12-25	WOS:000172573100114
J	Southall, MD; Isenberg, JS; Nakshatri, H; Yi, QF; Pei, Y; Spandau, DF; Travers, JB				Southall, MD; Isenberg, JS; Nakshatri, H; Yi, QF; Pei, Y; Spandau, DF; Travers, JB			The platelet-activating factor receptor protects epidermal cells from tumor necrosis factor (TNF) alpha and TNF-related apoptosis-inducing ligand-induced apoptosis through an NF-kappa B-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; HUMAN KERATINOCYTES; TRANSFORMED KERATINOCYTES; DEATH; SUPPRESSION; INHIBITOR; IAP; IDENTIFICATION; BIOSYNTHESIS; EXPRESSION	A number of chemical mediators can induce human keratinocytes and epidermal-derived carcinomas to undergo apoptosis, or programmed cell death. Recent evidence suggests pro-inflammatory cytokines, such as interleukin-1 beta or transforming growth factor alpha, protects carcinomas from numerous pro-apoptotic stimuli. Platelet-activating factor (1-alkyl-2-acetyl-3-glycerophosphocholine; PAF) is a lipid mediator with pro-inflammatory effects on numerous cell types. Although PAF can be metabolized to other bioactive lipids, the majority of PAF effects occur through activation of a G protein-coupled receptor. Using a model system created by retroviral transduction of the PAF receptor (PAF-R) into the PAF-R-negative human epidermal cell line KB and the PAF-R-expressing keratinocyte cell line HaCaT, we now demonstrate that activation of the epidermal PAF-R results in protection from apoptosis induced by tumor necrosis factor (TNF) alpha or TNF-related apoptosis-inducing ligand. The PAF-mediated protection was inhibited by PAF-R antagonists, and protection did not occur in PAF-R-negative KB cells. Additionally, we show protection from TNF alpha- or TRAIL-induced apoptosis by PAF-R activation is dependent on the transcription factor nuclear factor (NF)-kappaB, because PAF-R activation-induced NF-kappaB and epidermal cells transduced with a super-repressor form of inhibitor kappaB were not protected by the PAF-R. These studies provide a mechanism whereby the epidermal PAF-R, and possibly other G protein-coupled receptors, can exert anti-apoptotic effects through an NF-kappaB-dependent process.	Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Travers, JB (corresponding author), Indiana Univ, Sch Med, Riley Hosp Children, HB Wells Ctr Pediat Res, 702 Barnhill Dr,Rm 2659, Indianapolis, IN 46202 USA.			Travers, Jeffrey/0000-0001-7232-1039; Nakshatri, Harikrishna/0000-0001-8876-0052	NHLBI NIH HHS [R01HL62996] Funding Source: Medline; NIAMS NIH HHS [K08AR1993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; AZZOUZI BE, 1993, BIOCHEM BIOPH RES CO, V190, P320; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bours V, 2000, TOXICOLOGY, V153, P27, DOI 10.1016/S0300-483X(00)00302-4; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; DENIZOT Y, 1995, CANCER LETT, V88, P185, DOI 10.1016/0304-3835(94)03631-R; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DOSSANTOS OFP, 1991, KIDNEY INT, V40, P742, DOI 10.1038/ki.1991.269; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Dy LC, 1999, J BIOL CHEM, V274, P26917, DOI 10.1074/jbc.274.38.26917; EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Foo SY, 1999, TRENDS GENET, V15, P229; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Grignani F, 1998, CANCER RES, V58, P14; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Leverkus M, 2000, CANCER RES, V60, P553; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Mustapha S, 2000, AM J PHYSIOL-HEART C, V279, pH939, DOI 10.1152/ajpheart.2000.279.3.H939; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Pei Y, 1998, J IMMUNOL, V161, P1954; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Pulliam L, 1998, J NEUROSCI RES, V54, P530, DOI 10.1002/(SICI)1097-4547(19981115)54:4<530::AID-JNR10>3.0.CO;2-1; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reinartz J, 1996, EXP CELL RES, V228, P334, DOI 10.1006/excr.1996.0333; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Toledano BJ, 1999, CELL IMMUNOL, V191, P60, DOI 10.1006/cimm.1998.1410; Travers JB, 1999, J INVEST DERMATOL, V112, P279, DOI 10.1046/j.1523-1747.1999.00521.x; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Williams DA, 2000, BLOOD, V96, P1646; WOODCOCK A, 1976, BRIT J DERMATOL, V95, P459, DOI 10.1111/j.1365-2133.1976.tb00854.x	54	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45548	45554		10.1074/jbc.M105978200	http://dx.doi.org/10.1074/jbc.M105978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571293	hybrid, Green Published			2022-12-25	WOS:000172573100010
J	Bello, RI; Gomez-Diaz, C; Navarro, F; Alcain, FJ; Villalba, JM				Bello, RI; Gomez-Diaz, C; Navarro, F; Alcain, FJ; Villalba, JM			Expression of NAD(P)H : Quinone oxidoreductase 1 in HeLa cells - Role of hydrogen peroxide and growth phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANTIOXIDANT-RESPONSE-ELEMENT; DT-DIAPHORASE; RAT HEPATOCYTES; PROLIFERATING CELLS; AEROBIC GLYCOLYSIS; OXIDATIVE STRESS; MITOMYCIN-C; VITAMIN-E; REDUCTASE	The aim of this work was to study the role of H2O2 in the regulation of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.99.2) with relation to cell density of HeLa cells cultures and the function played by NQO1 in these cells. Levels of NQO1 activity were much higher (40-fold) in confluent HeLa cells than in sparse cells, the former cells being much more resistant to H2O2. Addition of sublethal concentrations of H2O2 (up to 24 muM) produced a significant increase of NQO1 (up to 16-fold at 12 muM) in sparse cells but had no effect in confluent cells. When cells reached confluency in the presence of pyruvate, a H2O2 scavenger, NQO1 activity was decreased compared with cultures grown to confluency without pyruvate. Inhibition of quinone reductases by dicumarol substantially decreased viability of confluent cells in serum-free medium. This is the first demonstration that regulation of NQO1 expression by H2O2 is dependent on the cell density in HeLa cells and that endogenous generation of H2O2 participates in the increase of NQO1 activity as cell density is higher. This enzyme is required to promote survival of confluent cells.	Univ Cordoba, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Cordoba 14071, Spain	Universidad de Cordoba	Villalba, JM (corresponding author), Univ Cordoba, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Edificio C-6,3A Planta, Cordoba 14014, Spain.	bc1vimoj@uco.es	Navarro Roldán, Francisco/H-8611-2015; Alcain, Francisco J./N-7503-2016	Navarro Roldán, Francisco/0000-0002-6384-5575; Alcain, Francisco J./0000-0002-6833-7940; Villalba Montoro, Jose Manuel/0000-0001-8554-3802				Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; Brand K, 1997, J BIOENERG BIOMEMBR, V29, P355, DOI 10.1023/A:1022498714522; Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507; BROWN JM, 1989, INFLAMMATION, V13, P583, DOI 10.1007/BF00916764; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; BURDON RH, 1993, FREE RADICAL RES COM, V18, P369, DOI 10.3109/10715769309147503; Burdon RH, 1996, FEBS LETT, V383, P150, DOI 10.1016/0014-5793(96)00230-X; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Del Bello B, 1999, FASEB J, V13, P69; DELBELLO B, 1976, FASEB J, V32, P465; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; ERNSTER L, 1958, FED PROC, V17, P216; ERNSTER L, 1958, ACTA CHEM SCAND, V12, P595, DOI 10.3891/acta.chem.scand.12-0595; Faig M, 2000, P NATL ACAD SCI USA, V97, P3177, DOI 10.1073/pnas.050585797; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200; Garrido C, 1997, CANCER RES, V57, P2661; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Joseph P, 2000, BRIT J CANCER, V82, P1305; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kreuzer T, 1998, FREE RADICAL BIO MED, V25, P42, DOI 10.1016/S0891-5849(98)00029-X; Landi L, 1997, FREE RADICAL BIO MED, V22, P329, DOI 10.1016/S0891-5849(96)00294-8; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; LIND C, 1990, METHOD ENZYMOL, V186, P287; Long DJ, 2000, CANCER RES, V60, P5913; Marin A, 1997, BRIT J CANCER, V76, P923, DOI 10.1038/bjc.1997.485; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Navarro F, 1999, BIOFACTORS, V9, P163, DOI 10.1002/biof.5520090211; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Petitpas I, 2001, J BIOL CHEM, V276, P22804, DOI 10.1074/jbc.M100575200; Phillips RM, 1997, BRIT J CANCER, V75, P196, DOI 10.1038/bjc.1997.33; PHILLIPS RM, 1994, CANCER RES, V54, P3766; Phillips RM, 2000, CANCER RES, V60, P6384; PREUSCH PC, 1991, FREE RADICAL BIO MED, V11, P77, DOI 10.1016/0891-5849(91)90191-5; RAHMAN MH, 1992, J PHARMACOBIO-DYNAM, V15, P7, DOI 10.1248/bpb1978.15.7; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHLAGER JJ, 1993, CANCER RES, V53, P1338; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; Sieger D, 2000, FREE RADICAL BIO MED, V29, P246, DOI 10.1016/S0891-5849(00)00310-5; Siemankowski LM, 2000, CANCER RES, V60, P3638; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Suzuki K, 1997, J BIOCHEM, V121, P496; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Takahashi T, 1999, BIOL PHARM BULL, V22, P1226; Uchida N, 2000, J BACTERIOL, V182, P6933, DOI 10.1128/JB.182.24.6933-6939.2000; WOSILAIT WD, 1981, DRUG METAB DISPOS, V9, P80; Wu KB, 1997, ARCH BIOCHEM BIOPHYS, V347, P221, DOI 10.1006/abbi.1997.0344; YOSHPEPURER Y, 1976, APPL ENVIRON MICROB, V32, P465, DOI 10.1128/AEM.32.4.465-469.1976	59	45	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44379	44384		10.1074/jbc.M107168200	http://dx.doi.org/10.1074/jbc.M107168200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567026	hybrid			2022-12-25	WOS:000172406700005
J	Bieberich, E; MacKinnon, S; Silva, J; Yu, RK				Bieberich, E; MacKinnon, S; Silva, J; Yu, RK			Regulation of apoptosis during neuronal differentiation by ceramide and b-series complex gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; NEUROBLASTOMA-CELLS; SIGNAL-TRANSDUCTION; STEM-CELLS; PKC-ZETA; PROTEIN; EXPRESSION; GROWTH; DEATH; INSULIN-LIKE-GROWTH-FACTOR-1	Lipid analysis of gestational day E14.5 mouse brain revealed elevation of ceramide to a tissue concentration that induced apoptosis when added to the medium of neuroprogenitor cells grown in cell culture. Elevation of ceramide was coincident with the first appearance of b-series complex gangliosides (BCGs). Expression of BCGs by stable transfection of murine neuroblastoma (F-11) cells with sialyltransferase-II (ST2) resulted in a 70% reduction of ceramide-induced apoptosis. This was most likely due to an 80% reduced expression of prostate apoptosis response-4 (PAR-4). PAR-4 expression and apoptosis were restored by preincubation of ST2-transfected cells with N-butyl deoxinojirimycin (NB-DNJ) or PD98059, two inhibitors of ganglioside biosynthesis or p42/44 mitogen-activated protein (MAPK) kinase, respectively. In sections of day E14.5 mouse brain, the intermediate zone showed intensive staining for complex gangliosides, but only low staining for apoptosis (TUNEL) and PAR-4. Apoptosis and PAR-4 expression, however, were elevated in the ventricular zone which only weakly stained for complex gangliosides. Whole cell patch clamping revealed a 2-fold increased calcium influx in ST2-transfected cells, the blocking of which with nifedipine restored apoptosis to the level of untransfected cells. In serum-free culture, supplementation of the medium with IGF-1 was required to maintain MAPK phosphorylation and the anti-apoptotic effect of BCG expression. BCG-enhanced calcium influx and the presence of insulin-like growth factor-1 may thus activate a cell survival mechanism that selectively protects developing neurons against ceramide-induced apoptosis by up-regulation of MAPK and reduction of PAR-4 expression.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Bieberich, E (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St CB-2803, Augusta, GA 30912 USA.			Silva, PhD, MPA, EdS, EdD, MB(ASCP)CM, Jeane/0000-0003-3368-3963	NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH061934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853] Funding Source: NIH RePORTER; NIMH NIH HHS [MH61934-04] Funding Source: Medline; NINDS NIH HHS [NS11853] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bieberich E, 2000, J NEUROCHEM, V74, P2359, DOI 10.1046/j.1471-4159.2000.0742359.x; Bieberich E, 2000, J BIOL CHEM, V275, P177, DOI 10.1074/jbc.275.1.177; Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Blair LAC, 1999, J NEUROSCI, V19, P1940; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Conway AM, 2000, CELL SIGNAL, V12, P737, DOI 10.1016/S0898-6568(00)00119-4; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FRANCEL PC, 1987, J NEUROCHEM, V48, P1624, DOI 10.1111/j.1471-4159.1987.tb05711.x; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Furuse H, 1998, EXP BRAIN RES, V123, P307, DOI 10.1007/s002210050573; Garcia-de Lacoba M, 1999, ENDOCRINOLOGY, V140, P233, DOI 10.1210/en.140.1.233; GERSHONI JM, 1983, ANAL BIOCHEM, V13, P1; Goswami R, 2000, J NEUROSCI RES, V60, P141, DOI 10.1002/(SICI)1097-4547(20000415)60:2<141::AID-JNR2>3.0.CO;2-5; Goswami R, 1999, J NEUROSCI RES, V57, P884, DOI 10.1002/(SICI)1097-4547(19990915)57:6<884::AID-JNR14>3.3.CO;2-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hancock CR, 2000, BIOCHEM BIOPH RES CO, V271, P418, DOI 10.1006/bbrc.2000.2631; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; Liour SS, 2000, J NEUROSCI RES, V62, P363, DOI 10.1002/1097-4547(20001101)62:3<363::AID-JNR6>3.0.CO;2-E; Liu B, 1999, MATER CHEM PHYS, V57, P219, DOI 10.1016/S0254-0584(98)00219-3; MACALA LJ, 1983, J LIPID RES, V24, P1243; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20-22-08435.2000; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; RAHMANN H, 1995, BEHAV BRAIN RES, V66, P105, DOI 10.1016/0166-4328(94)00131-X; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Schwarz A, 1997, J NEUROSCI, V17, P2929; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Tanaka Y, 1997, NEUROREPORT, V8, P2203, DOI 10.1097/00001756-199707070-00023; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Wu GS, 2001, P NATL ACAD SCI USA, V98, P307, DOI 10.1073/pnas.011523698; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; YU RK, 1994, PROG BRAIN RES, V101, P31; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	45	66	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44396	44404		10.1074/jbc.M107239200	http://dx.doi.org/10.1074/jbc.M107239200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574545	hybrid			2022-12-25	WOS:000172406700008
J	Cho, EG; Kim, MG; Kim, C; Kim, SR; Seong, IS; Chung, CH; Schwartz, RH; Park, D				Cho, EG; Kim, MG; Kim, C; Kim, SR; Seong, IS; Chung, CH; Schwartz, RH; Park, D			N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; HAGEMAN-FACTOR; DEPENDENT AUTOACTIVATION; PLASMINOGEN-ACTIVATOR; BLOOD-COAGULATION; 1ST COMPONENT; FACTOR-VII; IDENTIFICATION; MATRIPTASE	Epithin was originally identified as a mouse type II membrane serine protease. Its human orthologue membrane type-serine protease 1 (MT-SP1)/matriptase has been reported to be localized on the plasma membrane. In addition, soluble forms of matriptase were isolated from human breast milk and breast cancer cell-conditioned medium. In this paper, we report a processing mechanism that appears to be required for the release of epithin. CHO-K1 or COS7 cells transfected with single full-length epithin cDNA generated two different-sized proteins in cell lysates, 110 and 92 kDa. The 92-kDa epithin was found to be an N-terminally truncated form of the 110-kDa epithin, and it was the only form detected in the culture medium. The 92-kDa epithin was also found on the cell surface, where it was anchored by the N-terminal fragment. The results of in vivo cell labeling experiments indicate that the 110-kDa epithin is rapidly processed to the 92-kDa epithin. Using site-directed mutagenesis experiments, we identified Gly(149) of the GSVIA sequence in epithin as required for the processing and release of the protein. These results suggest that N-terminal processing of epithin at Gly149 is a necessary prerequisite step for release of the protein.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; NIAID, Cellular & Mol Immunol Lab, NIH, Bethesda, MD 20892 USA; Chungbuk Natl Univ, Coll Med, Cheongju 361763, South Korea	Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Chungbuk National University	Park, D (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000613] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander DS, 1998, J BIOL CHEM, V273, P7457, DOI 10.1074/jbc.273.13.7457; BENAUD C, 2001, EUR J BIOCHEM, V268, P1; BIANCHINO AC, 1988, J IMMUNOL, V141, P3930; DODDS AW, 1978, BIOCHEM J, V175, P383, DOI 10.1042/bj1750383; DUNN JT, 1982, J BIOL CHEM, V257, P1779; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; SHI YE, 1993, CANCER RES, V53, P1409; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; TANS G, 1983, J BIOL CHEM, V258, P8215; Vu TKH, 1997, J BIOL CHEM, V272, P31315, DOI 10.1074/jbc.272.50.31315; WIGGINS RC, 1979, J EXP MED, V150, P1122, DOI 10.1084/jem.150.5.1122; Yamada K, 2000, GENE, V252, P209, DOI 10.1016/S0378-1119(00)00225-0	22	72	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44581	44589		10.1074/jbc.M107059200	http://dx.doi.org/10.1074/jbc.M107059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567025	hybrid			2022-12-25	WOS:000172406700034
J	Gage, RM; Kim, KA; Cao, TT; von Zastrow, M				Gage, RM; Kim, KA; Cao, TT; von Zastrow, M			A transplantable sorting signal that is sufficient to mediate rapid recycling of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; DELTA-OPIOID RECEPTOR; DYNAMIN-DEPENDENT ENDOCYTOSIS; DOWN-REGULATION; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; BETA-2-ADRENERGIC RECEPTOR; VASOPRESSIN RECEPTOR; ACTIVATED RECEPTOR-1; THROMBIN RECEPTORS	The beta (2)-adrenergic receptor and delta opioid receptor represent distinct G protein-coupled receptors that undergo agonist-induced endocytosis via clathrin-coated pits but differ significantly in their postendocytic sorting between recycling and degradative membrane pathways, respectively. Previous results indicate that a distal portion of the carboxyl-terminal cytoplasmic domain of the beta (2)-adrenergic receptor, which engages in PDZ domain-mediated protein interaction, is required for efficient recycling of receptors after agonist-induced endocytosis. Here we demonstrate that a four-residue sequence (DSLL) comprising the core of this protein interaction domain functions as a transplantable endocytic sorting signal that is sufficient to re-route endocytosed delta opioid receptor into a rapid recycling pathway, to inhibit proteolytic down-regulation of receptors, and to mediate receptor-autonomous sorting of mutant receptors from the wild type allele when co-expressed in the same cells. These observations define a transplantable signal mediating rapid recycling of a heterologous G protein-coupled receptor, and they suggest that rapid recycling of certain membrane proteins does not occur by bulk membrane flow but is instead mediated by a specific endocytic sorting mechanism.	Univ Calif San Francisco, Dept Psychiat, Grad Program Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, Grad Program Cell Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gage, RM (corresponding author), Univ Calif San Francisco, Dept Psychiat, Grad Program Pharmaceut Chem, Box 0984, San Francisco, CA 94143 USA.							Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; HEIN L, 1994, J BIOL CHEM, V269, P27719; Innamorati G, 1999, J RECEPT SIGNAL TR R, V19, P315, DOI 10.3109/10799899909036654; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1982, MOL PHARMACOL, V72, P1; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; VON ZM, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	55	109	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44712	44720		10.1074/jbc.M107417200	http://dx.doi.org/10.1074/jbc.M107417200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11560936	hybrid			2022-12-25	WOS:000172406700051
J	Hiser, L; Hosler, JP				Hiser, L; Hosler, JP			Heme A is not essential for assembly of the subunits of cytochrome c oxidase of Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; ESCHERICHIA-COLI; GENE; CLONING; YEAST; COX10; PURIFICATION; RESOLUTION; DEFICIENCY; STABILITY	The aa(3)-type cytochrome c oxidase of Rhodohacter sphaeroides, a proteobacterium of the alpha subgroup, is structurally similar to the core subunits of the terminal oxidase in the mitochondrial electron transport chain. Subunit I, the product of the coil gene, normally binds two heme A molecules. A deletion of cox10, the gene for the farnesyltransferase required for heme A synthesis, did not prevent high level accumulation of subunit I in the cytoplasmic membrane. Thus, subunit I can be expressed and stably inserted into the cytoplasmic membrane in the absence of heme A. Aposubunit I was purified via affinity chromatography to a polyhistidine tag. Copurification of subunits II and III with aposubunit I indicated that assembly of the core oxidase complex occurred without the binding of heme A. In addition to formation of the apooxidase containing all three large structural proteins, CoxI-II and CoxI-III heterodimers were isolated from cox10 deletion strains harboring expression plasmids with coxI and coxII or with coxI and coxIII, respectively. This demonstrated that subunit assembly of the apoenzyme was not an inherently ordered or sequential process. Thus, multiple paths must be considered for understanding the assembly of this integral membrane metalloprotein complex.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Hosler, JP (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA.	jhosler@biochem.umsmed.edu			NIGMS NIH HHS [GM56824] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056824] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bratton MR, 2000, BIOCHEMISTRY-US, V39, P12989, DOI 10.1021/bi0003083; CAO J, 1992, J BIOL CHEM, V267, P24273; CAO JL, 1991, GENE, V101, P133, DOI 10.1016/0378-1119(91)90235-4; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; FENG YQ, 1991, BIOCHEMISTRY-US, V30, P10150, DOI 10.1021/bi00106a011; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Ostermeier C, 1996, CURR OPIN STRUC BIOL, V6, P460, DOI 10.1016/S0959-440X(96)80110-2; PEIFFER WE, 1990, BIOCHEMISTRY-US, V29, P8696, DOI 10.1021/bi00489a027; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; Robinson BH, 2000, PEDIATR RES, V48, P581, DOI 10.1203/00006450-200011000-00004; SAIKI K, 1993, J BIOL CHEM, V268, P26041; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; Toledo-Cuevas M, 1998, BBA-BIOENERGETICS, V1365, P421, DOI 10.1016/S0005-2728(98)00095-4; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; WIELBURSKI A, 1983, BIOCHEM J, V212, P829, DOI 10.1042/bj2120829; Wong C, 2000, BIOTECHNIQUES, V28, P426, DOI 10.2144/00283bm07; WOODS JS, 1977, MOL PHARMACOL, V13, P50; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; Zhen Y, 1998, PROTEIN EXPRES PURIF, V13, P326, DOI 10.1006/prep.1998.0903	36	17	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45403	45407		10.1074/jbc.M107016200	http://dx.doi.org/10.1074/jbc.M107016200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574544	hybrid			2022-12-25	WOS:000172406700137
J	Malek, S; Chen, Y; Huxford, T; Ghosh, G				Malek, S; Chen, Y; Huxford, T; Ghosh, G			I kappa B beta but not I kappa B alpha, functions as a classical cytoplasmic inhibitor of NF-kappa B dimers by masking both NF-kappa B nuclear localization sequences in resting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; EXPORT SIGNAL; PEST DOMAIN; P50/P65 HETERODIMER; CRYSTAL-STRUCTURE; C-REL; PHOSPHORYLATION; PROTEINS; MECHANISM; P50	NF-kappaB dimers, inhibitor I kappaB proteins, and NF-kappaB .I kappaB complexes exhibit distinct patterns in partitioning between nuclear and cytoplasmic cellular compartments. I kappaB-dependent modulation of NF-kappaB subcellular localization represents one of the more poorly understood processes in the NF-kappaB signaling pathway. In this study, we have combined in vitro biochemical and cell-based methods to elucidate differences in NF-kappaB regulation exhibited by the inhibitors I kappaB beta and I kappaB alpha. We show that although both I kappaB alpha and I kappaB beta bind to NF-kappaB with similar global architecture and stability, significant differences exist that contribute to their unique functional roles. I kappaB beta derives its high affinity toward NF-kappaB dimers by binding to both NF-kappaB subunit nuclear localization signals. In contrast, I kappaB alpha contacts only one NF-kappaB NLS and employs its carboxyl-terminal proline, glutamic acid, serine, and threonine-rich region for high affinity NF-kappaB binding. We show that the presence of one free NLS in the NF-kappaB .I kappaB alpha complex renders it a dynamic nucleocytoplasmic complex, whereas NF-kappaB .I kappaB beta complexes are localized to the cytoplasm of resting cells.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,Urey Hall 5230,9500 Gilman Dr, La Jolla, CA 92093 USA.			Malek, Shiva/0000-0002-9526-7968; Huxford, Tom/0000-0002-1939-7373	NCI NIH HHS [CA-78749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Huxford T, 2000, J BIOL CHEM, V275, P32800, DOI 10.1074/jbc.M006037200; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	46	138	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45225	45235		10.1074/jbc.M105865200	http://dx.doi.org/10.1074/jbc.M105865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571291	hybrid			2022-12-25	WOS:000172406700116
J	Miller, SA; Binder, EM; Blackman, MJ; Carruthers, VB; Kim, K				Miller, SA; Binder, EM; Blackman, MJ; Carruthers, VB; Kim, K			A conserved subtilisin-like protein TgSUB1 in microneme organelles of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN-1; MOLECULAR CHARACTERIZATION; HOST-CELLS; INVASION; PARASITE; HOMOLOG; SURFACE; REDISTRIBUTION; ERYTHROCYTE; SUBTILASES	Proteolytic processing plays a significant role in the process of invasion by the obligate intracellular parasite Toxoplasma gondii. We have cloned a gene, TgSUB1, encoding for a subtilisin-type serine protease found in T. gondii tachyzoites. TgSUB1 protein is homologous to other Apicomplexan and bacterial subtilisins and is processed within the secretory pathway of the parasite. Initial cleavage occurs in the endoplasmic reticulum, after which the protein is transported to micronemes, vesicles that secrete early during host cell invasion. Upon stimulation of microneme secretion, TgSUB1 is cleaved into smaller products that are secreted from the parasite. This secondary processing is inhibited by brefeldin A and serine protease inhibitors. TgSUB1 is a candidate processing enzyme for several microneme proteins cleaved within the secretory pathway or during invasion.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; MRC National Institute for Medical Research; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kim, K (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Infect Dis, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kkim@aecom.yu.edu		Carruthers, Vern/0000-0001-6859-8895; Kim, Kami/0000-0003-3384-152X	NIAID NIH HHS [T32-AI07506] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; PHS HHS [R01-A146985, 513504] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANYAL HS, 1981, J PARASITOL, V67, P623, DOI 10.2307/3280435; Barale JC, 1999, P NATL ACAD SCI USA, V96, P6445, DOI 10.1073/pnas.96.11.6445; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; Boothroyd JC, 1997, PHILOS T ROY SOC B, V352, P1347, DOI 10.1098/rstb.1997.0119; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; BRETON CB, 1992, P NATL ACAD SCI USA, V89, P9647, DOI 10.1073/pnas.89.20.9647; Brown PJ, 2000, MOL BIOCHEM PARASIT, V107, P91, DOI 10.1016/S0166-6851(00)00179-1; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Conseil V, 1999, ANTIMICROB AGENTS CH, V43, P1358, DOI 10.1128/AAC.43.6.1358; DEJKRIENGKRAIKHUL PN, 1983, Z PARASITENKD, V69, P313, DOI 10.1007/BF00927873; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; Garcia-Reguet N, 2000, CELL MICROBIOL, V2, P353, DOI 10.1046/j.1462-5822.2000.00064.x; Hackett F, 1999, MOL BIOCHEM PARASIT, V103, P183, DOI 10.1016/S0166-6851(99)00122-X; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; Kocken CHM, 2000, MOL BIOCHEM PARASIT, V109, P147, DOI 10.1016/S0166-6851(00)00250-4; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Louie K, 1999, MOL BIOCHEM PARASIT, V103, P211, DOI 10.1016/S0166-6851(99)00127-9; MAYER R, 1991, J MED CHEM, V34, P3029, DOI 10.1021/jm00114a011; OLAYA P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P217, DOI 10.1016/0925-4439(91)90008-W; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; Pacheco-Soares C, 1998, CELL STRUCT FUNCT, V23, P159, DOI 10.1247/csf.23.159; Qin CL, 1998, MOL BIOCHEM PARASIT, V93, P273, DOI 10.1016/S0166-6851(98)00042-5; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; Sajid M, 2000, J BIOL CHEM, V275, P631, DOI 10.1074/jbc.275.1.631; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; SussToby E, 1996, P NATL ACAD SCI USA, V93, P8413, DOI 10.1073/pnas.93.16.8413; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	41	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45341	45348		10.1074/jbc.M106665200	http://dx.doi.org/10.1074/jbc.M106665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564738	hybrid			2022-12-25	WOS:000172406700129
J	Polesskaya, A; Harel-Bellan, A				Polesskaya, A; Harel-Bellan, A			Acetylation of MyoD by p300 requires more than its histone acetyltransferase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COACTIVATORS P300; PCAF; TRANSCRIPTION; DISTINCT; BINDING; PROTEIN; ROLES; CBP	MyoD, an essential transcription factor involved in muscle cell terminal differentiation, is regulated by acetylation, as are a number of other transcription factors, but the histone acetyltransferase enzyme responsible for this acetylation is a matter of controversy. In particular, contradictory findings have been reported concerning the ability of CBP/p300 to acetylate MyoD in vitro. Here we provide an explanation for this discrepancy: although full-length p300 does indeed acetylate MyoD, a fragment of p300 corresponding to its histone acetyltransferase domain does not. In addition to clearly demonstrating that p300 acetylates MyoD in vitro, these results underscore the necessity of using full-length histone acetyltransferase enzymes to draw valid conclusions from acetylation experiments.	Inst Andre Lwoff, CNRS, Unite Propre Rech 9079, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Harel-Bellan, A (corresponding author), Inst Andre Lwoff, CNRS, Unite Propre Rech 9079, 7 Rue Guy Moquet, F-94800 Villejuif, France.		Harel-Bellan, Annick/M-9795-2015	Harel-Bellan, Annick/0000-0002-2339-153X				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Buckingham M, 1996, BIOCHEM SOC T, V24, P506, DOI 10.1042/bst0240506; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	17	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44502	44503		10.1074/jbc.M106501200	http://dx.doi.org/10.1074/jbc.M106501200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577095	hybrid			2022-12-25	WOS:000172406700022
J	Allen, DL; Sartorius, CA; Sycuro, LK; Leinwand, LA				Allen, DL; Sartorius, CA; Sycuro, LK; Leinwand, LA			Different pathways regulate expression of the skeletal myosin heavy chain genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER-TYPE; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; PROMOTER ELEMENTS; BINDING-SITE; MUSCLE-CELLS; E-BOX; MOUSE; STIMULATION; DIVERSITY	Mammalian skeletal muscles are a mosaic of different fiber types largely defined by differential myosin heavy chain (MyHC) expression. Little is known about the molecular mechanisms regulating expression of the MyHC gene family members in different fiber types. In this work, we identified several cis- and trans-elements that regulate expression of the three adult fast MyHC genes. Despite multiple DNA-binding motifs for well characterized muscle transcription factors upstream of all three fast MyHC genes, expression of MyoD/Myf-5, calcineurin, or NFAT3 had different effects on the three promoters. MyoD or Myf-5 overexpression preferentially activated the M promoter, whereas NFAT or activated calcineurin overexpression preferentially activated the IIa promoter. Calcineurin had a 50-100-fold stimulatory effect on the IIa promoter, and the known downstream effectors of calcineurin (myocyte enhancer factor-2 and NFAT) cannot completely account for this activation. Finally, we identified two elements critical for regulating MyHC-IId/x expression: a 130-base pair enhancer element and a CArG-like element that inhibited IId/x promoter activity in vitro. Thus, we have found specific regulatory pathways that are distinct for the three adult fast MyHC genes. These elements are logical candidates for fiber-specific control of skeletal muscle gene expression in vivo.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Leinwand, LA (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Campus Box 347, Boulder, CO 80309 USA.			Sycuro, Laura/0000-0002-2011-6305; LEINWAND, LESLIE/0000-0003-1470-4810	NIAMS NIH HHS [F32AR08443] Funding Source: Medline; NIGMS NIH HHS [R01-GM29090] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AcakpoSatchivi LJR, 1997, J CELL BIOL, V139, P1219, DOI 10.1083/jcb.139.5.1219; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BUTLERBROWNE GS, 1984, DEV BIOL, V102, P324, DOI 10.1016/0012-1606(84)90197-0; BUTTRICK PM, 1992, CIRC RES, V70, P193, DOI 10.1161/01.RES.70.1.193; Calvo S, 1999, MOL CELL BIOL, V19, P515; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Diagana TT, 1997, J MOL BIOL, V265, P480, DOI 10.1006/jmbi.1996.0752; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; GULICK J, 1985, J BIOL CHEM, V260, P1413; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; MILLER JB, 1989, J BIOL CHEM, V264, P13122; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RINDT H, 1993, J BIOL CHEM, V268, P5332; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Swoap SJ, 1998, AM J PHYSIOL-CELL PH, V274, pC681, DOI 10.1152/ajpcell.1998.274.3.C681; TAKEDA S, 1995, J BIOL CHEM, V270, P15664, DOI 10.1074/jbc.270.26.15664; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Talmadge Robert J., 1993, Current Opinion in Rheumatology, V5, P695; TAYLOR M, 1989, DEVELOPMENT, V106, P67; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WALSH K, 1988, MOL CELL BIOL, V8, P1800, DOI 10.1128/MCB.8.4.1800; WASSENBERG DR, 1987, J BIOL CHEM, V262, P10741; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; Wheeler MT, 1999, AM J PHYSIOL-CELL PH, V276, pC1069, DOI 10.1152/ajpcell.1999.276.5.C1069; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	39	113	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43524	43533		10.1074/jbc.M108017200	http://dx.doi.org/10.1074/jbc.M108017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551968	hybrid			2022-12-25	WOS:000172297700008
J	Siegmund, D; Hausser, A; Peters, N; Scheurich, P; Wajant, H				Siegmund, D; Hausser, A; Peters, N; Scheurich, P; Wajant, H			Tumor necrosis factor (TNF) and phorbol ester induce TNF-related apoptosis-inducing ligand (TRAIL) under critical involvement of NF-kappa B essential modulator (NEMO)/IKK gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; FAS LIGAND; MEDIATED CYTOTOXICITY; DEATH PATHWAY; IN-VITRO; ACTIVATION; GENE; EXPRESSION; IMMATURE; CYTOKINE	We show that tumor necrosis factor (TNF) and phorbol 12-myristate 13-acetate (PMA) induce TNF-related apoptosis-inducing ligand (TRAIL) in T cells. In cells deficient for NF-kappaB essential modulator (NEMO)/IKK gamma, an essential component of the NF-kappaB-inducing I-kappaB kinase (IKK) complex, induction of TRAIL expression was completely abrogated but was recovered in cells restored for IKK gamma expression. In cells deficient for receptor-interacting protein expression TNF, but not PMA-induced TRAIL expression was blocked. Inhibition of protein synthesis with cycloheximide blocked PMA, but not TNF-induced up-regulation of TRAIL. As both TNF and PMA rapidly induce NF-kappaB activation this suggests that NEMO/IKK gamma -dependent activation of the NF-kappaB pathway is necessary but not sufficient for up-regulation of TRAIL in T cells. The capability of the NF-kappaB pathway to induce the potent death ligand TRAIL may explain the reported proapoptotic features of this typically antiapoptotic pathway.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Hausser, Angelika/AAC-4531-2021; Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bartke T, 2001, ONCOGENE, V20, P571, DOI 10.1038/sj.onc.1204124; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LIPTON SA, 1997, NAT MED, P320; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Miura Y, 2001, J EXP MED, V193, P651, DOI 10.1084/jem.193.5.651; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Thomas WD, 1998, J IMMUNOL, V161, P2195; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wajant H, 1999, CYTOKINE GROWTH F R, V10, P15, DOI 10.1016/S1359-6101(98)00023-9; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375	34	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43708	43712		10.1074/jbc.M106421200	http://dx.doi.org/10.1074/jbc.M106421200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557763	hybrid			2022-12-25	WOS:000172297700031
J	Matsuda, T; Yamamoto, T; Muraguchi, A; Saatcioglu, F				Matsuda, T; Yamamoto, T; Muraguchi, A; Saatcioglu, F			Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MESANGIAL CELLS; TRANSCRIPTIONAL ACTIVATION; SEX-HORMONES; ER-BETA; MATRIX; GENE; GROWTH-FACTOR-BETA-1; IDENTIFICATION; ONCOPROTEIN	Transforming growth factor-beta (TGF-beta) plays central roles in embryonic development, organogenesis, and physiologic connective tissue remodeling during wound healing and tissue repair as well as in carcinogenesis. Estrogens have key roles in a variety of biological events, such as the development and maintenance of female reproductive organs and bone and lipid metabolism. Previous studies demonstrated that estrogens suppress TGF-beta -induced gene expression, such as type IV collagen in kidney mesangial cells. However, the molecular mechanisms that mediate this antagonistic effect are unknown. To elucidate the mechanisms of cross-talk between TGF-beta and estrogen receptor (ER) signaling pathways, we reconstituted TGF-beta and ER signaling in human kidney carcinoma cells. Here we demonstrate that TGF-beta -induced activation of Sma and MAD-related protein 3 (Smad3) activity, one of the major intracellular transducers of TGF-beta signaling, was suppressed by ER, whereas ER-mediated transcriptional activation was enhanced by TGF-beta signaling. We provide evidence that this two-way cross-talk between the estrogen and TGF-beta signaling pathways was the result of direct physical interactions between Smad3 and ER. These findings have implications for a variety of disease states, such as the pathophysiology of kidney function, atherosclerosis, and breast cancer.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Immunol, Toyama 9300194, Japan; Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway	University of Toyama; University of Oslo	Saatcioglu, F (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Immunol, 2630 Sugitani, Toyama 9300194, Japan.		Matsuda, Tadashi/A-3835-2012	Matsuda, Tadashi/0000-0002-3089-3757				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; Benson JR, 1996, BRIT J CANCER, V74, P993, DOI 10.1038/bjc.1996.475; Bitzer M, 2000, GENE DEV, V14, P187; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRUIJN JA, 1994, J LAB CLIN MED, V123, P34; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; HANSCH GM, 1995, J CELL PHYSIOL, V163, P451, DOI 10.1002/jcp.1041630304; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayes SA, 2001, CANCER RES, V61, P2112; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; IGNARTROWBRIDGE DM, 1995, ENVIRON HEALTH PERSP, V103, P35, DOI 10.2307/3432505; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kwan G, 1996, KIDNEY INT, V50, P1173, DOI 10.1038/ki.1996.425; LEI J, 1998, AM J PHYSIOL, V274, P252; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda T, 2000, FEBS LETT, V472, P235, DOI 10.1016/S0014-5793(00)01444-7; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NEUGARTEN J, 1995, AM J KIDNEY DIS, V26, P147, DOI 10.1016/0272-6386(95)90168-X; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PIERCE GF, 1989, P NATL ACAD SCI USA, V86, P2229, DOI 10.1073/pnas.86.7.2229; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SILBIGER S, 1998, AM J PHYSIOL, V274, P1113; SILBIGER SR, 1995, AM J KIDNEY DIS, V25, P515, DOI 10.1016/0272-6386(95)90119-1; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; SUZUKI S, 1993, EXP NEPHROL, V1, P229; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	49	198	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42908	42914		10.1074/jbc.M105316200	http://dx.doi.org/10.1074/jbc.M105316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555647	hybrid			2022-12-25	WOS:000172169300038
J	Hellyer, NJ; Kim, MS; Koland, JG				Hellyer, NJ; Kim, MS; Koland, JG			Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; EPIDERMAL GROWTH-FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; ERBB SIGNALING NETWORK; BREAST-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; REGULATORY SUBUNIT; SH2 DOMAINS; BINDING	The ErbB2/ErbB3 heregulin co-receptor has been shown to couple to phosphoinositide (PI) 3-kinase in a heregulin-dependent manner. The recruitment and activation of PI 3-kinase by this co-receptor is presumed to occur via its interaction with phosphorylated Tyr-Xaa-Xaa-Met (YXXM) motifs occurring in the ErbB3 C terminus. In this study, mutant ErbB3 receptor proteins expressed in COS7 cells were used to investigate PI 3-kinase-dependent signaling pathways activated by the ErbB2/ErbB3 co-receptor. We observed that a mutant ErbB3 protein with each of its six YXXM motifs containing a Tyr --> Phe substitution was unable to bind either the p85 regulatory or p110 catalytic subunit of PI 3-kinase. However, restoration of a single YXXM motif was sufficient to mediate association with the PI 3-kinase holoenzyme, although at a lower level han wild-type ErbB3. When ErbB3 YXXM motifs were restored in pairs, evidence for cooperativity between two, those incorporating Tyr-1273 and Tyr-1286, was observed. Interestingly, we have shown that an apparent association of PI 3-kinase activity with ErbB2/Neu was due to the residual presence of ErbB3 in ErbB2 immunoprecipitates. The necessity of ErbB3 association with PI 3-kinase for downstream signaling to the effector kinase Akt was also investigated. Here, the heregulin-dependent translocation of Akt to the plasma membrane and its subsequent activation was observed in intact NIH-3T3 fibroblasts. Recruitment of PI 3-kinase to ErbB3 was required for both activities, and it appeared that ErbB2 activation alone was not sufficient to activate PI 3-kinase signaling in these cells.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Chosun Univ, Coll Dent, Dept Pharmacol, Kwangju 501759, South Korea	University of Iowa; Chosun University	Koland, JG (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.	john-koland@uiowa.edu		Koland, John/0000-0002-5028-4297; HELLYER, NATHAN/0000-0002-2359-9082	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R01DK044684, R29DK044684] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295, DK44684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Juang SH, 1996, ONCOGENE, V12, P1033; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HH, 1994, J BIOL CHEM, V269, P24747; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PELES E, 1992, J BIOL CHEM, V267, P12266; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; YAMAGUCHI T, 1995, BIOCHEMISTRY-US, V34, P4962, DOI 10.1021/bi00015a007; Yenush L, 1996, MOL CELL BIOL, V16, P2509; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	60	126	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42153	42161		10.1074/jbc.M102079200	http://dx.doi.org/10.1074/jbc.M102079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546794	hybrid			2022-12-25	WOS:000172450400083
J	Crisanti, P; Raguenez, G; Blancher, C; Neron, B; Mamoune, A; Omri, B				Crisanti, P; Raguenez, G; Blancher, C; Neron, B; Mamoune, A; Omri, B			Cloning and characterization of a novel transcription factor involved in cellular proliferation arrest: PATF	ONCOGENE			English	Article						PATF; retina; transcription factor; proliferation arrest	ROUS-SARCOMA VIRUS; GENE-EXPRESSION; E2F FAMILY; RETINA; CELLS; DIFFERENTIATION; RETINOBLASTOMA; MECHANISMS; PROTEINS; GROWTH	Cell cycle withdrawal involves several transcription factors such as E2Fs members that play a key role in cell growth control. Here we describe a novel putative bZIP transcription factor isolated from the retina and involved in neuronal proliferation arrest at the terminal differentiation: PATF (Proliferation Arrest Transcription Factor). We show that PATF associates with E2F4 protein and interacts with the E2F consensus site. PATF expression increases with establishment of quiescent state. Furthermore, the nuclear PATF localization like E2F4, depends on cell growth arrest. The decrease of PATF amount, using a retroviral antisense strategy, results in pursued neuroretina cell mitosis. Our results indicate that PATF could be a new molecular signal implicated in the final neuronal cell cycle withdrawal.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; Univ Paris 06, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Crisanti, P (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.							BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRISANTI P, 1985, EMBO J, V4, P1467, DOI 10.1002/j.1460-2075.1985.tb03804.x; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Maniatis T., 1989, MOL CLONING LAB MANU; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Omri B, 1998, ONCOGENE, V16, P2351, DOI 10.1038/sj.onc.1201761; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347; ROUET P, 1992, J BIOL CHEM, V267, P20765; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WANG SZ, 1994, P NATL ACAD SCI USA, V91, P1351, DOI 10.1073/pnas.91.4.1351; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199	29	7	8	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5475	5483		10.1038/sj.onc.1204711	http://dx.doi.org/10.1038/sj.onc.1204711			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571645				2022-12-25	WOS:000170781100008
J	Chang, JY				Chang, JY			The folding pathway of alpha-lactalbumin elucidated by the technique of disulfide scrambling - Isolation of on-pathway and off-pathway intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; TICK ANTICOAGULANT PEPTIDE; SECONDARY STRUCTURE; BOND FORMATION; PROTEINS; COOPERATIVITY; DETERMINANTS; CYANYLATION; LEVINTHAL; STABILITY	The technique of disulfide scrambling permits reversible conversion of the native and denatured (scrambled) proteins via shuffling and reshuffling of disulfide bonds. Under strong denaturing conditions (e.g. 6 m guanidinium chloride) and in the presence of a thiol initiator, a-lactalbumin (alphaLA) denatures by shuffling its four native disulfide bonds and converts to an assembly of 45 species of scrambled isomers. Among them, two predominant isomers, designated as X-alphaLA-a and X-alphaLA-d, account for about 50% of the total denatured structure of alphaLA. X-alphaLA-a and X-alphaLA-d, which adopt the disulfide patterns of (1-2,3-4,5-6,7-8) and (1-2,3-6,4-5,7-8), respectively, represent the most unfolded structures among the 104 possible scrambled isomers (Chang, J.-Y., and Li, L. (2001) J. Biol. Chem. 276, 9705-9712). In this study, X-alphaLA-a and X-alphaLA-d were purified and allowed to refold through disulfide scrambling to form the native alphaLA. Folding intermediates were trapped kinetically by acid quenching and analyzed quantitatively by reversed phase high pressure liquid chromatography. The results revealed two major on-pathway productive intermediates, two major off-pathway kinetic traps, and at least 30 additional minor transient intermediates. Of the two major on-pathway intermediates, one takes on a native-like a-helical domain, and the other comprises a structured beta-sheet, calcium binding domain. The two major kinetic traps are apparently stabilized by locally formed non-native-like structures. Overall, the folding mechanism of alphaLA is essentially congruent with the model of "folding funnel" furnished with a rather intricate energy landscape.	Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA; Univ Texas, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas System	Chang, JY (corresponding author), Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA.	Rowen.Chang@uth.tmc.edu						Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; Baldwin RL, 2001, NAT STRUCT BIOL, V8, P92, DOI 10.1038/84189; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; Chang JY, 2000, J PROTEIN CHEM, V19, P299, DOI 10.1023/A:1007099430211; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHANG JY, 1995, J BIOL CHEM, V270, P25661; Chang JY, 2001, J BIOL CHEM, V276, P9705, DOI 10.1074/jbc.M010700200; Chang JY, 2000, FEBS LETT, V487, P298, DOI 10.1016/S0014-5793(00)02341-3; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; Creighton TE, 1997, TRENDS BIOCHEM SCI, V22, P6, DOI 10.1016/S0968-0004(96)20030-1; Dill KA, 1999, PROTEIN SCI, V8, P1166, DOI 10.1110/ps.8.6.1166; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; Forge V, 1999, J MOL BIOL, V288, P673, DOI 10.1006/jmbi.1999.2687; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Grantcharova V, 2001, CURR OPIN STRUC BIOL, V11, P70, DOI 10.1016/S0959-440X(00)00176-7; Honig B, 1999, J MOL BIOL, V293, P283, DOI 10.1006/jmbi.1999.3006; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Kim P S, 1986, Methods Enzymol, V131, P136; Kim S, 1998, PROTEIN SCI, V7, P1930, DOI 10.1002/pro.5560070908; KLEFHABER T, 1995, NATURE, V375, P513; KUWAJIMA K, 1993, FEBS LETT, V334, P265, DOI 10.1016/0014-5793(93)80691-M; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; Labhardt A M, 1986, Methods Enzymol, V131, P126; Luo YZ, 1999, P NATL ACAD SCI USA, V96, P11283, DOI 10.1073/pnas.96.20.11283; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Mirny L, 2001, ANNU REV BIOPH BIOM, V30, P361, DOI 10.1146/annurev.biophys.30.1.361; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; PARDON E, 1995, J BIOL CHEM, V270, P10514, DOI 10.1074/jbc.270.18.10514; Peng ZY, 2000, ADV PROTEIN CHEM, V53, P1; PENG ZY, 1995, BIOCHEMISTRY-US, V34, P3248, DOI 10.1021/bi00010a014; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; Plaxco KW, 2000, BIOCHEMISTRY-US, V39, P11177, DOI 10.1021/bi000200n; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Radford SE, 2000, TRENDS BIOCHEM SCI, V25, P611, DOI 10.1016/S0968-0004(00)01707-2; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; Redfield C, 1999, NAT STRUCT BIOL, V6, P948, DOI 10.1038/13318; Sadana A, 2001, BIOTECHNOL APPL BIOC, V33, P7, DOI 10.1042/BA20000044; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; Schultz CP, 2000, NAT STRUCT BIOL, V7, P7, DOI 10.1038/71197; SUGAI S, 1994, ADV BIOPHYS, V30, P37, DOI 10.1016/0065-227X(94)90010-8; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Troullier A, 2000, NAT STRUCT BIOL, V7, P78, DOI 10.1038/71286; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; Woycechowsky KJ, 2000, CURR OPIN CHEM BIOL, V4, P533, DOI 10.1016/S1367-5931(00)00128-9; Wu J, 1998, PROTEIN SCI, V7, P1017; Wu LC, 1996, BIOCHEMISTRY-US, V35, P859, DOI 10.1021/bi951408p; Wu LC, 1998, J MOL BIOL, V280, P175, DOI 10.1006/jmbi.1998.1825; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; Yang Y, 1999, J BIOL CHEM, V274, P37598, DOI 10.1074/jbc.274.53.37598	70	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					120	126		10.1074/jbc.M108057200	http://dx.doi.org/10.1074/jbc.M108057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11560938	hybrid			2022-12-25	WOS:000173087900017
J	Rotem, D; Sal-man, N; Schuldiner, S				Rotem, D; Sal-man, N; Schuldiner, S			In vitro monomer swapping in EmrE, a multidrug transporter from Escherichia coli, reveals that the oligomer is the functional unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ ANTIPORTER; MEMBRANE; BINDING; H+; GLUTAMATE; PROTEIN	EmrE is a small multidrug transporter, 110 amino acids long that extrudes various drugs in exchange with protons, thereby rendering Escherichia coli cells resistant to these compounds. Negative dominance studies and radiolabeled substrate-binding studies suggested that EmrE functions as an oligomer. Projection structure of two-dimensional crystals of the protein revealed an asymmetric dimer. To identify the functional unit of EmrE, a novel approach was developed. In this method, quantitative monomer swapping is induced in detergent-solubilized EmrE by exposure to 80 degreesC, a treatment that does not impair transport activity. Oligomer formation is highly specific as judged by several criteria, among them the fact that S-35-EmrE can be "pulled out" from a mixture prepared from generally labeled cells. Using this technique, we show that inactive mutant subunits are functionally complemented when mixed with wild type subunits. The hetero-oligomers thus formed display a decreased affinity to substrates. In addition, sulfhydryl reagents inhibit the above hetero-oligomer even though Cys residues are present only in the inactive monomer. It is concluded that, in EmrE, the oligomer is the functional unit.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012; Rotem, Dvir/G-1396-2013	Schuldiner, Shimon/0000-0002-4874-6237; Rotem, Dvir/0000-0002-1840-6530; Sal-Man, Neta/0000-0002-1109-479X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Friesen RHE, 2000, J BIOL CHEM, V275, P33527, DOI 10.1074/jbc.M004066200; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Jack DL, 2000, J BACTERIOL, V182, P2311, DOI 10.1128/JB.182.8.2311-2313.2000; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Lee A, 2000, J BACTERIOL, V182, P3142, DOI 10.1128/JB.182.11.3142-3150.2000; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	26	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48243	48249		10.1074/jbc.M108229200	http://dx.doi.org/10.1074/jbc.M108229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11572877	hybrid			2022-12-25	WOS:000172927000068
J	Strachan, GD; Rallapalli, R; Pucci, B; Lafond, TP; Hall, DJ				Strachan, GD; Rallapalli, R; Pucci, B; Lafond, TP; Hall, DJ			A transcriptionally inactive E2F-1 targets the MDM family of proteins for proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE-PRODUCT; CELL-GROWTH CONTROL; RETINOBLASTOMA PROTEIN; P53-BINDING PROTEIN; P53; APOPTOSIS; ONCOPROTEIN; PATHWAY; DOMAIN; P73	E2F-1-activated transcription promotes cell cycle progression and apoptosis. These functions are regulated by several factors including the E2F-1-binding protein MDM2 and the retinoblastoma protein pRb. Using a yeast two-hybrid screen we have identified the MDM2-related protein, MDMX as an E2F-1-binding protein. In these studies we find that coexpression of MDMX with E2F-1 results in degradation of the MDMX protein. Although this proteolytic degradation can be blocked by the protease inhibitors bafilomycin A(1), N-acetyl-Leu-Leu-Norleu-AL, and N-acetyl-Leu-Leu-Met-AL, MDMX degradation is not inhibited by lactacystin, suggesting that degradation occurs by a proteasome-independent mechanism. Using an E2F-1 deletion mutant (E2F-1(180-437)) we show that E2F-1-targeted degradation of MDMX does not require the E2F-1 DNA binding domain and therefore is independent of E2F-1-driven transcription. We also find that this transcriptionally inactive E2F-1 mutant is capable of degrading the MDMX-related protein MDM2 and the MDMX isoform MDMX-S. Mapping of the E2F-1 C terminus reveals that neither a previously characterized C-terminal MDM2 binding domain nor the pRb binding domain on E2F-1 is required for MDMX and MDM2 degradation.	Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Hall, DJ (corresponding author), NIAMS, Cartilage Biol & Orthoped Branch, NIH, Bldg 13,Rm 3W17,13 S Dr,MSC 5755, Bethesda, MD 20892 USA.				NCI NIH HHS [CA67032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Craighead MW, 1999, J NEUROSCI RES, V57, P236, DOI 10.1002/(SICI)1097-4547(19990715)57:2<236::AID-JNR9>3.3.CO;2-4; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Flores C, 2000, REV MED CHILE, V128, P539; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; INOUE S, 1991, J BIOL CHEM, V266, P13311; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JORDAN KL, 1994, ONCOGENE, V9, P1177; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Loughlin C, 2000, ASSEMBLY AUTOM, V20, P6; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PYRE JJ, 1992, BIOCHEMISTRY-US, V31, P4102; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yang HL, 1999, CLIN CANCER RES, V5, P2242; Zhu JH, 1998, CANCER RES, V58, P5061	46	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45677	45685		10.1074/jbc.M103765200	http://dx.doi.org/10.1074/jbc.M103765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11568180	hybrid			2022-12-25	WOS:000172573100026
J	Ingles-Esteve, J; Espinosa, L; Milner, LA; Caelles, C; Bigas, A				Ingles-Esteve, J; Espinosa, L; Milner, LA; Caelles, C; Bigas, A			Phosphorylation of Ser2078 modulates the Notch2 function in 32D cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; HEMATOPOIETIC PROGENITORS; INHIBITS DIFFERENTIATION; NUCLEAR TRANSLOCATION; EXPRESSION; CLEAVAGE; FATE; RECEPTOR; FRINGE; LIGAND	Notch signaling is involved in the regulation of many cell fate determination events in both embryonic development and adult tissue homeostasis. We previously demonstrated that Notch1 and Notch2 molecules inhibit myeloid differentiation in a cytokine-specific manner and that the Notch cytokine response domain is necessary for this functional specificity. We have now investigated the putative role of phosphorylation in the activity of Notch in response to cytokine signals. Our results show that the granulocyte colony-stimulating factor (G-CSF) stimulation of 32D cells expressing the intracellular Notch2 protein induces phosphorylation at specific sites of this molecule, rendering the molecule inactive and permitting differentiation of these cells. In contrast, when cells are stimulated with granulocyte macrophage colony-stimulating factor (GM-CSF), intracellular notch2 is not phosphorylated at these residues and differentiation is inhibited. We also show that deletion of the Ser/Thr-rich region between amino acids 2067 and 2099 abrogates G-CSF-induced phosphorylation and results in a molecule that inhibits differentiation in response to either G-CSF or GM-CSF. Our results further indicate that Ser(2078) is a critical residue for phosphorylation and modulation of Notch2 activity in the context of G-CSF-induced differentiation of 32D cells.	Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Barcelona, Fac Farm, Dept Bioquim, E-08028 Barcelona, Spain	Fred Hutchinson Cancer Center; University of Barcelona	Bigas, A (corresponding author), Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain.	abigas@iro.es	Bigas, Anna/A-7457-2014	Bigas, Anna/0000-0003-4801-6899				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Baonza A, 2000, P NATL ACAD SCI USA, V97, P2609, DOI 10.1073/pnas.040576497; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Egan SE, 1998, CURR TOP MICROBIOL, V228, P273; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Han W, 2000, BLOOD, V95, P1616, DOI 10.1182/blood.V95.5.1616.005k31_1616_1625; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Ikeya T, 1999, DEVELOPMENT, V126, P4455; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jehn BM, 1999, J IMMUNOL, V162, P635; JOHNSTON LA, 1998, NATURE, P62; Jones P, 1998, BLOOD, V92, P1505, DOI 10.1182/blood.V92.5.1505.417k42_1505_1511; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; MILNER LA, 1994, BLOOD, V83, P2057; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; MITSIADIS TA, 1995, J CELL BIOL, V130, P407, DOI 10.1083/jcb.130.2.407; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Ohishi K, 2000, BLOOD, V95, P2847, DOI 10.1182/blood.V95.9.2847.009k19_2847_2854; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 2000, J EXP MED, V191, P1085, DOI 10.1084/jem.191.7.1085; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Singh N, 2000, EXP HEMATOL, V28, P527, DOI 10.1016/S0301-472X(00)00146-6; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Sotillos S, 1997, DEVELOPMENT, V124, P4769; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tan-Pertel HT, 2000, J IMMUNOL, V165, P4428, DOI 10.4049/jimmunol.165.8.4428; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	70	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44873	44880		10.1074/jbc.M104703200	http://dx.doi.org/10.1074/jbc.M104703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577080	hybrid			2022-12-25	WOS:000172406700073
J	Lee, BC; Croonquist, PA; Hoff, WD				Lee, BC; Croonquist, PA; Hoff, WD			Mimic of photocycle by a protein folding reaction in photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; P-COUMARIC ACID; ECTOTHIORHODOSPIRA-HALOPHILA; TRANSITION-STATE; PROTON-TRANSFER; ACTIVE-SITE; CHROMOPHORE; INTERMEDIATE; KINETICS; THERMODYNAMICS	The blue light receptor photoactive yellow protein (PYP) displays rhodopsin-like photochemistry based on the trans to cis photoisomerization of its p-coumaric acid chromophore. Here, we report that protein refolding from the acid-denatured state of PYP mimics the last photocycle transition in PYP. This implies a direct link between transient protein unfolding and photosensory signal transduction. We utilize this link to study general issues in protein folding. Chromophore trans to cis photoisomerization in the acid-denatured state strongly decelerates refolding, and converts the pH dependence of the barrier for refolding from linear to nonlinear. We propose transition state movement to explain this phenomenon. The cis chromophore significantly stabilizes the acid-denatured state, but acidification of PYP results in the accumulation of the acid-denatured state containing a trams chromophore. This provides a clear example of kinetic control in a protein unfolding reaction. These results demonstrate the power of PYP as a light-triggered model system to study protein folding.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Hoff, WD (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063805] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM63805-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brudler R, 2000, BIOCHEMISTRY-US, V39, P13478, DOI 10.1021/bi0009946; Craven CJ, 2000, BIOCHEMISTRY-US, V39, P14392, DOI 10.1021/bi001628p; Demchuk E, 2000, BIOCHEMISTRY-US, V39, P1100, DOI 10.1021/bi991513p; Devanathan S, 1999, BIOCHEMISTRY-US, V38, P13766, DOI 10.1021/bi991634p; Devanathan S, 1998, BIOCHEMISTRY-US, V37, P11563, DOI 10.1021/bi9803776; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hoff WD, 1997, BBA-BIOENERGETICS, V1322, P151, DOI 10.1016/S0005-2728(97)00082-0; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; Lee BC, 2001, P NATL ACAD SCI USA, V98, P9062, DOI 10.1073/pnas.111153598; Lee BC, 2001, J BIOL CHEM, V276, P20821, DOI 10.1074/jbc.C100106200; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Ohishi S, 2001, BIOCHEMISTRY-US, V40, P2854, DOI 10.1021/bi001846i; Oliveberg M, 1996, BIOCHEMISTRY-US, V35, P2726, DOI 10.1021/bi9509661; Otzen DE, 1999, BIOCHEMISTRY-US, V38, P6499, DOI 10.1021/bi982819j; Parker MJ, 1999, J MOL BIOL, V293, P1195, DOI 10.1006/jmbi.1999.3204; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Richter HT, 1996, BIOCHEMISTRY-US, V35, P15461, DOI 10.1021/bi9612430; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Tan YJ, 1996, J MOL BIOL, V264, P377, DOI 10.1006/jmbi.1996.0647; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a	41	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44481	44487		10.1074/jbc.M104362200	http://dx.doi.org/10.1074/jbc.M104362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577076	hybrid			2022-12-25	WOS:000172406700019
J	Nishitani, H; Taraviras, S; Lygerou, Z; Nishimoto, T				Nishitani, H; Taraviras, S; Lygerou, Z; Nishimoto, T			The human licensing factor for DNA replication Cdt1 accumulates in G(1) and is destabilized after initiation of S-phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; CELL-CYCLE; FISSION YEAST; MCM PROTEINS; BUDDING YEAST; CHROMATIN ASSOCIATION; CDK PHOSPHORYLATION; NUCLEAR EXPORT; MAMMALIAN CDC6; MITOSIS	S-phase onset is controlled, so that it occurs only once every cell cycle. DNA is licensed for replication after mitosis in Gl, and passage through S-phase removes the license to replicate. In fission yeast, Cdc6/18 and Cdt1, two factors required for licensing, are central to ensuring that replication occurs once per cell cycle. We show that the human Cdt1 homologue (hCdt1), a nuclear protein, is present only during G(1). After S-phase onset, hCdt1 levels decrease, and it is hardly detected in cells in early S-phase or G(2). hCdt1 can associate with the DNA replication inhibitor Geminin, however these two proteins are mostly expressed at different cell cycle stages. hCdt1 mRNA, in contrast to hCdt1 protein, is expressed in S-phase-arrested cells, and its levels do not change dramatically during a cell cycle, suggesting that proteolytic rather than transcriptional controls ensure the timely accumulation of hCdt1. Consistent with this view, proteasome inhibitors stabilize hCdt1 in S-phase. In contrast, hCdc6/18 levels are constant through most of the cell cycle and are only low for a brief period at the end of mitosis. These results suggest that the presence of active hCdt1 may be crucial for determining when licensing is legitimate in human cells.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Univ Patras, Sch Med, GR-26110 Patras, Greece	Kyushu University; University of Patras	Nishitani, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.	hideonc@molbiol.med.kyushu-u.ac.jp	Taraviras, Stavros/AAJ-4690-2020	Taraviras, Stavros/0000-0002-7455-647X; Nishitani, Hideo/0000-0001-5907-9380				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Coverley D, 2000, J CELL SCI, V113, P1929; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Gillespie PJ, 2000, NUCLEIC ACIDS RES, V28, P472, DOI 10.1093/nar/28.2.472; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Johnston L H, 2000, Prog Cell Cycle Res, V4, P61; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lygerou Z, 1999, J CELL SCI, V112, P3703; Lygerou Z, 2000, COLD SPRING HARB SYM, V65, P323, DOI 10.1101/sqb.2000.65.323; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Whittaker AJ, 2000, GENE DEV, V14, P1765; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	61	215	216	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44905	44911		10.1074/jbc.M105406200	http://dx.doi.org/10.1074/jbc.M105406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11555648	hybrid			2022-12-25	WOS:000172406700077
J	Parizek, P; Roeckl, C; Weber, J; Flechsig, E; Aguzzi, A; Raeber, AJ				Parizek, P; Roeckl, C; Weber, J; Flechsig, E; Aguzzi, A; Raeber, AJ			Similar turnover and shedding of the cellular prion protein in primary lymphoid and neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICULAR DENDRITIC CELLS; PRP KNOCKOUT MICE; ASPARAGINE-LINKED GLYCOSYLATION; SOLUBLE FORM; HAMSTER SCRAPIE; CULTURED-CELLS; HUMAN BLOOD; EXPRESSION; REPLICATION; SUSCEPTIBILITY	The cellular prion protein (PrPc) is essential for pathogenesis and transmission of prion diseases. Although prion replication in the brain is accompanied by neurodegeneration, prions multiply efficiently in the lymphoreticular system without any detectable pathology. We have used pulse-chase metabolic radiolabeling experiments to investigate the turnover and processing of PrPc in primary cell cultures derived from lymphoid and nervous tissues. Similar kinetics of PrPc degradation were observed in these tissues. This indicates that the differences between these two organs with respect to their capacity to replicate prions is not due to differences in the turnover of PrPc. Substantial amounts of a soluble form of PrP that lacks the glycolipid anchor appeared in the medium of splenocytes and cerebellar granule cells. Soluble PrP was detected in murine and human serum, suggesting that it might be of physiological relevance.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; St Marys Hosp, Imperial Coll Med, Neurogenet Unit, London W2 1PG, England	University of Zurich; University Zurich Hospital; Imperial College London	Raeber, AJ (corresponding author), Cytos Proteome Therapeut GmbH, Fritz Arnold Str 23, D-78467 Constance, Germany.	raeber@cytos.com	Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY B, 1993, BRIT MED BULL, V49, P860, DOI 10.1093/oxfordjournals.bmb.a072651; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Holada K, 2000, BRIT J HAEMATOL, V110, P472, DOI 10.1046/j.1365-2141.2000.02158.x; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Kaeser PS, 2001, J VIROL, V75, P7097, DOI 10.1128/JVI.75.15.7097-7106.2001; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kubosaki A, 2001, BIOCHEM BIOPH RES CO, V282, P103, DOI 10.1006/bbrc.2001.4538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letho MT, 1998, BIOCHEM J, V332, P101, DOI 10.1042/bj3320101; Mabbott NA, 2000, NAT MED, V6, P719, DOI 10.1038/77401; MacGregor I, 1999, VOX SANG, V77, P88; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; MIZUKAMI IF, 1995, BLOOD, V86, P203; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Montrasio F, 2001, P NATL ACAD SCI USA, V98, P4034, DOI 10.1073/pnas.051609398; Perini F, 1996, BIOCHEM BIOPH RES CO, V223, P572, DOI 10.1006/bbrc.1996.0936; RACE RE, 1995, NEURON, V15, P1183, DOI 10.1016/0896-6273(95)90105-1; Raeber AJ, 1999, P NATL ACAD SCI USA, V96, P3987, DOI 10.1073/pnas.96.7.3987; Raeber AJ, 2000, IMMUNOL TODAY, V21, P66, DOI 10.1016/S0167-5699(99)01562-5; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Schneider SD, 1997, GENE THER, V4, P524, DOI 10.1038/sj.gt.3300432; SCHNIZLEIN CT, 1985, J IMMUNOL, V134, P1360; Smith GM, 1997, J CLIN IMMUNOL, V17, P502, DOI 10.1023/A:1027327912204; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAGLIAVINI F, 1992, BIOCHEM BIOPH RES CO, V184, P1398, DOI 10.1016/S0006-291X(05)80038-5; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262	45	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44627	44632		10.1074/jbc.M107458200	http://dx.doi.org/10.1074/jbc.M107458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571302	hybrid, Green Accepted			2022-12-25	WOS:000172406700040
J	Pawliczak, R; Cowan, MJ; Huang, XL; Nanavaty, UB; Alsaaty, S; Logun, C; Shelhamer, JH				Pawliczak, R; Cowan, MJ; Huang, XL; Nanavaty, UB; Alsaaty, S; Logun, C; Shelhamer, JH			p11 expression in human bronchial epithelial cells is increased by nitric oxide in a cGMP-dependent pathway involving protein kinase G activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-II TETRAMER; BIOCHEMICAL-CHARACTERIZATION; PHOSPHOLIPASE A(2); C-JUN; TRANSCRIPTION; BINDING; PHOSPHORYLATION; STIMULATION; SUBSTRATE; RELEASE	The effect of nitric oxide on p11 expression was studied in an immortalized human bronchial epithelial cell line (BEAS-2B cells). Three nitric oxide donors were used: spermine NONOate (SP), (+/-)-S-nitroso-N-acetylpenicillamine (SNAP), and S-nitrosoglutathione (SNOG). All three nitric oxide donors had similar effects resulting in dose-dependent and time-dependent accumulation of pll protein and an increase of steady-state p11 mRNA. Studies using a reporter gene containing the region from -1499 to +89 of the pll promoter demonstrated an increase in transcriptional activity after stimulation with NO donors for 4 h. These effects were abolished at the promoter and protein level using protein kinase G inhibitors (KT5823 and R-p-8-pCPT-cGMPS). Incubation of transfected cells with a cell permeable cGMP analogue (8-Br-cGMP) resulted in a dose-related increase of promoter activity. An electrophoretic mobility shift assay of nuclear proteins extracted from BEAS-2B cells identified an AP-1 site located at -82 to -77 of the p11 promoter region as an NO- and cGMP- dependent response element. These data were confirmed using a c-jun dominant negative mutant vector and a e-jun expression plasmid. Therefore, we conclude that nitric oxide-induced p11 expression in human bronchial epithelial cells is mediated at least in part through increased binding of activator protein one to the p11 promoter.	NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA; Med Univ Lodz, Dept Allergy & Clin Immunol, PL-92211 Lodz, Poland	National Institutes of Health (NIH) - USA; Medical University Lodz	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bldg 10,Rm 7D43,9000 Rockville Pike, Bethesda, MD 20892 USA.		Pawliczak, Rafa/S-2021-2019; Pawliczak, Rafal Tomasz/S-9649-2016	Pawliczak, Rafa/0000-0001-6784-453X; 	CLINICAL CENTER [Z01CL001160] Funding Source: NIH RePORTER	CLINICAL CENTER		Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BROWN PH, 1993, ONCOGENE, V8, P877; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; delaTorre A, 1998, SURGERY, V124, P137, DOI 10.1016/S0039-6060(98)70113-8; ERIKSON E, 1984, MOL CELL BIOL, V4, P77, DOI 10.1128/MCB.4.1.77; Filep JG, 1998, J IMMUNOL, V161, P5656; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GERKE V, 1990, BIOCHEM SOC T, V18, P1106, DOI 10.1042/bst0181106; GERKE V, 1991, P11 MEMBER S100 PROT, P139; Gertzberg N, 2000, AM J RESP CELL MOL, V22, P105, DOI 10.1165/ajrcmb.22.1.3801; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; LANDER HM, 1993, J IMMUNOL, V151, P7182; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Matsumoto T, 1997, PATHOL INT, V47, P339, DOI 10.1111/j.1440-1827.1997.tb04506.x; MOORE KG, 1992, PROTEIN EXPRES PURIF, V3, P1, DOI 10.1016/1046-5928(92)90049-3; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; von Knethen A, 2000, BIOCHEMISTRY-US, V39, P1532, DOI 10.1021/bi990820s; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	30	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44613	44621		10.1074/jbc.M104993200	http://dx.doi.org/10.1074/jbc.M104993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571284	hybrid			2022-12-25	WOS:000172406700038
J	Golfman, LS; Bakovic, M; Vance, DE				Golfman, LS; Bakovic, M; Vance, DE			Transcription of the CTP : phosphocholine cytidylyltransferase alpha gene is enhanced during the S phase of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; RAT-LIVER; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN; IDENTIFICATION; PHOSPHATIDYLETHANOLAMINE; METABOLISM; EXPRESSION; REQUIREMENT	We have studied the transcription of the CTP:phosphocholine cytidylyltransferase alpha (CT alpha) gene in C3H10T1/2 fibroblasts as a function of the cell cycle. The cells were incubated for 48 h with 0.5% fetal bovine serum. The cells were induced into the Gi phase of the cell cycle by the addition of medium with 10% fetal bovine serum. The cells began the synthesis of DNA after 12 h. At 16 and 20 h there was an increased amount of CT alpha mRNA that coincided with an increase in the expression of CTa proximal promoter-luciferase constructs (-201/+38 and -130/+38). Luciferase constructs with the basal promoter (-52/+38) showed no change in activity during the cell cycle. Incorporation of [H-3]choline into phosphatidylcholine began to increase by 8 h after the addition of serum and peaked at 18 h. The mass of phosphatidylcholine nearly doubled between 8 and 26 h after addition of serum. CT activity increased by 6 h after serum addition and was maintained until 22 h. Thus, the increase of phosphatidylcholine biosynthesis in the G(1) phase of the cell cycle is not due to enhanced transcription of the CT alpha gene. Instead increased transcription of the CT alpha gene occurred during the S phase of the cell cycle in preparation for mitosis.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6H 5S3, Canada; Univ Alberta, CIHR, Grp Mol & Cell Biol Lipids, Edmonton, AB T6H 5S3, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6H 5S3, Canada.	dennis.vance@ualberta.ca						Agellon LB, 1999, HEPATOLOGY, V30, P725, DOI 10.1002/hep.510300305; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; DeLong CJ, 2000, J BIOL CHEM, V275, P32325, DOI 10.1074/jbc.M004644200; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; GROSS G, 1988, BIOCHIM BIOPHYS ACTA, V962, P220, DOI 10.1016/0005-2760(88)90163-4; HABENICHT AJR, 1985, J BIOL CHEM, V260, P1370; Hogan M, 1996, BIOCHEM J, V314, P799, DOI 10.1042/bj3140799; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; HOUWELING M, 1997, BIOCHIM BIOPHYS ACTA, V1546, P7; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kast HR, 2001, J LIPID RES, V42, P1266; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; LYDIDIS A, 1998, J BIOL CHEM, V273, P14022; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Ryan AJ, 2000, J LIPID RES, V41, P1268; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Sugimoto H, 2001, J BIOL CHEM, V276, P12338, DOI 10.1074/jbc.M100090200; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TERCE F, 1994, J LIPID RES, V35, P2130; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; VANCE JE, 1985, CAN J BIOCHEM CELL B, V63, P870, DOI 10.1139/o85-108; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARDEN CH, 1984, BIOCHIM BIOPHYS ACTA, V792, P270, DOI 10.1016/0005-2760(84)90194-2; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Yang JL, 1997, BIOCHEM J, V325, P29, DOI 10.1042/bj3250029	48	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43688	43692		10.1074/jbc.M108170200	http://dx.doi.org/10.1074/jbc.M108170200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557772	hybrid			2022-12-25	WOS:000172297700028
J	Zwaal, RR; Van Baelen, K; Groenen, JTM; van Geel, A; Rottiers, V; Kaletta, T; Dode, L; Raeymaekers, L; Wuytack, F; Bogaert, T				Zwaal, RR; Van Baelen, K; Groenen, JTM; van Geel, A; Rottiers, V; Kaletta, T; Dode, L; Raeymaekers, L; Wuytack, F; Bogaert, T			The sarco-endoplasmic reticulum Ca2+ ATPase is required for development and muscle function in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR FUNCTION; SARCOPLASMIC-RETICULUM; TRANSGENIC MICE; TUMOR PROMOTER; C-ELEGANS; GENE; PHOSPHOLAMBAN; CA2+-ATPASE; OVEREXPRESSION; THAPSIGARGIN	The sarco-endoplasmic reticulum Ca2+-transport ATPase (SERCA) loads intracellular releasable Ca2+ stores by transporting cytosolic Ca2+ into the endoplasmic (ER) or sarcoplasmic reticulum (SR). We characterized the only SERCA homologue of the nematode Caenorhabditis elegans, which is encoded by the sca-1 gene. The sca-1 transcript is alternatively spliced in a similar mode as the vertebrate SERCA2 transcript, giving rise to two protein variants: CeSERCAa and CeSERCAb. These proteins showed structural and functional conservation to the vertebrate SERCA2a/b proteins. The CeSERCAs were primarily expressed in contractile tissues. Loss of CeSERCA through gene ablation or RNA interference resulted in contractile dysfunctioning and in early larval or embryonic lethality, respectively. Similar defects could be induced pharmacologically using the SERCA-specific inhibitor thapsigargin, which bound CeSERCA at a conserved site. The conservation of SERCA2 homologues in C. elegans will allow genetic and chemical suppressor analyses to identify promising drug targets and lead molecules for treatment of SERCA-related diseases such as heart disease.	Devgen NV, B-9052 Zwijnaarde, Belgium; Katholieke Univ Leuven, Dept Mol Celbiol, Fysiol Lab, B-3000 Louvain, Belgium	KU Leuven	Zwaal, RR (corresponding author), Devgen NV, Technol Pk 9, B-9052 Zwijnaarde, Belgium.	richard.zwaal@devgen.com	Kaletta, Titus/F-5361-2012					Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cho JH, 2000, GENE, V261, P211, DOI 10.1016/S0378-1119(00)00536-9; CHRISTENSEN SB, 1992, J CANCER RES CLIN, V118, P344, DOI 10.1007/BF01294438; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maryon EB, 1998, J CELL SCI, V111, P2885; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; McCarter J, 1999, DEV BIOL, V205, P111, DOI 10.1006/dbio.1998.9109; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Sakube Y, 1997, J MOL BIOL, V267, P849, DOI 10.1006/jmbi.1997.0910; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VERBOOMEN H, 1994, BIOCHEM J, V303, P979, DOI 10.1042/bj3030979; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; WUYTACK F, 1998, ADV MOL CEL A&B, V23, P205; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049	35	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43557	43563		10.1074/jbc.M104693200	http://dx.doi.org/10.1074/jbc.M104693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559701	hybrid			2022-12-25	WOS:000172297700012
J	Kim, SH; Leem, JY; Lah, JJ; Slunt, HH; Levey, AI; Thinakaran, G; Sisodia, SS				Kim, SH; Leem, JY; Lah, JJ; Slunt, HH; Levey, AI; Thinakaran, G; Sisodia, SS			Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; SUBCELLULAR-LOCALIZATION; ENDOGENOUS PRESENILIN-1; IN-VIVO; TRANSMEMBRANE ASPARTATES; INTRACELLULAR DOMAIN; TRANSFECTED CELLS	PS1 deficiency and expression of PS1 with substitutions of two conserved transmembrane aspartate residues ("PS1 aspartate variants") leads to the reduction of A beta peptide secretion and the accumulation of amyloid precursor protein (APP) C-terminal fragments. To define the nature of the "dominant negative" effect of the PS1 aspartate variants, we stably expressed PS1 harboring aspartate to alanine substitutions at codons 257 (D257A) or 385 (D385A), singly or in combination (D257A/ D385A), in mouse neuroblastoma, N2a cells. Expression of the PS1 aspartate variants resulted in marked accumulation of intracellular and cell surface APP C-terminal fragments. While expression of the D385A PS1 variant reduced the levels of secreted AP peptides, we now show that neither the PS1 D257A nor D257A/D385A variants impair A beta production. Surprisingly, the stability of both immature and mature forms of APP is dramatically elevated in cells expressing PS1 aspartate variants, commensurate with an increase in the cell surface levels of APP. These findings lead us to conclude that the stability and trafficking of APP can be profoundly modulated by coexpression of PS1 with mutations at aspartate 257 and aspartate 385.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Johns Hopkins Univ, Neuropathol Lab, Baltimore, MD 21205 USA	University of Chicago; Emory University; Johns Hopkins University	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Abbott 510,947 E 58th St, Chicago, IL 60637 USA.	ssisodia@drugs.bsd.uchicago.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X	NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER; NIA NIH HHS [AG14248] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ANNAERT WG, 2000, NEUROBIOL AGING, V21, pS133; Arduengo PM, 1998, J CELL SCI, V111, P3645; ARMOGIDA M, 2001, IN PRESS NAT CELL BI; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KIMBERLY WT, 2001, IN PRESS J BIOL CHEM; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lah JJ, 1997, J NEUROSCI, V17, P1971; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Morihara T, 2000, MOL BRAIN RES, V85, P85, DOI 10.1016/S0169-328X(00)00229-1; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VANNOSTRAND WE, 1989, NATURE, V341, P546; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILTFANG J, 2001, IN PRESS J BIOL CHEM; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YU C, 2001, IN PRESS J BIOL CHEM; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	72	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43343	43350		10.1074/jbc.M108245200	http://dx.doi.org/10.1074/jbc.M108245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11564743	hybrid			2022-12-25	WOS:000172169300093
J	Kopriva, S; Buchert, T; Fritz, G; Suter, M; Weber, M; Benda, R; Schaller, J; Feller, U; Schurmann, P; Schunemann, V; Trautwein, AX; Kroneck, PMH; Brunold, C				Kopriva, S; Buchert, T; Fritz, G; Suter, M; Weber, M; Benda, R; Schaller, J; Feller, U; Schurmann, P; Schunemann, V; Trautwein, AX; Kroneck, PMH; Brunold, C			Plant adenosine 5 '-phospho sulfate reductase is a novel iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; 5'-ADENYLYLSULFATE REDUCTASE; APS-SULFOTRANSFERASE; PAPS-REDUCTASE; MOFE PROTEIN; MOSSBAUER; ASSIMILATION; CLUSTERS; NITROGENASE	Adenosine 5'-phosphosulfate reductase (APR) catalyzes the two-electron reduction of adenosine 5'-phosphosulfate to sulfite and AMP, which represents the key step of sulfate assimilation in higher plants. Recombinant APRs from both Lemna minor and Arabidopsis thaliana were overexpressed in Escherichia coli and isolated as yellow-brown proteins. UV-visible spectra of these recombinant proteins indicated the presence of iron-sulfur centers, whereas flavin was absent. This result was confirmed by quantitative analysis of iron and acid-labile sulfide, suggesting a [4Fe-4S] cluster as the cofactor. EPR spectroscopy of freshly purified enzyme showed, however, only a minor signal at g = 2.01. Therefore, Mossbauer spectra of Fe-57-enriched APR were obtained at 4.2 K in magnetic fields of up to 7 tesla, which were assigned to a diamagnetic [4Fe-4S](2+) cluster. This cluster was unusual because only three of the iron sites exhibited the same Mossbauer parameters. The fourth iron site gave, because of the bistability of the fit, a significantly smaller isomer shift or larger quadrupole splitting than the other three sites. Thus, plant assimilatory APR represents a novel type of adenosine 5'-phosphosulfate reductase with a [4Fe-4S] center as the sole cofactor, which is clearly different from the dissimilatory adenosine 5'-phosphosulfate reductases found in sulfate reducing bacteria.	Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Univ Constance, Fachbereich Biol, D-78457 Constance, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany; Univ Bern, Dept Chem, CH-3013 Bern, Switzerland; Univ Neuchatel, Biochim Lab, CH-2000 Neuchatel, Switzerland	University of Bern; University of Konstanz; University of Zurich; University of Lubeck; University of Bern; University of Neuchatel	Kopriva, S (corresponding author), Inst Tree Physiol, Georges Kohler Allee 053, D-79085 Freiburg, Germany.		Feller, Urs/A-1807-2008; Fritz, Guenter/E-2933-2013; Kopriva, Stanislav/C-7401-2013; Schünemann, Volker/C-6603-2016	Feller, Urs/0000-0001-7858-5721; Fritz, Guenter/0000-0002-4571-8812; Kopriva, Stanislav/0000-0002-7416-6551; 				Bates DM, 2000, J BIOL CHEM, V275, P6234, DOI 10.1074/jbc.275.9.6234; Bick JA, 1998, P NATL ACAD SCI USA, V95, P8404, DOI 10.1073/pnas.95.14.8404; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNOLD C, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P13; BRUNOLD C, 1993, SULFUR NUTRITION AND ASSIMILATION IN HIGHER PLANTS, P61; Brunold C., 1990, METHODS PLANT BIOCH, P339; Buchanan BB, 1971, METHOD ENZYMOL, V23, P413, DOI [10.1016/S0076-6879(71)23115-3, DOI 10.1016/S0076-6879(71)23115-3]; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Coropceanu V, 2000, CHEM PHYS LETT, V323, P14, DOI 10.1016/S0009-2614(00)00502-9; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; Fritz G, 2000, FEBS LETT, V473, P63, DOI 10.1016/S0014-5793(00)01500-3; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Hawkesford MJ, 2000, ADV BOT RES, V33, P159, DOI 10.1016/S0065-2296(00)33043-9; HOLM RH, 1990, PROG INORG CHEM, V38, P2; HUYNH BH, 1980, BIOCHIM BIOPHYS ACTA, V623, P124, DOI 10.1016/0005-2795(80)90015-X; JONESMOR.MC, 1968, BIOCHEM J, V110, P589, DOI 10.1042/bj1100589; KRAHN E, 2001, IN PRESS J BIOL INOR; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; KREDICH NM, 1971, J BIOL CHEM, V246, P3474; KRONE FA, 1991, MOL GEN GENET, V225, P314, DOI 10.1007/BF00269864; Leustek T, 1999, PLANT PHYSIOL, V120, P637, DOI 10.1104/pp.120.3.637; LI JY, 1991, BIOCHEM J, V274, P355, DOI 10.1042/bj2740355; MACDONNELL FM, 1995, INORG CHEM, V34, P1815, DOI 10.1021/ic00111a032; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Prior A, 1999, BBA-PROTEIN STRUCT M, V1430, P25, DOI 10.1016/S0167-4838(98)00266-0; RAVI N, 1994, J BIOL CHEM, V269, P20920; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; SCHMIDT A, 1972, ARCH MIKROBIOL, V84, P77, DOI 10.1007/BF00408084; SCHMIDT A, 1975, PLANT SCI LETT, V5, P407, DOI 10.1016/0304-4211(75)90008-5; SCHWENN JD, 1989, Z NATURFORSCH C, V44, P504; Setya A, 1996, P NATL ACAD SCI USA, V93, P13383, DOI 10.1073/pnas.93.23.13383; STIEGER PA, 1994, PLANT SOIL, V166, P173, DOI 10.1007/BF00008330; Suter M, 2000, J BIOL CHEM, V275, P930, DOI 10.1074/jbc.275.2.930; Tamarit J, 2000, J BIOL CHEM, V275, P15669, DOI 10.1074/jbc.275.21.15669; TRAUTWEIN AX, 1991, STRUCT BOND, V78, P1; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; VERHAGEN MFJM, 1994, EUR J BIOCHEM, V221, P831, DOI 10.1111/j.1432-1033.1994.tb18797.x; Weber M, 2000, EUR J BIOCHEM, V267, P3647, DOI 10.1046/j.1432-1327.2000.01394.x; Xia JQ, 1997, J AM CHEM SOC, V119, P8301, DOI 10.1021/ja971025+; Yoo SJ, 2000, J AM CHEM SOC, V122, P4926, DOI 10.1021/ja000254k	41	60	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42881	42886		10.1074/jbc.M107424200	http://dx.doi.org/10.1074/jbc.M107424200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553635	hybrid, Green Submitted			2022-12-25	WOS:000172169300034
J	Panagotopulos, SE; Horace, EM; Maiorano, JN; Davidson, WS				Panagotopulos, SE; Horace, EM; Maiorano, JN; Davidson, WS			Apolipoprotein A-I adopts a belt-like orientation in reconstituted high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; MEMBRANE PENETRATION DEPTH; TANGIER-DISEASE; CHOLESTEROL TRANSPORT; INTERSTITIAL FLUID; APOA-I; FLUORESCENCE; MODEL; DEFICIENCY; MUTATIONS	Apolipoprotein A-I (apoA-I) is the major protein associated with high density lipoprotein (HDL), and its plasma levels have been correlated with protection against atherosclerosis. Unfortunately, the structural basis of this phenomenon is not fully understood. Over 25 years of study have produced two general models of apoA-I structure in discoidal HDL complexes. The "belt" model states that the amphipathic helices of apoA-I are aligned perpendicular to the acyl chains of the lipid bilayer, whereas the "picket fence" model argues that the helices are aligned parallel with the acyl chains. To distinguish between the two models, various single tryptophan mutants of apoA-I were analyzed in reconstituted, discoidal HDL particles composed of phospholipids containing nitroxide spin labels at various positions along the acyl chain. We have previously used this technique to show that the orientation of helix 4 of apoA-I is most consistent with the belt model. In this study, we performed additional control experiments on helix 4, and we extended the results by performing the same analysis on the remaining 22-mer helices (helices 1, 2,5,6,7,8, and 10) of human apoA-I. For each helix, two different mutants were produced that each contained a probe Trp occurring two helical turns apart. In the belt model, the two Trp residues in each helix should exhibit maximal quenching at the same nitroxide group position on the lipid acyl chains. For the picket fence model, maximal quenching should occur at two different levels in the bilayer. The results show that the majority of the helices are in an orientation that is consistent with a belt model, because most Trp residues localized to a position about 5 A from the center of the bilayer. This study corroborates a belt hypothesis for the majority of the helices of apoA-I in phospholipid discs.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.			Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062542] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BAKER HN, 1975, J BIOL CHEM, V250, P2725; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; GLOMSET JA, 1968, J LIPID RES, V9, P155; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCLACHLAN AD, 1977, NATURE, V267, P465, DOI 10.1038/267465a0; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; ROHEIM PS, 1990, EUR HEART J, V11, P225, DOI 10.1093/eurheartj/11.suppl_E.225; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1994, J LIPID RES, V35, P871; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; WALD JH, 1990, J BIOL CHEM, V265, P20044; WONG L, 1992, J CLIN INVEST, V90, P2370, DOI 10.1172/JCI116127	36	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42965	42970		10.1074/jbc.M106462200	http://dx.doi.org/10.1074/jbc.M106462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11557764	hybrid			2022-12-25	WOS:000172169300045
J	Bennett, SE; Sung, JS; Mosbaugh, DW				Bennett, SE; Sung, JS; Mosbaugh, DW			Fidelity of uracil-initiated base excision DNA repair in DNA polymerase beta-proficient and -deficient mouse embryonic fibroblast cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLASE INHIBITOR PROTEIN; PURIFIED HUMAN PROTEINS; NUCLEAR ANTIGEN; LIGASE-I; CRYSTAL-STRUCTURES; MAMMALIAN-CELLS; PCNA BINDING; SITE REPAIR; RAT-LIVER; UNG GENE	Uracil-initiated base excision DNA repair was conducted using homozygous mouse embryonic fibroblast DNA polymerase (+/+) and (-/-) cells to determine the error frequency and mutational specificity associated with the completed repair process. Form I DNA substrates were constructed with site-specific uracil residues at U-A, U-G, and U-T targets contained within the lacZ alpha gene of M13mp2 DNA. Efficient repair was observed in both DNA polymerase beta (+/+) and (-/-) cell free extracts. Repair was largely dependent on uracil-DNA glycosylase activity because addition of the PBS-2 uracil-DNA glycosylase inhibitor (Ugi) protein reduced (similar to 88%) the initial rate of repair in both types of cell-free extracts. In each case, the DNA repair patch size was primarily distributed between 1 and 8 nucleotides in length with 1 nucleotide repair patch constituting similar to 20% of the repair events. Addition of p21 peptide or protein to DNA polymerase beta (+/+) cell-free extracts increased the frequency of short-patch (1 nucleotide) repair by similar to2-fold. The base substitution reversion frequency associated with uracil-DNA repair of M13mp2op14 (U-T) DNA was determined to be 5.7-7.2 x 10(-4) when using DNA polymerase P (+/+) and (-/-) cell-free extracts. In these two cases, the error frequency was very similar, but the mutational spectrum was noticeably different. The presence or absence of Ugi did not dramatically influence either the error rate or mutational specificity. In contrast, the combination of Ugi and p21 protein promoted an increase in the mutation frequency associated with repair of M13mp2 (U-G) DNA. Examination of the mutational spectra generated by a forward mutation assay revealed that errors in DNA repair synthesis occurred predominantly at the position of the U-G target and frequently involved a 1-base deletion or incorporation of dTMP.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Environm Hlth Sci, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Mosbaugh, DW (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; ARAVIND L, 2000, GENOME BIOL, V1; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bellacosa A, 2001, J CELL PHYSIOL, V187, P137, DOI 10.1002/jcp.1064; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Chen XL, 2000, J BIOL CHEM, V275, P17677, DOI 10.1074/jbc.M910278199; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3223; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; MOSBAUGH DW, 1984, J BIOL CHEM, V259, P247; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nilsen H, 2001, CARCINOGENESIS, V22, P987, DOI 10.1093/carcin/22.7.987; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Putnam CD, 1999, J MOL BIOL, V287, P331, DOI 10.1006/jmbi.1999.2605; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; Radany EH, 2000, MUTAT RES-DNA REPAIR, V461, P41, DOI 10.1016/S0921-8777(00)00040-9; Sanderson RJ, 1998, J BIOL CHEM, V273, P24822, DOI 10.1074/jbc.273.38.24822; Sanderson RJ, 2001, PROG NUCLEIC ACID RE, V68, P165; SANDERSON RJ, 1998, THESIS OREGON STATE; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Sung JS, 2001, J BIOL CHEM, V276, P2276, DOI 10.1074/jbc.M008147200; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154	70	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42588	42600		10.1074/jbc.M106212200	http://dx.doi.org/10.1074/jbc.M106212200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551933	hybrid			2022-12-25	WOS:000172450400135
J	Fung, H; Bennett, RAO; Demple, B				Fung, H; Bennett, RAO; Demple, B			Key role of a downstream specificity protein 1 site in cell cycle-regulated transcription of the AP endonuclease gene APE1/APEX in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR ENZYME; HUMAN APURINIC ENDONUCLEASE; BASE EXCISION-REPAIR; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; APYRIMIDINIC ENDONUCLEASE; IONIZING-RADIATION; GROWTH-REGULATION; BINDING ACTIVITY; POLYMERASE-BETA; MAMMALIAN-CELLS	Abasic (apurinic/apyrimidinic or AP) sites are a frequent type of DNA damage that threatens genetic stability. The predominant mammalian enzyme initiating repair of AP sites is the Ape1 AP endonuclease (also called Apex or Hap1), which also facilitates DNA binding by several transcription factors (Ref1 activity). We found that expression of the APE1 gene was coordinated with the cell cycle in murine NIH3T3 cells: APE1 mRNA levels rose after the G(1)-S transition and peaked similar to4-fold higher in early to mid-S phase. The increased APE1 mRNA was the result of transcriptional activation rather than increased mRNA stability. Fusions of various APE1 promoter fragments to the chloramphenicol. acetyltransferase CAT reporter gene indicated that APE1 expression depends on two transcription factor Sp1 binding sites within the promoter region. Mutation of these sites or of two CCAAT elements within the APE1 promoter, in conjunction with protein binding studies, demonstrated their specific roles. The Sp1 site upstream of the transcription start, together with an adjacent CCAAT element, establishes a protein-DNA complex required for basal transcription of APE1. The Spl site downstream of the transcription start was required for the response to cell growth. Because Ape I is a dual function enzyme, its cell cycle-dependent expression might affect both DNA repair and the activity of various transcription factors as a function of the cell cycle.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32-ES07155] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Banfalvi G, 1997, DNA CELL BIOL, V16, P1155, DOI 10.1089/dna.1997.16.1155; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Bouziane M, 2000, MUTAT RES-DNA REPAIR, V461, P15, DOI 10.1016/S0921-8777(00)00036-7; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fung H, 1998, CANCER RES, V58, P189; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; Grosch S, 1998, CANCER RES, V58, P4410; Harrison L, 1997, MUTAT RES-DNA REPAIR, V385, P159, DOI 10.1016/S0921-8777(97)00053-0; Harrison L, 1996, CARCINOGENESIS, V17, P377, DOI 10.1093/carcin/17.2.377; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Izumi T, 1996, BIOCHEMISTRY-US, V35, P14679, DOI 10.1021/bi961995u; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOMMEL L, 1995, MUTAT RES-DNA REPAIR, V336, P181, DOI 10.1016/0921-8777(94)00055-B; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Marquis JC, 1998, CANCER RES, V58, P3435; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Nakamura J, 1999, CANCER RES, V59, P2522; Noe V, 1997, EUR J BIOCHEM, V249, P13, DOI 10.1111/j.1432-1033.1997.00013.x; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; Sorensen P, 1999, J BIOL CHEM, V274, P30943, DOI 10.1074/jbc.274.43.30943; Strauss PR, 1998, J BIOL CHEM, V273, P14435, DOI 10.1074/jbc.273.23.14435; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Wei SJ, 2000, CANCER RES, V60, P6688; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1995, NUCLEIC ACIDS RES, V23, P5027; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wilson TM, 1996, MUTAT RES-DNA REPAIR, V362, P237, DOI 10.1016/0921-8777(95)00053-4; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Xu Y, 1997, ANTICANCER RES, V17, P3713; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743	59	36	37	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42011	42017		10.1074/jbc.M106423200	http://dx.doi.org/10.1074/jbc.M106423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11555653	hybrid			2022-12-25	WOS:000172450400064
J	Beher, D; Wrigley, JDJ; Nadin, A; Evin, G; Masters, CL; Harrison, T; Castro, JL; Shearman, MS				Beher, D; Wrigley, JDJ; Nadin, A; Evin, G; Masters, CL; Harrison, T; Castro, JL; Shearman, MS			Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma-secretase inhibitor - Implications for presenilin biology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; BETA-SECRETASE; TRANSMEMBRANE ASPARTATES; SIGNAL-TRANSDUCTION; MISSENSE MUTATIONS; CLEAVAGE; GENE; CHROMOSOME-1; COMPLEX	Intramembranous cleavage of the beta -amyloid precursor protein by gamma -secretase is the final processing event generating amyloid-beta peptides, which are thought to be causative agents for Alzheimer's disease. Missense mutations in the presenilin genes co-segregate with early-onset Alzheimer's disease, and, recently, a close biochemical linkage between presenilins and the identity of gamma -secretase has been established. Here we describe for the first time that certain potent gamma -secretase inhibitors are able to interfere with the endoproteolytic processing of presenilin 1 (PS1). In addition, we identified a novel gamma -secretase inhibitor, {1S-benzyl-4R-[1-(5-cyclohexyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3(R,S)-ylcarbamoyl)-S-ethylcarbamoyl]-2R-hydroxy-5-phenyl-pentyl}-carbamic acid tertbutyl ester (CBAP), which not only physically interacts with PS1, but upon chronic treatment produces a "pharmacological knock-down" of PS1 fragments. This indicates that the observed accumulation of full-length PS1 is caused by a direct inhibition of its endoproteolysis. The subsequent use of CBAP as a biological tool to increase full-length PS1 levels in the absence of exogenous PS1 expression has provided evidence that wild-type PS1 endoproteolysis is not required either for PS1/gamma -secretase complex assembly or trafficking. Furthermore, in cell-based systems CBAP does not completely recapitulate PS1 loss-of-function phenotypes. Even though the beta -amyloid precursor protein cleavage and the S3 cleavage of the Notch receptor are inhibited by CBAP, an impairment of Trk receptor maturation was not observed.	Merck Sharp & Dohme Ltd, Res Labs, Dept Biochem & Mol Biol, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Merck Sharp & Dohme Ltd, Res Labs, Dept Med Chem, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Mental Hlth Inst Victoria, Neuropathol Lab, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia	Merck & Company; GlaxoSmithKline; Merck & Company; University of Melbourne	Beher, D (corresponding author), Merck Sharp & Dohme Ltd, Res Labs, Dept Biochem & Mol Biol, Neurosci Res Ctr, Terlings Pk, Harlow CM20 2QR, Essex, England.	dirk_beher@merck.com	Evin, Genevieve M/E-5891-2013	Beher, Dirk/0000-0001-8005-5359				Beher D, 1999, J NEUROCHEM, V72, P1564, DOI 10.1046/j.1471-4159.1999.721564.x; Bilsland JG, 1998, J NEUROSCI METH, V84, P121, DOI 10.1016/S0165-0270(98)00106-X; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHAMBERS MS, 1993, BIOORG MED CHEM LETT, V3, P1919, DOI 10.1016/S0960-894X(01)80987-2; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Clarke EE, 2000, J NEUROSCI METH, V102, P61, DOI 10.1016/S0165-0270(00)00280-6; Culvenor JG, 2000, EXP CELL RES, V255, P192, DOI 10.1006/excr.1999.4791; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESOLMS SJ, 1991, J MED CHEM, V34, P2852, DOI 10.1021/jm00113a025; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATRITZKY AR, 1990, J ORG CHEM, V55, P2206, DOI 10.1021/jo00294a042; Khorkova OE, 1998, J NEUROSCI METH, V82, P159, DOI 10.1016/S0165-0270(98)00053-3; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Nadin A, 2001, TETRAHEDRON, V57, P1861, DOI 10.1016/S0040-4020(00)01167-4; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRILL RG, 1995, J ORG CHEM, V60, P730, DOI 10.1021/jo00108a044; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YANG HJ, 1994, BIO-TECHNOL, V12, P193, DOI 10.1038/nbt0294-193; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	54	81	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45394	45402		10.1074/jbc.M103075200	http://dx.doi.org/10.1074/jbc.M103075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574530	hybrid			2022-12-25	WOS:000172406700136
J	Carr, KM; Kaguni, JM				Carr, KM; Kaguni, JM			Stoichiometry of DnaA and DnaB protein in initiation at the Escherichia coli chromosomal origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; STRANDED-DNA; HELICASE; INVITRO; COMPLEX; BINDING; PRIMASE; SITES; GENE; REVEALS	Initiation of DNA replication at the Escherichia coli chromosomal origin, oriC, occurs through an ordered series of events that depend first on the binding of DnaA protein, the replication initiator, to DnaA box sequences within oriC followed by unwinding of an AT-rich region near the left border. The prepriming complex then forms, involving the binding of DnaB helicase at oriC so that it is properly positioned at each replication fork. We assembled and isolated the prepriming complexes on an oriC plasmid, then determined the stoichiometries of proteins in these complexes by quantitative immunoblot analysis. DnaA protein alone binds to oriC with a stoichiometry of 4-5 monomers per oriC DNA. In the prepriming complex, the stoichiometries are 10 DnaA monomers and 2 DnaB hexamers per oriC plasmid. That only two DnaB hexamers are bound, one for each replication fork, suggests that the binding of additional molecules of DnaA in forming the prepriming complex restricts the loading of additional DnaB hexamers that can bind at oriC.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	kaguni@msu.edu		Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Galletto R, 2000, BIOCHEMISTRY-US, V39, P12959, DOI 10.1021/bi0012484; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kaguni JM, 1997, MOL CELLS, V7, P145; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; Majka J, 2001, J BIOL CHEM, V276, P6243, DOI 10.1074/jbc.M007876200; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; Sutton MD, 1997, J MOL BIOL, V274, P546, DOI 10.1006/jmbi.1997.1425; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; TOUGU K, 1994, J BIOL CHEM, V269, P4675; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	35	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44919	44925		10.1074/jbc.M107463200	http://dx.doi.org/10.1074/jbc.M107463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11551962	hybrid			2022-12-25	WOS:000172406700079
J	Degousee, N; Stefanski, E; Lindsay, TF; Ford, DA; Shahani, R; Andrews, CA; Thuerauf, DJ; Glembotski, CC; Nevalainen, TJ; Tischfield, J; Rubin, BB				Degousee, N; Stefanski, E; Lindsay, TF; Ford, DA; Shahani, R; Andrews, CA; Thuerauf, DJ; Glembotski, CC; Nevalainen, TJ; Tischfield, J; Rubin, BB			p38 MAPK regulates group IIa phospholipase A(2) expression in interleukin-1 beta-stimulated rat neonatal cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ARACHIDONIC-ACID; CARDIAC MYOCYTES; GENE-EXPRESSION; PROSTAGLANDIN PRODUCTION; INFLAMMATORY CYTOKINES; P388D(1) MACROPHAGES; SELECTIVE ACTIVATION	Group IIa phospholipase A(2) (GII(a) PLA(2)) is released by some cells in response to interleukin-1 beta. The purpose of this study was to determine whether interieukin-1 beta would stimulate the Synthesis and release of GIIa PLA2 from cardiomyocytes, and to define the role of p38 MAPK and cytosolic PLA(2) in the regulation of this process. Whereas GIIa PLA(2) mRNA was not identified in untreated cells, exposure to interleukin-1 beta resulted in the sustained expression of GIIa PLA(2) mRNA. Interleukin-1 beta also stimulated a progressive increase in cellular and extracellular GIIa PLA(2) protein levels and increased extracellular PLA(2) activity 70-fold. In addition, interleukin-1 beta stimulated the p38 MAPK-dependent activation of the downstream MAPK-activated protein kinase, MAPKAP-K2. Treatment with the p38 MAPK inhibitor, SB202190, decreased interleukin-1 beta stimulated,, mRNA expression, GIIa MAPKAP-K2 activity, GIIa PLA, PLA(2) protein synthesis, and the release of extracellular PLA(2) activity. Infection with an adenovirus encoding a constitutively active form of MKK6, MKK6(Glu), which selectively phosphorylates p38 MAPK, induced cellular GIIa PLA protein synthesis and the release of GIIa PLA(2) and increased extracellular PLA(2) activity 3-fold. In contrast, infection with an adenovirus encoding a phosphorylation-resistant MKK6, MKKK6(A), did not result in GIIa PLA(2) protein synthesis or release by unstimulated cardiomyocytes. In addition, infection with an adenovirus encoding MKK6(A) abrogated GIIa PLA(2) protein synthesis and release by interleukin-1 beta -stimulated cells. These results provide direct evidence that p38 MAPK activation was necessary for interleukin-1 beta -induced synthesis and release of GIIa PLA(2) by cardiomyocytes.	Toronto Gen Hosp, Div Vasc Surg, Max Bell Res Ctr 1 917, Toronto, ON M5G 2C4, Canada; St Louis Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; San Diego State Univ, Heart Inst, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Saint Louis University; California State University System; San Diego State University; California State University System; San Diego State University; University of Turku; Rutgers State University New Brunswick	Rubin, BB (corresponding author), Toronto Gen Hosp, Div Vasc Surg, Max Bell Res Ctr 1 917, 200 Elizabeth St,EC5-302A, Toronto, ON M5G 2C4, Canada.	barry.rubin@uhn.on.ca	; Ford, David/D-1819-2018	Tischfield, Jay/0000-0003-3217-8287; Ford, David/0000-0002-0029-1560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL042665, R01HL042665, R01HL063975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42665, HL-25037, HL-63975] Funding Source: Medline; NIDDK NIH HHS [DK38185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ALAM T, 1992, J BIOL CHEM, V267, P5021; Andreani M, 2000, BBA-MOL CELL BIOL L, V1488, P149, DOI 10.1016/S1388-1981(00)00117-7; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BORGEAT P, 1990, CLIN BIOCHEM, V23, P459, DOI 10.1016/0009-9120(90)90272-V; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; CHOCK SP, 1994, BIOCHEM J, V300, P619, DOI 10.1042/bj3000619; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Couturier C, 2000, ARTERIOSCL THROM VAS, V20, P2559, DOI 10.1161/01.ATV.20.12.2559; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; HUWILER A, 1994, FEBS LETT, V350, P135, DOI 10.1016/0014-5793(94)00754-3; Isenovic E, 2000, HYPERTENSION, V35, P249, DOI 10.1161/01.HYP.35.1.249; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KONIECZKOWSKI M, 1993, J CLIN INVEST, V92, P2524, DOI 10.1172/JCI116861; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LaPointe MC, 1996, HYPERTENSION, V27, P709, DOI 10.1161/01.HYP.27.3.709; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Massaad C, 2000, J BIOL CHEM, V275, P22686, DOI 10.1074/jbc.M001250200; MCDONALD PP, 1992, BRIT J PHARMACOL, V107, P226, DOI 10.1111/j.1476-5381.1992.tb14491.x; McHowat J, 1997, AM J PHYSIOL-CELL PH, V272, pC450, DOI 10.1152/ajpcell.1997.272.2.C450; McHowat J, 1998, AM J PHYSIOL-CELL PH, V274, pC1727, DOI 10.1152/ajpcell.1998.274.6.C1727; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Nyman KM, 2000, J HISTOCHEM CYTOCHEM, V48, P1469, DOI 10.1177/002215540004801104; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Shioi T, 1997, CIRC RES, V81, P664; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Testa M, 1996, J AM COLL CARDIOL, V28, P964, DOI 10.1016/S0735-1097(96)00268-9; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; van der Helm HA, 2001, BBA-MOL CELL BIOL L, V1530, P86, DOI 10.1016/S1388-1981(00)00171-2; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wen YS, 2001, CIRC RES, V88, P70, DOI 10.1161/01.RES.88.1.70; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	73	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43842	43849		10.1074/jbc.M101516200	http://dx.doi.org/10.1074/jbc.M101516200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571275	hybrid			2022-12-25	WOS:000172297700049
J	Perreault, N; Katz, JP; Sackett, SD; Kaestner, KH				Perreault, N; Katz, JP; Sackett, SD; Kaestner, KH			Foxl1 controls the Wnt/beta-catenin pathway by modulating the expression of proteoglycans in the gut	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX COMPONENTS; HEPARAN-SULFATE PROTEOGLYCANS; BETA-CATENIN; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; DIFFERENTIATION; MICE; PROLIFERATION; INTESTINE; CANCER	Foxl1 is a winged helix transcription factor expressed in the mesenchyme of the gastrointestinal tract. Foxl1 null mice display severe structural defects in the epithelia of the stomach, duodenum, and jejunum. Here we addressed the molecular mechanisms by which Foxl1 controls gastrointestinal differentiation. First we showed that the abnormalities found in the epithelia of the null mice are the result of an increase in the number of proliferating cells and not a change in the rate of cell migration. Next we investigated the regulatory circuits affected by Foxl1. We focused on the Wnt/beta -catenin signaling pathway as a possible target of Foxl1 as it has been shown to play a central role in gastrointestinal proliferation. We demonstrated that Foxl1 activates the Wnt/beta -catenin pathway by increasing extracellular proteoglycans, which act as co-receptors for Wnt. Thus we establish that Foxl1 is involved in the regulation of the Wnt/beta -catenin pathway, providing a novel link in mesenchymal/epithelial cross-talk in the gut. Moreover, we provide the first example implicating proteoglycans in the regulation of cellular proliferation in the gastrointestinal tract.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Kaestner, KH (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, R01DK053839, K08DK002809] Funding Source: NIH RePORTER; NIDDK NIH HHS [KO8 DK02809-01, P30DK50306, R01 DK53839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; BEAULIEU JF, 1991, ANAT EMBRYOL, V183, P363; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; Dale TC, 1998, BIOCHEM J, V329, P209; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Duncan SA, 1997, DEVELOPMENT, V124, P279; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Pabst O, 1999, DEVELOPMENT, V126, P2215; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PIGNATELLI A, 1997, GUT MODEL CELL MOL B; PODOLSKY DK, 1993, AM J PHYSIOL, V264, pG179, DOI 10.1152/ajpgi.1993.264.2.G179; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336	29	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43328	43333		10.1074/jbc.M104366200	http://dx.doi.org/10.1074/jbc.M104366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555641	hybrid			2022-12-25	WOS:000172169300091
J	Dai, GX; Steede, NK; Landry, SJ				Dai, GX; Steede, NK; Landry, SJ			Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; HUMAN CD4(+) CELLS; HEPATITIS-C VIRUS; ANTIGEN PRESENTATION; PEPTIDE BINDING; HIV GP120; EGG LYSOZYME; MOLECULES; PROTEIN; COMPLEX	The specificity and intensity of CD4(+) helper T-cell responses determine the effectiveness of immune effector functions. Promiscuously immunodominant helper T-cell epitopes in the human immunodeficiency virus (HIV) envelope glycoprotein gp120 could be important in the development of broadly protective immunity, but the underlying mechanisms of immunodominance and promiscuity remain poorly defined. In this study, gp120 helper T-cell epitopes were systematically mapped in CBA/J and BALB/c mice by restimulation assays using a set of overlapping peptides spanning the entire sequence of the gp120 encoded by HIV strain 89.6. The results were analyzed in the context of the HIV gp120 structure determined by x-ray crystallography. One major finding was that all of the promiscuously immunodominant gp120 sequences are located in the outer domain. Further analyses indicated that epitope immunogenicity in the outer domain correlates with structural disorder in adjacent N-terminal segments, as indicated by crystallographic D-factors or sequence divergence. In contrast, the correlation was poor when the analysis encompassed the entire gp120 sequence or was restricted to only the inner domain. These findings suggest that local disorder promotes the processing and presentation of adjacent epitopes in the outer domain of gp120 and therefore reveal how three-dimensional structure shapes the profile of helper T-cell epitope immunogenicity.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Tulane University	Landry, SJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA.		Landry, Samuel/AAK-5778-2020	Landry, Samuel/0000-0002-4082-0543	NIAID NIH HHS [R21-AI42702] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042702] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Bouhdoud L, 2000, J VIROL, V74, P2121, DOI 10.1128/JVI.74.5.2121-2130.2000; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; Cardenas-Freytag L, 1999, INFECT IMMUN, V67, P826; Castellino F, 1998, J IMMUNOL, V161, P4048; Chianese-Bullock KA, 1998, J IMMUNOL, V161, P1599; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DENG HK, 1993, J EXP MED, V178, P1675, DOI 10.1084/jem.178.5.1675; Diethelm-Okita BM, 2000, J INFECT DIS, V181, P1001, DOI 10.1086/315324; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Dormann D, 1998, CLIN EXP ALLERGY, V28, P1374; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; GAO XM, 1989, J IMMUNOL, V143, P3007; GERETY SJ, 1994, J IMMUNOL, V152, P908; Hagmann M, 2000, SCIENCE, V290, P80, DOI 10.1126/science.290.5489.80; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456; Haque MA, 2001, J IMMUNOL, V166, P4543, DOI 10.4049/jimmunol.166.7.4543; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; JANSSEN R, 1994, INT IMMUNOL, V6, P1187, DOI 10.1093/intimm/6.8.1187; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwong PD, 1999, J BIOL CHEM, V274, P4115, DOI 10.1074/jbc.274.7.4115; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Landry SJ, 1997, IMMUNOL TODAY, V18, P527, DOI 10.1016/S0167-5699(97)01152-3; Landry SJ, 2000, J THEOR BIOL, V203, P189, DOI 10.1006/jtbi.1999.1056; Lindner R, 1996, EMBO J, V15, P6910, DOI 10.1002/j.1460-2075.1996.tb01083.x; Ma CL, 1999, J IMMUNOL, V163, P6413; Manici S, 1999, J EXP MED, V189, P871, DOI 10.1084/jem.189.5.871; MEISTER GE, 1995, VACCINE, V13, P581, DOI 10.1016/0264-410X(94)00014-E; Moudgil KD, 1998, J IMMUNOL, V161, P6046; Moudgil KD, 1996, J EXP MED, V183, P535, DOI 10.1084/jem.183.2.535; Moudgil KD, 1997, J EXP MED, V185, P1307, DOI 10.1084/jem.185.7.1307; Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500; Nakagawa TY, 1999, IMMUNOL REV, V172, P121, DOI 10.1111/j.1600-065X.1999.tb01361.x; Nayak BP, 1999, FEBS LETT, V443, P159, DOI 10.1016/S0014-5793(98)01715-3; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; Nelson CA, 1997, P NATL ACAD SCI USA, V94, P628, DOI 10.1073/pnas.94.2.628; Niedermann G, 1999, IMMUNOL REV, V172, P29, DOI 10.1111/j.1600-065X.1999.tb01354.x; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Phelps RG, 1998, J BIOL CHEM, V273, P11440, DOI 10.1074/jbc.273.19.11440; Raju R, 1995, EUR J IMMUNOL, V25, P3207, DOI 10.1002/eji.1830251202; Roberts CGP, 1996, AIDS RES HUM RETROV, V12, P593, DOI 10.1089/aid.1996.12.593; RODRIGUEZ GM, 1995, EUR J IMMUNOL, V25, P1823, DOI 10.1002/eji.1830250705; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Shirai M, 1999, J IMMUNOL, V162, P568; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; Sjolander S, 1996, VACCINE, V14, P344, DOI 10.1016/0264-410X(95)00163-U; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STEVANOVIC S, 1996, STRUCTURE ANTIGENS, V3, P61; Surman S, 2001, P NATL ACAD SCI USA, V98, P4587, DOI 10.1073/pnas.071063898; Vanegas RA, 1997, VACCINE, V15, P321, DOI 10.1016/S0264-410X(96)00167-3; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; WAHREN B, 1989, J ACQ IMMUN DEF SYND, V2, P448; Wang H, 1999, J IMMUNOL, V162, P4177; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x; Zeiler T, 1999, J IMMUNOL, V162, P1415	63	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41913	41920		10.1074/jbc.M106018200	http://dx.doi.org/10.1074/jbc.M106018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551929	hybrid			2022-12-25	WOS:000172450400050
J	Han, JW; Ahn, SH; Kim, YK; Bae, GU; Yoon, JW; Hong, SY; Lee, HY; Lee, YW; Lee, HW				Han, JW; Ahn, SH; Kim, YK; Bae, GU; Yoon, JW; Hong, SY; Lee, HY; Lee, YW; Lee, HW			Activation of p21(WAF1-Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin - Involvement of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; GENE PROMOTER; WAF1/CIP1 GENE; IN-VIVO; P21(WAF1/CIP1); EXPRESSION; CELLS; INDUCTION; CANCER; P53	We previously reported that apicidin, a novel histone deacetylase inhibitor, inhibited the proliferation of tumor cells via induction of p21(WAF1/Cip1). In this study, we determined the molecular mechanisms by which apicidin induced the p21(WAF1/Cip1) gene expression in HeLa cells. Apicidin induced p21(WAF1/Cip1) mRNA independent of the de novo protein synthesis and activated the p21(WAF1/Cip1) promoter through Sp1-3 site located at -82 and -77 relative to the transcription start site. This transcriptional activation appears to be mediated by protein kinase C (PKC), because calphostin C, a PKC inhibitor, significantly attenuated the activation of p21(WAF1/Cip1) promoter via Spl sites, which was accompanied by a marked suppression of p21(WAF1/Cip1) mRNA and protein expression induced by apicidin. Consistent with the transcriptional activation of p21(WAF1/Cip1) promoter by apicidin, apicidin treatment led to the translocation of PKC epsilon from cytosolic to particulate fraction, which was reversed by pretreatment with calphostin C, indicating the involvement of PKC in the transcriptional activation of p21(WAF1/Cip1) via Sp1 sites by apicidin. However, the PKC-mediated transcriptional activation of p21(WAF1/Cip1) by apicidin appears to be independent of the histone hyperacetylation, because apicidin-induced histone hyperacetylation was not affected by calphostin C. Furthermore, a PKC activator, phorbol 12,13-dibutyrate, alone induced the transcriptional activation of p21(WAF1/Cip1) promoter, p21(WAF1/Cip1) mRNA, and protein expression without induction of the histone hyperacetylation, suggesting that the transcriptional activation of p21(WAF1/Cip1) by apicidin might have been mediated by a mechanism other than chromatin remodeling through the histone hyperacetylation. Taken together, these results suggest that the PKC signaling pathway plays a pivotal role in the transcriptional activation of the p21(WAF1/Cip1) gene by apicidin.	Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Changan Ku, Suwon 440746, Kyunggido, South Korea; Sungkyunkwan Univ, Coll Life Sci & nat Resources, Dept Genet Engn, Changan Ku, Suwon 440746, Kyunggido, South Korea; Konyang Univ, Coll Med, Dept Pharmacol, Nonsan 320711, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Konyang University; Konyang University Hospital; Seoul National University (SNU)	Lee, HY (corresponding author), Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Changan Ku, 300 Chonchondong, Suwon 440746, Kyunggido, South Korea.	hylee@yurim.skku.ac.kr		Ahn, Seong-Hoon/0000-0002-9174-4966				Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; CHEDID M, 1994, ONCOGENE, V9, P3021; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinos E, 1998, MOL BRAIN RES, V56, P118, DOI 10.1016/S0169-328X(98)00036-9; Frey MR, 1997, J BIOL CHEM, V272, P9424; Glick RD, 1999, CANCER RES, V59, P4392; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Han JW, 2000, CANCER RES, V60, P6068; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Lee BI, 2001, CANCER RES, V61, P931; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; LI YJ, 1995, ONCOGENE, V10, P599; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Park JS, 1999, APPL ENVIRON MICROB, V65, P126; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rivero JA, 1998, BIOCHEM BIOPH RES CO, V248, P664, DOI 10.1006/bbrc.1998.9041; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; SCHERR CJ, 1995, GENE DEV, V9, P1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sowa Y, 1999, CANCER RES, V59, P4266; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42084	42090		10.1074/jbc.M106688200	http://dx.doi.org/10.1074/jbc.M106688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551946	hybrid			2022-12-25	WOS:000172450400074
J	Webb, DC; McKenzie, ANJ; Foster, PS				Webb, DC; McKenzie, ANJ; Foster, PS			Expression of the Ym2 lectin-binding protein is dependent on interleukin (IL)-4 and IL-13 signal transduction - Identification of a novel allergy-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; AIRWAYS HYPERREACTIVITY; T-CELLS; BRONCHIAL HYPERREACTIVITY; DEFICIENT MICE; LUNG DAMAGE; BALB/C MICE; TH2 CELLS; INFLAMMATION; ASTHMA	Asthma pathophysiology is intimately regulated by CD4(+) Th2 lymphocytes and the cytokines interleukin (IL)-4 and IL-13. However, the mechanisms by which these cytokines promote disease have not been fully elucidated. In order to identify novel molecular mediators of allergy, a comparison was made of the bronchoalveolar lavage, which demonstrated that the Ym2 protein was abundantly up-regulated in the lung during the development of allergy. Low levels of the Ym1 isomer were also detected. Importantly, neither Ym1 nor Ym2 has been characterized previously in the context of allergic pulmonary inflammation. Western immunoblot showed that enhanced expression of these proteins was dependent on CD4(+) T cells and IL-4 or IL-13 signaling via the IL-4R alpha subunit. In addition, intratracheal instillation of IL-13 into naive mice was sufficient to induce expression. Ym1 is homologous to eosinophil chemotactic factor L. However, only weak eosinophil chemotaxis was observed in response to Ym protein in both in vitro and in vivo assays. By contrast, the homology of Ym1 and Ym2 to proteins associated with tissue remodeling, together with the previous findings that Ym1 is homologous to chitinase and binds heparin sulfate and GlcN oligomers (chitobiose, chitotriose, and chitotetraose), strongly suggests these proteins play an important role in airway wall remodeling in the allergic lung.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Australian National University; John Curtin School of Medical Research; MRC Laboratory Molecular Biology	Foster, PS (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia.		Webb, Dianne C/D-8626-2011; Foster, Paul/G-5057-2013	, Paul/0000-0002-0827-8299				BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DVORAK AM, 1988, BLOOD, V72, P150; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guo L, 2000, J BIOL CHEM, V275, P8032, DOI 10.1074/jbc.275.11.8032; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Hegele RG, 2000, IMMUNOPHARMACOLOGY, V48, P257, DOI 10.1016/S0162-3109(00)00238-1; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Homer RJ, 2000, CLIN CHEST MED, V21, P331, DOI 10.1016/S0272-5231(05)70270-7; Jin HM, 1998, GENOMICS, V54, P316, DOI 10.1006/geno.1998.5593; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Murata T, 1998, INT J MOL MED, V1, P551; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; Owhashi M, 1998, PARASITOL RES, V84, P136, DOI 10.1007/s004360050370; OWHASHI M, 1987, INT ARCH ALLER A IMM, V84, P185, DOI 10.1159/000234421; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; WARD JM, 1978, VET PATHOL, V15, P170, DOI 10.1177/030098587801500203; Ward JM, 2001, AM J PATHOL, V158, P323, DOI 10.1016/S0002-9440(10)63972-7; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; WEBB DC, 1999, CURR OPIN ANTIINFLAM, V1, P433; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YANG M, 2001, IN PRESS AM J RESP C; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839	42	132	135	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41969	41976		10.1074/jbc.M106223200	http://dx.doi.org/10.1074/jbc.M106223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553626	hybrid			2022-12-25	WOS:000172450400058
J	Worby, CA; Simonson-Leff, N; Clemens, JC; Kruger, RP; Muda, M; Dixon, JE				Worby, CA; Simonson-Leff, N; Clemens, JC; Kruger, RP; Muda, M; Dixon, JE			The sorting nexin, DSH3PX1, connects the axonal guidance receptor, dscam, to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SYNAPTIC VESICLE ENDOCYTOSIS; ADAPTER PROTEIN; SACCHAROMYCES-CEREVISIAE; MEDIATED ENDOCYTOSIS; ADHESION MOLECULE; ARP2/3 COMPLEX; DROSOPHILA; CLATHRIN; CELLS	Dock, an adaptor protein that functions in Drosophila axonal guidance, consists of three tandem Src homology 3 (SH3) domains preceding an SH2 domain. To develop a better understanding of axonal guidance at the molecular level, we used the SH2 domain of Dock to purify a protein complex from fly S2 cells. Five proteins were obtained in pure form from this protein complex. The largest protein in the complex was identified as Dscam ((D) under bar own (s) under bar yndrome (c) under bar ell (a) under bar dhesion (m) under bar olecule), which was subsequently shown to play a key role in directing neurons of the fly embryo to correct positions within the nervous system (Schmucker, D., Clemens, J. C., Shu, H., Worby, C. A., Xiao, J., Muda, M., Dixon, J. E., and Zipursky, S. L. (2000) Cell 101, 671-684). The smallest protein in this complex (p63) has now been identified. We have named p63 DSH3PXI because it appears to be the Drosophila orthologue of the human protein known as SH3PX1. DSH3PX1 is comprised of an NH2-terminal SH3 domain, an internal PHOX homology (PX) domain, and a carboxyl-terminal coiled-coil region. Because of its PX domain, DSH3PX1 is considered to be a member of a growing family of proteins known collectively as sorting nexins, some of which have been shown to be involved in vesicular trafficking. We demonstrate that DSH3PX1 immunoprecipitates with Dock and Dscam from S2 cell extracts. The domains responsible for the in vitro interaction between DSH3PX1 and Dock were also identified. We further show that DSH3PX1 interacts with the Drosophila orthologue of Wasp, a protein component of actin polymerization machinery, and that DSH3PX1 coimmunoprecipitates with AP-50, the clathrin-coat adapter protein. This evidence places DSH3PX1 in a complex linking cell surface receptors like Dscam to proteins involved in cytoskeletal rearrangements and/or receptor trafficking.	Univ Michigan, Sch Med, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dixon, JE (corresponding author), Univ Michigan, Sch Med, Inst Life Sci, Ann Arbor, MI 48109 USA.				PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Barr VA, 2000, TRAFFIC, V1, P904, DOI 10.1034/j.1600-0854.2000.011109.x; Ben-Yaacov S, 2001, J CELL BIOL, V152, P1, DOI 10.1083/jcb.152.1.1; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kamiguchi H, 2000, J NEUROSCI, V20, P3676, DOI 10.1523/JNEUROSCI.20-10-03676.2000; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; WORBY CA, 1997, CELL BIOL LAB MANUAL, P1; WORBY CA, 2001, SCI STKE; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P9273, DOI 10.1073/pnas.94.17.9273; Zhang YQ, 1999, GENE, V233, P171, DOI 10.1016/S0378-1119(99)00142-0; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	52	59	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41782	41789		10.1074/jbc.M107080200	http://dx.doi.org/10.1074/jbc.M107080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546816	hybrid			2022-12-25	WOS:000172450400033
J	Zhang, Z; Coomans, C; David, G				Zhang, Z; Coomans, C; David, G			Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling - Evidence in support of the "cooperative end structures" model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FGF RECEPTOR DIMERIZATION; HUMAN-LUNG FIBROBLASTS; CELL-SURFACE; CORE PROTEIN; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; SELF-ASSOCIATION; LIGAND-BINDING; BFGF BINDING	Fibroblast growth factor 2 (FGF2)-initiated FGF receptor (FGFR)-signaling requires the assistance of heparin/heparan sulfate. Here, we evaluated the effects of different heparan sulfate proteoglycan (HSPG)-expressing cell lines and HSPGs derived from these cells on FGF2-induced FGFR1-phosphorylation in heparan sulfate-negative BaF3 cells. HSPGs supplied in membrane-associated form, by presenting cells, were all effective promotors of FGF2-initiated FGFR1 phosphorylation, independently of their nature (syndecan/glypican) or cellular origin (human lung fibroblasts, transfected Namalwa cells, or transfected K562 cells). A treatment with heparitinase initially stimulated, but finally completely inhibited, the activity of these presenting cells. In comparison, equivalent amounts of soluble HSPGs, obtained by trypsinization of these cells or by immunopurification from cell extracts, did not promote FGF2-induced FGFR1-phosphorylation, yet removal of the less anionic species or a further treatment with heparitinase converted these soluble fractions into potent activators of FGF2/FGFR1 signaling. Extrapolating from current structural models, we suggest that FGFR dimerization and autophosphorylation is supported by cooperative "heparin-like end structures," and that cell surface association and concentration compensate for the relative scarcity of such end structures in native HSPGs. In this model, "proteolytic" shedding of heparan sulfate would act as a diluting, down-regulatory mechanism, while "heparanolytic" shedding might act as an up-regulatory mechanism, by increasing the concentration of these end structures.	Catholic Univ Louvain, Lab Glycobiol & Dev Genet, Dept Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Universite Catholique Louvain	David, G (corresponding author), Catholic Univ Louvain, Ctr Human Genet, Herestr 49,Campus Gasthuisberg,O&N, B-3000 Louvain, Belgium.							ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Carey DJ, 1997, BIOCHEM J, V327, P1; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; GALLAGHER JT, 1994, EUR J CLIN CHEM CLIN, V32, P239; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; GRASSEL S, 1995, MOL CELL BIOCHEM, V145, P61, DOI 10.1007/BF00925714; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Jones M, 2000, J BIOL CHEM, V275, P7964, DOI 10.1074/jbc.275.11.7964; KATO M, 1994, J BIOL CHEM, V269, P18881; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lin XH, 1999, DEVELOPMENT, V126, P3715; LORIES V, 1989, J BIOL CHEM, V264, P7009; LYON M, 1994, J BIOL CHEM, V269, P11208; MALI M, 1990, J BIOL CHEM, V265, P6884; MALI M, 1993, J BIOL CHEM, V268, P24215; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Uematsu F, 2000, BIOCHEM BIOPH RES CO, V272, P830, DOI 10.1006/bbrc.2000.2872; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; WALKER A, 1994, J BIOL CHEM, V269, P931; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	48	92	97	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41921	41929		10.1074/jbc.M106608200	http://dx.doi.org/10.1074/jbc.M106608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551944	hybrid			2022-12-25	WOS:000172450400051
J	Block, K; Boyer, TG; Yew, PR				Block, K; Boyer, TG; Yew, PR			Phosphorylation of the human ubiquitin-conjugating enzyme, CDC34, by casein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; CELL-CYCLE GENE; SACCHAROMYCES-CEREVISIAE; F-BOX; DEPENDENT DEGRADATION; SUBSTRATE-SPECIFICITY; MEDIATED PROTEOLYSIS; NEDD8 MODIFICATION; PROTEIN-KINASES; COMPLEX	The ubiquitin-conjugating enzyme, CDC34, has been implicated in the ubiquitination of a number of vertebrate substrates, including p27(Kipl), I kappaB alpha, Weel, and MyoD. We show that mammalian CDC34 is a phosphoprotein that is phosphorylated in proliferating cells. By yeast two-hybrid screening, we identified the regulatory (beta) subunit of human casein kinase 2 (CK2) as a CDC34-interacting protein and show that human CDC34 interacts in vivo with CK2 beta in transfected cells. CDC34 is specifically phosphorylated in vitro by recombinant CK2 and HeLa nuclear extract at five sites within the carboxyl-terminal 36 amino acids of CDC34. Importantly, this phosphorylation is inhibited by heparin, a substrate-specific inhibitor of CK2. We have also identified a kinase activity associated with CDC34 in proliferating cells, and we show that this kinase is sensitive to heparin and can utilize GTP, strongly suggesting it is CK2. Phosphorylation of CDC34 by the associated kinase maps predominantly to residues 203 and 222. Mutation of CDC34 at CK2-targeted residues, Ser-203, Ser-222, Ser-231, Thr-233, and Ser-236, abolishes the phosphorylation of CDC34 observed in vivo and markedly shifts nuclearly localized CDC34 to the cytoplasm. These results suggest a potential role for CK2-mediated phosphorylation in the regulation of CDC34 cell localization and function.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Yew, PR (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	yew@uthscsa.edu						ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; Gray N, 1999, CURR MED CHEM, V6, P859; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Mathias N, 1999, MOL CELL BIOL, V19, P1759; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Mitev Vanio, 1994, Journal of Dermatological Science, V8, P45, DOI 10.1016/0923-1811(94)90320-4; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Ohta T, 1999, ONCOGENE, V18, P6758, DOI 10.1038/sj.onc.1203115; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pati D, 1999, MOL CELL BIOL, V19, P5001; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; PTAK C, 1994, J BIOL CHEM, V269, P26539; Raymond F, 2000, J CELL SCI, V113, P1687; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Taylor JA, 1999, J MOL BIOL, V290, P839, DOI 10.1006/jmbi.1999.2912; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	59	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41049	41058		10.1074/jbc.M106453200	http://dx.doi.org/10.1074/jbc.M106453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546811	hybrid			2022-12-25	WOS:000171925600091
J	Xi, X; Han, JH; Zhang, JZ				Xi, X; Han, JH; Zhang, JZ			Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; OXIDATIVE-PHOSPHORYLATION; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; SELECTIVE ACTIVATION; GLUT4 TRANSLOCATION; SIGNAL-TRANSDUCTION; CLONE-9 CELLS; INSULIN	Activation of AMP-activated protein kinase (AMPK) has been recently demonstrated to be associated with 5-aminoimidazole-4-carboxa;de ribonucleoside (AICAR)stimulated glucose transport mediated by both GLUT1 and GLUT4 transporters. However, signaling events upstream and downstream of AMPK are unknown. Here we report that 1) p38 mitogen-activated protein kinase (MAPK) and mitogen-activated protein kinase kinase 3 (MKK3) were activated by AICAR in Clone 9 cells, which express only the GLUT1 transporters, and 2) activation of p38 was required for AICAR-stimulated glucose transport since treatment of the cells with p38 inhibitor SB203580 or overexpression of dominant negative p38 mutant inhibited glucose transport. Moreover, we found that overexpression of the constitutively active form of AMPK mutant also resulted in a significant activation of p38, and inhibition of p38 activity by SB203580 did not affect AICAR-stimulated activation of AMPK. These findings demonstrate that AICAR-stimulated activation of p38 is indeed mediated by AMPK, and the p38 MAPK cascade is downstream of AMPK in the signaling pathway of AICAR-stimulated glucose transport in Clone 9 cells.	Case Western Reserve Univ, Dept Med, Div Clin & Mol Endocrinol, Cleveland, OH 44106 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Case Western Reserve University; Scripps Research Institute	Zhang, JZ (corresponding author), Case Western Reserve Univ, Dept Med, Div Clin & Mol Endocrinol, 2109 Adelbert Rd, Cleveland, OH 44106 USA.		Han, J/G-4671-2010					Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; Barros LF, 1997, J PHYSIOL-LONDON, V504, P517, DOI 10.1111/j.1469-7793.1997.517bd.x; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; ISMAILBEIGI F, 1993, J MEMBRANE BIOL, V135, P1; Kayali AG, 2000, DIABETES, V49, P1783, DOI 10.2337/diabetes.49.11.1783; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Koseoglu MH, 1999, MOL CELL BIOCHEM, V194, P109, DOI 10.1023/A:1006965106331; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; Snedecor G W, 1976, STAT METHODS; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tong HY, 2000, J BIOL CHEM, V275, P11981, DOI 10.1074/jbc.275.16.11981; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Yamamoto Y, 2000, DIABETES, V49, P332, DOI 10.2337/diabetes.49.3.332; Zhang JZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1277, DOI 10.1152/ajpcell.2001.280.5.C1277	49	154	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41029	41034		10.1074/jbc.M102824200	http://dx.doi.org/10.1074/jbc.M102824200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546797	hybrid			2022-12-25	WOS:000171925600088
J	Bai, XM; Zhou, DP; Brown, JR; Crawford, BE; Hennet, T; Esko, JD				Bai, XM; Zhou, DP; Brown, JR; Crawford, BE; Hennet, T; Esko, JD			Biosynthesis of the linkage region of glycosaminoglycans - Cloning and activity of galactosyltransferase II, the sixth member of the beta 1,3-galactosyltransferase family (beta 3GalT6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE BIOSYNTHESIS; UDP-GALACTOSE; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; EXPRESSION CLONING; PROTEIN; GENE; IDENTIFICATION; GLYCOPROTEINS; CHONDROITIN	A family of five beta1,3-galactosyltransferases has been characterized that catalyze the formation of Gal beta1, 3GlcNAc beta and Gal beta1,3GalNAc beta linkages present in glycoproteins and glycolipids (beta 3Ga1T1, -2, -3, -4, and -5). We now report a new member of the family (beta 3GalT6), involved in glycosaminoglycan biosynthesis. The human and mouse genes were located on chromosomes 1p36.3 and 4E2, respectively, and homologs are found in Drosophila melanogaster and Caenorhabditis elegans. Unlike other members of the family, beta 3GalT6 showed a broad mRNA expression pattern by Northern blot analysis. Although a high degree of homology across several subdomains exists among other members of the beta3-galactosyltransferase family, recombinant enzyme did not utilize glucosamine- or galactosamine-containing acceptors. Instead, the enzyme transferred galactose from UDP-galactose to acceptors containing a terminal beta -linked galactose residue. This product, Gal beta1,3Gal beta is found in the linkage region of heparan sulfate and chondroitin sulfate (GlcA beta1, 3Gal beta1, 3Gal beta1, 4Xyl beta -O-Ser), indicating that beta 3GalT6 is the so-called galactosyltransferase II involved in glycosaminoglycan biosynthesis. Its identity was confirmed in vivo by siRNA-mediated inhibition of glycosaminoglycan synthesis in HeLa S3 cells. Its localization in the medial Golgi indicates that this is the major site for assembly of the linkage region.	Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of California System; University of California San Diego; University of Zurich	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jesko@ucsd.edu	zhou, dapeng/GXG-9715-2022; Zhou, Dapeng/A-6446-2019	Zhou, Dapeng/0000-0003-1347-3811	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal PK, 1999, GLYCOBIOLOGY, V9, P669, DOI 10.1093/glycob/9.7.669; Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Brown JR, 2001, BIOORGAN MED CHEM, V9, P815, DOI 10.1016/S0968-0896(00)00300-X; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; HELTING T, 1969, J BIOL CHEM, V244, P2790; Henion TR, 2001, J BIOL CHEM, V276, P30261, DOI 10.1074/jbc.M102979200; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KRISHNA NR, 1990, J BIOL CHEM, V265, P18256; Krishna NR, 2001, ADV CARBOHYD CHEM BI, V56, P201; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Qian R, 2001, J BIOL CHEM, V276, P28641, DOI 10.1074/jbc.M103664200; Salvini R, 2001, J BIOL CHEM, V276, P3564, DOI 10.1074/jbc.M006662200; Sarkar AK, 2000, CARBOHYD RES, V329, P287, DOI 10.1016/S0008-6215(00)00200-7; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SIAKOTOS AN, 1965, J AM OIL CHEM SOC, V42, P913, DOI 10.1007/BF02632444; TOYAYACHI A, 2001, J BIOL CHEM, V276, P22032; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P1; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; WIERUSZESKI JM, 1987, J BIOL CHEM, V262, P6650; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhou DP, 2000, P NATL ACAD SCI USA, V97, P11673; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200	45	129	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48189	48195		10.1074/jbc.M107339200	http://dx.doi.org/10.1074/jbc.M107339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11551958	hybrid			2022-12-25	WOS:000172927000061
J	Lim, HM; Kaneshige, M; Zhao, L; Zhang, XY; Hanover, JA; Cheng, SY				Lim, HM; Kaneshige, M; Zhao, L; Zhang, XY; Hanover, JA; Cheng, SY			An isoform of branched-chain aminotransferase is a novel co-repressor for thyroid hormone nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE-3; MYC REGULATION; GENE; PROTEIN; TARGET; IDENTIFICATION; COREPRESSOR; INTERACTS; CLONING	The functions of thyroid hormone receptors (TRs) are regulated by a host of co-regulatory proteins. Tissue-specific expression of these co-regulators leads to distinct expression patterns and regulation of thyroid hormone (T3) target genes in tissues. Previously we have found that human colon carcinoma RKO cells exhibit strong U-independent transcriptional activity. We therefore searched for co-regulatory proteins in RKO cells using a yeast two-hybrid system with the intact TR beta1 as bait. One of the three positive clones, designated as P3, was identified to be an isoform of human mitochondria branched-chain amino-transferase (BCATm). P3 was a spliced variant of BCATm with an internal 12-amino acid deletion near the carboxyl-terminal region and was abundantly expressed in RKO cells. The expressed protein localized both to the mitochondria and the nucleus of transfected CV1 cells. P3 physically interacted with TR beta1 in a T3-independent manner that led to the inhibition in binding of TRIM to thyroid hormone-responsive element. P3 not only enhanced the repressor activity of the unliganded TR but also repressed the ligand-dependent activation of TIL This repression was reversed by treatment of cells with trichostatin A, suggesting that in addition to the inhibition of DNA binding, the repression activity of P3 on TR may also be mediated by histone deacetylase activity. Thus, unlike the currently known corepressors, P3 is a novel ligand-independent co-repressor for TR.	NCI, Gene Regulat Sect, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cheng, SY (corresponding author), NCI, Gene Regulat Sect, Mol Biol Lab, NIH, Bldg 37,Rm 2D-24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Ben-Yosef T, 1998, MAMM GENOME, V9, P595, DOI 10.1007/s003359900825; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BHAT MK, 1995, BIOCHEMISTRY-US, V34, P10591, DOI 10.1021/bi00033a034; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Bledsoe RK, 1997, BBA-PROTEIN STRUCT M, V1339, P9, DOI 10.1016/S0167-4838(97)00044-7; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; Faure M, 1999, EUR J BIOCHEM, V259, P104, DOI 10.1046/j.1432-1327.1999.00009.x; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1993, J BIOL CHEM, V268, P3084; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; ING NH, 1992, J BIOL CHEM, V267, P17617; Kao HY, 2000, GENE DEV, V14, P55; LEVINE M, 1989, CELL, V59, P404; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Tong GX, 1996, MOL CELL BIOL, V16, P1909; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu XG, 2000, MOL CELL BIOL, V20, P2604, DOI 10.1128/MCB.20.7.2604-2618.2000	39	2	2	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48196	48205		10.1074/jbc.M104320200	http://dx.doi.org/10.1074/jbc.M104320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11574535	hybrid			2022-12-25	WOS:000172927000062
J	Frueauf, JB; Ballicora, MA; Preiss, J				Frueauf, JB; Ballicora, MA; Preiss, J			Aspartate residue 142 is important for catalysis by ADP-glucose pyrophosphorylase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DIPHOSPHATE GLUCOSE; SITE-DIRECTED MUTAGENESIS; ALLOSTERIC ACTIVATOR SITE; BACTERIAL GLYCOGEN; COVALENT MODIFICATION; NUCLEOTIDE-SEQUENCE; SUBUNIT STRUCTURE; BINDING SITES; POTATO-TUBER; GLGC GENE	Structural prediction of several bacterial and plant ADP-glucose pyrophosphorylases, as well as of other sugar-nucleotide pyrophosphorylases, was used for comparison with the three-dimensional structures of two crystallized pyrophosphorylases (Brown, K., Pompeo, F., Dixon, S., Mengin-Lecreulx, D., Cambillau, C., and Bourne, Y. (1999) EMBO J. 18,4096-4107; Blankenfeldt, W., Asuncion, M., Lam, J. S., and Naismith, J. H. (2000) EMBO J. 19, 6652-6663). This comparison led to the discovery of highly conserved residues throughout the superfamily of pyrophosphorylases despite the low overall homology. One of those residues, Asp(142) in the ADP-glucose pyrophosphorylase from Escherichia coli, was predicted to be near the substrate site. To elucidate the function that Asp(142) might play in the E. coli ADP-glucose pyrophosphorylase, aspartate was replaced by alanine, asparagine, or glutamate using site-directed mutagenesis. Kinetic analysis in the direction of synthesis or pyrophosphorolysis of the purified mutants showed a decrease in specific activity of up to 4 orders of magnitude. Comparison of other kinetic parameters, i.e. the apparent affinities for substrates and allosteric effectors, showed no significant changes, excluding this residue from the specific role of ligand binding. Only the D142E mutant exhibited altered K-m values but none as pronounced as the decrease in specific activity. These results show that residue Asp(142) is important in the catalysis of the ADP-glucose pyrophosphorylase from E. coli.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Preiss, J (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	preiss@msu.edu		Ballicora, Miguel/0000-0002-5324-0724				BALL K, 1994, J BIOL CHEM, V269, P24706; Ballicora MA, 1998, PLANT PHYSIOL, V118, P265, DOI 10.1104/pp.118.1.265; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; CHARNG YY, 1994, J BIOL CHEM, V269, P24107; ESPADA J, 1962, J BIOL CHEM, V237, P3577; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; GARDIOL A, 1990, ARCH BIOCHEM BIOPHYS, V280, P175, DOI 10.1016/0003-9861(90)90533-5; GENTNER N, 1967, BIOCHEM BIOPH RES CO, V27, P417, DOI 10.1016/S0006-291X(67)80116-5; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; GHOSH P, 1992, ARCH BIOCHEM BIOPHYS, V296, P122, DOI 10.1016/0003-9861(92)90553-9; HAUGEN TH, 1976, J BIOL CHEM, V251, P7880; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; HILL MA, 1991, J BIOL CHEM, V266, P12455; KRISHNAN HB, 1986, PLANT PHYSIOL, V81, P642, DOI 10.1104/pp.81.2.642; KUMAR A, 1988, J BIOL CHEM, V263, P14634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YM, 1986, ARCH BIOCHEM BIOPHYS, V244, P585, DOI 10.1016/0003-9861(86)90627-2; LEE YM, 1986, J BIOL CHEM, V261, P1058; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MELO A, 1965, J BIOL CHEM, V240, P398; MEYER CR, 1992, J BACTERIOL, V174, P4509, DOI 10.1128/JB.174.13.4509-4512.1992; MORELL M, 1988, J BIOL CHEM, V263, P633; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; NEUFELD E. F., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P602, DOI 10.1016/0003-9861(57)90524-6; OKITA TW, 1981, J BIOL CHEM, V256, P6944; OZAKI H, 1972, METHOD ENZYMOL, V28, P406; PARSONS TF, 1978, J BIOL CHEM, V253, P7638; PARSONS TF, 1978, J BIOL CHEM, V253, P6197; PAULE MR, 1971, J BIOL CHEM, V246, P4602; PREISS J, 1966, BIOCHEMISTRY-US, V5, P1833, DOI 10.1021/bi00870a008; PREISS J, 1984, ANNU REV MICROBIOL, V38, P419, DOI 10.1146/annurev.mi.38.100184.002223; Preiss J, 1998, COMPREHENSIVE NATURA, P441; Preiss J, 1973, ENZYMES, V8, P73; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SANWAL GG, 1967, ARCH BIOCHEM BIOPHYS, V119, P454, DOI 10.1016/0003-9861(67)90477-8; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHEN L, 1964, BIOCHEM BIOPH RES CO, V17, P424, DOI 10.1016/0006-291X(64)90023-3; Sivak M.N., 1998, ADV FOOD NUTR RES, V41, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; SOWOKINOS JR, 1982, PLANT PHYSIOL, V69, P1459, DOI 10.1104/pp.69.6.1459; TSUBOI KK, 1969, J BIOL CHEM, V244, P1008; Wu MX, 1998, ARCH BIOCHEM BIOPHYS, V358, P182, DOI 10.1006/abbi.1998.0846	48	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46319	46325		10.1074/jbc.M107408200	http://dx.doi.org/10.1074/jbc.M107408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567027	hybrid			2022-12-25	WOS:000172573100113
J	Kanamaru, C; Yasuda, H; Takeda, M; Ueda, N; Suzuki, J; Tsuchida, T; Mashima, H; Ohnishi, H; Fujita, T				Kanamaru, C; Yasuda, H; Takeda, M; Ueda, N; Suzuki, J; Tsuchida, T; Mashima, H; Ohnishi, H; Fujita, T			Smad7 is induced by norepinephrine and protects rat hepatocytes from activin A-induced growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; TGF-BETA RECEPTOR; LIVER-REGENERATION; DNA-SYNTHESIS; AUTOCRINE INHIBITOR; PARTIAL-HEPATECTOMY; GENE-EXPRESSION; ACTIVATION; CELLS	Activin A induces growth arrest of rat hepatocytes in vitro and in vivo. The alpha (1)-adrenergic agonist, norepinephrine (NE), enhances epidermal growth factor-stimulated DNA synthesis and inhibits activin A-induced growth inhibition, but the mechanisms of these actions are unclear. Smad proteins have recently been identified as intracellular signaling mediators of transforming growth factor-beta family members. In the present study, we explored how NE modulates the Smad signaling pathway in rat cultured hepatocytes. We demonstrate that NE inhibits activin A-induced nuclear accumulation of Smad2/3 and that NE rapidly induces inhibitory Smad7 mRNA expression. Infection of Smad7 adenovirus into rat hepatocytes inhibited activin A-induced nuclear accumulation of Smad2/3, enhanced epidermal growth factor-stimulated DNA synthesis, and abolished the growth inhibitory effect of activin A. We also demonstrated that the induction of Smad7 by NE is dependent on nuclear factor-kappaB (NF-kappaB). The amount of active NF-kappaB complex rapidly increased after NE treatment. Preincubation of the cells with an NF-kappaB pathway inhibitor N-tosyl-L-phenylalanine chloromethyl ketone or infection of the cells with an adenovirus expressing an I kappaB super-repressor (Ad5I kappaB) abolished the NE-induced Smad7 expression. These results indicate a mechanism of transmodulation between the Smad and trimeric G protein signaling pathways in rat hepatocytes.	Univ Tokyo, Sch Med, Dept Med, Tokyo 1138655, Japan	University of Tokyo	Yasuda, H (corresponding author), Univ Tokyo, Sch Med, Dept Med, 7-3-1 Hongo, Tokyo 1138655, Japan.	YASUDA-DIS@h.u-tokyo.ac.jp	Mashima, Hirosato/ABE-6412-2020					BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bitzer M, 2000, GENE DEV, V14, P187; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; CRUISE JL, 1985, SCIENCE, V227, P749, DOI 10.1126/science.2982212; CRUISE JL, 1987, HEPATOLOGY, V7, P1189, DOI 10.1002/hep.1840070604; Dajani OF, 1999, J CELL PHYSIOL, V180, P203, DOI 10.1002/(SICI)1097-4652(199908)180:2<203::AID-JCP8>3.3.CO;2-K; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOUCK KA, 1988, J CELL PHYSIOL, V135, P551, DOI 10.1002/jcp.1041350327; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; KAJIYAMA Y, 1994, BIOCHEM J, V303, P313, DOI 10.1042/bj3030313; Kajiyama Y, 1998, CELL SIGNAL, V10, P241, DOI 10.1016/S0898-6568(97)00122-8; KISO S, 1995, HEPATOLOGY, V22, P1584, DOI 10.1016/0270-9139(95)90168-X; Kogure K, 2000, HEPATOLOGY, V31, P916, DOI 10.1053/he.2000.6100; KOGURE K, 1995, GASTROENTEROLOGY, V108, P1136, DOI 10.1016/0016-5085(95)90212-0; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lieb K, 1997, J IMMUNOL, V159, P4952; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARI B, 1994, J BIOL CHEM, V269, P8517; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 2000, HEPATOLOGY, V32, P218, DOI 10.1053/jhep.2000.9145; MCNIEL PL, 1985, J CELL BIOL, V101, P372; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Rahman A, 1999, J IMMUNOL, V162, P5466; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; Zhang YQ, 1996, HEPATOLOGY, V23, P288	51	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45636	45641		10.1074/jbc.M105302200	http://dx.doi.org/10.1074/jbc.M105302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11551920	hybrid			2022-12-25	WOS:000172573100021
J	Kumar, JK; Kremsdorf, R; Tabor, S; Richardson, CC				Kumar, JK; Kremsdorf, R; Tabor, S; Richardson, CC			A mutation in the gene-encoding bacteriophage T7 DNA polymerase that renders the phage temperature-sensitive	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; REPLICATION INVITRO; PROTEIN STABILITY; FOLDING KINETICS; MUTANTS; THIOREDOXIN; COMPLEXES; FRAGMENT	Gene 5 of bacteriophage T7 encodes a DNA polymerase essential for phage replication. A single point mutation in gene 5 confers temperature sensitivity for phage growth. The mutation results in an alanine to valine substitution at residue 73 in the exonuclease domain. Upon infection of Escherichia coli by the temperature-sensitive phage at 42 degreesC, there is no detectable T7 DNA synthesis in vivo. DNA polymerase activity in these phage-infected cell extracts is undetectable at assay temperatures of 30 degreesC or 42 degreesC. Upon infection at 30 degreesC, both DNA synthesis in vivo and DNA polymerase activity in cell extracts assayed at 30 degreesC or 42 degreesC approach levels observed using wild-type T7 phage. The amount of soluble gene 5 protein produced at 42 degreesC is comparable to that produced at 30 degreesC, indicating that the temperature-sensitive phenotype is not due to reduced expression, stability, or solubility. Thus the polymerase induced at elevated temperatures by the temperature-sensitive phage is functionally inactive. Consistent with this observation, biochemical properties and heat inactivation profiles of the genetically altered enzyme over-produced at 30 degreesC closely resemble that of wild-type T7 DNA polymerase. It is likely that the polymerase produced at elevated temperatures is a misfolded intermediate in its folding pathway.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [GM-54397] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; Banavar JR, 2001, PROTEINS, V42, P433, DOI 10.1002/1097-0134(20010301)42:4<433::AID-PROT10>3.3.CO;2-J; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; CHEN HF, 1994, VIROLOGY, V205, P364, DOI 10.1006/viro.1994.1654; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; Clarke J, 2001, CURR OPIN STRUC BIOL, V11, P67, DOI 10.1016/S0959-440X(00)00179-2; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; HERSHFIELD MS, 1972, J BIOL CHEM, V247, P3393; HORI K, 1979, J BIOL CHEM, V254, P1598; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kumar JK, 2001, J BIOL CHEM, V276, P34905, DOI 10.1074/jbc.M104151200; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Liu RJ, 2000, J MOL BIOL, V295, P127, DOI 10.1006/jmbi.1999.3300; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; Mirny LA, 1999, J MOL BIOL, V291, P177, DOI 10.1006/jmbi.1999.2911; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MOSES RE, 1970, P NATL ACAD SCI USA, V67, P674, DOI 10.1073/pnas.67.2.674; Muir RS, 1997, J MOL BIOL, V274, P722, DOI 10.1006/jmbi.1997.1419; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Nossal NG, 1998, GENETICS, V148, P1535; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Plaxco KW, 2000, J MOL BIOL, V298, P303, DOI 10.1006/jmbi.1999.3663; Ptitsyn OB, 1999, J MOL BIOL, V291, P671, DOI 10.1006/jmbi.1999.2920; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; SAITO H, 1981, J VIROL, V37, P343, DOI 10.1128/JVI.37.1.343-351.1981; SANDKVIST M, 1993, MOL MICROBIOL, V10, P635, DOI 10.1111/j.1365-2958.1993.tb00935.x; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; Sunyaev S, 2001, CURR OPIN STRUC BIOL, V11, P125, DOI 10.1016/S0959-440X(00)00175-5; SWARTZ MN, 1972, VIROLOGY, V47, P338, DOI 10.1016/0042-6822(72)90269-3; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, J BIOL CHEM, V262, P15330; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; TABOR S, 1986, THIOREDOXIN GLUTARED, P285; THORNER J, 1975, VIROLOGY, V68, P338, DOI 10.1016/0042-6822(75)90277-9; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WETZEL R, 1994, FEBS LETT, V350, P245, DOI 10.1016/0014-5793(94)00775-6	52	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46151	46159		10.1074/jbc.M106319200	http://dx.doi.org/10.1074/jbc.M106319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11551938	hybrid, Green Published			2022-12-25	WOS:000172573100090
J	Caruso, M; Maitan, MA; Bifulco, G; Miele, C; Vigliotta, G; Oriente, F; Formisano, P; Beguinot, F				Caruso, M; Maitan, MA; Bifulco, G; Miele, C; Vigliotta, G; Oriente, F; Formisano, P; Beguinot, F			Activation and mitochondrial translocation of protein kinase C delta are necessary for insulin stimulation of pyruvate dehydrogenase complex activity in muscle and liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ADIPOSE-TISSUE; PHOSPHATE PHOSPHATASE; MAMMALIAN PYRUVATE; OUTER-MEMBRANE; RAT-LIVER; RECEPTOR; PHOSPHORYLATION; ALPHA; DEPHOSPHORYLATION	In L6 skeletal muscle cells and immortalized hepatocytes, insulin induced a 2-fold increase in the activity of the pyruvate dehydrogenase (PDH) complex. This effect was almost completely blocked by the protein kinase C (PKC) delta inhibitor Rottlerin and by PKC delta antisense oligonucleotides. At variance, overexpression of wild-type PKC delta or of an active PKC delta mutant induced PDH complex activity in both L6 and liver cells. Insulin stimulation of the activity of the PDH complex was accompanied by a 2.5-fold increase in PDH phosphatases 1 and 2 (PDP1/2) activity with no change in the activity of PDH kinase. PKC delta antisense blocked insulin activation of PDP1/2, the same as with PDH. In insulin-exposed cells, PDP1/2 activation was paralleled by activation and mitochondrial translocation of PKC8 delta, as revealed by cell subfractionation and confocal microscopy studies. The mitochondrial translocation of PKC delta, like its activation, was prevented by Rottlerin. In extracts from insulin-stimulated cells, PKC delta co-precipitated with PDP1/2. PKC delta also bound to PDP1/2 in overlay blots, suggesting that direct PKC delta -PDP interaction may occur in vivo as well. In intact cells, insulin exposure determined PDP1/2 phosphorylation, which was specifically prevented by PKC delta antisense. PKC delta also phosphorylated PDP in vitro, followed by PDP1/2 activation. Thus, in muscle and liver cells, insulin causes activation and mitochondrial translocation of PKC delta, accompanied by PDP phosphorylation and activation. These events are necessary for insulin activation of the PDH complex in these cells.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	beguino@unina.it	vigliotta, giovanni/AAW-6401-2020; Vigliotta, Giovanni/GPF-7237-2022; Formisano, Pietro/J-4237-2018; Bifulco, Giuseppe/A-5413-2011; ORIENTE, Francesco/J-6652-2018	vigliotta, giovanni/0000-0001-5132-0037; Bifulco, Giuseppe/0000-0002-1788-5170; ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		ASSIMACOPOULOSJEANNET F, 1983, FEBS LETT, V159, P83, DOI 10.1016/0014-5793(83)80421-9; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; BENELLI C, 1994, METABOLISM, V43, P1030, DOI 10.1016/0026-0495(94)90185-6; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; BUFFINGTON CK, 1984, DIABETES, V33, P681, DOI 10.2337/diabetes.33.7.681; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; Caruso M, 2000, DIABETES, V49, P1194, DOI 10.2337/diabetes.49.7.1194; Caruso R, 1999, J BIOL CHEM, V274, P28637, DOI 10.1074/jbc.274.40.28637; Chalfant CE, 2000, ENDOCRINOLOGY, V141, P2773, DOI 10.1210/en.141.8.2773; CLOT JP, 1988, METABOLISM, V37, P1101, DOI 10.1016/0026-0495(88)90075-3; CLOT JP, 1992, J CLIN ENDOCR METAB, V74, P1258, DOI 10.1210/jc.74.6.1258; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DAVIS PF, 1977, BIOCHEM BIOPH RES CO, V75, P541, DOI 10.1016/0006-291X(77)91506-6; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENTON RM, 1989, ANN NY ACAD SCI, V573, P285, DOI 10.1111/j.1749-6632.1989.tb15005.x; DENTON RM, 1975, MOL CELL BIOCHEM, V9, P27, DOI 10.1007/BF01731731; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Formisano P, 2001, J ENDOCRINOL INVEST, V24, P460, DOI 10.1007/BF03351048; GATEAU O, 1978, EUR J BIOCHEM, V88, P613, DOI 10.1111/j.1432-1033.1978.tb12488.x; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; LILLEY K, 1992, ARCH BIOCHEM BIOPHYS, V296, P170, DOI 10.1016/0003-9861(92)90559-F; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; MACAULAY SL, 1985, ARCH BIOCHEM BIOPHYS, V237, P142, DOI 10.1016/0003-9861(85)90263-2; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; MANDARINO LJ, 1987, J CLIN INVEST, V80, P655, DOI 10.1172/JCI113118; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; MUKHERJEE C, 1975, BIOCHEM J, V148, P229, DOI 10.1042/bj1480229; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SEALS JR, 1980, P NATL ACAD SCI-BIOL, V77, P77, DOI 10.1073/pnas.77.1.77; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; STEPP LR, 1983, J BIOL CHEM, V258, P9454; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WIELAND OH, 1972, EUR J BIOCHEM, V26, P426, DOI 10.1111/j.1432-1033.1972.tb01783.x; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072	46	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45088	45097		10.1074/jbc.M105451200	http://dx.doi.org/10.1074/jbc.M105451200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577086	hybrid			2022-12-25	WOS:000172406700099
J	Philip, S; Bulbule, A; Kundu, GC				Philip, S; Bulbule, A; Kundu, GC			Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; INTEGRIN; BINDING; INVASION; INVASIVENESS; TUMORIGENICITY; OVEREXPRESSION; TRANSCRIPTION	Matrix metalloproteinases (MMPs) degrade the extracellular matrix (ECM) and play critical roles in tissue repair, tumor invasion, and metastasis. MMPs are regulated by different cytokines, ECM proteins, and other factors. However, the molecular mechanisms by which osteopontin (OPN), an ECM protein, regulates ECM invasion and tumor growth and modulates MMP activation in B16F10 cells are not well defined. We have purified OPN from human milk and shown that OPN induces pro-MMP-2 production and activation in these cells. Moreover, our data revealed that OPN-induced membrane type 1 (MT1) MMP expression correlates with translocation of p65 (nuclear factor-kappaB (NF-kappaB)) into the nucleus. However, when the super-repressor form of I kappaB alpha (inhibitor of NF-kappaB) was transfected into cells followed by treatment with OPN, no induction of MT1-MMP expression was observed, indicating that OPN activates pro-MMP-2 via an NF-kappaB-mediated pathway. OPN also enhanced cell migration and ECM invasion by interacting with alpha (v)beta (3) integrin, but these effects were reduced drastically when the MMP-2-specific antisense S-oligonucleotide was used to suppress MMP-2 expression. Interestingly, when the OPN-treated cells were injected into nude mice, the mice developed larger tumors, and the MMP-2 levels in the tumors were significantly higher than in controls. The proliferation data indicate that OPN increases the growth rate in these cells. Both tumor size and MMP-2 expression were reduced dramatically when anti-MMP-2 antibody or antisense S-oligonucleotide-transfected cells were injected into the nude mice. To our knowledge, this is the first report that MMP-2 plays a direct role in OPN-induced cell migration, invasion, and tumor growth and that demonstrates that OPN-stimulated MMP-2 activation occurs through NF-kappaB-mediated induction of MT1-MMP.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHEN Y, 1992, J BIOL CHEM, V267, P24871; COTTAM DW, 1993, INT J ONCOL, V2, P861; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARDNER HAR, 1994, ONCOGENE, V9, P2321; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIOTTA LA, 1992, CELL, V71, P411; Maquoi E, 2000, EXP CELL RES, V261, P348, DOI 10.1006/excr.2000.5063; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; RITTER NM, 1992, J BONE MINER RES, V7, P877; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; SINGH K, 1990, J BIOL CHEM, V265, P18696; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; Sun Y, 1996, ANTICANCER RES, V16, P1; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; Zhang ZJ, 1999, P NATL ACAD SCI USA, V96, P3963, DOI 10.1073/pnas.96.7.3963	40	215	241	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44926	44935		10.1074/jbc.M103334200	http://dx.doi.org/10.1074/jbc.M103334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564733	hybrid			2022-12-25	WOS:000172406700080
J	Wang, J; Dreyfuss, G				Wang, J; Dreyfuss, G			Characterization of functional domains of the SMN protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; SURVIVAL MOTOR-NEURON; DISEASE GENE-PRODUCT; MOLECULAR ANALYSIS; BINDING-PROTEIN; SNRNP PROTEINS; MOUSE MODEL; COMPLEX; DELETIONS; POMBE	The Survival of Motor Neurons (SMN) is the disease gene of spinal muscular atrophy. We have previously established a genetic system based on the chicken pre-B cell line DT40, in which expression of SMN protein is regulated by tetracycline, to study the function of SMN in vivo. Depletion of SMN protein is lethal to these cells. Here we tested the functionality of mutant SMN proteins by determining their capacity to rescue the cells after depletion of wild-type SMN. Surprisingly, all of the spinal muscular atrophy-associated missense mutations tested were able to support cell viability and proliferation. Deletion of the amino acids encoded by exon 7 of the SMN gene resulted in a partial loss of function. A mutant SMN protein lacking both the tyrosine/glycine repeat (in exon 6) and exon 7 failed to sustain viability, indicating that the C terminus of the protein is critical for SMN activity. Interestingly, the Tudor domain of SMN, encoded by exon 3, does not appear to be essential for SMN function since a mutant deleted of this domain restored cell viability. Unexpectedly, a chicken SMN mutant (Delta N39) lacking the N-terminal 39 amino acids that encompass the Gemin2-binding domain also rescued the lethal phenotype. Moreover, the level of Gemin2 in Delta N39-rescued cells was significantly reduced, indicating that Gemin2 is not required for Delta N39 to perform the essential function of SMN in DT40 cells. These findings suggest that SMN may perform a novel function in DT40 cells.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774	NINDS NIH HHS [R0I-NS40575-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040575] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; CHANG JG, 1995, AM J HUM GENET, V57, P1503; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Cifuentes-Diaz C, 2001, J CELL BIOL, V152, P1107, DOI 10.1083/jcb.152.5.1107; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Frugier T, 2000, HUM MOL GENET, V9, P849, DOI 10.1093/hmg/9.5.849; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P165; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 1998, HUM MOL GENET, V7, P1269, DOI 10.1093/hmg/7.8.1269; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; Paushkin S, 2000, J BIOL CHEM, V275, P23841, DOI 10.1074/jbc.M001441200; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; Talbot K, 1998, HUM MOL GENET, V7, P2149, DOI 10.1093/hmg/7.13.2149; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; Wang J, 2001, J BIOL CHEM, V276, P9599, DOI 10.1074/jbc.M009162200; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869	43	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45387	45393		10.1074/jbc.M105059200	http://dx.doi.org/10.1074/jbc.M105059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572858	hybrid			2022-12-25	WOS:000172406700135
J	Zhao, DZ; Keates, AC; Kuhnt-Moore, S; Moyer, MP; Kelly, CP; Pothoulakis, C				Zhao, DZ; Keates, AC; Kuhnt-Moore, S; Moyer, MP; Kelly, CP; Pothoulakis, C			Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INFLAMMATORY-BOWEL-DISEASE; MAP KINASE; CELL-LINE; CALCIUM MOBILIZATION; DEPENDENT ACTIVATION; RECEPTOR STIMULATION; HELICOBACTER-PYLORI; COUPLED RECEPTORS	Neurotensin (NT), a neuropeptide released in the gastrointestinal tract in response to several stimuli, is involved in the pathophysiology of colonic inflammation. However, the molecular mechanism(s) mediating this proinflammatory response remains unclear. We found that NCM460, non-transformed human colonocytes, express a functional high affinity NT receptor that mediates NT-induced Erk activation. By using NCM460 cells stably transfected with NTR1, we show that NTR1 activation leads to interleukin (IL)-8 secretion that is mediated via both NF-kappaB- and Erk-dependent pathways. In addition, NT-stimulated NF-kappaB activation is dependent on intracellular calcium release. NT-stimulated Erk activity requires Ras activation because overexpression of the dominant negative Ras mutant Ras-17N almost completely inhibits the Erk activation. Furthermore, NT directly stimulates Ras-GTP formation as shown by a Ras-GTP pull-down assay. By using reporter gene constructs containing targeted substitutions in the IL-8 promoter, we show that the NF-kappaB, AP-1, and to a lesser degree the C/EBP sites in the IL-8 promoter region are required for IL-8 gene expression induced by NT. In summary, our results demonstrate that NT stimulates calcium-dependent NF-kappaB and Ras-dependent Erk pathways that mediate the release of IL-8 from non-transformed human colonocytes. We speculate that these NT-related proinflammatory pathways are important in the pathophysiology of colonic inflammation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA; INCELL Corp, San Antonio, TX 78249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pothoulakis, C (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.				NIDDK NIH HHS [DK 33506, DK54920] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054920, P01DK033506] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAR S, 1986, FEBS LETT, V201, P31, DOI 10.1016/0014-5793(86)80565-8; Ardite E, 1998, BRIT J PHARMACOL, V124, P431, DOI 10.1038/sj.bjp.0701887; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Bliss CM, 1998, INFECT IMMUN, V66, P5357, DOI 10.1128/IAI.66.11.5357-5363.1998; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; Castagliuolo I, 1996, P NATL ACAD SCI USA, V93, P12611, DOI 10.1073/pnas.93.22.12611; Castagliuolo I, 1999, J CLIN INVEST, V103, P843, DOI 10.1172/JCI4217; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; CASTAGLIUOLO I, 1999, GASTROENTEROLOGY, V116, P799; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ehlers RA, 1998, SURGERY, V124, P239, DOI 10.1067/msy.1998.90370; Ehlers RA, 2000, BIOCHEM BIOPH RES CO, V269, P704, DOI 10.1006/bbrc.2000.2335; Ellis RD, 1998, INFLAMM RES, V47, P440, DOI 10.1007/s000110050358; EVERS BM, 1992, GASTROENTEROLOGY, V103, P86, DOI 10.1016/0016-5085(92)91099-P; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOLDMAN R, 1983, FEBS LETT, V159, P63, DOI 10.1016/0014-5793(83)80417-7; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Keates S, 1999, J IMMUNOL, V163, P5552; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEMAIRE I, 1988, J IMMUNOL, V140, P2983; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Lieb K, 1997, J IMMUNOL, V159, P4952; Linevsky JK, 1997, AM J PHYSIOL-GASTR L, V273, pG1333, DOI 10.1152/ajpgi.1997.273.6.G1333; Lucchesi PA, 1996, CIRC RES, V78, P962, DOI 10.1161/01.RES.78.6.962; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maoret JJ, 1999, INT J CANCER, V80, P448, DOI 10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MILLER LA, 1995, BRIT J PHARMACOL, V114, P1466, DOI 10.1111/j.1476-5381.1995.tb13371.x; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Papadakis KA, 2000, ANNU REV MED, V51, P289, DOI 10.1146/annurev.med.51.1.289; PoinotChazel G, 1996, BIOCHEM J, V320, P145, DOI 10.1042/bj3200145; POLAK JM, 1977, NATURE, V270, P183, DOI 10.1038/270183a0; Pothoulakis C, 1998, ANN NY ACAD SCI, V840, P635, DOI 10.1111/j.1749-6632.1998.tb09602.x; Riegler M, 2000, GASTROENTEROLOGY, V119, P348, DOI 10.1053/gast.2000.9310; SCHAEFFER P, 1995, J BIOL CHEM, V270, P3409, DOI 10.1074/jbc.270.7.3409; Schmid RM, 1998, GUT, V43, P587; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Suzuki M, 2000, FEBS LETT, V465, P23, DOI 10.1016/S0014-5793(99)01717-2; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOR K, 1986, GASTROENTEROLOGY, V90, P27, DOI 10.1016/0016-5085(86)90070-3; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WALSH JH, 1987, PHYSL GASTROINTESTIN, P181; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WOOD JG, 1988, AM J PHYSIOL, V255, pG813, DOI 10.1152/ajpgi.1988.255.6.G813; WOOD JG, 1988, PANCREAS, V3, P332, DOI 10.1097/00006676-198805000-00015; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yoshinaga K, 1992, Surg Oncol, V1, P127, DOI 10.1016/0960-7404(92)90025-G	60	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44464	44471		10.1074/jbc.M104942200	http://dx.doi.org/10.1074/jbc.M104942200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574537	hybrid			2022-12-25	WOS:000172406700017
J	Caputi, M; Zahler, AM				Caputi, M; Zahler, AM			Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H '/F/2H9 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IN-VITRO; SPLICING SILENCER; GENE-EXPRESSION; A/B PROTEINS; C PROTEIN; A1; ELEMENTS; EXON; TRACT	Members of the heterogeneous nuclear ribonucleoprotein (hnRNP) H protein family, H, H', F, and 2H9, are involved in pre-mRNA processing. We analyzed the assembly of these proteins from splicing extracts onto four RNA regulatory elements as follows: a high affinity hnRNP Al-binding site (WA1), a sequence involved in Rev-dependent export (p17gag INS), an exonic splicing silencer from the beta -tropomyosin gene, and an intronic splicing regulator (downstream control sequence (DCS) from the c-src gene. The entire family binds the WA1, instability (INS), and beta -tropomyosin substrates, and the core-binding site for each is a run of three G residues followed by an A. Transfer of small regions containing this sequence to a substrate lacking hnRNP H binding activity is sufficient to promote binding of all family members. The c-src DCS has been shown to assemble hnRNP H, not hnRNP F, from HeLa cell extracts, and we show that hnRNP 2H9 does not bind this element. The DCS contains five G residues followed by a C. Mutation of the C to an A changes the specificity of the DCS from a substrate that binds only hnRNP H/H' to a binding site for all hnRNP H family members. We conclude that the sequence GGGA is recognized by all hnRNP H family proteins.	Univ Calif Santa Cruz, Dept Mol & Cellular & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Mol Biol RNA, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Zahler, AM (corresponding author), Univ Calif Santa Cruz, Dept Mol & Cellular & Dev Biol, Santa Cruz, CA 95064 USA.	zahler@biology.ucsc.edu		Zahler, Alan/0000-0003-0027-1647	NIGMS NIH HHS [1R01GM61646] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061646] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashiya M, 1997, RNA, V3, P996; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; CHAN RC, 1995, MOL CELL BIOL, V15, P6377; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENGELBRECHT J, 1992, J MOL BIOL, V227, P108, DOI 10.1016/0022-2836(92)90685-D; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; FORNE T, 1995, J BIOL CHEM, V270, P16476, DOI 10.1074/jbc.270.27.16476; Gamberi C, 1997, MOL CELL BIOL, V17, P2587, DOI 10.1128/MCB.17.5.2587; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; Holzmann K, 1997, EUR J BIOCHEM, V244, P479, DOI 10.1111/j.1432-1033.1997.00479.x; HONORE B, 1995, J BIOL CHEM, V270, P28780; Honore B, 2000, BBA-GENE STRUCT EXPR, V1492, P108, DOI 10.1016/S0167-4781(00)00092-0; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LANGLAND JO, 1995, PROTEIN EXPRES PURIF, V6, P25, DOI 10.1006/prep.1995.1004; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; Mahe D, 2000, BBA-GENE STRUCT EXPR, V1492, P414, DOI 10.1016/S0167-4781(00)00144-5; Mahe D, 1997, J BIOL CHEM, V272, P1827, DOI 10.1074/jbc.272.3.1827; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; Najera I, 1999, J MOL BIOL, V285, P1951, DOI 10.1006/jmbi.1998.2473; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; NUSSINOV R, 1988, J THEOR BIOL, V133, P73, DOI 10.1016/S0022-5193(88)80025-0; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Shahied-Milam L, 1998, J BIOL CHEM, V273, P21359, DOI 10.1074/jbc.273.33.21359; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Yoshida T, 1999, FEBS LETT, V457, P251, DOI 10.1016/S0014-5793(99)01048-0	58	155	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43850	43859		10.1074/jbc.M102861200	http://dx.doi.org/10.1074/jbc.M102861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571276	hybrid			2022-12-25	WOS:000172297700050
J	Gheorghiu, I; Deschenes, C; Blais, M; Boudreau, F; Rivard, N; Asselin, C				Gheorghiu, I; Deschenes, C; Blais, M; Boudreau, F; Rivard, N; Asselin, C			Role of specific CCAAT/enhancer-binding protein isoforms in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; HAPTOGLOBIN GENE-EXPRESSION; 3 C/EBP ISOFORMS; TRANSCRIPTION FACTORS; C-FOS; ADIPOCYTE DIFFERENTIATION; HEPATOCYTE PROLIFERATION; HORMONAL-REGULATION; MESSENGER-RNA; NEWBORN MICE	Intestinal epithelial cells participate in the acute phase response in response to inflammation. We have shown that acute phase protein genes are induced during intestinal acute phase response, and that the CCAAT/enhancer binding protein family of transcription factors are involved. To address the role of specific C/EBP isoforms, we generated IEC-6 rat intestinal epithelial cell lines expressing different C/EBP isoforms, by retroviral infection. Overexpression of C/EBP alpha p30 and C/EBP delta led to increases in C/EBP beta LAP and C/EBP beta LIP endogenous protein levels, as determined by electrophoretic mobility shift assays and Western blot. Inhibition of C/EBP activity with dominant negative C/EBPs (C/EBP beta LIP, 3hF, 4hF) decreased glucocorticoid-, cAMP- and IL-1 responsiveness of the endogenous haptoglobin gene, while overexpression of each C/EBP isoform increased the responsiveness to these regulators. In contrast, dominant negative C/EBPs or C/EBP isoforms did not alter the expression of alpha -acid glycoprotein in response to dexamethasone and of C/EBP beta and C/EBP delta in response to various regulators as assessed by Northern blot. These data show that the three C/EBP isoforms are involved in the regulation of haptoglobin and that C/EBP beta, C/EBP delta, and alpha -acid glycoprotein expression are not induced by C/EBP isoforms in contrast to other cell types. C/EBP beta LAP-expressing cells showed an inhibition of cell growth characterized by a delay in P27(Kip1) decrease in response to serum and a decrease in cyclin D isoforms and cyclin E protein levels. Finally, C/EBP isoforms interact with the E2F4 transcription factor. Thus, specific C/EBP isoforms are involved in the differential expression of acute phase protein genes in response to hormones and cytokines. Furthermore, C/EBP isoforms may play a role in the control of cell cycle progression.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Grp Rech BiolDev, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Asselin, C (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Grp Rech BiolDev, Sherbrooke, PQ J1H 5N4, Canada.							ALAM T, 1992, J BIOL CHEM, V267, P5021; Boudreau F, 1996, EXP CELL RES, V222, P1, DOI 10.1006/excr.1996.0001; Boudreau F, 1998, DNA CELL BIOL, V17, P669, DOI 10.1089/dna.1998.17.669; Boudreau F, 1999, MOL CELL BIOCHEM, V195, P99, DOI 10.1023/A:1006987313013; BOUDREAU F, 1997, GASTROENTEROLOGY, V112; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; CHANG EB, 2000, INFLAMM BOWEL DIS, P3; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Deschenes C, 2001, GASTROENTEROLOGY, V120, pA501; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; DESCOMBES P, 1991, CELL, V67, P559; Desilets A, 2000, BIOCHEM BIOPH RES CO, V276, P673, DOI 10.1006/bbrc.2000.3531; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FEDORAK RN, 2000, INFLAMM BOWEL DIS, P113; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Mackiewicz A, 1997, Int Rev Cytol, V170, P225, DOI 10.1016/S0074-7696(08)61623-X; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MAYER L, 2000, INFLAMM BOWEL DIS, P280; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Opitz OG, 2000, CANCER RES, V60, P2825; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; PODOLSKY DK, 2000, INFLAMM BOWEL DIS, P191; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Quaroni A, 1980, Methods Cell Biol, V21B, P403; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; SANDERSON AR, 2000, INFLAMM BOWEL DIS, P65; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SOULEIMANI A, 1993, BIOCHEM BIOPH RES CO, V193, P330, DOI 10.1006/bbrc.1993.1628; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Vietor I, 1996, J BIOL CHEM, V271, P5595, DOI 10.1074/jbc.271.10.5595; Wang H, 2001, BRIT J PHARMACOL, V133, P713, DOI 10.1038/sj.bjp.0704102; Yamada T, 1998, BIOCHEM BIOPH RES CO, V242, P88, DOI 10.1006/bbrc.1997.7915; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yu SJ, 1999, BIOCHEM BIOPH RES CO, V259, P544, DOI 10.1006/bbrc.1999.0808	54	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44331	44337		10.1074/jbc.M107591200	http://dx.doi.org/10.1074/jbc.M107591200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559710	Green Submitted, hybrid			2022-12-25	WOS:000172297700106
J	Kretz-Remy, C; Munsch, B; Arrigo, AP				Kretz-Remy, C; Munsch, B; Arrigo, AP			NF kappa B-dependent transcriptional activation during heat shock recovery - Thermolability of the NF-kappa B center dot I kappa B complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; MESSENGER-RNA EXPRESSION; DNA-BINDING ACTIVITY; INDUCED CELL-DEATH; GENE-EXPRESSION; TNF-ALPHA; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; TYPE-1 INFECTION	Heat shock induces the accumulation of misfolded proteins and results in the preferential expression of heat shock proteins, which help the cell to recover from thermal damage. Heat shock is a well known transcriptional activator of the human immunodeficiency virus type 1 long terminal repeat (LTR). We report here that mutations or deletions of the LTR KR sites impaired the LTR transcriptional activation by heat shock. Further analysis revealed that, during heat shock recovery, the NF-kappaB p65 and p50 subunits migrated into the nucleus of HeLa cells, bound to DNA, and induced kappaB-dependent reporter gene expression. This NF-kappaB activation did not depend on new transcriptional and/or translational events and on the pro-oxidant state generated by heat shock. It was not concomitant with I kappaB alpha phosphorylation and was not abolished by the expression of I kappaB kinase or I kappaB alpha dominant-negative mutants. Moreover, NF-KB activation and migration into the nucleus were not concomitant with I kappaB alpha/beta or p105 degradation. However, during heat shock recovery, NF-kappaB was dissociated from its complexing partners, allowing its migration into the nucleus. Hence, we describe here a novel mechanism for activation of NF-kappaB based on the thermolability of the NF-kappaB.I kappaB complex.	Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Lab Stress Oxydant Chaperons & Apoptose, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Arrigo, AP (corresponding author), Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Lab Stress Oxydant Chaperons & Apoptose, Batiment Gregor Mendel,16 Rue Dubois, F-69622 Villeurbanne, France.		Kretz-Remy, Carole/J-7850-2019	Kretz-Remy, Carole/0000-0002-9553-5598				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; ARRIGO AP, 1997, FREE RADICALS MOL BI, P183; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECKER J, 1990, EUR J BIOCHEM, V189, P553, DOI 10.1111/j.1432-1033.1990.tb15522.x; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; BUREL C, 1992, EXPERIENTIA, V48, P629, DOI 10.1007/BF02118307; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chung KC, 2000, J NEUROSCI RES, V59, P117, DOI 10.1002/(SICI)1097-4547(20000101)59:1<117::AID-JNR14>3.0.CO;2-Q; COURGEON AM, 1990, FREE RADICAL RES COM, V9, P147, DOI 10.3109/10715769009148582; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Hashimoto K, 1996, ARCH VIROL, V141, P439, DOI 10.1007/BF01718308; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISSELS RD, 1987, CANCER RES, V47, P2268; JAATTELA M, 1993, J IMMUNOL, V151, P4286; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; Jornot L, 1997, FEBS LETT, V416, P381, DOI 10.1016/S0014-5793(97)01244-1; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Katschinski DM, 2000, J BIOL CHEM, V275, P21094, DOI 10.1074/jbc.M001629200; Kretz-Remy C, 1998, J BIOL CHEM, V273, P3180, DOI 10.1074/jbc.273.6.3180; KRETZREMY C, 1994, FEBS LETT, V351, P191, DOI 10.1016/S0014-5793(94)80103-7; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; LOVE JD, 1986, J CELL PHYSIOL, V126, P60, DOI 10.1002/jcp.1041260109; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RE MC, 1989, J VIROL METHODS, V26, P313, DOI 10.1016/0166-0934(89)90113-4; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SAPPEY C, 1994, AIDS RES HUM RETROV, V10, P1451, DOI 10.1089/aid.1994.10.1451; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; STANLEY SK, 1990, J IMMUNOL, V145, P1120; STEFFY K, 1991, MICROBIOL REV, V55, P193, DOI 10.1128/MMBR.55.2.193-205.1991; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; VAN AD, 1996, SCIENCE, V274, P787; Vayssier M, 1998, BIOCHEM BIOPH RES CO, V252, P249, DOI 10.1006/bbrc.1998.9586; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; ZABEL U, 1991, J BIOL CHEM, V266, P252; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zou JY, 1998, CELL STRESS CHAPERON, V3, P130, DOI 10.1379/1466-1268(1998)003<0130:CBGOAT>2.3.CO;2	75	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43723	43733		10.1074/jbc.M010821200	http://dx.doi.org/10.1074/jbc.M010821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559696	hybrid			2022-12-25	WOS:000172297700033
J	Katayama, T; Imaizumi, K; Honda, A; Yoneda, T; Kudo, T; Takeda, M; Mori, K; Rozmahel, R; Fraser, P; St George-Hyslop, P; Tohyama, M				Katayama, T; Imaizumi, K; Honda, A; Yoneda, T; Kudo, T; Takeda, M; Mori, K; Rozmahel, R; Fraser, P; St George-Hyslop, P; Tohyama, M			Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; AMYLOID PRECURSOR PROTEIN; KNOCK-IN MICE; MISSENSE MUTATIONS; SIGNALING PATHWAY; GENE; CHROMOSOME-1; ATF6; IRE1; ACCUMULATION	Recent studies have shown independently that presenifin-1 (PS1) null mutants and familial Alzheimer's disease (FAD)-linked mutants should both down-regulate signaling of the unfolded protein response (UPR). However, it is difficult to accept that both mutants possess the same effects on the UPR. Furthermore, contrary to these observations, neither loss of PS1 and PS2 function nor expression of FAD-linked PS1 mutants were reported to have a discernable impact on the UPR. Therefore, re-examination and detailed analyses are needed to clarify the relationship between PS1 function and UPR signaling. Here, we report that PS1/PS2 null and dominant negative PS1 mutants, which are mutated at aspartate residue 257 or 385, did not affect signaling of the UPR. In contrast, FAD-linked PSI mutants were confirmed to disturb UPR signaling by inhibiting activation of both Ire1 alpha and ATF6, both of which are endoplasmic reticulum (ER) stress transducers in the UPR. Furthermore, PS1 mutants also disturbed activation of PERK (PKR-like ER kinase), which plays a crucial role in inhibiting translation during ER stress. Taken together, these observations suggested that PS1 mutations could affect signaling pathways controlled by each of the respective ER-stress transducers, possibly through a gain-of-function.	Nara Inst Sci & Technol, Div Struct Cell Biol, Nara 6300101, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5320031, Japan; Osaka Univ, Grad Sch Med, Dept Clin Neurosci, Suita, Osaka 5650871, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068304, Japan; Univ Toronto, Dept Med Neurol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 1A8, Canada; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Nara Institute of Science & Technology; Osaka University; Mitsubishi Tanabe Pharma Corporation; Osaka University; Kyoto University; University of Toronto; Japan Science & Technology Agency (JST)	Imaizumi, K (corresponding author), Nara Inst Sci & Technol, Div Struct Cell Biol, 8916-5 Takayama, Nara 6300101, Japan.		Mori, Kazutoshi/K-6106-2015	St George-Hyslop, Peter/0000-0003-0796-7209				Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 1997, J NEUROSCI, V17, P4212; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Imaizumi K, 2001, NAT CELL BIOL, V3, pE104, DOI 10.1038/35074613; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Nakano Y, 1999, EUR J NEUROSCI, V11, P2577, DOI 10.1046/j.1460-9568.1999.00698.x; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	38	150	163	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43446	43454		10.1074/jbc.M104096200	http://dx.doi.org/10.1074/jbc.M104096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551913	hybrid			2022-12-25	WOS:000172169300105
J	O'Connell, S; Wang, LJ; Robert, S; Jones, CA; Saint, R; Jones, RS				O'Connell, S; Wang, LJ; Robert, S; Jones, CA; Saint, R; Jones, RS			Polycomblike PHD fingers mediate conserved interaction with enhancer of zeste protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITHORAX GROUP GENES; DROSOPHILA-MELANOGASTER; SEQUENCE SIMILARITY; BMI-1 PROTOONCOGENE; PATTERN-FORMATION; BINDING-PROTEIN; SEX COMBS; COMPLEXES; EXPRESSION; CONTAINS	The products of Polycomb group (PcG) genes are required for the epigenetic repression of a number of important developmental regulatory genes, including homeotic genes. Enhancer of zeste (E(Z)) is a Drosophila PcG protein that previously has been shown to bind directly to another PcG protein, Extra Sex Combs (ESC), and is present along with ESC in a 600-kDa complex in Drosophila embryos. Using yeast two-hybrid and in vitro binding assays, we show that E(Z) binds directly to another PcG protein, Polycomblike (PCL). PCL-E(Z) interaction is shown to be mediated by the plant homeodomain (PHD) fingers domain of PCL, providing evidence that this motif can act as an independent protein interaction domain. An association was also observed between PHF1 and EZH2, human homologs of PCL and E(Z), respectively, demonstrating the evolutionary conservation of this interaction. EM was found to not interact with the PHD domains of three Drosophila trithorax group (trxG) proteins, which function to maintain the transcriptional activity of homeotic genes, providing evidence for the specificity of the interaction of E(Z) with the PCL PHD domain. Coimmunoprecipitation and gel filtration experiments demonstrate in vivo association of PCL with EM and ESC in Drosophila embryos. We discuss the implications of PCL association with ESC.E(Z) complexes and the possibility that PCL may either be a subunit of a subset of ESC.E(Z) complexes or a subunit of a separate complex that interacts with ESC.E(Z) complexes.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	Southern Methodist University; University of Adelaide; University of Adelaide	Saint, R (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	robert.saint@adelaide.edu.au; rjones@mail.smu.edu	Saint, Robert/A-4190-2008	Saint, Robert/0000-0002-7989-6043				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Adamson AL, 1996, GENETICS, V144, P621; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BREEN TR, 1986, DEV BIOL, V118, P442, DOI 10.1016/0012-1606(86)90015-1; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CAMPBELL RB, 1995, MOL GEN GENET, V246, P291, DOI 10.1007/BF00288601; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Chen HM, 1996, GENOMICS, V38, P30, DOI 10.1006/geno.1996.0588; CHENG NSN, 1994, GENETICS, V138, P1151; Coulson M, 1998, GENOMICS, V48, P381, DOI 10.1006/geno.1997.5201; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Gildea JJ, 2000, GENETICS, V156, P645; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; JONES RS, 1990, GENETICS, V126, P185; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; LAWRENCE PA, 1983, CELL, V35, P27, DOI 10.1016/0092-8674(83)90204-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LONIE A, 1994, DEVELOPMENT, V120, P2629; Mueller Juerg, 1995, Development (Cambridge), V121, P2847; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PHILLIPS MD, 1990, GENETICS, V125, P91; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SHEARN A, 1989, GENETICS, V121, P517; SHEARN A, 1978, GENETICS, V89, P341; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1992, DEVELOPMENT, V114, P493; SOTO MC, 1995, GENETICS, V140, P231; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; Tie F, 1998, DEVELOPMENT, V125, P3483; Tie F, 2001, DEVELOPMENT, V128, P275; Tripoulas N, 1996, GENETICS, V143, P913; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	53	86	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43065	43073		10.1074/jbc.M104294200	http://dx.doi.org/10.1074/jbc.M104294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11571280	hybrid			2022-12-25	WOS:000172169300058
J	Rice, AM; Sartorelli, AC				Rice, AM; Sartorelli, AC			Inhibition of 20 S and 26 S proteasome activity by lithium chloride - Impact on the differentiation of leukemia cells by all-trans-retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; DEPENDENT DEGRADATION; HIGH EXPRESSION; ACTIVATION; INDUCTION; PATHWAY; AGENTS; SYSTEM; ALPHA; P27	Lithium affects several enzymatic activities, however, the molecular mechanisms of lithium actions are not fully understood. We previously showed that LiCl interacts synergistically with all-trans-retinoic acid to promote terminal differentiation of WEHI-3B D+ cells, a phenomenon accompanied by the recovery of the retinoid-induced loss of retinoic acid receptor alpha protein pools. Here, we demonstrate the effects of LiCl on proteasome-dependent degradation of retinoic acid receptor alpha proteins. LiCl alone, or in combination with all-trans-retinoic acid, increased cellular levels of ubiquitinated retinoic acid receptor alpha and markedly reduced chymotryptic-like activity of WEHI-3B D+ 20 S and 26 S proteasome enzymes. Neither KCl nor all-trans-retinoic acid affected enzyme activity, whereas NaCl produced a modest reduction at relatively high concentrations. In addition, LiCl inhibited 20 S proteasome chymotryptic-like activity from rabbits but had no effect on tryptic-like activity of the 26 S proteasome. This effect has significant consequences in stabilizing the retinoic acid receptor alpha protein levels that are necessary to promote continued differentiation of leukemia cells in response to all-trans-retinoic acid. In support of this concept, combination of proteasome inhibitors beta -clastolactacystin or benzyloxycarbonyl-Leu-Leu-Phe with all-trans-retinoic acid increased differentiation of WEHI-3B D+ cells in a manner that was analogous to the combination of LiCl and all-trans-retinoic acid.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Canc, Dev Therapeut Program, New Haven, CT 06520 USA	Yale University; Yale University	Sartorelli, AC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA002817] Funding Source: NIH RePORTER; NCI NIH HHS [CA-02817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 1999, CANCER RES, V59, P2615; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; BOGGS DR, 1983, SEMIN HEMATOL, V20, P129; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Finch RA, 2000, BLOOD, V96, P2262; Frisan T, 2000, INT J CANCER, V88, P881, DOI 10.1002/1097-0215(20001215)88:6<881::AID-IJC7>3.0.CO;2-D; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Gianni' M, 2001, BLOOD, V97, P3234, DOI 10.1182/blood.V97.10.3234; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; Henry L, 1996, CELL PROLIFERAT, V29, P589, DOI 10.1111/j.1365-2184.1996.tb00974.x; Henry L, 1997, ANAL CELL PATHOL, V15, P131, DOI 10.1155/1997/869747; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hideshima T, 2001, CANCER RES, V61, P3071; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; PRICE LH, 1994, NEW ENGL J MED, V331, P591; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; SOKOLOSKI JA, 1993, LEUKEMIA RES, V17, P403, DOI 10.1016/0145-2126(93)90095-3; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	31	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42722	42727		10.1074/jbc.M106583200	http://dx.doi.org/10.1074/jbc.M106583200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555654	hybrid			2022-12-25	WOS:000172169300013
J	Burma, S; Chen, BP; Murphy, M; Kurimasa, A; Chen, DJ				Burma, S; Chen, BP; Murphy, M; Kurimasa, A; Chen, DJ			ATM phosphorylates histone H2AX in response to DNA double-strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; EXPRESSION; LYMPHOMA; DAMAGE; REPAIR; CELLS	A very early step in the response of mammalian cells to DNA double-strand breaks is the phosphorylation of histone H2AX at serine 139 at the sites of DNA damage. Although the phosphatidylinositol 3-kinases, DNA-PK (DNA-dependent protein kinase), ATM (ataxia telangiectasia mutated), and ATR (ATM and Rad3-related), have all been implicated in H2AX phosphorylation, the specific kinase involved has not yet been identified. To definitively identify the specific kinase(s) that phosphorylates H2AX in vivo, we have utilized DNA-PKcs -/- and Atm-/- cell lines and mouse embryonic fibroblasts. We find that H2AX phosphorylation and nuclear focus formation are normal in DNA-PKes-/- cells and severely compromised in Atm-/- cells. We also find that ATM can phosphorylate H2AX in vitro and that ectopic expression of ATM in Atm-/- fibroblasts restores H2AX phosphorylation in vivo. The minimal H2AX phosphorylation in Atm-/- fibroblasts can be abolished by low concentrations of wortmannin suggesting that DNA-PK, rather than ATR, is responsible for low levels of H2AX phosphorylation in the absence of ATM. Our results clearly establish ATM as the major kinase involved in the phosphorylation of H2AX and suggest that ATM is one of the earliest kinases to be activated in the cellular response to double-strand breaks.	Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Chen, DJ (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA050519, R37CA050519] Funding Source: NIH RePORTER; NCI NIH HHS [CA50519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sarkaria JN, 1998, CANCER RES, V58, P4375; SKOG S, 1992, ANTI-CANCER DRUG, V3, P379, DOI 10.1097/00001813-199208000-00011; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 2000, METH MOL B, V99, P99	28	1411	1457	3	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42462	42467		10.1074/jbc.C100466200	http://dx.doi.org/10.1074/jbc.C100466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11571274	Green Submitted, hybrid			2022-12-25	WOS:000172450400118
J	Paoli, P; Giannoni, E; Pescitelli, R; Camici, G; Manao, G; Ramponi, G				Paoli, P; Giannoni, E; Pescitelli, R; Camici, G; Manao, G; Ramponi, G			Hydrogen peroxide triggers the formation of a disulfide dimer of muscle acylphosphatase and modifies some functional properties of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; MUSCULAR ISOENZYME; PROTEIN; PURIFICATION; EXPRESSION; DIFFERENTIATION; NUCLEUS; ASSAY; FORMS	Acylphosphatase is expressed in vertebrates as two molecular forms, the organ common and the muscle types. The former does not contain cysteine residues, whereas the latter contains a single conserved cysteine (Cys-21). We demonstrated that H2O2 at micromolar levels induces, in vitro, the formation of a disulfide dimer of muscle acylphosphatase, which displays properties differing from those of the reduced enzyme. In particular, we observed changes in the kinetic behavior of its intrinsic ATPase activity, whereas the kinetic behavior of its benzoyl phosphatase activity does not change. Moreover, the disulfide dimer is capable of interacting with some polynucleotides such as poly(G), poly(C), and poly(T) but not with poly(A), whereas the reduced enzyme does not bind polynucleotides. Experiments performed with H2O2 in the presence of increasing SDS concentrations demonstrated that disulfide dimer formation is prevented by SDS concentrations higher than 300 mum, suggesting that a non-covalently-linked dimer is present in non-denaturing solvents. Light-induced cross-linking experiments performed on the Cys-21 Ser mutant in the pH range 3.8-9.0 have demonstrated that a non-covalently-linked dimer is in fact present in non-denaturing solutions and that an enzyme group with a pK(a) of 6.4 influences the monomer-dimer equilibrium.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Camici, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.		Paoli, Paolo/A-2040-2014; Giannoni, Elisa/AAE-2092-2020; Camici, Giovanni/H-1631-2018	Paoli, Paolo/0000-0001-6448-7266; Camici, Giovanni/0000-0002-0523-0695; Giannoni, Elisa/0000-0001-7136-1098				BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BERTI A, 1992, ARCH BIOCHEM BIOPHYS, V294, P261, DOI 10.1016/0003-9861(92)90166-T; BERTI A, 1987, ITAL J BIOCHEM, V36, P82; BERTI A, 1986, INT J PEPT PROT RES, V28, P15; CAMICI G, 1976, EXPERIENTIA, V32, P535, DOI 10.1007/BF01920843; Chiarugi P, 1996, BIOCHEM MOL BIOL INT, V40, P73; Chiarugi P, 1997, CELL DEATH DIFFER, V4, P334, DOI 10.1038/sj.cdd.4400230; CHIARUGI P, 1995, BIOCHEM J, V311, P567, DOI 10.1042/bj3110567; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V231, P717, DOI 10.1006/bbrc.1997.6176; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; GHETTI A, 1990, FEBS LETT, V277, P272, DOI 10.1016/0014-5793(90)80863-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANAO G, 1983, ARCH BIOCHEM BIOPHYS, V226, P414, DOI 10.1016/0003-9861(83)90310-7; MIZUNO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P437, DOI 10.1016/0003-9861(90)90282-4; Modesti A, 1995, PROTEIN EXPRES PURIF, V6, P799, DOI 10.1006/prep.1995.0011; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NASSI P, 1991, J BIOL CHEM, V266, P10867; NEDIANI C, 1991, BIOCHEM INT, V24, P959; Paoli P, 2000, BIOCHEM J, V349, P43, DOI 10.1042/0264-6021:3490043; RAMPONI G, 1966, EXPERIENTIA, V22, P705, DOI 10.1007/BF01901326; Raugei G, 1999, BIOCHEM MOL BIOL INT, V47, P127; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SEGEL IH, 1975, ENZYME KINETICS, P64; Steer BA, 1999, BIOCHEM J, V340, P631, DOI 10.1042/0264-6021:3400631; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Thunnissen MMGM, 1997, STRUCTURE, V5, P69, DOI 10.1016/S0969-2126(97)00167-6	30	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41862	41869		10.1074/jbc.M106886200	http://dx.doi.org/10.1074/jbc.M106886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551950	hybrid			2022-12-25	WOS:000172450400044
J	Wang, SSS; Rymer, DL; Good, TA				Wang, SSS; Rymer, DL; Good, TA			Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; RADICAL OXIDATIVE STRESS; MTT FORMAZAN EXOCYTOSIS; ALZHEIMERS-DISEASE BRAIN; PRECURSOR PROTEIN; CORTICAL-NEURONS; SPHINGOLIPID DEPLETION; HIPPOCAMPAL-NEURONS; SIGNAL-TRANSDUCTION; APOLIPOPROTEIN-E	beta -Amyloid (A beta) is the primary protein component of senile plaques associated with Alzheimer's disease and has been implicated in the neurotoxicity associated with the disease. A variety of evidence points to the importance of A beta -membrane interactions in the mechanism of A beta neurotoxicity and indicates that cholesterol and gangliosides are particularly important for A beta aggregation and binding to membranes. We investigated the effects of cholesterol and sialic acid depletion on A beta -induced GTPase activity in cells, a step implicated in the mechanism of A beta toxicity, and A beta -induced cell toxicity. Cholesterol reduction and depletion of membrane-associated sialic acid residues both significantly reduced the A beta -induced GTPase activity. In addition, cholesterol and membrane-associated sialic acid residue depletion or inhibition of cholesterol and ganglioside synthesis protected PC12 cells from A beta -induced toxicity. These results indicate the importance of A beta -membrane interactions in the mechanism of A beta toxicity. In addition, these results suggest that control of cellular cholesterol and/or ganglioside content may prove useful in the prevention or treatment of Alzheimer's disease.	Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Good, TA (corresponding author), Texas A&M Univ, Dept Chem Engn, TAMU 3122, College Stn, TX 77843 USA.							Abe K, 1999, BRAIN RES, V830, P146, DOI 10.1016/S0006-8993(99)01421-3; Abe K, 1999, NEUROSCI RES, V35, P165, DOI 10.1016/S0168-0102(99)00048-6; Abe K, 1998, NEUROSCI RES, V31, P295, DOI 10.1016/S0168-0102(98)00055-8; AKTORIES K, 1983, N-S ARCH PHARMACOL, V324, P196, DOI 10.1007/BF00503894; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Ariga T, 1999, NEUROCHEM RES, V24, P219, DOI 10.1023/A:1022557920150; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1994, ANN NY ACAD SCI, V747, P256; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Avdulov NA, 1999, BBA-MOL CELL BIOL L, V1437, P37, DOI 10.1016/S0005-2760(98)00178-7; Brouillet E, 1999, J NEUROSCI, V19, P1717; BUSCIGLIO J, 1993, J NEUROCHEM, V61, P1565, DOI 10.1111/j.1471-4159.1993.tb13658.x; Butterfield DA, 1999, METHOD ENZYMOL, V309, P746; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; BUTTERFIELD DA, 1994, BIOCHEM BIOPH RES CO, V200, P710, DOI 10.1006/bbrc.1994.1508; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; CZECH C, 1994, EUR ARCH PSY CLIN N, V243, P291, DOI 10.1007/BF02191587; De Strooper B, 2000, NATURE, V405, P627, DOI 10.1038/35015193; ETCHEBERRIGARAY R, 1994, ANN NY ACAD SCI, V747, P245; Evans RM, 2000, NEUROLOGY, V54, P240, DOI 10.1212/WNL.54.1.240; FERRARIDILEO G, 1995, MOL CHEM NEUROPATHOL, V24, P69, DOI 10.1007/BF03160113; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; Good TA, 1996, P NATL ACAD SCI USA, V93, P15130, DOI 10.1073/pnas.93.26.15130; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HEIDER JG, 1978, J LIPID RES, V19, P514; Hertel C, 1997, P NATL ACAD SCI USA, V94, P9412, DOI 10.1073/pnas.94.17.9412; Hirakura Y, 1998, BIOCHEM MOL BIOL INT, V46, P787; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Kanfer JN, 1999, NEUROCHEM RES, V24, P1621, DOI 10.1023/A:1021172620295; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Klinker JF, 1996, NEUROSCI LETT, V213, P25, DOI 10.1016/0304-3940(96)12816-0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Liu YB, 1998, J NEUROCHEM, V71, P2322; Liu YB, 1999, PROG NEURO-PSYCHOPH, V23, P377, DOI 10.1016/S0278-5846(99)00003-2; Liu YB, 2001, ANAL BIOCHEM, V289, P130, DOI 10.1006/abio.2000.4928; Martinez-Senac MD, 1999, EUR J BIOCHEM, V265, P744, DOI 10.1046/j.1432-1327.1999.00775.x; MASON RP, 1993, ANN NY ACAD SCI, V695, P54, DOI 10.1111/j.1749-6632.1993.tb23027.x; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MATTSON MP, 1994, ANN NY ACAD SCI, V747, P50; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Merrill AH, 1996, ADV EXP MED BIOL, V392, P297; Michikawa M, 1999, J NEUROCHEM, V72, P2278, DOI 10.1046/j.1471-4159.1999.0722278.x; MILLER RG, 1984, CELL BIOL INT REP, V8, P519, DOI 10.1016/0309-1651(84)90050-X; Mizuno T, 1998, BBA-BIOMEMBRANES, V1373, P119, DOI 10.1016/S0005-2736(98)00097-2; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; OFFERMANNS S, 1989, EUR J BIOCHEM, V180, P283, DOI 10.1111/j.1432-1033.1989.tb14645.x; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; POLLACK SJ, 1995, NEUROSCI LETT, V184, P113, DOI 10.1016/0304-3940(94)11182-I; Rolsma MD, 1998, J VIROL, V72, P9079, DOI 10.1128/JVI.72.11.9079-9091.1998; Rymer DL, 2001, J BIOL CHEM, V276, P2523, DOI 10.1074/jbc.M005800200; SCHNECKO A, 1994, BRAIN RES, V644, P291, DOI 10.1016/0006-8993(94)91692-6; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V146, P1296, DOI 10.1016/0006-291X(87)90790-X; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soomets U, 1999, BRAIN RES, V850, P179, DOI 10.1016/S0006-8993(99)02142-3; Stevens VL, 1997, J BIOL CHEM, V272, P18020, DOI 10.1074/jbc.272.29.18020; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; WEISS JH, 1994, J NEUROCHEM, V62, P372; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yanagisawa K, 1998, NEUROBIOL AGING, V19, pS65, DOI 10.1016/S0197-4580(98)00032-3; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; Yoo HS, 1996, TOXICOL APPL PHARM, V138, P211, DOI 10.1006/taap.1996.0119; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhou Y, 1996, NEUROREPORT, V7, P2487	96	82	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42027	42034		10.1074/jbc.M102834200	http://dx.doi.org/10.1074/jbc.M102834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11557751	hybrid			2022-12-25	WOS:000172450400066
J	Christian, S; Ahorn, H; Novatchkova, M; Garin-Chesa, P; Park, JE; Weber, G; Eisenhaber, F; Rettig, WJ; Lenter, MC				Christian, S; Ahorn, H; Novatchkova, M; Garin-Chesa, P; Park, JE; Weber, G; Eisenhaber, F; Rettig, WJ; Lenter, MC			Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; CDNA SEQUENCE; ORGANIZATION; MULTIMERIN; PROTEINS; IDENTIFICATION; LOCALIZATION; CADHERIN; ELASTIN; PEPTIDE	EndoGlyx-1, the antigen identified with the monoclonal antibody H572, is a pan-endothelial human cell surface glycoprotein complex composed of four different disulfide-bonded protein species with an apparent molecular mass of approximately 500 kDa. Here, we report the purification and peptide analysis of two EndoGlyx-1 subunits, p125 and p140, and the identification of a common, full-length cDNA with an open reading frame of 2847 base pairs. The EndoGlyx-1 cDNA encodes a protein of 949 amino acids with a predicted molecular mass of 105 kDa, found as an entry for an unnamed protein with unknown function in public data bases. A short sequence tag matching the cDNA of this gene was independently discovered by serial analysis of gene expression profiling as a pan-endothelial marker, PEM87. Bioinformatic evaluation classifies EndoGlyx-1 as an EMILIN-like protein composed of a signal sequence, an N-terminal EMI domain, and a C-terminal Clq-like domain, separated from each other by a central coiled-coil-rich region. Biochemical and carbohydrate analysis revealed that p125, p140, and the two additional EndoGlyx-1 subunits, p110 and p200, are exposed on the cell surface. The three smaller subunits show a similar pattern of N-linked and O-linked carbohydrates, as shown by enzyme digestion. Because the two globular domains of EndoGlyx-1 p125/p140 show structural features shared by EMILIN-1 and Multimerin, two oligomerizing glycoproteins implicated in cell-matrix adhesion and hemostasis, it will be of interest to explore similar functions for EndoGlyx-1 in human vascular endothelium.	Boehringer Ingelheim Pharma KG, Dept Oncol Res, D-88397 Biberach, Germany; Boehringer Ingelheim Austria GmbH, Dept Drug Discovery, A-1121 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	Boehringer Ingelheim; Boehringer Ingelheim; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Lenter, MC (corresponding author), Boehringer Ingelheim Pharma KG, Dept Oncol Res, D-88397 Biberach, Germany.	martin.lenter@bc.boehringer.ingelheim.com						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Belien JAM, 1999, J PATHOL, V189, P309; CARLOS TM, 1994, BLOOD, V84, P2068; Christian S, 2001, J BIOL CHEM, V276, P7408, DOI 10.1074/jbc.M009604200; COLOMBATTI A, 1985, COLLAGEN REL RES, V5, P181; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; Doliana R, 1999, J BIOL CHEM, V274, P16773, DOI 10.1074/jbc.274.24.16773; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Hayward CPM, 1999, BLOOD, V94, P1337, DOI 10.1182/blood.V94.4.1337.416k20_1337_1347; HAYWARD CPM, 1993, J CLIN INVEST, V91, P2630, DOI 10.1172/JCI116502; HAYWARD CPM, 1991, BLOOD, V77, P2556; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REID KBM, 1985, IMMUNOLOGY, V55, P185; SANZMONCASI MP, 1994, LAB INVEST, V71, P366; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; SOBEL M, 1992, J BIOL CHEM, V267, P8857; St Croix B, 2000, SCIENCE, V289, P1197; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	30	48	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48588	48595		10.1074/jbc.M106152200	http://dx.doi.org/10.1074/jbc.M106152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11559704	hybrid			2022-12-25	WOS:000172927000114
J	Ganguly, S; Mummaneni, P; Steinbach, PJ; Klein, DC; Coon, SL				Ganguly, S; Mummaneni, P; Steinbach, PJ; Klein, DC; Coon, SL			Characterization of the Saccharomyces cerevisiae homolog of the melatonin rhythm enzyme arylalkylamine N-acetyltransferase (EC 2.3.1.87)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-FORCE FIELD; DROSOPHILA-MELANOGASTER; CATALYTIC MECHANISM; ANGSTROM RESOLUTION; PINEAL-GLAND; MMFF94; PROTEIN; CLONING; GEOMETRIES; DYNAMICS	Arylalkylamine N-acetyltransferase (AANAT, serotonin N-acetyltransferase, EC 2.3.1.87) plays a unique transduction role in vertebrate physiology by converting information about day and night into a hormonal signal: melatonin. Only vertebrate members of the AANAT family have been functionally characterized. Here a putative AANAT from Saccharomyces cerevisiae (scAANAT) was studied to determine whether it possessed the catalytic activity of the vertebrate enzyme. scAANAT is 47% similar to ovine AANAT, but lacks the regulatory N- and C-terminal flanking regions conserved in all vertebrate AANATs. It was found to have enzyme activity generally typical for AANAT family members, although the substrate preference pattern was somewhat broader, the specific activity was lower, and the pH optimum was higher. Deletion of scAANAT reduced arylalkylamine acetylation by S. cerevisiae extracts, indicating that scAANAT contributes significantly to this process. The scAANAT sequence conformed to the three-dimensional structure of ovine AANAT catalytic core; however, an important structural element (loop 1) was found to be shorter and to lack a proline involved in substrate binding. These differences could explain the lower specific activity of scAANAT, because of the importance of loop 1 in catalysis. Data base analysis revealed the presence of putative AANATs in other fungi but not in the nearly complete genomes of Drosophila melanogaster or Caenorhabditis elegans. These studies indicate that the catalytic and kinetic characteristics of fungal and vertebrate enzymes can be considered to be generally similar, although some differences exist that appear to be linked to changes in one structural element. Perhaps the most striking difference is that fungal AANATs lack the regulatory domains of the vertebrate enzyme, which appear to be essential for the regulatory role the enzyme plays in photochemical transduction.	NICHHD, Dev Neurobiol Lab, Sect Neuroendocrinol, NIH, Bethesda, MD 20892 USA; NIH, Ctr Informat Technol, Ctr Mol Modeling, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Klein, DC (corresponding author), NICHHD, Dev Neurobiol Lab, Sect Neuroendocrinol, NIH, 49 Convent Dr,MSC 4480,Bldg 49,Rm 6A-82, Bethesda, MD 20892 USA.	klein@helix.nih.gov		Klein, David/0000-0002-1792-5806; Ganguly, Surajit/0000-0002-1876-9147	CENTER FOR INFORMATION TECHNOLOGY [ZIACT000265, Z01CT000265] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000095, ZIAHD000095] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amherd R, 2000, DNA CELL BIOL, V19, P697, DOI 10.1089/10445490050199081; Benyassi A, 2000, NEUROREPORT, V11, P255, DOI 10.1097/00001756-200002070-00006; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, PROTEINS, V4, P148, DOI 10.1002/prot.340040208; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Ganguly S, 2001, P NATL ACAD SCI USA, V98, P8083, DOI 10.1073/pnas.141118798; Halgren TA, 1996, J COMPUT CHEM, V17, P520, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<520::AID-JCC2>3.0.CO;2-W; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Halgren TA, 1996, J COMPUT CHEM, V17, P616, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X; Halgren TA, 1996, J COMPUT CHEM, V17, P553, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<553::AID-JCC3>3.0.CO;2-T; Halgren TA, 1996, J COMPUT CHEM, V17, P587, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<587::AID-JCC4>3.0.CO;2-Q; Hardeland R, 1999, REPROD NUTR DEV, V39, P399, DOI 10.1051/rnd:19990311; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Hintermann E, 1996, P NATL ACAD SCI USA, V93, P12315, DOI 10.1073/pnas.93.22.12315; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1998, HDB BEHAV STATE CONT, V4, P45; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; NAMBOODIRI MAA, 1979, J NEUROCHEM, V33, P807, DOI 10.1111/j.1471-4159.1979.tb05229.x; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; RIODAN JF, 1972, METHODS ENZYMOL B, V25, P494; Sprenger J., 1999, Cytologia (Tokyo), V64, P209; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	36	47	49	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47239	47247		10.1074/jbc.M107222200	http://dx.doi.org/10.1074/jbc.M107222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11559708	hybrid			2022-12-25	WOS:000172768500077
J	Snyder, JT; Rossman, KL; Baumeister, MA; Pruitt, WM; Siderovski, DP; Der, CJ; Lemmon, MA; Sondek, J				Snyder, JT; Rossman, KL; Baumeister, MA; Pruitt, WM; Siderovski, DP; Der, CJ; Lemmon, MA; Sondek, J			Quantitative analysis of the effect of phosphoinositide interactions on the function of Dbl family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PLECKSTRIN-HOMOLOGY-DOMAIN; HIGH-AFFINITY BINDING; CRYSTAL-STRUCTURE; RHO-FAMILY; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SIGNAL-TRANSDUCTION; MEMBRANE-BINDING; KINETIC-ANALYSIS; STRUCTURAL BASIS	Normally, Rho GTPases are activated by the removal of bound GDP and the concomitant loading of GTP catalyzed by members of the Db1 family of guanine nucleotide exchange factors (GEFs). This family of GEFs invariantly contain a Db1 homology (DH) domain adjacent to a pleckstrin homology (PH) domain, and while the DH domain usually is sufficient to catalyze nucleotide exchange, possible roles for the conserved PH domain remain ambiguous. Here we demonstrate that the conserved PH domains of three distinct Db1 family proteins, intersectin, Dbs, and Tiam1, selectively bind lipid vesicles only when phosphoinositides are present. While the PH domains of intersectin and Dbs promiscuously bind several multiphosphorylated phosphoinositides, Tiam1 selectively interacts with phosphatidylinositol 3-phosphate (K-D similar to5-10 muM). In addition, and in contrast to recent reports, catalysis of nucleotide exchange on nonprenylated Rac1 provided by various extended portions of Tiam1 is not influenced by (a) soluble phosphoinositide head groups, (b) dibutyl versions of phosphoinositides, or (c) lipid vesicles containing phosphoinositides. Likewise, GEF activity afforded by DH/PH fragments of intersectin and Dbs are also not altered by phosphoinositide interactions. These results strongly suggest that unless all relevant components are localized to a lipid membrane surface, Db1 family GEFs generally are not intrinsically modulated by binding phosphoinositides.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Penn, Sch Med, Johnson Fdn, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; University of Pennsylvania	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.	sondek@med.unc.edu	Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Lemmon, Mark/0000-0002-3379-5319; Sondek, John/0000-0002-1127-8310; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA92240] Funding Source: Medline; NIGMS NIH HHS [R01-GM56846, GM62299, R01 GM056846, GM57391] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299, R01GM057391, R01GM056846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER W, 1994, BIOCHEMISTRY-US, V33, P11875, DOI 10.1021/bi00205a025; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 1999, BRIT J CANCER, V80, P25; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Jin LH, 1999, BIOCHEMISTRY-US, V38, P15659, DOI 10.1021/bi9916729; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	53	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45868	45875		10.1074/jbc.M106731200	http://dx.doi.org/10.1074/jbc.M106731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577097	Green Published, hybrid			2022-12-25	WOS:000172573100051
J	Price, RD; Weiner, DM; Chang, MSS; Sanders-Bush, E				Price, RD; Weiner, DM; Chang, MSS; Sanders-Bush, E			RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G(13) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND INTRACELLULAR LOOP; MUSCARINIC ACETYLCHOLINE-RECEPTOR; INVERSE AGONIST ACTIVITY; HIGH-THROUGHPUT ASSAYS; STRESS FIBER FORMATION; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; CHIMERIC RECEPTORS; COUPLED RECEPTORS; CYTOPLASMIC LOOP	The recent completion of the human genome predicted the presence of only 30,000 genes, stressing the importance of mechanisms that increase molecular diversity at the post-transcriptional level. One such posttranscriptional event is RNA editing, which generates multiple protein isoforms from a single gene, often with profound functional consequences. The human serotonin 5-HT2C receptor undergoes RNA editing that creates multiple receptor isoforms. One consequence of RNA editing of cell surface receptors may be to alter the pattern of activation of heterotrimeric G-proteins and thereby shift preferred intracellular signaling pathways. We examined the ability of the nonedited 5-HT2C receptor isoform (INI) and two extensively edited isoforms, VSV and VGV, to interact with various G-protein a subunits. Two functional assays were utilized: the cell-based functional assay, Receptor Selection/Amplification Technology, in which the pharmacological consequences of co-expression of 5HT(2C) receptor isoforms with G-protein a subunits in fibroblasts were studied, and 5HT(2C) receptor-mediated rearrangements of the actin cytoskeleton in stable cell lines. These studies revealed that the nonedited 5-HT2C receptor functionally couples to G(q) and G(13). In contrast, coupling to G(13) was not detected for the extensively edited 5-HT2C receptors. Thus, RNA editing represents a novel mechanism for regulating the pattern of activation of heterotrimeric G-proteins, molecular switches that control an enormous variety of biological processes.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; ACADIA Pharmaceut, La Jolla, CA 92121 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92121 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92121 USA	Vanderbilt University; University of California System; University of California San Diego; University of California System; University of California San Diego	Sanders-Bush, E (corresponding author), Vanderbilt Univ, Dept Pharmacol, 459 Preston Res Bldg, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034007, R01MH034007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07623] Funding Source: Medline; NIMH NIH HHS [MH34007] Funding Source: Medline; NINDS NIH HHS [NS35891] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; Burstein ES, 1997, J NEUROCHEM, V68, P525; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Egan C, 2000, SYNAPSE, V35, P144, DOI 10.1002/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.3.CO;2-B; Fitzgerald LW, 1999, NEUROPSYCHOPHARMACOL, V21, pS82, DOI 10.1038/sj.npp.1395328; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Grotewiel MS, 1999, N-S ARCH PHARMACOL, V359, P21, DOI 10.1007/PL00005318; HAMM HE, 1994, METHOD ENZYMOL, V237, P423; Herrick-Davis K, 2000, J PHARMACOL EXP THER, V295, P226; Herrick-Davis K, 1999, J NEUROCHEM, V73, P1711, DOI 10.1046/j.1471-4159.1999.731711.x; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MESSIER TL, 1995, PHARMACOL TOXICOL, V76, P308, DOI 10.1111/j.1600-0773.1995.tb00152.x; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; Niswender CM, 1998, ANN NY ACAD SCI, V861, P38, DOI 10.1111/j.1749-6632.1998.tb10171.x; Niswender CM, 2001, NEUROPSYCHOPHARMACOL, V24, P478, DOI 10.1016/S0893-133X(00)00223-2; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Price RD, 2000, MOL PHARMACOL, V58, P859, DOI 10.1124/mol.58.4.859; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sanders-Bush Elaine, 1995, P431; Sodhi MS, 2001, MOL PSYCHIATR, V6, P373, DOI 10.1038/sj.mp.4000920; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; Wang YC, 1997, EXP BRAIN RES, V114, P321, DOI 10.1007/PL00005640; Weiner DM, 2001, J PHARMACOL EXP THER, V299, P268; Wurch T, 2000, J NEUROCHEM, V75, P1180, DOI 10.1046/j.1471-4159.2000.0751180.x; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	45	85	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44663	44668		10.1074/jbc.M106745200	http://dx.doi.org/10.1074/jbc.M106745200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572865	hybrid			2022-12-25	WOS:000172406700045
J	You, YH; Lee, DH; Yoon, JH; Nakajima, S; Yasui, A; Pfeifer, GP				You, YH; Lee, DH; Yoon, JH; Nakajima, S; Yasui, A; Pfeifer, GP			Cyclobutane pyrimidine dimers are responsible for the vast majority of mutations induced by UVB irradiation in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; DNA-POLYMERASE-ETA; ESCHERICHIA-COLI; SKIN-CANCER; CIS-SYN; IN-VIVO; ULTRAVIOLET-LIGHT; 6-4 PHOTOPRODUCT; SOS CONDITIONS; INDUCED CC	The most prevalent DNA lesions induced by UVB are the cyclobutane pyrimidine dimers (CPDs) and the pyrimidine (6-4) pyrimidone photoproducts ((6-4)PPs). It has been a long standing controversy as to which of these photoproduct is responsible for mutations in mammalian cells. Here we have introduced photoproduct-specific DNA photolyases into a mouse cell line carrying the transgenic mutation reporter genes lacI and cII. Exposure of the photolyase-expressing cell lines to photoreactivating light resulted in almost complete repair of either CPDs or (6-4)PPs within less than 3 h. The mutations produced by the remaining, nonrepaired photoproducts were scored. The mutant frequency in the cII gene after photoreactivation by CPD photolyase was reduced from 127 x 10(-5) to 34 x 10(-5) (background, 8-10 x 10(-5)). Photoreactivation with (6-4) photolyase did not lower the mutant frequency appreciably. In the lacI gene the mutant frequency after photoreactivation repair of CPDs was reduced from 148 x 10(-5) to 28 x 10(-5) (background, 6-10 x 10(-5)). Mutation spectra obtained with and without photoreactivation by CPD photolyase indicated that the remaining mutations were derived from background mutations, unrepaired CPDs, and other DNA photopoducts including perhaps a small contribution from (6-4)PPs. We conclude that CPDs are responsible for at least 80% of the UVB-induced mutations in this mammalian cell model.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi 98077, Japan	City of Hope; Beckman Research Institute of City of Hope; Tohoku University	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asahina H, 1999, MUTAT RES-DNA REPAIR, V435, P255, DOI 10.1016/S0921-8777(99)00051-8; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Chigancas V, 2000, CANCER RES, V60, P2458; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DOUKI T, 1994, BIOCHEMISTRY-US, V33, P11942, DOI 10.1021/bi00205a033; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; Drouin Regen, 1996, P37; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; FIX D, 1981, MOL GEN GENET, V182, P7, DOI 10.1007/BF00422759; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; GIBBS PEM, 1993, NUCLEIC ACIDS RES, V21, P4059, DOI 10.1093/nar/21.17.4059; Heddle JA, 1999, MUTAGENESIS, V14, P257, DOI 10.1093/mutage/14.3.257; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; JIANG N, 1993, BIOCHEMISTRY-US, V32, P472, DOI 10.1021/bi00053a011; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Kamiya H, 1998, NUCLEIC ACIDS RES, V26, P2611, DOI 10.1093/nar/26.11.2611; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; KOCHEVAR IE, 1990, BIOORGANIC PHOTOCHEM, V1, P274; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; Lehmann AR, 2000, GENE, V253, P1, DOI 10.1016/S0378-1119(00)00250-X; LEMAIRE DGE, 1993, BIOCHEMISTRY-US, V32, P2525, DOI 10.1021/bi00061a009; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Marionnet C, 1998, CANCER RES, V58, P102; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Monroe JJ, 1998, MUTAT RES-FUND MOL M, V421, P121, DOI 10.1016/S0027-5107(98)00171-7; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nouspikel T, 2000, MOL CELL BIOL, V20, P1562, DOI 10.1128/MCB.20.5.1562-1570.2000; Otoshi E, 2000, CANCER RES, V60, P1729; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; PROTICSABLJIC M, 1986, MOL CELL BIOL, V6, P3349, DOI 10.1128/MCB.6.10.3349; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SETLOW RB, 1965, P NATL ACAD SCI USA, V53, P1111, DOI 10.1073/pnas.53.5.1111; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; Spatz A, 2001, CANCER RES, V61, P2480; Stuart GR, 2000, MUTAT RES-FUND MOL M, V452, P101, DOI 10.1016/S0027-5107(00)00058-0; Tanaka M, 2001, MUTAGENESIS, V16, P1, DOI 10.1093/mutage/16.1.1; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Tommasi S, 2000, NUCLEIC ACIDS RES, V28, P3991, DOI 10.1093/nar/28.20.3991; Tommasi S, 1997, CANCER RES, V57, P4727; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; Wallin H, 2000, MUTAT RES-FUND MOL M, V447, P317, DOI 10.1016/S0027-5107(99)00214-6; YAJIMA H, 1995, EMBO J, V14, P2393, DOI 10.1002/j.1460-2075.1995.tb07234.x; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Yasui A, 1998, BIOESSAYS, V20, P291, DOI 10.1002/(SICI)1521-1878(199804)20:4<291::AID-BIES5>3.0.CO;2-T; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001; Zhao XD, 1996, NUCLEIC ACIDS RES, V24, P1561, DOI 10.1093/nar/24.8.1561; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	70	207	218	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44688	44694		10.1074/jbc.M107696200	http://dx.doi.org/10.1074/jbc.M107696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572873	hybrid			2022-12-25	WOS:000172406700048
J	Baldwin, ME; Roufail, S; Halford, MM; Alitalo, K; Stacker, SA; Achen, MG				Baldwin, ME; Roufail, S; Halford, MM; Alitalo, K; Stacker, SA; Achen, MG			Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; VEGF-C; EXPRESSION PATTERN; CHIRONOMUS-TENTANS; TYROSINE KINASES; BALBIANI RING-3; TUMOR-CELLS; IN-VIVO; GENE; RECEPTOR	The secreted glycoprotein vascular endothelial growth factor-D (VEGF-D) is angiogenic, lymphangiogenic, and promotes metastatic spread of tumor cells via lymphatic vessels. VEGF-D consists of a receptor-binding domain (VEGF homology domain) and N- and G terminal propeptides. Proteolytic processing produces numerous forms of human VEGF-D, including fully processed derivatives (containing only the VEGF homology domain), partially processed, and unprocessed derivatives. Proteolysis is essential to generate human VEGF-D that binds the angiogenic receptor VEGF receptor-2 (VEGFR-2) and the lymphangiogenic receptor VEGFR-3 with high affinity. Here, we report that alternative use of an RNA splice donor site in exon 6 of the mouse VEGF-D gene produces two different protein isoforms, VEGF-D-358 and VEGF-D-326, with distinct C termini. The two isoforms were both expressed in all adult mouse tissues and embryonic stages of development analyzed. Both isoforms are proteolytically processed in a similar fashion to human VEGF-D to generate a range of secreted derivatives and bind and cross-link VEGFR-3 with similar potency. The isoforms are differently glycosylated when expressed in vitro. This study demonstrates that RNA splicing, protein glycosylation, and proteolysis are mechanisms for generating structural diversity of mouse VEGF-D.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Helsinki	Achen, MG (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Stacker, Steven/0000-0003-4096-9273; Achen, Marc/0000-0002-3791-803X				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM SS, 1990, GENE, V88, P133, DOI 10.1016/0378-1119(90)90024-L; Farnebo F, 1999, BIOCHEM BIOPH RES CO, V257, P891, DOI 10.1006/bbrc.1999.0562; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Jenkins NA, 1997, CHROMOSOME RES, V5, P502; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lymboussaki A, 2000, CURR TOP MICROBIOL, V251, P75; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Mattei MG, 1996, GENOMICS, V32, P168, DOI 10.1006/geno.1996.0098; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Paavonen K, 1996, CIRCULATION, V93, P1079, DOI 10.1161/01.CIR.93.6.1079; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; PAULSSON G, 1990, J MOL BIOL, V211, P331, DOI 10.1016/0022-2836(90)90355-P; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Rocchigiani M, 1998, GENOMICS, V47, P207, DOI 10.1006/geno.1997.5079; Saleh M, 1996, CANCER RES, V56, P393; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wei MH, 1996, HUM GENET, V97, P794; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	49	57	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44307	44314		10.1074/jbc.M106188200	http://dx.doi.org/10.1074/jbc.M106188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11574540	hybrid			2022-12-25	WOS:000172297700103
J	DeLuna, A; Avendano, A; Riego, L; Gonzalez, A				DeLuna, A; Avendano, A; Riego, L; Gonzalez, A			NADP-glutamate dehydrogenase isoenzymes of Saccharomyces cerevisiae - Purification, kinetic properties, and physiological roles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; GENES; ASSIMILATION; SYNTHASE; ENZYME; BIOSYNTHESIS; EXPRESSION	In the yeast Saccharomyces cerevisiae, two NADP(+)-dependent glutamate dehydrogenases (NADP-GDHs) encoded by GDH1 and GDH3 catalyze the synthesis of glutamate from ammonium and a-ketoglutarate. The GDH2-encoded NAD(+)-dependent glutamate dehydrogenase degrades glutamate producing ammonium and a-ketoglutarate. Until very recently, it was considered that only one biosynthetic NADP-GDH was present in S. cerevisiae. This fact hindered understanding the physiological role of each isoenzyme and the mechanisms involved in a-ketoglutarate channeling for glutamate biosynthesis. In this study, we purified and characterized the GDH1- and GDH3-encoded NADP-GDHs; they showed different allosteric properties and rates of a-ketoglutarate utilization. Analysis of the relative levels of these proteins revealed that the expression of GDH1 and GDH3 is differentially regulated and depends on the nature of the carbon source. Moreover, the physiological study of mutants lacking or overexpressing GDH1 or GDH3 suggested that these genes play nonredundant physiological roles. Our results indicate that the coordinated regulation of GDH1-, GDH3-, and GDH2-encoded enzymes results in glutamate biosynthesis and balanced utilization of a-ketoglutarate under fermentative and respiratory conditions. The possible relevance of the duplicated NADP-GDH pathway in the adaptation to facultative metabolism is discussed.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Genet Mol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Gonzalez, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Genet Mol, Apartado Postal 70-242, Mexico City 04510, DF, Mexico.		DeLuna, Alexander/H-9986-2016	DeLuna, Alexander/0000-0002-9236-2804; Riego-Ruiz, Lina/0000-0002-2883-8871				Avendano A, 1997, J BACTERIOL, V179, P5594, DOI 10.1128/jb.179.17.5594-5597.1997; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BENACHENHOULAHFA N, 1993, J MOL EVOL, V36, P335; Bonete MJ, 1996, BBA-GEN SUBJECTS, V1289, P14, DOI 10.1016/0304-4165(95)00134-4; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CAMARDELLA L, 1976, BIOCHIM BIOPHYS ACTA, V429, P324, DOI 10.1016/0005-2744(76)90280-1; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COGONI C, 1995, J BACTERIOL, V177, P792, DOI 10.1128/jb.177.3.792-798.1995; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P4455, DOI 10.1128/MCB.11.9.4455; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Dang VD, 1996, J BACTERIOL, V178, P1842, DOI 10.1128/jb.178.7.1842-1849.1996; Doherty D., 1970, METHODS ENZYMOLOGY A, V17, P850; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DUBOIS E, 1974, EUR J BIOCHEM, V48, P603, DOI 10.1111/j.1432-1033.1974.tb03803.x; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FUGE EK, 1994, J BACTERIOL, V176, P5802, DOI 10.1128/JB.176.18.5802-5813.1994; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GRENSON M, 1974, MOL GEN GENET, V128, P73, DOI 10.1007/BF00267295; GUTIERREZCIRLOS EB, 1994, J BIOL CHEM, V269, P9147; HOLZER H, 1957, BIOCHEM Z, V329, P361; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Janes BK, 2001, J BACTERIOL, V183, P2709, DOI 10.1128/JB.183.8.2709-2714.2001; KANG L, 1982, J BACTERIOL, V151, P29, DOI 10.1128/JB.151.1.29-35.1982; Kuruvilla FG, 2001, P NATL ACAD SCI USA, V98, P7283, DOI 10.1073/pnas.121186898; Kwast KE, 1998, J EXP BIOL, V201, P1177; LASCU I, 1977, BIOCHIM BIOPHYS ACTA, V482, P251, DOI 10.1016/0005-2744(77)90239-X; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MAZON MJ, 1979, J BACTERIOL, V139, P686; MILLER SM, 1990, J BACTERIOL, V172, P4927, DOI 10.1128/jb.172.9.4927-4935.1990; Minambres B, 2000, J BIOL CHEM, V275, P39529, DOI 10.1074/jbc.M005136200; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; Piskur J, 2001, TRENDS GENET, V17, P302, DOI 10.1016/S0168-9525(01)02308-3; Romero M, 2000, MICROBIOL-SGM, V146, P239, DOI 10.1099/00221287-146-1-239; ROON RJ, 1974, J BACTERIOL, V118, P89, DOI 10.1128/JB.118.1.89-95.1974; Sambrook J., 1989, MOL CLONING, pA1; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith E. L., 1975, ENZYMES, V11; TEMPEST DW, 1970, BIOCHEM J, V117, P405, DOI 10.1042/bj1170405; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Towbin H, 1992, Biotechnology, V24, P145; Valenzuela L, 1998, J BACTERIOL, V180, P3533, DOI 10.1128/JB.180.14.3533-3540.1998; VENARD R, 1975, EUR J BIOCHEM, V57, P371, DOI 10.1111/j.1432-1033.1975.tb02310.x; VERONESE FM, 1975, BIOCHIM BIOPHYS ACTA, V377, P217, DOI 10.1016/0005-2744(75)90304-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	50	119	129	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43775	43783		10.1074/jbc.M107986200	http://dx.doi.org/10.1074/jbc.M107986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562373	hybrid			2022-12-25	WOS:000172297700040
J	Karatan, E; Saulmon, MM; Bunn, MW; Ordal, GW				Karatan, E; Saulmon, MM; Bunn, MW; Ordal, GW			Phosphorylation of the response regulator CheV is required for adaptation to attractants during Bacillus subtilis chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; COMPLETE GENOME SEQUENCE; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; PROTEIN METHYLTRANSFERASE; RHIZOBIUM-MELILOTI; METHYLESTERASE; PURIFICATION; RECEPTOR	In the Gram-positive soil bacterium Bacillus subtilis, the chemoreceptors are coupled to the central two-component kinase CheA via two proteins, CheW and CheV. CheV is a two-domain protein with an N-terminal CheW-like domain and a C-terminal two-component receiver domain. In this study, we show that CheV is phosphorylated in vitro on a conserved aspartate in the presence of phosphorylated CheA (CheA-P). This reaction is slower compared with the phospho-transfer reaction between CheA-P and one other response regulator of the system, CheB. CheV-P is also highly stable in comparison with CheB-P. Both of these properties are more pronounced in the full-length protein compared with a truncated form composed only of the receiver domain, that is, deletion of the CheW-like domain results in increase in the rate of the phospho-transfer reaction and decrease in stability of the phosphorylated protein. Phosphorylation of CheV is required for adaptation to the addition of the chemoattractant asparagine. In tethered-cell assays, strains expressing an unphosphorylatable point mutant of cheV or a truncated mutant lacking the entire receiver domain are severely impaired in adaptation to the addition of asparagine. Both of these strains, however, show near normal counterclockwise biases, suggesting that in the absence of the attractant the chemoreceptors are efficiently coupled to CheA kinase by the mutant CheV proteins. Inability of the CheW-like domain of CheV to support complete adaptation to the addition of asparagine also suggests that unlike CheW this domain by itself may lead to the formation of signaling complexes that stay overactive in the presence of the attractant. A possible structural basis for this feature is discussed.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Ordal, GW (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM54365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM054365, R01GM054365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLGREN JA, 1983, BIOCHEM J, V213, P759, DOI 10.1042/bj2130759; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAHNDARI P, 1997, J BACTERIOL, V179, P4403; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BISCHOFF DS, 1993, BIOCHEMISTRY-US, V32, P9256, DOI 10.1021/bi00086a035; BISHOFF DS, 1991, J BIOL CHEM, V266, P12301; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BURGESSCASSLER A, 1982, J BIOL CHEM, V257, P8412; Da Re S, 1999, MOL MICROBIOL, V34, P504, DOI 10.1046/j.1365-2958.1999.01614.x; DAHL MK, 1992, J BIOL CHEM, V267, P14509; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; FREDRICK KL, 1994, J BACTERIOL, V176, P2727, DOI 10.1128/JB.176.9.2727-2735.1994; FUHRER DK, 1991, J BACTERIOL, V173, P7443, DOI 10.1128/jb.173.23.7443-7448.1991; Garrity LF, 1997, MICROBIOL-UK, V143, P2945, DOI 10.1099/00221287-143-9-2945; Garrity LF, 1998, J BACTERIOL, V180, P4475, DOI 10.1128/JB.180.17.4475-4480.1998; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDMAN DJ, 1984, BIOCHEMISTRY-US, V23, P675, DOI 10.1021/bi00299a014; GueroutFleury AM, 1996, GENE, V180, P57, DOI 10.1016/S0378-1119(96)00404-0; HANLON DW, 1992, J BIOL CHEM, V267, P12055; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Kirby JR, 1999, J BIOL CHEM, V274, P11092, DOI 10.1074/jbc.274.16.11092; KIRSCH ML, 1993, J BIOL CHEM, V268, P18610; KLEENE SJ, 1977, J BIOL CHEM, V252, P3214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MCCARTER LL, 1995, J BACTERIOL, V177, P1595, DOI 10.1128/jb.177.6.1595-1609.1995; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; ROSARIO MML, 1995, BIOCHEMISTRY-US, V34, P3823, DOI 10.1021/bi00011a040; ROSARIO MML, 1994, J BACTERIOL, V176, P2736, DOI 10.1128/JB.176.9.2736-2739.1994; SCHON U, 1994, GENE, V147, P91, DOI 10.1016/0378-1119(94)90044-2; SIMMS SA, 1985, J BIOL CHEM, V260, P161; Sourjik V, 1996, MOL MICROBIOL, V22, P427, DOI 10.1046/j.1365-2958.1996.1291489.x; Sourjik V, 1998, BIOCHEMISTRY-US, V37, P2327, DOI 10.1021/bi972330a; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; Stewart RC, 1997, BIOCHEMISTRY-US, V36, P2030, DOI 10.1021/bi962261k; STEWART RC, 1993, J BIOL CHEM, V268, P1921; Stock J, 1999, CELL CALCIUM, V26, P157, DOI 10.1054/ceca.1999.0075; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Takami H, 1999, EXTREMOPHILES, V3, P227, DOI 10.1007/s007920050120; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WEIS RM, 1990, J BIOL CHEM, V265, P6817; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; YONEKAWA H, 1983, J BACTERIOL, V156, P1228, DOI 10.1128/JB.156.3.1228-1235.1983; Zimmer MA, 2000, J BIOL CHEM, V275, P24264, DOI 10.1074/jbc.M004001200	56	65	70	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43618	43626		10.1074/jbc.M104955200	http://dx.doi.org/10.1074/jbc.M104955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11553614	Green Submitted, hybrid			2022-12-25	WOS:000172297700020
J	Ohtake, S; Ito, Y; Fukuta, M; Habuchi, O				Ohtake, S; Ito, Y; Fukuta, M; Habuchi, O			Human N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase cDNA is related to human B cell recombination activating gene-associated gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE-E; SEROSAL MAST-CELLS; MOUSE BONE-MARROW; SECRETORY GRANULES; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; EXPRESSION; PURIFICATION; PROTEINS; BINDING	N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase (Ga1NAc4S-6ST) transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate to position 6 of N-acetylgalactosamine 4-sulfate (Ga1NAc(4SO(4))) in chondroitin. sulfate and dermatan sulfate. We have previously purified the enzyme to apparent homogeneity from the squid cartilage. We report here cloning and characterization of human Ga1NAc4S-6ST. The strategy for identification of human Ga1NAc4S-6ST consisted of. 1) determination of the amino acid sequences of peptides derived from the purified squid Ga1NAc4S-6ST, 2) amplification of squid DNA by polymerase chain reaction, and 3) homology search using the amino acid sequence deduced from the squid DNA. The human Ga1NAc4S-6ST cDNA contains a single open reading frame that predicts a type H transmembrane protein composed of 561 amino acid residues. The recombinant protein expressed from the human Ga1NAc4S-6ST cDNA transferred sulfate from 3'-phosphoadenosine 5'-phosphosulfate to position 6 of the nonreducing terminal and internal Ga1NAc(4SO(4)) residues contained in chondroitin sulfate A and dermatan sulfate. When a trisaccharide and a pentasaccharide having sulfate groups at position 4 of N-acetylgalactosamine residues were used as acceptors, only nonreducing terminal Ga1NAc(4SO(4)) residues were sulfated. The nucleotide sequence of the human Ga1NAc4S-6ST cDNA was nearly identical to the sequence of human B cell recombination activating gene-associated gene.	Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan	Aichi University Education	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan.	ohabuchi@auecc.aichi-edu.ac.jp						ARUFFO A, 1998, CURRENT PROTOCOL S43, V3; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ELIAKIM R, 1986, P NATL ACAD SCI USA, V83, P461, DOI 10.1073/pnas.83.2.461; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HARADA T, 1967, J BIOL CHEM, V242, P2288; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; KATZ HR, 1986, J BIOL CHEM, V261, P3393; KAWAI Y, 1966, J BIOCHEM-TOKYO, V60, P317, DOI 10.1093/oxfordjournals.jbchem.a128438; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; KINSTON RE, 1996, CURRENT PROTOCOL S36, V1; KOBAYASHI S, 1985, BIOCHIM BIOPHYS ACTA, V841, P71, DOI 10.1016/0304-4165(85)90275-2; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; OHHASHI Y, 1984, BIOCHEM J, V217, P199, DOI 10.1042/bj2170199; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; Sakai T, 2000, THROMB RES, V100, P557, DOI 10.1016/S0049-3848(00)00365-0; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; Verkoczy LK, 1998, EUR J IMMUNOL, V28, P2839, DOI 10.1002/(SICI)1521-4141(199809)28:09<2839::AID-IMMU2839>3.0.CO;2-6; Verkoczy LK, 2000, J BIOL CHEM, V275, P20967, DOI 10.1074/jbc.M001866200; YAOITA E, 1990, J BIOL CHEM, V265, P522; Yuki M, 2000, ONCOL REP, V7, P1339	47	84	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43894	43900		10.1074/jbc.M104922200	http://dx.doi.org/10.1074/jbc.M104922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11572857	hybrid			2022-12-25	WOS:000172297700055
J	Sohn, YC; Kwak, E; Na, YJ; Lee, JW; Lee, SK				Sohn, YC; Kwak, E; Na, YJ; Lee, JW; Lee, SK			Silencing mediator of retinoid and thyroid hormone receptors and activating signal cointegrator-2 as transcriptional coregulators of the orphan nuclear receptor Nur77	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DETERMINANTS; BINDING PROTEIN; FACTOR MEF2; KINASE-IV; COACTIVATOR; APOPTOSIS; EXPRESSION; GENE; COREPRESSOR; CELLS	For the orphan nuclear receptor subfamily that includes Nur77 (NGFI-B), Nurr1, and NOR-1, no transcriptional coregulators have been identified thus far. In this report, we found that Ca2+/calmodulin-dependent protein kinase IV enhances Nur77 transactivation in cotransfections either alone or in synergy with AF2-dependent coactivator ASC-2, whereas corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) is repressive. Interestingly, Nur77 interacted with SMRT but did not directly bind ASC-2, and accordingly, the putative AF2 core domain of Nur77 did not affect the Nur77 transactivation. SMRT harbors transferable repression domains that associate with various histone deacetylases. Surprisingly, histone deacetylase inhibitor trichostatin A was unable to block the repressive effect of SMRT while dramatically stimulating the Nur77 transactivation. These results suggest that SMRT and ASC-2 are specific coregulators of Nur77 and that SMRT may dynamically compete with a putative adaptor molecule, which links ASC-2 to Nur77, for the identical binding sites within Nur77 in vivo.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Salk Inst Biol Studies, Gene Express Lab, San Diego, CA 92185 USA	Pohang University of Science & Technology (POSTECH); Salk Institute	Lee, JW (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.			KWAK, EUNYEE/0000-0001-8336-9986				Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Kang HJ, 2000, EXP CELL RES, V256, P545, DOI 10.1006/excr.2000.4832; Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Lee SK, 2001, MOL ENDOCRINOL, V15, P241, DOI 10.1210/me.15.2.241; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Maruyama K, 1998, INT J ONCOL, V12, P1237; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; Means AR, 1997, RECENT PROG HORM RES, V52, P389; Moore DD, 1995, GLOB MOB SURV; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Schulman H, 1999, CALCIUM AS A CELLULAR REGULATOR, P311; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; YOUNG CYF, 1994, ONCOL RES, V6, P203; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	37	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43734	43739		10.1074/jbc.M107208200	http://dx.doi.org/10.1074/jbc.M107208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559707	hybrid			2022-12-25	WOS:000172297700034
J	Niemeyer, MI; Cid, LP; Barros, LF; Sepulveda, FV				Niemeyer, MI; Cid, LP; Barros, LF; Sepulveda, FV			Modulation of the two-pore domain acid-sensitive K+ channel TASK-2 (KCNK5) by changes in cell volume	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; POTASSIUM-CHANNEL; CHLORIDE CHANNELS; FLUORESCENT-PROBES; HELA-CELLS; DECREASE; CURRENTS; PH; EXPRESSION; CLONING	The molecular identity of K+ channels involved in Ehrlich cell volume regulation is unknown. A background K+ conductance is activated by cell swelling and is also modulated by extracellular pH. These characteristics are most similar to those of newly emerging TASK (TWIK-related acid-sensitive K+ channels)-type of two pore-domain K+ channels. mTASK-2, but not TASK-1 or -3, is present in Ehrlich cells and mouse kidney tissue from where the full coding sequences were obtained. Heterologous expression of mTASK-2 cDNA in HEK-293 cells generated K+ currents in the absence intracellular Ca2+. Exposure to hypotonicity enhanced mTASK-2 currents and osmotic cell shrinkage led to inhibition. This occurred without altering voltage dependence and with only slight decrease in pK(a) in hypotonicity but no change in hypertonicity. Replacement with other cations yields a permselectivity sequence for mTASK-2 of K+ > Rb+ >> Cs+ > NH4+ > Na+ congruent to Li+, similar to that for the native conductance (I-K,I- vol). Clofflium, a quaternary ammonium blocker of I-K, (vol), blocked the mTASK-2-mediated K+ current with an IC50 of 25 mum. The presence of mTASK-2 in Ehrlich cells, its functional similarities with I-K, (vol), and its modulation by changes in cell volume suggest that this two-pore domain K+ channel participates in the regulatory volume decrease phenomenon.	Ctr Estudios Cient, Valdivia, Chile		Niemeyer, MI (corresponding author), Ctr Estudios Cient, Av Arturo Prat 514,Casilla 1469, Valdivia, Chile.			Cid, Pablo/0000-0003-0394-0498; Sepulveda Valenzuela, Francisco Leandro/0000-0003-0022-6598				Altamirano J, 1998, J GEN PHYSIOL, V112, P145, DOI 10.1085/jgp.112.2.145; ALVAREZLEEFMANS FJ, 1995, METH NEUROSCI, V27, P361; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BUSCH AE, 1992, BIOCHEM BIOPH RES CO, V184, P804, DOI 10.1016/0006-291X(92)90661-4; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; Cid LP, 2000, AM J PHYSIOL-CELL PH, V279, pC1198, DOI 10.1152/ajpcell.2000.279.4.C1198; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; DIAZ M, 1995, PFLUG ARCH EUR J PHY, V430, P168, DOI 10.1007/BF00374647; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; FOSKETT JK, 1994, J EXP ZOOL, V268, P104, DOI 10.1002/jez.1402680206; Gallardo P, 2001, AM J PHYSIOL-GASTR L, V281, pG856, DOI 10.1152/ajpgi.2001.281.3.G856; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; Hougaard C, 2001, PFLUG ARCH EUR J PHY, V442, P622, DOI 10.1007/s004240100585; Hougaard C, 2000, PFLUG ARCH EUR J PHY, V440, P283, DOI 10.1007/s004240051050; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Jorgensen NK, 1997, J MEMBRANE BIOL, V157, P281, DOI 10.1007/s002329900236; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; LANG F, 1993, RENAL PHYSIOL BIOCH, V16, P48; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lock H, 2000, J BIOL CHEM, V275, P34849, DOI 10.1074/jbc.C000633200; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG405, DOI 10.1152/ajpgi.1991.260.3.G405; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; Niemeyer MI, 2000, J PHYSIOL-LONDON, V524, P757, DOI 10.1111/j.1469-7793.2000.00757.x; Niemeyer MI, 2000, J PHYSIOL-LONDON, V523, p6S; North RA, 2000, TRENDS NEUROSCI, V23, P234, DOI 10.1016/S0166-2236(00)01592-7; OBRIEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1070, P501, DOI 10.1016/0005-2736(91)90093-N; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Riquelme G, 1998, BBA-BIOMEMBRANES, V1371, P101, DOI 10.1016/S0005-2736(98)00006-6; Stutzin A, 1999, AM J PHYSIOL-CELL PH, V277, pC392, DOI 10.1152/ajpcell.1999.277.3.C392; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VALVERDE MA, 1995, FASEB J, V9, P509, DOI 10.1096/fasebj.9.7.7737459; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Vanoye CG, 1999, P NATL ACAD SCI USA, V96, P6511, DOI 10.1073/pnas.96.11.6511; Vazquez E, 2001, P NATL ACAD SCI USA, V98, P5329, DOI 10.1073/pnas.091096498; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANGEMANN P, 1995, J MEMBRANE BIOL, V147, P263	48	127	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43166	43174		10.1074/jbc.M107192200	http://dx.doi.org/10.1074/jbc.M107192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560934	hybrid			2022-12-25	WOS:000172169300070
J	Takei, N; Kawamura, M; Hara, K; Yonezawa, K; Nawa, H				Takei, N; Kawamura, M; Hara, K; Yonezawa, K; Nawa, H			Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes - Comparison with the effects of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; P70 S6 KINASE; SIGNAL-TRANSDUCTION PATHWAYS; MESSENGER-RNA TRANSLATION; MAMMALIAN TARGET; STIMULATED PHOSPHORYLATION; 4E-BP1 PHOSPHORYLATION; GLYCOGEN-SYNTHASE; EIF-4E BP1; PHAS-I	The effects of neurotrophic factors on translational activation were investigated in cortical neurons. Brain-derived neurotrophic factor (BDNF) increased protein synthesis within 30 min, whereas insulin produced a weaker enhancement of protein synthesis. BDNF-triggered protein synthesis was inhibited by LY294002, PD98059, and rapamycin, whereas the effect of insulin was unaffected by PD98059. To explore the mechanisms underlying this effect, the protein phosphorylation cascades that lead to the activation of translation initiation in neurons were examined. BDNF induced the phosphorylation of both eukaryote initiation factor (eIF) 4E and its binding protein (eIF4E-binding protein-1). The former reaction was inhibited by PD98059, whereas the latter was inhibited by LY294002 or rapamycin. In agreement, BDNF induced the phosphorylation of mammalian TOR ((t) under bar arget (o) under barf (r) under bar apamycin) and enhanced its kinase activity toward eIF4E-binding protein-1. In contrast, insulin failed to activate MAPK and did not induce the phosphorylation of eIF4E. Since BDNF and insulin increased the activity of eIF2B and eIF2, the only difference between them was eIF4E phosphorylation. Thus, this may explain the lower activity of insulin in potentiating neuronal protein synthesis. These results suggest strongly that BDNF simultaneously activates multiple signaling cascades consisting of phosphatidylinositol 3-kinase, mammalian TOR and MAPK to enhance translation initiation in neurons.	Niigata Univ, Inst Brain Res, Dept Mol Neurobiol, Niigata 9518585, Japan; Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan	Niigata University; Kobe University	Takei, N (corresponding author), Niigata Univ, Inst Brain Res, Dept Mol Neurobiol, Asahimachi 1, Niigata 9518585, Japan.	nobtak@bri.niigata-u.ac.jp						ALCAZAR A, 1995, J NEUROCHEM, V65, P754; ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEIDENREICH KA, 1993, ANN NY ACAD SCI, V692, P72; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; IP NY, 1991, J NEUROSCI, V11, P3124; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kauderer BS, 2000, P NATL ACAD SCI USA, V97, P13342, DOI 10.1073/pnas.97.24.13342; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Klintsova AY, 1999, CURR OPIN NEUROBIOL, V9, P203, DOI 10.1016/S0959-4388(99)80028-2; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; Martin KC, 2000, CURR OPIN NEUROBIOL, V10, P587, DOI 10.1016/S0959-4388(00)00128-8; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nawa H, 1997, CRIT REV NEUROBIOL, V11, P91, DOI 10.1615/CritRevNeurobiol.v11.i1.50; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; Nishiuma T, 1998, BIOCHEM BIOPH RES CO, V252, P440, DOI 10.1006/bbrc.1998.9671; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Proud CG, 1997, BIOCHEM J, V328, P329; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Quevedo C, 2000, J BIOL CHEM, V275, P19192, DOI 10.1074/jbc.M000238200; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; SONENBERG N, 1996, TRANSLATIONAL CONTRO, P249; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Takei N, 1998, J BIOL CHEM, V273, P27620, DOI 10.1074/jbc.273.42.27620; Takei N, 1998, Hum Cell, V11, P157; Takei N, 1997, J NEUROCHEM, V68, P370; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; YAMADA M, 1995, EUR J NEUROSCI, V7, P2130, DOI 10.1111/j.1460-9568.1995.tb00635.x; Yamada M, 2001, J NEUROCHEM, V78, P940, DOI 10.1046/j.1471-4159.2001.00497.x	57	170	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42818	42825		10.1074/jbc.M103237200	http://dx.doi.org/10.1074/jbc.M103237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551908	hybrid			2022-12-25	WOS:000172169300026
J	Wick, MJ; Dong, LQ; Hu, DR; Langlais, P; Liu, F				Wick, MJ; Dong, LQ; Hu, DR; Langlais, P; Liu, F			Insulin receptor-mediated p62(dok) tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; SRC HOMOLOGY 2; DOCKING PROTEIN; GRB-IR; PLECKSTRIN HOMOLOGY; SH2 DOMAIN; KINASE; IDENTIFICATION; SUBSTRATE; MUTAGENESIS	A GTPase-activating protein (GAP)-associated 60-kDa protein has been found to undergo rapid tyrosine phosphorylation in response to insulin stimulation. However, whether this protein is a direct in vivo substrate for the insulin receptor (IR) tyrosine kinase and whether the tyrosine phosphorylation plays a role in insulin signaling remain to be established. Here we show that the insulin-stimulated tyrosine phosphorylation of the GAP-associated protein, now identified as p62(dok), is inhibited by Grb10, an adaptor protein that binds directly to the kinase domain of the IR, both in vitro and in cells. Replacing Tyr(362). and Tyr(398) with phenylalanine greatly decreased the IR-catalyzed p62(dok) tyrosine phosphorylation in vitro, suggesting that these two residues are the major IR-mediated phosphorylation sites. However, mutations at Tyr362 and Tyr398 only partially blocked insulin-stimulated p62(dok) tyrosine phosphorylation in cells, indicating that p62(dok) is also a target for other cellular tyrosine kinase(s) in addition to the IR. Replacing Tyr(362) with phenylalanine abolished the interaction between p62(dok) and Nck. Mutations at Tyr(362/398) of p62(dok) disrupted the interaction between p62(dok) and GAP and decreased the inhibitory effect of p62(dok) on the insulin-stimulated activation of Ras and Akt, but not mitogen-activated protein kinase. Furthermore, the inhibitory effect of p62(dok) on Akt phosphorylation could be blocked by coexpression of a constitutively active Has. Taken together, our findings indicate that p62(dok) is a direct substrate for the IR tyrosine kinase and that phosphorylation at Tyr(362) and Tyr(398) plays an essential role for p62(dok) to interact with its effectors and negatively regulate the insulin signaling pathway.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Dong, LQ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	dongq@uthscsa.edu; liuf@uthscsa.edu			NIDDK NIH HHS [DK52933] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cong F, 1999, MOL CELL BIOL, V19, P8314; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU F, 1994, BIOCHEM J, V298, P471, DOI 10.1042/bj2980471; Marais R, 1996, CANCER SURV, V27, P101; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; OGAWA W, 1994, J BIOL CHEM, V269, P29602; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; van Dijk TB, 2000, BLOOD, V96, P3406; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; ZHANG B, 1992, J BIOL CHEM, V267, P18320	43	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42843	42850		10.1074/jbc.M102116200	http://dx.doi.org/10.1074/jbc.M102116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551902	hybrid			2022-12-25	WOS:000172169300029
J	Yanagita, M; Arai, H; Nakano, T; Ohashi, K; Mizuno, K; Fukatsu, A; Doi, T; Kita, T				Yanagita, M; Arai, H; Nakano, T; Ohashi, K; Mizuno, K; Fukatsu, A; Doi, T; Kita, T			Gas6 induces mesangial cell proliferation via latent transcription factor STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; IN-VIVO; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; SUPPRESSES GROWTH; TYROSINE KINASE; GLOMERULONEPHRITIS; INHIBITION; PATHWAY; ACTIVATION	Mesangial cell proliferation is essential for the pathogenesis and progression of glomerular disease. Previously, we showed that Gas6 plays a pivotal role in mesangial cell proliferation in vitro and in vivo. In the present study, we identified downstream targets of Gas6 signaling to examine the role in mesangial cell proliferation in vitro and in vivo. We found that Gas6 tyrosine phosphorylates STAT3 (signal transducers and activators of transcription) with concomitant translocation to the nucleus and induces STAT3-dependent transcriptional activation in cultured mesangial cells. Expressing dominant negative STAT3 inhibited Gas6-mediated transcriptional activation of STAT3 and abolished Gas6-induced mesangial cell proliferation. In a model of mesangial proliferative glomerulonephritis, STAT3 is phosphorylated in mesangial cells, and its phosphorylation peaks at day 8 after the injection of anti-Thy1.1 antibody. Inhibition of Gas6 by warfarin and the extracellular domain of its receptor, AxI, abolished phosphorylation of STAT3 in vivo. Thus, our in vitro and in vivo findings indicate that autocrine growth factor Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. Therefore, STAT3 might be a new therapeutic target for kidney disease induced by mesangial proliferation.	Kyoto Univ, Sch Med, Dept Geriatr Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Artificial Kidneys, Kyoto 6068507, Japan; Shionogi & Co Ltd, Discovery Res Lab, Osaka 5530002, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan; Univ Tokushima, Dept Lab Med, Tokushima 7708503, Japan	Kyoto University; Kyoto University; Shionogi & Company Limited; Tohoku University; Tokushima University	Arai, H (corresponding author), Kyoto Univ, Sch Med, Dept Geriatr Med, Sakyo Ku, 54 Kawaharacho, Kyoto 6068507, Japan.	harai@kuhp.kyoto-u.ac.jp	Arai, Hidenori/P-9816-2017; FUKATSU, ATSUSHI/R-7941-2019; Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Arai, Hidenori/0000-0002-9000-6849; Ohashi, Kazumasa/0000-0001-7617-403X; Yanagita, Motoko/0000-0002-0339-9008				Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bokemeyer D, 2000, J AM SOC NEPHROL, V11, P232, DOI 10.1681/ASN.V112232; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7; FLOEGE J, 1993, J CLIN INVEST, V92, P2952, DOI 10.1172/JCI116918; FLOEGE J, 1991, AM J KIDNEY DIS, V17, P673, DOI 10.1016/S0272-6386(12)80349-0; FLOEGE J, 1993, KIDNEY INT, V43, pS47; FOGO A, 1989, SEMIN NEPHROL, V9, P329; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; JOHNSON RJ, 1993, J AM SOC NEPHROL, V4, P119; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Nagasawa Y, 2000, KIDNEY INT, V57, P717, DOI 10.1046/j.1523-1755.2000.00894.x; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 1999, CANCER RES, V59, P5059; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Pichler RH, 1996, AM J PATHOL, V148, P1153; Pippin JW, 1997, J CLIN INVEST, V100, P2512, DOI 10.1172/JCI119793; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STRIKER LJ, 1991, LAB INVEST, V64, P446; STRIKER LJ, 1989, SEMIN NEPHROL, V9, P318; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X; Yanagita M, 1999, J AM SOC NEPHROL, V10, P2503; Ziswiler R, 1998, J AM SOC NEPHROL, V9, P2055; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	34	78	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42364	42369		10.1074/jbc.M107488200	http://dx.doi.org/10.1074/jbc.M107488200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546821	hybrid			2022-12-25	WOS:000172450400108
J	Zhu, HM; Duerr, JS; Varoqui, H; McManus, JR; Rand, JB; Erickson, JD				Zhu, HM; Duerr, JS; Varoqui, H; McManus, JR; Rand, JB; Erickson, JD			Analysis of point mutants in the Caenorhabditis elegans vesicular acetylcholine transporter reveals domains involved in substrate translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOAMINE TRANSPORTER; RESERPINE BINDING; MUTATIONAL ANALYSIS; LACTOSE PERMEASE; BLOCKING ACTION; GENE; RESIDUES; VESAMICOL; TORPEDO; RELEASE	Cholinergic neurotransmission depends upon the regulated release of acetylcholine. This requires the loading of acetylcholine into synaptic vesicles by the vesicular acetylcholine transporter (VAChT). Here, we identify point mutants in Caenorhabditis elegans that map to highly conserved regions of the VAChT gene of Caenorhabditis elegans (CeVAChT) (unc-17) and exhibit behavioral phenotypes consistent with a reduction in vesicular transport activity and neurosecretion. Several of these mutants express normal amounts of VAChT protein and exhibit appropriate targeting of VAChT to synaptic vesicles. By site-directed mutagenesis, we have replaced the conserved amino acid residues found in human VAChT with the mutated residue in CeVAChT and stably expressed these cDNAs in PC-12 cells. These mutants display selective defects in initial acetylcholine ;transport velocity (K-m), with values ranging from 2- to 8-fold lower than that of the wild-type. One of these mutants has lost its specific interaction with vesamicol, a selective inhibitor of VAChT, and displays vesamicol-insensitive uptake of acetylcholine. The relative order of behavioral severity of the CeVAChT point mutants is identical to the order of reduced affinity of VAChT for acetylcholine in vitro. This indicates that specific structural changes in VAChT translate into specific alterations in the intrinsic parameters of transport and in the storage and synaptic release of acetylcholine in vivo.	Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Oklahoma Medical Research Foundation	Erickson, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	jerick@lsuhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036936] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38679, R01 GM038679] Funding Source: Medline; NINDS NIH HHS [NS36936] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; AND JB, 1995, C ELEGANS MODERN BIO, P187; BAHR BA, 1986, J NEUROCHEM, V46, P1214, DOI 10.1111/j.1471-4159.1986.tb00640.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1974, GENETICS, V77, P71; BRITTAIN RT, 1969, EUR J PHARMACOL, V8, P93, DOI 10.1016/0014-2999(69)90133-2; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIEBLER MF, 1989, J NEUROCHEM, V52, P813, DOI 10.1111/j.1471-4159.1989.tb02526.x; Duerr JS, 2001, AM J PHYSIOL-CELL PH, V280, pC1616, DOI 10.1152/ajpcell.2001.280.6.C1616; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Eiden LE, 1998, J NEUROCHEM, V70, P2227; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; He MM, 1997, BIOCHEMISTRY-US, V36, P13688, DOI 10.1021/bi9715324; HENRY JP, 1987, ANN NY ACAD SCI, V493, P194, DOI 10.1111/j.1749-6632.1987.tb27201.x; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; HOSONO R, 1989, ZOOL SCI, V6, P697; KANNER BI, 1979, FEBS LETT, V100, P175, DOI 10.1016/0014-5793(79)81158-8; Keller JE, 2000, J NEUROCHEM, V74, P1739, DOI 10.1046/j.1471-4159.2000.0741739.x; Kim MH, 2000, J BIOL CHEM, V275, P6175, DOI 10.1074/jbc.275.9.6175; Kim MH, 1999, J BIOL CHEM, V274, P673, DOI 10.1074/jbc.274.2.673; Kitamoto T, 2000, J NEUROBIOL, V42, P161, DOI 10.1002/(SICI)1097-4695(20000205)42:2<161::AID-NEU1>3.0.CO;2-P; KOSHIMURA K, 1990, J NEUROCHEM, V54, P533, DOI 10.1111/j.1471-4159.1990.tb01904.x; LEE JA, 1989, BIOCHEMISTRY-US, V28, P2540, DOI 10.1021/bi00432a029; Lickteig KM, 2001, J NEUROSCI, V21, P2001, DOI 10.1523/JNEUROSCI.21-06-02001.2001; Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907; MARSHALL IG, 1970, BRIT J PHARMACOL, V38, P503, DOI 10.1111/j.1476-5381.1970.tb10592.x; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; NGUYEN M, 1995, GENETICS, V140, P527; Nguyen ML, 1998, BIOCHEMISTRY-US, V37, P13400, DOI 10.1021/bi9802263; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; Parsons SM, 2000, FASEB J, V14, P2423, DOI 10.1096/fj.00-0203rev; Pothos E, 1996, J NEUROCHEM, V66, P629; RAND JB, 1985, PSYCHOPHARMACOL BULL, V21, P623; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; SteinerMordoch S, 1996, J BIOL CHEM, V271, P13048, DOI 10.1074/jbc.271.22.13048; ULUS IH, 1989, BRAIN RES, V484, P217, DOI 10.1016/0006-8993(89)90364-8; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Varoqui H, 1997, MOL NEUROBIOL, V15, P165, DOI 10.1007/BF02740633; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; Varoqui H, 1998, J PHYSIOLOGY-PARIS, V92, P141, DOI 10.1016/S0928-4257(98)80152-6; Varoqui H, 1998, METHOD ENZYMOL, V296, P84; VIZI ES, 1989, BRIT J PHARMACOL, V98, P898, DOI 10.1111/j.1476-5381.1989.tb14619.x; Wadiche JI, 1998, J NEUROSCI, V18, P7650; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; WILLIAMS BD, 1992, GENETICS, V131, P609	58	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41580	41587		10.1074/jbc.M103550200	http://dx.doi.org/10.1074/jbc.M103550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551909	hybrid			2022-12-25	WOS:000172450400008
J	Rundle, NT; Xu, L; Andersen, RJ; Roberge, M				Rundle, NT; Xu, L; Andersen, RJ; Roberge, M			G(2) DNA damage checkpoint inhibition and antimitotic activity of 13-hydroxy-15-oxozoapatlin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; PROTEIN-KINASE; RADIOSENSITIZING AGENT; CHROMOSOME ALIGNMENT; P34(CDC2) KINASE; TYROSINE KINASE; BHK CELLS; G2 ARREST; CAFFEINE; UCN-01	Checkpoints activated in response to DNA damage cause arrest in the G(1) and G(2) phases of the cell cycle. Inhibitors of the G(2) checkpoint may be used as tools to study this response and also to increase the effectiveness of DNA-damaging therapies against cancers lacking p53 function. Using a cell-based assay for G(2) check. point inhibitors, we have screened extracts from the NCI National Institutes of Health Natural Products Repository and have identified 13-hydroxy-15-oxozoapatlin (OZ) from the African tree Parinari curatellifolia. Flow cytometry with a mitosis-specific antibody showed that checkpoint inhibition by OZ was maximal at 10 muM, which released 20% of irradiated MCF-7 cells expressing defective p53 and 30% of irradiated HCT116p53(-/-) cells from G(2) arrest. OZ additively increased the response to the checkpoint inhibitors isogranulatimide and debromohymenialdisine, but it did not augment the effects of UCN-01 or caffeine. Unlike other checkpoint inhibitors, OZ did not inhibit ataxia-telangiectasia mutated (ATM), ATM and Rad3-related (ATR), Chk1, Chk2, Plk1, or Ser/Thr protein phosphatases in vitro. Treatment with OZ also caused G(2)-arrested and cycling cells to arrest in mitosis in a state resembling prometaphase. In these cells, the chromosomes were condensed and scattered over disordered mitotic spindles. The results demonstrate that OZ is both a G(2) checkpoint inhibitor and an antimitotic agent.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Oceanog Earth & Ocean Sci, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Roberge, M (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							Abe K, 1999, BRAIN RES, V837, P306, DOI 10.1016/S0006-8993(99)01658-3; Adams PD, 1998, CURR OPIN CELL BIOL, V10, P791, DOI 10.1016/S0955-0674(98)80123-3; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; BADEN DG, 1981, TOXICON, V19, P455, DOI 10.1016/0041-0101(81)90003-9; BRAYLAN RC, 1982, CYTOMETRY, V2, P337; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Busby EC, 2000, CANCER RES, V60, P2108; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; FAN SJ, 1995, CANCER RES, V55, P1649; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Garo E, 1997, HELV CHIM ACTA, V80, P538, DOI 10.1002/hlca.19970800218; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL L, 1994, COLD SPRING HARB SYM, V59, P259, DOI 10.1101/SQB.1994.059.01.030; Jiang XX, 2000, INT J ONCOL, V16, P971; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; KUPCHAN SM, 1975, J ORG CHEM, V40, P648, DOI 10.1021/jo00893a023; Lee IS, 1996, CHEM-BIOL INTERACT, V99, P193; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnor PM, 1997, CANCER SURV, V29, P151; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETTIT GR, 1982, CAN J CHEM, V60, P1374, DOI 10.1139/v82-202; POWELL SN, 1995, CANCER RES, V55, P1643; Roberge M, 1998, CANCER RES, V58, P5701; Robinson JP, 1993, HDB FLOW CYTOMETRY; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; ROWLEY R, 1984, RADIAT RES, V97, P178, DOI 10.2307/3576199; Russell KJ, 1996, INT J RADIAT ONCOL, V36, P1099, DOI 10.1016/S0360-3016(96)00432-4; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SUFFNESS M, 1982, J NAT PROD, V45, P1, DOI 10.1021/np50019a001; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455	51	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48231	48236		10.1074/jbc.M103990200	http://dx.doi.org/10.1074/jbc.M103990200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11572854	hybrid			2022-12-25	WOS:000172927000066
J	Miles, RD; Iyer, PP; Ferry, JG				Miles, RD; Iyer, PP; Ferry, JG			Site-directed mutational analysis of active site residues in the acetate kinase from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN HEXOKINASE; MUTAGENESIS; BINDING; ATP; IDENTIFICATION; SUPERFAMILY; PROTEINS; HSC70; FOLD	Acetate kinase catalyzes the magnesium-dependent transfer of the gamma -phosphate of ATP to acetate. The recently determined crystal structure of the Methanosarcina thermophila enzyme identifies it as a member of the sugar kinase/Hsc70/actin superfamily based on the fold and the presence of five putative nucleotide and metal binding motifs that characterize the superfamily. Residues from four of these motifs in M. thermophila acetate kinase were selected for site-directed replacement and analysis of the variants. Replacement of Asp(148) and Asn(7) resulted in variants with catalytic efficiencies less than 1% of that of the wild-type enzyme, indicating that these residues are essential for activity. Glu(384) was also found to be essential for catalysis. A 30-fold increase in the magnesium concentration required for half-maximal activity of the E384A variant relative to that of the wild type implicated Glu(384) in magnesium binding. The kinetic analysis of variants and structural data is consistent with nonessential roles for active site residues Ser(10), Ser(12), and Lys(14) in catalysis. The results are discussed with respect to the acetate kinase catalytic mechanism and the relationship to other sugar kinase/Hsc70/actin superfamily members.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.							ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIJAL M, 1995, ARCH BIOCHEM BIOPHYS, V321, P413, DOI 10.1006/abbi.1995.1412; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buss KA, 2001, J BACTERIOL, V183, P680, DOI 10.1128/JB.183.2.680-686.2001; Buss KA, 1997, PROTEIN SCI, V6, P2659; Cane DE, 1996, BIOCHEMISTRY-US, V35, P12369, DOI 10.1021/bi961344y; CHEN X, 1995, J BIOL CHEM, V270, P11406, DOI 10.1074/jbc.270.19.11406; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FOX DK, 1986, J BIOL CHEM, V261, P3498; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; Hurley JH, 1996, ANNU REV BIOPH BIOM, V25, P137; Ingram-Smith C, 2000, J BIOL CHEM, V275, P33765, DOI 10.1074/jbc.M005303200; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; LIPMANN F, 1945, J BIOL CHEM, V159, P21; Lipmann F, 1944, J BIOL CHEM, V155, P55; Pettigrew DW, 1998, ARCH BIOCHEM BIOPHYS, V349, P236, DOI 10.1006/abbi.1997.0444; ROSE IA, 1954, J BIOL CHEM, V211, P737; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; Singh-Wissmann K, 2000, BIOCHEMISTRY-US, V39, P3671, DOI 10.1021/bi991998h; Singh-Wissmann K, 1998, J BACTERIOL, V180, P1129, DOI 10.1128/JB.180.5.1129-1134.1998; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; SPECTOR LB, 1980, P NATL ACAD SCI-BIOL, V77, P2626, DOI 10.1073/pnas.77.5.2626; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509; Zeng CB, 1998, J BIOL CHEM, V273, P700, DOI 10.1074/jbc.273.2.700	35	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45059	45064		10.1074/jbc.M108355200	http://dx.doi.org/10.1074/jbc.M108355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11562377	hybrid			2022-12-25	WOS:000172406700096
J	Seta, KA; Kim, R; Kim, HW; Millhorn, DE; Beitner-Johnson, D				Seta, KA; Kim, R; Kim, HW; Millhorn, DE; Beitner-Johnson, D			Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE-CELLS; CATALYTIC ACTIVATION; SELECTIVE ACTIVATION; ERYTHROPOIETIN GENE; SIGNALING PATHWAY; EXPRESSION; TRANSCRIPTION	Subtractive suppression hybridization was used to generate a cDNA library enriched in cDNA sequences corresponding to mRNA species that are specifically upregulated by hypoxia (6 h, 1% O-2) in the oxygen-responsive pheochromocytoma cell line. The dual specificity protein-tyrosine phosphatase (M) under bar AP (K) under bar (p) under bar hosphatase-(1) under bar (MKP-1) was highly represented in this library. Clones were arrayed on glass slides to create a hypoxia-specific cDNA microarray chip. Microarray, northern blot, and western blot analyses confirmed that MKP-1 mRNA and protein levels were up-regulated by hypoxia by similar to8-fold. The magnitude of the effect of hypoxia on MKP-1 was approximately equal to that induced by KCl depolarization and much larger than the effects of either epidermal growth factor or nerve growth factor on MKP-1 mRNA levels. In contrast to the calcium-dependent induction of MKP-1 by KCl depolarization, the effect of hypoxia on MKP-1 persisted under calcium-free conditions. Cobalt and deferoxamine also increased MKP-1 mRNA levels, suggesting that hypoxia-inducible factor proteins may play a role in the regulation of MKP-1 by hypoxia. Pretreatment of cells with SB203580, which inhibits p38 kinase activity, significantly reduced the hypoxia-induced increase in MKP-1 RNA levels. Thus, hypoxia robustly increases MKP-1 levels, at least in part through a p38 kinase-mediated mechanism.	Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Genome Res Inst, Cincinnati, OH 45267 USA	University of Cincinnati; University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, POB 67-0576, Cincinnati, OH 45267 USA.	david.millhorn@uc.edu			NHLBI NIH HHS [HL66312, HL59945, HL33831] Funding Source: Medline; NIDDK NIH HHS [DK58844] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL066312, R01HL059945, R01HL033831] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Burgun C, 2000, FEBS LETT, V484, P189, DOI 10.1016/S0014-5793(00)02153-0; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Jiang BH, 1997, CANCER RES, V57, P5328; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Martell KJ, 1998, MOL CELLS, V8, P2; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Millhorn DE, 2000, ADV EXP MED BIOL, V475, P131; Mishra RR, 1998, MOL BRAIN RES, V59, P74, DOI 10.1016/S0169-328X(98)00139-9; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PRABHAKAR NR, 1995, BRAIN RES, V697, P266, DOI 10.1016/0006-8993(95)00994-2; Rumora L, 2001, NEUROCHEM INT, V39, P25, DOI 10.1016/S0197-0186(01)00004-3; Sasaki H, 2001, J MOL CELL CARDIOL, V33, P283, DOI 10.1006/jmcc.2000.1299; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Sodhi A, 2000, CANCER RES, V60, P4873; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Wang GC, 2000, NUCLEIC ACIDS RES, V28, P2135, DOI 10.1093/nar/28.10.2135; WANG GL, 1993, BLOOD, V82, P3610; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Zawada WM, 2001, BRAIN RES, V891, P185; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	56	65	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44405	44412		10.1074/jbc.M103346200	http://dx.doi.org/10.1074/jbc.M103346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577072	hybrid			2022-12-25	WOS:000172406700009
J	Nakamura, M; Barber, AJ; Antonetti, DA; LaNoue, KF; Robinson, KA; Buse, MG; Gardner, TW				Nakamura, M; Barber, AJ; Antonetti, DA; LaNoue, KF; Robinson, KA; Buse, MG; Gardner, TW			Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; MESANGIAL CELLS; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; DIABETIC-RETINOPATHY; KINASE-B; IN-VITRO; RESISTANCE; PROTEIN; PATHWAY	In addition to microvascular abnormalities, neuronal apoptosis occurs early in diabetic retinopathy, but the mechanism is unknown. Insulin may act as a neurotrophic factor in the retina via the phosphoinositide 3-kinase/Akt pathway. Excessive glucose flux through the hexosamine biosynthetic pathway (HBP) is implicated in the development of insulin resistance in peripheral tissues and diabetic complications such as nephropathy. We tested whether increased glucose flux through the HBP perturbs insulin action and induces apoptosis in retinal neuronal cells. Exposure of R28 cells, a model of retinal neurons, to 20 mm glucose for 24 h attenuated the ability of 10 mm insulin to rescue them from serum deprivation-induced apoptosis and to phosphorylate Akt compared with 5 mm glucose. Glucosamine not only impaired the neuroprotective effect of insulin but also induced apoptosis in R28 cells in a dose-dependent fashion. UDP-N-acetylhexosamines (UDP-HexNAc), end products of the HBP, were increased similar to2- and 15-fold after a 24-h incubation in 20 mm glucose and 1.5 nim glucosamine, respectively. Azaserine, a glutamine:fructose-6-phosphate amidotransferase inhibitor, reversed the effect of 20 rum glucose, but not that of 1.5 mm glucosamine, on attenuation of the ability of insulin to promote cell survival and phosphorylate Akt as well as accumulation of UDP-HexNAc. Glucosamine also impaired insulin receptor processing in a dose-dependent manner but did not decrease ATP content. By contrast, in L6 muscle cells, glucosamine impaired insulin receptor processing but did not induce apoptosis. These results suggest that the excessive glucose flux through the HBP may direct retinal neurons to undergo apoptosis in a bimodal fashion; i.e. via perturbation of the neuroprotective effect of insulin mediated by Akt and via induction of apoptosis possibly by altered glycosylation of proteins. The HBP may be involved in retinal neurodegeneration in diabetes.	Penn State Univ, Coll Med,Dept Ophthalmol, Ulerich Ophthalmol Res Ctr, Penn State Retina Res Grp, Hershey, PA 17033 USA; Penn State Univ, Coll Med,Dept Cellular & Mol Physiol, Ulerich Ophthalmol Res Ctr, Penn State Retina Res Grp, Hershey, PA 17033 USA; Med Univ S Carolina, Dept Med, Div Endocrinol Diab & Med Genet, Charleston, SC 29425 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Medical University of South Carolina	Gardner, TW (corresponding author), Penn State Univ, Coll Med,Dept Ophthalmol, Ulerich Ophthalmol Res Ctr, Penn State Retina Res Grp, 500 Univ Dr,H166, Hershey, PA 17033 USA.	tgardner@psu.edu		antonetti, david/0000-0003-1130-6577; Nakamura, Makoto/0000-0002-6464-4302; Barber, Alistair/0000-0003-4235-2293; Gardner, Thomas/0000-0002-5112-5810	NATIONAL EYE INSTITUTE [R01EY012021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK002001, R56DK002001] Funding Source: NIH RePORTER; NEI NIH HHS [EY12021] Funding Source: Medline; NIDDK NIH HHS [DK02001] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; BEKESI JG, 1969, J BIOL CHEM, V244, P3766; CHANG JY, 2000, NEUROTOXICOLOGY, V2, P601; Crook ED, 2000, ENDOCRINOLOGY, V141, P1962, DOI 10.1210/en.141.6.1962; DAVIDSON MB, 1994, BBA-GEN SUBJECTS, V1201, P113, DOI 10.1016/0304-4165(94)90159-7; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Gardner T W, 2000, Diabetes Technol Ther, V2, P601; Giardino I, 1998, DIABETES, V47, P1114, DOI 10.2337/diabetes.47.7.1114; GORDEN P, 1989, YALE J BIOL MED, V62, P521; HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hawkins M, 1999, J BIOL CHEM, V274, P31312, DOI 10.1074/jbc.274.44.31312; HEACOCK AM, 1982, BRAIN RES, V241, P307, DOI 10.1016/0006-8993(82)91068-X; Heart E, 2000, AM J PHYSIOL-ENDOC M, V278, pE103, DOI 10.1152/ajpendo.2000.278.1.E103; HEATH H, 1975, DIABETOLOGIA, V11, P57, DOI 10.1007/BF00422819; Heath H, 1967, Diabetologia, V3, P515, DOI 10.1007/BF01213570; HEDO JA, 1983, J BIOL CHEM, V258, P20; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; HUCK S, 1983, BRAIN RES BULL, V10, P667, DOI 10.1016/0361-9230(83)90036-9; James LR, 2000, AM J PHYSIOL-RENAL, V279, pF718, DOI 10.1152/ajprenal.2000.279.4.F718; Kang J, 2001, AM J PHYSIOL-ENDOC M, V280, pE428, DOI 10.1152/ajpendo.2001.280.3.E428; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Kumagai AK, 1999, DIABETES-METAB RES, V15, P261, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<261::AID-DMRR43>3.0.CO;2-Z; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; LEIST M, 1995, EUR J PHARM-ENVIRON, V292, P201, DOI 10.1016/0926-6917(95)90013-6; MAHER F, 1991, BIOCHIM BIOPHYS ACTA, V1089, P27, DOI 10.1016/0167-4781(91)90080-6; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MAZLEN RG, 1970, EXP EYE RES, V9, P1, DOI 10.1016/S0014-4835(70)80052-5; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Naeser P, 1997, UPSALA J MED SCI, V102, P35, DOI 10.3109/03009739709178930; Nawano M, 1999, BIOCHEM BIOPH RES CO, V266, P252, DOI 10.1006/bbrc.1999.1797; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P10; Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; RODRIGUES M, 1988, BRAIN RES, V443, P389, DOI 10.1016/0006-8993(88)91639-3; Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971; Seigel GM, 1996, IN VITRO CELL DEV-AN, V32, P66; SEIGEL GM, 2000, MOL VIS, V6, P21; Singh LP, 2001, J DIABETES COMPLICAT, V15, P88, DOI 10.1016/S1056-8727(00)00140-9; Singh LP, 2000, AM J PHYSIOL-RENAL, V279, pF646, DOI 10.1152/ajprenal.2000.279.4.F646; Song XM, 1999, DIABETES, V48, P664, DOI 10.2337/diabetes.48.3.664; Tang J, 2000, DIABETOLOGIA, V43, P1417, DOI 10.1007/s001250051548; TESORIERE G, 1975, BIOCHIM BIOPHYS ACTA, V385, P58, DOI 10.1016/0304-4165(75)90074-4; TESORIERE G, 1984, EXPERIENTIA, V40, P705, DOI 10.1007/BF01949733; TESORIERE G, 1971, EUR J BIOCHEM, V19, P289, DOI 10.1111/j.1432-1033.1971.tb01317.x; Tezel G, 1999, INVEST OPHTH VIS SCI, V40, P2660; TOLKOVSKY AM, 1987, J NEUROSCI, V7, P110; WALKER F, 1968, DIABETES, V17, P105, DOI 10.2337/diab.17.2.105; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	62	139	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43748	43755		10.1074/jbc.M108594200	http://dx.doi.org/10.1074/jbc.M108594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11560942	hybrid			2022-12-25	WOS:000172297700036
J	Ohtani, K; Suzuki, Y; Eda, S; Kawai, T; Kase, T; Keshi, H; Sakai, Y; Fukuoh, A; Sakamoto, T; Itabe, H; Suzutani, T; Gasawara, M; Yoshida, I; Wakamiya, N				Ohtani, K; Suzuki, Y; Eda, S; Kawai, T; Kase, T; Keshi, H; Sakai, Y; Fukuoh, A; Sakamoto, T; Itabe, H; Suzutani, T; Gasawara, M; Yoshida, I; Wakamiya, N			The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT APOPROTEIN; MANNOSE-BINDING PROTEIN; BACTERICIDAL ACTIVITY; CLONING; MACROPHAGES; LIVER; VIRUS; IDENTIFICATION	Collectins are a family of C-type lectins that have collagen-like sequences and carbohydrate recognition domains (CRD). They are involved in host defense through their ability to bind to carbohydrate antigens of microorganisms. The scavenger receptors type A and MARCO are classical type scavenger receptors that have internal collagen-like domains. Here we describe a new scavenger receptor that is a membrane-type collectin from placenta (collectin placenta 1 (CL-P1)), which has a typical collectin collagen-like domain and a CRD. The cDNA has an insert of about 2.2 kilobases coding for a protein containing 742 amino acid residues. The deduced amino acid sequence shows that CL-P1 is a type II membrane protein, has a coiled-coil region, a collagen-like domain, and a CRD. It resembles type A scavenger receptors because the scavenger receptor cysteine-rich domain is replaced by a CRD. Northern analyses, reverse transcription-polymerase chain reaction, and immunohistochemistry show that CL-P1 is expressed in vascular endothelial cells but not in macrophages. By immunoblotting and flow cytometry CL-P1 appears to be a membrane glycoprotein of about 140 kDa in human umbilical vein or arterial endothelial cells, placental membrane extracts, and CL-P1 transfected Chinese hamster ovary cells. We found that CL-P1 can bind and phagocytose not only bacteria (Escherichia coli and Staphylococcus aureus) but also yeast (Saccharomyces cerevisiae). Furthermore, it reacts with oxidized low density lipoprotein (OxLDL) but not with acetylated LDL (AcLDL). These binding activities are inhibited by polyanionic ligands (polyinosinic acid, polyguanylic acid, dextran sulfate) and OxLDL but not by polycationic ligands (polyadenylic acid or polycytidylic acid), LDL, or AcLDL. These results indicate that CL-P1 might play important roles in host defenses that are different from those of soluble collectins in innate immunity.	Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan; Osaka Prefectural Inst Publ Hlth, Dept Pathol, Osaka 5370025, Japan; Osaka Prefectural Inst Publ Hlth, Dept Food Microbiol, Osaka 5370025, Japan; Osaka Prefectural Inst Publ Hlth, Dept Virol, Osaka 5370025, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 1990195, Japan	Asahikawa Medical College; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Teikyo University	Wakamiya, N (corresponding author), Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan.		板部板部, 洋之/ABC-7746-2020; Suzuki, Yasuhiko/F-6890-2012					Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; HARTLEY CA, 1992, J VIROL, V66, P4358, DOI 10.1128/JVI.66.7.4358-4363.1992; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Itabe H, 1996, J BIOL CHEM, V271, P33208, DOI 10.1074/jbc.271.52.33208; Kawai T, 1997, GENE, V186, P161, DOI 10.1016/S0378-1119(96)00664-6; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; Laursen SB, 1998, IMMUNOLOGY, V93, P421, DOI 10.1046/j.1365-2567.1998.00446.x; Ling WH, 1997, J CLIN INVEST, V100, P244, DOI 10.1172/JCI119528; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SCHWEINLE JE, 1989, J CLIN INVEST, V84, P1821, DOI 10.1172/JCI114367; SHIMAMOTO A, 1997, SEIKAGAKU, V69, P574; STEPHAN ZF, 1993, J LIPID RES, V34, P325; Suzuki H, 1997, J Atheroscler Thromb, V4, P1; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; WAKAMIYA N, 1992, BIOCHEM BIOPH RES CO, V187, P1270, DOI 10.1016/0006-291X(92)90440-V; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; Yoshida H, 1998, BIOCHEM J, V334, P9, DOI 10.1042/bj3340009	34	161	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44222	44228		10.1074/jbc.M103942200	http://dx.doi.org/10.1074/jbc.M103942200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564734	hybrid, Green Submitted			2022-12-25	WOS:000172297700094
J	Okuda, H; Saitoh, K; Hirai, S; Iwai, K; Takaki, Y; Baba, M; Minato, N; Ohno, S; Shuin, T				Okuda, H; Saitoh, K; Hirai, S; Iwai, K; Takaki, Y; Baba, M; Minato, N; Ohno, S; Shuin, T			The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEOLYSIS; LIGASE COMPLEX; CELL-POLARITY; BETA-DOMAIN; PKC-LAMBDA; GENE; PRODUCT; CARCINOMA; BINDING; GROWTH	The von Hippel-Lindau tumor-suppressor protein (pVHL) forms a protein complex (VCB-Cul2) with elongin C, elongin B, Cul-2, and Rbx1, which functions as a ubiquitin-protein ligase (EU The a-subunits of the bypoxia-inducible factors have been identified as targets for the VCB-Cul2 ubiquitin ligase. However, a variety of cellular defects caused by the depletion of pVHL cannot be explained solely by the ubiquitin-mediated degradation of hypoxia-inducible factor-a. We show here that a member of the atypical protein kinase C (PKC) group, PKC lambda, is ubiquitinated by the pVHL-containing E3 enzyme. An active PKC lambda mutant is ubiquitinated more extensively than wild-type PKC lambda in HEK293 cells, and the ubiquitination is further enhanced by the overexpression of pVHL. The activation of wild-type PKC lambda by serum stimulation of cells enhances the ubiquitination of the protein, supporting the notion that active PKC lambda is preferentially ubiquitinated by VCB-Cul2 ubiquitin ligase. Furthermore, we show that PKC lambda can be ubiquitinated in vitro in a cell-free ubiquitination assay using purified recombinant components including VCB-Cul2. Given the known function of aPKC in the regulation of cell polarity and cell growth, PKC lambda may be a target of pVHL in its function as a tumor suppressor.	Yokohama City Univ, Sch Med, Dept Mol & Cellular Biol, Yokohama, Kanagawa 2360004, Japan; Kochi Med Sch, Dept Urol, Kochi 7838505, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto 6068501, Japan	Yokohama City University; Kochi University; Kyoto University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol & Cellular Biol, Yokohama, Kanagawa 2360004, Japan.		Ohno, Shigeo/B-1768-2010; IWAI, KAZUHIRO/GSN-7385-2022; Baba, Masaya/ABE-4893-2020; Baba, Masaya/L-7490-2013	Ohno, Shigeo/0000-0002-1294-5269; Baba, Masaya/0000-0002-5308-6683; Iwai, Kazuhiro/0000-0001-5620-5951				Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHEN F, 1995, CANCER RES, V55, P4804; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamada M, 2001, CANCER RES, V61, P4184; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x	39	143	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43611	43617		10.1074/jbc.M107880200	http://dx.doi.org/10.1074/jbc.M107880200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11574546	hybrid			2022-12-25	WOS:000172297700019
J	Tomasin, R; Samir, AA; Vaccaro, MI; Pebusque, MJ; Dagorn, JC; Iovanna, JL; Dusetti, NJ				Tomasin, R; Samir, AA; Vaccaro, MI; Pebusque, MJ; Dagorn, JC; Iovanna, JL; Dusetti, NJ			Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing - SIP induced by stress and promotes cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERULEIN-INDUCED PANCREATITIS; ACUTE-PHASE; APOPTOSIS; EXPRESSION; INDUCTION; SEVERITY; SEQUENCES; ACID; MICE	We have used a quantitative fluorescent cDNA microarray hybridization approach to identify pancreatic genes induced by the cellular stress promoted by acute pancreatitis in the mouse. We report the cloning and characterization of one of them that encodes the stress-induced proteins (SIP). The mouse SIP gene is organized into five exons and expands over similar to 20 kilobase pairs. Exon 4 (38 base pairs) is alternatively spliced to generate two transcripts. Northern blot and in situ hybridization showed that both SIP mRNAs are rapidly and strongly induced in acinar cells of the pancreas with acute pancreatitis. They are also constitutively expressed in several other tissues, although with different ratios. They encode proteins of 18 and 27 kDa (SIP18 and SIP27). SIP27 is identical to the thymus-expressed acidic protein (TEAP) protein, formerly described as a thymus-specific protein. Expression of the SIP18 and SIP27/EGFP or V5 fusion proteins showed that both are nuclear factors. We monitored SIP expression in NIH3T3 cells submitted to various stress agents. UV stress, base damaging, mutagenic stress, ethanol, heat shock, and oxidative stress induced the concomitant expression of SIP's and SIP27 mRNAs. Finally, transient transfection of SIP's and SIP27 expression plasmids induced death by apoptosis in COS7 cells as measured by terminal deoxynuelcotidyltransferase-mediated dUTP nick end-labeling staining. In conclusion, the SIP gene is an important element of cellular stress response. It is expressed in many tissues and induced by a variety of stress agents affecting many cellular pathways. SIP generates, by alternative splicing, two nuclear proteins that can promote cell death by apoptosis.	INSERM, EMI 0116, Ctr Rech, F-13276 Marseille, France; Univ Buenos Aires, Dept Fisiol, RA-1121 Buenos Aires, DF, Argentina; INSERM, U119, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Buenos Aires; Institut National de la Sante et de la Recherche Medicale (Inserm)	Iovanna, JL (corresponding author), INSERM, EMI 0116, Ctr Rech, 163 Av Luminy,BP 172, F-13276 Marseille, France.		tomasini, richard/F-1130-2017; Iovanna, Juan/M-9805-2017; Vaccaro, Maria I./L-8348-2017; Dusetti, Nelson/O-7919-2017	tomasini, richard/0000-0003-0869-0811; Iovanna, Juan/0000-0003-1822-2237; Dusetti, Nelson/0000-0002-6161-8483; Vaccaro, Maria/0000-0002-2456-747X				Bhatia M, 1998, BIOCHEM BIOPH RES CO, V246, P476, DOI 10.1006/bbrc.1998.8519; Carrier A, 1999, IMMUNOGENETICS, V50, P255, DOI 10.1007/s002510050601; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dagorn JC, 1997, DIGESTION, V58, P50, DOI 10.1159/000201526; Dusetti NJ, 2000, BIOCHEM BIOPH RES CO, V277, P660, DOI 10.1006/bbrc.2000.3734; Hahm KB, 1998, PANCREAS, V17, P153, DOI 10.1097/00006676-199808000-00007; He ZJ, 2000, ANN CHIR GYNAECOL FE, V89, P65; IOVANNA JL, 1991, AM J PHYSIOL, V261, pG485, DOI 10.1152/ajpgi.1991.261.3.G485; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; Karne S, 1999, SURG CLIN N AM, V79, P699, DOI 10.1016/S0039-6109(05)70036-0; Kimura K, 1998, PANCREAS, V17, P120, DOI 10.1097/00006676-199808000-00002; KOMMINOTH P, 1995, LAB INVEST, V72, P424; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1192, DOI 10.1016/S0016-5085(85)80079-2; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Saluja A, 1996, BIOCHEM BIOPH RES CO, V220, P875, DOI 10.1006/bbrc.1996.0498; Steer ML, 1997, DIGESTION, V58, P46, DOI 10.1159/000201525; WILSON C, 1991, DRUGS, V41, P358, DOI 10.2165/00003495-199141030-00004	19	67	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44185	44192		10.1074/jbc.M105647200	http://dx.doi.org/10.1074/jbc.M105647200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557757	hybrid			2022-12-25	WOS:000172297700090
J	Cheng, AW; Chan, SL; Milhavet, O; Wang, SQ; Mattson, MP				Cheng, AW; Chan, SL; Milhavet, O; Wang, SQ; Mattson, MP			p38 MAP kinase mediates nitric oxide-induced apoptosis of neural progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; CENTRAL-NERVOUS-SYSTEM; AMYLOID BETA-PEPTIDE; ADULT HUMAN BRAIN; SIGNAL-TRANSDUCTION; NEURONAL APOPTOSIS; CYTOCHROME-C; NEURODEGENERATIVE DISORDERS; CASPASE ACTIVATION	Neural progenitor cells (NPC) can proliferate, differentiate into neurons or glial cells, or undergo a form of programmed cell death called apoptosis. Although death of NPC occurs during development of the nervous system and in the adult, the underlying mechanisms are unknown. Here we show that nitric oxide (NO) can induce death of C17.2 NPC by a mechanism requiring activation of p38 MAP kinase, poly(ADP-ribose) polymerase, and caspase-3. Nitric oxide causes release of cytochrome c from mitochondria, and Bcl-2 protects the neural progenitor cells against nitric oxide-induced death, consistent with a pivotal role for mitochondrial changes in controlling the cell death process. Inhibition of p38 MAP kinase by SB203580 abolished NO-induced cell death, cytochrome c release, and activation of caspase-3, indicating that p38 activation serves as an upstream mediator in the cell death process. The antiapoptotic protein Bcl-2 protected NPC against nitric oxide-induced apoptosis and suppressed activation of p38 MAP kinase. The ability of nitric oxide to trigger death of NPC by a mechanism involving p38 MAP kinase suggests that this diffusible gas may regulate NPC fate in physiological and pathological settings in which NO is produced.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, 4F02,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012	Milhavet, Ollivier/0000-0001-6236-0499	NATIONAL INSTITUTE ON AGING [ZIAAG000312, Z01AG000313, ZIAAG000313, Z01AG000312] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABEDOHMAE S, 1993, BIOCHEM BIOPH RES CO, V191, P915, DOI 10.1006/bbrc.1993.1304; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Ayata C, 1997, J NEUROSCI, V17, P6908; Bartsch H, 2000, EUR J CANCER, V36, P1229, DOI 10.1016/S0959-8049(00)00095-2; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Bernier PJ, 2000, NEUROSCI RES, V37, P67, DOI 10.1016/S0168-0102(00)00102-4; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; Bloodsworth A, 2000, ARTERIOSCL THROM VAS, V20, P1707, DOI 10.1161/01.ATV.20.7.1707; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Calabrese V, 2000, NEUROCHEM RES, V25, P1315, DOI 10.1023/A:1007604414773; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Contestabile A, 2000, BRAIN RES REV, V32, P476, DOI 10.1016/S0165-0173(00)00018-7; D'Sa-Eipper C, 2000, DEV NEUROSCI-BASEL, V22, P116, DOI 10.1159/000017433; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Didier C, 1999, FASEB J, V13, P1817, DOI 10.1096/fasebj.13.13.1817; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GIUILI G, 1994, DEV BRAIN RES, V81, P269, DOI 10.1016/0165-3806(94)90313-1; GRAHAM A, 1993, DEVELOPMENT, V119, P233; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Hagedorn L, 2000, DEV BIOL, V228, P57, DOI 10.1006/dbio.2000.9936; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jun CD, 1999, J IMMUNOL, V162, P3395; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kikuchi M, 2000, J NEUROSCI, V20, P5037; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Levison SW, 2000, DEV NEUROSCI-BASEL, V22, P106, DOI 10.1159/000017432; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; Messmer UK, 1996, FEBS LETT, V384, P162; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moreno-Lopez B, 2000, BRAIN RES, V869, P244, DOI 10.1016/S0006-8993(00)02474-4; Morshead CM, 1998, DEVELOPMENT, V125, P2251; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; Phung YT, 1999, MOL BRAIN RES, V64, P165, DOI 10.1016/S0169-328X(98)00315-5; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rakic S, 2000, EUR J NEUROSCI, V12, P2721, DOI 10.1046/j.1460-9568.2000.00153.x; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rialas CM, 2000, EXP CELL RES, V260, P268, DOI 10.1006/excr.2000.5017; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Samama B, 1996, DEV BRAIN RES, V96, P192; Santacana M, 1998, DEV BRAIN RES, V111, P205, DOI 10.1016/S0165-3806(98)00140-0; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; Tamatani M, 1998, CELL DEATH DIFFER, V5, P911, DOI 10.1038/sj.cdd.4400439; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; Weller M, 1997, J NEURAL TRANSM-SUPP, P115; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zilian O, 2001, CURR BIOL, V11, P494, DOI 10.1016/S0960-9822(01)00149-X	106	134	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43320	43327		10.1074/jbc.M107698200	http://dx.doi.org/10.1074/jbc.M107698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555660	hybrid			2022-12-25	WOS:000172169300090
J	Goldberg, AFX; Fales, LM; Hurley, JB; Khattree, N				Goldberg, AFX; Fales, LM; Hurley, JB; Khattree, N			Folding and subunit assembly of photoreceptor peripherin/rds is mediated by determinants within the extracellular/intradiskal EC2 domain - Implications for heterogeneous molecular pathologies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGENERATION SLOW RDS; RETINAL DEGENERATION; RETINITIS-PIGMENTOSA; ROD PHOTORECEPTORS; DISK MEMBRANE; CANDIDATE GENE; MESSENGER-RNA; ROM-1; PROTEIN; CLONING	Peripherin/rds is an integral membrane protein required for the elaboration of rod and cone photoreceptor outer segments in the vertebrate retina; it causes a surprising variety of progressive retinal degenerations in humans and dysmorphic photoreceptors in murine models if defective or absent. (Peripherin/rds is also known as photoreceptor peripherin, peripherin/rds, rds/peripherin, rds, and peripherin-2.) Peripherin/rds appears to act as a structural element in outer segment architecture. However, neither its function at the molecular level nor its role in retinal disease processes are well understood. This report initiates a systematic investigation of protein domain structure and function by examining the molecular and cellular consequences of a series of 14 insertional mutations distributed throughout the polypeptide sequence. Protein expression, disulfide bonding, sedimentation velocity, and subcellular localization of the COS-1 cell-expressed mutant variants were examined to test the hypothesis that protein folding and tetrameric subunit assembly are mediated primarily by EC2, a conserved extracellular/intradiskal domain. Protein folding and tetrameric subunit assembly were not affected by insertion of either an uncharged dipeptide (GA) or a highly charged hendecapeptide (GDYKDDDDKAA) into any one of nine sites residing outside of EC2 as assayed by nonreducing Western blot analysis, sedimentation velocity, and subcellular localization. In contrast, insertions at five positions within the EC2 domain did cause either gross protein misfolding (two sites) or a reduction in protein sedimentation coefficient (two sites) or both (one site). These results indicate that although the vast majority of extramembranous polypeptide sequence makes no measurable contribution to protein folding and tetramerization, discrete regions within the EC2 domain do contain determinants for normal subunit assembly. These findings raise the possibility that multiple classes of structural perturbation are produced by inherited defects in peripherin/rds and contribute to the observed heterogeneity of retinal disease phenotypes..	Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA; Univ Washington, Dept Biochem, Howard Hughes Med Inst, Seattle, WA 98195 USA	Oakland University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Goldberg, AFX (corresponding author), Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA.	goldberg@oakland.edu			NATIONAL EYE INSTITUTE [R01EY006641, R01EY013246] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY13246, R01 EY06641, R01 EY013246, R01 EY006641] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068; ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; Boesze-Battaglia K, 2000, BBA-BIOMEMBRANES, V1463, P343, DOI 10.1016/S0005-2736(99)00226-6; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; Chubet RG, 1996, BIOTECHNIQUES, V20, P136; Clarke G, 2000, NAT GENET, V25, P67, DOI 10.1038/75621; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; Goldberg AFX, 2000, METHOD ENZYMOL, V316, P671; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; GORIN MB, 1993, MAMM GENOME, V4, P544, DOI 10.1007/BF00364792; Gould DJ, 1997, ANIM GENET, V28, P391, DOI 10.1111/j.1365-2052.1997.00185.x; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; Kedzierski W, 1999, J BIOL CHEM, V274, P29181, DOI 10.1074/jbc.274.41.29181; Kedzierski W, 1996, J CELL SCI, V109, P2551; Kitadokoro K, 2001, EMBO J, V20, P12, DOI 10.1093/emboj/20.1.12; Kohl S, 1998, ACTA ANAT, V162, P75; Loewen CJR, 2001, J BIOL CHEM, V276, P22388, DOI 10.1074/jbc.M011710200; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MOGHRABI WN, 1995, EXP EYE RES, V61, P641, DOI 10.1016/S0014-4835(05)80059-4; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; Weng J, 1998, INVEST OPHTH VIS SCI, V39, P440; Wrigley JDJ, 2000, J BIOL CHEM, V275, P13191, DOI 10.1074/jbc.C900853199; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	41	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42700	42706		10.1074/jbc.M107511200	http://dx.doi.org/10.1074/jbc.M107511200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553636	hybrid, Green Accepted			2022-12-25	WOS:000172169300010
J	Leland, PA; Staniszewski, KE; Kim, BM; Raines, RT				Leland, PA; Staniszewski, KE; Kim, BM; Raines, RT			Endowing human pancreatic ribonuclease with toxicity for cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL STABILITY; CATALYTIC-ACTIVITY; RANA-CATESBEIANA; GROWTH-FACTOR; CYTOTOXIC RIBONUCLEASES; 3-DIMENSIONAL STRUCTURE; INHIBITOR INTERACTION; ANTITUMOR-ACTIVITY; ENDOTHELIAL-CELLS; HUMAN ANGIOGENIN	Onconase(R) is an amphibian protein that is now in Phase IH clinical trials as a cancer chemotherapeutic. Human pancreatic ribonuclease (RNase 1) is homologous to Onconase(R) but is not cytotoxic. Here, ERDD RNase 1, which is the L86E/N88R/G89D/R91D variant of RNase 1, is shown to have conformational. stability and ribonucleolytic activity similar to that of the wild-type enzyme but >10(3)-fold less affinity for the endogenous cytosolic ribonuclease inhibitor protein. Most significantly, ERDD RNase 1 is toxic to hum an leukemia cells. The addition of a non-native disulfide bond to ERDD RNase I not only increases the conformational stability of the enzyme but also increases its cytotoxicity such that its IC(50) value is only 8-fold greater than that of Onconase(R). Thus, only a few amino acid substitutions are necessary to make a human protein toxic to human cancer cells. This finding has significant implications for human cancer chemotherapy.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	raines@biochem.wisc.edu	Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719; Turkow, Kristine/0000-0002-6102-0668	NATIONAL CANCER INSTITUTE [R01CA073808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NCI NIH HHS [CA73808] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blackburn P, 1982, ENZYMES, VXV, P317; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BRAVO J, 1994, ANAL BIOCHEM, V219, P82, DOI 10.1006/abio.1994.1234; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; Canals A, 1999, PROTEIN EXPRES PURIF, V17, P169, DOI 10.1006/prep.1999.1112; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; Futami J, 1999, PROTEIN ENG, V12, P1013, DOI 10.1093/protein/12.11.1013; Futami J, 2000, J BIOCHEM-TOKYO, V128, P245, DOI 10.1093/oxfordjournals.jbchem.a022747; Gaur D, 2001, J BIOL CHEM, V276, P24978, DOI 10.1074/jbc.M102440200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; Hu GF, 2000, J CELL BIOCHEM, V76, P452, DOI 10.1002/(SICI)1097-4644(20000301)76:3<452::AID-JCB12>3.0.CO;2-Z; Imperiali B, 1995, BIOORGAN MED CHEM, V3, P1565, DOI 10.1016/0968-0896(95)00142-5; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; KIM JS, 1993, PROTEIN SCI, V2, P348; Klink TA, 2000, J BIOL CHEM, V275, P17463, DOI 10.1074/jbc.M001132200; Klink TA, 2000, EUR J BIOCHEM, V267, P566, DOI 10.1046/j.1432-1327.2000.01037.x; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Leland PA, 2000, FEBS LETT, V477, P203, DOI 10.1016/S0014-5793(00)01804-4; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; MIKULSKI SM, 1995, INT J ONCOL, V6, P889; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MIKULSKI SM, 1990, CELL TISSUE KINET, V23, P237, DOI 10.1111/j.1365-2184.1990.tb01119.x; MIKULSKI SM, 1992, INT J ONCOL, V1, P779; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOROIANU J, 1994, BIOCHEM BIOPH RES CO, V203, P1765, DOI 10.1006/bbrc.1994.2391; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; NITTA K, 1993, GLYCOBIOLOGY, V3, P37, DOI 10.1093/glycob/3.1.37; NITTA K, 1987, CANCER RES, V47, P4877; OKABE Y, 1991, J BIOCHEM-TOKYO, V109, P786, DOI 10.1093/oxfordjournals.jbchem.a123457; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; Piccoli R, 1999, P NATL ACAD SCI USA, V96, P7768, DOI 10.1073/pnas.96.14.7768; Pous J, 2000, J MOL BIOL, V303, P49, DOI 10.1006/jmbi.2000.4506; Pous J, 2001, ACTA CRYSTALLOGR D, V57, P498, DOI 10.1107/S0907444901001147; Psarras K, 1998, PROTEIN ENG, V11, P1285, DOI 10.1093/protein/11.12.1285; Raines RT, 1999, BIOM HLTH R, V27, P235; RIBO M, 1994, BIOL CHEM H-S, V375, P357; ROTH JS, 1967, METHOD CANCER RES, V3, P153; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; Rybak SM, 1996, J NATL CANCER I, V88, P747, DOI 10.1093/jnci/88.11.747; SAKAKIBARA F, 1979, CANCER RES, V39, P1347; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Suwa T, 1999, ANTICANCER RES, V19, P4161; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; Teter SA, 1999, TRENDS CELL BIOL, V9, P428, DOI 10.1016/S0962-8924(99)01652-9; TRAUTWEIN K, 1991, FEBS LETT, V281, P275, DOI 10.1016/0014-5793(91)80410-5; Vasandani VM, 1999, CANCER CHEMOTH PHARM, V44, P164, DOI 10.1007/s002800050962; Vasandani VM, 1996, CANCER RES, V56, P4180; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	63	78	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43095	43102		10.1074/jbc.M106636200	http://dx.doi.org/10.1074/jbc.M106636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555655	hybrid			2022-12-25	WOS:000172169300062
J	Sands, MS; Vogler, CA; Ohlemiller, KK; Roberts, MS; Grubb, JH; Levy, B; Sly, WS				Sands, MS; Vogler, CA; Ohlemiller, KK; Roberts, MS; Grubb, JH; Levy, B; Sly, WS			Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME REPLACEMENT THERAPY; BONE-MARROW TRANSPLANTATION; LYSOSOMAL STORAGE DISEASE; MANNOSE 6-PHOSPHATE; HEARING-LOSS; MOUSE; DEFICIENCY; EXPRESSION; CELLS; EMBRYOGENESIS	Enzyme replacement therapy (ERT) has been shown to be effective at reducing the accumulation of undegraded substrates in lysosomal storage diseases. Most ERT studies have been performed with recombinant proteins that are mixtures of phosphorylated and nonphosphorylated enzyme. Because different cell types use different receptors to take up phosphorylated or non-phosphorylated enzyme, it is difficult to determine which form of enzyme contributed to the clinical response. Here we compare the uptake, distribution, and efficacy of highly phosphorylated and non-phosphorylated P-glucuronidase (GUSB) in the MPS VII mouse. Highly phosphorylated murine GUSB was efficiently taken up by a wide range of tissues. In contrast, nonphosphorylated murine GUSB was taken up primarily by tissues of the reticuloendothelial (RE) system. Although the tissue distribution was different, the half-lives of both enzymes in any particular tissue were similar. Both preparations of enzyme were capable of preventing the accumulation of lysosomal storage in cell types they targeted. An important difference in clinical efficacy emerged in that phosphorylated GUSB was more efficient than non-phosphorylated enzyme at preventing the hearing loss associated with this disease. These data suggest that both forms of enzyme contribute to the clinical responses of ERT in MPS VII mice but that enzyme preparations containing phosphorylated GUSB are more broadly effective than non-phosphorylated enzyme.	Washington Univ, Sch Med, Cent Inst Deaf, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cent Inst Deaf, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cent Inst Deaf, Res Dept, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Saint Louis University; Saint Louis University	Sands, MS (corresponding author), Washington Univ, Sch Med, Cent Inst Deaf, Dept Internal Med, Box 8007,660 S Euclid Ave, St Louis, MO 63110 USA.			Sands, Mark/0000-0002-5559-0832	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034182] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD35671] Funding Source: Medline; NIGMS NIH HHS [R01 GM34182] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; AEED PA, 1994, BIOCHEMISTRY-US, V33, P8793, DOI 10.1021/bi00195a022; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1991, BLOOD, V78, P1183; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; Boose J A, 1990, Protein Expr Purif, V1, P111, DOI 10.1016/1046-5928(90)90003-H; CHANG PL, 1993, NEUROREPORT, V4, P507, DOI 10.1097/00001756-199305000-00011; COPPOLA G, 1994, GENE, V144, P197, DOI 10.1016/0378-1119(94)90378-6; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; Daly TM, 2000, PEDIATR RES, V47, P757, DOI 10.1203/00006450-200006000-00012; Dunder U, 2000, FASEB J, V14, P361, DOI 10.1096/fasebj.14.2.361; ENG DP, 2001, NEW ENGL J MED, V345, P9; GLASER JH, 1973, J LAB CLIN MED, V82, P969; GRUBB JH, 1993, FASEB J, V7, pA1255; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; MATZNER U, 1992, DEVELOPMENT, V114, P965; Miranda SRP, 2000, FASEB J, V14, P1988, DOI 10.1096/fj.00-0014com; NATOWICZ M, 1982, J BIOL CHEM, V257, P4412; NATOWICZ MR, 1979, P NATL ACAD SCI USA, V76, P4322, DOI 10.1073/pnas.76.9.4322; NEUFELD EF, 1970, SCIENCE, V169, P141, DOI 10.1126/science.169.3941.141; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P237, DOI 10.1159/000013847; Ohlemiller KK, 2000, EXP EYE RES, V71, P469, DOI 10.1006/exer.2000.0897; Sands MS, 1999, LAB ANIM SCI, V49, P328; SANDS MS, 1993, P NATL ACAD SCI USA, V90, P6567, DOI 10.1073/pnas.90.14.6567; SANDS MS, 1995, BLOOD, V86, P2033, DOI 10.1182/blood.V86.5.2033.bloodjournal8652033; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Sands MS, 1997, J CLIN INVEST, V99, P1596, DOI 10.1172/JCI119322; SENIOR PV, 1990, DEVELOPMENT, V109, P67; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; Takahashi K, 1998, CELL TISSUE RES, V292, P311, DOI 10.1007/s004410051062; Vogler C, 1999, PEDIATR RES, V45, P838, DOI 10.1203/00006450-199906000-00010; VOGLER C, 1990, AM J PATHOL, V136, P207; Vogler C, 1996, PEDIATR RES, V39, P1050, DOI 10.1203/00006450-199606000-00019; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028; WOLFE JH, 1996, GENE TRANSFER NEURON	40	59	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43160	43165		10.1074/jbc.M107778200	http://dx.doi.org/10.1074/jbc.M107778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562370	hybrid			2022-12-25	WOS:000172169300069
J	Werneburg, BG; Zoog, SJ; Dang, TTA; Kehry, MR; Crute, JJ				Werneburg, BG; Zoog, SJ; Dang, TTA; Kehry, MR; Crute, JJ			Molecular characterization of CD40 signaling intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; CROSS-LINKING CD40; CRYSTAL-STRUCTURE; FACTORS TRAFS; ANTENNAPEDIA HOMEODOMAIN; CYTOPLASMIC DOMAIN; ADAPTER PROTEINS; UP-REGULATION	Signal transduction through the CD40 receptor is initiated by binding of its trimeric ligand and propagated by interactions of tumor necrosis factor receptor-associated factor (TRAF) proteins with the multimerized CD40 cytoplasmic domain. Using defined multimeric constructs of the CD40 cytoplasmic domain expressed as either soluble or myristoylated proteins, we have addressed the extent of receptor multimerization needed to initiate signal transduction and identified components of CD40 signaling complexes. Signal transduction in human embryonic kidney 293 cells, measured by nuclear factor kappaB activation, was observed in cells expressing soluble trimeric CD40 cytoplasmic domain and to a lesser extent in cells expressing dimeric CD40 cytoplasmic domain. Nuclear factor kappaB activation was strongest in cells expressing myristoylated trimeric CD40 cytoplasmic domain. Signal transduction through trimeric CD40 cytoplasmic domains with various point mutations in the TRAF binding sites was similar to signal transduction through analogous full-length receptors. Transiently expressed soluble trimeric CD40 cytoplasmic domain was isolated as complexes that contained TRAF2, TRAF3, TRAF5, TRAF6, and the inhibitor of apoptosis protein (c-IAP1.). Association of c-IAP1 with the CD40 cytoplasmic domain complex was indirect and dependent on the presence of an intact TRAF1/2/3 binding site. These results suggest that extracellular ligation of CD40 can be bypassed and that soluble trimerized CD40 complexes can be isolated and used to identify components that link CD40 with signaling pathways.	Boehringer Ingelheim Pharmaceut Inc, Dept Biol, Ridgefield, CT 06877 USA	Boehringer Ingelheim	Crute, JJ (corresponding author), Aurora Biosci Corp, 11010 Torreyana Rd, San Diego, CA 92121 USA.							Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Clark LB, 1996, ADV IMMUNOL, V63, P43; Craxton A, 1998, J IMMUNOL, V161, P3225; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fang W, 1997, AM J PHYSIOL-CELL PH, V272, pC950, DOI 10.1152/ajpcell.1997.272.3.C950; Fenton M, 1998, J IMMUNOL METHODS, V212, P41, DOI 10.1016/S0022-1759(97)00208-1; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HU HM, 1994, J BIOL CHEM, V269, P30069; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; ICHIKI T, 1993, J IMMUNOL, V150, P5408; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; JACKSON S, 1982, J IMMUNOL METHODS, V48, P299, DOI 10.1016/0022-1759(82)90331-3; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Kehry M R, 1994, Semin Immunol, V6, P287, DOI 10.1006/smim.1994.1037; Kehry MR, 1996, J IMMUNOL, V156, P2345; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; McWhirter SM, 1999, COLD SPRING HARB SYM, V64, P551, DOI 10.1101/sqb.1999.64.551; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; PEREZ F, 1992, J CELL SCI, V102, P717; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schauer SL, 1996, J IMMUNOL, V157, P81; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	61	40	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43334	43342		10.1074/jbc.M104994200	http://dx.doi.org/10.1074/jbc.M104994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562359	hybrid			2022-12-25	WOS:000172169300092
J	Matsubayashi, Y; Fukuda, M; Nishida, E				Matsubayashi, Y; Fukuda, M; Nishida, E			Evidence for existence of a nuclear pore complex-mediated, cytosol-independent pathway of nuclear translocation of ERK MAP kinase in permeabilized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR; NUCLEOCYTOPLASMIC TRANSPORT; CYTOPLASMIC LOCALIZATION; IMPORT SUBSTRATE; EXPORT SIGNAL; BETA-CATENIN; PHOSPHORYLATION; IDENTIFICATION	The classical mitogen-activated protein kinase (MAPK, also known as ERK) pathway is widely involved in eukaryotic signal transductions. In response to extracellular stimuli, MAPK becomes activated and translocates from the cytoplasm to the nucleus. At least two pathways for the nuclear import of MAPK are shown to exist; passive diffusion of a monomer and Ran-dependent active transport of a dimer, the detailed molecular mechanism of which is unknown. In this study, we have reconstituted nuclear import of MAPK in vitro by using digitonin-permeabilized cells with GFP-fused MAPK protein (GFP-MAPK), which is too large to pass through the nuclear pore by passive diffusion. GFP-MAPK was able to accumulate in the nucleus irrespective of its phosphorylation state. This import of GFP-MAPK occurred even in the absence of any soluble cytosolic factors or ATP but was inhibited by wheat germ agglutinin or an excess amount of importin-beta or at low temperatures. Moreover, ALAPK directly bound to an FG repeat region of nucleoporin CAN/Nup214 in vitro. Taken together, these results suggest the third pathway for nuclear import of MAPK, in which MAPK passes through the nuclear pore by directly interacting with the nuclear pore complex.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kitashirekawa, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Matsubayashi, Yutaka/GRR-9659-2022; Fukuda, Makoto/S-9748-2019; Fukuda, Makoto/I-7915-2014; Fukuda, Makoto/C-9745-2009	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Matsubayashi, Yutaka/0000-0003-2196-8099				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1992, METHOD ENZYMOL, V219, P97; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GOTOH Y, 1994, ONCOGENE, V9, P1891; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kosako H, 1996, BIOCHEMISTRY-US, V35, P13212, DOI 10.1021/bi960956f; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LOMBILLO VA, 1993, METHOD CELL BIOL, V39, P149, DOI 10.1016/S0091-679X(08)60168-5; Lorenzen JA, 2001, DEVELOPMENT, V128, P1403; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MORIGUCHI T, 1995, EUR J BIOCHEM, V234, P32, DOI 10.1111/j.1432-1033.1995.032_c.x; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	59	130	138	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41755	41760		10.1074/jbc.M106012200	http://dx.doi.org/10.1074/jbc.M106012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546808	hybrid			2022-12-25	WOS:000172450400030
J	Napper, S; Brokx, SJ; Pally, E; Kindrachuk, J; Delbaere, LTJ; Waygood, EB				Napper, S; Brokx, SJ; Pally, E; Kindrachuk, J; Delbaere, LTJ; Waygood, EB			Substitution of aspartate and glutamate for active center histidines in the Escherichia coli phosphoenolpyruvate : sugar phosphotransferase system maintain phosphotransfer potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOCARRIER PROTEIN-IIIGLC; SALMONELLA-TYPHIMURIUM; ENZYME-I; BACTERIAL PHOSPHOENOLPYRUVATE; PHOSPHOGLYCERATE MUTASE; PHOSPHORYL TRANSFER; ENTERIC BACTERIA; TERMINAL DOMAIN; HPR; TRANSPORT	The active center histidines of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system proteins; histidine-containing protein, enzyme I, and enzyme HAG(Glc) were substituted with a series of amino acids (serine, threonine, tyrosine, cysteine, aspartate, and glutamate) with the potential to undergo phosphorylation. The mutants [H189E]enzyme I, [H15D]HPr, and [H90E]enzyme IIA(Glc) retained ability for phosphorylation as indicated by [P-32]phosphoenolpyruvate labeling. As the active center histidines of both enzyme I and enzyme IIA(Glc) undergo phosphorylation of the N-epsilon2 atom, while HPr is phosphorylated at the N-delta1 atom, a pattern of successful substitution of glutamates for N-epsilon2 phosphorylations and aspartates for N-delta1 phosphorylations emerges. Furthermore, phosphotransfer between acyl residues: P-aspartyl to glutamyl and P-glutaxnyl to aspartyl was demonstrated with these mutant proteins and enzymes.	Univ Saskatchewan, Vet Infect Dis Org, Dept Biochem, Saskatoon, SK S7N 5E3, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan	Napper, S (corresponding author), Univ Saskatchewan, Vet Infect Dis Org, Dept Biochem, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada.			Kindrachuk, Jason/0000-0002-3305-7084				ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; ANDERSON JW, 1993, J BIOL CHEM, V268, P12325; Brokx SJ, 2000, BIOCHEMISTRY-US, V39, P3624, DOI 10.1021/bi991250z; COLOMB MG, 1972, BIOCHEMISTRY-US, V11, P3378, DOI 10.1021/bi00768a010; ERNI B, 1989, J BIOL CHEM, V264, P18733; FOX DK, 1986, J BIOL CHEM, V261, P3487; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; JIA ZC, 1993, J BIOL CHEM, V268, P22490; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; MATTOO RL, 1984, ANAL BIOCHEM, V139, P1, DOI 10.1016/0003-2697(84)90383-X; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Napper S, 1996, BIOCHEMISTRY-US, V35, P11260, DOI 10.1021/bi9603480; Napper S, 1999, J BIOL CHEM, V274, P21776, DOI 10.1074/jbc.274.31.21776; NAPPER S, 1999, THESIS U SASKATCHEWA; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PAS HH, 1991, J BIOL CHEM, V266, P6690; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POSTMA PW, 1996, ESCHERICHIA COLI SAL; ROBERTSON EF, 1988, J BIOL CHEM, V263, P2477; ROSE ZB, 1982, METHOD ENZYMOL, V87, P42; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1993, J CELL BIOCHEM, V51, P62, DOI 10.1002/jcb.240510112; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TITEMEYER F, 1993, J CELL BIOCHEM, V51, P69; Trumbore MW, 1997, J BIOL CHEM, V272, P26394, DOI 10.1074/jbc.272.42.26394; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1984, J CELL BIOCHEM, V25, P139, DOI 10.1002/jcb.240250304; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WILLIAMS SP, 1985, BIOCHEMISTRY-US, V24, P5527, DOI 10.1021/bi00341a037; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	40	6	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41588	41593		10.1074/jbc.M104139200	http://dx.doi.org/10.1074/jbc.M104139200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551914	hybrid			2022-12-25	WOS:000172450400009
J	Schmitt, I; Gerace, L				Schmitt, I; Gerace, L			In vitro analysis of nuclear transport mediated by the C-terminal shuttle domain of tap	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; PORE COMPLEX; LEPTOMYCIN B; POLY(A)(+) RNA; HUMAN HOMOLOG; RAN-GTP; PROTEIN; BINDING; VIRUS; SIGNAL	The Tap protein of higher eukaryotes is implicated in the nuclear export of type D retroviral mRNA and some cellular mRNAs. Here we have developed an in vitro assay to study nuclear export mediated by the C-terminal shuttle domain of Tap involving the rapamycin-induced attachment of this transport domain to a nuclear green fluorescent protein-containing reporter. We found that export by the Tap transport domain does not involve cytosolic transport factors including the GTPase Ran. The transport domain directly binds to several nucleoporins positioned in different regions of the nuclear pore complex. These results argue that a direct interaction of the Tap transport domain with nucleoporins is responsible for its nucleocytoplasmic translocation. We found that the karyopherin beta -related export receptor CRM1 competes with the Tap transport domain for binding to Nup214 but not for binding to Nup62 or Nup153, suggesting that the Tap and CRM1 nuclear export pathways converge at the cytoplasmic periphery of the nuclear pore complex. Because the rates of in vitro nuclear import and export by the Tap transport domain are very similar, the directionality of mRNA export mediated by Tap probably is determined by mechanisms other than simple binding of the Tap transport domain to nucleoporins.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	lgerace@scripps.edu						Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Black BE, 1999, MOL CELL BIOL, V19, P8616; Black BE, 2001, J CELL BIOL, V152, P141, DOI 10.1083/jcb.152.1.141; Bodendorf U, 1999, J VIROL, V73, P7769, DOI 10.1128/JVI.73.9.7769-7779.1999; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Cullen BR, 2000, MOL CELL BIOL, V20, P4181, DOI 10.1128/MCB.20.12.4181-4187.2000; Daneholt B, 1999, CURR BIOL, V9, pR412, DOI 10.1016/S0960-9822(99)80256-5; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1996, ONCOGENE, V13, P1801; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Guan TL, 2000, MOL CELL BIOL, V20, P5619, DOI 10.1128/MCB.20.15.5619-5630.2000; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Hurt E, 2000, J BIOL CHEM, V275, P8361, DOI 10.1074/jbc.275.12.8361; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Kang YB, 2000, J VIROL, V74, P5863, DOI 10.1128/JVI.74.13.5863-5871.2000; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Noble SM, 1996, GENETICS, V143, P67; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Suyama M, 2000, EMBO REP, V1, P53, DOI 10.1093/embo-reports/kvd009; Truant R, 1999, J BIOL CHEM, V274, P32167, DOI 10.1074/jbc.274.45.32167; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	66	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42355	42363		10.1074/jbc.M103916200	http://dx.doi.org/10.1074/jbc.M103916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551912	hybrid			2022-12-25	WOS:000172450400107
J	Schmidt, SLG; Pautz, AL; Burgers, PMJ				Schmidt, SLG; Pautz, AL; Burgers, PMJ			ATP utilization by yeast replication factor C IV. RFC ATP-binding mutants show defects in DNA replication, DNA repair, and checkpoint regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; S-PHASE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; DAMAGE CHECKPOINT; PROTEIN-KINASE; SMALL-SUBUNIT; P-LOOP; COMPLEX; MUTATIONS; RAD24	Replication factor C is required to load proliferating cell nuclear antigen onto primer-template junctions, using the energy of ATP hydrolysis. Four of the five RFC genes have consensus ATP-binding motifs. To determine the relative importance of these sites for proper DNA metabolism in the cell, the conserved lysine in the Walker A motif of RFC1, RFC2, RFC3, or RFC4 was mutated to either arginine or glutamic acid. Arginine mutations in all RFC genes tested permitted cell growth, although poor growth was observed for rfc2-K71R. A glutamic acid substitution resulted in lethality in RFC2 and RFC3 but not in RFC1 or RFC4. Most double mutants combining mutations in two RFC genes were inviable. Except for the rfc1-K359R and rfc4-K55E mutants, which were phenotypically similar to wild type in every assay, the mutants were sensitive to DNA-damaging agents. The rfc2-K71R and rfc4-K55R mutants show checkpoint defects, most likely in the intra-S phase checkpoint. Regulation of the damage-inducible RNR3 promoter was impaired in these mutants, and phosphorylation of Rad53p in response to DNA damage was specifically defective when cells were in S phase. No dramatic defects in telomere length regulation were detected in the mutants. These data demonstrate that the ATP binding function of RFC2 is important for both DNA replication and checkpoint function and, for the first time, that RFC4 also plays a role in checkpoint regulation.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021		NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams AK, 1996, MOL CELL BIOL, V16, P4614; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BURGERS PMJ, 1986, J BACTERIOL, V166, P905, DOI 10.1128/jb.166.3.905-913.1986; Cai JS, 1998, P NATL ACAD SCI USA, V95, P11607, DOI 10.1073/pnas.95.20.11607; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gomes XV, 2001, J BIOL CHEM, V276, P34776, DOI 10.1074/jbc.M011743200; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; McAlear MA, 1996, GENETICS, V142, P65; Mizushima T, 2000, GENE DEV, V14, P1631; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; Neuwald AF, 1999, GENOME RES, V9, P27; Noskov VN, 1998, MOL CELL BIOL, V18, P4914, DOI 10.1128/MCB.18.8.4914; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; Reynolds N, 1999, NUCLEIC ACIDS RES, V27, P462, DOI 10.1093/nar/27.2.462; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; SCHUDDEMAT J, 1988, BIOCHIM BIOPHYS ACTA, V937, P81, DOI 10.1016/0005-2736(88)90229-5; Shimada M, 1999, MOL BIOL CELL, V10, P3991, DOI 10.1091/mbc.10.12.3991; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wang B, 1999, J BIOL CHEM, V274, P8291, DOI 10.1074/jbc.274.12.8291; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Yang G, 1997, BIOCHEMISTRY-US, V36, P4751, DOI 10.1021/bi9631677; ZHOU Z, 1992, GENETICS, V131, P851	47	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34792	34800		10.1074/jbc.M011671200	http://dx.doi.org/10.1074/jbc.M011671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11549622	hybrid			2022-12-25	WOS:000171024600061
J	Blanchette, P; Gilchrist, CA; Baker, RT; Gray, DA				Blanchette, P; Gilchrist, CA; Baker, RT; Gray, DA			Association of UNP, a ubiquitin-specific protease, with the pocket proteins pRb, p107 and p130	ONCOGENE			English	Article						ubiquitin; Ubp; deubiquitinating enzyme; retinoblastoma; pocket protein	RETINOBLASTOMA GENE-PRODUCT; RB-RELATED P107; CELL-CYCLE; REGULATED PROTEOLYSIS; MICE LACKING; C-MYC; PATHWAY; DEGRADATION; FAMILY; E2F	The murine Unp gene encodes a widely expressed ubiquitin-specific protease. The predicted sequence of the UNP protein features motifs common to viral oncoproteins through which these proteins interact with the retinoblastoma gene product pRb, as well as the related 'pocket proteins' p107 and p130. We have explored the possibility that UNP interacts with pocket proteins, and report here that such associations can be detected in vitro and in cells. Associations of UNP and pocket proteins are sensitive to site-directed mutations in a manner directly analogous to those documented in viral oncoproteins. We conclude that within cells UNP does physically associate with pRb, and can also associate with p107 and p130.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia	University of Ottawa; Ottawa Hospital Research Institute; Australian National University; John Curtin School of Medical Research	Gray, DA (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada.		Gilchrist, Catherine/GPW-8606-2022; /U-3554-2018	Gilchrist, Catherine/0000-0002-7467-7933; /0000-0002-8634-4984				BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Boyer SN, 1996, CANCER RES, V56, P4620; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DeSalle LM, 2001, ONCOGENE, V20, P5538, DOI 10.1038/sj.onc.1204824; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GRAY DA, 1995, ONCOGENE, V10, P2179; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GUPTA K, 1994, ONCOGENE, V9, P1729; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	30	25	30	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5533	5537		10.1038/sj.onc.1204823	http://dx.doi.org/10.1038/sj.onc.1204823			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571651				2022-12-25	WOS:000170781100014
J	Murata, T; Kakinuma, Y; Yamato, I				Murata, T; Kakinuma, Y; Yamato, I			ATP-dependent affinity change of Na+-binding sites of V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCOCCUS-HIRAE; TRANSLOCATING ATPASE; ENERGY TRANSDUCTION; ESCHERICHIA-COLI; F-ATPASE; EVOLUTION; SYNTHASE; ROTATION; MOTOR; POLYPEPTIDE	V-type Na+-ATPase of Enterococcus hirae binds about six (6 +/- 1) Na+ ions/enzyme molecule with a high affinity (Murata, T., Igarashi, K., Kakinuma, Y., and Yamato, 1. (2000) J. Biol. Chem. 275, 13415-13419). After the addition of 5 mM ATP, the binding capacity dropped to about 2 (1.8 +/- 0.3) Na+ ions/enzyme molecule, returning to the initial value concomitant with the decrease of ATP hydrolysis rate. These findings suggest that the affinity of four of six Na+-binding sites of the enzyme changes (lowers) in enzyme reaction. The ATP analogs (adenosine 5'-O-(3-thiotriphosphate) or 5'-adenylylimido-diphosphate), ADP, or aluminum fluoride that is postulated to trap ATPases at their transition state did not inhibit the Na+ binding capacity significantly. Therefore, the affinity decrease of Na+-binding sites was unlikely to be due to ATP binding alone or at the transition state of ATP hydrolysis. In the presence of 5 mM ATP, the ATPase showed strong negative cooperativity (n(H) = 0.16 +/- 0.03) for Na+ stimulation of ATPase activity. The Hill coefficient (n(H)) increased to 1 in parallel to the decrease of ATP concentration in the reaction mixture. Thus, the ATP-dependent affinity change cooperatively occurs in continuous enzyme reaction.	Tokyo Univ Sci, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan; Muroran Inst Technol, Dept Appl Chem, Muroran, Hokkaido 0508585, Japan	Tokyo University of Science; Muroran Institute of Technology	Murata, T (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	tm@mrc-dunn.cam.ac.uk	Murata, Takeshi/J-6181-2017; Murata, Takeshi/F-6114-2011	Murata, Takeshi/0000-0002-5748-4670; 				ARAI H, 1987, J BIOL CHEM, V262, P11006; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GLYNN LM, 1985, ENZYMES BIOL MEMBR, P35; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; Kaim G, 1998, EMBO J, V17, P5887, DOI 10.1093/emboj/17.20.5887; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Murata T, 2000, J BIOL CHEM, V275, P13415, DOI 10.1074/jbc.275.18.13415; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; Murata T, 1996, J BIOL CHEM, V271, P23661, DOI 10.1074/jbc.271.39.23661; Murata T, 2001, BBA-BIOENERGETICS, V1505, P75, DOI 10.1016/S0005-2728(00)00278-4; Murata T, 1999, J BIOCHEM, V125, P414, DOI 10.1093/oxfordjournals.jbchem.a022302; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PALI T, 1995, BIOCHEMISTRY-US, V34, P9211, DOI 10.1021/bi00028a034; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SUGINO Y, 1964, BIOCHEM BIOPH RES CO, V16, P362, DOI 10.1016/0006-291X(64)90041-5; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; YAMATO I, 1993, P JPN ACAD B-PHYS, V69, P218, DOI 10.2183/pjab.69.218; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	31	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48337	48340		10.1074/jbc.M106821200	http://dx.doi.org/10.1074/jbc.M106821200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11557766	hybrid			2022-12-25	WOS:000172927000081
J	Abreu, MT; Arnold, ET; Chow, JYC; Barrett, KE				Abreu, MT; Arnold, ET; Chow, JYC; Barrett, KE			Phosphatidylinositol 3-kinase-dependent pathways oppose Fas-induced apoptosis and limit chloride secretion in human intestinal epithelial cells - Implications for inflammatory diarrheal states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; BARRIER FUNCTION; TIGHT JUNCTIONS; MOLECULAR PHYSIOLOGY; CROHNS-DISEASE; HT-29 CELLS; EP-CAM; PROTEIN; KINASE; 3-KINASE	The epithelial lining of the intestine serves as a barrier to lumenal bacteria and can be compromised by pathologic Fas-mediated epithelial apoptosis. Phosphatidylinositol (PI)3-kinase signaling has been described to limit apoptosis in other systems. We hypothesized that PI3-kinase-dependent pathways regulate Fas-mediated apoptosis and barrier function in intestiynal epithelial cells (IEC). IEC lines (HT-29 and T84) were exposed to agonist anti-Fas antibody in the presence or absence of chemical inhibitors of PI3-kinase (LY294002 and wortmannin). Apoptosis, barrier function, changes in short circuit current and expression of adhesion molecules were assessed. Inhibition of PI3-kinase strongly sensitized IEC to Fas-mediated apoptosis. Expression of constitutively active Akt, a principal downstream effector of the PI3-kinase pathway, protected against Fas-mediated apoptosis to an extent that was comparable with expression of a genetic caspase inhibitor, p35. PI3-kinase inhibition sensitized to apoptosis by increasing and accelerating Fas-mediated caspase activation. Inhibition of PI3-kinase combined with cross-linking Fas was associated with increased permeability to molecules that were < 400 Da but not those that were > 3,000 Da. Inhibition of PI3-kinase resulted in chloride secretion that was augmented by cross-linking Fas. Confocal analyses revealed polymerization of actin and maintenance of epithelial cell adhesion molecule-mediated interactions in monolayers exposed to anti-Fas antibody in the context of PI3-kinase inhibition. PI3-kinase-dependent pathways, especially Akt, protect IEC against Fas-mediated apoptosis. Inhibition of PI3-kinase in the context of Fas signaling results in increased chloride secretion and barrier dysfunction. These findings suggest that agonists of PI3-kinase such as growth factors may have a dual effect on intestinal inflammation by protecting epithelial cells against immune-mediated apoptosis and limiting chloride secretory diarrhea.	Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif San Diego, Sch Med, Div Gastroenterol, San Diego, CA 92103 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California San Diego	Abreu, MT (corresponding author), Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, 8631 W 3rd St,Suite 245E, Los Angeles, CA 90048 USA.	Maria.Abreu@cshs.org	Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Abreu, Maria T./0000-0002-7294-0574	NCRR NIH HHS [1S10 RR 13717-01] Funding Source: Medline; NIDDK NIH HHS [1R03 DK 59469, K08 DK 02635, DK 28305] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305, K08DK002635, R03DK059469] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2000, GASTROENTEROLOGY, V119, P1524, DOI 10.1053/gast.2000.20232; Abreu-Martin MT, 1999, AM J PHYSIOL-GASTR L, V276, pG599, DOI 10.1152/ajpgi.1999.276.3.G599; ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Balzar M, 1998, MOL CELL BIOL, V18, P4833, DOI 10.1128/MCB.18.8.4833; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Chow JYC, 2000, J BIOL CHEM, V275, P21169, DOI 10.1074/jbc.M002160200; COLGAN SP, 1994, J IMMUNOL, V153, P2122; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEL PL, 1997, SCIENCE, V278, P687; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gassler N, 2001, AM J PHYSIOL-GASTR L, V281, pG216, DOI 10.1152/ajpgi.2001.281.1.G216; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Haller DG, 2001, SEMIN ONCOL, V28, P25, DOI 10.1053/sonc.2001.19719; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hilsden RJ, 1999, INFLAMM BOWEL DIS, V5, P85, DOI 10.1097/00054725-199905000-00003; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hrnjez BJ, 1999, AM J PHYSIOL-GASTR L, V277, pG521, DOI 10.1152/ajpgi.1999.277.3.G521; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466; Kitada S, 1998, AM J PATHOL, V152, P51; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; Lotz MM, 2000, AM J PATHOL, V156, P985, DOI 10.1016/S0002-9440(10)64966-8; MADARA JL, 1987, AM J PHYSIOL, V253, pC854, DOI 10.1152/ajpcell.1987.253.6.C854; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MARIN ML, 1983, AM J GASTROENTEROL, V78, P537; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; MATTHEWS JB, 1994, J SURG RES, V56, P505, DOI 10.1006/jsre.1994.1081; McNamara BP, 2001, J CLIN INVEST, V107, P621, DOI 10.1172/JCI11138; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Merlin D, 2001, AM J PHYSIOL-CELL PH, V280, pC296, DOI 10.1152/ajpcell.2001.280.2.C296; Miceli R, 1999, J PHARMACOL EXP THER, V290, P464; Moss SF, 1996, GUT, V39, P811, DOI 10.1136/gut.39.6.811; Mullin JM, 1997, J CELL PHYSIOL, V171, P226, DOI 10.1002/(SICI)1097-4652(199705)171:2<226::AID-JCP14>3.0.CO;2-B; NASH S, 1991, J CLIN INVEST, V87, P1474, DOI 10.1172/JCI115156; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nusrat A, 2000, AM J PHYSIOL-GASTR L, V279, pG851, DOI 10.1152/ajpgi.2000.279.5.G851; Nusrat A, 2001, INFECT IMMUN, V69, P1329, DOI 10.1128/IAI.69.3.1329-1336.2001; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; Nusrat A, 1997, GASTROENTEROLOGY, V113, P1489, DOI 10.1053/gast.1997.v113.pm9352851; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Pinkoski MJ, 2000, AM J PHYSIOL-GASTR L, V278, pG354, DOI 10.1152/ajpgi.2000.278.3.G354; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; Sasaki T, 2000, NATURE, V406, P897, DOI 10.1038/35022585; Sears CL, 2000, AM J PHYSIOL-GASTR L, V279, pG1129, DOI 10.1152/ajpgi.2000.279.6.G1129; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Slonim AE, 2000, NEW ENGL J MED, V342, P1633, DOI 10.1056/NEJM200006013422203; Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 2000, HEPATOLOGY, V32, P796, DOI 10.1053/jhep.2000.17738; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Taylor CT, 1997, GUT, V40, P634, DOI 10.1136/gut.40.5.634; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VinkvanWijngaarden T, 1996, EUR J CANCER, V32A, P842, DOI 10.1016/0959-8049(95)00647-8; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Warth R, 1999, PFLUG ARCH EUR J PHY, V438, P437, DOI 10.1007/s004240051059; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279, DOI 10.1152/ajpgi.1999.276.5.G1279; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w	97	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47563	47574		10.1074/jbc.M106226200	http://dx.doi.org/10.1074/jbc.M106226200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11551934	hybrid			2022-12-25	WOS:000172768500116
J	Katayama, H; Zhou, H; Li, Q; Tatsuka, M; Sen, S				Katayama, H; Zhou, H; Li, Q; Tatsuka, M; Sen, S			Interaction and feedback regulation between STK15/BTAK/aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED EXPRESSION; CATALYTIC SUBUNIT; HISTONE H3; PHOSPHORYLATION; GENE; CENTROSOME; SPINDLE; ENCODES; TYPE-1; KINETOCHORES	STK15 is an Aurora/Ipl-1 related serine/threonine kinase that is associated with centrosomes and induces aneuploidy when overexpressed in mammalian cells. It is well known that phosphorylation and dephosphorylation of kinases are important for regulation of their activity. But mechanisms by which STR15 activity is regulated have not been elucidated. We report that STK15 contains two functional binding sites for protein phosphatase type 1 (PPI), and the binding of these proteins is cell cycle-regulated peaking at mitosis. Activated STK15 at mitosis phosphorylates PP1 and inhibits PP1 activity in vitro. In vivo, PP1 activity co-immunoprecipitated with STK15 is also reduced. These data indicate that STK15 inhibits PPI activity during mitosis. Also, PPI is shown to dephosphorylate active STK15 and abolish its activity in vitro. Furthermore, we show that non-binding mutants of STK15 for PP1 are superphosphorylated, but their kinase activities are markedly reduced. Cells transfected with these non-binding mutants manifest aberrant chromosome alignment during mitosis. Our results suggest that a feedback regulation through phosphorylation/dephosphorylation events between STK15 kinase and PP1 phosphatase operates through the cell cycle. Deregulation of this balance may contribute to anomalous segregation of chromosomes during mitotic progression of cancer cells.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Hiroshima Univ, Dept Regulatory Radiobiol, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan	University of Texas System; UTMD Anderson Cancer Center; Hiroshima University	Sen, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ssen@mail.mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA061979, U01CA085078, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 16672-24, U01CA85078, CA 61979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BLACK S, 1995, YEAST, V11, P747, DOI 10.1002/yea.320110806; CHAN CSM, 1993, GENETICS, V135, P677; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Roghi C, 1998, J CELL SCI, V111, P557; SAADAT M, 1994, CANCER DETECT PREV, V18, P115; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; SOGAWA K, 1994, RES COMMUN MOL PATH, V85, P359; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VANDRE DD, 1991, J CELL SCI, V98, P577; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	37	167	177	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46219	46224		10.1074/jbc.M107540200	http://dx.doi.org/10.1074/jbc.M107540200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11551964	hybrid			2022-12-25	WOS:000172573100099
J	Richter, G; Hayden-Ledbetter, M; Irgang, M; Ledbetter, JA; Westermann, J; Korner, I; Daemen, K; Clark, EA; Aicher, A; Pezzutto, A				Richter, G; Hayden-Ledbetter, M; Irgang, M; Ledbetter, JA; Westermann, J; Korner, I; Daemen, K; Clark, EA; Aicher, A; Pezzutto, A			Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC CELLS; MOLECULE ICOS; ACTIVATION; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; MACROPHAGES; INHIBITORS; CD4(+); CTLA-4	The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We used soluble ICOSIg and a newly developed murine anti-human ICOS ligand (ICOSL) monoclonal antibody to further characterize the ICOSL during ontogeny of antigen presenting cells. In a previous study, we found that ICOSL is expressed on monocytes, dendritic cells, and B cells. To define when ICOSL is first expressed on myeloid antigen presenting cells, we examined ICOSL expression on CD34(+) cells in bone marrow. We found that CD34(bright) cells regardless of their myeloid commitment were ICOSL-, whereas ICOSL was first expressed when CD34 expression diminished and the myeloid marker CD33 appeared. However, acute myeloid leukemia cells were ICOSL-negative, whereas among B-cell malignancies only some cases of the most mature tumors such as prolymphocytic leukemia and hairy cell leukemia were positive. Next, we investigated purified CD34(+) hematopoietic progenitor cells that did not constitutively express ICOSL but were induced to express ICOSL within 12 h after granulocyte/macrophage colony-stimulating factor/tumor necrosis factor alpha (TNF-alpha) stimulation. Interestingly, ICOSL was induced prior to CD80/CD86 induction on CD34(+) cells so that ICOSL was expressed in the absence of CD80/CD86. This suggests that ICOSL is an early differentiation marker along the monocytic/ dendritic maturation pathway. Induction of ICOSL was dependent on TNF-a and was regulated via NF-kappaB as revealed by use of inhibitors specific for I kappaB alpha phosphorylation such as BAY 11-7082 and BAY 11-7085. The antigen presenting capacity of TNF-alpha stimulated CD34(+) cells was strongly inhibited by ICOSIg fusion proteins or by NF-kappaB inhibition. Thus, TNF-alpha -induced ICOSL expression seemed to be functionally important for the costimulatory capacity of CD34(+) hematopoietic progenitor cells.	Humboldt Univ, Charite, Robert Rossle Klin, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Washington; University of Washington Seattle	Richter, G (corresponding author), Univ Halle Wittenberg, Med Ctr, Dept Pediat, Lab Transplantat Biol, Heinrich Damerow Str 1, D-06120 Halle An Der Saale, Germany.	guenther.richter@medizin.uni-halle.de	Aicher, Alexandra/GZK-8031-2022	Aicher, Alexandra/0000-0002-8920-9577; Pezzutto, Antonio/0000-0002-3246-4470; Clark, Edward A/0000-0001-8061-5475				Aicher A, 2000, J IMMUNOL, V164, P4689, DOI 10.4049/jimmunol.164.9.4689; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Ling V, 2000, J IMMUNOL, V164, P1653, DOI 10.4049/jimmunol.164.4.1653; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; Mapara MY, 1997, BLOOD, V89, P337, DOI 10.1182/blood.V89.1.337.337_337_344; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 1998, IMMUNOL REV, V165, P231; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Oosterwegel MA, 1999, CURR OPIN IMMUNOL, V11, P294, DOI 10.1016/S0952-7915(99)80047-8; Ozkaynak E, 2001, NAT IMMUNOL, V2, P591, DOI 10.1038/89731; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Rondelli D, 1996, BLOOD, V88, P2619, DOI 10.1182/blood.V88.7.2619.bloodjournal8872619; Ryncarz RE, 1998, BLOOD, V91, P3892, DOI 10.1182/blood.V91.10.3892.3892_3892_3900; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Slavik JM, 1999, IMMUNOL RES, V19, P1, DOI 10.1007/BF02786473; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Wallin JJ, 2001, J IMMUNOL, V167, P132, DOI 10.4049/jimmunol.167.1.132; Wang SD, 2000, BLOOD, V96, P2808; Yoshinaga SK, 2000, INT IMMUNOL, V12, P1439, DOI 10.1093/intimm/12.10.1439; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zheng Z, 1998, J EXP CLIN CANC RES, V17, P251	34	44	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45686	45693		10.1074/jbc.M108509200	http://dx.doi.org/10.1074/jbc.M108509200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571308	hybrid			2022-12-25	WOS:000172573100027
J	Heyduk, E; Baichoo, N; Heyduk, T				Heyduk, E; Baichoo, N; Heyduk, T			Interaction of the alpha-subunit of Escherichia coli RNA polymerase with DNA - Rigid body nature of the protein-DNA contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; FACTOR-INDEPENDENT ACTIVATION; FOOTPRINTING TECHNIQUE; RECEPTOR PROTEIN; RRNB P1; COMPLEX-FORMATION; PROMOTER; BINDING; ELEMENT; TRANSCRIPTION	The alpha -subunit of Escherichia coli RNA polymerase plays an important role in the activity of many promoters by providing a direct protein-DNA contact with a specific sequence (UP element) located upstream of the core promoter sequence. To obtain insight into the nature of thermodynamic forces involved in the formation of this protein-DNA contact, the binding of the alpha -subunit of E. coli RNA polymerase to a fluorochrome-labeled DNA fragment containing the rrnB P1 promoter UP element sequence was quantitatively studied using fluorescence polarization. The alpha dimer and DNA formed a 1:1 complex in solution. Complex formation at 25 degreesC was enthalpy-driven, the binding was accompanied by a net release of 1-2 ions, and no significant specific ion effects were observed. The van't Hoff plot of temperature dependence of binding was linear suggesting that the heat capacity change (Deltac(p)) was close to zero. Protein footprinting with hydroxyradicals showed that the protein did not change its conformation upon protein-DNA contact formation. No conformational changes in the DNA molecule were detected by CD spectroscopy upon protein-DNA complex formation. The thermodynamic characteristics of the binding together with the lack of significant conformational changes in the protein and in the DNA suggested that the alpha -subunit formed a rigid body-like contact with the DNA in which a tight complementary recognition interface between alpha -subunit and DNA was not formed.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@slu.edu			NIGMS NIH HHS [GM50514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM050514, R01GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baichoo N, 1999, J MOL BIOL, V290, P37, DOI 10.1006/jmbi.1999.2858; Baichoo N, 1999, PROTEIN SCI, V8, P518; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; ELLINGER T, 1994, J MOL BIOL, V239, P466, DOI 10.1006/jmbi.1994.1389; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; HALFMAN CJ, 1972, BIOCHEMISTRY-US, V11, P3493, DOI 10.1021/bi00768a025; Hard T, 1996, BIOPHYS CHEM, V62, P121, DOI 10.1016/S0301-4622(96)02197-7; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Heyduk T, 2001, MET IONS BIOL SYST, V38, P255; IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109; IVANOV VI, 1995, J MOL BIOL, V245, P228, DOI 10.1006/jmbi.1994.0019; Jen-Jacobson L, 2000, STRUCTURE, V8, P1015, DOI 10.1016/S0969-2126(00)00501-3; Jen-Jacobson L, 2000, SUPRAMOL CHEM, V12, P143, DOI 10.1080/10610270008027446; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1996, EMBO J, V15, P4358, DOI 10.1002/j.1460-2075.1996.tb00809.x; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Riccelli PV, 1999, BIOCHEMISTRY-US, V38, P11197, DOI 10.1021/bi9904407; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Strainic MG, 1998, BIOCHEMISTRY-US, V37, P18074, DOI 10.1021/bi9813431; Tagami H, 1999, P NATL ACAD SCI USA, V96, P7202, DOI 10.1073/pnas.96.13.7202; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	39	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44598	44603		10.1074/jbc.M107760200	http://dx.doi.org/10.1074/jbc.M107760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571305	hybrid			2022-12-25	WOS:000172406700036
J	Paramio, JM; Segrelles, C; Ruiz, S; Martin-Caballero, J; Page, A; Martinez, J; Serrano, M; Jorcano, JL				Paramio, JM; Segrelles, C; Ruiz, S; Martin-Caballero, J; Page, A; Martinez, J; Serrano, M; Jorcano, JL			The ink4/arf tumor suppressors cooperate with p21(cip1/waf) in the processes of mouse epidermal differentiation, senescence, and carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA GENE FAMILY; REPLICATIVE SENESCENCE; CDK INHIBITORS; SKIN CARCINOGENESIS; MICE LACKING; TERMINAL DIFFERENTIATION; MALIGNANT CONVERSION; HUMAN FIBROBLASTS; ONCOGENIC RAS	In mammalian cells, cell cycle withdrawal is a prerequisite for terminal differentiation. Accordingly, in most tissues, including epidermis, the expression of the cyclin-dependent kinase inhibitors increases during differentiation. However, the actual role of cyclin-dependent kinase inhibitors is unclear. Different aspects of epidermal growth and differentiation in ink4a(Delta2,3)-null, p21-null, and ink4a(Delta2,3)/p21-doubly deficient mice were studied. Altered differentiation and decreased age-related senescence were found in the epidermis of ink4a(Delta2,3)/p21-null mice and, to a lesser extent, in ink4a(Delta2,3)- and p21-null mice. inh4a(Delta2,3)/p21-null primary keratinocytes underwent cell cycle arrest upon calcium or transforming growth factor-P treatment, but failed to differentiate. This differentiation deficiency was not observed in p21-or ink4a(Delta2,3) -deficient keratinocytes. Upon infection with a v-Ha-ras-coding retrovirus, wild-type keratinocytes displayed features indicative of premature cell senescence. In p21- or ink4a(Delta2,3)-deficient keratinocytes, only a partial response was observed. ink4a(Delta2,3)/p21-deficient keratinocytes did not display senescent features, but showed increased tumorigenic potential upon injection into nude mice. These results indicate that ink4a/ arf and cip1/waf genes cooperate to allow normal keratinocyte differentiation and that the absence of both favors malignant transformation.	CIEMAT, Cell Mol Biol & Gene Therapy Project, E-28040 Madrid, Spain; Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Paramio, JM (corresponding author), CIEMAT, Cell Mol Biol & Gene Therapy Project, Avenida Complutense 22, E-28040 Madrid, Spain.		Serrano, Manuel/H-2634-2015; Segrelles, Carmen/E-3655-2016; Paramio, Jesus M/M-8482-2014; Ruiz, Sergio/G-1561-2016	Serrano, Manuel/0000-0001-7177-9312; Segrelles, Carmen/0000-0001-9340-2102; Paramio, Jesus M/0000-0001-7520-3177; Ruiz, Sergio/0000-0002-0177-6965; Page, Angustias/0000-0002-0231-8536				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BRISSETTE J, 1992, MOL CARCINOGEN, V7, P21; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hara E, 1996, MOL CELL BIOL, V16, P859; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Harvat BL, 1998, J CELL SCI, V111, P1185; HARVEY M, 1993, ONCOGENE, V8, P2457; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Loughran O, 1996, ONCOGENE, V13, P561; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paramio JM, 2000, MOL CARCINOGEN, V29, P251, DOI 10.1002/1098-2744(200012)29:4<251::AID-MC1007>3.0.CO;2-O; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sayama K, 1999, J CELL PHYSIOL, V179, P40, DOI 10.1002/(SICI)1097-4652(199904)179:1<40::AID-JCP5>3.0.CO;2-Z; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Weinberg WC, 1999, CANCER RES, V59, P2050; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	59	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44203	44211		10.1074/jbc.M105650200	http://dx.doi.org/10.1074/jbc.M105650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551927	hybrid			2022-12-25	WOS:000172297700092
J	Wang, LQ; Wu, Q; Qiu, P; Mirza, A; McGuirk, M; Kirschmeier, P; Greene, JR; Wang, YL; Pickett, CB; Liu, SX				Wang, LQ; Wu, Q; Qiu, P; Mirza, A; McGuirk, M; Kirschmeier, P; Greene, JR; Wang, YL; Pickett, CB; Liu, SX			Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; EXPRESSION; PROMOTER; CELLS; TRANSACTIVATION; REPRESSION; APOPTOSIS; SEQUENCE; ELEMENT; BINDS	The completion of the human genome sequence (International Human Genome Sequence Consortium (2001) Nature 409, 860-921; Venter, J. C., et al (2001) Science 291, 1304-1351) allows for new ways to analyze global cellular regulatory mechanisms. Here we present a strategy to identify genes regulated by specific transcription factors in the human genome, and apply it to p53. We first collected promoters or introns of all genes available using two methods: GenBank (TM) annotation and a computationally derived transcript map. 4,852 genes analyzed in this way contained at least one p53 consensus binding sequence. Of 13 genes randomly selected for mRNA analysis, 11 were shown to respond to p53 expression. Five promoters were analyzed by chromatin immunoprecipitation, which revealed that all were bound by p53 in vivo. We then analyzed 33,615 unique human genes on cDNA microarrays, identifying 1,501 genes that respond to p53 expression. A parameter was derived that demonstrates that in silico prediction greatly enriches for genes that are activated and repressed by p53 and assists us to suggest other signaling pathways that may be connected to p53. The methods shown here illustrate a novel approach to analysis of global gene regulatory network through the integration of human genomic sequence information and genome-wide gene expression analysis.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Human Genom Res Dept, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Liu, SX (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA.	suxing.liu@spcorp.com						Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Daemen MARC, 2000, CIRCULATION, V102, P1420, DOI 10.1161/01.CIR.102.12.1420; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrer FA, 2000, J UROLOGY, V164, P1016, DOI 10.1016/S0022-5347(05)67240-0; FRANK SR, 2001, IN PRESS GENES DEV; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Hasegawa T, 1998, GROWTH HORM IGF RES, V8, P277, DOI 10.1016/S1096-6374(98)80122-6; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JUVEN T, 1993, ONCOGENE, V8, P3411; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SAMATAR A, 2001, ONCOGENOMICS DISSECT, P84; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wen SF, 2000, CANCER GENE THER, V7, P1469, DOI 10.1038/sj.cgt.7700257; YAGINUMA Y, 1992, CANCER RES, V52, P4196	36	132	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43604	43610		10.1074/jbc.M106570200	http://dx.doi.org/10.1074/jbc.M106570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571296	hybrid			2022-12-25	WOS:000172297700018
J	Cain, K; Langlais, C; Sun, XM; Brown, DG; Cohen, GM				Cain, K; Langlais, C; Sun, XM; Brown, DG; Cohen, GM			Physiological concentrations of K+ inhibit cytochrome c-dependent formation of the apoptosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT CASPASE CASCADES; MEDIATED OLIGOMERIZATION; NEGATIVE REGULATION; APAF-1 APOPTOSOME; ACTIVATION; PROCASPASE-9; PROTEASE; BINDING; COMPLEX; RECEPTOR	In many forms of apoptosis, cytochrome c released from mitochondria induces the oligomerization of Apaf-1 to form a caspase-activating apoptosome complex. Activation of lysates in vitro with dATP and cytochrome c results in the formation of an active caspase-processing similar to 700-kDa apoptosome complex, which predominates in apoptotic cells, and a relatively inactive similar to1.4-MDa complex. We now demonstrate that assembly of the active complex is suppressed by normal intracellular concentrations of K+. Using a defined apoptosome reconstitution system with recombinant Apaf-1 and cytochrome c, K+ also inhibits caspase activation by abrogating Apaf-1 oligomerization and apoptosome assembly. Once assembled, the apoptosome is relatively insensitive to the effects of ionic strength and processes/activates effector caspases. The inhibitory effects of K+ on apoptosome formation are antagonized in a concentration-dependent manner by cytochrome c. These studies support the hypothesis that the normal intracellular concentrations of K+ act to safeguard the cell against inappropriate formation of the apoptosome complex, caused by the inadvertent release of small amounts of cytochrome c. Thus, the assembly and activation of the apoptosome complex in the cell requires the rapid and extensive release of cytochrome c to overcome the inhibitory effects of normal intracellular concentrations of K+.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cain, K (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.		Cohen, Gerald M/A-1687-2008					Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hampton MB, 1998, BIOCHEM J, V329, P95; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Purring C, 1999, J AM CHEM SOC, V121, P7435, DOI 10.1021/ja991235h; Purring-Koch C, 2000, P NATL ACAD SCI USA, V97, P11928, DOI 10.1073/pnas.220416197; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Thompson GJ, 2001, BIOCHEM J, V357, P137, DOI 10.1042/0264-6021:3570137; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu TN, 2001, J BIOL CHEM, V276, P13034, DOI 10.1074/jbc.M009773200; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	38	156	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41985	41990		10.1074/jbc.M107419200	http://dx.doi.org/10.1074/jbc.M107419200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553634	hybrid			2022-12-25	WOS:000172450400060
J	Dodt, G; Warren, D; Becker, E; Rehling, P; Gould, SJ				Dodt, G; Warren, D; Becker, E; Rehling, P; Gould, SJ			Domain mapping of human PEX5 reveals functional and structural similarities to Saccharomyces cerevisiae Pex18p and Pex21p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL TARGETING SIGNAL; RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; PROTEIN IMPORT; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE; CAENORHABDITIS-ELEGANS; MUTATIONAL ANALYSIS; ZELLWEGER-SYNDROME; MATRIX PROTEINS; LONGER ISOFORM	PEX5 functions as an import receptor for proteins with the type-1 peroxisomal targeting signal (PTS1). Although PEX5 is not involved in the import of PTS2-targeted proteins in yeast, it is essential for PTS2 protein import in mammalian cells. Human cells generate two isoforms of PEX5 through alternative splicing, PEX5S and PEX5L, and PEX5L contains an additional insert 37 amino acids long. Only one isoform, PEX5L, is involved in PTS2 protein import, and PEX5L physically interacts with PEX7, the import receptor for PTS2-containing proteins. In this report we map the regions of human PEX5L involved in PTS2 protein import, PEX7 interaction, and targeting to peroxisomes. These studies revealed that amino acids 1-230 of PEX5L are required for PTS2 protein import, amino acids 191-222 are sufficient for PEX7 interaction, and amino acids 1-214 are sufficient for targeting to peroxisomes. We also identified a 21-amino acid-long peptide motif of PEX5L, amino acids 209-229, that overlaps the regions sufficient for fall PTS2 rescue activity and PEX7 interaction and is shared by Saccharomyces cerevisiae Pex18p and Pex21p, two yeast peroxins that act only in PTS2 protein import in yeast. A mutation in PEX5 that changes a conserved serine of this motif abrogates PTS2 protein import in mammalian cells and reduces the interaction of PEX5L and PEX7 in vitro. This peptide motif also lies within regions of Pex18p and Pex21p that interact with yeast PEX7. Based on these and other results, we propose that mammalian PEX5L may have acquired some of the functions that yeast Pex18p and/or Pex21p perform in PTS2 protein import. This hypothesis may explain the essential role of PEX51, in PTS2 protein import in mammalian cells and its lack of importance for PTS2 protein import in yeast.	Ruhr Univ Bochum, Inst Physiol, D-44801 Bochum, Germany; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	Ruhr University Bochum; Johns Hopkins University; University of Freiburg	Dodt, G (corresponding author), Ruhr Univ Bochum, Inst Physiol, Univ Str 150, D-44801 Bochum, Germany.	gabriele.dodt@ruhr-uni-bochum.de						Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Amery L, 1998, BIOCHEM J, V336, P367, DOI 10.1042/bj3360367; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; BLATTNER J, 1995, FEBS LETT, V360, P310, DOI 10.1016/0014-5793(95)00128-V; BRAVERMAN N, 1995, HUM MOL GENET, V4, P1791, DOI 10.1093/hmg/4.suppl_1.1791; Braverman N, 2000, GENOMICS, V63, P181, DOI 10.1006/geno.1999.6080; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; Brites P, 1998, J INHERIT METAB DIS, V21, P306, DOI 10.1023/A:1005301112923; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Chang CC, 1999, J CELL SCI, V112, P1579; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; de Walque S, 1999, MOL BIOCHEM PARASIT, V104, P107, DOI 10.1016/S0166-6851(99)00144-9; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; FUNG K, 1991, MOL BIOCHEM PARASIT, V45, P261, DOI 10.1016/0166-6851(91)90093-L; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ., 2001, METABOLIC MOL BASES, P3181; Gurvitz A, 2000, YEAST, V17, P188, DOI 10.1002/1097-0061(20000930)17:3<188::AID-YEA27>3.0.CO;2-E; HANSEN H, 1992, MOL GEN GENET, V235, P269, DOI 10.1007/BF00279370; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Jardim A, 2000, J BIOL CHEM, V275, P13637, DOI 10.1074/jbc.275.18.13637; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Jones JM, 2000, J BIOL CHEM, V275, P12590, DOI 10.1074/jbc.275.17.12590; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Kragler F, 1998, P NATL ACAD SCI USA, V95, P13336, DOI 10.1073/pnas.95.22.13336; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Luo Y, 1997, BIOTECHNIQUES, V22, P350, DOI 10.2144/97222pf02; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Moser HW, 1999, MOL GENET METAB, V68, P316, DOI 10.1006/mgme.1999.2926; Motley AM, 2000, EMBO REP, V1, P40, DOI 10.1093/embo-reports/kvd010; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Portsteffen H, 1997, NAT GENET, V17, P449, DOI 10.1038/ng1297-449; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Purdue PE, 1998, J CELL BIOL, V143, P1859; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 1999, BIOCHEM BIOPH RES CO, V262, P504, DOI 10.1006/bbrc.1999.1232; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 1999, NEUROCHEM RES, V24, P565, DOI 10.1023/A:1022592014988; Warren DS, 2000, HUM MUTAT, V15, P509, DOI 10.1002/1098-1004(200006)15:6<509::AID-HUMU3>3.0.CO;2-#; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Will GK, 1999, MOL CELL BIOL, V19, P2265; Wimmer C, 1998, PLANT J, V16, P453, DOI 10.1046/j.1365-313x.1998.00320.x; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	89	94	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41769	41781		10.1074/jbc.M106932200	http://dx.doi.org/10.1074/jbc.M106932200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546814	hybrid			2022-12-25	WOS:000172450400032
J	Mohammadi, K; Kometiani, P; Xie, ZJ; Askari, A				Mohammadi, K; Kometiani, P; Xie, ZJ; Askari, A			Role of protein kinase C in the signal pathways that link Na+/K+-ATPase to ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; TRANSDUCING FUNCTION; K+-ATPASE; DIFFERENTIAL REGULATION; ISOFORM EXPRESSION; INDUCED ACTIVATION; OUABAIN; INHIBITION; PHOSPHORYLATION; HYPERTROPHY	We have shown before that Na+/K+-ATPase acts as a signal transducer, through protein-protein interactions, in addition to being an ion pump. Interaction of ouabain with the enzyme of the intact cells causes activation of Src, transactivation of EGFR, and activation of the Ras/ERK1/2 cascade. To determine the role of protein kinase C (PKC) in this pathway, neonatal rat cardiac myocytes were exposed to ouabain and assayed for translocation/activation of PKC from cytosolic to particulate fractions. Ouabain caused rapid and sustained stimulation of this translocation, evidenced by the assay of Ca2+-dependent and Ca2+-independent PKC activities and by the immunoblot analysis of the alpha, delta, and epsilon isoforms of PKC. Dose-dependent stimulation of PKC translocation by ouabain (1-100 mum) was accompanied by no more than 50% inhibition of Na+/K+-ATPase and doubling of [Ca2+](i), changes that do not affect myocyte viability and are known to be associated with positive inotropic, but not toxic, effects of ouabain in rat cardiac ventricles. Ouabain-induced activation of ERK1/2 was blocked by PKC inhibitors calphostin C and chelerythrine. An inhibitor of phosphoinositide turnover in myocytes also antagonized ouabain-induced PKC translocation and ERK1/2 activation. These and previous findings indicate that ouabain-induced activation of PKC and Ras, each linked to Na+/K+-ATPase through Src/EGFR, are both required for the activation of ERK1/2. Ouabain-induced PKC translocation and ERK1/2 activation were dependent on the presence of Ca2+ in the medium, suggesting that the signal-transducing and ion-pumping functions of Na+/K+-ATPase cooperate in activation of these protein kinases and the resulting regulation of contractility and growth of the cardiac myocyte.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Askari, A (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	mheck@mco.edu			NHLBI NIH HHS [HL-63238, HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL063238] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1976, LIFE SCI, V18, P135, DOI 10.1016/0024-3205(76)90017-5; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CLERK A, 1994, J BIOL CHEM, V269, P32848; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; GOTOH H, 1993, BIOCHEM BIOPH RES CO, V194, P72, DOI 10.1006/bbrc.1993.1786; GRUPP G, 1984, P SOC EXP BIOL MED, V175, P39; GUSOVSKY F, 1986, P NATL ACAD SCI USA, V83, P3003, DOI 10.1073/pnas.83.9.3003; Haas M, 2000, J BIOL CHEM, V275, P27832; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HO AK, 1987, BIOCHEM BIOPH RES CO, V142, P819, DOI 10.1016/0006-291X(87)91487-2; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; Jiang TR, 1996, CIRC RES, V78, P553, DOI 10.1161/01.RES.78.4.553; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Kometiani P, 2001, AM J PHYSIOL-HEART C, V280, pH1415, DOI 10.1152/ajpheart.2001.280.3.H1415; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2000, J BIOL CHEM, V275, P27838; Lundmark JL, 1999, AM J PHYSIOL-HEART C, V277, pH999, DOI 10.1152/ajpheart.1999.277.3.H999; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; Mohammadi K, 1997, J MOL CELL CARDIOL, V29, P1687, DOI 10.1006/jmcc.1997.0411; Mohammadi K, 2000, BIOPHYS J, V78, p79A; Mohammadi K, 2001, FASEB J, V15, pA443; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; Naruse K, 2000, CIRC RES, V86, P1104; Nicolas JM, 1998, J MOL CELL CARDIOL, V30, P2591, DOI 10.1006/jmcc.1998.0816; OTANI H, 1989, MOL CELL BIOCHEM, V90, P111; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RouetBenzineb P, 1996, CIRC RES, V79, P153, DOI 10.1161/01.RES.79.2.153; Rybin V, 1996, CIRC RES, V79, P388, DOI 10.1161/01.RES.79.3.388; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwartz A, 1988, Prog Clin Biol Res, V268B, P321; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; STEMMER P, 1988, BIOCHIM BIOPHYS ACTA, V940, P188, DOI 10.1016/0005-2736(88)90194-0; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; THOMAS TP, 1987, METHOD ENZYMOL, V141, P399; Tian J, 2001, AM J PHYSIOL-HEART C, V281, pH1899, DOI 10.1152/ajpheart.2001.281.5.H1899; WARD CA, 1992, J MOL CELL CARDIOL, V24, P937, DOI 10.1016/0022-2828(92)91861-X; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323	52	115	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42050	42056		10.1074/jbc.M107892200	http://dx.doi.org/10.1074/jbc.M107892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11562372	hybrid			2022-12-25	WOS:000172450400069
J	Nishi, H; Senoo, M; Nishi, KH; Murphy, B; Rikiyama, T; Matsumura, Y; Habu, S; Johnson, AC				Nishi, H; Senoo, M; Nishi, KH; Murphy, B; Rikiyama, T; Matsumura, Y; Habu, S; Johnson, AC			p53 homologue p63 represses epidermal growth factor receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-LINES; P53-RELATED PROTEIN; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; BINDING FACTOR; RETINOIC ACID; HUMAN CANCERS; TRANSCRIPTION; PROMOTER	Tumor suppressor p53 has been shown to transactivate epidermal growth factor receptor (EGFR) expression through binding to a putative p53 responsive element in the EGFR promoter between nucleotides -265 and -239 (EGFRp53RE). Isotypes of p63 gene products, recently identified as p53 relatives, have a similar function to transactivate several p53 target gene promoters. However, our results indicate that TAp63 gamma has a very low ability to bind to the EGFRp53RE and surprisingly represses both basal EGFR promoter activity and e dogenous EGFR expression. Transient transfection a says show that the EGFR promoter region between -348 and -293, containing two Sp1 sites, is crucial for the repression of the EGFR expression by TAp63 gamma. Mutations in these Spl sites in the reporter constructs result in loss of the TAp63 gamma repression effect. We further show that TAp63 gamma directly interacts with Sp1 by immunoprecipitation analysis and that TAp63 gamma impairs Spl binding to the target DNA site in electrophoretic mobility shift assays. These results suggest that TAp63 gamma is involved in the regulation of the EGFR gene expression through interactions with basal transcription factors.	NCI, Mol Biol Lab, CCR, NIH, Bethesda, MD 20892 USA; Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 25911, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tokai University	Johnson, AC (corresponding author), NCI, Mol Biol Lab, CCR, NIH, Bldg 37,Rm 2D18,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.		nishi, Hiroaki/X-7736-2019	nishi, Hiroaki/0000-0002-6331-2947; Senoo, Makoto/0000-0002-0155-0683	NATIONAL CANCER INSTITUTE [Z01BC008000] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Augustin M, 1998, MAMM GENOME, V9, P899, DOI 10.1007/s003359900891; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHEN LL, 1993, CELL GROWTH DIFFER, V4, P975; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hagiwara K, 1999, CANCER RES, V59, P4165; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOU XY, 1994, CELL GROWTH DIFFER, V5, P801; HOU XY, 1994, J BIOL CHEM, V269, P4307; Hudson L G, 1991, Genet Eng (N Y), V13, P137; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931; Johnson AC, 1996, J BIOL CHEM, V271, P3033; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Lee LA, 1999, J INVEST DERMATOL, V113, P146, DOI 10.1046/j.1523-1747.1999.00651.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Merlino G T, 1990, Semin Cancer Biol, V1, P277; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Nishi H, 1999, INT J ONCOL, V15, P1149; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; PERREM K, 1995, ONCOGENE, V11, P1299; Reed AL, 1998, J BIOL CHEM, V273, P21594, DOI 10.1074/jbc.273.34.21594; Rubinstein YR, 1998, FEBS LETT, V431, P268, DOI 10.1016/S0014-5793(98)00774-1; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shimada A, 1999, CANCER RES, V59, P2781; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	63	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41717	41724		10.1074/jbc.M101241200	http://dx.doi.org/10.1074/jbc.M101241200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546792	hybrid			2022-12-25	WOS:000172450400025
J	St Onge, RP; Besley, BDA; Park, M; Casselman, R; Davy, S				St Onge, RP; Besley, BDA; Park, M; Casselman, R; Davy, S			DNA damage-dependent and -independent phosphorylation of the hRad9 checkpoint protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; HUMAN HOMOLOG; FAMILY MEMBERS; SLIDING CLAMP; CONTROL GENE; ATM KINASE; RAD9; COMPLEX	Cell cycle checkpoints are regulatory mechanisms that maintain genomic integrity by preventing cell cycle progression when genetic anomalies are present. The hRad9 protein is the human homologue of Schizosaccharomyces pombe Rad9, a checkpoint protein required for preventing the onset of mitosis if DNA damage is present or if DNA replication is incomplete. Genetic and biochemical analyses indicate that hRad9 is a component of the checkpoint response in humans and has possible roles in regulating the cell cycle, apoptosis, and DNA repair. Previous studies indicate that hRad9 is modified by phosphorylation, both in the absence of exogenous stress and in response to various genotoxins. In this study, we report the mapping of several sites of constitutive phosphorylation of hRad9 to (S/T)PX(R/P) sequences near the C terminus of the protein. We also demonstrate that a serine to alanine mutation at residue 272 abrogates an ionizing radiation (IR)-induced phosphorylation of hRad9 and further show that phosphorylation at (S/T)P sites is not a prerequisite for IR-induced phosphorylation of serine 272. Finally, we report that hRad9 undergoes cell cycle-regulated hyper-phosphorylation in G(2)/M that is enhanced by IR but distinct from that on serine 272. Unlike the IR-induced phosphorylation at serine 272, this event is dependent on serine 277 and threonine 292, two C-terminal (S/T)P sites in hRad9.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Oncol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada	Davy, S (corresponding author), Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada.				PHS HHS [E507940] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chen JJ, 2000, CANCER RES, V60, P5037; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LOEB LA, 1991, CANCER RES, V51, P3075; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	46	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41898	41905		10.1074/jbc.M105152200	http://dx.doi.org/10.1074/jbc.M105152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551919	hybrid			2022-12-25	WOS:000172450400048
J	Zhang, LJ; Beeler, DL; Lawrence, R; Lech, M; Liu, J; Davis, JC; Shriver, Z; Sasisekharan, R; Rosenberg, RD				Zhang, LJ; Beeler, DL; Lawrence, R; Lech, M; Liu, J; Davis, JC; Shriver, Z; Sasisekharan, R; Rosenberg, RD			6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HAMSTER OVARY CELLS; ANTITHROMBIN-BINDING SEQUENCE; EMBRYONAL CARCINOMA-CELLS; HUMAN CDNAS; PROTEOGLYCANS; MUTANTS; RESIDUES; EXPRESSION; ACID	Using recombinant retroviral transduction, we have introduced the heparin/heparan sulfate (HS) 3-O-sulfotransferase I (3-OST-1) gene into Chinese hamster ovary (CHO) cells. Expression of 3-OST-1 confers upon CHO cells the ability to produce anticoagulantly active HS (HSact). To understand how 6-OST and other proteins regulate HSact biosynthesis, a CHO cell clone with three copies of 3-OST-1 was chemically mutagenized. Resulting mutants that make HS but are defective in generating HSact were single-cell-cloned. One cell mutant makes fewer 6-O-sulfated residues. Modification of HS chains from the mutant with pure 6-OST-1 and 3'-phosphoadenosine 5'-phosphosulfate increased HSact from 7% to 51%. Transfection of this mutant with 6-OST-1 created a CHO cell line that makes HS, 50% of which is HSact. We discovered in this study that M 6-OST-1 is a limiting enzyme in the HSact biosynthetic pathway in vivo when the limiting nature of 3-OST-1 is removed; (ii) HS chains from the mutant cells serve as an excellent substrate for demonstrating that 6-OST-1 is the limiting factor for Hs(act) generation in vitro; (iii) in contradiction to the literature, 6-OST-1 can add 6-O-sulfate to GlcNAc residues, especially the critical 6-O-sulfate in the antithrombin binding motif; (iv) both 3-O- and 6-O-sulfation can be the final step in HSact biosynthesis in contrast to prior publications that concluded 3-O-sulfation is the final step in HSact biosynthesis; (v), in the presence of HS interacting protein peptide, 3-O-sulfate-containing sugars can be degraded into disaccharides by heparitinase digestion as demonstrated by capillary high performance liquid chromatography coupled with mass spectrometry.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Div Bioengn, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, BIDMC, Dept Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Bldg 68-480, Cambridge, MA 02139 USA.	rdrrosen@mit.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [5-P01-HL41484, 5-R01-HL-58479] Funding Source: Medline; NIGMS NIH HHS [GM-50573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Conrad H. E., 1998, HEPARIN BINDING PROT; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Lindqvist C, 1999, SKANDINAVISTIK, V29, P1; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu SC, 1997, P NATL ACAD SCI USA, V94, P1739, DOI 10.1073/pnas.94.5.1739; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Rostand KS, 1997, INFECT IMMUN, V65, P1; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Wei G, 2000, J BIOL CHEM, V275, P27733; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; Zaia J, 2001, ANAL CHEM, V73, P233, DOI 10.1021/ac000777a; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	42	62	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42311	42321		10.1074/jbc.M101441200	http://dx.doi.org/10.1074/jbc.M101441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551899	hybrid			2022-12-25	WOS:000172450400102
J	DeSalle, LM; Latres, E; Lin, D; Graner, E; Montagnoli, A; Baker, RT; Pagano, M; Loda, M				DeSalle, LM; Latres, E; Lin, D; Graner, E; Montagnoli, A; Baker, RT; Pagano, M; Loda, M			The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein	ONCOGENE			English	Article						Unp; retinoblastoma; isopeptidase; ubiquitin	FAT FACETS GENE; DEUBIQUITINATING ENZYME; MOUSE GENE; DEGRADATION; EXPRESSION; ENCODES; PROTOONCOGENE; ISOPEPTIDASE; PROTEASOME; SEQUENCES	The ubiquitin pathway is involved in the proteolytic turnover of many short-lived cellular regulatory proteins. Since selective degradation of substrates of this system requires the covalent attachment of a polyubiquitin chain to the substrates, degradation could be counteracted by de-ubiquitinating enzymes (or isopeptidases) which selectively remove the polyubiquitin chain. Unp is a human isopeptidase with still poorly understood biological functions. Here, we show that cellular Unp specifically interacts with the retinoblastoma gene product (pRb).	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Caplan Comprehens Canc Ctr, New York, NY 10016 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Harvard University; Dana-Farber Cancer Institute; New York University; New York University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Australian National University; John Curtin School of Medical Research	Pagano, M (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.		Graner, Edgard/K-4411-2012; Graner, Edgard/P-4651-2019	Graner, Edgard/0000-0002-4737-7935; pagano, michele/0000-0003-3210-2442; Lin, Douglas/0000-0003-0105-9760	NATIONAL CANCER INSTITUTE [R01CA076584, R01CA081755, P30CA016087, R21CA066229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1-CA81755, R21-CA66229, P30-CA16087, R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gilchrist CA, 1997, J BIOL CHEM, V272, P32280, DOI 10.1074/jbc.272.51.32280; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Isaksson A, 1997, MECH DEVELOP, V68, P59, DOI 10.1016/S0925-4773(97)00126-3; KANAIAZUMA M, 2000, MECH DEVELOP, V68, P59; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; PAGANO M, 1992, EMBO J, V11, P761; PAGANO M, 1995, CELL CYCLE MAT METHO, P271; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wood SA, 1997, MECH DEVELOP, V63, P29, DOI 10.1016/S0925-4773(97)00672-2; Wu ZR, 1999, DEV GENET, V25, P312, DOI 10.1002/(SICI)1520-6408(1999)25:4<312::AID-DVG5>3.0.CO;2-Z	29	29	34	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5538	5542		10.1038/sj.onc.1204824	http://dx.doi.org/10.1038/sj.onc.1204824			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571652				2022-12-25	WOS:000170781100015
J	Ma, YP; Li, DW; Chai, L; Luciani, AM; Ford, D; Morgan, J; Maizel, AL				Ma, YP; Li, DW; Chai, L; Luciani, AM; Ford, D; Morgan, J; Maizel, AL			Cloning and characterization of two promoters for the human HSAL2 gene and their transcriptional repression by the Wilms tumor suppressor gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOWNES-BROCKS-SYNDROME; ZINC-FINGER PROTEIN; HOMEOTIC GENE; DROSOPHILA EMBRYO; DNA METHYLATION; SPALT; EXPRESSION; HEDGEHOG; REGION; CANCER	HSAL2 is a member of a gene family that encodes a group of putative developmental transcription factors. The HSAL gene complex was originally identified on the basis of DNA sequence homology to a region-specific homeotic gene (SAL) in Drosophila. This study reveals a novel, functional 5' exon for HSAL2 and demonstrates that two distinct HSAL2 gene transcripts arise from two overlapping transcription units, resulting in proteins that differ by 25 amino acids. By utilizing functional luciferase reporter assays, two distinct promoters for HSAL2, P1 for the proximal promoter (upstream of exon 1) and P2 for the distal promoter (upstream of exon 1A), were identified. Evaluation of mRNA prevalence and tissue specificity, with particular focus on adult tissues, revealed that production of mRNA from P1 was selective and relatively rare. Production of mRNA from P2 was demonstrably higher and was expressed by a greater number of tissues. In contradistinction, HSAL2 expression directed by P2 was undetectable in some malignant populations as opposed to their normal human counterparts, suggesting a potential role as a tumor suppressor gene. Consensus-binding sites were identified for several transcriptional factors, with multiple sites for WT-1, and Hox-1.3 present within both the P1 and P2 regions. In transient transfection assays, transcription from both HSAL2 P1 and P2 was strikingly repressed by the WT-1 tumor suppressor protein. These findings suggest that an intracellular WT-1/HSAL2 pathway may play a role in development and hematopoiesis.	Boston Univ, Sch Med, Dept Pathol, Roger Williams Med Ctr, Providence, RI 02908 USA; Rhode Isl Hosp, Dept Pathol, Providence, RI 02903 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Boston University; Roger Williams Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital; Harvard University; Harvard Medical School	Maizel, AL (corresponding author), Boston Univ, Sch Med, Dept Pathol, Roger Williams Med Ctr, 825 Chalkstone Ave, Providence, RI 02908 USA.			Chai, Li/0000-0003-1937-4750	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049649] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-49649] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bandera CA, 1997, CANCER RES, V57, P513; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DRESSLER GR, 1995, SEMIN NEPHROL, V15, P263; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GLEAVE ME, 1993, CANCER RES, V53, P5300; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Hollemann T, 1996, MECH DEVELOP, V55, P19, DOI 10.1016/0925-4773(95)00485-8; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; Ingham PW, 1998, CURR OPIN GENET DEV, V8, P88, DOI 10.1016/S0959-437X(98)80067-1; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kohlhase J, 1999, GENOMICS, V62, P216, DOI 10.1006/geno.1999.6005; Kohlhase J, 1999, AM J HUM GENET, V64, P435, DOI 10.1086/302238; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Kohlhase J, 2000, MAMM GENOME, V11, P64, DOI 10.1007/s003350010012; Koster R, 1997, DEVELOPMENT, V124, P3147; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LI D, 2001, IN PRESS P NATL ACAD; Ma YP, 2001, PEDIATR NEPHROL, V16, P701, DOI 10.1007/s004670100624; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Ott T, 1996, MECH DEVELOP, V56, P117, DOI 10.1016/0925-4773(96)00516-3; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Schmutte C, 1998, BIOL CHEM, V379, P377; Stayner CK, 1998, J BIOL CHEM, V273, P25472, DOI 10.1074/jbc.273.39.25472; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135	37	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48223	48230		10.1074/jbc.M106468200	http://dx.doi.org/10.1074/jbc.M106468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11577094	hybrid			2022-12-25	WOS:000172927000065
J	Ferri-Fioni, ML; Schmitt, E; Soutourina, J; Plateau, P; Mechulam, Y; Blanquet, S				Ferri-Fioni, ML; Schmitt, E; Soutourina, J; Plateau, P; Mechulam, Y; Blanquet, S			Structure of crystalline D-Tyr-tRNA(Tyr) deacylase - A representative of a new class of tRNA-dependent hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN; REFINEMENT; RESOLUTION; METABOLISM; REJECTION; ISOLEUCYL; METHIONYL	Cell growth inhibition by several D-amino acids can be explained by an in vivo production Of D-aminoacyl-tRNA molecules. Escherichia coli and yeast cells express an enzyme, D-Tyr-tRNA(Tyr) deacylase, capable of recycling such D-aminoacyl-tRNA molecules into free tRNA and D-amino acid. Accordingly, upon inactivation of the genes of the above deacylases, the toxicity Of D-amino acids increases. Orthologs of the deacylase are found in many cells. In this study, the crystallographic structure of dimeric E. coli D-Tyr-tRNA(Tyr) deacylase at 1.55 Angstrom resolution is reported. The structure corresponds to a beta -barrel closed on one side by a beta -sheet lid. This barrel results from the assembly of the two subunits. Analysis of the structure in relation with sequence homologies in the orthologous family suggests the location of the active sites at the carboxy end of the beta -strands. The solved structure markedly differs from those of all other documented tRNA-dependent hydrolases.	Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris	Blanquet, S (corresponding author), Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France.		Mechulam, Yves/F-3313-2019; SCHMITT, Emmanuelle/F-2605-2019; Soutourina, Julie/F-8305-2014; Emmanuelle, SCHMITT/ABF-8658-2020	Mechulam, Yves/0000-0003-3586-3554; SCHMITT, Emmanuelle/0000-0001-7532-338X; Soutourina, Julie/0000-0001-5218-2350; Emmanuelle, SCHMITT/0000-0001-7532-338X				Abrahams JP, 1998, CURR OPIN STRUC BIOL, V8, P601, DOI 10.1016/S0959-440X(98)80151-6; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CUZIN F, 1967, P NATL ACAD SCI USA, V58, P2079, DOI 10.1073/pnas.58.5.2079; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FOURMY D, 1993, J MOL BIOL, V231, P1068, DOI 10.1006/jmbi.1993.1352; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SOURGOUTCHOV A, 1974, EUR J BIOCHEM, V46, P431, DOI 10.1111/j.1432-1033.1974.tb03636.x; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	29	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47285	47290		10.1074/jbc.M106550200	http://dx.doi.org/10.1074/jbc.M106550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11568181	hybrid			2022-12-25	WOS:000172768500082
J	Makino, T; Takaishi, M; Morohashi, M; Huh, NH				Makino, T; Takaishi, M; Morohashi, M; Huh, NH			Hornerin, a novel profilaggrin-like protein and differentiation-specific marker isolated from mouse skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; CALCIUM-BINDING PROTEIN; STRATUM-CORNEUM; INTERMEDIATE FILAMENTS; RHEUMATOID-ARTHRITIS; ICHTHYOSIS-VULGARIS; UROCANIC ACID; FILAGGRIN; LORICRIN; GENE	A novel mouse cDNA named hornerin was isolated by RNA differential display applied to developing mouse skin. Hornerin, which has 2,496 amino acids, comprises EF-hand domains at the N terminus followed by a spacer sequence and a large repetitive domain, indicating that hornerin is a novel member of the "fused gene"-type cornified envelope precursor protein family. The repetitive domain of hornerin was found to be rich in glycine, serine, and glutamine. Hornerin was expressed in the tongue, esophagus, forestomach, and skin among the adult mouse tissues examined, all of them cornifying stratified epithelium. In the embryonic mouse skin, hornerin mRNA was first detected on gestational day 15.5 in the epidermis coincidentally with the formation of a granular layer. In accordance with this, hornerin was detected in the granular and cornified layers of the mature epidermis. In the granular cells of the epidermis, the hornerin protein was detected in keratohyalin granules together with profilaggrin. Furthermore, Western blot analysis of the mouse skin showed that the hornerin protein was cleaved during the process of epidermal differentiation, indicating possible posttranslational proteolytic processing as is observed in profilaggrin. Differentiation of primary mouse epidermal keratinocytes with 0.12 mm Ca2+ resulted in the induction of hornerin. These results indicate that hornerin is structurally as well as functionally most similar to profilaggrin among the family members and possibly plays pleiotropic roles, including a role in cornification.	Okayama Univ, Grad Sch Med & Dent, Dept Cell Biol, Okayama 7008558, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Dermatol, Toyama 9300194, Japan	Okayama University; University of Toyama	Huh, NH (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Cell Biol, 2-5-1 Shikatachou, Okayama 7008558, Japan.	namu@md.okayama-u.ac.jp	HUH, Nam-ho/B-1613-2011					Dale B. A., 1994, KERATINOCYTE HDB, P323; DALE BA, 1977, BIOCHIM BIOPHYS ACTA, V491, P193, DOI 10.1016/0005-2795(77)90055-1; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531, DOI 10.1177/39.11.1717544; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOHL D, 1991, J BIOL CHEM, V266, P6626; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Ishida-Yamamoto A, 1998, HISTOL HISTOPATHOL, V13, P819, DOI 10.14670/HH-13.819; Ishisaki Z, 2001, GENOMICS, V74, P172, DOI 10.1006/geno.2001.6544; Korge BP, 1997, J INVEST DERMATOL, V109, P604, DOI 10.1111/1523-1747.ep12337534; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; KUBILUS J, 1985, J INVEST DERMATOL, V85, P513, DOI 10.1111/1523-1747.ep12277310; Kuechle MK, 2000, CELL DEATH DIFFER, V7, P566, DOI 10.1038/sj.cdd.4400687; LEE SC, 1993, J BIOL CHEM, V268, P12164; LONSDALEECCLES JD, 1984, BIOCHEMISTRY-US, V23, P1239, DOI 10.1021/bi00301a034; Maestrini E, 1996, NAT GENET, V13, P70, DOI 10.1038/ng0596-70; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; McGrath JA, 2001, ADV GENET, V43, P1, DOI 10.1016/S0065-2660(01)43002-1; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NIRUNSUKSIRI W, 1995, J BIOL CHEM, V270, P871, DOI 10.1074/jbc.270.2.871; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SCOTT IR, 1982, BIOCHIM BIOPHYS ACTA, V719, P110, DOI 10.1016/0304-4165(82)90314-2; SCOTT IR, 1981, BIOCHEM J, V194, P829, DOI 10.1042/bj1940829; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; SENGEL P, 1976, MORPHOGENESIS SKIN, P5; SIMON M, 1993, J CLIN INVEST, V92, P1387, DOI 10.1172/JCI116713; Slack SL, 1998, J RHEUMATOL, V25, P847; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; Takaishi M, 1999, BIOCHEM BIOPH RES CO, V264, P81, DOI 10.1006/bbrc.1999.1477; Takaishi M, 1998, J INVEST DERMATOL, V111, P128, DOI 10.1046/j.1523-1747.1998.00241.x	40	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47445	47452		10.1074/jbc.M107512200	http://dx.doi.org/10.1074/jbc.M107512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11572870	hybrid			2022-12-25	WOS:000172768500100
J	Bork, JM; Cox, MM; Inman, RB				Bork, JM; Cox, MM; Inman, RB			RecA protein filaments disassemble in the 5 ' to 3 ' direction on single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DUPLEX DNA; BINDING-PROTEIN; NUCLEOPROTEIN FILAMENTS; COMPLEXES; EXCHANGE; RECOMBINATION; SSDNA; ATP; ENDS	RecA protein forms filaments on both single- and double-stranded DNA. Several studies confirm that filament extension occurs in the 5' to 3' direction on single-stranded DNA. These filaments also disassemble in an end-dependent fashion, and several indirect observations suggest that the disassembly occurs on the end opposite to that at which assembly occurs. By labeling the 5' end of single-stranded DNA with a segment of duplex DNA, we demonstrate unambiguously that RecA filaments disassemble uniquely in the 5' to 3' direction.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM052725, R01GM032335, R01GM014711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52725, GM32335, GM14711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Churchill JJ, 1999, GENE DEV, V13, P901, DOI 10.1101/gad.13.7.901; COX MM, 1982, J BIOL CHEM, V257, P8523; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DAVIS RW, 1980, MANUAL GENETIC ENG A; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DUTREIX M, 1991, J MOL BIOL, V219, P645, DOI 10.1016/0022-2836(91)90661-O; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; KONFORTI BB, 1991, J BIOL CHEM, V266, P10112; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; McIlwraith MJ, 2001, J MOL BIOL, V305, P23, DOI 10.1006/jmbi.2000.4268; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SHANER SL, 1987, J BIOL CHEM, V262, P9211; SHANER SL, 1987, J BIOL CHEM, V262, P9220; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L	40	50	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45740	45743		10.1074/jbc.M109247200	http://dx.doi.org/10.1074/jbc.M109247200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574550	hybrid			2022-12-25	WOS:000172573100033
J	Frolov, A; Srivastava, K; Daphna-Iken, D; Traub, LM; Schaffer, JE; Ory, DS				Frolov, A; Srivastava, K; Daphna-Iken, D; Traub, LM; Schaffer, JE; Ory, DS			Cholesterol overload promotes morphogenesis of a Niemann-Pick C (NPC)-like compartment independent of inhibition of NPC1 or HE1/NPC2 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; INTRACELLULAR TRAFFICKING; DISEASE; TRANSPORT; PROTEIN; COMPLEMENTATION; LYSOSOMES; ESTERIFICATION; HOMEOSTASIS	Cholesterol accumulation in an aberrant endosomal/lysosomal compartment is the hallmark of Niemann-Pick type C (NPC) disease. To gain insight into the etiology of the NPC compartment, we studied a novel Chinese hamster ovary cell mutant that was identified through a genetic screen and phenocopies the NPC1 mutation. We show that the M87 mutant harbors a mutation in a gene distinct from the NPC1 and HE1/NPC2 disease genes. M87 cells have increased total cellular cholesterol with accumulation in an aberrant compartment that contains LAMP-1, LAMP-2, and NPC1, but not Cl-MPR, similar to the cholesterol-rich compartment in NPC mutant cells. We demonstrate that low-density lipoprotein receptor activity is increased 3-fold in the M87 mutant, and likely contributes to accumulation of excess cholesterol. In contrast to NPC1-null cells, the M87 mutant exhibits normal rates of delivery of endosomal cholesterol to the endoplasmic reticulum and to the plasma membrane. The preserved late endosomal function in the M87 mutant is associated with the presence of NPC1-containing multivesicular late endosomes and supports a role for these multivesicular late endosomes in the sorting and distribution of cholesterol. Our findings implicate cholesterol overload in the formation of an NPC-like compartment that is independent of inhibition of NPC1 or HE1/NPC2 function.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Washington University (WUSTL); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ory, DS (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.			Traub, Linton/0000-0002-1303-0298	NHLBI NIH HHS [T32HL07275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; Bright NA, 1997, J CELL SCI, V110, P2027; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAHL NK, 1994, J LIPID RES, V35, P1839; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; DENG YP, 1988, P NATL ACAD SCI USA, V85, P3860, DOI 10.1073/pnas.85.11.3860; Denzer K, 2000, J CELL SCI, V113, P3365; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Higaki K, 2001, J BIOCHEM-TOKYO, V129, P875, DOI 10.1093/oxfordjournals.jbchem.a002932; KINSKY SC, 1970, ANNU REV PHARMACOLOG, V10, P119, DOI 10.1146/annurev.pa.10.040170.001003; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Lusa S, 2001, J CELL SCI, V114, P1893; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Steinberg SJ, 1996, J INHERIT METAB DIS, V19, P769, DOI 10.1007/BF01799171; STEINBERG SJ, 1994, J MED GENET, V31, P317, DOI 10.1136/jmg.31.4.317; Vanier MT, 1996, AM J HUM GENET, V58, P118; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537	41	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46414	46421		10.1074/jbc.M108099200	http://dx.doi.org/10.1074/jbc.M108099200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571306	hybrid			2022-12-25	WOS:000172573100125
J	Gruendler, C; Lin, Y; Farley, J; Wang, TW				Gruendler, C; Lin, Y; Farley, J; Wang, TW			Proteasomal degradation of Smad1 induced by bone morphogenetic proteins.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA FAMILY; ORNITHINE DECARBOXYLASE; DEPENDENT DEGRADATION; SIGNALING PATHWAYS; I RECEPTORS; SUBUNIT; FKBP12; REGULATORS; ANTIZYME; CLONING	The bone morphogenetic proteins (BMPs) regulate early embryogenesis and morphogenesis of multiple organs, such as bone, kidney, limbs, and muscle. Smad1 is one of the key signal transducers of BMPs and is responsible for transducing receptor activation signals from the cytoplasm to the nucleus, where Smad1 serves as a transcriptional regulator of various BMP-responsive genes. Based upon the ability of Smad1 to bind multiple proteins involved in proteasome-mediated degradation pathway, we investigated whether Smad1 could be a substrate for proteasome. We found that Smad1 is targeted to proteasome for degradation in response to BMP type I receptor activation. The targeting of Smad1 to proteasome involves not only the receptor activation-induced Smad1 ubiquitination but also the targeting functions of the ornithine decarboxylase antizyme and the proteasome beta subunit HsN3. Our studies provide the first evidence for BMP-induced proteasomal targeting and degradation of Smad1 and also reveal new players and novel mechanisms involved in this important aspect of Smad1 regulation and function.	Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA	Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Harvard University; Massachusetts General Hospital	Wang, TW (corresponding author), Virginia Mason Res Ctr, 1201 9th Ave, Seattle, WA 98101 USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cruz M, 1997, GENE, V190, P251, DOI 10.1016/S0378-1119(97)00003-6; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Guo X, 2001, J NEUROBIOL, V48, P120, DOI 10.1002/neu.1046; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOPP F, 1995, J MOL BIOL, V248, P264; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Li XQ, 1996, J BIOL CHEM, V271, P4441; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1999, MOL CELL BIOL, V19, P7216; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Stockwell BR, 1998, CHEM BIOL, V5, P385, DOI 10.1016/S1074-5521(98)90072-2; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Thomson S, 1996, BIOCHEM J, V315, P733, DOI 10.1042/bj3150733; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	44	78	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46533	46543		10.1074/jbc.M105500200	http://dx.doi.org/10.1074/jbc.M105500200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571290	hybrid			2022-12-25	WOS:000172573100139
J	Kozin, SA; Bertho, G; Mazur, AK; Rabesona, H; Girault, JP; Haertle, T; Takahashi, M; Debey, P; Hoa, GHB				Kozin, SA; Bertho, G; Mazur, AK; Rabesona, H; Girault, JP; Haertle, T; Takahashi, M; Debey, P; Hoa, GHB			Sheep prion protein synthetic peptide spanning helix 1 and beta-strand 2 (residues 142-166) shows beta-hairpin structure in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETECTED CIRCULAR-DICHROISM; PUTATIVE ALPHA-HELICES; SECONDARY STRUCTURE; CONFORMATIONAL TRANSITIONS; MOLECULAR-DYNAMICS; AMINO-ACIDS; SCRAPIE; NMR; SPECTROSCOPY; PRP	According to the "protein only" hypothesis, a conformational conversion of the non-pathogenic "cellular" prion isoform. into a pathogenic "scrapie" isoform is the fundamental event in the onset of prion diseases. During this pathogenic conversion, helix H1 and two adjacent surface loops L2 and L3 of the normal prion protein are thought to undergo a conformational transition into an extended beta -like structure, which is prompted by interactions with the pre-existing beta -sheet. To get more insight into the interaction between the helix and one of the beta -strands in the partially unfolded prion protein, the solution structure of a synthetic linear peptide spanning helix HI and beta -strand S2 (residues 142-166 in human numbering) was studied by circular dichroism. and nuclear magnetic resonance spectroscopies. We found that, in contrast to many prion fragments studied earlier, this peptide (i) is highly soluble and does not aggregate up to a millimolar concentration range in aqueous medium and (ii) exhibits an intrinsic propensity to a beta -hairpin like conformation at neutral pH. This beta -propensity can be one of the internal driving forces of the molecular rearrangement responsible for the pathogenic conversion of the prion protein.	INSERM, U473, F-94276 Le Kremlin Bicetre, France; INSERM, Natl Museum Nat Hist, EA 2703, Inst Biol Physicochim, F-75005 Paris, France; Univ Paris 05, Chim & Biochim Pharmacol & Toxicol Lab, CNRS, UMR 8601, F-75270 Paris 06, France; CNRS, Lab Biochim Theor, Inst Biol Physicochim, F-75005 Paris, France; INRA, Lab Etud Interact Mol Alimentaires, F-44316 Nantes 3, France; Univ Nantes, FRE 2230, F-44322 Nantes 3, France; CNRS, F-44322 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; INRAE; Nantes Universite; Centre National de la Recherche Scientifique (CNRS)	Hoa, GHB (corresponding author), INSERM, U473, 84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	gaston@peptrans.org	Girault, Jean_Pierre JP/A-5403-2008; Haertlé, Thomas/K-1278-2013; HaertlÃ©, Thomas/K-1740-2017; Kozin, Sergey A/R-3637-2018	Haertlé, Thomas/0000-0002-7888-7698; Kozin, Sergey A/0000-0002-3018-7932; Haertle, Thomas/0000-0002-1696-2269; Mazur, Alexey/0000-0002-9371-0620; Bertho, Gildas/0000-0002-4929-763X				[Anonymous], 1996, CIRCULAR DICHROISM C; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BERTHO G, 2001, IN PRESS COMP REND A; BLANCO FJ, 1994, NAT STRUCT BIOL, V1, P584, DOI 10.1038/nsb0994-584; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Heller J, 1996, PROTEIN SCI, V5, P1655, DOI 10.1002/pro.5560050819; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; HURD RE, 1991, J MAGN RESON, V91, P648, DOI 10.1016/0022-2364(91)90395-A; Inouye H, 1997, J MOL BIOL, V268, P375, DOI 10.1006/jmbi.1997.0949; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOZIN SA, 2000, J PEPT SCI, V6, pS141; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liu AZ, 1999, BIOPOLYMERS, V51, P145, DOI 10.1002/(SICI)1097-0282(1999)51:2<145::AID-BIP4>3.0.CO;2-4; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; LOBENSTINE EW, 1981, J AM CHEM SOC, V103, P4936, DOI 10.1021/ja00406a044; Mazur AK, 1997, J COMPUT CHEM, V18, P1354, DOI 10.1002/(SICI)1096-987X(199708)18:11<1354::AID-JCC3>3.0.CO;2-K; Mazur AK, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P115; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; MUTO K, 1986, J AM CHEM SOC, V108, P6416, DOI 10.1021/ja00280a064; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pillot T, 1997, J MOL BIOL, V274, P381, DOI 10.1006/jmbi.1997.1382; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ragg E, 1999, EUR J BIOCHEM, V266, P1192, DOI 10.1046/j.1432-1327.1999.00985.x; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SERRANO L, 1995, J MOL BIOL, V254, P322, DOI 10.1006/jmbi.1995.0619; Sharman GJ, 1998, FOLD DES, V3, P313, DOI 10.1016/S1359-0278(98)00043-1; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	59	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46364	46370		10.1074/jbc.M108014200	http://dx.doi.org/10.1074/jbc.M108014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577109	hybrid			2022-12-25	WOS:000172573100118
J	Viard, T; Lamour, V; Duguet, M; de la Tour, CB				Viard, T; Lamour, V; Duguet, M; de la Tour, CB			Hyperthermophilic topoisomerase I from Thermotoga maritima. A very efficient enzyme that functions independently of zinc binding.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE TRANSCARBAMOYLASE; TRANSCRIPTION FACTOR IIE; ELONGATION-FACTOR TFIIS; ESCHERICHIA-COLI; DNA TOPOISOMERASE; REVERSE GYRASE; CLEAVAGE-SITE; DOMAIN; RIBBON; IDENTIFICATION	Topoisomerases, by controlling DNA supercoiling state, are key enzymes for adaptation to high temperatures in thermophilic organisms. We focus here on the topoisomerase I from the hyperthermophilic bacterium Thermotoga maritima (optimal growth temperature, 80 degreesC). To determine the properties of the enzyme compared with those of its mesophilic homologs, we overexpressed T. maritima topoisomerase I in Escherichia coli and purified it to near homogeneity. We show that T. maritima topoisomerase I exhibits a very high DNA relaxing activity. Mapping of the cleavage sites on a variety of single-stranded oligonucleotides indicates a strong preference for a cytosine at position -4 of the cleavage, a property shared by E. coli topoisomerase I and archaeal reverse gyrases. As expected, the mutation of the putative active site Tyr 288 to Phe led to a totally inactive protein. To investigate the role of the unique zinc motif (Cys-X-Cys-X-16-Cys-X-Cys) present in T. maritima topoisomerase I, experiments have been performed with the protein mutated on the tetracysteine motif. Strikingly, the results show that zinc binding is not required for DNA relaxation activity, contrary to the E. coli enzyme. Furthermore, neither thermostability nor cleavage specificity is altered in this mutant. This finding opens the question of the role of the zinc-binding motif in T. maritima topoisomerase I and suggests that this hyperthermophilic topoisomerase possesses a different mechanism from its mesophilic homolog.	Univ Paris 11, Lab Enzymol Acides Nucl,Ctr Orsay, Inst Genet & Microbiol, UMR 8621 CNRS, F-91405 Orsay, France; Inst Genet & Biol Mol & Cellulaire, Lab Biol & Genom Struct, UPR 9004 CNRS, F-67404 Illkirch Graffenstaden, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	de la Tour, CB (corresponding author), Univ Paris 11, Lab Enzymol Acides Nucl,Ctr Orsay, Inst Genet & Microbiol, UMR 8621 CNRS, Batiment 400, F-91405 Orsay, France.			Lamour, Valerie/0000-0001-7793-4029				Akimkina T, 1999, PLASMID, V42, P236, DOI 10.1006/plas.1999.1429; De la Tour CB, 1998, J BACTERIOL, V180, P274, DOI 10.1128/JB.180.2.274-281.1998; DEAN FB, 1985, J BIOL CHEM, V260, P4984; delaTour CB, 1995, BBA-GENE STRUCT EXPR, V1264, P279, DOI 10.1016/0167-4781(96)83596-2; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Grishin NV, 2000, J MOL BIOL, V299, P1165, DOI 10.1006/jmbi.2000.3841; Guipaud O, 1997, P NATL ACAD SCI USA, V94, P10606, DOI 10.1073/pnas.94.20.10606; HIASA H, 1994, J BIOL CHEM, V269, P2093; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Jaxel C, 1999, EUR J BIOCHEM, V260, P103, DOI 10.1046/j.1432-1327.1999.00128.x; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; Kaltoum H, 1997, SYST APPL MICROBIOL, V20, P505, DOI 10.1016/S0723-2020(97)80019-7; KIM RA, 1992, J BIOL CHEM, V267, P17178; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Li ZY, 2000, MOL MICROBIOL, V35, P888, DOI 10.1046/j.1365-2958.2000.01763.x; LopezGarcia P, 1997, MOL MICROBIOL, V23, P1267, DOI 10.1046/j.1365-2958.1997.3051668.x; MAXON ME, 1994, P NATL ACAD SCI USA, V91, P9529, DOI 10.1073/pnas.91.20.9529; MILLER KG, 1981, J BIOL CHEM, V256, P9334; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; TSE Y, 1980, CELL, V22, P269, DOI 10.1016/0092-8674(80)90174-9; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103; Zhang HL, 1996, J BIOL CHEM, V271, P9039, DOI 10.1074/jbc.271.15.9039; ZHANG HL, 1994, J BIOL CHEM, V269, P9052; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700; ZHU CX, 1995, J MOL BIOL, V250, P609, DOI 10.1006/jmbi.1995.0402; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46495	46503		10.1074/jbc.M107714200	http://dx.doi.org/10.1074/jbc.M107714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577108	hybrid			2022-12-25	WOS:000172573100135
J	van der Veen, BA; Leemhuis, H; Kralj, S; Uitdehaag, JCM; Dijkstra, BW; Dijkhuizen, L				van der Veen, BA; Leemhuis, H; Kralj, S; Uitdehaag, JCM; Dijkstra, BW; Dijkhuizen, L			Hydrophobic amino acid residues in the acceptor binding site are main determinants for reaction mechanism and specificity of cyclodextrin-glycosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS STRAIN-251; PRODUCT SPECIFICITY; ANGSTROM RESOLUTION; ACTIVE-CENTER; GLUCANOTRANSFERASE; INHIBITOR	Cyclodextrin-glycosyltransferases (CGTases) (EC 2.4.1.19) preferably catalyze transglycosylation reactions with glucosyl residues as acceptor, whereas the homologous alpha -amylases catalyze hydrolysis reactions using water as acceptor. This difference in reaction specificity is most likely caused by the acceptor binding site. To investigate this in detail we altered the acceptor site residues Lys-232, Phe-183, Phe-259, and Glu-264 of Bacillus circulans strain 251 CGTase using site-directed mutagenesis. Lys-232 is of general importance for catalysis, which appears to result mainly from stabilization of the conformation of the loop containing the catalytic nucleophile Asp-229 and His-233, a residue that has been implied in transition state stabilization. Glu-264 contributes to the disproportionation reaction only, where it is involved in initial binding of the (maltose) acceptor. Phe-183 and Phe-259 play important and distinct roles in the transglycosylation reactions catalyzed by CGTase. Mutation of Phe-183 affects especially the cyclization and coupling reactions, whereas Phe-259 is most important for the cyclization and disproportionation reactions. Moreover, the hydrophobisity of Phe-183 and Phe-259 limits the hydrolyzing activity of the enzyme. Hydrolysis can be enhanced by making these residues more polar, which concomitantly results in a lower transglycosylation activity. A double mutant was constructed that yielded an enzyme preferring hydrolysis over cyclization (15:1), whereas the wild type favors cyclization over hydrolysis (90:1).	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, BIOSON Res Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Dijkhuizen, L (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Dijkhuizen, Lubbert/K-3539-2019; Dijkhuizen, Lubbert/E-9454-2014; Dijkstra, Bauke W./H-4308-2019	Dijkhuizen, Lubbert/0000-0003-2312-7162; Dijkstra, Bauke W./0000-0001-9731-6586; Kralj, Slavko/0000-0001-7855-4888				Allegre M., 1994, Agro Food Industry hi-tech, V5, P9; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BRON S, 1990, MODERN MICROBIOLOGIC, P146; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; NAKAMURA A, 1993, BIOCHEMISTRY-US, V32, P6624, DOI 10.1021/bi00077a015; NAKAMURA A, 1994, BIOCHEMISTRY-US, V33, P9929, DOI 10.1021/bi00199a015; Penninga D, 1996, J BIOL CHEM, V271, P32777, DOI 10.1074/jbc.271.51.32777; PENNINGA D, 1995, BIOCHEMISTRY-US, V34, P3368, DOI 10.1021/bi00010a028; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH H, 1988, GENE, V70, P351, DOI 10.1016/0378-1119(88)90207-7; Strokopytov B, 1996, BIOCHEMISTRY-US, V35, P4241, DOI 10.1021/bi952339h; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Uitdehaag JCM, 2001, PROTEINS, V43, P327, DOI 10.1002/prot.1044; Uitdehaag JCM, 2000, BIOCHEMISTRY-US, V39, P7772, DOI 10.1021/bi000340x; van der Veen BA, 2000, EUR J BIOCHEM, V267, P658, DOI 10.1046/j.1432-1327.2000.01031.x; VANDERVOSSEN JMBM, 1992, APPL ENVIRON MICROB, V58, P3142, DOI 10.1128/AEM.58.9.3142-3149.1992; Vikmon M., 1982, 1ST P INT S CYCL BUD, P69; VOSS H, 1992, Methods in Molecular and Cellular Biology, V3, P30; Wind RD, 1998, J BIOL CHEM, V273, P5771, DOI 10.1074/jbc.273.10.5771; ZIMMERMANN J, 1990, NUCLEIC ACIDS RES, V18, P1067, DOI 10.1093/nar/18.4.1067	26	84	87	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44557	44562		10.1074/jbc.M107533200	http://dx.doi.org/10.1074/jbc.M107533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11555657	Green Published, hybrid			2022-12-25	WOS:000172406700030
J	Winklhofer, KF; Reintjes, A; Hoener, MC; Voellmy, R; Tatzelt, J				Winklhofer, KF; Reintjes, A; Hoener, MC; Voellmy, R; Tatzelt, J			Geldanamycin restores a defective heat shock response in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HSF1; K562 ERYTHROLEUKEMIC CELLS; STRESS-INDUCED APOPTOSIS; IN-VIVO; NEUROBLASTOMA-CELLS; DNA-BINDING; MOLECULAR CHAPERONES; PROTEIN EXPRESSION; ACTIVATION DOMAIN; TYROSINE KINASE	Induced expression of heat shock proteins (Hsps) plays a central role in promoting cellular survival after environmental and physiological stress. We have previously shown that scrapie-infected mouse neuroblastoma (ScN2a) cells fail to induce the expression of Hsp72 and Hsp28 after various stress conditions. Here we present evidence that this impaired stress response is due to an altered regulation of HSF1 activity. Upon stress in ScN2a cells, HSF1 was converted into hyperphosphorylated trimers but failed to acquire transactivation competence. A kinetic analysis of HSF1 activation revealed that in ScN2a cells trimer formation after stress was efficient, but disassembly of trimers proceeded much faster than in the uninfected cell line. Geldanamycin, a Hsp90-binding drug, significantly delayed disassembly of HSF1 trimers after a heat shock and restored stress-induced expression of Hsp72 in ScN2a cells. Heat-induced Hsp72 expression required geldanamycin to be present; following removal of the drug ScN2a cells again lost their ability to mount a stress response. Thus, our studies show that a defective stress response can be pharmacologically restored and suggest that the HSF1 deactivation pathway may play an important role in the regulation of Hsp expression.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	Max Planck Society; Max Planck Society; University of Miami	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de	Hoener, Marius C/I-6464-2012	Hoener, Marius C/0000-0001-6510-6250; Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECK SC, 1995, AM J PHYSIOL-REG I, V269, pR608, DOI 10.1152/ajpregu.1995.269.3.R608; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRUCE JL, 1993, CANCER RES, V53, P12; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHANG NT, 1993, J BIOL CHEM, V268, P1436; Chavany C, 1996, J BIOL CHEM, V271, P4974; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Drujan D, 1999, SHOCK, V12, P443, DOI 10.1097/00024382-199912000-00005; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GOLDENBERG CJ, 1988, J BIOL CHEM, V263, P19734; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HEYDARI AR, 1994, EXPERIENTIA, V50, P1092, DOI 10.1007/BF01923466; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Kim HR, 1999, IUBMB LIFE, V48, P425, DOI 10.1080/152165499306810; Kim HR, 1999, IUBMB LIFE, V48, P429, DOI 10.1080/713803536; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARINI AM, 1990, J NEUROCHEM, V54, P1509, DOI 10.1111/j.1471-4159.1990.tb01198.x; MATHUR SK, 1994, P NATL ACAD SCI USA, V91, P8695, DOI 10.1073/pnas.91.18.8695; McIlwrath AJ, 1996, CANCER CHEMOTH PHARM, V37, P423, DOI 10.1007/s002800050407; Morano KA, 1999, MOL CELL BIOL, V19, P402; Morimoto R I, 1996, EXS, V77, P139; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NISHIMURA RN, 1991, MOL BRAIN RES, V9, P39, DOI 10.1016/0169-328X(91)90128-K; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rosenhagen MC, 2001, BIOL CHEM, V382, P499, DOI 10.1515/BC.2001.063; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; VOELLMY R, 1985, P NATL ACAD SCI USA, V82, P4949, DOI 10.1073/pnas.82.15.4949; Voellmy R, 1996, EXS, V77, P121; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	72	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45160	45167		10.1074/jbc.M104873200	http://dx.doi.org/10.1074/jbc.M104873200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574536	hybrid			2022-12-25	WOS:000172406700108
J	Ito, Y; Zhao, J; Mogharei, A; Shuler, CF; Weinstein, M; Deng, CX; Chai, Y				Ito, Y; Zhao, J; Mogharei, A; Shuler, CF; Weinstein, M; Deng, CX; Chai, Y			Antagonistic effects of Smad2 versus Smad7 are sensitive to their expression level during tooth development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; LUNG BRANCHING MORPHOGENESIS; MAD-RELATED PROTEIN; TGF-BETA; TARGETED DISRUPTION; RECEPTOR; LACKING; MICE; DEFECTS; INHIBITION	Members of the transforming growth factor-beta (TGF-beta) superfamily regulate cell proliferation, differentiation, and apoptosis, controlling the development and maintenance of most tissues. TGF-beta signal is transmitted through the phosphorylation of Smad proteins by TGF-beta receptor serine/threonine kinase. During early tooth development, TGF-beta inhibits proliferation of enamel organ epithelial cells but the underlying molecular mechanisms are largely unknown. Here we tested the hypothesis that antagonistic effects between Smad2 and Smad7 regulate TGF-beta signaling during tooth development. Attenuation of Smad2 gene expression resulted in significant advancement of embryonic tooth development with increased proliferation of enamel organ epithelial cells, while attenuation of Smad7 resulted in significant inhibition of embryonic tooth development with increased apoptotic activity within enamel organ epithelium. These findings suggest that different Smads may have differential activities in regulating TGF-beta -mediated cell proliferation and death. Furthermore, functional haplo-insufficiency of Smad2, but not Smad3, altered TGF-beta -mediated tooth development. The results indicate that Smads are critical factors in orchestrating TGF-beta -mediated gene regulation during embryonic tooth development. The effectiveness of TGF-beta signaling is highly sensitive to the level of Smad gene expression.	Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, Los Angeles, CA 90033 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	University of Southern California; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Chai, Y (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, 2250 Alcazar St,CSA 103, Los Angeles, CA 90033 USA.	ychai@hsc.usc.edu	deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012711, P01DE012941] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12941, DE12711] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Chai Y, 2000, DEVELOPMENT, V127, P1671; CHAI Y, 1994, DEV BIOL, V162, P85, DOI 10.1006/dbio.1994.1069; CHAI Y, 1993, ANAT REC, V235, P303, DOI 10.1002/ar.1092350214; Chai Y, 1999, MECH DEVELOP, V86, P63, DOI 10.1016/S0925-4773(99)00112-4; Chai Y, 1998, DEV DYNAM, V213, P500, DOI 10.1002/(SICI)1097-0177(199812)213:4<500::AID-AJA14>3.0.CO;2-A; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Dick A, 1998, DEV DYNAM, V211, P293, DOI 10.1002/(SICI)1097-0177(199804)211:4<293::AID-AJA1>3.0.CO;2-C; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Flanders KC, 2001, DEV DYNAM, V220, P141, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1096>3.0.CO;2-4; HALL BK, 1992, BIOL MECH TOOTH MOVE; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEIKINHEIMO K, 1993, J CLIN INVEST, V91, P1019, DOI 10.1172/JCI116258; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KRONMILLER JE, 1991, DEV BIOL, V147, P485, DOI 10.1016/0012-1606(91)90307-O; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Laurikkala J, 2001, DEV BIOL, V229, P443, DOI 10.1006/dbio.2000.9955; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARCUSSEKURA CJ, 1988, TRENDS CELL BIOL, V7, P187; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Theiler K, 1989, HOUSE MOUSE ATLAS EM, DOI 10.1007/978-3-642-88418-4; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhao JS, 2000, J BIOL CHEM, V275, P23992, DOI 10.1074/jbc.M002433200; Zhao JS, 1998, MECH DEVELOP, V72, P89, DOI 10.1016/S0925-4773(98)00019-7; Zhao JS, 1996, DEV BIOL, V180, P242, DOI 10.1006/dbio.1996.0298; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	57	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44163	44172		10.1074/jbc.M011424200	http://dx.doi.org/10.1074/jbc.M011424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557747	hybrid			2022-12-25	WOS:000172297700087
J	Johansson, E; Majka, J; Burgers, PMJ				Johansson, E; Majka, J; Burgers, PMJ			Structure of DNA polymerase delta from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SMALL-SUBUNIT; REPLICATION FORK; YEAST; EPSILON; REPAIR; GENE; IDENTIFICATION; CHROMATOGRAPHY; STRANDS	DNA polymerase 8 (Pol 8) from Saccharomyces cerevisiae consists of three subunits, Pol3 (125 kDa), Pol31 (55 kDa), and Pol32 (40 kDa), present at a 1:1:1 stoichiometry in purified preparations. Previously, based on gel filtration studies of Pol delta, we suggested that the enzyme may be a dimer of catalytic cores, with dimerization mediated by the Pol32 subunit (Burgers, P. M., and Gerik, K J. (1998) J. Biol. Chem. 273, 19756-19762). We now report on extensive gel filtration, glycerol gradient sedimentation, and analytical equilibrium centrifugation studies of Pol delta and of several subassemblies of Pol S. The hydrodynamic parameters of these assemblies indicate that (i) Pol32 is a rod-shaped protein with a frictional ratio f/f(0) = 2.22; (ii) any complex containing Pol32 also has an extremely asymmetric shape; (iii) the results of these studies are independent of concentration (varied between 0.1-20 mum); (iv) all complexes are monomeric under the conditions studied (up to 20 muM). Moreover, a two-hybrid analysis of the Pol32 subunit did not detect a Pol32-Pol32 interaction in vivo. Therefore, we conclude that the assembly structure of Pol delta is that of a monomer.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid, St Louis, MO 63110 USA.		Burgers, Peter M/AAW-6621-2021	Johansson, Erik/0000-0002-8526-6224	NIGMS NIH HHS [GM58534, R01 GM032431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431, R01GM058534] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Giot L, 1997, GENETICS, V146, P1239; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; Hindges R, 1997, BIOL CHEM, V378, P345; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MacNeill SA, 2001, TRENDS BIOCHEM SCI, V26, P16, DOI 10.1016/S0968-0004(00)01709-6; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; PIGNEDE G, 1991, J MOL BIOL, V222, P209, DOI 10.1016/0022-2836(91)90207-M; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Shcherbakova PV, 1996, GENETICS, V142, P717; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 1975, HDB BIOCH MOL BIOL P, V2, P222; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	28	52	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43824	43828		10.1074/jbc.M108842200	http://dx.doi.org/10.1074/jbc.M108842200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11568188	hybrid			2022-12-25	WOS:000172297700046
J	Nguyen, BP; Ren, XD; Schwartz, MA; Carter, WG				Nguyen, BP; Ren, XD; Schwartz, MA; Carter, WG			Ligation of integrin alpha(3)beta(1) by laminin 5 at the wound edge activates Rho-dependent adhesion of leading keratinocytes on collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED EPITHELIAL-CELLS; PROTEIN-KINASE-C; ALPHA-3-BETA-1 INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; GENE-EXPRESSION; P120 CATENIN; LAMA3 GENE; HEMIDESMOSOMES	Wounding of the epidermis signals the transition of keratinocytes from quiescent anchorage on endogenous basement membrane laminin 5 to migration on exposed dermal collagen. In this study, we attempt to characterize activation signals that transform quiescent keratinocytes into migratory leading cells at the wound edge. Previously, we reported that adhesion and spreading on collagen via integrin alpha (2)beta (1) by cultured human foreskin keratinocytes (HFKs) requires RhoGTP, a regulator of actin stress fibers. In contrast, adhesion and spreading on laminin 5 requires integrins alpha (3)beta (1) and alpha (6)beta (4) and is dependent on phosphoinositide 3-hydroxykinase (Nguyen, B. P., Gil, S. G., and Carter, W. G. (2000) J. Biol. Chem. 275,31896-31907). Here, we report that quiescent HFKs do not adhere to collagen but adhere and spread on laminin 5. By using collagen adhesion as one criterion for conversion to a "leading wound cell," we found that activation of collagen adhesion requires elevation of RhoGTP. Adhesion of quiescent HFKs to laminin 5 via integrin alpha (3)beta (1), and alpha (6)beta (4) is sufficient to increase levels of RhoGTP required for adhesion and spreading on collagen. Consistently, adhesion of quiescent HFKs to laminin 5, but not collagen, also promotes expression of the precursor form of laminin 5, a characteristic of leading keratinocytes in the epidermal outgrowth. We suggest that wounding of quiescent epidermis initiates adhesion and spreading of keratinocytes at the wound edge on endogenous basement membrane laminin 5 via alpha (3)beta (1), and alpha (6)beta (4) in a Rho-independent mechanism. Spreading on endogenous laminin 5 via alpha (3)beta (1), is necessary but not sufficient to elevate expression of precursor laminin 5 and RhoGTP, allowing for subsequent collagen adhesion via alpha (2)beta (1), all characteristics of leading keratinocytes in the epidermal outgrowth.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Scripps Research Institute	Carter, WG (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.			schwartz, martin/0000-0002-2071-1243	NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER; NCI NIH HHS [CA49259] Funding Source: Medline; NIAMS NIH HHS [AR21557] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; Brock J, 1996, J CELL BIOL, V135, P1097, DOI 10.1083/jcb.135.4.1097; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; Decline F, 2001, J CELL SCI, V114, P811; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; GIPSON IK, 1993, EXP CELL RES, V207, P86, DOI 10.1006/excr.1993.1166; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Kainulainen T, 1998, J HISTOCHEM CYTOCHEM, V46, P353, DOI 10.1177/002215549804600309; Kikkawa Y, 1996, IN VITRO CELL DEV-AN, V32, P46; KIM JP, 1992, J INVEST DERMATOL, V98, P764, DOI 10.1111/1523-1747.ep12499947; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McGowan K, 1998, Subcell Biochem, V31, P173; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; PAWAR S, 1995, J CELL PHYSIOL, V165, P556, DOI 10.1002/jcp.1041650314; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; STEPP MA, 1993, INVEST OPHTH VIS SCI, V34, P1829; Stepp MA, 1996, INVEST OPHTH VIS SCI, V37, P1593; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; TODA KI, 1987, J CELL BIOL, V105, P3097, DOI 10.1083/jcb.105.6.3097; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Wallis S, 2000, MOL BIOL CELL, V11, P1077, DOI 10.1091/mbc.11.3.1077; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WOODLEY DT, 1999, PROGR DERMATOLOGY, V33, P1; Xia MH, 1996, J CELL BIOCHEM, V61, P452, DOI 10.1002/(SICI)1097-4644(19960601)61:3<452::AID-JCB12>3.3.CO;2-9; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	44	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43860	43870		10.1074/jbc.M103404200	http://dx.doi.org/10.1074/jbc.M103404200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571278	hybrid			2022-12-25	WOS:000172297700051
J	Schmidt-Mende, J; Bieck, E; Hugle, T; Penin, F; Rice, CM; Blum, HE; Moradpour, D				Schmidt-Mende, J; Bieck, E; Hugle, T; Penin, F; Rice, CM; Blum, HE; Moradpour, D			Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CELL-LINES; CRYSTAL-STRUCTURE; SUBCELLULAR-LOCALIZATION; BIOCHEMICAL-PROPERTIES; TRANSMEMBRANE HELICES; TARGETING SIGNAL; MAMMALIAN-CELLS; CYTOCHROME B(5); VIRAL-PROTEINS	The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp), represented by nonstructural protein 5B (NS5B), is believed to form a membrane-associated RNA replication complex together with other nonstructural proteins and as yet unidentified host components. However, the determinants for membrane association of this essential viral enzyme have not been defined. By double label immunofluorescence analyses, NS5B was found in the endoplasmic reticulum (ER) or an ER-like modified compartment both when expressed alone or in the context of the entire HCV polyprotein. The carboxyl-terminal 21 amino acid residues were necessary and sufficient to target NS5B or a heterologous protein to the cytosolic side of the ER membrane. This hydrophobic domain is highly conserved among 269 HCV isolates analyzed and predicted to form a transmembrane a-helix. Association of NS5B with the ER membrane occurred by a posttranslational mechanism that was ATP-independent. These features define the HCV RdRp as a new member of the tail-anchored protein family, a class of integral membrane proteins that are membrane-targeted posttranslationally via a carboxyl-terminal insertion sequence. Formation of the HCV replication complex, therefore, involves specific determinants for membrane association that represent potential targets for antiviral intervention.	Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany; CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Rockefeller Univ, Ctr Study Hepatitis C, New York, NY 10021 USA	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Rockefeller University	Moradpour, D (corresponding author), Univ Hosp Freiburg, Dept Med 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	moradpou@ruf.uni-freiburg.de	PENIN, Francois/A-7315-2008; Moradpour, Darius/G-7918-2017	Moradpour, Darius/0000-0003-1977-6792				Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; Blanchet C, 2000, BIOINFORMATICS, V16, P286, DOI 10.1093/bioinformatics/16.3.286; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAROS MG, 1994, COMPUT APPL BIOSCI, V269, P26898; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; da Fonseca FG, 2000, J VIROL, V74, P7508, DOI 10.1128/JVI.74.16.7508-7517.2000; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Egger D, 2000, J VIROL, V74, P6570, DOI 10.1128/JVI.74.14.6570-6580.2000; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Fauquet C. M., 2000, VIRUS TAXONOMY; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hagedorn CH, 2000, CURR TOP MICROBIOL, V242, P225; Honsho M, 1998, J BIOL CHEM, V273, P20860, DOI 10.1074/jbc.273.33.20860; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873; Hwang SB, 1997, VIROLOGY, V227, P439, DOI 10.1006/viro.1996.8357; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kim JE, 1999, ARCH VIROL, V144, P329, DOI 10.1007/s007050050507; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Kretzschmar E, 1996, VIROLOGY, V220, P37, DOI 10.1006/viro.1996.0283; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; LI ZM, 1993, J BIOL CHEM, V268, P4584; Lin C, 1997, J VIROL, V71, P6465, DOI 10.1128/JVI.71.9.6465-6471.1997; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luecke H, 2000, J MOL BIOL, V300, P1237, DOI 10.1006/jmbi.2000.3884; Mackenzie JM, 1999, J VIROL, V73, P9555, DOI 10.1128/JVI.73.11.9555-9567.1999; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; Moradpour D, 2001, SWISS MED WKLY, V131, P291; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; PRECIOUS B, 1995, J VIROL, V69, P8001, DOI 10.1128/JVI.69.12.8001-8010.1995; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; ROST B, 1995, PROTEIN SCI, V4, P521; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Towner JS, 1996, J BIOL CHEM, V271, P26810, DOI 10.1074/jbc.271.43.26810; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8	76	165	174	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44052	44063		10.1074/jbc.M103358200	http://dx.doi.org/10.1074/jbc.M103358200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557752	hybrid			2022-12-25	WOS:000172297700074
J	Sheng, SH; McNulty, KA; Harvey, JM; Kleyman, TR				Sheng, SH; McNulty, KA; Harvey, JM; Kleyman, TR			Second transmembrane domains of ENaC subunits contribute to ion permeation and selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; RECTIFIER K+ CHANNEL; CORTICAL COLLECTING TUBULE; POTASSIUM CHANNELS; HYDROPHOBIC DOMAIN; NA+ CHANNEL; MOLECULAR-BASIS; ATP CHANNELS; PORE; VOLTAGE	Epithelial sodium channels (ENaC) are composed of three structurally related subunits (alpha, beta, and gamma). Each subunit has two transmembrane domains termed Ml and M2, and residues conferring cation selectivity have been shown to reside in a pore region immediately preceding the M2 domains of the three subunits. Negatively charged residues are interspersed within the M2 domains, and substitution of individual acidic residues within human alpha -ENaC with arginine essentially eliminated channel activity in oocytes, suggesting that these residues have a role in ion permeation. We examined the roles of M2 residues in contributing to the permeation pore by individually mutating residues within the M2 domain of mouse alpha ENaC to cysteine and systematically characterizing functional properties of mutant channels expressed in Xenopus oocytes by two-electrode voltage clamp. The introduction of cysteine residues at selected sites, including negatively charged residues (alpha Glu(595), alpha Glu(598), and alpha Asp(602)) led to a significant reduction of expressed amiloride-sensitive Na+ currents. Two mutations (alpha E595C and alpha D602C) resulted in K+-permeable channels whereas multiple mutations altered Li+/ Na+ current ratios. Channels containing alpha D602K or alpha D602A also conducted K+ whereas more conservative mutations (alpha D602E and alpha D602N) retained wild type selectivity. Cysteine substitution at the site equivalent to alpha Asp(602) within beta mENaC (beta D544C) did not alter either Li+/Na+ or K+/Na+ current ratios, although mutation of the equivalent site within gamma mENaC (gamma D562C) significantly increased the Li+/Na+ current ratio. Mutants containing introduced cysteine residues at alpha GlU(595), alpha Glu(598), alpha Asp(602), or alpha Thr(607). did not respond to externally applied sulfhydryl reagent with significant changes in macroscopic currents. Our results suggest that some residues within the M2 domain of alpha ENaC contribute to the channel's conduction pore and that, in addition to the pore region, selected sites within M2 (alpha Glu(595) and alpha Asp(602)) may have a role in conferring ion selectivity.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA 15261 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania	Kleyman, TR (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.		Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NIDDK NIH HHS [DK54354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrams CJ, 1996, J PHYSIOL-LONDON, V493, P643, DOI 10.1113/jphysiol.1996.sp021411; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Choe H, 2000, J GEN PHYSIOL, V115, P391, DOI 10.1085/jgp.115.4.391; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Feng ZP, 2001, J BIOL CHEM, V276, P5726, DOI 10.1074/jbc.C000791200; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; HILLOE B, 2001, ION CHANNELS EXCITAB; Immke D, 1998, RECEPTOR CHANNEL, V6, P179; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Keynes RD, 1999, P ROY SOC B-BIOL SCI, V266, P843, DOI 10.1098/rspb.1999.0714; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; Liu Y, 1998, PFLUG ARCH EUR J PHY, V435, P654, DOI 10.1007/s004240050566; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Loussouarn G, 2001, P NATL ACAD SCI USA, V98, P4227, DOI 10.1073/pnas.061452698; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; LU Z, 1995, BIOCHEMISTRY-US, V34, P13133, DOI 10.1021/bi00040a026; LU Z, 1994, J GEN PHYSIOL, V104, P477, DOI 10.1085/jgp.104.3.477; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Miller C, 2000, CURR OPIN CHEM BIOL, V4, P148, DOI 10.1016/S1367-5931(99)00068-X; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Ogielska EM, 1998, J GEN PHYSIOL, V112, P243, DOI 10.1085/jgp.112.2.243; Oliver D, 2000, EUR J BIOCHEM, V267, P5824, DOI 10.1046/j.1432-1327.2000.01669.x; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3	47	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44091	44098		10.1074/jbc.M108522200	http://dx.doi.org/10.1074/jbc.M108522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564745	hybrid			2022-12-25	WOS:000172297700079
J	Tan, KML; Chan, SL; Tan, KO; Yu, VC				Tan, KML; Chan, SL; Tan, KO; Yu, VC			The Caenorhabditis elegans sex-determining protein FEM-2 and its human homologue, hFEM-2, are Ca (2+)/calmodulin-dependent protein kinase phosphatases that promote apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DETERMINING GENE; SIGNAL-TRANSDUCTION; MEDIATES APOPTOSIS; EVOLUTION; SUBSTRATE; CLONING; CED-3; 2C; CONSERVATION	In Caenorhabditis elegans, fem-1, fem-2, and fem-3 play pivotal roles in sex determination. Recently, a mammalian homologue of the C. elegans sex-determining protein FEM-1, F1A alpha, has been described. Although there is little evidence to link F1A alpha to sex determination, F1A alpha and FEM-1 both promote apoptosis in mammalian cells. Here we report the identification and characterization of a human homologue of the C. elegans sex-determining protein FEM-2, hFEM-2. Similar to FEM-2, hFEM-2 exhibited PP2C phosphatase activity and associated with FEM-3. hFEM-2 shows striking similarity (79% amino acid identity) to rat Ca2+/calmodulin (CaM)-dependent protein kinase phosphatase (rCaMKPase). hFEM-2 and FEM-2, but not PP2C alpha, were demonstrated to dephosphorylate CaM kinase H efficiently in vitro, suggesting that hFEM-2 and FEM-2 are specific phosphatases for CaM kinase. Furthermore, hFEM-2 and FEM-2 associated with F1A alpha and FEM-1 respectively. Overexpression of hFEM-2, FEM-2, or rCaMKPase all mediated apoptosis in mammalian cells. The catalytically active, but not the inactive, forms of hFEM-2 induced caspase-dependent apoptosis, which was blocked by Bcl-XL or a dominant negative mutant of caspase-9. Taken together, our data suggest that hFEM-2 and rCaMKPase are mammalian homologues of FEM-2 and they are evolutionarily conserved CaM kinase phosphatases that may have a role in apoptosis signaling.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Yu, VC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbyuck@imcb.nus.edu.sg	Chan, S.L./X-4154-2018; Yu, Victor/A-7899-2015	Chan, S.L./0000-0002-3270-0525; Yu, Victor/0000-0003-3270-4734; Tan, Kuan/0000-0002-0947-7337; Tan, Karen/0000-0002-7768-037X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AHRINGER J, 1992, EMBO J, V11, P2303, DOI 10.1002/j.1460-2075.1992.tb05289.x; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan SL, 2000, J BIOL CHEM, V275, P17925, DOI 10.1074/jbc.C000146200; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; ChinSang ID, 1996, GENE DEV, V10, P2314, DOI 10.1101/gad.10.18.2314; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; deBono M, 1996, GENETICS, V144, P587; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Fujisawa H, 2001, J BIOCHEM-TOKYO, V129, P193, DOI 10.1093/oxfordjournals.jbchem.a002843; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Hansen D, 1999, MECH DEVELOP, V83, P3, DOI 10.1016/S0925-4773(99)00024-6; Hansen D, 1998, GENETICS, V149, P1353; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Horvitz HR, 1999, CANCER RES, V59, p1701S; Ishida A, 1998, BIOCHEM BIOPH RES CO, V253, P159, DOI 10.1006/bbrc.1998.9771; Ishida A, 1998, J BIOL CHEM, V273, P1904, DOI 10.1074/jbc.273.4.1904; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Kuwabara PE, 1996, GENETICS, V144, P597; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990; Marley AE, 1998, FEBS LETT, V431, P121, DOI 10.1016/S0014-5793(98)00708-X; McGinnis KM, 2001, NEUROSCI LETT, V301, P99, DOI 10.1016/S0304-3940(01)01629-9; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PILGRIM D, 1995, MOL BIOL CELL, V6, P1159, DOI 10.1091/mbc.6.9.1159; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schafer AJ, 1996, BIOESSAYS, V18, P955, DOI 10.1002/bies.950181205; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; SHACKELFORD DA, 1995, J CEREBR BLOOD F MET, V15, P450, DOI 10.1038/jcbfm.1995.56; Shamloo M, 2000, NEUROSCIENCE, V96, P665, DOI 10.1016/S0306-4522(99)00586-2; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; Smith CA, 1999, NATURE, V402, P601, DOI 10.1038/45130; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366	56	45	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44193	44202		10.1074/jbc.M105880200	http://dx.doi.org/10.1074/jbc.M105880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559703	hybrid			2022-12-25	WOS:000172297700091
J	Gensure, RC; Carter, PH; Petroni, BD; Juppner, H; Gardella, TJ				Gensure, RC; Carter, PH; Petroni, BD; Juppner, H; Gardella, TJ			Identification of determinants of inverse agonism in a constitutively active parathyroid hormone/parathyroid hormone-related peptide receptor by photoaffinity cross-linking and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TERMINAL REGION; WILD-TYPE; BINDING; PTH; ANTAGONISTS; ACTIVATION; MUTAGENESIS; RESIDUES; ANALOGS	We have investigated receptor structural components responsible for ligand-dependent inverse agonism in a constitutively active mutant of the human parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor type 1 (hP1R). This mutant receptor, hP1R-H223R (hP1R(CAM-HR)), was originally identified in Jansen's chondrodysplasia and is altered in transmembrane domain (TM) 2. We utilized the PTHrP analog, [Bpa(2), Ile(5),Trp(23),Tyr(36)]PTHrP-(1-36)-amide (Bpa(2)-PTHrP- (1-36)), which has valine 2 replaced by p-benzoyl-L-phenylalanine (Bpa); this substitution renders the peptide a photoreactive inverse agonist at hP1R(CAM-HR). This analog cross-linked to hP1R(CAM-HR) at two contiguous receptor regions as follows: the principal cross-link site (site A) was between receptor residues Pro(415)-Met(441), spanning the TM6/extracellular loop three boundary; the second crosslink site (site B) was within the TM4/TM5 region. Within the site A interval, substitution of Met(425) to Leu converted Bpa(2)-PTHrP-(1-36) from an inverse agonist to a weak partial agonist; this conversion was accompanied by a relative shift of cross-linking from site A to site B. The functional effect of the M425L mutation was specific for Bpa(2)-containing analogs, as inverse agonism of Bpa(2)-PTH-(1-34) was similarly eliminated, whereas inverse agonism of [Leu(11), D-Trp(12)]PTHrP-(5-36) was not affected. Overall, our data indicate that interactions between residue 2 of the ligand and the extracellular end of TM6 of the hP1R play an important role in modulating the conversion between active and inactive receptor states.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.	gardella@helix.mgh.harvard.edu			NIDDK NIH HHS [DK11794, 1F32DK10034-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK010034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alewijnse AE, 1998, J NEUROCHEM, V71, P799; Bakker RA, 2000, EUR J PHARMACOL, V387, pR5, DOI 10.1016/S0014-2999(99)00803-1; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Bowen WP, 1995, TRENDS PHARMACOL SCI, V16, P413, DOI 10.1016/S0165-6147(00)89091-4; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Carter PH, 2001, ENDOCRINOLOGY, V142, P1534, DOI 10.1210/en.142.4.1534; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Claeysen S, 2000, MOL PHARMACOL, V58, P136, DOI 10.1124/mol.58.1.136; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; de Ligt RAF, 2000, BRIT J PHARMACOL, V130, P1, DOI 10.1038/sj.bjp.0703311; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Gardella T J, 2000, Rev Endocr Metab Disord, V1, P317, DOI 10.1023/A:1026522619828; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Hall DA, 1997, BRIT J PHARMACOL, V121, P731, DOI 10.1038/sj.bjp.0701196; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; HORIUCHI N, 1983, SCIENCE, V220, P1053, DOI 10.1126/science.6302844; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; Juppner H., 2000, ENDOCRINOLOGY, P969; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kronenberg HM, 1998, RECENT PROG HORM RES, V53, P283; Kronenberg HM, 1998, RECENT PROG HORM RES, V53, P301; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lattion AL, 1999, FEBS LETT, V457, P302, DOI 10.1016/S0014-5793(99)01064-9; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; Nagaraja S, 1999, BRIT J PHARMACOL, V127, P1099, DOI 10.1038/sj.bjp.0702645; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; Rolz C, 2001, BIOPHYS CHEM, V89, P119, DOI 10.1016/S0301-4622(00)00222-2; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schipani E, 1999, J CLIN ENDOCR METAB, V84, P3052, DOI 10.1210/jc.84.9.3052; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200	45	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42692	42699		10.1074/jbc.M106215200	http://dx.doi.org/10.1074/jbc.M106215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553625	hybrid			2022-12-25	WOS:000172169300009
J	Hayashi, M; Otsuka, M; Morimoto, R; Hirota, S; Yatsushiro, S; Takeda, J; Yamamoto, A; Moriyama, Y				Hayashi, M; Otsuka, M; Morimoto, R; Hirota, S; Yatsushiro, S; Takeda, J; Yamamoto, A; Moriyama, Y			Differentiation-associated Na+-dependent inorganic phosphate cotransporter (DNIPI) is a vesicular glutamate transporter in endocrine glutamatergic systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVESICLE-MEDIATED EXOCYTOSIS; SYNAPTIC-LIKE MICROVESICLES; RAT PINEALOCYTES; CHEMICAL TRANSDUCTION; REGIONAL EXPRESSION; PANCREATIC-ISLETS; AMPA SUBTYPE; CELLS; VESICLES; BRAIN	Vesicular glutamate transporter is present in neuronal synaptic vesicles and endocrine synaptic-like microvesicles and is responsible for vesicular storage of L-glutamate. A brain-specific Na+-dependent inorganic phosphate transporter (BNPI) functions as a vesicular glutamate transporter in synaptic vesicles, and the expression of this BNPI defines the glutamatergic phenotype in the central nervous system (Bellocchio, E. E., Reimer, R. J., Fremeau, R.T., Jr., and Edwards, R. H. (2000) Science 289, 957-960; Takamori, S., Rhee, J. S., Rosenmund, C., and Jahn, R. (2000) Nature 407, 189-194). However, since not all glutamatergic neurons contain BNPI, an additional transporter(s) responsible for vesicular glutamate uptake has been postulated. Here we report that differentiation-associated Na+-dependent inorganic phosphate cotransporter (DNPI), an isoform of BNPI (Aihara, Y., Mashima, H., Onda, H., Hisano, S., Kasuya, H., Hori, T., Yamada, S., Tomura, H., Yamada, Y., Inoue, I., Kojima, I., and Takeda, J. (2000) J. Neurochem. 74, 2622-2625), also transports L-glutamate at the expense of an electrochemical gradient of protons established by the vacuolar proton pump when expressed in COS7 cells. Molecular, biological, and immunohistochemical studies have indicated that besides its presence in neuronal cells DNPI is preferentially expressed in mammalian pinealocytes, alpha TC6 cells, clonal pancreatic alpha cells, and alpha cells of Langerhans islets, these cells being proven to secrete L-glutamate through Ca2+-dependent regulated exocytosis followed by its vesicular storage. Pancreatic polypeptide-secreting F cells of Langerhans islets also expressed DNPI. These results constitute evidence that DNPI functions as another vesicular transporter in glutamatergic endocrine cells as well as in neurons.	Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, Okayama 7008530, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Maebashi, Gumma 3718512, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan	Okayama University; Gunma University; Kansai Medical University	Moriyama, Y (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.							Aihara Y, 2000, J NEUROCHEM, V74, P2622, DOI 10.1046/j.1471-4159.2000.0742622.x; Bai LQ, 2001, J BIOL CHEM, V276, P36764, DOI 10.1074/jbc.M104578200; Bellocchio EE, 1998, J NEUROSCI, V18, P8648; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FOSTER AC, 1984, BRAIN RES REV, V7, P103, DOI 10.1016/0165-0173(84)90020-1; Fujiyama F, 2001, J COMP NEUROL, V435, P379, DOI 10.1002/cne.1037; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; Hayashi M, 1999, J NEUROCHEM, V73, P2538, DOI 10.1046/j.1471-4159.1999.0732538.x; Hayashi T, 1998, J NEUROCHEM, V71, P356; Hisano S, 2000, MOL BRAIN RES, V83, P34, DOI 10.1016/S0169-328X(00)00194-7; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MORIYAMA Y, 1995, FEBS LETT, V367, P233, DOI 10.1016/0014-5793(95)00559-R; Moriyama Y, 1996, BIOL CHEM H-S, V377, P155; Moriyama Y, 2000, J EXP BIOL, V203, P117; MORIYAMA Y, 1995, J BIOL CHEM, V270, P22314, DOI 10.1074/jbc.270.38.22314; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NERLSON N, 1999, PHYSIOL REV, V79, P361; NI BH, 1995, J NEUROSCI, V15, P5789; NI BH, 1994, P NATL ACAD SCI USA, V91, P5607, DOI 10.1073/pnas.91.12.5607; Otis TS, 2001, NEURON, V29, P11, DOI 10.1016/S0896-6273(01)00176-3; PAPASOZOMENOS SC, 1983, J NEUROPATH EXP NEUR, V42, P391, DOI 10.1097/00005072-198307000-00003; PEDERSEN EB, 1993, CELL TISSUE RES, V272, P257, DOI 10.1007/BF00302731; REDECKER P, 1993, J NEUROSCI RES, V34, P79, DOI 10.1002/jnr.490340109; Redecker P, 1999, INT REV CYTOL, V191, P201, DOI 10.1016/S0074-7696(08)60160-6; Sakata-Haga H, 2001, BRAIN RES, V902, P143, DOI 10.1016/S0006-8993(01)02290-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHNER M, 1984, CELL TISSUE RES, V237, P245, DOI 10.1007/BF00217142; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Weaver CD, 1998, J BIOL CHEM, V273, P1647, DOI 10.1074/jbc.273.3.1647; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977; Yamada H, 1996, J PINEAL RES, V21, P175, DOI 10.1111/j.1600-079X.1996.tb00285.x; Yamada H, 1997, J NEUROCHEM, V69, P1491; Yamada H, 1998, J NEUROSCI, V18, P2056; Yamada H, 2001, DIABETES, V50, P1012, DOI 10.2337/diabetes.50.5.1012; Yatsushiro S, 1997, J NEUROCHEM, V69, P340	46	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43400	43406		10.1074/jbc.M106244200	http://dx.doi.org/10.1074/jbc.M106244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551935	hybrid			2022-12-25	WOS:000172169300099
J	Dickson, KS; Thompson, SR; Gray, NK; Wickens, M				Dickson, KS; Thompson, SR; Gray, NK; Wickens, M			Poly(A) polymerase and the regulation of cytoplasmic polyadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTE MATURATION; B1 MESSENGER-RNA; SPECIFICITY FACTOR; TRANSLATION INITIATION; C-MOS; MUTATIONAL ANALYSIS; BINDING-PROTEIN; FROG OOCYTES; CPEB; CLEAVAGE	Translational activation in oocytes and embryos is often regulated via increases in poly(A) length. Cleavage and polyadenylation specificity factor (CPSF), cytoplasmic polyadenylation element binding protein (CPEB), and poly(A) polymerase (PAP) have each been implicated in cytoplasmic polyadenylation in Xenopus laevis oocytes. Cytoplasmic polyadenylation activity first appears in vertebrate oocytes during meiotic maturation. Data presented here shows that complexes containing both CPSF and CPEB are present in extracts of X. laevis oocytes prepared before or after meiotic maturation. Assessment of a variety of RNA sequences as polyadenylation substrates indicates that the sequence specificity of polyadenylation in egg extracts is comparable to that observed with highly purified mammalian CPSF and recombinant PAP. The two in vitro systems exhibit a sequence specificity that is similar, but not identical, to that observed in vivo, as assessed by injection of the same RNAs into the oocyte. These findings imply that CPSFs intrinsic RNA sequence preferences are sufficient to account for the specificity of cytoplasmic polyadenylation of some mRNAs. We discuss the hypothesis that CPSF is required for all polyadenylation reactions, but that the polyadenylation of some mRNAs may require additional factors such as CPEB. To test the consequences of PAP binding to mRNAs in vivo, PAP was tethered to a reporter mRNA in resting oocytes using MS2 coat protein. Tethered PAP catalyzed polyadenylation and stimulated translation similar to 40-fold; stimulation was exclusively cis-acting, but was independent of a CPE and AAUAAA. Both polyadenylation and translational stimulation required PAPs catalytic core, but did not require the putative CPSF interaction domain of PAP. These results demonstrate that premature recruitment of PAP can cause precocious polyadenylation and translational stimulation in the resting oocyte, and can be interpreted to suggest that the role of other factors is to deliver PAP to the mRNA.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wickens, M (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA.	wickens@biochen.wisc.edu		gray, nicola/0000-0002-0413-1767; Thompson, Sunnie/0000-0002-7338-8822	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031892] Funding Source: NIH RePORTER; Medical Research Council [MC_U127561111] Funding Source: Medline; NIGMS NIH HHS [R01 GM31892] Funding Source: Medline; MRC [MC_U127561111] Funding Source: UKRI	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALLANTYNE S, 1995, RNA, V1, P64; Ballantyne S, 1997, MOL BIOL CELL, V8, P1633, DOI 10.1091/mbc.8.8.1633; Barkoff AF, 2000, DEV BIOL, V220, P97, DOI 10.1006/dbio.2000.9613; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAVIDSON EH, 1986, GENE ACTIVATION EARL; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Dickson KS, 1999, MOL CELL BIOL, V19, P5707; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; GEBAUER F, 1995, MOL CELL BIOL, V15, P1422; Gillian-Daniel DL, 1998, MOL CELL BIOL, V18, P6152, DOI 10.1128/MCB.18.10.6152; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hake LE, 1998, MOL CELL BIOL, V18, P685, DOI 10.1128/MCB.18.2.685; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Keiper BD, 1999, DEV BIOL, V206, P1, DOI 10.1006/dbio.1998.9131; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Martin G, 1999, PROTEIN SCI, V8, P2380; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Minshall N, 1999, RNA, V5, P27, DOI 10.1017/S1355838299981220; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; RAABE T, 1994, MOL CELL BIOL, V14, P2946, DOI 10.1128/MCB.14.5.2946; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; Verrotti AC, 1996, P NATL ACAD SCI USA, V93, P9027, DOI 10.1073/pnas.93.17.9027; Wahle E, 1997, PROG NUCLEIC ACID RE, V57, P41, DOI 10.1016/S0079-6603(08)60277-9; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Wakiyama M, 2000, CURR BIOL, V10, P1147, DOI 10.1016/S0960-9822(00)00701-6; Walker J, 1999, RNA, V5, P14, DOI 10.1017/S1355838299981219; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; WICKENS M, 1992, SEM DEV BIOL, V3, P399; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	54	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41810	41816		10.1074/jbc.M103030200	http://dx.doi.org/10.1074/jbc.M103030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551905	hybrid			2022-12-25	WOS:000172450400037
J	Paulhe, F; Racaud-Sultan, C; Ragab, A; Albiges-Rizo, C; Chap, H; Iberg, N; Morand, O; Perret, B				Paulhe, F; Racaud-Sultan, C; Ragab, A; Albiges-Rizo, C; Chap, H; Iberg, N; Morand, O; Perret, B			Differential regulation of phosphoinositide metabolism by alpha(V)beta(3) and alpha(V)beta(5) integrins upon smooth muscle cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 4-KINASE; FACTOR-I; PYK2; ACTIVATION; 3-KINASE; VITRONECTIN; PHOSPHORYLATION	Smooth muscle cell migration is a key step of atherosclerosis and angiogenesis. We demonstrate that alpha (V)beta (3) and alpha (V)beta (5) integrins synergistically regulate smooth muscle cell migration onto vitronectin. Using an original haptotactic cell migration assay, we measured a strong stimulation of phosphoinositide metabolism in migrating vascular smooth muscle cells. Phosphatidic acid production and phosphoinositide 3-kinase IA activation were triggered only upon alpha (V)beta (3) engagement. Blockade of alpha (V)beta (3) engagement or phospholipase C activity resulted in a strong inhibition of smooth muscle cell spreading on vitronectin. By contrast, blockade of alpha (V)beta (5) reinforced elongation and polarization of cell shape. Moreover, Pyk2-associated tyrosine kinase and phosphoinositide 4-kinase activities measured in Pyk2 immunoprecipitates were stimulated upon cell migration. Blockade of either alpha (V)beta (3) or alpha (V)beta (5) function, as well as inhibition of phospholipase C activity, decreased both Pyk2-associated activities. We demonstrated that the Pyk2-associated phosphoinositide 4-kinase corresponded to the beta isoform. Our data point to the metabolism of phosphoinositides as a regulatory pathway for the differential roles played by alpha (V)beta (3) and alpha (V)beta (5) upon cell migration and identify the Pyk2-associated phosphoinositide 4-kinase beta as a common target for both integrins.	Hop Purpan, INSERM, Unite 326, Inst Federat Rech Claude De Preval, F-31059 Toulouse, France; F Hoffmann La Roche & Co Ltd, Div Pharmaceut, Preclin Cardiovasc Res, CH-4002 Basel, Switzerland; Fac Med Grenoble, Inst ALbert Bonniot, UJF, CNRS,UMR 5538,LEDAC, F-38706 La Tronche, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Roche Holding; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Racaud-Sultan, C (corresponding author), Hop Purpan, INSERM, Unite 326, Inst Federat Rech Claude De Preval, F-31059 Toulouse, France.	racaud@purpan.inserm.fr	Albiges-Rizo, Corinne/M-2568-2013	Racaud-Sultan, Claire/0000-0002-6549-1088; ALBIGES-RIZO, Corinne/0000-0002-6333-4150				AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Astier A, 1997, J BIOL CHEM, V272, P228; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; Corjay MH, 1999, J CELL BIOCHEM, V75, P492, DOI 10.1002/(SICI)1097-4644(19991201)75:3<492::AID-JCB13>3.3.CO;2-Q; DELANNET M, 1994, DEVELOPMENT, V120, P2687; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; Dufourcq P, 1998, ARTERIOSCL THROM VAS, V18, P168, DOI 10.1161/01.ATV.18.2.168; Fernandis AZ, 2000, MOL IMMUNOL, V37, P273, DOI 10.1016/S0161-5890(00)00053-5; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Greenwood JA, 1998, J BIOL CHEM, V273, P1755, DOI 10.1074/jbc.273.3.1755; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; JOLLES J, 1981, BIOCHIM BIOPHYS ACTA, V666, P90, DOI 10.1016/0005-2760(81)90094-1; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Sayed MR, 2000, J CELL PHYSIOL, V183, P314, DOI 10.1002/(SICI)1097-4652(200006)183:3<314::AID-JCP3>3.0.CO;2-J; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	52	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41832	41840		10.1074/jbc.M105459200	http://dx.doi.org/10.1074/jbc.M105459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551924	hybrid			2022-12-25	WOS:000172450400040
J	Zheng, XL; Chung, D; Takayama, TK; Majerus, EM; Sadler, JE; Fujikawa, K				Zheng, XL; Chung, D; Takayama, TK; Majerus, EM; Sadler, JE; Fujikawa, K			Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CYSTEINE SWITCH; GENE FAMILY; CDNA CLONES; PROCOLLAGEN; PROTEINS; IDENTIFICATION; AGGRECANASE-1; PREDICTION; SEQUENCES	Thrombotic thrombocytopenic purpura is associated with acquired or congenital deficiency of a plasma von Willebrand factor-cleaving protease (VWFCP). Based on partial amino acid sequence, VWFCP was identified recently as a new member of the ADAMTS family of metalloproteases and designated ADAMTS13. The 4.6-kilo-base pair cDNA sequence for VWFCP has now been determined. By Northern blotting, full-length VWFCP mRNA was detected only in liver. VWFCP consists of 1427 amino acid residues and has a signal peptide, a short propeptide terminating in the sequence RQRR, a reprolysin-like metalloprotease domain, a disintegrin-like domain, a thrombospondin-1 repeat, a Cys-rich domain, an ADAMTS spacer, seven additional thrombospondin-1 repeats, and two CUB domains. VWFCP apparently is made as a zymogen that requires proteolytic activation, possibly by furin intracellularly. Sites for Zn2+ and Ca2+ ions are conserved in the protease domain. The Cys-rich domain contains an RGDS sequence that could mediate integrin-dependent binding to platelets or other cells. Alternative splicing gives rise to at least seven potential variants that truncate the protein at different positions after the protease domain. Alternative splicing may have functional significance, producing proteins with distinct abilities to interact with cofactors, connective tissue, platelets, and von Wiliebrand factor.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.		Zheng, X. Long/ABD-7362-2021; Sadler, Evan/D-8556-2011	Zheng, X. Long/0000-0003-1680-5295; Sadler, J. Evan/0000-0001-5705-469X; Chung, Dominic/0000-0002-2645-5703	NHLBI NIH HHS [HL16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Adams JC, 2000, DEV DYNAM, V218, P280; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1997, BLOOD, V89, P3097, DOI 10.1182/blood.V89.9.3097; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kaushal GP, 2000, J CLIN INVEST, V105, P1335, DOI 10.1172/JCI10078; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Panetti TS, 1999, J BIOL CHEM, V274, P430, DOI 10.1074/jbc.274.1.430; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1995, PROTEIN SCI, V4, P823; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Xu Y, 1997, J COMPUT BIOL, V4, P325, DOI 10.1089/cmb.1997.4.325	49	620	688	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41059	41063		10.1074/jbc.C100515200	http://dx.doi.org/10.1074/jbc.C100515200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11557746	hybrid			2022-12-25	WOS:000171925600092
J	Knoepfler, PS; Sykes, DB; Pasillas, M; Kamps, MP				Knoepfler, PS; Sykes, DB; Pasillas, M; Kamps, MP			HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation	ONCOGENE			English	Article						HoxB8; Pbx; myeloid; differentiation	COOPERATIVE DNA-BINDING; HOMEOBOX GENE; SOMATOSTATIN PROMOTER; ONCOPROTEIN E2A-PBX1; IN-VIVO; PRE-B; LEUKEMIA; PROTEINS; HOMEODOMAIN; EXPRESSION	HoxB8 was the first homeobox gene identified as a cause of leukemia. In murine WEHI3B acute myeloid leukemia (AML) cells, proviral integration leads to the expression of both HoxB8 and Interleukin (IL-3). Enforced expression of HoxB8 blocks differentiation of factor-dependent myeloid progenitors, while IL-3 co-expression induces autocrine proliferation and overt leukemogenicity. Previously, we demonstrated that HoxB8 binds DNA cooperatively with members of the Pbx family of transcription factors, and that HoxB8 makes contact with the Pbx homeodomain through a hexameric sequence designated the Pbx-interaction motif (PIM). E2a-Pbx1, an oncogenic derivative of Pbx1, both retains its ability to heterodimerize with Hox proteins and arrest myeloid differentiation. This observation prompts the question of whether E2a-Pbx1 and Hox oncoproteins use endogenous Hox and Pbx proteins, respectively, to target a common set of cellular genes. Here, we use four different models of neutrophil and macrophage differentiation to determine whether HoxB8 needs to bind DNA or Pbx cofactors in order to arrest myeloid differentiation. The ability of HoxB8 to bind DNA or to bind Pbx was essential (1) to block differentiation of factor-dependent myeloid progenitors from primary marrow; (2) to block IL-6-induced monocytic differentiation of M1-AML cells; and (3) to block granulocytic differentiation of GM-CSF-dependent ECoM-G cells. However, while DNA-binding was required, the HoxB8 Pbx-interaction motif was unnecessary for preventing macrophage differentiation of ECoM-M cells. We conclude that HoxB8 prevents differentiation by directly influencing cellular gene expression, and that the genetic context within a cell dictates whether the effect of HoxB8 is dependent on a physical interaction with Pbx proteins.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA	University of California System; University of California San Diego; Fred Hutchinson Cancer Center	Kamps, MP (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Knoepfler, Paul/0000-0001-5444-334X	NCI NIH HHS [CA56876] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Izon DJ, 1998, BLOOD, V92, P383, DOI 10.1182/blood.V92.2.383.414k41_383_393; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SYKES DB, 2001, IN PRESS BLOOD; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Yaron Y, 2001, J IMMUNOL, V166, P5058, DOI 10.4049/jimmunol.166.8.5058	47	48	52	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5440	5448		10.1038/sj.onc.1204710	http://dx.doi.org/10.1038/sj.onc.1204710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571641				2022-12-25	WOS:000170781100004
J	Smith, ER; Capo-chichi, CD; He, JQ; Smedberg, JL; Yang, DH; Prowse, AH; Godwin, AK; Hamilton, TC; Xu, XX				Smith, ER; Capo-chichi, CD; He, JQ; Smedberg, JL; Yang, DH; Prowse, AH; Godwin, AK; Hamilton, TC; Xu, XX			Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN ADENOCARCINOMA CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR; TERATOCARCINOMA CELLS; ADAPTER PROTEIN; EXPRESSION; GENE; RECEPTOR; DOMAIN; MOUSE	F9 embryonic stem cell-like teratocarcinoma cells are widely used to study early embryonic development and cell differentiation. The cells can be induced by retinoic acid to undergo endodermal differentiation. The retinoic acid-induced differentiation accompanies cell growth suppression, and thus, F9 cells are also often used as a model for analysis of retinoic acid biological activity. We have recently shown that MAPK activation and c-Fos expression are uncoupled in F9 cells upon retinoic acid-induced endodermal differentiation. The expression of the candidate tumor suppressor Disabled-2 is induced and correlates with cell growth suppression in F9 cells. We were not able to establish stable Disabled-2 expression by cDNA transfection in F9 cells without induction of spontaneous cell differentiation. Transient transfection of Dab2 by adenoviral vector nevertheless suppresses Elk-1 phosphorylation, c-Fos expression, and cell growth. In PA-1, another teratocarcinoma cell line of human origin that has no or very low levels of Disabled-2, retinoic acid fails to induce Disabled-2, correlating with a lack of growth suppression, although PA-I is responsive to retinoic acid in morphological change. Transfection and expression of Disabled-2 in PA-1 cells mimic the effects of retinoic acid on growth suppression; the Disabled-2-expressing cells reach a much lower saturation density, and serum-stimulated c-Fos expression is greatly suppressed and disassociated from MAPK activation. Thus, Dab2 is one of the principal genes induced by retinoic acid involved in cell growth suppression, and expression of Dab2 alone is sufficient for uncoupling of MAPK activation and c-Fos expression. Resistance to retinoic acid regulation in PA-1 cells likely results from defects in retinoic acid up-regulation of Dab2 expression.	Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, Philadelphia, PA 19111 USA; Emory Univ, Sch Med, Atlanta, GA 30322 USA	Fox Chase Cancer Center; Emory University	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	X_XU@feee.edu			NATIONAL CANCER INSTITUTE [R01CA075389, R01CA079716] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 79716, R01 CA 75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BIELINSKA M, 1995, BIOCHEM J, V307, P183, DOI 10.1042/bj3070183; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Cho SY, 1999, MOL CELLS, V9, P179; CLARKSON B, 1991, CANCER CELL-MON REV, V3, P211; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DE LUCA LM, 1991, FASEB J, V5, P2924; EARLY E, 1995, J INVEST MED, V43, P337; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LERUPPERT K, 1992, INT J CANCER, V51, P646, DOI 10.1002/ijc.2910510423; Lin F, 2000, CANCER RES, V60, P3271; MENDRICK DL, 1990, EXP CELL RES, V188, P23, DOI 10.1016/0014-4827(90)90273-D; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Murakami A, 1999, J BIOL CHEM, V274, P17242, DOI 10.1074/jbc.274.24.17242; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Rice DS, 1999, GENE DEV, V13, P2758, DOI 10.1101/gad.13.21.2758; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng ZJ, 2000, GENOMICS, V70, P381, DOI 10.1006/geno.2000.6383; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHERMAN MI, 1978, DEV BIOL, V63, P27, DOI 10.1016/0012-1606(78)90110-0; Smith ER, 2001, J BIOL CHEM, V276, P32094, DOI 10.1074/jbc.M105009200; Soprano DR, 1996, ONCOGENE, V12, P577; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; TAYLOR DD, 1990, DIFFERENTIATION, V43, P123, DOI 10.1111/j.1432-0436.1990.tb00438.x; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1994, J BIOL CHEM, V269, P607; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	52	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47303	47310		10.1074/jbc.M106158200	http://dx.doi.org/10.1074/jbc.M106158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577091	hybrid			2022-12-25	WOS:000172768500085
J	Ho, CK; Shuman, S				Ho, CK; Shuman, S			Trypanosoma brucei RNA triphosphatase - Antiprotozoal drug target and guide to eukaryotic phylogeny	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING APPARATUS; GUANYLYLTRANSFERASE COMPONENT; NUCLEOSIDE TRIPHOSPHATASE; YEAST; MECHANISM; 5'-TRIPHOSPHATASE; ENZYMES	The mRNA capping apparatus of the protozoan parasite Trypanosoma brucei consists of separately encoded RNA triphosphatase and RNA guanylyltransferase enzymes. The triphosphatase ThCet1 is a member of a new family of metal-dependent phosphohydrolases that includes the RNA triphosphatases of fungi and the malaria parasite Plasmodium falciparum. The protozoal/fungal enzymes are structurally and mechanistically unrelated to the RNA triphosphatases of metazoans and plants. These results highlight the potential for discovery of broad spectrum antiprotozoal and antifungal. drugs that selectively block the capping of pathogen-encoded mRNAs. We propose a scheme of eukaryotic phylogeny based on the structure of RNA triphosphatase and its physical linkage to the guanylyltransferase component of the capping apparatus.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Ho, KIong/GPP-6051-2022					Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BANGS JD, 1992, J BIOL CHEM, V267, P9805; Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; Cattand P, 2001, TROP MED INT HEALTH, V6, P348, DOI 10.1046/j.1365-3156.2001.00669.x; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Docampo R, 2001, CURR PHARM DESIGN, V7, P1157, DOI 10.2174/1381612013397546; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Hausmann S, 2001, J BIOL CHEM, V276, P36116, DOI 10.1074/jbc.M105856200; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 2001, J VIROL, V75, P1744, DOI 10.1128/JVI.75.4.1744-1750.2001; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Mair G, 2000, J BIOL CHEM, V275, P28994, DOI 10.1074/jbc.M004193200; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Rodriguez JB, 2001, CURR PHARM DESIGN, V7, P1105, DOI 10.2174/1381612013397555; Schwer B, 2001, J BIOL CHEM, V276, P1857, DOI 10.1074/jbc.M006072200; Seed JR, 2001, INT J PARASITOL, V31, P434, DOI 10.1016/S0020-7519(01)00142-4; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Silva E, 1998, MOL CELL BIOL, V18, P4612, DOI 10.1128/MCB.18.8.4612; Takase Y, 2000, MOL CELL BIOL, V20, P9307, DOI 10.1128/MCB.20.24.9307-9316.2000; Tiggemann M, 2001, YEAST, V18, P815, DOI 10.1002/yea.728	28	23	23	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46182	46186		10.1074/jbc.M108706200	http://dx.doi.org/10.1074/jbc.M108706200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11553645	hybrid			2022-12-25	WOS:000172573100094
J	Christensen, M; Strange, K				Christensen, M; Strange, K			Developmental regulation of a novel outwardly rectifying mechanosensitive anion channel in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; VOLUME REGULATION; EPITHELIAL-CELLS; CL CHANNELS; NEURONS; CURRENTS; EXPRESSION; GENETICS; FAMILY; SENSITIVITY	The nematode Caenorhabditis elegans offers unique experimental advantages for defining the molecular basis of anion channel function and regulation. However, the relative inaccessibility of somatic cells in adult animals greatly limits direct electrophysiologcal studies of channel activity. We developed methods to routinely isolate and patch clamp C. elegans embryo cells and oocytes and to culture and patch clamp neurons and muscle cells. Dissociated embryonic cells express a robust outwardly rectifying anion current that is activated by membrane stretch and depolarization. This current, termed I-Cl,I-mec, is inhibited by anion and mechanosensitive channel inhibitors. I-Cl,I-mec has broad anion selectivity and the channel has a unitary conductance of 5-7 picosiemens. I-Cl,I-mec is not detectable in whole-cell or isolated patch recordings from oocytes, cultured muscle cells, and cultured neurons but is expressed in single cell and later embryos. Channel density is high, and the current is observed in >80% of membrane patches. Macroscopic currents of 40-120 pA at +100 mV are typically observed in inside-out membrane patches formed using low resistance patch pipettes. Isolated membrane patches of early embryonic cells therefore contain 60-200 I-Cl,I-mec channels. The apparent activation of I-Cl,I-mec shortly after fertilization and its down-regulation in terminally differentiated cells suggests that the channel may play important roles in embryogenesis and/or cytokinesis.	Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Anesthesiol Res Div,Med Ctr N T4202, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Strange, K (corresponding author), Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Anesthesiol Res Div,Med Ctr N T4202, Nashville, TN 37232 USA.	kevin.strange@mcmail.vanderbilt.edu			NIDDK NIH HHS [DK51610] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051610] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bamber BA, 1999, J NEUROSCI, V19, P5348; Barbier-Brygoo H, 2000, BBA-BIOMEMBRANES, V1465, P199, DOI 10.1016/S0005-2736(00)00139-5; BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; BRENNER S, 1974, GENETICS, V77, P71; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; Dieudonne S, 1997, J MEMBRANE BIOL, V159, P83, DOI 10.1007/s002329900271; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Eder C, 1998, J NEUROSCI, V18, P7127; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; Eggermont J, 1998, BIOCHEM J, V331, P347; FALKE LC, 1988, FEBS LETT, V237, P141, DOI 10.1016/0014-5793(88)80188-1; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hryciw DH, 2000, CLIN EXP PHARMACOL P, V27, P892, DOI 10.1046/j.1440-1681.2000.03356.x; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Jackson M B, 1999, Adv Neurol, V79, P511; Jackson PS, 1996, AM J PHYSIOL-CELL PH, V270, pC57, DOI 10.1152/ajpcell.1996.270.1.C57; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LEWIS JA, 1995, CAENORHABDITIS ELEGA, P4; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Lockery SR, 1998, METHOD ENZYMOL, V293, P201; Machaca K, 1996, DEV BIOL, V176, P1, DOI 10.1006/dbio.1996.9999; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Majid A, 2001, J PHYSIOL-LONDON, V534, P409, DOI 10.1111/j.1469-7793.2001.00409.x; Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Montell DJ, 1999, DEVELOPMENT, V126, P3035; Moody WJ, 1998, CURR TOP DEV BIOL, V39, P159, DOI 10.1016/S0070-2153(08)60455-X; Morris AP, 1999, ADV PHARMACOL, V46, P209, DOI 10.1016/S1054-3589(08)60472-X; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Pierce-Shimomura JT, 2001, NATURE, V410, P694, DOI 10.1038/35070575; Robertson AP, 1997, PARASITOLOGY, V115, P183, DOI 10.1017/S0031182097001273; Rutledge E, 2001, CURR BIOL, V11, P161, DOI 10.1016/S0960-9822(01)00051-3; Schriever AM, 1999, J BIOL CHEM, V274, P34238, DOI 10.1074/jbc.274.48.34238; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Tombola F, 2000, BIOPHYS J, V79, P863, DOI 10.1016/S0006-3495(00)76342-9; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zang JH, 1998, P NATL ACAD SCI USA, V95, P13652, DOI 10.1073/pnas.95.23.13652	57	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45024	45030		10.1074/jbc.M107652200	http://dx.doi.org/10.1074/jbc.M107652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11568185	hybrid			2022-12-25	WOS:000172406700092
J	Janowski, BA; Shan, B; Russell, DW				Janowski, BA; Shan, B; Russell, DW			The hypocholesterolemic agent LY295427 reverses suppression of sterol regulatory element-binding protein processing mediated by oxysterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE SPHINGOMYELIN; LEUCINE ZIPPER PROTEIN; A REDUCTASE-ACTIVITY; HAMSTER OVARY CELLS; HUMAN FIBROBLASTS; ENDOPLASMIC-RETICULUM; CHOLESTEROL-METABOLISM; CYSTEINE PROTEASE; LDL RECEPTOR	The sterol LY295427 reduces plasma cholesterol levels in animals by increasing the expression of hepatic low density lipoprotein (LDL) receptors. Here we trace the hypocholesterolemic activity of LY295427 to an ability to reverse oxysterol-mediated suppression of sterol regulatory element-binding protein (SREBP) processing. Micromolar concentrations of LY295427 induced the metabolism of LDL in oxysterol-treated cultured cells and inhibited the stimulation of cholesteryl ester synthesis mediated by oxysterols. cDNA microarray and RNA blotting experiments revealed that LY295427 increased levels of the LDL receptor mRNA and those of other SREBP target genes. The compound stimulated the accumulation of SREBPs in the nuclei of cells grown in the presence of oxysterols within 4-6 h of addition to the medium. Induction required components of the normal SREBP-processing pathway, including the SREBP cleavage-activating protein and the Site 1 protease. LY295427 overcame the suppression of SREBP processing mediated by several oxysterols but not by LDL-derived cholesterol. We conclude that LY295427 achieves a therapeutically desirable end point by an unique mechanism of action.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Tilarik Inc, San Francisco, CA 94080 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	russell@utsw.swmed.edu		Russell, David/0000-0002-0277-403X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bensch WR, 1999, J PHARMACOL EXP THER, V289, P85; Bowling N, 1996, J LIPID RES, V37, P2586; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1974, J BIOL CHEM, V249, P7306; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DAHL NK, 1994, J LIPID RES, V35, P1839; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Gardner RG, 2001, J BIOL CHEM, V276, P8681, DOI 10.1074/jbc.M007888200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lange Y, 1999, J LIPID RES, V40, P2264; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; Lin HS, 1999, STEROIDS, V64, P735, DOI 10.1016/S0039-128X(99)00053-7; LIN HS, 1995, J MED CHEM, V38, P277, DOI 10.1021/jm00002a010; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SAMBROOK J, 2000, MOL CLONING LAB MANU; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P251, DOI 10.1016/0005-2736(90)90301-4; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; Windaus A, 1909, BER DTSCH CHEM GES, V42, P238, DOI 10.1002/cber.19090420138; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	53	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45408	45416		10.1074/jbc.M108348200	http://dx.doi.org/10.1074/jbc.M108348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577112	hybrid			2022-12-25	WOS:000172406700138
J	Maga, G; Ramunno, A; Nacci, V; Locatelli, GA; Spadari, S; Fiorini, I; Baldanti, F; Paolucci, S; Zavattoni, M; Bergamini, A; Galletti, B; Muck, S; Hubscher, U; Giorgi, G; Guiso, G; Caccia, S; Campiani, G				Maga, G; Ramunno, A; Nacci, V; Locatelli, GA; Spadari, S; Fiorini, I; Baldanti, F; Paolucci, S; Zavattoni, M; Bergamini, A; Galletti, B; Muck, S; Hubscher, U; Giorgi, G; Guiso, G; Caccia, S; Campiani, G			The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464 - A novel generation of nonnucleoside inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; P-GLYCOPROTEIN; RT INHIBITORS; INFECTION; CHEMOTHERAPY; TRANSPORTER; NEVIRAPINE; METABOLISM	The human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitor pyrrolopyridooxazepinone (PPO) derivative, (+/-)-PPO294, was shown to be active toward wild type and mutated HIV-1 RT and to act synergistically in combination with 3'-azido-3'-deoxythymidine (Campiani, G., Morelli, E., Fabbrini, M., Nacci, V., Greco, G., Novellino, E., Ramunno, A., Maga, G., Spadari, S., Caliendo, G., Bergamini, A., Faggioli, E., Uccella, I., Bolacchi, F., Marini, S., (1999) J. Med. Chant. 42, 4462-4470). The (+/-)-PPO294 racemate was resolved into its pure enantiomers, and the absolute configuration was determined by x-ray analysis. Only one enantiomer, (R)-(-)-PPO464, displayed antiviral activity against both the wild type and the K103N mutant HIV-1 RT and was found to interact exclusively with the reaction intermediate formed by RT complexed with both the DNA and the nucleotide substrates. Being the first compound of its class to display this behavior, (R)-(-)-PPO464 is the representative of a novel generation of nonnucleoside inhibitors. (R)(-)-PPO464 showed significant synergism when tested in combination with other RT inhibitors and efficiently inhibited viral replication when tested against the laboratory strain HIV-1 IIIB or against either wild type or multidrug-resistant clinical isolates. Pharmacokinetic studies in mice and rats showed a more favorable profile for (R)-(-)-PPO464 than for the corresponding racemate. (R)-(-)-PPO464 was also found to easily cross the blood-brain barrier. The coadministration of the HIV-1 protease inhibitor ritonavir increased the bioavailability of (R)-(-)-PPO464, having little effect on its plasma and brain elimination rates.	Univ Siena, Dipartimento Farm Chim Tecnol, I-53100 Siena, Italy; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, Italy; Policlin San Matteo, IRCCS, Serv Virol, I-27100 Pavia, Italy; Univ Roma Tor Vergata, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy; Ind Farmaceut Riunite Spa, Sigma Tau, I-00040 Pomezia, Italy; Univ Zurich Irchel, Inst Vet Biochem, CH-8050 Zurich, Switzerland; Univ Siena, Ctr Interdipartimentale Anal & Determinaz Struttu, I-53100 Siena, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	University of Siena; Consiglio Nazionale delle Ricerche (CNR); University of Salerno; IRCCS Fondazione San Matteo; University of Pavia; University of Rome Tor Vergata; University of Zurich; University of Siena; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Campiani, G (corresponding author), Univ Siena, Dipartimento Farm Chim Tecnol, Via Laterina 8, I-53100 Siena, Italy.	campiani@unisi.it	Paolucci, Stefania/J-4055-2018; Maga, Giovanni/C-5409-2009; Baldanti, Fausto/J-4924-2018; Ramunno, Anna/ABD-7912-2021	Paolucci, Stefania/0000-0001-8447-8586; Maga, Giovanni/0000-0001-8092-1552; Baldanti, Fausto/0000-0002-3358-8969; Zavattoni, Maurizio/0000-0002-5199-0038; Campiani, Giuseppe/0000-0001-5295-9529; GIORGI, GIANLUCA/0000-0002-8817-7745				Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014; Arion D, 1996, MOL PHARMACOL, V50, P1057; Barnard J, 1997, BIOCHEMISTRY-US, V36, P7786, DOI 10.1021/bi970140u; Blake M, 2000, CLIN INFECT DIS, V30, pS96, DOI 10.1086/313859; Caccia S, 1998, CLIN PHARMACOKINET, V34, P281, DOI 10.2165/00003088-199834040-00002; Campiani G, 1999, J MED CHEM, V42, P4462, DOI 10.1021/jm990150o; Cattaneo E, 1999, MICROBIOLOGICA, V22, P281; CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clotet B, 1999, INT J CLIN PRACT, P21; De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7; De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4; DECLERCQ E, 1994, ANN NY ACAD SCI, V724, P438; Drewe J, 1999, BIOCHEM PHARMACOL, V57, P1147, DOI 10.1016/S0006-2952(99)00026-X; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762; Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRECO WR, 1995, PHARMACOL REV, V47, P331; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; HUBSCHER U, 1994, PHYSIOL REV, V74, P259, DOI 10.1152/physrev.1994.74.2.259; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lin JH, 1997, PHARMACOL REV, V49, P403; Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427; Maga G, 2000, ANTIMICROB AGENTS CH, V44, P1186, DOI 10.1128/AAC.44.5.1186-1194.2000; Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1; Masters Barry R., 1994, V8, P1; O'Brien WA, 2000, CLIN INFECT DIS, V30, pS185, DOI 10.1086/313858; Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; Sheldrick G.M., 1997, SHELX 97 RELEASE 97; TATSURA T, 1992, J BIOL CHEM, V267, P2383; Telenti A, 2000, REV MED VIROL, V10, P385, DOI 10.1002/1099-1654(200011/12)10:6&lt;385::AID-RMV296&gt;3.0.CO;2-1; Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6	39	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44653	44662		10.1074/jbc.M106702200	http://dx.doi.org/10.1074/jbc.M106702200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572864	Green Accepted, hybrid			2022-12-25	WOS:000172406700044
J	Robledo, MM; Bartolome, RA; Longo, N; Rodriguez-Frade, JM; Mellado, M; Longo, I; van Muijen, GNP; Sanchez-Mateos, P; Teixido, J				Robledo, MM; Bartolome, RA; Longo, N; Rodriguez-Frade, JM; Mellado, M; Longo, I; van Muijen, GNP; Sanchez-Mateos, P; Teixido, J			Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MALIGNANT MELANOMA; T-LYMPHOCYTES; CD34(+) CELLS; RHO GTPASES; ADHESION; MIGRATION; PROTEIN; MIG; METASTASIS; INVASION	Chemokines are secreted into the tumor microenvironment by tumor-infiltrating inflammatory cells as well as by tumor cells. Chemokine receptors mediate agonist-dependent cell responses, including migration and activation of several signaling pathways. In the present study we show that several human melanoma cell lines and melanoma cells on macroscopically infiltrated lymph nodes express the chemokine receptors CXCR3 and CXCR4. Using the highly invasive melanoma cell line BLM, we demonstrate that the chemokine Mig, a ligand for CXCR3, activates the small GTPases RhoA and Rac1, induces a reorganization of the actin cytoskeleton, and triggers cell chemotaxis and modulation of integrin VIA-5- and VIA-4-dependent cell adhesion to fibronectin. Furthermore, the chemokine SDF-1 alpha, the ligand of CXCR4, triggered modulation of beta (1) integrin-dependent melanoma cell adhesion to fibronectin. Additionally, Mig and SDF-1 alpha activated MAPKs p44/42 and p38 on melanoma cells. Expression of functional CXCR3 and CXCR4 receptors on melanoma cells indicates that they might contribute to cell motility during invasion as well as to regulation of cell proliferation and survival.	Ctr Invest Biol, Dept Immunol, E-28006 Madrid, Spain; Hosp Univ Gregorio Maranon, Serv Inmunooncol, Madrid 28007, Spain; Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain; Univ Nijmegen Hosp, Dept Pathol, NL-6500 Nijmegen, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); General University Gregorio Maranon Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Radboud University Nijmegen	Teixido, J (corresponding author), Ctr Invest Biol, Dept Immunol, Velazquez 144, E-28006 Madrid, Spain.		Bartolome, Ruben A/M-1873-2014; Sanchez-Mateos, Paloma/E-8931-2013; Mellado, Mario/M-9893-2014; Frade, Jose Miguel Rodriguez/K-4266-2014; Teixidó, Joaquin/J-8543-2014	Mellado, Mario/0000-0001-6325-1630; Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Sanchez-Mateos, Paloma/0000-0001-6589-4445				Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COCHRAN AJ, 1985, PATHOLOGY, V17, P340, DOI 10.3109/00313028509063777; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; del Peso L, 1997, ONCOGENE, V15, P3047; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Elenitsas Rosalie, 1998, Current Opinion in Oncology, V10, P162, DOI 10.1097/00001622-199803000-00014; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; GOWN AM, 1986, AM J PATHOL, V123, P195; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kunz M, 1999, J PATHOL, V189, P552, DOI 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I; Lane WJ, 2000, BLOOD, V96, P4152; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; Loetscher P, 2000, Adv Immunol, V74, P127; Luca M, 1997, AM J PATHOL, V151, P1105; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOULD AP, 1994, J BIOL CHEM, V269, P27224; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1999, Adv Immunol, V71, P211; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Poncelet P, 1993, METHODS IMMUNOLOGICA, P388; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robledo MM, 1998, J BIOL CHEM, V273, P12056, DOI 10.1074/jbc.273.20.12056; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; SINGH RK, 1994, CANCER RES, V54, P3242; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348	57	203	213	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45098	45105		10.1074/jbc.M106912200	http://dx.doi.org/10.1074/jbc.M106912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571298	Green Published, hybrid			2022-12-25	WOS:000172406700100
J	Perret, S; Merle, C; Bernocco, S; Berland, P; Garrone, R; Hulmes, DJS; Theisen, M; Ruggiero, F				Perret, S; Merle, C; Bernocco, S; Berland, P; Garrone, R; Hulmes, DJS; Theisen, M; Ruggiero, F			Unhydroxylated triple helical collagen I produced in transgenic plants provides new clues on the role of hydroxyproline in collagen folding and fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR PACKING; CRYSTAL-STRUCTURE; MODEL PEPTIDE; INVITRO; FIBRILLOGENESIS; STABILITY; MONOMERS; CLEAVAGE; BINDING; DRIVEN	Human unhydroxylated homotrimeric triple-helical collagen I produced in transgenic plants was used as an experimental model to provide insights into the role of hydroxyproline in molecular folding and fibril formation. By using chemically cross-linked molecules, we show here that the absence of hydroxyproline residues does not prevent correct folding of the recombinant collagen although it markedly slows down the propagation rate compared with bovine fully hydroxylated homotrimeric collagen 1. Relatively slow cis-trans-isomerization in the absence of hydroxyproline likely represents the rate-limiting factor in the propagation of the unhydroxylated collagen helix. Because of the lack of hydroxylation, recombinant collagen molecules showed increased flexibility as well as a reduced melting temperature compared with native homotrimers and heterotrimers, whereas the distribution of charged amino acids was unchanged. However, unlike with bovine collagen 1, the recombinant collagen did not self-assemble into banded fibrils in physiological ionic strength buffer at 20 degreesC. Striated fibrils were only obtained with low ionic strength buffer. We propose that, under physiological ionic strength conditions, the hydroxyl groups in the native molecule retain water more efficiently thus favoring correct fibril formation. The importance of hydroxyproline in collagen self-assembly suggested by others from the crystal structures of collagen model peptides is thus confirmed experimentally on the entire collagen molecule.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Meristem Therapeut, F-63100 Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ruggiero, F (corresponding author), Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.			RUGGIERO, Florence/0000-0003-2915-5359; Hulmes, David/0000-0002-0651-1317				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; FIEDLERNAGY C, 1981, ARCH BIOCHEM BIOPHYS, V212, P668, DOI 10.1016/0003-9861(81)90411-2; GEORGE A, 1991, BIOCHEMISTRY-US, V30, P2372, DOI 10.1021/bi00223a011; GUSTAVSON KH, 1955, NATURE, V175, P70, DOI 10.1038/175070a0; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; JIMENEZ SA, 1977, BIOCHEM BIOPH RES CO, V78, P1354, DOI 10.1016/0006-291X(77)91441-3; Kadler KE, 1996, BIOCHEM J, V316, P1; KADLER KE, 1987, J BIOL CHEM, V262, P15696; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kuznetsova N, 1999, J BIOL CHEM, V274, P36083, DOI 10.1074/jbc.274.51.36083; MCBRIDE DJ, 1992, MATRIX, V12, P256; Nagarajan V, 1998, J BIOCHEM-TOKYO, V124, P1117, DOI 10.1093/oxfordjournals.jbchem.a022229; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Olsen DR, 2001, J BIOL CHEM, V276, P24038, DOI 10.1074/jbc.M101613200; PAYNE KJ, 1986, BIOPOLYMERS, V25, P1185, DOI 10.1002/bip.360250703; Prockop DJ, 1998, J BIOL CHEM, V273, P15598, DOI 10.1074/jbc.273.25.15598; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; Ruggiero F, 2000, FEBS LETT, V469, P132, DOI 10.1016/S0014-5793(00)01259-X; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; Sato K, 2000, J BIOL CHEM, V275, P25870, DOI 10.1074/jbc.M003700200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Wess TJ, 1998, J STRUCT BIOL, V122, P92, DOI 10.1006/jsbi.1998.3991	28	68	74	4	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43693	43698		10.1074/jbc.M105507200	http://dx.doi.org/10.1074/jbc.M105507200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557756	hybrid			2022-12-25	WOS:000172297700029
J	Freelove, ACJ; Bolam, DN; White, P; Hazlewood, GP; Gilbert, HJ				Freelove, ACJ; Bolam, DN; White, P; Hazlewood, GP; Gilbert, HJ			A novel carbohydrate-binding protein is a component of the plant cell wall-degrading complex of Piromyces equi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-THERMOCELLUM; CELLULOMONAS-FIMI; ESCHERICHIA-COLI; XYLANASE; DOMAIN; CELLULASES; MODULES; CELLULOSOME; FUNGI; GENE	The recycling of photosynthetically fixed carbon by the action of microbial plant cell wall hydrolases is a fundamental biological process that is integral to one of the major geochemical cycles and, in addition, has considerable industrial potential. Enzyme systems that attack the plant cell wall contain noncatalytic carbohydrate-binding modules (CBMs) that mediate attachment to this composite structure and play a pivotal role in maximizing the hydrolytic process. Anaerobic fungi that colonize herbivores are the most efficient plant cell wall degraders known, and this activity is vested in a high molecular weight complex that binds tightly to the plant cell wall. To investigate whether plant cell wall attachment is mediated by noncatalytic proteins, a CDNA library of the anaerobic fungus Piromyces equi was screened for sequences that encode noncatalytic proteins that are components of the cellulase-hemicellulase complex. A 1.6-kilobase cDNA was isolated encoding a protein of 479 amino acids with a M-r of 52548 designated NCP1. The mature protein had a modular architecture comprising three copies of the noncatalytic dockerin module that targets anaerobic fungal proteins to the cellulase-hemicellulase complex. The two C-terminal modules of NCP1, CBM29-1 and CBM29-2, respectively, exhibit 33% sequence identity with each other but have no homologues in protein data bases. A truncated form of NCP1 comprising CBM29-1 and CBM29-2 (CBM29-1-2) and each of the two individual copies of CBM29 bind primarily to man-nan, cellulose, and glucomannan, displaying the highest affinity for the latter polysaccharide. CBM29-1-2 exhibits 4-45-fold higher affinity than either CBM29-1 or CBM29-2 for the various ligands, indicating that the two modules, when covalently linked, act in synergy to bind to an array of different polysaccharides. This paper provides the first report of a CBM-containing protein from an anaerobic fungal cellulase-hemicellulase complex. The two CBMs constitute a novel CBM family designated CBM29 whose members exhibit unusually wide ligand specificity. We propose, therefore, that NCP1 plays a role in sequestering the fungal enzyme complex onto the plant cell wall.	Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Babraham Inst, Lab Mol Enzymol, Cambridge CB2 4AT, England	Newcastle University - UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Gilbert, HJ (corresponding author), Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk		Bolam, David/0000-0003-0314-3122				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; ALI BRS, 1995, FEMS MICROBIOL LETT, V125, P15, DOI 10.1016/0378-1097(94)00472-4; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; Beguin P, 1998, BIOCHEM SOC T, V26, P178, DOI 10.1042/bst0260178; BLUM DL, 1997, APPL ENVIRON MICROB, V65, P3990; Bolam DN, 2001, BIOCHEMISTRY-US, V40, P2468, DOI 10.1021/bi002564l; Brett C., 1990, PHYSL BIOCH PLANT CE; Brun E, 2000, BIOCHEMISTRY-US, V39, P2445, DOI 10.1021/bi992079u; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Chen HZ, 1997, J BACTERIOL, V179, P6028, DOI 10.1128/jb.179.19.6028-6034.1997; COUGHLAN MP, 1985, BIOTECHNOL GENET ENG, V3, P39, DOI 10.1080/02648725.1985.10647809; Coutinho PM, 1999, ROY SOC CH, P3; DURRANT AJ, 1991, BIOCHEM J, V273, P289, DOI 10.1042/bj2730289; FANUTTI C, 1995, J BIOL CHEM, V270, P29314, DOI 10.1074/jbc.270.49.29314; Fernandes AC, 1999, BIOCHEM J, V342, P105, DOI 10.1042/0264-6021:3420105; Fillingham IJ, 1999, BIOCHEM J, V343, P215, DOI 10.1042/0264-6021:3430215; GHANGAS GS, 1989, J BACTERIOL, V171, P2963, DOI 10.1128/jb.171.6.2963-2969.1989; GILBERT HJ, 1992, MOL MICROBIOL, V6, P2065, DOI 10.1111/j.1365-2958.1992.tb01379.x; GILKES NR, 1992, J BIOL CHEM, V267, P6743; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Halstead JR, 1999, MICROBIOL-SGM, V145, P3101, DOI 10.1099/00221287-145-11-3101; KEMP P, 1984, J GEN MICROBIOL, V130, P27; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Lee SS, 2000, APPL ENVIRON MICROB, V66, P3807, DOI 10.1128/AEM.66.9.3807-3813.2000; Leibovitz E, 1996, J BACTERIOL, V178, P3077, DOI 10.1128/jb.178.11.3077-3084.1996; Linder M, 1996, J BIOL CHEM, V271, P21268, DOI 10.1074/jbc.271.35.21268; ORPIN CG, 1981, J GEN MICROBIOL, V123, P287; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Steenbakkers PJM, 2001, J BACTERIOL, V183, P5325, DOI 10.1128/JB.183.18.5325-5333.2001; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; TEUNISSEN MJ, 1992, ARCH MICROBIOL, V158, P276, DOI 10.1007/BF00245245; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; ZHOU LQ, 1994, BIOCHEM J, V297, P359, DOI 10.1042/bj2970359	37	57	59	2	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43010	43017		10.1074/jbc.M107143200	http://dx.doi.org/10.1074/jbc.M107143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560933	hybrid			2022-12-25	WOS:000172169300051
J	Hamoen, LW; Haijema, B; Bijlsma, JJ; Venema, G; Lovett, CM				Hamoen, LW; Haijema, B; Bijlsma, JJ; Venema, G; Lovett, CM			The Bacillus subtilis competence transcription factor, ComK, overrides LexA-imposed transcriptional inhibition without physically displacing LexA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECA PROTEIN ANALOG; POLYMERASE ALPHA-SUBUNIT; ESCHERICHIA-COLI LEXA; RNA-POLYMERASE; DNA-DAMAGE; TERMINAL DOMAIN; DINR; INDUCTION; PROMOTER; GENE	During the development of competence in Bacillus subtilis the recA gene is activated by the competence transcription factor, ComK which is presumably required to alleviate the transcriptional repression of recA by LexA. To investigate the mechanism by which ComK activates recA transcription we examined the binding of ComK and LexA to the recA promoter in vitro. Using hydroxyl radical protection analyses to establish the location of ComK dimer-binding sites within the recA promoter, we identified four AT-boxes in a configuration unique for ComK-regulated promoters. Gel mobility shift experiments showed that all four ComK dimer-binding sites were occupied at ComK concentrations in the physiological range. In addition, occupation of all ComK-binding sites did not prevent LexA from binding to the recA promoter, despite the fact that the ComK and LexA recognition motifs partially overlap. Although ComK did not replace LexA from the recA promoter, in vitro transcription analyses indicated that the presence of Com-K is sufficient to alleviate LexA repression of recA.	Univ Groningen, Dept Genet, NL-9751 NN Haren, Netherlands; Univ Utrecht, Inst Virol, NL-3584 CL Utrecht, Netherlands; Vrije Univ Amsterdam, Dept Med Microbiol, Amsterdam, Netherlands; Williams Coll, Dept Chem, Williamstown, MA 01267 USA	University of Groningen; Utrecht University; Vrije Universiteit Amsterdam; Williams College	Hamoen, LW (corresponding author), Univ Groningen, Dept Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.							Ausubel FM, 1998, CURRENT PROTOCOLS MO; BANNER CDB, 1983, J MOL BIOL, V168, P351, DOI 10.1016/S0022-2836(83)80023-0; CHEO DL, 1993, J BACTERIOL, V175, P5907, DOI 10.1128/JB.175.18.5907-5915.1993; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; DEVOS WM, 1982, MOL GEN GENET, V187, P439, DOI 10.1007/BF00332625; DUBNAU D, 1993, BACILLUS SUBTILIS OT; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; Fredrick K, 1997, P NATL ACAD SCI USA, V94, P4982, DOI 10.1073/pnas.94.10.4982; FRISBY D, 1991, J BACTERIOL, V173, P7557, DOI 10.1128/jb.173.23.7557-7564.1991; Hahn J, 1996, MOL MICROBIOL, V21, P763, DOI 10.1046/j.1365-2958.1996.371407.x; HAIJEMA BJ, 1995, MOL MICROBIOL, V15, P203, DOI 10.1111/j.1365-2958.1995.tb02235.x; Haijema BJ, 1996, MOL MICROBIOL, V22, P75, DOI 10.1111/j.1365-2958.1996.tb02657.x; Hamoen LW, 1998, GENE DEV, V12, P1539, DOI 10.1101/gad.12.10.1539; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LOVE PE, 1985, P NATL ACAD SCI USA, V82, P6201, DOI 10.1073/pnas.82.18.6201; LOVETT CM, 1993, J BACTERIOL, V175, P6842, DOI 10.1128/jb.175.21.6842-6849.1993; LOVETT CM, 1989, J BACTERIOL, V171, P2318, DOI 10.1128/jb.171.5.2318-2322.1989; LOVETT CM, 1988, J BACTERIOL, V170, P1467, DOI 10.1128/jb.170.4.1467-1474.1988; LOVETT CM, 1985, J BIOL CHEM, V260, P3305; LOVETT CM, 1994, J BACTERIOL, V176, P4914, DOI 10.1128/jb.176.16.4914-4923.1994; Miller MC, 1996, J BIOL CHEM, V271, P33502, DOI 10.1074/jbc.271.52.33502; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; Ozoline ON, 2000, J BIOL CHEM, V275, P1119, DOI 10.1074/jbc.275.2.1119; PREDICH M, 1992, J BACTERIOL, V174, P2771, DOI 10.1128/JB.174.9.2771-2778.1992; RAYMONDDENISE A, 1991, J BACTERIOL, V173, P7084, DOI 10.1128/jb.173.22.7084-7091.1991; RAYMONDDENISE A, 1992, J BACTERIOL, V174, P3171, DOI 10.1128/jb.174.10.3171-3176.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; Turgay K, 1998, EMBO J, V17, P6730; VANSINDEREN D, 1995, MOL MICROBIOL, V15, P455; VENEMA G, 1965, J BACTERIOL, V89, P1250, DOI 10.1128/JB.89.5.1250-1255.1965; Walker GC., 1996, E COLI SALMONELLA CE, V2, P1400; Winterling KW, 1998, J BACTERIOL, V180, P2201, DOI 10.1128/JB.180.8.2201-2211.1998; YASBIN RE, 1992, MOL MICROBIOL, V6, P1263, DOI 10.1111/j.1365-2958.1992.tb00847.x	36	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42901	42907		10.1074/jbc.M104407200	http://dx.doi.org/10.1074/jbc.M104407200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555642	hybrid			2022-12-25	WOS:000172169300037
J	Yabe, T; Wilson, D; Schwartz, JP				Yabe, T; Wilson, D; Schwartz, JP			NF kappa B activation is required for the neuroprotective effects of pigment epithelium-derived factor (PEDF) on cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; GLUTAMATE-INDUCED NEUROTOXICITY; MANGANESE SUPEROXIDE-DISMUTASE; PRIMARY HIPPOCAMPAL-NEURONS; NECROSIS-FACTOR-ALPHA; APOPTOTIC CELL-DEATH; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; FACTOR GENE; SURVIVAL FACTOR	Pigment epithelium-derived factor (PEDF) protects immature cerebellar granule cells (1-3 days in vitro) against induced apoptosis and mature cells (5+ days in vitro) against glutamate toxicity, but its precise mechanism is still unknown. Because the transcription factor NF kappaB blocks cell death, including neuronal apoptosis, we have investigated the ability of PEDF to exert its effects via NF kappaB activation. PEDF induced an increased phosphorylation of I kappaB alpha, decreased levels of I kappaB proteins, and translocation of p65 (RelA) to the nucleus followed by a time-dependent increase of NF kappaB-DNA binding activity in both immature and mature neurons. The protective effects of PEDF against both induced apoptosis and glutamate toxicity were blocked by the addition of either the I kappaB kinase inhibitor BAY 11-7082 which inhibits the phosphorylation of I kappaB, or N-acetyl-Leu-Leu-norleucinal, which blocks. proteosome degradation of I kappaB, demonstrating that NF kappaB is required for the neuroprotective effects of PEDF. Reverse transcription-polymerase chain reaction analysis revealed that up-regulation of the anti-apoptotic genes for Bcl-2, Bcl-x, and manganese superoxide dismutase was observed in PEDF-treated immature but not mature neurons. Up-regulation of nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor mRNA was long-lasting in mature neurons. These results suggest that PEDF promotes neuronal survival through activation of NF kappaB, which in turn induces expression of anti-apoptotic and/or neurotrophic factor genes.	NINCDS, NTFS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Schwartz, JP (corresponding author), NINCDS, NTFS, NIH, Bldg 36,Rm 4A31, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002752] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.3.CO;2-H; Atabay C, 1996, J NEUROSCI RES, V43, P465; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BALAZS R, 1992, MOL NEUROPHARMACOL, V2, P203; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.3.CO;2-D; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; Choi JS, 2000, BRAIN RES, V883, P60, DOI 10.1016/S0006-8993(00)02886-9; Courtney MJ, 1997, J NEUROSCI, V17, P4201; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; DeCoster MA, 1999, J NEUROSCI RES, V56, P604; Friedman WJ, 1996, J BIOL CHEM, V271, P31115, DOI 10.1074/jbc.271.49.31115; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Glazner GW, 2000, J NEUROCHEM, V75, P101, DOI 10.1046/j.1471-4159.2000.0750101.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Heese K, 1998, GLIA, V22, P401, DOI 10.1002/(SICI)1098-1136(199804)22:4<401::AID-GLIA9>3.0.CO;2-5; Houenou LJ, 1999, J COMP NEUROL, V412, P506; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JEHAN F, 1993, J NEUROCHEM, V60, P1843, DOI 10.1111/j.1471-4159.1993.tb13411.x; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Li QT, 2000, GENE DEV, V14, P1729; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mao XR, 1998, NEUROREPORT, V9, P759, DOI 10.1097/00001756-199803090-00036; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; Pasquini LA, 2000, NEUROCHEM RES, V25, P627, DOI 10.1023/A:1007554902352; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Post A, 1998, J NEUROSCI, V18, P8236; Post A, 2000, EUR J NEUROSCI, V12, P4331, DOI 10.1046/j.0953-816X.2000.01352.x; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sawada H, 2000, J NEUROCHEM, V74, P1175; Schow SR, 1997, CELL IMMUNOL, V175, P199, DOI 10.1006/cimm.1996.1061; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMOHAMA S, 1993, BRAIN RES, V632, P296, DOI 10.1016/0006-8993(93)91164-N; Skaper SD, 1998, J NEUROCHEM, V70, P1859, DOI 10.1046/j.1471-4159.1998.70051859.x; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka M, 2000, BBA-GENE STRUCT EXPR, V1494, P63, DOI 10.1016/S0167-4781(00)00218-9; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Taniwaki T, 1997, J NEUROCHEM, V68, P26; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Tombran-Tink J, 1996, Mol Vis, V2, P11; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	63	113	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43313	43319		10.1074/jbc.M107831200	http://dx.doi.org/10.1074/jbc.M107831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553640	hybrid			2022-12-25	WOS:000172169300089
J	McGlynn, P; Lloyd, RG				McGlynn, P; Lloyd, RG			Action of RuvAB at replication fork structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION COMPLEX; ESCHERICHIA-COLI; BRANCH MIGRATION; DNA-REPLICATION; IN-VITRO; HOMOLOGOUS RECOMBINATION; CRYSTAL-STRUCTURE; RECG; PROTEIN; PRIA	The replicative apparatus often encounters blocks to its progression that necessitate removal of the block and reloading of the replication machinery. In Escherichia coli, a major pathway of replication restart involves unwinding of the stalled fork to generate a four-stranded Holliday junction, which can then be cleaved by the RuvABC helicase-endonuclease. This fork regression may be catalyzed by RecG but is thought to occur even in its absence. Here we test whether RuvAB helicase can also catalyze the unwinding of forked DNA to form Holliday junctions. We find that fork DNA is unwound in the direction required for Holliday junction formation only if the loading of RuvB is restricted to the parental duplex DNA arm. If the binding of RuvB is unrestricted, then RuvAB preferentially unwinds forks in the opposite direction. This is probably related to the greater efficiency of two opposed RuvB hexamers operating across a junction compared with a single hexamer. These data argue against RuvAB acting directly at damaged replication forks and imply that other mechanisms must operate in vivo to catalyze Holliday junction formation.	Univ Nottingham, Queens Med Ctr, Genet Inst, Nottingham NG7 2UH, England	University of Nottingham	Lloyd, RG (corresponding author), Univ Nottingham, Queens Med Ctr, Genet Inst, Nottingham NG7 2UH, England.			McGlynn, Peter/0000-0001-8629-4713				Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; Flores MJ, 2001, EMBO J, V20, P619, DOI 10.1093/emboj/20.3.619; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; Hiom K, 1996, GENES CELLS, V1, P443, DOI 10.1046/j.1365-2443.1996.d01-253.x; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kornberg A., 1992, DNA REPLICATION; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; Lombardo MJ, 2000, J BACTERIOL, V182, P6287, DOI 10.1128/JB.182.22.6287-6291.2000; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Saveson CJ, 1999, GENETICS, V152, P5; Seigneur M, 2000, MOL MICROBIOL, V38, P565, DOI 10.1046/j.1365-2958.2000.02152.x; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; van Gool AJ, 1998, EMBO J, V17, P1838, DOI 10.1093/emboj/17.6.1838; van Gool AJ, 1999, GENE DEV, V13, P1861, DOI 10.1101/gad.13.14.1861; Wentzell LM, 2000, J MOL BIOL, V304, P779, DOI 10.1006/jmbi.2000.4266; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; Zerbib D, 1998, J MOL BIOL, V281, P621, DOI 10.1006/jmbi.1998.1959	40	51	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41938	41944		10.1074/jbc.M107945200	http://dx.doi.org/10.1074/jbc.M107945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551967	hybrid			2022-12-25	WOS:000172450400053
J	Ninio, S; Rotem, D; Schuldiner, S				Ninio, S; Rotem, D; Schuldiner, S			Functional analysis of novel multidrug transporters from human pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EFFLUX PUMP; EMRE; ANTIPORTER; PROTEINS; H+; RESISTANCE; ALIGNMENT; SEQUENCES; BINDING	Proteins of the Smr family are the smallest multidrug transporters, about 110 amino acids long, that extrude various drugs in exchange with protons, thereby rendering bacteria resistant to these compounds. One of these proteins, EmrE, is an Escherichia coli protein, which has been cloned based on its ability to confer resistance to ethidium and methyl viologen and which has been extensively characterized. More than 60 genes coding for Smr proteins have been identified in several bacteria based on amino acid sequence similarity to the emrE gene. In this work we have analyzed the sequence similarity among these homologues and identified some distinct signature sequence elements and several fully conserved residues. Five of these homologues, from human pathogens Mycobacterium tuberculosis, Bordetella pertussis, and Pseudomonas aeruginosa and from Escherichia coli, were cloned into an E. coli expression system. The proteins were further characterized and show varying degrees of methyl viologen uptake into proteoliposomes and [H-3]TPP binding in solubilized membranes. The homologues can also form mixed oligomers with EmrE that exhibit intermediate binding characteristics. A comparative study of various homologous proteins provides a tool for deciphering structure-function relationship and monomer-monomer interaction in multidrug transporters and in membrane proteins in general.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.		Rotem, Dvir/G-1396-2013; Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237; Rotem, Dvir/0000-0002-1840-6530	NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; De Rossi E, 1998, J BACTERIOL, V180, P6068, DOI 10.1128/JB.180.22.6068-6071.1998; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; Jack DL, 2000, J BACTERIOL, V182, P2311, DOI 10.1128/JB.182.8.2311-2313.2000; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Masaoka Y, 2000, J BACTERIOL, V182, P2307, DOI 10.1128/JB.182.8.2307-2310.2000; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torres J, 2000, EUR J BIOCHEM, V267, P3422, DOI 10.1046/j.1432-1327.2000.01324.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	26	48	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48250	48256		10.1074/jbc.M108231200	http://dx.doi.org/10.1074/jbc.M108231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11574548	hybrid			2022-12-25	WOS:000172927000069
J	Ding, K; Sandgren, S; Mani, K; Belting, M; Fransson, LA				Ding, K; Sandgren, S; Mani, K; Belting, M; Fransson, LA			Modulations of glypican-1 heparan sulfate structure by inhibition of endogenous polyamine synthesis - Mapping of spermine-binding sites and heparanase, heparin lyase, and nitric oxide/nitrite cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; TETRASACCHARIDES; INVOLVEMENT; NUCLEI; CELLS	Cell surface heparan sulfate proteoglycans facilitate uptake of growth-promoting polyamines (Belting, M., Persson, S., and Fransson, L.-A (1999) Biochem. J. 338, 317-323; Belting, M., Borsig, L., Fuster, M. M., Brown, J. R., Persson, L., Fransson, L.-A., and Esko, J. D. (2001) Proc. Natl. Acad. Sci. U. S. A., in press). Here, we have analyzed the effect of polyamine deprivation on the structure and polyamine affinity of the heparan sulfate chains in various glypican-1 glycoforms synthesized by a transformed cell line (ECV 304). Heparan sulfate chains of glypican-1 were either cleaved with heparanase at sites embracing the highly modified regions or with nitrite at N-unsubstituted glucosamine residues. The products were separated and further degraded by heparin lyase to identify sulfated iduronic acid. Polyamine affinity was assessed by chromatography on agarose substituted with the polyamine spermine. In heparan sulfate made by cells with undisturbed endogenous polyamine synthesis, free amino groups were restricted to the unmodified, unsulfated segments, especially near the core protein. Spermine high affinity binding sites were located to the modified and highly sulfated segments that were released by heparanase. In cells with up-regulated polyamine uptake, heparan sulfate contained an increased number of clustered N-unsubstituted glucosamines and sulfated iduronic acid residues. This resulted in a greater number of NO/nitrite-sensitive cleavage sites near the potential spermine-binding sites. Endogenous degradation by heparanase and NO-derived nitrite in polyamine-deprived cells generated a separate pool of heparan sulfate oligosaccharides with an exceptionally high affinity for spermine. Spermine uptake in polyamine-deprived cells was reduced when NO/nitrite-generated degradation of heparan sulfate was inhibited. The results suggest a functional interplay between glypican recycling, NO/nitrite-generated heparan sulfate degradation, and polyamine uptake.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, SE-22184 Lund, Sweden	Lund University	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, BMC C13, SE-22184 Lund, Sweden.	Lars-Ake.Fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634; Belting, Mattias/0000-0003-1585-5434				Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blachier F, 1997, NITRIC OXIDE-BIOL CH, V1, P268, DOI 10.1006/niox.1997.0127; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Colin S, 1999, MOL PHARMACOL, V55, P74, DOI 10.1124/mol.55.1.74; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69	32	44	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46779	46791		10.1074/jbc.M105419200	http://dx.doi.org/10.1074/jbc.M105419200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577085	hybrid			2022-12-25	WOS:000172768500016
J	Gao, M; Fan, SJ; Goldberg, ID; Laterra, J; Kitsis, RN; Rosen, EM				Gao, M; Fan, SJ; Goldberg, ID; Laterra, J; Kitsis, RN; Rosen, EM			Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT ACTIVATION; CYTOCHROME-C; SCATTER FACTOR; CASPASE ACTIVATION; FACTOR PROTECTS; SURVIVAL; RELEASE; INHIBITION; IDENTIFICATION; PROTEASE	The cytokine hepatocyte growth factor/scatter factor (HGF/SF) has been found to protect a variety of epithelial and cancer cell types against cytotoxicity and apoptosis induced by DNA damage, but the specific apoptotic signaling events and the levels at which they are blocked by HGF/SF have not been identified. We found that treatment of MDA-MB-453 human breast cancer cells with adriamycin (also known as doxorubicin, a DNA topoisomerase II alpha inhibitor) induced a series of time-dependent events, including the mitochondrial release of cytochrome c and apoptosis-inducing factor, mitochondrial membrane depolarization, activation of a set of caspases (caspase-9, -3, -7, -2, and -8), cleavage of poly(ADP-ribose) polymerase (PARP), and up-regulation of expression of the Fas ligand. All of these events were blocked by preincubation of the cells with HGF/SF. In contrast, the pan-caspase inhibitor benzyloxycarbonyl-VAD-fluoromethylketone blocked some of these events (e.g. caspase-3 activation and PARP cleavage) but did not block cytochrome c release or mitochondrial depolarization. These findings suggest that HGF/SF functions, in part, upstream of the mitochondria to block mitochondrial apoptosis signaling, prevent activation of multiple caspases, and protect breast cancer cells against apoptosis.	Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New Hyde Pk, NY 11040 USA; Kennedy Krieger Res Inst, Dept Neurol, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Neurosci, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; Kennedy Krieger Institute; Kennedy Krieger Institute; Kennedy Krieger Institute; Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rosen, EM (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	erosen@lij.edu			NIEHS NIH HHS [R01-ES 09169] Funding Source: Medline; PHS HHS [R01-80000, R01-82599] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Asselin E, 2001, CANCER RES, V61, P1862; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Gao CF, 2001, EXP CELL RES, V265, P145; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nomura M, 1999, CANCER RES, V59, P5542; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rosen EM, 1997, J UROLOGY, V157, P72, DOI 10.1016/S0022-5347(01)65286-8; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; Rosen EM, 2000, ANGIOGENESIS IN HEALTH AND DISEASE, P145; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yao Y, 1996, AM J PATHOL, V149, P1707; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47257	47265		10.1074/jbc.M106791200	http://dx.doi.org/10.1074/jbc.M106791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11571297	hybrid			2022-12-25	WOS:000172768500079
J	Nibbelink, M; Moulin, K; Arnaud, E; Duval, C; Penicaud, L; Casteilla, L				Nibbelink, M; Moulin, K; Arnaud, E; Duval, C; Penicaud, L; Casteilla, L			Brown fat UCP1 is specifically expressed in uterine longitudinal smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; GENETIC ABLATION; LIVER; MECHANISMS; PHYSIOLOGY; OBESITY; MICE	Until now, uncoupling protein I (UCP1) was considered as unique to brown adipocytes. It supports a highly regulated uncoupling of oxidative phosphorylation that is associated with diet as well as with non-shivering thermogenesis. Here we report that UCP1 is not specific to brown adipocytes and can be expressed in longitudinal smooth muscle layers. In the uterus, this conclusion was drawn from different convergent data. A specific antibody against mouse UCP1 revealed, in mitochondrial fractions, a protein with the same molecular weight as brown fat UCP1. Sensitive and specific reverse transcriptase-polymerase chain reaction detected a mRNA whose sequence was totally homologous to that of brown fat UCP1 mRNA. Antibody against UCP1 as well as a UCP1 antisense probe specifically stained uterine longitudinal smooth muscles. UCP1 was also ex. pressed in longitudinal smooth muscle of digestive and male reproductive tracts but was never expressed in other types of smooth muscle, including those of arterial vessels. In uterine tract, UCP1 content was increased after cold exposure or beta -adrenergic agonist treatment. It was also up-regulated during the postovulatory period after sexual cycle synchronization. Its content transiently increased during gestation and decreased markedly after birth. These regulations strongly argue about a role for UCP1 in thermogenesis as well as in relaxation of longitudinal smooth muscle layers.	IFR31 Rangueil Univ Hosp, UMR 5018 CNRS, F-31403 Toulouse 4, France		Casteilla, L (corresponding author), IFR31 Rangueil Univ Hosp, UMR 5018 CNRS, F-31403 Toulouse 4, France.	casteil@rangueil.inserm.fr		Casteilla, Louis/0000-0001-9647-3248				BATHGATE B, 1992, MOL MICROBIOL, V6, P363, DOI 10.1111/j.1365-2958.1992.tb01479.x; Brauner P, 2001, PEDIATR RES, V49, P440, DOI 10.1203/00006450-200103000-00022; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Hamann A, 1998, Z ERNAHRUNGSWISS, V37, P1; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kozak LP, 2000, ANNU REV NUTR, V20, P339, DOI 10.1146/annurev.nutr.20.1.339; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Masaki T, 1999, BBA-MOL CELL BIOL L, V1440, P81, DOI 10.1016/S1388-1981(99)00104-3; MIROUX B, 1992, J BIOL CHEM, V267, P13603; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OWEN JA, 1975, AM J CLIN NUTR, V28, P333; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1992, FEBS LETT, V303, P103, DOI 10.1016/0014-5793(92)80496-4; Ricquier D, 2000, J PHYSIOL-LONDON, V529, P3, DOI 10.1111/j.1469-7793.2000.00003.x; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; Riemer RK, 1998, PEDIATR RES, V44, P615, DOI 10.1203/00006450-199811000-00001; SHINOHARA Y, 1991, FEBS LETT, V293, P173, DOI 10.1016/0014-5793(91)81179-C; WRAY S, 1993, AM J PHYSIOL, V264, pC1, DOI 10.1152/ajpcell.1993.264.1.C1; Yoshida T, 1998, AM J PHYSIOL-ENDOC M, V274, pE469, DOI 10.1152/ajpendo.1998.274.3.E469; Zorov DB, 1997, BIOSCIENCE REP, V17, P507, DOI 10.1023/A:1027304122259	25	42	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47291	47295		10.1074/jbc.M105658200	http://dx.doi.org/10.1074/jbc.M105658200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11572862	hybrid			2022-12-25	WOS:000172768500083
J	Boylan, JM; Anand, P; Gruppuso, PA				Boylan, JM; Anand, P; Gruppuso, PA			Ribosomal protein S6 phosphorylation and function during late gestation liver development in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA-SYNTHESIS; FETAL-RAT; PERINATAL-PERIOD; CELL-CYCLE; KINASE; RAPAMYCIN; ACTIVATION; PROLIFERATION; P70(S6K)	The phosphorylation of ribosomal protein S6 is thought to be required for biosynthesis of the cell's translational apparatus, a critical component of cell growth and proliferation. We have studied the signal transduction pathways involved in hepatic S6 phosphorylation during late gestation in the rat. This is a period during which hepatocytes show a high rate of proliferation that is, at least in part, independent of mitogenic signaling pathways that are operative in mature hepatocytes. Our initial studies demonstrated that there was low basal activity of two S6 kinases in liver, S6K1 and S6K2, on embryonic day 19 (2 days preterm). In addition, insulin- and growth factor-mediated S6K1 and S6K2 activation was markedly attenuated compared with that in adult liver. Nonetheless, two-dimensional gel electrophoresis demonstrated that fetal liver S6 itself was highly phosphorylated. To characterize the fetal hepatocyte pathway for S6 phosphorylation, we went on to study the sensitivity of hepatocyte proliferation to the S6 kinase inhibitor rapamycin. Unexpectedly, administration of rapamycin to embryonic day 19 fetuses in. situ did not affect hepatocyte DNA synthesis. This resistance to the growth inhibitory effect of rapamycin occurred even though S6K1 and S6K2 were inhibited. Furthermore, fetal hepatocyte proliferation was sustained even though rapamycin administration resulted in the dephosphorylation of ribosomal protein S6. In contrast, rapamycin blocked hepatic DNA synthesis in adult rats following partial hepatectomy coincident with S6 dephosphorylation. We conclude that hepatocyte proliferation in the late gestation fetus is supported by a rapamycin-resistant mechanism that can function independently of ribosomal protein S6 phosphorylation.	Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, Providence, RI 02903 USA; Brown Univ, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, 593 Eddy St, Providence, RI 02903 USA.				NICHD NIH HHS [HD11343, HD24455, HD35831] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011343, P01HD011343, R01HD035831] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Boylan JM, 1998, J BIOL CHEM, V273, P3784, DOI 10.1074/jbc.273.6.3784; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fausto Nelson, 1994, P1059; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Gruppuso PA, 1997, IN VITRO CELL DEV-AN, V33, P562; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; MAYOR F, 1985, BIOL NEONATE, V48, P185, DOI 10.1159/000242171; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; Slavik JM, 2001, J IMMUNOL, V166, P3201, DOI 10.4049/jimmunol.166.5.3201; TERADA N, 1993, J BIOL CHEM, V268, P12062; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Withers DJ, 1997, J BIOL CHEM, V272, P2509	37	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44457	44463		10.1074/jbc.M103457200	http://dx.doi.org/10.1074/jbc.M103457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574531	hybrid			2022-12-25	WOS:000172406700016
J	Dunn, SE; Simard, AR; Bassel-Duby, R; Williams, RS; Michel, RN				Dunn, SE; Simard, AR; Bassel-Duby, R; Williams, RS; Michel, RN			Nerve activity-dependent modulation of calcineurin signaling in adult fast and slow skeletal muscle fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; HEAVY-CHAIN EXPRESSION; FUNCTIONAL-SIGNIFICANCE; GENE-EXPRESSION; STIMULATED FAST; RAT MUSCLES; IN-VIVO; HYPERTROPHY; ACTIVATION; PATHWAY	This study tested the hypothesis that calcineurin signaling is modulated in skeletal muscle cells by fluctuations in nerve-mediated activity. We show that dephosphorylation of NFATc1, MEF2A, and MEF2D transcription factors by calcineurin in all muscle types is dependent on nerve activity and positively correlated with muscle usage under normal weightbearing conditions. With increased nerve-mediated activity, calcineurin dephosphorylation of these targets was found to be potentiated in a way that paralleled the higher muscle activation profiles associated with functional overload or nerve electrical stimulation conditions. We also establish that muscle activity must be sustained above native levels for calcineurin-dependent dephosphorylation of MEF2A and MEF2D to be transduced into an increase in MEF2 transcriptional function, suggesting that calcineurin cooperates with other activity-linked events to signal via these proteins. Finally, examination of individual fiber responses to overload and nerve electrical stimulation revealed that calcineurin-MEF2 signaling occurs in all fiber types but most readily in fibers that are normally least active (i.e. those expressing IIx and IIb myosin heavy chain (MHC)), suggesting that signaling via this phosphatase is also dependent upon the activation history of the muscle cell.	Laurentian Univ, Dept Chem & Biochem, Neuromuscular Res Lab, Sudbury, ON P3E 2C6, Canada; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Western Ontario, Fac Hlth Sci, London, ON N6A 3K7, Canada	Laurentian University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Western University (University of Western Ontario)	Michel, RN (corresponding author), Laurentian Univ, Dept Chem & Biochem, Neuromuscular Res Lab, Sudbury, ON P3E 2C6, Canada.	rnmichel@nickel.laurentian.ca	Simard, Alain/E-1493-2013	Simard, Alain/0000-0002-3499-6235				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Adams GR, 1996, J APPL PHYSIOL, V81, P2509, DOI 10.1152/jappl.1996.81.6.2509; AUSONI S, 1990, J NEUROSCI, V10, P153; BENNETT MR, 1974, J PHYSIOL-LONDON, V238, P79, DOI 10.1113/jphysiol.1974.sp010511; Bigard X, 2000, J BIOL CHEM, V275, P19653, DOI 10.1074/jbc.M000430200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Carroll S, 1999, AM J PHYSIOL-CELL PH, V277, pC1122, DOI 10.1152/ajpcell.1999.277.6.C1122; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHIN ER, 1996, PHYSIOLOGIST, V39, pA75; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dunn SE, 2000, J CELL BIOL, V151, P663, DOI 10.1083/jcb.151.3.663; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Dunn SE, 1999, PFLUG ARCH EUR J PHY, V437, P432, DOI 10.1007/s004240050798; EKEN T, 1988, J PHYSIOL-LONDON, V402, P651, DOI 10.1113/jphysiol.1988.sp017227; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Garcia-Rodriguez C, 2000, EUR J IMMUNOL, V30, P2432, DOI 10.1002/1521-4141(2000)30:8<2432::AID-IMMU2432>3.0.CO;2-F; GARDINER P, 1986, BRAIN RES, V380, P114, DOI 10.1016/0006-8993(86)91435-6; Haddad F, 1998, J APPL PHYSIOL, V84, P2036, DOI 10.1152/jappl.1998.84.6.2036; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HENNEMAN E, 1985, J EXP BIOL, V115, P105; HENNIG R, 1985, NATURE, V314, P164, DOI 10.1038/314164a0; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; MIDRIO M, 1988, EXP NEUROL, V100, P216, DOI 10.1016/0014-4886(88)90214-2; MINAMIKAWA T, 1995, CELL CALCIUM, V17, P165, DOI 10.1016/0143-4160(95)90031-4; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PIEROTTI DJ, 1989, BRAIN RES, V481, P57, DOI 10.1016/0006-8993(89)90485-X; Prilutsky BI, 1996, J EXP BIOL, V199, P801; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; WAN KK, 1980, EXP NEUROL, V70, P475, DOI 10.1016/0014-4886(80)90174-0; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Zhao M, 1999, MOL CELL BIOL, V19, P21	47	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45243	45254		10.1074/jbc.M105445200	http://dx.doi.org/10.1074/jbc.M105445200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11555650	hybrid			2022-12-25	WOS:000172406700118
J	Fujioka, Y; Taira, T; Maeda, Y; Tanaka, S; Nishihara, H; Iguchi-Ariga, SMM; Nagashima, K; Ariga, H				Fujioka, Y; Taira, T; Maeda, Y; Tanaka, S; Nishihara, H; Iguchi-Ariga, SMM; Nagashima, K; Ariga, H			MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-DEPENDENT TRANSCRIPTION; TRANSFORMING ACTIVITY; IN-VIVO; ESSENTIAL COFACTOR; CELL-GROWTH; GENES; ASSOCIATION; EXPRESSION; INTERACTS; IDENTIFICATION	The c-myc oncogene product (c-Myc) is a transcription factor that dimerizes with Max and recognizes the E-box sequence, and it plays key functions in cell proliferation, differentiation, and apoptosis. We previously showed that MM-1 bound to myc box II within the transactivation domain of c-Myc and repressed the E-box-dependent transcriptional activity of c-Myc. Here we report that MM-1 showed features of a tumor suppressor. In an EST data base search for cDNAs homologous to MM-1, we found a frequent substitution of amino acid 157 of MM-1, from alanine to arginine (A157R), and the substitution was observed more in tumor cells than in normal cells. A survey of the A157R mutation of MM-1 in 57 cultured cancer cells and 90 tissues from cancer patients showed that the A157R was present in about 50-60% of leukemia/lymphoma cells and in more than 75% of squamous cell carcinoma of tongue cancer. Although both the A157R and the wild-type MM-1 bound to c-Myc, only A157R lost the activities to repress both the E-box-dependent transcriptional activity of c-Myc and the myc/ras cooperative transforming activity in rat 3Y1 cells. Furthermore, the wild-type MM-1, but not A157R, arrested the growth of 3Y1 cells. The human MM-1 gene was mapped at chromosome 12q12-12q13, where many chromosome abnormalities in cancer cells have been reported. The results suggest that MM-1 is a novel candidate for a tumor suppressor that controls the transcriptional activity of c-Myc.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0608012, Japan; Hokkaido Univ, Grad Sch Med, Dept Pathol, Sapporo, Hokkaido 0608012, Japan; Hokkaido Univ, Coll Med Technol, Sapporo, Hokkaido 0608012, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Ariga, Hiroyoshi/B-5895-2013; Ariga, Sanae/H-9647-2013	Ariga, Hiroyoshi/0000-0001-7384-2143; 				ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Bao JX, 1996, ONCOGENE, V12, P2171; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Guo QM, 2000, CANCER RES, V60, P5922; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Niki T, 2000, GENES CELLS, V5, P127, DOI 10.1046/j.1365-2443.2000.00311.x; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Okano HJ, 1999, GENE DEV, V13, P2087, DOI 10.1101/gad.13.16.2087; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Prendergast GC, 1999, ONCOGENE, V18, P2914, DOI 10.1038/sj.onc.1202784; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Taira T, 1997, NUCLEIC ACIDS RES, V25, P1975, DOI 10.1093/nar/25.10.1975; Takayama M, 2000, GENES CELLS, V5, P481, DOI 10.1046/j.1365-2443.2000.00338.x; Takayama M, 2000, FEBS LETT, V477, P43, DOI 10.1016/S0014-5793(00)01756-7; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403	44	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45137	45144		10.1074/jbc.M106127200	http://dx.doi.org/10.1074/jbc.M106127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567024	hybrid			2022-12-25	WOS:000172406700105
J	Sundararajan, R; Cuconati, A; Nelson, D; White, E				Sundararajan, R; Cuconati, A; Nelson, D; White, E			Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; PORE-FORMING DOMAIN; MITOCHONDRIAL-MEMBRANE; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; DELTA-ENDOTOXIN; X-RAY; PROTEIN; OLIGOMERIZATION	Tumor necrosis factor (TNF)-alpha -mediated death signaling induces oligomerization of proapoptotic Bcl-2 family member Bax into a high molecular mass protein complex in mitochondrial membranes. Bax complex formation is associated with the release of cytochrome c, which propagates death signaling by acting as a cofactor for caspase-9 activation. The adenovirus Bcl-2 homologue E1B 19K blocks TNT-alpha -mediated apoptosis by preventing cytochrome c release, caspase-9 activation, and apoptosis of virus-infected cells. TNF-alpha induces E1B 19K-Bax interaction and inhibits Bax oligomerization. Oligomerized Bax may form a pore to release mitochondrial proteins, analogous to the homologous pore-forming domains of bacterial toxins. E1B 19K can also bind to proapoptotic Bak, but the functional significance is not known. TNF-alpha signaling induced Bak-Bax interaction and both Bak and Bax oligomerization. E1B 19K was constitutively in a complex with Bak, and blocked the Bak-Bax interaction and oligomerization of both. The TNF-alpha -mediated cytochrome c and Smac/DIABLO release from mitochondria was inhibited by E1B 19K expression in adenovirus-infected cells. Since either Bax or Bak is essential for death signaling by TNF-alpha, the interaction between E1B 19K and both Bak and Bax may be required to inhibit their cooperative or independent oligomerization to release proteins from mitochondria which promote caspase activation and cell death.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	White, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021; Cuconati, Andrea/GWV-4662-2022; Cuconati, Andrea/AAI-7533-2020	White, Eileen/0000-0003-2961-3065; Nelson, Deirdre/0000-0001-5527-2570; Cuconati, Andrea/0000-0001-5123-0381	NATIONAL CANCER INSTITUTE [R37CA053370, R01CA053370] Funding Source: NIH RePORTER; NCI NIH HHS [CA53370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x; MANOJ KAS, 1999, J BACTERIOL, V181, P6103; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8	38	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45120	45127		10.1074/jbc.M106386200	http://dx.doi.org/10.1074/jbc.M106386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571294	hybrid			2022-12-25	WOS:000172406700103
J	Lamarre, C; LeMay, JD; Deslauriers, N; Bourbonnais, Y				Lamarre, C; LeMay, JD; Deslauriers, N; Bourbonnais, Y			Candida albicans expresses an unusual cytoplasmic manganese-containing superoxide dismutase (SOD3 gene product) upon the entry and during the stationary phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; SACCHAROMYCES-CEREVISIAE; YEAST-CELLS; ALTERNATIVE OXIDASE; COPPER; PROTECTS; OXYGEN; ATPASE	We report here that in addition to a cytoplasmic copper-zinc-containing superoxide dismutase (SOD) and a mitochondrial manganese-containing SOD, Candida albicans expresses a third SOD gene (SOD3). The deduced amino acid sequence contains all of the motifs found in previously characterized manganese-containing SODs, except the presence of a mitochondrial transit peptide. Recombinant Sod3p expressed and purified from Escherichia coli is a homotetramer with a subunit mass of 25.4 kDa. Mass absorption spectrometry detected the presence of both iron and manganese in purified Sod3p but, as determined by metal replacement experiments, the enzyme displays activity only when bound to manganese. Overexpression of SOD3 was shown to rescue the hypersensitivity to redox cycling agents of a Saccharomyces cerevisiae mutant lacking the cytoplasmic copper-zinc-containing SOD. Northern blot analyses showed that the transcription of SOD3 is induced neither by the transition from the yeast to the mycelial form of C. albicans nor by drug-induced oxidative stress. In continuous cultures, the expression of SOD3 was strongly stimulated upon the entity and during the stationary phase, concomitantly with the repression of SOD1. We conclude that Sod3p is an atypical cytosolic manganese-containing superoxide dismutase that is involved in the protection of C. albicans against reactive oxygen species during the stationary phase.	Univ Laval, Ctr Rech, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, Dept Biochim & Microbiol, Ste Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Bourbonnais, Y (corresponding author), Univ Laval, Ctr Rech, Ste Foy, PQ G1K 7P4, Canada.	yves.bourbonnais@bcm.ulaval.ca		Bourbonnais, Yves/0000-0002-8130-6612				Agius DR, 1998, BIOCHEM MOL BIOL INT, V44, P41; Averbeck NB, 2001, MOL GEN GENET, V264, P604, DOI 10.1007/s004380000346; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; BALZAN R, 1995, P NATL ACAD SCI USA, V92, P4219, DOI 10.1073/pnas.92.10.4219; Balzan R, 1999, BIOCHEM BIOPH RES CO, V256, P63, DOI 10.1006/bbrc.1999.0285; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Borghouts C, 2001, MOL CELL BIOL, V21, P390, DOI 10.1128/MCB.21.2.390-399.2001; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; Deslauriers N, 1996, MICROBIOL-SGM, V142, P1239, DOI 10.1099/13500872-142-5-1239; Diez B, 1998, CURR GENET, V33, P387, DOI 10.1007/s002940050351; Dinant M, 2001, CURR GENET, V39, P101, DOI 10.1007/s002940000183; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GREGORY EM, 1983, ARCH BIOCHEM BIOPHYS, V220, P293, DOI 10.1016/0003-9861(83)90413-7; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; Hwang CS, 1999, BBA-GEN SUBJECTS, V1427, P245, DOI 10.1016/S0304-4165(99)00020-3; Jamieson DJ, 1996, FEMS MICROBIOL LETT, V138, P83, DOI 10.1111/j.1574-6968.1996.tb08139.x; KAISER C, 1994, LAB COURSE MANUAL ME, P201; Kirimura K, 2000, BIOSCI BIOTECH BIOCH, V64, P2034, DOI 10.1271/bbb.64.2034; Kitayama K., 1995, PLANT PHYSIOL, V108, P1748; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KUH WK, 2001, BIOCHEM J, V356, P595; Lamarre C, 2000, MOL MICROBIOL, V35, P444, DOI 10.1046/j.1365-2958.2000.01715.x; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Melov S, 2000, ANN NY ACAD SCI, V908, P219; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; Rhie GE, 1999, BBA-GEN SUBJECTS, V1426, P409, DOI 10.1016/S0304-4165(98)00161-5; Riggle PJ, 2000, J BACTERIOL, V182, P4899, DOI 10.1128/JB.182.17.4899-4905.2000; Romani L, 1996, RES IMMUNOL, V147, P512, DOI 10.1016/S0923-2494(97)85216-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santos R, 1999, J BACTERIOL, V181, P4509, DOI 10.1128/JB.181.15.4509-4516.1999; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Vazquez N, 1998, INFECT IMMUN, V66, P145; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Weissman Z, 2000, P NATL ACAD SCI USA, V97, P3520, DOI 10.1073/pnas.97.7.3520; Yukioka H, 1998, BBA-GENE STRUCT EXPR, V1442, P161, DOI 10.1016/S0167-4781(98)00159-6	42	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43784	43791		10.1074/jbc.M108095200	http://dx.doi.org/10.1074/jbc.M108095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562375	hybrid			2022-12-25	WOS:000172297700041
J	Uversky, VN; Li, J; Fink, AL				Uversky, VN; Li, J; Fink, AL			Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein - A possible molecular link between Parkinson's disease and heavy metal exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; IN-VITRO; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; MOLTEN-GLOBULE; TRANSITION-METALS; BASAL GANGLIA; LEWY BODIES; IRON; ALUMINUM	Parkinson's disease involves the aggregation of alpha -synuclein to form fibrils, which are the major constituent of intracellular protein inclusions (Lewy bodies and Lewy neurites) in dopaminergic neurons of the substantia nigra. Occupational exposure to specific metals, especially manganese, copper, lead, iron, mercury, zinc, aluminum, appears to be a risk factor for Parkinson's disease based on epidemiological studies. Elevated levels of several of these metals have also been reported in the substantia nigra of Parkinson's disease subjects. We examined the effect of various metals on the kinetics of fibrillation of recombinant alpha -synuclein and in inducing conformational changes, as monitored by biophysical techniques. Several di- and trivalent metal ions caused significant accelerations in the rate of alpha -synuclein fibril format-ion. Aluminum was the most effective, along with copper(H), iron(III), cobalt(III), and manganese(II). The effectiveness correlated with increasing ion charge density. A correlation was noted between efficiency in stimulating fibrillation and inducing a conformational change, ascribed to formation of a partially folded intermediate. The potential for ligand bridging by polyvalent metal ions is proposed to be an important factor in the metal-induced conformational changes of a-synuclein. The results indicate that low concentrations of some metals can directly induce alpha -synuclein fibril formation.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142292, Moscow Region, Russia	University of California System; University of California Santa Cruz; Russian Academy of Sciences	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				Altschuler E, 1999, MED HYPOTHESES, V53, P22, DOI 10.1054/mehy.1997.0701; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; DUFFY PE, 1965, J NEUROPATH EXP NEUR, V24, P398, DOI 10.1097/00005072-196507000-00003; DUVOISIN RC, 1992, NEUROL CLIN, V10, P301, DOI 10.1016/S0733-8619(18)30211-1; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; FINK AL, 1999, ENCY MOL BIOL, P140; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; GOOD PF, 1992, BRAIN RES, V593, P343, DOI 10.1016/0006-8993(92)91334-B; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Gorell JM, 1997, NEUROLOGY, V48, P650, DOI 10.1212/WNL.48.3.650; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; GOURIEDEVI M, 1991, J ROY SOC MED, V84, P491, DOI 10.1177/014107689108400814; Griffiths PD, 1999, BRAIN, V122, P667, DOI 10.1093/brain/122.4.667; HERTZMAN C, 1994, MOVEMENT DISORD, V9, P69, DOI 10.1002/mds.870090111; HIRSCH EC, 1991, J NEUROCHEM, V56, P446, DOI 10.1111/j.1471-4159.1991.tb08170.x; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; Kienzl E, 1995, J NEUROL SCI, V134, P69, DOI 10.1016/0022-510X(95)00210-S; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuznetsova IM, 1999, BIOPHYS J, V77, P2788, DOI 10.1016/S0006-3495(99)77111-0; Le Couteur DG, 1999, BIOMED PHARMACOTHER, V53, P122, DOI 10.1016/S0753-3322(99)80077-8; Lewy F., 1912, HDB NEUROLOGIE; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matulis D, 1998, BIOPHYS J, V74, P422, DOI 10.1016/S0006-3495(98)77799-9; MONTGOMERY EB, 1995, TOXICOLOGY, V97, P3, DOI 10.1016/0300-483X(94)02962-T; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; OESTREICHER E, 1994, BRAIN RES, V660, P8, DOI 10.1016/0006-8993(94)90833-8; OKAZAKI H, 1961, J NEUROPATHOL EXP NE, V21, P422; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; RYBICKI BA, 1993, MOVEMENT DISORD, V8, P87, DOI 10.1002/mds.870080116; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TANNER CM, 1989, TRENDS NEUROSCI, V12, P49, DOI 10.1016/0166-2236(89)90135-5; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 1998, P NATL ACAD SCI USA, V95, P5480, DOI 10.1073/pnas.95.10.5480; Uversky VN, 1999, PROTEIN SCI, V8, P161; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wetzel R, 1996, CELL, V86, P699, DOI 10.1016/S0092-8674(00)80143-9; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; YASUI M, 1992, NEUROTOXICOLOGY, V13, P593; YOUDIM MBH, 1991, EUR NEUROL, V31, P34, DOI 10.1159/000116719; ZAYED J, 1990, CAN J NEUROL SCI, V17, P286, DOI 10.1017/S0317167100030584	79	847	860	6	151	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44284	44296		10.1074/jbc.M105343200	http://dx.doi.org/10.1074/jbc.M105343200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11553618	hybrid			2022-12-25	WOS:000172297700101
J	van Kats, JP; Methot, D; Paradis, P; Silversides, DW; Reudelhuber, TL				van Kats, JP; Methot, D; Paradis, P; Silversides, DW; Reudelhuber, TL			Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice - Direct and indirect effects of angiotensin II on the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESSURE-OVERLOAD HYPERTROPHY; RAT CARDIAC FIBROBLASTS; IN-VIVO; INTERSTITIAL FLUID; RECEPTOR SUBTYPES; BLOOD-PRESSURE; RENIN; FIBROSIS; SYSTEM; MYOCYTES	Angiotensin II is a peptide hormone regulator of blood pressure and fluid balance in mammals. Evidence obtained largely in vitro has also suggested that angiotensin II has growth-promoting effects and that it might thereby contribute to such pathological phenomena as cardiac hypertrophy, a major risk factor for cardiovascular mortality. It has been difficult to test for the direct growth-promoting effects of angiotensin II in vivo, however, because of the generalized effects of the peptide on hemodynamics. To overcome this limitation and to test for cardiac-specific functions of angiotensin II, we generated transgenic mice expressing an angiotensin II-producing fusion protein exclusively in cardiac myocytes. Our findings are the first to distinguish between local and systemic effects of angiotensin II on the heart and introduce a novel technique for studying tissue-specific peptide function.	Clin Res Inst Montreal, Lab Mol Biochem Hypertens, Montreal, PQ H2W 1R7, Canada; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Washington; University of Washington Seattle; Universite de Montreal	Reudelhuber, TL (corresponding author), Clin Res Inst Montreal, Lab Mol Biochem Hypertens, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	reudelt@ircm.qc.ca	van Kats, Jorge/A-8284-2008					Ammarguellat F, 2001, CIRCULATION, V103, P319; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BRILLA CG, 1994, J MOL CELL CARDIOL, V26, P809, DOI 10.1006/jmcc.1994.1098; BRUCKSCHLEGEL G, 1995, HYPERTENSION, V25, P250, DOI 10.1161/01.HYP.25.2.250; deLannoy LM, 1997, HYPERTENSION, V29, P1240, DOI 10.1161/01.HYP.29.6.1240; DESCHEPPER CF, 1986, ENDOCRINOLOGY, V119, P36, DOI 10.1210/endo-119-1-36; Dostal DE, 1999, CIRC RES, V85, P643, DOI 10.1161/01.RES.85.7.643; DZAU VJ, 1994, J HYPERTENS       S4, V12, P3; Fareh J, 1996, CIRC RES, V78, P302, DOI 10.1161/01.RES.78.2.302; GOMEZSANCHEZ EP, 1995, STEROIDS, V60, P69; GUARDA E, 1993, CARDIOVASC RES, V27, P2130, DOI 10.1093/cvr/27.12.2130; Hamawaki M, 1998, AM J PHYSIOL-HEART C, V274, pH868, DOI 10.1152/ajpheart.1998.274.3.H868; Harada K, 1999, CIRCULATION, V100, P2093, DOI 10.1161/01.CIR.100.20.2093; Harada K, 1998, CIRCULATION, V97, P1952, DOI 10.1161/01.CIR.97.19.1952; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hogan B, 1994, MANIPULATING MOUSE E; Kaddoura S, 1996, CIRCULATION, V93, P2068, DOI 10.1161/01.CIR.93.11.2068; KHOSLA MC, 1981, J MED CHEM, V24, P885, DOI 10.1021/jm00139a023; KIM SK, 1995, HYPERTENSION, V25, P1252, DOI 10.1161/01.HYP.25.6.1252; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; LEE AA, 1995, J MOL CELL CARDIOL, V27, P2347, DOI 10.1016/S0022-2828(95)91983-X; LEE MA, 1993, CIRCULATION, V87, P7; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; Liu Y, 1998, CIRC RES, V82, P1145, DOI 10.1161/01.RES.82.11.1145; MATSUBARA H, 1994, J CLIN INVEST, V93, P1592, DOI 10.1172/JCI117139; Matsusaka T, 1999, J CLIN INVEST, V103, P1451, DOI 10.1172/JCI5056; Mazzolai L, 1998, HYPERTENSION, V31, P1324, DOI 10.1161/01.HYP.31.6.1324; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; METHOT D, 1995, NUCLEIC ACIDS RES, V23, P4551, DOI 10.1093/nar/23.22.4551; Methot D, 2001, AM J HYPERTENS, V14, p38S, DOI 10.1016/S0895-7061(01)02068-4; Methot D, 1997, J BIOL CHEM, V272, P12994, DOI 10.1074/jbc.272.20.12994; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; Prescott G, 2000, PHYSIOL GENOMICS, V4, P67, DOI 10.1152/physiolgenomics.2000.4.1.67; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Schuijt MP, 1999, J HYPERTENS, V17, P1885, DOI 10.1097/00004872-199917121-00017; Silvestre JS, 1998, J BIOL CHEM, V273, P4883, DOI 10.1074/jbc.273.9.4883; STASCH JP, 1995, AM J HYPERTENS, V8, P1128, DOI 10.1016/0895-7061(95)00224-D; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; van Kats JP, 1998, CIRCULATION, V98, P73, DOI 10.1161/01.CIR.98.1.73; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; YOUNG M, 1995, AM J PHYSIOL-ENDOC M, V269, pE657, DOI 10.1152/ajpendo.1995.269.4.E657	45	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44012	44017		10.1074/jbc.M106132200	http://dx.doi.org/10.1074/jbc.M106132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11551931	hybrid			2022-12-25	WOS:000172297700069
J	Basran, J; Sutcliffe, MJ; Scrutton, NS				Basran, J; Sutcliffe, MJ; Scrutton, NS			Optimizing the Michaelis complex of trimethylamine dehydrogenase - Identification of interactions that perturb the ionization of substrate and facilitate catalysis with trimethylamine base	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON TRANSFERRING FLAVOPROTEIN; MONOAMINE-OXIDASE; ENZYME-SUBSTRATE; C30A MUTANT; WILD-TYPE; OXIDATION; MECHANISM; BENZYLAMINE; BACTERIUM; W(3)A(1)	Recent evidence from isotope studies supports the view that catalysis by trimethylamine dehydrogenase (TMADH) proceeds from a Michaelis complex involving trimethylamine base and not, as thought previously, trimethylammonium cation. In native TMADH reduction of the flavin by substrate (perdeuterated trimethylamine) is influenced by two ionizations in the Michaelis complex with pK(a) values of 6.5 and 8.4; maximal activity is realized in the alkaline region. The latter ionization has been attributed to residue His-172 and, more recently, the former to the ionization of substrate itself. In the Michaelis complex, the ionization of substrate (pK(a) similar to 6.5 for perdeuterated substrate) is perturbed by similar to -3.3 to -3.6 pH units compared with that of free trimethylamine (pK(a) = 9.8) and free perdeuterated trimethylamine (pK(a) = 10.1), respectively, thus stabilizing trimethylamine base by similar to2 kJ mol(-1). We show, by targeted mutagenesis and stopped-flow studies that this reduction of the pK(a) is a consequence of electronic interaction with residues Tyr-60 and His-172, thus these two residues are key for optimizing catalysis in the physiological pH range. We also show that residue Tyr-174, the remaining ionizable group in the active site that we have not targeted previously by mutagenesis, is not implicated in the pH dependence of flavin reduction. Formation of a Michaelis complex with trimethylamine base is consistent with a mechanism of amine oxidation that we advanced in our previous computational and kinetic studies which involves nucleophilic attack by the substrate nitrogen atom on the electrophilic C4a atom of the flavin isoalloxazine ring. Stabilization of trimethylamine base in the Michaelis complex over that in free solution is key to optimizing catalysis at physiological pH in TMADH, and may be of general importance in the mechanism of other amine dehydrogenases that require the unprotonated form of the substrate for catalysis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Sutcliffe, Mike/0000-0003-0414-1700				Basran J, 1999, J BIOL CHEM, V274, P13155, DOI 10.1074/jbc.274.19.13155; Basran J, 2000, BIOCHEMISTRY-US, V39, P9188, DOI 10.1021/bi0006868; Basran J, 1999, BIOCHEM J, V341, P307, DOI 10.1042/0264-6021:3410307; Basran J, 1997, BIOCHEMISTRY-US, V36, P1989, DOI 10.1021/bi962623o; Basran J, 2001, J BIOL CHEM, V276, P24581, DOI 10.1074/jbc.M101178200; Basran J, 2001, J BIOL CHEM, V276, P6234, DOI 10.1074/jbc.M008141200; Basran J, 1999, BIOCHEMISTRY-US, V38, P3218, DOI 10.1021/bi982719d; BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; DAVIDSON V, 2000, ENZYME CATALYZED ELE, V35, P119; DIXON HBF, 1973, BIOCHEM J, V131, P149, DOI 10.1042/bj1310149; EDMONDSON DE, 1995, XENOBIOTICA, V25, P735, DOI 10.3109/00498259509061889; GRANT KL, 1989, BIOCHEMISTRY-US, V28, P6597, DOI 10.1021/bi00442a010; Harris RJ, 2000, BIOCHEMISTRY-US, V39, P1189, DOI 10.1021/bi991941v; HUANG LX, 1995, J BIOL CHEM, V270, P23958, DOI 10.1074/jbc.270.41.23958; Jang MH, 1999, J BIOL CHEM, V274, P13147, DOI 10.1074/jbc.274.19.13147; KIM JM, 1993, J AM CHEM SOC, V115, P10591, DOI 10.1021/ja00076a017; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIM LW, 1986, J BIOL CHEM, V261, P5140; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mewies M, 1997, BIOCHEMISTRY-US, V36, P7162, DOI 10.1021/bi970621d; Miller JR, 1999, BIOCHEMISTRY-US, V38, P13670, DOI 10.1021/bi990920y; Miura R, 1997, J BIOCHEM-TOKYO, V122, P825; Mullis K B, 1991, PCR Methods Appl, V1, P1; NAGY J, 1979, J BIOL CHEM, V254, P2684; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; Scrutton, 2000, ENZYME CATALYZED ELE, V35, P183; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SCRUTTON NS, 2000, ENZYME CATALYZED ELE, V35, P145; SILVERMAN RB, 1995, ACCOUNTS CHEM RES, V28, P335, DOI 10.1021/ar00056a003; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024	37	30	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42887	42892		10.1074/jbc.M108296200	http://dx.doi.org/10.1074/jbc.M108296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553643	hybrid			2022-12-25	WOS:000172169300035
J	Berkovich, E; Ginsberg, D				Berkovich, E; Ginsberg, D			Ras induces elevation of E2F-1 mRNA levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE MACHINERY; S-PHASE ENTRY; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR E2F-1; MYC PROTEIN STABILITY; DEREGULATED EXPRESSION; FAMILY MEMBERS; MESSENGER-RNA; SUBCELLULAR-LOCALIZATION; RETINOBLASTOMA PROTEIN	Both E2F-1 and Ras play pivotal roles in the regulation of cell proliferation, and in some biological settings, they collaborate in cell transformation. We show here that activated Ras induces an increase in E2F-1 mRNA and protein levels. This Ras-induced increase in E2F-1 levels is dependent on both MEK and PKB, and it is retinoblastoma-independent. The effect of Ras on the up-regulation of E2F-1 mRNA is at the level of mRNA stability. Our data describe a novel functional link between Ras and the retinoblastoma/E2F pathway. Furthermore, we suggest that one of the molecular mechanisms underlying the collaboration between Ras and E2F-1 involves a Ras-induced elevation of transcriptionally active E2F-1 levels.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			ginsberg, doron/0000-0002-1257-4920				Aklilu F, 2000, CANCER RES, V60, P1753; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHANDLER LA, 1994, MOL CELL BIOL, V14, P3085, DOI 10.1128/MCB.14.5.3085; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Geng Y, 1996, ONCOGENE, V12, P1173; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NEBL G, 1994, J BIOL CHEM, V269, P7371; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Terada K, 2000, BIOCHEM BIOPH RES CO, V267, P449, DOI 10.1006/bbrc.1999.1955; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Winston JT, 1996, ONCOGENE, V12, P127; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420	57	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42851	42856		10.1074/jbc.M103596200	http://dx.doi.org/10.1074/jbc.M103596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551910	hybrid			2022-12-25	WOS:000172169300030
J	Fogg, VC; Azpiazu, I; Linder, ME; Smrcka, A; Scarlata, S; Gautam, N				Fogg, VC; Azpiazu, I; Linder, ME; Smrcka, A; Scarlata, S; Gautam, N			Role of the gamma subunit prenyl moiety in G protein beta gamma complex interaction with phospholipase C beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SF9 CELLS; ALPHA-SUBUNIT; GTP-BINDING; ACTIVATION; PURIFICATION; ISOZYMES; REQUIRES; DOMAIN	The G protein beta gamma complex regulates a wide range of effectors, including the phospholipase C beta isozymes (PLC betas). Prenyl modification of the gamma subunit is necessary for this activity. Evidence presented here supports a direct interaction between the G protein gamma subunit prenyl group and PLC isozymes. A geranylgeranylated peptide corresponding to the C-terminal region of the gamma subunit type, gamma2, strongly inhibits stimulation of PLC beta2 and PLC beta3 activity by the beta gamma complex. This effect is specific because the same peptide has no effect on stimulation of PLC beta by an a subunit type, alphaq. Prenylation of the gamma peptide is required for its inhibitory effect. W interaction of prenylated gamma subunit peptide to fluophore-tagged PLC beta2 was examined by fluorescence spectroscopy, prenylated but not unprenylated peptide increased PLC beta2 fluorescence emission energy, indic ting direct binding of the prenyl moiety to PLC. In addition, fluorescence resonance energy transfer was detected between fluorophore tagged PLC beta and wild type Py complex but not an unprenylated mutant beta gamma complex. We conclude that a major function of the gamma subunit prenyl group is to facilitate direct protein-protein interaction between the beta gamma complex and an effector, phospholipase C beta.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; SUNY Stony Brook, Dept Phys & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Rochester	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466, R01GM053132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51466, GM53536, GM46963, R01 GM053536, GM53132, R01 GM046963, R01 GM051466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; AZPIAZU I, 2001, IN PRESS METHODS ENZ; BLANK JL, 1993, J BIOL CHEM, V268, P25184; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dietrich A, 1996, BIOCHEMISTRY-US, V35, P15174, DOI 10.1021/bi960305j; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LEE SB, 1993, J BIOL CHEM, V268, P25952; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	30	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41797	41802		10.1074/jbc.M107661200	http://dx.doi.org/10.1074/jbc.M107661200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546822	hybrid			2022-12-25	WOS:000172450400035
J	He, B; Bowen, NT; Minges, JT; Wilson, EM				He, B; Bowen, NT; Minges, JT; Wilson, EM			Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; LIGAND-BINDING DOMAIN; PROTEASOME-MEDIATED DEGRADATION; VITAMIN-D-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; INTERDOMAIN COMMUNICATION; AF2 DOMAINS; SPECIFICITY; SEQUENCES; REGIONS	The androgen receptor undergoes an androgen-specific NH2- and COOH-terminal interaction between NH2- terminal motif FXXLF and activation function 2 in the ligand binding domain. We demonstrated previously that activation function 2 forms overlapping binding sites for the androgen receptor FXXLF motif and the LXXLL motifs of p160 coactivators. Here we investigate the influence of the NH2- and COOH-terminal interaction on androgen receptor function. Specificity and relative potency of the motif interactions were evaluated by ligand dissociation rate and the stability of chimeras of transcriptional intermediary factor 2 with full-length and truncated androgen or glucocorticoid receptor. The results indicate that the androgen receptor activation function 2 interacts specifically and with greater avidity with the single FXXLF motif than with the LXXLL motif region of p160 coactivators, whereas this region of the glucocorticoid receptor interacts preferentially with the LXXLL motifs. Expression of the LXXLL motifs as a fusion protein with the glucocorticoid receptor resulted in loss of agonist-induced receptor destabilization and increased half-time of ligand dissociation. The NH2- and COOH-terminal interaction inhibited binding and activation by transcriptional intermediary factor 2. We conclude that the androgen receptor NH2- and COOH-terminal interaction reduces the dissociation rate of bound androgen, stabilizes the receptor, and inhibits p160 coactivator recruitment by activation function 2.	Univ N Carolina, Reprod Biol Lab, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Reprod Biol Lab, Dept Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Reprod Biol Lab, Dept Biochem, CB 7500,Rm 374,Med Sci Res Bldg, Chapel Hill, NC 27599 USA.	emw@med.unc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016910, R01HD016910, U54HD035041] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16910, U54-HD35041] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Alen P, 1999, MOL CELL BIOL, V19, P6085; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gregory CW, 2001, CANCER RES, V61, P4315; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HOECK W, 1989, J BIOL CHEM, V264, P14396; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P1532, DOI 10.1210/endo-122-4-1532; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Osburn DL, 2001, MOL CELL BIOL, V21, P4909, DOI 10.1128/MCB.21.15.4909-4918.2001; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SANTISOMERE D, 1993, MOL ENDOCRINOL, V7, P833, DOI 10.1210/me.7.7.833; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SPANJAARD RA, 1993, MOL ENDOCRINOL, V7, P12, DOI 10.1210/me.7.1.12; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang Q, 2001, J BIOL CHEM, V276, P7493, DOI 10.1074/jbc.M009916200; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	56	109	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42293	42301		10.1074/jbc.M107492200	http://dx.doi.org/10.1074/jbc.M107492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551963	Green Published, hybrid			2022-12-25	WOS:000172450400100
J	Huber, TB; Kottgen, M; Schilling, B; Walz, G; Benzing, T				Huber, TB; Kottgen, M; Schilling, B; Walz, G; Benzing, T			Interaction with podocin facilitates nephrin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL NEPHROTIC SYNDROME; SLIT DIAPHRAGM; GLOMERULAR PROTEIN; FINNISH TYPE; GENE; ACTIVATION; MUTATIONS; APOPTOSIS; PATHWAY; NPHS1	Mutations of NPHS1 or NPHS2, the genes encoding for the glomerular podocyte proteins nephrin and podocin, cause steroid-resistant proteinuria. In addition, mice lacking CD2-associated protein (CD2AP) develop a nephrotic syndrome that resembles NPHS mutations suggesting that all three proteins are essential for the integrity of glomerular podocytes. Although the precise glomerular function of either protein remains unknown, it has been suggested that nephrin forms zipper-like interactions to maintain the structure of podocyte foot processes. We demonstrate now that nephrin is a signaling molecule, which stimulates mitogen-activated protein kinases. Nephrin-induced signaling is greatly enhanced by podocin, which binds to the cytoplasmic tail of nephrin. Mutational analysis suggests that abnormal or inefficient signaling through the nephrin-podocin complex contributes to the development of podocyte dysfunction and proteinuria.	Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany	University of Freiburg	Walz, G (corresponding author), Univ Hosp Freiburg, Div Renal, Hugstetterstr 55, D-79106 Freiburg, Germany.		Benzing, Thomas/X-5476-2019	Kottgen, Michael/0000-0003-2406-5039; Huber, Tobias B./0000-0001-7175-5062				Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Beltcheva O, 2001, HUM MUTAT, V17, P368, DOI 10.1002/humu.1111; BENZING T, 2000, J BIOL CHEM; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; HOLMBERG C, 1995, PEDIATR NEPHROL, V9, P87, DOI 10.1007/BF00858984; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Lenkkeri U, 1999, AM J HUM GENET, V64, P51, DOI 10.1086/302182; Patrakka J, 2000, KIDNEY INT, V58, P972, DOI 10.1046/j.1523-1755.2000.00254.x; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	20	265	303	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41543	41546		10.1074/jbc.C100452200	http://dx.doi.org/10.1074/jbc.C100452200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11562357	hybrid			2022-12-25	WOS:000172450400002
J	Ogden, SK; Lee, KC; Wernke-Dollries, K; Stratton, SA; Aronow, B; Barton, MC				Ogden, SK; Lee, KC; Wernke-Dollries, K; Stratton, SA; Aronow, B; Barton, MC			p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IN-VIVO; P53-MEDIATED REPRESSION; SYNTHETIC NUCLEI; PROMOTER INVITRO; DNA-BINDING; ACETYLATION; ACTIVATION; ENHANCER; PROTEIN	Many of the functions ascribed to p53 tumor suppressor protein are mediated through transcription regulation. We have shown that p53 represses hepatic-specific a-fetoprotein (A-FP) gene expression by direct interaction with a composite HNF-3/p53 DNA binding element. Using solid-phase, chromatin-assembled AFP DNA templates and analysis of chromatin structure and transcription in vitro, we find that p53 binds DNA and alters chromatin structure at the AFP core promoter to regulate transcription. Chromatin assembled in the presence of hepatoma extracts is activated for AFP transcription with an open, accessible core promoter structure. Distal (-850) binding of p53 during chromatin assembly, but not post-assembly, reverses transcription activation concomitant with promoter inaccessibility to restriction enzyme digestion. Inhibition of histone deacetylase activity by trichostatin-A (TSA) addition, prior to and during chromatin assembly, activated chromatin transcription in parallel with increased core promoter accessibility. Chromatin immunoprecipitation analyses showed increased H3 and H4 acetylated histones at the core promoter in the presence of TSA, while histone acetylation remained unchanged at the site of distal p53 binding. Our data reveal that p53 targets chromatin structure alteration at the core promoter, independently of effects on histone acetylation, to establish repressed AFP gene expression.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45267 USA	University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Barton, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Box 117, Houston, TX 77030 USA.		Ogden, Stacey K/P-9585-2019; Aronow, Bruce J/F-8438-2012; Ogden, Stacey K/N-2528-2018	Ogden, Stacey K/0000-0001-8991-3065; Barton, Michelle/0000-0002-4042-1374	NCI NIH HHS [T32 CA59268] Funding Source: Medline; NIGMS NIH HHS [GM53683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Barton MC, 1996, METHOD ENZYMOL, V274, P299; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Cai HN, 1996, P NATL ACAD SCI USA, V93, P9309, DOI 10.1073/pnas.93.18.9309; Chou J Y, 1989, Oxf Surv Eukaryot Genes, V6, P1; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Crowe AJ, 1999, METHODS, V17, P173, DOI 10.1006/meth.1998.0728; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; GODBOUT R, 1988, GENE DEV, V2, P949, DOI 10.1101/gad.2.8.949; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Liu L, 1999, MOL CELL BIOL, V19, P1202; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Mizzen C, 1998, COLD SPRING HARB SYM, V63, P469, DOI 10.1101/sqb.1998.63.469; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SPEAR BT, 1995, DNA CELL BIOL, V14, P635, DOI 10.1089/dna.1995.14.635; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Weiss J, 1995, Recent Results Cancer Res, V139, P137; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zaret KS, 1995, PROTEIN EXPRES PURIF, V6, P821, DOI 10.1006/prep.1995.0014; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	47	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42057	42062		10.1074/jbc.C100381200	http://dx.doi.org/10.1074/jbc.C100381200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11572852	hybrid			2022-12-25	WOS:000172450400070
J	Unniraman, S; Prakash, R; Nagaraja, V				Unniraman, S; Prakash, R; Nagaraja, V			Alternate paradigm for intrinsic transcription termination in eubacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RNA; MYCOBACTERIUM-SMEGMATIS; ATTENUATOR TEMPLATES; LOOP STRUCTURE; DNA GYRASE; POLYMERASE; RHO; ELONGATION; MECHANISM; GENE	Intrinsic transcription terminators are functionally defined as sites that bring about termination in vitro with purified RNA polymerase alone. Based on studies in Escherichia coli, intrinsic termination requires a palindromic stretch followed by a trail of T (or U) residues in the coding strand. We have developed a highly efficient algorithm to identify hairpin potential sequences in bacterial genomes in order to build a general model for intrinsic transcription termination. The algorithm was applied to analyze the Mycobacterium tuberculosis genome. We find that hairpin potential sequences are concentrated in the immediate downstream of stop codons. However, most of these structures either lack the U trail entirely or have a mixed A/U trail reflecting an evolutionarily relaxed requirement for the U trail in the mycobacterial genome. Predicted atypical structures were shown to work efficiently as terminators both inside the mycobacterial cell and in vitro with purified RNA polymerase. The results are discussed in light of the kinetic competition models for transcription termination. The algorithm identifies > 90% of experimentally tested terminators in bacteria and is an invaluable tool in identifying transcription units in whole genomes.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Nagaraja, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	vraj@mcbl.iisc.ernet.in						Abe H, 1996, BIOCHIMIE, V78, P1035, DOI 10.1016/S0300-9084(97)86727-2; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; BRENDEL V, 1986, J BIOMOL STRUCT DYN, V3, P705, DOI 10.1080/07391102.1986.10508457; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DASGUPTA SK, 1993, J BACTERIOL, V175, P5186, DOI 10.1128/JB.175.16.5186-5192.1993; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; Ermolaeva MD, 2000, J MOL BIOL, V301, P27, DOI 10.1006/jmbi.2000.3836; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FISHER R, 1983, J BIOL CHEM, V258, P9208; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; HARSHEY RM, 1977, J BACTERIOL, V129, P616, DOI 10.1128/JB.129.2.616-622.1977; HARTMANN RK, 1991, NUCLEIC ACIDS RES, V19, P5957, DOI 10.1093/nar/19.21.5957; INGHAM CJ, 1995, NUCLEIC ACIDS RES, V23, P370, DOI 10.1093/nar/23.3.370; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; LYNN SP, 1988, J BIOL CHEM, V263, P472; Madhusudan K, 1995, MICROBIOL-SGM, V141, P3029, DOI 10.1099/13500872-141-12-3029; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; NAGARAJA V, 1980, ARCH MICROBIOL, V124, P249, DOI 10.1007/BF00427734; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POSTLE K, 1985, CELL, V41, P577, DOI 10.1016/S0092-8674(85)80030-1; PREDICH M, 1995, MOL MICROBIOL, V15, P355, DOI 10.1111/j.1365-2958.1995.tb02249.x; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RYAN T, 1983, J BIOL CHEM, V258, P4690; STEINER K, 1995, MOL GEN GENET, V246, P374, DOI 10.1007/BF00288611; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; Unniraman S, 1999, GENES CELLS, V4, P697, DOI 10.1046/j.1365-2443.1999.00296.x; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; Washio T, 1998, NUCLEIC ACIDS RES, V26, P5456, DOI 10.1093/nar/26.23.5456; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG MT, 1989, J BIOL CHEM, V264, P2634; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124	41	42	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41850	41855		10.1074/jbc.M106252200	http://dx.doi.org/10.1074/jbc.M106252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551936	hybrid, Green Published			2022-12-25	WOS:000172450400042
J	Bulteau, AL; Verbeke, P; Petropoulos, I; Chaffotte, AF; Friguet, B				Bulteau, AL; Verbeke, P; Petropoulos, I; Chaffotte, AF; Friguet, B			Proteasome inhibition in glyoxal-treated fibroblasts and resistance of glycated glucose-6-phosphate dehydrogenase to 20 S proteasome degradation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED MAILLARD REACTION; COLI GLUTAMINE-SYNTHETASE; METAL-CATALYZED OXIDATION; OXIDIZED PROTEINS; END-PRODUCT; RAT-LIVER; PROTEOLYTIC ACTIVITIES; STRESS; AGE; PENTOSIDINE	Glycation and glycoxidation protein products are formed upon binding of sugars to NH2 groups of lysine and arginine residues and have been shown to accumulate during aging and in pathologies such as Alzheimer's disease and diabetes. Because the proteasome is the major intracellular proteolytic system involved in the removal of altered proteins, the effect of intracellular glycation on proteasome function has been analyzed in human dermal fibroblasts subjected to treatment with glyoxal that promotes the formation of N epsilon -carboxymethyl-lysine adducts on proteins. The three proteasome peptidase activities were decreased in glyoxal-treated cells as compared with control cells, and glyoxal was also found to inhibit these peptidase activities in vitro. In addition, the activity of glucose-6-phosphate dehydrogenase, a crucial enzyme for the regulation of the intracellular redox status, was dramatically reduced in glyoxal-treated cells. Further analysis was performed to determine whether glycated proteins are substrates for proteasome degradation. In contrast to the oxidized glucose-6-phosphate dehydrogenase, both N epsilon -carboxymethyl-lysine- and fluorescent-glycated enzymes were resistant to degradation by the 20 S proteasome in vitro, and this resistance was correlated with an increased conformational stability of the glycated proteins. These results provide one explanation for why glycated proteins build up both as a function of disease and aging. Finally, N epsilon -carboxymethyl-lysine-modified proteins were found to be ubiquitinated in glyoxal-treated cells suggesting a potential mechanism by which these modified proteins may be marked for degradation.	Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, F-75251 Paris 05, France; Univ Aarhus, Dept Biol Mol & Struct, Lab Cellular Ageing, DK-8000 Aarhus, Denmark; Inst Pasteur, CNRS, URA 1129, Unite Biochim Cellulaire, F-75724 Paris 15, France	UDICE-French Research Universities; Universite Paris Cite; Aarhus University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Friguet, B (corresponding author), Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, 2 Pl Jussieu,CC 7128, F-75251 Paris 05, France.	bfriguet@paris7.jussieu.fr	bulteau, anne-laure/AAN-4004-2020	Friguet, Bertrand/0000-0001-8085-1961; Petropoulos, Isabelle/0000-0001-9205-7458				Abordo EA, 1999, BIOCHEM PHARMACOL, V58, P641, DOI 10.1016/S0006-2952(99)00132-X; AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; ARAKI N, 1992, J BIOL CHEM, V267, P10211; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Bulteau AL, 2000, EXP GERONTOL, V35, P767, DOI 10.1016/S0531-5565(00)00136-4; Chondrogianni N, 2000, EXP GERONTOL, V35, P721, DOI 10.1016/S0531-5565(00)00137-6; Ciechanover A, 2000, J CELL BIOCHEM, P40; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DEUTSCH J, 1983, METHOD ENZYMAT AN, V3, P190; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Friguet B, 2000, ANN NY ACAD SCI, V908, P143; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hayashi T, 1998, MECH AGEING DEV, V102, P55, DOI 10.1016/S0047-6374(98)00011-6; Ho HY, 2000, FREE RADICAL BIO MED, V29, P156, DOI 10.1016/S0891-5849(00)00331-2; Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944; Kasper M, 1999, BIOCHEM BIOPH RES CO, V261, P175, DOI 10.1006/bbrc.1999.0902; Kimura T, 1998, PATHOL INT, V48, P575, DOI 10.1111/j.1440-1827.1998.tb03953.x; Kroll M, 1999, CHEM BIOL, V6, P689, DOI 10.1016/S1074-5521(00)80016-2; Lasch P, 2001, J BIOL CHEM, V276, P9492, DOI 10.1074/jbc.M008528200; Lee C, 1998, J BIOL CHEM, V273, P25272, DOI 10.1074/jbc.273.39.25272; Lenk SE, 1999, J CELL PHYSIOL, V178, P17, DOI 10.1002/(SICI)1097-4652(199901)178:1<17::AID-JCP3>3.0.CO;2-R; Miyata S, 1997, J BIOL CHEM, V272, P4037, DOI 10.1074/jbc.272.7.4037; Miyata T, 1999, KIDNEY INT, V55, P389, DOI 10.1046/j.1523-1755.1999.00302.x; Monnier VM, 1996, NEPHROL DIAL TRANSPL, V11, P20; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Niwa H, 1998, BIOCHEM BIOPH RES CO, V248, P93, DOI 10.1006/bbrc.1998.8899; ODETTI P, 1992, DIABETES, V41, P153, DOI 10.2337/diabetes.41.2.153; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; Petropoulos I, 2000, J GERONTOL A-BIOL, V55, pB220, DOI 10.1093/gerona/55.5.B220; Ponnappan U, 1999, CELL IMMUNOL, V192, P167, DOI 10.1006/cimm.1998.1418; Portero-Otin M, 1999, DIABETES, V48, P2215, DOI 10.2337/diabetes.48.11.2215; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Sell DR, 1998, MECH AGEING DEV, V105, P221, DOI 10.1016/S0047-6374(98)00090-6; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shibatani T, 1996, J GERONTOL A-BIOL, V51, pB316, DOI 10.1093/gerona/51A.5.B316; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; SUAREZ G, 1995, ARCH BIOCHEM BIOPHYS, V321, P209, DOI 10.1006/abbi.1995.1387; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Thornalley PJ, 1998, CHEM-BIOL INTERACT, V112, P137, DOI 10.1016/S0009-2797(97)00157-9; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Ullrich O, 1999, FREE RADICAL BIO MED, V27, P487, DOI 10.1016/S0891-5849(99)00060-X; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Verbeke P, 2000, EXP GERONTOL, V35, P787, DOI 10.1016/S0531-5565(00)00143-1; VLASSARA H, 1994, LAB INVEST, V70, P138	59	104	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45662	45668		10.1074/jbc.M105374200	http://dx.doi.org/10.1074/jbc.M105374200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11559702	hybrid			2022-12-25	WOS:000172573100024
J	Xiao, KH; Chandrasekaran, A; Yu, L; Yu, CA				Xiao, KH; Chandrasekaran, A; Yu, L; Yu, CA			Evidence for the intertwined dimer of the cytochrome bc(1) complex in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; WATER-SOLUBLE FRAGMENT; BOVINE HEART; RHODOBACTER-SPHAEROIDES; ELECTRON-TRANSFER; DOMAIN MOVEMENT; BC1 COMPLEX; SUBUNIT-IV; MITOCHONDRIAL; INVOLVEMENT	To confirm that the cytochrome bc(1) complex exists as a dimer with intertwining Rieske iron-sulfur proteins in solution, four Rhodobacter sphaeroides mutants expressing His-tagged cytochrome bc(1) complexes containing two pairs of cysteine substitutions, one in the interface between the head domain of iron-sulfur protein (ISP) and cytochrome b and the other between the tail domain of ISP and cytochrome b, were generated and characterized. They are: K70C(ISP)/A185C(cytb)(.)P33C(ISP)/G89C(cytb), K70C(ISP)/A185C(cytb)(.)P33C(ISP)/M92C (cytb), K70C (ISP)/A185C(cytb)(.)L34C(ISP)/V64C(cytb), and K70C(ISP)/A185C(cytb)(.)N36C(ISP)/G89C(cytb). The K70C(ISP)/A185C(cytb) cysteine pair cross-links the head domain of ISP and cytochrome b; the P33C(ISP)/G89C(cytb), P33C(ISP)/M92C (cytb), L34C(ISP)/V64C(cytb), and N36C(ISP)/G89C(cytb) cysteine pairs cross-link the tail domain of ISP and cytochrome b. An adduct protein with an apparent molecular mass of 128 kDa containing two cytochrome b and two ISP proteins is detected in the K70C(ISP)/A185C(cytb)(.)P33C(ISP)/G89C(cytb) and K70C(ISP)/A185C(cytb)(.)N36C(ISP)/G89C(cytb) mutant complexes, confirming that the be,. complex exists as a dimer with intertwining ISPs. The loss of activity in these two double-cysteine-pair mutant complexes was attributed to the disulfide bond between the head domain of ISP and cytochrome b and not the one between the tail domain of ISP and cytochrome b.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okstate.edu	Xiao, Kunhong/AAG-4275-2020	Xiao, Kunhong/0000-0002-1069-1226	NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Jungas C, 1999, EMBO J, V18, P534, DOI 10.1093/emboj/18.3.534; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P13005, DOI 10.1021/bi00248a009; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V240, P921; Obungu VH, 2000, BBA-BIOENERGETICS, V1457, P36, DOI 10.1016/S0005-2728(99)00116-4; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tso SC, 2000, J BIOL CHEM, V275, P15287, DOI 10.1074/jbc.M907367199; VONJAGOW G, 1977, BIOCHIM BIOPHYS ACTA, V462, P549, DOI 10.1016/0005-2728(77)90100-1; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	14	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46125	46131		10.1074/jbc.M107436200	http://dx.doi.org/10.1074/jbc.M107436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11562368	hybrid			2022-12-25	WOS:000172573100087
J	Zuniga, FA; Shi, GP; Haller, JF; Rubashkin, A; Flynn, DR; Iserovich, P; Fischbarg, J				Zuniga, FA; Shi, GP; Haller, JF; Rubashkin, A; Flynn, DR; Iserovich, P; Fischbarg, J			A three-dimensional model of the human facilitative glucose transporter Glut1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; POLYTOPIC MEMBRANE-PROTEINS; SUGAR PERMEATION PATHWAY; LACTOSE PERMEASE; ESCHERICHIA-COLI; TRANSMEMBRANE SEGMENTS; CONFORMATIONAL CHANGE; HUMAN-ERYTHROCYTES; N-ETHYLMALEIMIDE; CYTOCHALASIN-B	The human facilitative transporter Glut1 is the major glucose transporter present in all human cells, has a central role in metabolism, and is an archetype of the superfamily of major protein facilitators. Here we describe a three-dimensional structure of Glut1 based on helical packing schemes proposed for lactose permease and Glut1 and predictions of secondary structure, and refined using energy minimization, molecular dynamics simulations, and quality and environmental scores. The Ramachandran scores and the stereochemical quality of the structure obtained were as good as those for the known structures of the KesA K+ channel and aquaporin 1. We found two channels in Glut1. One of them traverses the structure completely, and is lined by many residues known to be solvent-accessible. Since it is delimited by the QLS motif and by several well conserved residues, it may serve as the substrate transport pathway. To validate our structure, we determined the distance between these channels and all the residues for which mutations are known. From the locations of sugar transporter signatures, motifs, and residues important to the transport function, we find that this Glut1 structure is consistent with mutagenesis and biochemical studies. It also accounts for functional deficits in seven pathogenic mutants.	Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA	Columbia University; Columbia University	Fischbarg, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol, 630 West & 168th St, New York, NY 10032 USA.		Zuniga, Felipe/Q-8035-2019; Rubashkin, Andrey A/H-8243-2016; Zuniga, Felipe A/L-7885-2013	Rubashkin, Andrey A/0000-0002-9054-0574; Zuniga, Felipe A./0000-0003-0286-565X	NATIONAL EYE INSTITUTE [R01EY008918] Funding Source: NIH RePORTER; NEI NIH HHS [EY08918] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Barrett MP, 1999, CURR OPIN CELL BIOL, V11, P496, DOI 10.1016/S0955-0674(99)80072-6; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; DAVIES A, 1990, BIOCHEM J, V266, P799; DAVIES A, 1987, J BIOL CHEM, V262, P9347; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ducarme P, 1996, J MOL MODEL, V2, P27, DOI 10.1007/s008940050018; Dwyer DS, 2001, PROTEINS, V42, P531, DOI 10.1002/1097-0134(20010301)42:4<531::AID-PROT110>3.3.CO;2-0; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; Klepper J, 1999, NEUROCHEM RES, V24, P587, DOI 10.1023/A:1022544131826; Klepper J, 2001, HUM MOL GENET, V10, P63, DOI 10.1093/hmg/10.1.63; Klepper J, 1999, PEDIATR RES, V46, P677, DOI 10.1203/00006450-199912000-00006; KRUPKA RM, 1986, BIOCHEM CELL BIOL, V64, P1099, DOI 10.1139/o86-145; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAY JM, 1989, BIOCHIM BIOPHYS ACTA, V986, P207, DOI 10.1016/0005-2736(89)90469-0; MORI H, 1994, J BIOL CHEM, V269, P11578; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Oliveira L, 1999, PROTEIN ENG, V12, P1087, DOI 10.1093/protein/12.12.1087; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Olsowski A, 1998, BIOCHEMISTRY-US, V37, P10738, DOI 10.1021/bi980440r; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; RAMPAL AL, 1987, BIOCHIM BIOPHYS ACTA, V896, P287, DOI 10.1016/0005-2736(87)90189-1; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; Rost B, 1996, METHOD ENZYMOL, V266, P525; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; SERGEANT S, 1985, J BIOL CHEM, V260, P4677; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; STULTZ CM, 1993, PROTEIN SCI, V2, P305; TAKATA K, 1992, CELL TISSUE RES, V267, P407, DOI 10.1007/BF00319362; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang D, 2000, HUM MUTAT, V16, P224, DOI 10.1002/1098-1004(200009)16:3<224::AID-HUMU5>3.0.CO;2-P; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6; WELLNER M, 1994, BIOCHEM J, V299, P813, DOI 10.1042/bj2990813; WELLNER M, 1992, FEBS LETT, V309, P293, DOI 10.1016/0014-5793(92)80792-F; Zeng H, 1996, BIOPHYS J, V70, P14, DOI 10.1016/S0006-3495(96)79560-7; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; ZOTTOLA RJ, 1995, BIOCHEMISTRY-US, V34, P9734, DOI 10.1021/bi00030a011	63	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44970	44975		10.1074/jbc.M107350200	http://dx.doi.org/10.1074/jbc.M107350200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571301	hybrid			2022-12-25	WOS:000172406700085
J	Toshima, JY; Toshima, J; Mizuno, K				Toshima, JY; Toshima, J; Mizuno, K			Binding of 14-3-3 beta regulates the kinase activity and subcellular localization of testicular protein kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC PROTEIN-KINASE-1; ACTIN CYTOSKELETAL DYNAMICS; LIM-KINASE; COFILIN PHOSPHORYLATION; SIGNALING PATHWAYS; STRUCTURAL BASIS; ACTIVATION LOOP; T-CELLS; 14-3-3-PROTEINS; IDENTIFICATION	Testicular protein kinase 1 (TESK1) is a serine/threonine kinase that phosphorylates cofilin and induces actin cytoskeletal reorganization. The kinase activity of TESK1 is stimulated by integrin-mediated signaling pathways, but the mechanism of regulation has remained unknown. By using the yeast two-hybrid system, we identified 14-3-3 beta to be the binding protein of TESK1. Specific interaction between TESK1 and 14-3-3 beta became evident in in vitro and in vivo co-precipitation assays. 14-3-3 beta interacts with TESK1 through the C-terminal region of TESK1 and in a manner dependent on the phosphorylation of Ser-439 within an RXXSXP motif. Binding of 14-3-3 beta inhibited the kinase activity of TESK1. During cell spreading on fibronectin, the TESK1/14-3-3 beta interaction significantly decreased, in a time course that inversely correlated with increase in TESK1 kinase activity. Thus, the dissociation of 14-3-3 beta from a TESK1/14-3-3 beta complex is likely to be involved in the integrin-mediated TESK1 activation. In HeLa cells, TESK1, together with 14-3-3 beta, accumulated at the cell periphery when cells were plated on fibronectin, whereas they were diffusely distributed in the cytoplasm in the case of non-stimulated cells. We propose that 14-3-3 beta plays important roles in regulating the kinase activity of TESK1 and localizing TESK1 to cell adhesion sites following integrin stimulation.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan; Tohoku Univ, Grad Sch Med, Dept Pharmacol, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan.		Mizuno, Kensaku/G-8631-2015; 純子, 十島 Y/GRS-7321-2022					Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BAX B, 1995, CURR BIOL, V5, P1119, DOI 10.1016/S0960-9822(95)00226-0; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chernoff J, 1999, NAT CELL BIOL, V1, pE115, DOI 10.1038/12942; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MIZUNO K, 1994, ONCOGENE, V9, P1605; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nagata K, 1999, BIOCHEM J, V343, P99, DOI 10.1042/0264-6021:3430099; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; PESO LD, 1997, SCIENCE, V278, P687; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Rosok O, 1999, GENOMICS, V61, P44, DOI 10.1006/geno.1999.5922; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Toshima J, 1998, BIOCHEM BIOPH RES CO, V249, P107, DOI 10.1006/bbrc.1998.9099; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; Toshima J, 2001, J BIOL CHEM, V276, P31449, DOI 10.1074/jbc.M102988200; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Toshima J, 1999, J BIOL CHEM, V274, P12171, DOI 10.1074/jbc.274.17.12171; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YAN Z, 1998, NATURE, V395, P507; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	43	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43471	43481		10.1074/jbc.M104620200	http://dx.doi.org/10.1074/jbc.M104620200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555644	hybrid			2022-12-25	WOS:000172169300108
J	Gual, P; Giordano, S; Anguissola, S; Comoglio, PM				Gual, P; Giordano, S; Anguissola, S; Comoglio, PM			Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness	ONCOGENE			English	Article						Met; C-terminal domain; regulatory domain; kinase activity; cell transformation; invasiveness	HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; TYROSINE KINASE DOMAIN; HGF-RECEPTOR; CONSTITUTIVE ACTIVATION; FACTOR/SCATTER FACTOR; RET PROTOONCOGENE; CRYSTAL-STRUCTURE; ADAPTER PROTEINS; INSULIN-RECEPTOR	Biological responses to Hepatocyte Growth Factor are mediated by the tyrosine kinase receptor encoded by the Met oncogene. Under physiological conditions, Met triggers a multi-step genetic program called 'invasive growth' including cell-dissociation, invasion of extracellular matrices and growth. When constitutively activated, Met can induce cell transformation and metastasis. Phosphorylation of two docking tyrosines in the receptor tail is essential for all biological responses. To investigate the role of the C-terminal part of Met, we have generated mutants lacking either the last 26 or 47 amino acids. As expected, mutants lacking the docking sites fail to mediate cell transformation and invasion. Interestingly, while Met Delta 26 can mediate invasion, its transforming ability is severely impaired. Moreover, the lack of the last 26 amino acids strongly reduces Met ability to phosphorylate substrates in vitro and in vivo. These data indicate that the last 26 amino acids are required to confer the kinase its full enzymatic activity, which is critical for cell transformation but dispensable for invasive properties. Finally, we also show that upregulation of Met enzymatic activity by insertion of a point mutation in the kinase domain (M1250T) overcomes the regulatory role played by the last 26 amino acids of the tail. It is concluded that the C-terminal domain of Met is crucial not only for recruitment of transducers but also for regulation of receptor enzymatic activity.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Giordano, Silvia/J-9858-2018; Gual, Philippe/P-9833-2019; Comoglio, Paolo/G-6323-2011	Giordano, Silvia/0000-0003-1854-1086; Gual, Philippe/0000-0001-7393-8356; Comoglio, Paolo/0000-0002-7056-5328				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Borrello MG, 1995, ONCOGENE, V11, P2419; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1995, ONCOGENE, V10, P739; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Iwashita T, 1996, ONCOGENE, V12, P481; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; LONGATI P, 1994, ONCOGENE, V9, P49; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1994, COLD SPRING HARB SYM, V59, P629, DOI 10.1101/SQB.1994.059.01.072; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Xiao ZQ, 2000, BIOCHEM BIOPH RES CO, V267, P669, DOI 10.1006/bbrc.1999.2011; ZHEN Z, 1994, ONCOGENE, V9, P1691	53	6	7	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5493	5502		10.1038/sj.onc.1204713	http://dx.doi.org/10.1038/sj.onc.1204713			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571647				2022-12-25	WOS:000170781100010
J	Hellborg, F; Qian, W; Mendez-Vidal, C; Asker, C; Kost-Alimova, M; Wilhelm, M; Imreh, S; Wiman, KG				Hellborg, F; Qian, W; Mendez-Vidal, C; Asker, C; Kost-Alimova, M; Wilhelm, M; Imreh, S; Wiman, KG			Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein	ONCOGENE			English	Article						p53; human wig-1; zinc finger; growth suppression	GENOMIC HYBRIDIZATION ANALYSIS; DOUBLE-STRANDED-RNA; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; PROMOTES APOPTOSIS; CANDIDATE MEDIATOR; CANCER; LOCALIZATION; TUMORS	We previously identified a novel p53-induced mouse gene, wig-1, that encodes a 290 amino acid zinc finger protein (Varmeh-Ziaie et al., 1997). Here we have identified and characterized the human homolog of mouse wig-1. The human wig-1 protein is 87% identical to the mouse protein and contains three zinc finger domains and a putative nuclear localization signal. Human wig-1 mRNA and protein is induced following activation of wild type p53 expression in our BL41-ts p53 Burkitt lymphoma cells. Wig-l is also induced in MCF7 cells following treatment with the DNA-damaging agent mitomycin C. Northern blotting detected low levels of wig-1 mRNA in normal human tissues. Fluorescence in situ hybridization mapped wig-1 to human chromosome 3q26.3-27. FLAG-tagged human wig-1 localizes to the nucleus. Ectopic overexpression of human wig-1 inhibits tumor cell growth in a colony formation assay. These results suggest that human wig-1 has a role in the p53-dependent growth regulatory pathway.	Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	Klas.Wiman@mtc.ki.se	IBIS, REPRODUCCION/P-3399-2015; Wiman, Klas/AAB-8399-2021; Méndez-Vidal, Cristina/F-1366-2015	Wiman, Klas/0000-0002-7113-524X; Méndez-Vidal, Cristina/0000-0002-1282-1688; Wilhelm, Margareta/0000-0002-0516-9724				Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; Attardi LD, 2000, GENE DEV, V14, P704; Balsara BR, 1997, CANCER RES, V57, P2116; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chung DC, 1998, CANCER RES, V58, P3706; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; Fedorova L, 1997, EUR J HUM GENET, V5, P110, DOI 10.1159/000484744; Finerty PJ, 1999, BIOCHEMISTRY-US, V38, P4001, DOI 10.1021/bi9825293; Finerty PJ, 1997, J MOL BIOL, V271, P195, DOI 10.1006/jmbi.1997.1177; Forozan F, 2000, CANCER RES, V60, P4519; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; HALDAR S, 1994, CANCER RES, V54, P2095; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kruzelock RP, 1997, CANCER RES, V57, P106; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	38	52	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5466	5474		10.1038/sj.onc.1204722	http://dx.doi.org/10.1038/sj.onc.1204722			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571644				2022-12-25	WOS:000170781100007
J	Yang, CL; Carrier, F				Yang, CL; Carrier, F			The UV-inducible RNA-binding protein A18 (A18 hnRNP) plays a protective role in the genotoxic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ULTRAVIOLET-LIGHT; TRANSLATION INITIATION; HUMAN THIOREDOXIN; DNA; GENES; IDENTIFICATION; CELLS; INDUCTION; DAMAGE	We have previously shown that specific RNA-binding proteins (RBP) are activated by genotoxic stress. The role and function of these stress-activated RBP are, however, poorly understood. The data presented here indicate that the RBP AIS heterogeneous ribonucleoprotein (hnRNP) is induced and translocated from the nuclei to the cytoplasm after exposure to UV radiation. Using a new in vitro system we identified potential cellular targets for A18 hnRNP. Forty-six mRNA transcripts were identified, most of which are stress- or UV-responsive genes. Two important stress-responsive transcripts, the replication protein A (RPA2) and thioredoxin, were studied in more detail. Northwestern analyses indicate that A18 hnRNP binds specifically to the 3'-untranslated region of RPA2 transcript independently of its poly(A) tail, whereas the poly(A) tail of thioredoxin mRNA reinforces binding. Overexpression of A18 hnRNP increases the mRNAs stability and consequently enhances translation in a dose-dependent manner. Moreover, cell lines expressing reduced levels of AIS hnRNP are more sensitive to UV radiation. These data suggest that A18 hnRNP plays a protective role against genotoxic stresses by translocating to the cytosol and stabilizing specific transcripts involved in cell survival.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Carrier, F (corresponding author), 108 N Greene St,Rm 330, Baltimore, MD 21201 USA.	fcarr001@umaryland.edu	Carrier, France/C-3063-2008	Carrier, France/0000-0002-5517-5284; Pfeffer, Lawrence/0000-0003-2809-1234	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057827] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 57827-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERER W, 1981, J INVEST DERMATOL, V76, P202, DOI 10.1111/1523-1747.ep12525745; Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Applegate LA, 1998, J INVEST DERMATOL, V111, P159, DOI 10.1046/j.1523-1747.1998.00254.x; BADEN HP, 1964, J INVEST DERMATOL, V43, P71, DOI 10.1038/jid.1964.117; Bae SK, 1999, CANCER RES, V59, P5989; Bertram J, 1998, EUR J CANCER, V34, P731, DOI 10.1016/S0959-8049(97)10081-8; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; Brzoska PM, 1996, GENOMICS, V36, P151, DOI 10.1006/geno.1996.0435; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; CARRIER F, 1994, P NATL ACAD SCI USA, V91, P1554, DOI 10.1073/pnas.91.4.1554; CARRIER F, 1994, AIDS RES HUM RETROV, V10, P767, DOI 10.1089/aid.1994.10.767; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Dubnau E, 1996, GENE, V170, P17, DOI 10.1016/0378-1119(95)00841-1; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Funasaka Y, 1997, PIGM CELL RES, V10, P68, DOI 10.1111/j.1600-0749.1997.tb00469.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gloe T, 1999, J BIOL CHEM, V274, P15996, DOI 10.1074/jbc.274.23.15996; Graumann P, 1996, J BACTERIOL, V178, P4611, DOI 10.1128/jb.178.15.4611-4619.1996; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Katoh K, 1998, MOL BIOL CELL, V9, P1919, DOI 10.1091/mbc.9.7.1919; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lewis BC, 2000, CANCER RES, V60, P6178; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; Melander Y, 1997, J BIOL CHEM, V272, P3254, DOI 10.1074/jbc.272.6.3254; Mendez-Alvarez S, 2000, BIOCHEM BIOPH RES CO, V267, P953, DOI 10.1006/bbrc.1999.2070; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Paunesku T, 2000, INT J RADIAT BIOL, V76, P189, DOI 10.1080/095530000138844; Peyruchaud O, 2000, CELL MOL LIFE SCI, V57, P1109; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Scott JM, 2000, J BACTERIOL, V182, P2771, DOI 10.1128/JB.182.10.2771-2777.2000; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; Toninello A, 2000, J BIOL INORG CHEM, V5, P612, DOI 10.1007/s007750000144; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Yamamoto M, 1997, EXP EYE RES, V65, P645, DOI 10.1006/exer.1997.0370; YOKOMIZO A, 1995, CANCER RES, V55, P4293; Zhang SY, 2001, J BACTERIOL, V183, P2316, DOI 10.1128/JB.183.7.2316-2321.2001	57	194	214	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47277	47284		10.1074/jbc.M105396200	http://dx.doi.org/10.1074/jbc.M105396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11574538	hybrid			2022-12-25	WOS:000172768500081
J	Saka, A; Abe, M; Okano, H; Minemura, M; Qadota, H; Utsugi, T; Mino, A; Tanaka, K; Takai, Y; Ohya, Y				Saka, A; Abe, M; Okano, H; Minemura, M; Qadota, H; Utsugi, T; Mino, A; Tanaka, K; Takai, Y; Ohya, Y			Complementing yeast rho1 mutation groups with distinct functional defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; 1,3-BETA-D-GLUCAN SYNTHASE; ACTIN CYTOSKELETON; CRYSTAL-STRUCTURE; CELL-CYCLE; PKC1; GENE; HOMOLOG	Saccharomyces cerevisiae is a multifunctional molecular switch involved in establishment of cell morphogenesis. We systematically characterized isolated temperature-sensitive mutations in the RHO1 gene and identified two groups of rho1 mutations (rho1A and rho1B) possessing distinct functional defects. Biochemical and cytological analyses demonstrated that mutant cells of the rho1A and rho1B groups have defects in activation of the Rho1p effectors Pkc1p kinase and 1,3-beta -glucan synthase, respectively. Heteroallelic diploid strains with rho1A and rho1B mutations were able to grow even at the restrictive temperature of the corresponding homoallelic diploid strains, showing intragenic complementation. The ability to activate both of the essential Rho1p effector proteins was restored in the heteroallelic diploid. Thus, each of the complementing rho1 mutation groups abolishes a distinct function of Rho1p, activation of Pkc1p kinase or 1,3-beta -glucan synthase activity.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan; Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Suita, Osaka 5650871, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Biochem,Kita Ku, Sapporo, Hokkaido 0608638, Japan	University of Tokyo; University of Tokyo; Osaka University; Hokkaido University	Ohya, Y (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bldg FSB-101,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	ohya@k.u-tokyo.ac.jp	Abe, Mitsuhiro/C-3602-2017; Tanaka, Kazuma/A-4240-2012					Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; Drgonova J, 1999, J CELL BIOL, V146, P373, DOI 10.1083/jcb.146.2.373; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FINK GR, 1966, GENETICS, V53, P445; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Haarer BK, 1996, GENETICS, V144, P495; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; OHYA Y, 1994, GENETICS, V138, P1041; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIKORSKI RS, 1989, GENETICS, V122, P19; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	39	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46165	46171		10.1074/jbc.M103805200	http://dx.doi.org/10.1074/jbc.M103805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574532	hybrid			2022-12-25	WOS:000172573100092
J	Harrop, SJ; DeMaere, MZ; Fairlie, WD; Reztsova, T; Valenzuela, SM; Mazzanti, M; Tonini, R; Qiu, MR; Jankova, L; Warton, K; Bauskin, AR; Wu, WM; Pankhurst, S; Campbell, TJ; Breit, SN; Curmi, PMG				Harrop, SJ; DeMaere, MZ; Fairlie, WD; Reztsova, T; Valenzuela, SM; Mazzanti, M; Tonini, R; Qiu, MR; Jankova, L; Warton, K; Bauskin, AR; Wu, WM; Pankhurst, S; Campbell, TJ; Breit, SN; Curmi, PMG			Crystal structure of a soluble form of the intracellular chloride ion channel CLIC1 (NCC27) at 1.4-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; MOLECULAR-CLONING; SUBCELLULAR-DISTRIBUTION; CL-CHANNEL; PROTEIN; P64; EXPRESSION; FAMILY; KIDNEY; IDENTIFICATION	CLIC1 (NCC27) is a member of the highly conserved class of chloride ion channels that exists in both soluble and integral membrane forms. Purified CLIC1 can integrate into synthetic lipid bilayers forming a chloride channel with similar properties to those observed in vivo. The structure of the soluble form of CLIC1 has been determined at 1.4-Angstrom resolution. The protein is monomeric and structurally homologous to the glutathione S-transferase superfamily, and it has a redox-active site resembling glutaredoxin. The structure of the complex of CLIC1 with glutathione shows that glutathione occupies the redox-active site, which is adjacent to an open, elongated slot lined by basic residues. Integration of CLIC1 into the membrane is likely to require a major structural rearrangement, probably of the N-domain (residues 1-90), with the putative transmembrane helix arising from residues in the vicinity of the redox-active site. The structure indicates that CLIC1 is likely to be controlled by redox-dependent processes.	Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia; Univ New S Wales, Dept Med, Sydney, NSW 2052, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW 2010, Australia; Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol, I-00185 Rome, Italy	University of New South Wales Sydney; University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Sapienza University Rome; Sapienza University Rome	Curmi, PMG (corresponding author), Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia.	p.curmi@unsw.edu.au	Valenzuela, Stella/R-6387-2019; Mazzanti, Michele/A-8941-2011; DeMaere, Matthew Zachariah/D-9002-2012; Curmi, Paul/G-7185-2011; Fairlie, Walter/M-8401-2015	Valenzuela, Stella/0000-0001-5934-6047; DeMaere, Matthew Zachariah/0000-0002-7601-5108; Curmi, Paul/0000-0001-5762-7638; Fairlie, Walter/0000-0002-2498-1160; Mazzanti, Michele/0000-0002-1819-3811; TONINI, Raffaella/0000-0003-1652-4709				ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Bunik V, 1999, PROTEIN SCI, V8, P65; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chuang JZ, 1999, J NEUROSCI, V19, P2919; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuefeind T, 1997, J MOL BIOL, V274, P446, DOI 10.1006/jmbi.1997.1402; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; Reinemer P, 1996, J MOL BIOL, V255, P289, DOI 10.1006/jmbi.1996.0024; Sakai H, 1998, J BIOCHEM, V124, P1051, DOI 10.1093/oxfordjournals.jbchem.a022199; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 2000, J PHYSIOL-LONDON, V529, P541, DOI 10.1111/j.1469-7793.2000.00541.x; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	54	159	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44993	45000		10.1074/jbc.M107804200	http://dx.doi.org/10.1074/jbc.M107804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11551966	hybrid			2022-12-25	WOS:000172406700088
J	Chen, W; Sun, Y; Welch, C; Gorelik, A; Leventhal, AR; Tabas, I; Tall, AR				Chen, W; Sun, Y; Welch, C; Gorelik, A; Leventhal, AR; Tabas, I; Tall, AR			Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK-DISEASE; TANGIER-DISEASE; INTRACELLULAR TRAFFICKING; CELLULAR CHOLESTEROL; PLASMA-MEMBRANE; C1 PROTEIN; CELLS; ABC1; FIBROBLASTS	Recently, ATP-binding cassette transporter Al (ABCA1), the defective molecule in Tangier disease, has been shown to stimulate phospholipid and cholesterol efflux to apolipoprotein A-I (apoA-I); however, little is known concerning the cellular cholesterol pools that act as the source of cholesterol for ABCA1-mediated efflux. We observed a higher level of isotopic and mass cholesterol efflux from mouse peritoneal macrophages labeled with [H-3]cholesterol/acetyl low density lipoprotein (where cholesterol accumulates in late endosomes and lysosomes) compared with cells labeled with [H-3]cholesterol with 10% fetal bovine serum, suggesting that late endosomes/lysosomes act as a preferential source of cholesterol for ABCA1-mediated efflux. Consistent with this idea, macrophages from Niemann-Pick C1 mice that have an inability to exit cholesterol from late endosomes/lysosomes showed a profound defect in cholesterol efflux to apoA-I. In contrast, phospholipid efflux to apoA-I was normal in Niemann-Pick C1 macrophages, as was cholesterol efflux following plasma membrane cholesterol labeling. These results suggest that cholesterol deposited in late endosomes/lysosomes preferentially acts as a source of cholesterol for ABCA1-mediated cholesterol efflux.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 603 W 168th St, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [HL-56984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assmann G., 2001, METABOLIC MOL BASIS; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Costet P, 2000, J BIOL CHEM, V275, P28240; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Ioannou YA, 2000, MOL GENET METAB, V71, P175, DOI 10.1006/mgme.2000.3061; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; LEVENTHAL AR, 2001, IN PRESS J BIOL CHEM; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1999, NAT CELL BIOL, V1, pE37, DOI 10.1038/10030; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Patterson M., 2001, METABOLIC MOL BASIS; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; Shamburek RD, 1997, J LIPID RES, V38, P2422; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TALL AR, 2001, METABOLIC MOL BASIS; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992; Xie CL, 2000, J LIPID RES, V41, P1278	51	141	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43564	43569		10.1074/jbc.M107938200	http://dx.doi.org/10.1074/jbc.M107938200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11559713	hybrid			2022-12-25	WOS:000172297700013
J	Jung, YW; Mikata, Y; Lippard, SJ				Jung, YW; Mikata, Y; Lippard, SJ			Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-DOMAIN PROTEIN; MOBILITY GROUP PROTEIN-1; HUMAN CELL-EXTRACTS; DAMAGED DNA; TRANSLESION SYNTHESIS; CRYSTAL-STRUCTURE; SEQUENCE CONTEXT; CANCER-PATIENTS; TRANS ISOMER; CROSS-LINKS	The TATA-binding protein (TBP) recognizes the TATA box element of transcriptional promoters and recruits other initiation factors. This essential protein binds selectively to cisplatin-damaged DNA. Electrophoretic mobility shift assays were performed to study the kinetics of TBP binding both to the TATA box and to cisplatin-damaged DNA in different sequence contexts. TBP binds with high affinity (K-d = 0.3 nM) to DNA containing site-specific cisplatin 1,2-intrastrand d(GpG) cross-links. The k(on) and k(off) values for the formation of these TBP complexes are 1-3 x 10(5) m(-1) s(-1) and similar to1-5 x 10(-4) S-1, respectively, similar to the corresponding values for the formation of a TBP-TATA box complex. In electrophoretic mobility shift assay competition assays, cisplatin-damaged DNA extensively sequesters TBP from its natural binding site, the TATA box. Nine DNA probes were prepared to determine the flanking sequence dependence of TBP binding to cisplatin-modified DNA. TBP clearly displays sequence context selectivity for platinated DNA, very similar to but not as dramatic as that of the high mobility group protein HMGB1. When TBP was added to an in vitro nucleotide excision repair assay, it specifically shielded cisplatin-modified 1,2(GpG) intrastrand cross-links from repair. These results indicate that TBP is likely to be a key protein in mediating the cytotoxicity of cisplatin.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Jung, Yongwon/G-7634-2012					Balasubramanian B, 1998, P NATL ACAD SCI USA, V95, P9738, DOI 10.1073/pnas.95.17.9738; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; Burstyn JN, 2000, NUCLEIC ACIDS RES, V28, P4237, DOI 10.1093/nar/28.21.4237; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P8259, DOI 10.1021/bi0004495; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Coin F, 1998, MOL CELL BIOL, V18, P3907, DOI 10.1128/MCB.18.7.3907; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; Das D, 2001, J BIOL CHEM, V276, P32597, DOI 10.1074/jbc.M011792200; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; FICHTINGERSCHEPMAN AMJ, 1987, CANCER RES, V47, P3000; GE H, 1994, J BIOL CHEM, V269, P17136; Grove A, 1998, J MOL BIOL, V282, P731, DOI 10.1006/jmbi.1998.2058; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; Hey T, 2001, BIOCHEMISTRY-US, V40, P2901, DOI 10.1021/bi002166i; Hoffmann JS, 1997, J MOL BIOL, V270, P539, DOI 10.1006/jmbi.1997.1143; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; Jamieson ER, 2000, BIOCHEMISTRY-US, V39, P8426, DOI 10.1021/bi000342h; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jamieson ER, 1999, J BIOL CHEM, V274, P12346, DOI 10.1074/jbc.274.18.12346; Jordan P, 1998, NUCLEIC ACIDS RES, V26, P2831, DOI 10.1093/nar/26.12.2831; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; Lu W, 2000, J BIOL CHEM, V275, P35006, DOI 10.1074/jbc.M004735200; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; McANulty MM, 1996, BIOCHEMISTRY-US, V35, P6089, DOI 10.1021/bi952877u; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Ohndorf UM, 1997, BIOCHEMISTRY-US, V36, P14807, DOI 10.1021/bi9717643; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; Pastor N, 2000, J MOL BIOL, V304, P55, DOI 10.1006/jmbi.2000.4173; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Patrick SM, 1999, J BIOL CHEM, V274, P14972, DOI 10.1074/jbc.274.21.14972; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Petri V, 1998, BIOCHEMISTRY-US, V37, P15842, DOI 10.1021/bi981072u; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Pilch DS, 2000, J MOL BIOL, V296, P803, DOI 10.1006/jmbi.2000.3496; REED E, 1986, J CLIN INVEST, V77, P545, DOI 10.1172/JCI112335; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000; Wolner BS, 2001, J BIOL CHEM, V276, P6260, DOI 10.1074/jbc.M008273200; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	72	30	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43589	43596		10.1074/jbc.M108299200	http://dx.doi.org/10.1074/jbc.M108299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11568187	hybrid			2022-12-25	WOS:000172297700016
J	Cabart, P; Murphy, S				Cabart, P; Murphy, S			BRFU, a TFIIB-like factor, is directly recruited to the TATA-box of polymerase III small nuclear RNA gene promoters through its interaction with TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-TFIIIB; PROXIMAL SEQUENCE ELEMENT; HUMAN U6 GENE; IN-VIVO; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; SNRNA GENES; DNA-BINDING; TBP; INITIATION	The human snRNA genes transcribed by RNA polymerase II (pol II) and III (pol III) have different core promoter elements. Both gene types contain similar proximal sequence elements (PSEs) but differ in the absence (pol II) or presence (pol III) of a TATA-box, which, together with the PSE, determines the assembly of a pol III-specific pre-initiation complex. BRFU is a factor exclusively required for transcription of the pol III-type snRNA genes. We report that recruitment of BRFU to the TATA-box of these promoters is TATA-binding protein (TBP)-dependent. BRFU in turn stabilizes TBP on TATA-containing template and extends the TBP footprint both upstream and downstream of the TATA element. The core domain of TBP is sufficient for BRFU.TBP.DNA complex formation and for interaction with BRFU off the template. We have mapped amino acid residues within TBP and domains of BRFU that mediate this interaction. BRFU has no specificity for sequences flanking the TATA-box and also forms a stable complex on the TATA-box of the pol II-specific adenovirus major late promoter (AdMLP). Furthermore, pol III-type transcription can initiate from an snRNA gene promoter containing an AdMLP TATA-box and flanking sequences. Therefore, the polymerase recruitment is not simply determined by the sequence of the TATA-box and immediate flanking sequences.	Univ Oxford, Sir William Dunn Sch Pathol, Chem Pathol Unit, Oxford OX1 3RE, England	University of Oxford	Cabart, P (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Chem Pathol Unit, S Parks Rd, Oxford OX1 3RE, England.			Cabart, Pavel/0000-0003-0065-367X				BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BOYD DC, 1995, J MOL BIOL, V253, P677, DOI 10.1006/jmbi.1995.0582; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Hahn S, 2000, GENE DEV, V14, P719; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; MURPHY S, 1986, NUCLEIC ACIDS RES, V14, P9243, DOI 10.1093/nar/14.23.9243; Murphy S, 1997, NUCLEIC ACIDS RES, V25, P2068, DOI 10.1093/nar/25.11.2068; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Tansey WP, 1997, SCIENCE, V275, P829, DOI 10.1126/science.275.5301.829; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Yoon JB, 1996, MOL CELL BIOL, V16, P1; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	46	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43056	43064		10.1074/jbc.M108515200	http://dx.doi.org/10.1074/jbc.M108515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11564744	hybrid			2022-12-25	WOS:000172169300057
J	Tahbaz, N; Carmichael, JB; Hobman, TC				Tahbaz, N; Carmichael, JB; Hobman, TC			GERp95 belongs to a family of signal-transducing proteins and requires Hsp90 activity for stability and Golgi localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; C-ELEGANS; GENE; INTERACTS; COMPLEX; PIWI; P23; IDENTIFICATION; IMMUNOPHILINS; EXPRESSION	GERp95 (Golgi-endoplasmic reticulum protein 95 kDa) is part of a large family of highly conserved proteins found in all metazoans and the fission yeast Schizosaccharomyces pombe. Genetic studies suggest that homologs of GERp95 are components of signaling pathways that regulate cellular differentiation, development, and RNA interference. However, the precise molecular functions of these proteins remain unknown. Genetic analysis of GERp95 homologs has been complicated by the presence of multiple genes with overlapping functions in most organisms. Binding partners for members of this protein family have not been identified. The purpose of this study was to identify proteins that associate with GERp95. Glutathione S-transferase-GERp95 fusions were expressed in transfected cells, and proteins that bound to GERp95 were co-purified using glutathione-agarose beads. The amino-terminal region of GERp95 was found to interact with the specialized chaperone Hsp90 and a number of its cognate binding proteins. Inhibition of Hsp90 activity with geldanamycin or radicicol resulted in rapid degradation of newly synthesized GERp95. The membrane-associated pool of GERp95 was not bound to Hsp90, although activity of this chaperone was required for stable association of GERp95 with the Golgi in normal rat kidney cells. These results indicate that GERp95 engages an Hsp90 chaperone complex prior to association with intracellular membranes.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Hobman, TC (corresponding author), Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.							Beatch MD, 2000, J VIROL, V74, P5569, DOI 10.1128/JVI.74.12.5569-5576.2000; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cikaluk DE, 1999, MOL BIOL CELL, V10, P3357, DOI 10.1091/mbc.10.10.3357; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Cox DN, 2000, DEVELOPMENT, V127, P503; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Goes FS, 2001, EUR J BIOCHEM, V268, P2281, DOI 10.1046/j.1432-1327.2001.02105.x; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kataoka Y, 2001, GENES CELLS, V6, P313, DOI 10.1046/j.1365-2443.2001.00427.x; King FJ, 2001, MOL CELL, V7, P497, DOI 10.1016/S1097-2765(01)00197-6; Lynn K, 1999, DEVELOPMENT, V126, P469; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Mizuno K, 2001, BIOCHEM BIOPH RES CO, V281, P663, DOI 10.1006/bbrc.2001.4405; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; Munoz MJ, 1999, GENETICS, V153, P1561; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Wilson JE, 1996, DEVELOPMENT, V122, P1631; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	36	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43294	43299		10.1074/jbc.M107808200	http://dx.doi.org/10.1074/jbc.M107808200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11553639	hybrid			2022-12-25	WOS:000172169300086
J	Whitworth, TL; Quick, MW				Whitworth, TL; Quick, MW			Substrate-induced regulation of gamma-aminobutyric acid transporter trafficking requires tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; PLASMA-MEMBRANE TRANSPORTERS; GLUTAMATE TRANSPORTERS; SEROTONIN TRANSPORTERS; GABA; RECEPTORS; EXPRESSION; RELEASE; COCAINE; INTERNALIZATION	Neurotransmitter transporters regulate synaptic transmitter levels and are themselves functionally regulated by a number of different signal transduction cascades. A common theme in transporter regulation is redistribution of transporter protein between intracellular stores and the plasma membrane. The triggers and mechanisms underlying this regulation are important in the control of extracellular transmitter concentrations and hence synaptic signaling. Previously, we demonstrated that the alpha -aminobutyric acid transporter GAT1 is regulated by direct tyrosine phosphorylation, resulting in an up-regulation of transporter expression on the plasma membrane. In the present report, we show that two tyrosine residues on GAT1 contribute to the phosphorylation and transporter redistribution. Tyrosine phosphorylation is concomitant with a decrease in the rate of transporter internalization from the plasma membrane. A decrease in GAT internalization rates also occurs in the presence of GAT1 substrates, suggesting the hypothesis that tyrosine phosphorylation is required for the substrate-induced up-regulation of GAT1 surface expression. In support of this hypothesis, incubation of GAT1-expressing cells with transporter ligands alters the amount of GAT1 tyrosine phosphorylation, and substrate-induced surface expression is unchanged in a GAT1 mutant lacking tyrosine phosphorylation sites. These data suggest a model in which substrates permit the phosphorylation of GAT1 on tyrosine residues and that the phosphorylated state of the transporter is refractory for internalization.	Univ Alabama Birmingham, Dept Neurobiol, CIRC 446, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Quick, MW (corresponding author), Univ Alabama Birmingham, Dept Neurobiol, CIRC 446, 1719 6th Ave S, Birmingham, AL 35294 USA.	quick@nrc.uab.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD038985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010509, R29DA010509] Funding Source: NIH RePORTER; NICHD NIH HHS [HD38985] Funding Source: Medline; NIDA NIH HHS [DA10509] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Bauman AL, 2000, J NEUROSCI, V20, P7571; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; CASADO M, 1993, J BIOL CHEM, V268, P27313; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; COREY JL, 1994, J BIOL CHEM, V269, P14759; Davis KE, 1998, J NEUROSCI, V18, P2475; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Diamond JS, 1997, J NEUROSCI, V17, P4672; DINGLEDINE R, 1985, J PHYSIOL-LONDON, V366, P387, DOI 10.1113/jphysiol.1985.sp015804; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; Gaspary HL, 1998, J NEUROPHYSIOL, V80, P270, DOI 10.1152/jn.1998.80.1.270; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Huff RA, 1997, J NEUROCHEM, V68, P225; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; IVERSEN LL, 1975, HDB PSYCHOPHARMACOLO, P381; Jankowski M, 1999, PFLUG ARCH EUR J PHY, V438, P689, DOI 10.1007/s004240051094; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Mennerick S, 1999, J NEUROSCI, V19, P9242; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ribak CE, 1996, J COMP NEUROL, V367, P595, DOI 10.1002/(SICI)1096-9861(19960415)367:4<595::AID-CNE9>3.0.CO;2-#; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; SCHWARTZ EA, 1987, SCIENCE, V238, P350, DOI 10.1126/science.2443977; SHARMA N, 1993, J CELL BIOL, V123, P1835, DOI 10.1083/jcb.123.6.1835; SOLIS JM, 1992, J NEUROSCI, V12, P3466; THOMSEN C, 1995, EPILEPSY RES, V21, P79, DOI 10.1016/0920-1211(95)00010-8; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Zhu MY, 2000, J PHARMACOL EXP THER, V295, P951; Zhu MY, 1998, J NEUROCHEM, V70, P1547	39	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42932	42937		10.1074/jbc.M107638200	http://dx.doi.org/10.1074/jbc.M107638200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555659	hybrid			2022-12-25	WOS:000172169300041
J	Zhou, NM; Luo, ZW; Luo, JS; Liut, DX; Hall, JW; Pomerantz, RJ; Huang, ZW				Zhou, NM; Luo, ZW; Luo, JS; Liut, DX; Hall, JW; Pomerantz, RJ; Huang, ZW			Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS CORECEPTOR; PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; 2ND EXTRACELLULAR LOOP; VMIP-II; CHARGED RESIDUES; MEMBRANE-FUSION; TYPE-1 ENTRY; INTERNALIZATION; LIGAND	The human CXC chemokine receptor 4 (CXCR4) is a receptor for the chemokine stromal cell-derived factor (SDF-1 alpha) and a co-receptor for the entry of specific strains of human immunodeficiency virus type I (HIV-1). CXCR4 is also recognized by an antagonistic chemokine, the viral macrophage inflammatory protein II (vMIP-II) encoded by human herpesvirus type VIII. SDF-1 alpha or vMIP-II binding to CXCR4 can inhibit HIV-1 entry via this co-receptor. An approach combining protein structural modeling and site-directed mutagenesis was used to probe the structure-function relationship of CXCR4, and interactions with its ligands SDF-1 alpha and vMIP-II and HIV-1 envelope protein gp120. Hypothetical three-dimensional structures were proposed by molecular modeling studies of the CXCR4-SDF-1 alpha complex, which rationalize extensive biological information on the role of CXCR4 in its interactions with HIV-1 envelope protein gp120. With site-directed mutagenesis, we have identified that the amino acid residues Asp (D20A) and Tyr (Y21A) in the N-terminal domain and the residue Glu (E268A) in extracellular loop 3 (ECL3) are involved in ligand binding, whereas the mutation Y190A in extracellular loop 2 (ECL2) impairs the signaling mediated by SDF-1 alpha. As an HIV-1 co-receptor, we found that the N-terminal domain, ECL2, and ECL3 of CXCR4 are involved in HIV-1 entry. These structural and mutational studies provide valuable information regarding the structural basis for CXCR4 activity in chemokine binding and HIV-1 viral entry, and could guide the design of novel targeted inhibitors.	Univ Illinois, Sch Mol & Cellular Biol, Dept Biochem, Urbana, IL 61801 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA	University of Illinois System; University of Illinois Urbana-Champaign; Jefferson University; Jefferson University	Huang, ZW (corresponding author), Univ Illinois, Sch Mol & Cellular Biol, Dept Biochem, 302 Burrill Hall,MC-119,407 S Goodwin Ave, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS027405, P01NS027405] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45414] Funding Source: Medline; NIGMS NIH HHS [GM57761] Funding Source: Medline; NINDS NIH HHS [NS27405] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Chabot DJ, 2000, J BIOL CHEM, V275, P23774, DOI 10.1074/jbc.M003438200; Chabot DJ, 1999, J VIROL, V73, P6598, DOI 10.1128/JVI.73.8.6598-6609.1999; Chabot DJ, 2000, J VIROL, V74, P4404, DOI 10.1128/JVI.74.9.4404-4413.2000; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 2001, FEBS LETT, V489, P171, DOI 10.1016/S0014-5793(00)02393-0; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; DONNADIEU E, 1994, CURR BIOL, V4, P584, DOI 10.1016/S0960-9822(00)00130-5; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fernandez EJ, 2000, BIOCHEMISTRY-US, V39, P12837, DOI 10.1021/bi001166f; Forster R, 1998, J IMMUNOL, V160, P1522; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1990, J BIOL CHEM, V265, P17988; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Kajumo F, 2000, VIROLOGY, V271, P240, DOI 10.1006/viro.2000.0308; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Liwang AC, 1999, PROTEIN SCI, V8, P2270; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Luo JS, 1999, BIOCHEM BIOPH RES CO, V264, P42, DOI 10.1006/bbrc.1999.1476; Luo ZW, 1997, PROTEIN ENG, V10, P1039, DOI 10.1093/protein/10.9.1039; Luo ZW, 2000, BIOCHEMISTRY-US, V39, P13545, DOI 10.1021/bi000633q; Luo ZW, 1999, BIOCHEM BIOPH RES CO, V263, P691, DOI 10.1006/bbrc.1999.1441; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pelchen-Matthews A, 1999, IMMUNOL REV, V168, P33, DOI 10.1111/j.1600-065X.1999.tb01281.x; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Rucker J, 1997, METHOD ENZYMOL, V288, P118; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Wang ZX, 1998, J BIOL CHEM, V273, P15007, DOI 10.1074/jbc.273.24.15007; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; Zhou HP, 2000, ARCH BIOCHEM BIOPHYS, V373, P211, DOI 10.1006/abbi.1999.1555; Zhou NM, 2000, EUR J IMMUNOL, V30, P164, DOI 10.1002/1521-4141(200001)30:1<164::AID-IMMU164>3.0.CO;2-X; Zhou NM, 2000, BIOCHEMISTRY-US, V39, P3782, DOI 10.1021/bi992750v; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	60	116	125	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42826	42833		10.1074/jbc.M106582200	http://dx.doi.org/10.1074/jbc.M106582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551942	hybrid			2022-12-25	WOS:000172169300027
J	Yang, YH; Cheng, P; Zhi, G; Liu, Y				Yang, YH; Cheng, P; Zhi, G; Liu, Y			Identification of a calcium/calmodulin-dependent protein kinase that phosphorylates the Neurospora circadian clock protein FREQUENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIOD PROTEIN; DOUBLE-TIME; CALMODULIN; CRASSA; LIGHT; GENE; PHASE; TRANSCRIPTION; CALCIUM; CLONING	Phosphorylation of circadian clock proteins represents a major regulatory step that controls circadian clocks. In Neurospora, the circadian clock protein FREQUENCY (FRQ) is progressively phosphorylated over time, and its level decreases when it is hyperphosphorylated. In this study, we showed that most of the kinase activity phosphorylating FRQ in vitro was calcium/ calmodulin-dependent, and the endogenous FRQ in the Neurospora extracts was phosphorylated by a Ca/ CaM-dependent kinase-like activity. From Neurospora cell extracts, an similar to 50-kDa Ca/CaM-dependent kinase (CAMK-1) that can specifically phosphorylate FRQ was purified. In vitro, this kinase accounts for near half of the FRQ kinase activity, and it can phosphorylate the FRQ region that contains the three known functionally important phosphorylation sites. To understand the function of camk-1 in vivo, it was disrupted in Neurospora by gene replacement. After germination from ascospores, the camk-1 null strains grew slowly, indicating that CAMK-1 plays an important role in growth and development of Neurospora. This phenotype was transient however, revealing redundancy in the system. Analysis of the camk-1 null strain revealed that the deletion of camk-1 affected phase, period, and light-induced phase shifting of the circadian conidiation rhythm. Taken together, our results suggest that multiple kinases may phosphorylate FRQ in vivo.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Liu, Y (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Yang, Yuhong/A-6033-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062591] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62591] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BellPedersen D, 1996, MOL CELL BIOL, V16, P513; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Cheng P, 2001, P NATL ACAD SCI USA, V98, P7408, DOI 10.1073/pnas.121170298; Cheng P, 2001, EMBO J, V20, P101, DOI 10.1093/emboj/20.1.101; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Denault DL, 2001, EMBO J, V20, P109, DOI 10.1093/emboj/20.1.109; DHARMANANDA S, 1980, STUDIES CIRCADIAN CL; Ding JM, 1998, NATURE, V394, P381, DOI 10.1038/28639; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EBBOLE D, 1990, FUNGAL GENET NEWSL, V37, P15; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ICHIISHI A, 1995, JPN J GENET, V70, P273, DOI 10.1266/jjg.70.273; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; Kloss B, 2001, NEURON, V30, P699, DOI 10.1016/S0896-6273(01)00320-8; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 1999, MOL CELL BIOL, V19, P5316; Lee K, 2000, SCIENCE, V289, P107, DOI 10.1126/science.289.5476.107; Liu Y, 2000, P NATL ACAD SCI USA, V97, P234, DOI 10.1073/pnas.97.1.234; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; MCMAHON DG, 1987, J COMP PHYSIOL A, V161, P335, DOI 10.1007/BF00603959; Merrow M, 2001, EMBO J, V20, P307, DOI 10.1093/emboj/20.3.307; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; NAKASHIMA H, 1986, Journal of Biological Rhythms, V1, P163, DOI 10.1177/074873048600100207; Nelson MA, 1997, FUNGAL GENET BIOL, V21, P348, DOI 10.1006/fgbi.1997.0986; Numata O, 2000, J BIOCHEM, V127, P51, DOI 10.1093/oxfordjournals.jbchem.a022583; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rasmussen C, 1999, BIOCHEM CELL BIOL, V77, P421, DOI 10.1139/bcb-77-5-421; Sadakane Y, 1996, J BIOL RHYTHM, V11, P234, DOI 10.1177/074873049601100305; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SHIBATA S, 1994, J BIOL RHYTHM, V9, P27, DOI 10.1177/074873049400900103; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; SUSUKI S, 1996, GENETICS, V143, P1175; Talora C, 1999, EMBO J, V18, P4961, DOI 10.1093/emboj/18.18.4961; TECHEL D, 1990, J COMP PHYSIOL B, V159, P695, DOI 10.1007/BF00691715; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Young MW, 1999, RECENT PROG HORM RES, V54, P87	47	93	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41064	41072		10.1074/jbc.M106905200	http://dx.doi.org/10.1074/jbc.M106905200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11551951	hybrid			2022-12-25	WOS:000171925600093
J	Tulla, M; Pentikainen, OT; Viitasalo, T; Kapyla, J; Impola, U; Nykvist, P; Nissinen, L; Johnson, MS; Heino, J				Tulla, M; Pentikainen, OT; Viitasalo, T; Kapyla, J; Impola, U; Nykvist, P; Nissinen, L; Johnson, MS; Heino, J			Selective binding of collagen subtypes by integrin alpha I-1, alpha I-2, and alpha I-10 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; CHONDROCYTE ADHESION; CRYSTAL-STRUCTURE; ALPHA-2-BETA-1; ALPHA-1-BETA-1; EXPRESSION; GENE; LOCALIZATION; CLONING; ALPHA(1)BETA(1)	Four integrins, namely alpha (1)beta (1), alpha (2)beta (1), alpha (10)beta (1), and alpha (11)beta (1), form a special subclass of cell adhesion receptors. They are all collagen receptors, and they recognize their ligands with an inserted domain (I domain) in their a subunit. We have produced the human integrin alpha I-10 domain as a recombinant protein to reveal its ligand binding specificity. In general, alpha I-10 did recognize collagen types I-VI and laminin-1 in a Mg2+-dependent manner, whereas its binding to tenascin was only slightly better than to albumin. When alpha I-10 was tested together with the alpha I-1 and alpha I-2 domains, all three I domains seemed to have their own collagen binding preferences. The integrin alpha I-2 domain bound much better to fibrillar collagens (I-III) than to basement membrane type IV collagen or to beaded filament-forming type VI collagen. Integrin all had the opposite binding pattern. The integrin alpha I-10 domain was similar to the all domain in that it bound very well to collagen types IV and VI. Based on the previously published atomic structures of the all and alpha I-2 domains, we modeled the structure of the alpha I-10 domain. The comparison of the three I domains revealed similarities and differences that could potentially explain their functional differences. Mutations were introduced into the al domains, and their binding to types I , IV, and VI collagen was tested. In the alpha I-2 domain, Asp-219 is one of the amino acids previously suggested to interact directly with type I collagen. The corresponding amino acid in both the alpha I-1 and alpha I-10 domains is oppositely charged (Arg-218). The mutation D219R in the alpha I-2 domain changed the ligand binding pattern to resemble that of the alpha I-1 and alpha I-10 domains and, vice versa, the R218D mutation in the all and alpha I-10 domains created an alpha I-2 domain-like ligand binding pattern. Thus, all three collagen receptors appear to differ in their ability to recognize distinct collagen subtypes. The relatively small structural differences on their collagen binding surfaces may explain the functional specifics.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland	University of Jyvaskyla; University of Turku; University of Turku; Abo Akademi University	Heino, J (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35, FIN-40351 Jyvaskyla, Finland.	jyrki.heino@utu.fi	Pentikäinen, Olli T/E-1980-2012; Impola, Ulla/T-5008-2018	Pentikäinen, Olli T/0000-0001-7188-4016; Impola, Ulla/0000-0003-3769-2648; Kapyla, Jarmo/0000-0003-3036-713X; Nissinen, Liisa/0000-0002-6743-6736				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Gardner H, 1999, J CELL SCI, V112, P263; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P270, DOI 10.1002/art.1780400211; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Meharra EJ, 2000, CELL IMMUNOL, V201, P1, DOI 10.1006/cimm.2000.1630; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Muller WEG, 1998, NATURWISSENSCHAFTEN, V85, P11, DOI 10.1007/s001140050444; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi M, 1998, J CELL BIOL, V142, P587; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; Setty S, 1998, J BIOL CHEM, V273, P12244, DOI 10.1074/jbc.273.20.12244; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; ZUTTER MM, 1990, AM J PATHOL, V137, P113	45	200	205	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48206	48212		10.1074/jbc.M104058200	http://dx.doi.org/10.1074/jbc.M104058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11572855	hybrid			2022-12-25	WOS:000172927000063
J	Miura, T; Ouchida, R; Yoshikawa, N; Okamoto, K; Makino, Y; Nakamura, T; Morimoto, C; Makino, I; Tanaka, H				Miura, T; Ouchida, R; Yoshikawa, N; Okamoto, K; Makino, Y; Nakamura, T; Morimoto, C; Makino, I; Tanaka, H			Functional modulation of the glucocorticoid receptor and suppression of NF-kappa B-dependent transcription by ursodeoxycholic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BILIARY-CIRRHOSIS; GENE-EXPRESSION; NUCLEAR RECEPTOR; IMMUNE-RESPONSES; LIGAND-BINDING; CROSS-TALK; BILE-ACIDS; TRANSACTIVATION; TRANSREPRESSION; DOMAIN	Ursodeoxycholic acid (UDCA) is the current mainstay of treatment for various liver diseases including primary biliary cirrhosis. UDCA acts as a bile secretagogue, cytoprotective agent, immunomodulator, and inhibitor of cellular apoptosis. Despite this cumulative evidence of the cytoprotective and immunosuppressive effects of UDCA, both the target molecule and pathway of UDCA action remain unknown. We previously described that, in the absence of glucocorticoid ligand, UDCA activates the glucocorticoid receptor (GR) into DNA binding species but does not elicit its transactivational function in a transient transfection assay. Here we further studied the molecular mechanism of UDCA action and revealed that the ligand binding domain of the GR is responsible for UDCA-dependent nuclear translocation of the GR. Indeed, we demonstrated that UDCA acts on the distinct region of the ligand binding domain when compared with the classical GR agonist dexamethasone, resulting in loss of coactivator recruitment and differential regulation of gene expression by the GR. Our data clearly indicated that UDCA, at least in part via activation of the GR, suppresses NF-kappaB-dependent transcription through the intervention of GR-p65 interaction. Together with the established clinical safety of UDCA, we may propose that UDCA could be a prototypical compound for development of a novel and selective GR modifier.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 0788510, Japan	University of Tokyo; Asahikawa Medical College	Tanaka, H (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hirotnk@ims.u-tokyo.ac.jp						Adcock IM, 1999, BRIT J PHARMACOL, V127, P1003, DOI 10.1038/sj.bjp.0702613; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; BOTLA R, 1995, J PHARMACOL EXP THER, V272, P930; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BOUSCAREL B, 1993, AM J PHYSIOL, V264, pG243, DOI 10.1152/ajpgi.1993.264.2.G243; CALMUS Y, 1992, HEPATOLOGY, V16, P719, DOI 10.1002/hep.1840160317; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; EVANS RM, 1989, RECENT PROG HORM RES, V45, P1; EWERTH S, 1985, GASTROENTEROLOGY, V88, P126, DOI 10.1016/S0016-5085(85)80144-X; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Gershwin ME, 2000, IMMUNOL REV, V174, P210, DOI 10.1034/j.1600-0528.2002.017402.x; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Gustafsson J A, 1990, Princess Takamatsu Symp, V21, P137; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; Heathcote EJ, 2000, HEPATOLOGY, V31, P1005, DOI 10.1053/he.2000.5984; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirano F, 1996, J GASTROENTEROL, V31, P55, DOI 10.1007/BF01211187; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; LACAILLE F, 1993, HEPATOLOGY, V18, P165, DOI 10.1002/hep.1840180125; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; LIANIDOU ES, 1989, ANAL BIOCHEM, V179, P341, DOI 10.1016/0003-2697(89)90140-1; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Makino I, 1998, J GASTROEN HEPATOL, V13, P659, DOI 10.1111/j.1440-1746.1998.tb00707.x; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nishigaki Y, 1996, DIGEST DIS SCI, V41, P1487, DOI 10.1007/BF02088577; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OZAKI S, 1979, J LIPID RES, V20, P240; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; Poupon R, 1999, J HEPATOL, V30, P408, DOI 10.1016/S0168-8278(99)80098-1; Prima V, 2000, J STEROID BIOCHEM, V72, P1, DOI 10.1016/S0960-0760(99)00146-6; Reichardt HM, 2000, ADV PHARMACOL, V47, P1; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Roux S, 1999, J BIOL CHEM, V274, P10059, DOI 10.1074/jbc.274.15.10059; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Tanaka H, 1996, J IMMUNOL, V156, P1601; Tu H, 2000, TRENDS CARDIOVAS MED, V10, P30, DOI 10.1016/S1050-1738(00)00043-8; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wan YH, 2001, MOL ENDOCRINOL, V15, P17, DOI 10.1210/me.15.1.17; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Yamazaki K, 1999, HEPATOLOGY, V30, P71, DOI 10.1002/hep.510300121; YOSHIKAWA M, 1992, HEPATOLOGY, V16, P358, DOI 10.1002/hep.1840160213	62	113	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47371	47378		10.1074/jbc.M107098200	http://dx.doi.org/10.1074/jbc.M107098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577102	hybrid, Green Submitted			2022-12-25	WOS:000172768500092
J	Corvi, MM; Soltys, CLM; Berthiaume, LG				Corvi, MM; Soltys, CLM; Berthiaume, LG			Regulation of mitochondrial carbamoyl-phosphate synthetase 1 activity by active site fatty acylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ACID OXIDATION; CARBAMYLPHOSPHATE SYNTHETASE; NITROGEN-METABOLISM; SIGNALING PROTEINS; PALMITOYL-COA; BOVINE LIVER; COENZYME-A; CHAIN; DEHYDROGENASE	In addition to its role in reversible membrane localization of signal-transducing proteins, protein fatty acylation could play a role in the regulation of mitochondrial metabolism. Previous studies have shown that several acylated proteins exist in mitochondria isolated from COS-7 cells and rat liver. Here, a prominent fatty-acylated 165-kDa protein from rat liver mitochondria was identified as carbamoyl-phosphate synthetase 1 (CPS 1). Covalently attached palmitate was linked to CPS 1 via a thioester bond resulting in an inhibition of CPS I activity at physiological concentrations of palmitoyl-CoA. This inhibition corresponds to irreversible inactivation of CPS 1 and occurred in a time- and concentration-dependent manner. Fatty acylation of CPS 1 was prevented by preincubation with N-ethylmaleimide and 5'-p-fluorosulfonylbenzoyladenosine, an ATP analog that reacts with CPS 1 active site cysteine residues. Our results suggest that fatty acylation of CPS 1 is specific for long-chain fatty acyl-CoA and very likely occurs on at least one of the essential cysteine residues inhibiting the catalytic activity of CPS 1. Inhibition of CPS 1 by long-chain fatty acyl-CoAs could reduce amino acid degradation and urea secretion, thereby contributing to nitrogen sparing during starvation.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Fac Med & Dent, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Berthiaume, LG (corresponding author), Univ Alberta, Dept Cell Biol, 555 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	Luc.Berthiaume@ualberta.ca		Berthiaume, Luc/0000-0003-0926-059X; Corvi, Maria/0000-0002-6192-5029				ALLAND L, 1994, J BIOL CHEM, V269, P16701; Aoki T T, 1975, Adv Enzyme Regul, V13, P329, DOI 10.1016/0065-2571(75)90023-0; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P455; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS EP, 1988, BIOCHEM J, V250, P819, DOI 10.1042/bj2500819; Cahill G F Jr, 1981, Curr Top Cell Regul, V18, P389; CAHILL GF, 1976, CLIN ENDOCRINOL META, V5, P397, DOI 10.1016/S0300-595X(76)80028-X; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CLARKE S, 1976, J BIOL CHEM, V251, P950; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DEICHAITE I, 1993, J BIOL CHEM, V268, P13738; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; ELLIOTT KRF, 1974, BIOCHEM J, V141, P807, DOI 10.1042/bj1410807; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FAHIEN LA, 1984, ARCH BIOCHEM BIOPHYS, V230, P213, DOI 10.1016/0003-9861(84)90102-4; GLUTHOHRLEIN G, 1968, EUR J BIOCHEM, V7, P119; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; Ishikawa E, 1976, Adv Enzyme Regul, V14, P117, DOI 10.1016/0065-2571(76)90010-8; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; KAWAGUCHI A, 1976, J BIOL CHEM, V251, P1406; Krebs H A, 1973, Adv Enzyme Regul, V11, P361, DOI 10.1016/0065-2571(73)90024-1; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MADDAIAH VT, 1989, PEDIATR RES, V25, P119, DOI 10.1203/00006450-198902000-00003; MADDAIAH VT, 1985, BIOCHEM BIOPH RES CO, V127, P565, DOI 10.1016/S0006-291X(85)80197-2; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; MCILHINNEY RAJ, 1995, LIPID MODIFICATIONS; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MILLER T, 1995, BYTE, V20, P18; MOORE KH, 1992, INT J BIOCHEM, V24, P809, DOI 10.1016/0020-711X(92)90017-U; MORAN LA, 1996, BIOCHEMISTRY; MOREL F, 1974, FEBS LETT, V39, P133, DOI 10.1016/0014-5793(74)80035-9; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; PARSONS DF, 1967, METHOD ENZYMOL, V10, P443; PIERSON DL, 1980, J BIOL CHEM, V255, P7891; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWELL GL, 1981, J BIOL CHEM, V256, P2740; POWERS SG, 1981, J BIOL CHEM, V256, P1160; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; RAIJMAN L, 1976, ARCH BIOCHEM BIOPHYS, V175, P270, DOI 10.1016/0003-9861(76)90508-7; RATNER S, 1973, ADV ENZYMOL RAMB, V39, P1; Roe C. R., 1995, METABOLIC MOL BASES, P1501; Saudubray J, 1995, METABOLIC MOL BASES, P327; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; TABIBANA M, 1976, UREA CYCLE, P301; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; VANCE JE, 1990, J BIOL CHEM, V265, P7248	55	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45704	45712		10.1074/jbc.M102766200	http://dx.doi.org/10.1074/jbc.M102766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577071	hybrid			2022-12-25	WOS:000172573100029
J	Martins, A; Shuman, S				Martins, A; Shuman, S			Mutational analysis of baculovirus capping enzyme lef4 delineates an autonomous triphosphatase domain and structural determinants of divalent cation specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-TRIPHOSPHATASE; GUANYLYLTRANSFERASE ACTIVITIES; NUCLEOSIDE TRIPHOSPHATASE; COMPONENT; YEAST; EXPRESSION; 5'-TRIPHOSPHATASE; MECHANISM; APPARATUS; SUBUNIT	The 464-amino acid baculovirus Left protein is a bifunctional mRNA capping enzyme with triphosphatase and guanylyltransferase activities. The hydrolysis of 5'-triphosphate RNA and free NTPs by Lef4 is dependent on a divalent cation cofactor. RNA triphosphatase activity is optimal at pH 7.5 with either magnesium or manganese, yet NTP hydrolysis at neutral pH is activated only by manganese or cobalt. Here we show that Lef4 possesses an intrinsic magnesium-dependent ATPase with a distinctive alkaline pH optimum and a high K-m for ATP (4 mm). Lef4 contains two conserved sequences, motif A ((IEKEISY14)-I-8) and motif C ((LEYEF184)-L-180), which define the fungal/viral/protozoal family of metal-dependent RNA triphosphatases. We find by mutational analysis that Glu(9), Glu(11), Glu(181), and Glu(183) are essential for phosphohydrolase chemistry and likely comprise the metal-binding site of Lef4. Conservative mutations E9D and E183D abrogate the magnesium-dependent triphosphatase activities of Lef4 and transform it into a strictly manganese-dependent RNA triphosphatase. Limited proteolysis of Lef4 and ensuing COOH-terminal deletion analysis revealed that the NH2-terminal 236-amino acid segment of Lef4 constitutes an autonomous triphosphatase catalytic domain.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CONG PJ, 1995, MOL CELL BIOL, V15, P6222; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Guarino LA, 1998, J VIROL, V72, P10003, DOI 10.1128/JVI.72.12.10003-10010.1998; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; Ho CK, 2001, J VIROL, V75, P1744, DOI 10.1128/JVI.75.4.1744-1750.2001; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; Tiggemann M, 2001, YEAST, V18, P815, DOI 10.1002/yea.728; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997	24	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45522	45529		10.1074/jbc.M107615200	http://dx.doi.org/10.1074/jbc.M107615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11553638	hybrid			2022-12-25	WOS:000172573100007
J	Sturgeon, BE; Glover, RE; Chen, YR; Burka, LT; Mason, RP				Sturgeon, BE; Glover, RE; Chen, YR; Burka, LT; Mason, RP			Tyrosine iminoxyl radical formation from tyrosyl radical/nitric oxide and nitrosotyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; PHOTOSYSTEM-II; RIBONUCLEOTIDE REDUCTASE; NITRIC-OXIDE; ESCHERICHIA-COLI; HORSERADISH-PEROXIDASE; ANACYSTIS-NIDULANS; MODEL COMPOUNDS; DNA PHOTOLYASE; OXYGEN	The quenching of the Y-D tyrosyl radical in photosystem II by nitric oxide was reported to result from the formation of a weak tyrosyl radical-nitric oxide complex (Petrouleas, V., and Diner, B. A (1990) Biochim. Biophys. Acta 1015, 131-140). This radical/radical reaction is expected to generate an electron spin resonance (ESR)silent 3-nitrosocyclohexadienone species that can reversibly regenerate the tyrosyl radical and nitric oxide or undergo rearrangement to form 3-nitrosotyrosine. It has been proposed that 3-nitrosotyrosine can be oxidized by one electron to form the tyrosine iminoxyl radical (>C=N-O). This proposal was put forth as a result of ESR detection of the iminoxyl radical intermediate when photosystem II was exposed to nitric oxide (Sanakis, Y., Goussias, C., Mason, R. P., and Petrouleas, V. (1997) Biochemistry 36, 1411-1417). A similar iminoxyl radical was detected in prostaglandin H synthase-2 (Gunther, M. R., Hsi, L. C., Curtis, J. F., Gierse, J. K., Marnett. L. J., Eling, T. E., and Mason, R. P. (1997) J. Biol. Chem., 272, 17086-17090). Although the iminoxyl radicals detected in the photosystem II and prostaglandin H synthase-2 systems strongly suggest a mechanism involving 3-nitrosotyrosine, the iminoxyl radical ESR spectrum was not unequivocally identified as originating from tyrosine. We report here the detection of the non-protein L-tyrosine iminoxyl radical generated by two methods: 1) peroxidase oxidation of synthetic 3-nitroso-N-acetyl-L-tyrosine and 2) peroxidase oxidation of free L-tyrosine in the presence of nitric oxide. A newly developed ESR technique that uses immobilized enzyme was used to perform the ESR experiments. Analysis of the high resolution ESR spectrum of the tyrosine iminoxyl radical generated from free tyrosine and nitric oxide reveals a 28.4-G isotropic nitrogen hyperfine coupling and a 2.2-G proton hyperfine coupling assigned to the proton originally ortho to the phenoxyl oxygen.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Sturgeon, BE (corresponding author), NC Sch Sci & Math, 1219 Broad St, Durham, NC 27705 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050139, ZIAES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aubert C, 1999, J AM CHEM SOC, V121, P8659, DOI 10.1021/ja991938z; Aubert C, 1999, P NATL ACAD SCI USA, V96, P5423, DOI 10.1073/pnas.96.10.5423; BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1990, J BIOL CHEM, V265, P20139; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; Berho F, 1998, J PHYS CHEM A, V102, P1, DOI 10.1021/jp972576p; Dole F, 1997, J AM CHEM SOC, V119, P11540, DOI 10.1021/ja9717727; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; GREEN RG, 1975, J CHEM SOC PERK T 2, P1380, DOI 10.1039/p29750001380; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; Ivancich A, 1996, J AM CHEM SOC, V118, P12852, DOI 10.1021/ja9628361; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; MARUYAMA K, 1967, J ORG CHEM, V32, P2516, DOI 10.1021/jo01283a033; MASON RP, 1984, METHOD ENZYMOL, V105, P416; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; RAO DNR, 1990, J BIOL CHEM, V265, P844; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P1734, DOI 10.1021/bi00173a016; ROMAN R, 1973, CAN J CHEM, V51, P588, DOI 10.1139/v73-089; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; Stanbro WD, 1999, J THEOR BIOL, V197, P557, DOI 10.1006/jtbi.1998.0895; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Szalai VA, 1996, BIOCHEMISTRY-US, V35, P15080, DOI 10.1021/bi961117w; THOMAS JR, 1964, J AM CHEM SOC, V86, P1446, DOI 10.1021/ja01061a043; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; WARNCKE K, 1994, J AM CHEM SOC, V116, P7332, DOI 10.1021/ja00095a042; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5; YAMAZAKI I, 1977, FREE RADICALS BIOL, V3, P183; YU T, 1995, J PHYS ORG CHEM, V8, P47, DOI 10.1002/poc.610080110	46	32	32	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45516	45521		10.1074/jbc.M106835200	http://dx.doi.org/10.1074/jbc.M106835200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11551949	hybrid			2022-12-25	WOS:000172573100006
J	Bellu, AR; Komori, M; van der Klei, IJ; Kiel, JAKW; Veenhuis, M				Bellu, AR; Komori, M; van der Klei, IJ; Kiel, JAKW; Veenhuis, M			Peroxisome biogenesis and selective degradation converge at Pex14p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICHIA-PASTORIS REQUIRES; HANSENULA-POLYMORPHA; DEFICIENT MUTANTS; TARGETING SIGNAL; ALCOHOL OXIDASE; YEAST; AUTOPHAGY; PROTEIN; IMPORT; GENE	We have analyzed the function of Hansenula polymorpha Pex14p in selective peroxisome degradation. Previously, we showed that Pex14p was involved in peroxisome biogenesis and functions in peroxisome matrix protein import. Evidence for the additional function of HpPex14p in selective peroxisome degradation (pexophagy) came from cells defective in HpPex14p synthesis. The suggestion that the absence of HpPex14p interfered with pexophagy was further analyzed by mutational analysis. These studies indicated that deletions at the C terminus of up to 124 amino acids of HpPex14p did not affect peroxisome degradation. Conversely, short deletions of the N terminus (31 and 64 amino acids, respectively) of the protein fully impaired pexophagy. Peroxisomes present in these cells remained intact for at least 6 h of incubation in the presence of excess glucose, conditions that led to the rapid turnover of the organelles in wild-type control cells. We conclude that the N terminus of HpPex14p contains essential information to control pexophagy in H. polymorpha and thus, that organelle development and turnover converge at Pex14p.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands; Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Dept Vet Sci, Cellular & Mol Biol Lab, Osaka 5998531, Japan	University of Groningen; Osaka Metropolitan University	Veenhuis, M (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.	M.Veenhuis@biol.rug.nl	van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Bellu AR, 2001, FEMS YEAST RES, V1, P23, DOI 10.1111/j.1567-1364.2001.tb00010.x; DIDION T, 1992, FEBS LETT, V303, P113, DOI 10.1016/0014-5793(92)80500-G; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Gunkel K, 1999, FEBS LETT, V451, P1, DOI 10.1016/S0014-5793(99)00513-X; HANSEN H, 1992, MOL GEN GENET, V235, P269, DOI 10.1007/BF00279370; Kiel JAKW, 1999, YEAST, V15, P741, DOI 10.1002/(SICI)1097-0061(19990630)15:9<741::AID-YEA416>3.0.CO;2-O; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Komori M, 1999, FEBS LETT, V457, P397, DOI 10.1016/S0014-5793(99)01087-X; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Sakai Y, 2000, CELL BIOCHEM BIOPHYS, V32, P51, DOI 10.1385/CBB:32:1-3:51; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Sepulveda J., 1992, FEMS MICROBIOL LETT, V91, P207; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; TUTTLE DL, 1993, EUR J CELL BIOL, V60, P283; TUTTLE DL, 1995, J CELL SCI, V108, P25; VANDERKLEI IJ, 1991, YEAST, V7, P813, DOI 10.1002/yea.320070806; VANDERKLEI IJ, 1991, ARCH MICROBIOL, V156, P15, DOI 10.1007/BF00418181; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Will GK, 1999, MOL CELL BIOL, V19, P2265; Yuan WP, 1997, J CELL SCI, V110, P1935; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	32	95	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44570	44574		10.1074/jbc.M107599200	http://dx.doi.org/10.1074/jbc.M107599200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564741	hybrid, Green Published			2022-12-25	WOS:000172406700032
J	Bubulya, A; Chen, SY; Fisher, CJ; Zheng, Z; Shen, XQ; Shemshedini, L				Bubulya, A; Chen, SY; Fisher, CJ; Zheng, Z; Shen, XQ; Shemshedini, L			c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; ACTIVATION FUNCTION-2; NUCLEAR RECEPTORS; IN-VIVO; COACTIVATOR; PROTEIN; TRANSACTIVATION; TRANSCRIPTION; IDENTIFICATION	The transactivation functions of the human androgen receptor (hAR) are regulated by several accessory factors that can be either positive or negative. One factor that has been previously shown to mediate hAR transactivation is the proto-oncoprotein c-Jun. The positive effect is a primary one, can be exerted by both endogenous and exogenous c-Jun, and requires multiple regions of c-Jun. However, the exact mechanism by which c-Jun exerts its enhancing function is unknown. In this study, we have used a mammalian two-hybrid system to ask if c-Jun influences the ligand-dependent amino- to carboxyl-terminal (N-to-C) interaction of hAR, which is thought to be responsible for the homodimerization of this receptor. Our results show that e-Jun enhances both hAR N-to-C terminal interaction and DNA binding in vitro. We have also tested a panel of c-Jun and c-Fos mutants for their activities on the N-to-C interaction, and the data demonstrate that the activities of these mutants parallel their activities on hAR transactivation. A mutation in the hAR activation function-2 (AF-2) abrogates N-to-C interaction, DNA binding, and transactivation, and these activities are not rescued by exogenous c-Jun. Interestingly, the p160 coactivator TIF2 can stimulate hAR N-to-C interaction, a finding consistent with the effect on hAR transactivation. These data strongly suggest that the hAR N-to-C interaction is the target of c-Jun action, and this activity requires a functional receptor AF-2.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft, Toledo, OH 43528 USA.		CHEN, Shaoyong/ABF-3357-2021					Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barthold JS, 2000, J UROLOGY, V164, P497, DOI 10.1016/S0022-5347(05)67411-3; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kelly C, 1996, CHILD PSYCHOL PSYCHI, V1, P59; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Park JJ, 2000, CANCER RES, V60, P5946; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SEMINTAL JA, 1991, J BIOL CHEM, V266, P510; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; THOLE HH, 1994, J STEROID BIOCHEM, V48, P463, DOI 10.1016/0960-0760(94)90194-5; THUMMEL C, 1995, CELL, V83, P571; Tillman K, 1998, ENDOCRINE, V9, P193, DOI 10.1385/ENDO:9:2:193; Wilson J D, 1981, Recent Prog Horm Res, V37, P1; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	51	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44704	44711		10.1074/jbc.M107346200	http://dx.doi.org/10.1074/jbc.M107346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577103	hybrid			2022-12-25	WOS:000172406700050
J	de Seny, D; Heinz, U; Wommer, S; Kiefer, M; Meyer-Klaucke, W; Galleni, M; Frere, JM; Bauer, R; Adolph, HW				de Seny, D; Heinz, U; Wommer, S; Kiefer, M; Meyer-Klaucke, W; Galleni, M; Frere, JM; Bauer, R; Adolph, HW			Metal ion binding and coordination geometry for wild type and mutants of metallo-beta-lactamase from Bacillus cereus 569/H/9 (BcII) - A combined thermodynamic, kinetic, and spectroscopic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTURBED-ANGULAR-CORRELATION; BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; ACTIVE-SITE; ANGSTROM RESOLUTION; MECHANISM; MONONUCLEAR; CYSTEINE	One high affinity (nm) and one low affinity (IM) macroscopic dissociation constant for the binding of metal ions were found for the wild-type metallo-beta -lactamase from Bacillus cereus as well as six single-site mutants in which all ligands in the two metal binding sites were altered. Surprisingly, the mutations did not cause a specific alteration of the affinity of metal ions for the sole modified binding site as determined by extended x-ray absorption fine structure (EXAFS) and perturbed angular correlation of gamma -rays spectroscopy, respectively. Also UV-visible absorption spectra for the mono-cobalt enzymes clearly contain contributions from both metal sites. The observations of the very similar microscopic dissociation constants of both binding sites in contrast to the significantly differing macroscopic dissociation constants inevitably led to the conclusion that binding to the two metal sites exhibits negative cooperativity. The slow association rates for forming the binuclear enzyme determined by stopped-flow fluorescence measurements suggested that fast metal exchange between the two sites for the mononuclear enzyme hinders the binding of a second metal ion. EXAFS spectroscopy of the mono- and di-zinc wild type enzymes and two di-zinc mutants provide a definition of the metal ion environments, which is compared with the available x-ray crystallographic data.	Univ Saarland, FR Biochem 8 8, D-66041 Saarbrucken, Germany; Univ Liege, Inst Chim B6, Ctr Ingn Prot, B-4000 Liege, Belgium; DESY, European Mol Biol Lab, Outstn Hamburg, D-22603 Hamburg, Germany; Royal Vet & Agr Univ, Dept Math & Phys, DK-1871 Frederiksberg C, Denmark	Saarland University; University of Liege; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Copenhagen	Adolph, HW (corresponding author), Univ Saarland, FR Biochem 8 8, D-66041 Saarbrucken, Germany.	hwadolph@mx.uni-saarland.de	Adolph, Hans W/A-2104-2008; Meyer-Klaucke, Wolfram/G-1148-2010					Bauer R, 1997, BIOCHEMISTRY-US, V36, P11514, DOI 10.1021/bi970936t; BAUER R, 1985, Q REV BIOPHYS, V18, P1, DOI 10.1017/S0033583500004972; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Chantalat L, 2000, PROTEIN SCI, V9, P1402, DOI 10.1110/ps.9.7.1402; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; Hemmingsen L, 1996, EUR J BIOCHEM, V241, P546, DOI 10.1111/j.1432-1033.1996.00546.x; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; JOYNER RW, 1987, J PHYS C SOLID STATE, V20, P4005, DOI 10.1088/0022-3719/20/25/028; LEE PA, 1975, PHYS REV B, V11, P2795, DOI 10.1103/PhysRevB.11.2795; Meneghini C, 1998, BIOPHYS J, V75, P1953, DOI 10.1016/S0006-3495(98)77636-2; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Paul-Soto R, 1999, BIOCHEMISTRY-US, V38, P16500, DOI 10.1021/bi9911381; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; SIMONS TJB, 1993, J BIOCHEM BIOPH METH, V27, P25, DOI 10.1016/0165-022X(93)90065-V; Teo, 1986, EXAFS BASIC PRINCIPL; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Valladares MH, 2000, FEBS LETT, V467, P221, DOI 10.1016/S0014-5793(00)01102-9; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4	28	107	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45065	45078		10.1074/jbc.M106447200	http://dx.doi.org/10.1074/jbc.M106447200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11551939	Green Published, hybrid			2022-12-25	WOS:000172406700097
J	Iwata, A; Maruyama, M; Kanazawa, I; Nukina, N				Iwata, A; Maruyama, M; Kanazawa, I; Nukina, N			alpha-Synuclein affects the MAPK pathway and accelerates cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MULTIPLE SYSTEM ATROPHY; GLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; C-JUN; OXIDATIVE STRESS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-D; LEWY BODIES; IN-VITRO	Insoluble alpha -synuclein accumulates in Parkinson's disease, diffuse Levy body disease, and multiple system atrophy. However, the relationship between its accumulation and pathogenesis is still unclear. Recently, we reported that overexpression of a-synuclein affects Elk-1 phosphorylation in cultured cells, which is mainly performed by mitogen-activated protein kinases (MAPKs). We further examined the relationship between MAPK signaling and the effects of a-synuclein expression on ecdysone-inducible neuro2a cell lines and found that cells expressing a-synuclein had less phosphorylated MAPKs. Moreover, they showed significant cell death when the concentration of serum in the culture medium was reduced. Under normal serum conditions, the addition of the MAPK inhibitor U0126 also caused cell death in alpha -synuclein-expressing cells. Transfection of constitutively active MEK-1 resulted in MAPK phosphorylation in a-synuclein-expressing cells and improved cell viability even under reduced serum conditions. Thus, we conclude that a-synuclein regulates the MAPK pathway by reducing the amount of available active MAPK. Our findings suggest a mechanism for pathogenesis and thus offer therapeutic insight into synucleinopathies.	RIKEN, Brain Sci Inst, Mol Neuropathol Grp, Lab CAG Repeat dis, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138655, Japan	RIKEN; University of Tokyo	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Mol Neuropathol Grp, Lab CAG Repeat dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Iwata, Atsushi/AAH-8924-2019; Iwata, Atsushi/A-9598-2013; Nukina, Nobuyuki/GPP-6265-2022	Iwata, Atsushi/0000-0001-7308-5314; Iwata, Atsushi/0000-0001-7308-5314; 				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; Bloch-Shilderman E, 2001, J PHARMACOL EXP THER, V296, P704; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Cox ME, 1997, J NEUROCHEM, V69, P1119; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Dickson DW, 1999, BRAIN PATHOL, V9, P721; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; ISHIZAWA M, 1991, NUCLEIC ACIDS RES, V19, P5792, DOI 10.1093/nar/19.20.5792; Ito Y, 1998, J NEUROCHEM, V71, P2278; Iwata A, 2001, J NEUROCHEM, V77, P239, DOI 10.1046/j.1471-4159.2001.t01-1-00232.x; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakamura S, 1998, J NEUROPATH EXP NEUR, V57, P690, DOI 10.1097/00005072-199807000-00006; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447	66	125	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45320	45329		10.1074/jbc.M103736200	http://dx.doi.org/10.1074/jbc.M103736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11560921	hybrid			2022-12-25	WOS:000172406700127
J	Lee, JH; Voo, KS; Skalnik, DG				Lee, JH; Voo, KS; Skalnik, DG			Identification and characterization of the DNA binding domain of CpG-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO METHYLATION; MAMMALIAN DEVELOPMENT; METHYLTRANSFERASE GENE; DROSOPHILA-TRITHORAX; CXXC DOMAIN; ALL-1 GENE; ACTIVATION; REPRESSOR; PROMOTER; ISLAND	CpG-binding protein is a transcriptional activator that exhibits a unique DNA binding specificity for unmethylated CpG motifs. CpG-binding protein contains a cysteine-rich CXXC domain that is conserved in DNA methyltransferase 1, methyl binding domain protein 1, and human trithorax. In vitro DNA binding assays reveal that CpG-binding protein contains a single DNA binding domain comprised of the CXXC domain and a short carboxyl extension. Specific mutation to alanine of individual conserved cysteine residues within the CXXC domain abolishes DNA binding activity. Denaturation/renaturation experiments in the presence of various metal cations demonstrate that the CXXC domain requires zinc for efficient DNA binding activity. Ligand selection of high affinity binding sites from a pool of degenerate oligonucleotides reveals that CpG-binding protein interacts with a variety of sequences that contains the CpG dinucleotide with a consensus binding site of (A/C)CpG(A/C). Mutation of the CpG motif(s) present within ligand-selected oligonucleotides ablates the interaction with CpG-binding protein, and mutation to thymine of the nucleotides flanking the CpG motifs reduces the affinity of CpG-binding protein. Hence, a CpG motif is necessary and sufficient to comprise a binding site for CpG-binding protein, although the immediate flanking sequence affects binding affinity.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Canc Res Bldg,1044 W Walnut St,Rm 472, Indianapolis, IN 46202 USA.				NATIONAL CANCER INSTITUTE [R29CA058947, R01CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Fujino T, 2000, BIOCHEM BIOPH RES CO, V271, P305, DOI 10.1006/bbrc.2000.2614; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Sambrook J., 2002, MOL CLONING LAB MANU; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	35	118	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44669	44676		10.1074/jbc.M107179200	http://dx.doi.org/10.1074/jbc.M107179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572867	hybrid			2022-12-25	WOS:000172406700046
J	Liu, A; Prenger, MS; Norton, DD; Mei, L; Kusiak, JW; Bai, G				Liu, A; Prenger, MS; Norton, DD; Mei, L; Kusiak, JW; Bai, G			Nerve growth factor uses Ras/ERK and phosphatidylinositol 3-kinase cascades to up-regulate the N-methyl-D-aspartate receptor 1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR INDUCES TRANSCRIPTION; PC12 CELLS; DNA-BINDING; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; SP1 PHOSPHORYLATION; SUBUNIT-1 PROMOTER; NMDA RECEPTOR; RAT-BRAIN	We reported previously that nerve growth factor (NGF) up-regulates activity of the N-methyl-D-aspartate receptor 1 (NR1) promoter. We have explored the pathways and nuclear targets of NGF signaling in regulating the NR1 promoter. PD98059 and wortmannin, but not rapamycin, significantly attenuated NGF-induced transcriptional activity from an NR1 promoter-luciferase construct. Coexpressing constitutively active forms of Ras, Raf, or MAPK/ERK kinase 1 (MEK1) increased promoter activity dramatically. The MEK1-induced increase was largely prevented by mutations of the tandem GC boxes in the promoter. Promoter activity was also increased significantly by coexpressed GC box-binding proteins (Sp1, 3, or 4) in nonstimulated PC12 cells. Either an extracellular signal-regulated kinase-1 (ERK1)- or Sp1-specific antibody coprecipitated Spl with ERKs, and the coprecipitation was enhanced significantly by NGF treatment of PC12 cells. ERK2 also incorporated radioactivity of [gamma P-32]ATP into recombinant Sp1. However, ERK2-treated Sp1 and PC12 nuclear extracts or nuclear extracts from NGF-treated cells exhibited reduced binding to the promoter or a consensus GC box. Our results suggest that NGF utilizes both the Ras/ERK and phosphatidylinositol 3-kinase pathways to up-regulate NR1 promoter activity and that Sp1 is a novel substrate of NGF-activated ERKs. NGF-increased NR1 promoter activity may involve a complicated mechanism of Sp1 phosphorylation and possible transcription factor exchange.	Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, Baltimore, MD 21201 USA; Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA; NIA, Mol Neurobiol Unit, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bai, G (corresponding author), Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, 666 W Baltimore St, Baltimore, MD 21201 USA.	GNB001@dental.umaryland.edu	Mei, Lin/G-8755-2012		NINDS NIH HHS [NS34062, NS38077] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062, R01NS038077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000500] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AZIZ N, 1993, ONCOGENE, V8, P2259; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOONSTRA J, 1985, BIOCHIMIE, V67, P1177, DOI 10.1016/S0300-9084(85)80117-6; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT RP, 1992, ONCOGENE, V7, P2281; Freeland K, 2000, BIOCHEM J, V345, P233, DOI 10.1042/0264-6021:3450233; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Groot M, 2000, EUR J CELL BIOL, V79, P924, DOI 10.1078/0171-9335-00126; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Hashimoto K, 2000, J NEUROCHEM, V74, P92, DOI 10.1046/j.1471-4159.2000.0740092.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KIM SJ, 1994, J BIOL CHEM, V269, P3739; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; Kumahara E, 1999, J BIOCHEM, V125, P541, DOI 10.1093/oxfordjournals.jbchem.a022319; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; PUJIC Z, 1993, NEUROSCI LETT, V162, P67, DOI 10.1016/0304-3940(93)90561-X; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; Rockow S, 1996, ONCOGENE, V12, P2351; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Si JT, 1997, J BIOL CHEM, V272, P10367; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WATANABE M, 1993, ANN NY ACAD SCI, V707, P463, DOI 10.1111/j.1749-6632.1993.tb38099.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zhang SY, 1997, ARCH BIOCHEM BIOPHYS, V338, P227, DOI 10.1006/abbi.1996.9809; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200; Zhong J, 1996, MOL PHARMACOL, V50, P631	67	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45372	45379		10.1074/jbc.M105399200	http://dx.doi.org/10.1074/jbc.M105399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571288	hybrid			2022-12-25	WOS:000172406700133
J	Perkins, S; Walsh, EJ; Deivanayagam, CCS; Narayana, SVL; Foster, TJ; Hook, M				Perkins, S; Walsh, EJ; Deivanayagam, CCS; Narayana, SVL; Foster, TJ; Hook, M			Structural organization of the fibrinogen-binding region of the clumping factor B MSCRAMM of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; DOMAIN; FIBRONECTIN; IDENTIFICATION; PATHOGENESIS; ADHERENCE; CLEAVAGE; CLFA	The clumping factor B (ClfB) of Staphylococcus aureus is a surface protein that binds to fibrinogen (Ni Eidhin, D., Perkins, S., Francois, P., Vaudaux, P., Hook, M., and Foster, T. J., 1998 Mol. Microbiol. 30, 245-257). The ligand-binding activity is located in the similar to 500-residue A-region (residues 44-542), which represents the N-terminal half of the MSCRAMM protein. We now hypothesize that the ClfB A-region is composed of three subdomains, which we have named N1, N2, and N3, respectively. To examine this hypothesis, we expressed recombinant forms of the individual putative subdomains, the tandem motifs N12 and N23, and the full-length A-region N123. Far UV circular dichroism spectra showed that each subdomain is composed mainly of beta -sheets with little or no discernible alpha -helices. Heat-induced unfolding of individual subdomains occurred with a single state transition and was reversible, indicating that the subdomains can fold as discreet units. Gel permeation chromatography indicated that N2, N3, and N23 are globular. In contrast, domain Nl appeared to be elongated and conferred a somewhat elongated structure on segments containing this subdomain (i.e. N12 or N123). N123, N12, and N23 all bound to fibrinogen, but N23 had a higher affinity for fibrinogen than that observed for the full-length A-region; N123 or for N12. However, an extended N terminus of N23 was required for ligand binding. A form of N23 that was generated by proteolytic processing and lacked the N-terminal extension was unable to bind fibrinogen. Recombinant forms of individual subdomains did not bind fibrinogen. The addition of recombinant N23 effectively inhibited ClfB-mediated bacterial adherence to fibrinogen, and N123 caused some reduction in bacterial attachment, whereas N12 was essentially inactive. Antibodies raised against the central N2 domain of the A-region were the most effective at inhibiting bacterial adhesion to immobilized fibrinogen, although anti-N3 or anti-N1 antibodies also caused some reduction in ClfB-mediated adherence to fibrinogen.	Texas Med Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Univ Alabama Birmingham, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35205 USA	Baylor College of Medicine; Trinity College Dublin; University of Alabama System; University of Alabama Birmingham	Hook, M (corresponding author), Texas Med Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.			Deivanayagam, Champion/0000-0003-2972-1824	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERS GK, 1967, J BIOL CHEM, V242, P3026; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Deivanayagam CCS, 1999, ACTA CRYSTALLOGR D, V55, P554, DOI 10.1107/S0907444998012426; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Entenza JM, 2000, INFECT IMMUN, V68, P5443, DOI 10.1128/IAI.68.9.5443-5446.2000; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; HATT J, 1992, STRATEGIES, V5, P81; Josefsson E, 1998, MICROBIOL-UK, V144, P3387, DOI 10.1099/00221287-144-12-3387; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; McAleese FM, 2001, J BIOL CHEM, V276, P29969, DOI 10.1074/jbc.M102389200; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; McGavin MJ, 1997, INFECT IMMUN, V65, P2621, DOI 10.1128/IAI.65.7.2621-2628.1997; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; OWEN P, 1985, ENTEROBACTERIAL SURF, P207; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633; VAUDAUX PE, 1995, INFECT IMMUN, V63, P585, DOI 10.1128/IAI.63.2.585-590.1995; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; Wolz C, 1996, INFECT IMMUN, V64, P3142, DOI 10.1128/IAI.64.8.3142-3147.1996; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44721	44728		10.1074/jbc.M106741200	http://dx.doi.org/10.1074/jbc.M106741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11568183	hybrid			2022-12-25	WOS:000172406700052
J	Rockman, SP; Currie, SA; Ciavarella, M; Vincan, E; Dow, C; Thomas, RJS; Phillips, WA				Rockman, SP; Currie, SA; Ciavarella, M; Vincan, E; Dow, C; Thomas, RJS; Phillips, WA			Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; RETINOBLASTOMA PROTEIN; PANCREATIC-CANCER; PROMOTER ACTIVITY; TUMORS; EXPRESSION; MUTATIONS; SEQUENCE; MOUSE	Activation of beta -catenin/T cell factor (TCF) transcription as a result of mutations in the adenomatous polyposis coli (APC) and/or beta -catenin genes occurs in the majority of colon tumors. An increasing number of genes, including c-myc and cyclin D1, have been implicated as targets of this pathway. We now report that the dominant negative helix-loop-helix regulator Id2 is also a target of the beta -catenin/TCF transcription pathway in colon adenocarcinoma. Investigation of the mechanism for the overexpression of Id2 in colon carcinoma cells demonstrated that the Id2 promoter is activated, and the Id2 protein is up-regulated by beta -catenin. Conversely, reducing free beta -catenin blocked this induction of promoter activity. We have also used an electrophoretic mobility shift assay and supershift to identify a motif in the Id2 promoter that binds to TCF4 protein. Site-directed mutagenesis of this motif abolished promoter reporter activity. Both transfection of Id2 into SW480 cells and induction of Id2 in HT29 colon cells was found to increase anchorage-independent survival of these cells. Growing evidence associates disruption to Id2 expression with tumorigenesis, and our findings suggest that this dysregulation of Id2 expression is due to the activation of the beta -catenin/TCF pathway.	Peter MacCallum Canc Inst, Surg Oncol Res Lab, Melbourne, Vic 3002, Australia; Western Hosp, Dept Anat Pathol, Footscray, Vic 3011, Australia	Peter Maccallum Cancer Center; Western Hospital	Phillips, WA (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, Locked Bag 1 ABeckett St, Melbourne, Vic 8006, Australia.	w.phillips@pmci.unimelb.edu.au	Phillips, Wayne A/H-8070-2013; rockman, steve/AAT-5105-2021	Phillips, Wayne A/0000-0002-7961-638X; Vincan, Elizabeth/0000-0002-8607-4849				Atherton GT, 1996, CELL GROWTH DIFFER, V7, P1059; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND K, 2001, DNA MICROARRAYS MOL; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Gerdes B, 1999, DIGESTION, V60, P544, DOI 10.1159/000007704; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hulsken J, 2000, J CELL SCI, V113, P3545; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Israel MA, 1999, CANCER RES, V59, p1726S; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kleeff J, 1998, CANCER RES, V58, P3769; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KURABAYASHI M, 1995, GENE, V156, P311, DOI 10.1016/0378-1119(95)00017-Z; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Mariadason JM, 2001, CANCER RES, V61, P3465; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Norton JD, 2000, J CELL SCI, V113, P3897; Pagliuca A, 2000, CANCER RES, V60, P1376; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Ramsay R G, 1995, Methods Mol Biol, V37, P369; Ramsay RG, 2000, CANCER RES, V60, P1805; ROCZO N, 2000, GI CANCER, V3, P259; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310	31	118	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45113	45119		10.1074/jbc.M107742200	http://dx.doi.org/10.1074/jbc.M107742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572874	hybrid			2022-12-25	WOS:000172406700102
J	Tornaletti, S; Maeda, LS; Lloyd, DR; Reines, D; Hanawalt, PC				Tornaletti, S; Maeda, LS; Lloyd, DR; Reines, D; Hanawalt, PC			Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMER; DNA-BASE DAMAGES; COUPLED REPAIR; ESCHERICHIA-COLI; COCKAYNE-SYNDROME; UREA RESIDUES; HUMAN-CELLS; DUPLEX DNA; STRAND; GENE	Thymine glycols are formed in DNA by exposure to ionizing radiation or oxidative stress. Although these lesions are repaired by the base excision repair pathway, they have been shown also to be subject to transcription-coupled repair. A current model for transcription-coupled repair proposes that RNA polymerase II arrested at a DNA lesion provides a signal for recruitment of the repair enzymes to the lesion site. Here we report the effect of thymine glycol on transcription elongation by T7 RNA polymerase and RNA polymerase II from rat liver. DNA substrates containing a single thymine glycol located either in the transcribed or nontranscribed strand were used to carry out in vitro transcription. We found that thymine glycol in the transcribed strand blocked transcription elongation by T7 RNA polymerise similar to 50% of the time but did not block RNA polymerise It. Thymine glycol in the nontranscribed strand did not affect transcription by either polymerase. These results suggest that arrest of RNA polymerase elongation by thymine glycol is not necessary for transcription-coupled repair of this lesion. Additional factors that recognize and bind thymine glycol in DNA may be required to ensure RNA polymerise arrest and the initiation of transcription-coupled repair in vivo.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Stanford University; Emory University	Hanawalt, PC (corresponding author), Stanford Univ, Dept Biol Sci, 385 Serra Mall, Stanford, CA 94305 USA.	hanawalt@stanford.edu	excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Lloyd, Daniel/0000-0002-4888-6790; Maeda, Lauren/0000-0001-9215-2965	NCI NIH HHS [CA-77712, R56 CA077712, R01 CA077712] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077712, R56CA077712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHEY PM, 1983, RADIAT RES, V93, P609, DOI 10.2307/3576040; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5404, DOI 10.1021/bi00391a028; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5398, DOI 10.1021/bi00391a027; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANAWALT PC, 1993, ALFRED BENZON SYMP S, V35, P231; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; HTUN H, 1992, METHOD ENZYMOL, V212, P272; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; KAO JY, 1993, J BIOL CHEM, V268, P17787; Kung HC, 1997, J BIOL CHEM, V272, P9227; LASPIA MF, 1988, J BACTERIOL, V170, P3359, DOI 10.1128/jb.170.8.3359-3366.1988; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1995, MUTAT RES-DNA REPAIR, V337, P169, DOI 10.1016/0921-8777(95)00021-B; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MORAN E, 1985, MUTAT RES, V146, P229, DOI 10.1016/0167-8817(85)90063-X; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; REINES D, 1991, J BIOL CHEM, V266, P10510; ROUET P, 1985, CANCER RES, V45, P6113; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SHI YB, 1988, J BIOL CHEM, V263, P527; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Tornaletti S, 1997, J BIOL CHEM, V272, P31719, DOI 10.1074/jbc.272.50.31719; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660	42	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45367	45371		10.1074/jbc.M105282200	http://dx.doi.org/10.1074/jbc.M105282200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571287	Green Accepted, hybrid			2022-12-25	WOS:000172406700132
J	Volk, KA; Snyder, PM; Stokes, JB				Volk, KA; Snyder, PM; Stokes, JB			Regulation of epithelial sodium channel activity through a region of the carboxyl terminus of the alpha-subunit - Evidence for intracellular kinase-mediated reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME; NA+ CHANNEL; PROTEIN-KINASE; BETA-SUBUNIT; PSEUDOHYPOALDOSTERONISM TYPE-1; MISSENSE MUTATION; MEMBRANE TOPOLOGY; CELL-SURFACE; WW DOMAINS; PY MOTIF	The epithelial sodium channel (ENaC) is a heteromultimer composed of three subunits, each having two membrane-spanning domains with intracellular amino and carboxyl termini. Several hormones and proteins regulate channel activity, but the molecular nature of this regulation is unknown. We conducted experiments to determine a possible new site within the carboxyl terminus of the a-subunit involved in enhanced channel activity through endogenous kinases. When an alpha -subunit that was truncated to remove a PY motif was expressed in Xenopus oocytes with wild type human beta- and gamma -ENaC subunits, channel activity was greatly enhanced. The removal of the entire intracellular carboxyl terminus of the alpha -subunit eliminated this enhanced basal activity. Using several point mutations, we localized this site to two amino acid residues (Pro(595)-Gly(596)) near the second membrane-spanning domain. The nonspecific kinase inhibitor staurosporine inhibits basal channel activity of wild type ENaC but was ineffective in inhibiting channels mutated at this site. The major effect of these mutations was not on channel kinetics but was largely, if not entirely, on the number of active channels on the cell surface. This region is potentially important in effecting kinase-mediated increases in ENaC activity.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52246 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52246 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Stokes, JB (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, E300 GH, Iowa City, IA 52246 USA.	john-stokes@uiowa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, P50DK052617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55006] Funding Source: Medline; NIDDK NIH HHS [DK52617, DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chalfant ML, 1996, AM J PHYSIOL-RENAL, V271, pF861, DOI 10.1152/ajprenal.1996.271.4.F861; Chalfant ML, 1996, J MEMBRANE BIOL, V152, P207, DOI 10.1007/s002329900098; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHEN L, 1991, AM J PHYSIOL, V261, pF126, DOI 10.1152/ajprenal.1991.261.1.F126; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FRINDT G, 1995, AM J PHYSIOL-RENAL, V268, pF480, DOI 10.1152/ajprenal.1995.268.3.F480; Frindt G, 1996, AM J PHYSIOL-RENAL, V270, pF371, DOI 10.1152/ajprenal.1996.270.2.F371; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Grunder S, 1997, J HYPERTENS, V15, P173, DOI 10.1097/00004872-199715020-00008; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HASSON JH, 1995, P NATL ACAD SCI USA, V92, P11495; Husted RF, 1996, AM J PHYSIOL-RENAL, V271, pF433, DOI 10.1152/ajprenal.1996.271.2.F433; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; Jeunemaitre X, 1997, J HYPERTENS, V15, P1091, DOI 10.1097/00004872-199715100-00007; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Lang F, 2000, P NATL ACAD SCI USA, V97, P8157, DOI 10.1073/pnas.97.14.8157; Melander O, 1998, HYPERTENSION, V31, P1118, DOI 10.1161/01.HYP.31.5.1118; NAGY E, 1994, AM J PHYSIOL-RENAL, V267, pF831, DOI 10.1152/ajprenal.1994.267.5.F831; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; RENARD S, 1994, J BIOL CHEM, V269, P12981; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Stockando JD, 2000, J BIOL CHEM, V275, P25760, DOI 10.1074/jbc.M003615200; Stokes JB, 1999, KIDNEY INT, V56, P2318, DOI 10.1046/j.1523-1755.1999.00803.x; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Volk KA, 2000, AM J PHYSIOL-CELL PH, V278, pC1047, DOI 10.1152/ajpcell.2000.278.5.C1047	49	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43887	43893		10.1074/jbc.M108714200	http://dx.doi.org/10.1074/jbc.M108714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571309	hybrid			2022-12-25	WOS:000172297700054
J	Luo, YJ; Goss, DJ				Luo, YJ; Goss, DJ			Homeostasis in mRNA initiation - Wheat germ poly(A)-binding protein lowers the activation energy barrier to initiation complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) TAIL; BINDING-PROTEIN; TRANSLATION; CAP; EFFICIENCY; SUBUNITS; ANALOGS	Previous kinetic binding studies of wheat germ protein synthesis eukaryotic initiation factor iso4F (eIFiso4F) and its subunit, eIF4E, with m(7)GTP and mRNA analogues indicated that binding occurred by a two-step process with the first step being too fast to measure by stopped-flow techniques (1). Further equilibrium studies showed that poly(A)-binding protein (PABP) enhanced the cap binding of eIFiso4F about 40-fold. The kinetic effects of PABP on cap binding and the temperature dependence of this reaction were measured and compared. Fluorescence stopped-flow studies of the PABP.eIFiso4F protein complex with cap show a concentration-independent conformational change. PABP did not significantly increase the rate of the conformational change, and because the initial second-order binding is essentially diffusion-controlled, the enhancement of cap affinity must reside in the dissociation rate. The dissociation rate was more than 5-fold slower in the presence of PABP. The temperature dependence of the cap binding reaction was markedly reduced in the presence of PABP. The reduced energy barrier for formation of a cap.eIFiso4F complex suggests a more stable platform for fm-ther initiation complex formation and a possible means of adapting to varying temperature conditions.	CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; CUNY, Grad Ctr, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System	Goss, DJ (corresponding author), CUNY Hunter Coll, Dept Chem, 695 Pk Ave, New York, NY 10021 USA.				NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BALASTA ML, 1993, J BIOL CHEM, V268, P18599; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1989, BIOCHEMISTRY-US, V28, P4771, DOI 10.1021/bi00437a038; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; OLSEN K, 1993, BIOCHEMISTRY-US, V32, P9686, DOI 10.1021/bi00088a021; Ren JH, 1996, NUCLEIC ACIDS RES, V24, P3629, DOI 10.1093/nar/24.18.3629; SHA M, 1995, J BIOL CHEM, V270, P29904; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570	17	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43083	43086		10.1074/jbc.M104970200	http://dx.doi.org/10.1074/jbc.M104970200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11571283	hybrid			2022-12-25	WOS:000172169300060
J	Vandenberghe, I; Kim, JK; Devreese, B; Hacisalihoglu, A; Iwabuki, H; Okajima, T; Kuroda, S; Adachi, O; Jongejan, JA; Duine, JA; Tanizawa, K; Van Beeumen, J				Vandenberghe, I; Kim, JK; Devreese, B; Hacisalihoglu, A; Iwabuki, H; Okajima, T; Kuroda, S; Adachi, O; Jongejan, JA; Duine, JA; Tanizawa, K; Van Beeumen, J			The covalent structure of the small subunit from Pseudomonas putida amine dehydrogenase reveals the presence of three novel types of internal cross-linkages, all involving cysteine in a thioether bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN-TRYPTOPHYLQUINONE; COFACTOR; OXIDASE; SEQUENCE; ENZYMES	Pseudomonas putida contains an amine dehydrogenase that is called a quinohemoprotein as it contains a quinone and two hemes c as redox active groups. Amino acid sequence analysis of the smallest (8.5 kDa), quinone-cofactor-bearing subunit of this heterotrimeric enzyme encountered difficulties in the interpretation of the results at several sites of the polypeptide chain. As this suggested posttranslational modifications of the subunit, the structural genes for this enzyme were determined and mass spectrometric de novo sequencing was applied to several peptides obtained by chemical or enzymatic cleavage. In agreement with the interpretation of the X-ray electronic densities in the diffraction data for the holoenzyme, our results show that the polypeptide of the small subunit contains four intrachain cross-linkages in which the sulfur atom of a cysteine residue is involved. Two of these cross-linkages occur with the beta -carbon atom of an aspartic acid, one with the gamma -carbon atom of a glutamic acid and the fourth with a tryptophanquinone residue, this adduct constituting the enzyme's quinone cofactor, CTQ. The thioether type bond in all four of these adducts has never been found in other proteins. CTQ is a novel cofactor in the series of the recently discovered quinone cofactors.	Lab Eiwitbiochem & Eiwitengn, B-9000 Ghent, Belgium; Osaka Univ, Inst Sci & Ind Res, Dept Struct Mol Biol, Osaka 5670047, Japan; Delft Univ Technol, Dept Microbiol & Enzymol, NL-2628 BC Delft, Netherlands; Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan	Osaka University; Delft University of Technology; Yamaguchi University	Van Beeumen, J (corresponding author), Lab Eiwitbiochem & Eiwitengn, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	jozef.vanbeeumen@rug.ac.be	Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581; Okajima, Toshihide/0000-0003-1733-9580				Adachi O, 1998, BIOSCI BIOTECH BIOCH, V62, P469, DOI 10.1271/bbb.62.469; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Devreese B, 2001, RAPID COMMUN MASS SP, V15, P50, DOI 10.1002/1097-0231(20010115)15:1<50::AID-RCM191>3.0.CO;2-V; DUINE JA, 1997, NATO ASI SER, P149; Gielens C, 1997, EUR J BIOCHEM, V248, P879, DOI 10.1111/j.1432-1033.1997.00879.x; Hacisalihoglu A, 1997, MICROBIOL-UK, V143, P505, DOI 10.1099/00221287-143-2-505; HACISALIHOGLU A, 2000, THESIS DELFT U TECHN; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Jiang W, 1998, ANAL BIOCHEM, V255, P47, DOI 10.1006/abio.1997.2395; JUE RA, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P179; KOZAK M, 1983, MICROBIOL REV, V47, P1; LERCH K, 1982, J BIOL CHEM, V257, P6414; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; PAGE MD, 1993, EUR J BIOCHEM, V218, P711, DOI 10.1111/j.1432-1033.1993.tb18425.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Rogers MS, 2000, J AM CHEM SOC, V122, P990, DOI 10.1021/ja993385y; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; VANDERPALEN CJNM, 1995, EUR J BIOCHEM, V230, P860; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078	21	30	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42923	42931		10.1074/jbc.M107164200	http://dx.doi.org/10.1074/jbc.M107164200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11555656	hybrid			2022-12-25	WOS:000172169300040
J	Zhang, Y; Repa, JJ; Gauthier, K; Mangelsdorf, DJ				Zhang, Y; Repa, JJ; Gauthier, K; Mangelsdorf, DJ			Regulation of lipoprotein lipase by the oxysterol receptors, LXR alpha and LXR beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; TUMOR NECROSIS FACTOR; MESSENGER-RNA LEVELS; GENE-EXPRESSION; NUCLEAR RECEPTOR; TRANSGENIC MICE; X-RECEPTOR; FATTY-ACID; DEVELOPMENTAL REGULATION; CHOLESTEROL EFFLUX	Lipoprotein lipase (LPL) is a key enzyme for lipoprotein metabolism and is responsible for hydrolysis of triglycerides in circulating lipoproteins, releasing free fatty acids to peripheral tissues. In liver, LPL is also believed to promote uptake of high density lipoprotein (HDL)-cholesterol and thereby facilitate reverse cholesterol transport. In this study we show that the Lpl gene is a direct target of the oxysterol liver X receptor, LXR alpha. Alice fed diets containing high cholesterol or an LXR-selective agonist exhibited a significant increase in LPL expression in the liver and macrophages, but not in other tissues (e.g. adipose and muscle). Studies in Lxr-deficient mice confirmed that this response was dependent more on the presence of LXR alpha than LXR beta. Analysis of the Lpl gene revealed the presence of a functional DR4 LXR response element in the intronic region between exons 1 and 2. This response element directly binds rexinoid receptor (RXR)/LXR heterodimers and is sufficient for rexinoid- and LXR agonist-induced transcription of the Lpl gene. Together, these studies further distinguish the roles of LXR alpha and beta and support a growing body of evidence that LXRs function as key regulators of lipid metabolism and are anti-atherogenic.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Mangelsdorf, David/0000-0002-4355-0796; Repa, Joyce/0000-0001-5740-1954				Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BURGAYA F, 1989, BIOCHEM J, V259, P159, DOI 10.1042/bj2590159; CAMPS L, 1991, J LIPID RES, V32, P1877; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1001, P316, DOI 10.1016/0005-2760(89)90116-1; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; Costet P, 2000, J BIOL CHEM, V275, P28240; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; ENERBACK S, 1988, GENE, V64, P97, DOI 10.1016/0378-1119(88)90484-2; Goldberg IJ, 1996, J LIPID RES, V37, P693; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUA XX, 1991, GENE, V107, P247, DOI 10.1016/0378-1119(91)90325-6; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LINDQVIST P, 1983, J BIOL CHEM, V258, P9086; LOWE ME, 1989, J BIOL CHEM, V264, P20042; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rinninger F, 1998, J LIPID RES, V39, P1335; Sartippour MR, 2000, ARTERIOSCL THROM VAS, V20, P104, DOI 10.1161/01.ATV.20.1.104; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Strauss JG, 2001, J BIOL CHEM, V276, P36083, DOI 10.1074/jbc.M104430200; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; VILARO S, 1988, BIOCHEM J, V249, P549, DOI 10.1042/bj2490549; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; Yang WS, 1998, J LIPID RES, V39, P2054; Zhang Z, 2001, J LIPID RES, V42, P649	51	243	255	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43018	43024		10.1074/jbc.M107823200	http://dx.doi.org/10.1074/jbc.M107823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562371	hybrid			2022-12-25	WOS:000172169300052
J	Elrouby, N; Bureau, TE				Elrouby, N; Bureau, TE			A novel hybrid open reading frame formed by multiple cellular gene transductions by a plant long terminal repeat retroelement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; SARCOMA-VIRUS; (1->4)-BETA-XYLAN ENDOHYDROLASES; MOLECULAR CHARACTERIZATION; REVERSE-TRANSCRIPTASE; L1 RETROTRANSPOSITION; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; MAIZE; RETROVIRUSES	The discovery that vertebrate retroviruses could transduce cellular sequences was central to cancer etiology and research. Although not well documented, transduction of cellular sequences by retroelements has been suggested to modify cellular functions. The maize Bs1 transposon was the first non-vertebrate retroelement reported to have transduced a portion of a cellular gene (c-pma). We show that Bs1 has, in addition, transduced portions of at least two more maize cellular genes, namely for 1,3-beta -glucanase (c-bg) and 1,4-beta -xylan endohydrolase (c-xe). We also show that Bs1 has maintained a truncated gag domain with similarity to the magellan gypsy-like long terminal repeat retrotransposon and a region that may correspond to an env-like domain. Our findings suggest that, like oncogenic retroviruses, the three transduced gene fragments and the Bs1 gag domain encode a fusion protein that has the potential to be expressed. We suggest that transduction by retroelements may facilitate the formation of novel hybrid genes in plants.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Bureau, TE (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.							Abe H, 1998, GENES GENET SYST, V73, P353, DOI 10.1266/ggs.73.353; Al-Khayat HA, 1999, J MOL BIOL, V292, P65, DOI 10.1006/jmbi.1999.3055; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aubourg S, 2000, PLANT MOL BIOL, V42, P603, DOI 10.1023/A:1006352315928; Banik M, 1997, MOL GEN GENET, V253, P599, DOI 10.1007/s004380050362; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; Boeke J. D., 1997, P343; BOVA CA, 1988, J VIROL, V62, P75, DOI 10.1128/JVI.62.1.75-83.1988; BRITTEN RJ, 1995, P NATL ACAD SCI USA, V92, P599, DOI 10.1073/pnas.92.2.599; BUREAU TE, 1994, CELL, V77, P479, DOI 10.1016/0092-8674(94)90210-0; CARRINGTON JC, 1989, VIROLOGY, V170, P219, DOI 10.1016/0042-6822(89)90369-3; Chang PFL, 1996, PHYSIOL PLANTARUM, V98, P505, DOI 10.1111/j.1399-3054.1996.tb05705.x; Cooper G.M., 1995, ONCOGENES, P21; Courseaux A, 2001, SCIENCE, V291, P1293, DOI 10.1126/science.1057284; DELLAPORTA SL, 1985, MOL BIOL PLANTS, P36; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; Eickbush Thomas H., 1994, P121; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; Elrouby N, 2000, PLANT PHYSIOL, V124, P369, DOI 10.1104/pp.124.1.369; FINCHER GB, 1989, ANNU REV PLANT PHYS, V40, P305, DOI 10.1146/annurev.pp.40.060189.001513; FINNEGAN DJ, 1983, NATURE, V302, P105, DOI 10.1038/302105a0; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; Goodier JL, 2000, HUM MOL GENET, V9, P653, DOI 10.1093/hmg/9.4.653; HERMAN SA, 1987, SCIENCE, V236, P845, DOI 10.1126/science.3033828; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JIN YK, 1994, PLANT CELL, V6, P1177, DOI 10.1105/tpc.6.8.1177; JIN YK, 1989, P NATL ACAD SCI USA, V86, P6235, DOI 10.1073/pnas.86.16.6235; JOHNS MA, 1985, EMBO J, V4, P1093, DOI 10.1002/j.1460-2075.1985.tb03745.x; JOHNS MA, 1989, PLANT MOL BIOL, V12, P633, DOI 10.1007/BF00044154; Jordan IK, 1999, P NATL ACAD SCI USA, V96, P12621, DOI 10.1073/pnas.96.22.12621; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KIM A, 1994, P NATL ACAD SCI USA, V91, P1285, DOI 10.1073/pnas.91.4.1285; Laten HM, 1998, P NATL ACAD SCI USA, V95, P6897, DOI 10.1073/pnas.95.12.6897; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Li WH, 2001, NATURE, V409, P847, DOI 10.1038/35057039; Malik HS, 2000, GENOME RES, V10, P1307, DOI 10.1101/gr.145000; Marillonnet S, 1998, GENETICS, V150, P1245; MELLOR J, 1985, NATURE, V313, P243, DOI 10.1038/313243a0; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; MOTTINGER JP, 1984, MOL GEN GENET, V195, P367, DOI 10.1007/BF00332775; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OMER CA, 1983, J VIROL, V47, P380, DOI 10.1128/JVI.47.2.380-382.1983; PALMGREN MG, 1994, PLANT MOL BIOL, V25, P137, DOI 10.1007/BF00023232; PURUGGANAN MD, 1994, P NATL ACAD SCI USA, V91, P11674, DOI 10.1073/pnas.91.24.11674; Sidhu P. K., 1999, Plant Physiology, V121, P685, DOI 10.1104/pp.121.2.685; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; SRINIVASAN A, 1987, GENE, V52, P71, DOI 10.1016/0378-1119(87)90396-9; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; SWANSTROM R, 1983, P NATL ACAD SCI-BIOL, V80, P2519, DOI 10.1073/pnas.80.9.2519; TEMIN HM, 1980, CELL, V21, P599, DOI 10.1016/0092-8674(80)90420-1; Wright DA, 1998, GENETICS, V149, P703; WU SC, 1994, PLANT PHYSIOL, V106, P1709, DOI 10.1104/pp.106.4.1709; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784	58	27	28	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41963	41968		10.1074/jbc.M105850200	http://dx.doi.org/10.1074/jbc.M105850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11553621	hybrid			2022-12-25	WOS:000172450400057
J	Klemm, DJ; Watson, PA; Frid, MG; Dempsey, EC; Schaack, J; Colton, LA; Nesterova, A; Stenmark, KR; Reusch, JEB				Klemm, DJ; Watson, PA; Frid, MG; Dempsey, EC; Schaack, J; Colton, LA; Nesterova, A; Stenmark, KR; Reusch, JEB			cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY-HYPERTENSION; TRANSCRIPTION FACTOR; GROWTH; CREB; DIFFERENTIATION; ACTIVATION; PHOSPHORYLATION; EXPRESSION; PATHWAY	We hypothesized that cAMP response element-binding protein (CREB) could function as a molecular determinant of smooth muscle cell fate. In arterial sections from the systemic and pulmonary circulation, CREB content was high in proliferation-resistant medial subpopulations of smooth muscle cells and low in proliferation-prone regions. In vessels from neonatal calves exposed to chronic hypoxia, CREB content was depleted and smooth muscle cell (SMC) proliferation was accelerated. Induction of quiescence by serum deprivation in culture led to increased CREB content. Highly proliferative SMC in culture were observed to have low CREB content. Exposure to proliferative stimuli such as hypoxia or platelet-derived growth factor decreased SMC CREB content. Assessment of CREB gene transcription by nuclear run-on analysis and transcription from a CREB promoter-luciferase construct indicate that CREB levels in SMC are in part controlled at the level of transcription. Overexpression of wild type or constitutively active CREB in primary cultures of SMC arrested cell cycle progression. Additionally, expression of constitutively active CREB decreased both proliferation and chemokinesis. Consistent with these functional properties, active CREB decreased the expression of multiple cell cycle regulatory genes, as well as genes encoding growth factors, growth factor receptors, and cytokines. Our data suggest a unique mode of cellular phenotype determination at the level of the nuclear content of CREB.	Vet Affairs Med Ctr, Endocrinol Sect, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Metab & Diabet, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm & Crit Care, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pediat Crit Care & Dev Lung Biol, Denver, CO 80220 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Reusch, JEB (corresponding author), Vet Affairs Med Ctr, Endocrinol Sect, 111H,1055 Clermont St, Denver, CO 80220 USA.	jane.reusch@uchsc.edu	stenmark, kurt/AAH-3124-2022; stenmark, kurt/AFI-6776-2022	Reusch, Jane/0000-0001-8620-1003	NHLBI NIH HHS [HL56481, HL14985] Funding Source: Medline; NIDDK NIH HHS [DK53969, K08 DK02351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002351, R01DK053969] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT KL, 2001, MOL CELL CARDIOL, V32, P391; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; DURMOWICZ AG, 1993, AM J PHYSIOL-HEART C, V34, pH2175; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Frid MG, 1999, ARTERIOSCL THROM VAS, V19, P2884, DOI 10.1161/01.ATV.19.12.2884; Frid MG, 1997, ARTERIOSCL THROM VAS, V17, P1203, DOI 10.1161/01.ATV.17.7.1203; FRID MG, 1994, CIRC RES, V75, P669, DOI 10.1161/01.RES.75.4.669; Frid MG, 1997, CIRC RES, V81, P940; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; Hoshiya M, 1998, HYPERTENSION, V31, P665, DOI 10.1161/01.HYP.31.2.665; Indolfi C, 1997, NAT MED, V3, P775, DOI 10.1038/nm0797-775; IVENGAR R, 1996, SCIENCE, V271, P461; Keller JN, 1998, NEUROREPORT, V9, P3731, DOI 10.1097/00001756-199811160-00029; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Kreisberg JI, 1996, KIDNEY INT, V50, P805, DOI 10.1038/ki.1996.379; Li Y, 1997, NEUROPEPTIDES, V31, P503, DOI 10.1016/S0143-4179(97)90046-9; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Musa NL, 1999, AM J RESP CELL MOL, V20, P352, DOI 10.1165/ajrcmb.20.2.3160; OIKE Y, 1999, AM SOC HEMATOL, V9, P2771; Owens GK, 1996, J HYPERTENS, V14, pS55; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Shimomura A, 1998, J NEUROCHEM, V70, P1029; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STENMARK KR, 1994, J CLIN INVEST, V93, P1234, DOI 10.1172/JCI117077; STENMARK KR, 1987, J APPL PHYSIOL, V62, P821, DOI 10.1152/jappl.1987.62.2.821; STENMARK KR, 1991, AM J PHYSIOL, V261, P97, DOI 10.1152/ajplung.1991.261.4.L97; Tabernero A, 1998, MOL CELL NEUROSCI, V10, P309, DOI 10.1006/mcne.1998.0662; Tintut Y, 1998, J BIOL CHEM, V273, P7547, DOI 10.1074/jbc.273.13.7547; Vadiveloo PK, 1997, ATHEROSCLEROSIS, V133, P61, DOI 10.1016/S0021-9150(97)00116-0; WHEAT WH, 1994, MOL CELL BIOL, V14, P5881, DOI 10.1128/MCB.14.9.5881; Yang XJ, 1996, J PHARMACOL EXP THER, V278, P338	38	119	120	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46132	46141		10.1074/jbc.M104769200	http://dx.doi.org/10.1074/jbc.M104769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11560924	hybrid			2022-12-25	WOS:000172573100088
J	Mishra, SK; Agostinelli, NR; Brett, TJ; Mizukami, I; Ross, TS; Traub, LM				Mishra, SK; Agostinelli, NR; Brett, TJ; Mizukami, I; Ross, TS; Traub, LM			Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; SACCHAROMYCES-CEREVISIAE; ARRESTIN/CLATHRIN INTERACTION; MEDIATED ENDOCYTOSIS; APPENDAGE DOMAIN; BINDING PROTEIN; ADAPTER COMPLEX; TERMINAL DOMAIN; YEAST; AP-2	Clathrin-mediated endocytosis is a major pathway for the internalization of macromolecules into the cytoplasm of eukaryotic cells. The principle coat components, clathrin and the AP-2 adaptor complex, assemble a polyhedral lattice at plasma membrane bud sites with the aid of several endocytic accessory proteins. Here, we show that huntingtin-interacting protein 1 (HIP1), a binding partner of huntingtin, copurifies with brain clathrin-coated vesicles and associates directly with both AP-2 and clathrin. The discrete interaction sequences within HIP1 that facilitate binding are analogous to motifs present in other accessory proteins, including AP180, amphiphysin, and epsin. Bound to a phosphoinositide-containing membrane surface via an epsin N-terminal homology (ENTH) domain, HIP1 associates with AP-2 to provide coincident clathrin-binding sites that together efficiently recruit clathrin to the bilayer. Our data implicate HIP1 in endocytosis, and the similar modular architecture and function of HIP1, epsin, and AP180 suggest a common role in lipid-regulated clathrin lattice biogenesis.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); University of Michigan System; University of Michigan	Traub, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S325BST, Pittsburgh, PA 15261 USA.		Mishra, Santosh/S-7516-2017; Brett, Thomas/AAC-9147-2019	Mishra, Santosh/0000-0001-8616-2606; Brett, Thomas/0000-0002-6871-6676; Ross, Theodora/0000-0002-9166-1802; Traub, Linton/0000-0002-1303-0298	NATIONAL CANCER INSTITUTE [K08CA076025, R01CA082363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82363-01A1, KO8 CA76025-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK53249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 2001, J CELL SCI, V114, P1041; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kim M, 1999, NEUROSCIENCE, V89, P1159, DOI 10.1016/S0306-4522(98)00400-X; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McCann RO, 1999, BIOCHEM BIOPH RES CO, V266, P135, DOI 10.1006/bbrc.1999.1776; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Morgan JR, 2000, J NEUROSCI, V20, P8667; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; Yeung BG, 1999, MOL BIOL CELL, V10, P3643, DOI 10.1091/mbc.10.11.3643; Zhu YX, 1999, P NATL ACAD SCI USA, V96, P5013, DOI 10.1073/pnas.96.9.5013	48	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46230	46236		10.1074/jbc.M108177200	http://dx.doi.org/10.1074/jbc.M108177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577110	hybrid			2022-12-25	WOS:000172573100101
J	Opresko, PL; Laine, JP; Brosh, RM; Seidman, MM; Bohr, VA				Opresko, PL; Laine, JP; Brosh, RM; Seidman, MM; Bohr, VA			Coordinate action of the helicase and 3 ' to 5 ' exonuclease of Werner syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SYNDROME FIBROBLASTS; SYNDROME CELLS; WRN PROTEIN; REPLICATION; REPAIR; KU; BINDING; DAMAGE; 3'->5'-EXONUCLEASE	Werner syndrome is a human disorder characterized by premature aging, genomic instability, and abnormal telomere metabolism. The Werner syndrome protein (WRN) is the only known member of the RecQ DNA helicase family that contains a 3' --> 5'-exonuclease. However, it is not known whether both activities coordinate in a biological pathway. Here, we describe DNA structures, forked duplexes containing telomeric repeats, that are substrates for the simultaneous action of both WRN activities. We used these substrates to study the interactions between the WRN helicase and exonuclease on a single DNA molecule. WRN helicase unwinds at the forked end of the substrate, whereas the WRN exonuclease acts at the blunt end. Progression of the WRN exonuclease is inhibited by the action of WRN helicase converting duplex DNA to single strand DNA on forks of various duplex lengths. The WRN helicase and exonuclease act in concert to remove a DNA strand from a long forked duplex that is not completely unwound by the helicase. We analyzed the simultaneous action of WRN activities on the long forked duplex in the presence of the WRN protein partners, replication protein A (RPA), and the Ku70/80 heterodimer. RPA stimulated the WRN helicase, whereas Ku stimulated the WRN exonuclease. In the presence of both RPA and Ku, the WRN helicase activity dominated the exonuclease activity.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Brosh, Robert/AAR-6124-2020; Bohr, Vilhelm/AAP-5931-2020	Opresko, Patricia/0000-0002-6470-2189	NATIONAL INSTITUTE ON AGING [Z01AG000726, Z01AG000741, ZIAAG000741, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hisama FM, 2000, CANCER RES, V60, P2372; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin GM, 1997, FASEB J, V11, pA1449; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN GM, 1970, LAB INVEST, V23, P86; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Oshima J, 2000, BIOESSAYS, V22, P894, DOI 10.1002/1521-1878(200010)22:10<894::AID-BIES4>3.0.CO;2-B; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Schulz VP, 1996, HUM GENET, V97, P750; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Smith J, 2000, BIOCHIMIE, V82, P71, DOI 10.1016/S0300-9084(00)00183-8; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Watt PM, 1996, GENETICS, V144, P935; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	45	83	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44677	44687		10.1074/jbc.M107548200	http://dx.doi.org/10.1074/jbc.M107548200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572872	hybrid			2022-12-25	WOS:000172406700047
J	Yabuta, Y; Takagi, H; Inouye, M; Shinde, U				Yabuta, Y; Takagi, H; Inouye, M; Shinde, U			Folding pathway mediated by an intramolecular chaperone - Propeptide release modulates activation precision of pro-subtilisin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; CRYSTAL-STRUCTURE; PRECURSOR; SEQUENCE; COMPLEX; BPN'	Propeptides of several proteases directly catalyze the protein folding reaction. Uncatalyzed folding traps these proteases into inactive molten-globule-like conformers that switch into active enzymes only when their cognate propeptides are added in trans. Although tight binding and proteolytic susceptibility forces propeptides to function as single turnover catalysts, the significance of their inhibitory function and the mechanism of activation remain unclear. Using pro-subtilisin as a model, we establish that precursor activation is a highly coordinated process that involves synchronized folding, autoprocessing, propeptide release, and protease activation. Our results demonstrate that activation is controlled by release of the first free active protease molecule. This triggers an exponential cascade that selectively targets the inhibitory propeptide in the autoprocessed complex as its substrate. However, a mutant precursor that enhances propeptide release can drastically reduce the folding efficiency by altering the synergy between individual stages. Our results represent the first demonstration that propeptide release, not precursor folding, is the rate-determining step and provides the basis for the proposed model for precise spatial and temporal activation that allows proteases to function as regulators of biological function.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Fukui Prefectural Univ, Dept Biosci, Fukui 9101195, Japan; Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Oregon Health & Science University; Fukui Prefectural University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Shinde, U (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, MRB631,3181 SW Sam Jackson Pk Rd,Mail Code L224, Portland, OR 97201 USA.	shindeu@ohsu.edu						Anderson DE, 1999, BIOCHEMISTRY-US, V38, P4728, DOI 10.1021/bi982165e; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; Herszenyi L, 1999, CANCER, V86, P1135, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2; Inouye M, 2001, NAT STRUCT BIOL, V8, P321, DOI 10.1038/86194; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; JOHNSON WJ, 1982, SCIENCE, V218, P574, DOI 10.1126/science.6289443; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Kojima S, 1998, J MOL BIOL, V277, P1007, DOI 10.1006/jmbi.1998.1671; LI YY, 1994, J BIOL CHEM, V269, P4169; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMITH SM, 1989, J BIOL CHEM, V264, P20487; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; WELLS JA, 1988, TRENDS BIOCHEM SCI, V13, P291, DOI 10.1016/0968-0004(88)90121-1; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	33	89	92	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44427	44434		10.1074/jbc.M107573200	http://dx.doi.org/10.1074/jbc.M107573200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577106	hybrid			2022-12-25	WOS:000172406700012
J	Ching, TT; Lin, HP; Yang, CC; Oliveira, M; Lu, PJ; Chen, CS				Ching, TT; Lin, HP; Yang, CC; Oliveira, M; Lu, PJ; Chen, CS			Specific binding of the c-terminal src homology 2 domain of the p85 alpha subunit of phosphoinositide 3-kinase to phosphatidylinositol 3,4,5-trisphosphate - Localization and engineering of the phosphoinositide-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PH DOMAIN; PHOSPHOLIPASE-C; LIPID PRODUCTS; HIGH-AFFINITY; HUMAN PROFILIN; SH2 DOMAIN; 4,5-BISPHOSPHATE; IDENTIFICATION; ACTIVATION	Phosphoinositide second messengers, generated from the action of phosphoinositide 3-kinase (PI3K) mediate an array of signaling pathways through the membrane recruitment and activation of downstream effector proteins. Although pleckstrin domains of many target proteins have been shown to bind phosphatidylinositol 3,4,5-trisphosphate (PIP3) and/or phosphatidylinositol 3,4-bisphosphate (PI(3,4)P-2) with high affinity, published data concerning the phosphoinositide binding specificity of Src homology 2 (SH2) domains remain conflicting. Using three independent assays, we demonstrated that the C-terminal (CT-)SH2 domain, but not the N-terminal SH2 domain, on the PI3K p85 alpha subunit displayed discriminative affinity for PIP3. However, the binding affinity diminished precipitously when the acyl chain of PEP, was shortened. In addition, evidence suggests that the charge density on the phosphoinositol ring represents a key factor in determining the phosphoinositide binding specificity of the CT-SH2 domain. In light of the largely shared structural features between PIP3 and PI(4,5)P-2, we hypothesized that the PIP3-binding site on the CT-SH2 domain encompassed a sequence that recognized PI(4,5)P-2. Based on a consensus PI(4,5)P-2-binding sequence (KXXXXXKXKK; K denotes Arg, Lys, and His), we proposed the sequence (18)RNKAENLLRGKR(29) as the PIP3-binding site. This binding motif was verified by using a synthetic peptide and site-directed mutagenesis. More importantly, neutral substitution of flanking Arg(18) and Arg(29) resulted in a switch of ligand specificity of the CT-SH2 domain to PI(4,5)P-2 and PI(3,4)P-2, respectively. Together with computer modeling, these mutagenesis data suggest a pseudosymmetrical relationship in the recognition of the phosphoinositol head group at the binding motif.	Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan	Ohio State University; University of Kentucky; National Sun Yat Sen University	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Pks Hall,Rm 336,500 W 12th Ave, Columbus, OH 43210 USA.	chen.844@osu.edu		Ching, Tsui-Ting/0000-0001-7650-1766	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Lo Surdo P, 1999, J BIOL CHEM, V274, P15678, DOI 10.1074/jbc.274.22.15678; Lu PJ, 1997, J BIOL CHEM, V272, P466; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; SIMOES AP, 1995, BIOCHEMISTRY-US, V34, P5113, DOI 10.1021/bi00015a023; SOHN RH, 1995, J BIOL CHEM, V270, P21114, DOI 10.1074/jbc.270.36.21114; Steffen P, 2000, CELL MOTIL CYTOSKEL, V45, P58; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Van Troys M, 2000, BIOCHEMISTRY-US, V39, P12181, DOI 10.1021/bi000816c; Wang DS, 1998, J ORG CHEM, V63, P5430, DOI 10.1021/jo980356h; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1992, J BIOL CHEM, V267, P14616; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	38	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43932	43938		10.1074/jbc.M105159200	http://dx.doi.org/10.1074/jbc.M105159200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11555646	hybrid			2022-12-25	WOS:000172297700060
J	Yague, J; Marina, A; Vazquez, J; de Castro, JAL				Yague, J; Marina, A; Vazquez, J; de Castro, JAL			Major histocompatibility complex class I molecules bind natural peptide ligands lacking the amino-terminal binding residue in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; VIRAL PEPTIDES; MHC; SPECIFICITY; STABILITY; HLA-B27; HLA; IMMUNOGENICITY; NOMENCLATURE; DISSOCIATION	Major histocompatibility complex (MHC) class I-peptide complexes are stabilized by multiple interactions, including those of the peptidic NH2-terminal group in the A pocket of the MHC molecule. In this study, the characterization of four natural HLA-1339 ligands lacking the amino-terminal binding residue is reported. These peptides were found in the endogenous peptide pool of one or more of the B*3901, B*3905, and B*3909 allotypes and sequenced by nanoelectrospray mass spectrometry. Control experiments ruled out that they resulted from exopeptidase trimming of their NH.-terminally extended counterparts: NAc-SHVAVENAL, EHGPNPIL, IHEPEPHIL, and EHAGVISVL, also present in the same peptide pools, during purification. HAGVISVL and HVAVENAL behaved similarly to the corresponding NH2-terminally extended peptides in their binding to B*3901 and B*3909 at the cell surface in vitro, and in cell surface stabilization of B*3901. This is, to our knowledge, the first demonstration that peptides lacking the amino-terminal binding residue bind in vivo to classical MHC class I molecules. The results indicate that canonical MHC-peptide interactions in the A pocket are not always necessary for endogenous peptide presentation.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientificas, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientificas, E-28049 Madrid, Spain.		Ramírez, Anabel Marina/ABG-7125-2021; Vazquez, Jesus/B-7697-2015	Ramírez, Anabel Marina/0000-0003-2927-6396; Vazquez, Jesus/0000-0003-1461-5092				Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BURSHTYN DN, 1993, J IMMUNOL, V151, P3082; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FALK K, 1995, IMMUNOGENETICS, V41, P162, DOI 10.1007/BF00182332; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Levitsky V, 1996, J EXP MED, V183, P915, DOI 10.1084/jem.183.3.915; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Mitta M, 1996, DNA Res, V3, P31, DOI 10.1093/dnares/3.1.31; OJCIUS DM, 1993, J IMMUNOL, V151, P6020; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Scaloni A, 1999, J PROTEIN CHEM, V18, P349, DOI 10.1023/A:1021047730831; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; UTZ U, 1992, J IMMUNOL, V149, P214; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; Yague J, 2000, TISSUE ANTIGENS, V56, P385, DOI 10.1034/j.1399-0039.2000.560501.x; Yague J, 2000, J EXP MED, V191, P2083, DOI 10.1084/jem.191.12.2083; Yague J, 1999, TISSUE ANTIGENS, V53, P227, DOI 10.1034/j.1399-0039.1999.530302.x; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43699	43707		10.1074/jbc.M105981200	http://dx.doi.org/10.1074/jbc.M105981200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11557759	hybrid			2022-12-25	WOS:000172297700030
J	Ishimi, Y; Komamura-Kohno, Y; Arai, K; Masai, H				Ishimi, Y; Komamura-Kohno, Y; Arai, K; Masai, H			Biochemical activities associated with mouse Mcm2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME-MAINTENANCE PROTEINS; HUMAN CDC7-RELATED KINASE; IN-VITRO PHOSPHORYLATION; DNA HELICASE ACTIVITY; S-PHASE CHECKPOINT; FISSION YEAST; CELL-CYCLE; HETEROHEXAMERIC COMPLEXES; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE	Mcm2, a member of the Mcm2-7 protein family essential for the initiation of DNA replication, has several biochemical activities including the ability to inhibit the Mcm4,6,7 helicase. In this study, we characterized the activities associated with Mcm2 and determined the region required for them. It was found that Mcm2 deleted at an amino-terminal portion is able to bind to an Mcm4,6,7 hexameric complex and to inhibit its DNA helicase activity. The same deletion mutant of Mcm2 and the carboxyl-terminal half of Mcm2 were both able to bind to Mcm4, suggesting that the carboxyl-half of Mcm2 binds to Mcm4 to disassemble the Mcm4,6,7 hexamer. Phosphorylation of Mcm2,4,6,7 complexes with Cdc7 kinase showed that the amino-terminal region of Mcm2 is required for the phosphorylation, and it contains major Cdc7-mediated phosphorylation sites. We also found that Mcm2 itself can assemble a nucleosome-like structure in vitro in the presence of H3/H4 histones. The amino-terminal region of Mcm2 was required for the activity where a histone-binding domain is located. Finally, we identified a region required for the nuclear localization of Mcm2. The function of Mcm2 is discussed based on these biochemical characteristics.	Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, Tokyo 1088639, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Tokyo	Ishimi, Y (corresponding author), Mitsubishi Kagaku Inst Life Sci, 11 Minamiooya, Tokyo 1948511, Japan.	yukio@libra.ls.m-kagaku.co.jp						Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BINASTEIN M, 1977, CELL, V11, P609, DOI 10.1016/0092-8674(77)90078-2; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; ISHIMI Y, 1984, EUR J BIOCHEM, V162, P19; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H., 1999, FRONT BIOSCI, V4, pD834; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sclafani RA, 2000, J CELL SCI, V113, P2111; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WAHLE E, 1989, J BIOL CHEM, V264, P2469; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; You ZY, 1999, MOL CELL BIOL, V19, P8003; Young MR, 1997, GENES CELLS, V2, P631, DOI 10.1046/j.1365-2443.1997.1510349.x; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	57	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42744	42752		10.1074/jbc.M106861200	http://dx.doi.org/10.1074/jbc.M106861200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11568184	hybrid			2022-12-25	WOS:000172169300016
J	Jiang, YL; Kwon, K; Stivers, JT				Jiang, YL; Kwon, K; Stivers, JT			Turning on uracil-DNA glycosylase using a pyrene nucleotide switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BASE EXCISION; CATALYSIS; MECHANISM; 2-AMINOPURINE; PROCESSIVITY; FLUORESCENCE; REPLICATION; PYRIMIDINE; CYTOSINE	Base flipping is a highly conserved process by which enzymes swivel an entire nucleotide from the DNA base stack into their active site pockets. Uracil DNA glycosylase (UDG) is a paradigm enzyme that uses a base flipping mechanism to catalyze the hydrolysis of the N-glycosidic bond of 2'-deoxyuridine (2'-dUrd) in DNA as the first step in uracil base excision repair. Flipping of 2'-dUrd by UDG has been proposed to follow a "pushing" mechanism in which a completely conserved leucine side chain (Leu-191) is inserted into the DNA minor groove to expel the uracil. Here we report a novel implementation of the "chemical rescue" approach to show that the weak binding affinity and low catalytic activity of L191A or L191G can be completely or partially restored by substitution of a pyrene (Y) nucleotide wedge on the DNA strand opposite to the uracil base (U/A to U/Y). These results indicate that pyrene acts both as a wedge to push the uracil from the base stack in the free DNA and as a "plug" to hinder its reinsertion after base flipping. Pyrene rescue should serve as a useful and novel tool to diagnose the functional roles of other amino acid side chains involved in base flipping.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056834] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056834, GM46835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; Drohat AC, 2000, BIOCHEMISTRY-US, V39, P11865, DOI 10.1021/bi000922e; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11876, DOI 10.1021/bi9910880; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; Fasman G.D, 1975, HDB BIOCH MOL BIOL N, V1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Handa P, 2001, J BIOL CHEM, V276, P17324, DOI 10.1074/jbc.M011166200; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HIGLEY M, 1993, MUTAT RES, V294, P109, DOI 10.1016/0921-8777(93)90019-D; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Jiang YL, 2001, BIOCHEMISTRY-US, V40, P7710, DOI 10.1021/bi010622c; JONES AS, 1963, J CHEM SOC, P3554, DOI 10.1039/jr9630003554; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Matray TJ, 1998, J AM CHEM SOC, V120, P6191, DOI 10.1021/ja9803310; Matray TJ, 1999, NATURE, V399, P704, DOI 10.1038/21453; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SCHWEITZER BA, 1994, J ORG CHEM, V59, P7238, DOI 10.1021/jo00103a013; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Werner RM, 2000, BIOCHEMISTRY-US, V39, P12585, DOI 10.1021/bi001532v; Xiao GY, 1999, PROTEINS, V35, P13	32	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42347	42354		10.1074/jbc.M106594200	http://dx.doi.org/10.1074/jbc.M106594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11551943	hybrid			2022-12-25	WOS:000172450400106
J	Kang, JS; Kim, SH; Hwang, MS; Han, SJ; Lee, YC; Kim, YJ				Kang, JS; Kim, SH; Hwang, MS; Han, SJ; Lee, YC; Kim, YJ			The structural and functional organization of the yeast mediator complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; REPEAT DOMAIN; HOLOENZYME; SIN4; BINDING; REQUIREMENT; REPRESSION; PROTEINS	The Mediator complex of Saccharomyces cerevisiae is required for diverse aspects of transcription by RNA polymerase II (pol II). Mediator is composed of two functionally distinct subcomplexes, Rgr1 and Srb4. To identify the structures and functions of each subcomplex, we expressed recombinant proteins for each subunit and assayed their interactions with each other and with basal transcription proteins. The Rgr1 subcomplex is composed of the Gal11 module, which binds activators, and the Med9/10 module. The Med9/10 module is required for both transcriptional activation and repression, and these activities appear to be carried out by two submodules. Proteins in the Med9 submodule interact physically and genetically with Srb10/11, suggesting that the Med9 submodule mediates the repression of pol II. Purified recombinant Srb4 subcomplex stimulated basal transcription of pol II but had little effect on activated transcription and phosphorylation of the C-terminal domain of the Rpb1 subunit of pol II. Both subcomplexes of Mediator interacted with a distinct set of basal transcription factors and pol II. The modular organization of Mediator and the associated functions suggest that the Mediator complex may recruit and/or stabilize the preinitiation complex through several points of contact with transcriptional regulators and basal transcription factors.	Yonsei Univ, Dept Biochem, Natl Creat Res Ctr Genome Regulat, Seodaemoon Ku, Seoul 120749, South Korea	Yonsei University	Kim, SH (corresponding author), Yonsei Univ, Dept Biochem, Natl Creat Res Ctr Genome Regulat, Seodaemoon Ku, 134 Shinchondong, Seoul 120749, South Korea.							Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; COVITZ PA, 1994, GENETICS, V138, P577; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Han SJ, 1999, MOL CELL BIOL, V19, P979; Han SJ, 2001, J BIOL CHEM, V276, P37020, DOI 10.1074/jbc.M105596200; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NONET ML, 1989, GENETICS, V123, P715; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Song WJ, 1996, MOL CELL BIOL, V16, P115; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; Zaman Z, 2001, P NATL ACAD SCI USA, V98, P2550, DOI 10.1073/pnas.041611198	37	116	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42003	42010		10.1074/jbc.M105961200	http://dx.doi.org/10.1074/jbc.M105961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11555651	hybrid			2022-12-25	WOS:000172450400063
J	Nittis, T; George, GN; Winge, DR				Nittis, T; George, GN; Winge, DR			Yeast Sco1, a protein essential for cytochrome c oxidase function is a Cu(I)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; COPPER-METABOLISM; GENE; PURIFICATION; EXPRESSION; IDENTIFICATION; COORDINATION; ACCUMULATION; DEFICIENCY; CRYSTAL	Sco1 is a conserved essential protein, which has been implicated in the delivery of copper to cytochrome c oxidase, the last enzyme of the electron transport chain. In this study, we show for the first time that the purified C-terminal domain of yeast Sco1 binds one Cu(I)/monomer. X-ray absorption spectroscopy suggests that the Cu(I) is ligated via three ligands, and we show that two cysteines, present in a conserved motif CXXXC, and a conserved histidine are involved in Cu(I) ligation. The mutation of any one of the conserved residues in Sco1 expressed in yeast abrogates the function of Sco1 resulting in a non-functional cytochrome c oxidase complex. Thus, the function of Sco1 correlates with Cu(I) binding. Data obtained from size-exclusion chromatography experiments with mitochondrial lysates suggest that full-length Sco1 may be oligomeric in vivo.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010; George, Graham N/E-3290-2013	George, Graham/0000-0002-0420-7493	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Bonnefoy N, 2000, MOL GEN GENET, V262, P1036, DOI 10.1007/PL00008646; Brachmann CB, 1998, YEAST, V14, P115; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CAMERON VL, 1989, J BIOL CHEM, V264, P13391; DANCE IG, 1983, POLYHEDRON, V2, P1031, DOI 10.1016/S0277-5387(00)81450-3; GarciaVasquez JA, 1997, INORG CHIM ACTA, V260, P221, DOI 10.1016/S0020-1693(96)05555-7; GEIER BM, 1995, EUR J BIOCHEM, V227, P296, DOI 10.1111/j.1432-1033.1995.tb20388.x; Glerum DM, 1997, FEBS LETT, V412, P410, DOI 10.1016/S0014-5793(97)00799-0; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Iwata S, 1998, J BIOCHEM-TOKYO, V123, P369; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KOCH SA, 1984, INORG CHEM, V23, P121, DOI 10.1021/ic00170a001; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; MAIRE ML, 2000, BIOCHIM BIOPHYS ACTA, V1509, P86; Mattatall NR, 2000, J BIOL CHEM, V275, P28802, DOI 10.1074/jbc.M002741200; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NITTIS T, 2001, MICROBIAL TRANSPORT, P419; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; RAMAPRABHU S, 1994, Z NATURFORSCH A, V49, P193; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Robinson BH, 2000, PEDIATR RES, V48, P581, DOI 10.1203/00006450-200011000-00004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; SPENO H, 1995, J BIOL CHEM, V270, P25363, DOI 10.1074/jbc.270.43.25363; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Valnot I, 2000, AM J HUM GENET, V67, P1104; [No title captured]	45	155	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42520	42526		10.1074/jbc.M107077200	http://dx.doi.org/10.1074/jbc.M107077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546815	hybrid			2022-12-25	WOS:000172450400126
J	Rivera-Walsh, I; Waterfield, M; Xiao, GT; Fong, A; Sun, SC				Rivera-Walsh, I; Waterfield, M; Xiao, GT; Fong, A; Sun, SC			NF-kappa B signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I tax-induced T-cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; ACTIVATION; LIGAND; APOPTOSIS; KINASE; LYMPHOCYTES; RETROVIRUS; IMMORTALIZATION; INVOLVEMENT; INDUCTION	The Tax oncoprotein encoded by human T-cell leukemia virus induces both T-cell activation and apoptosis. The mechanism by which Tax induces apoptosis has remained unclear. Using genetically manipulated T-cell lines, we demonstrate that Tax-induced T-cell death is dependent on NF-kappaB signaling. Tax fails to induce apoptosis in T cells lacking I kappaB kinase gamma (IKK gamma), an essential component of the NF-kappaB signaling pathway. This defect was rescued when the mutant cells were reconstituted with exogenous IKK gamma. We further demonstrate that the Tax-induced T-cell death is mediated by TNF (tumor necrosis factor)-related apoptosis-inducing ligand (TRAIL), because this event can be effectively inhibited by a TRAIL-blocking antibody. Consistent with this functional aspect, Tax stimulates the expression of TRAIL mRNA. Finally, we provide genetic evidence demonstrating that the NF-kappaB signaling pathway is essential for TRAIL gene induction by both Tax and T-cell activation signals. These studies reveal a novel function of the NF-kappaB signaling pathway and suggest a key mechanism by which Tax induces T-cell death.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [2 R01 CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gilmore TD, 1996, ONCOGENE, V13, P1367; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRILLI M, 1993, INT REV CYTOL, V143, P1; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Los M, 1998, J IMMUNOL, V161, P3050; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898-6568(98)00018-7; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rudolph D, 2000, GENE DEV, V14, P854; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Sharma S, 1996, P NATL ACAD SCI USA, V93, P11842, DOI 10.1073/pnas.93.21.11842; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; STENNICKE HR, 2000, BIOCHIM BIOPHYS ACTA, V477, P299; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	36	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40385	40388		10.1074/jbc.C100501200	http://dx.doi.org/10.1074/jbc.C100501200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11553609	hybrid			2022-12-25	WOS:000171925600005
J	Verissimo, F; Jordan, P				Verissimo, F; Jordan, P			WNK kinases, a novel protein kinase subfamily in multi-cellular organisms	ONCOGENE			English	Article						protein kinases; catalytic domain; MAP kinases; chromosome 12; gene cloning; alternative splicing	CATALYTIC SUBUNIT; ORGANIZATION	We have cloned and characterized a novel human serine/ threonine protein kinase gene from chromosome 12p13.3 encoding 2382 amino acids. Remarkably, the catalytic domain sequence contains a cysteine in place of a lysine residue conserved in subdomain II of most kinases. The same amino acid alteration was recently described for rat WNK1 (with no K=lysine) in which another nearby lysine residue was shown to confer kinase activity to the protein. Rat WNK1 is 85% identical to a splice variant lacking exons 11 and 12 of the described human kinase which we have called human WNK1. The WNK1 catalytic domain has closest homology with human PAK2, MEKK3, and Raf-1. Three additional, partial human protein kinase sequences, WNK2, WNK3 and WNK4, are also reported here with catalytic domains that are 95% homologous to WNK1. These genes differ both in chromosomal location and tissue-specific expression. Moreover, we have identified in the database a total of 18 WNK-related genes, all exclusively from multicellular organisms, which share a WNK kinase sequence signature within subdomains I and II of the catalytic domain. We suggest that they constitute a novel subfamily of protein kinases that evolved together with cell adhesion and tissue-formation.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, P-1649016 Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, Ave Padre Cruz, P-1649016 Lisbon, Portugal.		Jordan, Peter/G-9335-2012	Jordan, Peter/0000-0002-1425-9211				BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dhanasekaran N, 1998, ONCOGENE, V17, P1329, DOI 10.1038/sj.onc.1202170; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jordan P, 2000, BIOCHEM BIOPH RES CO, V279, P741, DOI 10.1006/bbrc.2000.3901; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795	17	209	222	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5562	5569		10.1038/sj.onc.1204726	http://dx.doi.org/10.1038/sj.onc.1204726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571656				2022-12-25	WOS:000170781100019
J	Wang, XQ; Sun, P; Paller, AS				Wang, XQ; Sun, P; Paller, AS			Inhibition of integrin-linked kinase/protein kinase B/Akt signaling - Mechanism for ganglioside-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-CYCLE PROGRESSION; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; GD3 GANGLIOSIDE; TYROSINE PHOSPHORYLATION; KERATINOCYTE ADHESION; MEDIATED MODULATION; SURVIVAL SIGNALS; EXPRESSION	Ganglioside GT1b inhibits keratinocyte attachment to and migration on a fibronectin matrix by binding to alpha (5)beta (1) and preventing alpha (5)beta (1) interaction with fibronectin. The role of gangliosides in triggering keratinocyte apoptosis, however, is unknown. Addition of GT1b to keratinocyte-derived SCC12 cells, grown in serum-free medium but exposed to fibronectin, suppressed Bad phosphorylation, activated caspase-9, and inhibited cyclin D and E expression, resulting in cell cycle arrest at G(1) phase and initiation of apoptosis. The mechanism of GT1b activation of caspase-9 involved inhibition of beta (1) integrin serine/threonine phosphorylation and decreased phosphorylation of both integrin-linked kinase and protein kinase B/Akt at its Ser-473 site, leading to cytochrome c release from mitochondria. Consistently, blockade of GT1b function with anti-GT1b antibody specifically activated the Ser-473 site of Akt, markedly suppressing apoptosis. The ganglioside-induced inhibition of Akt phosphorylation was GT1b-specific and was not observed when cells were treated with other keratinocyte gangliosides, including GD3. These studies suggest that the modulation of keratinocyte cell cycle and survival by GT1b is mediated by its direct interaction with alpha (5)beta (1) and resultant inhibition of the integrin/integrin-linked kinase/protein kinase B/Akt signaling pathway.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol 107, 2300 Childrens Plaza, Chicago, IL 60614 USA.			Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [R01 AR44619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044619] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BREMER EG, 1994, CURR TOP MEMBR, V40, P387, DOI 10.1016/S0070-2161(08)60989-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cavallini L, 1999, ARCH BIOCHEM BIOPHYS, V370, P156, DOI 10.1006/abbi.1999.1378; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Colell Anna, 2001, FASEB Journal, V15, P1068; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANAI N, 1988, J BIOL CHEM, V263, P10915; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Ilic D, 1998, J CELL BIOL, V143, P547; Iwabuchi K, 2000, J BIOL CHEM, V275, P15174, DOI 10.1074/jbc.275.20.15174; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Li FG, 1999, J CELL SCI, V112, P4589; MERZAK A, 1995, MOL CHEM NEUROPATHOL, V24, P121, DOI 10.1007/BF02962138; Nakatsuji Y, 2001, EXP NEUROL, V168, P290, DOI 10.1006/exnr.2000.7602; Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603; Okazaki T, 1998, CELL SIGNAL, V10, P685, DOI 10.1016/S0898-6568(98)00035-7; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PALLER AS, 1992, J INVEST DERMATOL, V98, P226, DOI 10.1111/1523-1747.ep12555896; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Ryu BR, 1999, J PHARMACOL EXP THER, V290, P811; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SPADARI S, 1995, MOL PHARMACOL, V47, P1231; Sung CC, 1998, EXP CELL RES, V239, P311, DOI 10.1006/excr.1997.3897; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Usuki S, 1999, NEUROCHEM RES, V24, P281, DOI 10.1023/A:1022522306946; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yoshida S, 2001, CANCER RES, V61, P4244; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	52	59	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44504	44511		10.1074/jbc.M106563200	http://dx.doi.org/10.1074/jbc.M106563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577096	hybrid			2022-12-25	WOS:000172406700023
J	Xing, BD; Jedsadayanmata, A; Lam, SCT				Xing, BD; Jedsadayanmata, A; Lam, SCT			Localization of an integrin binding site to the C terminus of talin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; PLATELET CYTOSKELETON; CELL-ADHESION; MONOCLONAL-ANTIBODIES; BETA(3) SUBUNIT; LIGAND-BINDING; ALPHA-ACTININ; GPIIB-IIIA; PROTEIN; MEMBRANE	Talin, consisting of a 47-kDa N-terminal head domain (residues 1-433) and a 190-kDa C-terminal rod domain (residues 434-2541), links integrins to the actin cytoskeleton. We previously reported that the binding stoichiometry of integrin alpha (IIb)beta (3):talin is similar to2:1. More recently, an integrin binding site has been localized to the talin head domain. In the present study, we identified another integrin binding site at the C-terminal region of the talin rod domain. In a solid phase binding assay, RGD affinity-purified alpha (IIb)beta (3) bound in a dose-dependent manner to microtiter wells coated with the isolated 190-kDa proteolytic fragment of the talin rod domain. Additionally, alpha (IIb)beta (3) also bound to the talin rod domain captured by 8d4, an anti-talin monoclonal antibody. Polyclonal antibodies raised against a recombinant protein fragment corresponding to the entire talin rod domain (anti-talin-R) inhibited alpha (IIb)beta (3) binding to intact talin by similar to 50% but completely blocked alpha (IIb)beta (3) binding to the talin rod domain. To localize the integrin binding site, we examined alpha (IIb)beta (3) binding to recombinant polypeptide fragments corresponding to partial sequences of the talin rod domain. Whereas alpha (IIb)beta (3) bound effectively to talin(1075-2541.) and talin-(1984-2541), it failed to bind to talin-(434-1076) and talin-(434-1975). Furthermore, the binding of alpha (IIb)beta (3) to talin-(1984-2541) was inhibited by anti-talin-R. These results indicate that an integrin binding site is located within residues 1984-2541 of the talin rod domain. Thus, talin contains two integrin binding sites, one in the homologous FERM (band (f) under bar our-point-one, (e) under bar zrin, (r) under bar adixin, (m) under bar oesin) domain and another near its C terminus. Because talin exists as an anti-parallel homodimer in focal adhesions, the two integrin binding sites in the adjacent talin molecules would be in close proximity with each other.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lam, SCT (corresponding author), Univ Illinois, Dept Pharmacol M C 868, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Jedsadayanmata, Arom/AAR-9251-2021	Jedsadayanmata, Arom/0000-0002-5776-1439	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041793, R01HL041793] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41793] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Bolton SJ, 1997, CELL MOTIL CYTOSKEL, V36, P363; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; COLLIER NC, 1982, J BIOL CHEM, V257, P6937; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; Hemmings L, 1996, J CELL SCI, V109, P2715; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MOLONY L, 1987, J BIOL CHEM, V262, P7790; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; NEWMAN PJ, 1985, BLOOD, V65, P227; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; NUCKOLLS GH, 1990, J CELL BIOL, V110, P1635, DOI 10.1083/jcb.110.5.1635; OTEY C, 1990, HYBRIDOMA, V9, P57, DOI 10.1089/hyb.1990.9.57; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Reddy KB, 1998, J BIOL CHEM, V273, P35039, DOI 10.1074/jbc.273.52.35039; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; TAPLEY P, 1989, ONCOGENE, V4, P325; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; TUSZYNSKI GP, 1984, J BIOL CHEM, V259, P5247; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; YLANNE J, 1995, J BIOL CHEM, V270, P9550	46	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44373	44378		10.1074/jbc.M108587200	http://dx.doi.org/10.1074/jbc.M108587200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11555663	hybrid			2022-12-25	WOS:000172406700004
J	Williams, EJ; Williams, G; Howell, FV; Skaper, SD; Walsh, FS; Doherty, P				Williams, EJ; Williams, G; Howell, FV; Skaper, SD; Walsh, FS; Doherty, P			Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CRYSTAL-STRUCTURE; AMINO-ACIDS; HAV MOTIF; IN-VIVO; FGF; OUTGROWTH; EXPRESSION; ACTIVATION; COMPLEX	In this study, we show that the neurite outgrowth response stimulated by N-cadherin is inhibited by a recently developed and highly specific fibroblast growth factor receptor (FGFR) antagonist. To test whether the N-cadherin response also requires FGF function, we developed peptide mimetics of the receptor binding sites on FGFs. Most mimetics inhibit the neurite outgrowth response stimulated by FGF in the absence of any effect on the N-cadherin response. The exceptions to this result were two mimetics of a short FGF1 sequence, which has been shown to interact with the region of the FGFR containing the histidine-alanine-valine motif. These peptides inhibited FGF and N-cadherin responses with similar efficacy. The histidine-alanine-valine region of the FGFR has previously been implicated in the N-cadherin response, and a candidate interaction site has been identified in extracellular domain 4 of N-cadherin. We now show that antibodies directed to this site on N-cadherin inhibit the neurite outgrowth response stimulated by N-cadherin, and peptide mimetics of the site inhibit N-cadherin and FGF responses. Thus, we can conclude that N-cadherin contains a novel motility motif in extracellular domain 4, and that peptide mimetics of this motif can interact with the FGFR.	Kings Coll London, MRC, Ctr Dev Neurobiol, Mol Neurobiol Grp, London SE1 1UL, England; GlaxoSmithKline Inc, Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of London; King's College London; GlaxoSmithKline	Doherty, P (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, Mol Neurobiol Grp, London SE1 1UL, England.	patrick.doherty@kcl.ac.uk	Doherty, Patrick/A-8752-2008; Williams, Gareth/B-3202-2010	Williams, Gareth/0000-0001-9205-4943; Doherty, Patrick/0000-0002-0407-5689				Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BALSAMO J, 1990, J BIOL CHEM, V265, P2923; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Hamby JM, 1997, J MED CHEM, V40, P2296, DOI 10.1021/jm970367n; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; Lom B, 1998, J NEUROBIOL, V37, P633, DOI 10.1002/(SICI)1097-4695(199812)37:4<633::AID-NEU11>3.0.CO;2-L; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Peluso JJ, 2000, BIOL SIGNAL RECEPT, V9, P115; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Riehl R, 1996, NEURON, V17, P837, DOI 10.1016/S0896-6273(00)80216-0; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shan WS, 1999, BIOPHYS CHEM, V82, P157, DOI 10.1016/S0301-4622(99)00115-5; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Skaper SD, 2000, J NEUROCHEM, V75, P1520, DOI 10.1046/j.1471-4159.2000.0751520.x; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1231; Williams EJ, 2000, MOL CELL NEUROSCI, V15, P456, DOI 10.1006/mcne.2000.0847	42	116	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43879	43886		10.1074/jbc.M105876200	http://dx.doi.org/10.1074/jbc.M105876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571292	hybrid			2022-12-25	WOS:000172297700053
J	Buttner, C; Sadtler, S; Leyendecker, A; Laube, B; Griffon, N; Betz, H; Schmalzing, G				Buttner, C; Sadtler, S; Leyendecker, A; Laube, B; Griffon, N; Betz, H; Schmalzing, G			Ubiquitination precedes internalization and proteolytic cleavage of plasma membrane-bound glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; GATED ION CHANNELS; ACETYLCHOLINE-RECEPTOR; NEUROMUSCULAR-JUNCTION; SPINAL-CORD; NEUROTRANSMITTER RECEPTORS; POSTSYNAPTIC CHANGES; SYNAPTIC PLASTICITY; AMPA RECEPTORS; BETA-SUBUNIT	The inhibitory glycine receptor (GlyR) in developing spinal neurones is internalized efficiently upon antagonist inhibition. Here we used surface labeling combined with affinity purification to show that homopentameric alpha1 GlyRs generated in Xenopus oocytes are proteolytically nicked into fragments of 35 and 13 kDa upon prolonged incubation. Nicked GlyRs do not exist at the cell surface, indicating that proteolysis occurs exclusively in the endocytotic pathway. Consistent with this interpretation, elevation of the lysosomal pH, but not the proteasome inhibitor lactacystin, prevents GlyR cleavage. Prior to internalization, al GlyRs are conjugated extensively with ubiquitin in the plasma membrane. Our results are consistent with ubiquitination regulating the endocytosis and subsequent proteolysis of GlyRs residing in the plasma membrane. Ubiquitin-conjugating enzymes thus may have a crucial role in synaptic plasticity by determining postsynaptic receptor numbers.	Univ Frankfurt, Bioctr, Dept Pharmacol, D-60439 Frankfurt, Germany; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Goethe University Frankfurt; Max Planck Society	Schmalzing, G (corresponding author), Rhein Westfal TH Aachen, Dept Mol Pharmacol, Wendlingweg 2, D-52074 Aachen, Germany.							Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; AKAGI H, 1991, FEBS LETT, V281, P160, DOI 10.1016/0014-5793(91)80383-E; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BECKER CM, 1988, EMBO J, V7, P3717, DOI 10.1002/j.1460-2075.1988.tb03255.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; CHAPMAN AP, 1994, NEUROSCI LETT, V168, P238, DOI 10.1016/0304-3940(94)90459-6; Colledge M, 1998, CURR OPIN NEUROBIOL, V8, P357, DOI 10.1016/S0959-4388(98)80061-5; de Stefano ME, 1998, J NEUROPATH EXP NEUR, V57, P1000, DOI 10.1097/00005072-199811000-00002; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Hackam AS, 1997, NEUROREPORT, V8, P1425, DOI 10.1097/00001756-199704140-00020; Harvey RJ, 2000, HANDB EXP PHARM, V147, P479; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; HUGANIR RL, 1980, J SUPRAMOL STR CELL, V14, P13, DOI 10.1002/jss.400140103; Kirsch J, 1998, NATURE, V392, P717, DOI 10.1038/33694; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Levi S, 1998, J CELL SCI, V111, P335; LINDSTROM J, 1980, BIOCHEMISTRY-US, V19, P4791, DOI 10.1021/bi00562a012; Lucero P, 2000, J BACTERIOL, V182, P241, DOI 10.1128/JB.182.1.241-243.2000; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; Missias AC, 1997, DEVELOPMENT, V124, P5075; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; PUMPLIN DW, 1982, ANNU REV PHYSIOL, V44, P319, DOI 10.1146/annurev.ph.44.030182.001535; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMALZING G, 1991, BIOCHEM J, V279, P829; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SEGLEN PO, 1980, MOL PHARMACOL, V18, P468; SERDAROGLU P, 1992, NEUROPATH APPL NEURO, V18, P232, DOI 10.1111/j.1365-2990.1992.tb00785.x; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1997, J BIOL CHEM, V272, P40; TAKAHASHI T, 1992, NEURON, V9, P1155, DOI 10.1016/0896-6273(92)90073-M; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Turrigiano GG, 2000, NEURON, V26, P5, DOI 10.1016/S0896-6273(00)81131-9; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xu RF, 1999, J CELL PHYSIOL, V181, P107, DOI 10.1002/(SICI)1097-4652(199910)181:1<107::AID-JCP11>3.3.CO;2-0; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	65	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42978	42985		10.1074/jbc.M102121200	http://dx.doi.org/10.1074/jbc.M102121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560918	hybrid			2022-12-25	WOS:000172169300047
J	Jiang, JH; Ballinger, CA; Wu, YX; Dai, Q; Cyr, DM; Hohfeld, J; Patterson, C				Jiang, JH; Ballinger, CA; Wu, YX; Dai, Q; Cyr, DM; Hohfeld, J; Patterson, C			CHIP is a U-box-dependent E3 ubiquitin ligase - Identification of Hsc70 as a target for ubiquitylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; PROTEIN; DEGRADATION; MUTANT; HSP70; LINK	Proper folding of proteins (either newly synthesized or damaged in response to a stressful event) occurs in a highly regulated fashion. Cytosolic chaperones such as Hsc/Hsp70 are assisted by cofactors that modulate the folding machinery in a positive or negative manner. CHIP (carboxyl terminus of Hsc70-interacting protein) is such a cofactor that interacts with Hsc70 and, in general, attenuates its most well characterized functions. In addition, CHIP accelerates ubiquitin-dependent degradation of chaperone substrates. Using an in vitro ubiquitylation assay with recombinant proteins, we demonstrate that CHIP possesses intrinsic E3 ubiquitin ligase activity an promotes ubiquitylation. This activity is dependent on the carboxyl-terminal U-box. CHIP interacts functionally and physically with the stress-responsive ubiquitin-conjugating enzyme family UBCH5. Surprisingly, a major target of the ubiquitin ligase activity of CHIP is Hsc70 itself. CHIP ubiquitylates Hsc70, primarily with short, noncanonical multiubiquitin chains but has no appreciable effect on steady-state levels or half-life of this protein. This effect may have heretofore unanticipated consequences with regard to the chaperoning activities of Hsc70 or its ability to deliver substrates to the proteasome. These studies demonstrate that CHIP is a bona fide ubiquitin ligase and indicate that U-box-containing proteins may comprise a new family of E3s.	Univ N Carolina, Div Cardiol, Program Mol Cardiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Sealy Ctr Mol Cardiol, Galveston, TX 77550 USA; Univ Bonn, Inst Cell Biol, D-53121 Bonn, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Bonn	Patterson, C (corresponding author), Univ N Carolina, Div Cardiol, Program Mol Cardiol, 324 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.	epatters@med.unc.edu		Cyr, Douglas/0000-0002-4928-3414	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL065619, K08HL003658, R01HL065619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056981, R01GM061728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03658, HL65619] Funding Source: Medline; NIGMS NIH HHS [GM56981, GM61728, R01 GM056981] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dul JL, 2001, J CELL BIOL, V152, P705, DOI 10.1083/jcb.152.4.705; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Nuber U, 1998, EUR J BIOCHEM, V254, P643, DOI 10.1046/j.1432-1327.1998.2540643.x; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; PICKART CM, 1988, J BIOL CHEM, V263, P12028; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Pukatzki S, 1998, J BIOL CHEM, V273, P24131, DOI 10.1074/jbc.273.37.24131; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Smith DF, 1998, PHARMACOL REV, V50, P493; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	38	453	477	3	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42938	42944		10.1074/jbc.M101968200	http://dx.doi.org/10.1074/jbc.M101968200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11557750	hybrid			2022-12-25	WOS:000172169300042
J	Miller, KA; Eklund, EA; Peddinghaus, ML; Cao, ZJ; Fernandes, N; Turk, PW; Thimmapaya, B; Weitzman, SA				Miller, KA; Eklund, EA; Peddinghaus, ML; Cao, ZJ; Fernandes, N; Turk, PW; Thimmapaya, B; Weitzman, SA			Kruppel-like factor 4 regulates laminin alpha 3A expression in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; BOX-BINDING PROTEIN; PROMOTER ACTIVITY; ERYTHROID-CELLS; FACTOR GENE; IDENTIFICATION; BREAST; GROWTH; CDNA; TRANSCRIPTION	Laminin-5, the major extracellular matrix protein produced by mammary epithelial cells, is composed of three chains (designated alpha 3A, beta3, and gamma2), each encoded by a separate gene. Laminin-5 is markedly down-regulated in breast cancer cells. Little is known about the regulation of laminin gene transcription in normal breast cells, nor about the mechanism underlying the down-regulation seen in cancer. In the present study, we cloned the promoter of the gene for the human laminin alpha 3A chain (LAMA3A) and investigated its regulation in functionally normal MCF10A breast epithelial cells and several breast cancer cell lines. Using site-directed mutagenesis of promoter-reporter constructs in transient transfection assays in MCF10A cells, we find that two binding sites for Kruppel-like factor 4 (KLF4/GKLF/EZF) are required for expression driven by the LAMA3A promoter. Electrophoretic mobility shift assays reveal absence of KLF4 binding activity in extracts from T47D, MDA-MB 231, ZR75-1, MDA-MB 436, and MCF7 breast cancer cells. Transient transfection of a plasmid expressing KLF4 activates transcription from the LAMA3A promoter in breast cancer cells. A reporter vector containing duplicate KLF4-binding sites in its promoter is expressed at high levels in MCF10A cells but at negligible levels in breast cancer cells. Thus, KLF4 is required for LAMA3A expression and absence of laminin alpha 3A in breast cancer cells appears, at least in part, attributable to the lack of KLF4 activity.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Dept Microbiol & Immunol, Chicago, IL 60611 USA; Vet Affairs Lakeside Med Ctr, Dept Med, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Weitzman, SA (corresponding author), Olson 8276,303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [T32CA009560, R01CA074403] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09560, CA74403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Henning K, 1999, HISTOPATHOLOGY, V34, P305; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Miller KA, 2000, J BIOL CHEM, V275, P8176, DOI 10.1074/jbc.275.11.8176; Pulkkinen L, 1998, LAB INVEST, V78, P1067; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Stahl S, 1997, J CELL SCI, V110, P55; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Virolle T, 2000, EMBO REP, V1, P328, DOI 10.1093/embo-reports/kvd066; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	27	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42863	42868		10.1074/jbc.M108130200	http://dx.doi.org/10.1074/jbc.M108130200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11551969	hybrid			2022-12-25	WOS:000172169300032
J	Valasek, L; Hasek, J; Nielsen, KH; Hinnebusch, AG				Valasek, L; Hasek, J; Nielsen, KH; Hinnebusch, AG			Dual function of eIF3j/Hcr1p in processing 20 S pre-rRNA and translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE HOMOLOG; P40/LAMININ RECEPTOR PRECURSOR; TRANS-ACTING FACTORS; ESCHERICHIA-COLI; 3 EIF3; PROTEIN; COMPLEX; SUBUNITS; GENES; PURIFICATION	eIF3j/Hcr1p, a protein associated with eIF3, was shown to bind to, and stabilize, the multifactor complex containing eIFs 1, 2, 3, and 5 and Met-tRNA(i)(Met), whose formation is required for an optimal rate of translation initiation. Here we present evidence that eIF3j/Hcr1p is an RNA binding protein that enhances a late step in 40 S ribosome maturation involving cleavage of the 20 S precursor of 18 S rRNA in the cytoplasm. Immunofluorescence staining shows that eIF3j/Hcr1p is localized predominantly in the cytoplasm. The herl A mutant exhibits a decreased amount of 40 S subunits, hypersensitivity to paromomycin, and increased levels of 20 S pre-rRNA. Combining the hcr1 Delta mutation with drs2 Delta or rps0a Delta, deletions of two other genes involved in the same step of 40 S subunit biogenesis, produced a synthetic growth defect. p35, the human ortholog of eIF3j/Hcr1p, partially complemented the slow growth phenotype conferred by hcr1 Delta when overexpressed in yeast. heIF3j/p35 was found physically associated with yeast eIF3 and 43 S initiation complexes in vitro and in vivo. Because it did not complement the 40 S biogenesis defect of hcr1 Delta, it appears that heIF3j can substitute for eIF3j/Hcr1p only in translation initiation. We conclude that eIF3j/Hcr1p is required for rapid processing of 20 S to IS S rRNA besides its role in translation initiation, providing an intriguing link between ribosome biogenesis and translation.	NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Hinnebusch, AG (corresponding author), NICHHD, Lab Gene Regulat & Dev, NIH, 6 Ctr Dr,Bldg 6A-B1A-13, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov	Hasek, Jiri/H-2427-2014; Valášek, Leoš Shivaya/I-5743-2014	Hasek, Jiri/0000-0001-6634-2386; Valášek, Leoš Shivaya/0000-0001-8123-8667	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALASEK L, 2001, EMBO J, V20, P891; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Basu U, 2001, MOL CELL BIOL, V21, P1453, DOI 10.1128/MCB.21.5.1453-1462.2001; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; Demianova M, 1996, J BIOL CHEM, V271, P11383, DOI 10.1074/jbc.271.19.11383; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; FOLLEY LS, 1994, GENETICS, V137, P369; Ford CL, 1999, CANCER RES, V59, P704; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hasek J, 2000, CELL MOTIL CYTOSKEL, V45, P235, DOI 10.1002/(SICI)1097-0169(200003)45:3<235::AID-CM6>3.0.CO;2-I; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; KLOOTWIJK J, 1989, METHOD ENZYMOL, V180, P96; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Kressler D, 1997, MOL CELL BIOL, V17, P7283, DOI 10.1128/MCB.17.12.7283; KRUISWIJK T, 1978, BIOCHIM BIOPHYS ACTA, V517, P378, DOI 10.1016/0005-2787(78)90204-6; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Linder P, 1999, YEAST, V15, P865; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; RUSSELL DW, 1979, J BIOL CHEM, V254, P8796; Sherman F., 1974, METHODS YEAST GENETI; Si K, 1999, MOL CELL BIOL, V19, P1416; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; UDEM SA, 1973, J BIOL CHEM, V248, P1412; Valasek L, 1998, J BIOL CHEM, V273, P21253, DOI 10.1074/jbc.273.33.21253; Valasek L, 1999, J BIOL CHEM, V274, P27567, DOI 10.1074/jbc.274.39.27567; VALASEK L, 1998, THESIS U VIENNA AUST; Zabetakis D, 2000, YEAST, V16, P1147, DOI 10.1002/1097-0061(20000915)16:12<1147::AID-YEA610>3.0.CO;2-M	35	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43351	43360		10.1074/jbc.M106887200	http://dx.doi.org/10.1074/jbc.M106887200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560931	hybrid			2022-12-25	WOS:000172169300094
J	Morimura, N; Tezuka, Y; Watanabe, N; Yasuda, M; Miyatani, S; Hozumi, N; Tezuka, K				Morimura, N; Tezuka, Y; Watanabe, N; Yasuda, M; Miyatani, S; Hozumi, N; Tezuka, K			Molecular cloning of POEM - A novel adhesion molecule that interacts with alpha(8)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; EGF-REPEAT; PROTEIN; RECEPTOR; BINDING; ALPHA-8-BETA-1; IDENTIFICATION; GENE; DIFFERENTIATION; OSTEOPONTIN	Cell adhesion molecules are involved in a number of biological functions, such as cell survival, cell differentiation, tissue repair, and development. A novel molecule, POEM (preosteoblast epidermal growth factor-like repeat protein with meprin, A5 protein, and receptor protein-tyrosine phosphatase mu domain), was isolated by reverse transcription-polymerase chain reaction using a set of degenerate primers designed after other known epidermal growth factor (EGF)-like motifs. From its structure, POEM was suggested to be a novel adhesion molecule with five EGF-like domains, an Arg-GlyAsp (RGD) cell binding motif, and a meprin, A5 protein, and receptor protein-tyrosine phosphatase mu (MAM) domain. By in situ hybridization using embryonic day 16.5 (E16.5) mouse embryos, strong expression of POEM mRNA was observed in developing kidney renal tubules, parathyroid and thyroid glands, developing bone, tooth germ, and endocrine organs of the brain. The inner ear, skeletal muscle, smooth muscle (except for the vascular system), and skin were also positive for POEM expression. Bacterial recombinant POEM protein containing the RGD sequence and MAM domain showed strong cell adhesion, spreading, and survival-promoting activities. By mutating the RGD sequence to RGE, the cell spreading and survival activities were significantly decreased, but the MAM domain was shown to contribute only to cell adhesion and not to cell. spreading and survival-promoting activities. The distribution of POEM in several tissues was close to that of alpha (8)beta (1) integrin. Therefore, we conducted cell adhesion assays using KA8 cells, a K562 leukemia clone stably expressing alpha (8) integrin. Parental K562 cells, which expressed alpha (5)beta (1) integrin, bound to fibronectin but not to POEM. On the other hand, KA8 cells showed strong binding and spreading on both fibronectin and POEM. These results suggest that POEM is a novel ligand for alpha (8)beta (1) integrin and that POEM may be involved in the development and function of various tissues, such as kidney, bone, muscles, and endocrine organs.	Tokyo Univ Sci, Res Inst Biol Sci, Noda, Chiba 2780022, Japan; Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Tokyo University of Science; RIKEN	Tezuka, K (corresponding author), Tokyo Univ Sci, Res Inst Biol Sci, Yamazaki 2669, Noda, Chiba 2780022, Japan.	tezuka@rs.noda.sut.ac.jp	Tezuka, Ken-ichi/B-3836-2012					ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; Brandenberger R, 2001, J CELL BIOL, V154, P447, DOI 10.1083/jcb.200103069; Buchner G, 2000, MECH DEVELOP, V98, P179, DOI 10.1016/S0925-4773(00)00462-7; Buchner G, 2000, GENOMICS, V65, P16, DOI 10.1006/geno.2000.6146; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Damsky CH, 1997, KIDNEY INT, V51, P1427, DOI 10.1038/ki.1997.195; Denda S, 1998, BIOCHEMISTRY-US, V37, P5464, DOI 10.1021/bi9727489; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; Evans AL, 2000, NAT GENET, V24, P424, DOI 10.1038/74286; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; Horton M. A., 1996, P217; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuriyama S, 2000, MECH DEVELOP, V93, P233, DOI 10.1016/S0925-4773(00)00280-X; Liaw L, 1998, J CLIN INVEST, V101, P1468; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Moursi AM, 1997, J CELL SCI, V110, P2187; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; MULLER U, 1995, MOL BIOL CELL, V6, P433; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Stein Gary S., 1996, P69; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	42	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42172	42181		10.1074/jbc.M103216200	http://dx.doi.org/10.1074/jbc.M103216200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546798	hybrid			2022-12-25	WOS:000172450400085
J	Yu, WP; Pallen, CJ; Tay, A; Jirik, FR; Brenner, S; Tan, YH; Venkatesh, B				Yu, WP; Pallen, CJ; Tay, A; Jirik, FR; Brenner, S; Tan, YH; Venkatesh, B			Conserved synteny between the Fugu and human PTEN locus and the evolutionary conservation of vertebrate PTEN function	ONCOGENE			English	Article						PTEN; phosphatase; tumor suppressor; Fugu	INOSITOL POLYPHOSPHATE PHOSPHATASE; RILEY-RUVALCABA-SYNDROME; TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; MOLECULAR-CLONING; FAMILY; BREAST; 10Q23; IDENTIFICATION; PTEN/MMAC1	Mutations of PTEN, which encodes a protein-tyrosine and lipid phosphatase, are prevalent in a variety of human cancers. The human genome 'draft' sequence still lacks organization and much of the PTEN and adjacent loci remain undefined. The pufferfish, Fugu rubripes, by virtue of having a compact genome represents an excellent template for rapid vertebrate gene discovery. Sequencing of 56 kb from the Fugu pten (fpten) locus identified four complete genes and one partial gene homologous to human genes. Genes neighboring fpten include a PAPS synthase (fpapss2) differentially expressed between non-metastatic/metastatic human carcinoma cell lines, an inositol phosphatase (fminpp1) and an omega class glutathione-S-transferase (fgsto). We have determined the order of human BAC clones at the hPTEN locus and that the locus contains hPAPSS2 and hMINPP1 genes oriented as are their Fugu orthologs. Although the human genes span 500 kb, the Fugu genes lie within only 22 kb due to the compressed intronic and intergenic regions that typify this genome. Interestingly, and providing striking evidence of regulatory element conservation between widely divergent vertebrate species, the compact 2.1 kb fpten promoter is active in human cells. Also, like hPTEN, fpten has a growth and tumor suppressor activity in human glioblastoma cells, demonstrating conservation of protein function.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of British Columbia	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbcp@imcb.nus.edu.sg		Venkatesh, Byrappa/0000-0003-3620-0277; Pallen, Catherine/0000-0002-3576-5295				AUSABEL FM, 1995, CURRENT PROTOCOLS MO, V2; Bostrom J, 1998, CANCER RES, V58, P29; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chi HB, 2000, MOL CELL BIOL, V20, P6496, DOI 10.1128/MCB.20.17.6496-6507.2000; Chi HB, 1999, GENOMICS, V56, P324, DOI 10.1006/geno.1998.5736; Craxton A, 1997, BIOCHEM J, V328, P75, DOI 10.1042/bj3280075; Dahia PM, 2000, J MED GENET, V37, P715, DOI 10.1136/jmg.37.9.715; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Feilotter HE, 1999, BRIT J CANCER, V79, P718, DOI 10.1038/sj.bjc.6690115; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Franzon VL, 1999, INT J BIOCHEM CELL B, V31, P613, DOI 10.1016/S1357-2725(98)00155-1; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huang H, 1999, DEVELOPMENT, V126, P5365; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; Kurima K, 1999, J BIOL CHEM, V274, P33306, DOI 10.1074/jbc.274.47.33306; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; MUTTER GL, 2000, JNCI-J NATL CANCER I, V92, P861; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reynolds SD, 1996, EXP CELL RES, V226, P197, DOI 10.1006/excr.1996.0219; Romano PR, 1998, J CELL SCI, V111, P803; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Simpkins SB, 1998, GYNECOL ONCOL, V71, P391, DOI 10.1006/gyno.1998.5208; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Venkatesh B, 2000, FEBS LETT, V476, P3, DOI 10.1016/S0014-5793(00)01659-8; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	46	15	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5554	5561		10.1038/sj.onc.1204679	http://dx.doi.org/10.1038/sj.onc.1204679			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571655				2022-12-25	WOS:000170781100018
